PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ChooSmith, LP; GarzonRodriguez, W; Glabe, CG; Surewicz, WK				ChooSmith, LP; GarzonRodriguez, W; Glabe, CG; Surewicz, WK			Acceleration of amyloid fibril formation by specific binding of A beta-(1-40) peptide to ganglioside-containing membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN GENE; ALZHEIMERS-DISEASE; BETA-PEPTIDE; SENILE PLAQUES; NEUROTOXICITY; CELLS; RECEPTOR; NEURONS; CONDUCTANCE; MECHANISM	The interaction of Alzheimer's A beta peptide and its fluorescent analogue with membrane vesicles was studied by spectrofluorometry, Congo Red binding, and electron microscopy. The peptide binds selectively to the membranes containing gangliosides with a binding affinity ranging from 10(-6) to 10(-7) M depending on the type of ganglioside sugar moiety. This interaction appears to be ganglioside-specific as under our experimental conditions (neutral pH, physiologically relevant ionic strength), no A beta binding was observed to ganglioside-free membranes containing zwitterionic or acidic phospholipids. Importantly, the addition of ganglioside-containing vesicles to the peptide solution dramatically accelerates the rate of fibril formation as compared with that of the peptide alone. The present results strongly suggest that the membrane-bound form of the peptide may act as a specific ''template'' (seed) that catalyzes the fibrillogenesis process in vivo.	CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106; UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92696	Case Western Reserve University; University of California System; University of California Irvine								ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; ARISPE N, 1994, MOL CELL BIOCHEM, V140, P119, DOI 10.1007/BF00926750; Avdulov NA, 1997, J NEUROCHEM, V68, P2086; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOLAND K, 1995, J BIOL CHEM, V270, P28022; Burdick D, 1997, BRAIN RES, V746, P275, DOI 10.1016/S0006-8993(96)01262-0; BUSCIGLIO J, 1992, NEUROBIOL AGING, V13, P609, DOI 10.1016/0197-4580(92)90065-6; Butterfield DA, 1997, CHEM RES TOXICOL, V10, P495, DOI 10.1021/tx960130e; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; Cribbs DH, 1997, J BIOL CHEM, V272, P7431, DOI 10.1074/jbc.272.11.7431; DAVIDSON RM, 1994, BRAIN RES, V643, P324, DOI 10.1016/0006-8993(94)90041-8; FELGNER PL, 1981, BIOCHEMISTRY-US, V20, P2168, DOI 10.1021/bi00511a015; FURUKAWA K, 1994, NEUROREPORT, V5, P2016, DOI 10.1097/00001756-199410270-00006; GALDZICKI Z, 1994, BRAIN RES, V646, P332, DOI 10.1016/0006-8993(94)90101-5; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Good TA, 1996, BIOPHYS J, V70, P296, DOI 10.1016/S0006-3495(96)79570-X; HANSSON HA, 1977, P NATL ACAD SCI USA, V74, P3782, DOI 10.1073/pnas.74.9.3782; JAIN MK, 1982, BIOCHIM BIOPHYS ACTA, V688, P341, DOI 10.1016/0005-2736(82)90345-5; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Mattson MP, 1997, CHEM RES TOXICOL, V10, P507, DOI 10.1021/tx9601317; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; Praprotnik D, 1996, ACTA NEUROPATHOL, V91, P1; PROBST A, 1991, ACTA NEUROPATHOL, V83, P21, DOI 10.1007/BF00294426; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SIMMONS LK, 1994, MOL PHARMACOL, V45, P375; SIMMONS MA, 1993, NEUROSCI LETT, V150, P133, DOI 10.1016/0304-3940(93)90519-Q; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; WIEGANDT H, 1982, ADV NEUROCHEM, V4, P149; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; Wood SJ, 1996, BIOCHEMISTRY-US, V35, P12623, DOI 10.1021/bi961074j; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062	39	285	294	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					22987	22990		10.1074/jbc.272.37.22987	http://dx.doi.org/10.1074/jbc.272.37.22987			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287293	hybrid			2022-12-27	WOS:A1997XV74400004
J	Matsubara, M; Hayashi, N; Titani, K; Taniguchi, H				Matsubara, M; Hayashi, N; Titani, K; Taniguchi, H			Circular dichroism and H-1 NMR studies on the structures of peptides derived from the calmodulin-binding domains of inducible and endothelial nitric-oxide synthase in solution and in complex with calmodulin - Nascent alpha-helical structures are stabilized by calmodulin both in the presence and absence of Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; RECOGNITION; PROTEIN; KINASE; MYOSIN; IDENTIFICATION; PURIFICATION; MACROPHAGES; SUBSTRATE; CYCLASE	There exist two types of nitric-oxide synthase (NOS); constitutive isozymes that are activated by binding calmodulin in response to elevated Ca2+ and an inducible isozyme that binds calmodulin regardless of Ca2+. To study the structural basis of the difference in Ca2+ sensitivity, we have designed synthetic peptides of minimal lengths derived from the calmodulin-binding domain of endothelial NOS (eNOS) and that of macrophage NOS (iNOS). A peptide, KRREIPLKVLVKAVLFACMLMRK, derived from human iNOS sequence, retained the ability to bind to calmodulin both in the presence and absence of Ca2+, while a peptide derived from human eNOS sequence, RKKTFKEVANAVKISASLMG, bound to calmodulin only in the presence of Ca2+. Circular dichroism and two-dimensional H-1 nuclear magnetic resonance studies suggested that both peptides assume nascent alpha-helical structures in aqueous solution. When mixed with calmodulin, both peptides showed circular dichroism spectra characteristic for alpha-helix. In contrast to other target proteins, the addition of iNOS peptide to calmodulin did not affect the Ca2+ binding of calmodulin appreciably. The peptide derived from the calmodulin-binding domain of iNOS, therefore, binds in alpha-helical structures both to Ca2+-calmodulin and apo-calmodulin, which is unique among various target proteins of calmodulin.	FUJITA HLTH UNIV,DIV BIOMED POLYMER SCI,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University			Hayashi, Nobuhiro/F-6088-2011; Matsubara, Mamoru/AAP-4016-2021; Taniguchi, Hisaaki/I-9171-2012	Hayashi, Nobuhiro/0000-0002-9950-094X; Matsubara, Mamoru/0000-0002-8893-0485; 				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ANAGLI J, 1995, EUR J BIOCHEM, V233, P701, DOI 10.1111/j.1432-1033.1995.701_3.x; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3147; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; FOROOD B, 1993, P NATL ACAD SCI USA, V90, P838, DOI 10.1073/pnas.90.3.838; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; GREENLEE DV, 1982, BIOCHEMISTRY-US, V21, P2759, DOI 10.1021/bi00540a028; Hayashi N, 1997, J BIOL CHEM, V272, P7639, DOI 10.1074/jbc.272.12.7639; HOUDUSSE A, 1995, P NATL ACAD SCI USA, V92, P10644, DOI 10.1073/pnas.92.23.10644; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; LINSE S, 1991, J BIOL CHEM, V266, P8050; MACMILLAN MA, 1992, P NATL ACAD SCI USA, V89, P11141; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Martin SR, 1996, BIOCHEMISTRY-US, V35, P3508, DOI 10.1021/bi952522a; Matsubara M, 1996, BIOCHEMISTRY-US, V35, P14651, DOI 10.1021/bi9613988; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; PORUMB T, 1994, ANAL BIOCHEM, V220, P227, DOI 10.1006/abio.1994.1332; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1443, DOI 10.1021/bi00120a022; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; SCHMIDT HHH, 1989, BIOCHEM BIOPH RES CO, V165, P813; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Swindells MB, 1996, NAT STRUCT BIOL, V3, P501, DOI 10.1038/nsb0696-501; TANIGUCHI H, 1984, BIOCHEM BIOPH RES CO, V118, P916, DOI 10.1016/0006-291X(84)91482-7; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Wuthrich K., 1986, NMR PROTEINS NUCL AC; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t	45	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23050	23056		10.1074/jbc.272.37.23050	http://dx.doi.org/10.1074/jbc.272.37.23050			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287303	hybrid			2022-12-27	WOS:A1997XV74400014
J	Zhao, KW; Faull, KF; Kakkis, ED; Neufeld, EF				Zhao, KW; Faull, KF; Kakkis, ED; Neufeld, EF			Carbohydrate structures of recombinant human alpha-L-iduronidase secreted by Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; MUCOPOLYSACCHARIDOSIS-TYPE; ENZYME REPLACEMENT; MASS-SPECTROMETRY; PURIFIED ENZYME; CANINE MODEL; OVEREXPRESSION; GLUCOSIDASE; PROTEINS	alpha-L-Iduronidase is a lysosomal hydrolase that is deficient in Hurler syndrome and clinically milder variants. Recombinant human alpha-L-iduronidase, isolated from secretions of an overexpressing Chinese hamster ovary cell line, is potentially useful for replacement therapy of these disorders. Because of the importance of carbohydrate residues for endocytosis and lysosomal targeting, we examined the oligosaccharides of recombinant alpha-L-iduronidase at each of its six N-glycosylation sites. Biosynthetic radiolabeling showed that three or four of the six oligosaccharides of the secreted enzyme were cleaved by endo-beta-N-acetylglucosaminidase H, with phosphate present on the sensitive oligosaccharides and L-fucose on the resistant ones. For structural analysis, tryptic and chymotryptic glycopeptides were isolated by lectin binding and reverse phase high pressure liquid chromatography; their molecular mass was determined by matrix-assisted laser desorption-time of flight mass spectrometry before and after treatment with endo- or exoglycosidases or with alkaline phosphatase. Identification of the peptides was assisted by amino-or carboxyl-terminal sequence analysis. The major oligosaccharide structures found at each site were as follows: Asn-110, complex; Asn-190, complex; Asn-336, bisphosphorylated (P(2)Man(7)GlcNAc(2)); Asn-372, high mannose (mainly Man(9)GlcNAc(2), some of which was monoglucosylated); Asn-415, mixed high mannose and complex; Asn-451, bisphosphorylated (P(2)Man(7)GlcNAc(2)). The Asn-451 glycopeptide was unexpectedly resistant to digestion by N-glycanase unless first dephosphorylated, but it was sensitive to endo-beta-N-acetylglucosaminidase H and to glycopeptidase A. The heterogeneity of carbohydrate structures must represent the accessibility of the glycosylation sites as well as the processing capability of the overexpressing Chinese hamster ovary cells.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BEHAV SCI,CTR MOL & MED SCI MASS SPECTROMETRY,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,CTR MOL & MED SCI MASS SPECTROMETRY,LOS ANGELES,CA 90095; HARBOR UCLA MED CTR,DEPT PEDIAT,TORRANCE,CA 90502	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038857] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16042-20] Funding Source: Medline; NIDDK NIH HHS [DK38857] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANSON DS, 1992, BIOCHEM J, V284, P789, DOI 10.1042/bj2840789; BIELICKI J, 1993, BIOCHEM J, V289, P241, DOI 10.1042/bj2890241; CALRKE LA, 1996, AM J HUM GENET, V59, pA196; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; Haskins M. E., 1995, American Journal of Human Genetics, V57, pA39; HUBERTY MC, 1993, ANAL CHEM, V65, P2791, DOI 10.1021/ac00068a015; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; Kakkis ED, 1996, BIOCHEM MOL MED, V58, P156, DOI 10.1006/bmme.1996.0044; KAKKIS ED, 1994, PROTEIN EXPRES PURIF, V5, P225, DOI 10.1006/prep.1994.1035; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; KHANDKE KM, 1989, INT J PEPT PROT RES, V34, P118; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING P, 1993, BIOL REPROD, V49, P1317, DOI 10.1095/biolreprod49.6.1317; MYEROWITZ R, 1981, J BIOL CHEM, V256, P3044; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; PATTERSON DH, ANAL CHEM, V67, P369; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PROIA RL, 1984, J BIOL CHEM, V259, P3350; SCOTT HS, 1991, P NATL ACAD SCI USA, V88, P9695, DOI 10.1073/pnas.88.21.9695; SCOTT HS, 1995, HUM MUTAT, V6, P288, DOI 10.1002/humu.1380060403; SHULL RM, 1994, P NATL ACAD SCI USA, V91, P12937, DOI 10.1073/pnas.91.26.12937; Starr CM, 1996, J CHROMATOGR A, V720, P295, DOI 10.1016/0021-9673(95)00749-0; STULTS NL, 1993, GLYCOBIOLOGY, V3, P589, DOI 10.1093/glycob/3.6.589; SUTTON CW, 1994, ANAL BIOCHEM, V218, P34, DOI 10.1006/abio.1994.1138; TAYLOR JA, 1991, BIOCHEM J, V274, P263, DOI 10.1042/bj2740263; UNGER EG, 1994, BIOCHEM J, V304, P43, DOI 10.1042/bj3040043; VanHove JLK, 1996, P NATL ACAD SCI USA, V93, P65, DOI 10.1073/pnas.93.1.65; ZHAO KW, 1996, FASEB J, V10, pA1108	30	44	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22758	22765		10.1074/jbc.272.36.22758	http://dx.doi.org/10.1074/jbc.272.36.22758			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278435	hybrid			2022-12-27	WOS:A1997XV49200056
J	Halleck, MM; Liu, H; North, J; Stevens, JL				Halleck, MM; Liu, H; North, J; Stevens, JL			Reduction of trans-4,5-dihydroxy-1,2-dithiane by cellular oxidoreductases activates gadd153/chop and grp78 transcription and induces cellular tolerance in kidney epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN (C/EBP)-RELATED GENE; CYSTEINE CONJUGATE TOXICITY; MESSENGER-RNA STABILITY; DNA-DAMAGE; ENDOPLASMIC-RETICULUM; LLC-PK1 CELLS; OXIDATIVE STRESS; REDOX REGULATION; C-FOS; LIPID-PEROXIDATION	Trans-4,5-Dihydroxy-1,2-dithiane, the intramolecular disulfide form of dithiothreitol (DTTox) transcription ally activates the stress-responsive genes gadd153(chop) and grp78, Herein, we used a renal epithelial cell line, LLC-PK1, to investigate the mechanism(s) whereby DTTox activates a molecular stress response, DTTox activated both grp78 and gadd153 transcriptionally, but gadd153 mRNA stability also increased suggesting that both transcriptional and posttranscriptional mechanisms are involved. DTTox did not activate hsp70 transcription indicating that a heat shock response was not induced. Structure-activity studies showed that DTTox analogues lacking the intramolecular disulfide were inactive, Furthermore, the ring-open intermolecular di sulfide form of DTTox, a-hydroxyethyl disulfide, was only a weak inducer of grp78 and gadd153 but was a strong inducer of hsp70 mRNA and a potent oxidant that lowered the NADPH/NADP(+) ratio and depleted reduced glutathione (GSH). DTTox had little effect on the overall GSH and NADPH levels; thus cells were not undergoing oxidative stress; however, the NADPH/NADP(+) ratio decreased slightly indicating that reducing equivalents were consumed. LLC-PK1 cells reduced DTTox to DTT, and the kinetics as well as the concentration dependence for reduction correlated with induction of both grp78 and gadd153 mRNA Prior treatment with DTTox rendered cells tolerant to the potent nephrotoxicant S-(1,1,2,2-tetrafluoroethyl)-L-cysteine. Bacitracin, an inhibitor of plasma membrane oxidoreductases, blocked DTTox reduction and gene activation as well as DTTox induced tolerance, Thus, activation of stress genes and induction of cellular tolerance by DTTox is mediated by a novel mechanism involving cellular oxidoreductases.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946						NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046267, R29DK038965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005569] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38965, DK46267] Funding Source: Medline; NIEHS NIH HHS [ES05569] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHEN Q, 1992, J BIOL CHEM, V267, P24322; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHEN Q, 1990, J BIOL CHEM, V265, P21603; CHEN Q, 1991, ARCH BIOCHEM BIOPHYS, V284, P422, DOI 10.1016/0003-9861(91)90318-D; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FREEMAN ML, 1995, J CELL PHYSIOL, V164, P356, DOI 10.1002/jcp.1041640216; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOMER CJ, 1991, CANCER RES, V51, P6574; GUY GR, 1993, J BIOL CHEM, V268, P2141; HAINAUT P, 1993, CANCER RES, V53, P4469; Halleck MM, 1997, CELL STRESS CHAPERON, V2, P31, DOI 10.1379/1466-1268(1997)002<0031:TMRTRS>2.3.CO;2; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HAYDEN PJ, 1991, J BIOL CHEM, V266, P18415; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JACKMAN J, 1994, CANCER RES, V54, P5656; KIM YK, 1987, MOL CELL BIOL, V7, P2974, DOI 10.1128/MCB.7.8.2974; LEE AS, 1983, J BIOL CHEM, V258, P597; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Liu H, 1996, J BIOL CHEM, V271, P4805; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LUETHY JD, 1994, CANCER RES, V54, pS1902; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUETHY JD, 1992, CANCER RES, V52, P5; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; MATSUOKA M, 1995, KIDNEY INT, V48, P383, DOI 10.1038/ki.1995.306; NAKAMURA K, 1993, ONCOGENE, V8, P3133; PASSONNEAU JV, 1974, METHOD ENZYMAT AN, P2059; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; PRICE BD, 1992, CANCER RES, V52, P3814; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROTHWARF DM, 1992, P NATL ACAD SCI USA, V89, P7944, DOI 10.1073/pnas.89.17.7944; ROY B, 1995, MOL CELL BIOL, V15, P2263; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCOTTO CF, 1970, EXPERIENTIA, V26, P172; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; STEVENS J, 1986, J BIOL CHEM, V261, P3325; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SUGAWARA S, 1993, CANCER RES, V53, P6001; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; UEDA N, 1992, AM J PHYSIOL, V263, pF214, DOI 10.1152/ajprenal.1992.263.2.F214; UEDA N, 1992, J CLIN INVEST, V90, P2593, DOI 10.1172/JCI116154; VAMVAKAS S, 1993, TOXICOL LETT, V67, P161, DOI 10.1016/0378-4274(93)90053-Z; VanDeWater B, 1996, AM J PHYSIOL-RENAL, V270, pF593, DOI 10.1152/ajprenal.1996.270.4.F593; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; YU KF, 1994, J CELL PHYSIOL, V161, P303, DOI 10.1002/jcp.1041610215	67	28	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21760	21766		10.1074/jbc.272.35.21760	http://dx.doi.org/10.1074/jbc.272.35.21760			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268305	hybrid			2022-12-27	WOS:A1997XT85000017
J	Kamitani, T; Nguyen, HP; Yeh, ETH				Kamitani, T; Nguyen, HP; Yeh, ETH			Activation-induced aggregation and processing of the human Fas antigen - Detection with cytoplasmic domain-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; POLY(ADP-RIBOSE) POLYMERASE; MEDIATED APOPTOSIS; TNF RECEPTOR; PROTEOLYTIC CLEAVAGE; SIGNALING COMPLEX; IL-6 RECEPTOR; DEATH DOMAIN; CELL-DEATH; IN-VITRO	Fas (APO1/CD95) is a type 1 transmembrane protein critically involved in receptor-mediated apoptosis. Previous studies have shown that Pas exists in monomeric form in resting cells and aggregates upon cross-linking to form a complex that serves to recruit additional signaling molecules to the cell membrane, To study the molecular fate of the Pas antigen following receptor activation, a monoclonal antibody specific for the cell death domain of Fas has been generated, This monoclonal antibody (3D5) could be used in Western blot analysis using total cell lysates to identify different forms of Fas antigens without immunoprecipitation. High molecular mass (>200 kDa), SDS- and beta-mercaptoethanol-resistant Fas aggregates were formed immediately following receptor cross-linking, and a 97-kDa band (p97) was detected about 2 h later, p97 could be detected by antibodies against either the death domain or the C terminus, However, p97 could not be precipitated by antiextracellular domain antibodies. Thus, p97 most likely represents a processed form of the high molecular weight Fas aggregates, Although p97 generation followed a similar time course as CPP32 activation and poly(ADP-ribose) polymerase cleavage, it could not be inhibited by cysteine protease, calpain, or proteasome inhibitors.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV MOL MED,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,CARDIOVASC RES CTR,INST MOL MED PREVENT HUMAN DIS,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NHLBI NIH HHS [HL-45851] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Estaquier J, 1996, BLOOD, V87, P4959, DOI 10.1182/blood.V87.12.4959.bloodjournal87124959; FRASER A, 1996, CELL, V85, P784; Fujita E, 1996, BIOCHEM BIOPH RES CO, V224, P74, DOI 10.1006/bbrc.1996.0986; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Papoff G, 1996, J IMMUNOL, V156, P4622; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMAS LJ, 1992, J CLIN INVEST, V89, P1172, DOI 10.1172/JCI115700; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	29	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22307	22314		10.1074/jbc.272.35.22307	http://dx.doi.org/10.1074/jbc.272.35.22307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268381	hybrid			2022-12-27	WOS:A1997XT85000093
J	TonThat, H; Faull, KF; Schneewind, O				TonThat, H; Faull, KF; Schneewind, O			Anchor structure of staphylococcal surface proteins - A branched peptide that links the carboxyl terminus of proteins to the cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; PENICILLIN-BINDING PROTEINS; ESCHERICHIA-COLI; MUREIN-LIPOPROTEIN; MASS-SPECTROMETRY; PEPTIDOGLYCAN COMPOSITION; SEQUENCE-ANALYSIS; TEICHOIC-ACIDS; AUREUS STRAIN; IDENTIFICATION	Surface proteins of Staphylococcus aureus are anchored to the cell wall by a mechanism requiring a COOH-terminal sorting signal, Previous work demonstrated that the sorting signal is cleaved at the conserved LPXTG motif and that the carboxyl of threonine (T) is linked to the staphylococcal cell wall. By employing different cell wall lytic enzymes, surface proteins were released from the staphylococcal peptidoglycan and their COOH-terminal anchor structure was revealed by a combination of mass spectrometry and chemical analysis, The results demonstrate that surface proteins are linked to a branched peptide (NH2-Ala-gamma-Gln-Lys-(NH2-Gly(5))-Ala-COOH) by an amide bond be tween the carboxyl of threonine and the amino of the pentaglycine cross-bridge that is attached to the epsilon-amino of lysyl, This branched anchor peptide is amide-linked to the carboxyl of N-acetylmuramic acid, thereby tethering the COOH-terminal end of surface proteins to the staphylococcal peptidoglycan.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOL BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PSYCHIAT & BIOBEHAV SCI, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Ton-That, Hung/AAB-6155-2020	Ton-That, Hung/0000-0003-1611-0469	NIAID NIH HHS [AI 33985, AI 38897] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033985, R01AI038897] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON JS, 1965, P NATL ACAD SCI USA, V53, P881, DOI 10.1073/pnas.53.4.881; ARAKI Y, 1989, CRIT REV MICROBIOL, V17, P121, DOI 10.3109/10408418909105745; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BRAUN V, 1970, EUR J BIOCHEM, V14, P387, DOI 10.1111/j.1432-1033.1970.tb00301.x; BRAUN V, 1974, ANNU REV BIOCHEM, V43, P89, DOI 10.1146/annurev.bi.43.070174.000513; BRAUN V, 1970, EUR J BIOCHEM, V13, P336, DOI 10.1111/j.1432-1033.1970.tb00936.x; Braun V., 1994, BACTERIAL CELL WALL, P319, DOI 10.1016/S0167-7306(08)60417-2; CHOI DS, 1986, J BIOL CHEM, V261, P8953; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11255; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; ENDL J, 1983, ARCH MICROBIOL, V135, P215, DOI 10.1007/BF00414483; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FOLKENING WJ, 1987, J BACTERIOL, V169, P4223, DOI 10.1128/jb.169.9.4223-4227.1987; FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5; GHUYSEN J. M., 1965, BIOCHEMISTRY, V4, P2245, DOI 10.1021/bi00886a043; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GHUYSEN JM, 1963, BIOCHEMISTRY-US, V2, P1119, DOI 10.1021/bi00905a036; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GHUYSEN JM, 1965, BIOCHEMISTRY-US, V3, P474; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; HANDWERGER S, 1994, J BACTERIOL, V176, P260, DOI 10.1128/JB.176.1.260-264.1994; HANDWERGER S, 1992, J BACTERIOL, V174, P5982, DOI 10.1128/jb.174.18.5982-5984.1992; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878; JONES CL, 1986, J BACTERIOL, V166, P29, DOI 10.1128/jb.166.1.29-33.1986; KEHOE MA, 1994, BACTERIAL CELL WALL, P217; LEE SF, 1992, INFECT IMMUN, V60, P4032, DOI 10.1128/IAI.60.10.4032-4039.1992; MARTIN SA, 1987, J BIOL CHEM, V262, P7514; Navarre WW, 1996, J BACTERIOL, V178, P441, DOI 10.1128/jb.178.2.441-446.1996; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; OSHIDA T, 1995, P NATL ACAD SCI USA, V92, P285, DOI 10.1073/pnas.92.1.285; PANCHOLI V, 1989, J EXP MED, V170, P2119, DOI 10.1084/jem.170.6.2119; PETIT JF, 1966, BIOCHEMISTRY-US, V5, P2764, DOI 10.1021/bi00872a037; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; STROMINGER JL, 1967, SCIENCE, V156, P213, DOI 10.1126/science.156.3772.213; STROMINGER JL, 1967, FED PROC, V26, P9; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TIPPER DJ, 1969, BIOCHEMISTRY-US, V8, P2183, DOI 10.1021/bi00833a060; TIPPER DJ, 1967, BIOCHEMISTRY-US, V6, P906, DOI 10.1021/bi00855a035; TIPPER DJ, 1965, BIOCHEMISTRY-US, V4, P468, DOI 10.1021/bi00879a015; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; WANG X, 1991, GENE, V102, P105; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; YOKOYAMA K, 1986, EUR J BIOCHEM, V161, P479, DOI 10.1111/j.1432-1033.1986.tb10469.x	53	98	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22285	22292		10.1074/jbc.272.35.22285	http://dx.doi.org/10.1074/jbc.272.35.22285			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268378	hybrid			2022-12-27	WOS:A1997XT85000090
J	Wang, AJ; Loo, R; Chen, ZL; Dennis, EA				Wang, AJ; Loo, R; Chen, ZL; Dennis, EA			Regiospecificity and catalytic triad of lysophospholipase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE P388D1; PHOSPHOLIPASE A(2); PURIFICATION; SPECIFICITY; LYSOPHOSPHATIDYLCHOLINE; ACETYLCHOLINESTERASE; IDENTIFICATION; DEMYELINATION; MACROPHAGES; HYDROLASE	A 25-kDa murine lysophospholipase (LysoPLA I) has been cloned and expressed, and Ser-119 has been shown to be essential for the enzyme activity (Wang, A., Deems, R. A., and Dennis, E. A. (1997) J. Biol, Chem, 272, 12723-12729). In the present study, we show that LysoPLA I represents a new member of the serine hydrolase family with Ser-119, Asp-174, and His-208 composing the catalytic triad, The Asp-174 and His-208 are conserved among several esterases and are demonstrated herein to be essential for LysoPLA I activity as the mutation of either residue to Ala abolished LysoPLA I activity, whereas the global conformation of the mutants remained unchanged, Furthermore, the predicted secondary structure of LysoPLA I resembles that of the alpha/beta-hydrolase fold, with Ser-119, Asp-174, and His-208 occupying the conserved topological location of the catalytic triad in the alpha/beta-hydrolases. Structural modeling of LysoPLA I also indicates that the above three residues orient in such a manner that they would comprise a charge-relay network necessary for catalysis, In addition, the regiospecificity of LysoPLA I was studied using P-31 NMR, and the result shows that LysoPLA I has similar LysoPLA(1) and LysoPLA(2) activity, This finding suggests that LysoPLA I may play an important role in removing lysophospholipids produced by both phospholipase A(1) and A(2) in vivo.	UNIV CALIF SAN DIEGO,DEPT BIOCHEM & CHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NIGMS NIH HHS [GM 51606] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLT G, 1988, ACTA NEUROPATHOL, V75, P456, DOI 10.1007/BF00687132; AMBUDKAR IS, 1988, MOL CELL BIOCHEM, V79, P81, DOI 10.1007/BF00229401; ANTTINEN H, 1976, BIOCHEM J, V160, P29, DOI 10.1042/bj1600029; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P380; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; KELLY RA, 1986, J BIOL CHEM, V261, P1704; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO RW, 1997, J BIOL CHEM, V271, P19214; LOW PA, 1983, BIOCHIM BIOPHYS ACTA, V754, P298, DOI 10.1016/0005-2760(83)90146-7; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; PLUCKTHUN A, 1982, BIOCHEMISTRY-US, V21, P1743; PLUCKTHUN A, 1985, J BIOL CHEM, V260, P1099; SHAIKH NA, 1981, CIRC RES, V49, P316, DOI 10.1161/01.RES.49.2.316; SHIER WT, 1976, P NATL ACAD SCI USA, V73, P1586, DOI 10.1073/pnas.73.5.1586; SOBEL BE, 1978, J CLIN INVEST, V62, P546, DOI 10.1172/JCI109159; STAFFORD RE, 1988, COLLOID SURFACE, V30, P47; STAFFORD RE, 1993, BIOCHIM BIOPHYS ACTA, V1167, P43, DOI 10.1016/0005-2760(93)90215-U; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; van den Boogaard M, 1988, SCRIPTA GEOLOGICA, V88, P1; Wallace AC, 1996, PROTEIN SCI, V5, P1001; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	31	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22030	22036		10.1074/jbc.272.35.22030	http://dx.doi.org/10.1074/jbc.272.35.22030			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268342	Green Published, hybrid			2022-12-27	WOS:A1997XT85000054
J	Akhter, SA; Milano, CA; Shotwell, KF; Cho, MC; Rockman, HA; Lefkowitz, RJ; Koch, WJ				Akhter, SA; Milano, CA; Shotwell, KF; Cho, MC; Rockman, HA; Lefkowitz, RJ; Koch, WJ			Transgenic mice with cardiac overexpression of alpha(1B)-adrenergic receptors - In vivo alpha(1)-adrenergic receptor-mediated regulation of beta-adrenergic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GENE-EXPRESSION; HYPERTROPHY; STIMULATION; MYOCYTES; IDENTIFICATION; ACTIVATION; INDUCTION; PROMOTER; FAMILY	Transgenic mice were generated with cardiac-specific overexpression of the wild-type (WT) alpha(1B)-adrenergic receptor (AR) using the murine alpha-myosin heavy chain gene promoter, Previously, we described transgenic mice with alpha-myosin heavy chain-directed expression of a constitutively active mutant alpha(1B)-AR that had a phenotype of myocardial hypertrophy (Milano, C, A., Dolber, P. C,, Rockman, H. A., Bond, R. A., Venable M, E,, Alien, L, F,, and Lefkowitz, R, J. (1994) Proc. Natl. Acad. Sci. U,S. A, 91, 10109-10113). In animals with >40-fold WT alpha(1)-AR overexpression, basal myocardial diacylglycerol content was significantly increased, indicating enhanced alpha(1)-adrenergic signaling and phospholipase C activity, In contrast to the mice overexpressing constitutively active mutant alpha(1B)-ARs, the hearts of these mice did not develop cardiac hypertrophy despite an 8-fold increase in ventricular mRNA for atrial natriuretic factor, In vivo physiology was studied in anesthetized intact animals and showed left ventricular contractility in response to the beta-agonist isoproterenol to be significantly depressed in animals overexpressing WT alpha(1B).ARs, Membranes purified from the hearts of WT alpha(1B).AR-overexpressing mice demonstrated significantly attenuated adenylyl cyclase activity basally and after stimulation with isoproterenol, norepinephrine, or phenylephrine, Interestingly, these in vitro changes in signaling were reversed after treating the mice with pertussis toxin, suggesting that the extraordinarily high levels of WT alpha(1B).ARs can lead to coupling to pertussis toxin-sensitive G proteins, Another potential contributor to the observed decreased myocardial signaling and function could be enhanced beta-AR desensitization as beta-adrenergic receptor kinase (beta ARK1) activity was found to be significantly elevated (>3-fold) in myocardial extracts isolated from WT alpha(1B)-AR-overexpressing mice, This type of altered signal transduction may become critical in disease conditions such as heart failure where beta ARK1 levels are elevated and beta-ARs are downregulated, leading to a higher percentage of cardiac alpha(1).Ars. Thus, these mice serve as a unique experimental model to study the in vivo interactions between alpha- and beta-ARs in the heart.	DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute; University of California System; University of California San Diego			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL09436, HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037, F32HL009436] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H; BRODINI A, 1991, BIOCHEM BIOPH RES CO, V174, P869; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; INGLESE J, 1993, J BIOL CHEM, V268, P23735; IWAKI K, 1990, J BIOL CHEM, V265, P13809; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Samama P, 1997, P NATL ACAD SCI USA, V94, P137, DOI 10.1073/pnas.94.1.137; STEINBERG SF, 1985, SCIENCE, V230, P186, DOI 10.1126/science.2994230; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; WEINBERG DH, 1994, BIOCHEM BIOPH RES CO, V201, P1296, DOI 10.1006/bbrc.1994.1845; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; WU DQ, 1992, J BIOL CHEM, V267, P25798	29	124	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21253	21259		10.1074/jbc.272.34.21253	http://dx.doi.org/10.1074/jbc.272.34.21253			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261135	hybrid			2022-12-27	WOS:A1997XR78900045
J	Feussner, I; Balkenhohl, TJ; Porzel, A; Kuhn, H; Wasternack, C				Feussner, I; Balkenhohl, TJ; Porzel, A; Kuhn, H; Wasternack, C			Structural elucidation of oxygenated storage lipids in cucumber cotyledons - Implication of lipid body lipoxygenase in lipid mobilization during germination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULOCYTE LIPOXYGENASE; MAMMALIAN LIPOXYGENASES; FATTY-ACIDS; PHOSPHOLIPIDS; PROTEIN; LIPOPROTEINS; LEUKOCYTE; MEMBRANES; OXIDATION; PLANTS	At early stages of germination, a special lipoxygenase is expressed in cotyledons of cucumber and several other plants, This enzyme is localized at the lipid storage organelles and oxygenates their storage triacylglycerols, We have isolated this lipid body lipoxygenase from cucumber seedlings and found that it is capable of oxygenating in vitro di- and trilinolein to the corresponding mono-, di-, and trihydroperoxy derivatives. To investigate the in vivo activity of this enzyme during germination, lipid bodies were isolated from cucumber seedlings at different stages of germination, and the triacylglycerols were analyzed for oxygenated derivatives by a combination of high pressure liquid chromatography, gas chromatography/mass spectrometry, and nuclear magnetic resonance spectroscopy, We identified as major oxygenation products triacylglycerols that contained one, two, or three 13S-hydroperoxy-9(Z),11(E)-octadecadienoic acid residues, During germination, the amount of oxygenated lipids increased strongly, reaching a maximum after 72 h and declining afterward. The highly specific pattern of hydroperoxy lipids formed suggested the involvement of the lipid body lipoxygenase in their biosynthesis. These data suggest that this lipoxygenase may play an important role during the germination process of cucumber and other plants and support our previous hypothesis that the specific oxygenation of the storage lipids may initiate their mobilization as a carbon and energy source for the growing seedling.	HUMBOLDT UNIV BERLIN,KLINIKUM CHAR,INST BIOCHEM,D-10115 BERLIN,GERMANY	Humboldt University of Berlin	Feussner, I (corresponding author), INST PFLANZENBIOL,WEINBERG 3,D-06120 HALLE,GERMANY.		Feussner, Ivo/H-9320-2013; Porzel, Andrea/B-1423-2014	Feussner, Ivo/0000-0002-9888-7003; Porzel, Andrea/0000-0002-8148-6895				BEEORTZAHAR T, 1995, FEBS LETT, V366, P151, DOI 10.1016/0014-5793(95)00521-A; BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BELKNER J, 1991, FEBS LETT, V279, P110, DOI 10.1016/0014-5793(91)80263-3; Bergey DR, 1996, P NATL ACAD SCI USA, V93, P12053, DOI 10.1073/pnas.93.22.12053; Blee Elizabeth, 1996, P138, DOI 10.1201/9781439831977.ch8; BRASH AR, 1987, BIOCHEMISTRY-US, V26, P5465, DOI 10.1021/bi00391a038; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; FEUSSNER I, 1995, P NATL ACAD SCI USA, V92, P11849, DOI 10.1073/pnas.92.25.11849; FEUSSNER I, 1992, FEBS LETT, V298, P223, DOI 10.1016/0014-5793(92)80062-L; Feussner I, 1997, FEBS LETT, V406, P1, DOI 10.1016/S0014-5793(97)00218-4; FEUSSNER I, 1994, PLANTA, V194, P22, DOI 10.1007/BF00201030; FISKUM G, 1985, PROSTAGLANDINS LEUKO, P87; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; FRANKEL EN, 1990, METHOD ENZYMOL, V186, P380; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; Kuhn H, 1996, PROG LIPID RES, V35, P203, DOI 10.1016/S0163-7827(96)00008-2; KUHN H, 1990, EUR J BIOCHEM, V191, P221, DOI 10.1111/j.1432-1033.1990.tb19113.x; KUHN H, 1990, J BIOL CHEM, V265, P18351; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; MACCARRONE M, 1994, BBA-BIOMEMBRANES, V1190, P164, DOI 10.1016/0005-2736(94)90046-9; MATSUI K, 1995, LIPIDS, V30, P733, DOI 10.1007/BF02537800; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; RAO SI, 1994, J BIOL CHEM, V269, P7210; Rosahl S, 1996, Z NATURFORSCH C, V51, P123; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SEMBDNER G, 1993, ANNU REV PLANT PHYS, V44, P569, DOI 10.1146/annurev.pp.44.060193.003033; SHIBATA D, 1995, J LIPID MEDIAT CELL, V12, P213, DOI 10.1016/0929-7855(95)00020-Q; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; STAHL U, 1995, PLANT PHYSIOL, V107, P953, DOI 10.1104/pp.107.3.953; TAKAHASHI Y, 1993, EUR J BIOCHEM, V218, P165, DOI 10.1111/j.1432-1033.1993.tb18362.x; Upston JM, 1996, J LIPID RES, V37, P2650; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Wang CX, 1997, PHYSIOLOGY, BIOCHEMISTRY AND MOLECULAR BIOLOGY OF PLANT LIPIDS, P268; WEITZEL F, 1993, J BIOL CHEM, V268, P6288; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	38	66	70	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21635	21641		10.1074/jbc.272.34.21635	http://dx.doi.org/10.1074/jbc.272.34.21635			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261186	hybrid			2022-12-27	WOS:A1997XR78900096
J	Ji, CH; Casinghino, S; McCarthy, TL; Centrella, M				Ji, CH; Casinghino, S; McCarthy, TL; Centrella, M			Multiple and essential Sp1 binding sites in the promoter for transforming growth factor-beta type I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	18th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research	SEP 07-11, 1996	SEATTLE, WA	Amer Soc Bone & Mineral Res			TRANSCRIPTION FACTOR FAMILY; GENE; REGION; EXPRESSION; PROTEIN; MEMBERS; IDENTIFICATION; PURIFICATION; BONE	Maximal gene expression driven by the promoter for the transforming growth factor beta type I receptor (TGF-beta RI) occurs with a 1.0-kilobase pair fragment immediately upstream of exon 1, This region lacks a typical TATA box but contains CCAAT boxes, multiple Spl, and PEBP2/CBF alpha binding sites among other possible cis-acting elements, Alterations within two CCAAT box sequences do not mitigate reporter gene expression driven by the basal promoter, and no nuclear factor binds to oligonucleotides encompassing these sites, In contrast, other deletions or site-specific mutations reveal an essential Sal site in the basal promoter and several dispersed upstream Spl sites that contribute to maximal reporter gene expression, The proportions of transcription factors Sp1 and Sp3, and their ratios of binding to consensus Elements, are maintained in bone cells at different stages of differentiation, Finally, nuclear factor that binds to PEBP2/CBF alpha-related cis-acting elements in the basal promoter sequence also occurs in osteoblasts. Our studies reveal that constitutive expression of TGF-beta RI may be determined by constitutive nuclear factor binding to Spl sites, whereas other elements may account for the variations in TGF-beta RI levels that parallel. changes in bane cell differentiation or activity.	YALE UNIV, SCH MED, DEPT SURG, SECT PLAST SURG, NEW HAVEN, CT 06520 USA	Yale University					NIAMS NIH HHS [AR-39201] Funding Source: Medline; NIDDK NIH HHS [DK-47421] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039201, R01AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1987, J BIOL CHEM, V262, P16186; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; CENTRELLA M, 1995, HORMONAL REGULATION, P211; CHEN XR, 1994, ONCOGENE, V9, P3179; COOKE DW, 1991, BIOCHEM BIOPH RES CO, V177, P1113, DOI 10.1016/0006-291X(91)90654-P; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hiebert SW, 1996, CURR TOP MICROBIOL, V211, P253; HUMPHRIES DE, 1994, BIOCHEM BIOPH RES CO, V203, P1020, DOI 10.1006/bbrc.1994.2284; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; Ji CH, 1996, J CELL BIOCHEM, V63, P478; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lian J B, 1993, J Oral Implantol, V19, P95; MAJELLO B, 1995, ONCOGENE, V10, P1841; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; PANG JHS, 1995, J BIOL CHEM, V270, P14123, DOI 10.1074/jbc.270.23.14123; SAITO H, 1992, BIOCHEM BIOPH RES CO, V183, P688, DOI 10.1016/0006-291X(92)90537-U; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SIF S, 1993, ONCOGENE, V8, P2501; Sjottem E, 1996, J VIROL, V70, P188; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; YE K, 1993, P NATL ACAD SCI USA, V90, P2295, DOI 10.1073/pnas.90.6.2295; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	44	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21260	21267		10.1074/jbc.272.34.21260	http://dx.doi.org/10.1074/jbc.272.34.21260			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	XR789	9261136	hybrid			2022-12-27	WOS:A1997XR78900046
J	Lee, W; Jung, CY				Lee, W; Jung, CY			A synthetic peptide corresponding to the GLUT4 C-terminal cytoplasmic domain causes insulin-like glucose transport stimulation and GLUT4 recruitment in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; TRANSLOCATION; 3-O-METHYLGLUCOSE; MODULATION; SEQUENCE; CONSTANT; PROTEIN; BINDING; SIGNAL	In rat epididymal adipocytes, practically all of the major glucose transporter isoform GLUT4 is constitutively sequestered in intracellular membranes and moves to the plasma membrane in response to insulin, whereas about half of GLUT1, the minor isoform, is constitutively functional at the plasma membrane and thus less affected by insulin, Transfection studies using cells whose glucose transport is normally not regulated by insulin have suggested that the C-terminal cytoplasmic domain of GLUT4 is responsible for its constitutive intracellular sequestration, To test if this was also the case in a classical insulin target cell, we introduced synthetic peptides corresponding to the C-terminal cytoplasmic domain of GLUT4 and GLUT1 (GLUT4C and GLUT1C, respectively) into rat adipocytes and studied their effects on the glucose transport activity and the steady state GLUT4 and GLUT1 distribution between the plasma membrane and intracellular membranes in host cells. GLUT4C introduced into basal adipocytes caused a large (up to 4.5-fold) and dose-dependent increase in the plasma membrane GLUT4, with a proportional reduction in microsomal GLUT4, without affecting GLUT1 distribution, GLUT4C incorporation also caused a large (up to 3-fold) dose-dependent stimulation of 3-O-methyl D-glucose (3OMG) flux in host cells, GLUT4C caused little if any GLUT4 or GLUT1 redistribution and changes in 3OMG flux in insulin-stimulated adipocytes. GLUT1C, on the other hand, did not affect GLUT1 or GLUT4 targeting and 3OMG flux in host cells, These findings not only underscore the importance of the C-terminal cytoplasmic domain of GLUT4 in its constitutive intracellular sequestration in a classical insulin target cell but also suggest the existence of a regulatory protein in adipocytes that interacts with GLUT4 at its cytoplasmic domain, thus participating in the constitutive intracellular sequestration of GLUT4.	VET ADM MED CTR, BIOPHYS LAB, BUFFALO, NY 14215 USA; SUNY BUFFALO, DEPT BIOPHYS SCI, BUFFALO, NY 14215 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Lee, Wan/B-6252-2013	Lee, Wan/0000-0002-5181-2135				ASANO T, 1992, J BIOL CHEM, V267, P19636; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JHUN BH, 1991, J BIOL CHEM, V266, P22260; JO L, 1992, BIOCHIM BIOPHYS ACTA, V1106, P45; JUNG CY, 1973, BIOCHIM BIOPHYS ACTA, V298, P101, DOI 10.1016/0005-2736(73)90014-X; LACHAAL M, 1990, J BIOL CHEM, V265, P15449; LACHAAL M, 1993, J CELL PHYSIOL, V156, P326, DOI 10.1002/jcp.1041560215; LIU HZ, 1995, J BIOL CHEM, V270, P7869, DOI 10.1074/jbc.270.14.7869; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MARTZ A, 1986, J BIOL CHEM, V261, P3606; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; RAMPAL AL, 1995, J BIOL CHEM, V270, P3938, DOI 10.1074/jbc.270.8.3938; SHI YW, 1995, J BIOL CHEM, V270, P21772, DOI 10.1074/jbc.270.37.21772; SHI YW, 1996, DIABETES S2, V45, P93; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276	31	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21427	21431		10.1074/jbc.272.34.21427	http://dx.doi.org/10.1074/jbc.272.34.21427			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261158	hybrid			2022-12-27	WOS:A1997XR78900068
J	Alkhatib, G; Berger, EA; Murphy, PM; Pease, JE				Alkhatib, G; Berger, EA; Murphy, PM; Pease, JE			Determinants of HIV-1 coreceptor function on CC chemokine receptor 3 - Importance of both extracellular and transmembrane/cytoplasmic regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RECOMBINANT VACCINIA VIRUS; ENVELOPE GLYCOPROTEIN; EXPRESSION; IDENTIFICATION; MACROPHAGES; CLONING; RANTES; FUSION; CELLS	The chemokine receptors CXCR4, CCR2b, CCR3, and CCR5 are cell entry coreceptors for HIV-1. Using an HIV-1 envelope (Env) dependent cell-cell fusion model of entry, we show that CCR3 can interact with Envs from certain macrophage (M)-tropic strains (which also use CCR5), T cell line (TCL)-tropic laboratory-adapted strains (which also use CXCR4), and a dual tropic primary isolate (which also uses CCR2b, CCR5, and CXCR4). Paradoxically, CCR1 is the closest homologue to CCR3 (63% amino acid identity), but lacked HIV-1 coreceptor activity, These results confirm and extend previous reports, Replacing the N-terminal segment of CCR3 with that of CCR1 abolished activity of the resulting chimera for M-tropic and TCL-tropic Envs, but not for the dual-tropic Env, Replacing extracellular loop 2 of CCR3 with that of CCR1 abolished activity for TCL-tropic Envs, but not for M- and dual-tropic Envs, A chimera containing all four extracellular regions of CCR3 on a backbone of CCR1 lacked any activity, Env-CCR3 interactions were strongly inhibited by the major CCR3 ligand eotaxin, but weakly or not at all by other CCR3 ligands, With primary macrophages, eotaxin induced transient calcium flux and partially inhibited fusion with cells expressing M-tropic Envs. We conclude that specificity determinants for different Envs are located in shared and distinct extracellular regions of CCR3, the transmembrane/cytoplasmic domains make major contributions to coreceptor function, and CCR3 may be used by certain HIV-1 strains as a cell fusion factor on macrophages.	NIAID,HOST DEF LAB,NIH,BETHESDA,MD 20892; NIAID,VIRAL DIS LAB,NIH,BETHESDA,MD 20892; UNIV SHEFFIELD,KREBS INST,DEPT MOL BIOL & BIOTECHNOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Sheffield			Pease, James/X-4521-2018	Pease, James/0000-0003-3749-0341				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1996, J VIROL, V70, P5487, DOI 10.1128/JVI.70.8.5487-5494.1996; ALKHATIB G, 1997, IN PRESS VIROLOGY, V234; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Berger EA, 1997, AIDS, V11, pS3; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COMBADIERE C, 1995, J BIOL CHEM, V270, P30235; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; Connor RI, 1996, J VIROL, V70, P8758, DOI 10.1128/JVI.70.12.8758-8764.1996; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dittmar MT, 1997, NATURE, V385, P495, DOI 10.1038/385495a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LAZDINS JK, 1990, AIDS RES HUM RETROV, V6, P1157, DOI 10.1089/aid.1990.6.1157; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; PEASE JE, 1994, EUR J IMMUNOL, V24, P211, DOI 10.1002/eji.1830240133; Pleskoff O, 1997, J VIROL, V71, P3259, DOI 10.1128/JVI.71.4.3259-3262.1997; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Rana S, 1997, J VIROL, V71, P3219, DOI 10.1128/JVI.71.4.3219-3227.1997; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Sabroe I, 1997, J IMMUNOL, V158, P1361; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	54	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20420	20426		10.1074/jbc.272.33.20420	http://dx.doi.org/10.1074/jbc.272.33.20420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252350	hybrid			2022-12-27	WOS:A1997XR22100020
J	Pearce, KH; Potts, BJ; Presta, LG; Bald, LN; Fendly, BM; Wells, JA				Pearce, KH; Potts, BJ; Presta, LG; Bald, LN; Fendly, BM; Wells, JA			Mutational analysis of thrombopoietin for identification of receptor and neutralizing antibody sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; C-MPL LIGAND; CRYSTAL-STRUCTURE; ANTIGEN INTERACTIONS; HUMAN INTERLEUKIN-4; FUNCTIONAL EPITOPE; CYTOPLASMIC DOMAIN; RESOLUTION; VARIANTS; PROTEINS	Thrombopoietin (TPO) is a hematopoietin important for megakaryocyte proliferation and production of blood platelets, We sought to characterize how TPO binds and activates its receptor, myeloproliferative leukemia virus receptor, The erythropoietin-like domain of TPO (TPO1-153) has been fused to the gIII coat protein of M13 bacteriophage. Forty residues were chosen for mutation to alanine using the criteria that they were charged residues or predicted to be solvent-exposed, based on a homology model, Phage enzyme-linked immunosorbent assay was used to determine affinities for binding to both the TPO receptor and five anti-TPO1-153 monoclonal antibodies, Mutations at mostly positively charged residues (Asp(8), Lys(14), Lys(52), Lys(59), Lys(136), Lys(138), Arg(140)) caused the greatest reduction in receptor-binding affinity. Most of these residues mapped to helices-1 and -4 and a loop region between helix-1 and helix-2. Two of the monoclonal antibodies that blocked TPO binding and bioactivity had determinants in helix-4. In contrast, the other three monoclonal antibodies, which were effective at blocking TPO activity but did not block initial binding of TPO to its receptor, had epitopes predominantly on helix or 3. These results suggest that TPO has two distinct receptor-binding sites that function to dimerize TPO receptors in a sequential fashion.	GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT ANTIBODY & BIOASSAY TECHNOL, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT IMMUNOL, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOISSEL JP, 1993, J BIOL CHEM, V268, P15983; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Feng YP, 1996, J MOL BIOL, V259, P524, DOI 10.1006/jmbi.1996.0337; GREEN JR, 1978, STATISTICAL TREATMEN, pCH7; GURNEY AL, 1995, BLOOD, V85, P981, DOI 10.1182/blood.V85.4.981.bloodjournal854981; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; MARK MR, 1994, J BIOL CHEM, V269, P10720; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; Sadick MD, 1996, ANAL BIOCHEM, V235, P207, DOI 10.1006/abio.1996.0114; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WADA T, 1995, BIOCHEM BIOPH RES CO, V213, P1091, DOI 10.1006/bbrc.1995.2239; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WLODAVER A, 1992, FEBS LETT, V309, P59, DOI 10.1016/0014-5793(92)80739-4	41	42	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20595	20602		10.1074/jbc.272.33.20595	http://dx.doi.org/10.1074/jbc.272.33.20595			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252374	hybrid			2022-12-27	WOS:A1997XR22100044
J	Hughes, CE; Buttner, FH; Eidenmuller, B; Caterson, B; Bartnik, E				Hughes, CE; Buttner, FH; Eidenmuller, B; Caterson, B; Bartnik, E			Utilization of a recombinant substrate rAgg1 to study the biochemical properties of aggrecanase in cell culture systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; ARTICULAR-CARTILAGE; INTERGLOBULAR DOMAIN; MONOCLONAL-ANTIBODIES; CLEAVAGE SITE; PROTEOGLYCAN; CATABOLISM; IDENTIFICATION; DEGRADATION; FRAGMENTS	This paper describes the first report of the production and use of an artificial recombinant protein substrate to study ''aggrecanase'' activity. The substrate (rAgg1) is composed of the complete interglobular domain (IGD) of human aggrecan flanked by the ''marker'' sequences FLAG(TM) at the amino terminus and the human immunoglobulin GI constant region at the carboxyl terminus. The expressed protein occurs as large multimolecular aggregates (>120 kDa) that, upon reduction, consist of a major isoform of 72 kDa (containing the IGD) and a minor 39-kDa species that through alternative splicing has had the IGD deleted. Using this recombinant substrate we developed a novel agarose cell culture system containing either rat chondrosarcoma or bovine chondrocytes that could be used in studies of the biochemical characterization of aggrecanase activities. These studies showed the following. (i) rAgg1 is a suitable substrate for aggrecanase proteolysis. (ii) Aggrecanase activity was specifically induced by exposing chondrocytes to retinoic acid. (iii) A considerable time period was required to synthesize and/or activate aggrecanase, with considerable differences in that found in rat chondrosarcoma versus bovine chondrocyte culture systems. (iv) Aggrecanase cleavage of the aggrecan IGD does not require the presence of the G1 or G2 globular domains or keratan sulfate post-translational modification in the IGD. (v) Aggrecanase is a diffusible activity that does not require association with the chondrocyte plasma membrane or immediate pericellular matrix for its action.	HOECHST AG,TA RHEUMATOL IMMUNOL,D-65174 WIESBADEN,GERMANY	Sanofi-Aventis	Hughes, CE (corresponding author), UNIV WALES COLL CARDIFF,SCH MOL & MED BIOSCI,CONNECT TISSUE BIOL LABS,POB 911,MUSEUM AVE,CARDIFF CF1 3US,S GLAM,WALES.		Hughes, Clare E/A-4526-2010; Caterson, Bruce/A-8085-2010	Caterson, Bruce/0000-0001-6016-0661; Hughes, Clare/0000-0003-4726-5877				ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P205, DOI 10.3109/03008208809016808; AYDELOTTE MB, 1992, CONNECT TISSUE RES, V27, P1; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, ORTHOP T, V17, P677; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; FOSANG AJ, 1991, MATRIX, V11, P17, DOI 10.1016/S0934-8832(11)80223-4; HANDLEY CJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P441, DOI 10.1016/0304-4165(78)90111-3; HANDLEY CJ, 1977, BIOCHIM BIOPHYS ACTA, V500, P132; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Maniglia C. A., 1991, T ORTHOP RES SOC, V16, P193; MORALES TI, 1992, ARCH BIOCHEM BIOPHYS, V293, P79, DOI 10.1016/0003-9861(92)90368-7; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; Saiki R.K., 1989, PCR TECHNOLOGY, P7; SANDY JD, 1978, BIOCHIM BIOPHYS ACTA, V543, P536, DOI 10.1016/0304-4165(78)90308-2; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; TYLER JA, 1985, BIOCHEM J, V225, P493, DOI 10.1042/bj2250493; VALHMU WB, 1995, BIOCHEM J, V309, P535, DOI 10.1042/bj3090535	31	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20269	20274		10.1074/jbc.272.32.20269	http://dx.doi.org/10.1074/jbc.272.32.20269			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242707	hybrid			2022-12-27	WOS:A1997XQ05900094
J	Mandal, A; Wang, YZ; Ernsberger, P; Kester, M				Mandal, A; Wang, YZ; Ernsberger, P; Kester, M			Interleukin-1-induced ether-linked diglycerides inhibit calcium-insensitive protein kinase C isotypes - Implications for growth senescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MESANGIAL CELLS; CANINE KIDNEY-CELLS; PHOSPHOLIPASE-D; EPSILON-ISOFORM; ACTIVATION; ALPHA; DIFFERENTIATION; EXPRESSION; PHOSPHATIDYLCHOLINE; DIACYLGLYCEROLS	It is hypothesized that inflammatory cytokines and vasoactive peptides stimulate distinct species of diglycerides that differentially regulate protein kinase C isotypes, In published data, we demonstrated that interleukin-1, in contrast to endothelin, selectively generates ether-linked diglyceride species (alkyl, acyl- and alkenyl, acylglycerols) in rat mesangial cells, a smooth muscle-like pericyte in the glomerulus. We now demonstrate both in intact cell and in cell-free preparations that these interleukin-l receptor-generated ether-linked diglycerides inhibit immunoprecipitated protein kinase C delta and epsilon but not zeta activity. Neither interleukin-1 not endothelin affect de novo protein expression of these protein kinase C isotypes. As down-regulation of calcium-insensitive protein kinase C isotypes has been linked to antimitogenic activity, we investigated growth arrest as a functional correlate for IL-l-generated ether-linked diglycerides. Cell-permeable ether-linked diglycerides mimic the effects of interleukin-1 to, induce a growth-arrested state in both G-protein-linked receptor- and tyrosine kinase receptor-stimulated mesangial cells. This signaling mechanism implicates cytokine receptor-induced ether-linked diglycerides as second messengers that inhibit the bioactivity of calcium-insensitive protein kinase C isotypes resulting in growth arrest.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA,ON K1A 0R6,CANADA	Case Western Reserve University; Case Western Reserve University; National Research Council Canada			Ernsberger, Paul/O-2702-2014	Ernsberger, Paul/0000-0003-2372-2500	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040225] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40225] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARAKI S, 1994, J BIOCHEM-TOKYO, V115, P245, DOI 10.1093/oxfordjournals.jbchem.a124325; BALDI E, 1994, AM J PHYSIOL, V269, P22574; BERKOVIC D, 1994, EUR J CANCER, V30A, P509, DOI 10.1016/0959-8049(94)90428-6; BISWAS P, 1995, FEBS LETT, V373, P146, DOI 10.1016/0014-5793(95)01025-A; CABOT MC, 1984, BIOCHEM BIOPH RES CO, V125, P163, DOI 10.1016/S0006-291X(84)80349-6; CACACE AM, 1993, ONCOGENE, V8, P2095; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; Coroneos E, 1996, BIOCHEM J, V316, P13, DOI 10.1042/bj3160013; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; FORD DA, 1989, J BIOL CHEM, V264, P13818; GALLELA G, 1992, BIOCHEM PHARMACOL, V44, P715; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; Ganz MB, 1996, AM J PHYSIOL-RENAL, V271, pF108, DOI 10.1152/ajprenal.1996.271.1.F108; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; HEYMANS F, 1987, FEBS LETT, V218, P35, DOI 10.1016/0014-5793(87)81013-X; HUWILER A, 1993, EXP NEPHROL, V1, P19; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; KESTER M, 1994, J BIOL CHEM, V269, P22574; KESTER M, 1993, J CELL PHYSIOL, V156, P317, DOI 10.1002/jcp.1041560214; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; MAHONEY CW, 1993, FASEB J, V7, pA1118; MANGOURA D, 1993, P NATL ACAD SCI USA, V90, P2915, DOI 10.1073/pnas.90.7.2915; MCNAMARA MJC, 1984, BIOCHEM BIOPH RES CO, V122, P824, DOI 10.1016/S0006-291X(84)80108-4; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Motulsky M. D. H., 1995, INTUITIVE BIOSTATIST; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; MUSIAL A, 1995, J BIOL CHEM, V270, P21632, DOI 10.1074/jbc.270.37.21632; PESSINO A, 1995, BIOCHEM J, V312, P549, DOI 10.1042/bj3120549; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; Rzymkiewicz DM, 1996, J BIOL CHEM, V271, P17241, DOI 10.1074/jbc.271.29.17241; SASSAGURI T, 1993, EXP CELL RES, V208, P311; SEDOR JR, 1992, KIDNEY INT, V41, P595, DOI 10.1038/ki.1992.89; STEVENSON FT, 1993, J AM SOC NEPHROL, V4, pA636; WARNE TR, 1995, J BIOL CHEM, V270, P11147, DOI 10.1074/jbc.270.19.11147; WEITZMANN MN, 1992, BIOCHEM BIOPH RES CO, V187, P1166, DOI 10.1016/0006-291X(92)91319-L; WIEDER T, 1995, LIPIDS, V30, P389, DOI 10.1007/BF02536296; Zhou X, 1996, J CLIN INVEST, V98, P937, DOI 10.1172/JCI118877	43	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20306	20311		10.1074/jbc.272.32.20306	http://dx.doi.org/10.1074/jbc.272.32.20306			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242712	hybrid			2022-12-27	WOS:A1997XQ05900099
J	Werman, A; Hollenberg, A; Solanes, G; Bjorbaek, C; VidalPuig, AJ; Flier, JS				Werman, A; Hollenberg, A; Solanes, G; Bjorbaek, C; VidalPuig, AJ; Flier, JS			Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPAR gamma) - Differential activity of PPAR gamma 1 and -2 isoforms and influence of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; GENE-EXPRESSION; PROTEIN-KINASE; ADIPOGENESIS; INDUCTION; APOPTOSIS; PROMOTER; CELLS	Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a member of the nuclear hormone receptor superfamily, and is an important regulator of adipogenesis and adipocyte gene expression. PPAR gamma exists as two isoforms, PPAR gamma 1 and PPAR gamma 2, that differ only in their N termini, Both isoforms are activated by ligands that include the antidiabetic thiazoladinedione drugs and 15-deoxy-Delta(12,14)-prostaglandin J2, and potential differences in their function have yet to be described. We report. that, in addition to a Ligand-activated transcriptional activity, when studied under conditions of ligand depletion, intact PPAR gamma has a ligand-independent activation domain. To identify the basis for this ligand-independent activation, we used GAL4-PPAR gamma chimeric expression constructs and UAS-TK-LUC in CV1 cells and isolated rat adipocytes. In both cell systems, isolated PPAR gamma 1 and PPAR gamma 2 N termini have activation domains, and the activation function of PPAR gamma 2 is 5-6-fold greater than that of PPAR gamma 1. Insulin enhances the transcriptional effect mediated by both PPAR gamma 1 and PPAR gamma 2 N-terminal domains. These data demonstrate that 1) PPAR gamma has an N-terminal (ligand-independent) activation domain; 2) PPAR gamma 1 and PPAR gamma 2 N terminal have distinct activation capacities; and 3) insulin can potentiate the activity of the N-terminal domain of PPAR gamma.	BETH ISRAEL DEACONESS MED CTR,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center			Flier, jeffrey/AAG-6223-2019; Bjorbaek, Christian/S-4727-2019	Vidal-Puig, Antonio/0000-0003-4220-9577	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082, P30DK046200, R01DK028082, K08DK002354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 28082, DK 46200, DK 02354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; DIEKEN ES, 1992, MOL CELL BIOL, V12, P589, DOI 10.1128/MCB.12.2.589; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GULLER S, 1988, ENDOCRINOLOGY, V122, P2084, DOI 10.1210/endo-122-5-2084; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWELL BB, 1990, ENDOCRINOLOGY, V127, P2898, DOI 10.1210/endo-127-6-2898; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKHAM BE, 1990, J BIOL CHEM, V265, P6489; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; OMALLEY BW, 1995, RECENT PROG HORM RES, V50, P333; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; RODBELL M, 1964, J BIOL CHEM, V239, P375; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; VIDALPUIG P, 1997, J CLIN INVEST, V99, P2416; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	35	244	253	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20230	20235		10.1074/jbc.272.32.20230	http://dx.doi.org/10.1074/jbc.272.32.20230			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242701	hybrid			2022-12-27	WOS:A1997XQ05900088
J	Lee, J; Dawes, IW; Roe, JH				Lee, J; Dawes, IW; Roe, JH			Isolation, expression, and regulation of the pgr1(+) gene encoding glutathione reductase absolutely required for the growth of Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YAP-1 TRANSCRIPTIONAL REGULATION; YEAST SACCHAROMYCES-CEREVISIAE; FISSION YEAST; ESCHERICHIA-COLI; OXIDATIVE STRESS; DISULFIDE OXIDOREDUCTASES; RIBONUCLEOTIDE REDUCTASE; GLUTAREDOXIN SYSTEMS; TARGET GENE; THIOREDOXIN	The pgr1(+) C gene encoding glutathione reductase (GR, EC 1.6.4.2) was isolated from Schizosaccharomyces pombe using a polymerase chain reaction fragment as a probe. The gene consists of two exons and an intron of 55 nucleotides, encoding a polypeptide of 465 amino acids (50,238 Da) with conserved residues characteristic of GR. The transcriptional start site was localized at 239 nucleotides upstream from the ATG initiation codon. The level of transcript as well as the GR enzyme activity increased more than 11-fold when the cloned pgr1(+) gene was expressed on a multicopy plasmid. This overexpression conferred on S. pombe cells snore resistance against menadione, a redox cycling agent, but not against H2O2. The level of pgr1(+) transcripts increased by treatment with oxidants such as menadione, cumene hydroperoxide, and diamide. It also increased by treatment with high osmolarity, heat shock, or at the stationary growth phase. The deletion of the pap1(+) C gene encoding an AP-1 homolog in S. pombe caused reduction in tale pgr1(+) gene expression. Furthermore, Delta pap1 cells lost the inducibility of pgr1(+) gene expression by the above stresses, implying that Pap1 is involved in general stress-inducible gene expression. When the pgr1(+) gene was disrupted, the haploid spores were not viable. Repression of nmt1 promoter-driven pgr1(+) expression by thiamine caused cessation of growth, which was rescued by the episomal pgi-IC gene. These results indicate that GR activity, which efficiently reduces GSSG, is essentially required for the growth of S. pombe, unlike in Saccharomyces cerevisiae or Escherichia coli.	SEOUL NATL UNIV, COLL NAT SCI, DEPT MICROBIOL, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, RES CTR MOL MICROBIOL, SEOUL 151742, SOUTH KOREA; UNIV NEW S WALES, SCH BIOCHEM & MOL GENET, SYDNEY, NSW 2052, AUSTRALIA	Seoul National University (SNU); Seoul National University (SNU); University of New South Wales Sydney								ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; CARLBERG I, 1975, J BIOL CHEM, V250, P5475; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; Chesney JA, 1996, J BACTERIOL, V178, P2131, DOI 10.1128/jb.178.7.2131-2135.1996; COLLINSON LP, 1995, GENE, V156, P123, DOI 10.1016/0378-1119(95)00026-3; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V22, P739, DOI 10.1046/j.1365-2958.1996.d01-1727.x; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; GREER S, 1986, BIOCHEMISTRY-US, V25, P2736, DOI 10.1021/bi00357a069; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; KISTLER M, 1990, MUTAGENESIS, V5, P39, DOI 10.1093/mutage/5.1.39; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Lee J, 1995, MICROBIOL-SGM, V141, P3127, DOI 10.1099/13500872-141-12-3127; LOPEZBAREA J, 1990, GLUTATHIONE METABOLI, P105; Manchenko GP., 1994, HDB DETECTION ENZYME, P82; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; MUTOH N, 1988, BIOCHEM BIOPH RES CO, V151, P32, DOI 10.1016/0006-291X(88)90555-4; NAKAGAWA CW, 1995, J BIOCHEM-TOKYO, V118, P109, DOI 10.1093/oxfordjournals.jbchem.a124864; Nasim A., 1989, MOL BIOL FISSION YEA; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSELL P, 1989, MOL BIOL FISSION YEA, P244; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; SMITH IK, 1988, ANAL BIOCHEM, V175, P408, DOI 10.1016/0003-2697(88)90564-7; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TUGGLE CK, 1985, J BACTERIOL, V162, P448, DOI 10.1128/JB.162.1.448-450.1985; TUTIC M, 1990, EUR J BIOCHEM, V188, P523, DOI 10.1111/j.1432-1033.1990.tb15431.x; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; ZHANG MQ, 1994, NUCLEIC ACIDS RES, V22, P1750, DOI 10.1093/nar/22.9.1750	57	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23042	23049		10.1074/jbc.272.37.23042	http://dx.doi.org/10.1074/jbc.272.37.23042			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287302	hybrid			2022-12-27	WOS:A1997XV74400013
J	Jacobsen, R; Yoshikami, D; Ellison, M; Martinez, J; Gray, WR; Cartier, GE; Shon, KJ; Groebe, DR; Abramson, SN; Olivera, RM; McIntosh, JM				Jacobsen, R; Yoshikami, D; Ellison, M; Martinez, J; Gray, WR; Cartier, GE; Shon, KJ; Groebe, DR; Abramson, SN; Olivera, RM; McIntosh, JM			Differential targeting of nicotinic acetylcholine receptors by novel alpha A-conotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONUS PEPTIDES; LIGAND-BINDING; SITES; VENOM; SELECTIVITY; ANTAGONIST; SUBUNIT; PROBES; GI; MI	We describe the isolation and characterization of two peptide toxins from Conus ermimeus venom targeted to nicotinic acetylcholine receptors (nAChRs). The peptide structures have been confirmed by mass spectrometry and chemical synthesis, In contrast to the 12-18 residue, 4 Cys-containing alpha-conotoxins, the new toxins have 30 residues and 6 Cys residues. The toxins, named alpha A-conotoxins EIVA and EIVB, block both Torpedo and mouse alpha 1-containing muscle subtype nAChRs expressed in Xenopus oocytes at low nanomolar concentrations. In contrast to alpha-bungarotoxin, alpha A-EIVA is inactive at alpha 7-containing nAChRs even at micromolar concentrations. In this regard, alpha A-EIVA is similar to the previously described alpha-conotoxins (e.g. alpha-MI and alpha-GI) which also selectively target alpha 1- versus alpha 7-containing nAChRs, However, alpha-MI and alpha-GI discriminate between the alpha/delta versus alpha/gamma subunit interfaces of the mouse muscle nAChR with 10,000-fold selectivity. In contrast, alpha A-conotoxin EIVA blocks both the alpha/gamma site and alpha/delta site with equally high affinity but with distinct kinetics. The alpha A-conotoxins thus represent novel probes for the alpha/gamma as well as the alpha/delta binding sites of the nAChR.	UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT PSYCHIAT,SALT LAKE CITY,UT 84112; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Case Western Reserve University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NIGMS NIH HHS [P01 GM48677] Funding Source: Medline; NIMH NIH HHS [K20 MH0929, MH53631] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053631, K20MH000929, R29MH053631] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CHARNET P, 1992, MOL PHARMACOL, V41, P708; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; GRAY WR, 1983, J BIOL CHEM, V258, P2247; GRAY WR, 1981, J BIOL CHEM, V256, P4734; GROEBE DR, 1995, MOL PHARMACOL, V48, P105; GROEBE DR, 1995, J BIOL CHEM, V270, P281, DOI 10.1074/jbc.270.1.281; Guddat LW, 1996, BIOCHEMISTRY-US, V35, P11329, DOI 10.1021/bi960820h; HANN RM, 1994, BIOCHEMISTRY-US, V33, P14058, DOI 10.1021/bi00251a014; Hille B., 1992, IONIC CHANNELS EXCIT; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; Hu SH, 1996, STRUCTURE, V4, P417, DOI 10.1016/S0969-2126(96)00047-0; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MYERS RA, 1991, BIOCHEMISTRY-US, V30, P9370, DOI 10.1021/bi00102a034; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; SEGUELA P, 1993, J NEUROSCI, V13, P596; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1991, J BIOL CHEM, V266, P13679; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; TAYLOR P, 1983, CURR TOP MEMBR TRANS, V18, P407; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	27	70	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22531	22537		10.1074/jbc.272.36.22531	http://dx.doi.org/10.1074/jbc.272.36.22531			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278406	hybrid			2022-12-27	WOS:A1997XV49200026
J	Jakobsson, PJ; Mancini, JA; Riendeau, D; FordHutchinson, AW				Jakobsson, PJ; Mancini, JA; Riendeau, D; FordHutchinson, AW			Identification and characterization of a novel microsomal enzyme with glutathione-dependent transferase and peroxidase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOTRIENE C-4 SYNTHASE; GUINEA-PIG LUNG; S-TRANSFERASE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; SUBSTRATE-SPECIFICITY; ARACHIDONIC-ACID; PURIFICATION; ACTIVATION; SEQUENCE; BINDING	5-Lipoxygenase activating protein (FLAP), leukotriene-C-4 (LTC4) synthase, and microsomal glutathione S-transferase II (microsomal GST-II) are all members of a common gene family that may also include microsomal GST-I; The present work describes the identification and characterization of a novel member of this family termed microsomal glutathione S-transferase III (microsomal GST-III). The open reading frame encodes a 16.5-kDa protein with a calculated pI of 10.2. Microsomal GST-III has 36, 27, 22, and 20% amino acid identity to microsomal GST-II, LTC, synthase, microsomal GST-I, and FLAP, respectively. Microsomal GST-III also has a similar hydrophobicity pattern to FLAP, LTC, synthase, and microsomal GST-I. Fluorescent in situ hybridization mapped microsomal GST-III to chromosomal localization 1q23. Like microsomal GST-II, microsomal GST-III has a wide tissue distribution (at the mRNA level) and is predominantly expressed in human heart, skeletal muscle, and adrenal cortex, and it is also found in brain, placenta, liver, and kidney tissues. Expression of microsomal GST-III mRNA was also detected in several glandular tissues such as pancreas, thyroid, testis, and ovary. In contrast, microsomal GST-III mRNA expression-was very low (if any) in lung, thymus, and peripheral blood leukocytes. Microsomal GST-III protein was expressed in a baculovirus insect cell system, and microsomes from Sf9 cells containing either microsomal GST-II or microsomal GST-III were both found to possess glutathione-dependent peroxidase activity as shown by their ability to reduce 5-HPETE to 5-HETE in the presence of reduced glutathione. The apparent K-m of 5-HPETE was determined to be approximately 7 mu M for microsomal GST-LI and 21 mu M for microsomal GST-III. Microsomal GST-III was also found to catalyze the production of LTC4 from LTA(4) and reduced glutathione. Based on these catalytic activities it is proposed that this novel membrane protein is a member of the microsomal glutathione S-transferase super family, which also includes microsomal GST-I, LTC4 synthase, FLAP, and microsomal GST-II.	MERCK FROSST CTR THERAPEUT RES,POINTE CLAIRE,PQ H9R 4P8,CANADA	Merck & Company			Jakobsson, Per-Johan/ABC-5594-2021					ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; Andersson C, 1994, Adv Pharmacol, V27, P19, DOI 10.1016/S1054-3589(08)61028-5; AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; DEJONG JL, 1990, GENOMICS, V6, P379, DOI 10.1016/0888-7543(90)90580-N; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; HABIG WH, 1974, J BIOL CHEM, V249, P7130; IZUMI T, 1988, BIOCHIM BIOPHYS ACTA, V959, P305; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MANCINI JA, 1994, LIFE SCI, V54, P137; MANTLE TJ, 1995, BIOCHEM SOC T, V23, P423, DOI 10.1042/bst0230423; MCLELLAN LI, 1989, BIOCHEM J, V258, P87, DOI 10.1042/bj2580087; METTERS KM, 1994, J BIOL CHEM, V269, P12816; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MORGENSTERN R, 1979, BIOCHEM BIOPH RES CO, V87, P657, DOI 10.1016/0006-291X(79)92009-6; MORGENSTERN R, 1984, BIOCHEM PHARMACOL, V33, P3609, DOI 10.1016/0006-2952(84)90145-X; MORGENSTERN R, 1983, EUR J BIOCHEM, V134, P591, DOI 10.1111/j.1432-1033.1983.tb07607.x; MORGENSTERN R, 1988, J BIOL CHEM, V263, P6671; MOSIALOU E, 1995, ARCH BIOCHEM BIOPHYS, V320, P210, DOI 10.1016/0003-9861(95)90002-0; MOSIALOU E, 1993, FEBS LETT, V315, P77, DOI 10.1016/0014-5793(93)81137-O; NICHOLSON DW, 1993, P NATL ACAD SCI USA, V90, P2015, DOI 10.1073/pnas.90.5.2015; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; Otieno MA, 1997, DRUG METAB DISPOS, V25, P12; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scoggan KA, 1997, J BIOL CHEM, V272, P10182; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; SINGHAL SS, 1992, ARCH BIOCHEM BIOPHYS, V299, P232, DOI 10.1016/0003-9861(92)90269-3; SODERSTROM M, 1988, BIOCHEM J, V250, P713, DOI 10.1042/bj2500713; VICKERS PJ, 1992, MOL PHARMACOL, V42, P94; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YOSHIMOTO T, 1988, J CLIN INVEST, V81, P866, DOI 10.1172/JCI113396	36	121	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22934	22939		10.1074/jbc.272.36.22934	http://dx.doi.org/10.1074/jbc.272.36.22934			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278457	hybrid			2022-12-27	WOS:A1997XV49200079
J	Zhao, X; Gschwend, JE; Powell, CT; Foster, RG; Day, KC; Day, ML				Zhao, X; Gschwend, JE; Powell, CT; Foster, RG; Day, KC; Day, ML			Retinoblastoma protein-dependent growth signal conflict and caspase activity are required for protein kinase c-signalled apoptosis of prostate epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; ALTERED EXPRESSION; CDK INHIBITORS; CYCLIN E-CDK2; ALLELIC LOSS; GENE; ACTIVATION; INDUCTION; DEATH; ALPHA	dBoth protein kinase C and the retinoblastoma tumor suppressor protein have been linked to the regulation of cell growth and bell death, suggesting the differential roles these factors play in mediating cell fate, In some cells, protein kinase C-induced activation of the retinoblastoma protein results in G(1) arrest, However, inducible overexpression and activation of the protein kinase C alpha isozyme or the addition of 12-O-tetradecanoylphorbol-13-acetate in the prostate epithelial cell line, LNCaP, resulted in apoptosis preceded by induction of p21 and dephosphorylation of the retinoblastoma protein, Consistent with a role for the retinoblastoma growth suppressor protein in protein kinase C-induced apoptosis, DU145 cells, which do not express functional retinoblastoma protein or LNCaP cells, which have been transfected with the retinoblastoma inhibitor, E1a, were resistant to apoptosis, LNCaP apoptosis was initiated by a unique conflict between the growth-suppressive activity of the retinoblastoma protein and growth-promoting mitogenic signals, Thus, when this conflict was prevented by serum depletion, apoptosis was suppressed, The caspase family of cysteine proteases is believed to encompass the execution machinery of mammalian apoptosis, and addition of the cell-permeable caspase inhibitor, Z-Val-Ala-Asp-fluoromethylketone, afforded nearly total protection from protein kinase C-signaled apoptosis, This protection correlated with the total loss of caspase activity as measured by the proteolytic cleavage of nuclear poly(ADP-ribose) polymerase, On the basis of these results, we propose that protein kinase C regulates a novel cell death pathway that is initiated by a cellular conflict between retinoblastoma growth-suppressive signals and serum mitogenic signals in proliferating prostate epithelial cells and that is executed by the caspase family of cysteine proteases.	DEPT SURG,UROL SECT,ANN ARBOR,MI 48109; UNIV MICHIGAN,CTR COMPREHENS CANC,ANN ARBOR,MI 48109; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; WASHINGTON UNIV,SCH MED,DEPT MED & CELL BIOL,ST LOUIS,MO 63110	University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center; Washington University (WUSTL)					NCI NIH HHS [P50 CA69568] Funding Source: Medline; NIDDK NIH HHS [DK/CA47650] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047650] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; Blagosklonny MV, 1997, CANCER RES, V57, P320; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BROOKS JD, 1995, PROSTATE, V26, P35, DOI 10.1002/pros.2990260108; CLEMENS MJ, 1992, J CELL SCI, V103, P881; Cooney KA, 1996, CANCER RES, V56, P1142; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; DAY ML, 1993, CANCER RES, V53, P5597; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Frey MR, 1997, J BIOL CHEM, V272, P9424; GAO X, 1995, ONCOGENE, V11, P1395; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; Ittmann MM, 1996, HUM PATHOL, V27, P28, DOI 10.1016/S0046-8177(96)90134-3; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; Livneh E, 1996, ONCOGENE, V12, P1545; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MICHIELI P, 1994, CANCER RES, V54, P3391; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; Wang H, 1996, ONCOGENE, V13, P373; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	42	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22751	22757		10.1074/jbc.272.36.22751	http://dx.doi.org/10.1074/jbc.272.36.22751			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278434	hybrid			2022-12-27	WOS:A1997XV49200055
J	Brownawell, AM; Creutz, CE				Brownawell, AM; Creutz, CE			Calcium-dependent binding of sorcin to the N-terminal domain of synexin (annexin VII)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; TYROSINE-PROTEIN-KINASE; CHROMAFFIN GRANULES; CHROMOSOMAL LOCALIZATION; ESCHERICHIA-COLI; LIGHT CHAIN; PURIFICATION; EXPRESSION; SEQUENCE; XI	The annexins are characterized by their ability to bind phospholipid membranes in a Ca2+-dependent manner. Sequence variability between the N-terminal domains of the family members may contribute to the specific cellular function of each annexin. To identify proteins that interact with the N-terminal domain of synexin (annexin VII), a fusion protein was constructed composed of glutathione S-transferase fused to amino acids 1-145 of human synexin, Affinity chromatography using this construct identified sorcin as a Ca2+-dependent synexin-binding protein. Overlay assays confirmed the interaction. The glutathione S-transferase construct associates with recombinant sorcin over the range of pCa(2+) = 4.7-3.1 with no binding observed at pCa(2+) = 5.4. Overlay assays using deletion constructs of the synexin N-terminal domain mapped the sorcin binding site to the N-terminal 31 amino acids of the synexin protein. Additionally, synexin forms a complex with sorcin and recruits this protein to chromaffin granule membranes in a Ca2+-dependent manner. Sorcin is able to inhibit synexin-mediated chromaffin granule aggregation in a manner saturable with increasing sorcin concentrations, but does not influence the Ca2+ sensitivity of synexin-mediated granule aggregation. Therefore, the interaction between sorcin and synexin may serve to regulate the functions of these proteins on membrane surfaces iri a Ca2+-dependent manner.			Brownawell, AM (corresponding author), UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053266] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53266] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownawell AM, 1996, BIOCHEMISTRY-US, V35, P6839, DOI 10.1021/bi952585t; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3798, DOI 10.1073/pnas.86.10.3798; CREUTZ CE, 1979, J BIOL CHEM, V254, P553; CREUTZ CE, 1981, J CELL BIOL, V91, P247, DOI 10.1083/jcb.91.1.247; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CREUTZ CE, 1983, J BIOL CHEM, V258, P4664; CREUTZ CE, 1992, J CELL SCI, V103, P1177; DORING V, 1991, J BIOL CHEM, V266, P17509; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; Fernandez MP, 1996, GENOMICS, V37, P366, DOI 10.1006/geno.1996.0571; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; GREENWOOD M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P429, DOI 10.1016/0167-4781(91)90137-B; Gruenberg Jean, 1993, Trends in Cell Biology, V3, P224, DOI 10.1016/0962-8924(93)90116-I; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMADA H, 1988, CANCER RES, V48, P3173; JOHNSSON N, 1988, FEBS LETT, V236, P201, DOI 10.1016/0014-5793(88)80314-4; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JONGSMA APM, 1987, CANCER RES, V47, P2875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MAGENDZO K, 1991, J BIOL CHEM, V266, P3228; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; MATSUSHIMA N, 1990, PROTEINS, V7, P125, DOI 10.1002/prot.340070204; MEYERS MB, 1987, BIOCHEM PHARMACOL, V36, P2373, DOI 10.1016/0006-2952(87)90606-X; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; MEYERS MB, 1997, BIOPHYS J, V72, pA333; MIZUTANI A, 1995, ARCH BIOCHEM BIOPHYS, V318, P157, DOI 10.1006/abbi.1995.1216; NAKA M, 1994, BBA-MOL CELL RES, V1223, P348, DOI 10.1016/0167-4889(94)90094-9; PAZOLES CJ, 1978, J BIOL CHEM, V253, P3962; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; Srivastava M, 1996, BIOCHEM J, V316, P729, DOI 10.1042/bj3160729; TOKUMITSU H, 1993, ARCH BIOCHEM BIOPHYS, V303, P302, DOI 10.1006/abbi.1993.1287; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; WANG SL, 1995, BBA-GENE STRUCT EXPR, V1260, P285, DOI 10.1016/0167-4781(94)00206-I; WATANABE M, 1993, BIOCHEM BIOPH RES CO, V196, P1376, DOI 10.1006/bbrc.1993.2405; ZHANGKECK ZY, 1993, BIOCHEM J, V289, P735, DOI 10.1042/bj2890735	46	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22182	22190		10.1074/jbc.272.35.22182	http://dx.doi.org/10.1074/jbc.272.35.22182			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268363	hybrid			2022-12-27	WOS:A1997XT85000075
J	Buchholz, CJ; Koller, D; Devaux, P; Mumenthaler, C; SchneiderSchaulies, J; Braun, W; Gerlier, D; Cattaneo, R				Buchholz, CJ; Koller, D; Devaux, P; Mumenthaler, C; SchneiderSchaulies, J; Braun, W; Gerlier, D; Cattaneo, R			Mapping of the primary binding site of measles virus to its receptor CD46	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COFACTOR PROTEIN CD46; EPSTEIN-BARR-VIRUS; AMINO-ACID-RESIDUES; POLIOVIRUS RECEPTOR; SCANNING MUTAGENESIS; CELLULAR RECEPTOR; ATOMIC-STRUCTURE; HUMAN BRAIN; DOMAINS; FUSION	The measles virus (Mn) hemagglutinin binds to the complement control protein (CCP) CD46 primarily through the two external modules, CCP-I and -II, To define the residues involved in binding, 40 amino acids predicted to be solvent-exposed on the CCP-I-II module surface were changed to either alanine or serine, Altered proteins were expressed on the cell surface, and their abilities to bind purified PUN particles, a soluble form of hemagglutinin (sH) and nine CD46-specific antibodies competing to different levels with sH attachment, were measured, All proteins retained, at least in part, PUN and sH binding, but some completely lost binding to certain antibodies. Amino acids essential for binding of antibodies weakly or moderately competing with sH attachment are situated in the membrane-distal tip of CCP-I, whereas residues involved in binding of strongly sH competing antibodies cluster in the center of CCP-I (Arg-25, Asp-27) or in CCP-II (Arg-69, Asp-70). Both clusters face the same side of CCP-I II and map close to amino acid exchanges impairing sH binding (E11A, R29A, P39A, and D70A) or MV binding (D70A and E84A) and to a six-amino acid loop, previously shown to be necessary for sH binding.	UCBI, IVMC, CNRS, UMR 5537, F-69372 LYON 08, FRANCE; ETH HONGGERBERG, INST MOL BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND; UNIV WURZBURG, INST IMMUNOL & VIROL, D-97078 WURZBURG, GERMANY; UNIV TEXAS, MED BRANCH, SEALY CTR STRUCT BIOL, GALVESTON, TX 77555 USA; UNIV ZURICH, INST MOL BIOL, ABT 1, CH-8093 ZURICH, SWITZERLAND	Centre National de la Recherche Scientifique (CNRS); Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Wurzburg; University of Texas System; University of Texas Medical Branch Galveston; University of Zurich			Braun, Werner/A-6642-2012; Gerlier, Denis/L-6094-2014	Gerlier, Denis/0000-0001-5539-456X; Devaux, Patricia/0000-0002-5345-8336; Buchholz, Christian/0000-0002-9837-7345				ADAMS EM, 1991, J IMMUNOL, V147, P3005; AOKI J, 1994, J BIOL CHEM, V269, P8431; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; BERNHARDT G, 1994, VIROLOGY, V203, P344, DOI 10.1006/viro.1994.1493; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Buchholz CJ, 1996, J VIROL, V70, P3716, DOI 10.1128/JVI.70.6.3716-3723.1996; Buchholz CJ, 1996, VIROLOGY, V217, P349, DOI 10.1006/viro.1996.0122; CATTANEO R, 1993, J VIROL, V67, P1493, DOI 10.1128/JVI.67.3.1493-1502.1993; CLARKSON NA, 1995, J VIROL, V69, P5497, DOI 10.1128/JVI.69.9.5497-5501.1995; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Devaux P, 1997, J VIROL, V71, P4157, DOI 10.1128/JVI.71.5.4157-4160.1997; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GERLIER D, 1995, TRENDS MICROBIOL, V3, P338, DOI 10.1016/S0966-842X(00)88972-6; GREWE JM, 1994, CELLULAR RECEPTORS A, P195; HARRISON SC, 1994, COLD SPRING HARBOR M, P33; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; KOLLER D, 1996, THESIS SWISS I TECHN; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; Maisner A, 1996, J VIROL, V70, P4973, DOI 10.1128/JVI.70.8.4973-4977.1996; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; MARTIN DR, 1991, J EXP MED, V174, P1299, DOI 10.1084/jem.174.6.1299; MCCLURE JE, 1992, PROG MED VIROL, V39, P116; MOEBIUS U, 1992, J EXP MED, V176, P507, DOI 10.1084/jem.176.2.507; MOLINA H, 1991, J BIOL CHEM, V266, P12173; MOORE MD, 1991, J VIROL, V65, P3559, DOI 10.1128/JVI.65.7.3559-3565.1991; MORRISON ME, 1994, J VIROL, V68, P2578, DOI 10.1128/JVI.68.4.2578-2588.1994; Mumenthaler C, 1997, PROTEIN SCI, V6, P588; Murakami Y, 1996, BIOL PHARM BULL, V19, P1541; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SCHNEIDERSCHAULIES J, 1995, J VIROL, V69, P2248, DOI 10.1128/JVI.69.4.2248-2256.1995; SEYA T, 1990, J IMMUNOL, V145, P238; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILD TF, 1991, J GEN VIROL, V72, P439, DOI 10.1099/0022-1317-72-2-439; WIMMER E, 1994, COLD SPRING HARBOR M, P1; WIMMER E, 1994, COLD SPRING HARBOR M, P101; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150	43	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22072	22079		10.1074/jbc.272.35.22072	http://dx.doi.org/10.1074/jbc.272.35.22072			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268348	hybrid			2022-12-27	WOS:A1997XT85000060
J	KahnPerles, B; Lipcey, C; Lecine, P; Olive, D; Imbert, J				KahnPerles, B; Lipcey, C; Lecine, P; Olive, D; Imbert, J			Temporal and subunit-specific modulations of the Rel/NF-kappa B transcription factors through CD28 costimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; COLONY-STIMULATING FACTOR; ALPHA-CHAIN GENE; HTLV-I TAX; C-REL; ADHESION MOLECULES; INTERLEUKIN-2 GENE; RESPONSE ELEMENT; SIGNAL-TRANSDUCTION; DOWN-REGULATION	Stimulation of highly purified primary T lymphocytes through CD2 and CD28 adhesion molecules induces a long-term proliferation, dependent on persistent autocrine secretion of interleukin 2 (IL-2), high and prolonged expression of inducible CD25/IL-2 receptor (alpha chain (IL-2R alpha), and secretion of growth factors such as the granulocyte-macrophage colony-stimulating factor (GM-CSF). CD28 costimulation appears to activate cytokine gene expression through conserved KB-related CD28 response (CD28RE) or cytokine 1 (CK-1) elements in addition to canonical NF-KB-binding sites. In this report, we assess: 1) the evolution of the expression, over an 8-day time period, of the Rel/NF-KB family of proteins in costimulated versus TcR/CD3 stimulated primary T cells; 2) the impact of changes on the in vitro occupancy of GM-CSF KB and CK-1, as well as IL-2R alpha KB sites; and 3) the differential regulation of newly synthesized p65 and c-Rel by IKB proteins. We show that CD2 + CD28 stimulation specifically induces, at maximal T cell proliferation phase, sustained nuclear overexpression of NFKB2 p52 and c-Rel subunits which might rely on long-lasting processing of p100 precursor for p52 and increased neosynthesis of c-Rel. This up-regulation correlates with sustained occupancy of GM-CSF KB and CK-1 elements by both proteins. Conversely, these subunits do not appear to bind to the IL-2R alpha KB site. Costimulation, but not TcR/CD3 stimulation, appears supported by sustained down-regulation of both IKB alpha and -beta regulators. Furthermore, contrary to p65, c-Rel appears to display little affinity for p105, p100 and IKB alpha regulators.			KahnPerles, B (corresponding author), INSERM,U119,UNITE CANCEROL EXPT,27 BLVD LEI ROURE,F-13009 MARSEILLE,FRANCE.		Imbert, Jean/AAG-1165-2020; Imbert, Jean/G-3248-2013; Lecine, Patrick/H-9338-2016	Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; Lecine, Patrick/0000-0002-8091-7286				ALGARTE M, 1995, EMBO J, V14, P5060, DOI 10.1002/j.1460-2075.1995.tb00188.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTTIER P, 1985, J IMMUNOL, V135, P1624; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Cantorna MT, 1996, J IMMUNOL, V156, P2674; CERDAN C, 1992, J IMMUNOL, V149, P2255; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; CIVIL A, 1992, EUR J IMMUNOL, V22, P3041, DOI 10.1002/eji.1830221142; COSTELLO R, 1993, EUR J IMMUNOL, V23, P608, DOI 10.1002/eji.1830230304; COSTELLO R, 1993, CELL GROWTH DIFFER, V4, P329; COSTELLO R, 1993, CELL GROWTH DIFFER, V4, P947; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Ghoshal K, 1996, BIOCHEM J, V317, P689, DOI 10.1042/bj3170689; Gilmore TD, 1996, ONCOGENE, V13, P1367; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRUTERS RA, 1991, EUR J IMMUNOL, V21, P167, DOI 10.1002/eji.1830210125; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HANNINK M, 1990, ONCOGENE, V5, P1843; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; Hughes CCW, 1996, J BIOL CHEM, V271, P5369, DOI 10.1074/jbc.271.10.5369; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAI JH, 1994, J BIOL CHEM, V269, P30077; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LANOIX J, 1994, ONCOGENE, V9, P841; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P1601, DOI 10.1002/eji.1830181020; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; MASUDA ES, 1994, BIOCHEM BIOPH RES CO, V205, P1518, DOI 10.1006/bbrc.1994.2839; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MEUER SC, 1983, J EXP MED, V158, P988, DOI 10.1084/jem.158.3.988; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; PIERCE JW, 1995, J IMMUNOL, V155, P1972; PIERRES A, 1988, EUR J IMMUNOL, V18, P685, DOI 10.1002/eji.1830180505; PIMENTELMUINOS FX, 1995, EUR J IMMUNOL, V25, P179, DOI 10.1002/eji.1830250130; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413	64	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21774	21783		10.1074/jbc.272.35.21774	http://dx.doi.org/10.1074/jbc.272.35.21774			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268307	hybrid			2022-12-27	WOS:A1997XT85000019
J	Rameh, LE; Arvidsson, AK; Carraway, KL; Couvillon, AD; Rathbun, G; Crompton, A; VanRenterghem, B; Czech, MP; Ravichandran, KS; Burakoff, SJ; Wang, DS; Chen, CS; Cantley, LC				Rameh, LE; Arvidsson, AK; Carraway, KL; Couvillon, AD; Rathbun, G; Crompton, A; VanRenterghem, B; Czech, MP; Ravichandran, KS; Burakoff, SJ; Wang, DS; Chen, CS; Cantley, LC			A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; HIGH-AFFINITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PH DOMAIN; PHOSPHOLIPASE C-DELTA(1); INOSITOL PHOSPHATES; BILAYER-MEMBRANES; CRYSTAL-STRUCTURE; EXCHANGE FACTOR; DYNAMIN	Pleckstrin homology (PH) and phosphotyrosine binding (PTB) domains are structurally related regulatory modules that are present in a variety of proteins involved in signal transduction, such as kinases, phospholipases, GTP exchange proteins, and adapter proteins. Initially these domains were shown to mediate protein-protein interactions, but more recently they were also found to bind phosphoinositides. Most studies to date have focused on binding of PH domains to phosphatidylinositol (PtdIns)-4-P and PtdIns-4,5-P-2 and have not considered the lipid products of phosphoinositide 3-kinase: PtdIns-3-P, PtdIns-3,4-P-2, and PtdIns-3,4,5-P-3. Here we have compared the phosphoinositide specificity of six different PH domains and the She PTB domain using all five phosphoinositides. We show that the Bruton's tyrosine kinase PH domain binds to PtdIns-3,4,5-P-3 with higher affinity than to PtdIns-4,5-P-2, PtdIns-3,4-P-2 or inositol 1,3,4,5-tetrakisphosphate (Ins-1,3,4,5 P-4). This selectivity is decreased by the rid mutation (R28C). Selective binding of PtdIns-3,4,5 P-3 over PtdIns-4,5-P-2 or PtdIns-3,4-P-2 was also observed for the amino-terminal PH domain of T lymphoma invasion and metastasis protein (Tiam-1), the PH domains of Son-of-sevenless (Sos) and, to a lesser extent, the PH domain of the beta-adrenergic receptor kinase. The oxysterol binding protein and beta-spectrin PH domains bound PtdIns-3,4,5-P-3 and PtdIns-4,5-P-2 with similar affinities. PtdIns-3,4,5-P-3 and PtdIns-4,5-P-2 also bound to the PTB domain of She with similar affinities and lipid binding was competed with phosphotyrosine (Tyr(P)-containing peptides. These results indicate that distinct PH domains select for different phosphoinositides.	BETH ISRAEL HOSP, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01605 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA; UNIV KENTUCKY, COLL PHARM, DIV MED CHEM PHARMACEUT, LEXINGTON, KY 40536 USA; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, BEIRNE CARTER CTR IMMUNOL RES, CHARLOTTESVILLE, VA 22908 USA	Harvard University; Beth Israel Deaconess Medical Center; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Kentucky; University of Virginia; University of Virginia	Rameh, LE (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.		Ravichandran, Kattur Soundarapandian/AAG-7319-2019; Cantley, Lewis C/D-1800-2014	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X; Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [GM41890, GM36624, R01 GM041890, GM 53448] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R01GM053448, R01GM036624, R37GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	42	412	417	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22059	22066		10.1074/jbc.272.35.22059	http://dx.doi.org/10.1074/jbc.272.35.22059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268346	hybrid			2022-12-27	WOS:A1997XT85000058
J	Uren, A; Jakus, J; deMora, JF; Yeudall, A; Santos, E; Gutkind, S; Heidaran, MA				Uren, A; Jakus, J; deMora, JF; Yeudall, A; Santos, E; Gutkind, S; Heidaran, MA			Carboxyl-terminal domain of p27(Kip1) activates CDC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; CDK INHIBITOR; P21; P21(CIP1); BINDING	A variant form of p27 was unexpectedly detected in a synchronized culture of NIH3T3 cells treated with serum. The expression levels of this form of p27 which lacked its amino (NH2)-terminal region reached maximum during G(2)/M phase. Since the appearance of the NH2-terminal truncated form of p27 coincided with increased expression of Cdc2, we hypothesized that p27 may play a role in regulating Cdc2 catalytic activity. To test this hypothesis, wild type p27, as well as the aminoterminal (Np27) and carboxyl-terminal (Cp27), were individually expressed, purified, and examined for their ability to regulate CDC2 kinase activity in vitro, Our data showed that both p27 and Np27 inhibited CDC2 kinase activity. However, in marked contrast, Cp27 enhanced the CDC2 kinase activity. In vitro kinase assays showed that Cp27 and p27 were phosphorylated by CDC2, whereas Np27 was not. In addition, we demonstrated that deletion of the putative CDC2 phosphorylation site in the carboxyl-terminal domain of Cp27 diminished activation of CDC2 kinase activity otherwise stimulated by Cp27. A similar deletion did not have any effect on the inhibitory function of p27. Together these results suggest that the carboxyl-terminal domain of p27 may activate CDC2 kinase activity in vivo during G(2)/M and that this effect may be regulated by serine/threonine phosphorylation.	NCI,NIH,BETHESDA,MD 20892; NIDR,ORAL & PHARYNGEAL CANC BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			de Mora, Jaime Font/H-6304-2015; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; de Mora, Jaime Font/AAK-7591-2021	de Mora, Jaime Font/0000-0002-6816-2095; Gutkind, J. Silvio/0000-0002-5150-4482; de Mora, Jaime Font/0000-0002-6816-2095				CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jakus J, 1996, ONCOGENE, V12, P2369; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nigg E A, 1991, Semin Cell Biol, V2, P261; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; PINES J, 1990, New Biologist, V2, P389; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8	25	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21669	21672		10.1074/jbc.272.35.21669	http://dx.doi.org/10.1074/jbc.272.35.21669			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268291	hybrid			2022-12-27	WOS:A1997XT85000003
J	Dittmar, KD; Demady, DR; Stancato, LF; Krishna, P; Pratt, WB				Dittmar, KD; Demady, DR; Stancato, LF; Krishna, P; Pratt, WB			Folding of the glucocorticoid receptor by the heat shock protein (hsp) 90-based chaperone machinery - The role of p23 is to stabilize receptor-hsp90 heterocomplexes formed by hsp90-p60-hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PROGESTERONE-RECEPTOR; STEROID-RECEPTOR; COMPLEX; RECONSTITUTION; BINDING; IDENTIFICATION; STI1; P50	In cytosols from animal and plant cells, the abundant heat shock protein hsp90 is associated with several proteins that act together to assemble steroid receptors into receptor-hsp90 heterocomplexes. We have reconstituted a minimal receptor hsp90 assembly system containing four required components, hsp90, hsp70, p60, and p23 (Dittmar, K, D,, Hutchison, K, A., Owens-Grille, J, IG,, and Pratt, W, B, (1996) J, Biol. Chem, 271, 12833-12839), We have shown that hsp90, p60, and hsp70 are sufficient for carrying out the folding change that converts the glucocorticoid receptor (GR) hormone binding domain (HBD) from a non-steroid binding to a steroid binding conformation, but to form stable GR hsp90 heterocomplexes, p23 must also be present in the incubation mix (Dittmar, K, D,, and Pratt, W, B. (1997) J, Biol, Chem. 272, 13047-13054), In this work, we show that addition of p23 to native GR.hsp90 heterocomplexes immunoadsorbed from L cell cytosol or to GR.hsp90 heterocomplexes prepared with the minimal (hsp90.p60.hsp70) assembly system inhibits both receptor heterocomplex disassembly and loss of steroid binding activity, p23 stabilizes the GR.hsp90 heterocomplex in a dynamic and ATP-independent manner. In contrast to hsp90 that is bound to the GR, free hsp90 binds p23 in an ATP-dependent manner, and hsp90 in the hsp90 p60 hsp70 heterocomplex is in a conformation that does not bind p23 at all, The effect of p23 in the minimal GR heterocomplex assembly system is to stabilize GR.hsp90 heterocomplexes once they are formed and it does not appear to affect the rate of heterocomplex assembly, Molybdate has the same ability as p23 to stabilize GR heterocomplexes with mammalian hsp90, but GR heterocomplexes with plant hsp90 are stabilized by p23 and not by molybdate, We propose that incubation of the GR.with hsp90 p60]hsp70 forms a GR hsp90 heterocomplex in which hsp90 is in an ATP-dependent conformation, The ATP dependent conformation of hsp90 is required for the hormone binding domain to have a steroid binding site, and binding of p23 to that state of hsp90 stabilizes the GR.hsp90 heterocomplex to inactivation and disassembly.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV WESTERN ONTARIO,DEPT PLANT SCI,LONDON,ON N6A 5B7,CANADA	University of Michigan System; University of Michigan; Western University (University of Western Ontario)				Krishna, Priti/0000-0001-6394-3012	NIDDK NIH HHS [DK31573] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KRISHNA P, 1995, PLANT PHYSIOL, V107, P915, DOI 10.1104/pp.107.3.915; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OwensGrillo JK, 1996, BIOCHEMISTRY-US, V35, P15249, DOI 10.1021/bi9615349; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Stancato LF, 1996, BIOCHEMISTRY-US, V35, P554, DOI 10.1021/bi9511649; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007	34	213	221	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21213	21220		10.1074/jbc.272.34.21213	http://dx.doi.org/10.1074/jbc.272.34.21213			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261129	hybrid			2022-12-27	WOS:A1997XR78900039
J	Takayama, TK; Fujikawa, K; Davie, EW				Takayama, TK; Fujikawa, K; Davie, EW			Characterization of the precursor of prostate-specific antigen - Activation by trypsin and by human glandular kallikrein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SEMINAL PLASMA; PROTEIN-C INHIBITOR; PLASMINOGEN-ACTIVATOR; ESCHERICHIA-COLI; RADICAL PROSTATECTOMY; SERINE PROTEINASE; HUMAN-SEMEN; CANCER; MARKER; SERUM	The precursor or zymogen form of prostate specific antigen (pro-PSA) is composed of 244 amino acid residues including an amino-terminal propiece of 7 amino acids. Recombinant pro-PSA was expressed in Escherichia coli, isolated from inclusion bodies, refolded, and purified. The zymogen was readily activated by trypsin at a weight Patio of 50:1 to generate PSA, a serine protease that cleaves the chromogenic chymotrypsin substrate 3-carbomethoxypropionyl-L-arginyl-L-prolyl-L-tyrosine-p-nitroaniline-HCl (S-2586). In this activation, the amino-terminal propiece Ala-Pro-Leu-Ile-Leu-Ser-Arg was released by cleavage at the Arg-ne peptide bond. The recombinant pro-PSA was also activated by recombinant human glandular kallikrein, another prostate-specific serine protease, as well as by a partially purified protease(s) from seminal plasma, The recombinant PSA was inhibited by alpha 1-antichymotrypsin, forming an equimolar complex with a molecular mass of approximately 100 kDa, The recombinant PSA failed to activate single chain urokinase-type plasminogen activator, in contrast to the recombinant hK2, which readily activated single chain urokinase-type plasminogen activator, These results indicate that pro-PSA is converted to an active serine protease by minor proteolysis analogous to the activation of many of the proteases present in blood, pancreas, and other tissues. Furthermore, PSA is probably generated by a cascade system involving a series of precursor proteins. These proteins may interact in a stepwise manner similar to the generation of plasmin during fibrinolysis or thrombin during blood coagulation.	UNIV WASHINGTON,DEPT UROL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Takayama, TK (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,BOX 357350,SEATTLE,WA 98195, USA.				NHLBI NIH HHS [HL16919] Funding Source: Medline; NIDDK NIH HHS [DK02447] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002447] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA K, 1987, FEBS LETT, V225, P168, DOI 10.1016/0014-5793(87)81151-1; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHAUDHURI JB, 1994, ANN NY ACAD SCI, V721, P374, DOI 10.1111/j.1749-6632.1994.tb47409.x; CHRISTENSSON A, 1990, EUR J BIOCHEM, V194, P755, DOI 10.1111/j.1432-1033.1990.tb19466.x; CLEMENTS JA, 1994, MOL CELL ENDOCRINOL, V99, pC1, DOI 10.1016/0303-7207(94)90138-4; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; Cramer SD, 1996, J UROLOGY, V156, P526, DOI 10.1016/S0022-5347(01)65919-6; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Deperthes D, 1995, BBA-GEN SUBJECTS, V1245, P311, DOI 10.1016/0304-4165(95)00118-2; ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E; Hara M, 1972, Nihon Hoigaku Zasshi, V26, P85; HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3; Iki, 1969, NIPPON HOIGAKU ZASSH, V23, P333; Iwamura M, 1996, UROLOGY, V48, P317, DOI 10.1016/S0090-4295(96)00182-3; KEER HN, 1991, PROSTATE, V18, P201, DOI 10.1002/pros.2990180303; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE PH, 1989, J UROLOGY, V141, P873; LAURELL M, 1992, J CLIN INVEST, V89, P1094, DOI 10.1172/JCI115689; LI TS, 1973, FERTIL STERIL, V24, P134; LIJNEN HR, 1986, J BIOL CHEM, V261, P1253; LILJA H, 1991, CLIN CHEM, V37, P1618; LILJA H, 1987, J CLIN INVEST, V80, P281, DOI 10.1172/JCI113070; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; LOVGREN J, 1997, J UROL S4, V157; LUNDWALL A, 1987, FEBS LETT, V214, P317, DOI 10.1016/0014-5793(87)80078-9; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; ORSINI G, 1978, J BIOL CHEM, V253, P3453; ORSINI G, 1991, EUR J BIOCHEM, V195, P691, DOI 10.1111/j.1432-1033.1991.tb15755.x; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PAPSIDERO LD, 1981, J NATL CANCER I, V66, P37; PARRIES G, 1996, J UROLOGY, V155, P507; RIEGMAN PHJ, 1989, FEBS LETT, V247, P123, DOI 10.1016/0014-5793(89)81253-0; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; SCHNEIDER K, 1989, BIOL CHEM H-S, V370, P353, DOI 10.1515/bchm3.1989.370.1.353; SENSABAUGH GF, 1978, J FORENSIC SCI, V23, P106; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STENMAN UH, 1991, CANCER RES, V51, P222; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; WANG MC, 1979, INVEST UROL, V17, P159; WANG MC, 1981, PROSTATE, V2, P89, DOI 10.1002/pros.2990020109; WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166; WINKLER ME, 1986, BIOCHEMISTRY-US, V25, P4041, DOI 10.1021/bi00362a008; Yoshida E, 1995, INT J CANCER, V63, P863, DOI 10.1002/ijc.2910630618; YU JX, 1994, J BIOL CHEM, V269, P18843	53	197	213	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21582	21588		10.1074/jbc.272.34.21582	http://dx.doi.org/10.1074/jbc.272.34.21582			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261179	hybrid			2022-12-27	WOS:A1997XR78900089
J	Berlett, BS; Stadtman, ER				Berlett, BS; Stadtman, ER			Protein oxidation in aging, disease, and oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CATALYZED OXIDATION; PROTEOLYSIS; ENZYME; AGE; MECHANISM; DAMAGE; SUSCEPTIBILITY; DEGRADATION; RADIOLYSIS; SYNTHETASE		NHLBI, BIOCHEM LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AGARWAL S, 1993, BIOCHEM BIOPH RES CO, V194, P1203, DOI 10.1006/bbrc.1993.1950; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Berlett BS, 1996, P NATL ACAD SCI USA, V93, P1776, DOI 10.1073/pnas.93.5.1776; Berlett BS, 1996, FASEB J, V10, P585; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CHOCK PB, 1996, PR MED BIOL, V4, P201; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Dreyfus J C, 1978, Curr Top Cell Regul, V14, P243; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; GARLAND D, 1988, OXYGEN RADICALS BIOL, P347; GARRISON WM, 1962, RADIAT RES, V16, P483, DOI 10.2307/3571084; GARRISON WM, 1987, CHEM REV, V87, P381, DOI 10.1021/cr00078a006; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; GRANT AJ, 1993, FREE RADICAL RES COM, V18, P259, DOI 10.3109/10715769309147493; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; KRISTAL BS, 1992, J GERONTOL, V47, pB107, DOI 10.1093/geronj/47.4.B107; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MONNIER VM, 1995, MCBU, P141; NAKAMURA K, 1985, ARCH BIOCHEM BIOPHYS, V240, P319, DOI 10.1016/0003-9861(85)90037-2; Oliver C.N., 1982, CYTOCHROME P 450 BIO, P531; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; RIVETT AJ, 1986, CURR TOP CELL REGUL, V28, P291; ROTHSTEIN M, 1977, MECH AGEING DEV, V6, P241, DOI 10.1016/0047-6374(77)90025-2; SCHUENSTEIN E, 1979, CIBA FDN SERIES, V67, P225; SCHUESSLER H, 1984, INT J RADIAT BIOL, V45, P267, DOI 10.1080/09553008414550381; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; SOHAL RS, 1993, BIOCHEM BIOPH RES CO, V196, P7, DOI 10.1006/bbrc.1993.2208; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; SOHAL RS, 1995, MECH AGEING DEV, V81, P15, DOI 10.1016/0047-6374(94)01578-A; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STARKE PE, 1987, FASEB J, V1, P36, DOI 10.1096/fasebj.1.1.2886388; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; SUAREZ G, 1995, ARCH BIOCHEM BIOPHYS, V321, P209, DOI 10.1006/abbi.1995.1387; SWALLOW AJ, 1960, RAD CHEM ORGANIC COM, P211; TAKAHASHI R, 1990, ARCH BIOCHEM BIOPHYS, V277, P228, DOI 10.1016/0003-9861(90)90573-H; UCHIDA K, 1990, BIOCHEM BIOPH RES CO, V169, P265, DOI 10.1016/0006-291X(90)91463-3; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; YOUNGMAN LD, 1992, P NATL ACAD SCI USA, V89, P9112, DOI 10.1073/pnas.89.19.9112; Yu CE, 1997, AM J HUM GENET, V60, P330; ZHOU JQ, 1991, J GERONTOL, V46, pB217, DOI 10.1093/geronj/46.6.B217	49	2575	2667	12	250	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20313	20316		10.1074/jbc.272.33.20313	http://dx.doi.org/10.1074/jbc.272.33.20313			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252331	hybrid			2022-12-27	WOS:A1997XR22100001
J	vantVeer, C; Kalafatis, M; Bertina, RM; Simioni, P; Mann, KG				vantVeer, C; Kalafatis, M; Bertina, RM; Simioni, P; Mann, KG			Increased tissue factor-initiated prothrombin activation as a result of the Arg(506)->Gln mutation in factor V-LEIDEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	37th Annual Meeting of the American-Society-of-Hematology	DEC 01-05, 1995	SEATTLE, WA	Amer Soc Hematol			PEPTIDE-BOND CLEAVAGES; PROTEIN-C RESISTANCE; FACTOR-XA; BLOOD-COAGULATION; FACTOR VA(R506Q); FACTOR PATHWAY; RISK FACTOR; FACTOR-IX; INACTIVATION; THROMBIN	The effect of the Arg(506) --> Gln mutation in factor V-LEIDEN on thrombin generation was evaluated in a reconstituted system using the purified components of the tissue factor (TF) pathway to thrombin and the components of the protein C pathway, Recombinant full-length tissue factor pathway inhibitor (RTFPI) was included in the system because of a previously observed synergistic inhibitory effect of TFPI and the protein C pathway on TF-initiated thrombin generation, Thrombin generation initiated by 1.25 pM factor VIIa.TF in the absence of the protein C pathway components occurs following an initiation phase, after which prothrombin is quantitatively converted to 1.4 mu M thrombin, The factor V-LEIDEN mutation did not influence thrombin generation in the reconstituted model in the absence of the protein C pathway, In the presence of 2.5 nM TFPI, 65 nM protein C, and 10 nar recombinant soluble thrombomodulin (Tm), thrombin generation catalyzed by normal factor V was abolished after the initial formation of 25 nM thrombin, In contrast, persistent thrombin generation was observed in the presence of factor V-LEIDEN in the same system, although the rate of thrombin generation was slower compared with the reaction without protein C and Tm, The rate of thrombin generation with factor V-LEIDEN increased with time and ultimately resulted in quanti tative prothrombin activation, When the TFPI concentration was reduced to 1.25 nM, thrombin generation is still curtailed in the presence of normal factor V, In contrast, under similar conditions using factor V-LEIDEN, the protein C pathway totally failed to down-regulate thrombin generation. The dramatic effect of a 50% reduction in TFPI concentration on the inhibitory potential of the protein C pathway on thrombin generation catalyzed by factor V-LEIDEN suggests that the observed synergy between TFPI and the protein C pathway is directly governed by the TFPI concentration and by cleavage of the factor Va heavy chain at Arg(506). This cleavage appears to have a dramatic regulatory effect in the presence of low concentrations of TFPI, Markedly increased thrombin generation in the presence of both 1.25 nM TFPI and factor V-LEIDEN was also observed when antithrombin-III was added to the system to complete the natural set of coagulation inhibitors, Protein S (300 nM) had a minimal effect in the model on the inhibition of thrombin generation by protein C, Tm, and TFPI, with either normal factor V or factor V-LEIDEN. Protein S also failed to significantly potentiate the action of the protein C pathway in the presence of antithrombin-III in reactions employing normal factor V or factor V-LEIDEN. The absence of an effect of protein S in the model, which employs saturating concentrations of phospholipid, suggests that the reported interactions of protein S with coagulation factors are not decisive in the reaction, Altogether the data predict that TFPI levels in the lower range of normal values are a risk factor for thrombosis when combined with the Arg(506) --> Gln mutation in factor V-LEIDEN.	UNIV VERMONT,DEPT BIOCHEM,BURLINGTON,VT 05405; UNIV LEIDEN HOSP,CTR HEMOSTASIS & THROMBOSIS RES,NL-2300 RC LEIDEN,NETHERLANDS; UNIV PADUA,IST SEMEIOT MED,I-35100 PADUA,ITALY	University of Vermont; Leiden University; Leiden University Medical Center (LUMC); University of Padua			SIMIONI, PAOLO/AAC-5438-2022; Simioni, Paolo/AAC-5416-2022; Bertina, Rogier/AGQ-5246-2022	SIMIONI, PAOLO/0000-0002-6744-383X; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703, R37HL034575] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL-34575, HL-46703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLAJCHMAN MA, 1992, BLOOD, V80, P2159; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; GRIFFIN JH, 1992, BLOOD, V79, P3203; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; HEEB MJ, 1994, P NATL ACAD SCI USA, V91, P2728, DOI 10.1073/pnas.91.7.2728; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; Huang Z.-F., 1996, Blood, V88, p470A; IKEDA K, 1985, THROMB RES, V39, P297, DOI 10.1016/0049-3848(85)90225-7; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; KOELEMAN BPC, 1994, BLOOD, V84, P1031; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; MANN KG, 1992, SEMIN HEMATOL, V29, P213; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; NOVOTNY WF, 1991, BLOOD, V78, P387; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PRATT CM, 1991, HEMOSTASIS SEMIN HEM, V28, P2; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P350; Van't Veer Cornelis, 1995, Blood, V86, p614A; vanBoven HH, 1996, THROMB HAEMOSTASIS, V75, P417; vantVeer C, 1997, J BIOL CHEM, V272, P4367, DOI 10.1074/jbc.272.7.4367; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/blood.V85.12.3518.bloodjournal85123518	42	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20721	20729		10.1074/jbc.272.33.20721	http://dx.doi.org/10.1074/jbc.272.33.20721			9	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252393	hybrid			2022-12-27	WOS:A1997XR22100063
J	Jang, YJ; Won, MS; Chung, KS; Kim, DU; Hoe, KL; Park, C; Yoo, HS				Jang, YJ; Won, MS; Chung, KS; Kim, DU; Hoe, KL; Park, C; Yoo, HS			A novel protein, Psp1, essential for cell cycle progression of Schizosaccharomyces pombe is phosphorylated by Cdc2-Cdc13 upon entry into G(0)-like stationary phase of cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; S-PHASE; DEPENDENT KINASES; SACCHAROMYCES-CEREVISIAE; CDK INHIBITORS; DIVISION CYCLE; G1 PHASE; MITOSIS; GENE; FAMILY	A novel gene, psp1(+), which functionally complements a temperature-sensitive mutant defective in cell cycle progression both in G(1)/S and G(2)/M has been isolated from the genomic and cDNA libraries of Schizosaccharomyces pombe, Disruption of this gene is lethal for cell growth at 30 degrees C indicating that it is an essential gene for vegetative cell growth, Western analysis of the protein by polyclonal antibody made from glutathione S-transferase-Psp1 fusion protein indicated that the Psp1 protein exists in two different molecular weight forms depending on the growth state of the cell, In vitro experiments with a phosphatase showed that this difference is due to phosphorylation. The dephosphorylated form of the protein is dominant in actively growing cells whereas the phosphorylated form becomes the major species when cells enter the stationary phase, The Cdc2-Cdc13 complex is shown to phosphorylate the GST-Psp1 fusion protein in vitro, and site-directed mutagenesis and phosphoamino acid analysis indicated that the serine residue at position 333 in the carboxyl-terminal region is required for phosphorylation. In situ fluorescein isothiocyanate-conjugated antibody staining showed that this protein tends to be localized to both ends of the cell upon entry into the stationary phase of cell growth, However, overexpression of the novel protein Psp1 in actively growing cells inhibits cell growth causing accumulation of DNA (4n or 8n), Thus we speculate that Psp1 can function at both G(1)/S and G(2)/M phases complementing the defect of the new mutant we have isolated, It is likely that Psp1 is required both for proper DNA replication and for the process of mitosis.	KIST, KOREA RES INST BIOSCI & BIOTECHNOL, CELL CYCLE & SIGNAL RES UNIT, TAEJON 305600, SOUTH KOREA; KOREA ADV INST SCI & TECHNOL, DEPT BIOL SCI, TAEJON 305608, SOUTH KOREA	Korea Institute of Science & Technology (KIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST)			Park, Chankyu/C-1936-2011	Hoe, Kwang Lae/0000-0002-3943-4549				ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; ALFA CE, 1990, J CELL SCI, V96, P71; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CLACKSON T, 1991, PCR PRACTICAL APPROA, P201; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Gutz H., 1974, HDB GENETICS, V1, P395; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; JANG YJ, 1994, MOL CELLS, V4, P419; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MACNEIL SA, 1993, CELL CYCLE PRACTICAL, P93; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MITCHISON JM, 1971, EXP CELL RES, V69, P244, DOI 10.1016/0014-4827(71)90337-5; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARK SK, 1995, BBA-GENE STRUCT EXPR, V1262, P87, DOI 10.1016/0167-4781(95)00063-M; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TODA T, 1981, J CELL SCI, V52, P271; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHUO S, 1993, J BIOL CHEM, V268, P17754	77	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19993	20002		10.1074/jbc.272.32.19993	http://dx.doi.org/10.1074/jbc.272.32.19993			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242669	hybrid			2022-12-27	WOS:A1997XQ05900056
J	Kooijman, M; Bloemendal, M; Traub, P; vanGrondelle, R; vanAmerongen, H				Kooijman, M; Bloemendal, M; Traub, P; vanGrondelle, R; vanAmerongen, H			Transient electric birefringence study of intermediate filament formation from vimentin and glial fibrillary acidic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; COILED-COIL MOLECULES; INTEGRAL-EQUATIONS; KERATIN FILAMENTS; EPIDERMAL KERATIN; ROD DOMAIN; DESMIN; MOUSE; MECHANISM; INVITRO	Mg2+-induced polymerization of type III intermediate filament proteins vimentin and glial fibrillary acidic protein was studied by transient electric birefringence. In the absence of MgCl2 we found a net permanent dipole moment, similar to 45-nm-long dimers for vimentin, similar to 65-nm-long tetramers, hexamers, and possibly octamers for both proteins, and 100-nm aggregates for glial fibrillary acidic protein. Controlled oligomerization occurred after the addition of MgCl2. Although the solutions contained (small) aggregates of different sizes, more or less discrete steps in polymer formation were observed, and it was possible to discriminate between an increase in width and length. At the first stage of polymerization (in 0.3 mM MgCl2 for vimentin and 0.2 mM MgCl2 for glial fibrillary acidic protein), the permanent dipole moment disappeared without a change in length of the particles. At higher MgCl2 concentrations, structures of approximately 100 nm were formed, which strongly tended to laterally assemble into full-width intermediate filament structures consisting of about 32 monomers. This contrasts with previous models where first full-width (similar to 10-nm) aggregates are formed, which then increase in length. Subsequently, two discrete elongation steps of 35 nm are observed that increase the length to 135 and 170 nm, respectively. Possible structural models are suggested for the polymerization.	FREE UNIV AMSTERDAM,DEPT PHYS & ASTRON,NL-1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM,INST MOL BIOL SCI,NL-1081 HV AMSTERDAM,NETHERLANDS; MAX PLANCK INST CELL BIOL,D-68526 LADENBURG,GERMANY	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Max Planck Society			van Amerongen, Herbert/J-9483-2016	van Amerongen, Herbert/0000-0002-9783-2895				AEBI U, 1983, J CELL BIOL, V97, P1131, DOI 10.1083/jcb.97.4.1131; AEBI U, 1988, PROTOPLASMA, V145, P73, DOI 10.1007/BF01349341; BROERSMA S, 1981, J CHEM PHYS, V74, P6989, DOI 10.1063/1.441071; BROERSMA S, 1960, J CHEM PHYS, V32, P1626, DOI 10.1063/1.1730994; EICHNER R, 1985, ANN NY ACAD SCI, V455, P381, DOI 10.1111/j.1749-6632.1985.tb50424.x; FREDERICQ E, 1973, ELECTRIC DICHROISM E; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEISLER N, 1993, FEBS LETT, V323, P63, DOI 10.1016/0014-5793(93)81449-A; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; IP W, 1985, J MOL BIOL, V183, P365, DOI 10.1016/0022-2836(85)90007-5; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; KOOIJMAN M, 1994, J MOL BIOL, V236, P1241, DOI 10.1016/0022-2836(94)90024-8; KOOIJMAN M, 1995, J BIOL CHEM, V270, P2931, DOI 10.1074/jbc.270.7.2931; KOOIJMAN M, 1995, FEBS LETT, V358, P185, DOI 10.1016/0014-5793(94)01419-2; MANDELKERN M, 1981, J MOL BIOL, V152, P153, DOI 10.1016/0022-2836(81)90099-1; PARRY DAD, 1995, PROTEINS, V22, P267, DOI 10.1002/prot.340220307; Parry DAD, 1996, INT J BIOL MACROMOL, V19, P45, DOI 10.1016/0141-8130(96)01099-9; POTSCHKA M, 1990, EUR J BIOCHEM, V190, P503, DOI 10.1111/j.1432-1033.1990.tb15602.x; Provencher S. W., 1976, Journal of Chemical Physics, V64, P2772, DOI 10.1063/1.432601; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1976, BIOPHYS J, V16, P27, DOI 10.1016/S0006-3495(76)85660-3; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; QUINLAN RA, 1982, P NATL ACAD SCI-BIOL, V79, P3452, DOI 10.1073/pnas.79.11.3452; QUINLAN RA, 1986, J MOL BIOL, V192, P337, DOI 10.1016/0022-2836(86)90369-4; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1993, BIOCHEMISTRY-US, V32, P10046, DOI 10.1021/bi00089a021; STEINERT PM, 1993, J BIOL CHEM, V268, P24916; STEINERT PM, 1993, J BIOL CHEM, V268, P2878; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1991, J STRUCT BIOL, V107, P157, DOI 10.1016/1047-8477(91)90019-S; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; VANHAERINGEN B, 1992, J BIOMOL STRUCT DYN, V9, P991, DOI 10.1080/07391102.1992.10507972; VORGIAS CE, 1983, BIOCHEM BIOPH RES CO, V115, P68, DOI 10.1016/0006-291X(83)90969-5; Weast RC, 1971, HDB CHEM PHYS, pC528; YANG ZW, 1988, BIOCHEMISTRY-US, V27, P7045, DOI 10.1021/bi00418a056; ZAKFROFF RV, 1979, P NATL ACAD SCI USA, V76, P6226	41	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22548	22555		10.1074/jbc.272.36.22548	http://dx.doi.org/10.1074/jbc.272.36.22548			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278408	hybrid, Green Published			2022-12-27	WOS:A1997XV49200028
J	Surya, A; Knox, BE				Surya, A; Knox, BE			Modulation of opsin apoprotein activity by retinal - Dark activity of rhodopsin formed at low temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PHOTORECEPTOR-MEMBRANES; TRANSDUCIN ACTIVATION; METARHODOPSIN-II; G-PROTEIN; CONFORMATIONAL-CHANGES; ROD PHOTORECEPTORS; BINDING-SITE; PHOTOTRANSDUCTION; ADAPTATION; ANALOGS	The bovine opsin apoprotein activates transducin, although at a much reduced level than light-activated rhodopsin (Surya, A., Foster, K., and Knox, B, (1995) J, Biol, Chem, 270, 5024-5031), The ability of retinal to modulate opsin apoprotein activity was investigated using a guanyl nucleotide exchange assay on transducin. 11-cis-Retinal reacted with opsin at 22 degrees C to (a) reform pigment having maximal absorbance at 500 nm and (b) reduce opsin activity by > 80%. Pigment formation also occurred at 0 degrees C with a t(1/2) of 260 min, However, unlike rhodopsin formed at 22 degrees C (R-22), th, rhodopsin formed at 0 degrees C (R-0) activated transducin with the same half saturating concentration as opsin in an exhaustive binding assay, Thus, the formation of a protonated Schiff base associated with 500 nm absorbance does not by itself lead to the inactivation of opsin. The R-0 conformation was partially inactivated by incubation at 22 degrees C (t(1/2) = 61 +/- 9 min), suggesting that it may be an intermediate conformation in the regeneration of rhodopsin.	SUNY HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,DEPT OPHTHALMOL,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NEI NIH HHS [EY09409, EY11256] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011256, R01EY009409, R55EY009409] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; ARNIS S, 1994, J BIOL CHEM, V269, P23879; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BALOGHNAIR V, 1982, STEREOCHEMISTRY, P283; BARLOW HB, 1964, VISION RES, V4, P47, DOI 10.1016/0042-6989(64)90031-8; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BRIN KP, 1977, J GEN PHYSIOL, V69, P97, DOI 10.1085/jgp.69.1.97; BUBIS J, 1990, J BIOL CHEM, V265, P12995; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; CATT M, 1982, BIOCHEM SOC T, V10, P343, DOI 10.1042/bst0100343; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; CORNWALL MC, 1990, J GEN PHYSIOL, V96, P345, DOI 10.1085/jgp.96.2.345; CORSON DW, 1990, P NATL ACAD SCI USA, V87, P6823, DOI 10.1073/pnas.87.17.6823; DAEMEN FJM, 1978, NATURE, V276, P847, DOI 10.1038/276847a0; DEGRIP WJ, 1973, BIOCHIM BIOPHYS ACTA, V325, P315, DOI 10.1016/0005-2728(73)90107-2; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HENSELMAN RA, 1976, BIOCHEMISTRY-US, V15, P5321, DOI 10.1021/bi00669a019; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HOFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60, DOI 10.1016/0005-2728(83)90224-4; HUBBARD R, 1958, J GEN PHYSIOL, V42, P259, DOI 10.1085/jgp.42.2.259; JIN J, 1993, NEURON, V11, P513, DOI 10.1016/0896-6273(93)90155-K; JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; LAMB TD, 1980, NATURE, V287, P349, DOI 10.1038/287349a0; LEIBROCK CS, 1994, VISION RES, V34, P2787, DOI 10.1016/0042-6989(94)90048-5; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; MATSUMOTO H, 1975, NATURE, V258, P523, DOI 10.1038/258523a0; MATSUMOTO H, 1978, BIOCHIM BIOPHYS ACTA, V501, P257, DOI 10.1016/0005-2728(78)90031-2; OKADA D, 1989, PHOTOCHEM PHOTOBIOL, V49, P197, DOI 10.1111/j.1751-1097.1989.tb04096.x; OTTOLENGHI M, 1989, J MEMBRANE BIOL, V112, P193, DOI 10.1007/BF01870951; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PEPPERBERG DR, 1978, J GEN PHYSIOL, V71, P369, DOI 10.1085/jgp.71.4.369; PEPPERBERG DR, 1987, EXP EYE RES, V45, P41; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RUSHTON WAH, 1961, J PHYSL, V156, P195; SAKAMOTO T, 1995, P NATL ACAD SCI USA, V92, P249, DOI 10.1073/pnas.92.1.249; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; SURYA A, 1994, BIOPHYS J, V66, pA47; THORGEIRSSON TE, 1993, BIOCHEMISTRY-US, V32, P13861, DOI 10.1021/bi00213a015; TOWNER P, 1981, EUR J BIOCHEM, V117, P353, DOI 10.1111/j.1432-1033.1981.tb06345.x; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; YOSHIZAWA T, 1983, BIOPHYS STRUCT MECH, V9, P245, DOI 10.1007/BF00535660; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0	54	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21745	21750		10.1074/jbc.272.35.21745	http://dx.doi.org/10.1074/jbc.272.35.21745			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268303	hybrid			2022-12-27	WOS:A1997XT85000015
J	Thomas, D; Bradshaw, RA				Thomas, D; Bradshaw, RA			Differential utilization of ShcA tyrosine residues and functional domains in the transduction of epidermal growth factor-induced mitogen-activated protein kinase activation in 293T cells and nerve growth factor-induced neurite outgrowth in PC12 cells - Identification of a new Grb2 center dot Sos1 binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SIGNAL-TRANSDUCTION; FACTOR-RECEPTOR; ADAPTER PROTEIN; SH2 DOMAIN; AUTOPHOSPHORYLATION SITES; PHOSPHOTYROSINE-BINDING; INSULIN-RECEPTOR; TERMINAL DOMAIN; SRC HOMOLOGY-2	By transient expression of both truncated forms of p52(SHCA) and those with point mutations in 293T cells, it has been shown that, in addition to Tyr-317, Tyr-239/240 is a major site of phosphorylation that serves as a docking site for Grb2.Sos1 complexes, In addition, analysis of epidermal growth factor (EGF)-induced activation of mitogen-activated protein kinase in 293T cells showed that the overexpression Shc SH2 or phosphotyrosine binding (PTB) domains of ShcA alone has a more potent negative effect than the overexpression of the forms of ShcA lacking Tyr-317 or Tyr 239/240 or both. In transiently transfected PC12 cells, the ShcA PTB domain and tyrosine phosphorylation in the CH1 domain, especially on Tyr-239/240, are crucial for mediating nerve growth factor (NGF)-induced neurite outgrowth, These findings suggest that the EGF and NGF (TrkA) receptor can utilize Shc in different ways to promote their activity, For EGF-induced mitogen-activated protein kinase activation in 293T cells, both Shc PTB and SH2 domains are essential for optimal activation, indicating that a mechanism independent of Grb2 engagement with Shc may exist, For NGF-induced neurite outgrowth in PC12 cells, Shc PTB plays an essential role, and phosphorylation on Tyr-239/240, but not on Tyr-317, is required.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92697	University of California System; University of California Irvine			Bradshaw, Ralph A/K-1515-2013		NIA NIH HHS [AG09735] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROWE AJ, 1994, ONCOGENE, V9, P537; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEPRONK GJ, 1994, MOL CELL BIOL, V14, P1575; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1995, ONCOGENE, V11, P2525; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; Nakamura T, 1996, ONCOGENE, V13, P1111; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; ROZAKIS AM, 1993, NATURE, V363, P83; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sasaoka T, 1996, J BIOL CHEM, V271, P20082, DOI 10.1074/jbc.271.33.20082; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOLER C, 1994, ONCOGENE, V9, P2207; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VERDERAME MF, 1995, MOL BIOL CELL, V6, P953, DOI 10.1091/mbc.6.8.953; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509	51	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22293	22299		10.1074/jbc.272.35.22293	http://dx.doi.org/10.1074/jbc.272.35.22293			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268379	hybrid			2022-12-27	WOS:A1997XT85000091
J	BenShahar, S; Cassouto, B; Novak, L; Porgador, A; Reiss, Y				BenShahar, S; Cassouto, B; Novak, L; Porgador, A; Reiss, Y			Production of a specific major histocompatibility complex class I-restricted epitope by ubiquitin-dependent degradation of modified ovalbumin in lymphocyte lysate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; PROTEOLYTIC PATHWAY; INTERFERON-GAMMA; 20-S PROTEASOME; PEPTIDES; ANTIGEN; ACTIVATOR; CELLS; PURIFICATION; MOLECULES	Peptide epitopes presented through class I major histocompatability complex (MHC class I) on the cell! surface, are generated by proteolytic processing of protein-antigens in the cytoplasm. The length and amino acid sequence determine whether a given peptide can fit into the peptide binding groove of class I heavy chain molecules and subsequently be presented to the immune system. The mode ai action of the processing pathway Is therefore of great interest. go study the processing mechanism of MHC class I-restricted intracellular antigens, me reconstituted the proteolytic processing of a model antigen in a cell-free system. Incubation of oxidized and urea-treated OVA in lymphocyte lysate resulted in partial degradation of the antigen, Degradation of the antigen depended on the presence of ATP, Addition of methylated ubiquitin abolished the reaction which was then restored by addition of am excess of native ubiquitin, indicating that the breakdown of the antigen in lymphocyte lysate is mediated by the ubiquitin proteolytic system, Upon incubation of modified OVA in lymphocyte lysate, a specific antigenic peptide was generated. The peptide was recognized by cytotoxic T lymphocytes directed against OVA-derived, H-2K(b)-restricted peptide (SIINFEKL), and by st monoclonal antibody that recognizes cell-bound K-b-SIINFEKL complexes. Formation of the peptide epitope depended on the presence of ATP and ubiquitin. These results indicate that proteolytic processing of modified OVA is carried out by the ubiquitin-mediated degradation system. The experimental system described provides a tool to analyze else molecular mechanisms underlying the generation of specific, MHC class I-restricted peptide epitopes.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL; NIAID,LYMPHOCYTE BIOL SECT,IMMUNOL LAB,BETHESDA,MD 20892	Tel Aviv University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Porgador, Angel/0000-0003-1540-4449				AKIYAMA K, 1994, FEBS LETT, V343, P85, DOI 10.1016/0014-5793(94)80612-8; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DICK LR, 1994, J IMMUNOL, V152, P3884; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Frisan T, 1996, INT J CANCER, V68, P251, DOI 10.1002/(SICI)1097-0215(19961009)68:2<251::AID-IJC19>3.0.CO;2-D; GRANT EP, 1995, J IMMUNOL, V155, P3750; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; MA CP, 1994, J BIOL CHEM, V269, P3539; Michalek MT, 1996, J IMMUNOL, V157, P617; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOTT JD, 1994, J BIOL CHEM, V269, P31466; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; REALINI C, 1994, J BIOL CHEM, V269, P20727; RESTIFO NP, 1995, J IMMUNOL, V154, P4414; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TANAKA K, 1988, J BIOL CHEM, V263, P16209; Tobery TW, 1997, J EXP MED, V185, P909, DOI 10.1084/jem.185.5.909; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	43	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21060	21066		10.1074/jbc.272.34.21060	http://dx.doi.org/10.1074/jbc.272.34.21060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261108	hybrid			2022-12-27	WOS:A1997XR78900018
J	Chatterjee, R; Allen, RM; Ludden, PW; Shah, VK				Chatterjee, R; Allen, RM; Ludden, PW; Shah, VK			In vitro synthesis of the iron-molybdenum cofactor and maturation of the nif-encoded apodinitrogenase - Effect of substitution of VNFH for NIFH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND ALTERNATIVE NITROGENASE; AZOTOBACTER-VINELANDII; MUTATIONAL ANALYSIS; STRUCTURAL GENES; FEMO-COFACTOR; KLEBSIELLA-PNEUMONIAE; VANADIUM NITROGENASE; NUCLEOTIDE-SEQUENCE; PROTEIN; DINITROGENASE	NIFH (the nifH gene product) has several functions in the nitrogenase enzyme system. In addition to reducing dinitrogenase during nitrogenase turnover, NIFH functions in the biosynthesis of the iron-molybdenum cofactor (FeMo-co), and in the processing of alpha(2) beta(2) apodinitrogenase 1 (a catalytically inactive form of dinitrogenase 1 that lacks the FeMo-co) to the FeMo-co-activatable alpha(2) beta(2) gamma(2) form, The molybdenum-independent nitrogenase 2 (unf-encoded) has a distinct dinitrogenase reductase protein, VNFH, We investigated the ability of VNFH to function in the in vitro biosynthesis of FeMo-co and in the maturation of apodinitrogenase 1. VNFH can replace NIFH in both the biosynthesis of FeMo-co and in the maturation of apodinitrogenase 1. These results suggest that the dinitrogenase reductase proteins do not specify the heterometal incorporated into the cofactors of the respective nitrogenase enzymes, The specificity for the incorporation of molybdenum into FeMo-co was also examined using the in vitro FeMo-co synthesis assay system.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA; UNIV WISCONSIN, COLL AGR & LIFE SCI, CTR STUDY NITROGEN FIXAT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; Allen RM, 1996, J BIOL CHEM, V271, P4256; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; ARBER JM, 1989, BIOCHEM J, V258, P733, DOI 10.1042/bj2580733; BISHOP PE, 1990, ANNU REV PLANT PHYS, V41, P109; BISHOP PE, 1986, SCIENCE, V232, P92, DOI 10.1126/science.232.4746.92; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CHATTERJEE R, 1994, J BACTERIOL, V176, P2747, DOI 10.1128/JB.176.9.2747-2750.1994; Chatterjee R, 1996, J BIOL CHEM, V271, P6819, DOI 10.1074/jbc.271.12.6819; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; Davis R, 1996, J BACTERIOL, V178, P1445, DOI 10.1128/jb.178.5.1445-1450.1996; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; EADY RR, 1991, ADV INORG CHEM, V36, P77, DOI 10.1016/S0898-8838(08)60037-9; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GOLLAN U, 1993, EUR J BIOCHEM, V215, P25, DOI 10.1111/j.1432-1033.1993.tb18003.x; HALES BJ, 1986, J BIOL CHEM, V261, P5301; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; JOERGER RD, 1986, J BACTERIOL, V168, P673, DOI 10.1128/jb.168.2.673-682.1986; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; JOERGER RD, 1989, J BACTERIOL, V171, P1075, DOI 10.1128/jb.171.2.1075-1086.1989; KENNEDY C, 1992, MOL GEN GENET, V231, P494, DOI 10.1007/BF00292722; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LUDDEN PW, 1978, BIOCHEM J, V175, P251, DOI 10.1042/bj1750251; LUQUE F, 1991, MOL GEN GENET, V227, P481, DOI 10.1007/BF00273941; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V292, P246, DOI 10.1016/0005-2728(73)90269-7; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; SMITH BE, 1988, BIOCHEM J, V250, P299, DOI 10.1042/bj2500299; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; UGALDE RA, 1985, J BACTERIOL, V164, P1081, DOI 10.1128/JB.164.3.1081-1087.1985; WOLFINGER ED, 1991, J BACTERIOL, V173, P7565, DOI 10.1128/jb.173.23.7565-7572.1991; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; Wright DW, 1996, J BIOL INORG CHEM, V1, P143, DOI 10.1007/s007750050033	42	19	22	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21604	21608		10.1074/jbc.272.34.21604	http://dx.doi.org/10.1074/jbc.272.34.21604			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261182	hybrid			2022-12-27	WOS:A1997XR78900092
J	Oh, IH; Reddy, EP				Oh, IH; Reddy, EP			Murine A-myb gene encodes a transcription factor, which cooperates with Ets-2 and exhibits distinctive biochemical and biological activities from c-myb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATORY DOMAIN; PROGENITOR-CELL LINE; DNA-BINDING ACTIVITY; V-MYB; MYELOID-LEUKEMIA; INDUCED-DIFFERENTIATION; HEMATOPOIETIC-CELLS; LYMPHOCYTES-T; MIM-1 GENE; B-MYB	The myb gene family consists of three members, named A-, B-, and c-myb, which encode nuclear proteins that bind to DNA and function as regulators of transcription, Our results show that murine A-myb is a poor transactivator of transcription compared with murine c-myb, Deletion of the COOH-terminal domain of A-Myb, or co-expression with Ets-a resulted in increased transactivation potential, While ectopic overexpression of c-myb in 32Dcl3 cells results in a block to the ability of these cells to undergo terminal differentiation resulting in indefinite growth in granulocyte-colony-stimulating,a factor (G-CSF), similar overexpression of A-myb results in growth arrest and concomitant terminal differentiation of 32D cells into granulocytes. Go-expression of A-myb and ets-2 in these cells results in the restoration of the proliferative activity of the cells in G-CSF, but fails to induce a block to G-CSF-induced terminal differentiation. However, overexpression of the COOH-terminal deletion mutant of A-myb results in a block to G-CSF-induced differentiation of 32D cells, suggesting that the distinctive biological phenotypes produced by A-myb and c-myb genes are mediated by their COOH-terminal domains.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOL BIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011					ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, P1061; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FOOS G, 1994, ONCOGENE, V9, P2481; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Golay J, 1996, BLOOD, V87, P1900; GOLAY J, 1994, ONCOGENE, V9, P2469; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HU YL, 1991, ONCOGENE, V6, P1549; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KUEHL WM, 1988, CURR TOP MICROBIOL, V141, P318; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; METTUS RV, 1994, ONCOGENE, V9, P3077; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Mink S, 1996, MOL CELL BIOL, V16, P1316; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; Patel G, 1996, ONCOGENE, V13, P1197; PAUZA CD, 1987, MOL CELL BIOL, V7, P342, DOI 10.1128/MCB.7.1.342; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REED JC, 1987, ONCOGENE, V1, P223; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROVERA G, 1989, ANN NY ACAD SCI, V567, P154, DOI 10.1111/j.1749-6632.1989.tb16467.x; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	54	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21432	21443		10.1074/jbc.272.34.21432	http://dx.doi.org/10.1074/jbc.272.34.21432			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261159	hybrid			2022-12-27	WOS:A1997XR78900069
J	Zhang, DH; Cohn, L; Ray, P; Bottomly, K; Ray, A				Zhang, DH; Cohn, L; Ray, P; Bottomly, K; Ray, A			Transcription factor GATA-3 is differentially expressed murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CD4+ LYMPHOCYTES-T; RECEPTOR-ALPHA; MESSENGER-RNA; ASTHMA; ENHANCER; CAMP; PROMOTER; ELEMENTS; ANTIGEN	Interleukin-5 (IL-5), which is produced by CD4(+) T helper 2 (Th2) cells, but not by Th1 cells, plays a key role in the development of eosinophilia in asthma. Despite increasing evidence that the outcome of many diseases is determined by the ratio of the two subsets of CD4(+) T helper cells, Th1 and Th2, the molecular basis for Th1- and Th2-specific gene expression remains to be elucidated. We previously established a critical role for the transcription factor GATA-3 in IL-5 promoter activation in EL-4 cells, which express both Th1- and Th2-type cytokines. Our studies reported here demonstrate that GATA-3 is critical for expression of the IL-5 gene in bona fide Th2 cells, Whereas mutations in the GATA-3 site abolished antigen- or cAMP-stimulated IL-5 promoter activation in Th2 cells, ectopic expression of GATA-3 in Th1 cells or in a nonlymphoid, non-IL-5-producing cell line activated the IL-5 promoter. During the differentiation of naive CD4(+) T cells isolated from T cell receptor transgenic mice, GATA-3 gene expression was up-regulated in developing Th2 cells, but was down-regulated in Th1 cells, and antigen- or cAMP-activated Th2 cells (but not Th1 cells) expressed the GATA-3 protein. Thus, GATA-3 may play an important role in the balance between Th1 and Th2 subsets in immune responses. Inhibition of GATA-3 activity has therapeutic potential in the treatment of asthma and other hypereosinophilic diseases.	YALE UNIV, SCH MED, DEPT INTERNAL MED, PULM & CRIT CARE SECT, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, IMMUNOBIOL SECT, NEW HAVEN, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University; Yale University					NHLBI NIH HHS [P50 HL56389, HL52014] Funding Source: Medline; NIAID NIH HHS [AI31137] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056389, R29HL052014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031137] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Amato SF, 1996, J IMMUNOL, V157, P146; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; DAVYDOV IV, 1995, J IMMUNOL, V155, P5273; Feuerstein N, 1996, J IMMUNOL, V156, P4582; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; Hattori N, 1996, J EXP MED, V184, P1137, DOI 10.1084/jem.184.3.1137; HENDERSON AJ, 1994, MOL CELL BIOL, V14, P4286, DOI 10.1128/MCB.14.6.4286; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KAMEI T, 1993, AM J RESP CELL MOL, V9, P378, DOI 10.1165/ajrcmb/9.4.378; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; KRISHNASWAMY G, 1993, AM J RESP CELL MOL, V9, P279, DOI 10.1165/ajrcmb/9.3.279; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE HJ, 1993, J IMMUNOL, V151, P6135; LiWeber M, 1997, J IMMUNOL, V158, P1194; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Nakamura T, 1997, J IMMUNOL, V158, P1085; NOMA T, 1989, J EXP MED, V169, P1853, DOI 10.1084/jem.169.5.1853; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAY A, 1991, P NATL ACAD SCI USA, V88, P7086, DOI 10.1073/pnas.88.16.7086; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; SMITH VM, 1995, J BIOL CHEM, V270, P1515, DOI 10.1074/jbc.270.4.1515; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; TAMIR A, 1994, J IMMUNOL, V152, P3391; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; WALKER C, 1991, J IMMUNOL, V146, P1829; Wenner CA, 1997, J IMMUNOL, V158, P765; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830	55	541	565	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21597	21603		10.1074/jbc.272.34.21597	http://dx.doi.org/10.1074/jbc.272.34.21597			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261181	hybrid			2022-12-27	WOS:A1997XR78900091
J	Alperin, ES; Shapiro, LJ				Alperin, ES; Shapiro, LJ			Characterization of point mutations in patients with X-linked ichthyosis - Effects on the structure and function of the steroid sulfatase protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARYLSULFATASE-B; FULL-LENGTH CDNA; NUCLEOTIDE-SEQUENCE; FREQUENT OCCURRENCE; SHORT ARM; EXPRESSION; CLONING; DEFICIENCY; DELETIONS; DNA	X-linked ichthyosis is the result of steroid sulfatase (STS) deficiency, While most affected individuals have extensive deletions of the STS gene, point mutations have been reported in three patients (1), In this study, we identify an additional three point mutations and characterize the effects of all six mutations on STS activity and expression. All six are unique single base pair substitutions, The mutations are located in a 105-amino acid region of the C-terminal half of the polypeptide, Five of the six mutations involve the substitutions of Pro or Arg for Trp(372), Arg for His(444), Tyr for Cys(446), or Leu for Cys(341). The other mutation is in a splice junction and results in a frameshift causing premature termination of the polypeptide at residue 427. All the affected residues are conserved to some degree within the sulfatase family, The six mutations were reproduced in normal STS cDNA and transiently expressed in STS-deficient cells. All six mutant vectors direct the expression of STS protein that lacks enzymatic activity, The mutant polypeptides show a shift in mobility on SDS-PAGE and resistance to proteinase K digestion when translated in the presence of dog pancreas microsomes, indicating glycosylation and normal translocation.	UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California Los Angeles					NIGMS NIH HHS [9ROI GM54907-17] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054907] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alperin E. S., 1994, American Journal of Human Genetics, V55, pA209; BALLABIO A, 1987, P NATL ACAD SCI USA, V84, P4519, DOI 10.1073/pnas.84.13.4519; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BALLABIO A, 1989, GENOMICS, V4, P36, DOI 10.1016/0888-7543(89)90311-X; BALLABIO A, 1995, METABOLIC MOL BASES, P2999; BASLER E, 1990, AM J HUM GENET, V47, pA150; BONIFAS JM, 1987, P NATL ACAD SCI USA, V84, P9248, DOI 10.1073/pnas.84.24.9248; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONARY JT, 1987, BIOCHEM BIOPH RES CO, V144, P1010, DOI 10.1016/S0006-291X(87)80064-5; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; GILLARD EF, 1987, NUCLEIC ACIDS RES, V15, P3977, DOI 10.1093/nar/15.10.3977; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; Harlow E., 1988, ANTIBODIES LAB MANUA; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HU ALW, 1920, FOCUS, V13, P26; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOLODNY EH, 1995, METABOLIC MOL BASES, V2, P2693; Li XM, 1996, SOMAT CELL MOLEC GEN, V22, P105, DOI 10.1007/BF02369901; Li XM, 1996, MAMM GENOME, V7, P420, DOI 10.1007/s003359900125; LI XM, 1992, NUCLEIC ACIDS RES, V20, P1117, DOI 10.1093/nar/20.5.1117; Maniatis T., 1982, MOL CLONING; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEUFELD EF, 1995, METABOLIC MOL BASIS, V2, P2645; PETERS C, 1990, J BIOL CHEM, V265, P3374; ROBERTSON DA, 1988, BIOCHEM BIOPH RES CO, V157, P218, DOI 10.1016/S0006-291X(88)80035-4; SALIDO EC, 1990, J CLIN ENDOCR METAB, V70, P1564, DOI 10.1210/jcem-70-6-1564; Salido EC, 1996, NAT GENET, V13, P83, DOI 10.1038/ng0596-83; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1988, EUR J BIOCHEM, V177, P9, DOI 10.1111/j.1432-1033.1988.tb14338.x; SCHUCHMAN EH, 1990, GENOMICS, V6, P149, DOI 10.1016/0888-7543(90)90460-C; SHAPIRO LJ, 1977, PEDIATR RES, V11, P894, DOI 10.1203/00006450-197708000-00008; SHAPIRO LJ, 1989, P NATL ACAD SCI USA, V86, P8477, DOI 10.1073/pnas.86.21.8477; SHAPIRO LJ, 1985, ADV HUM GENET, V14, P331; STEIN C, 1989, J BIOL CHEM, V264, P13865; STEIN C, 1989, J BIOL CHEM, V264, P1252; TOMATSU S, 1991, BIOCHEM BIOPH RES CO, V181, P677, DOI 10.1016/0006-291X(91)91244-7; VANDERLOOS CM, 1984, J INHERIT METAB DIS, V7, P97, DOI 10.1007/BF01801762; WILLEMSEN R, 1988, HISTOCHEM J, V20, P41, DOI 10.1007/BF01745968; WILSON PJ, 1990, P NATL ACAD SCI USA, V87, P8531, DOI 10.1073/pnas.87.21.8531; YANG Q, 1989, DEV BIOL, V135, P53, DOI 10.1016/0012-1606(89)90157-7; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q; YEN PH, 1987, CELL, V49, P443, DOI 10.1016/0092-8674(87)90447-8	44	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20756	20763		10.1074/jbc.272.33.20756	http://dx.doi.org/10.1074/jbc.272.33.20756			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252398	hybrid			2022-12-27	WOS:A1997XR22100068
J	Han, J; Ohno, N; Pasco, S; Monboisse, JC; Borel, JP; Kefalides, NA				Han, J; Ohno, N; Pasco, S; Monboisse, JC; Borel, JP; Kefalides, NA			A cell binding domain from the alpha 3 chain of type IV collagen inhibits proliferation of melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; GOODPASTURE ANTIGEN; IDENTIFICATION; ACTIVATION; ADHESION; LAMININ; PEPTIDE	Our previous studies have shown that a peptide corresponding to the residue sequence 185-203 of the NC1 domain of the alpha 3 chain of basement membrane collagen (type IV) inhibits the activation of polymorphonuclear leukocytes. Peptides from the same region of the alpha 1, alpha 2, alpha 4, and alpha 5(TV) chains did not exhibit this property, Because of the intimate relationship between metastasizing neoplastic cells and vascular as well as epithelial basement membranes, we measured the cell adhesion-promoting activity of peptides from the NC1 domain of type IV collagen and their effect on proliferation of human melanoma cells, We found that peptide alpha 3(IV)185-203 (CNYYSNSYSFWLASLNPER) not only promotes adhesion of human melanoma cells but also inhibits their proliferation. Adhesion increased by 50-60% over control. Melanoma cell proliferation was inhibited by 40% when cells were grown in a medium containing 5 mu g/ml peptide for 5 days, Studies showed that replacement of serine in position 189 or 191 by alanine resulted in significantly reduced adhesion. Similarly, serine replace ment resulted in reduced ability to inhibit proliferation. Our data suggest that a region of the NC1 domain of the alpha 3(TV) chain, contained within the sequence 185-203, not-only specifically promotes adhesion but also inhibits proliferation of melanoma cells. These properties appear to be dependent on the presence of the triplet sequence -SNS- (residues 189-191), which is unique to the alpha 3 chain and may represent an important functional epitope.	UNIV PENN,UNIV CITY SCI CTR,CTRI,DEPT MED,PHILADELPHIA,PA 19104; UNIV REIMS,CNRS EP89,BIOCHEM LAB,F-51095 REIMS,FRANCE	University of Pennsylvania; Universite de Reims Champagne-Ardenne				Brassart-Pasco, Sylvie/0000-0002-1340-7868	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553, T32AR007490] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29492] Funding Source: Medline; NIAMS NIH HHS [AR-07490, AR-20553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARANY G, 1980, PEPTIDES, V12, P1; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; CHARONIS AS, 1985, J CELL BIOL, V100, P1848, DOI 10.1083/jcb.100.6.1848; CHELBERG MK, 1989, CANCER RES, V49, P4796; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; ENGVALL E, 1972, J IMMUNOL, V109, P129; FENG LL, 1994, J BIOL CHEM, V269, P2342; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; KEFALIDES NA, 1993, KIDNEY INT, V43, P94, DOI 10.1038/ki.1993.16; LAUNE JM, 1986, METHOD ENZYMOL, V121, P183; LAURIE GW, 1986, J MOL BIOL, V189, P205, DOI 10.1016/0022-2836(86)90391-8; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MONBOISSE JC, 1994, J BIOL CHEM, V269, P25475; RAO CN, 1990, BIOCHEMISTRY-US, V29, P6769; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; SAUS J, 1988, J BIOL CHEM, V263, P13374; SHAHAN TA, 1996, MOL BIOL CELL, V7, P415; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; TYAGI SR, 1991, J BIOL CHEM, V266, P3498; ZHOU J, 1994, J BIOL CHEM, V269, P13193	24	80	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20395	20401		10.1074/jbc.272.33.20395	http://dx.doi.org/10.1074/jbc.272.33.20395			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252346	hybrid			2022-12-27	WOS:A1997XR22100016
J	Lee, HC; Aarhus, R				Lee, HC; Aarhus, R			Structural determinants of nicotinic acid adenine dinucleotide phosphate important for its calcium-mobilizing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INOSITOL TRISPHOSPHATE; METABOLITE; ENZYME; NAD+	Nicotinic acid adenine dinucleotide phosphate (NAADP) mobilizes Ca2+ through a mechanism totally independent of cyclic ADP-ribose or inositol trisphosphate, The structural determinants important for its Ca2+ release activity were investigated using a series of analogs, It is shown that changing the S-carboxyl group of the nicotinic acid (NA) moiety in NAADP to either an uncharged carbinol or from the 3-position to the 4-position of the pyridine ring totally eliminates the Ca2+ release activity, Conversion of the 3-carboxyl to other negatively charged groups, either 3-sulfonate, 3-acetate, or 3-quinoline carboxylate, retains the Ca2+ release activity, although their half-maximal effective concentrations (EC50) are 100-200-fold higher, Changing the 6-amino group of the adenine to a hydroxyl group results in more than a 1000-fold decrease in the Ca2+ release activity, Conversion of the 2'-phosphate to 2',3'-cyclic phosphate or 3'-phosphate likewise increases the EC50 by about 5- and 20-fold, respectively, Similar to NAADP, all of the active analogs can also desensitize the Ca2+ release mechanism at subthreshold concentrations, suggesting that this novel property is intrinsic to the release mechanism, The series of analogs used was produced by using ADP-ribosyl cyclase to catalyze the exchange of the nicotinamide group of various analogs of NADP with various analogs of NA. An important determinant in NA that is crucial to the base exchange reaction was shown to be the a-position of the pyridine ring, Neither pyridine-2-carboxylate nor 2-methyl-NA support the exchange reaction, The negative charge and the position of the 3-carboxyl group are nonessential since both pyridine-3-carbinol and pyridine-4-carboxylate support the base exchange reaction, In addition to the information on the structure-activity relationships of NAADP and NA, this study also demonstrates the utility of the base exchange reaction as a general approach for synthesizing NAADP analogs.			Lee, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,LYON LAB 6 182,MINNEAPOLIS,MN 55455, USA.		Lee, Hon Cheung/C-4329-2009		NICHD NIH HHS [HD17484] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Graeff RM, 1996, BIOCHEMISTRY-US, V35, P379, DOI 10.1021/bi952083f; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lee HC, 1997, METHOD ENZYMOL, V280, P331; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; Lee HC, 1996, RECENT PROG HORM RES, V51, P355; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; Prasad GS, 1996, PROTEINS, V24, P138, DOI 10.1002/(SICI)1097-0134(199601)24:1<138::AID-PROT10>3.3.CO;2-K; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; RUSINKO N, 1989, J BIOL CHEM, V264, P11725	16	48	50	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20378	20383		10.1074/jbc.272.33.20378	http://dx.doi.org/10.1074/jbc.272.33.20378			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252343	hybrid			2022-12-27	WOS:A1997XR22100013
J	Plaas, AHK; WongPalms, S; Roughley, PJ; Midura, RJ; Hascall, VC				Plaas, AHK; WongPalms, S; Roughley, PJ; Midura, RJ; Hascall, VC			Chemical and immunological assay of the nonreducing terminal residues of chondroitin sulfate from human aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; SYNOVIAL-FLUID; MONOCLONAL-ANTIBODIES; PROTEOGLYCANS; SERUM; GLYCOSAMINOGLYCANS; DETERMINANTS; CHAINS; OLIGOSACCHARIDES; OSTEOARTHRITIS	Samples of aggrecan chondroitin sulfate, isolated from normal human knee cartilages of individuals from fetal to 72 years of age, were digested with chondroitin lyases, The products were analyzed by fluorescence-based anion exchange high performance liquid chromatography to separate and quantitate nonreducing terminal structures, in addition to internal unsaturated disaccharide products, The predominant terminal structures mere the monosaccharides, GalNAc4S and GalNAc4,6S as they were present on 85-90% of all chains. The remaining chains terminated with the disaccharides GlcA beta 1,3GalNAc4S and GlcA beta 1,3GalNAc6S. Marked changes in the relative abundance of these terminals were identified in the transition from growth cartilage to adult articular cartilage, First, terminal GalNAc residues were almost exclusively 4-sulfated in aggrecan from fetal through 15 years of age, but were similar to 50% 4,6-disulfated in aggrecans from adults (22-72 years of age). Second, the terminal disaccharide GlcA beta 1,3GalNAc4S was on similar to 7% of chains on aggrecan from fetal through 15 years of age, but on only similar to 3% of chains on adult aggrecan. In contrast, the proportion of chains terminating in GlcA beta 1,3GalNAc6S, similar to 9%, was unchanged from fetal to 72 years of age, This terminal disaccharide is proposed to be recognized by the widely used monoclonal antibody 3B3, However, chemical quantitation of the structure together with solid phase 3B3(-) immunoassay of fetal and adult aggrecans showed that the content of the terminal disaccharide does not necessarily correlate with immunoreactivity of the proteoglycan, as chain density and presentation on the solid phase are critical factors for recognition of chain terminals by 3B3. The quantitative results obtained from chemical analyses of all nonreducing termini of aggrecan chondroitin sulfate chains revealed important changes in chain termination that occur when cellular activities are altered as adult articular cartilage is formed after removal of growth cartilage, These findings are discussed in relation to specific enzymatic steps that generate the nonreducing termini of chains in the biosynthesis pathway of chondroitin sulfate proteoglycans and their modulation in tissue development and pathology.	UNIV S FLORIDA,SCH MED,DEPT BIOCHEM & MOL BIOL,TAMPA,FL 33612; SHRINERS HOSP CRIPPLED CHILDREN,GENET UNIT,MONTREAL,PQ H3G 1A6,CANADA; CLEVELAND CLIN FDN,DEPT BIOMED ENGN,CLEVELAND,OH 44106	State University System of Florida; University of South Florida; McGill University; Cleveland Clinic Foundation	Plaas, AHK (corresponding author), SHRINERS HOSP CRIPPLED CHILDREN,CELL BIOL LAB,12502 N PINE DR,TAMPA,FL 33612, USA.							Archer CW, 1996, J ANAT, V189, P23; BAKER JR, 1991, BIOCHEM J, V273, P237, DOI 10.1042/bj2730237; Bayliss MT, 1995, ACTA ORTHOP SCAND, V66, P22, DOI 10.3109/17453679509157642; BUSCHMANN MD, 1995, J BIOMECH ENG-T ASME, V117, P179, DOI 10.1115/1.2796000; BYERS S, 1992, J HISTOCHEM CYTOCHEM, V40, P275, DOI 10.1177/40.2.1372629; CARDOSO LEM, 1992, LAB INVEST, V67, P588; CARLSON CS, 1995, J ORTHOP RES, V13, P399, DOI 10.1002/jor.1100130314; CATERSON B, 1990, J CELL SCI, V97, P411; CATERSON B, 1995, OSTEOARTHRITIC DISOR, P315; CHRISTNER JE, 1980, J BIOL CHEM, V255, P7102; COUCHMAN JR, 1984, MATRICES CELL DIFFER, P31; DEUTSCH AJ, 1995, J ORTHOPAED RES, V13, P230, DOI 10.1002/jor.1100130211; EVANKO SP, 1993, ARCH BIOCHEM BIOPHYS, V307, P153, DOI 10.1006/abbi.1993.1574; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; HARDINGHAM TE, 1994, CARBOHYD RES, V255, P241, DOI 10.1016/S0008-6215(00)90982-0; HASCALL VC, 1995, ADV EXP MED BIOL, V376, P205; INOUE H, 1986, J BIOL CHEM, V261, P4470; JENKINS RB, 1981, J BIOL CHEM, V256, P8279; KARAMANOS NK, 1995, ARCH BIOCHEM BIOPHYS, V316, P100, DOI 10.1006/abbi.1995.1015; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; KOVACK IS, 1994, BIOPHYS CHEM, V53, P181; MIDURA RJ, 1995, J BIOL CHEM, V270, P8009, DOI 10.1074/jbc.270.14.8009; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; PELLETIER JP, 1992, J ORTHOPAED RES, V10, P511, DOI 10.1002/jor.1100100406; Plaas AHK, 1996, GLYCOBIOLOGY, V6, P823, DOI 10.1093/glycob/6.8.823; POOLE AR, 1994, J CLIN INVEST, V94, P25, DOI 10.1172/JCI117314; RATCLIFFE A, 1993, ARTHRITIS RHEUM, V36, P543, DOI 10.1002/art.1780360416; RODEN L, 1980, BIOCH GLYCOPROTEINS, P39; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; ROUGHLEY PJ, 1987, PEDIATR RES, V22, P406; SCHONHERR E, 1993, ARTERIOSCLER THROMB, V13, P1026, DOI 10.1161/01.ATV.13.7.1026; SILBERT JE, 1978, J BIOL CHEM, V253, P6888; SLATER RR, 1995, ARTHRITIS RHEUM-US, V38, P655, DOI 10.1002/art.1780380513; SNOWDEN JM, 1976, BIOCHIM BIOPHYS ACTA, V428, P726; Sorrell JM, 1996, INT J DEV NEUROSCI, V14, P233, DOI 10.1016/0736-5748(96)00010-X; SZABO G, 1995, ARTHRITIS RHEUM, V38, P660; THONAR EJMA, 1986, J BIOL CHEM, V261, P2467; VANDENBERG WB, 1986, CLIN IMMUNOL IMMUNOP, V39, P187, DOI 10.1016/0090-1229(86)90083-8; VILIM V, 1994, BIOCHEM J, V304, P887, DOI 10.1042/bj3040887; VISCO DM, 1993, ARTHRITIS RHEUM, V36, P1718, DOI 10.1002/art.1780361211; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146	42	121	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20603	20610		10.1074/jbc.272.33.20603	http://dx.doi.org/10.1074/jbc.272.33.20603			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252375	hybrid			2022-12-27	WOS:A1997XR22100045
J	Ferry, AE; Baliga, SB; Monteiro, C; Pace, BS				Ferry, AE; Baliga, SB; Monteiro, C; Pace, BS			Globin gene silencing in primary erythroid cultures - An inhibitory role for interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; DOMINANT CONTROL REGION; SMALL MAF PROTEINS; CELL-LINE K562; MEGAKARYOBLASTIC DIFFERENTIATION; MEGAKARYOCYTIC DIFFERENTIATION; RECOMBINANT INTERLEUKIN-6; BINDING PROTEINS; DNA-BINDING; EXPRESSION	There are numerous similarities between the erythroid and megakaryocytic lineages which suggest that commitment to either lineage occurs relatively late in hematopoiesis. Commitment toward megakaryocyte development requires obligatory silencing of erythroid-specific genes, Therefore, we investigated the effects of interleukin-6, a known inducer of thrombocyte production, on globin gene expression during erythroid differentiation, Studies in K562 cells demonstrated inhibition of gamma globin gene mRNA production and chain biosynthesis in the presence of exogenous interleukin-6 which was abrogated by anti-interleukin-6 monoclonal antibody, Similar studies in primary erythroid progenitors showed inhibition of burst-forming unit-erythroid colony formation when interleukin-6 was added late in cultures with decreased gamma and beta globin gene mRNA production. Protein binding studies demonstrated an increase in activator protein-1 binding to its consensus sequence by 24 h of interleukin-6 treatment, Inhibition of activator protein-1 gene activity had no effect on gamma gene silencing by interleukin-6. A potential interleukin-6 response element was identified in the gamma globin gene, Interleukin-6 treatment led to a rapid increase in protein binding to the target DNA sequence. These results suggest that interleukin-fi may play an important role in globin gene silencing during megakaryocytic lineage commitment.	UNIV S ALABAMA,DEPT CELLULAR & STRUCT BIOL,MOBILE,AL 36688; UNIV S ALABAMA,DEPT PEDIAT,MOBILE,AL 36688	University of South Alabama; University of South Alabama					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038639] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38639-09] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALITALO R, 1988, BLOOD, V71, P899; ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; ARONSON FR, 1993, P AN M AM SOC CLIN, V12, P292; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNO E, 1989, EXP HEMATOL, V17, P1038; CARRINGTON PA, 1991, BLOOD, V77, P34; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; DAI W, 1993, BLOOD, V81, P1214; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GORDON MS, 1993, BLOOD S1, V82, P318; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HATTORI M, 1993, AM J PHYSIOL, V264, pG95; HILL RJ, 1991, BLOOD, V77, P42; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; JELKMANN WEB, 1994, ANN NY ACAD SCI, V718, P300; JIMINEZ G, 1992, P NATL ACAD SCI USA, V89, P10618; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LONGMORE GD, 1993, BLOOD, V82, P2386; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MOUTHON MA, 1993, BLOOD, V81, P647; MURATE T, 1993, EXP CELL RES, V208, P35, DOI 10.1006/excr.1993.1219; NAVARRO S, 1991, EXP HEMATOL, V19, P11; NAVARRO S, 1991, BLOOD, V77, P461; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PAPAYANNOPOULOU T, 1987, J CLIN INVEST, V79, P859, DOI 10.1172/JCI112895; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHELTON JB, 1985, HEMOGLOBIN, V9, P325, DOI 10.3109/03630268508997008; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SOLOMON WB, 1993, J BIOL CHEM, V268, P5089; SORRENTINO B, 1990, NUCLEIC ACIDS RES, V18, P2721, DOI 10.1093/nar/18.9.2721; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VAINCHENKER W, 1982, BLOOD, V59, P514; WARREN MK, 1989, EXP HEMATOL, V17, P1095; WILLIAMS N, 1990, EXP HEMATOL, V18, P69; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	59	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20030	20037		10.1074/jbc.272.32.20030	http://dx.doi.org/10.1074/jbc.272.32.20030			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242673	hybrid			2022-12-27	WOS:A1997XQ05900060
J	Hyatt, SL; Aulak, KS; Malandro, M; Kilberg, MS; Hatzoglou, M				Hyatt, SL; Aulak, KS; Malandro, M; Kilberg, MS; Hatzoglou, M			Adaptive regulation of the cationic amino acid transporter-1 (Cat-1) in Fao cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETASE GENE-EXPRESSION; RAT HEPATOMA-CELLS; MESSENGER-RNA; ASPARAGINE SYNTHETASE; SYSTEM-A; C-FOS; PROTEINS; LIVER; IDENTIFICATION; SPECIFICITY	The regulation of the high affinity cationic amino acid transporter Cat-1 in Fao rat hepatoma cells by amino acid availability has been studied, Cat-1 mRNA level increased (3-fold) in 4 h in response to amino acid starvation and remained high for at least 24 h, This induction was independent of the presence of serum in the media and transcription and protein synthesis were required for induction to occur, When Fao cells were shifted from amino acid-depleted media to amino acid-fed media, the levels of the induced cat-1 mRNA returned to the basal level, In amino acid-fed cells, accumulation of cat-1 mRNA was dependent on protein synthesis, indicating that a labile protein is required to sustain cat-1 mRNA level, No change in the transcription rate of the cat-1 gene during amino acid starvation was observed, indicating that cat-1 is regulated at a post-transcriptional step. System y+ mediated trans port of arginine was reduced by 50% in 1 h and by 70% in 24 h after amino acid starvation, However, when 24-h amino acid-starved Fao cells were preloaded with a mM lysine or arginine for 1 h prior to the transport assays, arginine uptake was trans-stimulated by 5-fold, This stimulation was specific for cationic amino acids, since alanine, proline, or leucine had no effect, These data lead to the hypothesis that amino acid starvation results in an increased cat-1 mRNA level to support synthesis of additional Cat-1 protein, The following lines of evidence support the hypothesis: (i) the use of inhibitors of protein synthesis in starved cells inhibits the trans-zero transport of arginine; (ii) cells starved for 1-24 h exhibited an increase of trans-stimulated arginine transport activity for the first 6 h and had no loss of activity at 24 h, suggesting that constant replenishment of the transporter protein occurs; (iii) immunofluorescent staining of 24-h fed and starved cells for cat-1 showed similar cell surface distribution; (iv) new protein synthesis is not required for trans-stimulation of arginine transport upon refeeding of 24-h starved cells. We conclude that the increased level of cat-1 mRNA in response to amino acid starvation support the synthesis of Cat-1 protein during starvation and increased amino acid transport upon substrate presentation, Therefore, the cat-1 mRNA content is regulated by a derepression/repression mechanism in response to amino acid availability. We propose that the amino acid-signal transduction pathway consists of a series of steps which include the post-transcriptional regulation of amino acid transporter genes.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NUTR,CLEVELAND,OH 44106; UNIV FLORIDA,COLL MED,DEPT BIOCHEM & MOL BIOL,GAINESVILLE,FL 32610	Case Western Reserve University; State University System of Florida; University of Florida					NIDDK NIH HHS [DK47431-0182, DK-52064] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064, R29DK047431] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; BRACY DS, 1986, J BIOL CHEM, V261, P1514; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CHEN ZP, 1992, J BIOL CHEM, V267, P6946; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HATZOGLOU M, 1991, J BIOL CHEM, V266, P8416; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; KAKUDA DK, 1994, J EXP BIOL, V196, P93; Kakuda DK, 1993, TRANSGENE, V1, P91; KIBERG MS, 1994, FASEB J, V8, P13; KILBERG MS, 1985, J CELL PHYSIOL, V122, P290, DOI 10.1002/jcp.1041220219; KILBERG MS, 1996, TRENDS BIOCHEM SCI, V2, P183; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; LAINE RO, 1991, J BIOL CHEM, V266, P16969; LAINE RO, 1994, J BIOL CHEM, V269, P9693; LAWLESS K, 1987, AM J PHYSIOL, V253, pG637, DOI 10.1152/ajpgi.1987.253.5.G637; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Maniatis T., 1982, MOL CLONING; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; Miyamoto K, 1996, J BIOL CHEM, V271, P16758, DOI 10.1074/jbc.271.28.16758; OGAWA H, 1991, J BIOL CHEM, V266, P20412; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PONJANPELTO P, 1990, MOL CELL BIOL, V10, P5814; SHOTWELL MA, 1982, J BIOL CHEM, V257, P2974; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WOODARD MH, 1994, AM J PHYSIOL, V266, pE817, DOI 10.1152/ajpendo.1994.266.5.E817; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994	38	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19951	19957		10.1074/jbc.272.32.19951	http://dx.doi.org/10.1074/jbc.272.32.19951			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242663	hybrid			2022-12-27	WOS:A1997XQ05900050
J	Watanabe, M; Matsuo, M; Tanaka, S; Akimoto, H; Asahi, S; Nishimura, S; Katze, JR; Hashizume, T; Crain, PF; McCloskey, JA; Okada, N				Watanabe, M; Matsuo, M; Tanaka, S; Akimoto, H; Asahi, S; Nishimura, S; Katze, JR; Hashizume, T; Crain, PF; McCloskey, JA; Okada, N			Biosynthesis of archaeosine, a novel derivative of 7-deazaguanosine specific to archaeal tRNA, proceeds via a pathway involving base replacement on the tRNA polynucleotide chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-GUANINE TRANSGLYCOSYLASE; TRANSFER RIBONUCLEIC-ACID; COLI TRANSFER-RNA; ESCHERICHIA-COLI; MODIFIED NUCLEOSIDES; INSERTION ENZYME; SEQUENCE; QUEUINE; QUEUOSINE; PRECURSOR	Archaeosine is a novel derivative of 7-deazaguanosine found in transfer RNAs of most organisms exclusively in the archaeal phylogenetic lineage and is present ill the D-loop at position 15. me show that this modification is formed by a posttranscriptional base replacement reaction, catalyzed by a new tRNA-guanine transglycosylase (TGT), which has been isolated from Haloferax volcanii and purified nearly to homogeneity. The molecular weight of the enzyme was estimated to be 78 kDa by SDS-gel electrophoresis, The enzyme can insert free 7-cyano-7-deazaguanine (preQ(0) base) in vitro at position 15 of an H. volcanii tRNA T7 transcript, replacing the guanine originally located at that position without breakage of the phosphodiester backbone. Since archaeosine base and 7-aminomethyl-7-deazaguanine (preQ(1) base) were not incorporated into tRNA by this enzyme, preQ(0) base appears to be the actual substrate for the TGT of H. volcanii, a conclusion supported by characterization of preQ(0) base in all acid-soluble extract of H. volcanii cells. Thus, this novel TGT in H. volcanii is a key enzyme for the biosynthetic pathway leading to archaeosine in archaeal tRNAs.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; TAKEDA CHEM IND LTD,OSAKA 532,JAPAN; BANYU TSUKUBA RES INST MERCK,TSUKUBA,IBARAKI 30026,JAPAN; UNIV TENNESSEE,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; UNIV UTAH,DEPT MED CHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112	Tokyo Institute of Technology; Takeda Chemical Industries; Merck & Company; University of Tennessee System; University of Tennessee Health Science Center; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			WATANABE, Masakatsu/V-9082-2019	WATANABE, Masakatsu/0000-0002-5744-197X				BEIER H, 1984, EMBO J, V3, P351, DOI 10.1002/j.1460-2075.1984.tb01810.x; BIENZ M, 1981, NATURE, V294, P188, DOI 10.1038/294188a0; BJORK GR, 1986, CHEM SCRIPTA, V26B, P91; BJORK GR, 1995, PROG NUCLEIC ACID RE, V50, P263, DOI 10.1016/S0079-6603(08)60817-X; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; Deshpande KL, 1996, ARCH BIOCHEM BIOPHYS, V326, P1, DOI 10.1006/abbi.1996.0039; DOCKBREGEON AC, 1989, J MOL BIOL, V206, P707, DOI 10.1016/0022-2836(89)90578-0; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; ELLIOTT MS, 1986, J BIOL CHEM, V261, P3019; FARKAS WR, 1980, J BIOL CHEM, V255, P6832; FREY B, 1988, J BACTERIOL, V170, P2078, DOI 10.1128/jb.170.5.2078-2082.1988; GREGSON JM, 1993, J BIOL CHEM, V268, P10076; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; GROSJEAN H, 1995, BIOCHIMIE, V77, P139, DOI 10.1016/0300-9084(96)88117-X; GUPTA R, 1984, J BIOL CHEM, V259, P9461; HARADA F, 1972, BIOCHEMISTRY-US, V11, P301, DOI 10.1021/bi00752a024; Hashizume T., 1994, NUCL ACIDS S SERIES, V31, P137; HATFIELD D, 1989, VIROLOGY, V173, P736, DOI 10.1016/0042-6822(89)90589-8; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; KASAI H, 1976, J AM CHEM SOC, V98, P5044, DOI 10.1021/ja00432a071; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KATZE JR, 1982, SCIENCE, V216, P55; KATZE JR, 1984, BIOCHEMISTRY-US, V23, P1171, DOI 10.1021/bi00301a022; KAURI T, 1990, SYST APPL MICROBIOL, V13, P14, DOI 10.1016/S0723-2020(11)80174-8; KILPATRICK MW, 1982, ZBL BAKT MIK HYG I C, V3, P79, DOI 10.1016/S0721-9571(82)80056-2; KONDO T, 1980, CHEM LETT, P559, DOI 10.1246/cl.1980.559; KRETZ KA, 1987, MOL CELL BIOL, V7, P3613, DOI 10.1128/MCB.7.10.3613; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; MORRIS RC, 1995, NUCLEIC ACIDS RES, V23, P2492, DOI 10.1093/nar/23.13.2492; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; NISHIMURA S, 1983, PROG NUCLEIC ACID RE, V28, P49, DOI 10.1016/S0079-6603(08)60082-3; NISHIMURA S, 1979, TRANSFER RNA STRUCTU, P59; NOGUCHI S, 1978, NUCLEIC ACIDS RES, V5, P4215, DOI 10.1093/nar/5.11.4215; OHGI T, 1979, CHEM LETT, P1283, DOI 10.1246/cl.1979.1283; OKADA N, 1977, NUCLEIC ACIDS RES, V4, P2931, DOI 10.1093/nar/4.8.2931; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1978, NUCLEIC ACIDS RES, V5, P2289, DOI 10.1093/nar/5.7.2289; OKADA N, 1978, P NATL ACAD SCI USA, V75, P4247, DOI 10.1073/pnas.75.9.4247; OKADA N, 1979, J BIOL CHEM, V254, P3061; PHILLIPSON DW, 1987, J BIOL CHEM, V262, P3462; REUTER K, 1991, J BACTERIOL, V173, P2256, DOI 10.1128/JB.173.7.2256-2264.1991; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; ROMIER C, 1996, EMBO J, V15, P2580; SHINDOOKADA N, 1980, BIOCHEMISTRY-US, V19, P395, DOI 10.1021/bi00543a023; SHINDOOKADA N, 1981, EUR J BIOCHEM, V115, P423, DOI 10.1111/j.1432-1033.1981.tb05254.x; SILBERKLANG M, 1977, EUR J BIOCHEM, V72, P465, DOI 10.1111/j.1432-1033.1977.tb11270.x; SLANY RK, 1995, EUR J BIOCHEM, V230, P221, DOI 10.1111/j.1432-1033.1995.0221i.x; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028; Sprinzl M, 1996, NUCLEIC ACIDS RES, V24, P68, DOI 10.1093/nar/24.1.68; STANLEY J, 1978, NATURE, V274, P87, DOI 10.1038/274087a0; TSUNASAWA S, 1989, J BIOL CHEM, V264, P3832; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	56	67	70	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20146	20151		10.1074/jbc.272.32.20146	http://dx.doi.org/10.1074/jbc.272.32.20146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242689	hybrid			2022-12-27	WOS:A1997XQ05900076
J	Laterza, OF; Hansen, WR; Taylor, L; Curthoys, NP				Laterza, OF; Hansen, WR; Taylor, L; Curthoys, NP			Identification of an mRNA-binding protein and the specific elements that may mediate the pH-responsive induction of renal glutaminase mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; PHOSPHATE-DEPENDENT GLUTAMINASE; 3' UNTRANSLATED REGION; CYCLIC-AMP ELEVATION; ACID-BASE-BALANCE; AU-RICH ELEMENTS; GENE-EXPRESSION; C-FOS; 3'-UNTRANSLATED REGION; METABOLIC-ACIDOSIS	Various segments of the 3'-nontranslated region of the renal glutaminase (GA) mRNA were tested for their ability to enhance turnover and pH responsiveness. The combined effects were retained in the 340-base R-2 segment, However, the combined R-l and R-3 fragments also imparted a partial destabilization and pH responsiveness to a chimeric beta-globin mRNA, RNA electrophoretic mobility shift assays indicated that cytosolic extracts of rat renal cortex contain a protein that binds to the R-2 and R-3 RNAs. The binding observed with the R-2 RNA was mapped to a direct repeat of an 8-base AU sequence, This binding was effectively competed with an excess of the same RNA, but not by adjacent or unrelated RNAs. UV cross-linking experiments identified a 48-kDa protein that binds to the AU repeats of the R-2 RNA. The apparent binding of this protein was greatly reduced in renal cytosolic extracts prepared from acutely acidotic rats, Two related RNA sequences in the R-3 segment also exhibited specific binding, However, the latter binding was more effectively competed by R-2 RNA than by itself, indicating that the homologous sites may be weaker binding sites for the same 48-kDa protein, Thus, a single protein may bind specifically to multiple instability elements within the 3'-nontranslated region of the GA mRNA and mediate its pH-responsive stabilization.	COLORADO STATE UNIV,DEPT MOL BIOL & BIOCHEM,FT COLLINS,CO 80523	Colorado State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037124] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37124] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brosnan JT, 1988, PH HOMEOSTASIS MECHA, P281; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; CURTHOYS NP, 1973, J BIOL CHEM, V248, P162; DAS AT, 1989, NUCLEIC ACIDS RES, V17, P2355, DOI 10.1093/nar/17.6.2355; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; GSTRAUNTHALER G, 1987, AM J PHYSIOL, V252, pC232, DOI 10.1152/ajpcell.1987.252.2.C232; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hansen WR, 1996, AM J PHYSIOL-RENAL, V271, pF126, DOI 10.1152/ajprenal.1996.271.1.F126; HARGROVE JL, 1993, FASEB J, V7, P1163, DOI 10.1096/fasebj.7.12.8375615; Holcomb T, 1996, AM J PHYSIOL-RENAL, V271, pF340, DOI 10.1152/ajprenal.1996.271.2.F340; HOLCOMB T, 1995, AM J PHYSIOL-CELL PH, V268, pC449, DOI 10.1152/ajpcell.1995.268.2.C449; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; HWANG JJ, 1991, BIOCHEMISTRY-US, V30, P7522, DOI 10.1021/bi00244a022; KAISER S, 1992, AM J PHYSIOL, V262, pF507, DOI 10.1152/ajprenal.1992.262.3.F507; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; PENG H, 1995, J BIOL CHEM, V270, P23996, DOI 10.1074/jbc.270.41.23996; PORTER D, 1995, AM J PHYSIOL-RENAL, V269, pF363, DOI 10.1152/ajprenal.1995.269.3.F363; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO RA, 1991, J BIOL CHEM, V266, P18792; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; TANNEN RL, 1993, HDB PHYSL RENAL PHYS, V1, P1017; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TONG J, 1987, BIOCHEMISTRY-US, V26, P2773, DOI 10.1021/bi00384a018; TONG J, 1986, BIOCHEM J, V233, P139, DOI 10.1042/bj2330139; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WRIGHT PA, 1990, AM J PHYSIOL, V259, pF961, DOI 10.1152/ajprenal.1990.259.6.F961; WRIGHT PA, 1990, AM J PHYSIOL, V259, pF53, DOI 10.1152/ajprenal.1990.259.1.F53; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	38	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22481	22488		10.1074/jbc.272.36.22481	http://dx.doi.org/10.1074/jbc.272.36.22481			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278399	hybrid			2022-12-27	WOS:A1997XV49200019
J	Panozzo, C; Capuano, V; Fillinger, S; Felenbok, B				Panozzo, C; Capuano, V; Fillinger, S; Felenbok, B			The zinc binuclear cluster activator AlcR is able to bind to single sites but requires multiple repeated sites for synergistic activation of the alcA gene in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; ETHANOL UTILIZATION REGULON; POSITIVE REGULATORY GENE; TRANSCRIPTIONAL ACTIVATOR; TRANSACTIVATOR ALCR; DNA RECOGNITION; CREA; GAL4; PROTEIN; SEQUENCE	The alcA gene which is part of the recently identified ethanol regulon, is one of the most strongly inducible genes in Aspergillus nidulans, Its transcriptional activation is mediated by the AlcR transactivator which contains a DNA-binding domain belonging to the C6 zinc binuclear cluster family, AlcR differs from the other members of this family by several features, the most striking characteristic being its binding to both. symmetric and asymmetric DNA sites with the same apparent affinity, However, AlcR is also able to bind to a single site with high affinity, suggesting that unlike the other C6 proteins, AlcR binds as a monomer. In this report, we show that AlcR targets, to be functional in vivo, have to be organized as inverted or direct repeats, In addition, we show a strong synergistic activation of alcA transcription in which the number and the position of the AlcR-binding sites are crucial, The fact that the AlcR unit for in vitro binding is a single site whereas the in vivo functional unit is a repeat ope:ns the question of the mechanism of the strong alcA transactivation, These results show that AlcR displays both in vitro and in vivo a new range of binding specificity and provides a novel example in the C6 zinc cluster protein family.	UNIV PARIS 11,URA CNRS D 2225,INST GENET & MICROBIOL,F-91405 ORSAY,FRANCE; CBAI,INA,PG,LAB GENET MICROORGANISMES,F-78850 THIVERVAL GRIGNON,FRANCE	UDICE-French Research Universities; Universite Paris Saclay				Capuano, Veronique/0000-0001-8738-0947				BAILEY C, 1975, EUR J BIOCHEM, V51, P573, DOI 10.1111/j.1432-1033.1975.tb03958.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHENG C, 1994, MOL CELL BIOL, V14, P3842, DOI 10.1128/MCB.14.6.3842; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; Creaser EH, 1984, BIOCHEM J, V225, P449; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; FELENBOK B, 1988, GENE, V73, P385, DOI 10.1016/0378-1119(88)90503-3; FELENBOK B, 1991, J BIOTECHNOL, V17, P11, DOI 10.1016/0168-1656(91)90023-O; Felenbok B, 1994, Prog Ind Microbiol, V29, P141; FILLINGER S, 1995, FEBS LETT, V368, P547, DOI 10.1016/0014-5793(95)00736-S; Fillinger S, 1996, MOL MICROBIOL, V20, P475, DOI 10.1046/j.1365-2958.1996.5301061.x; FILLINGER S, 1996, THESIS U PARIS SUD O; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GWYNNE DI, 1987, GENE, V51, P205, DOI 10.1016/0378-1119(87)90309-X; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KULMBURG P, 1992, J BIOL CHEM, V267, P21146; KULMBURG P, 1991, FEBS LETT, V280, P11, DOI 10.1016/0014-5793(91)80193-7; KULMBURG P, 1992, MOL CELL BIOL, V12, P1932, DOI 10.1128/MCB.12.5.1932; KULMBURG P, 1993, MOL MICROBIOL, V7, P847, DOI 10.1111/j.1365-2958.1993.tb01175.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANGDON T, 1995, MOL MICROBIOL, V17, P877, DOI 10.1111/j.1365-2958.1995.mmi_17050877.x; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LOCKINGTON R, 1987, MOL MICROBIOL, V1, P275, DOI 10.1111/j.1365-2958.1987.tb01933.x; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MATHIEU M, 1994, EMBO J, V13, P4022, DOI 10.1002/j.1460-2075.1994.tb06718.x; PATEMAN JA, 1983, PROC R SOC SER B-BIO, V217, P243, DOI 10.1098/rspb.1983.0009; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SCHERLING P, 1996, NUCLEIC ACIDS RES, V24, P4599; SEALYLEWIS HM, 1992, CURR GENET, V22, P293, DOI 10.1007/BF00317924; SEQUEVAL D, 1994, MOL GEN GENET, V242, P33, DOI 10.1007/BF00277345; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; XU HE, 1995, P NATL ACAD SCI USA, V92, P7677, DOI 10.1073/pnas.92.17.7677; Zhang L, 1996, EMBO J, V15, P4676, DOI 10.1002/j.1460-2075.1996.tb00844.x	40	35	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22859	22865		10.1074/jbc.272.36.22859	http://dx.doi.org/10.1074/jbc.272.36.22859			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278448	hybrid			2022-12-27	WOS:A1997XV49200069
J	Li, QB; Cerione, RA				Li, QB; Cerione, RA			Communication between switch II and switch III of the transducin alpha subunit is essential for target activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; NUCLEOTIDE-BINDING-PROTEIN; HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; GAMMA-SUBUNIT; SITE; G(I-ALPHA-1); ANTIBODIES; MECHANISM	Comparisons of the tertiary structures of the GDP-bound and guanosine 5'-O-(thiotriphosphate) (GTP gamma S)- bound forms of the alpha subunit of transducin (alpha(T)) indicate that there are three regions that undergo changes in conformation upon alpha(T) activation, Two of these regions, Switch I and Switch II, were originally identified in Ras, while Switch III appears to be unique to trimeric GTP-binding proteins (G proteins), We find that replacement of the Switch III region (aspartic acid 227 through asparagine 237) with a single alanine residue yields an alpha(T) subunit that fully binds and hydrolyzes GTP but no longer stimulates the activity of the cyclic GMP phosphodiesterase (PDE), the physiological target for transducin, We also show that changing glutamic acid 232 of alpha(T) to a leucine (E232L) had no effect on rhodopsin-stimulated GTP-GDP exchange nor on the GTP hydrolytic activity of alpha(T). However, the GTP gamma S-bound form of the alpha(T)E232L mutant was unable to stimulate the activity of the cyclic GMP PDE. The lack of stimulation was not due to an inability of the alpha(T)E232L mutant to bind to the target, Taken together, these results indicate that glutamic acid 232 mediates a conformational coupling between Snitch II and Switch III, which is essential for converting GTP-dependent G protein-target interactions into a stimulation of target/effector activity.	CORNELL UNIV,DEPT PHARMACOL,CTR VET MED,ITHACA,NY 14853	Cornell University					NEI NIH HHS [EY06429] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CUNNICK J, 1994, BIOCHEM J, V297, P87, DOI 10.1042/bj2970087; ERICKSON JW, 1995, BIOCHEMISTRY-US, V34, P8693, DOI 10.1021/bi00027a019; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOSWAMI BB, 1991, BIOTECHNIQUES, V5, P626; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; Mittal R, 1996, SCIENCE, V271, P1413, DOI 10.1126/science.271.5254.1413; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YEE R, 1978, J BIOL CHEM, V253, P8902	30	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21673	21676		10.1074/jbc.272.35.21673	http://dx.doi.org/10.1074/jbc.272.35.21673			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268292	hybrid			2022-12-27	WOS:A1997XT85000004
J	Xiao, CY; Hubner, S; Jans, DA				Xiao, CY; Hubner, S; Jans, DA			SV40 large tumor antigen nuclear import is regulated by the double-stranded DNA-dependent protein kinase site (serine 120) flanking the nuclear localization sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; TERMINAL TRANSACTIVATION DOMAIN; HUMAN KU-AUTOANTIGEN; II SITE; PHOSPHORYLATION SITES; V(D)J RECOMBINATION; KARYOPHERIN-ALPHA; PORE BINDING; BREAK REPAIR; MOUSE P53	Nuclear localization sequence (NLS)-dependent nuclear import of SV40 large tumor antigen (T-Ag) fusion proteins is regulated by phosphorylation sites for casein kinase II (CKII) and the cyclin dependent kinase Cdc2 amino-terminal to the NLS (amino acids 126-132), Between the T-Ag CKII and Cdc2 sites is a site (Ser(120)) for the double-stranded DNA-dependent protein kinase (dsDNA-PK), which we show here for the first time to play a role in regulating T-Ag nuclear import. We replaced Ser(120) by aspartic acid or alanine using site-directed mutagenesis and assessed the effects on nuclear transport kinetics both in vivo (microinjected cells) and in vitro (mechanically perforated cells) in HTC rat hepatoma cells, Maximal nuclear accumulation of the Asp(120) and Ala(120) protein derivatives was approximately 40% and 70% reduced in vivo, respectively, compared with that of the wild type protein, and similarly reduced in vitro, although to a lesser extent, This implies that the dsDNA-PK site regulates the maximal level of nuclear accumulation, normally functioning to enhance T-Ag nuclear transport; the higher accumulation of the Asp(120) protein compared with the Ala(120) protein indicates that negative charge at the dsDNA-PK site is mechanistically important in regulating nuclear import, The Asp(120) protein accumulated in the nucleus at a faster rate than the wild type protein, implying that phosphorylation at Ser(120) may also regulate the nuclear import rate, CKII phosphorylation of the Asp(120) protein in cytosol or by purified CKII was approximately 30% higher than that of the Ser(120) and Ala(120) proteins, while negative charge at the CKII site increased dsDNA-PK phosphorylation of Ser(120) by approximately 80% compared with wild type, implying physical and functional interactions between the two phosphorylation sites. Quantitation of NLS recognition by the importin 58/97 subunits using an enzyme-linked immunosorbent assay indicated that while the Ala(120) protein derivative had a binding affinity very similar to that of wild type, the Asp(120) derivative showed 40% higher affinity, In vitro CKII phosphorylation increased importin binding by about 30% in all cases, These results imply that negative charge at the dsDNA-PK site may enhance nuclear import through increasing both NLS recognition by importin subunits, and phosphorylation at the CKII site, which itself also facilitates NLS recognition by importin 58/97.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOL BIOL, NUCL SIGNALING LAB, CANBERRA, ACT 2601, AUSTRALIA	Australian National University; John Curtin School of Medical Research								ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOTTERELL SH, 1987, EUR J BIOCHEM, V164, P39, DOI 10.1111/j.1432-1033.1987.tb10989.x; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI GC, 1995, P NATL ACAD SCI USA, V92, P4512, DOI 10.1073/pnas.92.10.4512; LIU SH, 1993, J BIOL CHEM, V268, P21147; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SCHEIDTMANN KH, 1984, J VIROL, V50, P636, DOI 10.1128/JVI.50.2.636-640.1984; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; Seydel U, 1996, BIOCHEM J, V315, P33, DOI 10.1042/bj3150033; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451	53	115	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22191	22198		10.1074/jbc.272.35.22191	http://dx.doi.org/10.1074/jbc.272.35.22191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268364	hybrid			2022-12-27	WOS:A1997XT85000076
J	Zhang, YL; Sun, VY; Spremulli, LL				Zhang, YL; Sun, VY; Spremulli, LL			Role of domains in Escherichia coli and mammalian mitochondrial elongation factor Ts in the interaction with elongation factor Tu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-EF-TU; COMPLEX; PURIFICATION; EXPRESSION; CLONING; BOVINE	Bovine mitochondrial elongation factor Ts (EF-Ts-mt) stimulates the activity of Escherichia coli elongation factor Tu (EF-Tu), In contrast, E. coli EF-Ts is unable to stimulate mitochondrial EF-Tu. EF-Ts-mt forms a tight complex with E. coli EF-Tu governed by an association constant of 8.6 x 10(10), This value is 100-fold stronger than the binding constant for the formation of the E. coli EF-Tu . Ts complex. To test which domain of EF-Ts-mt is important for its strong binding with EF-Tu, chimeras were made between E. coli EF-Ts and EF-Ts-mt. Replacing the N-terminal domain of E, coli EF-Ts with that of EF-Ts-mt increases its binding to E. coli EF-Tu 2-3-fold, Replacing the N-terminal domain of EF-Ts-mt with the corresponding region of E. coli EF-Ts decreases its binding to E, coli EF Tu similar to 4-5-fold, A chimera consisting of the C-terminal half of E. cold EF-Ts and the N-terminal half of EF-Ts-mt binds to E. coli EF-Tu as strongly as EF-Ts-mt. A chimera in which Subdomain N of the core of EF-Ts is replaced by the corresponding region of EF-Ts-mt binds E, coli EF-Tu similar to 25-fold more tightly than E. coli EF-Ts, Thus, the higher strength of the interaction between EF-Ts-mt and EF-Tu can be localized primarily to a single subdomain.	UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM32734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI KI, 1978, EUR J BIOCHEM, V92, P509, DOI 10.1111/j.1432-1033.1978.tb12773.x; Blank J, 1996, EUR J BIOCHEM, V236, P222, DOI 10.1111/j.1432-1033.1996.00222.x; BOGESTRAND S, 1995, FEBS LETT, V368, P49, DOI 10.1016/0014-5793(95)00597-3; BOSCH L, 1983, PROG NUCLEIC ACID RE, V30, P91; FOX L, 1980, J BIOL CHEM, V255, P6018; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER DL, 1970, BIOCHEM BIOPH RES CO, V38, P1016, DOI 10.1016/0006-291X(70)90341-4; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Schwartzbach C J, 1996, Methods Enzymol, V264, P248, DOI 10.1016/S0076-6879(96)64025-7; SCHWARTZBACH CJ, 1991, J BIOL CHEM, V266, P16324; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; Woriax VL, 1995, BBA-GENE STRUCT EXPR, V1264, P347, DOI 10.1016/0167-4781(95)00176-X; Woriax VL, 1997, BBA-GENE STRUCT EXPR, V1352, P91, DOI 10.1016/S0167-4781(97)00002-X; XIN H, 1995, J BIOL CHEM, V270, P17243, DOI 10.1074/jbc.270.29.17243; Xin H, 1997, BBA-GENE STRUCT EXPR, V1352, P102, DOI 10.1016/S0167-4781(97)00003-1; Zhang YL, 1996, FEBS LETT, V391, P330, DOI 10.1016/0014-5793(96)00789-2	20	22	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21956	21963		10.1074/jbc.272.35.21956	http://dx.doi.org/10.1074/jbc.272.35.21956			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268331	hybrid			2022-12-27	WOS:A1997XT85000043
J	Collas, P; Thompson, L; Fields, AP; Poccia, DL; Courvalin, JC				Collas, P; Thompson, L; Fields, AP; Poccia, DL; Courvalin, JC			Protein kinase C-mediated interphase lamin B phosphorylation and solubilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENVELOPE BREAKDOWN; SEA-URCHIN EGG; IN-VITRO; CHROMATIN DECONDENSATION; MALE PRONUCLEUS; HISTONE-H1 KINASE; LEUKEMIA-CELLS; ACTIVATION; MEMBRANE; IDENTIFICATION	Disassembly of the sperm nuclear envelope at fertilization is one of the earliest events in the development of the male pronucleus. We report that nuclear lamina disassembly in interphase sea urchin egg cytosol is a result of lamin B phosphorylation mediated by protein kinase C (PKC). Lamin B of permeabilized sea urchin sperm nuclei incubated in fertilized egg G(1) phase cytosolic extract is phosphorylated within 1 min of incubation and solubilized prior to sperm chromatin decondensation. Phosphorylation is Ca2+-dependent. It is reversibly inhibited by the PKC-specific inhibitor chelerythrine, a PKC pseudosubstrate inhibitor peptide, and a PKC substrate peptide, but not by inhibitors of PKA, p34(cdc2) or calmodulin kinase II. Phosphorylation is inhibited by immunodepletion of cytosolic PKC and restored by addition of purified rat brain PKC. Sperm lamin B is a substrate for rat brain PKC in vitro, resulting in lamin B solubilization. Two-dimensional phosphopeptide maps of lamin B phosphorylated by the cytosolic kinase and by purified rat PKC are virtually identical. These data suggest that PKC is the major kinase required for interphase disassembly of the sperm lamina.	UNIV TEXAS,MED BRANCH,SEALY CTR ONCOL,GALVESTON,TX 77555; AMHERST COLL,DEPT BIOL,AMHERST,MA 01002; UNIV PARIS 07,INST JACQUES MONOD,CNRS,F-75251 PARIS,FRANCE	University of Texas System; University of Texas Medical Branch Galveston; Amherst College; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Collas, P (corresponding author), NORWEGIAN COLL VET MED,DEPT BIOCHEM,POB 8146 DEP,N-0033 OSLO,NORWAY.				NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NCI NIH HHS [CA56869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; CAMERON LA, 1994, DEV BIOL, V162, P568, DOI 10.1006/dbio.1994.1110; COLLAS P, 1995, DEV BIOL, V169, P123, DOI 10.1006/dbio.1995.1132; Collas P, 1996, J CELL SCI, V109, P1275; COLLAS P, 1995, MOL REPROD DEV, V42, P106, DOI 10.1002/mrd.1080420114; COLLAS P, 1995, EXP CELL RES, V219, P687, DOI 10.1006/excr.1995.1280; Collas P, 1996, J CELL BIOL, V135, P1715, DOI 10.1083/jcb.135.6.1715; COTHREN CC, 1993, EXP CELL RES, V205, P126, DOI 10.1006/excr.1993.1066; DICHEVA N, 1993, CELL, V74, P405; Fields A P, 1995, Prog Cell Cycle Res, V1, P271; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GOSS VL, 1994, J BIOL CHEM, V269, P19074; GREEN GR, 1985, DEV BIOL, V108, P235, DOI 10.1016/0012-1606(85)90026-0; GREEN GR, 1995, SEMIN CELL BIOL, V6, P219, DOI 10.1006/scel.1995.0030; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOLY J, 1995, DEV BIOL, V168, P464, DOI 10.1006/dbio.1995.1095; HORNBECK P, 1988, P NATL ACAD SCI USA, V85, P2279, DOI 10.1073/pnas.85.7.2279; Kill IR, 1995, FEBS LETT, V377, P26, DOI 10.1016/0014-5793(95)01302-4; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LONGO FJ, 1968, J CELL BIOL, V39, P335; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MEIJER L, 1996, TRENDS CELL BIOL, V6, P292; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Olds JL, 1995, DEV BIOL, V172, P675, DOI 10.1006/dbio.1995.8060; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; POCCIA D, 1990, EXP CELL RES, V188, P226, DOI 10.1016/0014-4827(90)90164-6; POCCIA DL, 1992, TRENDS BIOCHEM SCI, V17, P223, DOI 10.1016/0968-0004(92)90382-J; RAKOW TL, 1994, DEV GROWTH DIFFER, V36, P489; SCHATTEN G, 1985, P NATL ACAD SCI USA, V82, P4727, DOI 10.1073/pnas.82.14.4727; SHEN SS, 1990, DEV BIOL, V140, P272, DOI 10.1016/0012-1606(90)90077-V; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; STUURMAN N, 1995, J CELL SCI, V108, P3137; Stuurman N, 1997, FEBS LETT, V401, P171, DOI 10.1016/S0014-5793(96)01464-0; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U	45	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21274	21280		10.1074/jbc.272.34.21274	http://dx.doi.org/10.1074/jbc.272.34.21274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261138	hybrid			2022-12-27	WOS:A1997XR78900048
J	Roder, K; Wolf, SS; Beck, KF; Schweizer, M				Roder, K; Wolf, SS; Beck, KF; Schweizer, M			Cooperative binding of NF-Y and Sp1 at the DNase I-hypersensitive site, fatty acid synthase insulin-responsive element 1, located at -500 in the rat fatty acid synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN; CCAAT-BINDING; GENE-EXPRESSION; TRANSCRIPTION; IDENTIFICATION; COMPLEX; ACTIVATION; CLONING; YEAST; DIFFERENTIATION	In vitro DNase I footprint analysis of the rat fatty acid synthase (FAS) promoter from -568 to -468 revealed four protein binding sites: A, B, and C boxes and She FAS insulin-responsive element 1 (FIRE1), As demonstrated by gel mobility shift analysis and supershift experiments, FIRE1, located between -516 and -498, is responsible for binding NF-Y, The C box located downstream of FIRE 1 was shown by in vitro footprinting to be a Spl binding site, and furthermore, competition with Spl also abolished FIRE1 binding, Since the half-life of the Sp1.NF-Y.DNA complex is significantly longer than the half-lives of the Sp1.DNA or NF-Y.DNA complexes, the two transcription factors are deemed to bind cooperatively in the FAS promoter at -500, It is unusual that NF-Y binds at this distance from the start site of transcription, NF-Y binding sites are found in the promoters of at least three other FAS genes, viz. goose, chicken, and man, A second NF-Y binding site is located in the PAS promoter at the more usual position of -103 to -87, and it too has a neighboring Spl site, CTF/NF-1 competes for proteins binding to the B box, The A box binds Spl and contains a 12/13 match of the inverted repeat sequence responsible far binding the nuclear factor EF-C/RFX-1. in the enhancer regions of hepatitis B virus and the major histocompatibility complex class II antigen promoter, The same relative positions of NF-Y and Sp1 binding sites in the promoters of FAS genes of goose, rat, chicken, and man emphasize the involvement of these transcription factors in the diet and hormonal regulation of FAS.	INST FOOD RES, DEPT GENET & MICROBIOL, NORWICH NR4 7UA, NORFOLK, ENGLAND; UNIV FRANKFURT KLINIKUM, INST ALLGEMEINE PHARMAKOL & TOXICOL, D-60590 FRANKFURT, GERMANY	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; Goethe University Frankfurt; Goethe University Frankfurt Hospital								AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; Beck K F, 1992, DNA Seq, V2, P359, DOI 10.3109/10425179209020817; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; CADILLA C, 1992, GENE, V118, P223, DOI 10.1016/0378-1119(92)90192-R; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; DANG VD, 1995, YEAST, V11, pS176; DAVID E, 1995, J BIOL CHEM, V270, P8353, DOI 10.1074/jbc.270.14.8353; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FOUFELLE F, 1995, BIOCHEM J, V308, P521, DOI 10.1042/bj3080521; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Hsu MH, 1996, J BIOL CHEM, V271, P13584, DOI 10.1074/jbc.271.23.13584; IRITANI N, 1992, EUR J BIOCHEM, V205, P433, DOI 10.1111/j.1432-1033.1992.tb16797.x; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JIANG SW, 1995, NUCLEIC ACIDS RES, V23, P3607, DOI 10.1093/nar/23.17.3607; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAMEDA K, 1991, J BIOL CHEM, V266, P419; KIM JB, 1995, MOL CELL BIOL, V15, P2582; LAUX T, 1990, BIOCHEM J, V266, P793; LeFur N, 1996, EUR J BIOCHEM, V240, P323; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NYE JA, 1990, P NATL ACAD SCI USA, V87, P3992, DOI 10.1073/pnas.87.10.3992; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; REED GE, 1995, BRAIN RES, V685, P1; Roder K, 1997, GENE, V184, P21, DOI 10.1016/S0378-1119(96)00568-9; RODER K, 1994, GENE, V144, P189, DOI 10.1016/0378-1119(94)90377-8; RODER K, 1992, THESIS U ERLANGEN NU; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHLOKAT U, 1987, THESIS U HEIDELBERG; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VASSEURCOGNET M, 1993, CURR OPIN GENET DEV, V3, P238, DOI 10.1016/0959-437X(93)90029-O; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4521; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; WOLF SS, 1994, BIOCHEM BIOPH RES CO, V203, P943, DOI 10.1006/bbrc.1994.2273; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873	55	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21616	21624		10.1074/jbc.272.34.21616	http://dx.doi.org/10.1074/jbc.272.34.21616			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261184	hybrid			2022-12-27	WOS:A1997XR78900094
J	Waldmann, R; Bassilana, F; deWeille, J; Champigny, G; Heurteaux, C; Lazdunski, M				Waldmann, R; Bassilana, F; deWeille, J; Champigny, G; Heurteaux, C; Lazdunski, M			Molecular cloning of a non-inactivating proton-gated Na+ channel specific for sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; SODIUM-CHANNEL; HOMOLOGOUS SUBUNITS; CELLS; RAT; EXPRESSION; NEURODEGENERATION; IDENTIFICATION; RECEPTOR; CURRENTS	We have cloned and expressed a novel proton-gated Na+ channel subunit that is specific for sensory neurons. In COS cells, it forms a Na+ channel that responds to a drop of the extracellular pH with both a rapidly inactivating and a sustained Na+ current, This biphasic kinetic closely resembles that of the H+-gated current described in sensory neurons of dorsal root ganglia (1). Both the abundance of this novel H+-gated Na+ channel subunit in sensory neurons and the kinetics of the channel suggest that it is part of the channel complex responsible for the sustained H+-activated cation current in sensory neurons that is thought to be important for the prolonged perception of pain that accompanies tissue acidosis (1, 2).	CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Waldmann, Rainer/Q-2108-2016; HEURTEAUX, Catherine/M-4947-2016; de Weille, Jan R/F-8103-2014	Waldmann, Rainer/0000-0002-4599-2926; HEURTEAUX, Catherine/0000-0002-9741-9777; de Weille, Jan R/0000-0002-0505-3166; Bassilana, Frederic/0000-0003-2063-8450				AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GRANTYN R, 1989, DEV BRAIN RES, V49, P150, DOI 10.1016/0165-3806(89)90070-9; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KONNERTH A, 1987, J PHYSIOL-LONDON, V386, P603, DOI 10.1113/jphysiol.1987.sp016553; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; RANG HP, 1991, BRIT MED BULL, V47, P534, DOI 10.1093/oxfordjournals.bmb.a072491; STEEN KH, 1992, J NEUROSCI, V12, P86; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; VOILLEY N, 1995, GENOMICS, V28, P560, DOI 10.1006/geno.1995.1188; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411	25	449	471	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20975	20978		10.1074/jbc.272.34.20975	http://dx.doi.org/10.1074/jbc.272.34.20975			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261094	hybrid			2022-12-27	WOS:A1997XR78900004
J	Gasman, S; ChasserotGolaz, S; Popoff, MR; Aunis, D; Bader, MF				Gasman, S; ChasserotGolaz, S; Popoff, MR; Aunis, D; Bader, MF			Trimeric G proteins control exocytosis in chromaffin cells - G(o) regulates the peripheral actin network and catecholamine secretion by a mechanism involving the small GTP-binding protein Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; ESCHERICHIA-COLI; ALPHA-SUBUNIT; CLOSTRIDIUM-BOTULINUM; SYNTHETIC PEPTIDES; CARBOXYL TERMINUS; MAST-CELLS; KINASE-C; RELEASE; CYTOSKELETON	Besides having a role in signal transduction, heterotrimeric G proteins may be involved in membrane trafficking events, In chromaffin cells, G(o) is associated with secretory organelles and its activation by mastoparan inhibits the ATP-dependent priming of exocytosis, The effecters by which G(o) controls exocytosis are currently unknown. The subplasmalemmal actin network is one candidate, since it modulates secretion by controlling the movement of secretory granules to the plasma membrane, In streptolysin-O-permeabilized chromaffin cells, activation of exocytosis produces disassembly of cortical actin filaments, Mastoparan blocks the calcium-evoked disruption of cortical actin, and this effect is specifically inhibited by antibodies against G alpha(o) and by a synthetic peptide corresponding to the COOH-terminal domain of G alpha(o). Disruption of actin filaments with cytochalasin E and Clostridium perfringens iota toxin partially reverses the mastoparan-induced inhibition of secretion, Furthermore, the effects of mastoparan on cortical actin and exocytosis are greatly reduced in cells treated with Clostridium botulinum C3 exoenzyme, which specifically inactivates the small G protein Rho. We propose that the control exerted by the granule-associated G(o) on exocytosis may be related to effects on the cortical actin network through a sequence of events which eventually involves the participation of Rho.	INST PASTEUR, F-75724 PARIS 15, FRANCE; INSERM, U338 BIOL COMMUN CELLULAIRE, F-67084 STRASBOURG, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			stéphane, gasman/Q-1145-2019; Gasman, Stephane/D-5113-2017; Bader, Marie-France/O-2098-2016; Chasserot-Golaz, Sylvette/K-7625-2017; Dominique, Aunis/W-1419-2019	stéphane, gasman/0000-0001-8415-1276; Gasman, Stephane/0000-0001-8415-1276; 				AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; AUNIS D, 1988, J EXP BIOL, V139, P253; BADER MF, 1986, J BIOL CHEM, V261, P5777; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BENGTSSON T, 1990, P NATL ACAD SCI USA, V87, P2921, DOI 10.1073/pnas.87.8.2921; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERNSTEIN BW, 1985, J NEUROSCI, V5, P2565; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BURGOYNE RD, 1989, CELL SIGNAL, V1, P323, DOI 10.1016/0898-6568(89)90051-X; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; CHEEK TR, 1987, J BIOL CHEM, V262, P11663; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DELCASTILLO AR, 1992, J CELL BIOL, V119, P797, DOI 10.1083/jcb.119.4.797; FLODGAARD H, 1974, J BIOL CHEM, V249, P3465; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; GRANT NJ, 1992, EUR J NEUROSCI, V8, P1789; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JUNGERMANN J, 1995, AM J PHYSIOL-GASTR L, V268, pG328, DOI 10.1152/ajpgi.1995.268.2.G328; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; LANG J, 1995, EMBO J, V14, P3636; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; MATTER K, 1989, J NEUROCHEM, V52, P370, DOI 10.1111/j.1471-4159.1989.tb09131.x; NORGAUER J, 1992, BIOCHEM J, V282, P393, DOI 10.1042/bj2820393; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; Nurnberg B, 1996, FEBS LETT, V389, P61, DOI 10.1016/0014-5793(96)00584-4; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; Ozawa K, 1996, FEBS LETT, V382, P159, DOI 10.1016/0014-5793(96)00162-7; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; PERRIN D, 1985, NATURE, V315, P589, DOI 10.1038/315589a0; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROUOT B, 1989, BIOCHEM J, V260, P307, DOI 10.1042/bj2600307; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SCHODER S, 1996, P NATL ACAD SCI USA, V93, P2100; SILLEN LG, 1971, SPECIAL PUBLICATION, V25; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; THERRIEN S, 1989, J CELL BIOL, V109, P1125, DOI 10.1083/jcb.109.3.1125; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TRIFARO JM, 1992, EUR J PHARM-MOLEC PH, V225, P83, DOI 10.1016/0922-4106(92)90088-D; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Vitale N, 1996, EUR J NEUROSCI, V8, P1275, DOI 10.1111/j.1460-9568.1996.tb01296.x; VITALE N, 1994, J BIOL CHEM, V269, P30293; VITALE N, 1993, J BIOL CHEM, V268, P14715; VITALE N, 1994, BIOCHEM J, V300, P217, DOI 10.1042/bj3000217; VITALE N, 1996, CELL MOL NEUROBIOL, V17, P71; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHANG L, 1995, J NEUROCHEM, V65, P1297; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9	68	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20564	20571		10.1074/jbc.272.33.20564	http://dx.doi.org/10.1074/jbc.272.33.20564			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252370	hybrid			2022-12-27	WOS:A1997XR22100040
J	Fixman, ED; HolgadoMadruga, M; Nguyen, L; Kamikura, DM; Fournier, TM; Wong, AJ; Park, M				Fixman, ED; HolgadoMadruga, M; Nguyen, L; Kamikura, DM; Fournier, TM; Wong, AJ; Park, M			Efficient cellular transformation by the Met oncoprotein requires a functional Grb2 binding site and correlates with phosphorylation of the Grb2-associated proteins, Cbl and Gab1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; PRODUCT C-CBL; SCATTER FACTOR; PROTOONCOGENE PRODUCT; EGF RECEPTOR; NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; SH3 DOMAINS; ACTIVATION	The Tpr-Met oncoprotein consists of the catalytic kinase domain of the hepatocyte growth factor/scatter factor receptor tyrosine kinase (Met) fused downstream from sequences encoded by the tpr gene, Tpr-Met is a member of a family of tyrosine kinase oncoproteins generated following genomic rearrangement and has constitutive kinase activity, We have previously demonstrated that a single carboxyl-terminal tyrosine residue, Tyr(489), is essential for efficient transformation of Fr3T3 fibroblasts by Tpr-Met and forms a multisubstrate binding site for Grb2, phosphatidylinositol 3' kinase, phospholipase C gamma, SHP2, and an unknown protein of 110 kDa, A mutant Tpr-Met protein that selectively fails to bind Grba has reduced transforming activity, implicating pathways downstream of Grba in Tpr-Met mediated cell transformation, We show here that the 110-kDa Tpr-Met substrate corresponds to the recently identified Grb2-associated protein, Gab1, Moreover, we show that tyrosine phosphorylation of the Cbl protooncogene product as well as Gab1 required Tyr(489) and correlated with the ability of Tpr-Met to associate with Grba and to transform cells, providing evidence that pathways downstream of Gab1 and/or Cbl may Flay a role in Tpr-Met-mediated cell transformation.	MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT MED, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT ONCOL, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; KIMMEL CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA; KIMMEL CANC INST, DEPT PHARM, PHILADELPHIA, PA 19107 USA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Jefferson University; Jefferson University					NATIONAL CANCER INSTITUTE [R01CA069495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034514] Funding Source: NIH RePORTER; NCI NIH HHS [CA69495] Funding Source: Medline; NINDS NIH HHS [NS 34514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BASU T, 1994, ONCOGENE, V9, P3483; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YANG XM, 1995, LAB INVEST, V73, P483; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	105	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20167	20172		10.1074/jbc.272.32.20167	http://dx.doi.org/10.1074/jbc.272.32.20167			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242692	hybrid			2022-12-27	WOS:A1997XQ05900079
J	Patel, BN; David, S				Patel, BN; David, S			A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMERS-DISEASE; SUBSTANTIA-NIGRA; GENE-EXPRESSION; PARKINSONS-DISEASE; LIPID-PEROXIDATION; RAT CERULOPLASMIN; RADICAL FORMATION; CHOROID-PLEXUS; FET3 GENE	Ceruloplasmin is a copper-binding protein, which is the major ferroxidase in plasma of hepatic origin, We now provide evidence for a novel membrane-bound form of ceruloplasmin expressed by astrocytes in the mammalian central nervous system. Using a monoclonal antibody (1A1), we show that the cell surface antigen recognized by this antibody is ceruloplasmin and that it is directly anchored to the cell surface via a glycosylphosphatidylinositol (GPI) anchor, Our peptide mapping and other immunochemical studies indicate that, except for the GPI anchor, the membrane-bound and secreted plasma forms are similar, We also show that the membrane-bound form of ceruloplasmin has oxidase activity. These studies therefore suggest that the GPI-anchored form of ceruloplasmin may play a role similar to the secreted form in oxidizing ferrous iron, The GPI-anchored form of ceruloplasmin expressed by astrocytes is likely to be the major form of this molecule in the central nervous system because serum ceruloplasmin does not cross the blood-brain barrier, Lack of this form of ceruloplasmin in the central nervous system could lead to the generation of highly toxic free radicals, which can cause neuronal degeneration as seen in aceruloplasminemia and other neurodegenerative diseases such as Parkinson's and Alzheimer's disease.	MONTREAL GEN HOSP,RES INST,CTR RES NEUROSCI,MONTREAL,PQ H3G 1A4,CANADA; MCGILL UNIV,MONTREAL,PQ H3G 1A4,CANADA	McGill University; McGill University								ALDRED AR, 1987, J BIOL CHEM, V262, P2875; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BENSHACHAR D, 1991, J NEUROCHEM, V56, P1441, DOI 10.1111/j.1471-4159.1991.tb11444.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONNOR JR, 1993, NEUROSCI LETT, V159, P88, DOI 10.1016/0304-3940(93)90805-U; CONNOR JR, 1992, J NEUROSCI RES, V31, P327, DOI 10.1002/jnr.490310214; DAIMON M, 1995, BIOCHEM BIOPH RES CO, V208, P1028, DOI 10.1006/bbrc.1995.1437; DELPRINCIPE D, 1989, ACTA PAEDIATR SCAND, V78, P327; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DESILVA DM, 1993, CAN J PHYSIOL PHARM, V71, P715, DOI 10.1139/y93-107; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; DEXTER DT, 1994, MOVEMENT DISORD, V9, P92, DOI 10.1002/mds.870090115; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; GAITSKHOKI V S, 1990, Biokhimiya, V55, P927; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GIOMETTO B, 1990, J NEUROL SCI, V98, P81, DOI 10.1016/0022-510X(90)90183-N; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; GUTTERIDGE JMC, 1983, FEBS LETT, V157, P37, DOI 10.1016/0014-5793(83)81111-9; GUTTERIDGE JMC, 1993, BIOCHIM BIOPHYS ACTA, V1156, P144, DOI 10.1016/0304-4165(93)90129-V; Halliday W, 1995, J NEUROL SCI, V134, P84, DOI 10.1016/0022-510X(95)00212-K; Harlow E., 1988, ANTIBODIES LAB MANUA; Harris ZL, 1996, QJM-MON J ASSOC PHYS, V89, P355; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HIRSCH EC, 1991, J NEUROCHEM, V56, P446, DOI 10.1111/j.1471-4159.1991.tb08170.x; Jefferies WA, 1996, TRENDS CELL BIOL, V6, P223, DOI 10.1016/0962-8924(96)10019-2; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; KASARSKIS EJ, 1995, J NEUROL SCI, V130, P203, DOI 10.1016/0022-510X(95)00037-3; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGAN JI, 1994, Q J MED, V87, P663; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; MITTAL B, 1994, MOL CELL NEUROSCI, V5, P78, DOI 10.1006/mcne.1994.1007; MITTAL B, 1994, MOL CELL NEUROSCI, V5, P63, DOI 10.1006/mcne.1994.1006; Miyajima H, 1996, FREE RADICAL BIO MED, V20, P757, DOI 10.1016/0891-5849(95)02178-7; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; MOLLGARD K, 1988, DEV BIOL, V128, P207, DOI 10.1016/0012-1606(88)90283-7; MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NONAKA M, 1995, J IMMUNOL, V155, P3037; NONAKA M, 1995, J IMMUNOL, V155, P3048; OBA H, 1993, RADIOLOGY, V189, P843, DOI 10.1148/radiology.189.3.8234713; Okamoto N, 1996, HUM GENET, V97, P755; OSAKI S, 1966, J BIOL CHEM, V241, P2746; POPE A, 1977, DYNAMIC PROPERTIES G, P13; Rothenberger S, 1996, BRAIN RES, V712, P117, DOI 10.1016/0006-8993(96)88505-2; RUSKAMS AJ, 1990, J NEUROSCI RES, V31, P421; SAMOKYSZYN VM, 1989, J BIOL CHEM, V264, P21; SHVARTSMAN A L, 1990, Molekulyarnaya Biologiya (Moscow), V24, P657; SOFIC E, 1991, J NEUROCHEM, V56, P978, DOI 10.1111/j.1471-4159.1991.tb02017.x; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STURROCK A, 1990, J BIOL CHEM, V265, P3139; Takahashi Y, 1996, HUM MOL GENET, V5, P81, DOI 10.1093/hmg/5.1.81; THOMAS T, 1989, DEV BIOL, V134, P38, DOI 10.1016/0012-1606(89)90076-6; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; YANG FM, 1990, J BIOL CHEM, V265, P10780; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; YU JL, 1995, BIOCHEM BIOPH RES CO, V215, P497, DOI 10.1006/bbrc.1995.2492; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZHOU Y, 1995, NEUROSCI LETT, V195, P89, DOI 10.1016/0304-3940(94)11787-J	64	268	279	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20185	20190		10.1074/jbc.272.32.20185	http://dx.doi.org/10.1074/jbc.272.32.20185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242695	hybrid			2022-12-27	WOS:A1997XQ05900082
J	Roy, C; Martin, M; Mangeat, P				Roy, C; Martin, M; Mangeat, P			A dual involvement of the amino-terminal domain of ezrin in F- and G-actin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-CYTOSKELETAL LINKER; EPIDERMAL GROWTH-FACTOR; GASTRIC PARIETAL-CELLS; ERM FAMILY MEMBERS; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; 80-KDA PHOSPHOPROTEIN; APICAL MICROVILLI; MARGINAL BAND; PROTEIN EZRIN	Human recombinant ezrin, or truncated forms, were coated in microtiter plate and their capacity to bind actin determined. F-actin bound ezrin with a K-d of 504 +/- 230 nM and a molecular stoichiometry of 10.6 actin per ezrin. Ezrin bound both alpha- and beta/gamma-actin essentially as F-form. F-actin binding was totally prevented or drastically reduced when residues 534-586 or 13-30 were deleted, respectively. An actin binding activity was detected in amino-terminal constructs (ezrin 1-310 and 1-333) provided the glutathione S-transferase moiety of the fusion protein was removed, Series of carboxyl-terminal truncations confirmed the presence of this actin-binding site which bound both F- and G-actin, The F- and G-actin-binding sites were differently sensitive to various chemical effecters and distinct specific ezrin antibodies. The internal actin-binding Site Was mapped between residues 281 and 333. The association of ezrin amino-terminal fragment to full-length ezrin blocked F-actin binding to ezrin. It is proposed that, in full-length ezrin, the F-actin-binding site required the juxtaposition of the distal-most amino- and carboxyl-terminal residues of the ezrin molecule.			Roy, C (corresponding author), UNIV MONTPELLIER 2, UMR 5539,CNRS,LAB DYNAM MOL INTERACT MEMBRANAIRES, CC 107, BAT 24, F-34095 MONTPELLIER 5, FRANCE.			MARTIN, Marianne/0000-0001-8932-3129				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; AMIEVA MR, 1994, EXP CELL RES, V210, P140, DOI 10.1006/excr.1994.1021; AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; ANDREOLI C, 1994, J CELL SCI, V107, P2509; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BIRGBAUER E, 1989, J CELL BIOL, V109, P1609, DOI 10.1083/jcb.109.4.1609; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; CHEN J, 1994, AM J PHYSIOL, V267, pC784, DOI 10.1152/ajpcell.1994.267.3.C784; CHEN J, 1995, P NATL ACAD SCI USA, V92, P7495, DOI 10.1073/pnas.92.16.7495; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; EGERTON M, 1992, J IMMUNOL, V149, P1847; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FRANCK Z, 1993, J CELL SCI, V105, P219; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HANZEL DK, 1989, AM J PHYSIOL, V256, pG1082, DOI 10.1152/ajpgi.1989.256.6.G1082; HEIANDER TS, 1996, NATURE, V382, P265; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; KRIEG J, 1992, J BIOL CHEM, V267, P19258; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LANKES WT, 1993, BIOCHIM BIOPHYS ACTA, V1216, P479, DOI 10.1016/0167-4781(93)90018-9; Louvet S, 1996, DEV BIOL, V177, P568, DOI 10.1006/dbio.1996.0186; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; McCartney BM, 1996, J CELL BIOL, V133, P843, DOI 10.1083/jcb.133.4.843; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; PAKKANEN R, 1987, J HISTOCHEM CYTOCHEM, V35, P809, DOI 10.1177/35.8.3298422; PAKKANEN R, 1988, EUR J CELL BIOL, V46, P435; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; ROZYCKI M, 1991, METHOD ENZYMOL, V196, P100; SATO N, 1992, J CELL SCI, V103, P1; SCHWARTZALBIEZ R, 1995, EUR J CELL BIOL, V67, P189; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; THUILLIER L, 1994, CELL IMMUNOL, V156, P322, DOI 10.1006/cimm.1994.1178; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; WINCKLER B, 1994, J CELL SCI, V107, P2523; WOLF HJ, 1991, CELL TISSUE RES, V266, P385, DOI 10.1007/BF00318194; Yao XB, 1996, J BIOL CHEM, V271, P7224, DOI 10.1074/jbc.271.12.7224; YAO XB, 1995, MOL BIOL CELL, V6, P541, DOI 10.1091/mbc.6.5.541	61	88	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20088	20095		10.1074/jbc.272.32.20088	http://dx.doi.org/10.1074/jbc.272.32.20088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242682	hybrid			2022-12-27	WOS:A1997XQ05900069
J	Andberg, MB; Hamberg, M; Haeggstrom, JZ				Andberg, MB; Hamberg, M; Haeggstrom, JZ			Mutation of tyrosine 383 in leukotriene A(4) hydrolase allows conversion of leukotriene A(4) into 5S,6S-dihydroxy-7,9-trans-11,14-cis-eicosatetraenoic acid - Implications for the epoxide hydrolase mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HALOALKANE DEHALOGENASE; CATALYTIC MECHANISM; ARACHIDONIC-ACID; POLYMORPHONUCLEAR LEUKOCYTES; BIFUNCTIONAL ENZYME; ZINC METALLOENZYME; PEPTIDASE ACTIVITY; MOLECULAR-CLONING; AMINOPEPTIDASE	Leukotriene A(4) hydrolase is a bifunctional zinc metalloenzyme that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B-4. In previous studies with site-directed mutagenesis on mouse leukotriene A(4) hydrolase, we have identified Tyr-383 as a catalytic amino acid involved in the peptidase reaction. Further characterization of the mutants in position 383 revealed that [Y383H], [Y383F], and [Y383Q] leukotriene A(4) hydrolases catalyzed hydrolysis of leukotriene A(4) into a novel enzymatic metabolite. From analysis by high performance liquid chromatography, gas chromatography/mass spectrometry of material generated in the presence of (H2O)-O-16 or (H2O)-O-18, steric analysis of the hydroxyl groups, treatment with soybean lipoxygenase, and comparison with a synthetic standard, the novel metabolite was assigned the structure 5S,6S-dihydroxy-7,9-trans- 11,14-cis-eicosatetraenoic acid (5S,6S-DHETE). The kinetic parameters for the formation of 5S,6S-DHETE and leukotriene B-4 were found to be similar. Also, both activities were susceptible to suicide inactivation and were equally sensitive to inhibition by bestatin. Moreover, from the stereochemical configuration of the vicinal diol, it could be inferred that 5S,6S-DHETE is formed via an S(N)1 mechanism involving a carbocation intermediate, which in turn indicates that enzymatic hydrolysis of leukotriene A(4) into leukotriene B-4 follows the same mechanism. Inasmuch as soluble epoxide hydrolase utilizes leukotriene A(4) as substrate to produce 5S,6R-DHETE, our results also suggest a functional relationship between leukotriene A(4) hydrolase and xenobiotic epoxide hydrolases.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,DIV CHEM 2,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet				Hamberg, Mats/0000-0002-8910-7810; Blomster Andberg, Martina/0000-0002-8021-9947				ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; Arand M, 1996, J BIOL CHEM, V271, P4223; BLOMSTER M, 1995, EUR J BIOCHEM, V231, P528, DOI 10.1111/j.1432-1033.1995.tb20728.x; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; BORGEAT P, 1979, J BIOL CHEM, V254, P7865; BORHAN B, 1995, J BIOL CHEM, V270, P26923, DOI 10.1074/jbc.270.45.26923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHACOS N, 1983, ARCH BIOCHEM BIOPHYS, V223, P639, DOI 10.1016/0003-9861(83)90628-8; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; HAEGGSTROM J, 1986, J BIOL CHEM, V261, P6332; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V172, P965, DOI 10.1016/0006-291X(90)91540-9; HALARNKAR PP, 1992, ARCH BIOCHEM BIOPHYS, V294, P586, DOI 10.1016/0003-9861(92)90729-G; HAMBERG M, 1986, BIOCHIM BIOPHYS ACTA, V879, P410, DOI 10.1016/0005-2760(86)90233-X; HAMBERG M, 1973, LIPIDS, V8, P737, DOI 10.1007/BF02531842; HAMMOCK BD, 1994, BIOCHEM BIOPH RES CO, V198, P850, DOI 10.1006/bbrc.1994.1121; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; MALFROY B, 1989, BIOCHEM BIOPH RES CO, V161, P236, DOI 10.1016/0006-291X(89)91586-6; MEDINA JF, 1991, BIOCHEM BIOPH RES CO, V176, P1516, DOI 10.1016/0006-291X(91)90459-K; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; MEIJER J, 1988, CHEM-BIOL INTERACT, V64, P207, DOI 10.1016/0009-2797(88)90100-7; MINAMI M, 1992, FEBS LETT, V309, P353, DOI 10.1016/0014-5793(92)80806-R; MINAMI M, 1990, BIOCHEM BIOPH RES CO, V173, P620, DOI 10.1016/S0006-291X(05)80080-4; MUELLER MJ, 1995, P NATL ACAD SCI USA, V92, P8383, DOI 10.1073/pnas.92.18.8383; Mueller MJ, 1996, P NATL ACAD SCI USA, V93, P5931, DOI 10.1073/pnas.93.12.5931; Mueller MJ, 1996, J BIOL CHEM, V271, P24345, DOI 10.1074/jbc.271.40.24345; ORNING L, 1994, J BIOL CHEM, V269, P11269; PANGBURN MK, 1975, BIOCHEMISTRY-US, V14, P4050, DOI 10.1021/bi00689a019; PINOT F, 1995, J BIOL CHEM, V270, P7968, DOI 10.1074/jbc.270.14.7968; PUUSTINEN T, 1986, FEBS LETT, V207, P127, DOI 10.1016/0014-5793(86)80025-4; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SEIDEGARD J, 1983, BIOCHIM BIOPHYS ACTA, V695, P251, DOI 10.1016/0304-419X(83)90014-8; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WETTERHOLM A, 1988, EUR J BIOCHEM, V173, P531, DOI 10.1111/j.1432-1033.1988.tb14031.x; WETTERHOLM A, 1991, BIOCHIM BIOPHYS ACTA, V1080, P96, DOI 10.1016/0167-4838(91)90134-L; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141	39	24	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23057	23063		10.1074/jbc.272.37.23057	http://dx.doi.org/10.1074/jbc.272.37.23057			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287304	hybrid			2022-12-27	WOS:A1997XV74400015
J	Fang, WH; Wu, JY; Su, MJ				Fang, WH; Wu, JY; Su, MJ			Methyl-directed repair of mismatched small heterologous sequences in cell extracts from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETERODUPLEX DNA; SACCHAROMYCES-CEREVISIAE; GENE CONVERSION; BASE MISMATCHES; DUPLEX DNA; STRAND; EFFICIENCIES; SPECIFICITY; RESOLUTION; MOLECULES	The methyl-directed DNA repair efficiency of a set of M13mp18 heteroduplexes containing 1-8 or 22 unpaired bases was determined by using an in vitro DNA mismatch repair assay. The unpaired bases of each heteroduplex residing at overlapping recognition sites of two restriction endonucleases allow independent assay of repair on either DNA strand. Our results showed that the repair of small nucleotide heterologies in Escherichia coli extracts was very similar to base-base mismatch repair, being strand-specific and highly biased to the unmethylated strand. The in vitro activity was also dependent on products of mutH, mutL, mutS, and uvrD loci and was equally efficient on nucleotide insertions and deletions. The repair levels of small heterologies were affected by base composition of the heterologies. However, the extent of repair of heteroduplexes containing small heterologous sequences was found to decrease with an increase in the number of unpaired bases. Heteroduplexes containing an extra nucleotide of 22 bases provoked very low level of methyl-directed repair.			Fang, WH (corresponding author), NATL TAIWAN UNIV, COLL MED, SCH MED TECHNOL, TAIPEI 10016, TAIWAN.			FANG, WOEI-HORNG/0000-0003-4728-5931				AU KG, 1992, J BIOL CHEM, V267, P12142; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; COOPER DL, 1993, J BIOL CHEM, V268, P11823; DOHET C, 1986, P NATL ACAD SCI USA, V83, P3395, DOI 10.1073/pnas.83.10.3395; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1989, J BACTERIOL, V171, P3046, DOI 10.1128/jb.171.6.3046-3052.1989; FISHEL RA, 1986, J MOL BIOL, V188, P147, DOI 10.1016/0022-2836(86)90300-1; GASC AM, 1989, GENETICS, V121, P29; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; KENNARD O, 1985, J BIOMOL STRUCT DYN, V3, P205, DOI 10.1080/07391102.1985.10508412; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LEARN BA, 1989, J BACTERIOL, V171, P6473, DOI 10.1128/jb.171.12.6473-6481.1989; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MUSTERNASSAL C, 1986, P NATL ACAD SCI USA, V83, P7618, DOI 10.1073/pnas.83.20.7618; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PUKKILA PJ, 1983, GENETICS, V104, P571; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4004, DOI 10.1021/bi00131a016; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4015, DOI 10.1021/bi00131a017; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WANG YH, 1991, BIOCHEMISTRY-US, V30, P1358, DOI 10.1021/bi00219a028; WERNTGES H, 1986, NUCLEIC ACIDS RES, V14, P3773, DOI 10.1093/nar/14.9.3773; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22714	22720		10.1074/jbc.272.36.22714	http://dx.doi.org/10.1074/jbc.272.36.22714			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278429	hybrid			2022-12-27	WOS:A1997XV49200050
J	Gomes, CM; Silva, G; Oliveira, S; LeGall, J; Liu, MY; Xavier, AV; RodriguesPousada, C; Teixeira, M				Gomes, CM; Silva, G; Oliveira, S; LeGall, J; Liu, MY; Xavier, AV; RodriguesPousada, C; Teixeira, M			Studies on the redox centers of the terminal oxidase from Desulfovibrio gigas and evidence for its interaction with rubredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SPECTROSCOPIC CHARACTERIZATION; YEAST FLAVOCYTOCHROME-B2; BACILLUS-MEGATERIUM; REDUCING BACTERIA; IRON PROTEIN; OXYGEN; PURIFICATION; CYTOCHROME; BINDING	Rubredoxin-oxygen oxidoreductase (ROO) is the final component of a soluble electron transfer chain that couples NADH oxidation to oxygen consumption in the anaerobic sulfate reducer Desulfovibrio gigas. It is an 86-kDa homodimeric flavohemeprotein containing two FAD molecules, one mesoheme IX, and one Fe-uroporphyrin I per monomer, capable of fully reducing oxygen to water. EPR studies on the native enzyme reveal two components with g values at similar to 2.46, 2.29, and 1.89, which are assigned to low spin hemes and are similar to the EPR features of P-450 hemes, suggesting that ROO hemes have a cysteinyl axial ligation. At pH 7.6, the flavin redox transitions occur at 0 +/- 15 mV for the quinone/semiquinone couple and at -130 +/- 15 mV for the semiquinone/hydroquinone couple; the hemes reduction potential is -350 +/- 15 mV. Spectroscopic studies provided unequivocal evidence that the flavins are the electron acceptor centers from rubredoxin, and that their reduction proceed through an anionic semiquinone radical. The reaction with oxygen occurs in the flavin moiety. These data are strongly corroborated by the finding that rubredoxin and ROO are located in the same polycistronic unit of D. gigas genome. For the first time, a clear role for a rubredoxin in a sulfate-reducing bacterium is presented.	UNIV NOVA LISBOA,INST TECNOL QUIM & BIOL,P-2780 OEIRAS,PORTUGAL; INST GULBENKIAN CIENCIAS,GENET MOL LAB,OEIRAS,PORTUGAL; UNIV GEORGIA,DEPT BIOCHEM & MOL BIOL,ATHENS,GA 30602	Universidade Nova de Lisboa; Instituto Gulbenkian de Ciencia; University System of Georgia; University of Georgia			Gomes, Cláudio M./A-8152-2008; Teixeira, Miguel/M-1509-2019; Teixeira, Miguel/A-9098-2011; Oliveira, Solange/M-4047-2013	Gomes, Cláudio M./0000-0003-4662-6933; Teixeira, Miguel/0000-0003-4124-6237; Teixeira, Miguel/0000-0003-4124-6237; Oliveira, Solange/0000-0003-4984-4805; Silva, Gabriela/0000-0002-4004-9904; Rodrigues-Pousada, Claudina/0000-0002-5075-3639				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ALBERTA JA, 1989, J BIOL CHEM, V264, P20467; BLACK MT, 1989, BIOCHEM J, V258, P255, DOI 10.1042/bj2580255; BOLARD J, 1972, BIOCHIM BIOPHYS ACTA, V263, P535, DOI 10.1016/0005-2795(72)90034-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUSCHI M, 1972, BIOCHIM BIOPHYS ACTA, V263, P279, DOI 10.1016/0005-2795(72)90080-3; BRUSCHI M, 1977, J BACTERIOL, V129, P30, DOI 10.1128/JB.129.1.30-38.1977; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CALCATERRA NB, 1995, BIOCHEMISTRY-US, V34, P12842, DOI 10.1021/bi00039a045; CHEN L, 1993, BIOCHEM BIOPH RES CO, V193, P100, DOI 10.1006/bbrc.1993.1595; CHEN L, 1993, EUR J BIOCHEM, V216, P443, DOI 10.1111/j.1432-1033.1993.tb18162.x; COOPER CE, 1994, BIOCHEM SOC T, V22, P709, DOI 10.1042/bst0220709; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; DILING W, 1990, FEMS MICROBIOL LETT, V71, P123; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KRONECK PMH, 1991, BIOL MET, V4, P119, DOI 10.1007/BF01135389; LEGALL J, 1965, BIOCHIM BIOPHYS ACTA, V99, P385; LEGALL J, 1968, ANN I PASTEUR PARIS, V114, P109; LEGALL J, 1966, BIOCHEM BIOPH RES CO, V23, P145, DOI 10.1016/0006-291X(66)90519-5; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; MARSCHALL C, 1993, ARCH MICROBIOL, V159, P168, DOI 10.1007/BF00250278; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MCKNIGHT J, 1993, EUR J BIOCHEM, V213, P683, DOI 10.1111/j.1432-1033.1993.tb17808.x; Moore DD, 1995, GLOB MOB SURV; MORRIS CJ, 1994, BIOCHEM J, V302, P587, DOI 10.1042/bj3020587; MOURA I, 1977, BIOCHEM BIOPH RES CO, V75, P1037, DOI 10.1016/0006-291X(77)91486-3; MOURA I, 1979, FEBS LETT, V107, P419, DOI 10.1016/0014-5793(79)80421-4; NARHI LO, 1986, J BIOL CHEM, V261, P7160; Nielsen AK, 1996, MICROBIOL-UK, V142, P1289, DOI 10.1099/13500872-142-5-1289; NOLLING J, 1995, EUR J BIOCHEM, V231, P628, DOI 10.1111/j.1432-1033.1995.0628d.x; OSHINO R, 1973, EUR J BIOCHEM, V39, P581, DOI 10.1111/j.1432-1033.1973.tb03157.x; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; RAGSDALE SW, 1983, J BACTERIOL, V155, P1224, DOI 10.1128/JB.155.3.1224-1237.1983; Romero A, 1996, EUR J BIOCHEM, V239, P190, DOI 10.1111/j.1432-1033.1996.0190u.x; RUETTINGER RT, 1977, ARCH BIOCHEM BIOPHYS, V183, P528, DOI 10.1016/0003-9861(77)90388-5; SAEKI K, 1993, PLANT CELL PHYSIOL, V34, P185; Sambrook J., 2002, MOL CLONING LAB MANU; SANTOS H, 1993, BIOCHEM BIOPH RES CO, V195, P551, DOI 10.1006/bbrc.1993.2081; SIGAL N, 1963, J BACTERIOL, V85, P1315, DOI 10.1128/JB.85.6.1315-1318.1963; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TEGONI M, 1986, EUR J BIOCHEM, V155, P491, DOI 10.1111/j.1432-1033.1986.tb09516.x; TEIXEIRA M, 1995, EUR J BIOCHEM, V227, P322, DOI 10.1111/j.1432-1033.1995.tb20392.x; THOENES U, 1994, EUR J BIOCHEM, V220, P901, DOI 10.1111/j.1432-1033.1994.tb18693.x; TIMKOVICH R, 1994, BIOORG CHEM, V22, P284, DOI 10.1006/bioo.1994.1022; VANBEEUMEN JJ, 1991, J BIOL CHEM, V266, P12921; Yamazaki M, 1996, J BACTERIOL, V178, P2676, DOI 10.1128/jb.178.9.2676-2687.1996	49	126	127	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22502	22508		10.1074/jbc.272.36.22502	http://dx.doi.org/10.1074/jbc.272.36.22502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278402	hybrid			2022-12-27	WOS:A1997XV49200022
J	Harth, G; Horwitz, MA				Harth, G; Horwitz, MA			Expression and efficient export of enzymatically active Mycobacterium tuberculosis glutamine synthetase in Mycobacterium smegmatis and evidence that the information for export is contained within the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; GLNA; GENES; BACILLUS; REGION; LEPRAE	We have investigated the expression and extracellular release of active, recombinant Mycobacterium tuberculosis glutamine synthetase (EC 6.3.1.2), an enzyme that is a potentially important determinant of M. tuberculosis infection and whose extracellular release is correlated with pathogenicity, The M. tuberculosis glutamine synthetase gene encodes a polypeptide of 478 amino acids; 12 such subunits comprise the active enzyme, Northern blot, nuclease S1, and primer extension analyses revealed glutamine synthetase specific transcripts of similar to 1,550 and 1,650 nucleotides produced under low and high nitrogen conditions, respectively, Expression of recombinant M. tuberculosis glutamine synthetase in Escherichia coli YMC21E, a glutamine synthetase deletion mutant, led to transcomplementation of the mutant but not to release of active enzyme, Expression in Mycobacterium smegmatis 1-2c, from the gene's own promoter, resulted in the release of > 95% of all recombinant enzyme, No hybrid molecules containing M. tuberculosis and M. smegmatis glutamine synthetase subunits were detected, Native and recombinant exported and intracellular glutamine synthetase molecules were indistinguishable from one another by mass, N-terminal amino acid sequence, antibody reactivity, and enzymatic activity, Since M. tuberculosis glutamine synthetase is similar to other, strictly intracellular, bacterial glutamine synthetases and the DNA sequence upstream of the structural gene does not encode a leader peptide, the information to target the protein for export must be contained in its amino acid sequence and/or conformation.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV INFECT DIS,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCRR NIH HHS [1 S10RR05554] Funding Source: Medline; NIAID NIH HHS [AI 35275, AI 31338] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035275, R01AI031338] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; AUSUBEL FM, 1984, CELL, V37, P5, DOI 10.1016/0092-8674(84)90294-0; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P585; COLOMBO G, 1986, J BIOL CHEM, V261, P587; GARBE TR, 1994, MICROBIOL-SGM, V140, P133, DOI 10.1099/13500872-140-1-133; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANAU R, 1983, J BACTERIOL, V155, P82, DOI 10.1128/JB.155.1.82-89.1983; HARTH G, 1994, P NATL ACAD SCI USA, V91, P9342, DOI 10.1073/pnas.91.20.9342; HERRMANN JL, 1991, EMBIO J, V15, P3547; KEMPSELL KE, 1992, J GEN MICROBIOL, V138, P1717, DOI 10.1099/00221287-138-8-1717; KIMURA K, 1989, J BIOCHEM, V105, P648, DOI 10.1093/oxfordjournals.jbchem.a122719; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; NAKANO Y, 1989, FEMS MICROBIOL LETT, V57, P81, DOI 10.1016/0378-1097(89)90151-1; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; WEISBROD RE, 1973, J BIOL CHEM, V248, P3997	21	53	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22728	22735		10.1074/jbc.272.36.22728	http://dx.doi.org/10.1074/jbc.272.36.22728			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278431	hybrid			2022-12-27	WOS:A1997XV49200052
J	Skinner, J; Sinclair, C; Romeo, C; Armstrong, D; Charbonneau, H; Rossie, S				Skinner, J; Sinclair, C; Romeo, C; Armstrong, D; Charbonneau, H; Rossie, S			Purification of a fatty acid-stimulated protein-serine/threonine phosphatase from bovine brain and its identification as a homolog of protein phosphatase 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT DOMAIN; SERINE THREONINE PHOSPHATASES; LIGHT-CHAIN-PHOSPHATASE; SMOOTH-MUSCLE CELLS; ARACHIDONIC-ACID; ACTIVATING PROTEIN; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; RAT-BRAIN; CALCIUM	An arachidonic acid-stimulated Ser/Thr phosphatase activity was detected in soluble extracts prepared from rat pituitary clonal GH(4)C(1) cells, rat or bovine brain, and bovine heart. The enzyme activity was purified to homogeneity from bovine brain as a monomer with a M-r of 63,000 and a specific activity of 32 nmol of P-i released per min/mg of protein when assayed in the presence of 10 mu M phosphocasein in the absence of lipid. Arachidonic acid stimulated activity 4-14-fold, with half-maximal stimulation at 50-100 mu M, when assayed in the presence of a variety of phosphosubstrates including casein, reduced carboxamidomethylated and maleylated lysozyme, myelin basic protein, and histone. Oleic acid, linoleic acid, and palmitoleic acid also stimulated activity; however, saturated fatty acids and alcohol or methyl ester derivatives of fatty acids did not significantly affect activity. The lipid-stimulated phosphatase was identified as the bovine equivalent of protein phosphatase 5 or a closely related homolog by sequence analysis of proteolytic fragments generated from the purified enzyme, When recombinant rat protein phosphatase 5 was expressed as a cleavable glutathione S-transferase fusion protein, the affinity-purified thrombin-cleaved enzyme exhibited a specific activity and sensitivity to arachidonic acid similar to those of the purified bovine brain enzyme. These results suggest that protein phosphatase 5 may be regulated in vivo by a lipid second messenger or another endogenous activator.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; NIEHS,LAB SIGNAL TRANSDUCT,RES TRIANGLE PK,NC 27709	Purdue University System; Purdue University; Purdue University West Lafayette Campus; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)					NCI NIH HHS [CA59935] Funding Source: Medline; NIDDK NIH HHS [DK20542] Funding Source: Medline; NINDS NIH HHS [NS31221] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059935, R29CA059935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031221, R29NS031221] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ansai T, 1996, J BIOL CHEM, V271, P24401, DOI 10.1074/jbc.271.40.24401; ARMSTRONG DL, 1992, TRENDS NEUROSCI, V15, P403, DOI 10.1016/0166-2236(92)90192-B; AUSUBEL F, 1995, SHORT PROTOCOLS MOL, P1621; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BECKER W, 1994, J BIOL CHEM, V269, P22586; Becker W, 1996, MOL BRAIN RES, V36, P23, DOI 10.1016/0169-328X(95)00233-I; BLOBE GC, 1995, PROSTAG LEUKOTR ESS, V52, P129, DOI 10.1016/0952-3278(95)90011-X; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Duerson K, 1996, NEUROPHARMACOLOGY, V35, P949, DOI 10.1016/0028-3908(96)00131-1; Fukuda H, 1996, BIOCHEM BIOPH RES CO, V220, P160, DOI 10.1006/bbrc.1996.0374; Gailly P, 1996, EUR J BIOCHEM, V239, P326, DOI 10.1111/j.1432-1033.1996.0326u.x; Glick J, 1996, J BIOL CHEM, V271, P2949, DOI 10.1074/jbc.271.6.2949; GONG MC, 1992, J BIOL CHEM, V267, P21492; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lammers CH, 1996, J NEUROCHEM, V66, P147; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Maizel JV, 1971, METHOD VIROL, V5, P179; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; PetitJacques J, 1996, J PHYSIOL-LONDON, V493, P67, DOI 10.1113/jphysiol.1996.sp021365; PETROU S, 1995, PROSTAG LEUKOTR ESS, V52, P173, DOI 10.1016/0952-3278(95)90018-7; RAO GN, 1994, J BIOL CHEM, V269, P32586; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STONE KL, 1993, PRACTICAL GUIDE PROT, P45; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Xu XL, 1996, BIOCHEM BIOPH RES CO, V218, P514, DOI 10.1006/bbrc.1996.0092; YONG WH, 1995, GENOMICS, V29, P533, DOI 10.1006/geno.1995.9972; YU SP, 1995, J PHYSIOL-LONDON, V487, P797, DOI 10.1113/jphysiol.1995.sp020919	51	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22464	22471		10.1074/jbc.272.36.22464	http://dx.doi.org/10.1074/jbc.272.36.22464			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278397	hybrid			2022-12-27	WOS:A1997XV49200017
J	VuDac, N; Gervois, P; Grotzinger, T; DeVos, P; Schoonjans, K; Fruchart, JC; Auwerx, J; Mariani, J; Tedgui, A; Staels, B				VuDac, N; Gervois, P; Grotzinger, T; DeVos, P; Schoonjans, K; Fruchart, JC; Auwerx, J; Mariani, J; Tedgui, A; Staels, B			Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor ROR alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; GLAND HORMONE MELATONIN; TRANSGENIC MICE; RETINOIC ACID; ORPHAN RECEPTORS; MESSENGER-RNA; PLASMA-LEVELS; DNA-BINDING; RAT-LIVER; ATHEROSCLEROSIS	Since elevated concentrations of plasma high density lipoprotein (HDL) and its major apolipoprotein (ape), apoA-I, confer protection against atherosclerosis, considerable research efforts have focussed on the identification of factors regulating apoA-I gene expression in an attempt to increase its production. Nuclear receptors are interesting candidates because they are transcription factors whose activity is ligand-dependent. In the present study we identified the orphan receptor ROR alpha 1 as an activator of apoA-I gene transcription. In apoA-I-expressing intestinal Caco-2 cells, overexpression of the ROR alpha 1, but not the ROR alpha 2 or ROR alpha 3 isoforms, increased rat apoA-I gene transcription. Deletion and site-directed mutagenesis experiments identified a functional ROR-responsive element (RORE) in the rat; and mouse apoA-I gene promoters, which overlaps with the TATA box. Gel shift experiments indicated that this RORE binds the ROR alpha 1 isoform, but not the ROR alpha 2 or ROR alpha 3 isoforms, Furthermore, compared with wild type mice, apoA-I mRNA levels were significantly lower in small intestines of staggerer mice homozygous for a deletion in the ROR alpha gene. In addition, reverse transcriptase-polymerase chain reaction analysis revealed the expression of ROR alpha in small intestinal epithelium and in Caco-2 cells. These data indicate a novel, physiological role for ROR alpha 1 in the regulation of genes involved in lipid and lipoprotein metabolism and possibly in the development of metabolic diseases, such as atherosclerosis.	INST PASTEUR, DEPT ATHEROSCLEROSE, U325 INSERM, F-59019 LILLE, FRANCE; UNIV LILLE 2, F-59019 LILLE, FRANCE; U141 INSERM, F-75745 PARIS 10, FRANCE; INST FEDERAT RECH CIRCULAT LARIBOISIERE, F-75745 PARIS 10, FRANCE; INST NEUROSCI, DEV NEUROBIOL LAB, CNRS URA 1488, F-75005 PARIS, FRANCE; UNIV PARIS 06, F-75005 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Auwerx, Johan/0000-0002-5065-5393; Mariani, Jean/0000-0002-2701-1581; Schoonjans, Kristina/0000-0003-1247-4265				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BERTHOU L, 1994, ARTERIOSCLER THROMB, V14, P1657, DOI 10.1161/01.ATV.14.10.1657; BOSSU JP, 1994, BIOCHEM BIOPH RES CO, V202, P822, DOI 10.1006/bbrc.1994.2004; BRESLOW JL, 1989, METABOLIC BASIS INHE, V1, P1251; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; Duverger N, 1996, CIRCULATION, V94, P713, DOI 10.1161/01.CIR.94.4.713; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; FRUCHART JC, 1993, CIRCULATION, V87, P22; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; Saladin R, 1996, EUR J BIOCHEM, V239, P451, DOI 10.1111/j.1432-1033.1996.0451u.x; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; STAELS B, 1990, ENDOCRINOLOGY, V126, P2153; STAELS B, 1991, ARTERIOSCLER THROMB, V11, P760, DOI 10.1161/01.ATV.11.3.760; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; STAELS B, 1989, J LIPID RES, V30, P1137; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WALSH A, 1989, J BIOL CHEM, V264, P6488; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327	40	109	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22401	22404		10.1074/jbc.272.36.22401	http://dx.doi.org/10.1074/jbc.272.36.22401			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278389	hybrid			2022-12-27	WOS:A1997XV49200008
J	Chan, A; Berry, L; OBrodovich, H; Klement, P; Mitchell, L; Baranowski, B; Monagle, P; Andrew, M				Chan, A; Berry, L; OBrodovich, H; Klement, P; Mitchell, L; Baranowski, B; Monagle, P; Andrew, M			Covalent antithrombin-heparin complexes with high anticoagulant activity - Intravenous, subcutaneous, and intratracheal administration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SEQUENCE; ANTI-THROMBIN; CHAIN	Although heparin has been used clinically for prophylaxis and treatment of thrombosis, it has suffered from problems such as short duration within compartments in vivo that require long term anticoagulation. A covalent antithrombin-heparin complex has been produced with high anticoagulant activity and a long half-life relative to heparin. The product had high anti-factor Xa and antithrombin activities compared with noncovalent mixtures of antithrombin and heparin (861 and 753 units/mg versus 209 and 198 units/mg, respectively). Reaction with thrombin was rapid with bimolecular and second order rate constants of 1.3 x 10(9) M-1 s(-1) and 3.1 x 10(9) M-1 s(-1), respectively. The intravenous half-life of the complex in rabbits was 2.6 h as compared with 0.32 h for similar loads of heparin. Subcutaneous injection of antithrombin-heparin resulted in plasma levels (peaking at 24-30 h) that were still detectable 96 h post-injection. Given the increased lifetime in these vascular and intravascular spaces, use of the covalent complex in the lung was investigated. Activity of antithrombin-heparin instilled into rabbit lungs remained for 48 h with no detection of any complex systemically. Thus, this highly active agent has features required for pulmonary sequestration as a possible treatment for thrombotic diseases such as respiratory distress syndrome.	HAMILTON CIV HOSP,RES CTR,HENDERSON GEN DIV,HAMILTON,ON L8V 1C3,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DEPT PEDIAT,MRC,GRP DEV LUNG BIOL,RESP RES DIV,RES INST,TORONTO,ON M5G 1X8,CANADA	McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Chan, Anthony K. C./AAR-8892-2021	Chan, Anthony K. C./0000-0003-1551-3995; Monagle, Paul/0000-0002-3970-8984				BACHOFEN M, 1982, CLIN CHEST MED, V3, P35; Bergqvist D, 1996, J INTERN MED, V240, P63, DOI 10.1046/j.1365-2796.1996.494834000.x; BERGSTEIN JM, 1992, NEW ENGL J MED, V327, P755, DOI 10.1056/NEJM199209103271102; BJORK I, 1982, FEBS LETT, V143, P96, DOI 10.1016/0014-5793(82)80281-0; BREGMAN MD, 1977, BIOCHEM BIOPH RES CO, V78, P584, DOI 10.1016/0006-291X(77)90219-4; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CEUSTERMANS R, 1982, J BIOL CHEM, V257, P3401; COALSON JJ, 1992, AM REV RESPIR DIS, V145, P872, DOI 10.1164/ajrccm/145.4_Pt_1.872; CONOVER P T, 1990, Pediatric Pathology, V10, P707; DAWES J, 1994, BIOCHEMISTRY-US, V33, P4375, DOI 10.1021/bi00180a035; EVANS DL, 1991, J BIOL CHEM, V266, P22307; FUKUDA Y, 1987, AM J PATHOL, V126, P171; GITLIN D, 1956, PEDIATRICS, V17, P64; HATTON MWC, 1980, ANAL BIOCHEM, V106, P417, DOI 10.1016/0003-2697(80)90542-4; HIXON SH, 1975, BIOCHEMISTRY-US, V14, P4251; HORNER AA, 1971, J BIOL CHEM, V246, P231; HOYLAERTS M, 1984, J BIOL CHEM, V259, P5670; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KRUEGER RC, 1987, ANAL BIOCHEM, V167, P295, DOI 10.1016/0003-2697(87)90167-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLE B, 1994, J BIOL CHEM, V269, P29435; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OSCARSSON LG, 1989, J BIOL CHEM, V264, P296; PETERSEN LC, 1983, BIOCHEM J, V211, P91, DOI 10.1042/bj2110091; PLETCHER CH, 1982, J BIOL CHEM, V257, P5342; ROSENBERG RD, 1979, BIOCHEM BIOPH RES CO, V86, P1319, DOI 10.1016/0006-291X(79)90260-2; SALDEEN T, 1982, ANN NY ACAD SCI, V384, P319, DOI 10.1111/j.1749-6632.1982.tb21381.x; SEEGER W, 1985, J APPL PHYSIOL, V58, P326, DOI 10.1152/jappl.1985.58.2.326; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; WRIGHT CJ, 1981, CAN J SURG, V24, P130	30	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22111	22117		10.1074/jbc.272.35.22111	http://dx.doi.org/10.1074/jbc.272.35.22111			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268354	hybrid			2022-12-27	WOS:A1997XT85000066
J	Garrett, TA; Kadrmas, JL; Raetz, CRH				Garrett, TA; Kadrmas, JL; Raetz, CRH			Identification of the gene encoding the Escherichia coli lipid a 4'-kinase - Facile phosphorylation of endotoxin analogs with recombinant LpxK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE ENDOTOXIN; UDP-N-ACETYLGLUCOSAMINE; A DISACCHARIDE SYNTHASE; EUKARYOTIC SIGNAL-TRANSDUCTION; ACID-DEFICIENT MUTANT; HTRB GENE; SALMONELLA-TYPHIMURIUM; BACTERIAL-ENDOTOXINS; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; MUTATIONAL ANALYSIS	The genes for seven of nine enzymes needed for the biosynthesis of Kdo(2)-lipid A (Re endotoxin) in Escherichia coli have been reported, We have now identified a novel gene encoding the lipid A 4'-kinase (the sixth step of the pathway). The 4'-kinase transfers the (gamma) over dot-phosphate of ATP to the 4'-position of a tetraacyldisaccharide 1-phosphate intermediate (termed DS-1-P) to form tetraacyldisaccharide 1,4'-bis-phosphate (lipid IVA). The 4'-phosphate is required for the action of distal enzymes, such as Kdo transferase and also renders lipid A substructures active as endotoxin antagonists or mimetics, Lysates of E. coli generated using individual A clones from the ordered Kohara library were assayed for over-production of 4'-kinase. Only one clone, [218]E1D1, which directed 2-2.5-fold overproduction, was identified. This construct contains 20 kilobase pairs of E. coli DNA from the vicinity of minute 21. Two genes related to the lipid A system map in this region: msbA, encoding a putative translocator, and kdsB, the structural gene for CMP-Kdo synthase, msbA forms an operon with a downstream, essential open reading frame of unknown function, designated orfE. orfE was cloned into a T7 expression system. Washed membranes from cells overexpressing orfE display similar to 2000-fold higher specific activity of 4'-kinase than membranes from cells with vector alone. Membranes containing recombinant, overexpressed 4'-kinase (but not membranes with wild-type kinase levels) efficiently phosphorylate three DS-1-P analogs: 3-aza-DS-1-P, base-treated DS-1-P, and base-treated 3-aza-DS-1-P. A synthetic hexaacylated DS-1-P analog, compound 505, can also be phosphorylated by membranes from the overproducer, yielding [4'-P-32] lipid A (endotoxin). The overexpressed lipid A 4'-kinase is very useful for making new 4'-phosphorylated lipid A analogs with potential utility as endotoxin mimetics or antagonists, We suggest that orfE is the structural gene for the 4'-kinase and that it be redesignated IpxK.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NIGMS NIH HHS [GM-51310] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Ausubel FM, 1988, MOL REPROD DEV; BERLYN MKB, 1996, ESCHERICHIA COLI SAL, V2, P1715; BORODOVSKY M, 1994, TRENDS BIOCHEM SCI, V19, P309, DOI 10.1016/0968-0004(94)90067-1; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; BUNNELL E, 1995, CRIT CARE MED S, V23, pA151; BUNNELL E, 1995, CRIT CARE MED S, V23, pA147; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CLEMENTZ T, 1995, FASEB J, V9, pA1311; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; CROWELL DN, 1987, J BACTERIOL, V169, P5727, DOI 10.1128/jb.169.12.5727-5734.1987; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; HAMPTON RY, 1991, J BIOL CHEM, V266, P19499; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HASELBERGER A, 1987, TRIANGLE, V26, P33; IMOTO M, 1987, B CHEM SOC JPN, V60, P2205, DOI 10.1246/bcsj.60.2205; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KAROW M, 1991, MOL MICROBIOL, V5, P2285, DOI 10.1111/j.1365-2958.1991.tb02159.x; KAROW M, 1991, J BACTERIOL, V173, P741, DOI 10.1128/jb.173.2.741-750.1991; KAROW M, 1992, J BACTERIOL, V174, P7407, DOI 10.1128/jb.174.22.7407-7418.1992; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUSUMOTO S, 1992, BACTERIAL ENDOTOXIC, V1, P81; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; MCGRATH BC, 1991, J BACTERIOL, V173, P649, DOI 10.1128/jb.173.2.649-654.1991; MDLULI KE, 1994, MICROBIOL-SGM, V140, P3309, DOI 10.1099/13500872-140-12-3309; Miller J. H., 1972, EXPT MOL GENETICS, P433; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; RADIKA K, 1988, J BIOL CHEM, V263, P14859; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RAY BL, 1984, J BIOL CHEM, V259, P4852; RAY BL, 1987, J BIOL CHEM, V262, P1122; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; REEVES PR, 1994, BACTERIAL CELL WALL, V27, P281; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHOLZ D, 1992, J MED CHEM, V35, P2070, DOI 10.1021/jm00089a019; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; VYPLEL H, 1991, J MED CHEM, V34, P2759, DOI 10.1021/jm00113a013; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	69	87	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21855	21864		10.1074/jbc.272.35.21855	http://dx.doi.org/10.1074/jbc.272.35.21855			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268317	hybrid			2022-12-27	WOS:A1997XT85000029
J	Hsieh, M; Brenowitz, M				Hsieh, M; Brenowitz, M			Comparison of the DNA association kinetics of the Lac repressor tetramer, its dimeric mutant LacI(adi) and the native dimeric Gal repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFUSION-DRIVEN MECHANISMS; MEDIATED LOOPED COMPLEX; OPERATOR INTERACTION; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; REGULATORY PROTEINS; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; THERMODYNAMIC ORIGINS; LENGTH DEPENDENCE	The rates of association of the tetrameric Lac repressor (LacI), dimeric LacI(adi) (a deletion mutant of LacI), and the native dimeric Gal repressor (GalR) to DNA restriction fragments containing a single specific site were investigated using a quench-flow DNase I ''foot printing'' technique, The dimeric proteins, LacI(adi) and GalR, and tetrameric LacI possess one and two DNA binding sites, respectively, The nanomolar protein concentrations used in these studies ensured that the state of oligomerization of each protein was predominantly either dimeric or tetrameric, respectively, The bimolecular association rate constants (k(a)) determined for the LacI tetramer exceed those of the dimeric proteins, The values of k(a) obtained for LacI, LacI(adi), and GalR display different dependences on [KCl], For LacI(adi) and GalR, they diminish as [KCl] increases from 25 mM to 200 mM, approaching rates predicted for three-dimensional diffusion, In contrast, the k(a) values determined for the tetrameric LacI remain constant up to 300 mM [KCl] the highest salt concentration that could be investigated by quench-flow footprinting. The enhanced rate of association of the tetramer relative to the dimeric proteins can be modeled by enhanced ''sliding'' (Berg, O. G., Winter, R. B., and von Hippel, P.H. (1981) Biochemistry 20, 6929-6948) of the LacI tetramer relative to the LacI(adi) dimer or a combination of enhanced sliding and the superimposition of ''direct transfer'' mediated by the bidentate DNA interactions of the tetramer.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIGMS NIH HHS [F31-GM13850, GM39929] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039929, R29GM039929, F31GM013850] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3833, DOI 10.1021/bi00516a026; BELLOMY GR, 1988, BIOCHEMISTRY-US, V27, P3900, DOI 10.1021/bi00411a002; BERG OG, 1982, TRENDS BIOCHEM SCI, V7, P52, DOI 10.1016/0968-0004(82)90075-5; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BERG OG, 1988, TRENDS BIOCHEM SCI, V13, P207, DOI 10.1016/0968-0004(88)90085-0; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; BRENOWITZ M, 1993, BIOCHEMISTRY-US, V32, P8693, DOI 10.1021/bi00084a041; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRENOWITZ M, 1991, BIOCHEMISTRY-US, V30, P5986, DOI 10.1021/bi00238a024; Brenowitz M., 1989, CURRENT PROTOCOLS MO; BRENOWITZ M, 1993, FOOTPRINTING TECHNIQ, P1; BRESLOFF JL, 1975, J MOL BIOL, V95, P103, DOI 10.1016/0022-2836(75)90339-3; CHEN J, 1994, BIOCHEMISTRY-US, V26, P8728; DalmaWeiszhausz DD, 1996, BIOCHEMISTRY-US, V35, P3735, DOI 10.1021/bi952408s; DALMAWEISZHAUSZ DD, 1995, THESIS A EINSTEIN CO, P40; FICKERT R, 1992, J MOL BIOL, V226, P59, DOI 10.1016/0022-2836(92)90124-3; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GARNER MM, 1995, EMBO J, V14, P1257, DOI 10.1002/j.1460-2075.1995.tb07109.x; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; Hsieh M, 1996, METHOD ENZYMOL, V274, P478; HSIEH M, 1994, J BIOL CHEM, V269, P13825; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; JELTSCH A, 1994, BIOCHEMISTRY-US, V33, P10216; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KHOURY AM, 1990, BIOCHIM BIOPHYS ACTA, V1087, P55, DOI 10.1016/0167-4781(90)90120-Q; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; Levandoski MM, 1996, J MOL BIOL, V260, P697, DOI 10.1006/jmbi.1996.0431; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; MAZUR SJ, 1989, BIOPOLYMERS, V28, P929, DOI 10.1002/bip.360280503; MOSSING MC, 1985, J MOL BIOL, V186, P295, DOI 10.1016/0022-2836(85)90106-8; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; ROYER CA, 1990, BIOCHEMISTRY-US, V29, P4959, DOI 10.1021/bi00472a028; RUUSALA T, 1992, P NATL ACAD SCI USA, V89, P4903, DOI 10.1073/pnas.89.11.4903; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Sclavi B, 1997, J MOL BIOL, V266, P144, DOI 10.1006/jmbi.1996.0775; STICKLE DF, 1994, EUR J BIOCHEM, V226, P869, DOI 10.1111/j.1432-1033.1994.00869.x; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; Vossen KM, 1996, J MOL BIOL, V255, P44, DOI 10.1006/jmbi.1996.0005; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3852, DOI 10.1021/bi00361a017; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029	50	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22092	22096		10.1074/jbc.272.35.22092	http://dx.doi.org/10.1074/jbc.272.35.22092			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268351	hybrid			2022-12-27	WOS:A1997XT85000063
J	Zhan, XY; Crouch, RJ				Zhan, XY; Crouch, RJ			The isolated RNase H domain of murine leukemia virus reverse transcriptase - Retention of activity with concomitant loss of specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RIBONUCLEASE-H; ESCHERICHIA-COLI; DNA-POLYMERASE; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; PRIMER-TEMPLATE; STRAND TRANSFER; TYPE-1; MUTATIONS	Retroviral RNases H are similar in sequence and structure to Escherichia coli RNase HI and yet have differences in substrate specificities, metal ion requirements, and specific activities. Separation of reverse transcriptase (RT) into polymerase and RNase H domains yields an active RNase H from murine leukemia virus (MuLV) but an inactive human immunodeficiency virus (HN) RNase H. The ''handle region'' present in E. coli RNase HI but absent in HIV RNase H contributes to the binding to its substrate and when inserted into HIV RNase H results in an active enzyme retaining some degree of specificity. Here, we show MuLV protein containing the C-terminal 175 amino acids with its own handle region or that of E. coli RNase HI has the same specific activity as the RNase H of RT, retains a preference for Mn2+ as the cation required for activity, and has association rate (K-A) 10% that of E. coli RNase HI. However, with model substrates, specificities for removal of the tRNA(Pro) primer and polypurine tract stability are lost, indicating specificity of RNase H of MuLV requires the remainder of the RT. Differences in K-A, while significant, appear insufficient to account for the differences in specific activities of the bacterial and viral RNases H.	NICHHD, MOL GENET LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; BLAIN SW, 1995, J VIROL, V69, P4440, DOI 10.1128/JVI.69.7.4440-4452.1995; CARL PL, 1980, J BACTERIOL, V144, P28, DOI 10.1128/JB.144.1.28-35.1980; CERRITELLI SM, 1993, BIOCHIMIE, V75, P107, DOI 10.1016/0300-9084(93)90031-M; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DIRKSEN ML, 1981, J BIOL CHEM, V256, P1569; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; Haruki M, 1997, J BIOL CHEM, V272, P22015, DOI 10.1074/jbc.272.35.22015; HERR W, 1984, J VIROL, V49, P471, DOI 10.1128/JVI.49.2.471-478.1984; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; Keck JL, 1996, J BIOL CHEM, V271, P19883, DOI 10.1074/jbc.271.33.19883; KECK JL, 1995, P NATL ACAD SCI USA, V92, P2740, DOI 10.1073/pnas.92.7.2740; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MIZRAHI V, 1994, J BIOL CHEM, V269, P19245; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PALANIAPPAN C, 1995, J BIOL CHEM, V270, P4861, DOI 10.1074/jbc.270.9.4861; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; POST K, 1993, BIOCHEMISTRY-US, V32, P5508, DOI 10.1021/bi00072a004; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; REPASKE R, 1989, J VIROL, V63, P1460, DOI 10.1128/JVI.63.3.1460-1464.1989; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHULTZ SJ, 1995, J BIOL CHEM, V270, P24135, DOI 10.1074/jbc.270.41.24135; SKALKA A, 1993, REVERSE TRANSCRIPTAS; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; SMITH JK, 1984, J VIROL, V49, P200, DOI 10.1128/JVI.49.1.200-204.1984; SMITH JS, 1994, J VIROL, V68, P5721, DOI 10.1128/JVI.68.9.5721-5729.1994; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; STAHL SJ, 1994, PROTEIN ENG, V7, P1103, DOI 10.1093/protein/7.9.1103; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WONDRAK EM, 1986, J GEN VIROL, V67, P2791, DOI 10.1099/0022-1317-67-12-2791; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; ZHAN XY, 1994, BIOCHEMISTRY-US, V33, P1366, DOI 10.1021/bi00172a012	50	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22023	22029		10.1074/jbc.272.35.22023	http://dx.doi.org/10.1074/jbc.272.35.22023			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268341	hybrid			2022-12-27	WOS:A1997XT85000053
J	Zhang, BL; Wang, ZX; Zheng, Y				Zhang, BL; Wang, ZX; Zheng, Y			Characterization of the interactions between the small GTPase Cdc42 and its GTPase-activating proteins and putative effectors - Comparison of kinetic properties of Cdc42 binding to the Cdc42-interactive domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; ALDRICH SYNDROME PROTEIN; SACCHAROMYCES-CEREVISIAE; INORGANIC-PHOSPHATE; N-CHIMAERIN; RAS; KINASE; RAC1; FILOPODIA; ASSAY	The small GTPase Cdc42 interacts with multiple factors to transduce diverse intracellular signals, The factors that preferentially recognize the GTP bound, active state of Cdc42 include a panel of GTPase-activating proteins (GAPs), the Cdc42/Rac interactive binding (CRIB) motif-containing molecules, and the RasGAP domain containing IQGAP1 and IQGAP2. In the present study, we have determined the kinetic parameters underlying the functional interactions between the Cdc42-binding domains of some of these factors and Cdc42 by monitoring the continuous release of gamma P-i and have compared the ability of the domains to bind to Cdc42, The catalytic efficiencies (K-cat/K-m) of the GAP domains of Bcr, 3BP-1, and p190 on Cdc42 are found to be 60-, 160-, and over 500-fold less than that of Cdc42GAP, respectively, and the differences are due, to a large part, to differences in K-m. The K-m values of the GAP domains compare well to the binding affinity to the guanylyl imidodiphosphate-bound Cdc42, suggesting a rapid equilibrium reaction mechanism, The affinity of the Cdc42-binding domains of the CRIB motif of Wiskott Aldrich Syndrome protein and p21(cdc42/rac)-activated kinase 1, and the RasGAP-related domain of IQGAP1, which all inhibit the intrinsic rate of GTP hydrolysis of Cdc42, are found to be 4, 0.7, and 0.08 mu M, respectively, These quantitative analysis provide insight that Cdc42GAP functions as an effective negative regulator of Cdc42 by fast, relatively tight binding to the GTP-bound Cdc42, whereas IQGAP1 interacts with Cdc42 as a putative effector with over 10-fold higher affinity than the CRIB domains and GAPs, and suggest that various GAPs and effecters employ distinct mechanism to play roles in Cdc42-mediated signaling pathways.	UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163; ACAD SINICA,INST BIOPHYS,BEIJING 100080,PEOPLES R CHINA	University of Tennessee System; University of Tennessee Health Science Center; Chinese Academy of Sciences; Institute of Biophysics, CAS			Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM53943] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1993, J BIOL CHEM, V268, P10709; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Brill S, 1996, MOL CELL BIOL, V16, P4869; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; Bryant SS, 1996, J BIOL CHEM, V271, P5195; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dutartre H, 1996, J CELL SCI, V109, P367; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEOANRD DA, 1997, BIOCHEMISTRY-US, V36, P1173; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WEBB MR, 1992, BIOCHEM J, V287, P555, DOI 10.1042/bj2870555; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	59	81	84	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21999	22007		10.1074/jbc.272.35.21999	http://dx.doi.org/10.1074/jbc.272.35.21999			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268338	hybrid			2022-12-27	WOS:A1997XT85000050
J	Lavan, BE; Fantin, VR; Chang, ET; Lane, WS; Keller, SR; Lienhard, GE				Lavan, BE; Fantin, VR; Chang, ET; Lane, WS; Keller, SR; Lienhard, GE			A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; IN-VIVO; ADIPOCYTES; DOMAIN; SHC	We have previously identified a 160-kDa protein in human embryonic kidney (HEK) 293 cells that undergoes rapid tyrosine phosphorylation in response to insulin (PY160) (Kuhne, M. R., Zhao, Z., and Lienhard, G. E. (1995) Biochem. Biophys. Res. Commun. 211, 190-197). The phosphotyrosine form of PY160 was purified from insulin-treated HEK 293 cells by anti-phosphotyrosine immunoaffinity chromatography, the sequences of peptides determined, and its cDNA cloned, The PY160 cDNA encodes a 1257-amino acid protein that contains, in order from its N terminus, a pleckstrin homology (PH) domain, a phosphotyrosine binding (PTB) domain, and, spread over the C-terminal portion, 12 potential tyrosine phosphorylation sites. Several of these sites are in motifs expected to bind specific SH2 domain-containing proteins: YXXM (7 sites), phosphatidylinositol S-kinase; YVNM (1 site), Grb-2; and YIEV (1 site), either the protein-tyrosine phosphatase SHP-2 or phospholipase C gamma. Furthermore, the PH and PTB domains are highly homologous (at least 40% identical) to those found in insulin receptor substrates 1, 2, and 3 (IRS-1, IRS-2, and IRS-3). Thus, PY160 is a new member of the IRS family, which we have designated IRS-4.	DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; HARVARD UNIV, DEPT CELLULAR & MOL BIOL, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02318 USA	Dartmouth College; Harvard University			Chang, Ellen/E-3168-2010; Chang, Ellen/G-5700-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042816, R01DK042816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Dalphin ME, 1996, NUCLEIC ACIDS RES, V24, P216, DOI 10.1093/nar/24.1.216; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KUHNE MR, 1995, BIOCHEM BIOPH RES CO, V211, P190, DOI 10.1006/bbrc.1995.1795; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lavan BE, 1997, J BIOL CHEM, V272, P11439; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	21	271	279	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21403	21407		10.1074/jbc.272.34.21403	http://dx.doi.org/10.1074/jbc.272.34.21403			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261155	hybrid			2022-12-27	WOS:A1997XR78900065
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; SUBSTRATE-SPECIFICITY; MULTIDRUG-RESISTANCE; CYSTEINE RESIDUES; BINDING-SITE; NUCLEOTIDE; MUTATIONS; MEMBRANE; MUTANTS; MDR1	Transmembrane segments (TM) 6 and 12 are directly connected to the ATP-binding domain in each homologous half of P-glycoprotein and are postulated to be important for drug-protein interactions, Cysteines introduced into TM6 (L332C, F343C, G346C, and P350C) were oxidatively cross-linked to cysteines introduced into TIM12 (L975C, M986C, G989C, and S993C, respectively), The pattern of cross-linking was consistent with a left-handed coiled coil arrangement of the two helices. To detect conformational changes between the helices during drug-stimulated ATPase activity, we tested the effects of substrates and ATP on cross-linking. Cyclosporin A, verapamil, vinblastine, and colchicine inhibited cross-linking of mutants F343C/M986C, G346C/G989C, and P350C/S993C. By contrast, ATP promoted cross-linking between only L332C/L975C. Enhanced cross-linking between L332C/L975C was due to ATP hydrolysis, since cross-linked product was not observed in the presence of ATP and vanadate, ADP, ADP and vanadate, or AMP-PNP. Cross-linking between P350C/S993C inhibited verapamil-stimulated ATPase activity by about 75%, Drug-stimulated ATPase activity, however, was fully restored in the presence of dithiothreitol, These results show that TM6 and TM12 undergo different. conformational changes upon drug binding or during ATP hydrolysis, and that movement between these two helices is essential for drug-stimulated ATPase activity.	UNIV TORONTO,DEPT MED,MED RES COUNCIL GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	30	103	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20986	20989		10.1074/jbc.272.34.20986	http://dx.doi.org/10.1074/jbc.272.34.20986			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261097	hybrid			2022-12-27	WOS:A1997XR78900007
J	Morita, K; Kitayama, S; Dohi, T				Morita, K; Kitayama, S; Dohi, T			Stimulation of cyclic ADP-ribose synthesis by acetylcholine and its role in catecholamine release in bovine adrenal chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INDUCED CA2+ RELEASE; DEPENDENT PROTEIN-KINASE; PANCREATIC BETA-CELLS; RYANODINE RECEPTOR; CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; CA2+-RELEASE CHANNEL; INSULIN-SECRETION; CARDIAC-MUSCLE; ACINAR-CELLS	Cyclic ADP-ribose (cADPR) is suggested to be a novel messenger of ryanodine receptors in various cellular systems, However, the regulation of its synthesis in response to cell stimulation and its functional roles are still unclear, We examined the physiological relevance of cADPR to the messenger role in stimulation-secretion coupling in cultured bovine adrenal chromaffin cells. Sensitization of Ca2+-induced Ca2+ release (CICR) and stimulation of catecholamine release by cADPR in permeabilized cells were demonstrated along with the contribution of CICR to intracellular Ca2+ dynamics and secretory response during stimulation of intact chromaffin cells, ADP-ribosyl cyclase was activated in the membrane preparation from chromaffin cells stimulated with acetylcholine (ACh), excess KCI depolarization, and 8-bromo-cyclic-AMP, ACh-induced activation of ADP-ribosyl cyclase was dependent on the influx of Ca2+ into cells and on the activation of cyclic AMP-dependent protein kinase. These and previous findings that ACh activates adenylate cyclase by Ca2+ influx in chromaffin cells suggested that ACh induces activation of ADP-ribosyl cyclase through Ca2+ influx and cyclic AMP-mediated pathways, These results provide evidence that the synthesis of cADPR is regulated by cell stimulation, and the cADPR/CICR. pathway forms a significant signal transduction for secretion.	HIROSHIMA UNIV, SCH DENT, DEPT PHARMACOL, MINAMI KU, HIROSHIMA 734, JAPAN	Hiroshima University								BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; FENWICK EM, 1978, J CELL BIOL, V76, P12, DOI 10.1083/jcb.76.1.12; FRUEN BR, 1994, FEBS LETT, V352, P123, DOI 10.1016/0014-5793(94)00931-7; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Galione Antony, 1994, Trends in Cell Biology, V4, P431, DOI 10.1016/0962-8924(94)90104-X; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GROMADA J, 1995, FEBS LETT, V360, P303, DOI 10.1016/0014-5793(95)00131-R; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSE AH, 1995, J IMMUNOL, V155, P3353; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HIGASHIDA H, 1995, J PHYSIOL-LONDON, V482, P317, DOI 10.1113/jphysiol.1995.sp020520; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LI Q, 1994, BIOCHEM BIOPH RES CO, V202, P629, DOI 10.1006/bbrc.1994.1974; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MORITA K, 1987, J NEUROCHEM, V48, P243, DOI 10.1111/j.1471-4159.1987.tb13154.x; MORITA K, 1995, J LIPID MEDIAT CELL, V11, P219, DOI 10.1016/0929-7855(94)00038-E; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; Shibata K, 1996, BIOCHEM PHARMACOL, V52, P167, DOI 10.1016/0006-2952(96)00135-9; SIMPSON PB, 1995, TRENDS NEUROSCI, V18, P299, DOI 10.1016/0166-2236(95)93919-O; SIMPSON PB, 1993, J NEUROCHEM, V61, P760; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TANAKA Y, 1995, P NATL ACAD SCI USA, V92, P3244, DOI 10.1073/pnas.92.8.3244; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TSUJIMOTO A, 1991, PRESYNAPTIC REGULATI, P1085; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; VOLPE P, 1990, AM J PHYSIOL, V258, pC1086, DOI 10.1152/ajpcell.1990.258.6.C1086; VONEULER U, 1961, ACTA PHYSIOL SCAND, V51, P348, DOI 10.1111/j.1748-1716.1961.tb02145.x; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZHANG FJ, 1995, BIOORG MED CHEM LETT, V5, P2267, DOI 10.1016/0960-894X(95)00393-8	52	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21002	21009		10.1074/jbc.272.34.21002	http://dx.doi.org/10.1074/jbc.272.34.21002			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261101	hybrid			2022-12-27	WOS:A1997XR78900011
J	Barnabas, S; Hai, TW; Andrisani, OM				Barnabas, S; Hai, TW; Andrisani, OM			The hepatitis B virus X protein enhances the DNA binding potential and transcription efficacy of bZip transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; 3 C/EBP ISOFORMS; TRANS-ACTIVATION; GENE-EXPRESSION; HBX PROTEIN; I TAX; HEPATOCELLULAR-CARCINOMA; ESCHERICHIA-COLI; VIRAL ENHANCERS	The hepatitis B virus X protein interacts with the basic-region, leucine zipper protein (bZip) domain of cAMP response element binding protein increasing its affinity for the cAMP response element site in vitro and its transcriptional efficacy in vivo (Williams, J. S., and Andrisani, O. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3819-3823). Here we examine pX interactions with bZip transcription factors ATF(3), gadd153/Chop10, ICER II gamma and NF-IL6. We demonstrate direct interactions in vitro between pX and the bZip proteins tested. In contrast MyoD and Gal4(1-147) fail to interact with pX. We also demonstrate by the mammalian two-hybrid assay the direct interaction of pX with cAMP response element-binding protein, ICER II gamma, ATF(3), and NF-IL6 in hepatocytes. In addition, pX increases the DNA binding potential of bZip proteins for their cognate DNA-binding site in vitro. In transient transfections in hepatocytes (AML12 cell line), pX increases the transcriptional efficacy of the bZip transcription factors. NF-IL6-mediated transcriptional activation is enhanced 3-fold by pX. Most interestingly, pX augments the repression mediated by bZip repressors ATF, and ICER IL gamma, by 6- and 7-fold, respectively, demonstrating for the first time the involvement of pX in gene repression. We conclude that pX is an enhancer of the DNA binding potential of bZip transcription factors, thereby increasing the transactivation or repression efficacy of bZip-responsive genes.	PURDUE UNIV, SCH VET MED, DEPT BASIC MED SCI, W LAFAYETTE, IN 47907 USA; OHIO STATE UNIV, OHIO STATE BIOCHEM PROGRAM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, NEUROBIOTECHNOL CTR, COLUMBUS, OH 43210 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Hai, Tsonwin/H-4480-2011; Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315; Andrisani, Ourania/0000-0002-6230-0303	NIDDK NIH HHS [DK44533] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044533, R01DK044533] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ANDRISANI OM, 1991, J BIOL CHEM, V266, P21444; ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BALSANO C, 1993, ARCH VIROL, P63; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRISON TJ, 1990, J MED VIROL, V31, P33, DOI 10.1002/jmv.1890310107; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; KAY A, 1985, EMBO J, V4, P1287, DOI 10.1002/j.1460-2075.1985.tb03774.x; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; LUBER B, 1991, VIROLOGY, V184, P808, DOI 10.1016/0042-6822(91)90458-N; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; LUETHY JD, 1992, CANCER RES, V52, P5; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORIARTY AM, 1985, SCIENCE, V227, P429, DOI 10.1126/science.2981434; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PRICE BD, 1992, CANCER RES, V52, P3814; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Servillo G, 1997, ONCOGENE, V14, P1601, DOI 10.1038/sj.onc.1200996; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tesmer VM, 1996, J MOL BIOL, V262, P327, DOI 10.1006/jmbi.1996.0516; TESMER VM, 1993, P NATL ACAD SCI USA, V90, P7298, DOI 10.1073/pnas.90.15.7298; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; TWU JS, 1990, VIROLOGY, V177, P406, DOI 10.1016/0042-6822(90)90501-H; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WILLIAMS JS, 1993, DNA CELL BIOL, V12, P183, DOI 10.1089/dna.1993.12.183; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; YEN TSB, 1993, SEMIN VIROL, V4, P33; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; ZHU Z, 1989, J BIOL CHEM, V264, P6550; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	80	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20684	20690		10.1074/jbc.272.33.20684	http://dx.doi.org/10.1074/jbc.272.33.20684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252388	hybrid			2022-12-27	WOS:A1997XR22100058
J	Edgerton, MD; Graber, P; Willard, D; Consler, T; McKinnon, M; Uings, I; Arod, CY; Borlat, F; Fish, R; Peitsch, MC; Wells, TNC; Proudfoot, AEI				Edgerton, MD; Graber, P; Willard, D; Consler, T; McKinnon, M; Uings, I; Arod, CY; Borlat, F; Fish, R; Peitsch, MC; Wells, TNC; Proudfoot, AEI			Spatial orientation of the alpha and beta(c) receptor chain binding sites on monomeric human interleukin-5 constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-5; MURINE INTERLEUKIN-5; HUMAN EOSINOPHILS; ESCHERICHIA-COLI; IL-5; RESIDUES; DISEASE; HYPERREACTIVITY; IDENTIFICATION; PURIFICATION	Interleukin-5 (IL-5), a disulfide-linked homodimer, can be induced to fold as a biological active monomer by extending the loop between its third and fourth helices (Dickason, R, R., and Huston, D, P, (1996) Nature 379, 652-655), We have designed eight monomeric IL-5 proteins to optimize biological activity and stability of the monomer, This was achieved by (i) inserting the joining loop at three different positions, (ii) by introducing an additional intramolecular disulfide bridge onto these backbones, and (iii) by creating circular permutations to fix the position of the carboxyl-terminal helix relative to the three other helices, The proteins dimerize with K-d values ranging from 20 to 200 mu M and are therefore monomeric at the picomolar concentrations where they are biologically active, Introduction of a second disulfide confers increased stability, but this increased rigidity results in lower activity of the protein, Contrary to wild type IL-5, mutation of the beta(c) contact residue on the first helix, Glu(12), to Lys, into the circularly permutated constructs, did not abolish TF-1 proliferative and eosinophil activation activities, These results indicate that activation of the IL-5 receptor complex is not mediated solely by Glu(12) on the first helix, and alternative mechanisms are discussed.	GLAXO WELLCOME RES & DEV LTD, GENEVA BIOMED RES INST, CH-1228 PLAN LES OUATES, GENEVA, SWITZERLAND; GLAXO WELLCOME INC, RES & DEV, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME RES & DEV LTD, STEVENAGE SG1 2NY, HERTS, ENGLAND	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline			Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X; Wells, Timothy/0000-0001-9796-847X				AZUMA C, 1986, NUCLEIC ACIDS RES, V14, P9149, DOI 10.1093/nar/14.22.9149; BANKS M, 1995, ANAL BIOCHEM, V230, P321, DOI 10.1006/abio.1995.1481; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; DEVOS R, 1993, J BIOL CHEM, V268, P6581; Dickason RR, 1996, NATURE, V379, P652, DOI 10.1038/379652a0; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, V11, P431; EGAN RW, 1995, INT ARCH ALLERGY IMM, V107, P321, DOI 10.1159/000237014; Fattah D, 1996, CYTOKINE, V8, P248, DOI 10.1006/cyto.1996.0034; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; GRABER P, 1993, EUR J BIOCHEM, V212, P751, DOI 10.1111/j.1432-1033.1993.tb17714.x; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; INGLEY E, 1991, BLOOD, V78, P339; Jenkins BJ, 1996, J BIOL CHEM, V271, P29707, DOI 10.1074/jbc.271.47.29707; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Li J, 1996, J BIOL CHEM, V271, P1817, DOI 10.1074/jbc.271.4.1817; Li J, 1996, J BIOL CHEM, V271, P31729, DOI 10.1074/jbc.271.49.31729; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; MCKENZIE ANJ, 1992, CHEM IMMUNOL, V51, P135; MCKENZIE DT, 1987, J IMMUNOL, V139, P2661; McKinnon M, 1997, J EXP MED, V186, P121, DOI 10.1084/jem.186.1.121; MIGITA M, 1991, CELL IMMUNOL, V133, P484, DOI 10.1016/0008-8749(91)90120-Z; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Proudfoot AEI, 1996, J PROTEIN CHEM, V15, P491, DOI 10.1007/BF01886857; PROUDFOOT AEI, 1990, BIOCHEM J, V270, P357, DOI 10.1042/bj2700357; REED CE, 1994, ANN ALLERGY, V72, P376; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; STRYDOM DJ, 1993, TECHNIQUES PROTEIN C; TAVERNIER J, 1989, DNA-J MOLEC CELL BIO, V8, P491, DOI 10.1089/dna.1.1989.8.491; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARDLAW AJ, 1994, POSTGRAD MED J, V70, P536, DOI 10.1136/pgmj.70.826.536; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	46	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20611	20618		10.1074/jbc.272.33.20611	http://dx.doi.org/10.1074/jbc.272.33.20611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252376	hybrid			2022-12-27	WOS:A1997XR22100046
J	Lamaze, C; Fujimoto, LM; Yin, HL; Schmid, SL				Lamaze, C; Fujimoto, LM; Yin, HL; Schmid, SL			The actin cytoskeleton is required for receptor-mediated endocytosis in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNALIZATION STEP; BINDING-PROTEINS; CYTOCHALASIN-D; EXOCYTOSIS; MICROFILAMENTS; ORGANIZATION; INHIBITION; FILAMENT; GROWTH; ASSAYS	Actin filament organization is essential for endocytosis in yeast. In contrast, the actin-depolymerizing agent cytochalasin D has yielded ambiguous results as to a role for actin in receptor mediated endocytosis in mammalian cells. We have therefore re-examined this issue using highly specific reagents known to sequester actin monomers. Two of these reagents, thymosin beta 4 and DNase I, potently inhibited the sequestration of transferrin receptors into coated pits as measured in a cell-free system using perforated A431 cells. At low concentrations, thymosin beta 4 but not DNase I was stimulatory, Importantly, the effects of both reagents were specifically neutralized by the addition of actin monomers. A role for the actin cytoskeleton was also detected in intact cells where latrunculin A, a drug that sequesters actin monomers, inhibited receptor-mediated endocytosis. Biochemical and morphological analyses suggest that these reagents inhibit later events in coated vesicle budding. These results provide new evidence that the actin cytoskeleton is required for receptor-mediated endocytosis in mammalian cells.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA	Scripps Research Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Lamaze, Christophe/M-4912-2017	Schmid, Sandra/0000-0002-1690-7024; LAMAZE, Christophe/0000-0001-5430-2707	NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051112, R01GM042455] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline; NIGMS NIH HHS [GM51112, GM42455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Durrbach A, 1996, J CELL SCI, V109, P457; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; JACKMAN MR, 1994, J CELL SCI, V107, P2547; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SALISBURY JL, 1980, J CELL BIOL, V87, P132, DOI 10.1083/jcb.87.1.132; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; TRIFARO JM, 1992, MOL NEUROBIOL, V6, P339, DOI 10.1007/BF02757940; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; WEBER A, 1994, BIOCHEMISTRY-US, V33, P4780, DOI 10.1021/bi00182a005; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; YU FX, 1993, J BIOL CHEM, V268, P502	29	324	328	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20332	20335		10.1074/jbc.272.33.20332	http://dx.doi.org/10.1074/jbc.272.33.20332			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252336	hybrid			2022-12-27	WOS:A1997XR22100006
J	May, JM; Mendiratta, S; Hill, KE; Burk, RF				May, JM; Mendiratta, S; Hill, KE; Burk, RF			Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; GLUTATHIONE-PEROXIDASE; HUMAN NEUTROPHILS; PURIFICATION; ACID; IDENTIFICATION; DEHYDROGENASE; GLUTAREDOXIN; EXPRESSION; CLONING	Recycling of ascorbate from its oxidized forms is essential to maintain stores of the vitamin in human cells, Whereas reduction of dehydroascorbate to ascorbate is thought to be largely GSH-dependent, we reconsidered the possibility that the selenium-dependent thioredoxin system might contribute to ascorbate regeneration. We found that purified rat liver thioredoxin reductase fractions as an NADPH-dependent dehydroascorbate reductase, with an apparent K-m of 2.5 mM for dehydroascorbate, and a k(cat) of 90 min(-1), Addition of 2.8 mu M purified rat liver thioredoxin lowered the apparent K-m to 0.7 mM, without affecting the turnover (k(cat) of 71 min(-1)), Since thioredoxin reductase requires selenium, we tested the physiologic importance of this enzyme for dehydroascorbate reduction in livers from control and selenium-deficient rats, Selenium deficiency lowered liver thioredoxin reductase activity by 88%, glutathione peroxidase activity by 99%, and ascorbate content by 33%, but did not affect GSH content, NADPH-dependent dehydroascorbate reductase activity due to thioredoxin reductase, on the basis of inhibition by aurothioglucose, was decreased 88% in dialyzed liver cytosolic fractions from selenium-deficient rats, GSH-dependent dehydroascorbate reductase activity in liver cytosol was variable, but typically 2-3-fold that of NADPH-dependent activity. These results show that the thioredoxin system can reduce dehydroascorbate, and that this function is required for maintenance of liver ascorbate content.			May, JM (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MED,715 MED RES BLDG 2,NASHVILLE,TN 37232, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050435, P30DK026657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002497, R01ES002497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26657, DK50435] Funding Source: Medline; NIEHS NIH HHS [ES02497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arner ESJ, 1996, BIOCHEM BIOPH RES CO, V225, P268, DOI 10.1006/bbrc.1996.1165; BOX GEP, 1960, ANN NY ACAD SCI, V86, P792, DOI 10.1111/j.1749-6632.1960.tb42843.x; BURK RF, 1987, METHOD ENZYMOL, V143, P307; CHAUDIERE J, 1984, J INORG BIOCHEM, V20, P313, DOI 10.1016/0162-0134(84)85030-8; DELBELLO B, 1994, BIOCHEM J, V304, P385, DOI 10.1042/bj3040385; DUE AD, 1995, BIOCHEMISTRY-US, V34, P5462, DOI 10.1021/bi00016a017; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HUGHES RE, 1964, NATURE, V203, P1068, DOI 10.1038/2031068a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MAELLARO E, 1994, BIOCHEM J, V301, P471, DOI 10.1042/bj3010471; May JM, 1996, J BIOL CHEM, V271, P10577, DOI 10.1074/jbc.271.18.10577; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; Rikans LE, 1996, MECH AGEING DEV, V91, P165, DOI 10.1016/S0047-6374(96)01784-8; ROSE RC, 1992, ENZYME, V46, P196, DOI 10.1159/000468788; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WELLS WW, 1995, METHOD ENZYMOL, V252, P30; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; Xu DP, 1996, BIOCHEM BIOPH RES CO, V221, P117, DOI 10.1006/bbrc.1996.0555	29	257	267	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22607	22610		10.1074/jbc.272.36.22607	http://dx.doi.org/10.1074/jbc.272.36.22607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278416	hybrid			2022-12-27	WOS:A1997XV49200036
J	Michelotti, EF; Sanford, S; Freije, JMP; MacDonald, NJ; Steeg, PS; Levens, D				Michelotti, EF; Sanford, S; Freije, JMP; MacDonald, NJ; Steeg, PS; Levens, D			Nm23/PuF does not directly stimulate transcription through the CT element in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; NUCLEAR RIBONUCLEOPROTEIN-K; BREAST-CARCINOMA CELLS; TUMOR-METASTASIS; MYC PROMOTER; DROSOPHILA DEVELOPMENT; MYXOCOCCUS-XANTHUS; ESCHERICHIA-COLI; MELANOMA-CELLS; DNA-BINDING	Decreased levels of the nm23 gene product have been correlated with increased tumor metastatic potential in a variety of malignancies. At least a subset of the regulatory properties of Nm23 has been proposed to be due to transactivation of the human c-myc oncogene through binding to a homopyrimidine tract 140 base pairs upstream of the transcription start site (termed the CT element or the PuF site). Conventional transcription factors possess DNA binding and transactivation domains; Nm23 fusion proteins were used to address two questions. First, if provided with a well characterized DNA binding domain, does Nm23 possess a transactivation domain capable of stimulating transcription of an appropriate reporter? Second, if provided with a potent transactivation domain, is the DNA binding of Nm23 of sufficient specificity and affinity to direct the fusion protein to a CT-dependent reporter? Since reporter gene expression was not stimulated in either case, we conclude that Nm23 does not directly stimulate transcription through binding to the CT element and that its antimetastatic and other reported functions are likely due to other biochemical activities.	NCI,WOMENS CANC SECT,PATHOL LAB,DIV CLIN SCI,NIH,BETHESDA,MD 20892; NCI,GENE REGULAT SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Levens, David/C-9216-2009; Freije, José M.P./A-6535-2008	Levens, David/0000-0002-7616-922X; Freije, José M.P./0000-0002-4688-8266				ARCINAS M, 1994, ONCOGENE, V9, P2699; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BABA H, 1995, CANCER RES, V55, P1977; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; PARHAR RS, 1995, INT J CANCER, V60, P204; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; Zhang XL, 1996, J BACTERIOL, V178, P4115, DOI 10.1128/jb.178.14.4115-4121.1996	41	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22526	22530		10.1074/jbc.272.36.22526	http://dx.doi.org/10.1074/jbc.272.36.22526			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278405	hybrid			2022-12-27	WOS:A1997XV49200025
J	Acs, P; Bogi, K; Lorenzo, PS; Marquez, AM; Biro, T; Szallasi, Z; Blumberg, PM				Acs, P; Bogi, K; Lorenzo, PS; Marquez, AM; Biro, T; Szallasi, Z; Blumberg, PM			The catalytic domain of protein kinase C chimeras modulates the affinity and targeting of phorbol ester-induced translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-ISOFORM; BINDING-PROTEIN; CELLS; ISOZYMES; ACTIVATION; BETA; DIFFERENTIATION; IDENTIFICATION; LOCALIZATION; FIBROBLASTS	Emerging evidence suggests important differences among protein kinase C (PKC) isozymes in terms of their regulation and biological functions, PKC is regulated by multiple interdependent mechanisms, including enzymatic activation, translocation of the enzyme in response to activation, phosphorylation, and proteolysis. As part of our ongoing studies to define the factors contributing to the specificity of PKC isozymes, we prepared chimeras between the catalytic and regulatory domains of PKC alpha, -delta, and -epsilon. These chimeras, which preserve the overall structure of the native PKC enzymes, were stably expressed in NIH 3T3 fibroblasts. Their intracellular distribution was similar to that of the endogenous enzymes, and they responded with translocation upon treatment with phorbol 12-myristate 13-acetate (PMA). We found that the potency of PMA for translocation of the PKC alpha/x chimeras from the soluble fraction was influenced by the catalytic domain. The ED50 for translocation of PKC alpha/alpha was 26 nM, in marked contrast to the ED50 of 0.9 nM in the case of the PKC alpha/epsilon chimera. In addition to this increase in potency, the site of translocation was also changed; the PKC alpha/epsilon chimera translocated mainly into the cytoskeletal fraction. PKCx/epsilon chimeras displayed twin isoforms with different mobilities on Western blots. PMA treatment increased the proportion of the higher mobility isoform. The two PKCx/epsilon isoforms differed in their localization; moreover, their localization pattern depended on the regulatory domain, Our results emphasize the complex contributions of the regulatory and catalytic domains to the overall behavior of PKC.	NCI,MOL MECH TUMOR PROMOT SECT,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,NIH,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,DEPT PHARMACOL,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA				Szallasi, Zoltan/0000-0001-5395-7509				BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CACACE AM, 1993, ONCOGENE, V8, P2095; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; DISATNIK MH, 1994, CELL GROWTH DIFFER, V5, P873; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KILEY SC, 1995, J CELL SCI, V108, P1003; KILEY SC, 1995, BIOCHEM SOC T, V23, P601, DOI 10.1042/bst0230601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; ORR JW, 1994, J BIOL CHEM, V269, P27715; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; RAZIN E, 1994, P NATL ACAD SCI USA, V91, P7722, DOI 10.1073/pnas.91.16.7722; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	35	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22148	22153		10.1074/jbc.272.35.22148	http://dx.doi.org/10.1074/jbc.272.35.22148			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268359	hybrid			2022-12-27	WOS:A1997XT85000071
J	Graff, JR; Herman, JG; Myohanen, S; Baylin, SB; Vertino, PM				Graff, JR; Herman, JG; Myohanen, S; Baylin, SB; Vertino, PM			Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; DNA METHYLATION; DENOVO METHYLATION; HUMAN CANCERS; HUMAN BREAST; HYPERMETHYLATION; INACTIVATION; PROMOTER; RETINOBLASTOMA; CARCINOMAS	Promoter region CpG island methylation is associated with tumor suppressor gene silencing in neoplasia, Gen-Bank sequence analyses revealed that a number of CpG islands are juxtaposed to multiple Alu repeats, which have been proposed as ''de novo methylation centers.'' These islands also contain multiple Sp1 elements located upstream and downstream of transcription start, which have been shown to protect CpG islands from methylation. We mapped the methylation patterns of the E-cadherin (E-cad) and von Hippel-Lindau (VHL) tumor suppressor gene CpG island regions in normal and neoplastic cells, Although unmethylated in normal tissue, these islands were embedded between densely methylated flanking regions containing multiple Alu repeats, These methylated flanks were segregated from the unmethylated, island CpG sites by Sp1-rich boundary regions. Finally, in human fibroblasts overexpressing DNA methyltransferase, de novo methylation of the Ecad CpG island initially involved sequences at both ends of the island and the adjacent, flanking regions and progressed with time to encompass the entire CpG island region, Together, these data suggest that boundaries exist at both ends of a CpG island to maintain the unmethylated state in normal tissue and that these boundaries may be progressively overridden, eliciting the de novo methylation associated with tumor suppressor gene silencing in neoplasia.	JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21231	Johns Hopkins University	Graff, JR (corresponding author), JOHNS HOPKINS UNIV,CTR ONCOL,424 N BOND ST,RM 132,BALTIMORE,MD 21231, USA.				NCI NIH HHS [CA43318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BAYLIN SB, 1997, IN PRESS ADV CANC RE; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRAFF JR, 1995, CANCER RES, V55, P5195; GREGER V, 1994, HUM GENET, V94, P491; HASSE A, 1994, J BIOL CHEM, V269, P1821; HELLMANNBLUMBERG U, 1993, MOL CELL BIOL, V13, P4523, DOI 10.1128/MCB.13.8.4523; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 1996, CANCER RES, V56, P2463; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; KUZMIN I, 1995, ONCOGENE, V10, P2185; LAIRD PW, 1997, ANNU REV GENET, V30, P4441; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; MYOHANEN S, 1994, DNA SEQUENCE, V5, P1, DOI 10.3109/10425179409039698; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OTTERSON GA, 1995, ONCOGENE, V11, P1211; QUENTIN Y, 1994, NUCLEIC ACIDS RES, V25, P2222; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; TOTH M, 1989, P NATL ACAD SCI USA, V86, P3728, DOI 10.1073/pnas.86.10.3728; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	34	280	292	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22322	22329		10.1074/jbc.272.35.22322	http://dx.doi.org/10.1074/jbc.272.35.22322			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268383	hybrid			2022-12-27	WOS:A1997XT85000095
J	Haruki, M; Noguchi, E; Kanaya, S; Crouch, RJ				Haruki, M; Noguchi, E; Kanaya, S; Crouch, RJ			Kinetic and stoichiometric analysis for the binding of Escherichia coli ribonuclease HI to RNA-DNA hybrids using surface plasmon resonances	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 REVERSE-TRANSCRIPTASE; SITE-DIRECTED MUTAGENESIS; DOUBLE-STRANDED-RNA; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; DOMAIN; SUBSTRATE; SEQUENCE; RECOGNITION; RESOLUTION	To understand how ribonucleases H recognize RNA-DNA hybrid substrates, we analyzed kinetic parameters of binding of Escherichia coli RNase HI to RNA-DNA hybrids ranging in length from 18 to 36 base pairs (bp) using surface plasmon resonance (BIAcore((TM))). The k(on) and k(off) values for the binding of the enzyme to the 36 bp substrate were 1.5 x 10(6) M-1 s(-1) and 3.2 x 10(-2) s(-1), respectively, Similar values were obtained with the shorter substrates, Using uncleavable 2'-O-methylated RNA-DNA substrates, values for h(on) and h(off) were 2.1 x 10(5) M-1 s(-1) and 1.3 x 10(-1) s(-1) in the absence of Mg2+ that were further reduced in the presence of Mg2+ to 7.4 x 10(3) M-1 s(-1) and 2.6 x 10(-2) s(-1). Kinetic parameters similar to the wild-type enzyme were obtained using an active-site mutant enzyme, Asp(134) replaced by Ala, whereas a greatly reduced on-rate was observed for another inactive mutant enzyme, in which the basic protrusion is eliminated, thereby distinguishing between poor catalysis and inability to bind to the substrate. Stoichiometric analyses of RNase HI binding to substrates of 18, 24, 30, and 36 bp are consistent with previous reports suggesting that RNase HI binds to 9-10 bp of RNA DNA hybrid.	NICHHD,MOL GENET LAB,NIH,BETHESDA,MD 20892; OSAKA UNIV,GRAD SCH ENGN,DEPT MAT & LIFE SCI,SUITA,OSAKA 565,JAPAN; PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Osaka University								BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; BLOMMERS MJJ, 1994, NUCLEIC ACIDS RES, V22, P4187, DOI 10.1093/nar/22.20.4187; CERRITELLI SM, 1995, RNA, V1, P246; Crouch R. J., 1982, NUCLEASES, P211; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FISHER RJ, 1994, PROTEIN SCI, V3, P257; GERSHON PD, 1995, J IMMUNOL METHODS, V183, P65, DOI 10.1016/0022-1759(95)00032-6; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; HALL SH, 1977, J BIOL CHEM, V252, P4092; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; ITAYA M, 1991, MOL GEN GENET, V227, P438, DOI 10.1007/BF00273935; IWAI S, 1995, FEBS LETT, V368, P315, DOI 10.1016/0014-5793(95)00683-Z; Iwai S, 1996, J MOL BIOL, V263, P699, DOI 10.1006/jmbi.1996.0609; JELTSCH A, 1995, BIOCHEMISTRY-US, V34, P6239, DOI 10.1021/bi00018a028; KANAYA E, 1995, EUR J BIOCHEM, V231, P557, DOI 10.1111/j.1432-1033.1995.0557d.x; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1993, J BIOTECHNOL, V28, P117, DOI 10.1016/0168-1656(93)90129-B; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; Keck JL, 1996, J BIOL CHEM, V271, P19883, DOI 10.1074/jbc.271.33.19883; KECK JL, 1995, P NATL ACAD SCI USA, V92, P2740, DOI 10.1073/pnas.92.7.2740; KIMURA S, 1992, EUR J BIOCHEM, V206, P337, DOI 10.1111/j.1432-1033.1992.tb16932.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ma W P, 1994, Bioorg Med Chem, V2, P169, DOI 10.1016/S0968-0896(00)82012-X; Miller J. H., 1972, EXPT MOL GENETICS, P433; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; ODA Y, 1993, NUCLEIC ACIDS RES, V21, P4690, DOI 10.1093/nar/21.20.4690; ODA Y, 1993, J BIOL CHEM, V268, P88; STAHL SJ, 1994, PROTEIN ENG, V7, P1103, DOI 10.1093/protein/7.9.1103; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; UCHIYAMA Y, 1994, J MOL BIOL, V243, P782, DOI 10.1016/0022-2836(94)90047-7; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; Zhan XY, 1997, J BIOL CHEM, V272, P22023, DOI 10.1074/jbc.272.35.22023	40	55	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22015	22022		10.1074/jbc.272.35.22015	http://dx.doi.org/10.1074/jbc.272.35.22015			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268340	hybrid			2022-12-27	WOS:A1997XT85000052
J	Huang, CH; Lin, HN; Li, SS; Wang, GQ				Huang, CH; Lin, HN; Li, SS; Wang, GQ			Influence of the positions of cis double bonds in the sn-2-acyl chain of phosphatidylethanolamine on the bilayer's melting behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-TRANSITION TEMPERATURES; HETEROACID PHOSPHATIDYLCHOLINES; MOLECULAR MECHANICS; UNSATURATION; SERIES	In an attempt to examine the effects of different numbers and positions of cis double bonds in the sn-2-acyl chain of phosphatidylethanolamine (PE) on the bilayer's melting behavior, 21 molecular species of PE were first semisynthesized, and their T-m and Delta H values were subsequently determined by high resolution differential scanning calorimetry, In the plot of T-m versus the number of the cis double bond, some characteristic profiles were observed for the various series of PEs, For instance, if the cis double bond was first introduced into the sn-2-acyl chain of C(20):C(20)PE at the Delta(5)-position, the T-m was observed to reduce drastically. Subsequent stepwise additions of up to five cis double bonds at the methylene-interrupted positions toward the methyl end resulted in a progressive yet smaller decrease in T-m. If, on the other hand, the cis double bonds were introduced sequentially at the Delta(11)-, Delta(11,14)-, and Delta(11,14,17)-positions along the sn-2-acyl chain of C(20):C(20)PE, the T-m profile in the T-m versus the number of the cis double bond showed a down-and-up trend. Most interestingly, for positional isomers of C(20):C(20:3 Delta(5,8,11))PE,C(20):C(20:3 Delta(8,11,14))PE, and C(20):C(20:3 Delta(11,14,17))PE) an inverted bell-shaped T-m profile was detected in the plot of T-m against the position of the omega-carbon for these isomers. Similar T-m profiles were also observed for C(18):C(20)PE, C(20):C(18)PE, and their unsaturated derivatives. This work thus demonstrated that both the positions and the numbers of cis double bonds in the sn-2 acyl chain could exert noticeable influence on the gel-to-liquid crystalline phase transition behavior of the lipid bilayer. Finally, a molecular model was presented, with which the behavior of the gel-to-liquid crystalline phase transition observed for lipid bilayers composed of various sn-1-saturated/sn-2-unsaturated lipids can be rationalized.			Huang, CH (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,BOX 440,CHARLOTTESVILLE,VA 22908, USA.				NIGMS NIH HHS [GM-17452] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017452] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; CHANG H, 1983, BIOCHIM BIOPHYS ACTA, V728, P319, DOI 10.1016/0005-2736(83)90501-1; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; COOLBEAR KP, 1983, BIOCHEMISTRY-US, V22, P1466, DOI 10.1021/bi00275a022; HERNANDEZBORRELL J, 1993, BIOCHIM BIOPHYS ACTA, V1153, P277, DOI 10.1016/0005-2736(93)90416-W; HUANG C, 1994, BBA-BIOMEMBRANES, V1189, P7, DOI 10.1016/0005-2736(94)90273-9; Huang CH, 1996, ARCH BIOCHEM BIOPHYS, V334, P135, DOI 10.1006/abbi.1996.0438; KEOUGH KMW, 1987, BIOCHIM BIOPHYS ACTA, V902, P1, DOI 10.1016/0005-2736(87)90129-5; KEOUGH KMW, 1990, BIOCHEM SOC T, V18, P835, DOI 10.1042/bst0180835; LI SS, 1994, BIOPHYS J, V66, P2005, DOI 10.1016/S0006-3495(94)80993-2; LIN HN, 1990, BIOCHEMISTRY-US, V29, P7063, DOI 10.1021/bi00482a017; LIU S, 1994, BIOCHEM J, V299, P831, DOI 10.1042/bj2990831; MANTSCH HH, 1983, BIOCHIM BIOPHYS ACTA, V728, P325, DOI 10.1016/0005-2736(83)90502-3; MCCABE MA, 1994, BIOCHEMISTRY-US, V33, P8203; NIEBYLSKI CD, 1994, BIOPHYS J, V67, P2387, DOI 10.1016/S0006-3495(94)80725-8; SALEM N, 1995, MOL MEMBR BIOL, V12, P131, DOI 10.3109/09687689509038508; SanchezMigallon M, 1996, BBA-BIOMEMBRANES, V1279, P251; SEDDON JM, 1984, BIOCHEMISTRY-US, V23, P2634, DOI 10.1021/bi00307a015; WANG GQ, 1995, J BIOL CHEM, V270, P22738, DOI 10.1074/jbc.270.39.22738; Wang GQ, 1997, BIOPHYS J, V73, P283, DOI 10.1016/S0006-3495(97)78069-X; WANG ZQ, 1994, J BIOL CHEM, V269, P23491; WANG ZQ, 1995, J BIOL CHEM, V270, P2014, DOI 10.1074/jbc.270.5.2014; XU H, 1988, BIOCHIM BIOPHYS ACTA, V940, P63	23	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21917	21926		10.1074/jbc.272.35.21917	http://dx.doi.org/10.1074/jbc.272.35.21917			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268325	hybrid			2022-12-27	WOS:A1997XT85000037
J	Huang, W; Meng, Q; Suzuki, K; Nagase, H; Brew, K				Huang, W; Meng, Q; Suzuki, K; Nagase, H; Brew, K			Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases I (TIMP-1) locates an inhibitory region for matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; GROWTH-PROMOTING ACTIVITY; PROGELATINASE-A; ACTIVATION; CLONING; MEMBER; FAMILY; STROMELYSIN; SEQUENCE; COMPLEX	A bacterial expression system for the inhibitory N-terminal domain of human tissue inhibitor of metalloproteinases 1(N-TTMP-1) (Huang, W., Suzuki, K., Nagase, H., Arumugam, S., Van Doren, S. R., and Brew, K. (1996) FEBS Lett. 384, 155-161) has been used to produce 20 single-and double site mutants that probe the roles of different residues in its inhibitory action on metalloproteinases. Mutations that produce the largest increases in the K-i for a C-terminally truncated form of stromelysin 1, MMP-3(Delta C), but do not disturb the conformation involve substitutions of residues that are located in a ridge that is centered around the disulfide bond between Cys(1) and Cys(70). Specific residues that have a large influence on activity include Cys(1), Thr(2), Met(66), Val(69), and Cys(70) Of the mutations introduced, the greatest functional disturbances, reflected in K-i increases of 2-4 orders of magnitude, are generated by changes that disrupt the Cys(1)-Cys(70) disulfide bond and by substitution of Ala for Thr(2). Most mutations that perturb the interaction with MMP-3 have parallel effects on the affinity of N-TIMP-1 for MMP-1 (interstitial collagenase) and MMP-2 (gelatinase A). However, the Thr(2) to Ala mutation produces an inhibitor that is 17-fold more effective against MMP-3 than MMP-1, suggesting that it is feasible to engineer TIMP-1 variants that are more specifically targeted to selected matrix metalloproteinases, The reactive site identified by these studies is a structurally constrained but elongated region of TIMP that can fit the matrix metalloproteinase substrate-binding site.	UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOL BIOL, R629, MIAMI, FL 33101 USA; UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOL BIOL, KANSAS CITY, KS 66160 USA	University of Miami; University of Kansas; University of Kansas Medical Center			Brew, Keith/W-1643-2019; Brew, Keith/A-6746-2009	Brew, Keith/0000-0003-1306-1032	NIAMS NIH HHS [AR40994] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; BODDEN MK, 1994, ANN NY ACAD SCI, V732, P84, DOI 10.1111/j.1749-6632.1994.tb24727.x; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Edwards DR, 1996, INT J OBESITY, V20, pS9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Nagase H, 1996, ADV EXP MED BIOL, V389, P23; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, ZINC METALLOPROTEASE, P153; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SILBIGER SM, 1994, GENE, V141, P293, DOI 10.1016/0378-1119(94)90588-6; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMSON RA, 1993, BIOCHIM BIOPHYS ACTA, V1203, P147, DOI 10.1016/0167-4838(93)90049-W; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOODY RW, 1995, METHOD ENZYMOL, V246, P34	32	86	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22086	22091		10.1074/jbc.272.35.22086	http://dx.doi.org/10.1074/jbc.272.35.22086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268350	hybrid			2022-12-27	WOS:A1997XT85000062
J	Liu, CE; Liu, PQ; Ames, GFL				Liu, CE; Liu, PQ; Ames, GFL			Characterization of the adenosine triphosphatase activity of the periplasmic histidine permease, a traffic ATPase (ABC transporter)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING-PROTEIN; MALTOSE TRANSPORT; SALMONELLA-TYPHIMURIUM; MULTIDRUG-RESISTANCE; MEMBRANE-COMPONENTS; CYSTIC-FIBROSIS; DEPENDENT TRANSPORT; STRUCTURAL MODEL; P-GLYCOPROTEIN	The superfamily of traffic ATPases (ABC transporters) includes bacterial periplasmic transport systems (permeases) and eukaryotic transporters. The histidine permease of Salmonella typhimurium is composed of a membrane-bound complex (HisQMP(2)) containing four subunits, and of a soluble receptor, the histidine-binding protein (HisJ). Transport is energized by ATP, In this article the ATPase activity of HisQMP(2) has been characterized, using a novel assay that is independent of transport. The assay uses Mg2+ ions to permeabilize membrane vesicles or proteoliposomes, thus allowing access of ATP to both sides of the bilayer, HisQMP(2) displays a low level of intrinsic ATPase activity in the absence of HisJ; unliganded HisJ stimulates the activity and liganded HisJ stimulates to an even higher level, All three levels of activity display positive cooperativity for ATP with a Hill coefficient of 2 and a K-0.5 value of 0.6 mM. The activity has been characterized with respect to pH, salt, phospholipids, substrate, and inhibitor specificity, Free histidine has no effect. The activity is inhibited by orthovanadate, but not by N-ethylmaleimide, bafilomycin A(1), or ouabain. Several nucleotide analogs, ADP, 5'-adenylyl-beta,gamma-imidodiphosphate, adenosine 5'-(beta,gamma-imino)triphosphate, and adenosine 5'-O-(3-thio)triphosphate, inhibit the activity. Unliganded HisJ does not compete with liganded HisJ for the stimulation of the ATPase activity of HisQMP(2).	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012121, R37DK012121] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK12121] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN TM, 1990, BIOCHEMISTRY-US, V29, P2976, DOI 10.1021/bi00464a013; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMES BN, 1960, J BIOL CHEM, V235, P769; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GF, 1968, J BACTERIOL, V95, P833, DOI 10.1128/JB.95.3.833-843.1968; Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; AMES GFL, 1990, BACTERIAL ENERGETICS, P225; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; GUNTER KK, 1982, ANAL BIOCHEM, V120, P113, DOI 10.1016/0003-2697(82)90326-8; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HOR LI, 1993, J MOL BIOL, V233, P659, DOI 10.1006/jmbi.1993.1543; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOSHI AK, 1989, J BIOL CHEM, V264, P2126; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NIKAIDO H, 1994, FEBS LETT, V346, P55, DOI 10.1016/0014-5793(94)00315-7; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; PAPAHADJOPOULOS D, 1990, J BIOENERG BIOMEMBR, V22, P157, DOI 10.1007/BF00762944; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; RICHARME G, 1993, J BIOL CHEM, V268, P9473; ROSIER RN, 1979, ANAL BIOCHEM, V96, P384, DOI 10.1016/0003-2697(79)90596-7; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHAROM FJ, 1995, J BIOENERG BIOMEMBR, V27, P15, DOI 10.1007/BF02110326; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; SPEISER DM, 1989, THESIS U CALIFORNIA; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; WALTER C, 1992, J BIOL CHEM, V267, P8863	47	108	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21883	21891		10.1074/jbc.272.35.21883	http://dx.doi.org/10.1074/jbc.272.35.21883			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268321	hybrid			2022-12-27	WOS:A1997XT85000033
J	Goss, SPA; Hogg, N; Kalyanaraman, B				Goss, SPA; Hogg, N; Kalyanaraman, B			The effect of nitric oxide release rates on the oxidation of human low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMULTANEOUS GENERATION; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; L-ARGININE; ENDOTHELIAL DYSFUNCTION; VITAMIN-C; SUPEROXIDE; INHIBITION; CELLS; HYPERCHOLESTEROLEMIA	1-Substituted diazen-1-ium-1,2-diolates, a class of nitric oxide (. NO) donor compounds that spontaneously release . NO at different rates, were used to investigate the effect of . NO release rate upon the oxidation of low density lipoprotein (LDL), All donor compounds conferred an inhibitory effect upon the oxidation of LDL; however, the effect exhibited a biphasic dependence upon the rate of . NO release, The . NO release rate that maximally inhibited oxidation was dependent upon the rate of oxidation, When LDL was rapidly oxidized by copper(II) sulfate, a faster release rate was more effective. In contrast, when LDL was oxidized slowly by 2,2'-azobis-2-amidinopropane hydrochloride, a slower release rate was most effective, This biphasic relationship between . NO release rate and the duration of inhibition was also demonstrated when LDL oxidation was initiated with 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium, a peroxynitrite generator, We conclude that the antioxidant ability of . NO is dependent not only upon the rate of its release from . NO donors, but also upon the rate of oxidation, This conclusion is supported by a kinetic model of LDL oxidation in the presence of . NO.	MED COLL WISCONSIN, BIOPHYS RES INST, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047250] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL47250] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; CHANG GJ, 1994, ARTERIOSCLER THROMB, V14, P1808, DOI 10.1161/01.ATV.14.11.1808; COOKE JP, 1991, BASIC RES CARDIOL, V86, P173; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GOSS SPA, 1995, CHEM RES TOXICOL, V8, P800, DOI 10.1021/tx00047a021; HABERLAND ME, 1984, J BIOL CHEM, V259, P1305; HATCH FT, 1968, ADV LIPID RES, V6, P2, DOI 10.1016/B978-1-4831-9942-9.50008-5; HINO M, 1989, J ANTIBIOT, V42, P1578, DOI 10.7164/antibiotics.42.1578; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; HOGG N, 1995, J LIPID RES, V36, P1756; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; HOGG N, 1994, ARCH BIOCHEM BIOPHYS, V314, P153, DOI 10.1006/abbi.1994.1423; Hogg N, 1996, BIOCHEM BIOPH RES CO, V224, P696, DOI 10.1006/bbrc.1996.1086; HOGG N, 1993, FEBS LETT, V326, P199, DOI 10.1016/0014-5793(93)81790-7; JESSUP W, 1990, BIOCHEM J, V265, P399, DOI 10.1042/bj2650399; JOSEPH J, 1993, BIOCHEM BIOPH RES CO, V192, P926, DOI 10.1006/bbrc.1993.1504; KAOUADJI MN, 1987, BIOELECTROCH BIOENER, V18, P59, DOI 10.1016/0302-4598(87)85008-0; LAGERCRANTZ C, 1993, FREE RADICAL RES COM, V19, P387, DOI 10.3109/10715769309056528; LEFER AM, 1993, ARTERIOSCLER THROMB, V13, P771, DOI 10.1161/01.ATV.13.6.771; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MOORADIAN DL, 1995, J CARDIOVASC PHARM, V25, P674, DOI 10.1097/00005344-199504000-00023; NARUSE K, 1994, ARTERIOSCLER THROMB, V14, P746, DOI 10.1161/01.ATV.14.5.746; NIKI E, 1984, J BIOL CHEM, V259, P4177; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P181, DOI 10.1111/j.1476-5381.1987.tb11310.x; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V279, P402, DOI 10.1016/0003-9861(90)90508-V; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STRUCK AT, 1995, FEBS LETT, V361, P291, DOI 10.1016/0014-5793(95)00178-C; TAMIR S, 1993, CHEM RES TOXICOL, V6, P895, DOI 10.1021/tx00036a021; THOMAS JP, 1993, J LIPID RES, V34, P479	40	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21647	21653		10.1074/jbc.272.34.21647	http://dx.doi.org/10.1074/jbc.272.34.21647			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261188	hybrid			2022-12-27	WOS:A1997XR78900098
J	Mendre, C; Dufour, MN; LeRoux, S; Seyer, R; Guillou, L; Calas, B; Guillon, G				Mendre, C; Dufour, MN; LeRoux, S; Seyer, R; Guillou, L; Calas, B; Guillon, G			Synthetic rat V-1a vasopressin receptor fragments interfere with vasopressin binding via specific interaction with the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTORS; ADENYLATE-CYCLASE; MOLECULAR-CLONING; HORMONE-BINDING; V1A RECEPTOR; PEPTIDES; PROTEIN; IDENTIFICATION; ANTAGONISTS; MEMBRANES	To study the vasopressin receptor domains involved in the hormonal binding, we synthesized natural and modified fragments of V-1a vasopressin receptor and tested their abilities to affect hormone-receptor interactions. Natural fragments mimicking the external loops one, two, and three were able to inhibit specific vasopressin binding to V-1a receptor, In contrast, the natural N-terminal part of the V-1a vasopressin receptor was found inactive, One fragment, derived from the external second loop and containing an additional C-terminal cysteine amide, was able to fully inhibit the specific binding of both labeled vasopressin agonist and antagonist to rat liver V-1a vasopressin receptor and the vasopressin-sensitive phospholipase C of WRK1 cells, The peptide-mediated inhibition involved specific interactions between the V-1a receptor and synthetic V-1a vasopressin receptor fragment since 1) it was dependent upon the vasopressin receptor subtype tested (K-i(app) for the peptide: 3.7, 14.6, and 64.5 mu M for displacing [H-3]vasopressin from rat V-1a, V-1b, and V-2 receptors, respectively; 2) it was specific and did not affect sarcosin 1-angiotensin II binding to rat liver membranes; 3) it was not mimicked by vasopressin receptor unrelated peptides exhibiting putative detergent properties; and 4) no direct interaction between [H-3]vasopressin and synthetic peptide linked to an affinity chromatography column could be observed, Such an inhibition affected both the maximal binding capacity of the V-1a vasopressin receptor and its affinity for the labeled hormone, depending upon the dose of synthetic peptide used and was partially irreversible, Structure-activity studies using a serie of synthetic fragments revealed the importance of their size and cysteinyl composition, These data indicate that some peptides mimicking extracellular loops of the V-1a vasopressin receptor may interact with the vasopressin receptor itself and modify its coupling with phospholipase C.	CTR PHARMACOL ENDOCRINOL, CNRS, UPR 9023, F-34095 MONTPELLIER 5, FRANCE; CNRS, CTR RECH BIOCHIM MACROMOL, UPR 9008, F-34033 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mendre, C (corresponding author), CTR PHARMACOL ENDOCRINOL, INSERM, U469, RUE CARDONILLE, F-34095 MONTPELLIER 5, FRANCE.							AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; BUTLEN D, 1978, MOL PHARMACOL, V14, P1006; CANTAU B, 1980, J RECEPTOR RES, V1, P137, DOI 10.3109/10799898009044096; CARNAZZI E, 1994, J MED CHEM, V37, P1841, DOI 10.1021/jm00038a013; CARNAZZI E, 1997, IN PRESS EUR J BIOCH; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DATTATREYAMURTY B, 1993, MOL CELL ENDOCRINOL, V93, P39, DOI 10.1016/0303-7207(93)90137-9; DREIFUSS JJ, 1991, VASOPRESSIN, P159; EVERSHED RP, 1993, RAPID COMMUN MASS SP, V7, P882, DOI 10.1002/rcm.1290071005; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GUILLON G, 1995, ENDOCRINOLOGY, V136, P1285, DOI 10.1210/en.136.3.1285; GUILLON G, 1986, BIOCHEM J, V240, P189, DOI 10.1042/bj2400189; GUILLON G, 1989, ANN ENDOCRINOL-PARIS, V50, P425; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HERBERG JT, 1984, J BIOL CHEM, V259, P9285; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; Howl J, 1996, BIOCHEM J, V317, P577, DOI 10.1042/bj3170577; HWANG C, 1991, P ROY SOC B-BIOL SCI, V245, P115, DOI 10.1098/rspb.1991.0096; JARD S, 1986, MOL PHARMACOL, V30, P171; JARD S, 1988, INT CONGR SER, V799, P1183; KIRK CJ, 1986, BIOCHEM J, V240, P197, DOI 10.1042/bj2400197; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MANNING M, 1992, INT J PEPT PROT RES, V40, P261; Mendre C, 1996, PEPTIDES, V17, P521, DOI 10.1016/0196-9781(95)02128-0; MEZGUELDI M, 1995, J BIOL CHEM, V270, P8867, DOI 10.1074/jbc.270.15.8867; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MORRIS JC, 1993, J BIOL CHEM, V268, P10900; Mouillac B, 1995, ADV EXP MED BIOL, V395, P301; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; PAVO I, 1990, FEBS LETT, V272, P205, DOI 10.1016/0014-5793(90)80485-2; PRADELLE.P, 1972, FEBS LETT, V26, P189, DOI 10.1016/0014-5793(72)80570-2; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; ROY C, 1975, J BIOL CHEM, V250, P7885; SEYER R, 1990, J CHEM SOC PERK T, V1, P3289; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; THORNTON K, 1994, BIOCHEMISTRY-US, V33, P3532, DOI 10.1021/bi00178a009; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3445; VALEMBOIS C, 1992, TETRAHEDRON LETT, V33, P4005, DOI 10.1016/0040-4039(92)88085-J; VARRAULT A, 1994, J BIOL CHEM, V269, P16720; VENTER JC, 1983, TRENDS PHARMACOL SCI, V4, P256	47	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21027	21036		10.1074/jbc.272.34.21027	http://dx.doi.org/10.1074/jbc.272.34.21027			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261104	hybrid			2022-12-27	WOS:A1997XR78900014
J	Saino, T; Daiho, T; Kanazawa, T				Saino, T; Daiho, T; Kanazawa, T			Modification or arginine-198 in sarcoplasmic reticulum Ca2+-ATPase by 1,2-cyclohexanedione causes inhibition of formation of the phosphoenzyme intermediate from inorganic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ADENOSINE-TRIPHOSPHATASE; TIGHT-BINDING; FUNCTIONAL CONSEQUENCES; CONFORMATIONAL CHANGE; COMPLEMENTARY-DNA; MOLECULAR-CLONING; HIGH-AFFINITY; CA-2+ PUMP; ATPASE	Sarcoplasmic reticulum vesicles were modified with 1,2-cyclohexanedione (CHD), a specific arginine-modifying reagent, in sodium berate (pH 8.0 or 8.8). Phosphoenzyme formation ham P-i in the Ca2+-ATPase (reversal of hydrolysis of the phosphoenzyme intermediate) was almost completely inhibited by the modification with CHD. Tight binding of F- and Mg2+ and high affinity binding of vanadate in the presence of Mg2+, either of which produces a transition state analog for phosphoenzyme formation from the magnesium enzyme-phosphate complex, were also markedly inhibited, In contrast, phosphoenzyme formation from acetyl phosphate in the forward reaction was unaffected, The enzyme was appreciably protected by tight binding of F- and Mg2+ or by high affinity binding of vanadate in the presence of Mg2+, but not by the presence of 20 mM MgCl2 alone or 150 mm P-i alone, against the CHD-induced inhibition of phosphoenzyme formation from P-i. Peptide mapping of the tryptic digests, detection of peptides containing CHD-modified arginyl residues with Girard's reagent T, sequencing, and mass spectrometry showed that Arg-198 was a single major residue protected by tight binding of F- and Mg2+ against the modification with CHD. These results indicate that modification of Arg-198 with CHD is responsible for at least a part (the portion reduced by the transition state analogs) of the CHD-induced inhibition of phosphoenzyme formation from P-i and suggest that Arg-198 is located in or close to the catalytic site in the transition state for phosphoenzyme formation from the magnesium-enzyme-phosphate complex.	ASAHIKAWA MED COLL, DEPT BIOCHEM, ASAHIKAWA, HOKKAIDO 078, JAPAN	Asahikawa Medical College								ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BURK SE, 1989, J BIOL CHEM, V264, P18561; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHEN ZD, 1991, J BIOL CHEM, V266, P12386; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; DUX L, 1983, J BIOL CHEM, V258, P111; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; IMAMURA Y, 1989, J BIOCHEM-TOKYO, V105, P775, DOI 10.1093/oxfordjournals.jbchem.a122743; INESI G, 1984, J BIOL CHEM, V259, P996; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; Kimura K, 1996, J BIOL CHEM, V271, P28933, DOI 10.1074/jbc.271.46.28933; KOLASSA N, 1979, FEBS LETT, V108, P495, DOI 10.1016/0014-5793(79)80596-7; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MEDDA P, 1983, EUR J BIOCHEM, V137, P7, DOI 10.1111/j.1432-1033.1983.tb07788.x; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; PATTHY L, 1975, J BIOL CHEM, V250, P557; PATTHY L, 1979, EUR J BIOCHEM, V99, P309, DOI 10.1111/j.1432-1033.1979.tb13258.x; PUCELL A, 1971, J BIOL CHEM, V246, P3389; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; VERMA AK, 1988, J BIOL CHEM, V263, P14152; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; YAMASAKI K, 1991, J BIOCHEM, V110, P915, DOI 10.1093/oxfordjournals.jbchem.a123689	46	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21142	21150		10.1074/jbc.272.34.21142	http://dx.doi.org/10.1074/jbc.272.34.21142			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261119	hybrid			2022-12-27	WOS:A1997XR78900029
J	Somani, AK; Bignon, JS; Mills, GB; Siminovitch, KA; Branch, DR				Somani, AK; Bignon, JS; Mills, GB; Siminovitch, KA; Branch, DR			Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; CATALYTIC ACTIVITY; MONOCLONAL-ANTIBODIES; CELL-TRANSFORMATION; ACTIVATED PP60C-SRC; HOMOLOGY-2 DOMAINS; SH2 DOMAIN; PHOSPHORYLATION; EXPRESSION; PP60(C-SRC)	Activation of the cellular Src tyrosine kinase depends upon dephosphorylation of the carboxyl-terminal inhibitory tyrosine phosphorylation site. Herein we show that Src isolated from human platelets and Jurkat T cells is preferentially dephosphorylated at its inhibitory phosphotyrosine site by the SHP-1 tyrosine phosphatase. The data also revealed association of Src with SHP-1 in both platelets and lymphocytes and the capacity of Src to phosphorylate SHP-1 and interact with the SHP-1 NH2-terminal SH2 domain in vitro. Analysis of Src activity in thymocytes from SHP-1-deficient motheaten and viable motheaten mice revealed this kinase activity to be substantially lower than that detected in wild-type thymocytes, but to be enhanced by in vitro exposure to SHP-1. Similarly, immunoblotting analysis of thymocyte Src expression before and after selective depletion of active Src protein indicated that the proportion of active relative to inactive Src protein is markedly reduced in motheaten compared with wild-type cells. These observations, together with the finding of reduced Src activity in HEY cells expressing a dominant negative form of SHP-1, provide compelling evidence that SHP-1 functions include the positive regulation of Src activation.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT IMMUNOL & MED GENET,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MICROBIOL,TORONTO,ON M5G 1X5,CANADA; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL ONCOL,HOUSTON,TX 77030; TORONTO HOSP RES INST,TORONTO,ON M5G 2M1,CANADA; CANADIAN RED CROSS SOC,TORONTO,ON M5G 2M1,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Somani, ally-khan/AAA-9656-2020; Siminovitch, Katherine/K-1475-2013	Somani, Ally-Khan/0000-0003-2166-4896				BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BRANCH DR, 1995, J IMMUNOL, V154, P3678; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1983, J BIOL CHEM, V258, P1108; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; FANG KS, 1994, J BIOL CHEM, V269, P20194; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MILLS GB, 1992, INT IMMUNOL, V4, P1233, DOI 10.1093/intimm/4.11.1233; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PENG ZY, 1995, ONCOGENE, V11, P1955; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	52	143	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21113	21119		10.1074/jbc.272.34.21113	http://dx.doi.org/10.1074/jbc.272.34.21113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261115	hybrid			2022-12-27	WOS:A1997XR78900025
J	Ferrigno, O; Virolle, T; Galliano, MF; Chauvin, N; Ortonne, JP; Meneguzzi, G; Aberdam, D				Ferrigno, O; Virolle, T; Galliano, MF; Chauvin, N; Ortonne, JP; Meneguzzi, G; Aberdam, D			Murine laminin alpha 3A and alpha 3B isoform chains are generated by usage of two promoters and alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; EPITHELIAL BASEMENT-MEMBRANES; ADHESIVE LIGAND; INTEGRIN BETA-4; GENE LAMC2; B2 CHAIN; EXPRESSION; EPILIGRIN; MUTATIONS; NICEIN/KALININ	We already identified two distinct laminin alpha 3A and alpha 3B chain isoforms which differ in their amino-terminal ends and display different tissue-specific expression patterns, In this study we have investigated whether these two different isoforms are products of the same laminin alpha 3 (lama3) gene and transcribed from one or two separate promoters. Genomic clones were isolated that encompass the sequences upstream to the 5' ends of both the alpha 3A and the alpha 3B cDNAs, Sequence analysis of the region upstream to the alpha 3A open reading frame revealed the presence of a TATA box and potential binding sites for responsive elements. By primer extension analysis, the transcription start site of the alpha 3B mRNA isoform was defined. The sequences upstream to the alpha 3B mRNA transcription start site do not contain a TATA box near the transcription initiation sites, but AP-1, AP-2, and Sp1 consensus binding site sequences were identified, The genomic regions located immediately upstream of the alpha 3A and alpha 3B transcription start sites were shown to possess promoter activities in transfection experiments, In the promoter regions, response elements for the acute phase reactant signal and NF-interleukin 6 were found, and their possible relevance in the context of inflammation and wound healing is discussed, Our results demonstrate that the lama3 gene produces the two polypeptides by alternative splicing and contains two promoters, which regulate the production of the two isoforms alpha 3A and alpha 3B.	INSERM, U385, UFR MED, FAC MED, F-06107 NICE 2, FRANCE; HOP LARCHET, SERV DERMATOL, F-06002 NICE 1, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice			Virolle, Thierry/E-5838-2016; Aberdam, Daniel/G-3299-2013; ferrigno, olivier/GSN-8581-2022	ferrigno, olivier/0000-0001-7544-4384; Aberdam, Daniel/0000-0002-4019-5418; Meneguzzi, Guerrino/0000-0002-1609-6540				ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; Baker SE, 1996, J CELL SCI, V109, P2509; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; COMBATES NJ, 1994, J BIOL CHEM, V269, P29715; DELWEL GO, 1996, ADHESION RECEPTORS T, P9; DOMLOGEHULTSCH N, 1992, J CLIN INVEST, V90, P1628, DOI 10.1172/JCI116033; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; GagnouxPalacios L, 1996, J BIOL CHEM, V271, P18437, DOI 10.1074/jbc.271.31.18437; GALDIE J, 1991, CYTOKINES INFLAMMATI, P275; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GIL SG, 1994, J INVEST DERMATOL, V103, pS31, DOI 10.1111/1523-1747.ep12398953; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; JKJL, 1984, JKO, V8, P2313; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; McGrath JA, 1996, J INVEST DERMATOL, V106, P781, DOI 10.1111/1523-1747.ep12346349; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; RICHARDS AJ, 1994, GENOMICS, V22, P237, DOI 10.1006/geno.1994.1372; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seiffert D, 1996, J BIOL CHEM, V271, P5474, DOI 10.1074/jbc.271.10.5474; VAILLY J, 1995, J INVEST DERMATOL, V104, P462, DOI 10.1111/1523-1747.ep12605898; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VERRANDO P, 1991, LAB INVEST, V64, P85; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141	39	39	39	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20502	20507		10.1074/jbc.272.33.20502	http://dx.doi.org/10.1074/jbc.272.33.20502			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252362	hybrid			2022-12-27	WOS:A1997XR22100032
J	Ivessa, NE; Gravotta, D; DeLemosChiarandini, C; Kreibich, G				Ivessa, NE; Gravotta, D; DeLemosChiarandini, C; Kreibich, G			Functional protein prenylation is required for the brefeldin a-dependent retrograde transport from the Golgi apparatus to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; SENSITIVE G-PROTEIN; O-GLYCOSYLATION; RAB GTPASES; MEMBRANE; CELLS; TRAFFICKING; CALCIUM; GTP; ER	In cells exposed to brefeldin A (BFA), enzymes of the Golgi apparatus are redistributed to the endoplasmic reticulum (ER) by retrograde membrane flow, where they may cause modifications on resident ER proteins. We have used a truncated form of the rough ER-specific type I transmembrane glycoprotein ribophorin I as a probe to detect Golgi glycosyltransferases relocated to the ER in a BFA-dependent fashion. This polypeptide (RI332) comprises the 332 amino-terminal amino acids of ribophorin I and behaves like a luminal ER protein when expressed in HeLa cells. Upon treatment of the cells with BFA, RI332 becomes quantitatively O-glycosylated by Golgi glycosyltransferases that are transported back to the ER. Here we demonstrate that pretreatment of the cells with lovastatin, an inhibitor of HMG-CoA reductase, abrogates this modification and that mevalonate, the product formed in the step inhibited by the drug, is able to counteract the effect of lovastatin. We also show by immunofluorescence using mannosidase II as a Golgi marker that the BFA-induced retrograde transport of Golgi enzymes is blocked by lovastatin, although electron microscopy indicates that BFA causes disassembly of the Golgi apparatus into swollen vesicles and tubules. Our observations support the role of a prenylated protein, such as the geranylgeranylated small G protein Rab6, in the retrograde transport from the Golgi apparatus to the ER, since lovastatin acts by inhibiting its prenylation.	BIOCTR, A-1030 VIENNA, AUSTRIA; NYU, SCH MED, DEPT CELL BIOL, NEW YORK, NY 10016 USA; NYU, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University	Ivessa, NE (corresponding author), UNIV VIENNA, DEPT MOL GENET, DR BOHR GASSE 9-2, A-1030 VIENNA, AUSTRIA.				NIGMS NIH HHS [5RO1 GM 43583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DELEMOSCHIARANDINI C, 1992, EUR J CELL BIOL, V58, P187; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GOLDSTEIN JL, 1979, J BIOL CHEM, V254, P5403; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LIPPINCOTTSCHWA.J, 1993, CELL, V3, P81; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MALTESE WA, 1985, J CELL PHYSIOL, V125, P540, DOI 10.1002/jcp.1041250326; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RAO M, 1993, J CELL SCI, V106, P789; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SHEN BQ, 1995, J BIOL CHEM, V270, P25102, DOI 10.1074/jbc.270.42.25102; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; TAN A, 1992, J CELL BIOL, V116, P1357, DOI 10.1083/jcb.116.6.1357; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; ZERIAL M, 1995, GUIDEBOOK SMALL GTPA, P295; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	41	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20828	20834		10.1074/jbc.272.33.20828	http://dx.doi.org/10.1074/jbc.272.33.20828			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252408	hybrid			2022-12-27	WOS:A1997XR22100078
J	Fujiwara, K; OkamuraIkeda, K; Packer, L; Motokawa, Y				Fujiwara, K; OkamuraIkeda, K; Packer, L; Motokawa, Y			Synthesis and characterization of selenolipoylated H-protein of the glycine cleavage system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIPOIC ACID; LIVER-MITOCHONDRIA; T-PROTEIN; MECHANISM; PURIFICATION; METABOLISM	H-protein of the glycine cleavage system has a lipoic acid prosthetic group. Selenolipoic acid is a lipoic acid analog ire which both sulfur atoms sire replaced by selenium atoms. Two isoforms of bovine lipoyltransferase that are responsible for the attachment of lipoic acid to H-protein had an affinity for selenolipoyl-AMP and transferred the selenolipoyl moiety to bovine apoH-protein comparable to lipoyl-AMP. Selenolipoylated H-protein was overexpressed in Escherichia coli and purified. Selenolipoylated H-protein was 26% as effective as lipoylated H-protein in the glycine decarboxylation reaction, in which reduction of the diselenide bond of selenolipoylated H-protein is catalyzed by P-protein. The diselenide form of selenolipoylated H-protein was a poor substrate for L-protein, and the rate of reduction was 0.5% of that of lipoylated H-protein. The rate of the overall glycine cleavage reaction with selenolipoylated H-protein was <1% of that with lipoylated H-protein. These results are consistent with the difference in the redox potential between the diselenide and disulfide bonds, In contrast, selenolipoylated H-protein showed three times as high glycine-(CO2)-C-14 exchange activity as lipoylated H-protein, presumably because the rate of reoxidation of reduced selenolipoylated H-protein is much higher than that of lipoylated H-protein.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	Tokushima University; University of California System; University of California Berkeley								ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; FUJIWARA K, 1979, ARCH BIOCHEM BIOPHYS, V197, P454, DOI 10.1016/0003-9861(79)90267-4; FUJIWARA K, 1994, J BIOL CHEM, V269, P16605; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; FUJIWARA K, 1983, J BIOL CHEM, V258, P8156; FUJIWARA K, 1984, J BIOL CHEM, V259, P664; KE B, 1957, BIOCHIM BIOPHYS ACTA, V25, P650, DOI 10.1016/0006-3002(57)90544-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOTOKAWA Y, 1974, ARCH BIOCHEM BIOPHYS, V164, P624, DOI 10.1016/0003-9861(74)90074-5; OKAMURAIKEDA K, 1987, J BIOL CHEM, V262, P6746; OKAMURAIKEDA K, 1993, EUR J BIOCHEM, V216, P539, DOI 10.1111/j.1432-1033.1993.tb18172.x; OLIVER DJ, 1990, PLANT PHYSIOL, V94, P833, DOI 10.1104/pp.94.2.833; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED KE, 1994, P NATL ACAD SCI USA, V91, P3720, DOI 10.1073/pnas.91.9.3720; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1958, J BIOL CHEM, V232, P123; SCHEPKIN V, 1994, BIOCHEM MOL BIOL INT, V33, P879; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9	20	3	4	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19880	19883		10.1074/jbc.272.32.19880	http://dx.doi.org/10.1074/jbc.272.32.19880			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242652	hybrid			2022-12-27	WOS:A1997XQ05900039
J	Guy, HI; Evans, DR				Guy, HI; Evans, DR			Trapping an activated conformation of mammalian carbamyl-phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; INITIATES PYRIMIDINE BIOSYNTHESIS; CARBONIC-PHOSPHORIC ANHYDRIDE; GLUTAMINE BINDING-SITE; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; REVERSIBLE DISSOCIATION; AMIDOTRANSFERASE DOMAIN; HAMSTER CELLS; GENE	The amidotransferase or glutaminase domain (GLN domain) of mammalian carbamyl-phosphate synthetase II (CPSase II) catalyzes glutamine hydrolysis and transfers ammonia to the synthetase domain (CPS domain), where carbamyl phosphate formation is catalyzed in three consecutive reactions, The GLN and CPS domains are part of a single polypeptide and are connected via a 29-amino acid chain segment (GC linker). In contrast, the two comparable domains of Escherichia coli CPSase are not fused, but are separate, noncovalently associated subunits, To establish the function of the GC linker in mammalian CPSase, it was deleted, and the two domains were directly fused, The deletion mutant not only catalyzed glutamine-dependent carbamyl phosphate synthesis, but was activated 10-fold relative to its wildtype counterpart, However, ammonia-dependent synthesis of carbamyl phosphate was abolished, indicating that ammonia no longer had access to the active site on the CPS domain, The mutant was still sensitive to inhibition by the allosteric effector UTP, but was no longer activated by the allosteric effector phosphoribosyl pyrophosphate, although evidence indicated that the latter could bind to the enzyme, The linker appears to serve as a spacer that allows the complex to cycle between two conformations, an open low activity form in which the ammonia site on the CPS domain is accessible and an activated conformation in which the ammonia generated in situ from glutamine is directly channeled to the CPS active site and access to exogenous ammonia is blocked.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47399] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1975, BIOCHEMISTRY-US, V14, P3688, DOI 10.1021/bi00687a027; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; BEIN K, 1991, J BIOL CHEM, V266, P3791; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; Guy HI, 1997, J BIOL CHEM, V272, P19913, DOI 10.1074/jbc.272.32.19913; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; GUY HI, 1994, J BIOL CHEM, V269, P23808; GUY HI, 1994, J BIOL CHEM, V269, P7702; HAGER SE, 1967, J BIOL CHEM, V242, P5674; HAGER SE, 1967, J BIOL CHEM, V242, P5667; Hanahan D, 1985, DNA CLONING PRACTICA; KERN CB, 1992, J MOL EVOL, V35, P217; KHEDOURI E, 1966, BIOCHEMISTRY-US, V5, P3552, DOI 10.1021/bi00875a024; KIM HS, 1992, J BIOL CHEM, V267, P7177; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1971, J BIOL CHEM, V246, P3694; LIU X, 1994, J BIOL CHEM, V269, P27747; MALEY JA, 1988, BIOCHEM BIOPH RES CO, V154, P1047, DOI 10.1016/0006-291X(88)90246-X; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MARSHALL M, 1958, J BIOL CHEM, V233, P102; MATTHEWS SL, 1972, BIOCHEMISTRY-US, V11, P1176, DOI 10.1021/bi00757a010; McCudden CR, 1996, J BIOL CHEM, V271, P18285, DOI 10.1074/jbc.271.30.18285; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; METZENBERG RL, 1957, J BIOL CHEM, V229, P1019; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; MORI M, 1975, J BIOCHEM, V78, P239; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; PINKUS LM, 1972, J BIOL CHEM, V247, P6119; POST LE, 1990, J BIOL CHEM, V265, P7742; POWERS SG, 1976, P NATL ACAD SCI USA, V73, P3020, DOI 10.1073/pnas.73.9.3020; POWERS SG, 1977, J BIOL CHEM, V252, P3558; POWERS SG, 1978, J BIOL CHEM, V253, P1258; POWERS SG, 1978, J BIOL CHEM, V253, P800; RAUSHEL FM, 1978, J BIOL CHEM, V253, P6627; RAUSHEL FM, 1979, BIOCHEMISTRY-US, V18, P3424, DOI 10.1021/bi00582a033; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P3170, DOI 10.1021/bi00555a009; RAUSHEL FM, 1978, BIOCHEMISTRY-US, V17, P5587, DOI 10.1021/bi00619a001; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; TATIBANA M, 1969, J BIOL CHEM, V244, P5403; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P482; TROTTA PP, 1974, J BIOL CHEM, V249, P492; WIMMER MJ, 1979, J BIOL CHEM, V254, P1854; ZALKIN H, 1993, BIOCHEM SOC T, V21, P203, DOI 10.1042/bst0210203; ZALKIN H, 1980, MULTIFUNCTIONAL PROT, P123	60	5	5	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19906	19912		10.1074/jbc.272.32.19906	http://dx.doi.org/10.1074/jbc.272.32.19906			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242656	hybrid			2022-12-27	WOS:A1997XQ05900043
J	Kehres, DG; Subramanyan, GS; Hung, VS; Rogers, GW; Setzer, DR				Kehres, DG; Subramanyan, GS; Hung, VS; Rogers, GW; Setzer, DR			Energetically unfavorable interactions among the zinc fingers of transcription factor IIIA when bound to the 5 S rRNA gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CONTROL REGION; 5-S RNA GENE; DNA RECOGNITION; CRYSTAL-STRUCTURE; XENOPUS TFIIIA; RIBOSOMAL-RNA; BINDING DOMAINS; 5S-RNA GENE; COMPLEX; PROTEIN	Xenopus transcription factor IIIA (TFIIIA) binds to over 50 base pairs in the internal control region of the 5 S rRNA gene, yet the binding energy for this interaction (Delta G(0) = -12.8 kcal/mol) is no greater than that exhibited by many proteins that occupy much smaller DNA targets, Despite considerable study, the distribution of the DNA binding energy among the various zinc fingers of TFIIIA remains poorly understood By analyzing TFIIIA mutants with disruptions of individual zinc fingers, we have previously shown that each finger contributes favorably to binding (Del Rio, S., Menezes, S. R., and Setter, D. R. (1993) J. Mol. Biol. 233, 567-579), Those results also suggested, however, that simultaneous binding by all nine zinc fingers of TFIIIA may involve a substantial energetic cost, Using complementary N- and C-terminal fragments and full-length proteins containing pairs of disrupted fingers, we now show that energetic interference indeed occurs between zinc fingers when TFIIIA binds to the 5S rRNA gene and that the greatest interference occurs between fingers at opposite ends of the protein in the TFIIIA.5 S rRNA gene complex. Some, but not all, of the thermodynamically unfavorable strain in the TFIIIA.5 S rRNA gene complex may be derived from bending of the DNA that is necessary to accommodate simultaneous binding by all nine zinc fingers of TFIIIA, The energetics of DNA binding by TFIIIA thus emerges as a compromise between individual favorable contacts of importance along the length of the internal control region and long range strain or distortion in the protein, the 5 S rRNA gene, or both that is necessary to accommodate the various local interactions.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048035] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48035] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKAWA H, 1995, CYTOGENET CELL GENET, V70, P235, DOI 10.1159/000134041; ARCHAMBAULT J, 1992, J BIOL CHEM, V267, P3282; BAZETTJONES DP, 1989, MOL CELL BIOL, V9, P336, DOI 10.1128/MCB.9.1.336; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; Brown ML, 1996, J MOL BIOL, V262, P600, DOI 10.1006/jmbi.1996.0539; BROWN RS, 1988, P NATL ACAD SCI USA, V85, P3802, DOI 10.1073/pnas.85.11.3802; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; CAMPBELL FE, 1991, MOL CELL BIOL, V11, P3978, DOI 10.1128/MCB.11.8.3978; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; DARBY MK, 1988, P NATL ACAD SCI USA, V85, P5516, DOI 10.1073/pnas.85.15.5516; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; DELRIO S, 1993, J MOL BIOL, V233, P567, DOI 10.1006/jmbi.1993.1536; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; DELRIO S, 1993, P NATL ACAD SCI USA, V90, P168, DOI 10.1073/pnas.90.1.168; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; DREW PD, 1995, GENE, V159, P215, DOI 10.1016/0378-1119(95)00145-V; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FISERLITTELL RM, 1988, J BIOL CHEM, V263, P1607; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; GASKINS CJ, 1992, GENE, V120, P197, DOI 10.1016/0378-1119(92)90094-6; GASKINS CJ, 1990, NUCLEIC ACIDS RES, V18, P2117, DOI 10.1093/nar/18.8.2117; GASKINS CJ, 1989, NUCLEIC ACIDS RES, V17, P781, DOI 10.1093/nar/17.2.781; HANAS JS, 1992, PROG NUCLEIC ACID RE, V43, P205, DOI 10.1016/S0079-6603(08)61048-X; HANAS JS, 1989, BIOCHEMISTRY-US, V28, P4083, DOI 10.1021/bi00435a068; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE MS, 1991, FEBS LETT, V279, P289, DOI 10.1016/0014-5793(91)80170-8; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LIAO XB, 1994, J BIOMOL NMR, V4, P433; LUMPKIN OJ, 1985, BIOPOLYMERS, V24, P1573, DOI 10.1002/bip.360240812; MCBRYANT SJ, 1995, J MOL BIOL, V248, P44, DOI 10.1006/jmbi.1995.0201; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; OGILVIE MK, 1993, NUCLEIC ACIDS RES, V21, P4152, DOI 10.1093/nar/21.17.4152; OMICHINSKI JG, 1992, BIOCHEMISTRY-US, V31, P3907, DOI 10.1021/bi00131a004; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; PIELER T, 1993, TRENDS BIOCHEM SCI, V18, P226, DOI 10.1016/0968-0004(93)90194-R; QIAN XQ, 1992, BIOCHEMISTRY-US, V31, P7463, DOI 10.1021/bi00148a006; ROLLINS MB, 1993, MOL CELL BIOL, V13, P4776, DOI 10.1128/MCB.13.8.4776; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; SCHROTH GP, 1991, NUCLEIC ACIDS RES, V19, P511, DOI 10.1093/nar/19.3.511; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; Setzer DR, 1996, RNA, V2, P1254; SETZER DR, 1985, J BIOL CHEM, V260, P2483; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9	63	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20152	20161		10.1074/jbc.272.32.20152	http://dx.doi.org/10.1074/jbc.272.32.20152			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242690	hybrid			2022-12-27	WOS:A1997XQ05900077
J	Konieczny, I; Doran, KS; Helinski, DR; Blasina, A				Konieczny, I; Doran, KS; Helinski, DR; Blasina, A			Role of TrfA and DnaA proteins in origin opening during initiation of DNA replication of the broad host range plasmid RK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; OPEN-COMPLEX-FORMATION; NUCLEOTIDE-SEQUENCE; BINDING; INVITRO; MUTATIONS; BACTERIA; REGION; SITES; POLYMERASE	The Escherichia coli protein DnaA and the plasmid RK2-encoded TrfA protein are required for initiation of replication of the broad host range plasmid RK2, The TrfA protein has been shown to bind to five 17-base pair repeat sequences, referred to as iterons, at the minimal replication origin (oriV), Using DNase I footprinting and a gel mobility shift assay, purified DnaA protein was found to bind to four DnaA consensus binding sequences immediately upstream of the five iterons at the RK2 origin of replication. Binding of the TrfA protein to the iterons results in localized strand opening within the A+T-rich region of the replication origin as determined by reactivity of the top and bottom strands to potassium permanganate (KMnO4). The presence of either the E, coli DnaA or HU protein is required for the TrfA-mediated strand opening. Although the DnaA protein itself did not produce an RK2 open complex, it did enhance and/or stabilize the TrfA-induced strand opening.	UNIV CALIF SAN DIEGO,CTR GENET MOL,DEPT BIOL,SAN DIEGO,CA 92093	University of California System; University of California San Diego				Konieczny, Igor/0000-0002-1588-5601	NIAID NIH HHS [AI-07194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; BONNEFOY E, 1992, EMBO J, V11, P4489, DOI 10.1002/j.1460-2075.1992.tb05550.x; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CEREGHINO JL, 1993, J BIOL CHEM, V268, P24926; delSolar G, 1996, MOL MICROBIOL, V21, P661, DOI 10.1046/j.1365-2958.1996.6611376.x; DIEDERICH L, 1994, BIOTECHNIQUES, V16, P916; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GAYLO PJ, 1987, J BACTERIOL, V169, P4703, DOI 10.1128/jb.169.10.4703-4709.1987; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HELINSKI DR, 1996, ESCHERICHIA COLI SAL, V2, P2295; HOLZ A, 1992, MOL GEN GENET, V233, P81, DOI 10.1007/BF00587564; HSU J, 1994, MOL MICROBIOL, V11, P903, DOI 10.1111/j.1365-2958.1994.tb00369.x; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Kawasaki Y, 1996, MOL GEN GENET, V253, P42, DOI 10.1007/s004380050294; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; LIN J, 1992, J BACTERIOL, V174, P4110, DOI 10.1128/jb.174.12.4110-4119.1992; MASAI H, 1990, J BIOL CHEM, V265, P15134; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; MUKHOPADHYAY G, 1993, J MOL BIOL, V231, P19, DOI 10.1006/jmbi.1993.1253; MUKHOPADHYAY G, 1993, EMBO J, V12, P4547, DOI 10.1002/j.1460-2075.1993.tb06143.x; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; ORTEGAJIMENEZ S, 1992, NUCLEIC ACIDS RES, V20, P2547, DOI 10.1093/nar/20.10.2547; PANSEGRAU W, 1994, J MOL BIOL, V239, P623, DOI 10.1006/jmbi.1994.1404; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PERRI S, 1991, J BIOL CHEM, V266, P12536; PERRI S, 1993, J BIOL CHEM, V268, P3662; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SCHMIDHAUSER TJ, 1983, PLASMID, V9, P325, DOI 10.1016/0147-619X(83)90010-0; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEUFERT W, 1987, CELL, V48, P73, DOI 10.1016/0092-8674(87)90357-6; SHAH DS, 1995, J MOL BIOL, V254, P608, DOI 10.1006/jmbi.1995.0642; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SMITH CA, 1984, J MOL BIOL, V175, P251, DOI 10.1016/0022-2836(84)90347-4; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1980, J BACTERIOL, V141, P213, DOI 10.1128/JB.141.1.213-222.1980; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; Toukdarian AE, 1996, J BIOL CHEM, V271, P7072, DOI 10.1074/jbc.271.12.7072; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811	48	68	70	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20173	20178		10.1074/jbc.272.32.20173	http://dx.doi.org/10.1074/jbc.272.32.20173			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242693	hybrid			2022-12-27	WOS:A1997XQ05900080
J	Rolfs, A; Kvietikova, I; Gassmann, M; Wenger, RH				Rolfs, A; Kvietikova, I; Gassmann, M; Wenger, RH			Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE-DEHYDROGENASE-A; GENE ENHANCER; TRANSCRIPTIONAL REGULATION; IRON-ABSORPTION; CELL-LINES; FACTOR-I; ERYTHROPOIETIN; LIVER; ACTIVATION; ELEMENTS	Transferrin (Tf) is a liver-derived iron transport protein whose plasma concentration increases following exposure to hypoxia, Here, we present a cell culture model capable of expressing Tf mRNA in an oxygen-dependent manner, A C-kilobase pair Tf promoter/enhancer fragment as well as the 300-base pair liver-specific Tf enhancer alone conveyed hypoxia responsiveness to a heterologous reporter gene construct in hepatoma but not HeLa cells. Within this enhancer, a 32-base pair hypoxia-responsive element was identified, which contained two hypoxia-inducible factor-1 (HIF-1) binding sites (HBSs). Mutation analysis showed that both HBSs function as oxygen-regulated enhancers in Tf-expressing as well as in non-Tf-expressing cell lines, Mutation of both HBSs was necessary to completely abolish hypoxic reporter gene activation, Transient co-expression of the two HIF-1 subunits HIF-1 alpha and aryl hydrocarbon receptor nuclear translocator (ARNT)/HIF-1 beta resulted in enhanced reporter gene expression even under normoxic conditions, Overexpression of a dominant-negative ARNT/HIF-1 beta mutant reduced hypoxic activation, DNA binding studies using nuclear extracts from the mouse hepatoma cell line Hepa1 and the ARNT/HIF-1 beta-deficient subline Hepa1C4, as well as antibodies raised against HIF-1 alpha and ARNT/HIF-1 beta confirmed that HIF-1 binds the Tf HBSs. Mutation analysis and competition experiments suggested that the 5' HBS was more efficient in binding HIF-1 than the 3' HBS. Finally, hypoxic induction of endogenous Tf mRNA was abrogated in Hepa1C4 cells, confirming that HIF-1 confers oxygen regulation of Tf gene expression by binding to the two HBSs present in the Tf enhancer.	UNIV ZURICH, INST PHYSIOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich			Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839				AUGEGOUILLOU C, 1993, FEBS LETT, V323, P4, DOI 10.1016/0014-5793(93)81436-4; BOISSIER F, 1991, J BIOL CHEM, V266, P9822; BONKOVSKY HL, 1991, AM J MED SCI, V301, P32, DOI 10.1097/00000441-199101000-00006; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEHOUR JK, 1957, AM J PHYSIOL, V191, P113, DOI 10.1152/ajplegacy.1957.191.1.113; EBERT BL, 1995, J BIOL CHEM, V270, P29038; FINCH C, 1994, BLOOD, V84, P1697; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MENDEL GA, 1961, BLOOD, V18, P727, DOI 10.1182/blood.V18.6.727.727; OSTERLOH KRS, 1987, BLUT, V55, P421, DOI 10.1007/BF00367458; PETROPOULOS I, 1991, J BIOL CHEM, V266, P24220; Sambrook J., 2002, MOL CLONING LAB MANU; Sawaya BE, 1996, J NEUROSCI RES, V43, P261, DOI 10.1002/(SICI)1097-4547(19960201)43:3<261::AID-JNR1>3.0.CO;2-H; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SIMPSON RJ, 1992, ANN HEMATOL, V65, P260, DOI 10.1007/BF01836070; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Wenger RH, 1996, BLOOD, V87, P756, DOI 10.1182/blood.V87.2.756.bloodjournal872756; Wenger RH, 1997, BIOL CHEM, V378, P609; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117	42	314	328	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20055	20062		10.1074/jbc.272.32.20055	http://dx.doi.org/10.1074/jbc.272.32.20055			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242677	Green Accepted, hybrid			2022-12-27	WOS:A1997XQ05900064
J	Alvarez, L; SanchezGongora, E; Mingorance, J; Pajares, MA; Mato, JM				Alvarez, L; SanchezGongora, E; Mingorance, J; Pajares, MA; Mato, JM			Characterization of rat liver-specific methionine adenosyltransferase gene promoter - Role of distal upstream cis-acting elements in the regulation of the transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; ADENOSYL-L-METHIONINE; NUCLEAR FACTOR-III; HEPATOMA-CELLS; BINDING-PROTEIN; MESSENGER-RNA; DNA METHYLATION; EXPRESSION; ENHANCER; ACTIVATION	Methionine adenosyltransferase is a ubiquitous enzyme that catalyzes the only known route of biosynthesis of S-adenosylmethionine, the major methyl group donor in cell metabolism, In mammals, two different methionine adenosyltransferases exist: one is confined to the liver, and the other one is distributed in extrahepatic tissues, In the present study, we report the cloning of the 5'-flanking region of liver-specific methionine adenosyltransferase gene from rat. Two closely spaced sites for transcriptional initiation were identified by primer extension analysis, The major transcription start site was determined to be 29 nucleotides downstream from the putative TATA box, Transient transfection assays of constructs containing sequentially deleted 5'-flanking sequences fused to the luciferase gene showed that rat hepatic methionine adenosyltransferase promoter was able to efficiently drive reporter expression not only in liver-type cells (rat hepatoma H35 cells and human hepatoblastoma HepG2 cells) but also in Chinese hamster ovary cells, Two regions spanning nucleotides -1251 to -958 and -197 to +65 were found to be crucial for the promoter efficiency, The distal upstream region contains elements that positively regulate promoter activity in H35 and HepG2 cells but are ineffective in Chinese hamster ovary cells, Eight protein binding sites were characterized in both regions by DNase I footprinting analysis, Two of these elements, sites A and B, located in the distal region, were found to be essential for the regulation of promoter activity, Electrophoretic mobility shift assays and competition experiments showed that site A is recognized by an NF1 protein. Site B was able to interact with a member of HNF-3 family when nuclear extracts from rat liver and H35 cells were used in the in vitro assay, but an additional binding activity to an NHF1-like protein was obtained with the hepatoma cell extracts, It is suggested that this differential binding can contribute to the cell specificity of promoter function.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Mingorance, Jesus/B-7562-2009; MATO, JOSE/A-5187-2011; Pajares, Maria Angeles/I-5952-2012	Mingorance, Jesus/0000-0001-6173-5711; MATO, JOSE/0000-0003-1264-3153; Pajares, Maria Angeles/0000-0002-4714-9051				ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ALVAREZ L, 1994, BIOCHEM J, V301, P557, DOI 10.1042/bj3010557; ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Arenzana N, 1996, J IMMUNOL, V156, P168; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Avila MA, 1997, HEPATOLOGY, V25, P391; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CABRERO C, 1988, HEPATOLOGY, V8, P1530, DOI 10.1002/hep.1840080610; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; Cai JX, 1996, HEPATOLOGY, V24, P1090; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CANTONI GL, 1953, J BIOL CHEM, V204, P403; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHAWLA RK, 1994, BBA-GEN SUBJECTS, V1199, P45, DOI 10.1016/0304-4165(94)90094-9; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; Gil B, 1997, ENDOCRINOLOGY, V138, P1251, DOI 10.1210/en.138.3.1251; Gil B, 1996, HEPATOLOGY, V24, P876; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; Kotb M, 1997, TRENDS GENET, V13, P51; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mato Jose M., 1994, P461; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; SAKATA SF, 1993, J BIOL CHEM, V268, P13978; Sambrook J., 2002, MOL CLONING LAB MANU; SanchezGongora E, 1996, BIOCHEM J, V319, P767, DOI 10.1042/bj3190767; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek FM, 1992, CURR OPIN GENET DEV, V2, P256, DOI 10.1016/S0959-437X(05)80282-5; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; VALLET V, 1995, MOL CELL BIOL, V15, P5453; WU GD, 1994, J BIOL CHEM, V269, P17080; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; Zaret Kenneth S., 1994, P53	60	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22875	22883		10.1074/jbc.272.36.22875	http://dx.doi.org/10.1074/jbc.272.36.22875			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278450	Green Published, hybrid			2022-12-27	WOS:A1997XV49200071
J	Harris, CM; Massey, V				Harris, CM; Massey, V			Kinetic isotope effects and electron transfer in the reduction of xanthine oxidoreductase with 4-hydroxypyrimidine - A comparison between oxidase and dehydrogenase forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALF-REACTION; MOLECULAR-OXYGEN; RAPID REACTION; MOLYBDENUM; PURIFICATION; SUBSTRATE; FLAVIN; NADH	Isolated from bovine milk, xanthine oxidase (XO) and xanthine dehydrogenase (XDH) are two interconvertible forms of the same protein, differing in the number of protein cysteines versus cystines. Most differences between XO and XDH are localized to the FAD center, the site at which the oxidizing substrates NAD and molecular oxygen react. A comparative study of the reduction of XO and XDH has been performed to assess differences in reactivity of the molybdopterin site, as well as subsequent electron-transfer events from molybdenum to 2Fe/2S and FAD centers. The compound 4-hydroxypyrimidine (4-OH-P) was chosen as reducing substrate because its higher K-m value raised the possibility of binding weak enough to measure kinetically, and its high k(cat) value could allow detection of intramolecular electron-transfer reactions. As measured by stopped flow spectrophotometry, XO and XDH react with the first equivalent of 4-OH-P via similar mechanisms, differing in the magnitude of rate and dissociation constants. Using [2-H-2]4-OH-P as substrate, a (D)(k/K-d,) isotope effect of 1.9 to 2.3 suggests that movement of the hydrogen abstracted from substrate appreciably limits the rate of initial enzyme reduction from Mo(VI) to Mo(IV). Monitoring the visible spectrum of the enzymes, the first observed step is reduction of a single 2Fe/2S center and presumably re-oxidation of Mo(IV) to Mo(V). This suggests a common pathway for electron transfer involving reduction of a 2Fe/2S center prior to reduction of the second 2Fe/2S and FAD centers. Rates of the first electron transfer from molybdenum to the 2Fe/2S center are rapid, 290 s(-1) with XO and 180 s(-1) with XDH, and are consistent with rates measured by flash photolysis (Walker, M. C., Hazzard, J. T., Tollin, G., and Edmondson, D. E. (1991) Biochemistry 30, 5912-5917) allowing discrete observation of the electron-transfer reactions that occur during turnover. This step also exhibits a modest primary kinetic isotope effect of 1.5 to 1.6 when [2-H-2]4-OH-P is used, possibly due to deprotonation of the molybdenum center prior to electron transfer. A second one-electron transfer, presumably oxidizing Mo(V) to Mo(VI), follows in a step coincident with product dissociation, consistent with a role for product release in controlling electron transfer events. The kinetics of this complex system are described and interpreted quantitatively in models that are consistent with all the data.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008270] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08270] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RF, 1986, J BIOL CHEM, V261, P1570; BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; DARDENNE SC, 1990, BIOCHEMISTRY-US, V29, P9046, DOI 10.1021/bi00490a023; DAVIS MD, 1984, J BIOL CHEM, V259, P3526; EDMONDSON D, 1973, J BIOL CHEM, V248, P6135; GASSNER G, 1994, BIOCHEMISTRY-US, V33, P12184, DOI 10.1021/bi00206a022; Harris CM, 1997, J BIOL CHEM, V272, P8370, DOI 10.1074/jbc.272.13.8370; Harris CM, 1994, FLAVINS AND FLAVOPROTEINS 1993, P723; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1981, J BIOL CHEM, V256, P9090; HILLE R, 1991, BIOCHEMISTRY-US, V30, P8522, DOI 10.1021/bi00099a004; HILLE R, 1986, J BIOL CHEM, V261, P1241; Howes BD, 1996, BIOCHEMISTRY-US, V35, P1432, DOI 10.1021/bi9520500; HUNT J, 1992, J BIOL CHEM, V267, P21479; HUNT J, 1994, J BIOL CHEM, V269, P18904; HUNT J, 1993, J BIOL CHEM, V268, P18685; Kim JH, 1996, J BIOL CHEM, V271, P6771, DOI 10.1074/jbc.271.12.6771; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; KRENITSKY TA, 1972, ARCH BIOCHEM BIOPHYS, V150, P585, DOI 10.1016/0003-9861(72)90078-1; Lowe David J., 1997, Biochemical Society Transactions, V25, p527S; MASSEY V, 1989, J BIOL CHEM, V264, P10567; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MASSEY V, 1973, IRON SULPHUR PROTEIN, V1, P301; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; MULLER F, 1972, EUR J BIOCHEM, V25, P573, DOI 10.1111/j.1432-1033.1972.tb01730.x; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; NISHINO T, 1989, J BIOL CHEM, V264, P2518; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; OLSON JS, 1974, J BIOL CHEM, V249, P4350; OLSON JS, 1974, J BIOL CHEM, V249, P4663; PORRAS AG, 1981, J BIOL CHEM, V256, P9096; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; PORTER DJT, 1980, J BIOL CHEM, V255, P2969; RAJAGOPALAN KV, 1967, J BIOL CHEM, V242, P4097; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; Segel I. H., 1976, BIOCH CALCULATIONS, P414; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; WALKER MC, 1991, BIOCHEMISTRY-US, V30, P5912, DOI 10.1021/bi00238a015	41	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22514	22525		10.1074/jbc.272.36.22514	http://dx.doi.org/10.1074/jbc.272.36.22514			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278404	hybrid			2022-12-27	WOS:A1997XV49200024
J	Bonday, ZQ; Taketani, S; Gupta, PD; Padmanaban, G				Bonday, ZQ; Taketani, S; Gupta, PD; Padmanaban, G			Heme biosynthesis by the malarial parasite - Import of delta-aminolevulinate dehydrase from the host red cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; ERYTHROLEUKEMIA-CELLS; ACID DEHYDRATASE; IDENTIFICATION; ERYTHROCYTES; TRANSPORT	The mouse and human malarial parasites, Plasmodium berghei and Plasmodium falciparum, respectively, synthesize heme de novo following the standard pathway observed in animals despite the availability of large amounts of heme, derived from red cell hemoglobin, which is stored as hemozoin pigment, The enzymes, delta-aminolevulinate dehydrase (ALAD), coproporphyrinogen oxidase, and ferrochelatase are present at strikingly high levels in the P, berghei infected mouse red cell in vivo, The isolated parasite has low levels of ALAD and the data clearly indicate it to be of red cell origin. The purified enzyme preparations from the uninfected red cell and the parasite are identical in kinetic properties, subunit molecular weight, cross-reaction with antibodies to the human enzyme, and N-terminal amino acid sequence. Immunogold electron microscopy of the infected culture indicates that the enzyme is present inside the parasite and, therefore, is not a contaminant, The parasite derives functional ALAD from the host and the enzyme binds specifically to isolated parasite membrane in vitro, suggestive of the involvement of a receptor in its translocation into the parasite, While, ALAD, coproporphyrinogen oxidase, and ferrochelatase from the parasite and the uninfected red cell supernatant have identical subunit molecular weights on SDS-polyacrylamide gel electrophoresis and show immunological cross-reaction with antibodies to the human enzymes, as revealed by Western analysis, the first enzyme of the pathway, namely, delta-aminolevulinate synthase (ALAS) in the parasite, unlike that of the red cell host, does not cross-react with antibodies to the human enzyme, However, ALAS enzyme activity in the parasite is higher than that of the infected red cell supernatant. We therefore conclude that the parasite, while making its own ALAS, imports ALAD and perhaps most of the other enzymes of the pathway from the host to synthesize heme de novo, and this would enable it to segregate this heme from the heme derived from red cell hemoglobin degradation, ALAS of the parasite and the receptor(s) involved in the translocation of the host enzymes into the parasite would be unique drug targets.	KANSAI MED UNIV,OSAKA 570,JAPAN; CTR CELLULAR & MOL BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA; JAWAHARLAL NEHRU CTR ADV SCI RES,BANGALORE 560064,KARNATAKA,INDIA	Kansai Medical University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Bonday, ZQ (corresponding author), INDIAN INST SCI,DEPT BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA.							ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; BECUWE P, 1996, MOL BIOCHEM PARASIT, V76, P124; BHAT GJ, 1988, ARCH BIOCHEM BIOPHYS, V264, P584, DOI 10.1016/0003-9861(88)90324-4; BOESE QF, 1991, J BIOL CHEM, V266, P17060; Burnham B.F., 1970, METHOD ENZYMOL, V17, P195, DOI DOI 10.1016/0076-6879(71)17179-0; DAILEY HA, 1977, J BACTERIOL, V129, P815, DOI 10.1128/JB.129.2.815-820.1977; EBERT PS, 1979, BIOCHEM BIOPH RES CO, V88, P1382, DOI 10.1016/0006-291X(79)91133-1; ELFORD BC, 1995, BIOCHEM J, V308, P361, DOI 10.1042/bj3080361; FAIRFIELD AS, 1983, SCIENCE, V221, P764, DOI 10.1126/science.6348944; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FRY M, 1991, PARASITOLOGY, V102, P17, DOI 10.1017/S0031182000060297; GARDNER LC, 1991, J BIOL CHEM, V266, P22010; GAUGHAN PLZ, 1971, COMP BIOCHEM PHYSIOL, V39, P5, DOI 10.1016/0305-0491(71)90247-1; Jordan PM, 1990, BIOSYNTHESIS HEME CH, P55; LEVIN W, 1983, DRUG METAB DISPOS, V1, P267; LINGELBACH KR, 1993, EXP PARASITOL, V76, P318, DOI 10.1006/expr.1993.1039; LWOFF M, 1951, BIOCH PHYSL PROTOZOA, P131; MAUZERALL D, 1956, J BIOL CHEM, V219, P435; SALGANIK RI, 1987, B WORLD HEALTH ORGAN, V65, P381; SALZMAN TA, 1982, COMP BIOCHEM PHYS B, V72, P663, DOI 10.1016/0305-0491(82)90523-5; Scheibel L. W., 1988, Malaria: principles and practice of malariology. Volume 1., P219; SHAHABUDDIN M, 1992, EXP PARASITOL, V74, P11, DOI 10.1016/0014-4894(92)90134-V; Sullivan AD, 1996, PARASITOL TODAY, V12, P161, DOI 10.1016/0169-4758(96)40001-1; SUROLIA N, 1992, BIOCHEM BIOPH RES CO, V187, P744, DOI 10.1016/0006-291X(92)91258-R; SUROLIA N, 1991, P NATL ACAD SCI USA, V88, P4786, DOI 10.1073/pnas.88.11.4786; TAKETANI S, 1994, J BIOL CHEM, V269, P7527; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TSCHUDY DP, 1981, J BIOL CHEM, V256, P9915; Wilson CM, 1996, MOL BIOCHEM PARASIT, V79, P135, DOI 10.1016/0166-6851(96)02690-4	29	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21839	21846		10.1074/jbc.272.35.21839	http://dx.doi.org/10.1074/jbc.272.35.21839			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268315	hybrid			2022-12-27	WOS:A1997XT85000027
J	Hamer, I; Haft, CR; Paccaud, JP; Maeder, C; Taylor, S; Carpentier, JL				Hamer, I; Haft, CR; Paccaud, JP; Maeder, C; Taylor, S; Carpentier, JL			Dual role of a dileucine motif in insulin receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DI-LEUCINE MOTIF; DENSITY-LIPOPROTEIN RECEPTOR; TYROSINE KINASE-ACTIVITY; INTERNALIZATION SIGNALS; TRANSMEMBRANE DOMAIN; MEDIATED INTERNALIZATION; JUXTAMEMBRANE REGION; DOWN-REGULATION; BETA-SUBUNIT	Two leucines (Leu(986) and Leu(987)) have recently been shown to take part in the control of human insulin receptor (HIR) internalization (Renfrew-Haft, C,, Klausner, R, D,, and Taylor, S, I, (1994) J, Biol, Chem, 269, 26286-26294), The aim of the present study was to further investigate the exact mechanism of this control process, Constitutive and insulin-induced HIR internalizations were studied biochemically and morphologically in NIH 3T3 cells overexpressing either a double alanine (amino acid residues 986-987) mutant NIR (HIR AA1) or HIR truncated at either amino acid residue 981 (HIR Delta 981) or 1000 (HIR Delta 1000). Data collected indicate that: (a) the three mutant HIR show a reduced association with microvilli as compared with HIR wild-type; (b) the two receptors containing the dileucine motif (HIR WT and HIR Delta 1000) show the highest propensity to associate with clathrin-coated pits, independently of kinase activation; (c) the two receptors lacking the dileucine motif but containing two tyrosine-based motifs, previously described as participating in clathrin-coated pit segregation, associate with these surface domains with a lower affinity than the two others, (d) in the presence of the kinase domain, an unmasking of the tyrosine-based motifs mediated by kinase activation is required. These results indicate that the dileucine motif is not sufficient by itself, but participates in anchoring HIR on microvilli and that another sequence, located downstream from position 1000 is crucial for this event, This dileucine motif also plays a role in HIR segregation in clathrin-coated pits, This latter function is additive with that of the tyrosine-based motifs but the role of the dileucine motif predominates, Eventually, the clathrin-coated pit anchoring function of the dileucine motif is independent of receptor kinase activation in contrast to the tyrosine-based motifs.	CMU,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND; NIDDK,DIABET BRANCH,NIH,BETHESDA,MD 20892	University of Geneva; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1985, J CELL BIOL, V101, P887, DOI 10.1083/jcb.101.3.887; CARPENTIER JL, 1994, DIABETOLOGIA, V37, pS117, DOI 10.1007/BF00400835; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; CARPENTIER JL, 1993, J CELL BIOL, V118, P831; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FAN JY, 1982, P NATL ACAD SCI-BIOL, V79, P7788, DOI 10.1073/pnas.79.24.7788; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P2198, DOI 10.1210/en.136.5.2198; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HAFT CR, 1994, BIOCHEMISTRY-US, V33, P9143, DOI 10.1021/bi00197a017; HAFT CR, 1995, BIOCHEMISTRY-US, V34, P15880; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; Mangasarian A, 1997, IMMUNITY, V6, P67, DOI 10.1016/S1074-7613(00)80243-5; MORI S, 1994, J BIOL CHEM, V269, P4917; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PACCAUD JP, 1993, J BIOL CHEM, V268, P23191; PACCAUD JP, 1992, J BIOL CHEM, V267, P13101; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; THIES RS, 1990, J BIOL CHEM, V265, P10132; THUILLIER L, 1994, CELL IMMUNOL, V156, P322, DOI 10.1006/cimm.1994.1178; YAMADA K, 1995, BIOCHEMISTRY-US, V34, P946, DOI 10.1021/bi00003a029; YAMADA K, 1995, J BIOL CHEM, V270, P3115, DOI 10.1074/jbc.270.7.3115	48	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21685	21691		10.1074/jbc.272.35.21685	http://dx.doi.org/10.1074/jbc.272.35.21685			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268295	hybrid			2022-12-27	WOS:A1997XT85000007
J	Payne, MA; Igo, JD; Cao, ZH; Foster, SB; Newton, SMC; Klebba, PE				Payne, MA; Igo, JD; Cao, ZH; Foster, SB; Newton, SMC; Klebba, PE			Biphasic binding kinetics between FepA and its ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC ENTEROBACTIN RECEPTOR; ESCHERICHIA-COLI K-12; OUTER-MEMBRANE RECEPTOR; TRITON X-100; GROUP-B; ENTEROCHELIN; TRANSPORT; PROTEIN; SYSTEM; SPECIFICITY	The Escherichia coli FepA protein is an energy-and TonB dependent, ligand-binding porin that functions as a receptor for the siderophore ferric enterobactin and colicins B and D, We characterized the kinetic and thermodynamic parameters associated with the initial, energy-independent steps in ligand binding to FepA. In vivo experiments produced K-d values of 24, 185, and 560 nM for ferric enterobactin, colicin B, and colicin D, respectively, The siderophore and colicin B bound to FepA with a 1:1 stoichiometry, but colicin D bound to a maximum level that was 3-fold lower, Preincubation with ferric enterobactin prevented colicin B binding, and preincubation with colicin B prevented ferric enterobactin binding, Colicin B release from FepA was unexpectedly slow in vivo, about 10-fold slower than ferric enterobactin release, This slow dissociation of the coli cin B . FepA complex facilitated the affinity purification of FepA and FepA mutants with colicin B-Sepharose. Analysis of a fluorescent FepA derivative showed that ferric enterobactin and colicin B adsorbed with biphasic kinetics, suggesting that both ligands bind in at least two distinct steps, an initial rapid stage and a subsequent slower step, that presumably establishes a transport-competent complex.	UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019; UNIV SAO PAULO,DEPT MICROBIOL,BR-08805900 SAO PAULO,BRAZIL	University of Oklahoma System; University of Oklahoma - Norman; Universidade de Sao Paulo					NCRR NIH HHS [RR1182] Funding Source: Medline; NIGMS NIH HHS [GM53836] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053836] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; BENEDETTI H, 1991, J MOL BIOL, V217, P429, DOI 10.1016/0022-2836(91)90747-T; CARBONETTI NH, 1984, INFECT IMMUN, V46, P7, DOI 10.1128/IAI.46.1.7-12.1984; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DAVIES JK, 1975, J BACTERIOL, V123, P96, DOI 10.1128/JB.123.1.96-101.1975; DIMASI DR, 1973, J BACTERIOL, V115, P514; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FISS EH, 1982, BIOCHEMISTRY-US, V21, P4517, DOI 10.1021/bi00261a050; GUTERMAN SK, 1973, J BACTERIOL, V114, P1217, DOI 10.1128/JB.114.3.1217-1224.1973; GUTERMAN SK, 1971, BIOCHEM BIOPH RES CO, V44, P1149, DOI 10.1016/S0006-291X(71)80206-1; GUTERMAN SK, 1973, J BACTERIOL, V114, P1225, DOI 10.1128/JB.114.3.1225-1230.1973; HOLLIFIELD WC, 1978, BIOCHEMISTRY-US, V17, P1922, DOI 10.1021/bi00603a019; JEANTEUR D, 1994, P NATL ACAD SCI USA, V91, P10675, DOI 10.1073/pnas.91.22.10675; Jiang XQ, 1997, SCIENCE, V276, P1261, DOI 10.1126/science.276.5316.1261; KLUG CS, 1995, BIOCHEMISTRY-US, V34, P14230, DOI 10.1021/bi00043a030; LAZDUNSKI CJ, 1995, MOL MICROBIOL, V16, P1059, DOI 10.1111/j.1365-2958.1995.tb02331.x; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; LIU J, 1994, BIOCHEMISTRY-US, V33, P13274, DOI 10.1021/bi00249a014; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENDE J, 1990, MOL MICROBIOL, V4, P1523, DOI 10.1111/j.1365-2958.1990.tb02063.x; Mishell B.B., 1980, SELECTED METHODS CEL; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; Newton SMC, 1997, P NATL ACAD SCI USA, V94, P4560, DOI 10.1073/pnas.94.9.4560; OUDEGA B, 1979, J BACTERIOL, V138, P7, DOI 10.1128/JB.138.1.7-16.1979; PUGSLEY AP, 1977, ANTIMICROB AGENTS CH, V11, P345, DOI 10.1128/AAC.11.2.345; PUGSLEY AP, 1976, J BACTERIOL, V127, P218, DOI 10.1128/JB.127.1.218-228.1976; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; RUTZ JM, 1991, J BACTERIOL, V173, P5964, DOI 10.1128/jb.173.19.5964-5974.1991; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SCHNAITMAN CA, 1971, J BACTERIOL, V108, P553, DOI 10.1128/JB.108.1.553-563.1971; TIMMIS K, 1972, J BACTERIOL, V109, P12, DOI 10.1128/JB.109.1.12-20.1972; WANG CC, 1971, J BIOL CHEM, V246, P2147; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; WAYNE R, 1975, J BACTERIOL, V121, P497, DOI 10.1128/JB.121.2.497-503.1975; WAYNE R, 1976, J BACTERIOL, V126, P7, DOI 10.1128/JB.126.1.7-12.1976; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; WIENER M, 1997, NATURE, V385, P390	39	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21950	21955		10.1074/jbc.272.35.21950	http://dx.doi.org/10.1074/jbc.272.35.21950			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268330	hybrid			2022-12-27	WOS:A1997XT85000042
J	Empson, RM; Galione, A				Empson, RM; Galione, A			Cyclic ADP-ribose enhances coupling between voltage-gated Ca2+ entry and intracellular Ca2+ release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM-RELEASE; BULLFROG SYMPATHETIC NEURONS; HYBRID NG108-15 CELLS; RYANODINE RECEPTOR; CHANNELS; STORES; BRAIN; DIFFERENTIATION; EXPRESSION; METABOLITE	Ca2+ release from intracellular stores can be activated in neurons by influx of Ca2+ through voltage-gated Ca2+ channels, This process, called Ca2+-induced Ca2+ release, relies on the properties of the ryanodine receptor and represents a mechanism by which Ca2+ influx during neuronal activity can be amplified into large intracellular Ca2+ signals, In a differentiated neuroblastoma cell line, we show that caffeine, a pharmacological activator of the ryanodine receptor, released Ca2+ from intracellular stores in a Ca2+-dependent and ryanodine-sensitive manner. The pyridine nucleotide, cyclic ADP-ribose, thought to be an endogenous modulator of ryanodine receptors also amplified Ca2+-induced Ca2+ release in these neurons. Cyclic ADP-ribose enhanced the total cytoplasmic Ca2+ levels during controlled Ca2+ influx through voltage gated channels, in a concentration-dependent and ryanodine-sensitive manner and also increased the sensitivity with which a small amount of Ca2+ influx could trigger additional release from the ryanodine sensitive intracellular Ca2+ stores, Single cell imaging showed that following the Ca2+ influx, cyclic ADP-ribose enhanced the spatial spread of the Ca2+ signal from the edge of the cell into its center. These powerful actions suggest a role for cyclic ADP-ribose in the functional coupling of neuronal depolarization, Ca2+ entry, and global intracellular Ca2+ signaling.			Empson, RM (corresponding author), UNIV OXFORD,DEPT PHARMACOL,MANSFIELD RD,OXFORD OX1 3QT,ENGLAND.		Galione, Antony/E-5884-2011	Empson, Ruth/0000-0002-0415-6083; Galione, Antony/0000-0002-4132-7646	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRORSON JR, 1991, J NEUROSCI, V11, P4024; CHU A, 1990, MOL PHARMACOL, V37, P735; CHUEH SH, 1990, J NEUROCHEM, V55, P1281, DOI 10.1111/j.1471-4159.1990.tb03136.x; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DOCHERTY RJ, 1988, J PHYSIOL-LONDON, V398, P33, DOI 10.1113/jphysiol.1988.sp017027; DOCHERTY RJ, 1991, CELLULAR NEUROBIOLOG, P75; ECKERT R, 1991, NEUROSCI LETT, V119, P123; FRIEL DD, 1992, J PHYSIOL-LONDON, V450, P217, DOI 10.1113/jphysiol.1992.sp019125; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P316; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; HUA SY, 1993, J PHYSIOL-LONDON, V464, P245, DOI 10.1113/jphysiol.1993.sp019633; JIN WZ, 1993, BRAIN RES, V607, P17, DOI 10.1016/0006-8993(93)91484-A; KOHDA K, 1995, J NEUROPHYSIOL, V74, P2184, DOI 10.1152/jn.1995.74.5.2184; KOSTYUK PG, 1995, CALCIUM SIGNALLING N, P39; KUBA K, 1994, JPN J PHYSIOL, V44, P613, DOI 10.2170/jjphysiol.44.613; LAI FA, 1992, BIOCHEM J, V288, P553, DOI 10.1042/bj2880553; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; LO TM, 1993, AM J PHYSIOL, V264, pC641, DOI 10.1152/ajpcell.1993.264.3.C641; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; Peng YY, 1996, J NEUROSCI, V16, P6703; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; Reyes M, 1996, J NEUROSCI, V16, P5951; SAH P, 1993, NEUROSCIENCE, V54, P157, DOI 10.1016/0306-4522(93)90391-R; SAH P, 1991, NEURON, V7, P257, DOI 10.1016/0896-6273(91)90264-Z; SEYMOURLAURENT KJ, 1995, J NEUROSCI, V15, P2592; SHARP AH, 1993, J NEUROSCI, V13, P3051; Shmigol A, 1995, J PHYSIOL-LONDON, V489, P627, DOI 10.1113/jphysiol.1995.sp021078; SHMIGOL A, 1994, J PHYSIOL-LONDON, V433, pP63; TAKEMURA H, 1991, BIOCHEM BIOPH RES CO, V180, P1518, DOI 10.1016/S0006-291X(05)81368-3; THAYER SA, 1988, MOL PHARMACOL, V34, P664; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; USACHEV Y, 1993, NEUROSCIENCE, V57, P845, DOI 10.1016/0306-4522(93)90029-F; Verkhratsky A, 1996, CELL CALCIUM, V19, P1, DOI 10.1016/S0143-4160(96)90009-3; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Wang Y, 1997, J NEUROPHYSIOL, V77, P812, DOI 10.1152/jn.1997.77.2.812	43	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20967	20970		10.1074/jbc.272.34.20967	http://dx.doi.org/10.1074/jbc.272.34.20967			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261092	hybrid			2022-12-27	WOS:A1997XR78900002
J	Kuroda, A; Murphy, H; Cashel, M; Kornberg, A				Kuroda, A; Murphy, H; Cashel, M; Kornberg, A			Guanosine tetra- and pentaphosphate promote accumulation of inorganic polyphosphate in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPGPP; EXOPOLYPHOSPHATASE; PURIFICATION; MUTANTS; GENE	High levels of guanosine tetraphosphate (ppGpp) and guanosine pentaphosphate (pppGpp), generated in response to amino acid starvation in Escherichia coli, lead to massive accumulations of inorganic polyphosphate (polyP). Inasmuch as the activities of the principal enzymes that synthesize and degrade polyP fluctuate only slightly, the polyP accumulation can be attributed to a singular and profound inhibition by pppGpp and/or ppGpp of the hydrolytic breakdown of polyP by exopolyphosphatase, thereby blocking the dynamic turnover of polyP. The K-i values of 10 mu M for pppGpp and 200 mu M for ppGpp are far below the concentrations of these nucleotides in nutritionally stressed cells. In the complex metabolic network of pppGpp and ppGpp, the greater inhibitory effect of pppGpp (compared with ppGpp) leading to the accumulation of polyP, may have some significance in the relative roles played by these regulatory compounds.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; NICHHD,MOL GENET LAB,NIH,BETHESDA,MD 20892	Stanford University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; Cashel M., 1994, METH MOL G, V3, P341; CROOKE E, 1994, J BIOL CHEM, V269, P6290; HARA A, 1983, J BIOL CHEM, V258, P1678; KALMAN M, 1991, NEW BIOL, V3, P886; KEASLING JD, 1993, P NATL ACAD SCI USA, V90, P7029, DOI 10.1073/pnas.90.15.7029; KOONIN EV, 1994, TRENDS BIOCHEM SCI, V19, P156, DOI 10.1016/0968-0004(94)90275-5; KROHN M, 1995, ANAL BIOCHEM, V225, P188, DOI 10.1006/abio.1995.1138; Kulaev IS, 1979, BIOCH INORGANIC POLY; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Rao NN, 1996, J BACTERIOL, V178, P1394, DOI 10.1128/jb.178.5.1394-1400.1996; Shinagawa H., 1987, PHOSPHATE METABOLISM, P20; SPIRA B, 1995, J BACTERIOL, V177, P4053, DOI 10.1128/jb.177.14.4053-4058.1995; VOELZ H, 1966, ARCH MIKROBIOL, V53, P371, DOI 10.1007/BF00409874; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315; WOODY AYM, 1987, BIOCHIM BIOPHYS ACTA, V909, P115, DOI 10.1016/0167-4781(87)90033-9; XIAO H, 1991, J BIOL CHEM, V266, P5980	19	183	189	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21240	21243		10.1074/jbc.272.34.21240	http://dx.doi.org/10.1074/jbc.272.34.21240			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261133	hybrid			2022-12-27	WOS:A1997XR78900043
J	Okamoto, Y; Ninomiya, H; Tanioka, M; Sakamoto, A; Miwa, S; Masaki, T				Okamoto, Y; Ninomiya, H; Tanioka, M; Sakamoto, A; Miwa, S; Masaki, T			Palmitoylation of human endothelin(B) - Its critical role in G protein coupling and a differential requirement for the cytoplasmic tail by G protein subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; SF9 CELLS; CARBOXYL-TERMINUS; DOWN-REGULATION; LIGAND-BINDING; EXPRESSION; CYSTEINE; PHOSPHORYLATION; MUTATION; CLONING	By site-directed mutagenesis, three cysteine residues (amino acids 402, 403, and 405) in the carboxyl terminus of human endothelin(B) (ETB) were identified as potential palmitoylation sites. Substitutions of all of the three cysteine residues with serine gave an unpalmitoylated mutant, C2S/C3S/C5S, When expressed in Chinese hamster ovary cells, C2S/C3S/C5S was localized on the cell surface, retained high affinities to ET-1 and ET-3, and was rapidly internalized when bound to the ligand, However, unlike the wild-type ETB, C2S/C3S/C5S transmitted neither an inhibitory effect on adenylate cyclase nor a stimulatory effect on phospholipase C, indicating a critical role of palmitoylation in the coupling with G proteins, regardless of the G protein subtypes. Truncation of the carboxyl terminus including Cys(403)/Cys(405) gave a deletion mutant Delta 403 that was palmitoylated ton Cys(402) and lacked the carboxyl terminus downstream to the palmitoylation site. Delta 403 did transmit a stimulatory effect on phospholipase C via a pertussis toxin-insensitive G protein but it failed to transmit an inhibitory effect on adenylate cyclase. These results indicated a differential requirement for the carboxyl terminus downstream to the palmitoylation site in the coupling with G protein subtypes, i.e. it is required for the coupling with G(i) but not for that with G(q).	KYOTO UNIV, FAC MED, DEPT PHARMACOL, KYOTO 606, JAPAN	Kyoto University			Miwa, Soichi/D-8468-2012; OKAMOTO, Yasuo/J-8438-2015					ALALUF S, 1995, J NEUROCHEM, V64, P1548; Aquilla E, 1996, J BIOL CHEM, V271, P31572, DOI 10.1074/jbc.271.49.31572; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; Elshourbagy NA, 1996, J BIOL CHEM, V271, P25300, DOI 10.1074/jbc.271.41.25300; FUKURODA T, 1994, BIOCHEM BIOPH RES CO, V199, P1461, DOI 10.1006/bbrc.1994.1395; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KOSHIMIZU T, 1995, BIOCHEM BIOPH RES CO, V217, P354, DOI 10.1006/bbrc.1995.2784; KOZUKA M, 1991, J BIOL CHEM, V266, P16892; MASAKI T, 1993, ENDOCR REV, V14, P256, DOI 10.1210/er.14.3.256; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; OZAKI S, 1995, BIOCHEM BIOPH RES CO, V209, P483, DOI 10.1006/bbrc.1995.1527; ROSE PM, 1995, FEBS LETT, V361, P243, DOI 10.1016/0014-5793(95)00164-5; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Sugawara F, 1996, MOL PHARMACOL, V49, P447; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; VANKOPPEN CJ, 1991, J NEUROCHEM, V57, P1873, DOI 10.1111/j.1471-4159.1991.tb06397.x; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	37	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21589	21596		10.1074/jbc.272.34.21589	http://dx.doi.org/10.1074/jbc.272.34.21589			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261180	hybrid			2022-12-27	WOS:A1997XR78900090
J	Pierce, JW; Schoenleber, R; Jesmok, G; Best, J; Moore, SA; Collins, T; Gerritsen, ME				Pierce, JW; Schoenleber, R; Jesmok, G; Best, J; Moore, SA; Collins, T; Gerritsen, ME			Novel inhibitors of cytokine-induced I kappa B alpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR; E-SELECTIN; TYROSINE-PHOSPHATASE; LEUKOCYTE ADHESION; REGULATORY SYSTEM; MONOCYTE ADHESION; GENE-EXPRESSION	We have identified two compounds that inhibit the expression of endothelial-leukocyte adhesion molecules intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin, These compounds act by inhibiting tumor necrosis factor-alpha-induced phosphorylation of I kappa B-alpha, resulting in decreased nuclear factor-kappa B and decreased expression of adhesion molecules, The effects on both I kappa B-alpha phosphorylation and surface expression of E-selectin were irreversible and occurred at an IC50 of approximately 10 mu M. These agents selectively and irreversibly inhibited the tumor necrosis factor-alpha-inducible phosphorylation of I kappa B-alpha without affecting the constitutive I kappa B-alpha Phosphorylation. Although these compounds exhibited other activities, including stimulation of the stress-activated protein kinases, p38 and JNK-1, and activation of tyrosine phosphorylation of a 130-140-kDa protein, these effects are probably distinct from the effects on adhesion molecule expression since they were reversible, One compound was evaluated in vivo and shown to be a potent anti-inflammatory drug in two animal models of inflammation, The compound reduced edema formation in a dose-dependent manner in the rat carrageenan paw edema assay and reduced pam swelling in a rat adjuvant arthritis model, These studies suggest that inhibitors of cytokine-inducible I kappa B alpha phosphorylation exert anti-inflammatory activity in vivo.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL, VASC RES DIV, BOSTON, MA 02115 USA; BAYER CORP, West Haven, CT 06516 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Bayer AG								ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bennett BL, 1996, J BIOL CHEM, V271, P19680, DOI 10.1074/jbc.271.33.19680; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CARLOS TM, 1994, BLOOD, V84, P2068; CHEN CC, 1995, J IMMUNOL, V155, P3538; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1993, TRENDS CARDIOVAS MED, V3, P92, DOI 10.1016/1050-1738(93)90030-A; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GERRITSEN ME, 1995, AM J PATHOL, V147, P278; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; IIGO Y, 1991, J IMMUNOL, V147, P4167; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIU J, 1994, J BIOL CHEM, V269, P3047; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MENON SD, 1995, J BIOL CHEM, V270, P18881; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; ORTHNER CL, 1995, BLOOD, V86, P436, DOI 10.1182/blood.V86.2.436.bloodjournal862436; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pierce JW, 1996, J IMMUNOL, V156, P3961; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RICHTER SUK, 1924, Patent No. 1506186; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665; WEBER C, 1995, J IMMUNOL, V155, P445; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464	75	896	930	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21096	21103		10.1074/jbc.272.34.21096	http://dx.doi.org/10.1074/jbc.272.34.21096			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261113	hybrid			2022-12-27	WOS:A1997XR78900023
J	Wu, DY; Wallen, HD; Inohara, N; Nunez, G				Wu, DY; Wallen, HD; Inohara, N; Nunez, G			Interaction and regulation of the Caenorhabditis elegans death protease CED-3 by CED-4 and CED-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GENE CED-3; ENCODES; HOMOLOG; ENZYME; BCL-2	In the nematode Caenorhabditis elegans, three genes, ced-3, ced-4, and ced-9, play critical roles in the induction and execution of the death pathway, Genetic studies have suggested that ced-9 controls programmed cell death by regulating ced-4 and ced-3, However, the mechanism by which CED-9 controls the activities of CED-4 and the cysteine protease CED-3, the effector arm of the cell-death pathway, remains poorly understood, Immunoprecipitation analysis demonstrates that CED-9 forms a multimeric protein complex with CED-4, and CED-3 in vivo. Expression of wild-type CED-4 promotes the ability of CED-3 to induce apoptosis in mammalian cells, which is inhibited by CED-9, The pro-apoptotic activity of CED-4 requires the expression of a functional CED-3 protease, Significantly, loss-of-function CED-4 mutants are impaired in their ability to promote CED-3-mediated apoptosis, Expression of CED-4 enhances the proteolytic activation of CED-3, We also show that CED-9 inhibits the formation of p13 and p15, two cleavage products of CED-3 associated with its proteolytic activation in vivo. Moreover, CED-9 inhibits the enzymatic activity of CED-3 promoted by CED-4. Thus, these results provide evidence that CED-4 and CED-9 regulate the activity of CED-3 through physical interactions, which may provide a molecular basis for the control of programmed cell death in C. elegans.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Nuñez, Gabriel/A-7160-2014		NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline; PHS HHS [T32A107413-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	19	108	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21449	21454		10.1074/jbc.272.34.21449	http://dx.doi.org/10.1074/jbc.272.34.21449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261161	hybrid			2022-12-27	WOS:A1997XR78900071
J	Yamin, TT; Miller, DK				Yamin, TT; Miller, DK			The interleukin-1 receptor-associated kinase is degraded by proteasomes following its phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; DROSOPHILA EMBRYO; DORSOVENTRAL SIGNAL; ALPHA PROTEOLYSIS; IL-1 RECEPTOR; TNF RECEPTORS	Following interleukin (Lt)-1 stimulation, the majority of the cellular interleukin-1 receptor-associated kinase (IRAK) translocates to a discrete subset of the Type I IL-1 receptor (IL-IRI) in MRC-5 human lung fibroblasts. As the IRAK becomes multiphosphorylated, it is degraded by proteasomes at a rate comparable to that of the degradation of the phosphorylated I kappa B alpha protein, Proteasome inhibitors black the degradation of phosphorylated IRAK and correspondingly increase the amount of IL-1R1 that can be coimmunoprecipitated with IRAK. The nonspecific kinase inhibitor K-252b blocks IRAK phosphorylation and degradation, but does not inhibit IRAK association with She IL-1R1 indicating that translocation of IRAK to the IL-1R1 and its phosphorylation are independent events. The IL-1 specificity of these effects is indicated by the lack of IRAK phosphorylation and degradation by IL-1 in the presence of the IL-1 receptor antagonist or by the activation of MRC-B cells by tumor necrosis factor alpha. Long term exposure of MRC-5 cells to IL-1 desensitizes the resynthesized I kappa B alpha to IL-1, but not to tumor necrosis factor alpha stimulation, but no additional effects an IRAK are seen.	MERCK RES LABS, DEPT INFLAMMAT RES, RAHWAY, NJ 07065 USA	Merck & Company								ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chainy GBN, 1996, J IMMUNOL, V157, P2410; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIN J, 1987, J EXP MED, V165, P70, DOI 10.1084/jem.165.1.70; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; DARNAY BG, 1995, J BIOL CHEM, V270, P14867, DOI 10.1074/jbc.270.25.14867; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; DOWER SK, 1990, J INVEST DERMATOL, V94, pS68, DOI 10.1111/1523-1747.ep12875154; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HEGUY A, 1992, J BIOL CHEM, V267, P2605; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; INGHAM P, 1994, NATURE, V372, P500, DOI 10.1038/372500a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; MILLER DK, 1993, J BIOL CHEM, V268, P18062; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TOCCI MJ, 1997, IN PRESS CYTOKINES H; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Traenckner EBM, 1995, J CELL SCI, P79; Trofimova M, 1996, J BIOL CHEM, V271, P17609, DOI 10.1074/jbc.271.30.17609; URDAL DL, 1988, J BIOL CHEM, V263, P2870; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273	58	241	260	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21540	21547		10.1074/jbc.272.34.21540	http://dx.doi.org/10.1074/jbc.272.34.21540			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261174	hybrid			2022-12-27	WOS:A1997XR78900084
J	Zhao, H; Li, YY; Fucini, RV; Ross, SE; Pessin, JE; Koretzky, GA				Zhao, H; Li, YY; Fucini, RV; Ross, SE; Pessin, JE; Koretzky, GA			T cell receptor-induced phosphorylation of Sos requires activity of CD45, Lck, and protein kinase C, but not EPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; TYROSINE PHOSPHATASE CD45; GRB2 ADAPTER PROTEIN; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; RAS ACTIVATION; GROWTH-FACTOR; ZETA-CHAIN; SUBSTRATE RECOGNITION	Stimulation of the T cell antigen receptor (TCR) activates signaling pathways involving protein kinases, phospholipase C gamma 1, and Has. How these second messengers interact to initiate distal activation events is an area of intense scrutiny, In this report, we confirm that TCR ligation results in phosphorylation of Sos, a guanine nucleotide exchange factor for Has, This requires expression of both the CD45 tyrosine phosphatase and the Lck protein tyrosine kinase and depends upon signaling via protein kinase C. In contrast to previous studies examining requirements for Sos phosphorylation following insulin and epidermal growth factor receptor engagement, we show that TCR-induced phosphorylation of Sos does not require activation of the mitogen-activated protein kinase/extracellular signal regulated kinase (MEK/ERK) pathway, However, the basal phosphorylation of Sos in T cells is affected by either MEK or MEK-dependent kinases, Although Sos phosphorylation results in its dissociation from Grb2 following insulin stimulation in Chinese hamster ovary cells, TCR engagement on the Jurkat T cell line fails to elicit a similar effect, These data demonstrate that the kinases responsible for Sos phosphorylation differ following ligation of various cell surface receptors and that the consequences of Sos phosphorylation relies, at Yeast in part, on sites of its phosphorylation.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,PROGRAM MOL BIOL,IOWA CITY,IA 52242; UNIV IOWA,INTERDISCIPLINARY PROGRAM IMMUNOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; University of Iowa			Koretzky, Gary/AAU-5381-2021		NCI NIH HHS [P01CA66570] Funding Source: Medline; NIDDK NIH HHS [DK25925, DK33823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, R37DK033823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COBB MH, 1994, CELL MOL BIOL RES, V40, P253; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Holt KH, 1996, MOL CELL BIOL, V16, P577; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Li YY, 1996, J IMMUNOL, V157, P1440; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Motto DG, 1996, MOL CELL BIOL, V16, P2823; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; NEL AE, 1990, J IMMUNOL, V144, P2683; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PASTOR MI, 1995, CANCER SURV, V22, P75; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REIF K, 1994, J BIOL CHEM, V269, P14081; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	59	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21625	21634		10.1074/jbc.272.34.21625	http://dx.doi.org/10.1074/jbc.272.34.21625			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261185	hybrid			2022-12-27	WOS:A1997XR78900095
J	Ehnis, T; Dieterich, W; Bauer, M; Kresse, H; Schuppan, D				Ehnis, T; Dieterich, W; Bauer, M; Kresse, H; Schuppan, D			Localization of a binding site for the proteoglycan decorin on collagen XIV (Undulin)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; TISSUE-SPECIFIC EXPRESSION; GROWTH-FACTOR-BETA; FIBROBLAST ADHESION; MATRIX PROTEIN; RAT-LIVER; FIBRONECTIN; CARTILAGE; PURIFICATION; INHIBITION	Through its ability to bind extracellular matrix constituents and growth factors the small leucine rich chondroitin/dermatan sulfate proteoglycan decorin which is present in many types of connective tissues may play an important biological role in remodeling and maintenance of extracellular matrices during inflammation, fibrosis, and cancer growth, In this study we investigated the known binding of decorin to human collagen XIV, This binding was unaffected when the small collagenous moiety of collagen XIV was removed with collagenase. Therefore, fragments covering the large noncollagenous domain NC3 of collagen XIV were expressed in Escherichia coli, each fused to a 26-kDa fragment of glutathione S-transferase. Using radioiodinated decorin as ligand for the immobilized fusion proteins, a binding site that interacted with the decorin core protein could be assigned to the NH2-terminal fibronectin type III repeat of collagen XIV. In addition, an auxiliary binding site located COOH terminal to this fibronectin type III repeat interacted with the glycosaminoglycan component of decorin.	FREE UNIV BERLIN, KLINIKUM BENJAMIN FRANKLIN, DEPT GASTROENTEROL & HEPATOL, D-12200 BERLIN, GERMANY; UNIV MUNSTER, INST PHYSIOL CHEM & PATHOBIOCHEM, D-48149 MUNSTER, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster								AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CASTAGNOLA P, 1992, EUR J CELL BIOL, V59, P340; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DUBLET B, 1991, J BIOL CHEM, V266, P6853; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; FONT B, 1993, J BIOL CHEM, V268, P25015; GERECKE DR, 1993, J BIOL CHEM, V268, P12177; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; GORDON MK, 1991, EUR J BIOCHEM, V201, P333, DOI 10.1111/j.1432-1033.1991.tb16290.x; HAUSSER H, 1994, FEBS LETT, V353, P243, DOI 10.1016/0014-5793(94)01044-7; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JUST M, 1991, J BIOL CHEM, V266, P17326; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KNITTEL T, 1992, LAB INVEST, V67, P779; KOCH M, 1995, J CELL BIOL, V130, P1005, DOI 10.1083/jcb.130.4.1005; KRUMDIECK R, 1992, J IMMUNOL, V149, P3695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNON DP, 1991, MATRIX, V11, P412, DOI 10.1016/S0934-8832(11)80196-4; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MEYER DH, 1992, HEPATOLOGY, V16, P204, DOI 10.1002/hep.1840160131; NOYORI K, 1994, ARTHRITIS RHEUM, V37, P1656, DOI 10.1002/art.1780371115; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; SCOTT JE, 1992, FASEB J, V6, P2639, DOI 10.1096/fasebj.6.9.1612287; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; TRUEB J, 1992, EUR J BIOCHEM, V207, P549, DOI 10.1111/j.1432-1033.1992.tb17081.x; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WALCHLI C, 1994, J CELL SCI, V107, P669; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; WATT SL, 1992, J BIOL CHEM, V267, P20093; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZHANG XL, 1993, J HISTOCHEM CYTOCHEM, V41, P245, DOI 10.1177/41.2.7678270	54	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20414	20419		10.1074/jbc.272.33.20414	http://dx.doi.org/10.1074/jbc.272.33.20414			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252349	hybrid			2022-12-27	WOS:A1997XR22100019
J	Leroy, D; Heriche, JK; Filhol, O; Chambaz, EM; Cochet, C				Leroy, D; Heriche, JK; Filhol, O; Chambaz, EM; Cochet, C			Binding of polyamines to an autonomous domain of the regulatory subunit of protein kinase CK2 induces a conformational change in the holoenzyme - A proposed role for the kinase stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN-KINASE; BETA-SUBUNIT; CALMODULIN BINDING; PEPTIDES; PHOSPHORYLATION; ACTIVATION; CONTAINS; SITE; ONCOPROTEINS; PURIFICATION	The means by which the cell regulates protein kinase CK2 remain obscure, However, natural polyamines, cellular compounds required for cell proliferation, have been reported to strongly stimulate CK2-mediated phosphorylation of a number of substrates, Using spermine analogs, we have shown that polyamines directly interact with the CK2 beta subunit, and the chemical features of the highly acidic binding site (Asp(51)-Tyr(80)) have been determined, In the present study, we show that the isolated beta subunit region extending from residue Asp(51) to Pro(110) exhibits a specific and efficient polyamine binding activity similar to that of the entire beta subunit, Moreover, the replacement of Glu(60), Glu(61), and Glu(63) of the beta subunit by 3 alanine residues leads to a loss of the spermine-induced stimulation of CK2 activity which correlates with a decrease in spermine binding affinity, Thermal stability studies indicate that the binding of spermine induces a 4 degrees C decrease of the T-m value for the holoenzyme. This was confirmed by circular dichroism analyses, which show that the 6 degrees C negative shift of the CK2 T-m value provoked by spermine binding, reflects a conformational change in the kinase. Together, these observations strongly suggest that this newly defined polyamine binding domain is involved in the intrasteric regulation of CK2 activity.	CEA GRENOBLE, INSERM U244, DEPT BIOL MOL & STRUCT, LAB BIOCHIM REGULAT CELLULAIRES ENDOCRINES, F-38054 GRENOBLE 9, FRANCE	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)			Filhol-Cochet, Odile/I-3962-2016	Filhol, Odile/0000-0003-1964-7958; Cochet, Claude/0000-0002-1772-4270; Heriche, Jean-Karim/0000-0001-6867-9425				BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; BOLDYREFF B, 1994, J BIOL CHEM, V269, P4827; BUEB JL, 1992, BIOCHEM J, V282, P545, DOI 10.1042/bj2820545; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; COCHET C, 1981, BIOCHIM BIOPHYS ACTA, V658, P191, DOI 10.1016/0005-2744(81)90289-8; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; COCHET C, 1983, J BIOL CHEM, V258, P1403; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HATHAWAY GM, 1984, ARCH BIOCHEM BIOPHYS, V233, P133, DOI 10.1016/0003-9861(84)90609-X; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LEMONN MA, 1995, P NATL ACAD SCI USA, V92, P10472; Leroy D, 1997, BIOCHEMISTRY-US, V36, P1242, DOI 10.1021/bi961949u; LEROY D, 1995, J BIOL CHEM, V270, P17400, DOI 10.1074/jbc.270.29.17400; LEROY D, 1994, CELL MOL BIOL RES, V40, P441; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MORENO FJ, 1993, BIOCHEM J, V289, P631, DOI 10.1042/bj2890631; MORISHIMA Y, 1994, EUR J BIOCHEM, V219, P349, DOI 10.1111/j.1432-1033.1994.tb19946.x; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; SCALABRINO G, 1991, MOL CELL ENDOCRINOL, V77, P1, DOI 10.1016/0303-7207(91)90056-X; SRIVENUGOPAL KS, 1985, BIOCHEMISTRY-US, V24, P4766, DOI 10.1021/bi00339a009; TRAUGH JA, 1990, ADV SEC MESS PHOSPH, V24, P224; TUNG HYL, 1985, EUR J BIOCHEM, V149, P305, DOI 10.1111/j.1432-1033.1985.tb08927.x; WETZEL R, 1988, P NATL ACAD SCI USA, V85, P401, DOI 10.1073/pnas.85.2.401; XU QY, 1991, BIOCHEMISTRY-US, V30, P11811, DOI 10.1021/bi00115a011; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	40	82	84	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20820	20827		10.1074/jbc.272.33.20820	http://dx.doi.org/10.1074/jbc.272.33.20820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252407	hybrid			2022-12-27	WOS:A1997XR22100077
J	Stringer, SE; Gallagher, JT				Stringer, SE; Gallagher, JT			Specific binding of the chemokine platelet factor 4 to heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR-IV; MOLECULAR-ORGANIZATION; ENDOTHELIAL-CELLS; MURINE MELANOMA; RECEPTOR; PROTEOGLYCANS; INHIBITION; IDENTIFICATION; RESOLUTION	Platelet factor 4 is a tetrameric heparin binding chemokine released from the alpha-granules of activated platelets. In this study we show that platelet factor 4 binds with high affinity and specificity to an approximately 9-kDa sequence in heparan sulfate, which it protects from degradation by heparinase enzymes. This protected fragment is enriched in N-sulfated disaccharides and iduronate 2-O-sulfate residues, the latter being important for binding to platelet factor 4. The major structural motif of the fragment appears to consist of a pair of sulfated domains positioned at both ends separated by a central mainly N-acetylated region. On the basis of these findings, we propose a model in which the heparan sulfate fragment wraps around the ring of positive charges on platelet factor 4 with the iduronate 2-O-sulfates within the sulfated domains binding strongly to lysine clusters on opposite faces of the tetramer.	PATERSON INST CANC RES,DRUG DEV DEPT,MANCHESTER M20 9BX,LANCS,ENGLAND; UNIV MANCHESTER,CHRISTIE HOSP,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND	Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Stringer, SE (corresponding author), PATERSON INST CANC RES,CANC RES CAMPAIGN,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.							BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOCK PE, 1980, BIOCHEM J, V191, P769, DOI 10.1042/bj1910769; BUSCH C, 1980, THROMB RES, V19, P129, DOI 10.1016/0049-3848(80)90412-0; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HANSELL P, 1995, AM J PHYSIOL-HEART C, V269, pH829, DOI 10.1152/ajpheart.1995.269.3.H829; IBEL K, 1986, BIOCHIM BIOPHYS ACTA, V870, P58, DOI 10.1016/0167-4838(86)90008-7; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; KOLBER DL, 1995, J NATL CANCER I, V87, P304, DOI 10.1093/jnci/87.4.304; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LINDHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LOSCALZO J, 1985, ARCH BIOCHEM BIOPHYS, V240, P446, DOI 10.1016/0003-9861(85)90049-9; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MARSHALL SE, 1984, BIOCHIM BIOPHYS ACTA, V797, P34, DOI 10.1016/0304-4165(84)90379-9; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P925, DOI 10.1021/bi00218a007; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; SATO Y, 1993, JPN J CANCER RES, V84, P485, DOI 10.1111/j.1349-7006.1993.tb00163.x; SATO Y, 1990, BIOCHEM BIOPH RES CO, V172, P595, DOI 10.1016/0006-291X(90)90715-Y; SHARPE RJ, 1990, JNCI-J NATL CANCER I, V82, P848, DOI 10.1093/jnci/82.10.848; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; STRINGR SE, 1997, IN PRESS INT J BIOCH; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; TAYLOR RL, 1973, BIOCHEMISTRY-US, V12, P3633, DOI 10.1021/bi00743a010; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WHITSON RH, 1991, J CELL BIOCHEM, V47, P31, DOI 10.1002/jcb.240470105; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P693	39	161	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20508	20514		10.1074/jbc.272.33.20508	http://dx.doi.org/10.1074/jbc.272.33.20508			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252363	hybrid			2022-12-27	WOS:A1997XR22100033
J	Guy, HI; Rotgeri, A; Evans, DR				Guy, HI; Rotgeri, A; Evans, DR			Activation by fusion of the glutaminase and synthetase subunits of Escherichia coli carbamyl-phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATES PYRIMIDINE BIOSYNTHESIS; MULTIFUNCTIONAL PROTEIN CAD; REVERSIBLE DISSOCIATION; MAMMALIAN-CELLS; HAMSTER CELLS; GENE; DOMAIN; ENZYME; ORGANIZATION; MECHANISM	Escherichia coli carbamyl-phosphate synthetase consists of two subunits that act in concert to synthesize carbamyl phosphate, The 40-kDa subunit is an amidotransferase (GLN subunit) that hydrolyzes glutamine and transfers ammonia to the 120-kDa synthetase subunit (CPS subunit), The enzyme can also catalyze ammonia-dependent carbamyl phosphate synthesis if provided with exogenous ammonia, In mammalian cells, homologous amidotransferase and synthetase domains are carried on a single polypeptide chain called CAD. Deletion of the 29-residue linker that bridges the GLN and CPS domains of CAD stimulates glutamine-dependent carbamyl phosphate synthesis and abolishes the ammonia-dependent reaction (Guy, H. I., and Evans, D. R. (1997) J. Biol. Chem. 272, 19906-19912), suggesting that the deletion mutant is trapped in at closed high activity conformation, Since the catalytic mechanisms of the mammalian and bacterial proteins are the same, we anticipated that similar changes in the function of the E. coli protein could be produced by direct fusion of the GLN and CPS subunits, A construct was made in which the intergenic region between the contiguous carA and carB genes was deleted and the sequences encoding the carbamyl-phosphate synthetase subunits were fused in frame, The resulting fusion protein was activated 10-fold relative to the native protein, was unresponsive to the allosteric activator ornithine, and could no longer use ammonia as a nitrogen donor, Moreover, the functional linkage that coordinates the rate of glutamine hydrolysis with the activation of bicarbonate was abolished, suggesting that the protein was locked in an activated conformation similar to that induced by the simultaneous binding of all substrates.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University					NIGMS NIH HHS [GM47399] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1964, BIOCHEMISTRY-US, V3, P723, DOI 10.1021/bi00893a021; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1968, BIOCHEM BIOPH RES CO, V32, P928, DOI 10.1016/0006-291X(68)90116-2; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; BEIN K, 1991, J BIOL CHEM, V266, P3791; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; Guy HI, 1997, J BIOL CHEM, V272, P19906, DOI 10.1074/jbc.272.32.19906; Hanahan D, 1985, DNA CLONING PRACTICA; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; HONG J, 1995, J BIOL CHEM, V270, P14130, DOI 10.1074/jbc.270.23.14130; HORTON RM, 1991, DIRECTED MUTAGENESIS; KELLY RE, 1986, J BIOL CHEM, V261, P6073; KERN CB, 1992, J MOL EVOL, V35, P217; KIM HS, 1992, J BIOL CHEM, V267, P7177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTY CJ, 1992, FEBS LETT, V314, P135, DOI 10.1016/0014-5793(92)80959-K; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; POST LE, 1990, J BIOL CHEM, V265, P7742; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; RAUSHEL FM, 1978, BIOCHEMISTRY-US, V17, P5587, DOI 10.1021/bi00619a001; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P482; TROTTA PP, 1974, J BIOL CHEM, V249, P492; WELLNER VP, 1973, BIOCHEMISTRY-US, V12, P2061, DOI 10.1021/bi00735a006	46	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19913	19918		10.1074/jbc.272.32.19913	http://dx.doi.org/10.1074/jbc.272.32.19913			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242657	hybrid			2022-12-27	WOS:A1997XQ05900044
J	Xu, Y; Wong, SH; Zhang, T; Subramaniam, VN; Hong, WJ				Xu, Y; Wong, SH; Zhang, T; Subramaniam, VN; Hong, WJ			GS15, a 15-kilodalton Golgi soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) homologous to rbet1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSPORT; FUSION; YEAST; COMPLEX; MEMBERS; YPT1	Bet1p plays an essential role in vesicular transport from the endoplasmic reticulum (ER) to the Golgi in yeast, and it functions as a vesicle soluble N-ethylmaleimide-sensitive factor protein receptor (V-SNARE). A mammalian protein related to Bet1p has been reported. previously and was referred to as rbet1. Pie have now identified a new mammalian protein that is homologous to rbet1 (28% amino acid identity). mRNA for this rbet1 homologue is widely expressed in rat tissues. Affinity purified polyclonal antibodies raised against recombinant protein specifically recognized a <(15)under bar>-kilodalton integral membrane protein highly enriched in Golgi membranes. Indirect immunofluorescence microscopy revealed that this protein is specifically associated with the Golgi apparatus in diverse cell types. Biochemical characterization established that this protein behaves like a SNARE and was named GS15 (Golgi SNARE with a size of 15 kilodaltons). These properties raise the possibility that GS15 is a novel SNARE mediating a yet to be defined transport event associated with the Golgi apparatus.	INST MOL & CELL BIOL,MEMBRANE BIOL LAB,SINGAPORE 119067,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)			HONG, Wanjin/E-9927-2010; Subramaniam, V. Nathan/A-1901-2010	Subramaniam, V. Nathan/0000-0002-4583-7790				DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DASCHER C, 1994, J BIOL CHEM, V269, P29363; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; HAY JC, 1997, CELL, V89, P147; HONG W, 1996, PROTEIN TRAFFICKING; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; Lowe SL, 1996, J CELL SCI, V109, P209; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHELLER RH, 1995, NEURON, V14, P893; SEHEKMAN R, 1996, SCIENCE, V271, P1526; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	27	45	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20162	20166		10.1074/jbc.272.32.20162	http://dx.doi.org/10.1074/jbc.272.32.20162			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242691	hybrid			2022-12-27	WOS:A1997XQ05900078
J	Yin, TG; Sandhu, G; Wolfgang, CD; Burrier, A; Webb, RL; Rigel, DF; Hai, TW; Whelan, J				Yin, TG; Sandhu, G; Wolfgang, CD; Burrier, A; Webb, RL; Rigel, DF; Hai, TW; Whelan, J			Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ACUTE-RENAL-FAILURE; C-JUN; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MAPKAP KINASE-2; SHOCK PROTEINS; PHOSPHORYLATION; APOPTOSIS; MITOGEN	In this report we investigate the molecular mechanisms that contribute to tissue damage following ischemia and ischemia coupled with reperfusion (ischemia/reperfusion) in the rat heart and kidney, We observe the activation of three stress-inducible mitogen-activated protein (MAP) kinases in these tissues: p38 MAP kinase and the 46- and 55-kDa isoforms of Jun N-terminal kinase (JNK(46) and JNK(55)). The heart and kidney show distinct time courses in the activation of p38 MAP kinase during ischemia but no activation of either JNK(46) or JNK(55). These two tissues also respond differently to ischemia/reperfusion. In the heart we observe activation of JNK(55) and p38 MAP kinase, whereas in the kidney all three kinases are active. We also examined the expression pattern of two stress-responsive genes, c-Jun and ATF3. Our results indicate that in the heart both genes are induced by ischemia and ischemia/reperfusion. However, in the kidney c-Jun and ATF3 expression is induced only by ischemia/reperfusion. To correlate these molecular events with tissue damage we examined DNA laddering, a common marker of apoptosis. A significant increase in DNA laddering was evident in both heart and kidney following ischemia/reperfusion and correlated with the pattern of kinase activation, supporting a link between stress kinase activation and apoptotic cell death in these tissues.	NOVARTIS PHARMACEUT CORP,SUMMIT,NJ 07901; OHIO STATE UNIV,DEPT MED BIOCHEM,NEUROBIOTECHNOL CTR,COLUMBUS,OH 43210; OHIO STATE UNIV,OHIO STATE BIOCHEM PROGRAM,COLUMBUS,OH 43210	Novartis; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315				BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P102; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAYS SR, 1992, AM J MED SCI, V304, P93, DOI 10.1097/00000441-199208000-00005; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ITOH G, 1995, AM J PATHOL, V146, P1325; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kajstura J, 1996, LAB INVEST, V74, P86; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Knight RJ, 1996, BIOCHEM BIOPH RES CO, V218, P83, DOI 10.1006/bbrc.1996.0016; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; NEELY JR, 1984, CIRC RES, V55, P816, DOI 10.1161/01.RES.55.6.816; NOGUCHI S, 1993, J PHARMACOL EXP THER, V267, P919; POMBO CM, 1994, J BIOL CHEM, V269, P26546; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHUMER M, 1992, AM J PATHOL, V140, P831; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; UMANSKY SR, 1995, CELL DEATH DIFFER, V2, P235; UMANSKY SR, 1996, BASIC APPL MYOL, V6, P227; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Woodgett JR, 1996, PHILOS T R SOC B, V351, P135, DOI 10.1098/rstb.1996.0009; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	53	321	342	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19943	19950		10.1074/jbc.272.32.19943	http://dx.doi.org/10.1074/jbc.272.32.19943			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242662	hybrid			2022-12-27	WOS:A1997XQ05900049
J	Sutton, MD; Kaguni, JM				Sutton, MD; Kaguni, JM			Threonine 435 of Escherichia coli DnaA protein confers sequence-specific DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL ORIGIN; REPLICATION ORIGIN; INITIATOR PROTEIN; AUTO-REGULATION; GENE-PRODUCT; TRANSCRIPTION; COMPLEX; REGION; PURIFICATION; TERMINATION	The Escherichia coli DnaA protein, as a sequence-specific DNA binding protein, promotes the initiation of chromosomal replication by binding to four asymmetric 9-mer sequences termed DnaA boxes in oriC. Characterization of N terminal, C-terminal, and internal in-frame deletion mutants identified residues near the C terminus of DnaA protein required for DNA binding. Furthermore, genetic and biochemical characterization of 11 missense mutations mapping within the C-terminal 89 residues indicated that they were defective in DNA binding. Detailed biochemical characterization of one mutant protein bearing a threonine to methionine substitution at position 435 (T435M) revealed that it retained only nonspecific DNA binding activity, suggesting that threonine 435 imparts specificity in binding. Finally, T435M was inactive on its own for in vitro replication of an oriC plasmid but was able to augment limiting levels of wild type DnaA protein, consistent with the proposal that not all of the DnaA monomers in the initial complex are bound specifically to oriC and that direct interaction occurs among monomers.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University				Kaguni, Jon/0000-0002-3096-4447	NIGMS NIH HHS [GM33992, R01 GM033992] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATLUNG T, 1985, MOL GEN GENET, V200, P442, DOI 10.1007/BF00425729; AUGUSTIN LB, 1994, J BACTERIOL, V176, P378, DOI 10.1128/JB.176.2.378-387.1994; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BEYERSMANN D, 1974, J BACTERIOL, V118, P783, DOI 10.1128/JB.118.3.783-789.1974; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FLOWER AM, 1991, J MOL BIOL, V220, P649, DOI 10.1016/0022-2836(91)90107-H; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GIELOW A, 1988, MOL GEN GENET, V214, P474, DOI 10.1007/BF00330483; GINESCANDELARIA E, 1995, J BACTERIOL, V177, P705, DOI 10.1128/jb.177.3.705-715.1995; HANSEN EB, 1982, NUCLEIC ACIDS RES, V10, P7373, DOI 10.1093/nar/10.22.7373; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; HWANG DS, 1988, J BIOL CHEM, V263, P10625; KUCHERER C, 1986, MOL GEN GENET, V205, P115, DOI 10.1007/BF02428040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee YS, 1997, J BIOL CHEM, V272, P83; Margulies C, 1996, J BIOL CHEM, V271, P17035, DOI 10.1074/jbc.271.29.17035; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; MUKHOPADHYAY G, 1993, EMBO J, V12, P4547, DOI 10.1002/j.1460-2075.1993.tb06143.x; OGAWA T, 1994, J BACTERIOL, V176, P1609, DOI 10.1128/jb.176.6.1609-1615.1994; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; SCHAEFER C, 1988, GENE, V73, P347, DOI 10.1016/0378-1119(88)90499-4; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SUTTON MD, 1995, J BACTERIOL, V177, P6657, DOI 10.1128/jb.177.22.6657-6665.1995; TESFASELASE F, 1992, MOL GEN GENET, V231, P256, DOI 10.1007/BF00279799; TUCKER WT, 1984, CELL, V38, P191, DOI 10.1016/0092-8674(84)90540-3; WANG QP, 1989, J BIOL CHEM, V264, P7338; WANG QP, 1987, MOL GEN GENET, V209, P518, DOI 10.1007/BF00331158; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	41	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23017	23024		10.1074/jbc.272.37.23017	http://dx.doi.org/10.1074/jbc.272.37.23017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287298	hybrid			2022-12-27	WOS:A1997XV74400009
J	Tirode, F; Malaguti, C; Romero, F; Attar, R; Camonis, J; Egly, JM				Tirode, F; Malaguti, C; Romero, F; Attar, R; Camonis, J; Egly, JM			A conditionally expressed third partner stabilizes or prevents the formation of a transcriptional activator in a three-hybrid system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE MET25 GENE; RING FINGER PROTEIN; 2-HYBRID SYSTEM; YEAST; COMPLEX; RAS; MAT1; ASSOCIATION; KINASES; REPAIR	We describe a three-hybrid system that involves three polypeptides that allow or prevent the formation of the transcriptional activator. Beside the two-hybrid fusion proteins, the third partner is under the control of the Met25 promoter, which is positively regulated in medium lacking methionine. We document a situation where such a third partner promotes interaction between two proteins, one fused to a DNA-binding domain and the other fused to an activator domain. This is demonstrated for cdk7-MAT1 interaction stabilized by the presence of cyclin H; these three polypeptides are found either free or associated with the transcription/DNA repair factor TFIIH. We also document the capacity of our system to conditionally inhibit the interaction between two polypeptides that otherwise elicit a positive two-hybrid response. This is demonstrated for Ras-Raf interaction precluded by an excess of Raf. The presence of a methionine-regulated promoter provides an ''on'' or ''off'' switch for the formation of the transcriptional activator, thus also providing an excellent control to evaluate the activation or inhibition properties of the third partner.	CNRS,INSERM,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,COMMUNAUTE URBA,FRANCE; INST COCHIN GENET MOL,F-75014 PARIS,FRANCE; INST CURIE,INSERM,U248,F-75231 PARIS 05,FRANCE; BRISTOL MEYER SQUIBB,PRINCETON,NJ	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			TIRODE, Franck/HHS-7070-2022; Romero, Francisco/K-2101-2014; Tirode, Franck/B-4586-2009	Romero, Francisco/0000-0002-9588-6881; Tirode, Franck/0000-0003-4731-7817				Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; Bartel P. L., 1993, CELLULAR INTERACTION, P153; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARPER JW, 1993, CELL, V75, P805; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KERJAN P, 1986, NUCLEIC ACIDS RES, V14, P7861, DOI 10.1093/nar/14.20.7861; LEGRAIN P, 1994, NUCLEIC ACIDS RES, V22, P3241, DOI 10.1093/nar/22.15.3241; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Rose MD., 1990, METHODS YEAST GENETI; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Zhang J, 1996, ANAL BIOCHEM, V242, P68, DOI 10.1006/abio.1996.0429	29	89	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					22995	22999		10.1074/jbc.272.37.22995	http://dx.doi.org/10.1074/jbc.272.37.22995			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287295	hybrid			2022-12-27	WOS:A1997XV74400006
J	Hayashi, Y; Hirose, F; Nishimoto, Y; Shiraki, M; Yamagishi, M; Matsukage, A; Yamaguchi, M				Hayashi, Y; Hirose, F; Nishimoto, Y; Shiraki, M; Yamagishi, M; Matsukage, A; Yamaguchi, M			Identification of CFDD (common regulatory factor for DNA replication and DREF genes) and role of its binding site in regulation of the proliferating cell nuclear antigen gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE BETA-GENE; DROSOPHILA-MELANOGASTER; TRANSCRIPTION FACTOR; ELEMENT; PROTEIN; EXPRESSION; CYCLIN; E2F; PURIFICATION; CULTURE	The Drosophila proliferating cell nuclear antigen (PCNA) gene promoter contains at least three transcriptional regulatory elements, the URE (upstream regulatory element), DRE (DNA replication-related element), and E2F recognition sites, In nuclear extracts of Drosophila Kc cells, we detected a novel protein factor(s), CFDD (common regulatory factor for DNA replication and DREF genes) that appeared to recognize two unique nucleotide sequences (5'-CGATA and 5'-CAATCA) and bind to three sites in the PCNA gene promoter, These sites were located at positions -84 to -77 (site 1), -100 to -93 (site 2) and -134 to -127 (site 3) with respect to the transcription initiation sites, Sites 2 and 3 overlapped with DRE and URE, respectively, and the 5'-CGATA matched with the reported recognition sequence of BEAF-32 (boundary element-associated factor of 32 kDa), Detailed analyses of CFDD recognition sequences and experiments with specific antibodies to DREF (DRE-binding factor) and BEAF-32 suggest that CFDD is different from DREF, UREF (URE-binding factor) and BEAF-32, A UV cross-linking experiment revealed that polypeptides of similar to 76 kDa in the nuclear extract interact directly with the CFDD site 1 sequence, Transient expression assays of chloramphenicol acetyltransferase (CAT) in Ke cells transfected with PCNA promoter-CAT fusion genes carrying mutations in CFDD site 1 and examination of lacZ expression from PCNA promoter-lacZ fusion genes carrying mutations in site 1, introduced into flies by germ line transformation, revealed that CFDD site 1 plays an important role for the promoter activity both in cultured cells and in living flies, In addition to the PCNA gene, multiple CFDD sites were found in promoters of the DNA polymerase alpha and DREF genes, and CFDD binding to the DREF promoter was confirmed, Therefore, CFDD may play important roles in regulation of Drosophila DNA replication-related genes.	AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center				Yamaguchi, Masamitsu/0000-0002-6321-9750; Hirose, Fumiko/0000-0003-4586-4892				CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FRIDELL YWC, 1992, MOL CELL BIOL, V12, P4571, DOI 10.1128/MCB.12.10.4571; FUSE N, 1994, GENE DEV, V8, P2270, DOI 10.1101/gad.8.19.2270; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; HAO XF, 1995, J CELL SCI, V108, P2945; Hart CM, 1997, MOL CELL BIOL, V17, P999, DOI 10.1128/MCB.17.2.999; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KASAI Y, 1992, P NATL ACAD SCI USA, V89, P3414, DOI 10.1073/pnas.89.8.3414; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; Matsukage A, 1995, GENE, V166, P233, DOI 10.1016/0378-1119(95)00586-2; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MORIUCHI T, 1990, Medical Science Research, V18, P911; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; ROBERTSON HM, 1988, GENETICS, V118, P461; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; Sambrook J., 2002, MOL CLONING LAB MANU; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	40	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22848	22858		10.1074/jbc.272.36.22848	http://dx.doi.org/10.1074/jbc.272.36.22848			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278447	hybrid			2022-12-27	WOS:A1997XV49200068
J	Misaka, T; Kusakabe, Y; Emori, Y; Gonoi, T; Arai, S; Abe, K				Misaka, T; Kusakabe, Y; Emori, Y; Gonoi, T; Arai, S; Abe, K			Taste buds have a cyclic nucleotide-activated channel, CNGgust	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CATION CHANNEL; PROTEIN-COUPLED RECEPTORS; FUNCTIONAL EXPRESSION; ROD PHOTORECEPTOR; MOLECULAR-CLONING; ALPHA-SUBUNIT; CELLS; IDENTIFICATION; TRANSDUCTION; LOCALIZATION	Cyclic nucleotide-gated (CNG) channels have been characterized as important factors involved in physiological processes including sensory reception for vision and olfaction. The possibility thus exists that a certain CNG channel functions in gustation as well. In the present study, we carried out reverse transcription-polymerase chain reaction and genomic DNA cloning and characterized a CNG channel (CNGgust) as a cyclic nucleotide-activated species expressed in rat tongue epithelial tissues where taste reception takes place. Several types of 5'-rapid amplification of cDNA ends clones of CNGgust cDNA were obtained with various 5'-terminal sequences. As the CNGgust gene was a single copy, the formation of such CNGgust variants should result from alternative splicing. The encoded protein was homologous to known vertebrate CNG channels with 50-80% similarities in amino acid sequence, and particularly homologous to bovine testis CNG channel and human cone CNG channel with 82% similarities, CNGgust was functional when expressed in human embryonic kidney cells, where it opened upon the addition of cGMP or cAMP. Immunohistochemical analysis using an antibody raised against a CNGgust peptide demonstrated the channel to be localized on the pore side of each taste bud in the circumvallate papillae, with no signal observed for degenerated taste buds after denervation of the glossopharyngeal nerve. All these results, together with the indication that cyclic nucleotides play a role gustatory signaling pathway(s), strongly suggest the involvement of CNGgust in taste signal transduction.	UNIV TOKYO,GRAD SCH AGR & LIFE SCI,DEPT APPL BIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,DEPT BIOCHEM & BIOPHYS,FAC SCI,BUNKYO KU,TOKYO 113,JAPAN; CHIBA UNIV,RES CTR PATHOGEN FUNGI & MICROBIAL TOXICOSES,CHUO KU,CHIBA 260,JAPAN	University of Tokyo; University of Tokyo; Chiba University			gonoi, tohru/AAC-5181-2021; , gonoi/GRS-0648-2022	gonoi, tohru/0000-0003-3655-7911; , gonoi/0000-0003-3655-7911; Misaka, Takumi/0000-0002-9547-5767				ABE K, 1993, FEBS LETT, V316, P253, DOI 10.1016/0014-5793(93)81302-G; ABE K, 1993, J BIOL CHEM, V268, P12033; ASANUMA N, 1995, CHEM SENSES, V20, P231, DOI 10.1093/chemse/20.2.231; Barnstable CJ, 1995, J MOL NEUROSCI, V6, P289, DOI 10.1007/BF02736787; Biel M, 1996, J BIOL CHEM, V271, P6349, DOI 10.1074/jbc.271.11.6349; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DHALLAN RS, 1992, J NEUROSCI, V12, P3248, DOI 10.1523/JNEUROSCI.12-08-03248.1992; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; GUTH L, 1957, ANAT REC, V128, P715, DOI 10.1002/ar.1091280406; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Kinnamon SC, 1996, CURR OPIN NEUROBIOL, V6, P506, DOI 10.1016/S0959-4388(96)80057-2; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; KURIHARA K, 1972, BIOCHEM BIOPH RES CO, V48, P30, DOI 10.1016/0006-291X(72)90339-7; Kusakabe Y, 1996, CHEM SENSES, V21, P335, DOI 10.1093/chemse/21.3.335; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; MATSUOKA I, 1993, BIOCHEM BIOPH RES CO, V194, P504, DOI 10.1006/bbrc.1993.1848; MCLAUGHLIN SK, 1994, PHYSIOL BEHAV, V56, P1157, DOI 10.1016/0031-9384(94)90360-3; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; NINOMIYA Y, 1994, PHYSIOL BEHAV, V56, P1179, DOI 10.1016/0031-9384(94)90363-8; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Ressler Kerry J., 1994, Current Opinion in Neurobiology, V4, P588, DOI 10.1016/0959-4388(94)90061-2; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; TAL M, 1995, BIOCHEM BIOPH RES CO, V209, P752, DOI 10.1006/bbrc.1995.1563; Thomas MB, 1996, GENE, V178, P1, DOI 10.1016/0378-1119(96)00311-3; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; WONG GT, 1996, NATURE, V17, P681; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; Yu WP, 1996, FEBS LETT, V393, P211, DOI 10.1016/0014-5793(96)00889-7	35	76	86	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22623	22629		10.1074/jbc.272.36.22623	http://dx.doi.org/10.1074/jbc.272.36.22623			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278419	hybrid			2022-12-27	WOS:A1997XV49200039
J	Boese, M; Keese, MA; Becker, K; Busse, R; Mulsch, A				Boese, M; Keese, MA; Becker, K; Busse, R; Mulsch, A			Inhibition of glutathione reductase by dinitrosyl-iron-dithiolate complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; SERUM-ALBUMIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; GUANYLYL CYCLASE; S-NITROSOTHIOLS; DRUGS; NITROSYLATION; TRANSPORT; MECHANISM; NITROGEN	The biological signal molecule nitric oxide (NO) exists in a free and carrier-bound form. Since the structure of the carrier is likely to influence the interaction of NO with macromolecular targets, we assessed the interaction of a dinitrosyl-iron-dithiolate complex carrying different thiol ligands with glutathione reductase. The enzyme was irreversibly inhibited by dinitrosyl-iron-di-L-cysteine and dinitrosyl-iron-di-glutathione in a concentration-and time-dependent manner (IC50 30 and 3 mu m, respectively), Evaluation of the inhibition kinetics according to Kitz-Wilson yielded a K-i of 14 mu M, and a k(3) of 1.3 x 10(-3) s(-1), A participation of catalytic site thiols in the inhibitory mechanism was indicated by the findings that only the NADPH-reduced enzyme was inhibited by dinitrosyl-iron complex and that blockade of these thiols by Hg2+ afforded protection against irreversible inhibition, This inhibition was not accompanied by formation of a protein-bound dinitrosyl-iron complex and/or S-nitrosation of active site thiols (Cys-58 and Cys-63), However, one NO moiety exhibiting an acid lability similar to a secondary N-nitrosamine was present per mol of inhibited monomeric enzyme, These findings suggest specifically N-nitrosation of glutathione reductase as a likely mechanism of inhibition elicited by dinitrosyl-iron complex and demonstrate in general that structural resemblance of an NO carrier with a natural ligand enhances NO+ transfer to the ligand-binding protein.	UNIV FRANKFURT KLINIKUM, ZENTRUM PHYSIOL, D-60590 FRANKFURT, GERMANY; UNIV HEIDELBERG, INST BIOCHEM 2, D-69120 HEIDELBERG, GERMANY	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Ruprecht Karls University Heidelberg								BECKER K, 1995, EUR J BIOCHEM, V234, P472, DOI 10.1111/j.1432-1033.1995.472_b.x; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CHAMULITRAT W, 1995, ARCH BIOCHEM BIOPHYS, V316, P30, DOI 10.1006/abbi.1995.1006; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; FREEDMAN JE, 1995, J CLIN INVEST, V96, P394, DOI 10.1172/JCI118047; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; JOCHERSSCHERUBL MC, 1989, EUR J BIOCHEM, V180, P267; KARPLUS PA, 1988, EUR J BIOCHEM, V171, P193, DOI 10.1111/j.1432-1033.1988.tb13775.x; KITZ R, 1962, J BIOL CHEM, V237, P3245; LEE MH, 1994, BIOCHEMISTRY-US, V33, P3679, DOI 10.1021/bi00178a026; MCDONALD B, 1993, P NATL ACAD SCI USA, V90, P11122, DOI 10.1073/pnas.90.23.11122; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Mohr S, 1996, J BIOL CHEM, V271, P4209; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; MULSCH A, 1991, METHOD ENZYMOL, V195, P377; OAE S, 1977, CHEM LETT, V893, P65; PAI EF, 1983, J BIOL CHEM, V258, P1752; PIETRAFORTE D, 1995, BIOCHEMISTRY-US, V34, P7177, DOI 10.1021/bi00021a032; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; SCHALLREUTER KU, 1990, BIOCHIM BIOPHYS ACTA, V1054, P14, DOI 10.1016/0167-4889(90)90199-N; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TRAVIS MD, 1997, IN PRESS AM J PHYSL; VANIN AF, 1975, BIOFIZIKA+, V20, P1068; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WORTHINGTON DJ, 1976, EUR J BIOCHEM, V67, P231, DOI 10.1111/j.1432-1033.1976.tb10654.x	35	67	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21767	21773		10.1074/jbc.272.35.21767	http://dx.doi.org/10.1074/jbc.272.35.21767			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268306	hybrid			2022-12-27	WOS:A1997XT85000018
J	Bohlmann, J; Steele, CL; Croteau, R				Bohlmann, J; Steele, CL; Croteau, R			Monoterpene synthases from Grand fir (Abies grandis) - cDNA isolation, characterization, and functional expression of myrcene synthase, (-)(4S)-limonene synthase, and (-)-(1S,5S)-pinene synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-DIPHOSPHATE SYNTHASE; SITE-DIRECTED MUTAGENESIS; SAGE SALVIA-OFFICINALIS; RESIN ACID BIOSYNTHESIS; SCOLYTUS-VENTRALIS COLEOPTERA; HIGH-LEVEL EXPRESSION; BACTERIAL EXPRESSION; SESQUITERPENE CYCLASE; PARTIAL-PURIFICATION; (+)-DELTA-CADINENE SYNTHASE	Grand fir (Abies grandis) has been developed as a model system for studying defensive oleoresin formation in conifers in response to insect attack or other injury, The turpentine fraction of the oleoresin is a complex mixture of monoterpene (C-10) olefins in which (-)-limonene and (-)-alpha- and (-)-beta-pinene are prominent components; (-)-limonene and (-)-pinene synthase activities are also induced upon stem wounding, A similarity based cloning strategy yielded three new cDNA species from a mounded stem cDNA library that appeared to encode three distinct monoterpene synthases, After expression in Escherichia coli and enzyme assay with geranyl diphosphate as substrate, subsequent analysis of the terpene products by chiral phase gas chromatography and mass spectrometry showed that these sequences encoded a (-)-limonene synthase, a myrcene synthase, and a (-)-pinene synthase that produces both alpha-pinene and beta-pinene. In properties and reaction stereochemistry, the recombinant enzymes resemble the corresponding native monoterpene synthases of wound-induced grand fir stem. The deduced amino acid sequences indicated the limonene synthase to be 637 residues in length (73.5 kDa), the myrcene synthase to be 627 residues in length (72.5 kDa), and the pinene synthase to be 628 residues in length (71.5 kDa); all of these monoterpene synthases appear to be translated as preproteins bearing an amino-terminal plastid targeting sequence. Sequence comparison revealed that these monoterpene synthases from grand fir resemble sesquiterpene (C-15) synthases and diterpene (C-20) synthases from conifers more closely than other monoterpene synthases from angiosperm species. This similarity between extant monoterpene, sesquiterpene, and diterpene synthases of gymnosperms is surprising since functional diversification of this enzyme class is assumed to have occurred over 300 million years ago. Wound-induced accumulation of transcripts for monoterpene synthases was demonstrated by RNA blot hybridization using probes derived from the three monoterpene synthase cDNAs. The availability of cDNA species encoding these monoterpene synthases mill allow an understanding of the regulation of oleoresin formation in conifers and will ultimately permit the transgenic manipulation of this defensive secretion to enhance resistance to insects. These cDNAs also furnish tools for defining structure-function relationships in this group of catalysts that generate acyclic, monocyclic, and bicyclic olefin products.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Washington State University; Washington State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031354, R01GM031354] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31354] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam KP, 1996, ARCH BIOCHEM BIOPHYS, V332, P352, DOI 10.1006/abbi.1996.0352; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; Bohlmann J, 1996, PLANT PHYSIOL, V111, P507, DOI 10.1104/pp.111.2.507; BOHLMANN J, 1995, PLANT J, V7, P491, DOI 10.1046/j.1365-313X.1995.7030491.x; Byers John A., 1995, P154; CANE DE, 1992, CIBA F SYMP, V171, P163; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Chen XY, 1996, J NAT PROD, V59, P944, DOI 10.1021/np960344w; Chen XY, 1995, ARCH BIOCHEM BIOPHYS, V324, P255, DOI 10.1006/abbi.1995.0038; COLBY SM, 1993, J BIOL CHEM, V268, P23016; CROTEAU R, 1989, J BIOL CHEM, V264, P15309; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1994, ARCH BIOCHEM BIOPHYS, V309, P184, DOI 10.1006/abbi.1994.1101; CROTEAU R, 1989, J BIOL CHEM, V264, P2075; CROTEAU R, 1988, J BIOL CHEM, V263, P10063; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; CROTEAU RB, 1990, J CHROMATOGR, V500, P349, DOI 10.1016/S0021-9673(00)96076-X; CROTEAU RB, 1987, BIOCHEMISTRY-US, V26, P5383, DOI 10.1021/bi00391a025; DEHAL SS, 1988, ARCH BIOCHEM BIOPHYS, V261, P346, DOI 10.1016/0003-9861(88)90350-5; Dudareva N, 1996, PLANT CELL, V8, P1137, DOI 10.1105/tpc.8.7.1137; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUNK C, 1994, PLANT PHYSIOL, V106, P999, DOI 10.1104/pp.106.3.999; FUNK C, 1994, ARCH BIOCHEM BIOPHYS, V308, P258, DOI 10.1006/abbi.1994.1036; GAMBLIEL H, 1984, J BIOL CHEM, V259, P740; Gershenzon Jonathan, 1993, P339; GIJZEN M, 1991, ARCH BIOCHEM BIOPHYS, V289, P267, DOI 10.1016/0003-9861(91)90471-T; GIJZEN M, 1993, ACS SYM SER, V525, P8; HOHN TM, 1989, GENE, V79, P131, DOI 10.1016/0378-1119(89)90098-X; HOHN TM, 1992, MOL PLANT MICROBE IN, V5, P249, DOI 10.1094/MPMI-5-249; JOHNSON MA, 1987, ACS SYM SER, V325, P76; JOLY A, 1993, J BIOL CHEM, V268, P26983; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLEINIG H, 1989, ANNU REV PLANT PHYS, V40, P39, DOI 10.1146/annurev.pp.40.060189.000351; Koyama T, 1996, BIOCHEMISTRY-US, V35, P9533, DOI 10.1021/bi960137v; LAFEVER RE, 1994, ARCH BIOCHEM BIOPHYS, V313, P139, DOI 10.1006/abbi.1994.1370; LAFEVER RE, 1993, ARCH BIOCHEM BIOPHYS, V301, P361, DOI 10.1006/abbi.1993.1156; LANGENHEIM JH, 1990, AM SCI, V78, P16; LANGENHEIM JH, 1969, SCIENCE, V163, P1157, DOI 10.1126/science.163.3872.1157; LEWINSOHN E, 1991, PLANT PHYSIOL, V96, P38, DOI 10.1104/pp.96.1.38; LEWINSOHN E, 1992, ACS SYM SER, V497, P8; LEWINSOHN E, 1991, PLANT PHYSIOL, V96, P44, DOI 10.1104/pp.96.1.44; Lewinsohn E., 1994, Plant Molecular Biology Reporter, V12, P20, DOI 10.1007/BF02668660; LEWINSOHN E, 1993, PHYTOCHEM ANALYSIS, V4, P220, DOI 10.1002/pca.2800040506; LEWINSOHN E, 1992, ARCH BIOCHEM BIOPHYS, V293, P167, DOI 10.1016/0003-9861(92)90380-F; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MAU CJD, 1994, P NATL ACAD SCI USA, V91, P8497, DOI 10.1073/pnas.91.18.8497; MCCASKILL D, 1997, ADV BIOCHEM ENG BIOT, V55, P108; MCGARVEY DJ, 1995, PLANT CELL, V7, P1015, DOI 10.1105/tpc.7.7.1015; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; PROCTOR RH, 1993, J BIOL CHEM, V268, P4543; RAFFA KF, 1982, CAN ENTOMOL, V114, P797, DOI 10.4039/Ent114797-9; RAFFA KF, 1985, ENVIRON ENTOMOL, V14, P552, DOI 10.1093/ee/14.5.552; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V296, P49, DOI 10.1016/0003-9861(92)90543-6; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V299, P77, DOI 10.1016/0003-9861(92)90246-S; Sambrock J, 1989, MOL CLONING LAB MANU; SAVAGE TJ, 1995, ARCH BIOCHEM BIOPHYS, V320, P257, DOI 10.1016/0003-9861(95)90008-X; SAVAGE TJ, 1994, J BIOL CHEM, V269, P4012; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; STEELE CL, 1995, P NATL ACAD SCI USA, V92, P4164, DOI 10.1073/pnas.92.10.4164; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Vogel BS, 1996, J BIOL CHEM, V271, P23262, DOI 10.1074/jbc.271.38.23262; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAGSCHAL K, 1991, TETRAHEDRON, V47, P5933, DOI 10.1016/S0040-4020(01)86486-3; WAGSCHAL KC, 1994, ARCH BIOCHEM BIOPHYS, V308, P477, DOI 10.1006/abbi.1994.1068; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201; Yamaguchi S, 1996, PLANT J, V10, P203, DOI 10.1046/j.1365-313X.1996.10020203.x; Yuba A, 1996, ARCH BIOCHEM BIOPHYS, V332, P280, DOI 10.1006/abbi.1996.0343	75	190	229	2	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21784	21792		10.1074/jbc.272.35.21784	http://dx.doi.org/10.1074/jbc.272.35.21784			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268308	hybrid			2022-12-27	WOS:A1997XT85000020
J	Lee, H; Suh, BC; Kim, KT				Lee, H; Suh, BC; Kim, KT			Feedback regulation of ATP-induced Ca2+ signaling in HL-60 cells is mediated by protein kinase A- and C-mediated changes in capacitative Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-ENTRY; EXTRACELLULAR ATP; PLASMA-MEMBRANE; P2-PURINERGIC RECEPTORS; HUMAN-NEUTROPHILS; CA-2+ RELEASE; PC12 CELLS; INFLUX; ACTIVATION; INHIBITION	Extracellular ATP increases intracellular Ca2+ ([Ca2+](i)) in HL-60 cells. When cells are stimulated with supramaximal concentrations of ATP, although the initial [Ca2+](i) increase is similar over a range of 30, 100, and 300 mu M ATP, the rate of the return to basal [Ca2+](i) level is faster in cells treated with higher concentrations of ATP, This probably results from differences in Ca2+ influx rather than Ca2+ release, since the influx of the unidirectional Ca2+ surrogates Ba2+ and Mn2+ also exhibit similar responses, Furthermore, while 300 mu M ATP had an inhibitory effect on the thapsigargin-induced capacitative Ca2+ entry, 30 mu M ATP potentiated the response, However, the inhibitory action of 300 mu M ATP was blocked by protein kinase C (PKC) inhibitors, such as GF 109203X and chelerythrine, and the potentiating action of 30 mu M ATP was blocked by protein kinase A (PKA) inhibitors H89 and Rp-cAMPS, The PKC inhibitors also slowed the decay rate of the Ca2+ response induced by 300 mu M ATP, and the PKA inhibitors increased it when induced by 30 mu M ATP. In the measurements of PKA and PKC activity, 30 mu M ATP activates only PKA, while 300 mu M ATP activates both kinases, Taken together, these data suggest that the changes in the ATP-induced Ca2+ response result from differential modulation of ATP-induced capacitative Ca2+ entry by PKC and PKA in HL-60 cells.	POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,POSTECH,POHANG 790784,SOUTH KOREA	Pohang University of Science & Technology (POSTECH)				KIM, KYONG-TAI/0000-0001-7292-2627				BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; Buell G, 1996, BLOOD, V87, P2659, DOI 10.1182/blood.V87.7.2659.bloodjournal8772659; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; Choi SY, 1997, BIOCHEM PHARMACOL, V53, P429, DOI 10.1016/S0006-2952(96)00719-8; Clapham DE, 1996, NEURON, V16, P1069, DOI 10.1016/S0896-6273(00)80132-4; DAVIES WA, 1993, ENDOCRINOLOGY, V132, P2491, DOI 10.1210/en.132.6.2491; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; KRAUTWURST D, 1992, BIOCHEM J, V288, P1025, DOI 10.1042/bj2881025; LAGAST H, 1984, J CLIN INVEST, V73, P878, DOI 10.1172/JCI111284; LEE KM, 1993, J BIOL CHEM, V268, P9945; MCCARTHY SA, 1989, BIOCHEM J, V264, P357, DOI 10.1042/bj2640357; MONTERO M, 1993, J BIOL CHEM, V268, P13055; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; NOLAND TA, 1986, BIOL REPROD, V35, P863, DOI 10.1095/biolreprod35.4.863; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN CCH, 1995, BIOCHEM J, V307, P663, DOI 10.1042/bj3070663; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SUH BC, 1995, J NEUROCHEM, V64, P2500; Suh BC, 1996, J BIOL CHEM, V271, P32753, DOI 10.1074/jbc.271.51.32753; SUH BC, 1995, J NEUROCHEM, V64, P1071; SUH BC, 1994, BIOCHEM PHARMACOL, V47, P1262, DOI 10.1016/0006-2952(94)90399-9; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TEPEL M, 1994, J BIOL CHEM, V269, P26239; TORNQUIST K, 1993, BIOCHEM J, V290, P443; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	44	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21831	21838		10.1074/jbc.272.35.21831	http://dx.doi.org/10.1074/jbc.272.35.21831			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268314	hybrid			2022-12-27	WOS:A1997XT85000026
J	Yoshizumi, M; Wang, H; Hsieh, CM; Sibinga, NES; Perrella, MA; Lee, ME				Yoshizumi, M; Wang, H; Hsieh, CM; Sibinga, NES; Perrella, MA; Lee, ME			Down-regulation of the cyclin a promoter by transforming growth factor-beta 1 is associated with a reduction in phosphorylated activating transcription factor-1 and cyclic AMP-responsive element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NUCLEAR FACTOR CREB; FACTOR-BETA; TGF-BETA; GENE-EXPRESSION; A EXPRESSION; ENDOTHELIAL-CELLS; CDK INHIBITORS; KINASE-A; C-MYC	Transforming growth factor (TGF)-beta 1 prevents cell cycle progression by inhibiting several regulators, including cyclin A. To study the mechanisms by which TGF-beta 1 down-regulates cyclin A gene expression, we transfected reporter plasmids driven by the cyclin A prometer into mink lung epithelial cells in the absence and presence of TGF-beta 1, The TGF-beta 1-induced down-regulation of cyclin A promoter activity appeared to be mediated via the activating transcription factor (ATF) site, because mutation of this site abolished down-regulation, Surprisingly, although TGF-beta 1 treatment for 24 h markedly decreased cyclin A promoter activity, it did not decrease the abundance of the ATF-binding proteins ATF-1 and cyclic AMP-responsive binding protein (CREB), However, we detected 90 and 78% reductions (by Western analysis) in phosphorylated CREB and ATF-1, respectively, in mink lung epithelial cells treated with TGF-beta 1, TGF-beta 1-induced down-regulation of cyclin A promoter activity was reversed by okadaic acid (a phosphatase inhibitor) and by cotransfection with plasmids expressing the cAMP dependent protein kinase catalytic subunit or the simian virus small tumor antigen (Sm-t, an inhibitor of PP2A), These data indicate that TGF-beta 1 may down-regulate cyclin A promoter activity by decreasing phosphorylation of CREB and ATF-1.	HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PULM,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital			Sibinga, Nicholas/GOJ-8544-2022	Sibinga, Nicholas/0000-0003-4838-910X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03194, HL03274] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Huet X, 1996, MOL CELL BIOL, V16, P3789; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE ME, 1991, J BIOL CHEM, V266, P16188; LIU F, 1993, J BIOL CHEM, V268, P6714; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SCHNEIDER MD, 1986, MOL CELL BIOL, V6, P4140, DOI 10.1128/MCB.6.11.4140; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	51	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22259	22264		10.1074/jbc.272.35.22259	http://dx.doi.org/10.1074/jbc.272.35.22259			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268374	hybrid			2022-12-27	WOS:A1997XT85000086
J	Ghoda, L; Lin, X; Greene, WC				Ghoda, L; Lin, X; Greene, WC			The 90-kDa ribosomal S6 kinase (pp90(rsk)) phosphorylates the N-terminal regulatory domain of I kappa B alpha and stimulates its degradation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED PHOSPHORYLATION; MOUSE ORNITHINE DECARBOXYLASE; ACTIVATED PROTEIN-KINASE; DNA-BINDING; DISSOCIATION; PROTEOLYSIS; SEQUENCES; REQUIRES; TRANSDUCTION; SUFFICIENT	Nuclear factor kappa B (NF-kappa B) is a eukaryotic member of the Rel family of transcription factors whose biological activity is post-translationally regulated by its assembly with various ankyrin-rich cytoplasmic inhibitors, including I kappa B alpha. Expression of NF-kappa B in the nucleus occurs after signal-induced phosphorylation, ubiquitination, and proteasome-mediated degradation of I kappa B alpha. The induced proteolysis of I kappa B alpha unmasks the nuclear localization signal within NF-kappa B, allowing its rapid migration into the nucleus, where it activates the transcription of many target genes, At present, the identity of the I kappa B alpha kinase(s) that triggers the first step in I kappa B alpha degradation remains unknown. We have investigated the potential function of the 90-kDa ribosomal S6 kinase, or pp90(rsk), as a signal-inducible I kappa B alpha kinase. pp90(rsk) lies downstream of mitogen-activated protein (MAP) kinase in the well characterized Ras-Raf-MEK-MAP kinase pathway that is induced by various growth factors and phorbol ester. We now show that pp90(rsk), but not pp70(S6K) Or MAP kinase, phosphorylates the regulatory N terminus of I kappa B alpha principally on serine 32 and triggers effective I kappa B alpha degradation in vitro. When co-expressed in vivo in COS cells, I kappa B alpha and pp90(rsk) readily assemble into a complex that is immunoprecipitated with antibodies specific for either partner. While phorbol 12-myristate 13-acetate produced rapid activation of pp90(rsk), in vivo, other potent NF-kappa B inducers, including tumor necrosis factor alpha and the Tax transactivator of human T-cell lymphotrophic virus, type I, failed to activate pp90(rsk). These data suggest that more than a single I kappa B alpha kinase exists within the cell and that these I kappa B alpha kinases are differentially activated by different NF-kappa B inducers.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, GLADSTONE INST VIROL & IMMUNOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, DEPT MED, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94141 USA; UNIV COLORADO, HLTH SCI CTR, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; The J David Gladstone Institutes; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM049055] Funding Source: NIH RePORTER; NIAID NIH HHS [P30 AI27763, P30 AI27763-08] Funding Source: Medline; NIGMS NIH HHS [5RO1 GM49055] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHEN RH, 1993, BIOCHEM SOC T, V21, P895, DOI 10.1042/bst0210895; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GROSS M, 1980, MOL CELL BIOCHEM, V31, P25, DOI 10.1007/BF00817888; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSENBERGHASSON Y, 1991, BIOCHEM J, V277, P683, DOI 10.1042/bj2770683; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V197, P419, DOI 10.1111/j.1432-1033.1991.tb15927.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; STEWARD R, 1993, CURR OPIN GENET DEV, V3, P556, DOI 10.1016/0959-437X(93)90090-C; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WETTENHALL REH, 1992, J BIOL CHEM, V267, P9021; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	47	177	185	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21281	21288		10.1074/jbc.272.34.21281	http://dx.doi.org/10.1074/jbc.272.34.21281			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261139	hybrid			2022-12-27	WOS:A1997XR78900049
J	Peterson, FC; Brooks, CL				Peterson, FC; Brooks, CL			Identification of a motif associated with the lactogenic actions of human growth hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; PROLACTIN RECEPTOR; CRYSTAL-STRUCTURE; RATIONAL DESIGN; BINDING; DNA; MUTAGENESIS; RESOLUTION; VARIANTS; COMPLEX	Human growth hormone (hGH) stimulates somatogenic and lactogenic actions through the GH and prolactin (PRL) receptors, respectively, In contrast, non-primate GHs stimulate only somatotropic action, Phe(44), of the human GH sequence is present in all hormones stimulating lactogenic action and absent in all hormones stimulating only somato tropic action, We speculate that the presence of Phe(44) is a feature necessary for specifying lactogenic activity, In this report, the role of Phe(44) was investigated by its deletion or substitution with alanine or leucine. Deletion of Phe(44) or substitution with leucine did not significantly change the structure of hGH as determined by circular dichroism, absorbance, and fluorescence spectroscopies, In contrast, substitution of alanine perturbed the structure. Deletion of Phe(44) reduced binding affinity for the lactogenic receptor, resulting in a reduced activation, Substitution with either alanine or leucine partially restored lactogenic receptor binding affinity, which correlated with the hormones' activity in the Nb2 rat lymphoma cells, All the recombinant hGHs had similar somatotropic activities in FDC-P1 cells transfected with the hGH receptor, These data indicate that the hydrophobic side chain of Phe(44) is required for lactogenic receptor binding and activation but is unnecessary for somatotropic action.	OHIO STATE UNIV, DIV CARDIOL, DEPT VET BIOSCI, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, OHIO STATE BIOCHEM PROGRAM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NIDDK NIH HHS [R01-DK42604, K04-DK01989] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001989, R01DK042604] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; HOLZMAN TF, 1986, BIOCHEMISTRY-US, V25, P6907, DOI 10.1021/bi00370a026; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWMAN HB, 1991, J BIOL CHEM, V266, P10982; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; MULKERRIN MG, 1993, ACS SYM SER, V526, P240; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SINHA YN, 1995, ENDOCR REV, V16, P354, DOI 10.1210/er.16.3.354; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553	29	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21444	21448		10.1074/jbc.272.34.21444	http://dx.doi.org/10.1074/jbc.272.34.21444			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261160	hybrid			2022-12-27	WOS:A1997XR78900070
J	Hisatsune, C; Umemori, H; Inoue, T; Michikawa, T; Kohda, K; Mikoshiba, K; Yamamoto, T				Hisatsune, C; Umemori, H; Inoue, T; Michikawa, T; Kohda, K; Mikoshiba, K; Yamamoto, T			Phosphorylation-dependent regulation of N-methyl-D-aspartate receptors by calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE-C; METABOTROPIC GLUTAMATE RECEPTORS; NMDA RECEPTOR; HIPPOCAMPAL-NEURONS; BINDING-PROTEIN; CHANNEL; ENHANCEMENT; MODULATION; EXPRESSION	The N-methyl-D-aspartate (NMDA) receptor plays important roles in synaptic plasticity and brain development. The NMDA receptor subunits have large intracellular domains in the COOH-terminal region that may interact with signal-transducing proteins. By using the yeast two-hybrid system, we found that calmodulin interacts with the COOH terminus of the NR1 subunit and inactivates the channels in a Ca2+-dependent manner, Here we show that protein kinase C (PKC)-mediated phosphorylation on serine residues of NR1 decreases its affinity for calmodulin. This suggests that PKC-mediated phosphorylation of NR1 prevents calmodulin from binding to the NR1 subunit and thereby inhibits the inactivation of NMDA receptors by calmodulin, In addition, we show that stimulation of metabotropic glutamate receptor 1 alpha, which potentiates NMDA channels through PKC, decreases the ability of NR1 to bind to calmodulin, Thus, our data provide clues to understanding the basis of cross-talk between two types of receptors, metabotropic glutamate receptors and the NR1 subunit, in NMDA channel potentiation.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo; University of Tokyo			Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015; Hisatsune, Chihiro/C-6661-2017; Kohda, Kazuhisa/L-4731-2013	Inoue, Takafumi/0000-0002-2728-0060; Hisatsune, Chihiro/0000-0001-7811-7784; Umemori, Hisashi/0000-0001-7198-2062				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; ANIKSZTEJN L, 1991, EUR J PHARMACOL, V205, P327, DOI 10.1016/0014-2999(91)90921-C; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; ASZTELY F, 1992, EUR J NEUROSCI, V4, P681, DOI 10.1111/j.1460-9568.1992.tb00177.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORTOLOTTO ZA, 1994, NATURE, V368, P740, DOI 10.1038/368740a0; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOI DW, 1988, J NEUROSCI, V8, P185; CIMLER BM, 1985, J BIOL CHEM, V260, P784; CLARK KA, 1995, J PHYSIOL-LONDON, V482, P39, DOI 10.1113/jphysiol.1995.sp020498; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERBER G, 1989, J NEUROSCI, V9, P3606; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MEDINA I, 1995, J PHYSIOL-LONDON, V482, P567, DOI 10.1113/jphysiol.1995.sp020540; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; OCONNOR JJ, 1994, NATURE, V367, P557, DOI 10.1038/367557a0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; RADPOUR S, 1992, NEUROSCI LETT, V138, P119, DOI 10.1016/0304-3940(92)90486-Q; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VYKLICKY L, 1993, J PHYSIOL-LONDON, V470, P575, DOI 10.1113/jphysiol.1993.sp019876; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154	46	111	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20805	20810		10.1074/jbc.272.33.20805	http://dx.doi.org/10.1074/jbc.272.33.20805			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252405	hybrid			2022-12-27	WOS:A1997XR22100075
J	Lebrun, B; Sakaitani, M; Shimamoto, K; YasudaKamatani, Y; Nakajima, T				Lebrun, B; Sakaitani, M; Shimamoto, K; YasudaKamatani, Y; Nakajima, T			New beta-hydroxyaspartate derivatives are competitive blockers for the bovine glutamate/aspartate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROGENIC GLUTAMATE UPTAKE; RAT-BRAIN; ASPARTATE TRANSPORTER; GLIAL-CELLS; EXPRESSION; CLONING; SPECIFICITY; SALAMANDER; MEMBRANE; OOCYTES	Four subtypes of excitatory amino acid transporters (EAAT1-4) have been identified in the mammalian brain, A number of pharmacological agents have been developed to study their intrinsic properties and function, Up to now, blockers were available only for EAAT2, whereas all the inhibitors of glutamate uptake active on the other subtypes were proved to be substrates of the transporters, We synthesized five new derivatives of DL-threo-beta-hydroxyaspartic acid, a well known general substrate of EAATs, and investigated their potential blocking activity on the cloned bovine EAAT1 expressed in the Xenopus oocyte system, by using radiotracer and voltage-clamp techniques. Two of our derivatives proved to be substrates for bovine EAAT1, with reduced electrogenicity compared with their parent compound, and an affinity of 40 and 64 mu M. The last three derivatives displayed a blocking activity on bovine EAAT1. The affinity of DL-threo-beta-benzoyloxyaspartate and DL-threo-beta-(1-naphthoyl)oxyaspartate was determined by Schild analysis as 17.2 and 52.1 mu M, respectively, These blockers should help in the better understanding of the key intrinsic properties of EAAT1, Moreover, they appear as good candidates for a general blocking activity on EAATs.	SUNTORY INST BIOORGAN RES,SUNBOR,SHIMAMOTO,OSAKA 618,JAPAN	Suntory Holdings Ltd								ARRIZA JL, 1994, J NEUROSCI, V14, P5559; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; Billups B, 1996, J NEUROSCI, V16, P6722; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; BRIDGES RJ, 1993, BIOORG MED CHEM LETT, V3, P115, DOI 10.1016/S0960-894X(00)80103-1; BRIDGES RJ, 1994, NEUROSCI LETT, V174, P193, DOI 10.1016/0304-3940(94)90019-1; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FERKANY J, 1986, J NEUROSCI RES, V16, P491, DOI 10.1002/jnr.490160305; GRANT GB, 1992, THESIS U CALIFORNIA; INOUE K, 1995, MOL BRAIN RES, V28, P343, DOI 10.1016/0169-328X(94)00244-9; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KAWAKAMI H, 1994, BIOCHEM BIOPH RES CO, V199, P171, DOI 10.1006/bbrc.1994.1210; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; KLOCKNER U, 1994, J NEUROSCI, V14, P5759; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; LEHRE KP, 1995, J NEUROSCI, V15, P1835; PICAUD S, 1995, P NATL ACAD SCI USA, V92, P9417, DOI 10.1073/pnas.92.20.9417; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; SHASHIDHARAN P, 1993, BIOCHIM BIOPHYS ACTA, V1216, P161, DOI 10.1016/0167-4781(93)90057-K; SHASHIDHARAN P, 1994, BBA-BIOMEMBRANES, V1191, P393, DOI 10.1016/0005-2736(94)90192-9; Sonnenberg JD, 1996, BIOORG MED CHEM LETT, V6, P1607, DOI 10.1016/S0960-894X(96)00284-3; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TANAKA K, 1993, NEUROSCI LETT, V159, P183, DOI 10.1016/0304-3940(93)90829-A; TANAKA K, 1993, NEUROSCI RES, V16, P149, DOI 10.1016/0168-0102(93)90082-2; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	35	70	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20336	20339		10.1074/jbc.272.33.20336	http://dx.doi.org/10.1074/jbc.272.33.20336			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252337	hybrid			2022-12-27	WOS:A1997XR22100007
J	Scherer, PE; Lisanti, MP				Scherer, PE; Lisanti, MP			Association of phosphofructokinase-M with caveolin-3 in differentiated skeletal myotubes - Dynamic regulation by extracellular glucose and intracellular metabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; ALLOSTERIC PROPERTIES; GLYCOLYTIC-ENZYMES; RECEPTOR KINASE; PROTEIN-KINASE; LINKED PROTEIN; GROWTH-FACTORS; BLOOD-CELLS; MUSCLE; PHOSPHORYLATION	Caveolin-3 is a member of the caveolin family of proteins that is primarily expressed in striated muscle cell types (skeletal and cardiac). Here, we show that an similar to 80-kDa protein specifically co-immunoprecipitates with caveolin-3 expressed in differentiated skeletal C2C12 myotubes. Microsequence analysis of this similar to 80-kDa polypeptide revealed its identity as a key regulatory enzyme in the glycolytic pathway, namely phosphofructokinase M (PFK-M). Pulse-chase experiments demonstrate that PFK-M associates with caveolin-3 with a significant time lag after the biosynthesis of PFK-M. In addition, we show that this interaction is (i) highly regulated by the extracellular concentration of glucose and (ii) can be stabilized by a number of relevant intracellular metabolites, such as fructose 1,6-bisphosphate and fructose 2,6-bisphosphate, which are known allosteric activators of PFK. While the bulk of these experiments were performed in C2C12 cells, identical results were obtained using mouse skeletal muscle extracts. Taken together, our results suggest that glucose-dependent plasma membrane recruitment of activated PFK-M by caveolin-3 could have important implications for understanding the mechanisms that regulate energy metabolism in skeletal muscle fibers.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRONSTEIN WW, 1981, CAN J BIOCHEM CELL B, V59, P494, DOI 10.1139/o81-069; CHENZION M, 1992, INT J BIOCHEM, V24, P1661, DOI 10.1016/0020-711X(92)90185-4; CLARKE FM, 1975, BIOCHIM BIOPHYS ACTA, V381, P37, DOI 10.1016/0304-4165(75)90187-7; COLE F, 1993, J BIOL CHEM, V268, P1580; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DOHM GL, 1993, J CELL BIOCHEM, V52, P1, DOI 10.1002/jcb.240520102; DUNAWAY GA, 1983, MOL CELL BIOCHEM, V52, P75; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GEKAKIS N, 1989, J BIOL CHEM, V264, P3658; GUSTAVSSON J, 1996, J BIOL CHEM, V271, P367; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HOFER HW, 1985, BIOCHEM BIOPH RES CO, V129, P892, DOI 10.1016/0006-291X(85)91975-8; HUE L, 1993, ADV ENZYME REGUL, V33, P97; LEHOTZKY A, 1993, J BIOL CHEM, V268, P10888; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LILLING G, 1991, BIOCHEM MED METAB B, V45, P319, DOI 10.1016/0885-4505(91)90036-K; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MAHRENHOLZ AM, 1991, BIOCHEM BIOPH RES CO, V174, P1255, DOI 10.1016/0006-291X(91)91556-R; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; OVADI J, 1988, TRENDS BIOCHEM SCI, V13, P486, DOI 10.1016/0968-0004(88)90237-X; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; REISS N, 1986, BIOCHEM J, V239, P691, DOI 10.1042/bj2390691; SALE EM, 1987, J CELL BIOCHEM, V33, P15, DOI 10.1002/jcb.240330103; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHWEIZER E, 1982, BIOCHEMISTRY-US, V21, P6807, DOI 10.1021/bi00269a029; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TSAI MY, 1973, J BIOL CHEM, V248, P785; VORA S, 1981, P NATL ACAD SCI-BIOL, V78, P3738, DOI 10.1073/pnas.78.6.3738; VORA S, 1981, BLOOD, V57, P724; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WEIL D, 1980, ANN HUM GENET, V44, P11, DOI 10.1111/j.1469-1809.1980.tb00941.x	54	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20698	20705		10.1074/jbc.272.33.20698	http://dx.doi.org/10.1074/jbc.272.33.20698			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252390	hybrid			2022-12-27	WOS:A1997XR22100060
J	Hasegawa, K; Meyers, MB; Kitsis, RN				Hasegawa, K; Meyers, MB; Kitsis, RN			Transcriptional coactivator p300 stimulates cell type-specific gene expression in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; E1A-ASSOCIATED PROTEIN P300; MUSCLE-SPECIFIC EXPRESSION; BINDING FACTOR MEF-2; ADENOVIRUS E1A; IN-VIVO; TERMINAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; DNA-SYNTHESIS; BETA GENE	Terminal differentiation is characterized by cell cycle arrest and the expression of cell type-specific genes, Previous work has suggested that the p300 family of transcriptional coactivators plays an important role in preventing the re-initiation of DNA synthesis in terminally differentiated cardiac myocytes, In this study, we investigated whether p300 proteins are also involved in the transcriptional activation of cell type-specific genes in these cells. Since p300 function can be abrogated through direct binding by the adenovirus E1A protein, we overexpressed E1A in cardiac myocytes using recombinant adenoviral vectors, The expression of transfected reporter genes driven by alpha- or beta-myosin heavy chain promoters was markedly diminished by expression of the 12 S E1A protein, In contrast, the activity of a promoter derived from the ubiquitously expressed beta-actin gene was affected only modestly, While an E1A mutant unable to bind members of the retinoblastoma family of pocket proteins decreased the activity of alpha- and beta-myosin heavy chain promoters to nearly the same extent as wild type 12 S E1A, transcriptional repression by a mutant defective for p300 binding was severely impaired, Furthermore, overexpression of p300 and, to an even greater extent, p300de133, a mutant lacking residues required for binding by E1A, relieved E1A's repression of beta-myosin heavy chain promoter activity while having no effect on the activity of the beta-actin promoter, Thus, E1A's transcriptional repression of cell type-specific genes in cardiac myocytes is mediated through its binding of p300 proteins, and these proteins appear to be involved in maintaining both cell type-specific gene expression and cell cycle arrest in cardiac myocytes.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED CARDIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NHLBI NIH HHS [HL-02699] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BUTTRICK PM, 1993, CIRC RES, V72, P1211, DOI 10.1161/01.RES.72.6.1211; CARUSO M, 1993, ONCOGENE, V8, P267; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLAYCOMB WC, 1975, J BIOL CHEM, V250, P3229; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ENKEMANN SA, 1990, CELL GROWTH DIFFER, V1, P375; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GOLDSTEIN MA, 1974, SCIENCE, V183, P212, DOI 10.1126/science.183.4121.212; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUANG WY, 1995, GENE, V155, P219, DOI 10.1016/0378-1119(94)00893-W; Janknecht R, 1996, ONCOGENE, V12, P1961; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KASSEISLER A, 1993, P NATL ACAD SCI USA, V90, P11498, DOI 10.1073/pnas.90.24.11498; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; KITSIS RN, 1993, METHODS MOL GENET, V1, P374; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LITVIN J, 1992, TRENDS CARDIOVAS MED, V2, P27, DOI 10.1016/1050-1738(92)90041-P; Liu Y, 1996, J CELL BIOL, V133, P325, DOI 10.1083/jcb.133.2.325; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Rawles Mary E., 1943, PHYSIOL ZOOL, V16, P22; RUMYANTSEV PP, 1977, INT REV CYTOL, V51, P187; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; STRACESKI AJ, 1994, P NATL ACAD SCI USA, V91, P589, DOI 10.1073/pnas.91.2.589; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	63	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20049	20054		10.1074/jbc.272.32.20049	http://dx.doi.org/10.1074/jbc.272.32.20049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242676	hybrid			2022-12-27	WOS:A1997XQ05900063
J	Persson, E; Olsen, OH; Ostergaard, A; Nielsen, LS				Persson, E; Olsen, OH; Ostergaard, A; Nielsen, LS			Ca2+ binding to the first epidermal growth factor-like domain of factor VIIa increases amidolytic activity and tissue factor affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR-IX; EGF-LIKE DOMAINS; CALCIUM-BINDING; FACTOR-X; BLOOD-COAGULATION; HEMOPHILIA-B; STRUCTURAL REQUIREMENTS; CONTAINING MODULE; PROTEASE DOMAIN	Coagulation factor VIIa belongs to a family of homologous enzymes, including factors Ma and Xa and activated protein C, composed of two epidermal growth factor-like domains located between an N-terminal domain rich in gamma-carboxyglutamic acid residues and a C-terminal serine protease domain. The first epidermal growth factor-like domain in factor VIIa contains a Ca2+ binding site, the function of which is largely unknown, Site-directed mutagenesis of two Ca2+-liganding Asp residues in this domain abolished Ca2+ binding and resulted in a 2-3-fold decrease in amidolytic activity at optimal Ca2+ concentrations, The lower amidolytic activity persisted in complex with soluble tissue factor, apparently due to a lower k(cat) of the mutant factor VIIa. Mutant and wild type factor VIIa bound to lipidated tissue factor were equally efficient activators of factor X. The dissociation constants, derived from amidolytic activity and surface plasmon resonance measurements, were 2-5 nM and 50-60 nM for the interactions between wild-type and mutant factor VIIa, respectively, and soluble tissue factor. Binding to lipidated tissue factor was characterized by dissociation constants of 7.5 pm for factor VIIa and 160 phl for the factor VIIa mutant. Hence, a functional Ca2+ binding site in the first epidermal growth factor-like domain added 7-8 kJ/mol to the total binding energy of the interaction with both lipidated and soluble tissue factor.	NOVO NORDISK AS,HLTH CARE DISCOVEY,MED CHEM RES 4,DK-2760 MALOV,DENMARK	Novo Nordisk	Persson, E (corresponding author), NOVO NORDISK AS,HLTH CARE DISCOVERY,VESSEL WALL BIOL,HAGEDORNSVEJ 1,HAB3-93,DK-2820 GENTOFTE,DENMARK.			Persson, Egon/0000-0003-3005-4926				ANDERSSEN T, 1993, THROMB HAEMOSTASIS, V70, P414; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; CHANG JY, 1995, BIOCHEMISTRY-US, V34, P12227, DOI 10.1021/bi00038a017; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; DAVIS LM, 1987, BLOOD, V69, P140; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; DU ZJ, 1995, BIOTECHNIQUES, V18, P376; Freskgard PO, 1996, PROTEIN SCI, V5, P1531, DOI 10.1002/pro.5560050809; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; McCallum CD, 1996, J BIOL CHEM, V271, P28168, DOI 10.1074/jbc.271.45.28168; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MEDVED LV, 1994, BIOCHEMISTRY-US, V33, P478, DOI 10.1021/bi00168a012; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; NISOLAISEN EM, 1993, FEBS LETT, V317, P245; NISOLAISEN EM, 1992, FEBS LETT, V806, P157; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; Persson E, 1996, HAEMOSTASIS, V26, P31; PERSSON E, 1992, FEBS LETT, V314, P5, DOI 10.1016/0014-5793(92)81447-T; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PERSSON E, 1995, EUR J BIOCHEM, V234, P293, DOI 10.1111/j.1432-1033.1995.293_c.x; Persson E, 1996, FEBS LETT, V385, P241, DOI 10.1016/0014-5793(96)00400-0; RAO LVM, 1996, BLOOD, V87, P3788; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1991, BLOOD, V78, P1637; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; VALCARCE C, 1994, J BIOL CHEM, V269, P26011; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436; WALTER J, 1994, THROMB HAEMOSTASIS, V72, P74; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x	57	37	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19919	19924		10.1074/jbc.272.32.19919	http://dx.doi.org/10.1074/jbc.272.32.19919			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242658	hybrid			2022-12-27	WOS:A1997XQ05900045
J	Lopez, S; Reeves, R; Island, ML; Bandu, MT; Christeff, N; Doly, J; Navarro, S				Lopez, S; Reeves, R; Island, ML; Bandu, MT; Christeff, N; Doly, J; Navarro, S			Silencer activity in the interferon-A gene promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-BETA-GENE; MOBILITY-GROUP PROTEIN; STIMULATED RESPONSE ELEMENT; INDUCIBLE ENHANCER ELEMENT; REGULATORY FACTOR FAMILY; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; VIRUS INDUCTION; ALPHA PROMOTER; INDUCED EXPRESSION	Interferon-A (IFN-A) differential gene expression is modulated by a complex interplay between cis-acting DNA elements and the corresponding specific trans-regulating factors, Substitutions in the proximal virus-responsive element of the interferon-A (IFN-A) promoters contribute to their differential gene expression, The 5' distal silencing region in the weakly virus-inducible murine IFN-A11 gene has been previously delimited. DNase I footprinting experiments and transient gene expression assays demonstrate identical silencing activity in equivalent regions of the genes for IFN-A11 and IFN-A4 promoters. A minimal 20-mer distal negative regulatory element (DNRE) in both promoters is necessary and sufficient for the silencing and a region in the highly inducible IFN-A4 promoter located between the silencer and the virus-responsive element overrides the silencer activity. Mutations in the central region of the DNRE, causing derepression, also altered the formation of one of the two major DNA-protein complexes, One of these contains a protein related to or identical to the high mobility group I(Y) proteins, while the other complex contains a major protein present in uninduced and virus-induced cells with a molecular mass of 38 kDa, which may be related to the silencer activity. Similar DNREs are present in other virus-uninducible IFN-A promoters, and these data suggest that a common silencer may mediate the transcriptional repression in different genes of this family.	UNIV PARIS 05,CNRS,UFR BIOMED ST PERES,UPR 37,LAB REGULAT EXPRESS GENES EUCARYOTES,F-75270 PARIS 06,FRANCE; WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Washington State University								AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BISAT F, 1988, NUCLEIC ACIDS RES, V16, P6067, DOI 10.1093/nar/16.13.6067; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CIVAS A, 1991, NUCLEIC ACIDS RES, V19, P4497, DOI 10.1093/nar/19.16.4497; COULOMBEL C, 1991, GENE, V104, P187, DOI 10.1016/0378-1119(91)90249-B; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DION M, 1986, BIOCHEM BIOPH RES CO, V138, P826, DOI 10.1016/S0006-291X(86)80571-X; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; French SW, 1996, MOL CELL BIOL, V16, P5393; FRENKEL B, 1994, P NATL ACAD SCI USA, V91, P10923, DOI 10.1073/pnas.91.23.10923; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; Genin P, 1995, NUCLEIC ACIDS RES, V23, P5055; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GOPING IS, 1994, J BIOL CHEM, V269, P3891; GRANT CE, 1995, NUCLEIC ACIDS RES, V23, P2137, DOI 10.1093/nar/23.12.2137; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIN RT, 1994, J BIOL CHEM, V269, P17542; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; RAJ NBK, 1989, J BIOL CHEM, V264, P11149; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; REEVES R, 1990, J BIOL CHEM, V265, P8573; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Roffet P, 1996, BIOCHEM J, V317, P697, DOI 10.1042/bj3170697; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; STOVER DM, 1992, MOL CELL BIOL, V12, P2230, DOI 10.1128/MCB.12.5.2230; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Yoneyama M, 1996, J BIOCHEM-TOKYO, V120, P160	61	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22788	22799		10.1074/jbc.272.36.22788	http://dx.doi.org/10.1074/jbc.272.36.22788			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278440	hybrid			2022-12-27	WOS:A1997XV49200061
J	Renatus, M; Bode, W; Huber, R; Sturzebecher, J; Prasa, D; Fischer, S; Kohnert, U; Stubbs, MT				Renatus, M; Bode, W; Huber, R; Sturzebecher, J; Prasa, D; Fischer, S; Kohnert, U; Stubbs, MT			Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator - Implications for the design of low molecular weight substrates and inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ARG CHLOROMETHYLKETONE; RAY CRYSTAL-STRUCTURE; HUMAN ALPHA-THROMBIN; T-PA; FACTOR-XA; SYNTHETIC INHIBITORS; TRYPSIN-INHIBITOR; CATALYTIC DOMAIN; FIBRIN; ERYTHRINA	The recent structure determination of the catalytic domain of tissue-type plasminogen activator (tPA) suggested residue Arg(174) could play a role in P3/P4 substrate specificity, Six synthetic chromogenic tPA substrates of the type R-Xaa-Gly-Arg-p-nitroanilide, in which R is an N-terminal protection group, were synthesized to test this property, Although changing the residue Xaa (in its L or D form) at position P3 from the hydrophobic Phe to an acidic residue, Asp or Glu, gave no improvement in catalytic efficiency, comparative analysis of the substrates indicated a preference for an acidic substituent occupying the S3 site when the S4 site contains a hydrophobic or basic moiety, The 2.9 Angstrom structure determination of the catalytic domain of human tPA in complex with the bis-benzamidine inhibitor 2,7-bis (4-amidinobenzylidene)-cycloheptan-1-one reveals a three-site interaction, salt bridge formation of the proximal amidino group of the inhibitor with Asp(189) in the primary specificity pocket, extensive hydrophobic surface burial, and a weak electrostatic interaction between the distal amidino group of the inhibitor and two carbonyl oxygens of the protein, The latter position was previously occupied by the guanidino group of Arg(174), which swings out to form the western edge of the S3 pocket, These data suggest that the side chain of Arg(174) is flexible, and does not play a major role in the S4 specificity of tPA, On the other hand, this residue would modulate S3 specificity, and may be exploited to fine tune the specificity and selectivity of tPA substrates and inhibitors.	UNIV JENA,CTR VASC BIOL & MED,D-99089 ERFURT,GERMANY; BOEHRINGER MANNHEIM GMBH,BIOCHEM RES CTR,D-82372 PENZBERG,GERMANY	Friedrich Schiller University of Jena	Renatus, M (corresponding author), MAX PLANCK INST BIOCHEM,DEPT STRUCT RES,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Stubbs, Milton/ABC-7585-2020	Stubbs, Milton/0000-0003-1278-9013				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACHMANN F, 1994, HAEMOSTASIS THROMBOS, V1, P575; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; *BIOS TECHN SAN DI, 1993, INS VERS 2 2 0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1994, FIBRINOLYSIS, V8, P161, DOI 10.1016/0268-9499(94)90714-5; BODE W, 1992, PROTEIN SCI, V1, P426; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BRANDSTETTER H, 1992, J MOL BIOL, V226, P1085, DOI 10.1016/0022-2836(92)91054-S; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CAMANI C, 1994, J BIOL CHEM, V269, P5770; Coombs GS, 1996, J BIOL CHEM, V271, P4461; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; JOUBERT FJ, 1987, THROMB HAEMOSTASIS, V57, P356; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOHNERT U, 1992, PROTEIN ENG, V5, P93, DOI 10.1093/protein/5.1.93; Kohnert U, 1996, FIBRINOLYSIS, V10, P93, DOI 10.1016/S0268-9499(96)80084-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MACARTNEY HW, 1989, Patent No. 502503; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MARKWARDT F, 1989, DESIGN ENZYME INHIBI, P619; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PANNEKOEK H, 1990, THROMB HAEMOSTASIS, V64, P600; PAONI NF, 1993, THROMB HAEMOSTASIS, V70, P307; PAONI NF, 1993, PROTEIN ENG, V6, P529, DOI 10.1093/protein/6.5.529; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RENATUS M, 1997, IN PRESS BIOCHEMISTR; RENATUS M, 1997, IN PRESS EMBO J; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; RUDOLPH R, 1987, Patent No. 219874; Rudolph R, 1990, U.S. Patent, Patent No. [4,933,434, 4933434]; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; Stern A., 1990, European Patent Application, Patent No. [0382174 B1, 0382174]; STUBBS MT, 1995, FEBS LETT, V375, P103, DOI 10.1016/0014-5793(95)01190-P; STURZEBECHER J, 1982, PHARMAZIE, V37, P281; STURZEBECHER J, 1992, PROTEIN SCI, V1, P1007; STURZEBECHER J, 1978, ACTA BIOL MED GER, V35, P1665; SVENDSEN LG, 1983, Patent No. 34122; TEIXEIRA AV, 1994, BBA-GENE STRUCT EXPR, V1217, P23, DOI 10.1016/0167-4781(94)90120-1; TURK D, 1992, THESIS TU MUNCHEN; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; WALSMANN P, 1976, ACTA BIOL MED GER, V35, pK1	52	62	63	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21713	21719		10.1074/jbc.272.35.21713	http://dx.doi.org/10.1074/jbc.272.35.21713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268299	hybrid			2022-12-27	WOS:A1997XT85000011
J	Hagg, R; Hedbom, E; Mollers, U; Aszodi, A; Fassler, R; Bruckner, P				Hagg, R; Hedbom, E; Mollers, U; Aszodi, A; Fassler, R; Bruckner, P			Absence of the alpha 1(IX) chain leads to a functional knock-out of the entire collagen IX protein in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO CARTILAGE; MESSENGER-RNAS; FIBRILS; PROTEOGLYCAN; POLYPEPTIDE; ALPHA-2(IX); ANTIBODIES; SEQUENCE; MATRIX; DOMAIN	Cartilage fibrils contain collagen II as well as smaller amounts of collagens IX and XI, The three collagens are thought to co-assemble into cartilage-specific arrays, The precise role of collagen IX in cartilage has been addressed previously by generating mice harboring an inactivated Col9a1 gene encoding the alpha 1(IX) chain, i.e. one of the three constituent chains of collagen IX (Fassler, R., Schnegelsberg, P. N. J., Dausman, J., Shinya, T,, Muragaki, Y,, McCarthy, M, T,, Olsen, B, R,, and Jaenisch, R, (1994) Proc. Natl, Acad. Sci, U, S, A. 91, 5070-5074), The animals did not produce alpha 1(M) mRNA or polypeptides and were born with no conspicuous skeletal abnormality but post-natally developed early onset osteoarthritis, Here we show that the deficiency in alpha 1(M) chains leads to a functional knock-out of all polypeptides of collagen IX, whereas the Col9a2 and Col9a3 genes were normally transcribed, Therefore, synthesis of alpha 1(M) polypeptides is essential for the assembly of heterotrimeric collagen IX molecules, Surprisingly, cartilage fibrils of all shapes and banding patterns found in normal newborn, adolescent, or adult mice were formed in transgenic animals, although they lacked collagen IX. Therefore, collagen IX is not essen tial, and may be functionally redundant, in fibrillogenesis in cartilage in vivo, The protein is required, however, for long term tissue stability, presumably by mediating interactions between fibrillar and extrafibrillar macromolecules.	UNIV MUNSTER,INST PHYSIOL CHEM & PATHOBIOCHEM,D-48149 MUNSTER,GERMANY; MAX PLANCK INST BIOCHEM,PROT CHEM ABT,D-82152 MARTINSRIED,GERMANY	University of Munster; Max Planck Society			Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; BRUCKNER P, 1988, J BIOL CHEM, V263, P16911; BRUCKNER P, 1983, EUR J BIOCHEM, V136, P333, DOI 10.1111/j.1432-1033.1983.tb07746.x; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; ELIMA K, 1992, BIOCHIM BIOPHYS ACTA, V1130, P78, DOI 10.1016/0167-4781(92)90465-C; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; Haimes H. B., 1995, INFLAMM RES S2, V44, P127; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HOLMDAHL R, 1986, ARTHRITIS RHEUM, V29, P400, DOI 10.1002/art.1780290314; HUBER S, 1986, J BIOL CHEM, V261, P5965; HUBER S, 1988, J BIOL CHEM, V263, P752; HUNZIKER EB, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P183; JACENKO O, 1995, J RHEUMATOL, V22, P39; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; LABOURDETTE L, 1993, FEBS LETT, V320, P211, DOI 10.1016/0014-5793(93)80588-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MAYNE R, 1995, EXTRACELLULAR MATRIX, P73; MAYNE R, 1996, ARTHRITIS ALLIED CON, P207; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; Mechling DE, 1996, J BIOL CHEM, V271, P13781, DOI 10.1074/jbc.271.23.13781; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; NORO A, 1983, J BIOL CHEM, V258, P9323; TIMPL R, 1982, METHOD ENZYMOL, V82, P472; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105	33	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20650	20654		10.1074/jbc.272.33.20650	http://dx.doi.org/10.1074/jbc.272.33.20650			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252382	hybrid			2022-12-27	WOS:A1997XR22100052
J	Maisner, A; Zimmer, G; Liszewski, MK; Lublin, DM; Atkinson, JP; Herrler, G				Maisner, A; Zimmer, G; Liszewski, MK; Lublin, DM; Atkinson, JP; Herrler, G			Membrane cofactor protein (CD46) is a basolateral protein that is not endocytosed - Importance of the tetrapeptide FTSL at the carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; LYSOSOMAL ACID-PHOSPHATASE; TRANS-GOLGI NETWORK; CANINE KIDNEY-CELLS; MEASLES-VIRUS; MDCK CELLS; PLASMA-MEMBRANE; N-GLYCANS; CYTOPLASMIC DOMAIN; TARGETING SIGNAL	Membrane cofactor protein (MCP) is a widely distributed complement regulatory protein that is expressed on the basolateral surface of polarized epithelial cells. The basolateral targeting of the BC1 isoform of MCP was analyzed by generating deletion mutants and point mutants within the cytoplasmic tail of 16 amino acids, A sequence of four amino acids, FTSL, was found to be indispensable for the basolateral transport of MCP. This tetrapeptide has two unique features compared with the targeting motifs of other basolateral proteins: (i) it contains a phenylalanine rather than a tyrosine at position 1; (ii) it is located at the very COOH-terminal end, Replacement of the phenylalanine or the leucine by an alanine resulted in a nonpolarized delivery to the cell surface, On the other hand, substitution of a tyrosine for the phenylalanine did not affect the basolateral transport of MCP, The latter mutant, however, was efficiently internalized, whereas the wild type protein was not subject to endocytosis. Our results indicate that the targeting signal YXX-large aliphatic that is involved in various sorting events has been modulated in MCP in such a way that it allows basolateral transport but not endocytosis.	UNIV MARBURG,INST VIROL,D-35037 MARBURG,GERMANY; WASHINGTON UNIV,SCH MED,DEPT PATHOL & MED,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV RHEUMATOL,ST LOUIS,MO 63110	Philipps University Marburg; Washington University (WUSTL); Washington University (WUSTL)				Atkinson, John/0000-0002-2514-3441; Zimmer, Gert/0000-0002-2708-2507				BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Lazarovits J, 1996, J CELL BIOL, V134, P339, DOI 10.1083/jcb.134.2.339; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LISZEWSKI MK, 1994, J BIOL CHEM, V269, P10776; LISZEWSKI MK, 1992, CURR TOP MICROBIOL, V178, P45; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; Maisner A, 1996, J VIROL, V70, P4973, DOI 10.1128/JVI.70.8.4973-4977.1996; Maisner A, 1996, J BIOL CHEM, V271, P18853, DOI 10.1074/jbc.271.31.18853; MAISNER A, 1995, VIROLOGY, V210, P479, DOI 10.1006/viro.1995.1365; MAISNER A, 1994, J VIROL, V68, P6299, DOI 10.1128/JVI.68.10.6299-6304.1994; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; OGLESBY TJ, 1992, J EXP MED, V175, P1547, DOI 10.1084/jem.175.6.1547; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; ROTH MG, 1986, J CELL BIOL, V103, P2607; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHNORR JJ, 1995, EUR J IMMUNOL, V25, P976, DOI 10.1002/eji.1830250418; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TUCKER SP, 1993, ADV VIRUS RES, V42, P187, DOI 10.1016/S0065-3527(08)60086-X; VANTHOF W, 1995, J BIOL CHEM, V270, P24150; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987	41	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20793	20799		10.1074/jbc.272.33.20793	http://dx.doi.org/10.1074/jbc.272.33.20793			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252403	hybrid			2022-12-27	WOS:A1997XR22100073
J	Park, JB; Farnsworth, CC; Glomset, JA				Park, JB; Farnsworth, CC; Glomset, JA			Ca2+/calmodulin causes Rab3A to dissociate from synaptic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; CALMODULIN-BINDING; SMG P25A; NERVE-TERMINALS; PHOSPHOLIPID-BINDING; REGULATORY PROTEIN; GLUTAMATE RELEASE; CHROMAFFIN CELLS; EXCHANGE PROTEIN	The GTPase Rab3A has been postulated to cycle on and off synaptic membranes during the course of neurotransmission. Moreover, a Rab guanine nucleotide dissociation inhibitor has been shown to cause Rab3A to dissociate from synaptic membranes in vitro, Pie demonstrate here that Ca2+/calmodulin also can cause Rab3A to dissociate from synaptic membranes in vitro. Like Rab guanine nucleotide dissociation inhibitor, it forms a 1:1 complex with Rab3A that requires both the lipidated C terminus of Rab3A and the presence of bound guanine nucleotide. In addition, a synthetic peptide corresponding to the Lys(62)-Arg(85) sequence of Rab3A can prevent the dissociating effect of each protein and disrupt complexes between each protein and Rab3A. However, Ca2+/calmodulin's effect differs from that of Rab guanine nucleotide dissociation inhibitor not only in being Ca2+-dependent but also in having a less stringent requirement for GDP as opposed to GTP and in involving a less complete dissociation of Rab3A The functional significance in vivo of Ca2+/calmodulin's effect remains to be determined; it may depend in part on the relative amounts of Ca2+/calmodulin and Rab guanine nucleotide dissociation inhibitor that are available for binding to Rab3A in individual, activated nerve termini.	UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, REG PRIMATE RES CTR, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BARRIE AP, 1991, J NEUROCHEM, V57, P1398, DOI 10.1111/j.1471-4159.1991.tb08306.x; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURSTEIN ES, 1992, BIOCHEM J, V282, P387, DOI 10.1042/bj2820387; CAMPAGNE MV, 1989, J NEUROCYTOL, V18, P479, DOI 10.1007/BF01474544; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Estep R P, 1990, Curr Top Cell Regul, V31, P161; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GIEDROC DP, 1985, BIOCHEMISTRY-US, V24, P1203, DOI 10.1021/bi00326a023; GISPEN WH, 1991, MOL NEUROBIOL, V5, P61, DOI 10.1007/BF02935540; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GUERINI D, 1991, ADV PROT PHOSPHATASE, V6, P391; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HENS JJH, 1995, J NEUROCHEM, V64, P1127; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KENIGSBERG RL, 1985, NEUROSCIENCE, V14, P335, DOI 10.1016/0306-4522(85)90183-6; KIM JY, 1994, J BIOL CHEM, V269, P28214; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAHY JC, 1993, NEUROSCIENCE, V52, P563, DOI 10.1016/0306-4522(93)90406-6; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LIU JP, 1994, J BIOL CHEM, V269, P21043; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; LLEDO PM, 1994, TRENDS NEUROSCI, V17, P426, DOI 10.1016/0166-2236(94)90017-5; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LOPEZ MF, 1994, BBA-PROTEIN STRUCT M, V1205, P29, DOI 10.1016/0167-4838(94)90088-4; Marme D., 1983, CALCIUM CELL FUNCTIO, VIV, p263 ; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P269; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; NONAKA H, 1991, BIOCHEM BIOPH RES CO, V174, P556, DOI 10.1016/0006-291X(91)91453-J; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKABE T, 1992, BIOCHEM BIOPH RES CO, V186, P1006, DOI 10.1016/0006-291X(92)90846-D; Park JB, 1996, EXP MOL MED, V28, P147, DOI 10.1038/emm.1996.23; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SKENE JHP, 1990, NEUROSCI RES       S, V13, pS113; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; STONTEN PFW, 1993, FEBS LETT, V320, P1; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZUCKER RS, 1993, BIOCHEM SOC T, V21, P395, DOI 10.1042/bst0210395	75	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20857	20865		10.1074/jbc.272.33.20857	http://dx.doi.org/10.1074/jbc.272.33.20857			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252412	hybrid			2022-12-27	WOS:A1997XR22100082
J	Bouton, C; Hirling, H; Drapier, JC				Bouton, C; Hirling, H; Drapier, JC			Redox modulation of iron regulatory proteins by peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; RECEPTOR MESSENGER-RNA; NITRIC-OXIDE; RESPONSIVE ELEMENT; ACTIVATED MACROPHAGES; CYTOSOLIC ACONITASE; TRYPANOSOMA-CRUZI; ESCHERICHIA-COLI; SUPEROXIDE; METABOLISM	Expression of several proteins of higher eukaryotes is post-transcriptionally regulated by interaction of iron-responsive elements (IREs) on their mRNAs and iron regulatory proteins (IRP1 and IRP2), IRP1 is a redox-sensitive iron-sulfur protein whose regulatory activity is modulated by iron depletion, synthesis of nitric oxide, or oxidative stress, IRP2 is closely related to IRP1, but it does not possess a [Fe-S] cluster, IRPS is also regulated by intracellular iron level, but it is assumed that regulation is achieved by accelerated turn-over, In this report, the effect of peroxynitrite, a strong oxidant produced when nitric oxide and O(2)radical anion are biosynthesized simultaneously, on the RNA binding activity of IRP1 and IRP2 was investigated in vitro. Macrophage cytosolic extracts were exposed directly to a bolus addition of peroxynitrite or to SIN-1, which releases a continuous flux of peroxynitrite. Under these two experimental conditions, IRP1 lost its aconitase activity but did not gain increased capacity to bind IRE. However, addition of low amounts of the disulfide-reducing agent 2-ME during the binding assay revealed formation of a complier between IRP1 and IRE. Substrates of aconitase, which bind to the cluster of IRP1, prevented this effect, pointing to the [Fe-S] cluster as the target of peroxynitrite, Moreover, single mutation of the redox active Cys(437) precluded oxidation of human recombinant IRP1 by SIN-1. Collectively, these results imply that peroxynitrite predisposes IRP1 to bind IREs under a suitable reducing environment, It is assumed that in addition to disrupting the cluster peroxynitrite also promotes disulfide bridge(s) between proximal cysteine residues in the vicinity of the IRE-binding domain, in particular Cys(437) When exposed to peroxynitrite, IRPS lost its spontaneous IRE binding activity, which was restored by further exposure to 2-mercaptoethanol, thus showing that peroxynitrite can also regulate IRP2 by a post-translational event.	INST CURIE,U365 INSERM,F-75005 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Bouton, Cecile/J-8663-2013					ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BECKER K, 1995, EUR J BIOCHEM, V234, P472, DOI 10.1111/j.1432-1033.1995.472_b.x; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; Cairo G, 1996, FASEB J, V10, P1326, DOI 10.1096/fasebj.10.11.8836047; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; CASTRO L, 1994, J BIOL CHEM, V269, P29409; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; DANDEKAR T, 1991, EMBO J, V10, P1003; DENICOLA A, 1993, ARCH BIOCHEM BIOPHYS, V304, P279, DOI 10.1006/abbi.1993.1350; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; Fukuyama N, 1996, BIOCHEM BIOPH RES CO, V224, P414, DOI 10.1006/bbrc.1996.1041; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P14735; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Henderson BR, 1996, BIOESSAYS, V18, P739, DOI 10.1002/bies.950180909; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JAFFREY SR, 1994, P NATL ACAD SCI USA, V91, P12994, DOI 10.1073/pnas.91.26.12994; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LAZZAZERA BA, 1996, J BIOL CHEM, V271, P2762; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Mannick EE, 1996, CANCER RES, V56, P3238; Melefors O, 1996, BIOCHEM BIOPH RES CO, V221, P437, DOI 10.1006/bbrc.1996.0613; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Phillips JD, 1996, BLOOD, V87, P2983, DOI 10.1182/blood.V87.7.2983.bloodjournal8772983; Phillips JD, 1996, BIOCHEMISTRY-US, V35, P15704, DOI 10.1021/bi960653l; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; RADI R, 1991, J BIOL CHEM, V266, P4244; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; RUBBO H, 1994, J BIOL CHEM, V269, P26066; RUBBO H, 1994, ARCH BIOCHEM BIOPHYS, V308, P96, DOI 10.1006/abbi.1994.1014; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SCHLOSS JV, 1980, BIOCHEMISTRY-US, V19, P2358, DOI 10.1021/bi00552a012; Sellers VM, 1996, BIOCHEMISTRY-US, V35, P2699, DOI 10.1021/bi952631p; STAMLER JS, 1994, CELL, V78, P831; SWENSON GR, 1994, NUCLEIC ACIDS RES, V22, P2627, DOI 10.1093/nar/22.13.2627; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; TOTH I, 1995, J BIOL CHEM, V270, P19540, DOI 10.1074/jbc.270.33.19540; VazquezTorres A, 1996, INFECT IMMUN, V64, P3127, DOI 10.1128/IAI.64.8.3127-3133.1996; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	67	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19969	19975		10.1074/jbc.272.32.19969	http://dx.doi.org/10.1074/jbc.272.32.19969			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242665	hybrid			2022-12-27	WOS:A1997XQ05900052
J	Falkenberg, M; Bushnell, DA; Elias, P; Lehman, IR				Falkenberg, M; Bushnell, DA; Elias, P; Lehman, IR			The UL8 subunit of the heterotrimeric herpes simplex virus type 1 helicase-primase is required for the unwinding of single strand DNA-binding protein (ICP8)-coated DNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 GENE-41; PRIMER SYNTHESIS; POLYMERASE; ORIGIN; IDENTIFICATION; REPLICATION; COMPLEX; COMPONENT; PRODUCTS; ICP8	The Herpes simplex virus type 1 primosome consists of three subunits that are the products of the UL5, UL8, and UL52 genes. The heterotrimeric enzyme has DNA-dependent ATPase, helicase, and primase activities. Earlier studies show that a subassembly consisting of the UL5 and UL52 gene products was indistinguishable from the heterotrimeric enzyme in its helicase and primase activities. We demonstrate here that the UL8 protein is required for the helicase activity of the UL5/52 subassembly on long duplex DNA substrates (>30 nucleotides) with a single-stranded DNA loading site fully coated with the virus-encoded single strand DNA binding protein, ICP8. The Escherichia coli single strand PNA binding protein cannot substitute for ICP8, suggesting a specific physical interaction between ICPS and the UL8 protein. Surface plasmon resonance measurements demonstrated an interaction between ICP8 and the UL5/52/8 heterotrimer but not with the UL5/52 subassembly or the UL8 protein alone. At a subsaturating level of ICP8, the UL5/52 subassembly does show helicase activity, suggesting that the subassembly can bind to single-stranded DNA but not to ICP8-coated DNA.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT STRUCT BIOL,STANFORD,CA 94305; GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN	Stanford University; Stanford University; University of Gothenburg					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026538, R01AI121144] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26538, AI-121144] Funding Source: Medline; NIGMS NIH HHS [GM070276-20] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEHMER PE, 1993, J VIROL, V67, P711, DOI 10.1128/JVI.67.2.711-715.1993; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; LeGac NT, 1996, J BIOL CHEM, V271, P21645; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; ODONNELL ME, 1987, J BIOL CHEM, V262, P4242; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; PARRY ME, 1993, J GEN VIR, V607; POWELL KL, 1981, J VIROL, V39, P894, DOI 10.1128/JVI.39.3.894-902.1981; PURIFOY DJM, 1977, NATURE, V269, P621, DOI 10.1038/269621a0; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RUYECHAN WT, 1983, J VIROL, V46, P661, DOI 10.1128/JVI.46.2.661-666.1983; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; TENNEY DJ, 1994, J BIOL CHEM, V269, P5030; VAUGHAN PJ, 1985, J VIROL, V53, P501, DOI 10.1128/JVI.53.2.501-508.1985; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992	31	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22766	22770		10.1074/jbc.272.36.22766	http://dx.doi.org/10.1074/jbc.272.36.22766			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278436	hybrid			2022-12-27	WOS:A1997XV49200057
J	Finnis, ML; Gibson, MA				Finnis, ML; Gibson, MA			Microfibril-associated glycoprotein-1 (MAGP-1) binds to the pepsin-resistant domain of the alpha 3(VI) chain of type VI collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; SULFATE PROTEOGLYCANS; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; CL GLYCOPROTEIN; TERMINAL DOMAIN; FIBRILLIN	The interactions of type VI collagen have been investigated, using solid phase binding assays, with two components of the fibrillin-containing microfibrils, the elastin-binding protein, MAGP-1 and its structural relative MAGP-2. Both native and pepsin-treated forms of type VI collagen specifically bound to MAGP-1 but not to MAGP-2, Pepsin type VI collagen was shown to block the binding of MAGP-1 to native type VI collagen indicating that the major MAGP-1-binding site was in the triple-helical region of the molecule. MAGP-1 was found not to bind to collagens I, III, and V. Affinity blotting of pepsin-treated type VI collagen showed that MAGP-1 binding was specific for the collagenous domain of the alpha 3(VI) chain. Decorin and biglycan were found not to inhibit the interaction of pepsin-treated type VI collagen with MAGP-1, indicating that its binding site on the collagen is not close to that for the proteoglycans. Reduction and alkylation of disulfide bonds in MAGP-1 did not destroy its type VI collagen-binding properties, indicating. that the binding site was likely to be in the cysteine-free, N-terminal domain of MAGP-1. Interestingly, the interaction of MAGP-1 with type VI collagen was inhibit ed by tropoelastin, suggesting that the binding sites for tropoelastin and type VI collagen may be in the same domain of MAGP-1. A peptide, corresponding to amino acids 29-38 of MAGP-1, was found to inhibit the interactions of MAGP-1 with type VI collagen and tropoelastin. The results suggest that the peptide may contain the binding sequences for both type VI collagen and tropoelastin, and thus that these two proteins may share the same binding site on MAGP-1. The interactions of MAGP-1 with type VI collagen and tropoelastin were both determined to be of moderately high affinity, with K-d values of 5.6 x 10(-7) M and 2.6 x 10(-7) M, respectively. The findings indicate that MAGP-1 may mediate a molecular interaction between type M collagen microfibrils and fibrillin-containing microfibrils, structures which are often found in close proximity to each other in a wide range of extracellular matrices.	UNIV ADELAIDE,DEPT PATHOL,ADELAIDE,SA 5006,AUSTRALIA	University of Adelaide								ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; BROWN PL, 1992, BIOCHEM BIOPH RES CO, V186, P549, DOI 10.1016/S0006-291X(05)80843-5; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1987, EUR J BIOCHEM, V168, P309, DOI 10.1111/j.1432-1033.1987.tb13422.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; CHU ML, 1990, EMBO J, V9, P285; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; CLEARY EG, 1996, STRUCTURE FUNCTION E, V2, P95; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DENIS C, 1993, ARTERIOSCLER THROMB, V13, P398, DOI 10.1161/01.ATV.13.3.398; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GIBSON MA, 1985, J BIOL CHEM, V260, P1149; GIBSON MA, 1983, COLLAGEN REL RES, V3, P469; GIBSON MA, 1987, IMMUNOL CELL BIOL, V65, P349; GIBSON MA, 1997, IN PRESS J HISTOCHEM, V45; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; Kielty CM, 1996, FEBS LETT, V386, P169, DOI 10.1016/0014-5793(96)00423-1; KIELTY CM, 1992, J CELL BIOL, V118, P979, DOI 10.1083/jcb.118.4.979; KUMARATILAKE JS, 1989, EUR J CELL BIOL, V50, P117; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; MAIER A, 1987, AM J ANAT, V180, P226, DOI 10.1002/aja.1001800303; MCDEVITT CA, 1991, FEBS LETT, V294, P167, DOI 10.1016/0014-5793(91)80660-U; OKADA Y, 1990, LAB INVEST, V63, P647; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PROSSER IW, 1984, AUST J EXP BIOL MED, V62, P485, DOI 10.1038/icb.1984.46; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; RITTIG M, 1990, CELL TISSUE RES, V259, P305, DOI 10.1007/BF00318453; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; TOMASINIJOHANSSON BR, 1993, MATRIX, V13, P203, DOI 10.1016/S0934-8832(11)80004-1; TRUEB B, 1984, J BIOL CHEM, V259, P8597; WALLACE RN, 1991, CURR EYE RES, V10, P99, DOI 10.3109/02713689109007614; Wu XX, 1996, AM J PATHOL, V149, P283; YEH H, 1994, GENOMICS, V23, P443, DOI 10.1006/geno.1994.1521; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589; ZHU D, 1994, J HISTOCHEM CYTOCHEM, V42, P577, DOI 10.1177/42.5.8157929	54	78	82	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22817	22823		10.1074/jbc.272.36.22817	http://dx.doi.org/10.1074/jbc.272.36.22817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278443	hybrid			2022-12-27	WOS:A1997XV49200064
J	Kirkwood, KL; Homick, K; Dragon, MB; Bradford, PG				Kirkwood, KL; Homick, K; Dragon, MB; Bradford, PG			Cloning and characterization of the type I inositol 1,4,5-trisphosphate receptor gene promoter - Regulation by 17 beta-estradiol in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRISPHOSPHATE RECEPTOR; TRANSCRIPTIONAL REGULATION; FUNCTIONAL EXPRESSION; NUCLEOTIDE-SEQUENCE; ESTROGEN-RECEPTOR; HL-60 CELLS; LOCALIZATION; ACTIVATION; INTERLEUKIN-6; TISSUES	The inositol 1,4,5-trisphosphate (InsP(3)) receptor is essential for signal Ca2+ release from intracellular stores and for capacitative Ca2+ entry, We have isolated the promoter and proximal DNA segments of the human type I InsP(3) receptor gene, Transcription initiation in human 6-292 osteosarcoma and HL-60 promyelocytic leukemia cells was shown to occur predominantly from an adenine residue located 39 base pairs downstream of a consensus TATA box element, Upstream DNA including the TATA box promoted directional transcription of a chloramphenicol acetyltransferase reporter gene when transfected into 6-292 cells, A negative regulatory element in the distal promoter and a positive element in the proximal region were identified by deletion mapping and transcription assays, The proximal region enhanced transcription in response to 12-O-tetradecanoylphorbol-13-acetate or serum, but conferred transcriptional repression in response to 1,25-dihydroxyvitamin D-3 or 17 beta-estradiol. The repressive effect of 17 beta-estradiol was mediated by the nuclear estrogen receptor, as estrogen-dependent transcriptional repression was inhibited by the antiestrogen tamoxifen and the estrogen receptor antagonist ICI 182,780. This is the first study of the type I InsP(3) receptor gene promoter, and the results suggest a mechanism by which chronic estrogen treatment of osteoblasts affects type I InsP(3) receptor gene expression, signal transduction, and secretion.	SUNY BUFFALO, DEPT PHARMACOL & TOXICOL, SCH MED & BIOMED SCI, BUFFALO, NY 14214 USA; SUNY BUFFALO, SCH DENT MED, DEPT ORAL BIOL, BUFFALO, NY 14214 USA; SUNY BUFFALO, CTR MOL MECHANISMS DIS & AGING, BUFFALO, NY 14214 USA; SUNY BUFFALO, HOWARD HUGHES MED INST, UNDERGRAD BIOL SCI EDUC PROGRAM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Kirkwood, Keith L/L-4728-2018	Kirkwood, Keith/0000-0003-4519-8973	NIDCR NIH HHS [F32 DE005697-01, F32 DE005697, F32 DE005697-02] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F32DE005697] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; BRADFORD PG, 1993, MOL PHARMACOL, V44, P292; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NUCLEIC ACIDS RES, V17, P5385, DOI 10.1093/nar/17.13.5385; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; JONES TH, 1994, CLIN ENDOCRINOL, V40, P703, DOI 10.1111/j.1365-2265.1994.tb02502.x; Kirkwood K, 1997, J DENT RES, V76, P2625; Kirkwood KL, 1996, J BONE MINER RES, V11, P1889; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARTIN TJ, 1993, OSTEOPOROSIS INT, V3, pS121, DOI 10.1007/BF01621884; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STROBL JS, 1990, CANCER RES, V50, P5399; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9	38	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22425	22431		10.1074/jbc.272.36.22425	http://dx.doi.org/10.1074/jbc.272.36.22425			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278393	Green Accepted, hybrid			2022-12-27	WOS:A1997XV49200012
J	Whiteley, EM; Hsu, TA; Betenbaugh, MJ				Whiteley, EM; Hsu, TA; Betenbaugh, MJ			Thioredoxin domain non-equivalence and anti-chaperone activity of protein disulfide isomerase mutants in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; ENDOPLASMIC-RETICULUM; PEPTIDE BINDING; ESCHERICHIA-COLI; SITE CYSTEINE; BONDS; PDI; IMMUNOGLOBULINS; YIELD; CELL	Coexpression of the enzyme, protein disulfide isomerase (PDI), has been shown to increase soluble and secreted IgG levels from baculovirus-infected insect cells (Hsu, T.-A., Watson, S., Eiden, J. J., and Betenbaugh, M. J. (1996) Protein Expression Purif. 7, 281-288), PDI is known to include catalytic active sites in two separate thioredoxin-like domains, one near the amino terminus and another near the carboxyl terminus, To examine the role of these catalytic active sites in enhancing immunoglobulin solubility, baculovirus constructs were utilized with cysteine to serine mutations at the first cysteine of one or both of the CGHC active site sequences, Trichoplusia ni insect cells were coinfected with a baculovirus vector coding for IgG in concert with either the wild-type human PDI virus, amino-terminal mutant (PDI-N), carboxyl-terminal mutant (PDI-C), or mutant with both active sites altered (PDI-NC), Western blot analysis revealed that both immunoglobulins and PDI protein were expressed in the coinfected cells, To evaluate the effect of the PDI variants on immunoglobulin solubility and secretion, the infected cells were labeled with S-35-amino-acids for different periods, and the soluble immunoglobulins were immunoprecipitated from clarified cell lysates and culture medium using anti-IgG antibodies, Only coinfections with the wild-type PDI and PDI-N mutant led to increased immunoglobulin solubility and higher IgG secretion, In contrast, infection with the PDI-C and PDI-NC variants actually lowered immunoglobulin solubility levels below those achieved with a negative control virus, Immunoprecipitation with anti-PDI antibody revealed that heterologous PDI-C and PDI-NC were insoluble, even though PDI-N and wild-type PDI protein were detected in soluble form, The capacity for PDI-N to increase immunoglobulin solubility whereas the PDI-C mutant lowered solubility indicates that the amino-and carboxyl-terminal thioredoxin domains of PDI are functionally distinct in vivo following mutations to the active site, Furthermore, mutations at the active site of the carboxyl-terminal thioredoxin domain result in PDI variants that can act as anti-chaperones of immunoglobulin solubility in vivo as has been observed in vitro for lysozyme aggregation by wild-type PDI and PDI mutants (Puig, A., and Gilbert, H. F. (1994) J. Biol. Chem. 269, 7764-7771).	JOHNS HOPKINS UNIV, DEPT CHEM ENGN, BIOTECHNOL LAB, BALTIMORE, MD 21218 USA	Johns Hopkins University			Hsu, John Tsu-An/C-1199-2010; Betenbaugh, Michael J./A-3252-2010	Betenbaugh, Michael J./0000-0002-6336-4659				BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CAI H, 1994, J BIOL CHEM, V269, P24550; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; DAVIS TR, 1993, IN VITRO CELL DEV-AN, V29A, P842, DOI 10.1007/BF02631361; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; Hsu TA, 1997, BIOTECHNOL PROGR, V13, P96, DOI 10.1021/bp960088d; HSU TA, 1994, PROTEIN EXPRES PURIF, V5, P595, DOI 10.1006/prep.1994.1082; Hsu TA, 1996, PROTEIN EXPRES PURIF, V7, P281, DOI 10.1006/prep.1996.0040; HSU TA, 1994, ANN NY ACAD SCI, V721, P208, DOI 10.1111/j.1749-6632.1994.tb47393.x; Humphreys DP, 1996, FEBS LETT, V380, P194, DOI 10.1016/0014-5793(96)00028-2; JARVIS DL, 1993, J BIOL CHEM, V268, P16754; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILIE H, 1994, J BIOL CHEM, V269, P14290; LINDSAY DA, 1993, VIROLOGY, V193, P367, DOI 10.1006/viro.1993.1133; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; Luckow Verne A., 1995, P51; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1991, J BIOL CHEM, V266, P19645; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Ostermeier M, 1996, J BIOL CHEM, V271, P10616, DOI 10.1074/jbc.271.18.10616; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; PUTLITZ JZ, 1990, BIO-TECHNOL, V8, P651, DOI 10.1038/nbt0790-651; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; ROTH RA, 1981, BIOCHEMISTRY-US, V20, P6594, DOI 10.1021/bi00526a012; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; SAWYER JT, 1994, J BIOL CHEM, V269, P22440; SCHULTZ LD, 1994, ANN NY ACAD SCI, V721, P148, DOI 10.1111/j.1749-6632.1994.tb47387.x; Shuler Michael L., 1995, P1; SUMMERS MD, 1987, B TEXAS A M U COLLEG, V1555; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, J BIOL CHEM, V267, P7211; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WALKER KW, 1995, BIOCHEMISTRY-US, V34, P13642, DOI 10.1021/bi00041a045; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; Wittrup K. Dane, 1995, Current Opinion in Biotechnology, V6, P203, DOI 10.1016/0958-1669(95)80033-6	50	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22556	22563		10.1074/jbc.272.36.22556	http://dx.doi.org/10.1074/jbc.272.36.22556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278409	hybrid			2022-12-27	WOS:A1997XV49200029
J	Bundgaard, JR; Vuust, J; Rehfeld, JF				Bundgaard, JR; Vuust, J; Rehfeld, JF			New consensus features for tyrosine O-sulfation determined by mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSYLPROTEIN SULFOTRANSFERASE; HUMAN PROGASTRIN; BALANCE-SHEET; P-SELECTIN; GASTRIN; PEPTIDES; CHOLECYSTOKININ; SEQUENCE; EXPRESSION; PROTEINS	Tyrosine sulfation is an ubiquitous modification of proteins synthesized along the secretory pathway, It enhances protein-protein interactions and may be necessary for the bioactivity of secreted proteins and peptides. To predict tyrosine sulfation, a consensus has been proposed based on sequence comparisons of known substrates and on in vitro studies using synthetic peptides, This consensus predicts the presence of acidic residues on the amino-terminal side of the target tyrosine as the key feature, Using site-directed mutagenesis, we have examined the role of residues neighboring the sulfation site of an intact protein, human progastrin, in vivo. The results show that the charge of the residue in the amino-terminal position (-1) of the tyrosine is critical and can be neutral or acidic, whereas a basic residue abolishes sulfation, In addition, the degree of sulfation is influenced by the residues in positions -2 and -3, Hence, surprisingly a basic residue in position -2 enhances sulfation, Our data suggest a considerably broader range of substrates for the tyrosylprotein sulfotransferase than hitherto assumed and that the tyrosylprotein sulfotransferase is cell-specifically expressed.	STATENS SERUM INST,MOL BIOL LAB,DK-2300 COPENHAGEN,DENMARK	Statens Serum Institut	Bundgaard, JR (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT CLIN BIOCHEM,KB3014,BLEGDAMSVEJ 9,DK-2100 COPENHAGEN,DENMARK.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ANDERSEN BN, 1985, REGUL PEPTIDES, V10, P329, DOI 10.1016/0167-0115(85)90045-X; ANDERSEN BN, 1983, CLIN CHIM ACTA, V127, P29, DOI 10.1016/0009-8981(83)90072-4; ANDERSEN BN, 1985, GEN COMP ENDOCR, V58, P44, DOI 10.1016/0016-6480(85)90134-0; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAEUERLE PA, 1985, J BIOL CHEM, V260, P6434; BALDWIN GS, 1983, NATURE, V301, P435, DOI 10.1038/301435a0; BARDRAM L, 1989, SCAND J CLIN LAB INV, V49, P173, DOI 10.3109/00365518909105418; BARDRAM L, 1990, P NATL ACAD SCI USA, V87, P298, DOI 10.1073/pnas.87.1.298; BUNDGAARD JR, 1995, EMBO J, V14, P3073, DOI 10.1002/j.1460-2075.1995.tb07310.x; Bundgaard JR, 1996, DNA CELL BIOL, V15, P147, DOI 10.1089/dna.1996.15.147; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FRIISHANSEN L, 1994, FEBS LETT, V343, P115, DOI 10.1016/0014-5793(94)80301-3; GREGORY RA, 1966, NATURE, V209, P583, DOI 10.1038/209583a0; HILLE A, 1990, EUR J BIOCHEM, V188, P577, DOI 10.1111/j.1432-1033.1990.tb15438.x; HILLE A, 1990, EUR J BIOCHEM, V188, P587, DOI 10.1111/j.1432-1033.1990.tb15439.x; HILSTED L, 1986, ANAL BIOCHEM, V152, P119, DOI 10.1016/0003-2697(86)90129-6; HOFSTEENGE J, 1990, EUR J BIOCHEM, V188, P55, DOI 10.1111/j.1432-1033.1990.tb15370.x; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JOHNSEN AH, 1990, J BIOL CHEM, V265, P3054; JOHNSEN AH, 1992, EUR J BIOCHEM, V207, P419, DOI 10.1111/j.1432-1033.1992.tb17065.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEYTE A, 1991, J BIOL CHEM, V266, P740; LIN WH, 1992, J BIOL CHEM, V267, P2876; MONSTEIN HJ, 1993, FEBS LETT, V331, P60, DOI 10.1016/0014-5793(93)80297-8; MUTT V, 1980, GASTROINTESTINAL HOR, P169; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NIEHRS C, 1990, J BIOL CHEM, V265, P8525; NIEHRS C, 1994, CHEM-BIOL INTERACT, V92, P257, DOI 10.1016/0009-2797(94)90068-X; PAUWELS S, 1989, BIOCHIM BIOPHYS ACTA, V996, P82, DOI 10.1016/0167-4838(89)90098-8; PAUWELS S, 1987, GASTROENTEROLOGY, V92, P1220, DOI 10.1016/S0016-5085(87)91081-X; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; REHFELD JF, 1981, J BIOL CHEM, V256, P426; REHFELD JF, 1978, NATURE, V271, P771, DOI 10.1038/271771a0; REHFELD JF, 1995, EMBO J, V14, P389, DOI 10.1002/j.1460-2075.1995.tb07013.x; REHFELD JF, 1978, J BIOL CHEM, V253, P4016; RENSDOMIANO S, 1989, MOL PHARMACOL, V36, P647; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; UNSWORTH CD, 1982, NATURE, V295, P519, DOI 10.1038/295519a0; VANSOLINGE WW, 1990, CLIN CHIM ACTA, V192, P35, DOI 10.1016/0009-8981(90)90269-X; WALSH JH, 1987, PHYSL GASTROINTESTIN, P181; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677	45	95	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21700	21705		10.1074/jbc.272.35.21700	http://dx.doi.org/10.1074/jbc.272.35.21700			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268297	hybrid			2022-12-27	WOS:A1997XT85000009
J	Jagiello, I; Beullens, M; Vulsteke, V; Wera, S; Sohlberg, B; Stalmans, W; vonGabain, A; Bollen, M				Jagiello, I; Beullens, M; Vulsteke, V; Wera, S; Sohlberg, B; Stalmans, W; vonGabain, A; Bollen, M			NIPP-1, a nuclear inhibitory subunit of protein phosphatase-1, has RNA-binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-A; PHOSPHORYLATION; POLYPEPTIDES; MECHANISM	NIPP-1 is a nuclear inhibitory subunit of protein phosphatase-1 with structural similarities to some proteins involved in RNA processing, We report here that baculovirus-expressed recombinant NIPP-1 displays RNA-binding properties, as revealed by North-Western analysis, by UV-mediated cross-linking, by RNA mobility-shift assays, and by chromatography on poly(U)- Sepharose, NIPP-1 preferentially bound to U-rich sequences, including RNA-destabilizing AUUUA motifs. NIPP-1 also associated with single-stranded DNA, but had no affinity for double-stranded DNA. The binding of NIPP-1 to RNA was blocked by antibodies directed against the COOH terminus of NIPP-1, but was not affected by prior phosphorylation of NIPP-1 with protein kinase A or casein kinase-2, which decreases the affinity of NIPP-1 for protein phosphatase-1. The catalytic sub unit of protein phosphatase-1 did not bind to poly(U)Sepharose, but it bound very tightly after complexation with NIPP-1. These data are in agreement with a function of NIPP-1 in targeting protein phosphatase-1 to RNA.	CATHOLIC UNIV LEUVEN,AFDELING BIOCHEM,FAC GENEESKUNDE,B-3000 LOUVAIN,BELGIUM; UNIV VIENNA,INST MICROBIOL & GENET,VIENNA BIOCTR,A-1030 VIENNA,AUSTRIA	KU Leuven; University of Vienna; Vienna Biocenter (VBC)								ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARDINALI B, 1994, FEBS LETT, V352, P276, DOI 10.1016/0014-5793(94)00973-2; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; FAN XC, 1996, RNA 96 1 ANN M RNA S, P208; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; SHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; VAN EYNDE A, 1994, BIOCHEM J, V297, P447, DOI 10.1042/bj2970447; WANG M, 1994, P NATL ACAD SCI USA, V91, P10591, DOI 10.1073/pnas.91.22.10591; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322; WILL CL, 1995, NUCLEIC ACIDS MOL BI, V9, P342	22	35	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22067	22071		10.1074/jbc.272.35.22067	http://dx.doi.org/10.1074/jbc.272.35.22067			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268347	hybrid			2022-12-27	WOS:A1997XT85000059
J	Li, W; Dennis, CA; Moore, GR; James, R; Kleanthous, C				Li, W; Dennis, CA; Moore, GR; James, R; Kleanthous, C			Protein-protein interaction specificity of Im9 for the endonuclease toxin colicin E9 defined by homologue-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNITY PROTEIN; ESCHERICHIA-COLI; RECEPTOR; DNASE; BINDING; SITE; IDENTIFICATION; ASSIGNMENTS; COMPLEXES; COGNATE	The colicin DNase-specific immunity proteins interact with the endonuclease domain of the bacterial toxin colicin E9 with dissociation constants that span the millimolar to femtomolar affinity range, Among the noncognate interactions Im2 shows the strongest binding toward the E9 DNase domain with a K-d of 10(-8) M, 6 orders of magnitude weaker than that of the cognate immunity protein Im9, Based on a NMR structure of Im9 that shows it to be a 4-helix protein, we have conducted a mutagenic scan in which elements of Im9 secondary structure were substituted into Im2 to precisely delineate regions that define specificity, Eleven chimeras were constructed, and their biological cross-reactivity toward colicins E2 and E9 was evaluated, From this set of mutants seven proteins were purified, and the K-d for their interaction with the E9 DNase domain was measured by a combination of stopped-flow fluorescence and subunit exchange kinetics. Our results show that immunity specificity is dominated by residues on helix II, accounting for 5 orders of magnitude binding specificity relative to Im2, and that packing interactions of helix II with its neighbor helix I and the loop connecting helix III with helix IV play minor roles, The conformational stability of these chimeric proteins was also determined, Proteins displaying an Im9 phenotype were all more stable than the parent Im2 protein, and surprisingly some chimeras were significantly more stable than either Im2 or Im9.	UNIV E ANGLIA, SCH BIOL SCI, NORWICH NR4 7TJ, NORFOLK, ENGLAND; ZENECA PHARMACEUT, PROT STRUCT GRP, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND; UNIV E ANGLIA, SCH CHEM SCI, NORWICH NR4 7TJ, NORFOLK, ENGLAND	University of East Anglia; University of East Anglia			James, Richard/B-2252-2009	James, Richard/0000-0002-5086-788X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BETTLER B, 1992, J BIOL CHEM, V267, P185; BOWMAN CM, 1971, P NATL ACAD SCI USA, V68, P964, DOI 10.1073/pnas.68.5.964; Chak KF, 1996, P NATL ACAD SCI USA, V93, P6437, DOI 10.1073/pnas.93.13.6437; CHAK KF, 1991, J GEN MICROBIOL, V137, P91, DOI 10.1099/00221287-137-1-91; COOPER PC, 1984, J GEN MICROBIOL, V130, P209; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DIMASI DR, 1973, J BACTERIOL, V115, P506, DOI 10.1128/JB.115.2.506-513.1973; EATON T, 1989, NUCLEIC ACIDS RES, V17, P1761, DOI 10.1093/nar/17.4.1761; Elkins P, 1997, STRUCTURE, V5, P443, DOI 10.1016/S0969-2126(97)00200-1; GarinotSchneider C, 1996, J MOL BIOL, V260, P731, DOI 10.1006/jmbi.1996.0433; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; JANIN J, 1990, J BIOL CHEM, V265, P16027; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LAU CK, 1992, NATO ASI SERIES H, P353; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; Luisi B., 1995, DNA PROTEIN STRUCTUR, P1; OSBORNE MJ, 1994, BIOCHEMISTRY-US, V33, P12347, DOI 10.1021/bi00207a001; Osborne MJ, 1997, BIOCHEM J, V323, P823, DOI 10.1042/bj3230823; Osborne MJ, 1996, BIOCHEMISTRY-US, V35, P9505, DOI 10.1021/bi960401k; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHALLER K, 1976, P NATL ACAD SCI USA, V73, P3989, DOI 10.1073/pnas.73.11.3989; SENIOR BW, 1971, P NATL ACAD SCI USA, V68, P959, DOI 10.1073/pnas.68.5.959; TOBA M, 1988, J BACTERIOL, V170, P3237, DOI 10.1128/jb.170.7.3237-3242.1988; WALLIS R, 1992, EUR J BIOCHEM, V210, P923, DOI 10.1111/j.1432-1033.1992.tb17496.x; WALLIS R, 1995, BIOCHEMISTRY-US, V34, P13751, DOI 10.1021/bi00042a005; WALLIS R, 1992, EUR J BIOCHEM, V207, P687, DOI 10.1111/j.1432-1033.1992.tb17096.x; WALLIS R, 1995, BIOCHEMISTRY-US, V34, P13743, DOI 10.1021/bi00042a004; WATSON RJ, 1985, PLASMID, V13, P205, DOI 10.1016/0147-619X(85)90044-7	29	38	38	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22253	22258		10.1074/jbc.272.35.22253	http://dx.doi.org/10.1074/jbc.272.35.22253			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268373	hybrid			2022-12-27	WOS:A1997XT85000085
J	Pena, TL; Rane, SG				Pena, TL; Rane, SG			The small conductance calcium-activated potassium channel regulates ion channel expression in C3H10T1/2 cells ectopically expressing the muscle regulatory factor MRF4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CURRENT; ACETYLCHOLINE-RECEPTORS; MOUSE FIBROBLASTS; DIFFERENTIATION; TRANSFORMATION; LYMPHOCYTES; INDUCTION; LINE	We investigated small conductance (SK) potassium channel-mediated regulation of muscle-specific, ion channel functional expression in the C3H10T1/2-MRF4 cell model system, a stable fibroblast line ectopically overexpressing the myogenic regulatory transcription factor, MRF4. Mitogenic stimulation of C3H10T1/2-MRF4 cells with basic fibroblast growth factor negatively regulates MRF4 transcriptional activity, inhibiting myogenesis. Using patch clamp techniques we found that mitogenic stimulation of C3H10T1/2-MRF4 cells also up-regulated SK. SK is a charybdotoxin-sensitive, apamin-insensitive channel that exerts positive proliferative control in fibroblasts. Mitogen withdrawal, which removes negative regulation of MRF4 thus initiating myogenesis, also eliminated SK channel currents, coincident both with induction of acetylcholine receptor channels, and up-regulation of muscle inward rectifier potassium channels. Addition of the SK channel blocker charybdotoxin to growth factor-containing culture medium overcame basic fibroblast growth factor-induced negative regulation of MRF4, as evidenced by induction of inward rectifier potassium and acetylcholine receptor channel expression identical to that observed in mitogen-withdrawn cells. Thus, the SK channel can govern electrophysiological phenotype in C3H10T1/2-MRF4 cells, consistent with an ability of SK to affect MRF4-dependent transcriptional activity. SK appears to be a pivotal signaling component for growth factor regulation of both cell proliferation and differentiation.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [R01GM43462] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043462] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAMACHO P, 1993, J NEUROSCI, V13, P605; DAY ML, 1993, NATURE, V365, P560, DOI 10.1038/365560a0; DRAHEIM HJ, 1995, BBA-MOL CELL RES, V1269, P57, DOI 10.1016/0167-4889(95)00106-3; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; GONOI T, 1991, PFLUG ARCH EUR J PHY, V419, P657, DOI 10.1007/BF00370311; HAMANN M, 1994, J PHYSIOL-LONDON, V475, P305, DOI 10.1113/jphysiol.1994.sp020071; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; HUANG CF, 1994, NEURON, V13, P167, DOI 10.1016/0896-6273(94)90467-7; HUANG Y, 1993, J PHYSIOL-LONDON, V461, P601, DOI 10.1113/jphysiol.1993.sp019531; HUANG Y, 1994, J BIOL CHEM, V269, P31183; KOPTA C, 1994, J NEUROSCI, V14, P3922; Krause RM, 1995, J PHYSIOL-LONDON, V489, P779, DOI 10.1113/jphysiol.1995.sp021091; KUBO Y, 1991, J PHYSIOL-LONDON, V442, P711, DOI 10.1113/jphysiol.1991.sp018816; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; RANE SG, 1991, AM J PHYSIOL, V260, pC104, DOI 10.1152/ajpcell.1991.260.1.C104; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SU CT, 1995, FEBS LETT, V366, P131, DOI 10.1016/0014-5793(95)00496-V; TRAUTMANN A, 1986, PFLUG ARCH EUR J PHY, V406, P163, DOI 10.1007/BF00586678; WANG Z, 1993, AM J PHYSIOL, V265, pC1239, DOI 10.1152/ajpcell.1993.265.5.C1239; WIELAND SJ, 1995, AM J PHYSIOL-CELL PH, V268, pC490, DOI 10.1152/ajpcell.1995.268.2.C490; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	26	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21909	21916		10.1074/jbc.272.35.21909	http://dx.doi.org/10.1074/jbc.272.35.21909			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268324	hybrid			2022-12-27	WOS:A1997XT85000036
J	Raibekas, AA; Massey, V				Raibekas, AA; Massey, V			Glycerol-assisted restorative adjustment of flavoenzyme conformation perturbed by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDASE; FLAVIN BINDING-SITES; PIG-KIDNEY; ESCHERICHIA-COLI; PROTEIN STABILIZATION; GEL-ELECTROPHORESIS; FLAVOPROTEINS; PURIFICATION; 8-MERCAPTOFLAVINS; TYROSINE-224	The replacement of histidine 307 with leucine in pig kidney D amino acid oxidase perturbs its active site conformation accompanied by dramatic losses in protein-flavin interactions and enzymatic activity. However, the negative effect of this mutation on the holoenzyme structure is essentially eliminated in the presence of glycerol, resulting in up to 50% activity recovery and greater than 16-fold increase in the flavin affinity. Further analysis revealed that glycerol assists in the rearrangement of the protein toward its holoenzyme-like conformation together with reduction in the solvent-accessible protein hydrophobic area as demonstrated by limited proteolysis and use of affinity and hydrophobic probes. A substantial decrease in the protein-flavin interactions was demonstrated at a low temperature, but this reversible process was completely blocked in the presence of 40% glycerol. We suggest that the perturbation of the D-amino acid oxidase active site is due to the nonpolar nature of the mutation whose negative impact on the holoenzyme structure can be overcome by glycerol-induced strengthening of protein internal hydrophobic interactions.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CURTI B, 1973, BIOCHIM BIOPHYS ACTA, V327, P266, DOI 10.1016/0005-2744(73)90409-9; Curti B., 1991, CHEM BIOCH FLAVOENZY, V3, P69; FAOTTO L, 1995, BIOTECHNOL LETT, V17, P193, DOI 10.1007/BF00127987; FARRIS FJ, 1978, J AM CHEM SOC, V100, P4469, DOI 10.1021/ja00482a026; FITZPATRICK PF, 1983, J BIOL CHEM, V258, P9700; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GHISLA S, 1986, BIOCHEM J, V239, P1; HORIIKE K, 1975, J BIOCHEM-TOKYO, V78, P57; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macheroux P, 1996, J BIOL CHEM, V271, P25850, DOI 10.1074/jbc.271.42.25850; MARCOTTE P, 1976, BIOCHEMISTRY-US, V15, P3070, DOI 10.1021/bi00659a021; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1979, J BIOL CHEM, V254, P9640; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; MIYANO M, 1991, J BIOCHEM-TOKYO, V109, P171, DOI 10.1093/oxfordjournals.jbchem.a123340; Mizutani H, 1996, J BIOCHEM-TOKYO, V120, P14; Murthy YVSN, 1996, J BIOL CHEM, V271, P19915, DOI 10.1074/jbc.271.33.19915; MURTHY YVSN, 1995, J BIOL CHEM, V270, P28586, DOI 10.1074/jbc.270.48.28586; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P2034, DOI 10.1021/bi00329a035; NAOI M, 1973, J BIOCHEM-TOKYO, V74, P1097, DOI 10.1093/oxfordjournals.jbchem.a130337; NICHOLSON BH, 1988, BIOCHEM J, V255, P907, DOI 10.1042/bj2550907; Palfey B. A., 1995, ACTIVE OXYGEN BIOCH, P37, DOI DOI 10.1007/978-94-011-0609-2_2; POLLEGIONI L, 1994, J BIOL CHEM, V269, P31666; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; Raibekas AA, 1996, P NATL ACAD SCI USA, V93, P7546, DOI 10.1073/pnas.93.15.7546; RAIBEKAS AA, 1994, BIOCHEMISTRY-US, V33, P12656, DOI 10.1021/bi00208a017; RAIBEKAS AA, 1994, BIOCHEMISTRY-US, V33, P12649, DOI 10.1021/bi00208a016; RAIBEKAS AA, 1997, FLAVINS FLAVOPROTEIN; RONCHI S, 1982, J BIOL CHEM, V257, P8824; RONCHI S, 1980, FLAVINS FLAVOPROTEIN, P511; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TARELLI GT, 1990, J BIOL CHEM, V265, P21242; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TURNER DC, 1968, BIOCHEMISTRY-US, V7, P3381, DOI 10.1021/bi00850a011; WATANABE F, 1989, BIOCHEM BIOPH RES CO, V165, P1422, DOI 10.1016/0006-291X(89)92762-9; WATANABE F, 1989, J BIOCHEM-TOKYO, V105, P1024, DOI 10.1093/oxfordjournals.jbchem.a122760	40	23	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22248	22252		10.1074/jbc.272.35.22248	http://dx.doi.org/10.1074/jbc.272.35.22248			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268372	hybrid			2022-12-27	WOS:A1997XT85000084
J	Han, JH; Hajjar, DP; Febbraio, M; Nicholson, AC				Han, JH; Hajjar, DP; Febbraio, M; Nicholson, AC			Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; VASCULAR ENDOTHELIUM; MEMBRANE-PROTEIN; HUMAN-MONOCYTES; BINDING-SITE; OXIDIZED LDL; FATTY-ACIDS; SR-BI	The uptake of oxidized low density lipoprotein (OxLDL) by macrophages is a key event implicated in the initiation and development of atherosclerotic lesions, Two macrophage surface receptors, CD36 (a class B scavenger receptor) and the macrophage scavenger receptor (a class A scavenger receptor), have been identified as the major receptors that bind and internalize OxLDL. Expression of CD36 in monocyte/macrophages in tissue culture is dependent both on the differentiation state as well as exposure to soluble mediators (cytokines and growth factors), The regulatory mechanisms of this receptor in vivo are undetermined as is the role of lipoproteins themselves in modulating CD36 expression. We studied the effect of lipoproteins, native LDL and modified LDL (acetylated LDL (AcLDL) and OxLDL) on the expression of CD36 in J774 cells, a murine macrophage cell line, Exposure to lipoproteins resulted in a marked induction of CD36 mRNA expression (4-8-fold), Time course studies showed that maximum induction was observed 2 h after treatment with AcLDL and at 4 h with LDL and OxLDL, Increased expression of CD36 mRNA persisted for 24 h with each treatment group, Induction of CD36: mRNA expression was paralleled by an increase in CD36 protein as determined by Western blot with the greatest induction by OxLDL (4-fold), In the presence of actinomycin D, treatment of macrophages with LDL, AcLDL, or OxLDL did not affect. CD36 mRNA stability, implying that CD36 mRNA was transcriptionally regulated by lipoproteins. To determine the mechanism(s) by which lipoproteins increased expression of CD36 we evaluated the effects of lipoprotein components on CD36 mRNA. expression, ApoB 100 increased CD36 mRNA expression significantly, whereas phospholipid/cholesterol liposomes had. less effect, Incubation of macrophages with bovine serum albumin or HDL reduced expression of CD36 mRNA in a dose-dependent manner. Finally, to evaluate the in vivo relevance of the induction of CD36 mRNA expression by lipoproteins, peritoneal macrophages were isolated from mice following intraperitoneal injection of lipoproteins. Macrophage expression of CD36 mRNA was significantly increased by LDL, AcLDL, or OxLDL in relation to mice infused with phosphate-buffered saline, with OxLDL causing the greatest induction (8-fold). This is the first demonstration that exposure to free and esterified lipids augments functional expression of the class B scavenger receptor, CD36, These data imply that lipoproteins can further contribute to foam cell development in atherosclerosis by up-regulating a major OxLDL receptor.	CORNELL UNIV, COLL MED, DEPT PATHOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DIV HEMATOL & ONCOL, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; Cornell University					NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000085] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007423] Funding Source: NIH RePORTER; NCRR NIH HHS [K01 RR00085] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07423-17] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDALIBI A, 1993, BIOCHEM SOC T, V21, P651, DOI 10.1042/bst0210651; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; Armesilla AL, 1996, J BIOL CHEM, V271, P7781, DOI 10.1074/jbc.271.13.7781; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BOCHKOV VN, 1993, ARTERIOSCLER THROMB, V13, P1261, DOI 10.1161/01.ATV.13.9.1261; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CALVO D, 1993, J BIOL CHEM, V268, P18929; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; EDELMAN P, 1986, BLOOD, V67, P56; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FEI HH, 1993, ARTERIOSCLER THROMB, V13, P1711, DOI 10.1161/01.ATV.13.11.1711; FOGELMAN AM, 1988, J CELL SCI, P135; GENG YJ, 1994, ARTERIOSCLER THROMB, V14, P798, DOI 10.1161/01.ATV.14.5.798; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOWN AM, 1986, AM J PATHOL, V125, P191; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; HIRAI A, 1994, J CLIN INVEST, V94, P2215, DOI 10.1172/JCI117583; HOFFER MJV, 1993, BIOCHEM BIOPH RES CO, V191, P880, DOI 10.1006/bbrc.1993.1299; HUH HY, 1995, J BIOL CHEM, V270, P6267, DOI 10.1074/jbc.270.11.6267; KASHIWAGI H, 1994, BLOOD, V83, P3545; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LI YS, 1993, MOL CELL BIOCHEM, V126, P61, DOI 10.1007/BF01772208; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSIS AJ, 1993, BIOCHEM PHARMACOL, V46, P2119, DOI 10.1016/0006-2952(93)90599-R; MAZZONE T, 1989, J LIPID RES, V30, P1055; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NICHOLSON AC, 1995, LEUKOCYTE TYPING, V5, P1278; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; PHILLIPS MC, 1980, ATHEROSCLEROSIS, V36, P409, DOI 10.1016/0021-9150(80)90220-8; PIETSCH A, 1995, CELL BIOCHEM FUNCT, V13, P211, DOI 10.1002/cbf.290130312; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Ryeom SW, 1996, J CELL SCI, V109, P387; SAKAI M, 1994, J BIOL CHEM, V269, P31430; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBERG D, 1987, CIRCULATION, V76, P508, DOI 10.1161/01.CIR.76.3.508; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TERKELTAUB R, 1994, ARTERIOSCLER THROMB, V14, P47, DOI 10.1161/01.ATV.14.1.47; VEGA MA, 1991, J BIOL CHEM, V266, P16818; VIA DP, 1985, J BIOL CHEM, V260, P7379; Villanova JG, 1996, BBA-LIPID LIPID MET, V1300, P135, DOI 10.1016/0005-2760(96)00008-2; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Yesner LM, 1996, ARTERIOSCL THROM VAS, V16, P1019, DOI 10.1161/01.ATV.16.8.1019	56	215	225	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21654	21659		10.1074/jbc.272.34.21654	http://dx.doi.org/10.1074/jbc.272.34.21654			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261189	hybrid			2022-12-27	WOS:A1997XR78900099
J	Sugiura, N; Suga, T; Ozeki, Y; Mamiya, G; Takishima, K				Sugiura, N; Suga, T; Ozeki, Y; Mamiya, G; Takishima, K			The mouse extracellular signal-regulated kinase 2 gene - Gene structure and characterization of the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; REGIONAL DISTRIBUTION; BINDING-PROTEIN; MAP KINASE; TRANSCRIPTION; FAMILY; IDENTIFICATION; SPECIFICITY; SEQUENCE	ERK2 (extracellular-signal regulated kinase 2, also known as p42 mitogen-activated protein kinase) is an integral member of the mitogen-activated protein kinase cascade that is crucial for many cellular events such as proliferation and differentiation. Here, we determined the genomic organization of the Erk2 gene and characterized its promoter, The Erk2 gene spans over 60 kilobases, and the coding region is split into eight exons. In the coding region, exon-intron organization was exactly conserved between the two mouse genes for ERK2 and ERK1 except one junction shifted by one nucleotide. Primer extension and S1 nuclease analyses identified two major transcription start sites located at -219 and -223 relative to the translation start site, The 5'-flanking sequence lacked TATA box but contained a CCAAT box located approximately 60 base pairs upstream of transcription start sites, Sequencing of the 5'-flanking region also revealed potential cis acting elements for multiple transcriptional regulatory factors including Spl, zif268, Ets, CREB, and PuF sites, The promoter activity of the 5'-flanking region was examined using chloramphenicol acetyltransferase as a reporter gene, Transient transfection experiments using Chinese hamster ovary cells defined a maximal promoter activity in a 371-base pair region immediately upstream of the translation start site. Furthermore, we demonstrated, using mouse P19 embryonal carcinoma cells, that this 371-base pair sequence is likely to be sufficient to confer the transcriptional activation of the ERK2 promoter during the retinoic acid-induced differentiation of P19 cells.	NATL DEF MED COLL, DEPT BIOCHEM 1, TOKOROZAWA, SAITAMA 359, JAPAN	National Defense Medical College - Japan								AHN NG, 1991, J BIOL CHEM, V266, P4220; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BARABAN JM, 1993, J NEUROCHEM, V60, P330, DOI 10.1111/j.1471-4159.1993.tb05855.x; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAWLEY KC, 1993, J BIOL CHEM, V268, P1194; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIORE RS, 1993, J NEUROCHEM, V61, P1626, DOI 10.1111/j.1471-4159.1993.tb09796.x; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, NATURE, V245, P371; ORTIZ J, 1995, J NEUROSCI, V15, P1285; PAGES G, 1995, J BIOL CHEM, V270, P26986, DOI 10.1074/jbc.270.45.26986; PARKOFF J, 1994, MOL CELL BIOL, V14, P463; PENN RB, 1994, J BIOL CHEM, V269, P14924; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schramek H, 1996, AM J PHYSIOL-CELL PH, V270, pC40, DOI 10.1152/ajpcell.1996.270.1.C40; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; STERNBERG N, 1994, GENET ANAL-BIOMOL E, V11, P171, DOI 10.1016/1050-3862(94)90038-8; SUKHATME VP, 1992, KIDNEY INT, V41, P550, DOI 10.1038/ki.1992.79; THOMAS KL, 1993, NEUROSCIENCE, V56, P741, DOI 10.1016/0306-4522(93)90371-L; TSUKIYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1477, DOI 10.1093/nar/20.7.1477; VOSS H, 1991, J BIOL CHEM, V266, P13706; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WINSTON BW, 1995, J IMMUNOL, V155, P1525; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	53	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21575	21581		10.1074/jbc.272.34.21575	http://dx.doi.org/10.1074/jbc.272.34.21575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261178	hybrid			2022-12-27	WOS:A1997XR78900088
J	Bose, S; Seetharam, B				Bose, S; Seetharam, B			Effect of disulfide bonds of transcobalamin II receptor on its activity and basolateral targeting in human intestinal epithelial Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; GOLGI-APPARATUS; PLASMA-MEMBRANE; KIDNEY-CELLS; PROTEIN; DITHIOTHREITOL; EXPRESSION; COBALAMIN; RAT	Transcobalamin II-receptor (TC II-R) contains 10 half-cysteines, of which 8 are involved in intramolecular disulfide bonding. Reduction followed by alkylation with N-ethylmaleimide (NEM) of the 62-kDa TC II-R monomer in vitro or treatment of human intestinal epithelial Caco-2 cells with low concentrations (10(-6) nr) of NEM resulted in TC II-R exhibiting a loss of ligand binding and an increase in its apparent molecular mass by 10 kDa to 72 kDa. Domain-specific biotinylation studies using NEM-treated filter-grown cells revealed loss of TC II-R but not cation-independent mannose 6-phosphate receptor protein at the basolateral cell surface. Pulse chase labeling of NEM-treated cells with [S-35]methionine revealed that the modified 72-kDa TC II-R, like the native 62-kDa TC II-R in untreated cells, turned over rapidly with a t(1/2) of 7.5 h and was sensitive to treatment with peptide N-glycosidase F, sialidase alone, or sialidase and O-glycanase but not to treatment with endoglycosidase H. Labeled 72-kDa TC II-R, which was retained intracellularly following treatment of Caco-2 cells with methyl methanethiosulfonate, returned to the basolateral cell surface following withdrawal of cells from methyl methanethiosulfonate treatment and exposure to dithiothreitol. Based on these results, we suggest that formation and maintenance of intramolecular disulfide bonds of TC II-R is important for its acquisition of ligand binding and post-trans-Golgi trafficking to basolateral surface membranes but not for its turnover and exit from the endoplasmic reticulum or trafficking through the Golgi.	MED COLL WISCONSIN, MACC, FUND CTR, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT MED, MILWAUKEE, WI 53226 USA; VET ADM MED CTR, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)				, Santanu/0000-0002-5501-3293	PHS HHS [50052] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bose S, 1996, J BIOL CHEM, V271, P4195; BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; Bose S, 1997, J BIOL CHEM, V272, P3538, DOI 10.1074/jbc.272.6.3538; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; Bose S, 1996, J BIOL CHEM, V271, P11718, DOI 10.1074/jbc.271.20.11718; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; Dahms NM, 1996, BBA-BIOMEMBRANES, V1279, P84, DOI 10.1016/0005-2736(95)00234-0; FINKLER AE, 1967, ARCH BIOCHEM BIOPHYS, V120, P79, DOI 10.1016/0003-9861(67)90600-5; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOIVU J, 1987, J BIOL CHEM, V262, P6159; KOLAND JG, 1982, J BIOL CHEM, V257, P6023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDEMANS J, 1986, SCAND J CLIN LAB INV, V46, P223, DOI 10.3109/00365518609083663; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LOSCH A, 1995, J BIOL CHEM, V270, P11543, DOI 10.1074/jbc.270.19.11543; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MILLS A, 1988, J BIOL CHEM, V263, P13; MOXHAM CP, 1988, MOL PHARMACOL, V33, P486; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PETERS T, 1982, J BIOL CHEM, V257, P8847; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RAMANUJAM KS, 1994, ARCH BIOCHEM BIOPHYS, V315, P8, DOI 10.1006/abbi.1994.1464; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SELIGMAN PA, 1978, J BIOL CHEM, V253, P1766; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P766, DOI 10.1021/bi00675a019; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; VOORBERG J, 1991, CELL, V57, P195; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WIKSTROM L, 1992, J BIOL CHEM, V267, P5	45	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20920	20928		10.1074/jbc.272.33.20920	http://dx.doi.org/10.1074/jbc.272.33.20920			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252420	hybrid			2022-12-27	WOS:A1997XR22100090
J	Green, WN; Wanamaker, CP				Green, WN; Wanamaker, CP			The role of the cystine loop in acetylcholine receptor assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIN IMMUNOGENIC REGION; DISULFIDE BOND FORMATION; ALPHA-SUBUNIT; BINDING-SITE; FUNCTIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; ION-CHANNEL; RESIDUES; PROTEIN	Nicotinic acetylcholine receptors (AChRs) are composed of alpha,beta,gamma, and delta subunits, assembled into alpha(2) beta gamma delta pentamers, A highly conserved feature of ionotropic neurotransmitter receptors, such as AChRs, is a 15-amino acid cystine ''loop.'' We find that an intact cystine loop is necessary for complete AChR assembly, By preventing formation of the loop with 5 mM dithiothreitol, AChR subunits assemble into alpha beta gamma trimers, but the subsequent steps in assembly are blocked, When alpha subunit loop cysteines are mutated to serines, assembly is blocked at the same step as with dithiothreitol, In contrast, when beta subunit loop cysteines are mutated to serines, assembly is blocked at a later step, i,e, after assembly of alpha beta gamma delta tetramers and before the addition of the second alpha subunit, After formation of the cystine loop, the alpha subunit undergoes a conformational change, which buries the loop, This conformational change is concurrent with the step in assembly blocked by removal of the disulfide bond of the cystine loop, i.e. after assembly of alpha beta gamma trimers and before the addition of the delta subunit, The data indicate that the alpha subunit conformational change involving the cystine loop is key to a series of folding events that allow the addition of unassembled subunits.			Green, WN (corresponding author), UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS033826] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS33826-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARCHAN D, 1992, P NATL ACAD SCI USA, V89, P7717, DOI 10.1073/pnas.89.16.7717; BARKAS T, 1988, J BIOL CHEM, V263, P5916; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CHATURVEDI V, 1992, BIOCHEMISTRY-US, V31, P1370, DOI 10.1021/bi00120a012; CLAUDIO T, 1977, ARCH BIOCHEM BIOPHYS, V181, P484, DOI 10.1016/0003-9861(77)90254-5; CLAUDIO T, 1987, SCIENCE, V238, P1688, DOI 10.1126/science.3686008; CRIADO M, 1986, BIOCHEMISTRY-US, V25, P2839, DOI 10.1021/bi00358a015; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; Fu DX, 1996, J BIOL CHEM, V271, P31479, DOI 10.1074/jbc.271.49.31479; Gelman MS, 1996, J BIOL CHEM, V271, P10709, DOI 10.1074/jbc.271.18.10709; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KELLARIS KV, 1989, BIOCHEMISTRY-US, V28, P3469, DOI 10.1021/bi00434a048; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; PAULSON HL, 1990, J CELL BIOL, V110, P1705, DOI 10.1083/jcb.110.5.1705; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SEGUELA P, 1993, J NEUROSCI, V13, P596; SUMIKAWA K, 1992, J BIOL CHEM, V267, P6286; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TREININ M, 1995, NEURON, V14, P871, DOI 10.1016/0896-6273(95)90231-7; TZARTOS SJ, 1980, P NATL ACAD SCI-BIOL, V77, P755, DOI 10.1073/pnas.77.2.755; TZARTOS SJ, 1988, P NATL ACAD SCI USA, V85, P2899, DOI 10.1073/pnas.85.9.2899	40	68	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20945	20953		10.1074/jbc.272.33.20945	http://dx.doi.org/10.1074/jbc.272.33.20945			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252423	hybrid			2022-12-27	WOS:A1997XR22100093
J	Kennedy, HJ; Viollet, B; Rafiq, I; Kahn, A; Rutter, GA				Kennedy, HJ; Viollet, B; Rafiq, I; Kahn, A; Rutter, GA			Upstream stimulatory factor-2 (USF2) activity is required for glucose stimulation of L-pyruvate kinase promoter activity in single living islet beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; METABOLIC-REGULATION; TRANSCRIPTION; PROTEINS; INSULIN; DNA; LUCIFERASE; BINDING; TISSUE	Elevated glucose concentrations stimulate L-pyruvate kinase (L-PK) gene transcription in liver and islet beta-cells, A glucose response element termed the L4 box (two noncanonical E-boxes located -165 and -154 base pairs upstream of the transcriptional start point) has previously been defined within the proximal promoter region of the gene, However, the identity of the trans acting factor(s) which binds to this site remains unclear, We have used photon counting digital imaging of firefly luciferase activity to monitor promoter activity continuously in single living islet beta and derived INS-1 cells, and to analyze the molecular basis of the regulation by glucose, L-PK promoter activity, normalized to cytomegalovirus promoter activity using the distinct Renilla reniformis luciferase, was greater than or equal to 6-fold higher in cells cultured at 16 mM glucose or above compared with cells cultured at 3 mM glucose, Microinjection of antibodies against the ubiquitous transcription factor USF2 inhibited L-PK promoter activity in beta- and INS-1 cells incubated at 30 mm glucose by 71-87%. Anti-USF2 antibodies had a much smaller effect on promoter activity in INS-1 cells cultured at 3 mM glucose, and on the activity of a modified promoter construct lacking an L4 box, These data support the view that glucose enhances L-PK gene transcription in beta-cells by modifying the transactivational capacity of USF2 bound to the upstream L4 box.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV PARIS 05,U129 INSERM,INST COCHIN GENET MOL,F-75014 PARIS,FRANCE	University of Bristol; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Viollet, Benoit/N-2397-2019; Viollet, Benoit/O-6927-2017	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Rutter, Guy/0000-0001-6360-0343	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COGNET M, 1991, J BIOL CHEM, V266, P7368; CUIF MH, 1993, J BIOL CHEM, V268, P13769; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; LAKE SP, 1987, TRANSPLANTATION, V43, P805, DOI 10.1097/00007890-198743060-00006; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Luo X, 1996, MOL CELL BIOL, V16, P1367; MARIE S, 1993, J BIOL CHEM, V268, P23881; MATTHEWS JC, 1977, BIOCHEMISTRY-US, V16, P85, DOI 10.1021/bi00620a014; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; RUTTER GA, 1997, IN PRESS IMAGING LIV; Sambrook J., 2002, MOL CLONING LAB MANU; SEKINE N, 1994, J BIOL CHEM, V269, P4895; Sherf BA, 1994, PROMEGA NOTES, V49, P14; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405	30	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20636	20640		10.1074/jbc.272.33.20636	http://dx.doi.org/10.1074/jbc.272.33.20636			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252379	hybrid			2022-12-27	WOS:A1997XR22100049
J	Leal, SM; Liu, QJ; Huang, SS; Huang, JS				Leal, SM; Liu, QJ; Huang, SS; Huang, JS			The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TGF-BETA; IGF-I; FIBROBLASTS; INHIBITION; RESPONSIVENESS; EXPRESSION; MECHANISM	Insulin-like growth factor-binding protein 3 (IGFBP-3) has been shown to inhibit cell growth by IGF-dependent and -independent mechanisms, The putative cell-surface IGFBP-3 receptor that mediates the IGF-independent growth inhibition has not been identified, Here we show that recombinant human IGFBP-3 inhibits I-125-transforming growth factor (TGF)-beta(1) binding to the type V TGF-beta receptor (M-r 400,000) in mink lung epithelial cells, We also demonstrate that the similar to 400-kDa I-125-IGFBP-3 affinity-labeled putative IGFBP-3 receptor is immunoprecipitated by specific antiserum to the type V TGF-beta receptor, The I-125-IGFBP-3 affinity labeling of the putative receptor and IGFBP-3-induced growth inhibition as measured by DNA synthesis in these cells is blocked by a TGF-beta(1) peptide antagonist, The I-125-IGFBP-3 affinity-labeled putative receptor can only be detected in cells expressing the type V TGF-beta receptor, but not in cells lacking the type V TGF-beta receptor, These results indicate that the type V TGF-beta receptor is the putative IGFBP-3 receptor and that IGFBP-3 is a functional ligand for the type V TGF-beta receptor.	ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,ST LOUIS,MO 63104	Saint Louis University					NCI NIH HHS [CA 38808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CONOVER CA, 1991, J CLIN INVEST, V88, P1354, DOI 10.1172/JCI115441; DELBE J, 1991, BIOCHEM BIOPH RES CO, V179, P495, DOI 10.1016/0006-291X(91)91398-V; Gucev ZS, 1996, CANCER RES, V56, P1545; HODGKINSON S, 1995, J ENDOCRINOL, V145, pR2; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIU L, 1992, J CELL PHYSIOL, V153, P15, DOI 10.1002/jcp.1041530104; LIU Q, 1997, IN PRESS J BIOL CHEM, V272; LIU QJ, 1994, J BIOL CHEM, V269, P9221; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; OGRADY P, 1992, J BIOL CHEM, V267, P21033; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, V1, P419; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	30	214	224	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20572	20576		10.1074/jbc.272.33.20572	http://dx.doi.org/10.1074/jbc.272.33.20572			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252371	hybrid			2022-12-27	WOS:A1997XR22100041
J	Li, CJ; Englund, PT				Li, CJ; Englund, PT			A mitochondrial DNA primase from the trypanosomatid Crithidia fasciculata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETOPLAST DNA; REPLICATION; MINICIRCLES; TOPOISOMERASE; LOCALIZATION; PURIFICATION; POLYMERASE; EVOLUTION; SITES	We have purified to near homogeneity a DNA primase from a mitochondrial fraction of the trypanosomatid Crithidia fasciculata. The enzyme is a single polypeptide chain of 28 kDa. Using a poly(dT) template and ATP as a substrate, the enzyme makes oligonucleotides of which the vast majority are about 10 nucleotides in size or smaller. With a single-stranded M13 DNA template and the four rNTPs as substrates, the enzyme makes heterogeneous oligonucleotides in the same size range. These oligonucleotides efficiently prime the synthesis of DNA by the Klenow DNA polymerase. Immunolocalization with antibodies against the purified enzyme confirms that the primase is mitochondrial. Furthermore, the enzyme localizes to specific regions of the cell's single mitochondrion, above and below the condensed kinetoplast DNA. The primase does not co-localize with the mitochondrial topoisomerase II and DNA polymerase beta, both of which are associated with two protein complexes positioned on opposite sides of the kinetoplast disc. These localization studies have significant implications for the mechanism of kinetoplast DNA replication.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University			Li, Cong-jun/J-8572-2014	Li, Cong-jun/0000-0003-1389-9820	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027608, R01GM027608] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27608] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		EFFRON PN, 1993, MOL BIOCHEM PARASIT, V59, P191, DOI 10.1016/0166-6851(93)90217-L; ENGMAN DM, 1989, MOL CELL BIOL, V9, P5163, DOI 10.1128/MCB.9.11.5163; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; HAJDUK SL, 1993, FASEB J, V7, P54, DOI 10.1096/fasebj.7.1.8422975; Harlow E, 1988, ANTIBODIES LAB MANUA, P418; KITCHIN PA, 1985, J BIOL CHEM, V260, P3844; LI C, 1995, NUCLEIC ACIDS RES, V23, P4426, DOI 10.1093/nar/23.21.4426; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; MELENDY T, 1987, MOL BIOCHEM PARASIT, V24, P215, DOI 10.1016/0166-6851(87)90108-3; Mendelman LV, 1995, METHOD ENZYMOL, V262, P405; PEREZMORGA DL, 1993, CELL, V74, P703, DOI 10.1016/0092-8674(93)90517-T; PODUST VN, 1991, FEBS LETT, V280, P281, DOI 10.1016/0014-5793(91)80312-Q; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; SHLOMAI J, 1994, PARASITOL TODAY, V10, P341, DOI 10.1016/0169-4758(94)90244-5; SIMPSON L, 1994, SCIENCE, V264, P1870, DOI 10.1126/science.8009214; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; STUART K, 1992, INT REV CYTOL, V141, P65, DOI 10.1016/S0074-7696(08)62063-X; TORRI AF, 1992, J BIOL CHEM, V267, P4786; TORRI AF, 1994, J BIOL CHEM, V269, P8165; Xu CW, 1996, MOL CELL BIOL, V16, P564	21	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20787	20792		10.1074/jbc.272.33.20787	http://dx.doi.org/10.1074/jbc.272.33.20787			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252402	hybrid			2022-12-27	WOS:A1997XR22100072
J	Tobin, AB; Totty, NF; Sterlin, AE; Nahorski, SR				Tobin, AB; Totty, NF; Sterlin, AE; Nahorski, SR			Stimulus-dependent phosphorylation of G-protein-coupled receptors by casein kinase 1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PURIFICATION; EXPRESSION; GRK5; IMMUNOPRECIPITATION; DESENSITIZATION; ACTIVATION; SUBUNITS; CLONING; MEMBER	We have previously demonstrated that the phospholipase C-coupled m3-muscarinic receptor is phosphorylated in an agonist sensitive manner by a protein kinase of similar to 40 kDa purified from porcine cerebellum (Tobin, A. B., Keys, B,, and Nahorski, S. R, (1996) J, Biol Chem. 271, 3907-3916), This kinase, called muscarinic receptor kinase (MRK), is distinct from second messenger-regulated protein kinases and from beta-adrenergic receptor kinase and other members of the G-protein-coupled re ceptor kinase family, In the present study we propose that MRK is casein kinase 1 alpha (CK1 alpha) based on the following evidence: 1) the amino acid sequence from two proteolytic peptide fragments derived from purified MRK corresponded exactly to sequences within CK1 alpha. 2) Casein kinase activity co-eluted with MRK activity from the final two chromatography steps in the purification of porcine brain MRK. 3) Recombinant CK1 alpha expressed in Sf9 cells is able to phosphorylate both casein and the bacterial fusion protein, Ex-m3, that contains a portion of the third intracellular loop of the m3-muscarinic receptor downstream of glutathione S-transferase, 4) Partially purified CK1 alpha increased the level of muscarinic receptor phosphorylation in an agonist-sensitive manner when reconstituted with membranes from Chinese hamster ovary-m3 cells expressing the human recombinant m3-muscarinic receptor, 5) Partially-purified CK1 alpha phosphorylated rhodopsin, contained in urea treated bovine rod outer segment membranes, and the extent of phosphorylation was increased in the presence of light, These data demonstrate that the kinase previously called MRK is CK1 alpha, and that CK1 alpha offers an alternative protein kinase pathway from that of the G-protein coupled receptor kinase family for the stimulus-dependent phosphorylation of the m3-muscarinic receptor, rhodopsin, and possibly other G-protein-coupled receptors.	UCL, LUDWIG INST CANC RES, SCH MED, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School	Tobin, AB (corresponding author), UNIV LEICESTER, DEPT CELL PHYSIOL & PHARMACOL, UNIV RD, LEICESTER LE1 9HN, LEICS, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Batty IH, 1996, BIOCHEM J, V317, P347, DOI 10.1042/bj3170347; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; Diviani D, 1996, J BIOL CHEM, V271, P5049; FISHER SK, 1994, NEUROCHEM RES, V19, P549, DOI 10.1007/BF00971329; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Haga K, 1997, BIOCHEMISTRY-US, V36, P1315, DOI 10.1021/bi961613k; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; JENKINSON S, 1994, MOL PHARMACOL, V46, P1138; KONG GH, 1994, J BIOL CHEM, V269, P13084; KOREH K, 1986, J BIOL CHEM, V261, P88; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; MILNE DM, 1992, ONCOGENE, V7, P1361; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PEI G, 1995, MOL PHARMACOL, V48, P173; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; TOBIN AB, 1995, BRIT J PHARMACOL, V116, P1723, DOI 10.1111/j.1476-5381.1995.tb16654.x; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; TOBIN AB, 1993, FEBS LETT, V335, P353, DOI 10.1016/0014-5793(93)80418-T; Tobin AB, 1996, J BIOL CHEM, V271, P3907; TOBIN AB, 1996, PHOSPHOLIPASE C PATH, P65; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WAUGH MG, 1997, IN PRESS MOL PHARM; Willars GB, 1996, BIOCHEM J, V316, P905, DOI 10.1042/bj3160905; WILSON DB, 1985, J BIOL CHEM, V260, P1046; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	41	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20844	20849		10.1074/jbc.272.33.20844	http://dx.doi.org/10.1074/jbc.272.33.20844			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252410	hybrid			2022-12-27	WOS:A1997XR22100080
J	Tu, YQ; Bates, S; Pfeifer, GP				Tu, YQ; Bates, S; Pfeifer, GP			Sequence-specific and domain-specific DNA repair in xeroderma pigmentosum and Cockayne syndrome cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; C-JUN PROMOTER; TRANSCRIPTION-COUPLED REPAIR; HUMAN-SKIN-CANCER; PYRIMIDINE DIMERS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; UV PHOTOPRODUCTS; ACTIVE GENES; DHFR GENE	Xeroderma pigmentosum (XP) and Cockayne syndrome (CS) cells have specific DNA repair defects, We had previously analyzed repair rates of cyclobutane pyrimidine dimers at nucleotide resolution along the human JUN gene in normal fibroblasts and found very efficient repair of sequences near the transcription initiation site but slow repair along the promoter, To investigate sequence-specific repair rate patterns in XP and CS cells, we conducted a similar analysis in XPA XPB, XPC, XPD, and CSB fibroblasts, XPA cells were almost completely repair-deficient at all sequences analyzed, XPC cells repaired only the transcribed DNA strand beginning at position -20 relative to the transcription start site, Both XBP and XPD cells were deficient in repair of nontranscribed DNA and also very inefficiently repaired the transcribed strand including sequences near the transcription start site. CSB cells exhibited rapid repair near the transcription initiation site but were deficient in repair of sequences encountered by RNA polymerase during elongation (beginning at position +20). Since transcription of the JUN gene was UV-induced in all fibroblast strains, including CSB, the defective repair of the transcribed strand in CSB cannot be explained by a lack of transcription; rather, it appears to be a true DNA repair defect.	CITY HOPE NATL MED CTR,BECKMAN RES INST,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NIEHS NIH HHS [ES06070] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070, R37ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bohr VA, 1995, CARCINOGENESIS, V16, P2885, DOI 10.1093/carcin/16.12.2885; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Dammann R, 1997, MOL CELL BIOL, V17, P219, DOI 10.1128/MCB.17.1.219; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRAPKIN R, 1994, NATURE, V368, P709; Drouin Regen, 1996, P37; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Friedberg EC, 1996, BIOESSAYS, V18, P731, DOI 10.1002/bies.950180908; FRIEDBERG EC, 1995, DNA REPAIR; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERRLICH P, 1994, CURR OPIN CELL BIOL, V6, P425, DOI 10.1016/0955-0674(94)90036-1; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KANTOR GJ, 1981, CANCER RES, V41, P819; KUNALA S, 1992, P NATL ACAD SCI USA, V89, P11031, DOI 10.1073/pnas.89.22.11031; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAEGELI H, 1995, FASEB J, V9, P1043, DOI 10.1096/fasebj.9.11.7649403; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; ROZEK D, 1995, J CELL BIOCHEM, V57, P479, DOI 10.1002/jcb.240570313; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; SUQUET C, 1995, J BIOL CHEM, V270, P16507, DOI 10.1074/jbc.270.28.16507; SWEDER KS, 1994, J BIOL CHEM, V269, P1852; Sweder KS, 1996, NUCLEIC ACIDS RES, V24, P1540, DOI 10.1093/nar/24.8.1540; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; Tijsterman M, 1996, NUCLEIC ACIDS RES, V24, P3499, DOI 10.1093/nar/24.18.3499; TORMANEN VT, 1992, ONCOGENE, V7, P1729; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tornaletti Silvia, 1996, P199; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VONHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890; WANG ZG, 1991, J BIOL CHEM, V266, P22472; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	65	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20747	20755		10.1074/jbc.272.33.20747	http://dx.doi.org/10.1074/jbc.272.33.20747			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252397	hybrid			2022-12-27	WOS:A1997XR22100067
J	Eichhorn, E; vanderPloeg, JR; Kertesz, MA; Leisinger, T				Eichhorn, E; vanderPloeg, JR; Kertesz, MA; Leisinger, T			Characterization of alpha-ketoglutarate-dependent taurine dioxygenase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPENICILLIN N-SYNTHASE; HYDROXYLASE REACTION; BINDING-SITE; ACID; IDENTIFICATION; GENES; MONOOXYGENASE; REASSESSMENT; MUTAGENESIS; METABOLISM	The Escherichia coli tauD gene is required for the utilization of taurine (2-aminoethanesulfonic acid) as a sulfur source and is expressed only under conditions of sulfate starvation. The sequence relatedness of the TauD protein to the alpha-ketoglutarate-dependent 2,4-dichlorophenoxyacetate dioxygenase of Alcaligenes eutrophus suggested that TauD is an alpha-ketoglutarate-dependent dioxygenase catalyzing the oxygenolytic release of sulfite from taurine (van der Ploeg, J. R., Weiss, M. A., Sailer, E.. Nashimoto, H., Saito, N., Kertesz, M. A., and Leisinger, T. (1996) J. Bacteriol. 178, 5438-5446). TauD was overexpressed in E. coli to similar to 70% of the total soluble protein and purified to apparent homogeneity by a simple two-step procedure. The apparent M-r of 81,000 of the native protein and the subunit M-r of 37,400 were consistent with a homodimeric structure. The pure enzyme converted taurine to sulfite and aminoacetaldehyde, which was identified by high pressure liquid chromatography after enzymatic conversion to ethanolamine. The reaction also consumed equimolar amounts of oxygen and alpha-ketoglutarate; ferrous iron was absolutely required for activity; and ascorbate stimulated the reaction. The properties and amino acid sequence of this enzyme thus define it as a new member of the alpha-ketoglutarate-dependent dioxygenase family. The pure enzyme showed maximal activity at pH 6.9 and retained activity on storage at -20 degrees C for several weeks. Taurine (K-m = 55 mu M) was the preferred substrate, but pentane-sulfonic acid, 3-(N-morpholino)propanesulfonic acid, and 1,3-dioxo-2-isoindolineethanesulfonic acid were also desulfonated at significant rates. Among the cosubstrates tested, only alpha-ketoglutarate (K-m = 11 mu M) supported significant dioxygenase activity.	ETH ZENTRUM, SWISS FED INST TECHNOL, INST MIKROBIOL, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			KERTESZ, Michael/Q-7642-2019; Kertesz, Michael/A-6720-2011	KERTESZ, Michael/0000-0003-2112-4451; Kertesz, Michael/0000-0003-2112-4451; Eichhorn, Eric/0000-0003-2113-6305				Abbott MT, 1974, MOL MECHANISMS OXYGE, P167; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; Borovok I, 1996, BIOCHEMISTRY-US, V35, P1981, DOI 10.1021/bi951534t; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; DON RH, 1985, J BACTERIOL, V161, P85, DOI 10.1128/JB.161.1.85-90.1985; FUKUMORI F, 1993, J BIOL CHEM, V268, P24311; FUKUMORI F, 1993, J BACTERIOL, V175, P2083, DOI 10.1128/JB.175.7.2083-2086.1993; *GEN COMP GROUP IN, 1995, GCG PROGR MAN WISC P; Higgins TP, 1996, MICROBIOL-SGM, V142, P251, DOI 10.1099/13500872-142-2-251; JOHNSTON JB, 1975, A VAN LEEUW J MICROB, V41, P493, DOI 10.1007/BF02565092; MAJAMAA K, 1984, EUR J BIOCHEM, V138, P239, DOI 10.1111/j.1432-1033.1984.tb07907.x; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; MYLLYLA R, 1978, BIOCHEM BIOPH RES CO, V83, P441, DOI 10.1016/0006-291X(78)91010-0; NG SF, 1991, J BIOL CHEM, V266, P1526; ONEILL GP, 1991, J BACTERIOL, V173, P94, DOI 10.1128/jb.173.1.94-100.1991; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; PUISTOLA U, 1980, BIOCHIM BIOPHYS ACTA, V611, P40, DOI 10.1016/0005-2744(80)90040-6; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STOLL VS, 1990, METHOD ENZYMOL, V182, P24; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THYSSE GJE, 1974, A VAN LEEUW J MICROB, V40, P25, DOI 10.1007/BF00394550; URIANICKELSEN MR, 1993, J GEN MICROBIOL, V139, P203, DOI 10.1099/00221287-139-2-203; URIANICKELSEN MR, 1994, ARCH MICROBIOL, V161, P434, DOI 10.1007/s002030050078; vanderPloeg JR, 1996, J BACTERIOL, V178, P5438, DOI 10.1128/jb.178.18.5438-5446.1996; Whiting AK, 1997, J AM CHEM SOC, V119, P3413, DOI 10.1021/ja964449x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	30	204	210	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23031	23036		10.1074/jbc.272.37.23031	http://dx.doi.org/10.1074/jbc.272.37.23031			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287300	hybrid			2022-12-27	WOS:A1997XV74400011
J	Bobkova, EV; Hall, BD				Bobkova, EV; Hall, BD			Substrate specificity of the RNase activity of yeast RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATED TRANSCRIPT CLEAVAGE; ELONGATION-FACTOR; TERNARY COMPLEXES; ESCHERICHIA-COLI; NASCENT RNA; DEPENDENT TRANSCRIPTION; TERMINATION; BINDING; GENE; IDENTIFICATION	Using yeast RNA polymerase III ternary complexes stalled at various positions on the template, we have analyzed the cleavage products that are retained and released by the transcription complexes. The retained 5' products result from cleavage at uridine residues during retraction, whereas the yield of mononucleotides and dinucleotides released indicates that multiple cuts occur near the 3' end, Comparison of the cleavage patterns of uridine-containing and 5-bromouridine-containing transcripts suggests that RNA within an RNA-DNA hybrid duplex is the substrate for the 3'-5' exonuclease. During transcription of the SUP4 tRNA(Tyr) gene, RNA polymerase III produces not only full-length pre-tRNA(Tyr) but also short oligonucleotides, indicating that exonuclease digestion and transcription are concurrent processes. To explore the possibility that these oligonucleotides are released by the action of the RNA polymerase III nuclease at previously observed uridine-rich pause sites, we tested modified templates lacking the arrest sites present in the SUP4 tRNA(Tyr) gene, Comparative studies of cleavage during transcription for these templates show a direct correlation between the number of natural pause sites and the yield of 3' products made, At the natural arrest sites and the terminator, RNA polymerase III carries out multiple cleavage resynthesis steps, producing short Oligoribonucleotides with uridine residues at the 3' terminus.	UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM11895] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011895] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1983, CELL, V34, P655, DOI 10.1016/0092-8674(83)90398-7; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HAGLER J, 1993, J BIOL CHEM, V268, P2166; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JACOBS BL, 1988, J INTERFERON RES, V8, P617, DOI 10.1089/jir.1988.8.617; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KORNBERG A, 1980, DNA REPLICATION, P127; KORNBERG A, 1980, DNA REPLICATION, P232; KURJAN J, 1982, MOL CELL BIOL, V2, P1501, DOI 10.1128/MCB.2.12.1501; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SONENBERG N, 1981, CELL, V27, P563, DOI 10.1016/0092-8674(81)90398-6; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; UCHIDA T, 1970, J BIOCHEM-TOKYO, V67, P91, DOI 10.1093/oxfordjournals.jbchem.a129239; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299	31	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22832	22839		10.1074/jbc.272.36.22832	http://dx.doi.org/10.1074/jbc.272.36.22832			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278445	hybrid			2022-12-27	WOS:A1997XV49200066
J	Jenkins, CM; Genzor, CG; Fillat, MF; Waterman, MR; GomezMoreno, C				Jenkins, CM; Genzor, CG; Fillat, MF; Waterman, MR; GomezMoreno, C			Negatively charged Anabaena flavodoxin residues (Asp(144) and Glu(145)) are important for reconstitution of cytochrome P450 17 alpha-hydroxylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERREDOXIN-NADP+ REDUCTASE; LASER FLASH-PHOTOLYSIS; AMINO-ACID-RESIDUES; ELECTRON-TRANSFER; FLAVIN MONONUCLEOTIDE; CODING NUCLEOTIDE; P-450 REDUCTASE; OXIDOREDUCTASE; PURIFICATION; BINDING	Catalysis by microsomal cytochromes P450 requires the membrane-bound enzyme NADPH-cytochrome P450 reductase (P450 reductase), which transfers electrons to the P450 heme via a flavodoxin-like domain, Previously, we reported that Escherichia coli flavodoxin (Fld), a soluble electron transfer protein, directly interacts with bovine cytochrome P450 17 alpha-hydroxylase/17,20-lyase (P450c17) and donates electrons to this enzyme when reconstituted with NADPH-ferredoxin (flavodoxin) reductase (FNR) (Jenkins, C. M., and Waterman, M. R. (1994) J. Biol. Chem. 269, 27401-27408). To investigate whether flavodoxins can serve as useful models of the analogous domain in P450 reductase, we have examined the FNR-Fld system from the cyanobacterium Anabaena, Mutagenesis of two acidic Anabaena Fld residues (D144A and E145A) significantly decreased flavodoxin-supported P450c17 progesterone 17 alpha-hydroxylase activity, Specifically, D144A exhibited only 15% of the activity of wild-type Fld, whereas the adjacent mutation, E145A, caused a 40% loss in activity. P450-dependent hydrogen peroxide/superoxide production by wild-type FNR-Fld was measurably higher than that generated by FNR-D144A or FNR E145A, indicating that the mutations do not lead to P450 heme-mediated electron uncoupling, Interestingly, the D144A and E145A mutants bind with equal or even greater affinity to P450c17 than wild-type Fld, Furthermore, these mutations (D144A and E145A) actually increased cytochrome c reductase activity (35 and 100% higher than wild type), Anabaena Fld residues Asp(144) and Glu(145) align closely with rat P450 reductase residue Asp(208), which has been shown by mutagenesis to be important in electron transfer to P4502B1 but not to cytochrome c (Shen, A. L., and Rasper, C. B. (1995) J. Biol. Chem. 270, 27475-27480). Thus, these residues in flavodoxins and P450 reductase appear to have similar functions in P450 recognition and/or electron transfer, supporting the hypothesis that flavodoxins represent valid models for the FMN-binding domain of P450 reductase.	UNIV ZARAGOZA,FAC CIENCIAS,DEPT BIOQUIM & BIOL MOL & CELULAR,E-50009 ZARAGOZA,SPAIN	University of Zaragoza	Jenkins, CM (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.		Fillat, María F/G-2609-2015	Fillat Castejon, Maria Francisca/0000-0001-8644-4574	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037942, R37GM037942] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES07208, P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM37942] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURKHART BM, 1995, ACTA CRYSTALLOGR D, V51, P318, DOI 10.1107/S0907444994011716; DEISTUNG J, 1985, BIOCHEM J, V231, P743, DOI 10.1042/bj2310743; Dong MS, 1996, ARCH BIOCHEM BIOPHYS, V327, P11, DOI 10.1006/abbi.1996.0086; Estabrook RW, 1996, ARCH BIOCHEM BIOPHYS, V333, P308, DOI 10.1006/abbi.1996.0395; FILLAT MF, 1988, ARCH MICROBIOL, V150, P160, DOI 10.1007/BF00425156; FUJII K, 1974, J BIOL CHEM, V249, P6745; Genzor CG, 1996, PROTEIN SCI, V5, P1376, DOI 10.1002/pro.5560050716; GOMEZMORENO C, 1994, BIOCHEM SOC T, V22, P796, DOI 10.1042/bst0220796; GRANDORI R, 1994, PROTEIN SCI, V3, P2185, DOI 10.1002/pro.5560031204; GROSS EL, 1993, PHOTOSYNTH RES, V37, P103, DOI 10.1007/BF02187469; HAZZARD JT, 1988, BIOCHEMISTRY-US, V27, P4445, DOI 10.1021/bi00412a035; HAZZARD JT, 1991, BIOCHEMISTRY-US, V30, P213, DOI 10.1021/bi00215a031; HILDEBRANDT AG, 1978, METHOD ENZYMOL, V52, P346; HURLEY JK, 1993, BIOCHEMISTRY-US, V32, P9346, DOI 10.1021/bi00087a013; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; KIM JJ, 1996, 11 INT S MICR DRUG O, pL120; KLUGKIST J, 1986, EUR J BIOCHEM, V155, P33, DOI 10.1111/j.1432-1033.1986.tb09455.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; MEDINA M, 1992, EUR J BIOCHEM, V203, P373, DOI 10.1111/j.1432-1033.1992.tb16560.x; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P622, DOI 10.1021/bi00053a030; NADLER SG, 1988, ARCH BIOCHEM BIOPHYS, V261, P418, DOI 10.1016/0003-9861(88)90358-X; NAVARRO JA, 1995, ARCH BIOCHEM BIOPHYS, V321, P229, DOI 10.1006/abbi.1995.1390; NISIMOTO Y, 1988, BIOCHEMISTRY-US, V27, P5869, DOI 10.1021/bi00416a008; OSTER T, 1991, J BIOL CHEM, V266, P22718; PALMA PN, 1994, BIOCHEMISTRY-US, V33, P6394, DOI 10.1021/bi00187a003; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PUEYO JJ, 1991, EUR J BIOCHEM, V202, P1065, DOI 10.1111/j.1432-1033.1991.tb16471.x; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SANCHO J, 1988, ARCH BIOCHEM BIOPHYS, V260, P200, DOI 10.1016/0003-9861(88)90441-9; SCHMITZ S, 1995, BBA-BIOENERGETICS, V1231, P335, DOI 10.1016/0005-2728(95)00097-3; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VOZNESENSKY AI, 1994, J BIOL CHEM, V269, P15724; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020	39	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22509	22513		10.1074/jbc.272.36.22509	http://dx.doi.org/10.1074/jbc.272.36.22509			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278403	hybrid			2022-12-27	WOS:A1997XV49200023
J	Kaartinen, MT; Pirhonen, A; LinnalaKankkunen, A; Maenpaa, PH				Kaartinen, MT; Pirhonen, A; LinnalaKankkunen, A; Maenpaa, PH			Transglutaminase-catalyzed cross-linking of osteopontin is inhibited by osteocalcin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CRYSTAL-GROWTH; FACTOR-XIII; BONE; PROTEIN; TISSUES; PHOSPHOPROTEIN; LOCALIZATION; SUBSTRATE; MATRIX	Osteocalcin, the most abundant noncollagenous protein of bone matrix, has been demonstrated to inhibit bone growth by gene knockout experiments (Ducy, P., Desbois, C., Boyce, B., Pinero, G., Story, B., Dunstan, C., Smith, E., Bonadio, J., Goldstein, S., Gundberg, C., Bradley, A., and Karsenty, G. (1996) Nature 382, 448-452). Its specific functional mechanism in bone metabolism is, however, largely unknown. In this study, we provide evidence that osteocalcin has an inhibitory effect on tissue transglutaminase activity, as measured by cross-linking of osteopontin, another bone matrix protein. Using a set of synthetic peptides, we found that the inhibitory activity resided within the first 13 N-terminal amino acid residues of osteocalcin. An N-terminal peptide also inhibited cross-linking of another tissue transglutaminase substrate, beta-casein. The inhibitory peptide was shown to have affinity for the substrates of transglutaminase rather than for the enzyme. Since the N terminus of osteocalcin exhibits homology to the substrate recognition site sequences of two transglutaminases, we conclude that the inhibitory effect is most likely due to competition with the enzyme for the transglutaminase-binding region of the substrates, osteopontin and beta-casein, which prevents access of the enzyme to them to perform its function. The interference of osteocalcin with osteopontin cross-linking gives osteocalcin a new potential function as the first protein inhibitor of tissue transglutaminase. This suggests a specific role and a plausible mechanism for it as a modulator of maturation, stabilization, and calcification of bone matrix.			Kaartinen, MT (corresponding author), UNIV KUOPIO,DEPT BIOCHEM & BIOTECHNOL,POB 1627,FIN-70211 KUOPIO,FINLAND.			Kaartinen, Mari/0000-0003-2999-6502				ACHYUTHAN KE, 1993, J BIOL CHEM, V268, P21284; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BENINATI S, 1994, J BIOCHEM-TOKYO, V115, P675, DOI 10.1093/oxfordjournals.jbchem.a124395; BOSKEY AL, 1992, CLIN ORTHOP RELAT R, V281, P244; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; Christensen BM, 1996, J AGR FOOD CHEM, V44, P1943, DOI 10.1021/jf9602131; COLOMBO G, 1993, J BONE MINER RES, V8, P733; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HAUSCHKA PV, 1982, BIOCHEMISTRY-US, V21, P2538, DOI 10.1021/bi00539a038; HOHENADL C, 1995, J BIOL CHEM, V270, P23415, DOI 10.1074/jbc.270.40.23415; HULTENBY K, 1991, MATRIX, V11, P206, DOI 10.1016/S0934-8832(11)80160-5; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; IKURA K, 1980, AGR BIOL CHEM TOKYO, V44, P1567, DOI 10.1080/00021369.1980.10864171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAN JB, 1984, J CLIN INVEST, V73, P1223, DOI 10.1172/JCI111308; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MARK MP, 1987, J HISTOCHEM CYTOCHEM, V35, P707, DOI 10.1177/35.7.3295029; MARK MP, 1988, DIFFERENTIATION, V37, P123, DOI 10.1111/j.1432-0436.1988.tb00804.x; McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097-0029(19960201)33:2<141::AID-JEMT5>3.0.CO;2-W; McKee MD, 1996, ANAT RECORD, V245, P394, DOI 10.1002/(SICI)1097-0185(199606)245:2<394::AID-AR19>3.0.CO;2-K; PRICE PA, 1982, P NATL ACAD SCI-BIOL, V79, P7734, DOI 10.1073/pnas.79.24.7734; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; RITTER NM, 1992, J BONE MINER RES, V7, P877; ROMBERG RW, 1986, BIOCHEMISTRY-US, V25, P1176, DOI 10.1021/bi00353a035; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SHIRAGA H, 1992, P NATL ACAD SCI USA, V89, P426, DOI 10.1073/pnas.89.1.426; SORENSEN ES, 1994, BIOCHEM J, V304, P13, DOI 10.1042/bj3040013; SORENSEN ES, 1993, J DAIRY RES, V60, P189, DOI 10.1017/S0022029900027503; WIEBE RI, 1991, BIOCHEM CELL BIOL, V69, P821, DOI 10.1139/o91-122	38	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22736	22741		10.1074/jbc.272.36.22736	http://dx.doi.org/10.1074/jbc.272.36.22736			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278432	hybrid			2022-12-27	WOS:A1997XV49200053
J	Klein, BK; Feng, YQ; McWherter, CA; Hood, WF; Paik, K; McKearn, JP				Klein, BK; Feng, YQ; McWherter, CA; Hood, WF; Paik, K; McKearn, JP			The receptor binding site of human interleukin-3 defined by mutagenesis and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING-FACTOR; HIGH-AFFINITY BINDING; HUMAN GROWTH-HORMONE; COMMON BETA-CHAIN; GM-CSF; ALPHA-CHAIN; BIOLOGICAL-ACTIVITY; HEMATOPOIETIC ACTIVITY; INTERSPECIES CHIMERA; SECONDARY STRUCTURE	Interleukin-3 (IL-3) is a member of the cytokine superfamily that promotes multi-potential hematopoietic cell growth by interacting with a cell surface receptor composed of alpha and beta chains, The newly available three-dimensional structure of a variant of human (h) IL-3 allowed us to evaluate new and existing mutagenesis data and to rationally interpret the structure-function relationship of hIL-3 on a structural basis, The amino acid residues that were identified to be important for hIL-3 activity are grouped into two classes, The first class consists of largely hydrophobic residues required for the structural integrity of the protein, including the residues in IL-3 that are largely conserved among 10 mammalian species, These residues form the core of a scaffold for the second class of more rapidly diverging solvent-exposed residues, likely to be required for interaction with the receptor, Ten important and solvent-exposed residues, Asp(21), Gly(42), Glu(43), Gln(45), Asp(46), Met(49), Arg(94), Pro(96), Phe(113), and Lys(116), map to one side of the protein and form a putative binding site for the alpha subunit of the receptor, A model of the IL-3.IL-3 receptor complex based on the human growth hormone (hGH).hGH soluble receptor complex structure suggests that the interface between IL-3 and the IL-3 receptor alpha subunit consists of a cluster of hydrophobic residues flanked by electrostatic interactions, Although the IL-3/IL-3 receptor beta subunit interface cannot be uniquely located due to the lack of sufficient experimental data, several residues of the beta subunit that may interact with Glu(22) of IL-3 are proposed, The role of these residues can be tested in future mutagenesis studies to define the interaction between IL-3 and IL-3 receptor beta subunit.			Klein, BK (corresponding author), GD SEARLE & CO,700 CHESTERFIELD PKY N,ST LOUIS,MO 63198, USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; Bagley CJ, 1996, J BIOL CHEM, V271, P31922, DOI 10.1074/jbc.271.50.31922; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROWN CB, 1994, EUR J BIOCHEM, V225, P873, DOI 10.1111/j.1432-1033.1994.0873b.x; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURGER H, 1994, BIOCHIM BIOPHYS ACTA, V217, P195; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLARKLEWIS I, 1988, P NATL ACAD SCI USA, V85, P7897, DOI 10.1073/pnas.85.21.7897; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DORSSERS LCJ, 1994, GROWTH FACTORS, V11, P93, DOI 10.3109/08977199409001051; DORSSERS LCJ, 1991, J BIOL CHEM, V266, P21310; Feng YP, 1996, J MOL BIOL, V259, P524, DOI 10.1006/jmbi.1996.0337; FENG YQ, 1995, BIOCHEMISTRY-US, V34, P6540, DOI 10.1021/bi00019a036; *GEN COMP GROUP, 1991, UWGCG SOFTW PACK; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; HERCUS TR, 1994, BLOOD, V83, P3500; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAUSHANSKY K, 1992, J CLIN INVEST, V90, P1879, DOI 10.1172/JCI116065; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOKKER NA, 1991, EMBO J, V10, P2125, DOI 10.1002/j.1460-2075.1991.tb07746.x; LOKKER NA, 1991, J IMMUNOL, V146, P893; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LOPEZ AF, 1992, P NATL ACAD SCI USA, V89, P11872; LYNE PD, 1995, PROTEIN SCI, V4, P2223, DOI 10.1002/pro.5560041027; MCINNES CJ, 1994, GENE, V139, P289, DOI 10.1016/0378-1119(94)90772-2; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLINS PO, 1995, J BIOL CHEM, V270, P23754, DOI 10.1074/jbc.270.40.23754; ROZARSKI DA, 1994, STRUCTURE, V2, P159; SANTOLI D, 1987, J IMMUNOL, V139, P3348; SCHRADER JW, 1986, ANNU REV IMMUNOL, V4, P205, DOI 10.1146/annurev.iy.04.040186.001225; SEELIG GF, 1994, J BIOL CHEM, V269, P5548; SHANAFELT AB, 1991, J BIOL CHEM, V266, P1804; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THOMAS JW, 1995, P NATL ACAD SCI USA, V92, P3779, DOI 10.1073/pnas.92.9.3779; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999	50	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22630	22641		10.1074/jbc.272.36.22630	http://dx.doi.org/10.1074/jbc.272.36.22630			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278420	Green Published, hybrid			2022-12-27	WOS:A1997XV49200040
J	Oguri, S; Minowa, MT; Ihara, Y; Taniguchi, N; Ikenaga, H; Takeuchi, M				Oguri, S; Minowa, MT; Ihara, Y; Taniguchi, N; Ikenaga, H; Takeuchi, M			Purification and characterization of UDP-N-acetylglucosamine: alpha 1,3-D-mannoside beta 1,4-N-acetylglucosaminyltransferase (N-acetylglucosaminyltransferase-IV) from bovine small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SUGAR CHAINS; HAMSTER-KIDNEY CELLS; GLYCOPROTEIN-SYNTHESIS; UDP-N-ACETYLGLUCOSAMINE-ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFE; MOLECULAR-CLONING; CDNA CLONING; OVARY CELLS; HEN OVIDUCT; RAT-KIDNEY; EXPRESSION	A new beta 1,4-N-acetylglucosaminyltransferase (GnT) which involves in branch formation of Asn-linked complex-type sugar chains has been purified 224,000-fold from bovine small intestine. This enzyme requires divalent cations, such as Mn2+, and catalyzes the transfer of GlcNAc from UDP-GlcNAc to biantennary oligosaccharide and produces triantennary oligosaccharide with the beta 1-4-linked GlcNAc residue on the Man alpha 1-3 arm. The purified enzyme shows a single band of M-r 58,000 and behaves as a monomer. The substrate specificity demonstrated that the beta 1-2-linked GlcNAc residue on the Man alpha 1-3 arm (GnT-I product) is essential for the enzyme activity, beta 1-4-Galactosylaion to this essential beta 1-2-linked GlcNAc residue or N-acetylglucosaminylation to the beta-linked Man residue (bisecting GlcNAc, GnT-III product) blocks the enzyme action, while beta 1-6-N-acetylglucosaminylation to the Man alpha 1-6 arm (GnT-V product) increases the transfer. Based on these findings, we conclude that the purified enzyme is UDP-N-acetylglucosamine:alpha-3-D-mannoside beta-1,4-N-acetylglucosaminyltransferase IV (GnT-IV), that has been a missing link on biosynthesis of complex-type sugar chains.	KIRIN BREWERY CO LTD, CENT LABS KEY TECHNOL, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN; OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN	Kirin Brewery Company Limited; Osaka University			Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BROCKHAUSEN I, 1989, J BIOL CHEM, V264, P11211; DAGOSTARO GAF, 1995, J BIOL CHEM, V270, P15211, DOI 10.1074/jbc.270.25.15211; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DO KY, 1994, J BIOL CHEM, V269, P23456; GLEESON PA, 1983, J BIOL CHEM, V258, P6162; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KOBATA A, 1988, J CELL BIOCHEM, V37, P79, DOI 10.1002/jcb.240370108; KOBATA A, 1993, GLYCOBIOLOGY PRACTIC, P165; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIZUOCHI T, 1983, J BIOL CHEM, V258, P4126; NILSSON B, 1979, J BIOL CHEM, V254, P4545; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P799; PIERCE M, 1986, J BIOL CHEM, V261, P772; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1989, METHOD ENZYMOL, V179, P351; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; TAKEUCHI M, 1989, P NATL ACAD SCI USA, V86, P7819, DOI 10.1073/pnas.86.20.7819; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; TAKEUCHI M, 1991, Glycobiology, V1, P337, DOI 10.1093/glycob/1.4.337; TANIGUCHI N, 1995, GLYCOCONJUGATE J, V12, P733, DOI 10.1007/BF00731232; TOKUGAWA K, 1995, GLYCOCOJUGATE J, V13, P95; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMAMOTO K, 1981, BIOCHEM J, V195, P701, DOI 10.1042/bj1950701; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1989, J BIOCHEM-TOKYO, V105, P728, DOI 10.1093/oxfordjournals.jbchem.a122736; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	35	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22721	22727		10.1074/jbc.272.36.22721	http://dx.doi.org/10.1074/jbc.272.36.22721			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278430	hybrid			2022-12-27	WOS:A1997XV49200051
J	Gurvitz, A; Rottensteiner, H; Kilpelainen, SH; Hartig, A; Hiltunen, JK; Binder, M; Dawes, IW; Hamilton, B				Gurvitz, A; Rottensteiner, H; Kilpelainen, SH; Hartig, A; Hiltunen, JK; Binder, M; Dawes, IW; Hamilton, B			The Saccharomyces cerevisiae peroxisomal 2,4-dienoyl-CoA reductase is encoded by the oleate-inducible gene SPS19	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; BETA-OXIDATION; ESCHERICHIA-COLI; COENZYME-A; RAT-LIVER; TRANSCRIPTIONAL CONTROL; CANDIDA-TROPICALIS; GOLD PARTICLES; BOVINE LIVER; PURIFICATION	beta-Oxidation is compartmentalized in mammals into both mitochondria and peroxisomes. Fatty acids with double bonds at even-numbered positions require for their degradation the auxiliary enzyme 2,4-dienoyl-CoA reductase, and at least three isoforms, two mitochondrial and one peroxisomal, exist in the rat. The Saccharomyces cerevisiae Sps19p is 34% similar to the human and rat mitochondrial reductases, and an SPS19 deleted strain was unable to utilize petroselineate (cis-C-18:1(6)) as the sole carbon source, but remained viable on oleate (cis-C-18:1(9)). Sps19p was purified to homogeneity from oleate-induced cells and the homodimeric enzyme (native molecular weight 69,000) converted 2,4-hexadienoyl-CoA into 3-hexenoyl-CoA in an NADPH-dependent manner and therefore contained 2,4-dienoyl-CoA reductase activity, Antibodies raised against Sps19p decorated the peroxisomal matrix of oleate-induced cells. SPS19 shares with the sporulation-specific SPS18 a common promoter region that contains an oleate response element, This element unidirectionally regulates transcription of the reductase and is sufficient for oleate induction of a promoterless CYC1-lacZ reporter gene. SPS19 is dispensable for growth and sporulation on solid acetate and oleate media, but is essential for these processes to occur on petroselineate.	UNIV NEW S WALES,SCH BIOCHEM & MOL GENET,SYDNEY,NSW 2052,AUSTRALIA; UNIV VIENNA,INST BIOCHEM & MOL ZELLBIOL,A-1030 VIENNA,AUSTRIA; VIENNA BIOCTR,LUDWIG BOLTZMANN FORSCHUNGSSTELLE BIOCHEM,A-1030 VIENNA,AUSTRIA; UNIV OULU,DEPT BIOCHEM,BIOCTR OULU,FIN-90570 OULU,FINLAND; UNIV VIENNA,INST TUMORBIOL KREBSFORSCH,A-1090 VIENNA,AUSTRIA	University of New South Wales Sydney; University of Vienna; Ludwig Boltzmann Institute; Vienna Biocenter (VBC); Finland National Institute for Health & Welfare; University of Oulu; University of Vienna				Hartig, Andreas/0000-0003-3334-2763; Hiltunen, Kalervo/0000-0002-3073-9602				BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHEN LS, 1994, BIOCHEMISTRY-US, V33, P10527, DOI 10.1021/bi00200a039; COE JGS, 1994, MOL GEN GENET, V244, P661, DOI 10.1007/BF00282757; COE JGS, 1992, MOL MICROBIOL, V6, P75, DOI 10.1111/j.1365-2958.1992.tb00839.x; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; DOMMES P, 1983, J BIOL CHEM, V258, P846; DOMMES V, 1984, J BIOL CHEM, V259, P1781; DOMMES V, 1981, J BIOL CHEM, V256, P8259; DOMMES V, 1982, EUR J BIOCHEM, V125, P335, DOI 10.1111/j.1432-1033.1982.tb06688.x; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; GOLDMAN P, 1961, J BIOL CHEM, V236, P2620; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HAKKOLA EH, 1989, J HISTOCHEM CYTOCHEM, V37, P1863, DOI 10.1177/37.12.2584694; HAKKOLA EH, 1993, EUR J BIOCHEM, V215, P199, DOI 10.1111/j.1432-1033.1993.tb18023.x; HARTIG A, 1990, CURR GENET, V18, P23, DOI 10.1007/BF00321111; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; HILTUNEN JK, 1993, BIOCHIMIE, V75, P175, DOI 10.1016/0300-9084(93)90075-4; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, P627; HIROSE A, 1990, BIOCHIM BIOPHYS ACTA, V1049, P346, DOI 10.1016/0167-4781(90)90109-F; JONES EW, 1977, GENETICS, V85, P23; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KIMURA C, 1984, J BIOCHEM, V96, P1463, DOI 10.1093/oxfordjournals.jbchem.a134975; KOIVURANTA KT, 1994, BIOCHEM J, V304, P787, DOI 10.1042/bj3040787; KRAGLER F, 1993, J CELL BIOL, V120, P665, DOI 10.1083/jcb.120.3.665; KUNAU WH, 1978, EUR J BIOCHEM, V91, P533, DOI 10.1111/j.1432-1033.1978.tb12707.x; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; MCKIE JH, 1991, FEBS LETT, V279, P5, DOI 10.1016/0014-5793(91)80236-V; Miller J. H, 1972, EXPT MOL GENETICS; MIZUGAKI M, 1982, J BIOCHEM-TOKYO, V92, P1671, DOI 10.1093/oxfordjournals.jbchem.a134095; MIZUGAKI M, 1983, J BIOCHEM, V94, P409, DOI 10.1093/oxfordjournals.jbchem.a134370; MIZUGAKI M, 1985, J BIOCHEM-TOKYO, V97, P837, DOI 10.1093/oxfordjournals.jbchem.a135124; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; RICHTER K, 1980, J BIOL CHEM, V255, P8019; ROE CR, 1990, J CLIN INVEST, V85, P1703, DOI 10.1172/JCI114624; ROTH J, 1982, HISTOCHEM J, V14, P791, DOI 10.1007/BF01033628; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; SIMON MM, 1995, MOL GEN GENET, V249, P289, DOI 10.1007/BF00290529; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WANG TW, 1994, J BIOL CHEM, V269, P24480; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; YOKOTA S, 1988, HISTOCHEM J, V20, P679, DOI 10.1007/BF01002748; YOU SY, 1989, J BIOL CHEM, V264, P16489; ZEELEN JP, 1992, J MOL BIOL, V244, P273	61	77	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22140	22147		10.1074/jbc.272.35.22140	http://dx.doi.org/10.1074/jbc.272.35.22140			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268358	hybrid			2022-12-27	WOS:A1997XT85000070
J	Holliday, LS; Welgus, HG; Fliszar, CJ; Veith, GM; Jeffrey, JJ; Gluck, SL				Holliday, LS; Welgus, HG; Fliszar, CJ; Veith, GM; Jeffrey, JJ; Gluck, SL			Initiation of osteoclast bone resorption by interstitial collagenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN FIBROBLAST COLLAGENASE; MATRIX METALLOPROTEINASES; CATHEPSIN-K; CYSTEINE-PROTEINASES; GELATINOLYTIC ACTIVITY; RESORBING COMPARTMENT; OSTEOBLASTIC CELLS; MOLECULAR-CLONING; MARROW CULTURES; SMOOTH-MUSCLE	Osteoclasts form an acidic compartment at their attachment site in which bone demineralization and matrix degradation occur, Although both the cysteine proteinases and neutral collagenases participate in bone resorption, their roles have remained unclear, Here we show that interstitial collagenase has an essential role in initiating bone resorption, distinct from that of the cysteine proteinases. Treatment of osteoclasts with cysteine proteinase inhibitors did not affect the number of resorption lacunae (''pits'') formed on the surface of dentine slices, but it generated abnormal pits that were demineralized but filled with undegraded matrix. Treatment with metalloproteinase inhibitors did not alter the qualitative features of lacunae, but it greatly reduced the number of pits and surface area resorbed, Treatment of bone cells with an inhibitory anti-rat interstitial collagenase antiserum reduced bone resorption markedly, In the presence of collagenase inhibitors, resorption was restored by pretreatment of dentine slices with rat interstitial collagenase or by precoating the dentine slices with collagenase-derived gelatin peptides or heat-gelatinized collagen. Immunostaining revealed that interstitial collagenase is produced at high levels by stromal cells and osteoblasts adjacent to osteoclasts, These results indicate that interstitial collagenase can function as a ''coupling factor,'' allowing osteoblasts to initiate bone resorption by generating collagen fragments that activate osteoclasts.	WASHINGTON UNIV,SCH MED,DIV RENAL,GEORGE M OBRIEN CTR KIDNEY & UROL DIS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOL,ST LOUIS,MO 63110; ALBANY MED COLL,DEPT BIOCHEM,ALBANY,NY 12208	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Albany Medical College			Holliday, Lexie/GYQ-4972-2022	Holliday, Lexie/0000-0002-0844-1965	NIAMS NIH HHS [AR32087] Funding Source: Medline; NICHD NIH HHS [HD05291] Funding Source: Medline; NIDDK NIH HHS [DK38848] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD005291, R01HD005291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038848] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BLAIR HC, 1986, J CELL PHYSIOL, V129, P111, DOI 10.1002/jcp.1041290116; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BUTLER TA, 1991, BIOL REPROD, V44, P1183, DOI 10.1095/biolreprod44.6.1183; CHAMBERS TJ, 1985, CELL TISSUE RES, V241, P671; CHAMBERS TJ, 1985, J CELL SCI, V76, P155; CRUWYS SC, 1990, BRIT J PHARMACOL, V100, P631, DOI 10.1111/j.1476-5381.1990.tb15858.x; DELAISSE JM, 1985, BIOCHEM BIOPH RES CO, V133, P483, DOI 10.1016/0006-291X(85)90932-5; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; DELAISSE JM, 1993, J CELL SCI, V106, P1071; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FULLER K, 1995, J CELL SCI, V108, P2221; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GILLET C, 1977, FEBS LETT, V74, P126, DOI 10.1016/0014-5793(77)80768-0; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; Helfrich MH, 1996, BONE, V19, P317, DOI 10.1016/S8756-3282(96)00223-2; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIGHBERGER JH, 1978, BIOCHEM BIOPH RES CO, V83, P43, DOI 10.1016/0006-291X(78)90395-9; HILL PA, 1994, J CELL SCI, V107, P3055; HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; JEFFREY JJ, 1990, J CELL PHYSIOL, V143, P396, DOI 10.1002/jcp.1041430226; KAHN AJ, 1987, AM J OTOLARYNG, V8, P258, DOI 10.1016/S0196-0709(87)80044-3; LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAGE AE, 1993, INT J BIOCHEM, V25, P545, DOI 10.1016/0020-711X(93)90662-X; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Schnebli H P, 1985, Prog Clin Biol Res, V180, P287; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; VAANANEN HK, 1993, ANN MED, V25, P353, DOI 10.3109/07853899309147297; Vaes G, 1992, Matrix Suppl, V1, P383; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1985, J BIOL CHEM, V260, P3601; WELGUS HG, 1982, J BIOL CHEM, V257, P1534; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	45	198	204	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22053	22058		10.1074/jbc.272.35.22053	http://dx.doi.org/10.1074/jbc.272.35.22053			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268345	hybrid			2022-12-27	WOS:A1997XT85000057
J	Jacobi, A; HuberWunderlich, M; Hennecke, J; Glockshuber, R				Jacobi, A; HuberWunderlich, M; Hennecke, J; Glockshuber, R			Elimination of all charged residues in the vicinity of the active-site helix of the disulfide oxidoreductase DsbA - Influence of electrostatic interactions on stability and redox properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; BOND FORMATION INVIVO; FORMATION IN-VIVO; CYSTEINE RESIDUES; EFFICIENT CATALYSIS; ASPARTIC-ACID; CRYSTAL-STRUCTURE; FOLDING PATHWAY; ISOMERASE DSBA; PROTEIN	Disulfide oxidoreductases are structurally related proteins that share the thioredoxin fold and a catalytic disulfide bond that is located at the N terminus of an alpha-helix, The different redox potentials of these enzymes varying from -270 mV for thioredoxin to -125 mV for DsbA have been attributed to the lowered pK(a) values of their nucleophilic, active-site cysteines and the difference in thermodynamic stability between their oxidized and reduced forms (Delta Delta G(ox/red)). The lowered pK(a) of the nucleophilic cysteine thiols was proposed to result from favorable interactions with the helix dipole and charged residues in their vicinity, In this study, we have eliminated all charged residues in the neighborhood of the active-site disulfide of DsbA from Escherichia coli to analyze their contribution to the physicochemical properties of the protein, We show that the conserved charge network among residues Glu(24), Glu(37), and Lys(58) stabilizes the oxidized form of DsbA and thus does not cause the high redox potential of the enzyme, The pK(a) values of the nucleophilic cysteine (Cys(30)) and the redox potentials of the DsbA variants E24Q, E37Q, K58M, E24Q/K58M, E37Q/K58M, E24Q/E37Q, E24Q/E37Q/K58M, and E24Q/E37Q/E38Q/K58M are similar to those of DsbA wild type, The redox potentials of the variants neither correlate with the Cys(30) pK(a) values nor with the Delta Delta G(ox/red) values, demonstrating that the relationship between these parameters is far more complex than previously thought.			Jacobi, A (corresponding author), ETH HONGGERBERG,INST MOL BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND.							BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; CREIGHTON T, 1995, PHILOS T ROY SOC B, V348, P5, DOI 10.1098/rstb.1995.0039; Creighton T. E., 1993, PROTEINS STRUCTURES, P6; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; CREIGHTON TE, 1988, SCIENCE, V240, P344; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FORMANKAY JD, 1992, BIOCHEMISTRY-US, V31, P3442, DOI 10.1021/bi00128a019; Frech C, 1996, EMBO J, V15, P392, DOI 10.1002/j.1460-2075.1996.tb00369.x; GANE PJ, 1995, J MOL BIOL, V249, P376, DOI 10.1006/jmbi.1995.0303; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; Hennecke J, 1997, J BIOL CHEM, V272, P189; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOROVITZ A, 1996, FOLDING DESIGN, V1, P121, DOI DOI 10.1016/S1359-0278(96)00056-9; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jeng MF, 1996, BIOCHEMISTRY-US, V35, P1, DOI 10.1021/bi952404n; JENG MF, 1995, BIOCHEMISTRY-US, V34, P10101, DOI 10.1021/bi00032a001; JENG MF, 1995, BIOCHEMISTRY-US, V34, P611, DOI 10.1021/bi00002a028; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KELLEY RF, 1987, BIOCHEMISTRY-US, V26, P1406, DOI 10.1021/bi00379a029; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LADBURY JE, 1993, BIOCHEMISTRY-US, V32, P7526, DOI 10.1021/bi00080a026; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7603, DOI 10.1021/bi00244a032; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7609, DOI 10.1021/bi00244a033; LI HM, 1993, BIOCHEMISTRY-US, V32, P5800, DOI 10.1021/bi00073a012; MARKWARDT F, 1967, H-S Z PHYSIOL CHEM, V348, P1381, DOI 10.1515/bchm2.1967.348.1.1381; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Nozaki Y, 1972, Methods Enzymol, V26, P43; Oliveberg M, 1996, BIOCHEMISTRY-US, V35, P6795, DOI 10.1021/bi9529317; Pace C N, 1986, Methods Enzymol, V131, P266; POLGAR L, 1974, FEBS LETT, V38, P187, DOI 10.1016/0014-5793(74)80110-9; Qin J, 1996, BIOCHEMISTRY-US, V35, P7, DOI 10.1021/bi952299h; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; ROST N, 1964, NATURE, V201, P185; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Takahashi N, 1996, BIOCHEMISTRY-US, V35, P8342, DOI 10.1021/bi960465v; TANFORD C, 1956, J AM CHEM SOC, V78, P5287, DOI 10.1021/ja01601a036; Tissot AC, 1996, BIOCHEMISTRY-US, V35, P6786, DOI 10.1021/bi952930e; Warwicker J, 1996, FEBS LETT, V385, P105, DOI 10.1016/0014-5793(96)00358-4; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; Williams S, 1996, BIOCHEMISTRY-US, V35, P691, DOI 10.1021/bi952217p; WILSON NA, 1995, BIOCHEMISTRY-US, V34, P8931, DOI 10.1021/bi00028a001; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P1907, DOI 10.1021/bi00173a038	66	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21692	21699		10.1074/jbc.272.35.21692	http://dx.doi.org/10.1074/jbc.272.35.21692			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268296	hybrid			2022-12-27	WOS:A1997XT85000008
J	Kawaide, H; Imai, R; Sassa, T; Kamiya, Y				Kawaide, H; Imai, R; Sassa, T; Kamiya, Y			ent-kaurene synthase from the fungus Phaeosphaeria sp. L487 - cDNA isolation, characterization, and bacterial expression of a bifunctional diterpene cyclase in fungal gibberellin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-GROWTH RETARDANT; CELL-FREE SYSTEM; MOLECULAR-CLONING; CUCURBITA-MAXIMA; SYNTHETASE; PURIFICATION; GENE; METABOLISM; PLASTIDS; PROTEINS	ent-Kaurene is the first cyclic diterpene intermediate of gibberellin biosynthesis in both plants and fungi, In plants, ent-kaurene is synthesized from geranylgeranyl diphosphate via copalyl diphosphate in a two-step cyclization catalyzed by copalyl diphosphate synthase and ent-kaurene synthase. A cell-free system of the fungus Phaeosphaeria sp, L487 converted labeled geranylgeranyl diphosphate to ent-kaurene, A cDNA fragment, which possibly encodes copalyl diphosphate synthase, was isolated by reverse transcription-polymerase chain reaction using degenerate primers based on the consensus motifs of plant enzymes, Translation of a full-length cDNA sequence isolated from the fungal cDNA library revealed an open reading frame for a 106-kDa polypeptide, The deduced amino acid sequence shared 24 and 21% identity with maize copalyl diphosphate synthase and pumpkin ent-kaurene synthase, respectively, A fusion protein produced by expression of the cDNA in Escherichia coli catalyzed the two-step cyclization of geranylgeranyl diphosphate to ent-kaurene, Amo-1618 completely inhibited the copalyl diphosphate synthase activity of the enzyme at 10(-6) M, whereas it did not inhibit the ent-kaurene synthase activity even at 10(-4) M, These results indicate that the fungus has a bifunctional diterpene cyclase that can convert geranylgeranyl diphosphate into ent-kaurene. They may be separate catalytic sites for the two cyclization reactions.	YAMAGATA UNIV,FAC AGR,DEPT BIOPROD,TSURUOKA,YAMAGATA 997,JAPAN	Yamagata University	Kawaide, H (corresponding author), RIKEN,INST PHYS & CHEM RES,FRONTIER RES PROGRAM,LAB PLANT HORMONE FUNCT,WAKO,SAITAMA 35101,JAPAN.		Kawaide, Hiroshi/F-9243-2013; Kamiya, Yuji/F-9420-2010	Kawaide, Hiroshi/0000-0001-6693-1332; Kamiya, Yuji/0000-0003-4415-520X				AACH H, 1995, PLANTA, V197, P333, DOI 10.1007/BF00202655; AitAli T, 1997, PLANT J, V11, P443, DOI 10.1046/j.1365-313X.1997.11030443.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bearder JR, 1983, BIOCH PHYSL GIBBEREL, V1, P251; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER B, 1991, CRIT REV BIOTECHNOL, V11, P163, DOI 10.3109/07388559109040621; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; Cane DE, 1996, BIOCHEMISTRY-US, V35, P12369, DOI 10.1021/bi961344y; CHAPPELL J, 1995, ANNU REV PLANT PHYS, V46, P521, DOI 10.1146/annurev.pp.46.060195.002513; COOLBAUGH RC, 1983, BIOCH PHYSL GIBBEREL, V1, P53; CROSS BE, 1964, J CHEM SOC, P295, DOI 10.1039/jr9640000295; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; DUNCAN JD, 1981, PLANT PHYSIOL, V68, P1128, DOI 10.1104/pp.68.5.1128; FALL RR, 1971, J BIOL CHEM, V246, P6913; GRAEBE JE, 1974, PLANTA, V120, P307, DOI 10.1007/BF00390299; HEDDEN P, 1977, PHYTOCHEMISTRY, V16, P1913, DOI 10.1016/0031-9422(77)80095-2; Hedden P, 1997, ANNU REV PLANT PHYS, V48, P431, DOI 10.1146/annurev.arplant.48.1.431; HORN TM, 1989, GENE AMST, V79, P131; IZUMI K, 1985, PLANT CELL PHYSIOL, V26, P821; KAWAIDE H, 1993, BIOSCI BIOTECH BIOCH, V57, P1403, DOI 10.1271/bbb.57.1403; KAWAIDE H, 1995, PHYTOCHEMISTRY, V39, P305, DOI 10.1016/0031-9422(95)00006-S; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIRSCHNER K, 1976, ANNU REV BIOCHEM, V45, P143, DOI 10.1146/annurev.bi.45.070176.001043; KLEINIG H, 1989, ANNU REV PLANT PHYS, V40, P39, DOI 10.1146/annurev.pp.40.060189.000351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAU CJD, 1994, P NATL ACAD SCI USA, V91, P8497, DOI 10.1073/pnas.91.18.8497; PORALLA K, 1994, TRENDS BIOCHEM SCI, V19, P157, DOI 10.1016/0968-0004(94)90276-3; PROCTOR RH, 1993, J BIOL CHEM, V268, P4543; RADEMACHER W, 1994, PLANT GROWTH REGUL, V15, P303, DOI 10.1007/BF00029903; SAITO T, 1995, PLANT PHYSIOL, V109, P1239, DOI 10.1104/pp.109.4.1239; SAMSON SM, 1987, BIO-TECHNOL, V5, P1207, DOI 10.1038/nbt1187-1207; SHECHTER I, 1969, J BIOL CHEM, V244, P3200; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; TURNER WB, 1983, FUNGAL METABOLITES, V2, P272; VIAL MV, 1981, TETRAHEDRON, V37, P2351, DOI 10.1016/S0040-4020(01)88888-8; Vogel BS, 1996, J BIOL CHEM, V271, P23262, DOI 10.1074/jbc.271.38.23262; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201; Yamaguchi S, 1996, PLANT J, V10, P203, DOI 10.1046/j.1365-313X.1996.10020203.x; YOURNO J, 1970, NATURE, V228, P820, DOI 10.1038/228820a0	40	130	136	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21706	21712		10.1074/jbc.272.35.21706	http://dx.doi.org/10.1074/jbc.272.35.21706			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268298	hybrid			2022-12-27	WOS:A1997XT85000010
J	Sorsa, T; Salo, T; Koivunen, E; Tyynela, J; Konttinen, YT; Bergmann, U; Tuuttila, A; Niemi, E; Teronen, O; Heikkila, P; Tschesche, H; Leinonen, J; Osman, S; Stenman, UH				Sorsa, T; Salo, T; Koivunen, E; Tyynela, J; Konttinen, YT; Bergmann, U; Tuuttila, A; Niemi, E; Teronen, O; Heikkila, P; Tschesche, H; Leinonen, J; Osman, S; Stenman, UH			Activation of type IV procollagenases by human tumor-associated trypsin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL GELATINASE; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; EXTRACELLULAR-MATRIX; PROGELATINASE-A; CELL-LINES; 4-AMINOPHENYLMERCURIC ACETATE; 72-KDA GELATINASE; COMPLEX-FORMATION	Increased production of proteinases, such as matrix metalloproteinases (MMPs), is a characteristic feature of malignant tumors. Some human cancers :Ind cell lines derived from them also express trypsinogen, but the function of the extrapancreatic trypsin has remained unclear, In this study we cloned and sequenced trypsinogen-a cDNA from human COLO 205 colon carcinoma cells and characterized the ability of the enzyme to activate latent human type TV procollagenases (proMMP-2 and proMMP-9). As shown by cloning and N-terminal amino acid sequencing, the amino acid sequence of tumor associated trypsin-a is identical to that of pancreatic trypsin-a. We found that both pancreatic trypsin-a and tumor cell-derived trypsin-a are efficient activators of proMMP-9 and are capable of activating proMMP-9 at a molar ratio of 1:1000, the lowest reported so far. Human trypsin-a was a more efficient activator than widely used bovine trypsin and converted the 92-kDa proMMP-9 to a single 77-kDa product that was not fragmented further. The single peptide bond cleaved by trypsin-a in proMMP-9 was Arg(87)-Phe(88), The generation of the 77-kDa species coincided with the increase in specific activity of MMP-9. In contrast, trypsin-2 only partially activated proMMP-2. Trypsin-a cleaved the Arg(99)-Lys(100) peptide bond of proMMP-2 generating 62-65-kDa MMP-2 species. Trypsin-a-induced proMMP-2 and -9 conversions were inhibited by tumor-associated trypsin inhibitor added either prior to or during activation indicating that proMMPs were not activated autocatalytically. Trypsin-2 also activated proMMPs associated with tissue inhibitor of matrix metalloproteinases, the complexes of which are thought to be the major MMP forms in vivo. The ability of human tumor cell-derived trypsin-a to activate latent MMPs suggests a role fbr trypsin-a in initiating the proteinase cascade that mediates tumor invasion and metastasis formation.	UNIV HELSINKI, DEPT MED CHEM, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, DEPT CLIN CHEM, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, DIV BIOCHEM, FIN-00014 HELSINKI, FINLAND; UNIV OULU, DEPT ORAL SURG & PATHOL, FIN-99020 OULU, FINLAND; UNIV OULU, DEPT BIOCHEM, FIN-99020 OULU, FINLAND; UNIV OULU, BIOCTR, FIN-99020 OULU, FINLAND; UNIV HELSINKI, DEPT ANAT, HELSINKI, FINLAND; UNIV HELSINKI, DEPT MED 4, HELSINKI, FINLAND; UNIV HELSINKI, DEPT ORAL SURG, HELSINKI, FINLAND; UNIV HELSINKI, DEPT SURG, HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, HELSINKI, FINLAND; UNIV BIELEFELD, DEPT BIOCHEM, D-33501 BIELEFELD, GERMANY	University of Helsinki; University of Helsinki; University of Helsinki; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Bielefeld	Sorsa, T (corresponding author), UNIV HELSINKI, INST DENT, DEPT PERIODONT, POB 41, MANNERHEIMINTIE 172, FIN-00014 HELSINKI, FINLAND.		, tuula/ABG-2051-2021	Heikkila, Pia/0000-0002-5925-1993; Stenman, Ulf-Hakan/0000-0002-2695-3454; Salo, Tuula/0000-0001-6039-0088; Koivunen, Erkki/0000-0002-6443-9595; Teronen, Olli/0000-0003-2211-9187				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BALLDIN G, 1981, SCAND J GASTROENTERO, V16, P603, DOI 10.3109/00365528109182018; BAUMANN M, 1990, ANAL BIOCHEM, V190, P198, DOI 10.1016/0003-2697(90)90181-8; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PD, 1990, CANCER RES, V50, P6184; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; BU CH, 1995, J BIOL CHEM, V270, P18563, DOI 10.1074/jbc.270.31.18563; CHEN JM, 1991, J BIOL CHEM, V266, P5113; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECARLO A, 1994, THESISU ALABAMA BIRM; EMI M, 1986, GENE, V41, P305; FIGARELLA C, 1975, EUR J BIOCHEM, V53, P457, DOI 10.1111/j.1432-1033.1975.tb04086.x; FRENCH DL, 1994, ANN NY ACAD SCI, V732, P324, DOI 10.1111/j.1749-6632.1994.tb24747.x; FRIDMAN R, 1995, CANCER RES, V55, P2548; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Hedstrom J, 1996, BRIT MED J, V313, P333, DOI 10.1136/bmj.313.7053.333; Hedstrom J, 1996, INT J CANCER, V66, P326, DOI 10.1002/(SICI)1097-0215(19960503)66:3<326::AID-IJC10>3.0.CO;2-9; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIRAHARA F, 1995, INT J CANCER, V63, P176, DOI 10.1002/ijc.2910630205; HUHTALA ML, 1982, J BIOL CHEM, V257, P13713; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; Itkonen O, 1996, J LAB CLIN MED, V128, P98, DOI 10.1016/S0022-2143(96)90118-3; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KNAUPER V, 1993, BIOCHEM J, V295, P581; Knauper V, 1996, EUR J BIOCHEM, V235, P187, DOI 10.1111/j.1432-1033.1996.00187.x; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; KOIVUNEN E, 1990, CANCER RES, V50, P2375; KOIVUNEN E, 1989, J BIOL CHEM, V264, P14095; KOIVUNEN E, 1991, INT J CANCER, V47, P592, DOI 10.1002/ijc.2910470419; KOIVUNEN E, 1991, CANCER RES, V51, P2107; KOSHIKAWA N, 1994, BIOCHEM J, V303, P187, DOI 10.1042/bj3030187; MAKELA M, 1994, J DENT RES, V73, P1397, DOI 10.1177/00220345940730080201; MASUI Y, 1977, BIOCHEM MED METAB B, V17, P215, DOI 10.1016/0006-2944(77)90026-6; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OGRADY RL, 1984, ANAL BIOCHEM, V140, P490, DOI 10.1016/0003-2697(84)90199-4; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; QUIGLEY JP, 1990, CELL DIFFER DEV, V32, P263, DOI 10.1016/0922-3371(90)90039-Y; RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; REINKE H, 1991, ADV LIF SCI, P55; RISTELI L, 1987, METHOD ENZYMOL, V145, P391; SAARI H, 1990, BIOCHEM BIOPH RES CO, V171, P979, DOI 10.1016/0006-291X(90)90780-Q; SALO T, 1991, J BIOL CHEM, V266, P11436; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHEELE G, 1981, GASTROENTEROLOGY, V80, P461; SORSA T, 1994, ANN NY ACAD SCI, V732, P112, DOI 10.1111/j.1749-6632.1994.tb24729.x; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STENMAN UH, 1988, BIOL CHEM H-S, V369, P9; STENMAN UH, 1990, SCAND J CLIN LAB INV, V50, P93, DOI 10.3109/00365519009085805; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; SUZUKI K, 1995, BIOCHEM J, V305, P301, DOI 10.1042/bj3050301; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TERADA T, 1995, AM J PATHOL, V147, P1207; TERADA T, 1995, HUM PATHOL, V26, P746, DOI 10.1016/0046-8177(95)90222-8; Terada T, 1996, PATHOL INT, V46, P183, DOI 10.1111/j.1440-1827.1996.tb03596.x; TRIEBEL S, 1992, FEBS LETT, V314, P386, DOI 10.1016/0014-5793(92)81511-J; TRIEBEL S, 1992, FEBS LETT, V298, P280, DOI 10.1016/0014-5793(92)80077-T; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; Tschesche H, 1992, Matrix Suppl, V1, P245; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YU M, 1995, CANCER RES, V55, P3272; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	91	177	179	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21067	21074		10.1074/jbc.272.34.21067	http://dx.doi.org/10.1074/jbc.272.34.21067			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261109	hybrid			2022-12-27	WOS:A1997XR78900019
J	Tselepis, VH; Green, LJ; Humphries, MJ				Tselepis, VH; Green, LJ; Humphries, MJ			An RGD to LDV motif conversion within the disintegrin kistrin generates an integrin antagonist that retains potency but exhibits altered receptor specificity - Evidence for a functional equivalence of acidic integrin-binding motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; CELL-ADHESION MOLECULE-1; GLYCOPROTEIN-IIB-IIIA; PLATELET-AGGREGATION; CONTAINING PEPTIDE; SNAKE-VENOM; INHIBITS ALPHA-4-BETA-1; VITRONECTIN RECEPTOR; PROTEIN ANTAGONISTS; PLASMA FIBRONECTIN	Integrin ligands almost invariably employ a variant of either the RGD or LDV motif as a key element of their receptor recognition site, These short acidic peptide sequences collaborate with specific nonhomologous flanking residues and spatially separate ''synergy'' sequences to determine receptor binding specificity, Although the consensus sequences for RGD and LDV motifs are quite different, their common use suggests that they might share a critical role in receptor-ligand engagement, To date, the effects of interconversion of the two motifs within a natural protein framework have not been tested; however, in this study, we have converted the natural RGD site found in the snake venom disintegrin kistrin into an LDV motif and examined the effects of the change on the specificity of integrin recognition and on disintegrin potency, While an assessment of receptor binding using cell adhesion and purified integrin solid-phase assays demonstrated recognition of recombinant RGD kistrin by alpha V beta 3 and alpha 5 beta 1, a series of LDV kistrin chimeras did not bind to these integrins, but instead were recognized specifically by alpha 4 beta 1. The minimal change to elicit this distinct switch in receptor specificity was found to involve alteration of only three residues within kistrin, Alanine scanning mutagenesis was used to provide further information on the functional contribution of the three residues, More important, the LDV kistrin chimeras also retained much of the characteristic potency of RGD kistrin, indicating that the kistrin scaffold is optimized for presentation of both RGD and LDV sequences, These findings provide evidence for similarities in motif pharmacophore and reinforce the hypothesis that RGD and LDV sites have an equivalent functional role in receptor binding, They also demonstrate the potential for other disintegrin-containing proteins, perhaps from the ADAM family, to employ LDV sequences for integrin binding.	UNIV MANCHESTER,SCH BIOL SCI,WELLCOME TRUST CTR CELL MATRIX RES,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester				Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AOTA S, 1994, J BIOL CHEM, V269, P24756; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; CALVETE JJ, 1991, BIOCHEMISTRY-US, V30, P5225, DOI 10.1021/bi00235a016; CARDARELLI PM, 1994, J BIOL CHEM, V269, P18668; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; DENNIS MS, 1993, PROTEINS, V15, P312, DOI 10.1002/prot.340150308; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; EDWARDS JG, 1988, J CELL SCI, V89, P507; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; GREEN LJ, 1995, BIOCH SOC T, V23; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUMPHRIES M, 1994, EXPERT OPIN THER PAT, V4, P227; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KNAPP A, 1992, J BIOL CHEM, V267, P24230; KNUDSEN KA, 1988, EXP CELL RES, V179, P42, DOI 10.1016/0014-4827(88)90346-1; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KRAIZSCHMAR J, 1996, J BIOL CHEM, V271, P4593; LAM SCT, 1987, J BIOL CHEM, V262, P947; Lazarus Robert A., 1993, Current Opinion in Biotechnology, V4, P438, DOI 10.1016/0958-1669(93)90009-L; LI R, 1993, J BIOL CHEM, V268, P17513; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LU XJ, 1994, BIOCHEM J, V304, P929, DOI 10.1042/bj3040929; Lu XJ, 1996, J BIOL CHEM, V271, P289, DOI 10.1074/jbc.271.1.289; MAEDA T, 1989, J BIOL CHEM, V264, P15165; MAEDA T, 1993, J BIOCHEM, V113, P29, DOI 10.1093/oxfordjournals.jbchem.a123998; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, J BIOL CHEM, V266, P3579; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; NOWLIN DM, 1993, J BIOL CHEM, V268, P20352; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RAHMAN S, 1995, BIOCHEM J, V312, P223, DOI 10.1042/bj3120223; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; RUCINSKI B, 1990, BIOCHIM BIOPHYS ACTA, V1054, P257, DOI 10.1016/0167-4889(90)90096-V; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH JW, 1990, J BIOL CHEM, V265, P2168; STAIANO N, 1995, BIOCHEM MOL BIOL INT, V35, P11; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YAMADA T, 1993, J BIOL CHEM, V268, P10588	63	56	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21341	21348		10.1074/jbc.272.34.21341	http://dx.doi.org/10.1074/jbc.272.34.21341			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261147	hybrid			2022-12-27	WOS:A1997XR78900057
J	Wu, JG; Ohta, N; Benson, AK; Ninfa, AJ; Newton, A				Wu, JG; Ohta, N; Benson, AK; Ninfa, AJ; Newton, A			Purification, characterization, and reconstitution of DNA-dependent RNA polymerases from Caulobacter crescentus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SIGMA-SUBUNIT; TRANSCRIPTION; GENE; SEQUENCE; CHROMATOGRAPHY; BACTERIAL; INVITRO; REGION; FLBD	Cell differentiation in the Caulobacter crescentus cell cycle requires differential gene expression that is regulated primarily at the transcriptional level. Until now, however, a defined in vitro transcription system for the biochemical study of developmentally regulated transcription factors had not been available in this bacterium, We report here the purification of C. crescentus RNA polymerase holoenzymes and resolution of the core RNA polymerase from holoenzymes by chromatography on single-stranded DNA cellulose, The three RNA polymerase holoenzymes E sigma(54), E sigma(32), and E sigma(73) were reconstituted exclusively from purified C. crescentus core and sigma factors. Reconstituted E sigma(54) initiated transcription from the sigma(54)-dependent fljK promoter of C. crescentus in the presence of the transcription activator flbD, and active E sigma(32) specifically initiated transcription from the sigma(32)-dependent promoter of the C. crescentus heat-shock gene dnaK. For reconstitution of the E sigma(73) holoenzyme, we overexpressed the C. crescentus rpoD gene in Escherichia coli and purified the full-length sigma(73) protein. The reconstituted E sigma(73) recognized the sigma(70)-dependent promoters of the E. coli lacUV5 and neo genes, as well as the sigma(73)-dependent housekeeping promoters of the C. crescentus pleC and rsaA genes. The ability of the C. crescentus E sigma(73) RNA polymerase to recognize E. coli sigma(70)-dependent promoters is consistent with relaxed promoter specificity of this holoenzyme previously observed in vivo.	PRINCETON UNIV, DEPT MOL BIOL, PRINCETON, NJ 08544 USA	Princeton University				Benson, Andrew/0000-0001-6330-0252; Wu, Jianguo/0000-0002-8326-2895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022299] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22299] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMEMIYA K, 1977, J BIOL CHEM, V252, P4157; ANDERSON DK, 1995, MOL GEN GENET, V246, P697, DOI 10.1007/BF00290715; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BENSON AK, 1994, P NATL ACAD SCI USA, V91, P4989, DOI 10.1073/pnas.91.11.4989; BERG D, 1971, METHOD ENZYMOL, V21, P506; BRUN YV, 1992, GENE DEV, V6, P2395, DOI 10.1101/gad.6.12a.2395; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; Burgess R.R., 1987, RNA POLYM REGULATION, P3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; CHEUNG KK, 1978, J BIOL CHEM, V253, P2254; ELY B, 1989, GENETICS, V123, P649; ELY B, 1991, METHOD ENZYMOL, V204, P372; FISHER JA, 1988, J BACTERIOL, V170, P4706, DOI 10.1128/jb.170.10.4706-4713.1988; GILCHRIST A, 1991, J BACTERIOL, V173, P921, DOI 10.1128/jb.173.2.921-925.1991; GOMES SL, 1990, J BACTERIOL, V172, P3051, DOI 10.1128/jb.172.6.3051-3059.1990; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HALDENWANG WG, 1995, MICROBIOL REV, V59, P1; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; INOUYE S, 1990, J BACTERIOL, V172, P80, DOI 10.1128/JB.172.1.80-85.1990; JORGENSEN RA, 1979, MOL GEN GENET, V177, P65, DOI 10.1007/BF00267254; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; MALAKOOTI J, 1995, J BACTERIOL, V177, P4372, DOI 10.1128/jb.177.15.4372-4376.1995; MALAKOOTI J, 1995, J BACTERIOL, V177, P6854, DOI 10.1128/jb.177.23.6854-6860.1995; MASUI Y, 1983, EXPT MANIPULATION GE; NEWTON A, 1972, P NATL ACAD SCI USA, V69, P447, DOI 10.1073/pnas.69.2.447; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5905; NUSSLEIN C, 1972, BIOCHEM BIOPH RES CO, V47, P282, DOI 10.1016/S0006-291X(72)80040-8; Ohta N, 1996, TRENDS MICROBIOL, V4, P326, DOI 10.1016/0966-842X(96)10050-0; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; Reisenauer A, 1996, J BACTERIOL, V178, P1919, DOI 10.1128/jb.178.7.1919-1927.1996; STRAGIER P, 1990, MOL MICROBIOL, V4, P1801, DOI 10.1111/j.1365-2958.1990.tb02028.x; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; WU JG, 1995, J BACTERIOL, V177, P3241, DOI 10.1128/jb.177.11.3241-3250.1995; Wu JG, 1997, MOL MICROBIOL, V24, P233, DOI 10.1046/j.1365-2958.1997.3281691.x; Wu JG, 1996, J BACTERIOL, V178, P2094, DOI 10.1128/jb.178.7.2094-2101.1996	40	8	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21558	21564		10.1074/jbc.272.34.21558	http://dx.doi.org/10.1074/jbc.272.34.21558			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261176	hybrid			2022-12-27	WOS:A1997XR78900086
J	Bevilacqua, MA; Faniello, MC; Quaresima, B; Tiano, MT; Giuliano, P; Feliciello, A; Avvedimento, VE; Cimino, F; Costanzo, F				Bevilacqua, MA; Faniello, MC; Quaresima, B; Tiano, MT; Giuliano, P; Feliciello, A; Avvedimento, VE; Cimino, F; Costanzo, F			A common mechanism underlying the E1A repression and the cAMP stimulation of the H ferritin transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E1A-ASSOCIATED PROTEIN P300; ENCODING GENE FERH; MESSENGER-RNA; HEAVY-CHAIN; ADENOVIRUS E1A; NUCLEAR FACTOR; CELLS; EXPRESSION; PROMOTER; CREB	Transcription of the H ferritin gene in vivo is stimulated by cAMP and repressed by the E1A oncoprotein. We report here the identification of the cis-element in the human promoter responsive to both cAMP- and E1A-mediated signals. This promoter region is included between positions -62 to -45 and binds a approximate 120-kDa transcription factor called Bbf. Bbf forms a complex in vivo with the coactivator molecules p300 and CBP. Recombinant E1A protein reduces the formation of these complexes. In vivo overexpression of p300 in HeLa cells reverses the E1A-mediated inhibition of the ferritin promoter transcription driven by Bbf. These data suggest the existence of a common mechanism for the cAMP activation and the E1A-mediated repression of H ferritin transcription.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CANTANZARO,ITALY; UNIV NAPLES FEDERICO II,CNR,CEOS,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,I-80131 NAPLES,ITALY	University of Naples Federico II; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II			Costanzo, Francesco Saverio/K-3168-2018	Costanzo, Francesco Saverio/0000-0002-3096-9416; FANIELLO, Concetta Maria/0000-0001-6938-2754; QUARESIMA, Barbara/0000-0003-3462-624X; Feliciello, Antonio/0000-0002-7932-2170				ALPERT E, 1973, NATURE, V242, P194, DOI 10.1038/242194a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; BEVILACQUA MA, 1994, GENE, V141, P287, DOI 10.1016/0378-1119(94)90587-8; BEVILACQUA MA, 1992, GENE, V111, P255, DOI 10.1016/0378-1119(92)90696-M; BEVILACQUA MA, 1995, BIOCHEM J, V311, P769, DOI 10.1042/bj3110769; BOMFORD AB, 1992, PATHOBIOLOGY, V60, P10, DOI 10.1159/000163691; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P666; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CORSI PS, 1988, GENE DEV, V2, P1529; DAMATO LGC, 1989, BIOCHEM BIOPH RES CO, V165, P506; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GALLO A, 1995, CELL GROWTH DIFFER, V6, P91; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IWASA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1279, DOI 10.1016/0006-291X(90)90662-7; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; NORDHEIM A, 1994, NATURE, V370, P177, DOI 10.1038/370177a0; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TSUJI Y, 1993, J BIOL CHEM, V268, P7270; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; YOKOMORI N, 1991, ENDOCRINOLOGY, V128, P1474, DOI 10.1210/endo-128-3-1474	32	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20736	20741		10.1074/jbc.272.33.20736	http://dx.doi.org/10.1074/jbc.272.33.20736			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252395	hybrid			2022-12-27	WOS:A1997XR22100065
J	Gschwendt, M; Johannes, FJ; Kittstein, W; Marks, F				Gschwendt, M; Johannes, FJ; Kittstein, W; Marks, F			Regulation of protein kinase C mu by basic peptides and heparin - Putative role of an acidic domain in the activation of the kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; POLYLYSINE; EXPRESSION; BINDING	Protein kinase C mu is a novel member of the protein kinase C (PKC) family that differs from the other isoenzymes in structural and enzymatic properties. No substrate proteins of PKC mu have been identified as yet. Moreover, the regulation of PKC mu activity remains obscure, since a structural region corresponding to the pseudosubstrate domains of other PKC isoenzymes has not been found for PKC mu. Here we show that aldolase is phosphorylated by PKC mu in vitro. Phosphorylation of aldolase and of two substrate peptides by PKC mu is inhibited by various proteins and peptides, including typical PKC substrates such as histone H1, myelin basic protein, and p53. This inhibitory activity seems to depend on clusters of basic amino acids in the protein/peptide structures. Moreover, in contrast to other PRC isoenzymes PKC mu is activated by heparin and dextran sulfate. Maximal activation by heparin is about twice and that by dextran sulfate four times as effective as maximal activation by phosphatidylserine plus 12-O-tetradecanoylphorbol-13-acetate, the conventional activators of c-and nPKC isoforms. We postulate that PKC mu contains an acidic domain, which is involved in the formation and stabilization of an active state and which, in the inactive enzyme, is blocked by an intramolecular interaction with a basic domain. This intramolecular block is thought to be released by heparin and possibly also by 12-P-tetradecanoylphorbol-13-acetate/phosphatidylserine, whereas basic peptides and proteins inhibit PKC mu activity by binding to the acidic domain of the active enzyme.	UNIV STUTTGART,INST CELL BIOL & IMMUNOL,D-70569 STUTTGART,GERMANY	University of Stuttgart	Gschwendt, M (corresponding author), GERMAN CANC RES CTR,DIV TUMOR CELL REGULAT,D-69009 HEIDELBERG,GERMANY.							BRUNATI AM, 1991, BIOCHIM BIOPHYS ACTA, V1091, P123, DOI 10.1016/0167-4889(91)90232-M; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P343; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Herbert JM, 1996, J BIOL CHEM, V271, P25928; HERBERT JM, 1991, BIOCHIM BIOPHYS ACTA, V1091, P432; HOUSE C, 1989, FEBS LETT, V249, P243, DOI 10.1016/0014-5793(89)80632-5; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LIEBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; Marks Friedrich, 1996, P81, DOI 10.1002/9783527615032.ch3; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PATEL RC, 1994, J BIOL CHEM, V269, P18593; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; Rennecke J, 1996, EUR J BIOCHEM, V242, P428, DOI 10.1111/j.1432-1033.1996.0428r.x; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; ZHAI LM, 1992, BIOCHEM BIOPH RES CO, V189, P944, DOI 10.1016/0006-291X(92)92295-9	29	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20742	20746		10.1074/jbc.272.33.20742	http://dx.doi.org/10.1074/jbc.272.33.20742			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252396	hybrid			2022-12-27	WOS:A1997XR22100066
J	Kumar, AS; Venkatesh, VC; Planer, BC; Feinstein, SI; Ballard, PL				Kumar, AS; Venkatesh, VC; Planer, BC; Feinstein, SI; Ballard, PL			Phorbol ester down-regulation of lung surfactant protein B gene expression by cytoplasmic trapping of thyroid transcription factor-1 and hepatocyte nuclear factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; PULMONARY SURFACTANT; KINASE-C; LOCALIZATION SIGNAL; TNF-ALPHA; FACTOR-I; SP-A; PROMOTER; ENHANCER; INVITRO	The lung-specific surfactant protein B (SP-B) is essen tial for surfactant function and normal respiration, We investigated the role of thyroid transcription factor-1 (TTF-1) and hepatocyte nuclear factor 3 (HNFS) in the down-regulation of SP-B gene expression by phorbol ester in pulmonary adenocarcinoma H441 cells, Responsiveness to 12-O-tetradecanoylphorbol-13-acetate (TPA) localized to the SP-B proximal promoter (-140/-65 bp) and specifically to binding sites for TTF-1 and HNF3, which act as cell specific enhancers of SP-B expression. Treatment of cells with TPA (10 nM) caused a time-dependent decrease in both TTF-1 and HNF3 in nuclear extracts and accumulation of both factors in the cytoplasm as assessed by electromobility shift, Western, Southwestern, and immunofluorescence assays. Treatment did not alter the mRNA content or DNA binding activity for either transcription factor. We conclude that down-regulation of SP-B gene expression by phorbol ester involves cytoplasmic trapping and loss of TTF-1 and HNF3 from the nucleus, This mechanism of action is independent of AP-1 and other transcription factors known to be influenced by phorbol ester.	UNIV PENN,SCH MED,CHILDRENS HOSP,DEPT PEDIAT,ABRAMSON RES CTR 416,PHILADELPHIA,PA 19104; UNIV BRITISH COLUMBIA,DEPT PEDIAT,VANCOUVER,BC V5Z 4H4,CANADA; UNIV PENN,SCH MED,INST ENVIRONM MED,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of British Columbia; University of Pennsylvania					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737, T32HL007748, R01HL053566] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07748, R01 HL53566, PPG HL19737] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; Ballard P L, 1996, J Perinatol, V16, pS28; Ballard PL, 1996, AM J RESP CELL MOL, V14, P599, DOI 10.1165/ajrcmb.14.6.8652188; BALLARD PL, 1989, ENDOCR REV, V10, P165, DOI 10.1210/edrv-10-2-165; BEERS MF, 1995, PEDIATR RES, V38, P668, DOI 10.1203/00006450-199511000-00007; BEERS MF, 1992, AM J RESP CELL MOL, V7, P368, DOI 10.1165/ajrcmb/7.4.368; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DEKOWSKI SA, 1995, PEDIATR RES, V38, P513, DOI 10.1203/00006450-199510000-00007; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERALY SA, 1995, MOL ENDOCRINOL, V9, P848, DOI 10.1210/me.9.7.848; ERNST MK, 1994, EXP CELL RES, V214, P481; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAYASHI Y, 1993, MOL ENDOCRINOL, V7, P1049, DOI 10.1210/me.7.8.1049; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KUMAR AS, 1997, AM J RESP CRIT CARE, V155, pA695; KUMAR AS, 1996, PEDIATR RES, V39, pA359; LEUKEL M, 1995, EUR J CELL BIOL, V68, P133; Lonigro R, 1996, CELL GROWTH DIFFER, V7, P251; MANISCALCO WM, 1994, AM J PHYSIOL-LUNG C, V267, pL569, DOI 10.1152/ajplung.1994.267.5.L569; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; McGonigle B, 1996, GENE DEV, V10, P1812, DOI 10.1101/gad.10.14.1812; NIELSEN HC, 1992, BIOCHIM BIOPHYS ACTA, V1175, P95, DOI 10.1016/0167-4889(92)90014-3; Ohe K, 1996, MOL ENDOCRINOL, V10, P826, DOI 10.1210/me.10.7.826; Planer BC, 1997, BBA-GENE STRUCT EXPR, V1353, P171, DOI 10.1016/S0167-4781(97)00070-5; PRYHUBER GS, 1994, AM J PHYSIOL, V267, pL16, DOI 10.1152/ajplung.1994.267.1.L16; PRYHUBER GS, 1990, J BIOL CHEM, V265, P20822; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Ray MK, 1996, MOL CELL BIOL, V16, P2056; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Saito T, 1997, ENDOCRINOLOGY, V138, P602, DOI 10.1210/en.138.2.602; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; SINGH K, 1990, PLANT CELL, V2, P891, DOI 10.1105/tpc.2.9.891; Solarin KO, 1997, PEDIATR RES, V42, P356, DOI 10.1203/00006450-199709000-00017; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; Suh DS, 1996, MOL ENDOCRINOL, V10, P1227, DOI 10.1210/me.10.10.1227; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; VANDENBROUCK Y, 1995, FEBS LETT, V376, P99, DOI 10.1016/0014-5793(95)01252-X; VENKATESH VC, 1995, AM J PHYSIOL-LUNG C, V268, pL674, DOI 10.1152/ajplung.1995.268.4.L674; Wang DP, 1996, J LIPID RES, V37, P1831; WHITESIDE ST, 1993, J CELL SCI, V104, P949; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WHITSETT JA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P257, DOI 10.1016/0005-2760(92)90004-F; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249	60	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20764	20773		10.1074/jbc.272.33.20764	http://dx.doi.org/10.1074/jbc.272.33.20764			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252399	hybrid			2022-12-27	WOS:A1997XR22100069
J	Xie, XZ; Gillies, RJ; Gerner, EW				Xie, XZ; Gillies, RJ; Gerner, EW			Characterization of a diamine exporter in Chinese hamster ovary cells and identification of specific polyamine substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE; MAMMALIAN-CELLS; ORNITHINE DECARBOXYLASE; PUTRESCINE EXPORT; HEPATOMA-CELLS; RAW-264 CELLS; L1210 CELLS; RAT-LIVER; TRANSPORT; EXCRETION	Export of the diamine putrescine was studied using inside-out plasma membrane vesicles prepared from Chinese hamster cells, Putrescine uptake into vesicles was a saturable and an ATP- and antizyme-independent process, Excess amounts of a series of diamines or mono acetyl spermidine, but not monoacetyl putrescine, spermidine, or spermine, inhibited putrescine transport. Putrescine uptake into vesicles prepared at pH 7.4 was suppressed at pH 5, compared with pH 7.4; was stimulated similar to 2.5-fold at pH 7.4 in vesicles prepared at pH 6.25, compared with vesicles prepared at pH 7.4; and was not inhibited by valinomycin in the presence of potassium ions, Reserpine and verapamil blocked [H-3]putrescine uptake into inverted vesicles. Verapamil treatment caused an increase in intracellular contents of putrescine, cadaverine, and N-8-acetylspermidine, in unstressed proliferating cells, or of N-1-acetylspermidine, in cells subjected to heat shock to induce acetylation of spermidine at N-1, These data indicate that putrescine export in Chinese hamster cells is mediated by a non electrogenic antiporter capable of using protons as the counter ion. Physiological substrates for this exporter include putrescine, cadaverine, and monoacetyl spermidine and have the general structure NH3+-(CH2)(n)-NH2 + R at acidic or neutral pH.	UNIV ARIZONA,ARIZONA CANC CTR,COMM CANC BIOL,TUCSON,AZ 85724; UNIV ARIZONA,ARIZONA CANC CTR,DEPT RADIAT ONCOL,TUCSON,AZ 85724; UNIV ARIZONA,ARIZONA CANC CTR,DEPT BIOCHEM,TUCSON,AZ 85724	Arizona Center Cancer Care; University of Arizona; Arizona Center Cancer Care; University of Arizona; Arizona Center Cancer Care; University of Arizona				Gillies, Robert/0000-0002-8888-7747	NCI NIH HHS [CA-30052, CA-23074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030052, P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED M, 1995, J BACTERIOL, V177, P3904, DOI 10.1128/jb.177.14.3904-3910.1995; AZIZ SM, 1994, BIOCHEM PHARMACOL, V48, P1611, DOI 10.1016/0006-2952(94)90206-2; CARPER SW, 1991, BIOCHEM J, V280, P289, DOI 10.1042/bj2800289; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; DAVIS RH, 1989, ARCH BIOCHEM BIOPHYS, V271, P315, DOI 10.1016/0003-9861(89)90281-6; DAVIS RH, 1990, J CELL BIOCHEM, V44, P199, DOI 10.1002/jcb.240440402; DELLARAGIONE F, 1983, BIOCHEM J, V213, P701, DOI 10.1042/bj2130701; DESIDERIO MA, 1992, EXP CELL RES, V202, P501, DOI 10.1016/0014-4827(92)90105-H; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fukumoto GH, 1996, BBA-BIOMEMBRANES, V1282, P48, DOI 10.1016/0005-2736(96)00036-3; Fukumoto GH, 1997, BBA-BIOMEMBRANES, V1324, P215, DOI 10.1016/S0005-2736(96)00227-1; FULGOSI B, 1991, BIOL CHEM H-S, V372, P79, DOI 10.1515/bchm3.1991.372.1.79; FULLER DJM, 1990, BIOCHEM J, V267, P601, DOI 10.1042/bj2670601; GERNER EW, 1980, ANN NY ACAD SCI, V333, P215; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GRILLO MA, 1994, BIOCHEM SOC T, V22, P894, DOI 10.1042/bst0220894; HARARI PM, 1989, BIOCHEM J, V260, P487, DOI 10.1042/bj2600487; HAWEL L, 1994, J BIOL CHEM, V269, P7412; HAWEL L, 1994, BBA-MOL CELL RES, V1222, P15, DOI 10.1016/0167-4889(94)90020-5; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HYVONEN T, 1989, INT J BIOCHEM, V21, P313, DOI 10.1016/0020-711X(89)90189-4; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KHAN NA, 1994, NEUROPHARMACOLOGY PO, P37; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; NG EYW, 1994, ANTIMICROB AGENTS CH, V38, P1345, DOI 10.1128/AAC.38.6.1345; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1990, BIOCHEM J, V267, P331, DOI 10.1042/bj2670331; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PEGG AE, 1988, CANCER RES, V48, P2678; SAXENA M, 1995, J BIOL CHEM, V270, P5312, DOI 10.1074/jbc.270.10.5312; SCHAUB T, 1991, FEBS LETT, V279, P83, DOI 10.1016/0014-5793(91)80256-3; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SEILER N, 1980, J CHROMATOGR, V221, P227, DOI 10.1016/S0378-4347(00)84307-8; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; Sha Q, 1996, J BIOL CHEM, V271, P3392; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TJANDRAWINATA RR, 1994, BIOCHEM PHARMACOL, V48, P2237, DOI 10.1016/0006-2952(94)00420-X; TJANDRAWINATA RR, 1995, BIOCHEM J, V305, P291, DOI 10.1042/bj3050291; TJANDRAWINATA RR, 1994, J IMMUNOL, V152, P3039; WALLACE HM, 1986, FEBS LETT, V194, P60, DOI 10.1016/0014-5793(86)80051-5; WARREN L, 1959, J BIOL CHEM, V234, P1971; Woolridge DP, 1997, J BIOL CHEM, V272, P8864; Xie XZ, 1997, EXP CELL RES, V230, P386, DOI 10.1006/excr.1996.3442	44	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20484	20489		10.1074/jbc.272.33.20484	http://dx.doi.org/10.1074/jbc.272.33.20484			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252359	hybrid			2022-12-27	WOS:A1997XR22100029
J	Massotte, D; Baroche, L; Simonin, F; Yu, L; Kieffer, B; Pattus, F				Massotte, D; Baroche, L; Simonin, F; Yu, L; Kieffer, B; Pattus, F			Characterization of delta, kappa, and mu human opioid receptors overexpressed in baculovirus-infected insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE G-PROTEINS; FUNCTIONAL EXPRESSION; SF9 CELLS; RECOMBINANT BACULOVIRUS; INTRINSIC ACTIVITY; ADENYLYL-CYCLASE; BINDING PROTEIN; BRAIN MEMBRANES; CHO CELLS; RECONSTITUTION	The cDNAs encoding human delta (hDOR), kappa (hKOR) and mu (hMOR) opioid receptors were cloned in the baculovirus Autographa californica (AcMNPV) under the control of the polyhedrin promoter with or without an amino-terminal hexahistidine tag, Expression levels were optimized in Spodoptera frugiperda (Sf9) cells and were in the following order hMOR > hDOR > hKOR, The receptors bound antagonists with affinity values similar to those published previously for the receptors expressed in mammalian cells, They also retained selectivity toward specific antagonists, The three receptors bound peptidic agonists with low affinity, suggesting that they might not be functionally coupled to intracellular effectors, Introduction of an amino-terminal hexahistidine tag decreased the levels of expression markedly, Only hMOR-his was expressed at a level allowing binding study, but no difference could be detected in the affinities of both agonists and antagonists compared with the nontagged protein, hMOR expression was also optimized in High Five cells leading to a further increase in protein production, The pharmacological profile was similar to the one obtained when the receptor was expressed in Sf9 cells. Our results show that the baculovirus expression system is suitable for large scale production of human opioid receptors.	INDIANA UNIV,SCH MED,DEPT MED & MOL GENET,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis	Massotte, D (corresponding author), ECOLE SUPER BIOTECHNOL STRASBOURG,DEPT RECEPTEURS & PROT MEMBRANAIRES,CNRS UPR 9050,F-67400 ILLKIRCH GRAFFENS,FRANCE.			massotte, dominique/0000-0002-8758-1009				Alkorta I, 1996, PROTEIN ENG, V9, P573, DOI 10.1093/protein/9.7.573; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Befort K, 1996, MOL PHARMACOL, V49, P216; CHAKRABARTI S, 1995, J NEUROCHEM, V64, P2534; CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; CHILDERS SR, 1993, MOL PHARMACOL, V44, P827; DAVIS TR, 1993, IN VITRO CELL DEV-AN, V29A, P388; DONNELLY D, 1994, CURR OPIN STRUC BIOL, V4, P582, DOI 10.1016/S0959-440X(94)90221-6; EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630; FAN LQ, 1995, J NEUROCHEM, V65, P2537; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GRISSHAMMER R, 1995, Q REV BIOPHYS, V28, P315, DOI 10.1017/S0033583500003504; Gruenewald Sylvia, 1996, Biochemistry, V35, P15149; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HabibiNezhad B, 1996, J MOL MODEL, V2, P362, DOI 10.1007/s0089460020362; HEITZ F, 1995, J RECEPT SIGNAL TR R, V15, P55, DOI 10.3109/10799899509045207; HEITZ F, 1996, THESIS U STRASBOURG; HERBERT TE, 1996, J BIOL CHEM, V271, P16384; Hjorth SA, 1996, MOL PHARMACOL, V50, P977; JENKINS N, 1996, NAT BIOTECHNOL, V14, P976; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAW PY, 1995, PHARM OPIOID PEPTIDE, P109; MASSOTTE D, 1995, PROTEIN EXPRES PURIF, V6, P220, DOI 10.1006/prep.1995.1028; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MESTEK A, 1995, J NEUROSCI, V15, P501; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; NEBIGIL CG, 1995, BIOCHEMISTRY-US, V34, P11954, DOI 10.1021/bi00037a037; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; Obermeier H, 1996, EUR J PHARMACOL, V318, P161, DOI 10.1016/S0014-2999(96)00743-1; OKERBLOM C, 1993, BIOCHIM BIOPHYS ACTA, V1176, P269, DOI 10.1016/0167-4889(93)90055-T; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PAJOTAUGY E, 1995, J MOL ENDOCRINOL, V14, P51, DOI 10.1677/jme.0.0140051; PASTERNAK GW, 1986, LIFE SCI, V38, P1889, DOI 10.1016/0024-3205(86)90217-1; PATEL G, 1992, NUCLEIC ACIDS RES, V20, P97, DOI 10.1093/nar/20.1.97; PORTOGHESE PS, 1988, EUR J PHARMACOL, V146, P185, DOI 10.1016/0014-2999(88)90502-X; PRATHER PL, 1995, MOL BRAIN RES, V29, P336, DOI 10.1016/0169-328X(94)00264-F; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; REED L. J., 1938, AMER JOUR HYG, V27, P493; Schertler G. F. X., 1992, CURR OPIN STRUC BIOL, V2, P534, DOI DOI 10.1016/0959-440X(92)90083-J; SCHILLER PW, 1992, P NATL ACAD SCI USA, V89, P11871, DOI 10.1073/pnas.89.24.11871; SIMONIN F, 1995, P NATL ACAD SCI USA, V92, P7006, DOI 10.1073/pnas.92.15.7006; SIMONIN F, 1994, MOL PHARMACOL, V46, P1015; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; UEDA H, 1990, FEBS LETT, V266, P178, DOI 10.1016/0014-5793(90)81534-U; VASUDEVAN S, 1992, FEBS LETT, V311, P7, DOI 10.1016/0014-5793(92)81354-O; VASUDEVAN S, 1995, EUR J BIOCHEM, V227, P466, DOI 10.1111/j.1432-1033.1995.tb20411.x; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; WICKHAM TJ, 1992, BIOTECHNOL PROGR, V8, P391, DOI 10.1021/bp00017a003; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003; ZASTAWNY RL, 1994, 3 DIMENSIONAL CONFOC, P233	56	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19987	19992		10.1074/jbc.272.32.19987	http://dx.doi.org/10.1074/jbc.272.32.19987			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242668	hybrid			2022-12-27	WOS:A1997XQ05900055
J	Lyman, S; Gilmore, A; Burridge, K; Gidwitz, S; White, GC				Lyman, S; Gilmore, A; Burridge, K; Gidwitz, S; White, GC			Integrin-mediated activation of focal adhesion kinase is independent of focal adhesion formation or integrin activation - Studies with activated and inhibitory beta(3) cytoplasmic domain mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; TYROSINE PHOSPHORYLATION; LIGAND-BINDING; CELL-ADHESION; MONOCLONAL-ANTIBODIES; FIBRONECTIN RECEPTOR; PLATELET ACTIVATION; SIGNAL-TRANSDUCTION; FIBRINOGEN BINDING; MOLECULAR-CLONING	Integrin alpha(IIb)beta(3) functions as the fibrinogen receptor on platelets and mediates platelet aggregation and clot retraction. Among the events that occur during either ''inside-out'' or ''outside-in'' signaling through alpha(IIb)beta(3) is the phosphorylation of focal adhesion kinase (pp125(FAK)) and the association of pp125(FAK) with cytoskeletal components. To examine the role of pp125(FAK) in these integrin-mediated events, pp125(FAK) phosphorylation and association with the cytoskeleton was determined in cells expressing two mutant forms of alpha(IIb)beta(3): alpha(IIb)beta(3)(D723A/E726A), a constitutively active integrin in which the putative binding site for pp125(FAK) in altered, and alpha(IIb)beta(3)(F727A/K729E/F730A), in which the putative binding site for a-actinin is altered. Both mutants were expressed on the cell surface and were able to bind ligand, either spontaneously or upon activation. Whereas cells expressing alpha(IIb)beta(3)(D723A/E726A) were able to form focal adhesions and stress fibers upon adherence to fibrinogen, cells expressing alpha(IIb)beta(3)(F727A/K729E/F730A) adhere to fibrinogen, but had reduced focal adhesions and stress fibers. pp125(FAK) is recruited to focal adhesions in adherent cells expressing alpha(IIb)beta(3)(D723A/E726A) and is phosphorylated in adherent cells or in cells in suspension in the presence of fibrinogen. In adherent cells expressing alpha(IIb)beta(3)(F727A/K729E/F730A), pp125(FAK) was phosphorylated despite reduced formation of focal adhesions and stress fibers. We conclude that activation of pp125(FAK) can be dissociated from two important events in integrin signaling, the assembly of focal adhesions in adherent cells and integrin activation following ligand occupation.	UNIV N CAROLINA,DIV HEMATOL ONCOL,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL45100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; BELIN AM, 1996, J CELL BIOL, V132, P211; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BRIESEWITZ R, 1995, MOL BIOL CELL, V6, P997, DOI 10.1091/mbc.6.8.997; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DORAHY DJ, 1995, BIOCHEM J, V309, P481, DOI 10.1042/bj3090481; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GINSBERG MH, 1992, COLD SPRING HARB SYM, V57, P221, DOI 10.1101/SQB.1992.057.01.027; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KATAGIRI Y, 1995, J BIOL CHEM, V270, P1785, DOI 10.1074/jbc.270.4.1785; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOUNS WC, 1994, BLOOD, V84, P1108; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMON KO, 1994, THESIS U N CAROLINA; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAPLEY P, 1989, ONCOGENE, V4, P325; TURNER CE, 1994, J CELL SCI, V107, P1583; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	70	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22538	22547		10.1074/jbc.272.36.22538	http://dx.doi.org/10.1074/jbc.272.36.22538			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278407	hybrid			2022-12-27	WOS:A1997XV49200027
J	Ren, DJ; Hall, LM				Ren, DJ; Hall, LM			Functional expression and characterization of skeletal muscle dihydropyridine receptors in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; BETA-SUBUNIT; CA2+ CHANNEL; ALLOSTERIC REGULATION; RYANODINE RECEPTOR; ALPHA(1) SUBUNIT; CHARGE MOVEMENT; GAMMA-SUBUNITS; CA-2+ CHANNEL; FAST-TWITCH	Dihydropyridine receptors in vertebrate skeletal muscle serve a dual role: as voltage sensors for excitation-contraction coupling and as voltage-activated calcium channels. Although they were the first of six classes of calcium channels to be cloned, skeletal muscle dihydropyridine receptors remain the only ones not functionally expressed as calcium channels in Xenopus oocytes, leading to the hypothesis that an interacting component is missing. Using beta(1b), an isoform previously found in brain, we have for the first time reconstituted skeletal muscle calcium channel function in Xenopus oocytes. We show that this beta subunit is necessary for functional expression and that the alpha(2) delta subunit significantly enhances the expressed current. The majority of the alpha(1) subunit in skeletal muscle is a truncated form. Here we show that both the full-length and truncated forms produce functional calcium channels in Xenopus oocytes, but the truncated form gives significantly larger currents. In addition, we show that the beta(1b) transcript is expressed in rat skeletal muscle, although at a much lower level than the abundant beta(1a) isoform.	SUNY BUFFALO,DEPT BIOCHEM PHARMACOL,BUFFALO,NY 14260; SUNY BUFFALO,DEPT BIOPHYS,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Tuluc, Petronel/C-2527-2011		NHLBI NIH HHS [HL39369] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039369, R37HL039369] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; CASTELLANO A, 1994, BIOCHEM SOC T, V22, P483, DOI 10.1042/bst0220483; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; DASCAL N, 1992, J PHYSIOL-LONDON, V450, P469, DOI 10.1113/jphysiol.1992.sp019137; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; DONALDSON PL, 1983, J GEN PHYSIOL, V82, P449, DOI 10.1085/jgp.82.4.449; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Fleig A, 1996, J PHYSIOL-LONDON, V496, P339, DOI 10.1113/jphysiol.1996.sp021689; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; Johnson BD, 1997, J NEUROSCI, V17, P1243; KIM HS, 1990, J BIOL CHEM, V265, P11858; KRIZANOVA O, 1995, BIOCHEM BIOPH RES CO, V211, P921, DOI 10.1006/bbrc.1995.1900; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LAMB GD, 1987, J PHYSIOL-LONDON, V393, P595, DOI 10.1113/jphysiol.1987.sp016843; LORY P, 1992, BIOPHYS J, V63, P1421, DOI 10.1016/S0006-3495(92)81705-8; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; NARGEOT J, 1992, J MEMBRANE BIOL, V126, P97; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Strube C, 1996, BIOPHYS J, V71, P2531, DOI 10.1016/S0006-3495(96)79446-8; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WANG ZY, 1995, J PHYSIOL-LONDON, V486, P131, DOI 10.1113/jphysiol.1995.sp020797; WEI XY, 1994, J BIOL CHEM, V269, P1635; WEI XY, 1995, J BIOL CHEM, V270, P27106, DOI 10.1074/jbc.270.45.27106; WEI XY, 1991, J BIOL CHEM, V266, P21943; ZHENG W, 1995, J NEUROSCI, V15, P1132	43	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22393	22396		10.1074/jbc.272.36.22393	http://dx.doi.org/10.1074/jbc.272.36.22393			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278387	hybrid			2022-12-27	WOS:A1997XV49200006
J	Shiba, K; Stello, T; Motegi, H; Noda, T; MusierForsyth, K; Schimmel, P				Shiba, K; Stello, T; Motegi, H; Noda, T; MusierForsyth, K; Schimmel, P			Human lysyl-tRNA synthetase accepts nucleotide 73 variants and rescues Escherichia coli double-defective mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SPECIES-SPECIFIC AMINOACYLATION; DISCRIMINATOR BASE; SINGLE NUCLEOTIDE; CRYSTAL-STRUCTURE; BINDING DOMAIN; AMINO-ACIDS; IN-VITRO; SEQUENCE; RECOGNITION	The nucleotide 73 (N-73) ''discriminator'' base in the acceptor stem is a key element for efficient and specific aminoacylation of tRNAs and of microhelix substrates derived from tRNA acceptor stems, This nucleotide was possibly one of the first to be used for differentiating among groups of early RNA substrates by tRNA synthetases, In contrast to many other synthetases, we report here that the class II human lysyl-tRNA synthetase is relatively insensitive to the nature of N-73. We cloned, sequenced, and expressed the enzyme, which is a close homologue of the class II yeast aspartyl-tRNA synthetase whose co-crystal structure (with tRNA(Asp)) is known. The latter enzyme has a strong requirement for G(73), which interacts with 4 of the 14 residues within the ''motif 2'' loop of the enzyme. Even though eukaryotic lysine tRNAs also encode G(73), the motif 2 loop sequence of lysyl-tRNA synthetase differs at multiple positions from that of the aspartate enzyme, Indeed, the recombinant human lysine enzyme shows little preference fair G, and even charges human tRNA transcripts encoding the A(73) found in E. coli lysine tRNAs, Moreover, while the lysine enzyme is the only one in E. coli to be encoded by two separate genes, a double mutant that disables both genes is complemented by a cDNA expressing the human protein. Thus, the sequence of the loop of motif 2 of human lysyl-tRNA synthetase specifies a structural variation that accommodates nucleotide degeneracy at position 73, This sequence might be used as a starting point for obtaining highly specific interactions with any given N-73 by Simple amino acid replacements.	UNIV MINNESOTA, JAPAN SCI & TECHNOL CORP, PRESTO, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Massachusetts Institute of Technology (MIT)	Shiba, K (corresponding author), JAPANESE FDN CANC RES, INST CANC, DEPT CELL BIOL, TOSHIMA KU, TOKYO 170, JAPAN.		Shiba, Kiyotaka/I-9588-2014; Noda, Tetsuo/B-1667-2016	Shiba, Kiyotaka/0000-0001-6459-0204; 				ACHSEL T, 1993, EMBO J, V12, P3333, DOI 10.1002/j.1460-2075.1993.tb06003.x; Agou F, 1996, BIOCHEMISTRY-US, V35, P15322, DOI 10.1021/bi9617926; AULD DS, 1995, SCIENCE, V267, P1994, DOI 10.1126/science.7701322; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHAN VL, 1992, J BACTERIOL, V174, P695, DOI 10.1128/jb.174.3.695-701.1992; CHEN JS, 1994, J BACTERIOL, V176, P2699, DOI 10.1128/JB.176.9.2699-2705.1994; CLARK RL, 1990, J BACTERIOL, V172, P3237, DOI 10.1128/jb.172.6.3237-3243.1990; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRUGIER M, 1994, EMBO J, V13, P2218, DOI 10.1002/j.1460-2075.1994.tb06499.x; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HEDGCOTH C, 1984, NUCLEIC ACIDS RES, V12, P2535, DOI 10.1093/nar/12.5.2535; HIPPS D, 1995, P NATL ACAD SCI USA, V92, P5550, DOI 10.1073/pnas.92.12.5550; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; KAWAKAMI K, 1989, MOL GEN GENET, V219, P333, DOI 10.1007/BF00259604; KAWAKAMI K, 1992, MOL MICROBIOL, V6, P1739, DOI 10.1111/j.1365-2958.1992.tb01346.x; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE CP, 1993, P NATL ACAD SCI USA, V90, P7149, DOI 10.1073/pnas.90.15.7149; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; LI SH, 1993, J BIOL CHEM, V268, P18335; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LIU HJ, 1995, NUCLEIC ACIDS RES, V23, P165, DOI 10.1093/nar/23.1.165; LIU HJ, 1994, BIOCHEMISTRY-US, V33, P12708, DOI 10.1021/bi00208a023; LIU MS, 1993, BIOTECHNIQUES, V15, P264; MARTINEZ R, 1992, EUR J BIOCHEM, V207, P1, DOI 10.1111/j.1432-1033.1992.tb17012.x; Martinis Susan A., 1995, P349; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P6147, DOI 10.1073/pnas.88.14.6147; MCCLAIN WH, 1994, NUCLEIC ACIDS RES, V22, P522, DOI 10.1093/nar/22.3.522; MCCLAIN WH, 1988, J MOL BIOL, V202, P697, DOI 10.1016/0022-2836(88)90551-7; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; NADA S, 1993, J BIOL CHEM, V268, P7660; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Saks ME, 1996, EMBO J, V15, P2843, DOI 10.1002/j.1460-2075.1996.tb00645.x; SALUTA MV, 1995, J BACTERIOL, V177, P1872, DOI 10.1128/jb.177.7.1872-1878.1995; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHIMMEL P, 1995, J MOL EVOL, V40, P531; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; SHIBA K, 1994, J BIOL CHEM, V269, P30049; SHIBA K, 1992, J BIOL CHEM, V267, P22703; SHIBA K, 1995, BIOCHEMISTRY-US, V34, P10340, DOI 10.1021/bi00033a004; SHIBA K, 1994, P NATL ACAD SCI USA, V91, P7435, DOI 10.1073/pnas.91.16.7435; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; YAN W, 1994, J BIOL CHEM, V269, P10022	59	73	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22809	22816		10.1074/jbc.272.36.22809	http://dx.doi.org/10.1074/jbc.272.36.22809			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278442	hybrid			2022-12-27	WOS:A1997XV49200063
J	Takahashi, T; Guron, C; Shetty, S; Matsui, H; Raghow, R				Takahashi, T; Guron, C; Shetty, S; Matsui, H; Raghow, R			A minimal murine Msx-1 gene promoter - Organization of its cis-regulatory motifs and their role in transcriptional activation in cells in culture and in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; APICAL ECTODERMAL RIDGE; DEVELOPING VERTEBRATE LIMBS; HOMEOBOX-CONTAINING GENE; IN-SITU HYBRIDIZATION; RNA-POLYMERASE-II; HOMEOTIC GENES; COLLAGEN GENE; CHROMOSOMAL LOCATION; NUCLEOTIDE-SEQUENCE	To dissect the cis-regulatory elements of the murine Msx-1 promoter, which lacks a conventional TATA element, a putative Msx-1 promoter DNA fragment (from -1282 to +106 base pairs (bp)) or its congeners containing site-specific alterations were fused to luciferase reporter and introduced into NIH3T3 and C2C12 cells, and the expression of luciferase was assessed in transient expression assays, The functional consequences of the sequential 5' deletions of the promotor revealed that multiple positive and negative regulatory elements participate in regulating transcription of the Msx-1 gene, Surprisingly, however, the optimal expression of Msx-1 promoter in either NIH3T3 or C2C12 cells required only 165 bp of the upstream sequence to warrant detailed examination of its structure, Therefore, the functional consequences of site-specific deletions and point mutations of the cis-acting elements of the minimal Msx-1 promoter were systematically examined, Concomitantly, potential transcriptional factor(s) interacting with the cis-acting elements of the minimal promoter were also studied by gel electrophoretic mobility shift assays and DNase I footprinting. Combined analyses of the minimal promoter by DNase I footprinting, electrophoretic mobility shift assays, and super shift assays with specific antibodies revealed that 5'-flanking regions from -161 to -154 and from -26 to -13 of the Msx-1 promoter contains an authentic E box (proximal E box), capable of binding a protein immunologically related to the upstream stimulating factor 1 (USF-1) and a CC-rich sequence motif which can bind to Sp1 (proximal Sp1), respectively, Additionally, we observed that the promoter activation was seriously hampered if the proximal. E box was removed or mutated, and the promoter activity was eliminated completely if the proximal sp1 site was similarly altered, Absolute dependence of the Msx-1 minimal promoter on Sp1 could be demonstrated by transient expression assays in the Sp1-deficient Drosophila cell line cotransfected with Msx-1-luciferase and an Sp1 expression vector pPacSp1, The transgenic mice embryos containing -165/106-bp Msx-1 promoter-LacZ DNA in their genomes abundantly expressed beta-galactosidase in maxillae and mandibles and in the cellular primordia involved in the formation of the meninges and the bones of the skull, Thus, the truncated murine Msx-1 promoter can target expression of a heterologous gene in the craniofacial tissues of transgenic embryos known for high level of expression of the endogenous Msx-1 gene and found to be severely defective in the Msx-1 knock-out mice.	DEPT VET AFFAIRS MED CTR,RES SERV 151,MEMPHIS,TN 38104; UNIV TENNESSEE,COLL MED,DEPT PHARMACOL,MEMPHIS,TN 38163; UNIV TENNESSEE,COLL MED,DEPT MED,MEMPHIS,TN 38163	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center					NIAMS NIH HHS [AR-39166] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039166] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIMENKO MA, 1995, DEVELOPMENT, V121, P347; ARMENDARIZBORUNDA J, 1994, BIOCHEM J, V304, P817, DOI 10.1042/bj3040817; Ausubel FM, 1988, MOL REPROD DEV; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELL JR, 1993, GENOMICS, V16, P123, DOI 10.1006/geno.1993.1149; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; COELHO CND, 1991, DEVELOPMENT, V113, P1487; COELHO CND, 1993, DEV BIOL, V156, P303, DOI 10.1006/dbio.1993.1078; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; CONLON RA, 1993, METHOD ENZYMOL, V225, P373; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; GEHRING WJ, 1992, TRENDS BIOCHEM SCI, V17, P277, DOI 10.1016/0968-0004(92)90434-B; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HOGAN B, 1994, MANIPULATING MOUSE E, P1; HOLLAND PWH, 1991, GENE, V98, P253, DOI 10.1016/0378-1119(91)90182-B; HOLLAND PWH, 1994, DEVELOPMENT, P125; IGNATIUSOU SH, 1994, J VIROL, V68, P7188; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; JOWETT AK, 1993, DEVELOPMENT, V117, P461; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KESSEL M, 1990, SCIENCE, V249, P4374; KRABBENHOFT KM, 1992, DEV DYNAM, V194, P52, DOI 10.1002/aja.1001940107; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUZUOKA M, 1994, GENOMICS, V21, P85, DOI 10.1006/geno.1994.1228; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEVINE EM, 1993, P NATL ACAD SCI USA, V90, P2729, DOI 10.1073/pnas.90.7.2729; MacKenzie A, 1997, MECH DEVELOP, V62, P29, DOI 10.1016/S0925-4773(96)00646-6; MACKENZIE A, 1991, DEVELOPMENT, V111, P269; MACKENZIE A, 1991, DEVELOPMENT, V113, P601; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MANAK JR, 1994, DEVELOPMENT, P61; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; MUNEOKA K, 1992, DEV BIOL, V152, P37, DOI 10.1016/0012-1606(92)90154-9; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; RILEY BB, 1993, DEVELOPMENT, V118, P95; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SATOKATA I, 1994, NAT GENET, V6, P3248; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SIMON HG, 1995, DEV DYNAM, V202, P1, DOI 10.1002/aja.1002020102; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; SU MW, 1991, DEVELOPMENT, V111, P1179; TAKAHASHI Y, 1990, P NATL ACAD SCI USA, V87, P7482, DOI 10.1073/pnas.87.19.7482; Wang QJ, 1996, MOL CELL BIOCHEM, V158, P33; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; YOKOUCHI Y, 1991, DEVELOPMENT, V113, P431; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	75	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22667	22678		10.1074/jbc.272.36.22667	http://dx.doi.org/10.1074/jbc.272.36.22667			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278425	hybrid			2022-12-27	WOS:A1997XV49200045
J	Breyton, C; Tribet, C; Olive, J; Dubacq, JP; Popot, JL				Breyton, C; Tribet, C; Olive, J; Dubacq, JP; Popot, JL			Dimer to monomer conversion of the cytochrome b(6)f complex - Causes and consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; PHOTOSYNTHETIC REACTION-CENTER; CHLAMYDOMONAS-REINHARDTII; C REDUCTASE; 3-DIMENSIONAL STRUCTURE; PHOTOSYSTEM-II; B6-F COMPLEX; BOVINE HEART; BF COMPLEX; RHODOPSEUDOMONAS-VIRIDIS	The molecular weight of the cytochrome b(6)f complex purified from Chlamydomonas reinhardtii thylakoid membranes has been determined by combining velocity sedimentation measurements, molecular sieving analyses, and determination of its lipid and detergent content. The complex in its enzymatically active form is a dimer. Upon incubation in detergent solution, it converts irreversibly into an inactive, monomeric form that has lost the Rieske iron-sulfur protein, the b(6)f-associated chlorophyll, and, under certain conditions, the small 32-residue subunit PetL. The results are consistent with the view that the dimer is the predominant form of the b(6)f in situ while the monomer observed in detergent solution is a breakdown product. Indirect observations suggest that subunit PetL plays a role in stabilizing the dimeric state. Delipidation is shown to be a critical factor in detergent-induced monomerization.	INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE; UNIV PARIS 07,CNRS UPR 9052,F-75005 PARIS,FRANCE; ECOLE SUPER PHYS & CHIM IND VILLE PARIS,F-75231 PARIS 05,FRANCE; UNIV PARIS 06,CNRS URA 278,F-75231 PARIS 05,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,CNRS UMR 9922,F-75251 PARIS 05,FRANCE; ECOLE NORMALE SUPER,CNRS URA 1810,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)			TRIBET, Christophe/N-3390-2019; TRIBET, christophe/C-2868-2008	TRIBET, Christophe/0000-0002-5953-0968; TRIBET, christophe/0000-0002-5953-0968				ADAM Z, 1987, FEBS LETT, V225, P67, DOI 10.1016/0014-5793(87)81132-8; Akiba T, 1996, NAT STRUCT BIOL, V3, P553, DOI 10.1038/nsb0696-553; ATTEIA A, 1994, CR ACAD SCI III-VIE, V317, P11; ATTEIA A, 1992, J BIOL CHEM, V267, P226; Bald D., 1992, RES PHOTOSYNTHESIS, VI, P629; BECHMANN G, 1992, EUR J BIOCHEM, V208, P315, DOI 10.1111/j.1432-1033.1992.tb17189.x; BERRY EA, 1995, ACTA CRYSTALLOGR D, V51, P235, DOI 10.1107/S0907444994010486; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOEKEMA EJ, 1994, J BIOENERG BIOMEMBR, V26, P17, DOI 10.1007/BF00763217; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BREYTON C, 1995, PHOTOSYNTHESIS LIGHT, V2, P591; CHAIN RK, 1985, FEBS LETT, V180, P321, DOI 10.1016/0014-5793(85)81095-4; Chain RK, 1995, PHOTOSYNTH RES, V46, P419, DOI 10.1007/BF00032296; CHAIN RK, 1991, PHOTOSYNTH RES, V28, P59, DOI 10.1007/BF00033715; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRAMER WA, 1994, CURR OPIN STRUC BIOL, V4, P536, DOI 10.1016/S0959-440X(94)90216-X; CRAMER WA, 1987, LIGHT REACTIONS, P447; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P263; DEFORESTA B, 1989, BIOCHEMISTRY-US, V28, P2558, DOI 10.1021/bi00432a032; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DEMANDRE C, 1986, BIOCHIM BIOPHYS ACTA, V877, P380, DOI 10.1016/0005-2760(86)90203-1; deVitry C, 1996, J BIOL CHEM, V271, P10667, DOI 10.1074/jbc.271.18.10667; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; DEVRIES S, 1986, J BIOENERG BIOMEMBR, V18, P195, DOI 10.1007/BF00743464; ENGEL WD, 1983, EUR J BIOCHEM, V132, P395, DOI 10.1111/j.1432-1033.1983.tb07376.x; GONZALEZHALPHEN D, 1991, J BIOL CHEM, V266, P3870; GRAAN T, 1986, ARCH BIOCHEM BIOPHYS, V248, P445, DOI 10.1016/0003-9861(86)90497-2; GUTIERREZCIRLOS EB, 1994, J BIOL CHEM, V269, P9147; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; HOVMOLLER S, 1981, FEBS LETT, V123, P118, DOI 10.1016/0014-5793(81)80033-6; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, FEBS LETT, V134, P1, DOI 10.1016/0014-5793(81)80537-6; HURT E, 1981, EUR J BIOCHEM, V117, P591; Ketchner SL, 1996, BBA-BIOENERGETICS, V1273, P195, DOI 10.1016/0005-2728(95)00157-3; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; LEONARD K, 1981, J MOL BIOL, V149, P259, DOI 10.1016/0022-2836(81)90301-6; LINKE P, 1986, EUR J BIOCHEM, V158, P615, DOI 10.1111/j.1432-1033.1986.tb09799.x; MALKIN R, 1992, PHOTOSYNTH RES, V33, P121, DOI 10.1007/BF00039175; MATAGNE RF, 1989, J CELL BIOL, V108, P1221, DOI 10.1083/jcb.108.4.1221; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; METCALFE LD, 1966, ANAL CHEM, V38, P514, DOI 10.1021/ac60235a044; Moller J. V., 1986, PROGR PROTEIN LIPID, P147; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; MORSCHEL E, 1983, J CELL BIOL, V97, P301, DOI 10.1083/jcb.97.2.301; MOSSER G, 1997, IN PRESS J BIOL CHEM, V272; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P13005, DOI 10.1021/bi00248a009; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V236, P619; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V240, P921; NIEBOER P, 1992, BIOCHIM BIOPHYS ACTA, V1011, P90; NUGENT JHA, 1987, BIOCHIM BIOPHYS ACTA, V893, P177, DOI 10.1016/0005-2728(87)90037-5; ORTIZ W, 1985, BIOCHIM BIOPHYS ACTA, V808, P164, DOI 10.1016/0005-2728(85)90039-8; Pierre Y, 1997, J BIOL CHEM, V272, P21901, DOI 10.1074/jbc.272.35.21901; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; POPOT JL, 1981, EUR J BIOCHEM, V118, P203; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; POPOT JL, 1995, PHOTOSYNTHESIS LIGHT, V2, P507; RICH PR, 1991, BIOCHIM BIOPHYS ACTA, V1058, P312, DOI 10.1016/S0005-2728(05)80252-X; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; RIVAS E, 1980, BIOCHEMISTRY-US, V19, P2943, DOI 10.1021/bi00554a020; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; SCHMIDT CL, 1993, PHOTOSYNTH RES, V38, P73, DOI 10.1007/BF00015063; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SHIMOMURA Y, 1984, J BIOL CHEM, V259, P4059; SHIMOMURA Y, 1984, BIOCHEM INT, V8, P187; SONE N, 1990, BIOCHIM BIOPHYS ACTA, V1020, P207, DOI 10.1016/0005-2728(90)90052-6; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; TSIOTIS G, 1992, RES PHOTOSYNTHESIS, V2, P511; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VALPUESTA JM, 1985, BIOCHIM BIOPHYS ACTA, V807, P96, DOI 10.1016/0005-2728(85)90056-8; WEISS H, 1979, EUR J BIOCHEM, V99, P139, DOI 10.1111/j.1432-1033.1979.tb13240.x; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WOLLMAN FA, 1980, J CELL BIOL, V87, P728, DOI 10.1083/jcb.87.3.728; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; ZHANG H, 1986, J BIOL CHEM, V271, P31360	78	125	126	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21892	21900		10.1074/jbc.272.35.21892	http://dx.doi.org/10.1074/jbc.272.35.21892			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268322	hybrid			2022-12-27	WOS:A1997XT85000034
J	Ichiba, T; Kuraishi, Y; Sakai, O; Nagata, S; Groffen, J; Kurata, T; Hattori, S; Matsuda, M				Ichiba, T; Kuraishi, Y; Sakai, O; Nagata, S; Groffen, J; Kurata, T; Hattori, S; Matsuda, M			Enhancement of guanine-nucleotide exchange activity of C3G for Rap1 by the expression of Crk, CrkL, and Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT MANNER; GTP-BINDING PROTEIN; COMPLEXES IN-VIVO; SH3 DOMAINS; TYROSINE PHOSPHORYLATION; PC12 CELLS; KINETIC-PROPERTIES; MOLECULAR-CLONING; ADAPTER PROTEIN; ENCODE PROTEINS	Crk is an adaptor protein that consists almost entirely of SH2 and SH3 domains, We have previously demonstrated, by using in vivo and in vitro systems, that C3G, which was identified as a Crk SH3 domain-binding guanine nucleotide exchange factor, specifically activates Rap1, C3G also binds to other adaptor proteins, including CrkL and Grb2. In the present study, we analyzed the effect of Crk, CrkL, and Grb2 on the C3G-Rap1 pathway, Expression of Crk, CrkL, and Grb2 with C3G in Cos1 cells significantly increased the ratio of GTP/GDP bound to Rap1, Both the SH2 and SH3 domains of Crk were required for this activity, However, Crk did not stimulate the guanine nucleotide exchange activity of C3G for Rap1 in vitro, suggesting that Crk does not activate C3G by an allosteric mechanism. The requirement of the SH2 domain of Crk for the enhancement of guanine nucleotide exchange activity for Rap1 could be compensated for by the addition of a farnesylation signal to Crk, indicating that Crk enhanced the guanine nucleotide exchange activity of C3G by membrane recruitment of C3G, These results demonstrate that Crk, CrkL, and Grb2 positively modulate the C3G-Rap1 pathway primarily by recruiting C3G to the cell membrane.	NATL INST HLTH,DEPT PATHOL,SHINJUKU KU,TOKYO 162,JAPAN; JIKEI UNIV,SCH MED,DEPT INTERNAL MED 3,MINATO KU,TOKYO 105,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN; INT MED CTR JAPAN,DEPT PATHOL,RES INST,SHINJUKU KU,TOKYO 162,JAPAN; CHILDRENS HOSP,DEPT PATHOL,SECT MOL CARCINOGENESIS,LOS ANGELES,CA 90027	Jikei University; National Center for Neurology & Psychiatry - Japan; National Center for Global Health & Medicine - Japan; Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012; Nagata, Satoshi/B-5781-2008	Heisterkamp, Nora/0000-0003-2769-2273; Nagata, Satoshi/0000-0001-9156-5215; Matsuda, Michiyuki/0000-0002-5876-9969				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HATA Y, 1991, J BIOL CHEM, V266, P6571; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; NAKANISHI H, 1994, BIOCHEM BIOPH RES CO, V198, P1255, DOI 10.1006/bbrc.1994.1177; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ORITA S, 1993, J BIOL CHEM, V268, P25542; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIZON V, 1988, ONCOGENE, V3, P201; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAKODA T, 1992, ONCOGENE, V7, P1705; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; WEINECKE R, 1995, J BIOL CHEM, V270, P16409; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	46	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22215	22220		10.1074/jbc.272.35.22215	http://dx.doi.org/10.1074/jbc.272.35.22215			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268367	hybrid			2022-12-27	WOS:A1997XT85000079
J	Wissink, S; vanHeerde, EC; Schmitz, ML; Kalkhoven, E; vanderBurg, H; Baeuerle, PA; vanderSaag, PT				Wissink, S; vanHeerde, EC; Schmitz, ML; Kalkhoven, E; vanderBurg, H; Baeuerle, PA; vanderSaag, PT			Distinct domains of the RelA NF-kappa B subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; TRANSCRIPTIONAL ACTIVATION; P65 SUBUNIT; TRANSACTIVATION DOMAIN; DNA; PROTEIN; P50; IMMUNOSUPPRESSION; COACTIVATORS; REPRESSION	The RelA subunit of NF-kappa B and the glucocorticoid receptor mutually repress each others transcriptional activity, thus providing a mechanism for immunosuppression, Deletion analysis of the glucocorticoid receptor has shown that the DNA binding domain and the ligand binding domain are essential components for repression, Here, we show by deletions and point mutations that both the Rel homology domain and the transactivation domains of RelA are required for repression of the transcriptional activity of the glucocorticoid receptor in intact cells, However, only the Rel homology domain of RelA was found to associate with the glucocorticoid receptor in vitro. RelA mutants, not able to repress glucocorticoid receptor activity, but still able to dimerize, behaved as transdominant inhibitors of the repressive activity of wild type RelA. Furthermore, we show that the 13 S E1A protein is able to interfere with the transrepressive activity of RelA. We propose that negative cross-talk between the glucocorticoid receptor and RelA is due to direct interaction via the Rel homology domain of RelA and the DNA binding domain of the glucocorticoid receptor in combination with interference by the transactivation domains of RelA with the transcriptional activity of the glucocorticoid receptor.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS; UNIV FREIBURG,INST BIOCHEM & MOL BIOL,FREIBURG,GERMANY	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of Freiburg			Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; FOLKERS GE, 1995, MOL CELL BIOL, V15, P5868; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHMITZ ML, 1996, MOL CELL BIOL, V15, P4052; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185	35	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22278	22284		10.1074/jbc.272.35.22278	http://dx.doi.org/10.1074/jbc.272.35.22278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268377	hybrid			2022-12-27	WOS:A1997XT85000089
J	Gunnery, S; Maivali, U; Mathews, MB				Gunnery, S; Maivali, U; Mathews, MB			Translation of an uncapped mRNA involves scanning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MESSENGER-RNAS; MOSAIC-VIRUS; REINITIATION; INITIATION; GENE; TRANSCRIPTION; INHIBITION; EFFICIENCY; MECHANISM; SEQUENCE	tat, an essential gene of human immunodeficiency virus, when placed under the control of the RNA polymerase III promoter from the adenovirus VA RNA(1) gene, is transcribed into an uncapped and nonpolyadenylated mRNA, This VA-Tat RNA is translated to produce functional Tat protein in transfected mammalian cells (Gunnery, S., and Mathews, M. B. (1995) Mol. Cell. Biol. 15, 3597-3607), The presence of an upstream open reading frame (ORF) in VA-Tat RNA is inhibitory to the translation of the Tao ORF, suggesting that the RNA is scanned during translation even though it is uncapped. Because the effect of the upstream ORF is relatively small (about a-fold), we sought more definitive evidence of scanning by introducing secondary structures of varying stabilities into the 5'-untranslated region of VA-Tat RNA, The results of transfection experiments showed that highly stable secondary structure was inhibitory to Tat synthesis, whereas structures of lower stability were not inhibitory, confirming that uncapped mRNA is subject to scanning, Furthermore, translation of the downstream ORF was reduced but not eliminated by mutations that caused the upstream ORF to overlap the Tar ORF. Extending the overlap of the two ORFs further decreased the translation of the downstream ORF, This observation implies that ribosomes reinitiate after termination, possibly after migrating in a 3' to 5' direction through the overlap region of the mRNA, Similar results were obtained with a capped polymerase II transcript, indicating that the translation of polymerase II and polymerase III transcripts occurs through similar mechanisms.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory					NCI NIH HHS [CA13106] Funding Source: Medline; NIAID NIH HHS [AI31822] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031822] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; CAO JH, 1995, J VIROL, V69, P1030, DOI 10.1128/JVI.69.2.1030-1036.1995; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLETCHER L, 1990, J BIOL CHEM, V265, P19582; GALLIE DR, 1990, GENE DEV, V4, P1149, DOI 10.1101/gad.4.7.1149; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GRANT CM, 1994, MOL CELL BIOL, V14, P2616, DOI 10.1128/MCB.14.4.2616; GUNNERY S, 1995, MOL CELL BIOL, V15, P3597; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; JANZ L, 1994, MOL CELL BIOL, V14, P5804, DOI 10.1128/MCB.14.9.5804; JOHANSEN H, 1984, P NATL ACAD SCI-BIOL, V81, P7698, DOI 10.1073/pnas.81.24.7698; KOZAK M, 1991, GENE EXPRESSION, V1, P111; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; MICHELET B, 1994, PLANT CELL, V6, P1375, DOI 10.1105/tpc.6.10.1375; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; Peterlin B. Matija, 1993, P75; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; Sambrook J., 2002, MOL CLONING LAB MANU; Sonenberg Nahum, 1993, Gene Expression, V3, P317; THOMAS KR, 1986, NATURE, V324, P34, DOI 10.1038/324034a0; TIMMER RT, 1993, J BIOL CHEM, V268, P9504	26	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21642	21646		10.1074/jbc.272.34.21642	http://dx.doi.org/10.1074/jbc.272.34.21642			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261187	hybrid			2022-12-27	WOS:A1997XR78900097
J	Li, HL; Bergeron, L; Cryns, V; Pasternack, MS; Zhu, H; Shi, LF; Greenberg, A; Yuan, JY				Li, HL; Bergeron, L; Cryns, V; Pasternack, MS; Zhu, H; Shi, LF; Greenberg, A; Yuan, JY			Activation of caspase-2 in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROGRAMMED CELL-DEATH; FAS-MEDIATED APOPTOSIS; GENE CED-3; IL-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASES; ICE/CED-3 PROTEASE; COLORIMETRIC ASSAY; MOLECULAR-CLONING; MAMMALIAN HOMOLOG	Members of the CED-3/interleukin-1 beta-converting enzyme (ICE) protease (caspase) family are synthesized as proforms, which are proteolytically cleaved and activated during apoptosis. We report here that caspase-2 (ICH-1/NEDD-2), a member of the ICE family, is activated during apoptosis by another ICE member, a caspase-3 (CPP32)-like protease(s). When cells are induced to undergo apoptosis, endogenous caspase-2 is first cleaved into three fragments of 32-33 kDa and 14 kDa, which are then further processed into 18- and 12-kDa active subunits. Up to 50 mu m N-acetyl-Asp-Glu-Val-Asp-aldehyde (DEVD-CHO), a caspase-3-preferred peptide inhibitor, inhibits caspase-2 activation and DNA fragmentation in vivo, but does not prevent lass of mitochondrial function, while higher concentrations of DEVD-CHO (>50 mu M) inhibit both. In comparison, although the activity of caspase-3 is very sensitive to the inhibition of DEVD-CHO (<50 nm), inhibition of caspase-3 activation as marked by processing of the proform requires more than 100 mu M DEVD-CHO. Our results suggest that the first cleavage of caspase-2 is accomplished by a caspase-3-like activity, and other ICE-hire proteases less sensitive to DEVD-CHO may be responsible for activation of caspase-3 and loss of mitochondrial function.	MASSACHUSETTS GEN HOSP E,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CHARLESTOWN,MA 02129; UNIV MANITOBA,MANITOBA INST CELL BIOL,MANITOBA CANC TREATMENT & RES FDN,WINNIPEG,MB R3E 0V9,CANADA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Manitoba				Zhu, Hong/0000-0002-2575-4031	NCI NIH HHS [K08-CA01752] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001752] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anel A, 1997, J IMMUNOL, V158, P1999; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CARMICHAEL J, 1987, CANCER RES, V47, P943; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hasegawa J, 1996, CANCER RES, V56, P1713; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	54	164	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21010	21017		10.1074/jbc.272.34.21010	http://dx.doi.org/10.1074/jbc.272.34.21010			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261102	hybrid, Green Published			2022-12-27	WOS:A1997XR78900012
J	McLachlin, DT; Dunn, SD				McLachlin, DT; Dunn, SD			Dimerization interactions of the b subunit of the Escherichia coli F1F0-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-SYNTHASE; PROTEINS; MECHANISM; F1-ATPASE; BINDING; SECTOR; F1F0; MUTAGENESIS; STABILITY; BACTERIA	Site-directed mutagenesis and N-terminal truncations were used to examine dimerization interactions in the b subunit of Escherichia coli F1F0-ATPase. Individual cysteine residues were incorporated into b(syn), a soluble form of the protein lacking the membrane-spanning N-terminal domain, in two main areas: the heptad repeat region and the hydrophobic region which begins at residue Val-124. The tendencies of these cysteine residues to form disulfide bonds with the corresponding cysteine in the b(syn) dimer were tested using disulfide exchange by glutathione and air oxidation catalyzed by Cu2+. Within the heptad repeat region, only cysteines at residues 59 and 60, which occupy the b and c positions of the heptad repeat, showed significant tendencies to form disulfides, a result inconsistent with a coiled-coil model for b(syn). Mixed disulfide formation most readily occurred with the S60C + L65C and A61C + L65C pairs, Cysteines at positions 124, 128, 132, and 139 showed strong tendencies to form disulfides with their mates in the dimer, suggesting a parallel alpha-helical interaction between the subunits in this region, Deletion of residues N-terminal to either Glu-34 or Asp-53 had no apparent effect on dimerization as determined by sedimentation equilibrium, while deletion of all residues N-terminal to Lys-67 produced a monomeric form, These results imply that residues 53-66 but not 24-52 are essential for b(syn) dimerization, Taken together the results are consistent with a model in which the two b subunits interact in more than one region, including a parallel alignment of helices containing residues 124-139.	UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON,ON N6A 5C1,CANADA	Western University (University of Western Ontario)			Dunn, Stanley/D-3418-2013					AHMED AK, 1975, J BIOL CHEM, V250, P8477; Blair A, 1996, MICROBIOL-SGM, V142, P17, DOI 10.1099/13500872-142-1-17; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1992, J BIOL CHEM, V267, P7630; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Fillingame RH, 1997, J EXP BIOL, V200, P217; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Gray W R, 1972, Methods Enzymol, V25, P121, DOI 10.1016/S0076-6879(72)25010-8; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; Howitt SM, 1996, J BIOL CHEM, V271, P7038, DOI 10.1074/jbc.271.12.7038; JANS DA, 1985, J BACTERIOL, V162, P420, DOI 10.1128/JB.162.1.420-426.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1996, PROTEIN EXPRES PURIF, V7, P275, DOI 10.1006/prep.1996.0039; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; NAKAMOTO RK, 1996, BIOMEMBR, V5, P343; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; Smith SP, 1996, BIOCHEMISTRY-US, V35, P8805, DOI 10.1021/bi952698c; TAKAGI T, 1964, J BIOCHEM-TOKYO, V56, P344, DOI 10.1093/oxfordjournals.jbchem.a127999; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VIK SB, 1994, J BIOL CHEM, V269, P30364; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WILKENS S, 1994, FEBS LETT, V354, P37, DOI 10.1016/0014-5793(94)01059-5; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P3178, DOI 10.1021/bi00063a033	37	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21233	21239		10.1074/jbc.272.34.21233	http://dx.doi.org/10.1074/jbc.272.34.21233			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261132	hybrid			2022-12-27	WOS:A1997XR78900042
J	Pantazatos, DP; MacDonald, RI				Pantazatos, DP; MacDonald, RI			Site-directed mutagenesis of either the highly conserved Trp-22 or the moderately conserved Trp-95 to a large, hydrophobic residue reduces the thermodynamic stability of a spectrin repeating unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL UNIT; COMPLETE SEQUENCE; ALPHA-SPECTRIN; DYSTROPHIN; TRYPTOPHAN; PROTEINS; MUTATIONS; MEMBRANE; DOMAINS; ACTININ	As reported previously (MacDonald, a. I., Musacchio, ih,, Holmgren, R. a., and Saraste, M. (1994) PI oc. Natl. Acad Sci. U. S. A. 91, 1299-1303), an unfolded peptide was obtained by site-directed mutagenesis of Trp-22 to Ala in the cloned, wild type 17th repeating unit (alpha 17) of chicken brain alpha-spectrin, Trp occurs in position 22 of nearly all repeating units of spectrin, In the present study, Trp-22 was mutated to Phe or to Tyr to compare thermodynamic stabilities of urea-induced unfolding of alpha 16 and mutants thereof, alpha 16 was chosen for this study instead of alpha 17, because alpha 16 has two tryptophans, allowing urea-induced unfolding to be tracked by the fluorescence of the Trp remaining in each mutant peptide and by circular dichroism in the far UV. The free energies of unfolding of W22Y and W22F were 50% that of alpha 16, showing that Trp-22 if crucial in stabilizing the triple helical bundle motif of the spectrin repeating unit, Mutation of the moderately conserved Trp-95 of alpha 16 to Val, which occupies position 95 in alpha 17, also yielded a peptide? with 50% of the free energy of unfolding of alpha 16, Thus, the thermodynamic stability of a given spectrin repeating unit may depend on both moderately and highly conserved tryptophans. Different structural roles: of Trp-22 and Trp-95 in alpha 16 are suggested by the slightly higher wavelength of maximum emission of Trp-22, the greater acrylamide quenching of Trp-95 than Trp-22, and the longer lifetime of Trp-95. For comparison with alpha 16, urea-induced unfolding of spectrin dimer isolated from human red cells was monitored by far W-CD and by tryptophan fluorescence, Thermodynamic parameters could not be rigorously derived for the stability of spectrin dimer because unfolding of spectrin dimer involved more than two states, unlike unfolding of cloned repeating units. However, the similar midpoints of CD-monitored denaturation curves of alpha 16 and spectrin dimer, i.e, 2.7 and 3.2 Rr urea, respectively, indicate that investigation of cloned repeating units of spectrin can provide physiologically relevant information an these structures.	NORTHWESTERN UNIV,DEPT BIOCHEM MOL BIOL & CELL BIOL,EVANSTON,IL 60208	Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045168] Funding Source: NIH RePORTER; NHLBI NIH HHS [1PO1 HL45168] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BIER M, 1957, METHOD ENZYMOL, V4, P147, DOI 10.1016/0076-6879(57)04053-7; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BUDZYNSKI DM, 1992, BIOCHEMISTRY-US, V31, P3653, DOI 10.1021/bi00129a014; Calvert R, 1996, BIOPHYS J, V71, P1605, DOI 10.1016/S0006-3495(96)79363-3; DAVISON MD, 1989, INT J BIOL MACROMOL, V11, P81, DOI 10.1016/0141-8130(89)90047-0; DeSilva TM, 1997, BIOCHEMISTRY-US, V36, P3991, DOI 10.1021/bi962412j; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; Dubreuil RR, 1996, CURR TOP MEMBR, V43, P147; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; FASMAN GD, 1989, PRACTICAL HDB BIOCH, P81; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hanahan D., 1985, TECHNIQUES TRANSFORM, P109; HARRIS DL, 1990, BIOCHEMISTRY-US, V29, P5276, DOI 10.1021/bi00474a009; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P16; KAHANA E, 1995, BIOCHEMISTRY-US, V34, P8110, DOI 10.1021/bi00025a017; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAWS WR, 1992, METHOD ENZYMOL, V210, P448; LUX SE, 1995, DISORDERS RED CELL M, P1701; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; Menhart N, 1996, J BIOL CHEM, V271, P30410, DOI 10.1074/jbc.271.48.30410; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PALEK J, 1992, BLOOD, V80, P308; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; Pascual J, 1996, FEBS LETT, V383, P201, DOI 10.1016/0014-5793(96)00251-7; Ralston G, 1996, BIOCHEMISTRY-US, V35, P5257, DOI 10.1021/bi952224d; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P4901, DOI 10.1021/bi00135a022; SCHOLTZ JM, 1995, P NATL ACAD SCI USA, V92, P185, DOI 10.1073/pnas.92.1.185; SPANGLER CJ, 1992, METHOD ENZYMOL, V210, P305; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUBBARAO NK, 1993, ANALYST, V118, P913, DOI 10.1039/an9931800913; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WINDER SJ, 1995, FEBS LETT, V369, P27, DOI 10.1016/0014-5793(95)00398-S; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YAO M, 1995, BIOCHEMISTRY-US, V34, P3771, DOI 10.1021/bi00011a035	45	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21052	21059		10.1074/jbc.272.34.21052	http://dx.doi.org/10.1074/jbc.272.34.21052			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261107	hybrid			2022-12-27	WOS:A1997XR78900017
J	Bishopric, NH; Zeng, GQ; Sato, B; Webster, KA				Bishopric, NH; Zeng, GQ; Sato, B; Webster, KA			Adenovirus E1A inhibits cardiac myocyte-specific gene expression through its amino terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; ALPHA-ACTIN GENE; HEAVY-CHAIN GENE; MUSCLE-SPECIFIC EXPRESSION; SERUM RESPONSE FACTOR; RETINOBLASTOMA PROTEIN; ENHANCER-BINDING; SKELETAL-MUSCLE; DNA-SYNTHESIS; CELL-GROWTH	Adenovirus E1A oncoproteins inhibit muscle specific gene expression and myogenic differentiation by suppressing the transcriptional activating functions of basic helix-loop-helix proteins. As one approach to identifying cardiac-specific gene regulatory proteins, we analyzed the functional regions of E1A proteins that are required for muscle gene repression in cardiac cells, Myocyte-specific promoters, including the alpha-actins and alpha-myosin heavy chain, were selectively and potently inhibited (> 90%) by E1A, while the ubiquitously expressed beta-actin promoter was only partially (similar to 30%) repressed; endogenous gene expression was also affected. Distinct E1A protein binding sites mediated repression of muscle-specific and ubiquitous actin promoters. E1A-mediated inhibition of beta-actin required both an intact binding site for the tumor repressor proteins pRb and p107 and a second E1A domain (residues 15-35). In contrast, cardiac specific promoter repression required the E1A amino-terminal residues 2-36. The proximal skeletal actin promoter (3' to base pair -153) was a target for repression by E1A. Although E1A binding to p300 was not required for inhibition of either promoter, co-expression of p300 partially reversed E1A-mediated transcriptional repression. We conclude that cardiac-specific and general promoter inhibition by E1A occurs by distinct mechanisms and that cardiac-specific gene expression is modulated by cellular factors interacting with the E1A p300/CBP-binding domain.	SRI INT, MOL CARDIOL LAB, MENLO PK, CA 94125 USA	SRI International				Webster, Keith A/0000-0002-6431-3642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044578, R01HL044578, R01HL049891] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49891, HL44578] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Akusjarvi G, 1993, Trends Microbiol, V1, P163, DOI 10.1016/0966-842X(93)90085-6; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BANERJEE AC, 1994, ONCOGENE, V9, P1733; BARBEAU D, 1994, ONCOGENE, V9, P359; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P20932; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FLINT SJ, 1984, MOL CELL BIOL, V4, P1363, DOI 10.1128/MCB.4.7.1363; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; GIORDANO A, 1991, ONCOGENE, V6, P481; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSWAMI S, 1994, MOL CELL BIOL, V14, P5130, DOI 10.1128/MCB.14.8.5130; Green M, 1979, Methods Enzymol, V58, P425; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KAO HT, 1986, NUCLEIC ACIDS RES, V14, P7253, DOI 10.1093/nar/14.18.7253; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LI HO, 1995, BIOCHIM BIOPHYS ACTA, V266, P148; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Liu Y, 1996, J CELL BIOL, V133, P325, DOI 10.1083/jcb.133.2.325; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NEVINS JR, 1993, BIOCHEM SOC T, V21, P935, DOI 10.1042/bst0210935; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; SHENK T, 1991, ADV CANCER RES, V57, P47; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; VIERRA CA, 1995, MOL ENDOCRINOL, V9, P64, DOI 10.1210/me.9.1.64; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	91	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20584	20594		10.1074/jbc.272.33.20584	http://dx.doi.org/10.1074/jbc.272.33.20584			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252373	hybrid			2022-12-27	WOS:A1997XR22100043
J	Lin, KM; Wenegieme, E; Lu, PJ; Chen, CS; Yin, HL				Lin, KM; Wenegieme, E; Lu, PJ; Chen, CS; Yin, HL			Gelsolin binding to phosphatidylinositol 4,5-bisphosphate is modulated by calcium and pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-FILAMENTS; MONOMER-BINDING; PHOSPHOLIPASE-C; HUMAN-NEUTROPHILS; CAPPING PROTEIN; HUMAN-PLATELETS; DOMAIN; IDENTIFICATION; POLYMERIZATION; TRISPHOSPHATE	The actin cytoskeleton of nonmuscle cells undergoes extensive remodeling during agonist stimulation, Lamellipodial extension is initiated by uncapping of actin nuclei at the cortical cytoplasm to allow filament elongation, Many actin filament capping proteins are regulated by phosphatidylinositol 4,5-bisphosphate (PIP2), which is hydrolyzed by phospholipase C. It is hypothesized that PIP2 dissociates capping proteins from filament ends to promote actin assembly, However, since actin polymerization often occurs at a time when PIP2 concentration is decreased rather than increased, capping protein interactions with PIP2 may not be regulated solely by the bulk PIP2 concentration. We present evidence that PIP2 binding to the gelsolin family of capping proteins is enhanced by Ca2+. Binding was examined by equilibrium and nonequilibrium gel filtration and by monitoring intrinsic tryptophan fluorescence, Gelsolin and CapG affinity for PIP2 were increased 8- and 4-fold, respectively, by mu M Ca2+, and the Ca2+ requirement was reduced by lowering the pH from 7.5 to 7.0. Studies with the NH2- and COOH-terminal halves of gelsolin showed that PIP2 binding occurred primarily at the NH2-terminal half, and Ca2+ exposed its PIP2 binding sites through a change in the COOH-terminal half, Mild acidification promotes PIP2 binding by directly affecting the NH2-terminal sites, Our findings can explain increased PIP2-induced uncapping even as the PIP2 concentration drops during cell activation. The change in gelsolin family PIP2 binding affinity during cell activation can impact divergent PIP2-dependent processes by altering PIP2 availability, Cross-talk between these proteins provides a multilayered mechanism for positive and negative modulation of signal transduction from the plasma membrane to the cytoskeleton.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235; UNIV KENTUCKY,COLL PHARM,DIV MED CHEM & PHARMACEUT,LEXINGTON,KY 40536	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Kentucky					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017997, R01GM053448] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM5112, GM17997, GM53448] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APGAR JR, 1995, MOL BIOL CELL, V6, P97, DOI 10.1091/mbc.6.1.97; Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; BANNO Y, 1992, J BIOL CHEM, V267, P6488; Barkalow K, 1996, J CELL BIOL, V134, P389, DOI 10.1083/jcb.134.2.389; BENGTSSON T, 1988, J BIOL CHEM, V263, P17385; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAMB JA, 1993, J BIOL CHEM, V268, P8999; LASSING I, 1985, NATURE, V314, P604; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; RITTENHOUSE SE, 1985, J BIOL CHEM, V260, P8657; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SELVE N, 1987, EUR J BIOCHEM, V168, P111, DOI 10.1111/j.1432-1033.1987.tb13394.x; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Singh SS, 1996, BIOCHEMISTRY-US, V35, P16544, DOI 10.1021/bi9609634; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; SUN HQ, 1994, J BIOL CHEM, V269, P9473; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; VANPARIDON PA, 1986, BIOCHIM BIOPHYS ACTA, V877, P216, DOI 10.1016/0005-2760(86)90137-2; VANTROYS M, 1996, FEBS LETT, V96, P191; WARD LD, 1985, METHOD ENZYMOL, V117, P400; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1980, J BIOL CHEM, V255, P9494; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YOUNG CL, 1994, J BIOL CHEM, V269, P13997; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269; YU FX, 1992, J BIOL CHEM, V267, P14616; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	60	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20443	20450		10.1074/jbc.272.33.20443	http://dx.doi.org/10.1074/jbc.272.33.20443			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252353	hybrid			2022-12-27	WOS:A1997XR22100023
J	PattonVogt, JL; Griac, P; Sreenivas, A; Bruno, V; Dowd, S; Swede, MJ; Henry, SA				PattonVogt, JL; Griac, P; Sreenivas, A; Bruno, V; Dowd, S; Swede, MJ; Henry, SA			Role of the yeast phosphatidylinosito/phosphatidylcholine transfer protein (sec14p) in phosphatidylcholine turnover and INO1 regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PHOSPHOLIPID TRANSFER PROTEINS; CROSS-PATHWAY REGULATION; CDP-CHOLINE PATHWAY; SACCHAROMYCES-CEREVISIAE; INOSITOL SYNTHESIS; BIOSYNTHESIS; GENE; METHYLATION; MUTANTS	In yeast, mutations in the CDP-choline pathway for phosphatidylcholine biosynthesis permit the cell to grow even when the SEC14 gene is completely deleted (Cleves, A., McGee, T., Whitters, E,, Champion, K,, Aitken, J,, Dowhan, W,, Goebl, M,, and Bankaitis, V, (1991) Cell 64, 789-800), We report that strains carrying mutations in the CDP-choline pathway, such as cki1, exhibit a choline excretion phenotype due to production of choline during normal turnover of phosphatidylcholine, Cells carrying cki1 in combination with sec14(ts), a temperature-sensitive allele in the gene encoding the phosphatidylinositol/phosphatidylcholine transporter, have a dramatically increased choline excretion phenotype when grown at the sec14(ts)-restrictive temperature, We show that the increased choline excretion in sec14(ts) cki1 cells is due to increased turnover of phosphatidylcholine via a mechanism consistent with phospholipase D-mediated turnover, We propose that the elevated rate of phosphatidylcholine turnover in sec14(ts) cki1 cells provides the metabolic condition that permits the secretory pathway to function when Sec14p is inactivated, As phosphatidylcholine turnover increases in sec14(ts) cki1 cells shifted to the restrictive temperature, the INO1 gene (encoding inositol-l-phosphate synthase) is also derepressed, leading to an inositol excretion phenotype (Opi(-)). Misregulation of the INO1 gene has been observed in many strains with altered phospholipid metabolism, and the relationship between phosphatidylcholine turnover and regulation of INO1 and other coregulated genes of phospholipid biosynthesis is discussed.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213; SLOVAK ACAD SCI,INST ANIM BIOCHEM & GENET,IVANKA PRI DUNAJ 90028,CZECH REPUBLIC; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Carnegie Mellon University; Slovak Academy of Sciences; Washington University (WUSTL)			Henry, Susan/K-5464-2014; , Peter/ABA-9227-2020; Swede, Marci/AAD-3921-2021	, Peter/0000-0003-3538-0405; Swede, Marci/0000-0002-3003-4258	NIGMS NIH HHS [GM-19629] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019629, R37GM019629] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BREMER J, 1960, BIOCHIM BIOPHYS ACTA, V37, P173, DOI 10.1016/0006-3002(60)90104-9; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GREENBERG ML, 1983, J BACTERIOL, V153, P791, DOI 10.1128/JB.153.2.791-799.1983; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; GRIAC P, 1996, NATO ASI SERIES MOL, V96, P339; HELMKAMP GM, 1986, J BIOENERG BIOMEMBR, V18, P71, DOI 10.1007/BF00743477; HENRY SA, 1982, MOL BIOL YEAST SACCH, V2, P101; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HONIGBERG SM, 1992, GENETICS, V130, P703; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HUDAK KA, 1994, GENETICS, V136, P475; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KODAKI T, 1987, J BIOL CHEM, V262, P15428; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LAMPING E, 1995, GENETICS, V137, P55; LEE KS, 1994, J BIOL CHEM, V269, P19725; LETTS VA, 1985, J BACTERIOL, V163, P560, DOI 10.1128/JB.163.2.560-567.1985; Liscovitch M, 1996, J LIPID MEDIAT CELL, V14, P215, DOI 10.1016/0929-7855(96)00528-7; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Seaman MNJ, 1996, TRENDS CELL BIOL, V6, P473, DOI 10.1016/0962-8924(96)84944-0; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; SUMMERS EF, 1988, GENETICS, V120, P909; SWEDE M, 1994, THESIS CARNEGIE MELL; SWEDE MJ, 1992, METHOD ENZYMOL, V29, P21; SZOLDERITS G, 1989, BIOCHIM BIOPHYS ACTA, V986, P301, DOI 10.1016/0005-2736(89)90481-1; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; WIRTZ KWA, 1990, EXPERIENTIA, V46, P592, DOI 10.1007/BF01939698	51	115	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20873	20883		10.1074/jbc.272.33.20873	http://dx.doi.org/10.1074/jbc.272.33.20873			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252414	hybrid			2022-12-27	WOS:A1997XR22100084
J	Yu, H; Kaung, G; Kobayashi, S; Kopito, RR				Yu, H; Kaung, G; Kobayashi, S; Kopito, RR			Cytosolic degradation of T-cell receptor alpha chains by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ANTIGEN RECEPTOR; ORNITHINE DECARBOXYLASE; PROTEIN; PATHWAY; HYBRID; REDUCTASE; RETENTION; SUBUNIT	The T-cell antigen receptor (TCR) is an hetero-oligomeric membrane complex composed of at least seven transmembrane polypeptide chains that has served as a model for the assembly and degradation of integral membrane proteins in the endoplasmic reticulum (ER), Unassembled TCR alpha chains fail to mature to the Golgi apparatus and are rapidly degraded by a non-lysosomal ''ER degradation'' pathway that has been proposed to be autonomous to the ER. In these studies we show that the degradation of core glycosylated TCR alpha is blocked by N-acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN) and lactacystin, implicating the proteasome in ER degradation, Either acute or chronic treatment of TCR alpha-transfected cells with proteasome inhibitors cause the core-glycosylated TCR alpha chains to progressively shift to an similar to 28-kDa form that lacks N-linked oligosaccharides and the N-terminal signal peptide. The susceptibility of this 28-kDa species to extravesicular protease indicates that it is not protected by the ER membrane and, hence, cytoplasmic, These data suggest a model in which TCR alpha chains that are translocated across the membrane, core-glycosylated, but fail to assemble are dislocated back to the cytoplasm for degradation by cytoplasmic proteasomes. Our data also suggest that covalent modification of TCR alpha with ubiquitin is not required for its degradation.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43994] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; Bonifacino JS, 1996, NATURE, V384, P405, DOI 10.1038/384405a0; BONIFACINO JS, 1988, J BIOL CHEM, V263, P8965; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; INOUE S, 1992, J BIOL CHEM, V267, P9080; JOHNSTON JA, 1995, J BIOL CHEM, V270, P8172, DOI 10.1074/jbc.270.14.8172; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1985, J IMMUNOL, V134, P2529; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	32	200	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20800	20804		10.1074/jbc.272.33.20800	http://dx.doi.org/10.1074/jbc.272.33.20800			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252404	hybrid			2022-12-27	WOS:A1997XR22100074
J	Chen, DS; Davies, MPA; Rudland, PS; Barraclough, R				Chen, DS; Davies, MPA; Rudland, PS; Barraclough, R			Transcriptional down-regulation of the metastasis-inducing S100A4 (p9Ka) in benign but not in malignant rat mammary epithelial cells by GC-factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MTS1 GENE; MESSENGER-RNA; MOLECULAR-CLONING; ELONGATED CELLS; DNA; TUMOR; LINES; EXPRESSION; TRANSFECTION	The S100-related calcium-binding protein S100A4 (p9Ka) is expressed at a low level in rat mammary epithelial cells from normal mammary gland and benign mammary tumors, In transgenic mice, expressed rat S100A4 transgenes co-operate with the activated c-erbB-2 oncogene, neu, to form metastatic mammary tumors, Elevated levels of S100A4 (p9Ka) in cultured benign rat or mouse mammary epithelial cells are associated with the induction of metastatic capability, A cis-acting sequence related to the consensus recognition sequence of GC-factor, 1,300 base pairs upstream of the start site of transcription of the rat S100A4 gene, acts as a cis-acting inhibitor of transcription of the S100A4 (p9Ka) gene in a low S100A4 (p9Ka)-expressing benign rat mammary epithelial cell line, but not in highly expressing rat mammary epithelial cell lines, There is an inverse relationship between the level of S100A4 (p9Ka) mRNA and the level of GC-factor mRNA in a range of rat mammary cell lines, The results suggest a novel mechanism for regulating the expression of the mRNA encoding an S100 protein.	UNIV LIVERPOOL,SCH BIOL SCI,CANC & POLIO RES FUND LABS,LIVERPOOL L69 7ZB,MERSEYSIDE,ENGLAND	University of Liverpool			Barraclough, Roger/AAH-6516-2020; Davies, Michael/GWV-2527-2022	Davies, Michael Peter Alan/0000-0002-7609-4977; Barraclough, Roger/0000-0002-7203-1194				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1982, EUR J BIOCHEM, V129, P335, DOI 10.1111/j.1432-1033.1982.tb07056.x; BARRACLOUGH R, 1984, BIOCHEM BIOPH RES CO, V120, P351, DOI 10.1016/0006-291X(84)91261-0; BENNETT DC, 1978, CELL, V15, P283, DOI 10.1016/0092-8674(78)90104-6; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES M, 1995, DNA CELL BIOL, V14, P825, DOI 10.1089/dna.1995.14.825; Davies MPA, 1996, ONCOGENE, V13, P1631; DOCHERTY K, 1993, GENE TRANSCRIPTION P, P108; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, CANCER RES, V44, P5338; DUNNINGTON DJ, 1984, THESIS U LONDON; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIMURA FK, 1986, NUCLEIC ACIDS RES, V14, P2845, DOI 10.1093/nar/14.7.2845; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARABEDIAN MJ, 1993, GENE TRANSCRIPTION P, P243; GARRITY P, 1992, P NATL ACAD SCI USA, V89, P10021; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KROEKER WD, 1978, BIOCHEMISTRY-US, V17, P3236, DOI 10.1021/bi00609a010; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ORMEROD EJ, 1985, IN VITRO CELL DEV B, V21, P143, DOI 10.1007/BF02621351; Sambrook J., 2002, MOL CLONING LAB MANU; TULCHINSKY E, 1992, P NATL ACAD SCI USA, V89, P9146, DOI 10.1073/pnas.89.19.9146; TULCHINSKY E, 1993, ONCOGENE, V8, P79; TULCHINSKY E, 1995, BBA-GENE STRUCT EXPR, V1261, P243, DOI 10.1016/0167-4781(95)00013-7; Tulchinsky EM, 1996, ONCOGENE, V12, P1737; WILLIAMS JC, 1985, J NATL CANCER I, V74, P415	40	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20283	20290		10.1074/jbc.272.32.20283	http://dx.doi.org/10.1074/jbc.272.32.20283			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242709	hybrid			2022-12-27	WOS:A1997XQ05900096
J	Matthews, SA; Pettit, GR; Rozengurt, E				Matthews, SA; Pettit, GR; Rozengurt, E			Bryostatin 1 induces biphasic activation of protein kinase D in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; CARCINOMA-CELLS; C FAMILY; PHASE-I; DIACYLGLYCEROL; POTENT; GROWTH	Bryostatin 1 and phorbol esters are both potent activators of protein kinase C (PKC), although their specific biological effects can differ in many systems, Here, we report that bryostatin 1 activates protein kinase D (PKD), a novel serine/threonine protein kinase, in intact Swiss 3T3 cells and secondary mouse embryo fibroblasts and in COS-7 cells transiently transfected with a PKD expression construct. The dose response of PKD activation induced by bryostatin 1 follows a striking biphasic pattern with maximal activation achieved at a concentration of 10 nM. Higher concentrations of bryostatin 1 (100 nM) reduced PKD activation induced by phorbol 12,13-dibutyrate to levels stimulated by bryostatin 1 alone. Bryostatin 1-induced PKD activation was markedly attenuated by treatment of cells with the PKC inhibitors bisindolylmaleimide I and Ro 31-8220. However, these agents did not inhibit PKD activity when added directly to in vitro kinase assays, suggesting that bryostatin 1 stimulates PKD activation through a PKC-dependent pathway in intact cells, Our results raise the possibility that activated PKD in intact cells could mediate some of the multiple biphasic biological responses induced by bryostatin 1.	IMPERIAL CANC RES FUND,GROWTH REGULAT LAB,LONDON WC2A 3PX,ENGLAND; ARIZONA STATE UNIV,CANC RES INST,TEMPE,AZ 85287; ARIZONA STATE UNIV,DEPT CHEM,TEMPE,AZ 85287	Cancer Research UK; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe				Matthews, Sharon/0000-0002-8634-9355				BASU A, 1992, CANCER RES, V52, P3119; BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; DALE IL, 1989, INT J CANCER, V43, P158, DOI 10.1002/ijc.2910430129; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; GSCHWENDT M, 1992, CANCER LETT, V66, P139, DOI 10.1016/0304-3835(92)90226-L; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KRAFT AS, 1988, J BIOL CHEM, V263, P8437; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; PHILIP PA, 1993, J NATL CANCER I, V85, P1812, DOI 10.1093/jnci/85.22.1812; PRENDIVILLE J, 1993, BRIT J CANCER, V68, P418, DOI 10.1038/bjc.1993.352; RAMSDELL JS, 1986, J BIOL CHEM, V261, P7073; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; SCHUCHTER LM, 1991, CANCER RES, V51, P682; SMITH JB, 1985, BIOCHEM BIOPH RES CO, V132, P939, DOI 10.1016/0006-291X(85)91898-4; SREDNI B, 1990, IMMUNOLOGY, V70, P473; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; Szallasi Z, 1996, CANCER RES, V56, P2105; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	26	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20245	20250		10.1074/jbc.272.32.20245	http://dx.doi.org/10.1074/jbc.272.32.20245			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242703	hybrid			2022-12-27	WOS:A1997XQ05900090
J	Saji, M; Shong, MH; Napolitano, G; Palmer, LA; Taniguchi, S; Ohmori, M; Ohta, M; Suzuki, K; Kirshner, SL; Giuliani, C; Singer, DS; Kohn, LD				Saji, M; Shong, MH; Napolitano, G; Palmer, LA; Taniguchi, S; Ohmori, M; Ohta, M; Suzuki, K; Kirshner, SL; Giuliani, C; Singer, DS; Kohn, LD			Regulation of major histocompatibility complex class I gene expression in thyroid cells - Role of the cAMP response element-like sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN RECEPTOR GENE; SYSTEMIC LUPUS-ERYTHEMATOSUS; TRANSCRIPTION FACTOR-I; DNA-BINDING PROTEIN; PANCREATIC-ISLET CELLS; CYCLIC-AMP; FOAMY VIRUS; SOMATOSTATIN EXPRESSION; PROMOTER INTERACTS; INTERFERON THERAPY	The major histocompatibility complex (MBC) class I gene cAMP response element (CBE)-like site, -107 to - 100 base pairs, is a critical component of a previously unrecognized silencer, -127 to -90 bp, important for thyrotropin (TSH)/cAMP-mediated repression in thyrocytes, TSH/cAMP induced-silencer activity is associated with the formation of novel complexes with the 38-base pair silencer, whose appearance requires the CRE and. involves ubiquitous and thyroid-specific proteins as follows: the CRE-binding protein, a Y-box protein termed thyrotropin receptor (TSHR) suppressor element protein-1 (TSEP-1); thyroid transcription factor-1 (TTF-1); and Pax-8. TTF-1 is as enhancer of Glass I promoter activity; Pax-8 and TSEP-1 are suppressors, TSH/cAMP decreases TTF-1 complex formation with the silencer, thereby decreasing maximal class I expression; TSH/cAMP enhance TSEP-1 and Pax-8 complex formation in association with their repressive actions, Oligonucleotides that bind TSEP-1, not Pax-8, prevent formation of the TSH/cAMP-induced complexes associated with TSH-induced class I suppression, i.e. TSEP-1 appears to be the dominant repressor factor associated with TSH/cAMP-decreased class I activity and formation of the novel complexes. TSEP-1, TTF-1, and/or Pax-8 are involved in TSH/cAMP-induced negative regulation of the TSH receptor Gene in thyrocytes, suppression-of MHC class II, and up-regulation of thyroglobulin. TSH/cAMP coordinate regulation of common transcription factors may, therefore, be the basis fop self-tolerance and the absence of autoimmunity iu. the face of TSHR-mediated increases in gene products that are important for thyroid growth and function but are able to act as autoantigens.	NIDDK,METAB DIS BRANCH,NIH,CELL REGULAT SECT,BETHESDA,MD 20892; NCI,EXPT IMMUNOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Saji, Motoyasu/E-4007-2011; /H-7803-2012; Suzuki, Koichi/C-4177-2013	Suzuki, Koichi/0000-0001-8659-4660; shong, minho/0000-0002-0247-7115				AGUZZI A, 1993, BIOCHIM BIOPHYS ACTA, V1155, P1, DOI 10.1016/0304-419X(93)90019-9; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; CHAMBERLAIN JW, 1991, MOL CELL BIOL, V11, P3564, DOI 10.1128/MCB.11.7.3564; CHAN CC, 1995, J IMMUNOL, V154, P4830; CIVITAREALE D, 1993, MOL ENDOCRINOL, V7, P1589, DOI 10.1210/me.7.12.1589; DAVIS LG, 1986, BASIC METHODS MOL BI, P93; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GIULIANI C, 1995, J BIOL CHEM, V270, P11453, DOI 10.1074/jbc.270.19.11453; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUAZZI S, 1990, EMBO J, V9, P631; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HARRIS HW, 1986, TRANSPLANTATION, V42, P109, DOI 10.1097/00007890-198608000-00001; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P1701, DOI 10.1210/me.6.10.1701; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; IVASHKIV LB, 1991, J EXP MED, V174, P1583, DOI 10.1084/jem.174.6.1583; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; Kohn L D, 1995, Vitam Horm, V50, P287, DOI 10.1016/S0083-6729(08)60658-5; Kohn L D, 1992, Int Rev Immunol, V9, P135, DOI 10.3109/08830189209061788; KOHN LD, 1975, J BIOL CHEM, V250, P6503; Kohn LD., 1995, THYROID IMMUNITY, P115; KOHN LD, 1986, Patent No. 4609622; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOLLURI R, 1991, NUCLEIC ACIDS RES, V19, P4771, DOI 10.1093/nar/19.17.4771; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAGAYE S, 1992, P NATL ACAD SCI USA, V89, P10070, DOI 10.1073/pnas.89.21.10070; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; MAGUIRE JE, 1992, MOL CELL BIOL, V12, P3078, DOI 10.1128/MCB.12.7.3078; MARCELLIN P, 1995, J HEPATOL, V22, P364, DOI 10.1016/0168-8278(95)80291-6; Maxam A M, 1980, Methods Enzymol, V65, P499; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOZES E, 1993, SCIENCE, V261, P91, DOI 10.1126/science.8316860; Ohmori M, 1996, MOL ENDOCRINOL, V10, P76, DOI 10.1210/me.10.1.76; OHMORI M, 1995, ENDOCRINOLOGY, V136, P269, DOI 10.1210/en.136.1.269; Ohmori M, 1996, MOL ENDOCRINOL, V10, P1407, DOI 10.1210/me.10.11.1407; PESTOV DG, 1991, NUCLEIC ACIDS RES, V1, P6527; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; SABATH DE, 1990, J BIOL CHEM, V265, P12671; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAJI M, 1992, ENDOCRINOLOGY, V130, P520, DOI 10.1210/en.130.1.520; SAJI M, 1992, J CLIN ENDOCR METAB, V75, P871, DOI 10.1210/jc.75.3.871; SAJI M, 1992, P NATL ACAD SCI USA, V89, P1944, DOI 10.1073/pnas.89.5.1944; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuppert F, 1996, J CLIN ENDOCR METAB, V81, P3622, DOI 10.1210/jc.81.10.3622; SHIMURA H, 1995, MOL ENDOCRINOL, V9, P527, DOI 10.1210/me.9.5.527; SHIMURA H, 1993, J BIOL CHEM, V268, P24125; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; SHIMURA Y, 1994, J BIOL CHEM, V269, P31908; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SINGER DS, 1994, J IMMUNOL, V153, P873; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; STANCEK D, 1975, MED MICROBIOL IMMUN, V161, P133, DOI 10.1007/BF02121755; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TODD I, 1986, ANN NY ACAD SCI, V475, P241, DOI 10.1111/j.1749-6632.1986.tb20873.x; TOMER Y, 1993, ENDOCR REV, V14, P107, DOI 10.1210/er.14.1.107; TRAN A, 1993, HEPATOLOGY, V18, P253, DOI 10.1002/hep.1840180205; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VOLPE R, 1967, J CLIN ENDOCR METAB, V27, P1275, DOI 10.1210/jcem-27-9-1275; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WATINE BD, 1990, IMMUNOL TODAY, V11, P286; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; WERNER J, 1979, LANCET, V2, P258; WICK G, 1992, INT ARCH ALLERGY IMM, V99, P153, DOI 10.1159/000236350; WOLFFE AP, 1992, NEW BIOL, V4, P290; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	76	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20096	20107		10.1074/jbc.272.32.20096	http://dx.doi.org/10.1074/jbc.272.32.20096			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242683	hybrid			2022-12-27	WOS:A1997XQ05900070
J	Ervasti, JM; Burwell, AL; Geissler, AL				Ervasti, JM; Burwell, AL; Geissler, AL			Tissue-specific heterogeneity in alpha-dystroglycan sialoglycosylation - Skeletal muscle alpha-dystroglycan is a latent receptor for Vicia villosa agglutinin B-4 masked by sialic acid modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; SYNAPSE-SPECIFIC CARBOHYDRATE; SULFATIDE-BINDING DOMAIN; AGRIN RECEPTOR; ACETYLCHOLINE-RECEPTOR; MDX MOUSE; NEUROMUSCULAR-JUNCTION; MUSCULAR-DYSTROPHIES; EXTRACELLULAR-MATRIX; PERIPHERAL-NERVE	Because the polypeptide core of alpha-dystroglycan is encoded by a single gene, the difference in apparent molecular mass between alpha-dystroglycans expressed in various tissues is presumably due to differential glycosylation, However, little is presently known about the tissue-specific differences in alpha-dystroglycan glycosylation and whether these modifications may confer functional variability to alpha-dystroglycan. We recently observed that laminin-1 binding to skeletal muscle alpha-dystroglycan was dramatically inhibited by heparin, whereas the binding of commercial merosin to skeletal muscle alpha-dystroglycan was only marginally inhibited (Pall, E. A., Bolton, K. M., and Ervasti, J. M. (1996) J. Biol. Chem. 3817-3821). In contrast to 156-kDa skeletal muscle alpha-dystroglycan, both laminin-1 and merosin binding to 120-kDa brain alpha-dystroglycan were sensitive to heparin, We have now examined the laminin binding properties of 140-kDa alpha-dystroglycan purified from cardiac muscle and observed that like skeletal muscle alpha-dystroglycan, heparin inhibited cardiac alpha-dystroglycan binding to laminin-1, but not to merosin. On the other hand, cardiac and brain alpha-dystroglycans could be distinguished from skeletal muscle alpha-dystroglycan by their reactivity with the terminal GalNAc-specific lectin Vicia villosa agglutinin, Interestingly, skeletal muscle alpha-dystroglycan became reactive with V. villosa agglutinin upon digestion with sialidase from Clostridium perfringens, Arthrobacter neurofaciens, or Streptococcus, but not Vibrio cholerae or Newcastle disease virus sialidase, While none of the sialidase treatments affected the laminin binding properties of alpha-dystroglycan, the sum of our results suggests that skeletal muscle alpha-dystroglycan contains a novel sialic acid residue linked alpha 2-6 to GalNAc, These properties are also consistent with the cellular characteristics of a GalNAc-terminated glycoconjugate recently implicated in neuromuscular synaptogenesis, Thus, variations in alpha-dystroglycan sialoglycosylation may prove as useful markers to further elucidate the role of alpha-dystroglycan glycoforms in different tissues and perhaps within a single cell type.			Ervasti, JM (corresponding author), UNIV WISCONSIN,DEPT PHYSIOL,SERV MEM INST 120,SCH MED,1300 UNIV AVE,MADISON,WI 53706, USA.		Ervasti, James/AAZ-4786-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR001985, R01AR042423] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42423, AR01985] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chiba A, 1997, J BIOL CHEM, V272, P2156; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; HIRSH EF, 1970, INNVERVATION VERTEBR; Hopf C, 1996, J BIOL CHEM, V271, P5231; Horackova M, 1996, TISSUE CELL, V28, P411, DOI 10.1016/S0040-8166(96)80027-9; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KATZ AM, 1977, PHYSL HEART, P1; KLIETSCH R, 1993, CIRC RES, V72, P349, DOI 10.1161/01.RES.72.2.349; MA JY, 1993, J BIOL CHEM, V268, P25108; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Meier T, 1996, EMBO J, V15, P2625, DOI 10.1002/j.1460-2075.1996.tb00622.x; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OToole JJ, 1996, P NATL ACAD SCI USA, V93, P7369, DOI 10.1073/pnas.93.14.7369; Pall EA, 1996, J BIOL CHEM, V271, P3817; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010; ROBERTS DD, 1986, J BIOL CHEM, V261, P6872; Rosenberg A, 1976, BIOL ROLES SIALIC AC, P295; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; SANES JR, 1982, NATURE, V300, P646, DOI 10.1038/300646a0; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SCOTT LJC, 1988, J NEUROSCI, V8, P932; SHIBUYA N, 1987, ARCH BIOCHEM BIOPHYS, V254, P1, DOI 10.1016/0003-9861(87)90074-9; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; SMALHEISER NR, 1993, J NEUROSCI RES, V36, P528, DOI 10.1002/jnr.490360505; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUNADA Y, 1995, NEUROLOGY, V45, P2084, DOI 10.1212/WNL.45.11.2084; TARABOLETTI G, 1990, J BIOL CHEM, V265, P12253; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yamada H, 1996, J NEUROCHEM, V66, P1518; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; YAMAMOTO H, 1993, J BIOCHEM-TOKYO, V114, P132, DOI 10.1093/oxfordjournals.jbchem.a124128; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; Yotsumoto S, 1996, HUM MOL GENET, V5, P1259, DOI 10.1093/hmg/5.9.1259	61	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22315	22321		10.1074/jbc.272.35.22315	http://dx.doi.org/10.1074/jbc.272.35.22315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268382	hybrid			2022-12-27	WOS:A1997XT85000094
J	Liu, H; Bowes, RC; vandeWater, B; Sillence, C; Nagelkerke, JF; Stevens, JL				Liu, H; Bowes, RC; vandeWater, B; Sillence, C; Nagelkerke, JF; Stevens, JL			Endoplasmic reticulum chaperones GRP78 and calreticulin prevent oxidative stress, Ca2+ disturbances, and cell death in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULAR CELLS; HEAT-SHOCK PROTEINS; INTRACELLULAR CALCIUM; LLC-PK1 CELLS; LIPID-PEROXIDATION; COVALENT BINDING; REDUCING AGENTS; GROWTH ARREST; DNA-DAMAGE; C-FOS	Activation of stress response genes can impart cellular tolerance to environmental stress, Iodoacetamide (IDAM) is an alkylating toxicant that up-regulates expression of hsp70 (Liu, H,, Lightfoot, D, L., and Stevens, J. L. (1996) J. Blot. Chem. 271, 4805-4812) and grp78 in LLC-PK1 renal epithelial cells, Therefore, we used IDAM to determine the role of these genes in tolerance to toxic chemicals, Prior heat shock did not protect cells from IDAM but pretreatment with trans-4,5-dihydroxy-1,2-dithiane (DTTox), thapsigargin, or tunicamycin enhanced expression of the endoplasmic reticulum (ER) chaperones GRP78 and GRP94 and rendered cells tolerant to IDAM. Cells expressing a 524-base pair antisense grp78 fragment (pkASgrp78) had a diminished capacity to upregulate grp78 and grp94 expression after ER stress, Protection against IDAM due to prior ER stress was also attenuated in pkASgrp78 cells suggesting that ER chaperones of the GRP family are critical for tolerance, Covalent binding of IDAM to cellular macromolecules and depletion of cellular thiols was similar in tolerant and naive cells, However, DTTox pretreatment blocked the increases in cellular Ca2+ and lipid peroxidation observed after IDAM treatment, Overexpressing the ER Ca2+-binding protein calreticulin prevented IDAM-induced cell death, the rise in cytosolic Ca2+, and oxidative stress, Although activation of the ER stress response did not prevent toxicity due to Ca2+ influx, EGTA-ARI and ruthenium red both blocked cell death suggesting that redistribution of intracellular Ca2+ to the mitochondria may be important in toxicity, The data support a model in which induction of ER stress proteins prevents disturbances of intracellular Ca2+ homeostasis, thus uncoupling toxicant exposure from oxidative stress and cell death, Multiple ER stress proteins are likely to be involved in this tolerance response.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946; CLARKSON UNIV,DEPT CHEM,POTSDAM,NY 13676; LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV TOXICOL,LEIDEN,NETHERLANDS	Clarkson University; Leiden University; Leiden University - Excl LUMC					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046267, F32DK009253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005670] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46267, DK09253] Funding Source: Medline; NIEHS NIH HHS [ES05670] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Black A R, 1991, Methods Achiev Exp Pathol, V15, P126; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CHATTERJEE S, 1994, CANCER RES, V54, P4405; CHEN Q, 1992, J BIOL CHEM, V267, P24322; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHEN Q, 1990, J BIOL CHEM, V265, P21603; CHEN Q, 1991, ARCH BIOCHEM BIOPHYS, V284, P422, DOI 10.1016/0003-9861(91)90318-D; CHEN Q, 1994, J CELL PHYSIOL, V161, P293, DOI 10.1002/jcp.1041610214; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; Distelhorst CW, 1996, ONCOGENE, V12, P2051; FARBER JL, 1990, CHEM RES TOXICOL, V3, P503, DOI 10.1021/tx00018a003; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GOLDSTEIN RS, 1996, TOXICOLOGY, P417; GOMER CJ, 1991, CANCER RES, V51, P6574; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Halleck MM, 1997, J BIOL CHEM, V272, P21760, DOI 10.1074/jbc.272.35.21760; HARMAN AW, 1995, ANNU REV PHARMACOL, V35, P129, DOI 10.1146/annurev.pa.35.040195.001021; HENSCHKE PN, 1995, BIOCHEM J, V312, P485, DOI 10.1042/bj3120485; Hoyal CR, 1996, J BIOL CHEM, V271, P29205, DOI 10.1074/jbc.271.46.29205; HUGHES CS, 1989, CANCER RES, V49, P4452; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jeong JMK, 1996, MOL PHARMACOL, V50, P592; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Liu H, 1996, J BIOL CHEM, V271, P4805; LIU NG, 1994, J BIOL CHEM, V269, P28635; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MACER DRJ, 1988, J CELL SCI, V91, P61; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MAYEUX PR, 1993, J PHARMACOL EXP THER, V266, P47; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; Mitchell J. R., 1984, DRUG METABOLISM DRUG, P301; MOORE L, 1976, J BIOL CHEM, V251, P1197; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NICOTERA P, 1990, CHEM RES TOXICOL, V3, P484, DOI 10.1021/tx00018a001; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; Reynolds JE, 1996, J BIOL CHEM, V271, P27739, DOI 10.1074/jbc.271.44.27739; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROY B, 1995, MOL CELL BIOL, V15, P2263; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHACHAR I, 1994, J BIOL CHEM, V269, P27344; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; STEVENS J, 1986, J BIOL CHEM, V261, P3325; SUGAWARA S, 1993, CANCER RES, V53, P6001; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; UEDA N, 1992, AM J PHYSIOL, V263, pF214, DOI 10.1152/ajprenal.1992.263.2.F214; VAMVAKAS S, 1993, TOXICOL LETT, V67, P161, DOI 10.1016/0378-4274(93)90053-Z; VAMVAKAS S, 1990, MOL PHARMACOL, V38, P455; vandeWater B, 1996, ARCH BIOCHEM BIOPHYS, V327, P71, DOI 10.1006/abbi.1996.0094; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; VANDEWATER B, 1993, BIOCHEM PHARMACOL, V45, P2259, DOI 10.1016/0006-2952(93)90197-5; VILLA A, 1991, J CELL BIOL, V113, P779, DOI 10.1083/jcb.113.4.779; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YU KF, 1994, J CELL PHYSIOL, V161, P303, DOI 10.1002/jcp.1041610215	79	328	349	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21751	21759		10.1074/jbc.272.35.21751	http://dx.doi.org/10.1074/jbc.272.35.21751			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268304	hybrid			2022-12-27	WOS:A1997XT85000016
J	Myllyharju, J; Lamberg, A; Notbohm, H; Fietzek, PP; Pihlajaniemi, T; Kivirikko, KI				Myllyharju, J; Lamberg, A; Notbohm, H; Fietzek, PP; Pihlajaniemi, T; Kivirikko, KI			Expression of wild-type and modified pro alpha chains of human type I procollagen in insect cells leads to the formation of stable [alpha 1(I)](2)alpha 2(I) collagen heterotrimers and [alpha 1(I)](3) homotrimers but not [alpha 2(I)](3) homotrimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE ISOMERASE; MOLECULAR-CLONING; 4-HYDROXYLASE; SUBUNIT; SECRETION; SYSTEM; HSP47; GENE; GLYCOSYLATION; DOMAIN	Insect cells coinfected with a baculovirus coding for the pro alpha 1(I) chain of human type I procollagen and a double promoter virus coding for the alpha and beta subunits of human prolyl 4-hydroxylase produced homotrimeric [pro alpha 1(I)](3) procollagen molecules, The use of an additional virus coding for the pro alpha 2(I) chain led to the formation of a heterotrimeric molecule with the correct 2:1 ratio of pro alpha 1 to pro alpha 2 chains of type I procollagen (pro alpha 1(I) and pro alpha 2(I) chains, respectively), unless the pro alpha 1(I) chain was expressed in a relatively large excess, Replacement of the sequences coding for the signal peptide and the N propeptide of the pro alpha 1(I) chain with those of the pro alpha 1(III) chain increased level of expression of the pro alpha 1(I) chain, whereas no similar effect was found when the corresponding modification was made to the virus coding for the pro alpha 2(I) chain, Molecules containing such modified N propeptides were found to be processed at their N terminus more rapidly than those containing the wild-type propeptides, The T-m of the type I collagen homotrimer was similar to that of the heterotrimer, both values being about 42-43 degrees C when determined by circular dichroism. The wild-type pro alpha 2(I) chain formed no homotrimers. Replacement of the C propeptide of the pro alpha 2(I) chain with that of the pro alpha 1(I) chain or pro alpha 1 chain of type III procollagen (pro alpha 1(III) chain) led to the formation of homotrimers, but the alpha 2(I) chains in such molecules were completely digested by pepsin in 1 h at 22 degrees C, The data thus suggest that, in addition to control at the level of the C propeptide, other restrictions may exist at the level of the collagen domain that prevent the formation of stable homotrimeric [pro alpha 2(I)](3) molecules in insect cells.	UNIV OULU, DEPT MED BIOCHEM, FIN-90220 OULU, FINLAND; UNIV OULU, COLLAGEN RES UNIT, BIOCTR, FIN-90220 OULU, FINLAND; UNIV LUBECK, INST MED MOL BIOL, D-23538 LUBECK, GERMANY	University of Oulu; University of Oulu; University of Lubeck				Pihlajaniemi, Taina/0000-0002-1664-9045				BREWTON RG, 1994, EXTRACELLULAR MATRIX, P129; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; COOPERMAN L, 1984, J AM ACAD DERMATOL, V10, P638, DOI 10.1016/S0190-9622(84)80271-6; FUJIOKA K, 1995, J CONTROL RELEASE, V33, P307, DOI 10.1016/0168-3659(94)00107-6; GEDDIS AE, 1993, MATRIX, V13, P399, DOI 10.1016/S0934-8832(11)80045-4; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HU G, 1995, J CELL BIOCHEM, V59, P350, DOI 10.1002/jcb.240590307; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; Kadler KE, 1996, BIOCHEM J, V316, P1; Kielty Cay M., 1993, P103; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; KIVIRIKKO KI, 1995, PR MED BIOL, V3, P233; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MILLER EJ, 1982, METHOD ENZYMOL, V82, P3; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; Pachence JM, 1996, J BIOMED MATER RES, V33, P35, DOI 10.1002/(SICI)1097-4636(199621)33:1<35::AID-JBM6>3.0.CO;2-N; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ramshaw JAM, 1996, BIOTECHNOL GENET ENG, V13, P335, DOI 10.1080/02648725.1996.10647934; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; TKOCZ C, 1969, EUR J BIOCHEM, V7, P454; TRAUB W, 1976, FEBS LETT, V68, P245, DOI 10.1016/0014-5793(76)80446-2; VANDERPLAATS GN, 1993, STRUCT OPTIMIZATION, V6, P1, DOI 10.1007/BF01743168; VERNET T, 1990, J BIOL CHEM, V265, P16661; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x	34	68	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21824	21830		10.1074/jbc.272.35.21824	http://dx.doi.org/10.1074/jbc.272.35.21824			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268313	hybrid			2022-12-27	WOS:A1997XT85000025
J	Ocaktan, A; Yoneyama, H; Nakae, T				Ocaktan, A; Yoneyama, H; Nakae, T			Use of fluorescence probes to monitor function of the subunit proteins of the MexA-MexB-OprM drug extrusion machinery in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; OUTER-MEMBRANE; ANTIBIOTIC-RESISTANCE; MULTIDRUG-RESISTANCE; EFFLUX SYSTEMS; P-GLYCOPROTEIN; 2-(4-DIMETHYLAMINOSTYRYL)-1-ETHYLPYRIDINIUM; INVOLVEMENT; NORFLOXACIN	The MexA-MexB-OprM efflux pump of Pseudomonas aeruginosa consists of two inner membrane proteins, MexA and MexB, and one outer membrane protein, OprM, We investigated the role of the components of this drug extrusion system by evaluating the repercussions of deleting these subunit components on the accumulation of several fluorescent probes, Fluorescence intensities of positively charged 2-(4-dimethylaminostyryl)-1-ethylpyridinium and uncharged N-phenyl-1-naphtylamine were 7 and 4 times higher, respectively, in the mutant lacking OprM and 4 and 1.7 times higher, respectively, in the mutants lacking MexA or MexB than in the wild type strain, This order of fluorescence intensity was fully consistent with a previously reported minimum inhibitory concentration of antibiotics such as tetracycline, chloramphenicol, and fluoroquinolones, Ethidium bromide accumulation in all the Mex mutants proceeded at about 5 times faster than the rate in the wild type cells, This result is in accord with the minimum inhibitory concentration of beta-lactam antibiotics. These results suggest that the fluorescence probes could be successfully used in real time monitoring of the function of the drug extrusion machinery in Gram-negative bacteria, The downhill extrusion kinetics of 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene, which orients perpendicular to the inner leaflet of the cytoplasmic membrane, from preloaded cells lacking the extrusion pump was preceded by a slow increase in fluorescence intensity, whereas the wild type cell immediately released the dye, This observation was explained by a slow trans-cytoplasmic membrane crossing of intracellular dye in the mutants, These results reflected higher accumulation of the probe in the cytoplasmic membrane in the mutants and strengthened the hypothesis that extrusion of hydrophobic substrate mediated by MexA-MexB-OprM mainly takes place from the interior of the cytoplasmic membrane.	TOKAI UNIV,SCH MED,DEPT MOL LIFE SCI,ISEHARA,KANAGAWA 25911,JAPAN	Tokai University								Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; COHEN SP, 1988, ANTIMICROB AGENTS CH, V32, P1187, DOI 10.1128/AAC.32.8.1187; CRAMER WA, 1976, BIOCHIM BIOPHYS ACTA, V449, P401, DOI 10.1016/0005-2728(76)90151-1; Fralick JA, 1996, J BACTERIOL, V178, P5803, DOI 10.1128/jb.178.19.5803-5805.1996; FUKUDA H, 1990, ANTIMICROB AGENTS CH, V34, P15757; George AM, 1996, FEMS MICROBIOL LETT, V139, P1, DOI 10.1016/0378-1097(96)00127-9; HIRAI K, 1987, ANTIMICROB AGENTS CH, V31, P582, DOI 10.1128/AAC.31.4.582; Kohler T, 1997, MOL MICROBIOL, V23, P345, DOI 10.1046/j.1365-2958.1997.2281594.x; LEI Y, 1991, BIOCHEM BIOPH RES CO, V178, P1043, DOI 10.1016/0006-291X(91)90997-L; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; MIDGLEY M, 1986, J GEN MICROBIOL, V132, P3187; MORSHED SRM, 1991, BIOCHEM BIOPH RES CO, V210, P356; MORTIMER PGS, 1991, J ANTIMICROB CHEMOTH, V28, P639, DOI 10.1093/jac/28.5.639; MULDER HS, 1993, EUR J BIOCHEM, V218, P871, DOI 10.1111/j.1432-1033.1993.tb18443.x; NAKAE T, 1995, MICROBIOL IMMUNOL, V39, P221, DOI 10.1111/j.1348-0421.1995.tb02193.x; NAKAMURA H, 1968, J BACTERIOL, V96, P987, DOI 10.1128/JB.96.4.987-996.1968; NIEVAGOMEZ D, 1977, P NATL ACAD SCI USA, V74, P1811, DOI 10.1073/pnas.74.5.1811; NIKAIDO H, 1989, ANTIMICROB AGENTS CH, V33, P1831, DOI 10.1128/AAC.33.11.1831; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; Poole K, 1996, MOL MICROBIOL, V21, P713, DOI 10.1046/j.1365-2958.1996.281397.x; Ringe D, 1995, CURR OPIN STRUC BIOL, V5, P825, DOI 10.1016/0959-440X(95)80017-4; SEDGWICK EG, 1993, BIOCHIM BIOPHYS ACTA, V1146, P113, DOI 10.1016/0005-2736(93)90345-Z; Sedgwick EG, 1996, BBA-BIOMEMBRANES, V1278, P205, DOI 10.1016/0005-2736(95)00228-6; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; STEIN WD, 1994, MOL PHARMACOL, V45, P763; YONEYAMA H, 1986, BIOCHEM BIOPH RES CO, V134, P106; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506; YONEYAMA H, 1986, EUR J BIOCHEM, V157, P33, DOI 10.1111/j.1432-1033.1986.tb09634.x	33	85	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21964	21969		10.1074/jbc.272.35.21964	http://dx.doi.org/10.1074/jbc.272.35.21964			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268332	hybrid			2022-12-27	WOS:A1997XT85000044
J	Sabharwal, AK; Padmanabhan, K; Tulinsky, A; Mathur, A; Gorka, J; Bajaj, SP				Sabharwal, AK; Padmanabhan, K; Tulinsky, A; Mathur, A; Gorka, J; Bajaj, SP			Interaction of calcium with native and decarboxylated human factor X. Effect of proteolysis in the autolysis loop on catalytic efficiency and factor Va binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BLOOD-COAGULATION FACTOR; AFFINITY CA2+-BINDING SITE; CA-PROTHROMBIN FRAGMENT-1; SERINE-PROTEASE DOMAIN; HUMAN FACTOR-VIIA; HUMAN FACTOR-IX; TISSUE FACTOR; BOVINE PROTHROMBIN; MEMBRANE-BINDING	Human factor X is a two-chain, 58-kDa, vitamin K-dependent blood coagulation zymogen, The light chain of factor X consists of an NH2-terminal gamma-carboxyglutamic acid (Cia) domain, followed by a few helical hydrophobic residues and the two epidermal growth factor-like domains, whereas the heavy chain contains the serine protease domain, In this study, native factor X was found to contain three classes of Ca2+-binding sites: two high affinity (K-d 100 +/- 30 mu M), four intermediate affinity (K-d 450 +/- 70 mu M), and five to six low affinity (K-d 2 +/- 0.2 mm). Decarboxylated factor X in which the Gla residues were converted to Glu retained the two high affinity sites (K-d 140 +/- 20 mu M). In contrast, factor X lacking the Gla domain as well as a part of the helical hydrophobic residues (des-44-X) retained only one high affinity Ca2+-binding site (K-d 130 +/- 20 mu M). Moreover, a synthetic peptide composed of residues 238-277 (58-97 in chymotrypsinogen numbering) from the protease domain of factor X bound one Ca2+ with high affinity (K-d 150 +/- 20 mu M). From competitive inhibition assays for binding of active site-blocked factor Xa to factor Va in the prothrombinase complex, the K-d for peptide-Va interaction was calculated to be similar to 10 mu M as compared with 30 phn for factor Xa and similar to 1.5 mu M for decarboxylated factor Xa, A peptide containing residues 238-262 (58-82) bound Ca2+ with reduced affinity (K-d similar to 600 mu M) and did not inhibit Xa:Va interaction, In contrast, a peptide containing residues 253-277(73-97) inhibited Xa:Va interaction (K-d similar to 10 mu M) but did not bind Ca2+. In additional studies, Ca2+ increased the amidolytic activity of native and des-44-Xa toward a tetrapeptide substrate (benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide) by approximately 1.6-fold. The half-maximal increase was observed at similar to 150 mu M Ca2+ and the effect was primarily on the k(cat). Ca2+ also significantly protected cleavage at Arg-332-Gln-333(150-151) in the protease domain autolysis loop, Des-44-Xa in which the autolysis loop was cleaved possessed less than or equal to 5% of the amidolytic activity of the noncleaved form; however, the S1 binding site was not affected, as determined by the p-aminobenzamidine binding, Additionally, autolysis loop-cleaved, active site-blocked native factor Xa was calculated to have similar to 10-fold reduced affinity for factor Va as compared with that of the noncleaved form.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110; ST LOUIS UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63104; MICHIGAN STATE UNIV,DEPT CHEM,E LANSING,MI 48824	Washington University (WUSTL); Saint Louis University; Saint Louis University; Saint Louis University; Michigan State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL036365, R55HL036365, R01HL025942, R01HL036365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25942, HL36365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNI RK, 1994, CHEM PHYS LIPIDS, V67-8, P59, DOI 10.1016/0009-3084(94)90124-4; Bajaj MS, 1994, ANTICOAGULANTS PHYSL, P41; BAJAJ SP, 1982, J BIOL CHEM, V257, P3726; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJAJ SP, 1975, J BIOL CHEM, V250, P98; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BREZNIAK DV, 1990, BIOCHEMISTRY-US, V29, P3536, DOI 10.1021/bi00466a017; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CHRISTIANSEN WT, 1994, BIOCHEMISTRY-US, V33, P14993, DOI 10.1021/bi00254a007; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P10376, DOI 10.1021/bi00033a008; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEERFIELD DW, 1987, J BIOL CHEM, V262, P4017; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GORKA J, 1989, Peptide Research, V2, P376; GRAHAM JB, 1957, J CLIN INVEST, V36, P497, DOI 10.1172/JCI103447; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HUH NW, 1991, ANAL BIOCHEM, V198, P391, DOI 10.1016/0003-2697(91)90445-Y; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; LINDHOUT MJ, 1978, BIOCHIM BIOPHYS ACTA, V553, P318; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MANN KG, 1990, BLOOD, V76, P1; MATHUR A, 1997, IN PRESS J BIOL CHEM, V272; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; Monroe D M, 1990, Blood Coagul Fibrinolysis, V1, P633; MONROE DM, 1988, ANAL BIOCHEM, V172, P427, DOI 10.1016/0003-2697(88)90465-4; MORITA T, 1986, J BIOL CHEM, V261, P4015; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; PRICE PA, 1981, J BIOL CHEM, V256, P1172; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; Pryzdial ELG, 1996, J BIOL CHEM, V271, P16614, DOI 10.1074/jbc.271.28.16614; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Rosenberg I.M., 1996, PROTEIN ANAL PURIFIC, V1996, P153; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SABHARWAL AK, 1993, BLOOD, V82, pA64; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SESHADRI TP, 1994, BIOCHEMISTRY-US, V33, P1087, DOI 10.1021/bi00171a006; SHERRILL GB, 1988, THROMB RES, V52, P53; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; YE J, 1995, BIOCHEMISTRY-US, V34, P6448, DOI 10.1021/bi00019a026	65	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22037	22045		10.1074/jbc.272.35.22037	http://dx.doi.org/10.1074/jbc.272.35.22037			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268343	hybrid			2022-12-27	WOS:A1997XT85000055
J	Giraldez, RR; Panda, A; Xia, Y; Sanders, SP; Zweier, JL				Giraldez, RR; Panda, A; Xia, Y; Sanders, SP; Zweier, JL			Decreased nitric-oxide synthase activity causes impaired endothelium-dependent relaxation in the postischemic heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXING FACTOR; MYOCARDIAL-ISCHEMIA; CORONARY-ARTERIES; TIME COURSE; REPERFUSION; CELLS; ACETYLCHOLINE; DYSFUNCTION; INJURY; PARTICULATE	Endothelial nitric-oxide synthase (eNOS) is an important regulator of endothelial function and vascular tone in biological tissues, While endothelial dysfunction occurs following ischemia and has been attributed to altered NO. formation, the biochemical basis for this dysfunction is unknown, Therefore, studies were performed to determine the effects of myocardial ischemia and reperfusion on eNOS in isolated rat hearts subjected to periods of global ischemia or ischemia followed by reperfusion. eNOS activity was assayed by L-[C-14]arginine to L-[C-14]citrulline conversion and alterations in the amount and distribution of eNOS determined by Western blotting and immunohistochemistry. While activity was preserved after 30 min of ischemia with a value of 1.1 +/- 0.1 pmol x min(-1) x mg of protein(-1), it decreased by 77% after 60 min and became nearly undetectable after 120 min. Reperfusion resulted in only a partial restoration of activity, The decline in activity with ischemia was due, in part, to a loss of eNOS protein, Hemodynamic studies showed that the onset of impaired vascular reactivity paralleled the loss of functional eNOS, Subjecting isolated eNOS to conditions of acidosis, which occur during ischemia, followed by restoration of pH as occurs on reperfusion, caused a combination of reversible and irreversible loss of activity similar 60 that seen in ischemic and reperfused hearts, Thus, Loss of endothelial function following ischemia is paralleled by a loss of eNOS activity due to a combination of pa-dependent denaturation and proteolysis.	JOHNS HOPKINS BAYVIEW MED CTR, JOHNS HOPKINS MED INST, DIV CARDIOL, DEPT MED, BALTIMORE, MD 21224 USA; JOHNS HOPKINS BAYVIEW MED CTR, JOHNS HOPKINS MED INST, ELECTRON PARAMAGNET RESONANCE CTR, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, R29HL038324, P50HL052315] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52315, HL-38324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; COSENTINO F, 1995, CIRCULATION, V91, P139, DOI 10.1161/01.CIR.91.1.139; FLEMING I, 1994, CIRC RES, V74, P1220, DOI 10.1161/01.RES.74.6.1220; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRIFFITH TM, 1986, CARDIOVASC RES, V20, P7, DOI 10.1093/cvr/20.1.7; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; JOHNS RA, 1989, CIRC RES, V65, P1508, DOI 10.1161/01.RES.65.6.1508; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEHTA JL, 1989, CIRC RES, V64, P43, DOI 10.1161/01.RES.64.1.43; MEHTA JL, 1989, AM J PHYSIOL, V257, pH1240, DOI 10.1152/ajpheart.1989.257.4.H1240; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH815, DOI 10.1152/ajpheart.1986.250.5.H815; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; SESSA WC, 1990, P NATL ACAD SCI USA, V87, P8607, DOI 10.1073/pnas.87.21.8607; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; TSAO PS, 1990, CIRCULATION, V82, P1402, DOI 10.1161/01.CIR.82.4.1402; TSAO PS, 1990, AM J PHYSIOL, V259, pH1660, DOI 10.1152/ajpheart.1990.259.6.H1660; URSELL PC, 1993, CARDIOVASC RES, V27, P1920, DOI 10.1093/cvr/27.11.1920; VALLANCE P, 1992, J VASC RES, V29, P217; VANBENTHUYSEN KM, 1987, J CLIN INVEST, V79, P265, DOI 10.1172/JCI112793; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; WEISS RG, 1990, J CLIN INVEST, V85, P757, DOI 10.1172/JCI114501; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; ZEIHER AM, 1993, J CLIN INVEST, V92, P652, DOI 10.1172/JCI116634; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	35	146	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21420	21426		10.1074/jbc.272.34.21420	http://dx.doi.org/10.1074/jbc.272.34.21420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261157	hybrid			2022-12-27	WOS:A1997XR78900067
J	Huber, M; Yee, VC; Burri, N; Vikerfors, E; Lavrijsen, APM; Paller, AS; Hohl, D				Huber, M; Yee, VC; Burri, N; Vikerfors, E; Lavrijsen, APM; Paller, AS; Hohl, D			Consequences of seven novel mutations on the expression and structure of keratinocyte transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL KERATINOCYTES; COAGULATION-FACTOR-XIII; RECESSIVE LAMELLAR ICHTHYOSIS; CORNIFIED CELL-ENVELOPE; CROSS-LINKING ENZYMES; MEMBRANE ANCHORAGE; SENSITIVE METHOD; A-SUBUNIT; GENE; PROTEIN	We report the molecular characterization of seven new keratinocyte transglutaminase mutations (R315C, S358R, V379L, G473S, R687C, deletion Delta 679-696, R127Stop) found in lamellar ichthyosis patients, Arg 315, Ser-358, Val-379, and Gly-473 are highly conserved residues in transglutaminases while Arg-687 and Delta 679-696 are not. All mutations strongly decreased transglutaminase activity and protein levels, The mutation R127Stop diminished the amount of mRNA, Structural analysis of these mutations based. on the factor XIII A-subunit crystal structure demonstrated that Arg-315, Ser-358, Val-379, and Gly-413 are located in the catalytic core domain, and Arg-687 and the deletion are in the beta-barrel domains, The side chains of amino acids Arg-315, Ser-358, and Gly-473 make ionic and hydrogen bonds important for folding and structural stability of the enzyme but are not directly involved in catalysis. Val-379 is two amino acids away from the active site cysteine, and its change into leucine disturbs the active site structure. The decreased activity and protein level after expression of the R687C and Delta 619-696 TGIC cDNA in TGK negative keratinocytes excluded that they are polymorphisms. These results identify important amino acids in the central core domain of transglutaminases and show that the C-terminal end influences the structural and functional integrity of TGK.	CHU VAUDOIS, DHURDV, DERMATOL SERV, CH-1011 LAUSANNE, SWITZERLAND; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; OREBRO MED CTR HOSP, DEPT DERMATOL, S-70185 OREBRO, SWEDEN; UNIV LEIDEN HOSP, DEPT DERMATOL, NL-2300 AK LEIDEN, NETHERLANDS; NORTHWESTERN UNIV, CHILDRENS MEM HOSP, SCH MED, DEPT DERMATOL, CHICAGO, IL 60614 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Washington; University of Washington Seattle; Leiden University; Leiden University Medical Center (LUMC); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University			Huber, Marcel/M-8822-2016; Hohl, Daniel M/N-7554-2016	Huber, Marcel/0000-0003-3821-2378; Paller, Amy/0000-0001-6187-6549				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ANTONLAMPRECHT I, 1992, SKIN, P459; ASLAM S, 1995, BRIT J HAEMATOL, V91, P452, DOI 10.1111/j.1365-2141.1995.tb05321.x; BOARD P, 1992, BLOOD, V80, P937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER DN, 1993, ANN MED, V25, P11, DOI 10.3109/07853899309147851; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; CORTEN M, 1994, GENE THER, V1, P239; DEVIRAGH PA, 1994, J INVEST DERMATOL, V103, P815, DOI 10.1111/1523-1747.ep12413482; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HETTASCH JM, 1994, J BIOL CHEM, V269, P28309; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HUBER M, 1995, J INVEST DERMATOL, V105, P653, DOI 10.1111/1523-1747.ep12324122; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; ICHINOSE A, 1993, METHOD ENZYMOL, V222, P36; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1992, J BIOL CHEM, V267, P7710; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1994, J BIOL CHEM, V269, P27979; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI TS, 1994, J BIOL CHEM, V269, P24596; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Mikkola H, 1996, BLOOD, V87, P141; MIKKOLA H, 1994, BLOOD, V84, P517; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PARMENTIER L, 1995, HUM MOL GENET, V4, P1391, DOI 10.1093/hmg/4.8.1391; Parmentier L, 1996, HUM MOL GENET, V5, P555, DOI 10.1093/hmg/5.4.555; PECERSEN L, 1994, PROTEIN SCI, V3, P1131; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; PHILLIPS SB, 1993, DERMATOLOGY GEN MED, P531; POLAKOWSKA RR, 1991, CYTOGENET CELL GENET, V56, P105, DOI 10.1159/000133060; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Rice RH, 1996, BIOCHEM J, V320, P547, DOI 10.1042/bj3200547; ROSSMANNRINGDAHL I, 1986, ARCH DERMATOL, V122, P559; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TRAUPE H, 1989, ICHTHYOSES, P111; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296	65	64	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21018	21026		10.1074/jbc.272.34.21018	http://dx.doi.org/10.1074/jbc.272.34.21018			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261103	hybrid, Green Published			2022-12-27	WOS:A1997XR78900013
J	Saras, J; Engstrom, U; Gonez, LJ; Heldin, CH				Saras, J; Engstrom, U; Gonez, LJ; Heldin, CH			Characterization of the interactions between PDZ domains of the protein-tyrosine phosphatase PTPL1 and the carboxyl-terminal tail of Fas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE KINASES; CLONING; APOPTOSIS; BAND-4.1; HOMOLOG; ANTIGEN; FAMILY; CDNA	The intracellular protein-tyrosine phosphatase PTPL1 has five PDZ domains and one of them, PDZ 2, has previously been shown to interact with the C-terminal tail of Fas, a member of the tumor necrosis factor receptor family. Using a peptide binding assay, we show that not only PDZ 2 but also PDZ 4 of PTPL1 interacts with high affinity with peptides derived from the C terminus of Fas. The five most C-terminal amino acid residues of Fas influence the affinity of the interaction. Whereas the glutamine and isoleucine residues in the 4th and 5th positions from the C terminus affect the interaction in a negative and positive manner, respectively, the three C-terminal amino acid residues (SLV) are necessary and sufficient for a high affinity interaction to occur. Both the carboxyl group and side chain of the valine residue at the C terminus of Fas are essential, and the leucine and serine residues in the 2nd and 3rd positions, respectively, from the C terminus are important for the interactions with PDZ 2 and PDZ 4 of PTPL1.			Saras, J (corresponding author), BIOMED CTR,LUDWIG INST CANC RES,BOX 595,S-75124 UPPSALA,SWEDEN.							ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	26	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20979	20981		10.1074/jbc.272.34.20979	http://dx.doi.org/10.1074/jbc.272.34.20979			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261095	hybrid			2022-12-27	WOS:A1997XR78900005
J	Shin, KS; Park, JY; Kwon, H; Chung, CH; Kang, MS				Shin, KS; Park, JY; Kwon, H; Chung, CH; Kang, MS			Opposite effect of intracellular Ca2+ and protein kinase C on the expression of inwardly rectifying K+ channel 1 in mouse skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ RELEASE CHANNEL; MEMBRANE DEPOLARIZATION; SARCOPLASMIC-RETICULUM; GENE-EXPRESSION; CALCIUM INFLUX; RAT; RECEPTOR; CELLS; DENERVATION; INNERVATION	The level of inwardly rectifying K+ channel 1 (IRK1) mRNA decreased upon denervation and increased during muscle differentiation in mouse skeletal muscle, To identify the mechanism(s) underlying the regulation of IRK1 mRNA expression, we examined its expression using the well differentiated C2C12 mouse skeletal muscle cell line as a model system, Since nerve-induced muscle activity results in contraction, it was questioned whether the changes in IRK1 expression might be relevant to the increased intracellular calcium that functions as a cytoplasmic messenger in excitation-contraction coupling, Indeed, activation of either L-type calcium channels or ryanodine receptors increased the level of IRK1 mRNA, More directly, ionomycin activated the IRK1 expression in time-and dose-dependent manners, which was abolished by treatment with EGTA, Genistein, a tyrosine kinase inhibitor, also abolished the stimulating effect of ionomycin. Meanwhile, activation of protein kinase C by 12-O-tetradecanoylphorbol acetate (TPA) markedly decreased the level of IRK1 mRNA, which required ongoing protein synthesis, Actinomycin D experiments revealed that ionomycin increased the half life of IRK1 mRNA from 0.86 to 1.97 h, but TPA decreased it to 0.38 h, However, neither ionomycin nor TPA appreciably altered the rate of IRK1 gene transcription, Based on these observations, we conclude that intracellular calcium and protein kinase C are oppositely involved in the muscle activity dependent regulation of IRK1 gene expression and that both act at the level of mRNA stability.	SEOUL NATL UNIV,DEPT MOL BIOL,SEOUL 151742,SOUTH KOREA; SEOUL NATL UNIV,RES CTR CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA; DANKOOK UNIV,DEPT MOL BIOL,SEOUL 140714,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU); Dankook University			Tuluc, Petronel/C-2527-2011					ADRIAN RH, 1962, J PHYSIOL-LONDON, V163, P61, DOI 10.1113/jphysiol.1962.sp006959; ADRIAN RH, 1973, J PHYSIOL-LONDON, V235, P103, DOI 10.1113/jphysiol.1973.sp010380; ALBUQUERQUE EX, 1971, PFLUG ARCH EUR J PHY, V328, P36, DOI 10.1007/BF00587359; ALMERS W, 1972, J PHYSIOL-LONDON, V225, P57, DOI 10.1113/jphysiol.1972.sp009929; BIRNBAUM M, 1980, PFLUG ARCH EUR J PHY, V385, P37, DOI 10.1007/BF00583913; BLOCH RJ, 1986, J NEUROSCI, V6, P691; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BRIMIJOIN S, 1988, NERVE MUSCLE CELL TR, P23; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLELAND PJF, 1989, J BIOL CHEM, V264, P17704; DAVID JD, 1981, DEV BIOL, V82, P308, DOI 10.1016/0012-1606(81)90454-1; DAVIS HL, 1985, BRAIN RES, V343, P176, DOI 10.1016/0006-8993(85)91174-6; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; GONOI T, 1991, PFLUG ARCH EUR J PHY, V418, P601, DOI 10.1007/BF00370577; GREENBERG ME, 1989, CURRENT PROTOCOLS  S, V9; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HNIK P, 1976, PFLUG ARCH EUR J PHY, V362, P85, DOI 10.1007/BF00588685; HUANG CF, 1994, FEBS LETT, V338, P277, DOI 10.1016/0014-5793(94)80283-1; HUANG CF, 1993, FEBS LETT, V319, P21, DOI 10.1016/0014-5793(93)80029-T; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; KATZ B, 1949, ARCH SCI PHYSIOL, V3, P285; KEAN CJC, 1974, J PHYSIOL-LONDON, V237, P103, DOI 10.1113/jphysiol.1974.sp010472; KIM HS, 1992, DEV BIOL, V150, P223, DOI 10.1016/0012-1606(92)90237-B; KLOCKE R, 1994, J BIOL CHEM, V269, P27635; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; MATSUDA H, 1989, J PHYSIOL-LONDON, V414, P111, DOI 10.1113/jphysiol.1989.sp017679; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; NESTLER EJ, 1978, NATURE, V275, P451, DOI 10.1038/275451a0; PAPPONE PA, 1980, J PHYSIOL-LONDON, V306, P377, DOI 10.1113/jphysiol.1980.sp013403; REDFERN P, 1971, ACTA PHYSIOL SCAND, V81, P557, DOI 10.1111/j.1748-1716.1971.tb04932.x; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROTSHENKER S, 1976, J NEUROCYTOL, V5, P719, DOI 10.1007/BF01181583; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; RUBIN LL, 1985, P NATL ACAD SCI USA, V82, P7121, DOI 10.1073/pnas.82.20.7121; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHIMID A, 1984, FEBS LETT, V172, P114; SCHMIDANTOMARCHI H, 1985, P NATL ACAD SCI USA, V82, P2188, DOI 10.1073/pnas.82.7.2188; SHERMAN SJ, 1985, J NEUROSCI, V5, P1570; Shin KS, 1997, AM J PHYSIOL-CELL PH, V272, pC894, DOI 10.1152/ajpcell.1997.272.3.C894; STEINBACH JH, 1981, J PHYSIOL-LONDON, V313, P513, DOI 10.1113/jphysiol.1981.sp013679; SYROVY I, 1972, PHYSIOL BOHEMOSLOV, V21, P353; WAKELAM MJO, 1985, BIOCHEM J, V228, P1; WALKE W, 1994, J BIOL CHEM, V269, P19447; WESTGAARD RH, 1975, J PHYSIOL-LONDON, V251, P683, DOI 10.1113/jphysiol.1975.sp011116; [No title captured]	47	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21227	21232		10.1074/jbc.272.34.21227	http://dx.doi.org/10.1074/jbc.272.34.21227			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261131	hybrid			2022-12-27	WOS:A1997XR78900041
J	Coso, OA; Montaner, S; Fromm, C; Lacal, JC; Prywes, R; Teramoto, H; Gutkind, JS				Coso, OA; Montaner, S; Fromm, C; Lacal, JC; Prywes, R; Teramoto, H; Gutkind, JS			Signaling from G protein coupled receptors to the c-jun promoter involves the MEF2 transcription factor - Evidence for a novel c-Jun amino-terminal kinase-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; MAP KINASE; ACTIVATION DOMAIN; FOS; DIFFERENTIATION; PHOSPHORYLATION; TRANSFORMATION; FAMILY; MUSCLE; BINDS	The c-Jun amino-terminal kinases (JNKs) are a subfamily of mitogen-activated protein kinases that phosphorylate c-Jun and ATF2, and it has been postulated that phosphorylated c-Jun enhances its own expression through AP-1 sites on the c-jun promoter. In this study, we asked whether signals activating JNK regulate the c-jun promoter, Using NIH 3T3 cells expressing G protein-coupled mi acetylcholine receptors as an experimental model, we have recently shown that the cholinergic agonist carbachol, but not platelet derived growth factor, potently elevates JNK activity, Consistent with these findings, carbachol, but not platelet-derived growth factor, increased the activity of a c-jun promoter-driven reporter gene (for chloramphenicol acetyltransferase), However, coexpression of JNK kinase kinase (MEKK) effectively increased JNK activity, but resulted in surprisingly limited induction of the c- jun promoter, This raised the possibility that pathway(s) distinct from JNK control the c-jun promoter, and prompted us to explore which of its regulatory elements participate in transcriptional control. We observed that deletion of the 3' AP-1 site diminished chloramphenicol acetyltransferase activity in response to carbachol, but only to a limited extent, In contrast, deletion of a MEF2 site dramatically reduced expression, and deletion of both the MEF2 and 3' AP-1 sites abolished induction, Furthermore, cotransfection with MEF2C and MEF2D cDNAs potently enhanced the activity of the c-jun promoter in response to carbachol, and stimulation of mi receptors, but not direct JNK activation, induced expression of a MEF2-responsive plasmid. Taken together, these data strongly suggest that MEF2 mediates c-jun promoter expression by G protein-coupled receptors through a yet to be identified pathway, distinct from that of JNK.	NIDR,MOL SIGNALING UNIT,ORAL & PHARYNGEAL CANC BRANCH,NIH,BETHESDA,MD 20892; INST INVEST BIOMED,MADRID 28029,SPAIN; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Columbia University			Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Gutkind, J. Silvio/0000-0002-5150-4482; Lacal, Juan Carlos/0000-0002-1908-2777				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DODOU E, 1995, NUCLEIC ACIDS RES, V23, P4267, DOI 10.1093/nar/23.21.4267; Graves JD, 1995, ANN NY ACAD SCI, V766, P320, DOI 10.1111/j.1749-6632.1995.tb26684.x; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; YAN MH, 1994, NATURE, V372, P798	31	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20691	20697		10.1074/jbc.272.33.20691	http://dx.doi.org/10.1074/jbc.272.33.20691			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252389	hybrid			2022-12-27	WOS:A1997XR22100059
J	Kennedy, MC; Antholine, WE; Beinert, H				Kennedy, MC; Antholine, WE; Beinert, H			An EPR investigation of the products of the reaction of cytosolic and mitochondrial aconitases with nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; NITROSYL COMPLEX-FORMATION; IRON-SULFUR CLUSTER; ACTIVATED MACROPHAGES; TRANSFERRIN RECEPTOR; TRANSLATIONAL REGULATION; MESSENGER-RNA; CYTO-TOXICITY; TUMOR-CELLS; EXPRESSION	Cellular studies have indicated that some Fe-S proteins, and the aconitases in particular, are targets for nitric oxide, Specifically, NO has been implicated in the intracellular process of the conversion of active cytosolic aconitase containing a [4Fe-4S] cluster, to its apo-form which functions as an iron-regulatory protein, We have undertaken the in vitro study of the reaction of NO with purified forms of both mitochondrial and cytosolic aconitases by following enzyme activity and by observing the formation of EPR signals not shown by the original reactants, Inactivation by either NO solutions or NO-producing NONOates under anaerobic conditions is seen for both enzyme isoforms, This inactivation, which occurs in the presence or absence of substrate, is accompanied by the appearance of the g = 2.02 signals of the [3Fe-4S] clusters and the g approximate to 2.04 signal of a protein-bound dinitrosyl-iron-dithiol complex in the d(7) state, In addition, in the reaction of cytosolic aconitase, the transient formation of a thiyl radical, g(parallel to) = 2.11 and g(perpendicular to) = 2.03, is observed, Disassembly of the [3Fe-4S] clusters of the inactive forms of the enzymes upon the anaerobic addition of NO is also accompanied by the formation of the g approximate to 2.04 species and in the case of mitochondrial aconitase, a transient signal atg approximate to 2.032 appeared. This signal is tentatively assigned to the d(9) form of an iron-nitrosylhistidyl complex of the mitochondrial protein. Inactivation of the [4Fe-4S] forms of both aconitases by either superoxide anion or peroxynitrite produces the g = 2.02 [3Fe-4S] proteins.	MED COLL WISCONSIN,BIOPHYS RES INST,MILWAUKEE,WI 53226; UNIV WISCONSIN,INST ENZYME RES,GRAD SCH,MADISON,WI 53705; UNIV WISCONSIN,DEPT BIOCHEM,COLL AGR & LIFE SCI,MADISON,WI 53705	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kennedy, MC (corresponding author), MED COLL WISCONSIN,DEPT BIOCHEM,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051831] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51831] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASTIAN NR, 1994, J BIOL CHEM, V269, P5127; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; CAIRO G, 1995, EUR J BIOCHEM, V232, P358, DOI 10.1111/j.1432-1033.1995.tb20819.x; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CASTRO L, 1994, J BIOL CHEM, V269, P29409; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; EATON DR, 1987, ELECT MAGNETIC RESON; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Gruer MJ, 1997, TRENDS BIOCHEM SCI, V22, P3, DOI 10.1016/S0968-0004(96)10069-4; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIBBS JB, 1984, BIOCHEM BIOPH RES CO, V123, P716, DOI 10.1016/0006-291X(84)90288-2; ISCHIROPOLOUS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P597; JAFFREY SR, 1994, P NATL ACAD SCI USA, V91, P12994, DOI 10.1073/pnas.91.26.12994; KEEFER LK, 1996, METHOD ENZYMOL, V268, P271; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LEE MH, 1994, BIOCHEMISTRY-US, V33, P3679, DOI 10.1021/bi00178a026; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NELSON D, 1975, CHEM PHYS LETT, V36, P340, DOI 10.1016/0009-2614(75)80250-8; ORIA R, 1995, BLOOD, V85, P2962, DOI 10.1182/blood.V85.10.2962.bloodjournal85102962; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; REDDY D, 1983, SCIENCE, V221, P769, DOI 10.1126/science.6308761; REED JW, 1974, J AM CHEM SOC, V96, P1248, DOI 10.1021/ja00811a062; RICHARDSON DR, 1995, BLOOD, V86, P3211; ROUAULT TA, 1991, CELL, V64, P861; RYDEN L, 1984, J BIOL CHEM, V259, P3141; SALERNO JC, 1976, BIOCHEM BIOPH RES CO, V73, P833, DOI 10.1016/0006-291X(76)90884-6; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STEVENS TH, 1979, P NATL ACAD SCI USA, V76, P3320, DOI 10.1073/pnas.76.7.3320; THEIL EC, 1994, BIOCHEM J, V304, P1; VANIN A F, 1967, Biofizika, V12, P829; VANIN AF, 1995, BIOCHEMISTRY-MOSCOW+, V60, P225; VANIN AF, 1967, BIOCHEMISTRY-MOSCOW+, V32, P228; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3	51	216	222	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20340	20347		10.1074/jbc.272.33.20340	http://dx.doi.org/10.1074/jbc.272.33.20340			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252338	hybrid			2022-12-27	WOS:A1997XR22100008
J	Kuttkat, A; Edhofer, I; Eichacker, LA; Paulsen, H				Kuttkat, A; Edhofer, I; Eichacker, LA; Paulsen, H			Light-harvesting chlorophyll a/b-binding protein stably inserts into etioplast membranes supplemented with Zn-pheophytin a/b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LESS BARLEY MUTANT; A-B PROTEIN; THYLAKOID MEMBRANES; STROMAL FACTOR; COMPLEX-II; INTEGRATION; APOPROTEINS; PRECURSOR; POLYPEPTIDE; ETIOCHLOROPLASTS	Light-harvesting chlorophyll alb-binding protein, LHCP, or its precursor, pLHCP, cannot be stably inserted into barley etioplast membranes in vitro. However, when these etioplast membranes are supplemented with the chlorophyll analogs Zn-pheophytin a/b, synthesized in situ from Zn-pheophorbide a/b and digeranyl pyrophosphate, pLHCP is inserted into a protease-resistant state, This proves that chlorophyll is the only component lacking in etioplast membranes that is necessary for stable LHCP insertion, Synthesis of Zn-pheophytin b alone promotes insertion of LHCP in. vitro into a protease-resistant state, whereas synthesis of Zn-pheophytin a alone does not, Insertion of pLHCP into etioplast membranes can also be stimulated by adding chlorophyll a and chlorophyll b to the membranes, albeit at a significantly lower efficiency as compared with Zn-pheophytin a/b synthesized in situ, When pLHCP is inserted into chlorophyll-or Zn-pheophytin-supplemented etioplast membranes and then assayed with protease, only the protease digestion product indicative of the monomeric major light-harvesting chlorophyll a/b complex (LHCII) is found but not the one indicating trimeric complexes, In this respect, chlorophyll-or Zn-pheophytin-supplemented etioplast membranes resemble thylakoid membranes at an early greening stage: pLHCP inserted into plastid membranes from greening barley is assembled into trimeric LHCII only after more than 1 h of greening.	UNIV MAINZ,INST ALLGEMEINE BOT,D-55099 MAINZ,GERMANY; UNIV MUNICH,INST BOT,D-80638 MUNICH,GERMANY	Johannes Gutenberg University of Mainz; University of Munich			Paulsen, Harald/D-3742-2011					ADAMSKA I, 1995, LIGHT BIOSPHERE, V3, P887; APEL K, 1980, PLANTA, V150, P426, DOI 10.1007/BF00390180; BASSI R, 1985, CARLSBERG RES COMMUN, V50, P145, DOI 10.1007/BF02907142; BENNETT J, 1981, EUR J BIOCHEM, V118, P61, DOI 10.1111/j.1432-1033.1981.tb05486.x; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CHITNIS PR, 1988, PLANT MOL BIOL, V11, P95, DOI 10.1007/BF00015663; CHITNIS PR, 1987, PLANT MOL BIOL, V10, P3, DOI 10.1007/BF00014181; CHITNIS PR, 1986, J CELL BIOL, V102, P982, DOI 10.1083/jcb.102.3.982; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; COHEN Y, 1995, BBA-REV BIOMEMBRANES, V1241, P1, DOI 10.1016/0304-4157(94)00012-3; DREYFUSS BW, 1994, PLANT PHYSIOL, V106, P829, DOI 10.1104/pp.106.3.829; DUBACQ JP, 1983, PHYSIOL VEG, V21, P293; Eichacker LA, 1996, FEBS LETT, V395, P251, DOI 10.1016/0014-5793(96)01026-5; Eichacker LA, 1996, J BIOL CHEM, V271, P32174, DOI 10.1074/jbc.271.50.32174; EICHACKER LA, 1990, J BIOL CHEM, V265, P13566; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; HELFRICH M, 1992, Z NATURFORSCH C, V47, P231; HELFRICH M, 1994, EUR J BIOCHEM, V219, P267, DOI 10.1111/j.1432-1033.1994.tb19938.x; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; ITO H, 1994, J BIOL CHEM, V269, P22034; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; JONES ID, 1977, J AGR FOOD CHEM, V25, P146, DOI 10.1021/jf60209a025; JOO CN, 1973, CAN J BIOCHEM, V51, P1517; Klosgen RB, 1997, J PHOTOCH PHOTOBIO B, V38, P1, DOI 10.1016/S1011-1344(96)07408-8; KROL M, 1995, PLANT PHYSIOL, V107, P873, DOI 10.1104/pp.107.3.873; KUTTKAT A, 1995, PLANT PHYSIOL, V109, P1267, DOI 10.1104/pp.109.4.1267; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; NECHUSHTAI R, 1995, PHOTOSYNTH RES, V44, P165, DOI 10.1007/BF00018307; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; PAULSEN H, 1995, PHOTOCHEM PHOTOBIOL, V62, P367, DOI 10.1111/j.1751-1097.1995.tb02357.x; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PORRA RJ, 1995, FEBS LETT, V371, P21, DOI 10.1016/0014-5793(95)00854-3; PREISS S, 1995, PLANT PHYSIOL, V107, P709, DOI 10.1104/pp.107.3.709; Scheumann V, 1996, Z NATURFORSCH C, V51, P185; SHIMADA Y, 1990, PLANT CELL PHYSIOL, V31, P639; TANAKA A, 1991, PLANT CELL PHYSIOL, V32, P195, DOI 10.1093/oxfordjournals.pcp.a078064; TANAKA A, 1994, PLANTA, V192, P92; TREMOLIERES A, 1991, TRENDS PHOTOCHEM PHO, V2, P13; WIDEMAIER R, 1980, ARCH BIOCHEM BIOPHYS, V200, P609; YUAN JG, 1993, P NATL ACAD SCI USA, V90, P8552, DOI 10.1073/pnas.90.18.8552	44	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20451	20455		10.1074/jbc.272.33.20451	http://dx.doi.org/10.1074/jbc.272.33.20451			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252354	hybrid			2022-12-27	WOS:A1997XR22100024
J	Lin, WH; Hung, CH; Hsu, CI; Lin, JY				Lin, WH; Hung, CH; Hsu, CI; Lin, JY			Dimerization of the N-terminal amphipathic alpha-helix domain of the fungal immunomodulatory protein from Ganoderma tsugae (Fip-gts) defined by a yeast two-hybrid system and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LING ZHI-8 LZ-8; TRANSFORMATION; POLYPEPTIDES; CLONING	A fungal immunomodulatory protein (Fip-gts) was purified from Ganoderma tsugae, The DNA encoding Fip-gts was isolated from a cDNA library of G. tsugae by reverse transcriptase-polymerase chain reaction, The complete amino acid sequence of Fip-gts, deduced from the nucleotide sequence of the cDNA, was the same as LZ-8 isolated from Ganodermn lucidum, Recombinant Fip-gts was expressed as a glutathione S-transferase fusion protein in Escherichia coli with a yield of 20 mg/liter of culture, Recombinant Fip-gts, purified to homogeneity, had the same blast formation stimulatory activity to human peripheral blood lymphocytes as native Fip-gts. The yeast two-hybrid system and site directed mutagenesis were used to determine whether dimerization of Fip-gts occurred, Deletion analysis of the N-terminal amphipathic alpha-helix domain of Fip-gts identified a sequence of about 10 amino acids responsible for inducing immunomodulatory activity. Non-functional Fip-gts deletion mutants did not form dimers, whereas wild type Fip-gts did as determined by gel filtration, A mutant with deletions at Leu-5, Phe-7, and Leu-9 lost the amphipathic characteristics of the N-terminal domain and the ability to form dimers as well as its immunomodulatory activity. Fusion of Fip-gts with the DNA binding and the transactivation domains of GAL4 resulted in the activation of the lacZ activator gene, indicating the interaction of Fip-gts with it itself, The dimerization domain was further defined by analyzing the ability of the N-terminal 13 amino acids or Leu-5, Phe-7, and Leu-9 deletion mutants of Fip-gts to interact with the wild type Fip-gts. These experiments confirmed the N-terminal amphipathic alpha-helix as the dimerization domain and suggest that the dimerization of Fip-gts may play an important role in Fip-gts immunomodulatory activity.	NATL TAIWAN UNIV,COLL MED,INST BIOCHEM,TAIPEI 100,TAIWAN	National Taiwan University			Lin, Jung-Yaw/AGW-9336-2022	Lin, Jung-Yaw/0000-0002-6341-1160				CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DAVID DS, 1980, JAMA-J AM MED ASSOC, V243, P532; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; Eisenberg D., 1982, FARADAY S CHEM SOC, V17, P109, DOI DOI 10.1039/FS9821700109; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUBLER U, 1983, GENE, V25, P283; HAHN HJ, 1986, TRANSPLANTATION, V41, P44, DOI 10.1097/00007890-198601000-00008; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Hsu HC, 1997, BIOCHEM J, V323, P557, DOI 10.1042/bj3230557; HUNG CH, 1993, GENE, V127, P215, DOI 10.1016/0378-1119(93)90722-F; KINO K, 1990, DIABETOLOGIA, V33, P713, DOI 10.1007/BF00400340; KINO K, 1989, J BIOL CHEM, V264, P472; KO JL, 1995, EUR J BIOCHEM, V228, P244, DOI 10.1111/j.1432-1033.1995.tb20256.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin SH, 1996, EUR J BIOCHEM, V240, P564, DOI 10.1111/j.1432-1033.1996.0564h.x; Miller J.H., 1972, EXPT MOL GENETICS; MURASUGI A, 1991, J BIOL CHEM, V266, P2486; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDERHEM LG, 1995, TRANSPLANTATION, V60, P438, DOI 10.1097/00007890-199509000-00006	23	101	125	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20044	20048		10.1074/jbc.272.32.20044	http://dx.doi.org/10.1074/jbc.272.32.20044			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242675	hybrid			2022-12-27	WOS:A1997XQ05900062
J	Shresta, S; Goda, P; Wesselschmidt, R; Ley, TJ				Shresta, S; Goda, P; Wesselschmidt, R; Ley, TJ			Residual cytotoxicity and granzyme K expression in granzyme A-deficient cytotoxic lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE SERINE PROTEASES; CYTO-TOXIC LYMPHOCYTES; NATURAL-KILLER; RAPID INDUCTION; CELL LEUKEMIA; ESTERASE GENE; TARGET-CELLS; CLONING; PURIFICATION; CDNA	Cytotoxic lymphocytes contain granules that have the ability to induce apoptosis in susceptible target cells, The granule contents include perforin, a pore-forming molecule, and several granzymes, including A and B, which are the most abundant serine proteases in these granules. Granzyme B-deficient cytotoxic T lymphocytes (CTL) have a severe defect in their ability to rapidly induce apoptosis in their targets, but have an intact late cytotoxicity pathway that is in part perforin-dependent, In this report, we have created mice that are deficient for granzyme A acid characterized their phenotype, These mice have normal growth and development and normal lymphocyte development, activation, and proliferation, Granzyme A-deficient CTL have a small but reproducible defect in their ability to induce Cr-51 and I-125-UdR release from susceptible allogeneic target cells. Since other granzyme Alike tryptases could potentially account for the residual cytotoxicity in granzyme A-deficient CTL, we cloned the murine granzyme If,belle, which is linked to granzyme A in humans, and proved that it is also tightly linked with murine granzyme A. The murine granzyme if gene (which encodes a tryptase similar to granzyme A) is expressed at much lower levels than granzyme A in CTL and LAIC cells, but its expression is unaltered in granzyme A-/- mice, The minimal cytotoxic defect in granzyme A-/- CTL could be due to the existence of an intact, functional early killing pathway (granzyme B dependent), or to the persistent expression of additional granzyme tryptases like granzyme K.	WASHINGTON UNIV,SCH MED,DIV BONE MARROW TRANSPLANTAT & STEM CELL BIOL,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BONE MARROW TRANSPLANTAT & STEM CELL BIOL,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049786] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NIDDK NIH HHS [DK49786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER E, 1994, IMMUNOGENETICS, V40, P235, DOI 10.1007/BF00167085; BLEACKLEY RC, 1988, FEBS LETT, V234, P153, DOI 10.1016/0014-5793(88)81323-1; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; CAPUTO A, 1988, J BIOL CHEM, V263, P6363; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EBNET K, 1992, GENOMICS, V13, P502, DOI 10.1016/0888-7543(92)90117-B; EBNET K, 1995, EMBO J, V14, P4230, DOI 10.1002/j.1460-2075.1995.tb00097.x; FINK TM, 1993, GENOMICS, V18, P401, DOI 10.1006/geno.1993.1483; FRUTH U, 1987, EUR J IMMUNOL, V17, P1625, DOI 10.1002/eji.1830171116; GERSHENFELD HK, 1988, P NATL ACAD SCI USA, V85, P1184, DOI 10.1073/pnas.85.4.1184; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; Graubert TA, 1996, BLOOD, V87, P1232, DOI 10.1182/blood.V87.4.1232.bloodjournal8741232; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; HAMEED A, 1988, J IMMUNOL, V141, P3142; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HARPER K, 1988, IMMUNOGENETICS, V28, P439, DOI 10.1007/BF00355376; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HERSHBERGER RJ, 1992, J BIOL CHEM, V267, P25488; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; JENNE DE, 1989, BIOCHEMISTRY-US, V28, P7953, DOI 10.1021/bi00445a060; Kelly JM, 1996, IMMUNOGENETICS, V44, P340, DOI 10.1007/BF02602778; KRAHENBUHL O, 1988, J IMMUNOL, V141, P3471; LEY TJ, 1989, J CLIN INVEST, V83, P1032, DOI 10.1172/JCI113944; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1988, BIOCHEMISTRY-US, V27, P6941, DOI 10.1021/bi00418a040; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MATTEI MG, 1987, CYTOGENET CELL GENET, V46, P657; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; Mullbacher A, 1996, P NATL ACAD SCI USA, V93, P5783, DOI 10.1073/pnas.93.12.5783; NAKAJIMA H, 1995, J EXP MED, V181, P1037, DOI 10.1084/jem.181.3.1037; PASTERNACK MS, 1986, NATURE, V322, P740, DOI 10.1038/322740a0; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; PRZETAK MM, 1995, FEBS LETT, V364, P268, DOI 10.1016/0014-5793(95)00407-Z; RUSSELL JH, 1982, J IMMUNOL, V128, P2087; Sayers TJ, 1996, J LEUKOCYTE BIOL, V59, P763, DOI 10.1002/jlb.59.5.763; SAYERS TJ, 1994, J IMMUNOL, V152, P2289; SAYERS TJ, 1992, J IMMUNOL, V148, P292; SCHMID J, 1987, J IMMUNOL, V139, P250; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHIM L, 1992, J EXP MED, V175, P553; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SHRESTA S, 1995, P NATL ACAD SCI USA, V92, P5679, DOI 10.1073/pnas.92.12.5679; Shresta S, 1997, BLOOD, V89, P4085, DOI 10.1182/blood.V89.11.4085; SIMON MM, 1986, EMBO J, V5, P3267, DOI 10.1002/j.1460-2075.1986.tb04638.x; SMYTH MJ, 1992, J BIOL CHEM, V267, P24418; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924; YOUNG JDE, 1986, CELL, V47, P183, DOI 10.1016/0092-8674(86)90441-1; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	52	48	49	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20236	20244		10.1074/jbc.272.32.20236	http://dx.doi.org/10.1074/jbc.272.32.20236			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242702	hybrid			2022-12-27	WOS:A1997XQ05900089
J	Arystarkhova, E; Sweadner, KJ				Arystarkhova, E; Sweadner, KJ			Tissue-specific expression of the Na,K-ATPase beta 3 subunit - The presence of beta 3 in lung and liver addresses the problem of the missing subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+-ATPASE COMPLEXES; DIFFERENTIAL EXPRESSION; MESSENGER-RNAS; ALPHA-SUBUNIT; K+-ATPASE; HEPATIC (NA+,K+)-ATPASE; MONOCLONAL-ANTIBODIES; ENZYMATIC-PROPERTIES; KINETIC-PROPERTIES; ADHESION MOLECULE	The Na,R-ATPase belongs to a family of P-type ion-translocating ATPases sharing homologous catalytic subunits (alpha) that traverse the membrane several times and contain the binding sites for ATP and cations, In this family, only Na,K- and H,K-ATPases have been shown to have a second subunit, a single-span glycoprotein called beta. Recently a new isoform (beta 3) has been identified in mammals. Here we describe structural features and tissue distribution of the beta 3 protein, utilizing an antiserum specific for its N terminus, beta 3 was the only beta detected in Na,K-ATPase purified from C6 glioma, Treatment with N-glycosidase F confirmed that beta 3 is a glycoprotein containing N-linked carbohydrate chains, Molecular masses of the glycosylated protein and core protein were estimated to be 42 and 35 kDa, respectively, which are different from those of the beta 1 and beta 2 subunits. Detection of beta subunits has historically been difficult in certain tissues, Sensitivity was improved by deglycosylating, and expression was evaluated by obtaining estimates of beta 3/alpha ratio. The proportion of beta 3 protein in the rat was highest in lung and testis, It was also present in liver and skeletal muscle, whereas kidney, heart, and brain contained it only as a minor component of the Na,K-ATPase. In P7 rat, we found skeletal muscle and lung Na,K-ATPase to be the most enriched in beta 3 subunit, whereas expression in liver was very low, illustrating developmentally regulated changes in expression. The substantial expression in lung and adult liver very likely explains long-standing puzzles about an apparent paucity of beta subunit in membranes or in discrete cellular or subcellular structures.	MASSACHUSETTS GEN HOSP,CTR NEUROSCI,LAB MEMBRANE BIOL,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital					NINDS NIH HHS [NS27653] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027653] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Besirli CG, 1997, BBA-GENE STRUCT EXPR, V1350, P21, DOI 10.1016/S0167-4781(96)00192-3; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P9897, DOI 10.1021/bi00031a011; BROWN TA, 1987, BIOCHIM BIOPHYS ACTA, V912, P244, DOI 10.1016/0167-4838(87)90095-1; CHOW DC, 1995, J EXP BIOL, V198, P1; CRUMP RG, 1995, AM J PHYSIOL-LUNG C, V269, pL299, DOI 10.1152/ajplung.1995.269.3.L299; DESAIYAJNIK V, 1995, ENDOCRINOLOGY, V136, P629, DOI 10.1210/en.136.2.629; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; EMANUEL JR, 1987, P NATL ACAD SCI USA, V84, P9030, DOI 10.1073/pnas.84.24.9030; FAHRIG T, 1990, EUR J NEUROSCI, V2, P153, DOI 10.1111/j.1460-9568.1990.tb00407.x; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; GICK GG, 1993, J MEMBRANE BIOL, V131, P229, DOI 10.1007/BF02260111; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HUBERT JJ, 1986, BIOCHEMISTRY-US, V25, P4156, DOI 10.1021/bi00362a025; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; LEFFERT HL, 1985, HEPATOLOGY, V5, P501, DOI 10.1002/hep.1840050327; LEMAS MV, 1993, BIOCHIM BIOPHYS ACTA, V1149, P339; LEVENSON R, 1994, REV PHYSIOL BIOCH P, V123, P1, DOI 10.1007/BFb0030902; LU XP, 1991, J BIOL CHEM, V266, P9276; Malik N, 1996, J BIOL CHEM, V271, P22754, DOI 10.1074/jbc.271.37.22754; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; OBRODOVICH H, 1993, AM J PHYSIOL, V264, pC1137, DOI 10.1152/ajpcell.1993.264.5.C1137; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; PINTER E, 1991, J CLIN INVEST, V87, P821, DOI 10.1172/JCI115085; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; SCHNEEBERGER EE, 1986, J APPL PHYSIOL, V60, P1584, DOI 10.1152/jappl.1986.60.5.1584; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SIMON FR, 1995, AM J PHYSIOL-CELL PH, V269, pC69, DOI 10.1152/ajpcell.1995.269.1.C69; Simon FR, 1996, J BIOL CHEM, V271, P24967, DOI 10.1074/jbc.271.40.24967; SUN Y, 1992, AM J PHYSIOL, V262, pC1491, DOI 10.1152/ajpcell.1992.262.6.C1491; SUTHERLAND E, 1988, P NATL ACAD SCI USA, V85, P8673, DOI 10.1073/pnas.85.22.8673; SWEADNER KJ, 1988, METHOD ENZYMOL, V156, P65; TREUHEIT MJ, 1993, J BIOL CHEM, V268, P13914	37	97	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22405	22408		10.1074/jbc.272.36.22405	http://dx.doi.org/10.1074/jbc.272.36.22405			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278390	hybrid			2022-12-27	WOS:A1997XV49200009
J	Orlowski, J; Grinstein, S				Orlowski, J; Grinstein, S			Na+/H+ exchangers of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RAT NA/H EXCHANGER; RENAL BRUSH-BORDER; H+ EXCHANGER; GROWTH-FACTOR; MOLECULAR-CLONING; PROTEIN-KINASE; ATP DEPENDENCE; FUNCTIONAL EXPRESSION; CYTOPLASMIC DOMAIN; INTRACELLULAR PH		HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University				Orlowski, John/0000-0001-7371-175X				Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; Bianchini L, 1997, J BIOL CHEM, V272, P271; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Bookstein C, 1996, AM J PHYSIOL-CELL PH, V271, pC1629, DOI 10.1152/ajpcell.1996.271.5.C1629; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BOOKSTEIN C, 1994, J BIOL CHEM, V269, P29704; BRIERLEY GP, 1989, BIOCHEMISTRY-US, V28, P4337; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CASSEL D, 1986, J BIOL CHEM, V261, P5460; COLLINS JF, 1993, P NATL ACAD SCI USA, V90, P3938, DOI 10.1073/pnas.90.9.3938; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; Demaurex N, 1997, J GEN PHYSIOL, V109, P117, DOI 10.1085/jgp.109.2.117; DEMAUREX N, 1995, J GEN PHYSIOL, V106, P85, DOI 10.1085/jgp.106.1.85; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FLIEGEL L, 1993, BIOCHEM J, V296, P273, DOI 10.1042/bj2960273; FLIEGEL L, 1993, BIOCHEM J, V289, P101, DOI 10.1042/bj2890101; FRANCHI A, 1986, J BIOL CHEM, V261, P4614; Garlid K D, 1988, Adv Exp Med Biol, V232, P37; Goss G, 1996, AM J PHYSIOL-CELL PH, V270, pC1493, DOI 10.1152/ajpcell.1996.270.5.C1493; GOSS GG, 1994, J BIOL CHEM, V269, P8741; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HAWORTH RS, 1993, BIOCHEM J, V289, P637, DOI 10.1042/bj2890637; HENSLEY CB, 1990, KIDNEY INT, V37, P707, DOI 10.1038/ki.1990.37; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; IVES HE, 1983, J BIOL CHEM, V258, P9710; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KAPUS A, 1994, J BIOL CHEM, V269, P23544; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; MA YH, 1994, J BIOL CHEM, V269, P30734; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; POST MA, 1994, J GEN PHYSIOL, V103, P895, DOI 10.1085/jgp.103.5.895; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; REITHMEIER RAF, 1994, CURR OPIN CELL BIOL, V6, P583, DOI 10.1016/0955-0674(94)90080-9; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SILVA NLCL, 1995, BIOCHEMISTRY-US, V34, P10412, DOI 10.1021/bi00033a013; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; TSE CM, 1994, BIOCHEMISTRY-US, V33, P12954, DOI 10.1021/bi00248a003; TSE M, 1993, J MEMBRANE BIOL, V135, P93; VANDYKE RW, 1995, AM J PHYSIOL-CELL PH, V269, pC943, DOI 10.1152/ajpcell.1995.269.4.C943; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767	67	503	521	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22373	22376		10.1074/jbc.272.36.22373	http://dx.doi.org/10.1074/jbc.272.36.22373			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278382	hybrid			2022-12-27	WOS:A1997XV49200001
J	Skrincosky, D; Kain, R; ElBattari, A; Exner, M; Kerjaschki, D; Fukuda, M				Skrincosky, D; Kain, R; ElBattari, A; Exner, M; Kerjaschki, D; Fukuda, M			Altered golgi localization of core 2 beta-1,6-N-acetylglucosaminyltransferase leads to decreased synthesis of branched O-glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; WISKOTT-ALDRICH SYNDROME; HAMSTER OVARY CELLS; MAJOR SIALOGLYCOPROTEIN; LINKED OLIGOSACCHARIDES; LYMPHOBLASTOID-CELLS; MOLECULAR-CLONING; EPITHELIAL-CELLS; CYTOPLASMIC TAIL; MEMBRANE-PROTEIN	Mucin type O-glycans with core 2 branches are distinct from nonbranched O-glycans, and the amount of core 2 branched O-glycans changes dramatically during T cell differentiation. This oligosaccharide is synthesized only when core 2 beta-1,6-N-acetylglucosaminyltransferase (C2GnT) is present, and the expression of this glycosyltransferase is highly regulated. To understand how O-glycan synthesis is regulated by the orderly appearance of glycosyltransferases that form core 2 branched O-glycans, the subcellular localization of C2GnT was determined by using antibodies generated that are specific to C2GnT. The studies using confocal light microscopy demonstrated that C2GnT was localized mainly in cis to medial-cisternae of the Golgi. We then converted C2GnT to a trans-Golgi enzyme by replacing its Golgi retention signal with that of alpha-2,6-sialyltransferase, which resides in trans-Golgi. Chinese hamster ovary cells expressing wild type C2GnT and the chimeric C2GnT were then subjected to oligosaccharide analysis. The results obtained clearly indicate that the conversion of C2GnT into a trans-Golgi enzyme resulted in a substantial decrease of core 2 branched oligosaccharides. These results, taken together, strongly suggest that the predominance of core 2 branched oligosaccharides in those cells expressing C2GnT is due to the fact; that C2GnT is located earlier in the Golgi than alpha-2,3-sialyltransferase that competes with C2GnT far the common substrate. Furthermore, alteration of Golgi localization renders the chimeric C2GnT much less efficient in synthesizing core 2 branched oligosaccharides, indicating the critical role of orderly subcellular localization of glycosyltransferases.	BURNHAM INST, GLYCOBIOL PROGRAM, LA JOLLA, CA 92037 USA; UNIV MEDITERRANEAN, FAC MED, MARSEILLE 5, FRANCE; UNIV VIENNA, INST CLIN PATHOL, VIENNA, AUSTRIA	Sanford Burnham Prebys Medical Discovery Institute; UDICE-French Research Universities; Aix-Marseille Universite; University of Vienna			Kain, Renate/ACR-4709-2022	Kain, Renate/0000-0002-2428-543X	NATIONAL CANCER INSTITUTE [R37CA033000] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA33000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON LC, 1978, BLOOD, V52, P57; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; ARDMAN B, 1990, J EXP MED, V172, P1151, DOI 10.1084/jem.172.4.1151; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; BURKE J, 1992, J BIOL CHEM, V267, P24433; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; FRANKEL S, 1991, P NATL ACAD SCI USA, V88, P1192, DOI 10.1073/pnas.88.4.1192; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; Fukuda M, 1996, CANCER RES, V56, P2237; FUKUDA MN, 1995, GENE DEV, V9, P1199, DOI 10.1101/gad.9.10.1199; HAKOMORI S, 1985, CANCER RES, V45, P2405; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; KAIN R, 1995, J EXP MED, V181, P585, DOI 10.1084/jem.181.2.585; KERJASCHKI D, 1989, J IMMUNOL, V143, P546; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEFEBVRE JC, 1994, J EXP MED, V180, P1609, DOI 10.1084/jem.180.5.1609; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OGATA S, 1994, J BIOL CHEM, V269, P5210; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; PILLER V, 1990, J BIOL CHEM, V265, P9264; REMOLD-O'DONNELL E, 1990, Immunodeficiency Reviews, V2, P151; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SAITOH O, 1991, BLOOD, V77, P1491; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; UEMURA M, 1992, CANCER RES, V52, P6153; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	46	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22695	22702		10.1074/jbc.272.36.22695	http://dx.doi.org/10.1074/jbc.272.36.22695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278427	hybrid			2022-12-27	WOS:A1997XV49200048
J	Bouaboula, M; Perrachon, S; Milligan, L; Canat, X; RinaldiCarmona, M; Portier, M; Barth, F; Calandra, B; Pecceu, F; Lupker, J; Maffrand, JP; LeFur, G; Casellas, P				Bouaboula, M; Perrachon, S; Milligan, L; Canat, X; RinaldiCarmona, M; Portier, M; Barth, F; Calandra, B; Pecceu, F; Lupker, J; Maffrand, JP; LeFur, G; Casellas, P			A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 - Evidence for a new model of receptor/ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED ADP-RIBOSYLATION; BLASTOMA CELL-MEMBRANES; SENSITIVE G-PROTEINS; SIGNAL-TRANSDUCTION; ADENYLATE-CYCLASE; GTP-BINDING; RAT-BRAIN; PHOSPHATIDYLINOSITOL 3-KINASE; BETA(2)-ADRENERGIC RECEPTOR; TRANSCRIPTION FACTOR	In the present study, we showed that Chinese hamster ovary (CHO) cells transfected with human central cannabinoid receptor (CB1) exhibit high constitutive activity at both levels of mitogen-activated protein kinase (MAPK) and adenylyl cyclase, These activities could be blocked by the CB1-selective ligand, SR 141716A, that functions as an inverse agonist. Moreover, binding studies showed that guanine nucleotides decreased the binding of the agonist CP-55,940, an effect usually observed with agonists, whereas it enhanced the binding of SR 141716A, a property of inverse agonists, Unexpectedly, me found that CB1-mediated effects of SR 141716A included inhibition of MAPK activation by pertussis toxin-sensitive receptor-tyrosine kinase such as insulin or insulin-like growth factor 1 receptors but not by pertussis toxin-insensitive receptor-tyrosine kinase such as the fibroblast growth factor receptor, We also observed similar results when cells were stimulated with Mas-7, a mastoparan analog, that directly activates the G(i) protein. Furthermore, SR 141716A inhibited guanosine 5'-0-(thiotriphosphate) uptake induced by CP-55,940 or Mas-7 in CHO-CB1 cell membranes, This indicates that, in addition to the inhibition of autoactivated CB1, SR 141716A can deliver a biological signal that blocks the G(i) protein and consequently abrogates most of the G(i)-mediated responses, By contrast, SR 141716A had no effect on MAPK activation by insulin or IGF1 in CHO cells lacking CB1 receptors, ruling out the possibility of a direct interaction of SR 141716A with the G(i) protein, This supports the notion that the G(i) protein may act as a negative intracellular signaling cross-talk molecule, From these original results, which considerably enlarge the biological properties of the inverse agonist, we propose a novel model for receptor/ligand interactions.	SANOFI RECH,F-34184 MONTPELLIER 04,FRANCE; SANOFI RECH,F-31676 LABEGE,FRANCE; SANOFI RECH,F-31036 TOULOUSE,FRANCE; SANOFI RECH,F-75374 PARIS 08,FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France				Milligan, Laura/0000-0001-6985-3034				BARKER EL, 1994, J BIOL CHEM, V269, P11687; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; BOUABOULA M, 1995, J BIOL CHEM, V270, P13973, DOI 10.1074/jbc.270.23.13973; BRAESTRUP C, 1982, SCIENCE, V216, P1241, DOI 10.1126/science.6281892; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CHIDIAC P, 1995, TRENDS PHARMACOL SCI, V16, P83, DOI 10.1016/S0165-6147(00)88986-5; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GLASS M, 1995, NEUROREPORT, V6, P241, DOI 10.1097/00001756-199501000-00004; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HOWLETT AC, 1984, MOL PHARMACOL, V26, P532; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; JAHANGEER S, 1993, P NATL ACAD SCI USA, V90, P8782, DOI 10.1073/pnas.90.19.8782; JO H, 1992, ENDOCRINOLOGY, V131, P2855, DOI 10.1210/en.131.6.2855; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KELLERER M, 1991, BIOCHEM J, V276, P103, DOI 10.1042/bj2760103; Kenakin T, 1996, PHARMACOL REV, V48, P413; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LABRECQUE J, 1995, MOL PHARMACOL, V48, P150; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MAILLEUX P, 1994, NEUROREPORT, V5, P1265, DOI 10.1097/00001756-199406020-00028; MATESIC DF, 1989, J BIOL CHEM, V264, P21638; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MINTY A, 1993, EUR CYTOKINE NETW, V4, P99; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; Mullaney L, 1996, BIOCHEM J, V315, P227, DOI 10.1042/bj3150227; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OKAMOTO T, 1993, FEBS LETT, V334, P143, DOI 10.1016/0014-5793(93)81700-A; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PYNE NJ, 1989, BIOCHEM BIOPH RES CO, V165, P251, DOI 10.1016/0006-291X(89)91062-0; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; RinaldiCarmona M, 1996, LIFE SCI, V58, P1239, DOI 10.1016/0024-3205(96)00085-9; RinaldiCarmona M, 1996, J PHARMACOL EXP THER, V278, P871; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; SA G, 1994, J BIOL CHEM, V269, P3219; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHLEGEL W, 1979, J BIOL CHEM, V254, P5168; Selley DE, 1996, LIFE SCI, V59, P659, DOI 10.1016/0024-3205(96)00347-5; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Siebler T, 1996, REGUL PEPTIDES, V62, P65, DOI 10.1016/0167-0115(95)00159-X; TIBERI M, 1994, J BIOL CHEM, V269, P27925; UEKI K, 1994, J BIOL CHEM, V269, P15756; VALIQUETTE M, 1995, EMBO J, V14, P5542, DOI 10.1002/j.1460-2075.1995.tb00241.x; Weiss JM, 1996, J THEOR BIOL, V178, P169, DOI 10.1006/jtbi.1996.0015; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937	66	396	413	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22330	22339		10.1074/jbc.272.35.22330	http://dx.doi.org/10.1074/jbc.272.35.22330			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268384	hybrid			2022-12-27	WOS:A1997XT85000096
J	Elmgren, A; Mollicone, R; Costache, M; Borjeson, C; Oriol, R; Harrington, J; Larson, G				Elmgren, A; Mollicone, R; Costache, M; Borjeson, C; Oriol, R; Harrington, J; Larson, G			Significance of individual point mutations, T202C and C314T, in the human Lewis (FUT3) gene for expression of Lewis antigens by the human alpha(1,3/1,4)-fucosyltransferase, Fuc-TIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; BLOOD-GROUP SYSTEM; FUCOSYL-TRANSFERASE; MOLECULAR-CLONING; SIALYL-LEWIS; DETERMINES EXPRESSION; NEGATIVE INDIVIDUALS; HUMAN-MILK; RECOGNITION; SEQUENCE	The Lewis alpha(1,3/1,4)-fucosyltransferase, Fuc-TIII, encoded by the FUT3 gene is responsible for the final synthesis of Le(a) and Le(b) antigens, Various point mutations have been described explaining the Lewis negative phenotype, Le(a-b-), on erythrocytes and secretions, Two of these, T202C and C314T originally described in a Swedish population, have not been found as single isolated point mutations so far, To define the relative contribution of each of these two mutations to the Lewis negative phenotype, we cloned and made chimeric FUT3 constructs separating the T202C mutation responsible for the amino acid change Trp(68) --> Arg, from the C314T mutation leading to the Thr(l05) --> Met shift, COS-7 cells were transfected and the expression of Fuc-TIII enzyme activity and the presence of Lewis antigens were determined, There was no decrease in enzyme activity nor of immunofluorescence staining on cells transfected with the construct containing the isolated C314T mutation compared with cells transfected with a wild type FUT3 allele control, No enzyme activity nor immunoreactivity for Lewis antigens was detected in FUT3 constructs containing both mutations in combination, The T202C mutation alone decreased the enzyme activity to less than 1% of the activity of the wild type FUT3 allele, These results demonstrate, that the Trp(68) --> Arg substitution in human Fuc-TIII is the capital amino acid change responsible for the appearance of the Le(a-b-) phenotype on human erythrocytes in individuals homozygous for both the T202C and C314T mutations.	SAHLGRENS UNIV HOSP, DEPT CLIN CHEM & TRANSFUS MED, INST LAB MED, S-41345 GOTHENBURG, SWEDEN; INSERM, U178, F-94807 VILLEJUIF, FRANCE; NEW S WALES RED CROSS BLOOD TRANSFUS SERV, SYDNEY, NSW 2000, AUSTRALIA	Sahlgrenska University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Australian Red Cross Blood Service			Costache, Marieta D/F-2806-2016; Larson, Göran/AAF-3404-2019	Costache, Marieta D/0000-0002-8103-3693; 				ANDRESEN PH, 1948, ACTA PATHOL MIC SC, V24, P616; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Battey, 1986, BASIC METHODS MOL BI; BERGER SL, 1987, METHODS ENZYMOLOGY G; Breton C, 1996, GLYCOBIOLOGY, V6, pR7; CANDELIER JJ, 1993, LAB INVEST, V69, P449; CEPPELLINI R., 1955, RIV 1ST SIEROTEROP ITAL, V30, P431; CHESTER MA, 1990, P 2 INT WORKSH MON A; ELMGREN A, 1993, BIOCHEM BIOPH RES CO, V196, P515, DOI 10.1006/bbrc.1993.2280; Elmgren A, 1996, VOX SANG, V70, P97, DOI 10.1111/j.1423-0410.1996.tb01300.x; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOD AH, 1992, VOX SANG, V62, P180, DOI 10.1111/j.1423-0410.1992.tb01195.x; GRUBB R, 1951, ACTA PATHOL MIC SC, V28, P61; Henry S, 1997, GLYCOCONJUGATE J, V14, P209, DOI 10.1023/A:1018541821819; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P241, DOI 10.1007/BF00731136; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KODA Y, 1993, BLOOD, V82, P2915; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MARCUS DM, 1969, SCIENCE, V164, P553, DOI 10.1126/science.164.3879.553; Mollicone R, 1996, GLYCOCONJUGATE J, V13, P263, DOI 10.1007/BF00731501; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MOURANT AE, 1946, NATURE, V158, P237, DOI 10.1038/158237c0; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; Orntoft TF, 1996, J BIOL CHEM, V271, P32260, DOI 10.1074/jbc.271.50.32260; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Schenkel-Brunner H, 1995, HUMAN BLOOD GROUPS; WESTON BW, 1993, J BIOL CHEM, V268, P18398; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	43	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21994	21998		10.1074/jbc.272.35.21994	http://dx.doi.org/10.1074/jbc.272.35.21994			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268337	hybrid			2022-12-27	WOS:A1997XT85000049
J	Sudbeck, BD; Pilcher, BK; Welgus, HG; Parks, WC				Sudbeck, BD; Pilcher, BK; Welgus, HG; Parks, WC			Induction and repression of collagenase-1 by keratinocytes is controlled by distinct components of different extracellular matrix compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; INTERSTITIAL COLLAGENASE; INTEGRIN EXPRESSION; TISSUE INHIBITOR; DOWN-REGULATION; CELL CARCINOMA; MESSENGER-RNA; METALLOPROTEINASES; ADHESION; INVITRO	In all forms of cutaneous wounds, collagenase-1 (matrix metalloproteinase-1 (MMP-1)) is invariably expressed by basal keratinocytes migrating over the dermal matrix, We report that native type I collagen mediates induction of MMP-1 by primary human keratinocytes, Collagen-mediated induction of MMP-1 was rapid, being detected 2 h after plating, and was transcriptionally regulated, As demonstrated by in situ hybridization, only migrating keratinocytes expressed MMP-1, suggesting that contact with collagen is not sufficient to induce MMP-1 expression in keratinocytes; the cells must also be migrating, Upon denaturation, type I collagen lost its ability to induce MMP-1 expression but still supported cell adhesion, Other dermal or wound matrix proteins, such as type III collagen, fibrin, and fibronectin, and a mixture of basement membrane proteins did not induce MMP-1 production. In the presence of collagen, laminin-1 inhibited induction of MMP-1 but laminin-5 did not, Taken together, these observations suggest that as basal keratinocytes migrate from the basal lamina onto the dermal matrix contact with native type I collagen induces MMP-1 expression, In addition, our findings suggest that re-establishment of the basement membrane and, in particular, contact with laminin-1 provides a potent signal to down-regulate MMP-1 production as the epithelium is repaired.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED DERMATOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Parks, William C./AAH-6786-2021		NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29594] Funding Source: Medline; NIADDK NIH HHS [AM35805] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; Fini ME, 1996, AM J PATHOL, V149, P1287; Garlick JA, 1996, J DENT RES, V75, P912, DOI 10.1177/00220345960750030801; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GUO M, 1991, EXP CELL RES, V195, P315, DOI 10.1016/0014-4827(91)90379-9; HERTLE MD, 1991, DEVELOPMENT, V112, P193; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; JUHASZ I, 1993, AM J PATHOL, V143, P1458; LANGE TS, 1994, EXP CELL RES, V214, P381, DOI 10.1006/excr.1994.1271; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Mignatti P., 1996, MOL CELLULAR BIOL WO, P427; PARKS WC, 1992, BIOCHEMISTRY-US, V31, P6639, DOI 10.1021/bi00144a003; PARKS WC, 1995, WOUNDS, V7, pA23; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; PETERSEN MJ, 1987, J BIOL CHEM, V262, P835; PETERSEN MJ, 1989, J INVEST DERMATOL, V92, P156, DOI 10.1111/1523-1747.ep12276678; PETERSEN MJ, 1990, J INVEST DERMATOL, V94, P341, DOI 10.1111/1523-1747.ep12874471; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; PROSSER IW, 1989, AM J PATHOL, V135, P1073; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1995, J INVEST DERMATOL, V104, P982, DOI 10.1111/1523-1747.ep12606231; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; STAHLEBACKDAHL M, 1992, J INVEST DERMATOL, V99, P497, DOI 10.1111/1523-1747.ep12616171; STAHLEBACKDAHL M, 1993, AM J PATHOL, V142, P995; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Sudbeck BD, 1997, MOL BIOL CELL, V8, P811, DOI 10.1091/mbc.8.5.811; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; SWEE MH, 1995, J BIOL CHEM, V270, P14899, DOI 10.1074/jbc.270.25.14899; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; UITTO J, 1989, J INVEST DERMATOL, V92, pS61; Vaalamo M, 1996, BRIT J DERMATOL, V135, P52; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOODLEY DT, 1986, J INVEST DERMATOL, V86, P418, DOI 10.1111/1523-1747.ep12285689; Yamada K.M., 1996, MOL CELLULAR BIOL WO, P51; YAMADA KM, 1996, MOL CELLULAR BIOL WO, P311; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	42	93	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22103	22110		10.1074/jbc.272.35.22103	http://dx.doi.org/10.1074/jbc.272.35.22103			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268353	hybrid			2022-12-27	WOS:A1997XT85000065
J	Dodds, DC; Omeis, IA; Cushman, SJ; Helms, JA; Perin, MS				Dodds, DC; Omeis, IA; Cushman, SJ; Helms, JA; Perin, MS			Neuronal pentraxin receptor, a novel putative integral membrane pentraxin that interacts with neuronal pentraxin 1 and 2 and taipoxin-associated calcium-binding protein 49	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P COMPONENT; C-REACTIVE PROTEIN; ACUTE-PHASE PROTEINS; ENDOPLASMIC-RETICULUM; DEPENDENT BINDING; A-PROTEIN; EXPRESSION; PENTAXIN; MEMBER; FAMILY	We have identified the first putative integral membrane pentraxin and named it neuronal pentraxin receptor (NPR). NPR, is enriched by affinity chromatography on columns of a snake venom toxin, taipoxin, and columns of the taipoxin-binding proteins neuronal pentraxin 1 (NP1), neuronal pentraxin 2 (NP2), and taipoxin-associated calcium-binding protein 49 (TCBP49), The predominant form of NPR contains an putative NH2-terminal transmembrane domain and all forms of NPR are glycosylated. NPR has 49 and 48% amino acid identity to NP1 and NP2, respectively, and NPR message is expressed in neuronal regions that express NP1 and NP2, We suggest that NPR, NP1, NP2, and TCBP49 are involved in a pathway responsible for the transport of taipoxin into synapses and that this may represent a novel neuronal uptake pathway involved in the clearance of synaptic debris.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030; UNIV CALIF SAN FRANCISCO,DEPT ORTHOPED SURG,SAN FRANCISCO,CA 94143	Baylor College of Medicine; University of California System; University of California San Francisco				Helms, Jill/0000-0002-0463-396X				BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CULLCANDY SG, 1976, NEUROSCIENCE, V1, P175, DOI 10.1016/0306-4522(76)90074-9; DODDS D, 1995, J NEUROCHEM, V64, P2339; DOWTON SB, 1990, BIOCHEM J, V270, P553, DOI 10.1042/bj2700553; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; FOHLMAN J, 1976, EUR J BIOCHEM, V68, P457, DOI 10.1111/j.1432-1033.1976.tb10833.x; Goodman Adam R., 1996, Cytokine and Growth Factor Reviews, V7, P191, DOI 10.1016/1359-6101(96)00019-6; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANN SR, 1994, BIOCHIMIE, V76, P880, DOI 10.1016/0300-9084(94)90190-2; HSU YC, 1995, GENOMICS, V28, P220, DOI 10.1006/geno.1995.1134; NOLAND TD, 1994, J BIOL CHEM, V269, P32607; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; PERIN MS, 1988, EMBO J, V7, P2697, DOI 10.1002/j.1460-2075.1988.tb03123.x; REID MS, 1994, J BIOL CHEM, V269, P32615; ROBBI M, 1991, J BIOL CHEM, V266, P20498; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tsui CC, 1996, J NEUROSCI, V16, P2463; WEIS K, 1994, J BIOL CHEM, V269, P19142; WHITEHEAD AS, 1990, BIOCHEM J, V266, P283, DOI 10.1042/bj2660283; Wilkinson D.G., 1993, ESSENTIAL DEV BIOL P, P257; WILSON DW, 1993, J BIOL CHEM, V268, P7465	26	121	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21488	21494		10.1074/jbc.272.34.21488	http://dx.doi.org/10.1074/jbc.272.34.21488			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261167	hybrid			2022-12-27	WOS:A1997XR78900077
J	Holland, KA; Owczarek, CM; Hwang, SY; Tymms, MJ; Constantinescu, SN; Pfeffer, LM; Kola, I; Hertzog, PJ				Holland, KA; Owczarek, CM; Hwang, SY; Tymms, MJ; Constantinescu, SN; Pfeffer, LM; Kola, I; Hertzog, PJ			A type I interferon signaling factor, ISF21, encoded on chromosome 21 is distinct from receptor components and their down-regulation and is necessary for transcriptional activation of interferon-regulated genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INTERFERON; CELLS; EXPRESSION; BETA; RESPONSIVENESS; SUBTYPES; CLONING	The type I interferons (IFNs) are a family of cytokines, comprising at least 17 subtypes, which exert pleiotropic actions by interaction with a multi-component cell surface receptor and at least one well characterized signal transduction pathway involving JAK/STAT (Janus kinase/signal transducer and activator of transcription:) proteins, In a previous report, we showed that a signaling factor, encoded by a gene located on the distal portion of chromosome 21, distinct from the IFNAR-1 receptor, was necessary for 2'-5'-oligoadenylate synthetase activity and antiviral responses, but not for high affinity ligand binding, In the present studies using hybrid Chinese hamster ovary cell lines containing portions of human chromosome 21, we show that the type I IFN signaling molecule, designated herein as ISF21, is distinct from the second receptor component, IFNAR-2, which is expressed in signaling and non-signaling cell lines, The location of the gene encoding ISF21 is narrowed to a region between the 10;21 and the r21 breakpoints, importantly eliminating the Mr gene located at 21q22.3 (the product of which is involved in IFN-induced antiviral responses) as a candidate for the signaling factor, To characterize the action of this factor in the type I IFN signaling pathway, we show that it acts independently of receptor down-regulation following ligand binding, both of which occur equally in the presence or absence of the factor, In addition, we demonstrate that ISF21 is necessary for transcriptional activation of 2'-5'-oligoadenylate synthetase, 6-16, and guanylate-binding protein gene promoter reporter constructs, which are mediated by several signaling pathways, ISF21 represents a novel factor as the localization to chromosome 21, and the data presented in this study exclude any of the known type I IFN signal-transducing molecules.	MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,MOL GENET & DEV GRP,CLAYTON,VIC 3168,AUSTRALIA; UNIV TENNESSEE,CTR HLTH SCI,DEPT PATHOL,MEMPHIS,TN 38163	Monash University; University of Tennessee System; University of Tennessee Health Science Center			Constantinescu, Stefan N/E-5277-2012; Hertzog, Paul J/G-6734-2013; Hertzog, Paul J/I-7053-2013; Kola, Ismail/C-5254-2013	Hertzog, Paul J/0000-0002-1373-8472; Hertzog, Paul J/0000-0002-1373-8472; Constantinescu, Stefan N./0000-0002-8599-2699; Pfeffer, Lawrence/0000-0003-2809-1234				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; CONSTANTINESCU SN, 1995, P NATL ACAD SCI USA, V92, P10187; DOMANKSI P, 1995, J BIOL CHEM, V270, P1; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HART AH, 1995, ONCOGENE, V10, P1423; HERTZOG PJ, 1990, BIOCHEM INT, V22, P1095; HERTZOG PJ, 1988, CLIN IMMUNOL IMMUNOP, V48, P192, DOI 10.1016/0090-1229(88)90083-9; HERTZOG PJ, 1994, J BIOL CHEM, V269, P14088; JOHNS TG, 1992, J NATL CANCER I, V84, P1185, DOI 10.1093/jnci/84.15.1185; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LIM JK, 1994, FEBS LETT, V350, P281, DOI 10.1016/0014-5793(94)00787-X; LUTFALLA G, 1990, J INTERFERON RES, V10, P515, DOI 10.1089/jir.1990.10.515; LUTFALLA G, 1995, EMBO J, V14, P101; MOGENSEN KE, 1986, METHOD ENZYMOL, V119, P267; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OVERALL ML, 1992, MOL IMMUNOL, V29, P391, DOI 10.1016/0161-5890(92)90027-U; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, CANCER RES, V50, P2654; RUSSELLHARDE D, 1995, J BIOL CHEM, V270, P26033, DOI 10.1074/jbc.270.44.26033; SOH JM, 1994, J BIOL CHEM, V269, P18102; TYMMS MJ, 1988, GENE ANAL TECH, V5, P9, DOI 10.1016/0735-0651(88)90021-0; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WATHELET M, 1987, EUR J BIOCHEM, V155, P11; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; WHYATT LM, 1993, MOL CELL BIOL, V13, P7971, DOI 10.1128/MCB.13.12.7971	29	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21045	21051		10.1074/jbc.272.34.21045	http://dx.doi.org/10.1074/jbc.272.34.21045			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261106	hybrid			2022-12-27	WOS:A1997XR78900016
J	Narko, K; Ristimaki, A; MacPhee, M; Smith, E; Haudenschild, CC; Hla, T				Narko, K; Ristimaki, A; MacPhee, M; Smith, E; Haudenschild, CC; Hla, T			Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER; SYNOVIAL TISSUES; GENE DISRUPTION; EXPRESSION; ANGIOGENESIS; APOPTOSIS; INDUCTION; GROWTH; INHIBITORS; RAT	The cyclooxygenase (Cox) enzyme catalyzes the rate-limiting oxidative and peroxidative enzymatic steps in the biosynthesis of prostanoids. Both Cox-1 and -2 genes encode the two isoenzymes that carry out similar enzymatic steps, Enhanced Cox activity is associated with proliferative diseases such as colon cancer, To determine if a cause and effect relationship exists between Cox isoenzyme overexpression and tumorigenesis, the human Cox-1 and Cox-2 isoenzymes were transfected into ECV immortalized endothelial cells, Although numerous clones of Cox-1 expressing cells were obtained, Cox-a overexpression resulted in growth disadvantage and increased cell death, In contrast, Cox-1 overexpressing cells expressed high levels of the functional Cox-1 polypeptide in the endoplasmic reticulum and the nucleus, In vitro proliferation of these cells was reduced compared with vector-transfected ECV cells, Cox-1 overexpression also enhanced the tumor necrosis factor-alpha-induced apoptosis of ECV cells a-fold, In contrast to the in vitro behavior, ECV-Cox-1 cells proliferated aggressively and formed tumors in athymic ''nude'' mice, whereas the vector-transfected counterparts did not, The growth of Cox-1-induced tumors was not inhibited by indomethacin, suggesting a nonprostanoid function of Cox-1. ECV-Cox-1-derived tumors were angiosarcoma-like and contained numerous host-derived neovessels. These data suggest that Cox-1 overexpression in immortalized ECV endothelial cells results in nuclear localization of the polypeptide and tumorigenesis.	UNIV CONNECTICUT,SCH MED,DEPT PHYSIOL,FARMINGTON,CT 06030; UNIV HELSINKI,HAARTMAN INST,DEPT CLIN CHEM & OBSTET & GYNECOL,HELSINKI,FINLAND; AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD 20855	University of Connecticut; University of Helsinki; American Red Cross			Hla, Timothy/G-5873-2012; Christian, Haudenschild C/D-1602-2009	Hla, Timothy/0000-0001-8355-4065; 	FOGARTY INTERNATIONAL CENTER [F05TW004963] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094, P01HL054710] Funding Source: NIH RePORTER; FIC NIH HHS [F05 TWO4963] Funding Source: Medline; NHLBI NIH HHS [HL49094, HL54710] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DuBois RN, 1996, CANCER RES, V56, P733; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hughes SE, 1996, EXP CELL RES, V225, P171, DOI 10.1006/excr.1996.0168; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PETERSON HI, 1983, INVAS METAST, V3, P151; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; REDDY BS, 1987, CANCER RES, V47, P5340; RIGAS B, 1993, J LAB CLIN MED, V122, P518; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; SANO H, 1995, CANCER RES, V55, P3785; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SILVER RM, 1995, J CLIN INVEST, V95, P725, DOI 10.1172/JCI117719; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WEIDNER N, 1996, IMPORTANT ADV ONCOL, V136, P167; ZICHE M, 1982, JNCI-J NATL CANCER I, V69, P475	33	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21455	21460		10.1074/jbc.272.34.21455	http://dx.doi.org/10.1074/jbc.272.34.21455			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261162	hybrid			2022-12-27	WOS:A1997XR78900072
J	Scheidegger, KJ; Butler, S; Witztum, JL				Scheidegger, KJ; Butler, S; Witztum, JL			Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LIPID-PROTEIN ADDUCTS; OXIDATIVE MODIFICATION; MESSENGER-RNA; ATHEROSCLEROTIC LESIONS; HUMAN 15-LIPOXYGENASE; GLOMERULOSA CELLS; RECEPTOR SUBTYPES; GENE-EXPRESSION; RAT	The molecular and cellular mechanisms by which hypertension enhances atherosclerosis are poorly understood. Angiotensin II (Ang II) has been implicated in the regulation of cellular lipoxygenases (LO), which are thought to play a role in atherogenesis by inducing oxidative modification of low density lipoprotein (LDL), We sought to test the hypothesis that Ang II would stimulate murine macrophage LO activity (which has both 12- and 15-LO activity), Competitive binding studies revealed the presence of Ang II AT(1) receptors on mouse peritoneal macrophages (MPM) and J-774 cells, but not on the RAW cell line. Valsartan, a specific AT(1) receptor antagonist inhibited Ang II binding, whereas PD 123319, an AT(2) receptor antagonist did not. Incubation of MPM or J-774 cells with Ang II (10 pM to 1 mu M) for 24 h led to a 2.5-3.5-fold increase in LO activity, measured as generated 13-HODE or 12(S)-HETE. This stimulation was Inhibited by valsartan, but not by PD 123319. In contrast, Ang II did not stimulate LO activity in RAW macrophages. Semiquantitative reverse transcriptase-polymerase chain reaction showed a 2-3-fold increase in LO mRNA in MPM, but not in RAW cells after treatment with Ang II. Ang II also induced an increase in 12-LO protein. In addition, pretreatment of J-774 cells with Ang II increased in a dose-dependent manner the ability of the cells to modify LDL, resulting ilk greater chemotactic activity for monocytes, typical of minimally modified LDL, This stimulation was inhibited by AT(1) receptor blockade. In summary, these data suggest that Ang II increases macrophage LO activity via AT(1) receptor-mediated mechanisms and this further increases the ability of the cells to generate minimally oxidized LDL. These studies provide a link between hypertension and the associated increased atherosclerosis observed in hypertensive patients.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego					PHS HHS [14197] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERTHOLD F, 1981, BLUT, V43, P367, DOI 10.1007/BF00320315; Buege J A, 1978, Methods Enzymol, V52, P302; BUNKENBURG B, 1992, HYPERTENSION, V20, P746, DOI 10.1161/01.HYP.20.6.746; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; Cornicelli JA, 1996, ARTERIOSCL THROM VAS, V16, P1488, DOI 10.1161/01.ATV.16.12.1488; CRAWFORD DC, 1994, CIRC RES, V74, P727, DOI 10.1161/01.RES.74.4.727; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DEZSO B, 1981, IMMUNOLOGY, V42, P277; Douglas JG, 1996, J CLIN INVEST, V97, P1787, DOI 10.1172/JCI118607; DZAU VJ, 1988, CIRCULATION, V77, P4; EVERETT AD, 1994, HYPERTENSION, V23, P587, DOI 10.1161/01.HYP.23.5.587; EZAKI M, 1995, J LIPID RES, V36, P1996; FERNANDEZCASTELO S, 1987, J INTERFERON RES, V7, P261, DOI 10.1089/jir.1987.7.261; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; FORIS G, 1983, IMMUNOLOGY, V48, P529; FRUEBIS J, 1996, IN PRESS ATHEROSCLER; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GUILLON G, 1988, BIOCHEM J, V253, P765, DOI 10.1042/bj2530765; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KEIDAR S, 1995, ATHEROSCLEROSIS, V115, P201, DOI 10.1016/0021-9150(94)05514-J; Keidar S, 1996, ARTERIOSCL THROM VAS, V16, P97, DOI 10.1161/01.ATV.16.1.97; KHOUW AS, 1993, J LIPID RES, V34, P1483; KIM JA, 1995, ARTERIOSCL THROM VAS, V15, P942, DOI 10.1161/01.ATV.15.7.942; KINOSHITA T, 1992, ANAL BIOCHEM, V206, P231, DOI 10.1016/0003-2697(92)90358-E; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MCNALLY AK, 1990, J IMMUNOL, V145, P254; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NATARAJAN R, 1988, J CLIN ENDOCR METAB, V67, P584, DOI 10.1210/jcem-67-3-584; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; NUSSBERGER J, 1984, J LAB CLIN MED, V103, P304; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; RANKIN SM, 1991, J LIPID RES, V32, P449; Sendobry SM, 1997, BRIT J PHARMACOL, V120, P1199, DOI 10.1038/sj.bjp.0701007; Shen JH, 1996, J CLIN INVEST, V98, P2201, DOI 10.1172/JCI119029; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGARI F, 1997, IN PRESS ARTERIOSCLE; SPARROW CP, 1992, P NATL ACAD SCI USA, V89, P128, DOI 10.1073/pnas.89.1.128; SPARROW CP, 1988, J LIPID RES, V29, P745; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; VALENTE AJ, 1988, BIOCHEMISTRY-US, V27, P4162, DOI 10.1021/bi00411a039; WEINSTOCK JV, 1984, CELL IMMUNOL, V89, P46, DOI 10.1016/0008-8749(84)90196-5; WEINSTOCK JV, 1983, J IMMUNOL, V131, P2529; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971	53	105	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21609	21615		10.1074/jbc.272.34.21609	http://dx.doi.org/10.1074/jbc.272.34.21609			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261183	hybrid			2022-12-27	WOS:A1997XR78900093
J	Abe, J; Takahashi, M; Ishida, M; Lee, JD; Berk, BC				Abe, J; Takahashi, M; Ishida, M; Lee, JD; Berk, BC			c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1 (BMK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SMOOTH-MUSCLE CELLS; TYROSINE KINASE; MAP KINASE; REDOX REGULATION; ANGIOTENSIN-II; FAMILY; PHOSPHORYLATION; GENE; TRANSFORMATION	Big mitogen-activated kinase 1 (BMK1) or extracellular signal-regulated kinase-5 (ERK5) has recently been identified as a new member of the mitogen-activated protein kinase family, We have shown that BMK1 is activated to a greater extent by H2O2 than growth factors, suggesting that in comparison with other mitogen-activated protein kinase family members, BMK1 is a redox-sensitive kinase, Previous investigations indicate that the tyrosine kinase c-Src mediates signal transduction by reactive oxygen species, including H2O2. Therefore, the role of Src kinase family members (c-Src and Fyn) in activation of the BMK1 by H2O2 in mouse fibroblasts was studied, An essential role for c-Src was suggested by four experiments, First, H2O2 stimulated c-Src activity rapidly in fibroblasts (peak at 5 min), which preceded peak activity of BMK1 (20 min), Second, specific Src family tyrosine kinase inhibitors (herbimycin A and CP-118,556) blocked BMK1 activation by H2O2 in a concentration-dependent manner. Third, BMK1 activation in the response to H2O2 was completely inhibited in cells derived from mice deficient in c-Src, but not Fyn, Finally, BMK1 activity was much greater in v-Src-transformed NIH-3T3 cells than wild type cells. These results demonstrate an essential role for c-Src in H2O2-mediated activation of BMK1 and suggest that redox-sensitive regulation of BMK1 is a new function for c-Src.	UNIV WASHINGTON, DIV CARDIOL, DEPT MED, SEATTLE, WA 98195 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of Washington; University of Washington Seattle; Scripps Research Institute				Berk, Bradford/0000-0002-2767-4115	NHLBI NIH HHS [HL49192, HL44721] Funding Source: Medline; NIGMS NIH HHS [GM53214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049192, R01HL044721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; AUCHSCHWELK W, 1992, J CARDIOVASC PHARM, V20, pS62; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	35	237	240	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20389	20394		10.1074/jbc.272.33.20389	http://dx.doi.org/10.1074/jbc.272.33.20389			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252345	hybrid			2022-12-27	WOS:A1997XR22100015
J	Azem, A; Oppliger, W; Lustig, A; Jeno, P; Feifel, B; Schatz, G; Horst, M				Azem, A; Oppliger, W; Lustig, A; Jeno, P; Feifel, B; Schatz, G; Horst, M			The mitochondrial hsp70 chaperone system - Effect of adenine nucleotides, peptide substrate, and mGrpE on the oligomeric state of mhsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; ATPASE ACTIVITY; INNER MEMBRANE; GRPE; DNAJ; IMPORT; HOMOLOG; TRANSLOCATION; HYDROLYSIS	Mitochondrial hsp70 (mhsp78) is a key component in the import and folding of mitochondrial proteins. In both processes, mhsp70 cooperates with the mitochondrial nucleotide exchange factor mGrpE (also termed Mge1p). In this work we have characterized the self-association of purified mhsp70, the interaction of mhsp70 with isolated mGrpE and protein substrate, and the effect of nucleotides on these interactions, mhsp70 can form oligomers that are dissociated by ATP or by a nonhydrolyzable ATP analog, A substrate peptide binds to mhsp70 in the absence of added nucleotides and is released by ATP but not by ADP. Binding of the peptide causes nucleotide-independent dissociation of the mhsp70 oligomers and enhances the mhsp70 ATPase. Purified mGrpE forms a homodimer, In the absence of added nucleotides, one mGrpE dimer binds to one molecule of mhsp70, forming a stable 122 kDa hetero-oligomer, This complex is weakened by ADP and completely dissociated by ATP.	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	University of Zurich	Azem, A (corresponding author), UNIV BASEL,BIOCTR,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.							AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BENAROUDJ N, 1995, BIOCHEMISTRY-US, V34, P15282, DOI 10.1021/bi00046a037; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; Deloche O, 1996, J BIOL CHEM, V271, P23960, DOI 10.1074/jbc.271.39.23960; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; Horst M, 1996, PROTEIN SCI, V5, P759; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; JENO P, 1995, ANAL BIOCHEM, V224, P75, DOI 10.1006/abio.1995.1010; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PripBuus C, 1996, FEBS LETT, V380, P142, DOI 10.1016/0014-5793(96)00049-X; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; Rospert S, 1996, EMBO J, V15, P764, DOI 10.1002/j.1460-2075.1996.tb00412.x; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHELL DJ, 1995, CELL, V83, P521; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; Wu B, 1996, EMBO J, V15, P4806, DOI 10.1002/j.1460-2075.1996.tb00861.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	41	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20901	20906		10.1074/jbc.272.33.20901	http://dx.doi.org/10.1074/jbc.272.33.20901			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252417	hybrid			2022-12-27	WOS:A1997XR22100087
J	Booth, JW; Guidotti, G				Booth, JW; Guidotti, G			Phosphate transport in yeast vacuoles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; SACCHAROMYCES-CEREVISIAE; MEMBRANE-VESICLES; ACTIVE-TRANSPORT; CANDIDA-UTILIS; AMINO-ACIDS; POLYPHOSPHATE; ARGININE; GENE; COMPARTMENTS	The vacuole of the yeast Saccharomyces cerevisiae is a major storage compartment for phosphate. We have measured phosphate transport across the vacuolar membrane. Isolated intact vacuoles take up large amounts of added [P-32]phosphate by counterflow exchange with phosphate present in the vacuoles at the time of their isolation. The bidirectional phosphate transporter has an intrinsic dissociation constant for phosphate of 0.4 mM. Exchange mediated by this carrier is faster than unidirectional efflux of phosphate from the vacuoles. The transporter is highly selective for phosphate; of other anions tested, only arsenate is also a substrate. Transport is strongly pH dependent with increasing activity at lower pH. Similar phosphate transport behavior was observed in right-side-out vacuolar membrane vesicles.	HARVARD UNIV, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University					NHLBI NIH HHS [HL 08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; Andreeva N A, 1993, Biokhimiia, V58, P1053; BERTL A, 1990, P NATL ACAD SCI USA, V87, P7824, DOI 10.1073/pnas.87.20.7824; BOLLER T, 1975, EUR J BIOCHEM, V54, P81, DOI 10.1111/j.1432-1033.1975.tb04116.x; BOLLER T, 1989, METHOD ENZYMOL, V174, P504; BOOTH JW, 1995, J BIOL CHEM, V270, P19377, DOI 10.1074/jbc.270.33.19377; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; BOSTIAN KA, 1983, MOL CELL BIOL, V3, P839, DOI 10.1128/MCB.3.5.839; BOURNE RM, 1991, BIOCHIM BIOPHYS ACTA, V1067, P81, DOI 10.1016/0005-2736(91)90028-7; BOURNE RM, 1990, BIOCHIM BIOPHYS ACTA, V1055, P1, DOI 10.1016/0167-4889(90)90084-Q; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; DURR M, 1979, ARCH MICROBIOL, V121, P169, DOI 10.1007/BF00689982; GILLIES RJ, 1981, P NATL ACAD SCI-BIOL, V78, P2125, DOI 10.1073/pnas.78.4.2125; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KAKINUMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P126, DOI 10.1016/0005-2736(92)90337-L; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; NAGY M, 1979, BIOCHIM BIOPHYS ACTA, V558, P221, DOI 10.1016/0005-2736(79)90062-2; NICOLAY K, 1983, ARCH MICROBIOL, V134, P270, DOI 10.1007/BF00407801; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OKOROKOV LA, 1980, J BACTERIOL, V144, P661, DOI 10.1128/JB.144.2.661-665.1980; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SATO T, 1984, J BIOL CHEM, V259, P1505; SCHWENCKE J, 1976, EUR J BIOCHEM, V65, P49, DOI 10.1111/j.1432-1033.1976.tb10388.x; Stein W., 2012, TRANSPORT DIFFUSION; TAMAI Y, 1985, J BACTERIOL, V164, P964, DOI 10.1128/JB.164.2.964-968.1985; URECH K, 1978, ARCH MICROBIOL, V116, P275, DOI 10.1007/BF00417851; VOGEL K, 1990, MOL MICROBIOL, V4, P2013, DOI 10.1111/j.1365-2958.1990.tb00560.x; WADA Y, 1992, BIOCHIM BIOPHYS ACTA, V1101, P296, DOI 10.1016/0005-2728(92)90085-G; WADA Y, 1987, J BIOL CHEM, V262, P17260; Wiemken A, 1975, Methods Cell Biol, V12, P99; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995	38	15	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20408	20413		10.1074/jbc.272.33.20408	http://dx.doi.org/10.1074/jbc.272.33.20408			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252348	Green Published, hybrid			2022-12-27	WOS:A1997XR22100018
J	Fisher, EA; Zhou, MY; Mitchell, DM; Wu, XJ; Omura, S; Wang, HX; Goldberg, AL; Ginsberg, HN				Fisher, EA; Zhou, MY; Mitchell, DM; Wu, XJ; Omura, S; Wang, HX; Goldberg, AL; Ginsberg, HN			The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; CLASS-I MOLECULES; INTRACELLULAR DEGRADATION; ENDOPLASMIC-RETICULUM; HERBIMYCIN-A; TRANSLOCATION; SECRETION; INHIBITOR; DOMAINS; LIPOPROTEINS	Apolipoprotein B (apoB) is the major protein component of atherogenic lipoproteins of hepatic origin, In HepG2 cells, the standard cell culture model of human hepatic lipoprotein metabolism, there is a limited availability of core lipids in the endoplasmic reticulum for association with nascent apoB. Under these conditions, apoB is partially translocated, interacts with cytosolic Hsp70, and undergoes rapid degradation. We show that increasing the expression of Hsp70 in HepG2 cells promotes apoB degradation. In addition, apoB is polyubiquitinated and its degradation both normally and after Hsp70 induction is blocked by inhibitors of the proteasome. The apoB that accumulates after proteasome inhibition is endoplasmic reticulum-associated and can be assembled into lipoproteins and secreted if new lipid synthesis is stimulated. Thus, apoB is the first example of a wild-type mammalian protein whose secretion is regulated by degradation in the cytosol via the ubiquitin-proteasome pathway. Furthermore, targeting of this secretory protein to the proteasome is regulated by the molecular chaperone Hsp70 and the availability of apoB's lipid-ligands.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; MT SINAI SCH MED,CARDIOVASC INST,LAB LIPOPROT RES,NEW YORK,NY 10029; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; KITASATO INST,TOKYO 108,JAPAN	Columbia University; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; Kitasato University			Mitchell, Deborah/I-4556-2019; Mitchell, Deborah/AAB-6706-2020	Mitchell, Deborah/0000-0003-0364-9107; Fisher, Edward/0000-0001-9802-143X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055638, R01HL036000] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55638, HL07824, HL36000] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GINSBERG HN, 1994, MED CLIN N AM, V78, P1; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HEGDE RS, 1995, J CELL PHYSIOL, V165, P186, DOI 10.1002/jcp.1041650122; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HOHFELD J, 1994, CURR OPIN CELL BIOL, V6, P499, DOI 10.1016/0955-0674(94)90068-X; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Lord JM, 1996, CURR BIOL, V6, P1067, DOI 10.1016/S0960-9822(02)70666-0; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; Morris SD, 1996, J CLIN INVEST, V97, P706, DOI 10.1172/JCI118468; MURAKAMI Y, 1991, EXP CELL RES, V195, P338, DOI 10.1016/0014-4827(91)90382-5; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; Oda K, 1996, BIOCHEM BIOPH RES CO, V219, P800, DOI 10.1006/bbrc.1996.0314; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Pease RJ, 1996, CURR OPIN LIPIDOL, V7, P132, DOI 10.1097/00041433-199606000-00004; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHERMAN MYS, 1996, STRESS INDUCIBLE CEL, P57; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SNIDERMAN AD, 1988, CAN J CARDIOL, V4, pA24; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; VEGA GL, 1991, CIRCULATION, V84, P118, DOI 10.1161/01.CIR.84.1.118; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; WETTERAU JR, 1992, SCIENCE, V258, P999; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	61	251	254	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20427	20434		10.1074/jbc.272.33.20427	http://dx.doi.org/10.1074/jbc.272.33.20427			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252351	hybrid			2022-12-27	WOS:A1997XR22100021
J	Grishina, G; Berlot, CH				Grishina, G; Berlot, CH			Identification of common and distinct residues involved in the interaction of alpha(i2) and alpha(s) with adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; G-PROTEINS; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; ACTIVATION; RECEPTOR; TRANSDUCIN; BINDING; SUBUNITS; EPITOPE	The G protein alpha subunits, alpha(s) and alpha(i2), have stimulatory and inhibitory effects, respectively, on a common effector protein, adenylyl cyclase, These effects require a GTP-dependent conformational change that involves three alpha subunit regions (Switches I-III). alpha(s) residues in three adjacent loops, including Switch II, specify activation of adenylyl cyclase. The adenylyl cyclase-specifying region of alpha(i2) is located within a 78-residue segment that includes two of these loops but none of the conformational switch regions, We have used an alanine-scanning mutagenesis approach within Switches I-III and the 78-residue segment of alpha(i2) to identify residues required for inhibition of adenylyl cyclase, We found a cluster of conserved residues in Switch II in which substitutions cause major losses in the abilities of both alpha(i2) and alpha(s) to modulate adenylyl cyclase activity but do not affect alpha subunit expression or the GTP-induced conformational change, We also found two regions within the 78-residue segment of alpha(i2) in which substitutions reduce the ability of alpha(i2) to inhibit adenylyl cyclase, one of which corresponds to an effector-activating region of alpha(s). Thus, both alpha(i2) and alpha(s) interact with adenylyl cyclase using: 1) conserved Switch II residues that communicate the conformational state of the alpha subunit and 2) divergent residues that specify particular effecters and the nature of their modulation.	YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06520	Yale University								ARKINSTALL S, 1995, FEBS LETT, V364, P45, DOI 10.1016/0014-5793(95)00351-9; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HO RM, 1989, GENE AMST, V77, P51; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; ITOH H, 1991, J BIOL CHEM, V266, P16226; JONES DT, 1987, J BIOL CHEM, V262, P14241; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE E, 1992, J BIOL CHEM, V267, P1212; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; Mittal R, 1996, SCIENCE, V271, P1413, DOI 10.1126/science.271.5254.1413; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PARIS S, 1987, J BIOL CHEM, V262, P1970; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	44	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20619	20626		10.1074/jbc.272.33.20619	http://dx.doi.org/10.1074/jbc.272.33.20619			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252377	hybrid			2022-12-27	WOS:A1997XR22100047
J	Kubler, E; Mosch, HU; Rupp, S; Lisanti, MP				Kubler, E; Mosch, HU; Rupp, S; Lisanti, MP			Gpa2p, a G-protein alpha-subunit, regulates growth and pseudohyphal development in Saccharomyces cerevisiae via a cAMP-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENTOUS GROWTH; ADENYLATE-CYCLASE; BUDDING YEAST; RAS PROTEINS; CYCLIC-AMP; PHOSPHODIESTERASE; EXPRESSION; ELEMENTS; PATHWAY; GENES	The small GTP-binding protein Ras and heterotrimeric G-proteins are key regulators of growth and development in eukaryotic cells. In mammalian cells, Ras functions to regulate the mitogen-activated protein kinase pathway in response to growth factors, whereas many heterotrimeric GTP-binding protein alpha-subunits modulate cAMP levels through adenylyl cyclase as a consequence of hormonal action. In contrast, in the yeast Saccharomyces cerevisiae, it is the Ras1 and Ras2 proteins that regulate adenylyl cyclase. Of the two yeast G-protein alpha-subunits (GPA1 and GPA2), only GPA1 has been well studied and shown to negatively regulate the mitogen-activated protein kinase pathway upon pheromone stimulation, In this report, we show that deletion of the GPA2 gene encoding the other yeast G-protein alpha-subunit leads to a defect in pseudohyphal development, Also, the GPA2 gene is indispensable for normal growth in the absence of Ras2p. Both of these phenotypes can be rescued by deletion of the PDE2 gene product, which inactivates cAMP by cleavage, suggesting that these phenotypes can be attributed to low levels of intracellular cAMP. In support of this notion, addition of exogenous cAMP to the growth media was also sufficient to rescue the phenotype of a GPA2 deletion strain, Taken together, our results directly demonstrate that a G-protein alpha-subunit can regulate the growth and pseudohyphal development of S. cerevisiae via a cAMP-dependent mechanism, Heterologous expression of mammalian G-protein alpha-subunits in these yeast GPA2 deletion strains could provide a valuable tool for the mutational analysis of mammalian G-protein function in an in vivo null setting.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461; UNIV GOTTINGEN,INST MIKROBIOL,D-37077 GOTTINGEN,GERMANY; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Yeshiva University; Albert Einstein College of Medicine; University of Gottingen; Massachusetts Institute of Technology (MIT); Whitehead Institute			Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; 				BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BREVIARIO D, 1988, EMBO J, V7, P1805, DOI 10.1002/j.1460-2075.1988.tb03012.x; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GIMENO CJ, 1994, MOL CELL BIOL, V14, P2100, DOI 10.1128/MCB.14.3.2100; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KRON SJ, 1995, CURR OPIN CELL BIOL, V7, P845, DOI 10.1016/0955-0674(95)80069-7; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WILSON RB, 1988, MOL CELL BIOL, V8, P505, DOI 10.1128/MCB.8.1.505; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0	20	164	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20321	20323		10.1074/jbc.272.33.20321	http://dx.doi.org/10.1074/jbc.272.33.20321			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252333	hybrid			2022-12-27	WOS:A1997XR22100003
J	PanayotovaHeiermann, M; Eskandari, S; Turk, E; Zampighi, GA; Wright, EM				PanayotovaHeiermann, M; Eskandari, S; Turk, E; Zampighi, GA; Wright, EM			Five transmembrane helices form the sugar pathway through the Na+/glucose cotransporter.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER	To test the hypothesis that the C-terminal half of the Na+/glucose cotransporter (SGLT1) contains the sugar permeation pathway, a cDNA construct (C-5) coding for rabbit SGLT1 amino acids 407-662, helices 10-14, was expressed in Xenopus oocytes, Expression and function of C-5 followed by Western blotting, electron microscopy, radioactive tracer, and electrophysiological methods. The C-5 protein was synthesized in 20-fold higher levels than SGLT1. The particle density in the protoplasmic face of the oocyte plasma membrane increased C-5-cRNA injection compared with noninjected oocytes. The diameters of the C-5 particles were heterogeneous (4.8 +/- 0.3, 7.1 +/- 1.2, and 10.3 +/- 0.8 nm) in contrast to the endogenous particles (7.6 +/- 1.2 nm), C-5 increased the alpha-methyl-D-glucopyranoside (alpha MDG) uptake up to 20-fold above that of noninjected oocytes and showed an apparent K-0.5(alpha MDG) Of 50 mM and a turnover of similar to 660 s(-1). Influx was independent of Na+ with transport characteristics similar to those of SGLT1 in the absence of Na+:1) selective (alpha MDG > D-glucose > D-galactose much greater than L-glucose approximate to D-mannose), 2) inhibited by phloretin, K-i(PT) = similar to 500 mu M, and 3) insensitive to phlorizin, These results indicate that C-5 behaves as a specific low affinity glucose uniporter. Preliminary studies with three additional constructs, hC(5) (the human equivalent of C-5), hC(4) (human SGLT1 amino acids 407-648, helices 10-13), and hN(13) (amino acids 1-648, helices 1-13), further suggest that helices 10-13 form the sugar permeation pathway for SGLT1.	UNIV CALIF LOS ANGELES,MED CTR,DEPT NEUROBIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	PanayotovaHeiermann, M (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,MED CTR,DEPT PHYSIOL,CHS BOX 951751,LOS ANGELES,CA 90095, USA.				NATIONAL EYE INSTITUTE [R01EY004110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS025554] Funding Source: NIH RePORTER; NEI NIH HHS [EY04110] Funding Source: Medline; NIDDK NIH HHS [DK19567] Funding Source: Medline; NINDS NIH HHS [NS25554] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; HIRAYAMA BA, 1991, AM J PHYSIOL, V261, pC296, DOI 10.1152/ajpcell.1991.261.2.C296; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; KIMMICH GA, 1975, J MEMBRANE BIOL, V23, P57, DOI 10.1007/BF01870244; Loo DDF, 1996, P NATL ACAD SCI USA, V93, P13367, DOI 10.1073/pnas.93.23.13367; Lostao MP, 1995, FEBS LETT, V377, P181, DOI 10.1016/0014-5793(95)01339-3; LOSTAO MP, 1996, PHYSIOL RES, V45, pP1; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; PANAYOTOVAHEIER.M, 1995, PFLUGERS ARCH EUR S, V430, P116; PANAYOTOVAHEIERMANN M, 1994, J BIOL CHEM, V269, P21016; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; PANAYOTOVAHEIERMANN M, 1995, J BIOL CHEM, V270, P27099, DOI 10.1074/jbc.270.45.27099; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PEERCE BE, 1986, P NATL ACAD SCI USA, V83, P8092, DOI 10.1073/pnas.83.21.8092; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; TURK E, 1997, IN PRESS J MEMBR BIO, V159; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; Wu JH, 1996, BIOCHEMISTRY-US, V35, P5213, DOI 10.1021/bi960064f; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	20	76	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20324	20327		10.1074/jbc.272.33.20324	http://dx.doi.org/10.1074/jbc.272.33.20324			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252334	hybrid			2022-12-27	WOS:A1997XR22100004
J	Belusa, R; Wang, ZM; Matsubara, T; Sahlgren, B; Dulubova, I; Nairn, AC; Ruoslahti, E; Greengard, P; Aperia, A				Belusa, R; Wang, ZM; Matsubara, T; Sahlgren, B; Dulubova, I; Nairn, AC; Ruoslahti, E; Greengard, P; Aperia, A			Mutation of the protein kinase C phosphorylation site on rat alpha 1 Na+,K+-ATPase alters regulation of intracellular Na+ and pH and influences cell shape and adhesiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4TH TRANSMEMBRANE SEGMENT; PROXIMAL TUBULE CELLS; KIDNEY NA+,K+-ATPASE; SODIUM-TRANSPORT; NA,K-ATPASE; SUBUNIT; ATPASE; STIMULATION; FIBROBLASTS; PATHWAY	The enzyme Na+,K+-ATPase creates the transmembrane Na+ gradient that is of vital importance for functioning of all eukaryotic cells. Na+,K+-ATPase can be phosphorylated by protein kinase A (PKA) and protein kinase C (PKC), and these sites of phosphorylation have been identified, In the present study, we have examined the physiological significance of PKC phosphorylation of rat Na+,K+-ATPase. In COS cells transfected with wild type rat Na+,K+-ATPase alpha 1, intracellular Na+ was higher and pH was lower than in cells transfected with rat Na+,K+-ATPase alpha 1 in which the PKC phosphorylation site, Ser-23, had been mutated into alanine. Phorbol dibutyrate inhibited Na+,K+-ATPase-dependent ATP hydrolysis and Rb+ uptake in cells expressing wild type Na+,K+-ATPase but not in cells expressing S23A Na+,K+-ATPase. Cells expressing the S23A mutant had a more rounded appearance and attached less well to fibronectin than did untransfected cells or cells transfected with wild type rat Na+,K+-ATPase alpha 1. These results indicate a functional role for PKC-mediated phosphorylation of rat Na+,K+-ATPase alpha 1 and suggest a connection between this enzyme and cell adhesion.	KAROLINSKA INST,DEPT WOMEN & CHILD HLTH,S-11281 STOCKHOLM,SWEDEN; ROCKEFELLER UNIV,MOL & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037	Karolinska Institutet; Rockefeller University; Sanford Burnham Prebys Medical Discovery Institute				Nairn, Angus/0000-0002-7075-0195	NIMH NIH HHS [MH-40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APERIA A, 1994, FASEB J, V8, P436, DOI 10.1096/fasebj.8.6.8168694; BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF370, DOI 10.1152/ajprenal.1989.256.2.F370; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BORIN ML, 1993, AM J PHYSIOL, V264, pC1513, DOI 10.1152/ajpcell.1993.264.6.C1513; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; EKBLAD H, 1992, AM J PHYSIOL, V263, pF716, DOI 10.1152/ajprenal.1992.263.4.F716; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; FISONE G, 1994, J BIOL CHEM, V269, pS936; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HORIUCHI A, 1993, MOL PHARMACOL, V43, P281; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1986, KIDNEY INT, V29, P10, DOI 10.1038/ki.1986.3; KANSRA V, 1995, EUR J PHARM-MOLEC PH, V289, P391, DOI 10.1016/0922-4106(95)90119-1; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; MINTA A, 1989, J BIOL CHEM, V264, P19449; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; NOCL J, 1995, AM J PHYSIOL, V268, pC283; OKAYAMA H, 1991, GENE TRANSFER EXPRES, P15; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; TURNHEIM K, 1994, PHYSIOL RES, V43, P211; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7	31	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20179	20184		10.1074/jbc.272.32.20179	http://dx.doi.org/10.1074/jbc.272.32.20179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242694	hybrid			2022-12-27	WOS:A1997XQ05900081
J	Brady, MJ; Printen, JA; Mastick, CC; Saltiel, AR				Brady, MJ; Printen, JA; Mastick, CC; Saltiel, AR			Bole of protein targeting to glycogen (PTG) in the regulation of protein phosphatase-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; ADIPOSE-TISSUE; 3T3-L1 ADIPOCYTES; INSULIN; KINASE; PHOSPHORYLATION; STIMULATION; INHIBITOR-1; SUBUNIT; DEPHOSPHORYLATION	We have recently cloned from 3T3-L1 adipocytes a novel glycogen-tageting subunit of protein phosphatase-1, termed PTG (Printen, 5, A., Brady, M. J., and Saltiel, A. R. (1997) Science 275, 1475-1478), Differentiation of 3T3-L1 fibroblasts into highly insulin-responsive adipocytes resulted in a marked increase: in PTG expression, Immobilized glutathione S-transferase (GST)-PTG fusion protein specifically bound either PP1 or phosphorylase a, Addition of soluble GST-PTG to 3T3-L1. lysates increased PP1 activity against P-32-labeled phosphorylase a by decreasing the K-m of PP1 for phosphorylase 5-fold, while having ma effect on the V-max, of the dephosphorylation reaction, Alternatively, PTG did not affect PP1 activity against hormone-sensitive lipase, PTG was not a direct target of intracellular signaling, as insulin or forskolin treatment of cells did not activate a kinase capable of phosphorylating PTG in vivo or irt vitro, Finally, PTG decreased the ability of DARPP-32 to inhibit PP1 activity from 3T3-L1 adipocyte lysates, These data cumulatively suggest that PTG increases PPI activity against specific proteins by several distinct mechanisms.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CELL BIOL,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019; Mastick, Cynthia/G-9841-2017	Mastick, Cynthia/0000-0003-4769-5412; Saltiel, Alan/0000-0002-9726-9828				Azpiazu I, 1996, J BIOL CHEM, V271, P5033; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISTER B, 1988, P NATL ACAD SCI USA, V85, P8713, DOI 10.1073/pnas.85.22.8713; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; NAIRN AC, 1995, NEUROPROTOCOLS, V6, P108; NEMENOFF RA, 1983, J BIOL CHEM, V258, P9437; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; STRALFORS P, 1989, EUR J BIOCHEM, V180, P143, DOI 10.1111/j.1432-1033.1989.tb14624.x; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; TANG PM, 1991, J BIOL CHEM, V266, P15782; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	26	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20198	20204		10.1074/jbc.272.32.20198	http://dx.doi.org/10.1074/jbc.272.32.20198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242697	hybrid			2022-12-27	WOS:A1997XQ05900084
J	Doorty, KB; Bevan, S; Wadsworth, JDF; Strong, PN				Doorty, KB; Bevan, S; Wadsworth, JDF; Strong, PN			A novel small conductance Ca2+-activated K+ channel blocker from Oxyuranus scutellatus Taipan venom - Re-evaluation of taicatoxin as a selective Ca2+ channel probe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; APAMIN-BINDING; CALCIUM CHANNELS; SCORPION TOXIN; BEE VENOM; MUSCLE; CELLS; HEPATOCYTES; POLYPEPTIDE; SCYLLATOXIN	Taicatoxin, isolated from the venom of the Australian taipan snake Oxyuranus scutellatus, has been previously regarded as a specific blocker of high threshold Ca2+ channels in heart. Here we show that taicatoxin (in contrast to a range of other Ca2+ channel blockers) interacts with apamin-sensitive, small conductance, Ca2+-activated potassium channels on both chromaffin cells and in the brain. Taicatoxin displays high affinity recognition of I-125-apamin acceptor-binding sites, present on rat synaptosomal membranes (K-i 1.45 +/- 0.22 nM) and also specifically blocks affinity-labeling of a 33-kDa I-125-apamin-binding polypeptide on rat brain membranes. Taicatoxin (50 nM) completely blocks apamin-sensitive after-hyperpolarizing slow tail K+ currents generated in rat chromaffin cells (mean block 97 +/- 3%, n = 12) while only partially reducing total voltage-dependent Ca2+ currents (mean block 12 +/- 4%, n = 6). In view of these findings, the use of taicatoxin as a specific ligand for Ca2+ channels should now be reconsidered.	NOVARTIS INST MED SCI,LONDON WC1E 6BN,ENGLAND	Novartis	Doorty, KB (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT PAEDIAT & NEONATAL MED,NEUROMUSCULAR UNIT,LONDON W12 0NN,ENGLAND.		Bevan, Stuart/A-8821-2008	Wadsworth, Jonathan/0000-0002-4797-2259; Bevan, Stuart John/0000-0002-8977-1797	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS ME, 1996, TRENDS NEUROSCI S, V19; AUGUSTE P, 1992, BIOCHEMISTRY-US, V31, P648, DOI 10.1021/bi00118a003; AUGUSTE P, 1989, FEBS LETT, V248, P150, DOI 10.1016/0014-5793(89)80451-X; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; BKAILY G, 1992, AM J PHYSIOL, V262, pH463, DOI 10.1152/ajpheart.1992.262.2.H463; BKAILY G, 1985, AM J PHYSIOL, V248, pH961, DOI 10.1152/ajpheart.1985.248.6.H961; BREWSTER BS, 1992, POTASSIUM CHANNEL MO, P272; BROWN AM, 1987, CIRC RES, V61, P6; CASTLE NA, 1989, TRENDS NEUROSCI, V12, P59, DOI 10.1016/0166-2236(89)90137-9; CHICCHI GG, 1988, J BIOL CHEM, V263, P10192; COOK NS, 1985, J PHYSIOL-LONDON, V358, P373, DOI 10.1113/jphysiol.1985.sp015556; Dunn PM, 1996, BRIT J PHARMACOL, V117, P35, DOI 10.1111/j.1476-5381.1996.tb15151.x; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRYKLUND L, 1975, BIOCHEMISTRY-US, V14, P2860, DOI 10.1021/bi00684a011; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GRANIER C, 1978, EUR J BIOCHEM, V82, P293, DOI 10.1111/j.1432-1033.1978.tb12023.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARVEY AL, 1985, J TOXICOL-TOXIN REV, V4, P41, DOI 10.3109/15569548509014413; HUGUES M, 1982, J BIOL CHEM, V257, P2762; HUGUES M, 1982, BIOCHEM BIOPH RES CO, V107, P1577, DOI 10.1016/S0006-291X(82)80180-0; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LABBEJULLIE C, 1991, EUR J BIOCHEM, V196, P689; Legros C, 1996, FEBS LETT, V390, P81, DOI 10.1016/0014-5793(96)00616-3; MARQUEZE B, 1987, EUR J BIOCHEM, V169, P295, DOI 10.1111/j.1432-1033.1987.tb13611.x; MARTINS JC, 1990, FEBS LETT, V260, P249, DOI 10.1016/0014-5793(90)80115-Y; MONTIEL C, 1995, J PHYSIOL-LONDON, V486, P427, DOI 10.1113/jphysiol.1995.sp020823; MORI Y, 1994, HDB MEMBRANE CHANNEL, P163; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; PARK Y, 1994, J PHYSIOL-LONDON, V481, P555, DOI 10.1113/jphysiol.1994.sp020463; POSSANI LD, 1992, TOXICON, V30, P1343, DOI 10.1016/0041-0101(92)90511-3; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SCHMIDANTOMARCHI H, 1985, P NATL ACAD SCI USA, V82, P2188, DOI 10.1073/pnas.82.7.2188; SEAGAR MJ, 1986, BIOCHEMISTRY-US, V25, P4051, DOI 10.1021/bi00362a010; Strong P. N., 1992, Methods in Neurosciences, V8, P15; STRONG PN, 1990, PHARMACOL THERAPEUT, V46, P137, DOI 10.1016/0163-7258(90)90040-9; VINCENT JP, 1975, BIOCHEMISTRY-US, V14, P2521, DOI 10.1021/bi00682a035; WADSWORTH JDF, 1994, J BIOL CHEM, V269, P18053; Wadsworth JDF, 1996, BIOCHEMISTRY-US, V35, P7917, DOI 10.1021/bi9602371; ZERROUK H, 1993, FEBS LETT, V320, P189, DOI 10.1016/0014-5793(93)80583-G	43	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19925	19930		10.1074/jbc.272.32.19925	http://dx.doi.org/10.1074/jbc.272.32.19925			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242659	hybrid			2022-12-27	WOS:A1997XQ05900046
J	Niswender, KD; Postic, C; Jetton, TL; Bennett, BD; Piston, DW; Efrat, S; Magnuson, MA				Niswender, KD; Postic, C; Jetton, TL; Bennett, BD; Piston, DW; Efrat, S; Magnuson, MA			Cell-specific expression and regulation of a glucokinase gene locus transgene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELL; DEPENDENT DIABETES-MELLITUS; INSULIN-SECRETION; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; RAT HEPATOCYTES; GLUCOSE SENSOR; X-INACTIVATION; GLOBIN GENE; HIGH-LEVEL	Transgenic mice containing one or more extra copies of the entire glucokinase (GK) gene locus were generated and characterized. The GK transgene, an 83-kilobase pair mouse genomic DNA fragment containing both promoter regions, was expressed and regulated in a cell-specific manner, and rescued GK null lethality when crossed into mice bearing a targeted mutation of the endogenous GK gene. Livers from the transgenic mice had elevated GK mRNA, protein, and activity levels, compared with controls, and the transgene was regulated in liver by dietary manipulations. The amount of GK immunoreactivity in hepatocyte nuclei, where GK binds to the GK regulatory protein, was also increased. Pancreatic islets displayed increased GK immunoreactivity and NAD(P)H responses to glucose, but only when isolated and cultured in 20 mM glucose, as a result of the hypoglycemic phenotype of these mice (Niswender, K. D., Shiota, M., Postic, C., Cherrington, A. D., and Magnuson, M. A. (1997) J. Biol. Chem. 272, 22604-22609). Together, these results indicate that the region of the gene from -55 to +28 kilobase pairs (relative to the liver GK transcription start site) contains all the regulatory sequences necessary for expression of both GK isoforms, thereby placing an upper limit on the size of the GK gene locus.	VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOL BIOPHYS, NASHVILLE, TN 37232 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA	Vanderbilt University; Yeshiva University; Albert Einstein College of Medicine			Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009; Postic, Catherine/P-2271-2017	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499; Postic, Catherine/0000-0002-1875-6960; Efrat, Shimon/0000-0001-5987-232X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42612, DK 42502] Funding Source: Medline; PHS HHS [5T3Z C-M07347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; Bennett BD, 1996, J BIOL CHEM, V271, P3647; CHAUHAN J, 1991, J BIOL CHEM, V266, P10035; CHEN C, 1994, J CLIN INVEST, V94, P1616, DOI 10.1172/JCI117503; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DISTECHE CM, 1995, TRENDS GENET, V11, P17, DOI 10.1016/S0168-9525(00)88981-7; EXTON JH, 1972, METABOLISM, V21, P945, DOI 10.1016/0026-0495(72)90028-5; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; HOGAN B, 1994, MANIPULATING MOUSE E, P217; Iynedjian PB, 1996, J BIOL CHEM, V271, P29113, DOI 10.1074/jbc.271.46.29113; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JETTON TL, 1994, J BIOL CHEM, V269, P3641; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; JETTON TL, 1994, DIABETES, P193; KRAUSFRIEDMANN N, 1984, PHYSIOL REV, V64, P170, DOI 10.1152/physrev.1984.64.1.170; KRUMLAUF R, 1986, NATURE, V319, P224, DOI 10.1038/319224a0; LEIBIGER IB, 1994, FEBS LETT, V337, P161, DOI 10.1016/0014-5793(94)80265-3; LI QL, 1994, MOL CELL BIOL, V14, P6087, DOI 10.1128/MCB.14.9.6087; LIANG Y, 1994, DIABETES, V43, P1138, DOI 10.2337/diabetes.43.9.1138; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MIWA I, 1990, BIOCHEM INT, V22, P759; Moates JM, 1996, MOL ENDOCRINOL, V10, P723, DOI 10.1210/me.10.6.723; MOORMAN AFM, 1991, FEBS LETT, V287, P47, DOI 10.1016/0014-5793(91)80013-S; NAGAI K, 1978, BRAIN RES, V142, P384, DOI 10.1016/0006-8993(78)90648-0; NARKEWICZ MR, 1990, BIOCHEM J, V271, P585, DOI 10.1042/bj2710585; NISWENDER KD, 1997, J BIOL CHEM, V272, P22604; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; POSTIC C, 1995, GENOMICS, V29, P740, DOI 10.1006/geno.1995.9943; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHARP DW, 1973, TRANSPLANTATION, V16, P686, DOI 10.1097/00007890-197312000-00028; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; STEFAN Y, 1987, J CLIN INVEST, V80, P175, DOI 10.1172/JCI113045; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; TOYODA Y, 1995, BIOCHEM BIOPH RES CO, V215, P467, DOI 10.1006/bbrc.1995.2488; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; WU H, 1992, DEVELOPMENT, V116, P687; YIN L, 1992, DIABETES, V41, P792	53	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22564	22569		10.1074/jbc.272.36.22564	http://dx.doi.org/10.1074/jbc.272.36.22564			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278410	hybrid			2022-12-27	WOS:A1997XV49200030
J	Braganca, J; Genin, P; Bandu, MT; Darracq, N; Vignal, R; Casse, C; Doly, J; Civas, A				Braganca, J; Genin, P; Bandu, MT; Darracq, N; Vignal, R; Casse, C; Doly, J; Civas, A			Synergism between multiple virus-induced factor-binding elements involved in the differential expression of interferon A genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; IFN-BETA GENE; REGULATORY FACTOR FAMILY; ALPHA PROMOTER REGION; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATOR; DNA-BINDING; RESPONSE ELEMENT; IRF FAMILY; INDUCTION	Comparative transfection analysis of murine interferon A4 and interferon All promoter constructs transiently transfected in mouse L929 and human HeLa S3 cells infected with Newcastle disease virus showed that the second positive regulatory domain I-like domain (D motif), located between nucleotides -57 and -46 upstream of the transcription start site, contributes to the activation of virus-induced transcription of the interferon (IFN)-A4 gene promoter by cooperating with the positive regulatory domain I-like and TG-like domains previously described. Electrophoretic mobility shift assay performed with the virus-inducible fragments containing these motifs indicated that the binding activity that we have denoted as virus-induced factor (Genin, P., Braganca, J., Darracq, N., Doly, J., and Civas, A. (1995) Nucleic Acids Res. 23, 5055-5063) is different from inter feron-stimulated gene factor 3, It binds to the D motif but not to the virus-unresponsive form of the D motif disrupted by a G(-57) --> C substitution. We show that the low levels of IFN-A11 gene expression are caused essentially by the lack of two inducible enhancer domains disrupted by the A(-78) --> G and the G(-57) --> C substitutions, These data suggest a model taking account of the differential regulation of IFN-A gene family members, They also suggest that virus-induced factor may correspond to the primary transcription factor directly activated by virus that is involved in the initiation of IFN-A gene transcription.	UNIV PARIS 05,LAB REGULAT EXPRESS GENES EUCARYOTES,CNRS,UPR 37,UFR BIOMED ST PERES,F-75270 PARIS 06,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite			Braganca, Jose/F-4410-2012	Braganca, Jose/0000-0001-9566-400X; Genin, Pierre/0000-0002-7502-3851				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; CIVAS A, 1991, NUCLEIC ACIDS RES, V19, P4497, DOI 10.1093/nar/19.16.4497; COULOMBEL C, 1991, GENE, V104, P187, DOI 10.1016/0378-1119(91)90249-B; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; DALY C, 1995, J BIOL CHEM, V270, P23739, DOI 10.1074/jbc.270.40.23739; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; De Maeyer E., 1994, CYTOKINE HDB, P265; Dent CL, 1996, EUR J BIOCHEM, V236, P895, DOI 10.1111/j.1432-1033.1996.t01-1-00895.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; Genin P, 1995, NUCLEIC ACIDS RES, V23, P5055; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRANT CE, 1995, NUCLEIC ACIDS RES, V23, P2137, DOI 10.1093/nar/23.12.2137; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, NATURE, V337, P270; HISCOTT J, 1988, MOL CELL BIOL, V8, P3397, DOI 10.1128/MCB.8.8.3397; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P368; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; KELLER AD, 1992, MOL CELL BIOL, V12, P1940, DOI 10.1128/MCB.12.5.1940; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P825, DOI 10.1093/nar/13.3.825; KELLEY KA, 1985, VIROLOGY, V147, P382, DOI 10.1016/0042-6822(85)90140-0; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, V2, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PITHA PM, 1995, SEMIN VIROL, V6, P151, DOI 10.1006/smvy.1995.0020; RAJ NBK, 1989, J BIOL CHEM, V264, P11149; RAJ NBK, 1989, J BIOL CHEM, V264, P16658; Roffet P, 1996, BIOCHEM J, V317, P697, DOI 10.1042/bj3170697; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; RYALS J, 1985, CELL, V41, P497, DOI 10.1016/S0092-8674(85)80023-4; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUTTLEWORTH J, 1983, EUR J BIOCHEM, V133, P399, DOI 10.1111/j.1432-1033.1983.tb07476.x; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; XANTHOUDAKIS S, 1989, J BIOL CHEM, V264, P1139; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; Yoneyama M, 1996, J BIOCHEM-TOKYO, V120, P160	65	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22154	22162		10.1074/jbc.272.35.22154	http://dx.doi.org/10.1074/jbc.272.35.22154			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268360	hybrid			2022-12-27	WOS:A1997XT85000072
J	Efthymiadis, A; Shao, HM; Hubner, S; Jans, DA				Efthymiadis, A; Shao, HM; Hubner, S; Jans, DA			Kinetic characterization of the human retinoblastoma protein bipartite nuclear localization sequence (NLS) in vivo and in vitro - A comparison with the SV40 large T-antigen NLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II SITE FLANKING; NUCLEOCYTOPLASMIC TRANSPORT; BETA-GALACTOSIDASE; ESCHERICHIA-COLI; PORE COMPLEX; GENE-PRODUCT; GRANZYME-B; IN-VIVO; IMPORT; PHOSPHORYLATION	The retinoblastoma (RE) tumor suppressor is a nuclear phosphoprotein important for cell growth control and able to bind specifically to viral oncoproteins such as the SV40 large tumor antigen (T-ag), Human RE possesses a bipartite nuclear localization sequence (NLS) consisting of two clusters of basic amino acids within amino acids 860-877, also present in mouse and Xenopus homologs, which resembles that of nucleoplasmin, The T-ag NLS represents a different type of NLS, consisting of only one stretch of basic amino acids, To compare the nuclear import kinetics conferred by the bipartite NLS of RE to those conferred by the T-ag NLS, we used beta-galactosidase fusion proteins containing the NLSs of either RE or T-ag, The RE NLS was able to target beta-galactosidase to the nucleus both in vivo (in microinjected cells of the HTC rat hepatoma line) and in vitro (in mechanically perforated HTC cells), Mutational substitution of the proximal basic residues of the NLS abolished nuclear targeting activity, confirming its bipartite character, Nuclear accumulation of the RE fusion protein was half-maximal within about 8 min in vivo maximal levels being between 3-4-fold those in the cytoplasm, which was less than 50% of the maximal levels attained by the T-ag fusion protein, while the initial rate of nuclear import of the RE protein was also less than half that of T-ag, Nuclear import conferred by both NLSs in vitro was dependent on cytosol and ATP and inhibited by the nonhydrolyzable GTP analog GTP gamma S. Using an ELISA-based binding assay, we determined that the RE bipartite NLS had severely reduced affinity, compared with the T-ag NLS, for the high affinity heterodimeric NLS-binding protein complex importin 58/97, this difference presumably representing the basis of the reduced maximal nuclear accumulation and import rate in vivo, The results support the hypothesis that the affinity of NLS recognition by NLS-binding proteins is critical in determining the kinetics of nuclear protein import.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOL BIOL, NUCL SIGNALING LAB, CANBERRA, ACT 2601, AUSTRALIA	Australian National University; John Curtin School of Medical Research								ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AGUTTER PS, 1994, BIOCHEM J, V300, P609, DOI 10.1042/bj3000609; DESTREE OHJ, 1992, DEV BIOL, V153, P141, DOI 10.1016/0012-1606(92)90098-2; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; Jans DA, 1997, FEBS LETT, V406, P315, DOI 10.1016/S0014-5793(97)00293-7; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605, DOI 10.1002/j.1460-2075.1988.tb02986.x; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; STOCHAJ U, 1992, EUR J CELL BIOL, V59, P1; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588	44	108	110	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22134	22139		10.1074/jbc.272.35.22134	http://dx.doi.org/10.1074/jbc.272.35.22134			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268357	hybrid			2022-12-27	WOS:A1997XT85000069
J	Finlin, BS; Andres, DA				Finlin, BS; Andres, DA			Rem is a new member of the Rad- and Gem/Kir ras-related GTP-binding protein family repressed by lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GENE; EXPRESSION; SEQUENCE; SUPERFAMILY; FIBROBLASTS; ACTIVATION; MEMBRANE; MUSCLE; P21RAS	We report the cDNA cloning and characterization of a novel GTP-binding protein, termed Rem (for Rad and Gem-related), that was identified as a product of polymerase chain reaction amplification using oligonucleotide primers derived from conserved regions of the Rad, Gem, and Kir Ras subfamily, Alignment of the full-length open reading frame of mouse Rem revealed the encoded protein to be 47% identical to the Rad, Gem, and Kir proteins, The distinct structural features of the Rad, Gem, and Kir subfamily are maintained including a series of nonconservative amino acid substitutions at positions important for GTPase activity and a unique sequence motif thought to direct membrane association. Recombinant Rem binds GTP in a specific and saturable manner, Ribonuclease protection analysis found Rem to be expressed at comparatively high levels in cardiac muscle and at moderate levels in lung, skeletal muscle, and kidney, The administration of lipopolysaccharide to mice, a potent activator of the inflammatory and immune systems, results in the general repression of Rem mRNA levels in a dose-and time-dependent manner, Thus, Rem is the first Ras-related gene whose mRNA levels have been shown to be regulated by repression.	UNIV KENTUCKY,COLL MED,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky					NEI NIH HHS [EY 11231] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY011231] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Dorin D, 1995, ONCOGENE, V11, P2267; FARRELL FX, 1990, NUCLEIC ACIDS RES, V18, P4281, DOI 10.1093/nar/18.14.4281; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOBBS MV, 1993, J IMMUNOL, V150, P3602; HOD Y, 1992, BIOTECHNIQUES, V13, P852; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KAHN CR, 1993, SCIENCE, V262, P1441; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; Lowry D. R., 1993, ANNU REV BIOCHEM, V62, P4637; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; PIZON V, 1988, ONCOGENE, V3, P201; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; SAMBROOK J, 1989, MOL CLONING LAB CLIN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; WANG K, 1994, BIOTECHNIQUES, V17, P236; ZERIAL M, 1995, GUIDEBOOK SMALL GTPA; Zhu JH, 1996, J BIOL CHEM, V271, P768, DOI 10.1074/jbc.271.2.768; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	38	86	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21982	21988		10.1074/jbc.272.35.21982	http://dx.doi.org/10.1074/jbc.272.35.21982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268335	hybrid			2022-12-27	WOS:A1997XT85000047
J	Nakano, K; Mizuno, T; Sowa, Y; Orita, T; Yoshino, T; Okuyama, Y; Fujita, T; OhtaniFujita, N; Matsukawa, Y; Tokino, T; Yamagishi, H; Oka, T; Nomura, H; Sakai, T				Nakano, K; Mizuno, T; Sowa, Y; Orita, T; Yoshino, T; Okuyama, Y; Fujita, T; OhtaniFujita, N; Matsukawa, Y; Tokino, T; Yamagishi, H; Oka, T; Nomura, H; Sakai, T			Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; RNA POLYMERASE-II; SODIUM-BUTYRATE; POTENTIAL MEDIATOR; CARCINOMA CELLS; PROTEIN-KINASE; HT-29 CELLS; P21; DIFFERENTIATION; GROWTH	Butyrate is a well known colonic luminal short chain fatty acid, which arrests cell growth and induces differentiation in various cell types. We examined the effect of butyrate on the expression of WAF1/Cip1, a potent inhibitor of cyclin-dependent kinases, and its relation to growth arrest in a p53-mutated human colon cancer cell line WiDr, Five millimolar butyrate completely inhibited the growth of WiDr and caused G(1)-phase arrest. WAF1/Cip1 mRNA was rapidly induced within 3 h by treatment with 5.0 mM butyrate, and drastic WAF1/Cip1 protein induction was detected. Using several mutant WAF1/Cip1 promoter fragments, we found that the butyrate responsive elements are two Spl sites at -82 and -69 relative to the transcription start site. We also found that a TATA element at -46 and two overlapping consensus Spl sites at -60 and -55 are essential for the basal promoter activity of WAF1/Cip1. These findings suggest that butyrate arrests the growth of WiDr by activating the WAF1/Cip1 promoter through specific Sp1 sites in a p53-independent fashion.	KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT SURG 2,KAMIKYO KU,KYOTO 602,JAPAN; CHUGAI RES INST MOL MED,NIIHARI,IBARAKI 30041,JAPAN; UNIV TOKYO,INST MED SCI,TOKYO 108,JAPAN	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; University of Tokyo			Tokino, Takashi/AAI-9887-2021					BARNARD JA, 1993, CELL GROWTH DIFFER, V4, P495; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BuquetFagot C, 1996, J CELL PHYSIOL, V166, P631, DOI 10.1002/(SICI)1097-4652(199603)166:3<631::AID-JCP18>3.0.CO;2-9; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG QG, 1993, ANTI-CANCER DRUG, V4, P617, DOI 10.1097/00001813-199312000-00003; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAHAM KA, 1988, J CELL PHYSIOL, V136, P63, DOI 10.1002/jcp.1041360108; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HEROLD KM, 1988, ONCOGENE, V3, P423; Hodin RA, 1996, CELL GROWTH DIFFER, V7, P647; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JIANG HP, 1994, ONCOGENE, V9, P3397; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM YS, 1980, CANCER-AM CANCER SOC, V45, P1185, DOI 10.1002/1097-0142(19800315)45:5+<1185::AID-CNCR2820451324>3.0.CO;2-W; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI YJ, 1995, ONCOGENE, V10, P599; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MICHIELI P, 1994, CANCER RES, V54, P3391; MORITA A, 1982, CANCER RES, V42, P4540; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SAITO H, 1991, INT J CANCER, V48, P291, DOI 10.1002/ijc.2910480223; SAKAI T, 1996, JPN J HYG, V50, P1036; Sambrook J., 2002, MOL CLONING LAB MANU; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAMURA T, 1995, ONCOGENE, V11, P1939; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAO D, 1982, CANCER RES, V42, P1052; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	44	354	367	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22199	22206		10.1074/jbc.272.35.22199	http://dx.doi.org/10.1074/jbc.272.35.22199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268365	hybrid			2022-12-27	WOS:A1997XT85000077
J	Williams, EJ; Dunican, DJ; Green, PJ; Howell, FV; Derossi, D; Walsh, FS; Doherty, P				Williams, EJ; Dunican, DJ; Green, PJ; Howell, FV; Derossi, D; Walsh, FS; Doherty, P			Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; FACTOR RECEPTOR; INTACT-CELLS; EGF-RECEPTOR; SH2 DOMAIN; ACTIVATION; GRB2; RAS; IDENTIFICATION	The activation of the mitogen-activated protein kinase (MAPK) cascade by a variety of growth factors and other agents is central to a mitogenic response, In the case of polypeptide growth factors such as the epidermal growth factor (EGF) and platelet derived growth factor (PDGF), the steps leading to activation of MAPK require the function of the adaptor protein Grb2 (growth factor receptor binding protein 2), which can bind either directly or indirectly via its Src homology 2 domain to activated receptor tyrosine kinases, A cell-permeable mimetic of the EGF receptor Grb2 binding site has been investigated for its ability to inhibit biological responses stimulated by a variety of growth factors, Pretreatment of cells with this peptide results in the accumulation of the peptide in cells and its association with Grb2. This is associated with a complete inhibition of the mitogenic response stimulated by EGF and PDGF, In contrast, the peptide has no effect on the mitogenic response stimulated by fibroblast growth factor, The peptide could also inhibit the phosphorylation of MAPK stimulated with EGF and PDGF in the absence of an effect on the fibroblast growth factor response, These data demonstrate that cell-permeable mimetics of Src homology 2 binding sites can selectively inhibit growth factor stimulated mitogenesis, and also directly demonstrate specificity in the coupling of activated receptor tyrosine kinases to the MAPK cascade.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS HOSP, DEPT EXPT PATHOL, LONDON SE1 9RT, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Dunican, Dara/A-1208-2010; Doherty, Patrick/A-8752-2008	Dunican, Dara/0000-0001-6563-8089; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRETTI P, 1988, J EXP ZOOL, V247, P77, DOI 10.1002/jez.1402470111; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI NX, 1994, ONCOGENE, V9, P3457; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Wang JK, 1996, ONCOGENE, V13, P721; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	25	79	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22349	22354		10.1074/jbc.272.35.22349	http://dx.doi.org/10.1074/jbc.272.35.22349			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268386	hybrid			2022-12-27	WOS:A1997XT85000098
J	Landino, LM; Crews, BC; Gierse, JK; Hauser, SD; Marnett, LJ				Landino, LM; Crews, BC; Gierse, JK; Hauser, SD; Marnett, LJ			Mutational analysis of the role of the distal histidine and glutamine residues of prostaglandin-endoperoxide synthase-2 in peroxidase catalysis, hydroperoxide reduction, and cyclooxygenase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HIGHER OXIDATION-STATES; H SYNTHASE; CRYSTAL-STRUCTURE; IRON(III) PORPHYRINS; HYDROGEN-PEROXIDE; ANGSTROM RESOLUTION; BACULOVIRUS SYSTEM; LIGNIN PEROXIDASE; MECHANISM	Site-directed mutants of prostaglandin-endoperoxide synthase-a (PGHS-2) with changes in the peroxidase active site were prepared by mutagenesis, expressed in Sf-9 cells, and purified to homogeneity, The distal histidine, His(193), was mutated to alanine and the distal glutamine, Gln(189), was changed to asparagine, valine, and arginine. The guaiacol peroxidase activities of H193A, Q189V, and Q189R were drastically reduced to levels observed in the absence of protein; only Q189N retained wild-type PGHS-2 (wtPGHS-2) activity, The mechanism of hydroperoxide reduction by the PGHS-2 mutants was investigated using 15-hydroperoxyeicosatetraenoic acid (15-HPETE), a diagnostic probe of hydroperoxide reduction pathways, The hydroperoxide reduction activity of Q189V and Q189R was reduced to that of free Fe(III) protoporphyrin IX levels, whereas Q189N catalyzed more reduction events than wtPGHS-2. The percentage of two-electron reduction events was identical for wt PGHS-2 and Q189N, The number of hydroperoxide reductions catalyzed by H193A was reduced to similar to 60% of wtPGHS-2 activity, but the majority of products were the one-electron reduction products, 15-KETE and epoxyalcohols, Thus, mutation of the distal histidine to alanine leads to a change in the mechanism of hydroperoxide reduction. Reaction of wtPGHS-2, Q189N, and H193A with varying concentrations of 15-HPETE revealed a change in product profile that suggests that 15-HPETE can compete with the reducing substrate for oxidation by the peroxidase higher oxidation state, compound I. The ability of the PGHS-2 proteins to catalyze two-electron hydroperoxide reduction correlated with the activation of cyclooxygenase activity, The reduced ability of H193A to catalyze two-electron hydroperoxide reduction resulted in a substantial lag phase in the cyclooxygenase assay, The addition of 2-methylimidazole chemically reconstituted the two-electron hydroperoxide reduction activity of H193A and abolished the cyclooxygenase lag phase, These observations are consistent with the involvement of the two-electron oxidized peroxidase intermediate, compound I, as the mediator of the activation of the cyclooxygenase of PGHS.	VANDERBILT UNIV, SCH MED,DEPT BIOCHEM,CTR MOL TOXICOL, AB HANCOCK JR MEM LAB CANC RES, NASHVILLE, TN 37232 USA; MONSANTO CO, SEARLE INFLAMMATORY DIS RES, ST LOUIS, MO 63167 USA	Vanderbilt University; Monsanto					NCI NIH HHS [CA47479] Funding Source: Medline; NIEHS NIH HHS [ES00267, T32ES07028] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028, P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bakovic M, 1996, J BIOL CHEM, V271, P2048, DOI 10.1074/jbc.271.4.2048; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BLEE E, 1989, BIOCHEMISTRY-US, V28, P4962, DOI 10.1021/bi00438a009; Chance B, 1943, J BIOL CHEM, V151, P553; CHANCE B, 1984, ARCH BIOCHEM BIOPHYS, V235, P596, DOI 10.1016/0003-9861(84)90234-0; CHOUDHURY K, 1992, J BIOL CHEM, V267, P25656; CROMLISH WA, 1994, ARCH BIOCHEM BIOPHYS, V314, P193, DOI 10.1006/abbi.1994.1429; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DOLPHIN D, 1974, ACCOUNTS CHEM RES, V7, P26, DOI 10.1021/ar50073a005; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; Everse J., 1991, PEROXIDASES CHEM BIO; FUNK MO, 1976, LIPIDS, V11, P113, DOI 10.1007/BF02532660; GEORGE P, 1955, BIOCHEM J, V60, P596, DOI 10.1042/bj0600596; GIERSE JK, 1994, BIOCHEM J, V304, P1; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Klebanoff SJ, 1991, PEROXIDASES CHEM BIO, V1, P1; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LABEQUE R, 1987, J AM CHEM SOC, V109, P2828, DOI 10.1021/ja00243a048; LABEQUE R, 1989, J AM CHEM SOC, V111, P6621, DOI 10.1021/ja00199a022; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; Landino LM, 1996, BIOCHEMISTRY-US, V35, P2637, DOI 10.1021/bi952546h; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; MARNETT LJ, 1979, J BIOL CHEM, V254, P5077; MARNETT LJ, 1995, CYTOCHROME P450 STRU; Newmyer SL, 1996, J BIOL CHEM, V271, P14891, DOI 10.1074/jbc.271.25.14891; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; O'Brien P J, 1980, Adv Prostaglandin Thromboxane Res, V6, P145; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; OHKI S, 1979, J BIOL CHEM, V254, P829; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PLE P, 1989, J BIOL CHEM, V264, P13983; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P575; POULOS TL, 1993, J BIOL CHEM, V268, P4429; Putter J, 1975, METHOD ENZYMAT AN, P685; Sambrook J, 1989, MOL CLONING LAB MANU, P82; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SCOTT SL, 1993, J PHYS CHEM-US, V97, P6710, DOI 10.1021/j100127a022; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1992, BIOCHEM BIOPH RES CO, V183, P975, DOI 10.1016/S0006-291X(05)80286-4; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; SUNDARAMOORTHY M, 1991, J AM CHEM SOC, V113, P7755, DOI 10.1021/ja00020a044; TRAYLOR TG, 1993, J AM CHEM SOC, V115, P2775, DOI 10.1021/ja00060a027; TRAYLOR TG, 1990, J AM CHEM SOC, V112, P178, DOI 10.1021/ja00157a029; TRAYLOR TG, 1995, J AM CHEM SOC, V117, P3468, DOI 10.1021/ja00117a015; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; Welinder KG., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]; WELLER PE, 1985, ARCH BIOCHEM BIOPHYS, V243, P633, DOI 10.1016/0003-9861(85)90541-7; WILCOX AL, 1993, CHEM RES TOXICOL, V6, P413, DOI 10.1021/tx00034a003; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	61	58	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21565	21574		10.1074/jbc.272.34.21565	http://dx.doi.org/10.1074/jbc.272.34.21565			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261177	hybrid			2022-12-27	WOS:A1997XR78900087
J	Hunt, JA; Fierke, CA				Hunt, JA; Fierke, CA			Selection of carbonic anhydrase variants displayed on phage - Aromatic residues in zinc binding site enhance metal affinity and equilibration kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC POCKET; CATALYTIC MECHANISM; RANDOM MUTAGENESIS; PROTON-TRANSFER; PROTEIN; BACTERIOPHAGE; CHROMATOGRAPHY; PURIFICATION; CONSEQUENCES; EXPRESSION	In all metalloenzymes, hydrophobic residues surround the metal binding site, In carbonic anhydrase II (CAII) residues Phe(93), Phe(95), and Trp(97) flank two of the three histidines that coordinate zinc to form a hydrophobic cluster beneath the zinc binding site. A library of CAII variants differing in these hydrophobic amino acids was prepared using cassette mutagenesis, then displayed on filamentous phage, and screened for proteins retaining high zinc affinity, Wild-type CAII was enriched 20-fold by selection, and consensus residues at each position were identified from the enriched CAII variants (lie, Phe, Leu, and Met at position 93; lie, Leu, and Met at position 95; and Trp and Val at position 97), Highly selected variants have zinc affinity and catalytic activity nearly equal to that of wild-type CAII, indicating that the aromatic residues are not absolutely essential, However, the zinc dissociation rate constant and catalytic activity of the variants correlate with the volume of the amino acids at positions 93, 95, and 97, In summary, metalloenzyme variants displayed on phage can be selected on the basis of metal affinity; such methods will be useful for optimization of metal ion biosensors.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017467, R29GM040602, R01GM040602] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17467, GM40602] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RS, 1993, BIOCHEMISTRY-US, V32, P1510, DOI 10.1021/bi00057a015; ARKIN AP, 1992, BIO-TECHNOL, V10, P297, DOI 10.1038/nbt0392-297; ARMSTRONG JM, 1966, J BIOL CHEM, V241, P5137; Christianson DW, 1996, ACCOUNTS CHEM RES, V29, P331, DOI 10.1021/ar9501232; COREY DR, 1993, GENE, V128, P129; DODGSON SJ, 1991, CARBONIC ANHYDRASES; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ERIKSSON AE, 1988, PROTEINS, V4, P283, DOI 10.1002/prot.340040407; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; FIERKE CA, 1991, INT WORKSH CARB ANH, P22; HAKANSSON K, 1992, J MOL BIOL, V227, P1192, DOI 10.1016/0022-2836(92)90531-N; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Hellinga HW, 1996, CURR OPIN BIOTECH, V7, P437, DOI 10.1016/S0958-1669(96)80121-2; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; HOLYER RH, 1966, INORG CHEM, V5, P622, DOI 10.1021/ic50038a027; HOLYER RH, 1965, INORG CHEM, V4, P929, DOI 10.1021/ic50029a002; Huang CC, 1996, BIOCHEMISTRY-US, V35, P3439, DOI 10.1021/bi9526692; HUNT JB, 1984, J BIOL CHEM, V259, P4793; HUNT JB, 1977, ANAL BIOCHEM, V64, P297; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; IPPOLITO JA, 1994, BIOCHEMISTRY-US, V33, P15241, DOI 10.1021/bi00255a004; Jackman JE, 1996, BIOCHEMISTRY-US, V35, P16421, DOI 10.1021/bi961786+; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KIEFER LL, 1995, J AM CHEM SOC, V117, P6831, DOI 10.1021/ja00131a004; KIEFER LL, 1994, BIOCHEMISTRY-US, V33, P15233, DOI 10.1021/bi00255a003; KIEFER LL, 1993, J AM CHEM SOC, V115, P12581, DOI 10.1021/ja00079a046; KING RW, 1976, PROC R SOC SER B-BIO, V193, P107, DOI 10.1098/rspb.1976.0034; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREBS JF, 1993, J BIOL CHEM, V268, P948; KREBS JF, 1993, BIOCHEMISTRY-US, V32, P4496, DOI 10.1021/bi00068a004; KUMAR K, 1976, BIOCHEMISTRY-US, V15, P2195, DOI 10.1021/bi00655a026; LESBURG CA, 1995, J AM CHEM SOC, V117, P6838, DOI 10.1021/ja00131a005; LINDSKOG S, 1982, ADV INORG BIOCHEM, V4, P115; MARKS JD, 1992, J BIOL CHEM, V267, P16007; MCCAFFERTY J, 1991, PROTEIN ENG, V4, P955, DOI 10.1093/protein/4.8.955; MULLER HN, 1994, BIOCHEMISTRY-US, V33, P14126; NAIR SK, 1991, J BIOL CHEM, V266, P17320; OSBORNE WRA, 1975, ANAL BIOCHEM, V64, P297, DOI 10.1016/0003-2697(75)90434-0; PESSI A, 1993, NATURE, V362, P367, DOI 10.1038/362367a0; POCKER Y, 1972, BIOCHEMISTRY-US, V11, P698, DOI 10.1021/bi00755a005; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; REN XL, 1995, BIOCHEMISTRY-US, V34, P8492, DOI 10.1021/bi00026a033; RIEPE ME, 1968, J BIOL CHEM, V243, P2779; ROBERTS VA, 1990, P NATL ACAD SCI USA, V87, P6654, DOI 10.1073/pnas.87.17.6654; ROWLETT RS, 1982, J AM CHEM SOC, V104, P6737, DOI 10.1021/ja00388a043; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILLEN LG, 1964, SPECIAL PUBLICATION, V17, P546; SILVERMAN DN, 1993, BIOCHEMISTRY-US, V32, P10757, DOI 10.1021/bi00091a029; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SOUMILLION P, 1994, J MOL BIOL, V237, P415, DOI 10.1006/jmbi.1994.1244; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAINER J A, 1992, Current Opinion in Biotechnology, V3, P378, DOI 10.1016/0958-1669(92)90166-G; Tamai S, 1996, P NATL ACAD SCI USA, V93, P13647, DOI 10.1073/pnas.93.24.13647; Tang Y, 1996, J BIOL CHEM, V271, P15682, DOI 10.1074/jbc.271.26.15682; Thompson R B, 1996, J Biomed Opt, V1, P131, DOI 10.1117/12.227108; THOMPSON RB, 1995, ANAL BIOCHEM, V227, P123, DOI 10.1006/abio.1995.1260; VIERA J, 1987, METHOD ENZYMOL, V153, P3; VITA C, 1995, P NATL ACAD SCI USA, V92, P6404, DOI 10.1073/pnas.92.14.6404; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	68	64	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20364	20372		10.1074/jbc.272.33.20364	http://dx.doi.org/10.1074/jbc.272.33.20364			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252341	hybrid			2022-12-27	WOS:A1997XR22100011
J	Komada, M; Masaki, R; Yamamoto, A; Kitamura, N				Komada, M; Masaki, R; Yamamoto, A; Kitamura, N			Hrs, a tyrosine kinase substrate with a conserved double zinc finger domain, is localized to the cytoplasmic surface of early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PREVACUOLAR COMPARTMENT; ENDOPLASMIC-RETICULUM; CARCINOMA A431-CELLS; SIGNAL-TRANSDUCTION; INTERNALIZATION; PROTEIN; CELLS; TRANSFERRIN; ACTIVATION	Hrs is a 115-kDa double zinc finger protein that is rapidly tyrosine phosphorylated in growth factor stimulated cells, However, its function remains unknown, Here we show that Hrs is localized to early endosomes, Intracellular localization of endogenous Hrs and exogenously expressed Hrs tagged with the hemagglutinin epitope was examined by immunofluorescence staining using anti-Hrs and anti-hemagglutinin epitope antibodies, respectively, Hrs was detected in vesicular structures and was colocalized with the transferrin receptor, a marker for early endosomes, but only partially with CD63, a marker for late endosomes, A zinc finger domain deletion mutant of Hrs was also colocalized with the transferrin receptor, suggesting that the zinc finger domain is not required for its correct localization, Immunoelectron microscopy showed that Hrs was localized to the cytoplasmic surface of these structures, By subcellular fractionation, Hrs was recovered both in the cytoplasmic and membrane fractions, The membrane-associated Hrs was extracted from the membrane by alkali treatment, suggesting that it is peripherally associated with early endosomes. These results, together with our finding that Hrs is homologous to Vps27p, a protein essential for protein traffic through a prevacuolar compartment in yeast, suggest that Hrs is involved in vesicular transport through early endosomes.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; KANSAI MED UNIV,INST LIVER RES,MORIGUCHI,OSAKA 570,JAPAN; KANSAI MED UNIV,DEPT PHYSIOL,MORIGUCHI,OSAKA 570,JAPAN	Tokyo Institute of Technology; Kansai Medical University; Kansai Medical University								BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; KOMADA M, 1994, J BIOL CHEM, V269, P16131; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MRINI A, 1995, J HISTOCHEM CYTOCHEM, V43, P1285, DOI 10.1177/43.12.8537644; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PASTERIS NG, 1994, CELL, V79, P669; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; SORKIN A, 1993, J CELL PHYSIOL, V156, P373, DOI 10.1002/jcp.1041560221; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	32	150	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20538	20544		10.1074/jbc.272.33.20538	http://dx.doi.org/10.1074/jbc.272.33.20538			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252367	hybrid			2022-12-27	WOS:A1997XR22100037
J	Lazarowski, ER; Homolya, L; Boucher, RC; Harden, TK				Lazarowski, ER; Homolya, L; Boucher, RC; Harden, TK			Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE KINASE; TUMOR-METASTASIS; GENE; ATP	The P2Y(4) receptor is selectively activated by UTP, Although addition of neither ATP nor UDP alone increased intracellular Ca2+ in 1321N1 human astrocytoma cells stably expressing the P2Y(4) receptor, combined addition of these nucleotides resulted in a slowly occurring elevation of Ca2+. The possibility that the stimulatory effect of the combined nucleotides reflected formation of UTP by an extracellular transphosphorylating activity was investigated, Incubation of cells with [H-3]UDP or [H-3]ADP under conditions in which cellular release of ATP occurred or in the presence of added ATP resulted in rapid formation of the corresponding triphosphates, Transfer of the gamma-phosphate from [gamma-P-33]ATP to nucleoside diphosphates confirmed that the extracellular enzymatic activity was contributed by a nucleoside diphosphokinase. The majority of this activity was associated with the cell surface of 1321N1 cells, suggesting involvement of an ectoenzyme, Both ADP and UDP were effective substrates for transphosphorylation. Since ecto-nucleotidase(s) has been considered previously to be the primary enzyme(s) responsible for metabolism of extracellular nucleotides, the relative rates of hydrolysis of ATP, ADP, UTP, and UDP also were determined for 1321N1 cells, All four nucleotides were hydrolyzed with similar K-m and V-max values, Kinetic analyses of the ecto-nucleoside diphosphokinase and ecto-nucleotidase activities indicated that the rate of extracellular transphosphorylation exceeds that of nucleotide hydrolysis by up to 20-fold. Demonstration of the existence of a very active ecto-nucleoside diphosphokinase together with previous observations that stress induced release of ATP occurs from most cell types indicates that transphosphorylation is physiologically important in the extracellular metabolism of adenine and uridine nucleotides, Since the P2Y receptor class of signaling proteins differs remarkably in their respective specificity for adenine and uridine nucleotides and di- and triphosphates, these results suggest that extracellular interconversion of adenine and uridine nucleotides plays a key role in defining activities in nucleotide-mediated signaling.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599; HUNGARIAN ACAD SCI,RES GRP,BUDAPEST,HUNGARY	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Hungarian Academy of Sciences			Homolya, Laszlo/N-1154-2016	Homolya, Laszlo/0000-0003-1639-8140	NHLBI NIH HHS [HL32322] Funding Source: Medline; NIGMS NIH HHS [GM38213] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUDOIN AR, 1996, BIOMEMBRANE, P369; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; Charlton SJ, 1996, BRIT J PHARMACOL, V119, P1301, DOI 10.1111/j.1476-5381.1996.tb16038.x; Communi D, 1997, TRENDS PHARMACOL SCI, V18, P83, DOI 10.1016/S0165-6147(96)01035-8; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; PARKS RW, 1973, ENZYMES, P307; Picher M, 1996, BIOCHEM PHARMACOL, V51, P1453, DOI 10.1016/0006-2952(96)00086-X; PLESNER L, 1995, INT REV CYTOL, V158, P141; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SEVIGNY J, 1995, BIOCHEM J, V312, P351, DOI 10.1042/bj3120351; SLAKEY LL, 1990, ANN NY ACAD SCI, V603, P366; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898	26	100	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20402	20407		10.1074/jbc.272.33.20402	http://dx.doi.org/10.1074/jbc.272.33.20402			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252347	Green Published, hybrid			2022-12-27	WOS:A1997XR22100017
J	Nemes, Z; Adany, R; Balazs, M; Boross, P; Fesus, L				Nemes, Z; Adany, R; Balazs, M; Boross, P; Fesus, L			Identification of cytoplasmic actin as an abundant glutaminyl substrate for tissue transglutaminase in HL-60 and U937 cells undergoing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; TERMINAL DIFFERENTIATION; RETINOIC ACID; RAT-LIVER; F-ACTIN; EXPRESSION; DEATH; MATRIX; GROWTH; 5-(BIOTINAMIDO)PENTYLAMINE	A lysine derivative, 3-[N-alpha[N-epsilon-[2',4'-dinitrophenyl]-amino-n-hexanoyl-L-lysylamido]-propane-1-ol, a novel amine substrate of transglutaminases, was synthesized and delivered into intact HL-60 and U937 human leukemia cells to probe the function of the intracellular enzyme. The novel substrate compound was covalently incorporated into intracellular proteins in these cells expressing high levels of tissue transglutaminase and undergoing apoptosis following the induction of their differentiation with dimethyl sulfoxide and retinoic acid. Immunoaffinity purification and microsequencing of labeled proteins identified cytoplasmic actin as the main endogenous glutaminyl substrate in these cells. As shown by confocal image analysis, cells revealed distinct labeling of the microfilament meshwork structures by the novel compound as the result of the intracellular action of transglutaminase.	DEBRECEN UNIV MED,SCH MED,DEPT BIOCHEM,H-4012 DEBRECEN,HUNGARY; DEBRECEN UNIV MED,SCH MED,DEPT HYG & EPIDEMIOL,H-4012 DEBRECEN,HUNGARY	University of Debrecen; University of Debrecen								AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; ANDO Y, 1991, J BIOL CHEM, V266, P1101; Benedetti L, 1996, BLOOD, V87, P1939; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; COHEN I, 1980, BIOCHIM BIOPHYS ACTA, V628, P365, DOI 10.1016/0304-4165(80)90386-4; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COTTER TG, 1992, CANCER RES, V52, P997; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; DEFACQUE H, 1995, LEUKEMIA, V9, P1762; Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; ENDRESEN PC, 1995, CYTOMETRY, V20, P162, DOI 10.1002/cyto.990200209; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; Fesus L, 1988, Adv Exp Med Biol, V231, P119; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FINK ML, 1983, METHOD ENZYMOL, V94, P347; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1977, ADV PROTEIN CHEM, V31, P127; FUKUDA K, 1994, J CELL BIOCHEM, V54, P67, DOI 10.1002/jcb.240540108; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; HARSFALVI J, 1991, BIOCHIM BIOPHYS ACTA, V1073, P268, DOI 10.1016/0304-4165(91)90131-Y; HEGYI G, 1992, PROTEIN SCI, V1, P132; JOHNSON TS, 1994, ONCOGENE, V9, P2935; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KNIGHT RL, 1993, EUR J CELL BIOL, V60, P210; KVEDAR JC, 1992, BIOCHEMISTRY-US, V31, P49, DOI 10.1021/bi00116a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KN, 1992, BIOCHIM BIOPHYS ACTA, V1136, P12, DOI 10.1016/0167-4889(92)90078-P; LORAND L, 1986, BIOCHEM BIOPH RES CO, V134, P685, DOI 10.1016/S0006-291X(86)80474-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MINTA JO, 1985, AM J PATHOL, V119, P111; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Nemes Z, 1996, EUR J CELL BIOL, V70, P125; OLIVEIRO S, 1997, IN PRESS MOL CELL BI; PARWARESCH MR, 1984, CELL IMMUNOL, V89, P385, DOI 10.1016/0008-8749(84)90340-X; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; PIACENTINI M, 1994, APOPTOSIS, V2, P143; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Song QZ, 1997, P NATL ACAD SCI USA, V94, P157, DOI 10.1073/pnas.94.1.157; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; TARCSA E, 1990, ANAL BIOCHEM, V186, P135, DOI 10.1016/0003-2697(90)90586-X; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; TRICHIERI G, 1987, CANCER RES, V47, P2236; Wyllie A H, 1980, Int Rev Cytol, V68, P251	54	96	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20577	20583		10.1074/jbc.272.33.20577	http://dx.doi.org/10.1074/jbc.272.33.20577			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252372	hybrid			2022-12-27	WOS:A1997XR22100042
J	Schmitz, A; Short, M; Ammerpohl, O; Asbrand, C; Nickel, J; Renkawitz, R				Schmitz, A; Short, M; Ammerpohl, O; Asbrand, C; Nickel, J; Renkawitz, R			Cis-elements required for the demethylation of the mouse M-lysozyme downstream enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; GENE-EXPRESSION; CHICKEN EMBRYOS; BINDING SITE; PROMOTER; CELLS; TRANSCRIPTION; INVOLVEMENT; SEQUENCE; PROTEINS	The mouse lysozyme downstream enhancer was previously colocalized with the DNase I-hypersensitive site in the chromatin of mature macrophages. This hyper sensitive site was shown to be macrophage differentiation-dependent, Demethylation of CpG sequences within the enhancer is correlated with lysozyme expression in mature macrophages. Binding of the GABP heterotetrameric transcription factor to the enhancer core element (MLDE), only seen in vivo on the demethylated MLDE element in macrophages, is inhibited by DNA methylation, Here, we analyzed the DNA sequences required for demethylation. In electrophoretic mobility shift experiments we found that in addition to the complete methylated MLDE the hemimethylated form of the lower strand inhibits GABP binding as well, Therefore, GABP is unlikely to be the mediator of demethylation. In addition, we show by stable DNA transfections of methylated mouse lysozyme enhancer sequences that MLDE flanking sequences are required for demethylation, We narrowed down these DNA elements to two short regions of 163 and 79 base pairs on either side of the MLDE, each of which is sufficient to mediate demethylation of the GABP site.	UNIV GIESSEN KLINIKUM,GENET INST,D-35392 GIESSEN,GERMANY	University Hospital of Giessen & Marburg			Ammerpohl, Ole/G-2691-2010					Ausubel FM., 1988, CURRENT PROTOCOLS MO; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Benvenuto G, 1996, MOL CELL BIOL, V16, P2736; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; CROSS M, 1990, EMBO J, V9, P1283, DOI 10.1002/j.1460-2075.1990.tb08237.x; DELALUNA S, 1988, GENE, V62, P121; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; FELGNER J, 1992, LEUKEMIA, V6, P420; FERGUSON AT, 1995, CANCER RES, V55, P2279; GASTON K, 1995, GENE, V157, P257, DOI 10.1016/0378-1119(95)00120-U; Iannello RC, 1997, MOL CELL BIOL, V17, P612, DOI 10.1128/MCB.17.2.612; JOST JP, 1991, NUCLEIC ACIDS RES, V19, P5771, DOI 10.1093/nar/19.20.5771; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; KLAGES S, 1992, NUCLEIC ACIDS RES, V20, P1925, DOI 10.1093/nar/20.8.1925; Koetsier PA, 1996, TRANSGENIC RES, V5, P235, DOI 10.1007/BF01972877; LEENEN PJM, 1986, DIFFERENTIATION, V32, P157, DOI 10.1111/j.1432-0436.1986.tb00568.x; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; Lubbert M, 1996, BLOOD, V87, P447, DOI 10.1182/blood.V87.2.447.bloodjournal872447; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MOLLERS B, 1992, NUCLEIC ACIDS RES, V20, P1917, DOI 10.1093/nar/20.8.1917; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nickel J, 1995, NUCLEIC ACIDS RES, V23, P4785, DOI 10.1093/nar/23.23.4785; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PHILIPSEN JNJ, 1985, BIOCHIM BIOPHYS ACTA, V826, P186, DOI 10.1016/0167-4781(85)90005-3; ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150; SALUZ HP, 1988, P NATL ACAD SCI USA, V85, P6697, DOI 10.1073/pnas.85.18.6697; SHIMADA T, 1987, MOL CELL BIOL, V7, P2830, DOI 10.1128/MCB.7.8.2830; Short ML, 1996, CELL GROWTH DIFFER, V7, P1545; SZYF M, 1995, J BIOL CHEM, V270, P12690, DOI 10.1074/jbc.270.21.12690; Takei S, 1996, BIOCHEM BIOPH RES CO, V220, P606, DOI 10.1006/bbrc.1996.0450; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355	37	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20850	20856		10.1074/jbc.272.33.20850	http://dx.doi.org/10.1074/jbc.272.33.20850			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252411	hybrid			2022-12-27	WOS:A1997XR22100081
J	Murakami, M; Kuwata, H; Amakasu, Y; Shimbara, S; Nakatani, Y; Atsumi, G; Kudo, I				Murakami, M; Kuwata, H; Amakasu, Y; Shimbara, S; Nakatani, Y; Atsumi, G; Kudo, I			Prostaglandin E-2 amplifies cytosolic phospholipase A(2)- and cyclooxygenase-2-dependent delayed prostaglandin E-2 generation in mouse osteoblastic cells - Enhancement by secretory phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A(2); MAST-CELLS; ENDOPEROXIDE SYNTHASE-1; GENE DISRUPTION; D-2 GENERATION; EXPRESSION; ACID; RELEASE; FIBROBLASTS; ACTIVATION	We used the MC3T3-E1 cell line, which originates from C57BL/6J mouse that is genetically type IIA secretory phospholipase A(2) (sPLA(2))-deficient, to reveal the type IIA sPLA(2)-independent route of the prostanglandin (PG) biosynthetic pathway, Kinetic and pharmacological studies showed that delayed PGE(2) generation by this cell line in response to interleukin (IL)-1 beta and tumor necrosis factor alpha (TNF alpha) was dependent upon cytosolic phospholipase A(2) (cPLA(2)) and cyclooxygenase (COX)-2. Expression of these two enzymes was reduced by cPLA(2) or COX-2 inhibitors and restored by adding exogenous arachidonic acid or PGE(2), indicating that PGE(2) produced by these cells acted as an autocrine amplifier of delayed PGE(2) generation through enhanced cPLA(2) and COX-2 expression, Exogenous addition or enforced expression of type IIA sPLA(2) significantly increased IL-1 beta/TNF alpha-initiated PGE(2) generation, which was accompanied by increased expression of both cPLA(2) and COX-2 and suppressed by inhibitors of these enzymes. Thus, our results revealed a particular cross-talk between the two PLA(2) enzymes and COX-2 for delayed PGE(2) biosynthesis by a type IIA sPLA(2)-deficient cell line, cPLA(2) is responsible for initiating COX-2-dependent delayed PGE(2) generation, and sPLA(2), if introduced, enhances PGE(2) generation by increasing cPLA(2) and COX-2 expression via endogenous PGE(2).	SHOWA UNIV,SCH PHARMACEUT SCI,DEPT HLTH CHEM,SHINAGAWA KU,TOKYO 142,JAPAN	Showa University			Kuwata, Hiro/N-2023-2019	Kuwata, Hiro/0000-0002-5023-1777				Ashraf MDM, 1996, BIOCHEM BIOPH RES CO, V229, P726, DOI 10.1006/bbrc.1996.1872; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; Chapdelaine Joan M., 1995, Arthritis and Rheumatism, V38, pS293; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MEDAE EA, 1993, J BIOL CHEM, V268, P6610; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MURAKAMI M, 1995, J LIPID MEDIAT CELL, V12, P119, DOI 10.1016/0929-7855(95)00013-G; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; MURAKAMI M, 1990, FEBS LETT, V268, P113, DOI 10.1016/0014-5793(90)80986-S; OKA S, 1991, J BIOL CHEM, V266, P9956; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; PrigentTessier A, 1996, EUR J BIOCHEM, V241, P872, DOI 10.1111/j.1432-1033.1996.00872.x; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TAKAHASHI Y, 1994, BBA-LIPID LIPID MET, V1212, P217, DOI 10.1016/0005-2760(94)90256-9; TANAKA K, 1993, INFLAMMATION, V17, P107, DOI 10.1007/BF00916098; TOHKIN M, 1993, J BIOL CHEM, V268, P268; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009	43	113	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19891	19897		10.1074/jbc.272.32.19891	http://dx.doi.org/10.1074/jbc.272.32.19891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242654	hybrid			2022-12-27	WOS:A1997XQ05900041
J	Beziat, F; Touraille, S; Debise, R; Morel, F; Petit, N; Lecher, P; Alziari, S				Beziat, F; Touraille, S; Debise, R; Morel, F; Petit, N; Lecher, P; Alziari, S			Biochemical and molecular consequences of massive mitochondrial gene loss in different tissues of a mutant strain of Drosophila subobscura	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KEARNS-SAYRE SYNDROME; MULTIPLE DELETIONS; DNA; HETEROPLASMY; DISEASE; GENOME; PODOSPORA; PROTEIN; REGION; CELLS	In the studied mutant strain of Drosophila subobscura, 78% of the mitochondrial genomes lost > 30% of the coding region by deletion, The mutations was genetically stable, Despite this massive loss of mitochondrial genes, the mutant did not seem to be affected, Distribution of the two genome types, cell levels of mitochondrial DNA, steady-state concentrations of the mitochondrial gene transcripts, mitochondrial enzymatic activities, and ATP synthesis capacities were measured in the head, thorax, and abdomen fractions of the mutant strain in comparison with a wild type strain, Results indicate that the deleted genomes are detected in all fractions but to a lesser extent in the male and female abdomen, In all fractions, there is a 50% increase in cellular mitochondrial DNA content, Although there is a decrease in steady-state concentrations of mitochondrial transcripts of genes affected by deletion, this is smaller than expected, The variations in mitochondrial biochemical activities in the different fractions of the wild strain are upheld in the mutant strain, Activity of complex I (involved in mutation) nevertheless shows a decrease in all fractions; activity of complex III (likewise involved) shows little or no change; finally, mitochondrial ATP synthesis capacity is identical to that observed in the wild strain, This latter finding possibly accounts for the lack of phenotype, This mutant is a good model for studying mitochondrial genome alterations and the role of the nuclear genome in these phenomena.	UNIV CLERMONT FERRAND,UMR CNRS 6547,EQUIPE GENOME MITOCHONDRIAL,F-63177 AUBIERE,FRANCE									ALZIARI S, 1981, BIOCHEM BIOPH RES CO, V99, P1, DOI 10.1016/0006-291X(81)91704-6; ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; BEZIAT F, 1993, NUCLEIC ACIDS RES, V21, P387, DOI 10.1093/nar/21.3.387; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN X, 1995, AM J HUM GENET, V57, P239; DEBISE R, 1993, BIOCHEM BIOPH RES CO, V196, P355, DOI 10.1006/bbrc.1993.2256; DELUCA M, 1976, ADV ENZYMOL RAMB, V44, P37; DEQUARDCHABLAT M, 1994, J BIOL CHEM, V269, P14951; DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008; Errede B, 1978, Methods Enzymol, V53, P40; GARDNER RS, 1974, ANAL BIOCHEM, V59, P272, DOI 10.1016/0003-2697(74)90033-5; Hatefi Y, 1978, Methods Enzymol, V53, P11; Hatefi Y, 1978, Methods Enzymol, V53, P35; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HOHORST HJ, 1971, METHOD ENZYMAT AN, P215; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1990, AM J HUM GENET, V46, P428; Kaukonen JA, 1996, AM J HUM GENET, V58, P763; LECHER P, 1994, BIOL CELL, V80, P25, DOI 10.1016/0248-4900(94)90013-2; Lecher P, 1996, EUR J CELL BIOL, V71, P423; LESTIENNE P, 1988, LANCET, V1, P885; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; Moraes CT, 1995, PROG CELL R, V5, P209; PONZETTO C, 1990, J NEUROL SCI, V96, P207, DOI 10.1016/0022-510X(90)90133-8; Sacktor B, 1974, PHYSIOL INSECT, V4, P271; Shepherd D., 1969, METHODS ENZYMOL, V13, P11, DOI [10.1016/0076-6879(69)13006-2, DOI 10.1016/0076-6879(69)13006-2]; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; VOLZLINGENHOHL A, 1992, P NATL ACAD SCI USA, V89, P11528, DOI 10.1073/pnas.89.23.11528; WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WIBOM R, 1991, J BIOLUM CHEMILUM, V6, P123, DOI 10.1002/bio.1170060210; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	33	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22583	22590		10.1074/jbc.272.36.22583	http://dx.doi.org/10.1074/jbc.272.36.22583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278413	hybrid			2022-12-27	WOS:A1997XV49200033
J	Kuo, CL; Vaz, ADN; Coon, MJ				Kuo, CL; Vaz, ADN; Coon, MJ			Metabolic activation of trans-4-hydroxy-2-nonenal, a toxic product of membrane lipid peroxidation and inhibitor of P450 cytochromes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; ASCITES TUMOR-CELLS; OXYGEN ACTIVATION; OLEFIN FORMATION; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; DEHYDROGENASE; DEFORMYLATION; INACTIVATION; PURIFICATION; HISTIDINE	Lipid peroxidation in biological membranes is known to yield reactive aldehydes, of which trans-4-hydroxy-2-nonenal (HNE) is particularly cytotoxic. This laboratory previously reported that purified liver microsomal P450 cytochromes are directly inactivated to varying extents by HNE. We have now found a mechanism-based reaction in which P450s are inactivated by HNE in the presence of molecular oxygen, NADPH, and NADPH-cytochrome P450 reductase. The sensitivity of the various isozymes in the two pathways is different as follows: P450 2B4 and the orthologous 2B1 are inactivated to the greatest extent and 2C3, 1A2, 2E1, and 1A1 to a somewhat lesser extent by the pathway in which HNE undergoes metabolic activation, In contrast, 2B4 and 2B1 are insensitive to direct inactivation, and the reductase is unaffected by HNE by either route, Recent studies on the catalytic activities of the T302A mutant of P450 2B4 have shown that the rate of oxidation of a variety of xenobiotic aldehydes to carboxylic acids is decreased, but the rates of aldehyde deformylation and mechanism-based inactivation of the cytochrome are stimulated over those of the wild-type enzyme (Raner, G. M., Vaz, A. D. N., and Coon, M. J. (1997) Biochemistry 36, 4895-4902). Inactivation by those aldehydes apparently occurs by homolytic cleavage of a peroxyhemiacetal intermediate to yield formate and an alkyl radical that reacts with the heme. In sharp contrast, the rate of mechanism-based inactivation by HNE is decreased with the T302A. mutant relative to that of the wild-type P450 2B4, and mass spectral analysis of the heme adduct formed shows that deformylation does not occur. We therefore propose that the metabolic activation of HNE involves formation of an acyl carbon radical that leads to the carboxylic acid or alternatively reacts with the heme.	UNIV MICHIGAN,DEPT BIOL CHEM,SCH MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006221] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-06221] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BESTERVELT LL, 1995, P NATL ACAD SCI USA, V92, P3764, DOI 10.1073/pnas.92.9.3764; COLE PA, 1990, J MED CHEM, V33, P2933, DOI 10.1021/jm00173a001; Coon M J, 1978, Methods Enzymol, V52, P109; COON MJ, 1991, OXIDATIVE DAMAGE & REPAIR, P726; DING X, 1988, BIOCHEMISTRY-US, V27, P8330, DOI 10.1021/bi00422a007; DING XX, 1991, ARCH BIOCHEM BIOPHYS, V291, P270, DOI 10.1016/0003-9861(91)90134-5; ESTERBAUER H, 1989, FREE RADICAL BIO MED, V7, P197, DOI 10.1016/0891-5849(89)90015-4; ESTERBAUER H, 1985, BIOCHEM J, V228, P363, DOI 10.1042/bj2280363; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GROVES JT, 1986, ANN NY ACAD SCI, V471, P99, DOI 10.1111/j.1749-6632.1986.tb48029.x; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; GUO Z, 1994, ARCH BIOCHEM BIOPHYS, V312, P59; HARTLEY DP, 1995, ARCH BIOCHEM BIOPHYS, V316, P197, DOI 10.1006/abbi.1995.1028; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HOCHSTEIN P, 1963, BIOCHEM BIOPH RES CO, V12, P388, DOI 10.1016/0006-291X(63)90111-6; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; KOOP DR, 1985, P NATL ACAD SCI USA, V82, P4065, DOI 10.1073/pnas.82.12.4065; Mariano P, 1993, ADV ELECT T, V3, P191; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MORGAN ET, 1983, BIOCHEM BIOPH RES CO, V112, P8, DOI 10.1016/0006-291X(83)91789-8; NADKARNI DV, 1995, CHEM RES TOXICOL, V8, P284, DOI 10.1021/tx00044a014; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OSAWA Y, 1990, J BIOL CHEM, V265, P10340; OSAWA Y, 1994, J BIOL CHEM, V269, P15481; PENG HM, 1993, J BIOL CHEM, V268, P17253; RANER GM, 1997, BIOCHEMISTRY-US, V34, P4905; ROBERTS ES, 1991, P NATL ACAD SCI USA, V88, P8963, DOI 10.1073/pnas.88.20.8963; SCHAUENSTEIN E, 1971, MONATSH CHEM, V102, P517, DOI 10.1007/BF00909348; Schauenstein E., 1979, CIBA F S, V67, P225; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; ULLRICH V, 1968, 19 C GES BIOL CHEM B, P229; VAZ ADN, 1994, BIOCHEMISTRY-US, V33, P13651, DOI 10.1021/bi00250a015; VAZ ADN, 1990, P NATL ACAD SCI USA, V87, P5499, DOI 10.1073/pnas.87.14.5499; VAZ ADN, 1994, BIOCHEMISTRY-US, V33, P6442, DOI 10.1021/bi00187a008; VAZ ADN, 1991, J AM CHEM SOC, V113, P5886, DOI 10.1021/ja00015a066; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; WINKLER P, 1984, BIOCHIM BIOPHYS ACTA, V796, P232, DOI 10.1016/0005-2760(84)90122-X; WINKLER P, 1984, BIOCHIM BIOPHYS ACTA, V796, P226, DOI 10.1016/0005-2760(84)90121-8	41	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22611	22616		10.1074/jbc.272.36.22611	http://dx.doi.org/10.1074/jbc.272.36.22611			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278417	hybrid			2022-12-27	WOS:A1997XV49200037
J	Kuramochi, S; Moriguchi, T; Kuida, K; Endo, J; Semba, K; Nishida, E; Karasuyama, H				Kuramochi, S; Moriguchi, T; Kuida, K; Endo, J; Semba, K; Nishida, E; Karasuyama, H			LOK is a novel mouse STE20-like protein kinase that is expressed predominantly in lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; CELL DEVELOPMENT; ADAPTER PROTEIN; LIGHT-CHAIN; MITOGEN; PATHWAY; CLONING; BINDING; STRESS; FAMILY	We have identified a new gene, designated lok (lymphocyte-oriented kinase), that encodes a 966-amino acid protein kinase whose catalytic domain at the N terminus shows homology to that of the STE20 family members involved in mitogen-activated protein (MAP) kinase cascades, The non-catalytic domain of LOK does not have any similarity to that of other known members of the family, There is a proline-rich motif with Src homology region 3 binding potential, followed by a long coiled-coil structure at the C terminus. LOK is expressed as a 130-kDa protein, which was detected predominantly in lymphoid organs such as spleen, thymus, and bone marrow, in contrast to other mammalian members of the STE20 family, LOK phosphorylated itself as well as substrates such as myelin basic protein and histone IIA on serine and threonine residues but not on tyrosine residues, establishing LOK as a novel serine/threonine kinase, When coexpressed in COS7 cells with the known MAP kinase isoforms (ERK, JNK, and p38), LOK activated none of them in contrast to PAK-and GCK-related kinases, These results suggest that LOK could be involved in a novel signaling pathway in lymphocytes, which is distinct from the known MAP kinase cascades.	TOKYO METROPOLITAN INST MED SCI, DEPT IMMUNOL, BUNKYO KU, TOKYO 113, JAPAN; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYO KU, KYOTO 60601, JAPAN; UNIV TOKYO, INST MED SCI, DEPT CELLULAR & MOL BIOL, MINATO KU, TOKYO 108, JAPAN	Tokyo Metropolitan Institute of Medical Science; Kyoto University; University of Tokyo			Moriguchi, Tetsuo/D-7061-2012; Karasuyama, Hajime/A-7966-2011	Moriguchi, Tetsuo/0000-0002-9598-4991; Karasuyama, Hajime/0000-0003-0689-0836				BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Borst J, 1996, CURR OPIN IMMUNOL, V8, P181, DOI 10.1016/S0952-7915(96)80056-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Earle WR, 1943, J NATL CANCER I, V4, P165; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDY RR, 1986, P NATL ACAD SCI USA, V83, P1438, DOI 10.1073/pnas.83.5.1438; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Karasuyama H, 1996, ADV IMMUNOL, V63, P1, DOI 10.1016/S0065-2776(08)60853-6; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAW CL, 1994, CURR OPIN IMMUNOL, V6, P238, DOI 10.1016/0952-7915(94)90097-3; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE SC, 1993, J BIOL CHEM, V268, P12164; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; Owen MJ, 1996, CURR OPIN IMMUNOL, V8, P191, DOI 10.1016/S0952-7915(96)80057-4; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Schaar DG, 1996, BRAIN RES, V721, P217, DOI 10.1016/0006-8993(96)00176-X; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SHEVACH EM, 1972, J IMMUNOL, V108, P1146; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; WARNER NL, 1979, IMMUNOL REV, V48, P197, DOI 10.1111/j.1600-065X.1979.tb00304.x; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZLOTNIK A, 1995, CURR OPIN IMMUNOL, V7, P206, DOI 10.1016/0952-7915(95)80005-0	48	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22679	22684		10.1074/jbc.272.36.22679	http://dx.doi.org/10.1074/jbc.272.36.22679			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278426	hybrid			2022-12-27	WOS:A1997XV49200046
J	Wang, WF; Zhou, GS; Hu, MCT; Yao, ZB; Tan, TH				Wang, WF; Zhou, GS; Hu, MCT; Yao, ZB; Tan, TH			Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor beta (TGF-beta)-activated kinase (TAK1), a kinase mediator of TGF beta signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; GAMMA-RADIATION; CARCINOMA-CELLS; RETINOIC-ACID; APOPTOSIS; CASCADE; DOMAIN; AP-1; PHOSPHORYLATES; IDENTIFICATION	Transforming growth factor beta (TGF-beta)-activated kinase (TAK1) is known for its involvement in TGF-beta signaling and its ability to activate the p38-mitogen-activated protein kinase (MAPK) pathway, This report shows that TAK1 is also a strong activator of c-Jun N-terminal kinase (JNK). Both the wild-type and a constitutively active mutant of TAK1 stimulated JNK in transient transfection assays, Mitogen-activated protein kinase kinase 4 (MKK4)/stress-activated protein kinase/extracellular signal-regulated kinase (SEK1), a dual-specificity kinase that phosphorylates and activates JNK, synergized with TAK1 in activating JNK. Conversely, a dominant-negative (MKK4/SEK1 mutant inhibited TAK1-induced JNK activation. A kinase-defective mutant of TAK1 effectively suppressed hematopoietic progenitor kinase-1 (HPK1)-induced JNK activity but had little effect on germinal center kinase activation of JNK. There are two additional MAPK kinase kinases, MEKK1 and mixed lineage kinase 3 (MLK3), that are also downstream of HPK1 and upstream of MKK4/SEK mutant, However, because the dominant-negative mutants of MEKK1 and MLK3 did not inhibit TAK1-induced JNK activity, we conclude that activation of JNK1 by TAK1 is independent of MEKK1 and MLK3. In addition to TAK1, TGF-beta also stimulated JNK activity, Taken together, these results identify TAK1 as a regulator in the HPK1 --> TAK1 --> MKK4/SEK1 --> JNK kinase cascade and indicate the involvement of JNK in the TGF-beta signaling pathway, Our results also suggest the potential roles of TAK1 not only in the TGF-beta pathway but also in the other HPK1/JNK1-mediated pathways.	AMGEN INC,DEPT EXPT HEMATOL,THOUSAND OAKS,CA 91320; AMGEN INC,DEPT BIOL,BOULDER,CO 80301	Amgen; Amgen	Wang, WF (corresponding author), BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,M929,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170	NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NIGMS NIH HHS [R01-GM49875] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Glozak MA, 1996, DEV BIOL, V179, P458, DOI 10.1006/dbio.1996.0275; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hirai S, 1996, ONCOGENE, V12, P641; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798	29	165	179	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22771	22775		10.1074/jbc.272.36.22771	http://dx.doi.org/10.1074/jbc.272.36.22771			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278437	hybrid			2022-12-27	WOS:A1997XV49200058
J	Hesterkamp, T; Deuerling, E; Bukau, B				Hesterkamp, T; Deuerling, E; Bukau, B			The amino-terminal 118 amino acids of Escherichia coli trigger factor constitute a domain that is necessary and sufficient for binding to ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL ISOMERASE; MEMBRANE; PROTEIN; RECOGNITION; FOLDS; OMPA	Escherichia coli trigger factor has prolyl-isomerase and chaperone activities and associates with nascent polypeptide chains. Trigger factor has a binding site on ribosomes, which is a prerequisite for its efficient association with nascent chains and its proposed function as a cotranslational folding catalyst. We set out to identify the domain of trigger factor that mediates ribosome binding. Of a series of recombinant fragments, the amino-terminal fragments, TF (1-144) and TF (1-247), cofractionated with ribosomes from cell extracts and rebound to isolated ribosomes in vitro. They competed efficiently with full-length trigger factor for stoichio metric binding to a single site on the large ribosomal subunit. However, TF (1-144) and TF (1-247) differed from full-length trigger factor in that their association with ribosomes was not strengthened by the presence of nascent chains, indicating a role for carboxyl-terminal trigger factor segment in sensing the translational status, The domain responsible for ribosome binding was further investigated by limited proteolysis of recombinant fragments. A stable domain comprising the aminoterminal 118 residues was identified that was still capable of ribosome binding and thus represents a novel structural and functional element of trigger factor.	UNIV HEIDELBERG,ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg				Bukau, Bernd/0000-0003-0521-7199				CALLEBAUT I, 1995, FEBS LETT, V374, P211, DOI 10.1016/0014-5793(95)01109-R; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; GUTHRIE B, 1990, J BACTERIOL, V172, P5555, DOI 10.1128/jb.172.10.5555-5562.1990; Hesterkamp T, 1996, FEBS LETT, V385, P67, DOI 10.1016/0014-5793(96)00351-1; Hesterkamp T, 1996, FEBS LETT, V389, P32, DOI 10.1016/0014-5793(96)00582-0; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; LANZER M, 1988, THESIS U HEIDELBERG; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; Stoller G, 1996, FEBS LETT, V384, P117, DOI 10.1016/0014-5793(96)00282-7; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x	17	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21865	21871		10.1074/jbc.272.35.21865	http://dx.doi.org/10.1074/jbc.272.35.21865			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268318	Green Published, hybrid			2022-12-27	WOS:A1997XT85000030
J	GarzonRodriguez, W; SepulvedaBecerra, M; Milton, S; Glabe, CG				GarzonRodriguez, W; SepulvedaBecerra, M; Milton, S; Glabe, CG			Soluble amyloid A beta-(1-40) exists as a stable dimer at low concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; TIME-RESOLVED FLUORESCENCE; ALZHEIMERS-DISEASE; BETA-PEPTIDES; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; APOLIPOPROTEIN-E; PROTEIN; AGGREGATION; DEPOSITION	Recent studies have implicated the amyloid A beta peptide and its ability to self-assemble as key factors in the pathogenesis of Alzheimer's disease, Relatively little is known about the structure of soluble A beta or its oligomeric state, and the existing data are often contradictory, In this study, we used intrinsic fluorescence of wild type A beta-(1-40), fluorescence resonance energy transfer (FRET), and gel filtration chromatography to examine the structure of A beta-(1-40) in solution, We synthesized a series of mono-substituted fluorescent A beta-(1-40) derivatives to use as donors and accepters in FRET experiments, We selected fluorescent peptides that exhibit aggregation properties comparable to wild type A beta for analysis in donor-acceptor pairs; two labeled with 5-(2-((iodoacetyl)amino)ethyl)aminonaphthylene-1-sulfonic acid at Cys-25 or Cys-34 and fluorescein maleimide at Cys-4 or Cys-7, Another peptide containing a Trp substitution at position 10 was used as an acceptor for the intrinsic Tyr fluorescence of wild type A beta-(1-40). Equilibrium studies of the denaturation of A beta-(1-40) by increasing concentrations of dimethyl sulfoxide (Me2SO) were conducted by monitoring fluorescence, with a midpoint value for the unfolding transition of both the substituted and wild type peptides at among 40 and 50% Me2SO. A beta-(1-40) is well solvated and largely monomeric in Me2SO as evidenced by a lack of FRET, When donor and acceptor AP derivatives are mixed together in Me2SO and then diluted 10-fold into aqueous Tris-HCl buffer at pH 7.4, efficient FRET is observed immediately for all pairs of fluorescent peptides, indicating that donor-acceptor dimers exist in solution, FRET is abolished by the addition of an excess of unlabeled A beta-(1-40), demonstrating that the fluorescent peptides interact with wild type A beta-(1-40) to form heterodimers that do not exhibit FRET, The A beta-(1-40) dimers appear to be very stable, because no subunit exchange is observed after 24 h between fluorescent homodimers. Gel filtration confirms that nanomolar concentrations of C-14-labeled A beta-(1-40) and fluorescein-labeled A beta-(1-40) elute at the same dimeric position as wild type A beta-(1-40), suggesting that soluble A beta-(1-40) is also dimeric at more physiologically plausible concentrations.	UNIV CALIF IRVINE, DEPT MOL BIOL & BIOCHEM, IRVINE, CA 92696 USA; UNIV CALIF IRVINE, DEPT PSYCHOBIOL, IRVINE, CA 92696 USA; NATL AUTONOMOUS UNIV MEXICO, FAC QUIM, MEXICO CITY 04510, DF, MEXICO	University of California System; University of California Irvine; University of California System; University of California Irvine; Universidad Nacional Autonoma de Mexico					NINDS NIH HHS [NS31230] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; FRIEDEN C, 1985, ANNU REV BIOPHYS BIO, V14, P189, DOI 10.1146/annurev.bb.14.060185.001201; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HO GJ, 1994, FEBS LETT, V349, P151, DOI 10.1016/0014-5793(94)00663-6; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MAJOCHA RE, 1992, J NUCL MED, V33, P2184; MASTERS CL, 1987, CIBA F SYMP, V126, P49; MELY Y, 1994, BIOCHEMISTRY-US, V33, P12085, DOI 10.1021/bi00206a011; MIYAKAWA T, 1989, ANN MED, V21, P99, DOI 10.3109/07853898909149193; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SepulvedaBecerra MA, 1996, BIOCHEMISTRY-US, V35, P15915, DOI 10.1021/bi961548e; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SNOW AD, 1988, AM J PATHOL, V133, P456; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; STEVENS FJ, 1995, BIOCHEMISTRY-US, V34, P10697, DOI 10.1021/bi00034a001; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; TAYLOR DL, 1981, J CELL BIOL, V89, P362, DOI 10.1083/jcb.89.2.362; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WANG YL, 1981, CELL, V27, P429, DOI 10.1016/0092-8674(81)90384-6; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; WU PG, 1994, BIOCHEMISTRY-US, V33, P7415, DOI 10.1021/bi00189a048; ZAGORSKI MG, 1992, BIOCHEMISTRY-US, V31, P5621, DOI 10.1021/bi00139a028	42	183	190	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21037	21044		10.1074/jbc.272.34.21037	http://dx.doi.org/10.1074/jbc.272.34.21037			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261105	hybrid			2022-12-27	WOS:A1997XR78900015
J	Tiganis, T; Flint, AJ; Adam, SA; Tonks, NK				Tiganis, T; Flint, AJ; Adam, SA; Tonks, NK			Association of the T-cell protein tyrosine phosphatase with nuclear import factor p97	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; SEQUENCE; LOCALIZATION; PURIFICATION; NUCLEOPORINS; EXPRESSION; RAN/TC4	Alternative splicing of the T-cell protein tyrosine phosphatase (TCPTP) transcript, generates two forms of the enzyme that differ at their extreme C termini: a 48-kDa endoplasmic reticulum-associated form and a 45-kDa nuclear form, By affinity chromatography, using GST-TCPTP fusion proteins, we have isolated three cytoplasmic proteins of 120, 116, and 97 kDa that interact with TCPTP, The p120 protein associated with residues 377-415 from the C terminus of the 48-kDa form of TCPTP, whereas the recognition site for p97 and p116 was mapped to residues 350-381 encompassing the TCPTP nuclear localization sequence (NLS). The TCPTP NLS was shown to be bipartite, requiring basic residues 350-358 (basic cluster I) and 377-381 (basic cluster II), the sites of interaction with p97 and p116, for efficient nuclear translocation, The interaction between p97, p116, and the TCPTP NLS appeared unique in that these proteins did not form a stable interaction with the classical NLS of SV40 large T antigen or the standard bipartite NLS of nucleoplasmin. Sequence analysis of p97 identified it as the nuclear import factor p97 (importin-beta), which is an essential component of the nuclear import machinery, In assays in vitro in permeabilized cells, p97 was necessary but not sufficient for optimal nuclear import of TCPTP, We found that TCPTP co-immunoprecipitated with the nuclear import factor p97 from cell lysates and that purified recombinant p97 and TCPTP interacted directly in vitro, These results indicate selectivity in the binding of p97 and p116 to the TCPTP NLS and suggest that p97 may mediate events that are distinct from the classical nuclear import process, Moreover, these results demonstrate that the C-terminal segment of TCPTP contains docking sites for interaction with proteins that may function to target the enzyme to defined intracellular locations and in the process regulate TCPTP function.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; NORTHWESTERN UNIV, SCH MED, CHICAGO, IL 60611 USA	Cold Spring Harbor Laboratory; Northwestern University			Tiganis, Tony/AAV-3495-2020	Tiganis, Tony/0000-0002-8065-9942; Adam, Stephen/0000-0003-3444-7655	NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P1203; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; CHI NC, 1997, IN PRESS MOL BIOL CE; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	31	99	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21548	21557		10.1074/jbc.272.34.21548	http://dx.doi.org/10.1074/jbc.272.34.21548			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261175	hybrid			2022-12-27	WOS:A1997XR78900085
J	Zhao, RB; Seither, R; Brigle, KE; Sharina, IG; Wang, PJ; Goldman, ID				Zhao, RB; Seither, R; Brigle, KE; Sharina, IG; Wang, PJ; Goldman, ID			Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; METHOTREXATE TRANSPORT; TETRAHYDROFOLATE COFACTOR; DIHYDROFOLATE-REDUCTASE; MEDIATED TRANSPORT; BINDING PROTEINS; EXPRESSION; SENSITIVITY; SYSTEM; CDNA	Transport of reduced folates in murine leukemia cells is mediated by the bidirectional reduced folate carrier (RFC1) and independent unidirectional exit pumps, RFC1 has been proposed to be intrinsically equilibrating, generating transmembrane gradients by exchange with inorganic and organic anions. his paper defines the role of high level carrier expression, through transfection with RFC1 cDNA, on concentrative transport of the folate analog, methotrexate (MTX) in murine L1210 leukemia cells, RFC1 was expressed in the MTX(r)A line, which lacks a functional endogenous carrier to obtain the MTX(r)A-R16 clonal derivative, Influx was increased similar to 9-fold in MTX(r)A-R16 cells without a change in K-m. The efflux rate constant was increased by a factor of 5.1 relative to L1210 cells, and this resulted in only a a,l-fold increase in the steady-state level of free intracellular MTX, [MTX](i), when [MTX](e) was 1 mu M. The concentrative advantage for RFC1 (the ratio of [MTX](i) in MTX(r)A-R16 to L1210 cells) increased from 1.8 at 0.1 mu MTX to 3.8 at an [MTX](e) level of 30 mu M. Augmented transport in MTX(r)A-R16 cells was accompanied by a 2-fold increase in accumulation of MTX polyglutamate derivatives and a similar to 50% decrease in the EC50 for 5-formyltetrahydrofolate and folic acid and the MTX IC50 relative to L1210 cells. These alterations paralleled changes in [MTX], and not the much larger change in influx at low [MTX](e) levels, consistent with the critical role that free intracellular folates and drug play in meeting cellular needs for folates and as a determinant of antifolate activity, respectively, The data indicate that RFC1 produces a large and near symmetrical increase in the bidirectional fluxes of MTX resulting in only a small increase in the transmembrane chemical gradient at low extracellular folate levels, Hence, increased expression of RFC1, alone, may not be an efficient adaptive response to folate deprivation, and other factors may come into play to account for the marked increases in concentrative folate transport which occur when cells are subjected to low folate-selective pressure.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,ALBERT EINSTEIN CANC CTR,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Sharina, Iraida/C-9888-2014		NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39807] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; DIXON KH, 1994, J BIOL CHEM, V269, P17; FRY DW, 1982, J BIOL CHEM, V257, P1890; FRY DW, 1983, CANCER RES, V43, P1087; FYFE MJ, 1973, J BIOL CHEM, V248, P5067; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; GOLDMAN ID, 1977, CANCER TREAT REP, V61, P549; GOLDMAN ID, 1986, MEMBRANE TRANSPORT A, P283; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1987, BIOCHEM PHARMACOL, V36, P3007, DOI 10.1016/0006-2952(87)90216-4; HENDERSON GB, 1982, BIOCHEM BIOPH RES CO, V104, P474, DOI 10.1016/0006-291X(82)90661-1; HENDERSON GB, 1982, BIOCHEM INT, V4, P493; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V200, P149, DOI 10.1016/0003-9861(80)90341-0; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; JANSEN G, 1990, J BIOL CHEM, V265, P18272; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; MATHERLY LH, 1991, CANCER RES, V51, P3420; MOSCOW JA, 1995, CANCER RES, V55, P3790; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; Saxena M, 1996, BIOCHEM PHARMACOL, V51, P975, DOI 10.1016/0006-2952(96)00051-2; SCHLEMMER SR, 1992, J BIOL CHEM, V267, P14746; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; SIROTNAK FM, 1986, MEMBRANE TRANSPORT A, P241; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; Spinella MJ, 1996, BIOCHEM PHARMACOL, V52, P703, DOI 10.1016/0006-2952(96)00347-4; WHITE JC, 1981, J BIOL CHEM, V256, P5722; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067	39	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21207	21212		10.1074/jbc.272.34.21207	http://dx.doi.org/10.1074/jbc.272.34.21207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261128	hybrid			2022-12-27	WOS:A1997XR78900038
J	Ikeda, Y; Tanaka, T; Noguchi, T				Ikeda, Y; Tanaka, T; Noguchi, T			Conversion of non-allosteric pyruvate kinase isozyme into an allosteric enzyme by a single amino acid substitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; M-GENE; RAT; PHENYLALANINE; TRANSITION; EXPRESSION; EFFICIENT; RESIDUES	Pyruvate kinase M-1, a non-allosteric isozyme, was converted into an allosteric enzyme by replacement of an amino acid in the intersubunit contact. The substitution of Ala-398 with Arg resulted in the pronounced allosteric enzyme. The Hill coefficient and the substrate concentration giving one-half of V-max for the mutant with respect to phosphoenolpyruvate were 2.7 and 0.41 mM, respectively, whereas those values for the wild type were 1.0 and 0.049 nM. This mutation, however, gave rise to only minor effects on the apparent values of K-m for ADP and on V-max. Furthermore, in contrast to the wildtype enzyme, the mutant was activated by fructose 1,6-bisphosphate. The Hill coefficient of the mutant was no longer increased by the allosteric inhibitor, L-phenylalanine, indicating that the equilibrium for the unligated enzyme is largely shifted toward the T-state. These results suggest that Ala-398 is one of the most critical residues allowing the enzyme to prefer the R-state and that allosteric regulation of pyruvate kinase involves amino acid residues in the intersubunit contact.	FUKUI MED SCH,DEPT BIOCHEM,MATSUOKA,FUKUI 91002,JAPAN; OSAKA UNIV,SCH MED,DEPT NUTR & PHYSIOL CHEM,SUITA,OSAKA 565,JAPAN	University of Fukui; Osaka University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLINS RA, 1995, BIOCHEM J, V310, P117, DOI 10.1042/bj3100117; COLLINS RA, 1992, BIOCHEM SOC T, V21, pS63; CONSLER TG, 1990, BIOCHEMISTRY-US, V29, P10765, DOI 10.1021/bi00500a007; CONSLER TG, 1989, BIOCHEMISTRY-US, V28, P8756, DOI 10.1021/bi00448a012; CONSLER TG, 1992, BIOCHEMISTRY-US, V31, P7870, DOI 10.1021/bi00149a018; CROW VL, 1982, METHOD ENZYMOL, V90, P165, DOI 10.1016/S0076-6879(82)90122-7; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GARDENAS JM, 1982, METHOD ENZYMOL, V90, P140; GARDENAS JM, 1975, ISOZYMES, V1, P523; IBSEN KH, 1977, CANCER RES, V37, P341; IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126; IKEDA Y, 1995, J BIOL CHEM, V270, P12471, DOI 10.1074/jbc.270.21.12471; IKEDA Y, 1995, J BIOL CHEM, V270, P22223, DOI 10.1074/jbc.270.38.22223; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; IMAMURA K, 1986, MARKERS HUMAN NEUROE, P191; KAHN A, 1982, METHOD ENZYMOL, V90, P131; KAYNE FJ, 1972, BIOCHEMISTRY-US, V11, P4415, DOI 10.1021/bi00773a031; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LONBERG N, 1983, P NATL ACAD SCI-BIOL, V80, P3661, DOI 10.1073/pnas.80.12.3661; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MALCOVATI M, 1982, METHOD ENZYMOL, V90, P170; Mattevi A, 1996, FEBS LETT, V389, P15, DOI 10.1016/0014-5793(96)00462-0; MATTEVI A, 1995, STRUCTURE, V3, P729, DOI 10.1016/S0969-2126(01)00207-6; MCNALLY T, 1990, BIOCHEM SOC T, V18, P258, DOI 10.1042/bst0180258; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; MUIRHEAD H, 1990, BIOCHEM SOC T, V18, P193, DOI 10.1042/bst0180193; MURCOTT THL, 1991, EUR J BIOCHEM, V198, P513, DOI 10.1111/j.1432-1033.1991.tb16044.x; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; OBERFELDER RW, 1984, BIOCHEMISTRY-US, V23, P3813, DOI 10.1021/bi00312a004; PIWNICAWORMS H, 1987, CURRENT PROTOCOLS MO; SCHERING B, 1982, BIOCHIM BIOPHYS ACTA, V717, P337, DOI 10.1016/0304-4165(82)90188-X; TAKENAKA M, 1991, EUR J BIOCHEM, V198, P101, DOI 10.1111/j.1432-1033.1991.tb15991.x; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; WALKER D, 1992, J MOL BIOL, V228, P265, DOI 10.1016/0022-2836(92)90505-E	38	64	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20495	20501		10.1074/jbc.272.33.20495	http://dx.doi.org/10.1074/jbc.272.33.20495			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252361	hybrid			2022-12-27	WOS:A1997XR22100031
J	Loetscher, H; Deuschle, U; Brockhaus, M; Reinhardt, D; Nelboeck, P; Mous, J; Grunberg, J; Haass, C; Jacobsen, H				Loetscher, H; Deuschle, U; Brockhaus, M; Reinhardt, D; Nelboeck, P; Mous, J; Grunberg, J; Haass, C; Jacobsen, H			Presenilins are processed by caspase-type proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; GENE; APOPTOSIS	Presenilin 1 (PS1) and presenilin 2 (PS2) are endoproteolytically processed in vivo and in cell transfectants to yield 27-35-kDa N-terminal and 15-24-kDa C-terminal fragments. We have studied the cleavage of PS1 and PS2 in transiently and stably transfected hamster kidney and mouse and human neuroblastoma cells by immunoblot and pulse-chase experiments. C terminal fragments were isolated by affinity chromatography and SDS-polyacrylamide gel electrophoresis and sequenced. The processing sites identified in PS1 and PS2 (Asp(345)/Ser(346) and Asp(329)/Ser(330), respectively) are typical for caspase-type proteases. Specific caspase inhibitors and cleavage site mutations confirmed the involvement of caspase(s) in PS1 and PS2 processing in cell transfectants. Fluorescent peptide substrates carrying the PS-identified cleavage sites were hydrolyzed by proteolytic activity from mouse brain. The PS2-derived peptide substrate was also cleaved by recombinant human caspase-3. Additional processing of PS2 by non-caspase-type proteases was also observed.	F HOFFMANN LA ROCHE & CO LTD,PRPN G,PRECLIN CENT NERVOUS SYST RES GENE TECHNOL,DIV PHARMA,CH-4070 BASEL,SWITZERLAND; CENT INST MENTAL HLTH,DEPT BIOL MOL,D-68159 MANNHEIM,GERMANY	Roche Holding; Central Institute of Mental Health								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; Hartmann H, 1997, J BIOL CHEM, V272, P14505, DOI 10.1074/jbc.272.23.14505; Kim TW, 1997, J BIOL CHEM, V272, P11006; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TANZI RE, 1996, ALZHEIMERS DIS REV, V1, P90; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Ward RV, 1996, NEURODEGENERATION, V5, P293, DOI 10.1006/neur.1996.0040; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977	28	138	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20655	20659		10.1074/jbc.272.33.20655	http://dx.doi.org/10.1074/jbc.272.33.20655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252383	hybrid			2022-12-27	WOS:A1997XR22100053
J	SchmidtRose, T; Jentsch, TJ				SchmidtRose, T; Jentsch, TJ			Reconstitution of functional voltage-gated chloride channels from complementary fragments of CLC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; EXPRESSION; MYOTONIA; MUTATIONS; RESIDUES; ANION; CFTR; RECEPTORS; DOMINANT; PERMEASE	We investigated the effect of truncations on the human muscle chloride channel CLC-1 and studied the functional complementation from partial proteins. Almost complete deletion of the cytoplasmic amino terminus did not affect currents, but truncating the intracellular COOH terminus after Leu(720) abolished function. Currents were restored by coexpressing this membrane-embedded part with the lacking cytoplasmic fragment that contains domain D13, the second of the two conserved cystathionine beta-synthase (CBS) motifs present in all eukaryotic CLC proteins. However, if the cut was after Gln(597) before the first CBS domain, no functional complementation was seen. Complementation was also obtained with channels ''split'' between transmembrane domains D7 and D8 or domains D8 and D9, but not when split between D10 and D11. Specificity of currents was tested by inserting point mutations in NH2-terminal (G188A and G230E) or COOH-terminal (K585E) fragments. In contrast to G188A and K585E, split channels did not tolerate the D136G mutation, suggesting that it may impede association from nonlinked fragments. Duplication, but not a lack of domain D8 was tolerated in ''split'' channels. Membrane domains D9-D12 can insert into the membrane without adding a preceding signal peptide to ensure the extracellular amino terminus of D9, Eventually, we succeeded in reconstituting CLC-1 channels from three separate polypeptides: the amino-terminal part up to D8, D9 through CBS1, and the remainder of the cytoplasmic carboxyl terminus. In summary, several regions of CLC channels behave autonomously regarding membrane insertion and folding and mediate protein-protein interactions strong enough to yield functional channels without a direct covalent link.	UNIV HAMBURG,CTR MOL NEUROBIOL HAMBURG,ZMNH,D-20246 HAMBURG,GERMANY	University of Hamburg				Jentsch, Thomas/0000-0002-3509-2553				AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; FAHLKE C, 1995, NEURON, V15, P463, DOI 10.1016/0896-6273(95)90050-0; GROVES JD, 1995, J BIOL CHEM, V270, P9097, DOI 10.1074/jbc.270.16.9097; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Lloyd SE, 1997, J CLIN INVEST, V99, P967, DOI 10.1172/JCI119262; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; LORENZ C, 1994, HUM MOL GENET, V3, P941, DOI 10.1093/hmg/3.6.941; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Maduke M., 1997, Biophysical Journal, V72, pA5; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; MEYERKLEINE C, 1995, AM J HUM GENET, V57, P1325; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Morales MM, 1996, AM J PHYSIOL-RENAL, V270, pF1038, DOI 10.1152/ajprenal.1996.270.6.F1038; Ponting CP, 1997, J MOL MED-JMM, V75, P160; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; PUSCH M, 1995, NEURON, V15, P1; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; ZEN KH, 1994, BIOCHEMISTRY-US, V33, P8198, DOI 10.1021/bi00193a005	42	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20515	20521		10.1074/jbc.272.33.20515	http://dx.doi.org/10.1074/jbc.272.33.20515			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252364	hybrid			2022-12-27	WOS:A1997XR22100034
J	Brigstock, DR; Steffen, CL; Kim, GY; Vegunta, RK; Diehl, JR; Harding, PA				Brigstock, DR; Steffen, CL; Kim, GY; Vegunta, RK; Diehl, JR; Harding, PA			Purification and characterization of novel heparin-binding growth factors in uterine secretory fluids - Identification as heparin-regulated M-r 10,000 forms of connective tissue growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; IMMEDIATE EARLY GENE; FIBROBLAST GROWTH; CELL-SURFACE; EGF-RECEPTOR; PIG; BLASTOCYST; SULFATE; IMPLANTATION; AMPHIREGULIN	Uterine growth factors are potential effector molecules in embryo growth signaling pathways. Pig uterine luminal flushings contained a heparin-binding growth factor (HBGF) that required 0.8 M NaCl for elution from heparin columns and was termed HBGF-0.8, This factor, which was heat- and acid-labile and of M-r 10,000 as assessed by gel filtration, stimulated DNA synthesis in fibroblasts and smooth muscle cells but not endothelial cells. Two forms of HBGF-0.8, termed HBGF-0.8-P1 and HBGF-0.8-P2, exhibited differential heparin-binding properties. SDS-polyacrylamide gel electrophoresis showed that each form of HBGF-0.8 migrated with an apparent M-r of 10,000 under reducing conditions, Amino acid sequencing revealed the N-terminal sequence EENIKKGKKXIRTPKI for HBGF-0.8-P1 and EENIKKGKKXIRT for HBGF-0.8-P2. These sequences corresponded, respectively, to residues 247-262 and 248-259 of the 349-residue predicted primary translation product of porcine connective tissue growth factor (pCTGF). 10-kDa CTGF-mediated fibroblast DNA synthesis was modulated by exogenous heparin, and CTGF-immunoreactive proteins of 10, 16, and 20 kDa were present in unfractionated uterine luminal flushings. These data reveal the identity of a novel growth factor in uterine fluids as a highly truncated form of CTGF and show that the N-terminal two-thirds of the CTGF primary translation product is not required for mitogenic activity or heparin binding.	OHIO STATE UNIV, DEPT SURG, COLUMBUS, OH 43205 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43205 USA; OHIO STATE UNIV, MOL CELLULAR & DEV BIOL PROGRAM, COLUMBUS, OH 43205 USA; CLEMSON UNIV, DEPT ANIM DAIRY & VET SCI, CLEMSON, SC 29634 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Clemson University	Brigstock, DR (corresponding author), CHILDRENS HOSP, WEXNER INST PEDIAT RES, DEPT SURG, DIV PEDIAT SURG, 700 CHILDRENS DR, COLUMBUS, OH 43205 USA.				NICHD NIH HHS [HD 30334] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD030334] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON LL, 1978, ANAT REC, V190, P143, DOI 10.1002/ar.1091900112; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; Besner GE, 1992, GROWTH FACTORS, V7, P289, DOI 10.3109/08977199209046411; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRAY W, 1994, AM LAB, V26, P38; Brigstock DR, 1996, J ENDOCRINOL, V148, P103, DOI 10.1677/joe.0.1480103; Brigstock DR, 1996, J REPROD FERTIL, V108, P313; BRIGSTOCK DR, 1989, J REPROD FERTIL, V85, P747, DOI 10.1530/jrf.0.0850747; BRIGSTOCK DR, 1994, ASSIST REPROD TECHNO, V6, P252; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1995, J CELL PHYSIOL, V163, P418, DOI 10.1002/jcp.1041630222; CULLINGFORD TE, 1994, PROTOONCOGENES GROWT, P13; DARDIK A, 1992, DEV BIOL, V154, P396, DOI 10.1016/0012-1606(92)90078-U; DAS SK, 1994, DEVELOPMENT, V120, P1071; DIEHL JR, 1994, BIOL REPRODUCTION S1, V50, pA272; GEISERT RD, 1982, BIOL REPROD, V27, P925, DOI 10.1095/biolreprod27.4.925; GROTENDORST GR, 1996, J INVEST DERMATOL, V7, P469; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KIM GY, 1995, BIOL REPROD, V52, P561, DOI 10.1095/biolreprod52.3.561; LETCHER R, 1989, BIOL REPROD, V41, P1143, DOI 10.1095/biolreprod41.6.1143; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MURZIN AG, 1992, CURR OPIN STRUC BIOL, V2, P895; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; Pope WF, 1994, EMBRYONIC MORTALITY, P53; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBERTS RM, 1988, J REPROD FERTIL, V82, P875, DOI 10.1530/jrf.0.0820875; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOYAB M, 1991, METHOD ENZYMOL, V198, P213; SIMMEN FA, 1989, BIOCHEM SOC T, V17, P587, DOI 10.1042/bst0170587; SIMMEN RCM, 1990, ENDOCRINOLOGY, V127, P2166, DOI 10.1210/endo-127-5-2166; STEFFEN CL, 1993, MOL BIOL CELL S, V4, pA108; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Weich HA, 1990, GROWTH FACTORS, V2, P313, DOI 10.3109/08977199009078019; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	46	182	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20275	20282		10.1074/jbc.272.32.20275	http://dx.doi.org/10.1074/jbc.272.32.20275			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242708	hybrid			2022-12-27	WOS:A1997XQ05900095
J	Cao, YH; Chen, A; An, SSA; Ji, RWD; Davidson, D; Cao, YM; Llinas, M				Cao, YH; Chen, A; An, SSA; Ji, RWD; Davidson, D; Cao, YM; Llinas, M			Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWIS-LUNG-CARCINOMA; ANGIOGENESIS INHIBITOR; POTENT INHIBITOR; PURIFICATION; FRAGMENT; THROMBOSPONDIN-1; PROLIFERATION; SUPPRESSION; ANGIOSTATIN; CHEMOKINE	Angiostatin is a potent angiogenesis inhibitor which has been identified as an internal fragment of plasminogen that includes its first four kringle modules. We have recently demonstrated that the anti-endothelial cell proliferative activity of angiostatin is also displayed by the first three kringle structures of plasminogen and marginally so by kringle 4 (Cao, Y., Ji, R.-W., Davidson, D., Schaller, J., Marti, D., Sohndel, S., McCance, S. G., O'Reilly, M. S., Llinas, M., and Folkman, J. (1996) J. Biol. Chem. 271, 29461-29467). We now report that the kringle 5 fragment of human plasminogen is a specific inhibitor for endothelial cell proliferation. Kringle 5 obtained as a proteolytic fragment of human plasminogen displays potent inhibitory effect on bovine capillary endothelial cells with a half-maximal concentration (ED50) of approximately 50 nM. Thus, kringle 5 would appear to be more potent than angiostatin on inhibition of basic fibroblast growth factor-stimulated capillary endothelial cell proliferation. Appropriately folded recombinant mouse kringle 5 protein, expressed in Escherichia coli, exhibits a comparable inhibitory effect as the proteolytic kringle 5 fragment. Thus, kringle 5 domain of human plasminogen is a novel endothelial inhibitor that is sufficiently potent to block the growth factor-stimulated endothelial cell growth.	HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CARNEGIE MELLON UNIV,DEPT CHEM,PITTSBURGH,PA 15213; ABBOTT LABS,DIV PHARMACEUT PROD,AGING & DEGENERAT DIS RES,ABBOTT PK,IL 60064; UNIV BERN,INSELSPITAL,INST PHARMACOL,CH-3010 BERN,SWITZERLAND	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Carnegie Mellon University; Abbott Laboratories; University of Bern; University Hospital of Bern	Cao, YH (corresponding author), KAROLINSKA INST,DEPT CELL & MOL BIOL,LAB ANGIOGENESIS RES,S-17177 STOCKHOLM,SWEDEN.			Davidson, Donald/0000-0002-8669-9814	NATIONAL CANCER INSTITUTE [R01CA064481] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029409] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64481] Funding Source: Medline; NHLBI NIH HHS [HL-29409] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CAO Y, 1990, Technique (Philadelphia), V2, P109; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CHEN C, 1995, CANCER RES, V55, P4230; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; COX M, 1994, CHEM PHYS LIPIDS, V67-8, P43, DOI 10.1016/0009-3084(94)90123-6; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gately S, 1996, CANCER RES, V56, P4887; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; HORI A, 1991, CANCER RES, V51, P6180; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; MENHART N, 1993, BIOCHEMISTRY-US, V32, P8799, DOI 10.1021/bi00085a010; MULICHAK AM, 1991, BIOCHEMISTRY-US, V30, P10576, DOI 10.1021/bi00107a029; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OREILLY MS, 1997, CELL, V88, P1; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; SENGER DR, 1990, CANCER RES, V50, P1774; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; THEWES T, 1987, BIOCHIM BIOPHYS ACTA, V912, P254, DOI 10.1016/0167-4838(87)90096-3; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497	39	256	346	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22924	22928		10.1074/jbc.272.36.22924	http://dx.doi.org/10.1074/jbc.272.36.22924			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278456	hybrid			2022-12-27	WOS:A1997XV49200077
J	Spiess, C; Happersberger, HP; Glocker, MO; Spiess, E; Rippe, K; Ehrmann, M				Spiess, C; Happersberger, HP; Glocker, MO; Spiess, E; Rippe, K; Ehrmann, M			Biochemical characterization and mass spectrometric disulfide bond mapping of periplasmic alpha-amylase MalS of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ASSISTED LASER-DESORPTION; MOLECULAR-STRUCTURE; CLOSTRIDIUM-THERMOSACCHAROLYTICUM; ALKALINE-PHOSPHATASE; NUCLEOTIDE-SEQUENCE; ANGSTROM RESOLUTION; SIGNAL SEQUENCE; OUTER-MEMBRANE; PROTEINS	Periplasmic alpha-amylase of Escherichia coli, the malS gene product, hydrolyzes linear maltodextrins. The purified enzyme exhibited a K-m of 49 mu M and a V-max of 0.36 mu mol of p-nitrophenylhexaoside hydrolyzed per min per mg of protein. Amylase activity was optimal at pH 8 and was dependent on divalent cations such as Ca2+. MalS exhibited altered migration on SDS polyacrylamide gel electrophoresis under nonreducing conditions, Analytical ultracentrifugation and electrospray mass spectrometry indicated that MalS is monomeric, The four cysteine residues are involved in intramolecular disulfide bonds, To map disulfide bonds, MalS was proteolytically digested, The resulting peptides were separated by reverse phase-high performance liquid chromatography, and matrix-assisted laser desorption/ionization mass spectrometry analysis indicated the presence of two disulfide bonds, i.e. Cys(40-58) and Cys(104-520). The disulfide bond at Cys(40-58) is located in an N-terminal extension of about 160 amino acids which has no homology to other amylases but to the proposed peptide binding domain of GroEL, the Hsp60 of E. coli. The N-terminal extension is linked to the C-terminal amylase domain via disulfide bond Cys(104-520). Reduction of disulfide bonds by dithiothreitol treatment led to aggregation suggesting that the N terminus of MalS may represent an internal chaperone domain.	UNIV KONSTANZ, FAK BIOL, D-78457 CONSTANCE, GERMANY; UNIV KONSTANZ, FAK CHEM, D-78457 CONSTANCE, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY	University of Konstanz; University of Konstanz; Helmholtz Association; German Cancer Research Center (DKFZ)			Rippe, Karsten/A-3562-2012; Ehrmann, Michael/A-7307-2012	Rippe, Karsten/0000-0001-9951-9395; Ehrmann, Michael/0000-0002-1927-260X; Spiess, Christoph/0000-0002-0570-9700				ARAKAWA T, 1992, J PROTEIN CHEM, V11, P111, DOI 10.1007/BF01025216; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BOOS W, 1996, CELLULAR MOL BIOL, P1175; BRAYER GD, 1995, PROTEIN SCI, V4, P1730, DOI 10.1002/pro.5560040908; CARR SA, 1990, BIOLOGICAL MASS SPECTROMETRY /, P621; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CREIGHTON T, 1995, PHILOS T ROY SOC B, V348, P5, DOI 10.1098/rstb.1995.0039; CRIMMINS DL, 1995, ANAL BIOCHEM, V226, P355, DOI 10.1006/abio.1995.1236; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; FELLER G, 1992, J BIOL CHEM, V267, P5217; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; FREUNDLIEB S, 1986, J BIOL CHEM, V261, P2946; Gehrig PM, 1996, PEPTIDE RES, V9, P308; GLOCKER MO, 1995, J AM SOC MASS SPECTR, V6, P638, DOI 10.1016/1044-0305(95)00250-H; GLOCKER MO, 1993, BIOCHEMISTRY-US, V32, P482, DOI 10.1021/bi00053a012; Glocker MO, 1996, BIOCHEMISTRY-US, V35, P14625, DOI 10.1021/bi961199o; GLOCKER O, 1994, P NATL ACAD SCI USA, V91, P5868; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAN JC, 1994, ANAL BIOCHEM, V220, P5, DOI 10.1006/abio.1994.1290; Hatada Y, 1996, J BIOL CHEM, V271, P24075, DOI 10.1074/jbc.271.39.24075; ITOH T, 1987, FEBS LETT, V219, P339, DOI 10.1016/0014-5793(87)80248-X; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LARSON SB, 1994, J MOL BIOL, V235, P1560, DOI 10.1006/jmbi.1994.1107; LUCKEY M, 1991, J BIOL CHEM, V266, P1866; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J. H., 1972, EXPT MOL GENETICS, P431; MORRIS HR, 1985, BIOCHEM BIOPH RES CO, V126, P1122, DOI 10.1016/0006-291X(85)90302-X; MORRIS HR, 1988, TRENDS BIOTECHNOL, V6, P140, DOI 10.1016/0167-7799(88)90083-2; NEU HC, 1965, J BIOL CHEM, V240, P3685; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; PATTERSON SD, 1994, ANAL CHEM, V66, P3727, DOI 10.1021/ac00093a030; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; Prinz WA, 1996, EMBO J, V15, P5209, DOI 10.1002/j.1460-2075.1996.tb00906.x; SCHNEIDER E, 1992, J BIOL CHEM, V267, P5148; SCHULTZ SC, 1987, PROTEINS, V2, P290, DOI 10.1002/prot.340020405; SCHWARTZ M, 1967, EUR J BIOCHEM, V2, P132, DOI 10.1111/j.1432-1033.1967.tb00117.x; SCHWARTZ M, 1987, CELLULAR MOL BIOL, P1482; SHIBUYA I, 1992, BIOSCI BIOTECH BIOCH, V56, P174, DOI 10.1271/bbb.56.174; SMITH DL, 1990, METHOD ENZYMOL, V193, P374, DOI 10.1016/0076-6879(90)93428-N; SORENSEN HH, 1990, BIOMED ENVIRON MASS, V19, P713, DOI 10.1002/bms.1200191110; SPECKA U, 1993, ARCH MICROBIOL, V160, P284, DOI 10.1007/BF00292078; SPECKA U, 1991, APPL ENVIRON MICROB, V57, P2317, DOI 10.1128/AEM.57.8.2317-2323.1991; STRASSER AWM, 1989, EUR J BIOCHEM, V184, P699, DOI 10.1111/j.1432-1033.1989.tb15069.x; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; TAPIO S, 1991, J BIOL CHEM, V266, P19450; TOTSUKA A, 1994, EUR J BIOCHEM, V221, P649, DOI 10.1111/j.1432-1033.1994.tb18777.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIESMEYER H, 1960, BIOCHIM BIOPHYS ACTA, V39, P427, DOI 10.1016/0006-3002(60)90195-5; YAZDANPARAST R, 1987, J BIOL CHEM, V262, P2507; ZHOU J, 1993, INT J MASS SPECTROM, V126, P115, DOI 10.1016/0168-1176(93)80076-Q	62	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22125	22133		10.1074/jbc.272.35.22125	http://dx.doi.org/10.1074/jbc.272.35.22125			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268356	Green Submitted, hybrid			2022-12-27	WOS:A1997XT85000068
J	Sun, J; Xu, Q; Chitnis, VP; Jin, P; Chitnis, PR				Sun, J; Xu, Q; Chitnis, VP; Jin, P; Chitnis, PR			Topography of the photosystem I core proteins of the cyanobacterium Synechocystis sp. PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; ENCODING SUBUNIT-II; SP PCC-6803; MUTATIONAL ANALYSIS; TARGETED INACTIVATION; MOLECULAR-CLONING; ELECTRON-TRANSFER; POLYPEPTIDES; ORGANIZATION; FERREDOXIN	PsaA and PsaB are homologous integral membrane proteins that form the heterodimeric core of photosystem I. Domain-specific antibodies were generated to examine the topography of PsaA and PsaB, The purified photosystem I complexes from the wild type strain of Synechocystis sp, PCC 6803 were treated with eight proteases to study the accessibility of cleavage sites in PsaA and PsaB. Proteolytic fragments were identified using the information from N-terminal amino acid sequencing, reactivity to antibodies, apparent mass, and specificity of proteases. The extramembrane loops of PsaA and PsaB differed in their accessibility to proteases, which indicated the folded structure of the loops or their shielding by the small subunits of photosystem I, NaI-treated and mutant photosystem I complexes were used to identify the extramembrane loops that were exposed in the absence of specific small subunits. The absence of PsaD exposed additional proteolytic sites in PsaB, whereas the absence of PsaE exposed sites in PsaA. These studies distinguish PsaA and PsaB in the structural model for photosystem I that has been proposed on the basis of x-ray diffraction studies (KrauB, N,, Schubert, W,-D,, Klukas, O., Fromme, P., Witt, H. T,, and Saenger, W, (1996) Nat. Struct. Biol, 3, 965-973), Using osmotically shocked cells for protease treatments, the N terminus of PsaA was determined to be on the n side of the photosynthetic membranes. Based on these data and available published information, we propose a topological model for PsaA and PsaB.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053104] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53104] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armbrust TS, 1996, PLANT PHYSIOL, V111, P1307, DOI 10.1104/pp.111.4.1307; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BOEKEMA EJ, 1994, J BIOENERG BIOMEMBR, V26, P17, DOI 10.1007/BF00763217; Chitnis PR, 1996, PLANT PHYSIOL, V111, P661, DOI 10.1104/pp.111.3.661; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; CHITNIS PR, 1992, PLANT PHYSIOL, V99, P239, DOI 10.1104/pp.99.1.239; CHITNIS PR, 1995, PHOT LIGHT BIOSPH, P17; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; COHEN Y, 1993, PLANT MOL BIOL, V23, P895, DOI 10.1007/BF00021544; FISH LE, 1985, J BIOL CHEM, V260, P1413; Fromme P, 1996, CURR OPIN STRUC BIOL, V6, P473, DOI 10.1016/S0959-440X(96)80112-6; GOLBECK JH, 1994, MOL BIOL CYANOBACTER, P179; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HENRY RL, 1992, PLANT PHYSIOL BIOCH, V30, P357; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KRUIP J, 1997, J BIOL CHEM, V271, P10761; KUHN M, 1994, TRENDS BIOCHEM SCI, V19, P401, DOI 10.1016/0968-0004(94)90085-X; LELONG C, 1994, J BIOL CHEM, V269, P10034; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V34, P339, DOI 10.1016/0003-9861(51)90012-4; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V33, P65, DOI 10.1016/0003-9861(51)90082-3; OHOKA H, 1988, J BIOCHEM-TOKYO, V103, P962, DOI 10.1093/oxfordjournals.jbchem.a122394; REILLY P, 1988, J BIOL CHEM, V263, P17658; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; SMART LB, 1993, P NATL ACAD SCI USA, V90, P1132, DOI 10.1073/pnas.90.3.1132; SONOIKE K, 1993, BIOCHIM BIOPHYS ACTA, V1141, P52, DOI 10.1016/0005-2728(93)90188-L; STROTMANN H, 1993, BIOCHIM BIOPHYS ACTA, V1143, P204; TAE GS, 1994, BIOCHEMISTRY-US, V33, P10060, DOI 10.1021/bi00199a033; VALLON O, 1993, EUR J BIOCHEM, V214, P907, DOI 10.1111/j.1432-1033.1993.tb17994.x; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P4411, DOI 10.1021/bi00067a034; WYNN RM, 1989, PLANT PHYSIOL, V91, P445, DOI 10.1104/pp.91.1.445; XU Q, 1994, PLANT PHYSIOL, V106, P1057, DOI 10.1104/pp.106.3.1057; XU Q, 1994, PLANT MOL BIOL, V26, P291, DOI 10.1007/BF00039540; XU Q, 1994, J BIOL CHEM, V269, P21512; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; XU Q, 1995, PLANT PHYSIOL, V108, P1067, DOI 10.1104/pp.108.3.1067; XU Q, 1995, PHOTOSYNTHESIS LIGHT, V2, P87; XU QA, 1994, J BIOL CHEM, V269, P3205; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	49	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21793	21802		10.1074/jbc.272.35.21793	http://dx.doi.org/10.1074/jbc.272.35.21793			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268309	hybrid			2022-12-27	WOS:A1997XT85000021
J	Wang, JW; Dong, ZH; Bell, LR				Wang, JW; Dong, ZH; Bell, LR			Sex-lethal interactions with protein and RNA - Roles of glycine-rich and RNA binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SPLICING FACTOR U2AF; CIS-ACTING ELEMENTS; POLYPYRIMIDINE TRACT; DROSOPHILA-MELANOGASTER; PREMESSENGER RNA; SNRNP PROTEIN; HNRNP PROTEIN; MALE EXON; IN-VITRO	Sex-lethal (Sxl) is an RNA-binding protein, containing two conserved RNA binding domains (RBDs) and a glycine-rich region, which functions as a regulator of alternative splicing in Drosophila sex determination, Previous work demonstrated that Sxl monomers interact cooperatively upon binding to target RNAs and that the cooperativity depends on the glycine-rich N terminus, Here we use band shift experiments to show that RNA binding patterns are altered when Sxl is combined with other proteins having similar glycine-rich domains, including mammalian heterogeneous nuclear (hn) RNP L and Drosophila Hrb87F (an hnRNP A/B homolog). Direct involvement of the Sxl glycine-rich region in protein interactions was verified by Far-Western analysis, Two interaction domains, the Sxl N terminus and the Sxl first RNA binding domain, were suggested by the yeast two-hybrid assay, In a systematic examination of the RNA binding properties of Sxl domains, it was found that the Sxl termini as well as the RBDs influence RNA binding specificity, Finally, selection of the Sxl optimal binding site (SELEX) confirms the importance of U-runs in the Sxl binding site and suggests a second type of non-U-run target that may be associated with RNA secondary structure.	UNIV SO CALIF,DEPT BIOL SCI,PROGRAM MOL BIOL,LOS ANGELES,CA 90089	University of Southern California								BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CALVIO C, 1995, RNA, V1, P724; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FLICKINGER TW, 1994, GENE DEV, V8, P914, DOI 10.1101/gad.8.8.914; FU XD, 1995, RNA, V1, P663; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GRANADINO B, 1992, GENETICS, V130, P597; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARPER DS, 1992, NUCLEIC ACIDS RES, V20, P3645, DOI 10.1093/nar/20.14.3645; HAYNES SR, 1990, MOL CELL BIOL, V10, P316, DOI 10.1128/MCB.10.1.316; HAYNES SR, 1991, NUCLEIC ACIDS RES, V19, P25; Hilfiker A, 1995, DEVELOPMENT, V121, P4017; HORABIN JI, 1993, MOL CELL BIOL, V13, P1408, DOI 10.1128/MCB.13.3.1408; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LIU XD, 1995, GENE DEV, V9, P1766, DOI 10.1101/gad.9.14.1766; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MAYEDA A, 1993, MOL CELL BIOL, V13, P2992; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; NEITFELD W, 1990, EMBO, V9, P3699; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SIEBEL CW, 1995, GENE DEV, V9, P269, DOI 10.1101/gad.9.3.269; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	54	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22227	22235		10.1074/jbc.272.35.22227	http://dx.doi.org/10.1074/jbc.272.35.22227			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268369	hybrid			2022-12-27	WOS:A1997XT85000081
J	Zhen, RG; Kim, EJ; Rea, PA				Zhen, RG; Kim, EJ; Rea, PA			Acidic residues necessary for pyrophosphate-energized pumping and inhibition of the vacuolar H+-pyrophosphatase by N,N'-dicyclohexylcarbodiimide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN STRUCTURE; SITE-SPECIFIC MUTAGENESIS; INORGANIC PYROPHOSPHATASE; PHENOTYPIC SELECTION; ATP SYNTHASE; SUBUNIT; SEQUENCE; TOPOLOGY; GENE; BACTERIORHODOPSIN	On the basis of a revised topological model of the vacuolar H+-pyrophosphatase (V-PPase; EC 3.6.1.1) derived from the analysis of four published sequences using two structure-predicting programs, TopPred II and MEMSAT, eight acidic amino acid residues located near or within transmembrane alpha-helices were identified, The codons specifying these amino acids in the cDNA encoding the V-PPase from Arabidopsis thaliana were singly mutated to examine their involvement in pyrophosphate (PPi) hydrolysis and PPi-dependent H+ translocation and the functional significance of the similarities between the sequences encompassing GlU(229) (227-245) of the V-PPase and the N,N'-dicyclohexylcarbodiimide (DCCD)-binding transmembrane alpha-helix of the c-subunits of F-ATPases (Nyren, P., Sakai-Nore, Y., and Strid, A. (1993) Plant Cell Physiol. 34, 375-378). Three functional classes were identified after heterologous expression of mutated enzyme in Saccharomyces cerevisiae, Class I (E119Q, E229Q, D573N, E667Q, and E751Q) mutants exhibited PPi hydrolytic and H+ translocation activities and DCCD sensitivities similar to wild type. The one class II mutant obtained (E427Q) was preferentially impaired for H+ translocation over PPi hydrolysis but retained sensitivity to DCCD, Class III (E305Q and D504N) mutants exhibited a near complete abolition of both PPi hydrolysis and H+ translocation and residual activities with decreased DCCD sensitivity, In none of the mutants was diminished insertion of the V-PPase into the membrane or an increase in the background conductance of the membrane to H+ evident, The decoupled character of E427Q mutants and the enhancement of H+ pumping in E427D mutants by comparison with wild type, in conjunction with the retention of DCCD inhibitability in both E427Q and E427D mutants, implicate a role for Glu(427) in DCCD-insensitive H+ translocation by the V-PPase, The proportionate diminution of PPi hydrolytic and H+ translocation activity and con servation of wild type DCCD sensitivity in E229Q mutants refute the notion that Glu(229) is the residue whose covalent modification by DCCD is responsible for the abolition of PPi-dependent H+ translocation. Instead, the diminished sensitivity of the residual activities of E305Q and D504N mutants, but not E305D or D504E mutants, to inhibition by DCCD is consistent with the involvement of acidic residues at these positions in inhibitory DCCD binding, The results are discussed with regard to the possible involvement of Glu(427) in coupling PPi hydrolysis with transmembrane H+ translocation and earlier interpretations of the susceptibility of the V-PPase to inhibition by carbodiimides.	UNIV PENN, DEPT BIOL, INST PLANT SCI, PHILADELPHIA, PA 19104 USA	University of Pennsylvania								BALTSCHEFFSKY M, 1993, MOL MECH BIOENERGETI, P331; BAYKOV AA, 1993, FEBS LETT, V327, P199, DOI 10.1016/0014-5793(93)80169-U; BAYKOV AA, 1993, EUR J BIOCHEM, V217, P755, DOI 10.1111/j.1432-1033.1993.tb18303.x; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; FALK G, 1988, BIOCHEM J, V254, P109, DOI 10.1042/bj2540109; FETTER JR, 1995, P NATL ACAD SCI USA, V92, P1604, DOI 10.1073/pnas.92.5.1604; GordonWeeks R, 1996, PLANT PHYSIOL, V111, P195, DOI 10.1104/pp.111.1.195; HARLOWE E, 1988, ANTIBODIES LAB MANUA; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HASSINEN IE, 1993, BIOCHIM BIOPHYS ACTA, V1144, P107, DOI 10.1016/0005-2728(93)90164-B; HEBERLE J, 1993, EMBO J, V12, P3721, DOI 10.1002/j.1460-2075.1993.tb06049.x; HUTTLY AK, 1990, GENE, V90, P227, DOI 10.1016/0378-1119(90)90184-S; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KIM EJ, 1995, J BIOL CHEM, V270, P2630, DOI 10.1074/jbc.270.6.2630; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; KIM YC, 1994, PLANT PHYSIOL, V106, P375, DOI 10.1104/pp.106.1.375; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEIGH RA, 1992, PLANT PHYSIOL, V100, P1698, DOI 10.1104/pp.100.4.1698; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MORIKAMI A, 1987, NUCLEIC ACIDS RES, V15, P4692, DOI 10.1093/nar/15.11.4692; NYREN P, 1993, PLANT CELL PHYSIOL, V34, P375; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rea P.A., 1990, METHODS PLANT BIOCH, V3, P385, DOI DOI 10.1016/B978-0-12-461013-2.50035-6; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; TANAKA Y, 1993, BIOCH BIOPHYSICAL RE, V190, P962; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; ZHEN RG, 1994, J BIOL CHEM, V269, P23342; Zhen RG, 1997, ADV BOT RES, V25, P297, DOI 10.1016/S0065-2296(08)60156-1	40	83	91	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22340	22348		10.1074/jbc.272.35.22340	http://dx.doi.org/10.1074/jbc.272.35.22340			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268385	hybrid			2022-12-27	WOS:A1997XT85000097
J	Crawford, EK; Ensor, JE; Kalvakolanu, I; Hasday, JD				Crawford, EK; Ensor, JE; Kalvakolanu, I; Hasday, JD			The role of 3' poly(A) tail metabolism in tumor necrosis factor-alpha regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; UNTRANSLATED REGION; MEIOTIC MATURATION; ESCHERICHIA-COLI; PROTECTS MICE; MOUSE OOCYTES; TNF-ALPHA; EXPRESSION; CACHECTIN; ENDOTOXIN	In unstimulated RAW 264.7 macrophage-like cells, tumor necrosis factor-alpha (TNF-alpha) mRNA was transcribed and accumulated in the cytoplasm, but the TNF-alpha transcripts failed to associate with polysomes, and TNF-alpha protein was not detected. Stimulation with lipopolysaccharide(LPS) induced an increase in TNF-alpha transcription, cytoplasmic TNF-alpha mRNA accumulation, polysome association, and secretion of TNF-alpha protein, This process was associated with a 200-nucleotide increase in the apparent length of the TNF-alpha mRNA. The difference in TNF-alpha mRNA size was caused by marked truncation of the 3' poly(A) tail in unstimulated cells. Fully adenylated TNF-alpha mRNA appeared within 15 min of LPS stimulation, We speculate that removal of the poly(A) tail blocks initiation of TNF-alpha translation in unstimulated macrophages LPS inactivates this process, allowing synthesis of translatable polyadenylated TNF-alpha mRNA.	BALTIMORE VA MED CTR, MED SERV, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT MED, DIV PULM & CRIT CARE MED, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT PATHOL, DIV PULM & CRIT CARE MED, BALTIMORE, MD 21201 USA; UNIV MARYLAND, BALTIMORE CYTOKINE CARE LAB, BALTIMORE, MD 21201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NCI NIH HHS [R29 CA52751] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDYOPADHYAY R, 1990, MOL CELL BIOL, V10, P2060, DOI 10.1128/MCB.10.5.2060; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1995, J INVEST MED, V43, P227; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1990, ONCOGENESIS, V2, P9; BIRAGYN A, 1995, J IMMUNOL, V155, P674; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOLLETMARTIN S, 1992, AM REV RESPIR DIS, V146, P990, DOI 10.1164/ajrccm/146.4.990; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; CRAWFORD EK, 1994, AM J RESP CRIT CARE, V149, pA716; CROSS A, 1995, J CLIN INVEST, V96, P676, DOI 10.1172/JCI118110; CROSS AS, 1989, J EXP MED, V169, P2021, DOI 10.1084/jem.169.6.2021; DEMARCO R, 1992, CELL IMMUNOL, V140, P304, DOI 10.1016/0008-8749(92)90198-X; ENSOR JE, 1995, AM J PHYSIOL, V269, pC1440; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; HASKILL S, 1988, J IMMUNOL, V140, P1690; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JONGENEEL CV, 1989, EUR J IMMUNOL, V19, P549; JONGENEEL CV, 1995, IMMUNOBIOLOGY, V193, P210, DOI 10.1016/S0171-2985(11)80545-0; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; MULLER WEG, 1976, EUR J BIOCHEM, V70, P241, DOI 10.1111/j.1432-1033.1976.tb10975.x; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; NEDOSPASOV SA, 1986, NUCLEIC ACIDS RES, V14, P7713, DOI 10.1093/nar/14.19.7713; OSIPOVICH OA, 1993, J IMMUNOL, V150, P4958; PARIS J, 1990, DEV BIOL, V140, P221, DOI 10.1016/0012-1606(90)90070-Y; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; PRADA J, 1993, INFECT IMMUN, V61, P2737, DOI 10.1128/IAI.61.6.2737-2740.1993; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIDHU RS, 1993, PHARMACOL THERAPEUT, V57, P79, DOI 10.1016/0163-7258(93)90037-E; ULICH TR, 1991, AM J PATHOL, V138, P1485; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; VOURNAKIS JN, 1975, P NATL ACAD SCI USA, V72, P2959, DOI 10.1073/pnas.72.8.2959; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WALLER SJ, 1993, REGUL PEP, P37; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; YENOFSKY R, 1982, P NATL ACAD SCI-BIOL, V79, P5876, DOI 10.1073/pnas.79.19.5876	46	62	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21120	21127		10.1074/jbc.272.34.21120	http://dx.doi.org/10.1074/jbc.272.34.21120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261116	hybrid			2022-12-27	WOS:A1997XR78900026
J	Jung, DW; Bradshaw, PC; Pfeiffer, DR				Jung, DW; Bradshaw, PC; Pfeiffer, DR			Properties of a cyclosporin-insensitive permeability transition pore in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-TRANSPORT PROTEIN; INNER-MEMBRANE; CA-2+ RELEASE; SACCHAROMYCES-CEREVISIAE; CONDUCTANCE CHANNEL; HEART-MITOCHONDRIA; RUTHENIUM RED; CELL LINE; ATP; CALCIUM	Yeast mitochondria (Saccharomyces cerevisiae) contain a permeability transition pore which is regulated differently than the pore in mammalian mitochondria. In a mannitol medium containing 10 mM P-i and ethanol (oxidizable substrate), yeast mitochondria accumulate large amounts of Ca2+ (>400 nmol/mg of protein) upon the addition of an electrophoretic Ca2+ ionophore (ETH129). Pore opening does not occur following Ca2+ uptake, even though ruthenium red-inhibited rat liver mitochondria undergo rapid pore opening under analogous conditions. However, a pore does arise in yeast mitochondria when Ca2+ and P-i are not present, as monitored by swelling, ultrastructure, and matrix solute release, Pore opening is slow unless a respiratory substrate is provided (ethanol or NADH) but also occurs rapidly in response to ATP (2 mM) when oligomycin is present, P-i and ADP inhibit pore opening (EC50 similar to 1 and 4 mar, respectively), however, cyclosporin A (7 mu g/ml), oligomycin (20 mu g/ml), or carboxyatractyloside (25 mu M) have no effect. The pare arising during respiration is also inhibited by nigericin or uncoupler, indicating that an acidic matrix pH antagonizes the process, P-i also inhibits pore opening by lowering the matrix pH (P-i/OH- antiport), However, inhibition of the ATP-induced pore by P-i is seen in the presence of mersalyl, suggesting a second mechanism of action. Since pore induction by ATP is not sensitive to carboxyatractyloside, ATP appears to act at an external site and P-i may antagonize the interaction. Isoosmotic polyethylene glycol-induced contraction of yeast mitochondria swollen during respiration, or in the presence of ATP, is 50% effective at a solute size of 1.0-1.1 kDa. This suggests that the same pore is induced in bath cases and is comparable in size with the permeability transition pore of heart and Liver mitochondria.			Jung, DW (corresponding author), OHIO STATE UNIV,DEPT MED BIOCHEM,333 HAMILTON HALL,COLUMBUS,OH 43210, USA.		Bradshaw, Patrick C./AAR-9189-2020	Bradshaw, Patrick C./0000-0002-4591-6798	NHLBI NIH HHS [HL49182] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049182] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BALLARIN C, 1995, J BIOL CHEM, V270, P19262, DOI 10.1074/jbc.270.33.19262; BEATRICE MC, 1982, J BIOL CHEM, V257, P7161; BEAUVOIT B, 1989, FEBS LETT, V244, P255, DOI 10.1016/0014-5793(89)80539-3; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; CARAFOLI E, 1970, BIOCHIM BIOPHYS ACTA, V205, P18, DOI 10.1016/0005-2728(70)90057-5; CARONI P, 1977, BIOCHIM BIOPHYS ACTA, V470, P437, DOI 10.1016/0005-2736(77)90134-1; CHAVEZ E, 1990, J BIOENERG BIOMEMBR, V22, P679, DOI 10.1007/BF00809071; DAUM G, 1982, J BIOL CHEM, V257, P3028; DAVIS ES, 1992, P NATL ACAD SCI USA, V89, P11169, DOI 10.1073/pnas.89.23.11169; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; GUERIN B, 1990, J BIOL CHEM, V265, P19736; GUERIN B, 1994, J BIOL CHEM, V269, P25406; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; Kakhniashvili D, 1997, J BIOL CHEM, V272, P4516, DOI 10.1074/jbc.272.7.4516; KASS GEN, 1992, BIOCHEM PHARMACOL, V44, P1995, DOI 10.1016/0006-2952(92)90102-O; KINNALLY KW, 1993, P NATL ACAD SCI USA, V90, P1374, DOI 10.1073/pnas.90.4.1374; KOLAROV J, 1972, BIOCHIM BIOPHYS ACTA, V267, P457, DOI 10.1016/0005-2728(72)90173-9; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; LEQUOC K, 1985, J BIOL CHEM, V260, P7422; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; LOHRET TA, 1995, BIOPHYS J, V68, P2299, DOI 10.1016/S0006-3495(95)80412-1; MANON S, 1995, BBA-BIOENERGETICS, V1231, P282, DOI 10.1016/0005-2728(95)00088-Z; MANON S, 1993, J BIOENERG BIOMEMBR, V25, P671; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; MCGUINNESS O, 1990, EUR J BIOCHEM, V194, P671, DOI 10.1111/j.1432-1033.1990.tb15667.x; MIYASHITA T, 1993, BLOOD, V81, P151; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; NOVGORODOV SA, 1987, J BIOENERG BIOMEMBR, V19, P191, DOI 10.1007/BF00762412; OHNISHI T, 1966, J BIOL CHEM, V241, P1797; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; PON L, 1991, MOL CELLULAR BIOL YE, V1, P333; PRESTIPINO G, 1993, ANAL BIOCHEM, V210, P119, DOI 10.1006/abio.1993.1160; Prieto S, 1996, ARCH BIOCHEM BIOPHYS, V334, P43, DOI 10.1006/abbi.1996.0427; PRIETO S, 1995, BIOCHEM J, V307, P657, DOI 10.1042/bj3070657; RAININA EI, 1980, HISTOCHEM J, V12, P57, DOI 10.1007/BF01066537; RILEY WW, 1985, J BIOL CHEM, V260, P2416; RITOV VB, 1993, BIOCHIM BIOPHYS ACTA, V1148, P257, DOI 10.1016/0005-2736(93)90137-O; ROUCOU X, 1995, FEBS LETT, V364, P161, DOI 10.1016/0014-5793(95)00380-R; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SCARPA A, 1978, BIOCHEMISTRY-US, V17, P1378, DOI 10.1021/bi00601a004; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; SZABO I, 1995, BBA-BIOMEMBRANES, V1235, P115, DOI 10.1016/0005-2736(94)00306-A; VELOURS J, 1977, FEBS LETT, V81, P18, DOI 10.1016/0014-5793(77)80918-6; VERCESI AE, 1984, ARCH BIOCHEM BIOPHYS, V232, P86, DOI 10.1016/0003-9861(84)90523-X; VODYANOY I, 1993, BIOPHYS J, V65, P2097, DOI 10.1016/S0006-3495(93)81245-1; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	67	119	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21104	21112		10.1074/jbc.272.34.21104	http://dx.doi.org/10.1074/jbc.272.34.21104			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261114	hybrid			2022-12-27	WOS:A1997XR78900024
J	Kim, B; Leventhal, PS; Saltiel, AR; Feldman, EL				Kim, B; Leventhal, PS; Saltiel, AR; Feldman, EL			Insulin-like growth factor-I-mediated neurite outgrowth in vitro requires mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; MAP KINASE; SIGNAL-TRANSDUCTION; BLASTOMA CELLS; PC12 CELLS; IGF-I; C-MYC; NEURONAL DIFFERENTIATION; EXPRESSION; RECEPTOR	Insulin-like growth factor-I (IGF-I) induces neuronal differentiation in vitro. In the present study, we examined the signaling pathway underlying IGF-I-mediated neurite outgrowth. In SH-SY5Y human neuroblastoma cells, treatment with IGF-I induced concentration- and time-dependent tyrosine phosphorylation of the type I IGF receptor (IGF-IR) and extracellular signal-regulated protein kinases (ERK) 1 and 2. These effects of IGF-I were blocked by a neutralizing antibody against IGF-IR. Whereas IGF-IR phosphorylation was observed within 1 min, maximal phosphorylation of ERKs was not reached for 30 min. Both IGF-IR and ERK phosphorlyation were maintained for at least 24 h. Also, the concentration dependence of IGF-I-stimulated IGF-IR and ERK tyrosine phosphorylation paralleled that of IGF-I-mediated neurite outgrowth. We further examined the role of mitogen-activated protein kinase activation in IGF-I-stimulated neuronal differentiation using the mitogen-activated protein kinase-ERK kinase inhibitor PD98059. Whereas PD98059 had no effect on IGF-IR phosphorylation, PD98059 reduced IGF-I-mediated ER tyrosine phosphorylation and ERK phosphorylation of the substrate Elk-1. PD98059 also produced a parallel reduction of IGF-I-stimulated neurite outgrowth. Finally, consistence with its ability to block neuronal differentiation, PD98059 inhibited IGF-I-dependent changes of GAp-43 and c-myc gene expression. Together these results suggest that activation of ERKs is essential for IGF-I-stimulated neuronal differentiation.	UNIV MICHIGAN, DEPT NEUROL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, NEUROSCI PROGRAM, ANN ARBOR, MI 48109 USA; SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, SYRACUSE, NY 13210 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Pfizer			Saltiel, Alan/L-3632-2019	Feldman, Eva/0000-0002-9162-2694; Saltiel, Alan/0000-0002-9726-9828	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009912, R29NS032843] Funding Source: NIH RePORTER; NINDS NIH HHS [F32 NS09912, R29 NS32843] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; CHUANG CF, 1994, FEBS LETT, V346, P229, DOI 10.1016/0014-5793(94)00480-3; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FELDMAN EL, 1991, BRAIN RES, V562, P111, DOI 10.1016/0006-8993(91)91194-6; FELDMAN EL, 1993, ANN NY ACAD SCI, V692, P262; HAMMERLING U, 1987, ONCOGENE, V2, P73; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JALAVA AM, 1988, EXP CELL RES, V179, P10, DOI 10.1016/0014-4827(88)90343-6; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KATO H, 1993, J BIOL CHEM, V268, P2655; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; Kim Bhumsoo, 1996, Molecular Biology of the Cell, V7, p342A; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN DM, 1993, J CELL PHYSIOL, V155, P290, DOI 10.1002/jcp.1041550210; MARTIN DM, 1992, MOL BRAIN RES, V15, P241, DOI 10.1016/0169-328X(92)90114-Q; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOZELL RL, 1991, J NEUROSCI RES, V30, P382, DOI 10.1002/jnr.490300214; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; OLIVER BL, 1995, P SOC EXP BIOL MED, V210, P162; PAHLMAN S, 1991, P NATL ACAD SCI USA, V88, P9994, DOI 10.1073/pnas.88.22.9994; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RECIOPINTO E, 1984, BRAIN RES, V302, P323, DOI 10.1016/0006-8993(84)90246-4; RECIOPINTO E, 1986, J NEUROSCI, V6, P1211; SETH A, 1992, J BIOL CHEM, V267, P24796; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SUMANTRAN VN, 1993, ENDOCRINOLOGY, V132, P2017, DOI 10.1210/en.132.5.2017; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANOBBERGHEN E, 1994, DIABETOLOGIA, V37, pS125, DOI 10.1007/BF00400836; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZACKENFELS K, 1995, NEURON, V14, P731, DOI 10.1016/0896-6273(95)90217-1	45	143	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21268	21273		10.1074/jbc.272.34.21268	http://dx.doi.org/10.1074/jbc.272.34.21268			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261137	hybrid			2022-12-27	WOS:A1997XR78900047
J	Steinberg, D				Steinberg, D			Low density lipoprotein oxidation and its pathobiological significance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SMOOTH-MUSCLE CELLS; ENHANCED MACROPHAGE DEGRADATION; MOUSE PERITONEAL-MACROPHAGES; RECEPTOR-DEFICIENT RABBITS; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; VITAMIN-E; BETA-CAROTENE; EXPRESSION CLONING; ALPHA-TOCOPHEROL				Steinberg, D (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED 0682,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							ACTON SL, 1994, J BIOL CHEM, V269, P21003; BASU SK, 1979, J BIOL CHEM, V254, P7141; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Chatterjee S, 1996, GLYCOBIOLOGY, V6, P303, DOI 10.1093/glycob/6.3.303; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DEJAGER S, 1993, J CLIN INVEST, V92, P894, DOI 10.1172/JCI116664; DIEBERROTHENEDER M, 1991, J LIPID RES, V32, P1325; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESTERBAUER H, 1987, J LIPID RES, V28, P495; Exner M, 1996, AM J PATHOL, V149, P1313; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FRUEBIS J, 1994, J CLIN INVEST, V94, P392, DOI 10.1172/JCI117334; HABERLAND ME, 1982, P NATL ACAD SCI-BIOL, V79, P1712, DOI 10.1073/pnas.79.6.1712; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HEIPLE JM, 1990, CELL MOTIL CYTOSKEL, V15, P260, DOI 10.1002/cm.970150408; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENRIKSEN T, 1982, ANN NY ACAD SCI, V401, P102, DOI 10.1111/j.1749-6632.1982.tb25711.x; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; Horkko S, 1996, J CLIN INVEST, V98, P815, DOI 10.1172/JCI118854; Itabe H, 1996, J LIPID RES, V37, P45; JACKSON RL, 1991, ADV EXP MED BIOL, V285, P367; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1992, ARTERIOSCLER THROMB, V12, P1258, DOI 10.1161/01.ATV.12.11.1258; KLIMOV AN, 1985, ATHEROSCLEROSIS, V58, P1, DOI 10.1016/0021-9150(85)90051-6; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PALINSKI W, 1995, ARTERIOSCL THROM VAS, V15, P1569, DOI 10.1161/01.ATV.15.10.1569; PALINSKI W, 1995, P NATL ACAD SCI USA, V92, P821, DOI 10.1073/pnas.92.3.821; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; QUINN MT, 1985, P NATL ACAD SCI USA, V82, P5949, DOI 10.1073/pnas.82.17.5949; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; RAY BR, 1954, J PHYS CHEM-US, V58, P841, DOI 10.1021/j150520a010; REAVEN P, 1991, AM J CLIN NUTR, V54, P701, DOI 10.1093/ajcn/54.4.701; REAVEN PD, 1994, ARTERIOSCLER THROMB, V14, P1162, DOI 10.1161/01.ATV.14.7.1162; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P601, DOI 10.1161/01.ATV.13.4.601; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAMBRANO GR, 1994, P NATL ACAD SCI USA, V91, P3265, DOI 10.1073/pnas.91.8.3265; SASAHARA M, 1994, J CLIN INVEST, V94, P155, DOI 10.1172/JCI117301; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; Steinberg D, 1997, CIRCULATION, V95, P1062; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBERG D, 1995, ISRAEL J MED SCI, V32, P469; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WEINSTEIN DB, 1976, BIOCHIM BIOPHYS ACTA, V424, P404, DOI 10.1016/0005-2760(76)90030-8; YLAHERTTUALA S, 1990, EUR HEART J, V11, P88, DOI 10.1093/eurheartj/11.suppl_E.88; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	74	1327	1374	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20963	20966		10.1074/jbc.272.34.20963	http://dx.doi.org/10.1074/jbc.272.34.20963			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261091	hybrid			2022-12-27	WOS:A1997XR78900001
J	Demmer, A; Thole, H; Kubesch, P; Brandt, T; Raida, M; Fislage, R; Tummler, B				Demmer, A; Thole, H; Kubesch, P; Brandt, T; Raida, M; Fislage, R; Tummler, B			Localization of the iodomycin binding site in hamster P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; PREDICTED TRANSMEMBRANE DOMAIN; PEROXISOMAL MEMBRANE-PROTEIN; N-TERMINAL DOMAIN; FUNCTIONAL CONSEQUENCES; MONOCLONAL-ANTIBODIES; SUBSTRATE-SPECIFICITY; CHEMICAL CLEAVAGE; MULTIPLE-MYELOMA; ESCHERICHIA-COLI	P-glycoprotein, the overexpression of which is a major cause for the failure of cancer chemotherapy in man, recognizes and transports a broad range of structurally unrelated amphiphilic compounds, This study reports on the localization of the binding site of P-glycoprotein for iodomycin, the Bolton-Hunter derivative of the anthracycline daunomycin. Plasma membrane vesicles isolated from multidrug-resistant Chinese hamster ovary B30 cells were photolabeled with [I-125]iodomycin. After chemical cleavage behind the tryptophan residues, I-125-labeled peptides were separated by electrophoresis and high performance liquid chromatography. Edman sequencing revealed that [I-125]iodomycin had been predominantly incorporated into the fragment 230-312 of isoform I of hamster P-glycoprotein. According to models based on hydropathy plots, the amino acid sequence 230-312 forms the distal part of transmembrane segment 4, the second cytoplasmic loop, and the proximal part of transmembrane segment 5 in the N-terminal half of P-glycoprotein. The binding site for iodomycin is recognized with high affinity by vinblastine and cyclosporin A.	HANNOVER MED SCH,ZENTRUM KINDERHEILKUNDE,D-30623 HANNOVER,GERMANY; MAX PLANCK INST EXPT ENDOKRINOL,D-30625 HANNOVER,GERMANY; NIEDERSACHS INST PEPTIDFORSCH,D-30625 HANNOVER,GERMANY	Hannover Medical School; Max Planck Society	Demmer, A (corresponding author), HANNOVER MED SCH,KLIN FORSCHERGRP,ZENTRUM BIOCHEM,OE 4350,CARL NEUBERG STR 1,D-30623 HANNOVER,GERMANY.							Ayesh S, 1996, BBA-MOL BASIS DIS, V1316, P8, DOI 10.1016/0925-4439(96)00008-7; BEJA O, 1995, J BIOL CHEM, V270, P12351; BIBI E, 1994, J BIOL CHEM, V269, P19910; Boer R, 1996, BIOCHEMISTRY-US, V35, P1387, DOI 10.1021/bi951912u; BOKENKAMP D, 1994, MOL CELL ENDOCRINOL, V104, P163, DOI 10.1016/0303-7207(94)90119-8; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSCHE R, 1989, MOL PHARMACOL, V35, P414; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V34, P2115; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CRIMMINS DL, 1990, ANAL BIOCHEM, V187, P27, DOI 10.1016/0003-2697(90)90412-3; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; Demmer A, 1996, EUR J PHARMACOL, V315, P339, DOI 10.1016/S0014-2999(96)00616-4; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; FRICHE E, 1993, BRIT J CANCER, V67, P226, DOI 10.1038/bjc.1993.44; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GLOSSMANN H, 1987, TRENDS PHARMACOL SCI, V8, P95, DOI 10.1016/0165-6147(87)90082-4; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOFMANN J, 1995, BIOCHEM PHARMACOL, V49, P603, DOI 10.1016/0006-2952(94)00479-6; HOOF T, 1994, J BIOL CHEM, V269, P20575; JURANKA PF, 1989, FASEB J, V3, P2588; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KOSTER W, 1992, MOL GEN GENET, V232, P399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1993, J BIOL CHEM, V268, P19965; MORGAN JH, 1991, BIOTECHNIQUES, V11, P256; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; SAFA AR, 1993, CANCER INVEST, V11, P46, DOI 10.3109/07357909309020260; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SAURIN W, 1994, MOL MICROBIOL, V12, P993, DOI 10.1111/j.1365-2958.1994.tb01087.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shan N, 1996, J BIOL CHEM, V271, P8725, DOI 10.1074/jbc.271.15.8725; SHANI N, 1995, P NATL ACAD SCI USA, V92, P6012, DOI 10.1073/pnas.92.13.6012; Shao YM, 1997, BBA-MOL BASIS DIS, V1360, P30, DOI 10.1016/S0925-4439(96)00065-8; SHECHTER Y, 1976, BIOCHEMISTRY-US, V15, P5071, DOI 10.1021/bi00668a019; SKACH WR, 1993, J BIOL CHEM, V268, P69603; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; SONNEVELD P, 1992, LANCET, V340, P255, DOI 10.1016/0140-6736(92)92353-H; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TAMAI I, 1990, J BIOL CHEM, V265, P16509; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZHANG JT, 1993, J BIOL CHEM, V268, P15101; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	69	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20913	20919		10.1074/jbc.272.33.20913	http://dx.doi.org/10.1074/jbc.272.33.20913			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252419	hybrid			2022-12-27	WOS:A1997XR22100089
J	Zhang, Y; Wisner, A; Maroun, RC; Choumet, V; Xiong, YL; Bon, C				Zhang, Y; Wisner, A; Maroun, RC; Choumet, V; Xiong, YL; Bon, C			Trimeresurus stejnegeri snake venom plasminogen activator - Site-directed mutagenesis and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; PROTEOLYTIC-ENZYMES; SERINE PROTEASES; THROMBIN; CLONING; CDNA; BATROXOBIN; EXPRESSION; UROKINASE; SEQUENCE	The specific plasminogen activator from Trimeresurus stejnegeri venom (TSV-PA) is a serine proteinase presenting 23% sequence identity with the proteinase domain of tissue type plasminogen activator, and 63% with batroxobin, a fibrinogen clotting enzyme from Bothrops atrox venom that does not activate plasminogen. TSV-PA contains six disulfide bonds and has been successfully overexpressed in Escherichia coli (Zhang, Y., Wisner, A., Xiong, Y. L,, and Bon, C, (1995) J. Biol. Chem. 270, 10246-10255), To identify the functional domains of TSV-PA, we focused on three short peptide fragments of TSV-PA showing important sequence differences with batroxobin and other venom serine proteinases. Molecular modeling shows that these sequences are located in surface loop regions, one of which is next to the catalytic site, When these sequences were replaced in TSV-PA by the equivalent batroxobin residues none generated either fibrinogen-clotting or direct fibrinogenolytic activity, Two of the replacements had little effect in general and are not critical to the specificity of TSV-PA for plasminogen. Nevertheless, the third replacement, produced by the conversion of the sequence DDE 96a-98 to NVI, significantly increased the K-m for some tripeptide chromogenic substrates and resulted in undetectable plasminogen activation, indicating the key role that the sequence plays in substrate recognition by the enzyme.	INST PASTEUR,UNITE VENINS,F-75724 PARIS 15,FRANCE; CHINESE ACAD SCI,KUNMING INST ZOOL,KUNMING 650223,PEOPLES R CHINA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Chinese Academy of Sciences; Kunming Institute of Zoology			maroun, rachid c/T-1549-2019; Maroun, Rachid C/B-3311-2014	maroun, rachid c/0000-0002-8124-815X; Maroun, Rachid C/0000-0002-8124-815X; Zhang, Yun/0000-0002-8636-183X				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHOUMET V, 1989, FEBS LETT, V244, P167, DOI 10.1016/0014-5793(89)81185-8; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HESSEL B, 1971, FEBS LETT, V18, P318, DOI 10.1016/0014-5793(71)80476-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; ITOH N, 1987, J BIOL CHEM, V262, P3132; ITOH N, 1988, J BIOL CHEM, V263, P7628; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MAEDA M, 1991, J BIOCHEM-TOKYO, V109, P632, DOI 10.1093/oxfordjournals.jbchem.a123432; MCMULLEN BA, 1989, BIOCHEMISTRY-US, V28, P674, DOI 10.1021/bi00428a039; NEURATH H, 1985, FED PROC, V44, P2907; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NIKAI T, 1995, ARCH BIOCHEM BIOPHYS, V318, P89, DOI 10.1006/abbi.1995.1208; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PERONA JJ, 1995, PROTEIN SCI, V4, P337; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043; TOKUNAGA F, 1988, J BIOL CHEM, V263, P17471; WALLEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P122, DOI 10.1016/0005-2795(72)90261-9; WOHL RC, 1980, J BIOL CHEM, V255, P2005; ZHANG Y, 1995, J BIOL CHEM, V270, P10246, DOI 10.1074/jbc.270.17.10246	29	48	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20531	20537		10.1074/jbc.272.33.20531	http://dx.doi.org/10.1074/jbc.272.33.20531			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252366	hybrid			2022-12-27	WOS:A1997XR22100036
J	Pfister, MF; Lederer, E; Forgo, J; Ziegler, U; Lotscher, M; Quabius, ES; Biber, J; Murer, H				Pfister, MF; Lederer, E; Forgo, J; Ziegler, U; Lotscher, M; Quabius, ES; Biber, J; Murer, H			Parathyroid hormone-dependent degradation of type II Na+/P-i cotransporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPOSSUM KIDNEY-CELLS; PHOSPHATE-TRANSPORT; FUNCTIONAL ASYMMETRY; MOLECULAR-CLONING; EPITHELIAL-CELLS; OK CELLS; EXPRESSION; PROTEIN; INHIBITION	Parathyroid hormone (PTH) inhibits proximal tubular brush border membrane Na+/P-i cotransport activity; this decrease in the transport activity was found to be associated with a decrease in type II Na+/P-i cotransporter protein content in rat brush border membranes, In the present study we investigated the PTH-dependent regulation of the type II Na+/P-i cotransporter in opossum kidney cells, a previously established model to study cellular mechanisms involved in the regulation of proximal tubular Na+/P-i cotransport. We transfected opossum kidney cells with a cDNA coding for NaPi-2 (rat renal type II Na+/P-i cotransporter), This allowed the study of PTH-dependent regulation of the transfected NaPi-2 and of the corresponding intrinsic cotransporter (NaPi-4). The results show (i) that the intrinsic and the transfected cotransporters are functionally (transport) and morphologically (immunofluorescence) localized at the apical membrane, (ii) that the intrinsic as well as the transfected Na+/P-i cotransport activities are inhibited by PTH, (iii) that PTH leads to a retrieval of both cotransporters from the apical membrane, (iv) that both cotransporters are rapidly degraded in response to PTH, and (v) that the reappearance/recovery of type II Na+/P-i cotransporter protein and function from PTH inhibition requires de novo protein synthesis. These results document that PTH leads to a removal of type II Na+/P-i cotransporters from the apical membrane and to their subsequent degradation.	UNIV ZURICH IRCHEL,INST PHYSIOL,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH IRCHEL,INST ANAT,CH-8057 ZURICH,SWITZERLAND; UNIV LOUISVILLE,DEPT MED,DIV NEPHROL,LOUISVILLE,KY 40292	University of Zurich; University of Zurich; University of Louisville								BIBER J, 1993, PFLUG ARCH EUR J PHY, V424, P210, DOI 10.1007/BF00384344; BIBER J, 1988, AM J PHYSIOL, V255, pC155, DOI 10.1152/ajpcell.1988.255.2.C155; CAVERZASIO J, 1986, J BIOL CHEM, V261, P3233; CAVERZASIO J, 1989, AM J PHYSIOL, V257, pF712, DOI 10.1152/ajprenal.1989.257.5.F712; CHONG SS, 1993, GENOMICS, V18, P355, DOI 10.1006/geno.1993.1476; COLLINS JF, 1994, FASEB J, V8, P862, DOI 10.1096/fasebj.8.11.8070635; CUSTER M, 1994, AM J PHYSIOL, V266, pF767, DOI 10.1152/ajprenal.1994.266.5.F767; HARTMANN CM, 1995, PFLUG ARCH EUR J PHY, V430, P830, DOI 10.1007/BF00386183; HAYES G, 1994, J BIOL CHEM, V269, P24143; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; KEMPSON SA, 1995, AM J PHYSIOL-RENAL, V268, pF784, DOI 10.1152/ajprenal.1995.268.4.F784; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MALMSTROM K, 1987, FEBS LETT, V216, P257, DOI 10.1016/0014-5793(87)80701-9; MIYAMOTO KI, 1995, BIOCHEM J, V305, P81, DOI 10.1042/bj3050081; Murer H, 1994, Curr Opin Nephrol Hypertens, V3, P504, DOI 10.1097/00041552-199409000-00005; MURER H, 1992, J AM SOC NEPHROL, V2, P1649; MURER H, 1992, KIDNEY PHYSL PATHOPH, P2481; Quabius ES, 1996, AM J PHYSIOL-RENAL, V270, pF220, DOI 10.1152/ajprenal.1996.270.1.F220; QUAMME G, 1989, BIOCHIM BIOPHYS ACTA, V1013, P159, DOI 10.1016/0167-4889(89)90044-X; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P624, DOI 10.1007/BF00370606; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P554, DOI 10.1007/BF00382689; RESHKIN SJ, 1991, PFLUG ARCH EUR J PHY, V419, P256, DOI 10.1007/BF00371104; SORRIBAS V, 1994, J BIOL CHEM, V269, P6615; TENENHOUSE HS, 1994, J CLIN INVEST, V93, P671, DOI 10.1172/JCI117019; VERRI T, 1995, AM J PHYSIOL-RENAL, V268, pF626, DOI 10.1152/ajprenal.1995.268.4.F626; WERNER A, 1994, AM J PHYSIOL, V267, pF311, DOI 10.1152/ajprenal.1994.267.2.F311; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608	29	107	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20125	20130		10.1074/jbc.272.32.20125	http://dx.doi.org/10.1074/jbc.272.32.20125			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242686	Green Accepted, hybrid			2022-12-27	WOS:A1997XQ05900073
J	Ueda, K; Inagaki, N; Seino, S				Ueda, K; Inagaki, N; Seino, S			MgADP antagonism to Mg2+-independent ATP binding of the sulfonylurea receptor SUR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; SENSITIVE K+ CHANNELS; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; INSULIN-SECRETION; NUCLEOTIDE; REGULATOR; CELLS; HYDROLYSIS; MUTATIONS	Pancreatic beta-cell ATP-sensitive potassium (K-ATP) channels play an important role in the regulation of glucose-induced insulin secretion. The beta-cell K-ATP channel comprises two subunits, the sulfonylurea receptor SUR1, a member of the ATP-binding cassette (ABC) superfamily, and Kir6.2, a member of the inward rectifier K+ channel family. The activity of the K-ATP, channel is under complex regulation by the intracellular ATP and ADP. To understand the roles of the two nucleotide-binding folds (NBFs) of SUR1 in the regulation of K-ATP channel activity, we introduced point mutations into the core consensus sequence of the Walker A or B motif of each NBF of SUR1 and characterized ATP binding and ADP or MgADP antagonism to it, SUR1 was efficiently photolabeled with 8-azido-[alpha-P-32]ATP and 8-azido-[gamma-P-32]ATP in the presence or absence of Mg2+ or vanadate. NBF1 mutations impaired ATP binding, but NBF2 mutations did not. MgADP strongly antagonized ATP binding, and the NBF2 mutation reduced MgADP antagonism. These results show that SUR1, unlike other ABC proteins, strongly binds ATP at NBF1 even in the absence of Mg2+ and that MgADP, through binding at NBF2, antagonizes the Mg2+-independent high affinity ATP binding at NBF1.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOL MED,CHUO KU,CHIBA 260,JAPAN	Chiba University	Ueda, K (corresponding author), KYOTO UNIV,BIOCHEM LAB,DIV APPL LIFE SCI,GRAD SCH AGR,KYOTO 60601,JAPAN.			Ueda, Kazumitsu/0000-0003-2980-6078; Inagaki, Nobuya/0000-0001-8261-2593				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; DUNNE MJ, 1986, FEBS LETT, V208, P59, DOI 10.1016/0014-5793(86)81532-0; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; Muller M, 1996, J BIOL CHEM, V271, P1877; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; SEINO S, 1996, DIABETES REV, V4, P177; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; TAGAYA M, 1987, J BIOL CHEM, V262, P3092; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; UEDA K, 1992, J BIOL CHEM, V267, P24248; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	29	144	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					22983	22986		10.1074/jbc.272.37.22983	http://dx.doi.org/10.1074/jbc.272.37.22983			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287292	hybrid			2022-12-27	WOS:A1997XV74400003
J	Li, JY; English, MA; Ball, HJ; Yeyati, PL; Waxman, S; Licht, JD				Li, JY; English, MA; Ball, HJ; Yeyati, PL; Waxman, S; Licht, JD			Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RECEPTOR-ALPHA; TRANS-RETINOIC ACID; GLUTATHIONE-S-TRANSFERASE; TUMOR GENE-PRODUCT; RAR-ALPHA; FUSION PROTEINS; T(15-17) TRANSLOCATION; PLZF GENE; PML; DIFFERENTIATION	Chromosomal translocation t(11;17)(q23;21) is associated with a retinoic acid-resistant form of acute promyelocytic leukemia. The translocation fuses the RAR alpha gene to the PLZF gene, resulting in the formation of reciprocal fusion proteins, hypothesized to play prominent roles in leukemogenesis. Promyelocytic leukemia zinc finger (PLZF) encodes a transcription factor with nine Kruppel-like zinc fingers, seven of which are retained in the t(11;17) fusion protein RAR alpha-PLZF. We identified a specific DNA-binding site for the PLZF protein and showed that PLZF binds to this site through its most carboxyl seven zinc fingers, In co-transfection experiments, PLZF repressed transcription through its cognate binding site, This repression function of PLZF was mapped to two regions on the protein, including the evolutionarily conserved POZ domain, In contrast, the RAR alpha-PLZF protein activated transcription of a promoter containing a PLZF response element, These results suggest that RAR alpha-PLZF, generated in acute promyelocytic leukemia, is an aberrant transcription factor that can deregulate the expression of PLZF target genes and contribute to leukemogenesis.	MT SINAI SCH MED,BROOKDALE CTR DEV & MOL BIOL,NEW YORK,NY 10029; MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai			Ball, Helen J/A-4242-2010; Licht, Jonathan/L-4239-2019	Ball, Helen J/0000-0003-3733-9748; Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; Ausubel FM, 1988, MOL REPROD DEV; AVANTAGGIATO V, 1995, J NEUROSCI, V15, P4927; BALL HJ, 1996, BLOOD S1, V88, P555; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHANG CC, 1996, BIOCHEMISTRY-US, V93, P6947; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DUONG S, 1996, P NATL ACAD SCI USA, V93, P3624; FAINSOD A, 1991, NUCLEIC ACIDS RES, V19, P4005, DOI 10.1093/nar/19.14.4005; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; Fenaux P, 1997, SEMIN ONCOL, V24, P92; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1991, CR SOC BIOL, V185, P391; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; McBryant SJ, 1996, NUCLEIC ACIDS RES, V24, P2567, DOI 10.1093/nar/24.13.2567; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Seyfert VL, 1996, ONCOGENE, V12, P2331; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SITTERLIN S, 1997, ONCOGENE, V14, P1067; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TESTA U, 1994, CANCER RES, V54, P4508; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YEYATI PL, 1996, BLOOD S1, V88, P291; ZELENT A, 1994, BRIT J HAEMATOL, V86, P451, DOI 10.1111/j.1365-2141.1994.tb04773.x	57	150	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22447	22455		10.1074/jbc.272.36.22447	http://dx.doi.org/10.1074/jbc.272.36.22447			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278395	hybrid			2022-12-27	WOS:A1997XV49200015
J	Pedersen, WA; Guo, Q; Hartman, BK; Mattson, MP				Pedersen, WA; Guo, Q; Hartman, BK; Mattson, MP			Nerve growth factor-independent reduction in choline acetyltransferase activity in PC12 cells expressing mutant presenilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BASAL FOREBRAIN; IN-VITRO; PROTEIN; NEURONS; ACETYLCHOLINE; MUTATIONS; APOPTOSIS; DEMENTIA; MEMORY	Mutations in the presenilin genes (PS-l and PS-2) are linked to early onset familial Alzheimer's disease (AD), but the mechanisms by which these mutations cause the cognitive impairment characteristic of AD are unknown. Basal forebrain cholinergic neurons are involved in learning and memory processes, and reductions in choline acetyl-transferase (ChAT) activity are a characteristic feature of AD brain. We therefore hypothesized that presenilin mutations suppress expression of the cholinergic phenotype. In rat PC12 cells stably transfected with the human PS-I gene containing the Leu --> Val mutation at codon 286 (L286V), we observed a drastic reduction (>90%) in basal ChAT activity compared with cells transfected with vector alone. By immunocytochemistry, a similar decrease in ChAT protein levels was found in the mutant transfectants. In cells differentiated with nerve growth factor, ChAT activity was again markedly lower in L286V-expressing cells than in control cells. We also observed reductions in ChAT activity in PC12 cells expressing the wild-type human PS-I gene but to a lesser extent than in L286V-expressing cells. The viability of cells transfected with either the wild-type or the mutant PS-I gene was not compromised. Our results suggest that PS-I mutations may contribute to the cognitive impairment in AD by causing a nontoxic suppression of the cholinergic phenotype.	UNIV KENTUCKY,SANDERS BROWN CTR AGING,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT ANAT & NEUROBIOL,LEXINGTON,KY 40536; UNIV MINNESOTA,DEPT PSYCHIAT,MINNEAPOLIS,MN 55455	University of Kentucky; University of Kentucky; University of Minnesota System; University of Minnesota Twin Cities			Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005144] Funding Source: NIH RePORTER; NIA NIH HHS [AG05119, AG05144] Funding Source: Medline; NINDS NIH HHS [NS30583] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BIERER LM, 1995, J NEUROCHEM, V64, P749; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; DUTAR P, 1995, PHYSIOL REV, V75, P393, DOI 10.1152/physrev.1995.75.2.393; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HARKANY T, 1995, BRAIN RES, V698, P270, DOI 10.1016/0006-8993(95)01013-L; Hoshi M, 1997, J BIOL CHEM, V272, P2038, DOI 10.1074/jbc.272.4.2038; IVERSEN LL, 1995, BIOCHEM J, V311, P1; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; Kar S, 1996, J NEUROSCI, V16, P1034; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XH, 1996, J NEUROSCI, V16, P5914; Mattson M.P., 1996, MOL MECH DEMENTIA, P103; MATTSON MP, 1992, J NEUROSCI, V12, P375; OAKMAN SA, 1995, J NEUROSCI, V15, P5859; Pedersen WA, 1996, P NATL ACAD SCI USA, V93, P8068, DOI 10.1073/pnas.93.15.8068; PIKE CJ, 1993, NEUROSCIENCE, V56, P269, DOI 10.1016/0306-4522(93)90331-9; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; WU DH, 1994, J NEUROCHEM, V62, P1653; YAMADA M, 1994, BRAIN RES, V661, P137, DOI 10.1016/0006-8993(94)91190-8; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	31	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22397	22400		10.1074/jbc.272.36.22397	http://dx.doi.org/10.1074/jbc.272.36.22397			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278388	hybrid			2022-12-27	WOS:A1997XV49200007
J	Schumacher, MA; Glasfeld, A; Zalkin, H; Brennan, RG				Schumacher, MA; Glasfeld, A; Zalkin, H; Brennan, RG			The X-ray structure of the PurR-guanine-purF operator complex reveals the contributions of complementary electrostatic surfaces and a water-mediated hydrogen bond to corepressor specificity and binding affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PURINE REPRESSOR; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MET REPRESSOR; DNA-BINDING; PROTEIN; AUTOREGULATION; RECOGNITION; RESOLUTION; FAMILY	The purine repressor, PurR, is the master regulatory protein of de novo purine nucleotide biosynthesis in Escherichia coli. This dimeric transcription factor is activated to bind to cognate DNA operator sites by initially binding either of its physiologically relevant, high affinity corepressors, hypoxanthine (K-d = 9.3 mu M) or guanine (K-d = 1.5 mu M). Here, we report the 2.5-Angstrom crystal structure of the PurR-guanine-purF operator ternary complex and complete the atomic description of 6-oxopurine-induced repression by PurR. As anticipated, the structure of the PurR-guanine-purF operator complex is isomorphous to the PurR-hypoxanthine-purF operator complex, and their protein-DNA and protein-corepressor interactions are nearly identical. The former finding confirms the use of an identical allosteric DNA-binding mechanism whereby corepressor binding 40 Angstrom from the DNA-binding domain juxtaposes the hinge regions of each monomer, thus favoring the formation and insertion of the critical minor groove-binding hinge helices. Strikingly, the higher binding affinity of guanine for PurR and the ability of PurR to discriminate against 2-oxopurines do not result from direct protein-ligand interactions, but rather from a water-mediated contact with the exocyclic N-2 of guanine, which dictates the presence of a donor group on the corepressor, and the better electrostatic complementarity of the guanine base and the corepressor-binding pocket.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA; REED COLL, DEPT CHEM, PORTLAND, OR 97202 USA; PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Oregon Health & Science University; Reed College - Oregon; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049244, R01GM024658, R37GM024658] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24658, GM49244] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIN H, 1993, J BACTERIOL, V175, P3598, DOI 10.1128/jb.175.11.3598-3606.1993; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; FUJINAGA M, 1987, J MOL BIOL, V195, P397, DOI 10.1016/0022-2836(87)90659-0; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; Glasfeld A, 1996, J AM CHEM SOC, V118, P13073, DOI 10.1021/ja962416b; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JOACHIMIAK A, 1994, EMBO J, V13, P367, DOI 10.1002/j.1460-2075.1994.tb06270.x; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVORY R, 1990, J BIOMOL STRUCT DYN, V6, P215; LAWSON CL, 1993, NATURE, V366, P178, DOI 10.1038/366178a0; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NAGADOI A, 1995, STRUCTURE, V3, P1217, DOI 10.1016/S0969-2126(01)00257-X; Nguyen CC, 1995, FEBS LETT, V377, P98, DOI 10.1016/0014-5793(95)01344-X; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PHILLIPS K, 1994, STRUCTURE, V2, P309, DOI 10.1016/S0969-2126(00)00032-0; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; ROLFES RJ, 1990, J BACTERIOL, V172, P5758, DOI 10.1128/jb.172.10.5758-5766.1990; ROLFES RJ, 1990, J BACTERIOL, V172, P5637, DOI 10.1128/jb.172.10.5637-5642.1990; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SCHUMACHER MA, 1994, J MOL BIOL, V242, P302, DOI 10.1006/jmbi.1994.1580; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STEIERT JG, 1990, J BACTERIOL, V172, P3799, DOI 10.1128/jb.172.7.3799-3803.1990; Tame JRH, 1996, NAT STRUCT BIOL, V3, P998, DOI 10.1038/nsb1296-998; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	40	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22648	22653		10.1074/jbc.272.36.22648	http://dx.doi.org/10.1074/jbc.272.36.22648			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278422	hybrid			2022-12-27	WOS:A1997XV49200042
J	Tran, H; VanDusen, WJ; Argraves, WS				Tran, H; VanDusen, WJ; Argraves, WS			The self-association and fibronectin-binding sites of fibulin-1 map to calcium-binding epidermal growth factor-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; BETA-HYDROXYASPARTIC ACID; EGF-LIKE DOMAIN; HUMAN FACTOR-IX; EXTRACELLULAR-MATRIX; MARFAN-SYNDROME; DEPENDENT BINDING; FACTOR-X; PROTEIN; GLYCOPROTEIN	Fibulin-1 is a modular glycoprotein with amino-terminal anaphylatoxin-like modules followed by nine epidermal growth factor (EGF)-like modules and, depending on alternative splicing, four possible carboxyl termini. Fibulin-1 has been shown to self-associate as well as to bind calcium, fibronectin (FN), laminin, nidogen, and fibrinogen. To map ligand-binding sites within fibulin-1, polypeptides corresponding to various regions of fibulin-1 were expressed recombinantly and evaluated for their capacity to bind calcium, FN, or fibulin-1. A calcium-binding site(s) was mapped to EGF-like modules 5-9. A fibulin-1 self-association site was localized to EGF-like modules 5 and 6 (amino acid residues 356-440), as was a binding site for FN. The self-association interaction mediated by this pair of modules involved calcium since divalent cation chelators reduced the binding affinity of the interaction. By contrast, FN binding to EGF-like modules 5 and 6 was unaffected by the presence of divalent cation chelators. It can be concluded that EGF-like modules 5 and 6 bind calcium and mediate homotypic interaction between EGF-like modules 5 and 6 present in different fibulin-1 molecules and heterotypic interaction between EGF-like modules 5 and 6 and type III repeats 13 and 14 in FN. While additional binding sites for calcium or FN were not detected, another fibulin-1 self-association site was found within amino acid residues 30-173. However, unlike the self-association site in EGF-like modules 5 and 6, which was functional in the native protein, the amino-terminal site was cryptic and revealed only after the protein was denatured.	MED UNIV S CAROLINA,DEPT ANAT & CELL BIOL,CHARLESTON,SC 29425; AMER RED CROSS,DEPT BIOCHEM,ROCKVILLE,MD 20855; MERCK RES LABS,W POINT,PA 19486	Medical University of South Carolina; American Red Cross; Merck & Company					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL052813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52813] Funding Source: Medline; NIGMS NIH HHS [GM 42912] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BROWN JC, 1994, J CELL SCI, V107, P329; BUSBY TF, 1988, BIOCHEMISTRY-US, V27, P6127, DOI 10.1021/bi00416a045; Dietz Harry C., 1992, Human Mutation, V1, P366, DOI 10.1002/humu.1380010504; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; GODYNA S, 1994, MATRIX BIOL, V14, P467; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V353, P395, DOI 10.1038/353395a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Ingham KC, 1997, J BIOL CHEM, V272, P1718, DOI 10.1074/jbc.272.3.1718; INGHAM KC, 1981, BIOCHIM BIOPHYS ACTA, V670, P181, DOI 10.1016/0005-2795(81)90007-6; KLUGE M, 1990, EUR J BIOCHEM, V193, P651, DOI 10.1111/j.1432-1033.1990.tb19383.x; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; Miosge N, 1996, HISTOCHEM J, V28, P109, DOI 10.1007/BF02331415; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SPENCE SG, 1992, DEV BIOL, V151, P473, DOI 10.1016/0012-1606(92)90186-K; STENFLO J, 1988, J BIOL CHEM, V263, P21; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; SUGO T, 1984, J BIOL CHEM, V259, P5705; TRAN H, 1995, J BIOL CHEM, V270, P19458, DOI 10.1074/jbc.270.33.19458; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; ZHANG HY, 1993, DIFFERENTIATION, V52, P211, DOI 10.1111/j.1432-0436.1993.tb00633.x	42	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22600	22606		10.1074/jbc.272.36.22600	http://dx.doi.org/10.1074/jbc.272.36.22600			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278415	hybrid			2022-12-27	WOS:A1997XV49200035
J	Dreier, B; Fritz, S; Volkert, G; Brachvogel, B; Lottspeich, F; Fey, GH				Dreier, B; Fritz, S; Volkert, G; Brachvogel, B; Lottspeich, F; Fey, GH			A 32-kDa proteolytic fragment of transcription factor Stat3 is capable of specific DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-6 RESPONSE ELEMENT; ACUTE-PHASE RESPONSE; RAT ALPHA-2-MACROGLOBULIN GENE; EPIDERMAL GROWTH-FACTOR; GEL-ELECTROPHORESIS; SIGNAL TRANSDUCER; PROTEINS; ACTIVATION; DOMAIN; PHOSPHORYLATION	Fragments of characteristic size retaining the ability of sequence-specific DNA binding were generated by partial proteolysis of transcription factor Stat3 with trypsin, chymotrypsin, or Staphylococcus V8 proteinase, The molecular masses of the smallest DNA-binding fragments were 75, 48, and 32 kDa after digestion with V8 proteinase, chymotrypsin, and trypsin, respectively, The fragments contained major parts of the domain controlling the sequence specificity of DNA binding (amino acids 406-514), the SH3 and SH2 domains, and the phosphorylated tyrosine residue Tyr-705, but not the C-terminal 20 amino acids, The N terminus of the 32-kDa tryptic fragment (ANCDASLIV) matched the sequence of amino acids 424-432 deduced from cDNA. The fragments were observed after proteolytic treatment of preformed complexes between DNA and native factors eluted from rat liver nuclei or recombinant, tyrosine-phosphorylated rat Stat3 from insect cells. It was possible to elute all three minimal fragments from their complexes with DNA and to obtain specific re-binding, The minimal fragments eluted from complexes with DNA still contained the phosphorylated Tyr-705 and the SH2 domain suggesting that they were probably bound to DNA as dimers, The DNA-binding domain of Stat3 identified by these experiments overlapped the domain previously identified by genetic experiments as the domain controlling the sequence specificity of DNA binding, The DNA-binding domain defined here by partial proteolysis probably represents an autonomously folding portion of Stat3.	UNIV ERLANGEN NURNBERG,CHAIR GENET,D-91058 ERLANGEN,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	University of Erlangen Nuremberg; Max Planck Society				Brachvogel, Bent/0000-0002-3923-0554				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BRECHNER T, 1991, MOL BIOL MED, V8, P267; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kordula T, 1996, J BIOL CHEM, V271, P6752, DOI 10.1074/jbc.271.12.6752; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; Leung S, 1996, SCIENCE, V273, P750, DOI 10.1126/science.273.5276.750; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Schneider K, 1995, ANN NY ACAD SCI, V762, P502; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	34	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22118	22124		10.1074/jbc.272.35.22118	http://dx.doi.org/10.1074/jbc.272.35.22118			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268355	hybrid			2022-12-27	WOS:A1997XT85000067
J	QuilletMary, A; Jaffrezou, JP; Mansat, V; Bordier, C; Naval, J; Laurent, G				QuilletMary, A; Jaffrezou, JP; Mansat, V; Bordier, C; Naval, J; Laurent, G			Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; PROGRAMMED CELL-DEATH; IONIZING-RADIATION; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; MONOCLONAL-ANTIBODY; HL-60 CELLS; SPHINGOMYELIN	The key events implicated in ceramide-triggered apoptosis remain unknown. In this study we show that 25 mu M CG-ceramide induced significant H2O2, production within 60 min, which increased up to 180 min in human myeloid leukemia U937 cells. Inactive analogue dihydro-C6-ceramide had no effect, Furthermore, no H2O2 production was observed in CG-ceramide-treated U937 rho degrees cells, which are mitochondrial respiration-deficient. We also present evidence that ceramide-induced activation of the transcription factors NF-kappa B and AP-I is mediated by mitochondrial derived reactive oxygen species, Both H2O2 production, transcription factor activation as well as apoptosis could be inhibited by rotenone and thenoyltrifluoroacetone (specific mitochondrial complexes I and II inhibitors) and antioxidants, N-acetylcysteine and pyrrolidine dithiocarbamate. These effects could be potentiated by antimycin A (specific complex III mitochondrial inhibitor); H2O2 production was also inhibitable by ruthenium red, suggesting a role of mitochondrial calcium homeostasis alterations in ceramide-induced oxidative stress, Finally, CG-ceramide had no influence on mitochondrial membrane potential within the first 6 h. Altogether, our study points to reactive oxygen species, generated at the ubiquinone site of the mitochondrial respiratory chain, as an early major mediator in ceramide-induced apoptosis.	UNIV ZARAGOZA, DEPT BIOCHEM & MOL BIOL, E-50009 ZARAGOZA, SPAIN; CHU PURPAN, SERV HEMATOL, TOULOUSE, FRANCE	University of Zaragoza; CHU de Toulouse	QuilletMary, A (corresponding author), CTR CLAUDIUS REGAUD, CJF INSERM 9503, 20-24 RUE PONT ST PIERRE, F-31052 TOULOUSE, FRANCE.			QUILLET-MARY, Anne/0000-0002-1849-6388				ANDRIEU N, 1994, BIOCHEM J, V270, P24518; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CHACON E, 1991, TOXICOL APPL PHARM, V107, P117, DOI 10.1016/0041-008X(91)90336-D; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHAO CP, 1994, J BIOL CHEM, V269, P5849; CHEN M, 1995, CANCER RES, V55, P991; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; Decaudin D, 1997, CANCER RES, V57, P62; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; FANG W, 1995, J IMMUNOL, V155, P66; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GAMEN S, 1995, FEBS LETT, V376, P15, DOI 10.1016/0014-5793(95)01236-1; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GIL ML, 1992, J IMMUNOL, V148, P2826; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KIM MY, 1991, J BIOL CHEM, V266, P484; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KONSTANTINOV AA, 1987, BIOCHIM BIOPHYS ACTA, V894, P1, DOI 10.1016/0005-2728(87)90206-4; KORSMEYER SJ, 1992, BLOOD, V80, P879; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PENNINGTON MW, 1994, PEPTIDE RES, V7, P72; QuilletMary A, 1996, LEUKEMIA, V10, P417; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENSON MA, 1994, CANCER RES, V54, P12; STRUM JC, 1994, J BIOL CHEM, V269, P15493; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	62	438	446	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21388	21395		10.1074/jbc.272.34.21388	http://dx.doi.org/10.1074/jbc.272.34.21388			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261153	hybrid			2022-12-27	WOS:A1997XR78900063
J	Alyonycheva, TN; Mikawa, T; Reinach, FC; Fischman, DA				Alyonycheva, TN; Mikawa, T; Reinach, FC; Fischman, DA			Isoform-specific interaction of the myosin-binding proteins (MyBPs) with skeletal and cardiac myosin is a property of the C-terminal immunoglobulin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN PECTORALIS-MUSCLE; THICK FILAMENT PROTEIN; 86 KD PROTEIN; STRIATED-MUSCLE; H-PROTEIN; CREATINE KINASE; X-PROTEIN; EXPRESSION; MYOFIBRILS; TITIN	Full-length cDNAs encoding chicken and human skeletal MyBP-H and MyBP-C have been isolated and sequenced (1-5). All are members of a protein family with repetitive immunoglobulin C2 and fibronectin type III motifs. The myosin binding domain was mapped to a single immunoglobulin motif in cardiac MyBP-C and skeletal MyBP-H. Limited alpha-chymotryptic digestion of cardiac MyBP-C generated three peptides, similar in relative mobility to those of skeletal MyBP-C: similar to 100, 40, and 15 kDa. Tryptic digestion of MyBP-H yielded two peptides: similar to 50 and 14 kDa. Partial amino acid sequences proved that the 15 and 14-kDa fragments are located at the C termini of cardiac MyBP-C and skeletal My PP-H, respectively. Only the 14- and 15-kDa peptides bound to myosin. Thus, the myosin binding site in all three proteins resides within an homologous, C-terminal immunoglobulin domain. Binding reactions (2) between the skeletal and cardiac MyBPs and corresponding myosin isoforms demonstrated saturable binding of the MyBP proteins and their C-terminal peptides to myosin, but there are higher limiting stoichiometries with the homologous isoform partners. Evidence is presented indicating that MS BP-H and -C compete for binding to a discrete number of sites in myosin filaments.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,BR-01498 SAO PAULO,BRAZIL	Cornell University; Universidade de Sao Paulo					NIAMS NIH HHS [AR32147] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032147] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYMESOUTHGATE A, 1991, P NATL ACAD SCI USA, V88, P7973, DOI 10.1073/pnas.88.18.7973; BAHLER M, 1985, J MOL BIOL, V186, P381, DOI 10.1016/0022-2836(85)90112-3; BAHLER M, 1985, J MOL BIOL, V186, P393, DOI 10.1016/0022-2836(85)90113-5; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BENNETT P, 1986, J MUSCLE RES CELL M, V7, P550, DOI 10.1007/BF01753571; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; CALLAWAY JE, 1981, BIOCHEM J, V195, P463, DOI 10.1042/bj1950463; COOPER J, 1984, J MOL BIOL, V177, P137, DOI 10.1016/0022-2836(84)90061-5; CRAIG R, 1976, PROC R SOC SER B-BIO, V192, P451, DOI 10.1098/rspb.1976.0023; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DENNIS JE, 1984, J CELL BIOL, V98, P1514, DOI 10.1083/jcb.98.4.1514; DHOOT GK, 1985, J MUSCLE RES CELL M, V6, P487, DOI 10.1007/BF00712585; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; Freiburg A, 1996, EUR J BIOCHEM, V235, P317, DOI 10.1111/j.1432-1033.1996.00317.x; FURST DO, 1992, J CELL SCI, V102, P769; FYRBERG CC, 1992, P ROY SOC B-BIOL SCI, V249, P33, DOI 10.1098/rspb.1992.0080; Gilbert R, 1996, J CELL SCI, V109, P101; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; GROVE BK, 1985, J CELL BIOL, V101, P1413, DOI 10.1083/jcb.101.4.1413; HARTZELL HC, 1985, J CELL BIOL, V100, P208, DOI 10.1083/jcb.100.1.208; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; MARUYAMA K, 1986, INT REV CYTOL, V104, P81, DOI 10.1016/S0074-7696(08)61924-5; MASAKI T, 1974, J BIOCHEM, V75, P367, DOI 10.1093/oxfordjournals.jbchem.a130403; MOOS C, 1975, J MOL BIOL, V97, P1, DOI 10.1016/S0022-2836(75)80017-9; MOOS C, 1981, J CELL BIOL, V90, P25, DOI 10.1083/jcb.90.1.25; MOOS C, 1978, J MOL BIOL, V124, P5714; NABESHIMA YI, 1984, NATURE, V308, P333, DOI 10.1038/308333a0; NOGUCHI J, 1992, J BIOL CHEM, V267, P20302; OBINATA T, 1984, DEV BIOL, V101, P116, DOI 10.1016/0012-1606(84)90122-2; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; OKAGAKI T, 1993, J CELL BIOL, V123, P619, DOI 10.1083/jcb.123.3.619; PRICE MG, 1987, J CELL BIOL, V104, P1325, DOI 10.1083/jcb.104.5.1325; PRICE MG, 1993, J BIOL CHEM, V268, P21800; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; REINACH FC, 1983, J CELL BIOL, V96, P297, DOI 10.1083/jcb.96.1.297; SQUIRE J, 1981, STRUCTURAL BASIS MUS, P344; STARR R, 1983, J MOL BIOL, V170, P675, DOI 10.1016/S0022-2836(83)80127-2; TAKANOOHMURO H, 1989, J MUSCLE RES CELL M, V10, P369, DOI 10.1007/BF01758433; TRINICK J, 1977, J MOL BIOL, V113, P343, DOI 10.1016/0022-2836(77)90146-2; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; VAUGHAN KT, 1993, GENOMICS, V16, P34, DOI 10.1006/geno.1993.1136; WALLIMANN T, 1983, J CELL BIOL, V96, P1772, DOI 10.1083/jcb.96.6.1772; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698; WATKINS H, 1995, NAT GENET, V11, P433; WEBER FE, 1993, EUR J BIOCHEM, V216, P661, DOI 10.1111/j.1432-1033.1993.tb18186.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAMOTO K, 1984, J BIOL CHEM, V259, P7163; YAMAMOTO K, 1986, FEBS LETT, V208, P123, DOI 10.1016/0014-5793(86)81545-9; YASUDA M, 1995, J MOL CELL CARDIOL, V27, P2275, DOI 10.1016/S0022-2828(95)91731-4; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	51	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20866	20872		10.1074/jbc.272.33.20866	http://dx.doi.org/10.1074/jbc.272.33.20866			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252413	hybrid			2022-12-27	WOS:A1997XR22100083
J	Zeeuwen, PLJM; Hendriks, W; deJong, WW; Schalkwijk, J				Zeeuwen, PLJM; Hendriks, W; deJong, WW; Schalkwijk, J			Identification and sequence analysis of two new members of the SKALP/elafin and SPAI-2 gene family - Biochemical properties of the transglutaminase substrate motif and suggestions for a new nomenclature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ELASTASE-SPECIFIC INHIBITOR; HUMAN EPIDERMAL-KERATINOCYTES; LEUKOCYTE PROTEASE INHIBITOR; CORNIFIED CELL-ENVELOPE; REACTIVE CENTER REGIONS; PROTEINASE-INHIBITOR; ANTILEUKOPROTEINASE SKALP; CROSS-LINKING; TISSUE TRANSGLUTAMINASE	The human epithelial proteinase inhibitor SKALP/elafin and the porcine sodium-potassium ATPase inhibitor SPAI-2 are two highly homologous proteins that share an NH2-terminal transglutaminase substrate domain and a COOH-terminal whey acidic protein (WAP) domain, Here we describe the bovine and simian orthologs of SKALP/elafin as well as two new bovine family members that are designated Trappin-4 and Trappin-5 on the basis of a new nomenclature that we propose (Trappin = TRansglutaminase substrate and WAP motif containing ProteIN). Sequence analysis of Trappin-4 and Trappin-5 revealed a domain structure that is very similar to SPAI-2 (Trappin-1) and SKALP/elafin (Trappin-2). The transglutaminase substrate motifs are conserved although the number of repeats varies among species and among family members, The sequence of Trappin-4 and Trappin-5 diverges from Trappin-1 and Trappin a at the putative reactive site in the WAP domain, The bovine ortholog of Trappin a is expressed in tongue and snout epidermis; Trappin-4 is expressed in trachea, ileum, and tongue; and Trappin-5 is expressed at low levels in trachea, as determined by RNase protection and Northern blot analysis. Based on the analysis of 67 transglutaminase substrate repeats as present in all known Trappin gene family members from four different mammalian species a consensus sequence could be established: Gly-Gln-Asp-Pro-Val-Lys (GQDPVK). Using biotinylated hexapeptide probes we found that the GQDPVK sequence is a very efficient transglutaminase substrate both for guinea pig liver transglutaminase and for epidermal transglutaminase, and it acts as acyl donor as well as acceptor, We propose that the Trappin protein family forms a new group of enzyme inhibitors with various specificities of the WAP domain, which share transglutaminase substrate motifs that can act as an anchoring sequence.	UNIV NIJMEGEN, INST CELLULAR SIGNALING, DEPT DERMATOL, NL-6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN, INST CELLULAR SIGNALING, DEPT CELL BIOL & HISTOL, NL-6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN, INST CELLULAR SIGNALING, DEPT BIOCHEM, NL-6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen			Zeeuwen, Patrick/N-1779-2013; Hendriks, Wiljan J.A.J./A-5214-2013; Schalkwijk, Joost/N-1774-2013; Schalkwijk, Joost/R-7509-2019; Hendriks, Wiljan/Q-4325-2019	Zeeuwen, Patrick/0000-0002-6878-2438; Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Schalkwijk, Joost/0000-0002-1308-1319; Hendriks, Wiljan/0000-0001-9481-8281				ALKEMADE H, 1992, J INVEST DERMATOL, V99, P3, DOI 10.1111/1523-1747.ep12611375; ALKEMADE HAC, 1995, J INVEST DERMATOL, V104, P189, DOI 10.1111/1523-1747.ep12612749; ALKEMADE JAC, 1994, J CELL SCI, V107, P2335; ARAKI K, 1990, BIOCHEM BIOPH RES CO, V172, P42, DOI 10.1016/S0006-291X(05)80170-6; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GENTILE V, 1994, GENOMICS, V20, P295, DOI 10.1006/geno.1994.1170; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROENEN PJTA, 1994, EUR J BIOCHEM, V220, P795, DOI 10.1111/j.1432-1033.1994.tb18681.x; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; Hiemstra PS, 1996, INFECT IMMUN, V64, P4520, DOI 10.1128/IAI.64.11.4520-4524.1996; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HILL RE, 1984, NATURE, V311, P175, DOI 10.1038/311175a0; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1994, J INVEST DERMATOL, V103, P137, DOI 10.1111/1523-1747.ep12392470; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; KRAMPS JA, 1990, BIOCHIM BIOPHYS ACTA, V1038, P178, DOI 10.1016/0167-4838(90)90202-Q; KUROKI J, 1995, J BIOL CHEM, V270, P22428, DOI 10.1074/jbc.270.38.22428; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1991, P NATL ACAD SCI USA, V88, P82, DOI 10.1073/pnas.88.1.82; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOLHUIZEN HOF, 1994, CYTOGENET CELL GENET, V66, P129, DOI 10.1159/000133683; MOORE JT, 1987, P NATL ACAD SCI USA, V84, P6712, DOI 10.1073/pnas.84.19.6712; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; Pfundt R, 1996, J CLIN INVEST, V98, P1389, DOI 10.1172/JCI118926; POLAKOWSKA R, 1991, J INVEST DERMATOL, V96, P285, DOI 10.1111/1523-1747.ep12464554; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SALLENAVE JM, 1993, AM J RESP CELL MOL, V8, P439, DOI 10.1165/ajrcmb/8.4.439; SALLENAVE JM, 1992, BIOL CHEM H-S, V373, P27, DOI 10.1515/bchm3.1992.373.1.27; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALKWIJK J, 1993, J INVEST DERMATOL, V100, P390, DOI 10.1111/1523-1747.ep12471990; SCHALKWIJK J, 1991, BIOCHIM BIOPHYS ACTA, V1096, P148, DOI 10.1016/0925-4439(91)90053-C; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHELLENBERGER V, 1994, BIOCHEMISTRY-US, V33, P4251, DOI 10.1021/bi00180a020; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Tamechika I, 1996, J BIOL CHEM, V271, P7012, DOI 10.1074/jbc.271.12.7012; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; Tsunemi M, 1996, BIOCHEMISTRY-US, V35, P11570, DOI 10.1021/bi960900l; ULVSBACK M, 1992, J BIOL CHEM, V267, P18080; vanRuissen F, 1996, J CELL PHYSIOL, V168, P442; WANG M, 1994, GENOMICS, V23, P721, DOI 10.1006/geno.1994.1571; WIEDOW O, 1991, BIOCHEM BIOPH RES CO, V174, P6, DOI 10.1016/0006-291X(91)90476-N; WIEDOW O, 1990, J BIOL CHEM, V265, P14791	56	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20471	20478		10.1074/jbc.272.33.20471	http://dx.doi.org/10.1074/jbc.272.33.20471			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252357	Green Published, hybrid			2022-12-27	WOS:A1997XR22100027
J	Starr, R; Novak, U; Willson, TA; Inglese, M; Murphy, V; Alexander, WS; Metcalf, D; Nicola, NA; Hilton, DJ; Ernst, M				Starr, R; Novak, U; Willson, TA; Inglese, M; Murphy, V; Alexander, WS; Metcalf, D; Nicola, NA; Hilton, DJ; Ernst, M			Distinct roles for leukemia inhibitory factor receptor alpha-chain and gp130 in cell type-specific signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; COLONY-STIMULATING FACTOR; CILIARY NEUROTROPHIC FACTOR; ONCOSTATIN-M; TRANSCRIPTION FACTOR; NEURONAL CELLS; DIFFERENTIATION; INTERLEUKIN-6; EXPRESSION; FAMILY	Leukemia inhibitory factor (LIF) induces a variety of disparate biological responses ill different cell types. These responses are thought to be mediated through the functional LIF receptor (LIFR), consisting of a heterodimeric complex of LIFE alpha-chain (LIFR alpha) and gp130. The present study investigated the relative capacity of the cytoplasmic domains of each receptor subunit to signal particular responses in several cell types, To monitor the signaling potential of LIFR alpha and gp130 individually, we constructed chimeric receptors by linking the extracellular domain of granulocyte colony-stimulating factor receptor (GCSFR) to the transmembrane and cytoplasmic regions of either LIFR alpha or gp130, Both chimeric receptors and the fall-length GCSFR in expressed in M1 myeloid leukemic cells to measure differentiation induction, in embryonic stem cells to measure differentiation inhibition, and in Ba/F3 cells to measure cell proliferation. Our results demonstrated that whereas GCSFR-gp130 receptor homodimer mediated a GCSF-induced signal in all three cell types, the GCSFR-LIFR alpha receptor homodimer was only functional in embryonic stem cells, These findings suggest that the signaling potential of gp130 and LIFR alpha cytoplasmic domains may differ depending upon the tissue and cellular response initiated.	LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,DEPT MED,PARKVILLE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,COOPERAT RES CTR CELLULAR GROWTH FACTORS,PARKVILLE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; University of Melbourne; University of Melbourne; University of Melbourne; Walter & Eliza Hall Institute			Ernst, Matthias/D-5111-2012; Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011	Ernst, Matthias/0000-0002-6399-1177; Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889; Murphy, Vincent/0000-0003-2791-303X				BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LEARY AG, 1990, BLOOD, V75, P1960; LOCK P, 1990, MOL CELL BIOL, V10, P4602; METCALF D, 1988, LEUKEMIA, V2, P216; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NICHOLS J, 1994, EXP CELL RES, V215, P237, DOI 10.1006/excr.1994.1338; NICOLA NA, 1997, GROWTH FACTORS CYTOK, V23, P605; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TANIGAWA T, 1995, BLOOD, V85, P379; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YIN TG, 1993, J IMMUNOL, V151, P2555	38	39	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19982	19986		10.1074/jbc.272.32.19982	http://dx.doi.org/10.1074/jbc.272.32.19982			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242667	hybrid			2022-12-27	WOS:A1997XQ05900054
J	Stubbs, MT; Morenweiser, R; Sturzebecher, J; Bauer, M; Bode, W; Huber, R; Piechottka, GP; Matschiner, G; Sommerhoff, CP; Fritz, H; Auerswald, EA				Stubbs, MT; Morenweiser, R; Sturzebecher, J; Bauer, M; Bode, W; Huber, R; Piechottka, GP; Matschiner, G; Sommerhoff, CP; Fritz, H; Auerswald, EA			The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin - Implications for the structure of human mast cell tryptase and its inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION CRYSTAL-STRUCTURE; KAZAL-TYPE INHIBITOR; FACTOR-XA; SUBSTRATE-SPECIFICITY; PROTEASE INHIBITOR; COMPLEMENTARY-DNA; SEQUENCE-ANALYSIS; SERINE-PROTEASE; SQUASH FAMILY; THROMBIN	The x-ray crystal structure of recombinant leech-derived tryptase inhibitor (rLDTI) has been solved to a resolution of 1.9 Angstrom in complex with porcine trypsin. The nonclassical Kazal-type inhibitor exhibits the same overall architecture as that observed in solution and in rhodniin. The complex reveals structural aspects of the mast cell proteinase tryptase. The conformation of the binding region of rLDTI suggests that tryptase has a restricted active site cleft. The basic amino terminus of rLDTI, apparently flexible from previous NMR measurements, approaches the 148-loop of trypsin. This loop has an acidic equivalent in tryptase, suggesting that the basic amino terminus could make favorable electrostatic interactions with the tryptase molecule. A series of rLDTI variants constructed to probe this hypothesis confirmed that the amino-terminal Lys-Lys sequence plays a role in inhibition of human lung tryptase but not of trypsin or chymotrypsin. The location of such an acidic surface patch is in accordance with the known low molecular weight inhibitors of tryptase.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; UNIV MUNICH, KLINIKUM INNENSTADT, KLIN CHEM & KLIN BIOCHEM ABT, CHIRURG KLIN & POLIKLIN, D-80336 MUNICH, GERMANY; KLINIKUM UNIV JENA, ZENTRUM VASK BIOL & MED, D-99089 ERFURT, GERMANY	Max Planck Society; University of Munich; Friedrich Schiller University of Jena			Stubbs, Milton/ABC-7585-2020	Stubbs, Milton/0000-0003-1278-9013				AUERSWALD EA, 1994, BIOL CHEM H-S, V375, P695, DOI 10.1515/bchm3.1994.375.10.695; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BIETH J, 1974, PROTEINASE INHIBITOR, P463; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BRUNGER AT, 1992, XPLOR MANUAL; Burgering MJM, 1997, J MOL BIOL, V269, P395, DOI 10.1006/jmbi.1997.1029; BUTTERFIELD JH, 1990, J LEUKOCYTE BIOL, V47, P409, DOI 10.1002/jlb.47.5.409; CAUGHEY GH, 1993, J PHARMACOL EXP THER, V264, P676; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHEN XM, 1992, J BIOCHEM-TOKYO, V112, P45, DOI 10.1093/oxfordjournals.jbchem.a123863; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FINK E, 1986, BIOL CHEM H-S, V367, P1235, DOI 10.1515/bchm3.1986.367.2.1235; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; HARA T, 1994, THROMB HAEMOSTASIS, V71, P314; HARVIMA IT, 1993, BIOCHEM J, V292, P711, DOI 10.1042/bj2920711; HUANG QC, 1993, J MOL BIOL, V229, P1022, DOI 10.1006/jmbi.1993.1102; HUANG QC, 1994, BBA-PROTEIN STRUCT M, V1209, P77, DOI 10.1016/0167-4838(94)90139-2; ITOH H, 1994, J BIOL CHEM, V269, P3818; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIDO H, 1988, J BIOL CHEM, V263, P18104; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE AGW, 1994, MOSFLM USER GUIDE; LIN GD, 1993, EUR J BIOCHEM, V212, P549, DOI 10.1111/j.1432-1033.1993.tb17692.x; LITTLE SS, 1995, BIOCHEM J, V307, P341, DOI 10.1042/bj3070341; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Morenweiser R, 1997, J BIOL CHEM, V272, P19938, DOI 10.1074/jbc.272.32.19938; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MUHLHAHN P, 1994, FEBS LETT, V355, P290, DOI 10.1016/0014-5793(94)01225-3; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1994, METHOD ENZYMOL, V244, P88; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; SOMMERHOFF CP, 1994, BIOL CHEM H-S, V375, P685, DOI 10.1515/bchm3.1994.375.10.685; STUBBS MT, 1995, FEBS LETT, V375, P103, DOI 10.1016/0014-5793(95)01190-P; STURZEBECHER J, 1989, THROMB RES, V54, P245, DOI 10.1016/0049-3848(89)90232-6; STURZEBECHER J, 1992, BIOL CHEM H-S, V373, P1025, DOI 10.1515/bchm3.1992.373.2.1025; STURZEBECHER J, 1995, BIOL CHEM HOPPESEYLE, V105, P725; TIDWELL RR, 1980, THROMB RES, V19, P339, DOI 10.1016/0049-3848(80)90262-5; TURK D, 1992, THESIS TU MUNCHEN; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; vonderSaal W, 1996, ARCH PHARM, V329, P73, DOI 10.1002/ardp.19963290204; WEBER E, 1981, J MOL BIOL, V140, P109	58	83	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19931	19937		10.1074/jbc.272.32.19931	http://dx.doi.org/10.1074/jbc.272.32.19931			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242660	hybrid			2022-12-27	WOS:A1997XQ05900047
J	Yamauchi, E; Titani, K; Taniguchi, H				Yamauchi, E; Titani, K; Taniguchi, H			Specific binding of acidic phospholipids to microtubule-associated protein MAP1B regulates its interaction with tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; ALZHEIMERS-DISEASE; RAT-BRAIN; MEMBRANE PHOSPHOLIPIDS; MESSENGER-RNA; PHOSPHORYLATION; TAU; IDENTIFICATION; DOMAIN; CELLS	Microtubule-associated protein MAP1B, a major neuronal cytoskeletal protein, is expressed highly during the early stage of brain development and is thought to play an important role in brain development. Although it has been shown that MAP1B localizes both in cytosol and particulate fractions, the underlying molecular mechanism in the membrane localization has yet to be elucidated. In the present study, we show that MAP1B purified from young rat brain can bind to acidic phospholipids, such as phosphatidylserine, but not to a neutral phospholipid, phosphatidylcholine. Furthermore, the binding of MAP1B to taxol-stabilized microtubules was inhibited by the addition of phosphatidylserine or phosphatidylinositol. The addition of phosphatidylcholine showed no effect on the binding of MAP1B to the microtubules. A 120-kDa microtubule-binding fragment of MAP1B was also released from microtubules by the addition of acidic phospholipids. Synthetic peptides derived from the C-terminal half of the tubulin-binding domain, but not that corresponding to the N-terminal half, bound to acidic phospholipids specifically. These results suggest that MAP1B binds to biological membranes through its tubulin-binding site, and the binding may play a regulatory role in MAP1B-microtubule interaction.	FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DEPT BIOMED POLYMER SCI,TOYOAKE,AICHI 47011,JAPAN; NAGOYA CITY UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,MIZUHO KU,NAGOYA,AICHI 467,JAPAN	Fujita Health University; Nagoya City University			Taniguchi, Hisaaki/I-9171-2012					AINSZTEIN AM, 1994, J BIOL CHEM, V269, P28465; ANDERSON PJ, 1979, J BIOL CHEM, V254, P2168; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5404, DOI 10.1073/pnas.82.16.5404; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P1270, DOI 10.1073/pnas.93.3.1270; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUZMAN L, 1994, MOL CELL BIOCHEM, V131, P105, DOI 10.1007/BF00925946; HASEGAWA M, 1990, NEURON, V4, P909, DOI 10.1016/0896-6273(90)90144-5; HAYACHI N, 1997, IN PRESS TECHNIQUES, V3; Hayashi N, 1997, J BIOL CHEM, V272, P7639, DOI 10.1074/jbc.272.12.7639; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; Lee VMY, 1996, ANN NY ACAD SCI, V777, P107, DOI 10.1111/j.1749-6632.1996.tb34408.x; Liu D, 1996, GENE, V171, P307, DOI 10.1016/0378-1119(95)00061-5; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; Matsubara M, 1996, BIOCHEMISTRY-US, V35, P14651, DOI 10.1021/bi9613988; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MURAMOTO K, 1994, BIOCHEM BIOPH RES CO, V205, P1467, DOI 10.1006/bbrc.1994.2830; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Pedrotti B, 1996, FEBS LETT, V388, P131, DOI 10.1016/0014-5793(96)00520-0; PEDROTTI B, 1995, CELL MOTIL CYTOSKEL, V30, P301, DOI 10.1002/cm.970300407; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROCHA MG, 1995, DEV BRAIN RES, V89, P47, DOI 10.1016/0165-3806(95)00105-M; SAFAEI R, 1989, J NEUROCHEM, V52, P1871, DOI 10.1111/j.1471-4159.1989.tb07270.x; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SURRIDGE CD, 1992, BIOCHEMISTRY-US, V31, P6140, DOI 10.1021/bi00141a026; SURRIDGE CD, 1994, BIOCHEMISTRY-US, V33, P8051, DOI 10.1021/bi00192a009; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; ULLOA L, 1993, J NEUROCHEM, V61, P961, DOI 10.1111/j.1471-4159.1993.tb03609.x; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; YAMAUCHI PS, 1987, J BIOL CHEM, V262, P3369; ZAUNER W, 1992, EUR J CELL BIOL, V57, P66	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22948	22953		10.1074/jbc.272.36.22948	http://dx.doi.org/10.1074/jbc.272.36.22948			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278459	hybrid			2022-12-27	WOS:A1997XV49200081
J	Dessauer, CW; Scully, TT; Gilman, AG				Dessauer, CW; Scully, TT; Gilman, AG			Interactions of forskolin and ATP with the cytosolic domains of mammalian adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALPHA-SUBUNITS; P-GLYCOPROTEIN; BINDING; KINETICS; PURIFICATION; ACTIVATION; INHIBITION; ADENOSINE; FORM	Fragments of the two cytoplasmic domains of mammalian adenylyl cyclases can be synthesized independently (and abundantly) as soluble proteins; G(s alpha)- and forskolin-stimulated enzymatic activity is restored upon their mixture. We have utilized this system to characterize the interactions of adenylyl cyclase with forskolin and its substrate, ATP, In the presence of G(s alpha), adenylyl cyclase is activated in response to occupation of only one forskolin-binding site, A single binding site for forskolin was identified by equilibrium dialysis; its K-d (0.1 mu M) corresponds to the EC50 for enzyme activation, The affinity of forskolin for adenylyl cyclase is greatly reduced in the absence of G(s alpha) (similar to 40 mu M). Binding of forskolin to the individual cytoplasmic domains of the enzyme was not detected. A single binding site for the ATP analog, alpha,beta-methylene ATP (Ap(CH2)pp), was also detected by equilibrium dialysis, Such binding was not observed with the individual domains, Binding of Ap(CH2)pp was unaffected by P-site inhibitors of adenylyl cyclase, A modified P-loop sequence located near the carboxyl terminus of adenylyl cyclase has been implicated in ATP binding, Mutation of the conserved, non-glycine residues within this region caused no significant changes in the K-m for ATP or the K-i for Ap(CH2)pp. It thus seems unlikely that this region is part of the active site, However, a mutation in the C-1 domain (E518A) cause a 10-fold decrease in the binding affinity for Ap(CH2)pp, This residue and the active site of the enzyme may lie at the interface between the two cytosolic domains.			Dessauer, CW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.		Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34497, GM16905] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; Droste M, 1996, FEBS LETT, V391, P209, DOI 10.1016/0014-5793(96)00735-1; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; FLORIO VA, 1983, THESIS U VIRGINIA; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JOHNSON RA, 1979, J BIOL CHEM, V254, P1094; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEWIN LR, 1995, J BIOL CHEM, V270, P7573; LONDOS C, 1977, J BIOL CHEM, V252, P5957; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Sutkowski EM, 1996, MOL PHARMACOL, V50, P299; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELTON AF, 1980, BIOCHIM BIOPHYS ACTA, V615, P252, DOI 10.1016/0005-2744(80)90028-5; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; YEE R, 1978, J BIOL CHEM, V253, P8902; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	31	103	103	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22272	22277		10.1074/jbc.272.35.22272	http://dx.doi.org/10.1074/jbc.272.35.22272			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268376	hybrid			2022-12-27	WOS:A1997XT85000088
J	Vacca, RA; Giannattasio, S; Graber, R; Sandmeier, E; Marra, E; Christen, P				Vacca, RA; Giannattasio, S; Graber, R; Sandmeier, E; Marra, E; Christen, P			Active-site Arg->Lys substitutions alter reaction and substrate specificity of aspartate aminotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ASPARTATE; AMINO-ACIDS; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURES; MECHANISM; RESIDUE; MUTANT; ENZYME; RECOGNITION; HISTIDINE	Arg(386) and Arg(292) of aspartate aminotransferase bind the alpha and the distal carboxylate group, respectively, of dicarboxylic substrates. Their substitution with lysine residues markedly decreased aminotransferase activity. The k(cat) values with L-aspartate and 2-oxoglutarate as substrates under steady-state conditions at 25 degrees C were 0.5, 2.0, and 0.03 s(-1) for the R292K, R386K, and R292K/R386K mutations, respectively, k(cat) of the wild-type enzyme being 220 s(-1). Longer dicarboxylic substrates did not compensate for the shorter side chain of the lysine residues. Consistent with the different roles of Arg(292) and Arg(386);, substrate binding, the effects of their substitution on the activity toward long chain monocarboxylic (norleucine/2-oxocaproic acid) and aromatic substrates diverged. Whereas the R292K mutation did not impair the aminotransferase activity toward these substrates, the effect of the R386K substitution was similar to that on the activity toward dicarboxylic substrates. All three mutant enzymes catalyzed as side reactions the beta-decarboxylation of L-aspartate and the racemization of amino acids at faster rates than the wild-type enzyme. The changes in reaction specificity were most pronounced in aspartate aminotransferase R292K, which decarboxylated L-aspartate to L-alanine 15 times faster (k(cat) = 0.002 s(-1)) than the wild-type enzyme. The rates of racemization of L-aspartate, L-glutamate, and L-alanine were 3, 5, and 2 times, respectively, faster than with the wild-type enzyme. Thus, Arg --> Lys substitutions in the active site of aspartate aminotransferase decrease aminotransferase activity but increase other pyridoxal 5'-phosphate-dependent catalytic activities. Apparently, the reaction specificity of pyridoxal 5'-phosphate-dependent enzymes is not only achieved by accelerating the specific reaction but also by preventing potential side reactions of the coenzyme substrate adduct.	UNIV ZURICH, INST BIOCHEM, CH-8057 ZURICH, SWITZERLAND; CNR, CTR STUDIO MITOCONDRI & METAB ENERGET, I-70126 BARI, ITALY; CNR, CTR STUDIO MITOCONDRI & METAB ENERGET, TRANI, ITALY; UNIV ZURICH, INST BIOCHEM, CH-8057 ZURICH, SWITZERLAND	University of Zurich; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Zurich			Vacca, Rosa Anna/AAX-1388-2020	Vacca, Rosa Anna/0000-0003-2438-6449; Giannattasio, Sergio/0000-0001-5559-5556				ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ALMO SC, 1994, PROTEIN ENG, V7, P405, DOI 10.1093/protein/7.3.405; Arnone A, 1985, TRANSAMINASES, P138; CRONIN CN, 1988, BIOCHEMISTRY-US, V27, P4572, DOI 10.1021/bi00412a052; DANISHEFSKY AT, 1991, BIOCHEMISTRY-US, V30, P1980, DOI 10.1021/bi00221a035; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; FONDA ML, 1970, J BIOL CHEM, V245, P2709; FRATTE SD, 1994, EUR J BIOCHEM, V225, P395, DOI 10.1111/j.1432-1033.1994.00395.x; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; GRABER R, 1995, EUR J BIOCHEM, V232, P686, DOI 10.1111/j.1432-1033.1995.tb20861.x; HART KW, 1987, BIOCHIM BIOPHYS ACTA, V914, P294, DOI 10.1016/0167-4838(87)90289-5; HAYASHI H, 1989, BIOCHEM BIOPH RES CO, V159, P337, DOI 10.1016/0006-291X(89)92443-1; HWANG JK, 1988, NATURE, V334, P270, DOI 10.1038/334270a0; INOUE Y, 1989, J BIOL CHEM, V264, P9673; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; KAMITORI S, 1987, J BIOCHEM, V101, P813, DOI 10.1093/jb/101.3.813; KAMITORI S, 1990, J BIOCHEM-TOKYO, V108, P175, DOI 10.1093/oxfordjournals.jbchem.a123178; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KOCHHAR S, 1992, EUR J BIOCHEM, V203, P563, DOI 10.1111/j.1432-1033.1992.tb16584.x; KOCHHAR S, 1988, EUR J BIOCHEM, V175, P433, DOI 10.1111/j.1432-1033.1988.tb14213.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; MALASHKEVICH VN, 1993, BIOCHEMISTRY-US, V32, P13451, DOI 10.1021/bi00212a010; MALCOLM BA, 1985, BIOCHEM BIOPH RES CO, V132, P915, DOI 10.1016/0006-291X(85)91894-7; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; MITCHELL JBO, 1992, J MOL BIOL, V226, P251, DOI 10.1016/0022-2836(92)90137-9; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1743, DOI 10.1002/pro.5560040909; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; TONEY MD, 1991, BIOCHEMISTRY-US, V30, P7456, DOI 10.1021/bi00244a013; VACCA RA, 1995, EUR J BIOCHEM, V227, P481, DOI 10.1111/j.1432-1033.1995.tb20413.x; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; YAN HG, 1990, BIOCHEMISTRY-US, V29, P6385, DOI 10.1021/bi00479a007; YANO T, 1991, J BIOL CHEM, V266, P6079; YANO T, 1993, J MOL BIOL, V234, P1218, DOI 10.1006/jmbi.1993.1672; ZIAK M, 1993, EUR J BIOCHEM, V211, P475, DOI 10.1111/j.1432-1033.1993.tb17573.x	38	39	41	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21932	21937		10.1074/jbc.272.35.21932	http://dx.doi.org/10.1074/jbc.272.35.21932			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268327	hybrid			2022-12-27	WOS:A1997XT85000039
J	Araki, T; Zimonjic, DB; Popescu, NC; Milbrandt, J				Araki, T; Zimonjic, DB; Popescu, NC; Milbrandt, J			Mechanism of homophilic binding mediated by ninjurin, a novel widely expressed adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DILATED CARDIOMYOPATHY; MASA SYNDROME; GENE; CELLS; HYBRIDIZATION; LOCALIZATION; RECEPTORS; MUTATIONS; FISH; RNA	Ninjurin is a novel protein that is up-regulated after nerve injury both in dorsal root ganglion (DRG) neurons and in Schwann cells, We previously reported that ninjurin demonstrates properties of a homophilic adhesion molecule and promotes neurite outgrowth from primary cultured DRG neurons, We have now found that ninjurin is widely expressed in both adult and embryonic tissues, primarily in those of epithelial origin, Aggregation assays were used to demonstrate that ninjurin-mediated adhesion requires divalent cations and is an energy-dependent process, The critical domain for ninjurin-mediated homophilic adhesion was localized to an Ii-residue region (between Pro(26) and Asn(37)) by mutagenesis and by employing synthetic oligopeptides as competitive inhibitors of ninjurin-mediated adhesion, Of particular importance are the Trp residue at position 29 and the 3 arginines in the region, Furthermore, we show that the peptide which inhibits aggregation of Jurkat cells expressing ninjurin is also capable of blocking the ability of ninjurin to promote neurite extension from DRG neurons, Using FISH analysis, the ninjurin gene was localized to human chromosome 9q22. Several genetic diseases of unknown etiology have been mapped to this region, including hereditary sensory neuropathy type 1, self-healing squamous epithelioma, split-hand/foot deformity type 1, and familial dilated cardiomyopathy.	WASHINGTON UNIV, SCH MED, DEPT PATHOL & MED, DIV LAB MED, ST LOUIS, MO 63110 USA; NCI, MOL CYTOGENET SECT, EXPT CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Zimonjic, Drazen/AAX-7513-2020; Araki, Toshiyuki/H-4289-2019	Araki, Toshiyuki/0000-0003-3625-2042; Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL CANCER INSTITUTE [P01CA053524] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53524] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1993, SEMIN CANCER BIOL, V4, P215; Araki T, 1996, NEURON, V17, P353, DOI 10.1016/S0896-6273(00)80166-X; Bernstein Lori R., 1994, Current Opinion in Oncology, V6, P106, DOI 10.1097/00001622-199401000-00015; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JOHNSON KR, 1995, GENOMICS, V29, P457, DOI 10.1006/geno.1995.9981; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; KRAJINOVIC M, 1995, AM J HUM GENET, V57, P846; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Nicholson GA, 1996, NAT GENET, V13, P101, DOI 10.1038/ng0596-101; PATEL DD, 1993, SEMIN IMMUNOL, V5, P283; RAO Y, 1994, J BIOL CHEM, V269, P27540; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Svaren J, 1996, MOL CELL BIOL, V16, P3545; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VITS L, 1994, NAT GENET, V7, P408, DOI 10.1038/ng0794-408; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; XU J, 1994, CANCER GENET CYTOGEN, V74, P1, DOI 10.1016/0165-4608(94)90020-5; YAMADA KM, 1987, J CELL PHYSIOL, V130, P21, DOI 10.1002/jcp.1041300105; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V80, P100, DOI 10.1016/0165-4608(94)00161-4	33	64	71	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21373	21380		10.1074/jbc.272.34.21373	http://dx.doi.org/10.1074/jbc.272.34.21373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261151	hybrid			2022-12-27	WOS:A1997XR78900061
J	Mizushima, T; Yokoyama, K; Mima, S; Tsuchiya, T; Sekimizu, K				Mizushima, T; Yokoyama, K; Mima, S; Tsuchiya, T; Sekimizu, K			Inhibition of thymidine transport in dnaA mutants of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION PROTEIN; THYA GENE; REPLICATION; CHROMOSOME; ENZYME; PRODUCT; ORIGIN; KINASE; CELLS	DnaA protein is the initiator of chromosomal DNA replication in Escherichia coli, We report here our evidence that thymidine transport across cytoplasmic membranes in temperature-sensitive dnaA mutants is greatly decreased at a permissive temperature for growth of the mutants, Complementation analysis with a plasmid containing the wild type dnaA gene and P1 phage-mediated transduction confirmed that mutations in the dnaA gene were responsible for the phenotype, A low level of nucleoside transport in the dnaA mutant was specific for thymidine; transport activities for other nucleosides were much the same as those in wild type cells, Membrane vesicles prepared from the dnaA mutant showed much the same activity of thymidine transport as did those from the wild type cells, No significant difference in the activity of thymidine kinase, which is known to facilitate thymidine transport, was seen between the mutant and the wild type cells. An increase in the pool of dTTP, a negative regulator far thymidine kinase, was observed in the dnaA mutant, Based on these observations, we suggest that inhibition of thymidine transport in dnaA mutants is caused by increases in the dTTP pool.	KYUSHU UNIV,FAC PHARMACEUT SCI,HIGASHI KU,FUKUOKA 81282,JAPAN; OKAYAMA UNIV,FAC PHARMACEUT SCI,OKAYAMA 700,JAPAN	Kyushu University; Okayama University								BELFORT M, 1983, P NATL ACAD SCI-BIOL, V80, P1858, DOI 10.1073/pnas.80.7.1858; BELFORT M, 1983, P NATL ACAD SCI-BIOL, V80, P4914, DOI 10.1073/pnas.80.16.4914; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; DUBE DK, 1991, GENE, V99, P25, DOI 10.1016/0378-1119(91)90029-B; ECHOLS H, 1961, J MOL BIOL, V3, P425, DOI 10.1016/S0022-2836(61)80055-7; FILPULA D, 1977, J BACTERIOL, V130, P107, DOI 10.1128/JB.130.1.107-113.1977; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; IWAKURA M, 1995, J BIOCHEM-TOKYO, V118, P67, DOI 10.1093/oxfordjournals.jbchem.a124893; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; KOMATSU Y, 1973, BIOCHIM BIOPHYS ACTA, V330, P206, DOI 10.1016/0005-2736(73)90226-5; KUBISTA M, 1987, BIOCHEMISTRY-US, V26, P4545, DOI 10.1021/bi00388a057; LINDBERG U, 1970, ANAL BIOCHEM, V34, P152, DOI 10.1016/0003-2697(70)90096-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIZUSHIMA T, 1994, J BACTERIOL, V176, P5544, DOI 10.1128/JB.176.17.5544-5546.1994; Mizushima T, 1996, J BIOL CHEM, V271, P3633; Mizushima T, 1996, J BIOL CHEM, V271, P25178, DOI 10.1074/jbc.271.41.25178; Mizushima T, 1996, BIOCHEM BIOPH RES CO, V218, P137, DOI 10.1006/bbrc.1996.0024; Mizushima T, 1996, BIOCHEMISTRY-US, V35, P11512, DOI 10.1021/bi953088f; Mizushima T, 1996, MOL GEN GENET, V252, P212, DOI 10.1007/BF02173222; Mollgaard H, 1983, METABOLISM NUCLEOTID, P149; MUNCHPETERSEN A, 1976, J CELL PHYSIOL, V89, P551, DOI 10.1002/jcp.1040890410; MUNCHPETERSEN A, 1979, J BIOL CHEM, V254, P3730; MYGIND B, 1975, EUR J BIOCHEM, V59, P365, DOI 10.1111/j.1432-1033.1975.tb02463.x; NEUHARD J, 1971, EUR J BIOCHEM, V20, P36, DOI 10.1111/j.1432-1033.1971.tb01359.x; OKAZAKI R, 1964, J BIOL CHEM, V239, P275; SAITO H, 1984, J GEN MICROBIOL, V130, P1863; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SHINPUKU T, 1995, BIOCHEM BIOPH RES CO, V212, P84, DOI 10.1006/bbrc.1995.1939; SINGER M, 1989, MICROBIOL REV, V53, P1; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	37	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21195	21200		10.1074/jbc.272.34.21195	http://dx.doi.org/10.1074/jbc.272.34.21195			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261126	hybrid			2022-12-27	WOS:A1997XR78900036
J	Ryan, DG; Lin, TW; Brownie, E; Bridger, WA; Wolodko, WT				Ryan, DG; Lin, TW; Brownie, E; Bridger, WA; Wolodko, WT			Mutually exclusive splicing generates two distinct isoforms of pig heart succinyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; COENZYME-A SYNTHETASE; ESCHERICHIA-COLI; ALPHA-SUBUNIT; DIRECTED MUTAGENESIS; EXPRESSION; DNA; SITE; THIOKINASE; SEQUENCE	We have identified two distinct cDNAs encoding the cu-subunit of pig heart succinyl-CoA synthetase. The derived amino acid sequence of one of these, PH alpha 57, is highly similar to the cti-subunit of the rat liver precursor enzyme. The second cDNA, PH alpha 108, was identical throughout its sequence with PH alpha 57 except for a stretch of 108 nucleotides which replaced a 57 nucleotide sequence in PH alpha 57. Coexpression of either alpha-subunit cDNA with a common pig heart P-subunit cDNA produced isozymes with GTP-specific enzyme activity, The enzyme produced by the combination of PH alpha 57 and the beta-subunit cDNA resembled the ''native'' enzyme purified from pig heart tissue, In contrast, the expressed enzyme from the combination with PH alpha 108 was clearly distinguishable from the native enzyme by, for example, hydroxyapatite chromatography, Moreover, it was now apparent that this isoform had been observed in previous preparations of the native enzyme, but always in very low amounts and, thus, disregarded, We have shown further that the two mRNA transcripts arise from a single gene and are generated by mutually exclusive splicing, The production of the PH alpha 108 message involves the use of a non-canonical splice site pair, AT-AA, Finally, we provide evidence for tissue specific regulation in the splicing of the PH alpha 108 message.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA	University of Alberta								BACCANARI DP, 1973, J BIOL CHEM, V248, P15; BACCANARI DP, 1973, BIOCHIM BIOPHYS ACTA, V119, P226; BAILEY DL, 1993, PROTEIN SCI, V2, P1255, DOI 10.1002/pro.5560020808; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRIDGER WA, 1971, BIOCHEM BIOPH RES CO, V42, P948, DOI 10.1016/0006-291X(71)90522-5; BROWNIE ER, 1972, CAN J BIOCHEM CELL B, V50, P719, DOI 10.1139/o72-100; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; CAROTHERS AM, 1993, MOL CELL BIOL, V13, P5085, DOI 10.1128/MCB.13.8.5085; CHA S, 1967, J BIOL CHEM, V242, P2577; Cha S, 1969, METHOD ENZYMOL, V13, P62, DOI 10.1016/0076-6879(69)13017-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAAS MJ, 1988, ANAL BIOCHEM, V168, P239, DOI 10.1016/0003-2697(88)90313-2; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; HENNING WD, 1988, P NATL ACAD SCI USA, V85, P1432, DOI 10.1073/pnas.85.5.1432; HUYNH TV, 1985, DNA CLONING, V1; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JACOB M, 1989, NUCLEIC ACIDS RES, V17, P2159, DOI 10.1093/nar/17.6.2159; JENKINS TM, 1986, FEBS LETT, V205, P215, DOI 10.1016/0014-5793(86)80900-0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABBE RF, 1965, BIOCHIM BIOPHYS ACTA, V111, P403, DOI 10.1016/0304-4165(65)90050-4; LAHTI CJ, 1992, J BACTERIOL, V174, P6822, DOI 10.1128/JB.174.21.6822-6830.1992; LASCELLES J, 1964, TETRAPYRROLE BIOSYNT, P84; LIN TW, 1992, J BIOL CHEM, V267, P975; LUO GX, 1991, J BIOL CHEM, V266, P20781; MAJUMDAR R, 1990, BIOCHEM CELL BIOL, V68, P292, DOI 10.1139/o90-040; Maniatis T., 1982, MOL CLONING; MCCLELLAN JA, 1980, COMP BIOCHEM PHYS B, V67, P679, DOI 10.1016/0305-0491(80)90430-7; MESHKOVA NP, 1970, BIOCHEMISTRY-USSR+, V35, P374; Mount SM, 1996, SCIENCE, V271, P1690, DOI 10.1126/science.271.5256.1690; MURAKAMI K, 1972, J BIOL CHEM, V247, P6247; NISHIMURA JS, 1986, ADV ENZYMOL RAMB, V58, P141; NISHIYAMA M, 1991, MOL GEN GENET, V226, P1, DOI 10.1007/BF00273580; Ottaway JH, 1979, BIOCHEM SOC T, V7, P411, DOI 10.1042/bst0070411; OTTAWAY JH, 1981, INT J BIOCHEM, V13, P401, DOI 10.1016/0020-711X(81)90111-7; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; REED SI, 1989, J CELL SCI, P29; RYAN DG, 1991, J MOL BIOL, V219, P165, DOI 10.1016/0022-2836(91)90559-O; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Stryer L., 1988, BIOCHEMISTRY-US; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; WANG T, 1972, BIOCHEMISTRY-US, V11, P2067, DOI 10.1021/bi00761a011; WEITZMAN PDJ, 1986, FEBS LETT, V199, P57, DOI 10.1016/0014-5793(86)81223-6; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	53	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21151	21159		10.1074/jbc.272.34.21151	http://dx.doi.org/10.1074/jbc.272.34.21151			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261120	hybrid			2022-12-27	WOS:A1997XR78900030
J	Shao, DL; Lazar, MA				Shao, DL; Lazar, MA			Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CONVERSION; TRIGLYCERIDE ACCUMULATION; TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE; PPAR-GAMMA; EXPRESSION; ENHANCER; PPAR-GAMMA-2; ADIPOGENESIS; INHIBITION	Terminal differentiation of stem cells is characterized by cessation of cell proliferation as well as changes in cell morphology associated with the differentiated state. For adipocyte differentiation, independent lines of evidence show that the transcription factors peroxisome proliferator activated receptor gamma (PPAR gamma) and CCAAT/enhancer-binding protein alpha (C/EBP alpha) as well as the tumor suppressor retinoblastoma (Rb) protein are essential. How these proteins promote adipocyte conversion and how they function cooperatively during the differentiation process remain unclear. We have used retinoic acid (RA) inhibition of adipogenesis to investigate these issues. RA blocked adipogenesis of 3T3-L1 cells induced to differentiate by ectopic expression of PPAR gamma and C/EBP alpha independently or together. However, under these circumstances RA was only effective at preventing adipogenesis when added prior to confluence, suggesting that factors involved in regulation of the cell cycle might play a role in establishing the commitment state of adipogenesis that is insensitive to RA. During differentiation of wild type 3T3 L1 preadipocytes, we found that Rb protein is hyperphosphorylated early in adipogenesis, corresponding to previously quiescent cells reentering the cell cycle, and later becomes hypophosphorylated, The data suggest that, together with the coexpression of PPAR gamma and C/EBP alpha, permanent exit from the cell cycle establishes the irreversible commitment to adipocyte differentiation.	UNIV PENN,SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,DIV ENDOCRINOL DIABET & METAB,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			Lazar, Mitchell A/AAF-3738-2019		NIDDK NIH HHS [DK49780] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049780] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Higgins C, 1996, J VIROL, V70, P745, DOI 10.1128/JVI.70.2.745-752.1996; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; IMAKADO S, 1995, GENE DEV, V9, P347; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; KURIHARCUCH W, 1978, CELL, V14, P53, DOI 10.1016/0092-8674(78)90300-8; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Livneh E, 1996, ONCOGENE, V12, P1545; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; STONE RL, 1990, DIFFERENTIATION, V45, P119, DOI 10.1111/j.1432-0436.1990.tb00465.x; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Xue JC, 1996, MOL CELL BIOL, V16, P1567; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	35	230	241	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21473	21478		10.1074/jbc.272.34.21473	http://dx.doi.org/10.1074/jbc.272.34.21473			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261165	hybrid			2022-12-27	WOS:A1997XR78900075
J	Brix, J; Dietmeier, K; Pfanner, N				Brix, J; Dietmeier, K; Pfanner, N			Differential recognition of preproteins by the purified cytosolic domains of the mitochondrial import receptors Tom20, Tom22, and Tom70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; GENERAL INSERTION PORE; PRECURSOR PROTEINS; YEAST MITOCHONDRIA; COMPLEX; MOM19; PRESEQUENCE; SUBUNIT; CARRIER; MOM22	The preprotein translocase of the outer mitochondrial membrane (Tom) is a multi-subunit complex required for specific recognition and membrane translocation of nuclear-encoded preproteins. We have expressed and purified the cytosolic domains of three postulated import receptors, Tom20, Tom22, and Tom70. Each receptor domain is able to bind mitochondrial preproteins but with different specificity, Tom20 binds both preproteins with N-terminal presequences and preproteins with internal targeting signals; the binding is enhanced by the addition of salt. Tom22 selectively recognizes presequence-carrying preproteins in a salt-sensitive manner, Tom70 preferentially binds preproteins with internal targeting information, A chemically synthesized presequence peptide competes with preproteins for binding to Tom20 and Tom22 but not to Tom70. We conclude that each of the three import receptors binds preproteins independently and by a different mechanism, Both Tom20 and Tom22 function as presequence receptors.	UNIV FREIBURG,INST BIOCHEM & MOL BIOL,D-79104 FREIBURG,GERMANY	University of Freiburg			Pfanner, Nikolaus/AAV-7878-2021					ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Bomer U, 1996, FEBS LETT, V382, P153, DOI 10.1016/0014-5793(96)00156-1; DIETMEIER K, 1997, IN PRESS NATURE; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; HONLINGER A, 1995, BIOL CHEM H-S, V376, P515; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schleiff E, 1997, FEBS LETT, V404, P314, DOI 10.1016/S0014-5793(97)00145-2; Schlossmann J, 1996, J BIOL CHEM, V271, P17890, DOI 10.1074/jbc.271.30.17890; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; TAMM LK, 1990, FEBS LETT, V272, P29, DOI 10.1016/0014-5793(90)80441-K; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; ZARA V, 1992, J BIOL CHEM, V267, P12077	44	210	212	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20730	20735		10.1074/jbc.272.33.20730	http://dx.doi.org/10.1074/jbc.272.33.20730			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252394	hybrid			2022-12-27	WOS:A1997XR22100064
J	Haataja, L; Groffen, J; Heisterkamp, N				Haataja, L; Groffen, J; Heisterkamp, N			Characterization of RAC3, a novel member of the Rho family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; NADPH OXIDASE; RAS TRANSFORMATION; ACTIVATING PROTEIN; EXCHANGE PROTEINS; RESPIRATORY BURST; MESSENGER-RNA; CDC42 GTPASES; GROWTH-FACTOR; CELL-CYCLE	The small GTP-binding proteins Rad and Rac2 are critically important in regulating multiple signal transduction pathways in eukaryotic cells, Here we report the isolation of a novel third Rac family member, Rac3. Rac3 differs from Rac1/2 at its carboxyl-terminal end, a domain associated with subcellular localization and binding to specific cellular regulators. RAC3 mRNA expression patterns differ from those of RAGS, which is hematopoietic specific and also from those of RAC1. The RAC3 gene was mapped to chromosome 17q23-25, a region frequently deleted in breast cancer. Rac3 protein levels ape not affected by organization of the actin cytoskeleton but remarkably, are serum-inducible, Rac3 is an active GTPase, and this activity is regulated by Bcr. When constitutively activated, Rac3 is able to stimulate efficiently the c-Jun amino-terminal kinase signaling pathway, These findings support a role for Rac3 in intracellular signaling.	CHILDRENS HOSP LOS ANGELES,RES INST,SECT MOL CARCINOGENESIS,DEPT PATHOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90027	Children's Hospital Los Angeles; University of Southern California			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NCI NIH HHS [CA47456, CA 50248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456, R01CA050248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ANDO S, 1992, J BIOL CHEM, V267, P25709; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUANG TH, 1993, J BIOL CHEM, V268, P775; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; CORNELIS RS, 1993, ONCOGENE, V8, P781; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; Foster R, 1996, MOL CELL BIOL, V16, P2689; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOLL J, 1991, ONCOGENE, V6, P863; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SHIRSAT NV, 1990, ONCOGENE, V5, P769; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; TAN EC, 1993, J BIOL CHEM, V268, P27291; TENHOEVE J, 1994, CANCER RES, V54, P2563; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZALCMAN G, 1995, ONCOGENE, V10, P1935; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	45	202	212	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20384	20388		10.1074/jbc.272.33.20384	http://dx.doi.org/10.1074/jbc.272.33.20384			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252344	Green Published, hybrid			2022-12-27	WOS:A1997XR22100014
J	Wu, SM; Boyer, CM; Pizzo, SV				Wu, SM; Boyer, CM; Pizzo, SV			The binding of receptor-recognized alpha(2)-macroglobulin to the low density lipoprotein receptor-related protein and the alpha(2)M signaling receptor is decoupled by oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; FAST FORMS; OXYGEN RADICALS; MACROGLOBULIN RECEPTOR; PERITONEAL-MACROPHAGES; ELECTRON-MICROSCOPY; HYPOCHLOROUS ACID; ESCHERICHIA-COLI; AMINO-ACIDS; MYELOPEROXIDASE	Receptor-recognized forms of alpha(2)-macroglobulin (alpha(2)M*) bind to two classes of cellular receptors, a high affinity site comprising approximately 1500 sites/cell and a lower affinity site comprising about 60,000 sites/cell. The latter class has been identified as the so-called low density lipoprotein receptor-related protein (LRP), Ligation of receptors distinct from LRP activates cell signaling pathways, Strong circumstantial evidence suggests that the high affinity binding sites are responsible for cell signaling induced by alpha(2)M*. Using sodium hypochlorite, a powerful oxidant produced by the H2O2-myeloperoxidase-Cl- system, we now demonstrate that binding to the high affinity sites correlates directly with activation of the signaling cascade, Oxidation of alpha(2)M* using 200 mu M hypochlorite completely abolishes its binding to LRP without affecting its ability to activate the macrophage signaling cascade, Scatchard analysis shows binding to a single class of high affinity sites (K-d -71 +/- 12 pM). Surprisingly, oxidation of native alpha(2)-macroglobulin (alpha(2)M) with 125 mu M hypochlorite results in the exposure of its receptor-binding site to LRP, but the ligand is unable to induce cell signaling, Scatchard analysis shows binding to a single class of lower affinity sites (K-d - 0.7 +/- 0.15 nM), Oxidation of a cloned and expressed carboxyl-terminal 20-kDa fragment of alpha(2)M (RBF), which is capable of binding to both LRP and the signaling receptor, results in no significant change in its binding K-d, supporting our earlier finding that the oxidation-sensitive site is predominantly outside of RBF, Attempts to understand the mechanism responsible for the selective exposure of LRP-binding sites in oxidized native alpha(2)M suggest that partial protein unfolding may be the most likely mechanism, These studies provide strong evidence that the high affinity sites (K-d - 71 pM) are the alpha(2)M* signaling receptor.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University				Wu, Sean/0000-0002-0000-3821	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN GR, 1995, J BIOL CHEM, V270, P25133, DOI 10.1074/jbc.270.42.25133; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BENNETT B, 1992, J IMMUNOL METHODS, V153, P31, DOI 10.1016/0022-1759(92)90302-A; BIRKENMEIER G, 1993, J IMMUNOL METHODS, V162, P59, DOI 10.1016/0022-1759(93)90407-X; CHU CT, 1994, LAB INVEST, V71, P792; CHU G, 1994, J BIOL CHEM, V269, P787; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; GONIAS SL, 1988, J BIOL CHEM, V263, P393; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1981, J BIOL CHEM, V256, P2478; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HOFFMAN M, 1988, AGENTS ACTIONS, V25, P360, DOI 10.1007/BF01965043; HOFFMAN M, 1983, BIOCHIM BIOPHYS ACTA, V760, P421, DOI 10.1016/0304-4165(83)90384-7; HOLTET TL, 1994, FEBS LETT, V344, P242, DOI 10.1016/0014-5793(94)00349-1; Howard GC, 1996, ARCH BIOCHEM BIOPHYS, V333, P19, DOI 10.1006/abbi.1996.0359; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; HUSSAIN A, 1970, J PHARM SCI, V59, P1168, DOI 10.1002/jps.2600590824; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; ISAACS IJ, 1988, J BIOL CHEM, V263, P6709; KRIEGER T, 1994, ANN REV BIOCH, V63, P601; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; MARTINI JL, 1989, BIOCHIMIE, V71, P325, DOI 10.1016/0300-9084(89)90004-7; MARYNEN P, 1981, J IMMUNOL, V127, P1782; Misra UK, 1996, J CELL BIOCHEM, V61, P61, DOI 10.1002/(SICI)1097-4644(19960401)61:1<61::AID-JCB8>3.3.CO;2-N; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MISRA UK, 1994, J BIOL CHEM, V269, P18303; Misra UK, 1996, J CELL BIOCHEM, V61, P39, DOI 10.1002/(SICI)1097-4644(19960401)61:1<39::AID-JCB6>3.3.CO;2-8; Nielsen KL, 1996, J BIOL CHEM, V271, P12909, DOI 10.1074/jbc.271.22.12909; OHLSSON K, 1975, EUR J CLIN INVEST, V5, P221, DOI 10.1111/j.1365-2362.1975.tb02288.x; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; PETERSEN CM, 1993, DAN MED BULL, V40, P409; PIZZO SV, 1986, BIOCHEM J, V238, P217, DOI 10.1042/bj2380217; REDDY VY, 1994, J BIOL CHEM, V269, P4683; REDDY VY, 1989, J BIOL CHEM, V264, P13801; ROCHE PA, 1988, J BIOL CHEM, V263, P6715; SALVESEN G, 1992, FEBS LETT, V313, P198, DOI 10.1016/0014-5793(92)81443-P; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; STELMASZYNSKA T, 1978, EUR J BIOCHEM, V92, P301, DOI 10.1111/j.1432-1033.1978.tb12748.x; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; THOMAS EL, 1979, INFECT IMMUN, V23, P522, DOI 10.1128/IAI.23.2.522-531.1979; THOMAS EL, 1979, INFECT IMMUN, V25, P117; UHING RJ, 1991, BIOCHIM BIOPHYS ACTA, V1093, P115, DOI 10.1016/0167-4889(91)90111-A; WEBB DJ, 1995, EUR J BIOCHEM, V318, P1; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Wu SM, 1996, ARCH BIOCHEM BIOPHYS, V326, P39, DOI 10.1006/abbi.1996.0044; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6	56	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20627	20635		10.1074/jbc.272.33.20627	http://dx.doi.org/10.1074/jbc.272.33.20627			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252378	hybrid			2022-12-27	WOS:A1997XR22100048
J	Hajjar, DP; Haberland, ME				Hajjar, DP; Haberland, ME			Lipoprotein trafficking in vascular cells - Molecular Trojan horses and cellular saboteurs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; CORONARY ATHEROSCLEROTIC PLAQUES; MACROPHAGE SCAVENGER RECEPTORS; HUMAN MONOCYTE-MACROPHAGES; FACTOR GENE-EXPRESSION; PROTEIN-KINASE-C; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; ADHESION MOLECULES		UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hajjar, DP (corresponding author), CORNELL UNIV MED COLL,RM A-626,1300 YORK AVE,NEW YORK,NY 10021, USA.				NHLBI NIH HHS [HL-07423, HL-49666, HL-46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007423, R01HL049666, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; AUPEIX K, 1995, IMMUNOBIOLOGY, V194, P417; BASHEERUDDIN K, 1995, ARTERIOSCL THROM VAS, V15, P1248, DOI 10.1161/01.ATV.15.8.1248; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Carlson SA, 1996, J BIOL CHEM, V271, P23146, DOI 10.1074/jbc.271.38.23146; CHEN JK, 1986, J CELL PHYSIOL, V129, P207, DOI 10.1002/jcp.1041290212; CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452; CLINTON SK, 1992, AM J PATHOL, V140, P301; Colles SM, 1996, J LIPID RES, V37, P2018; FALCONE DJ, 1991, J BIOL CHEM, V266, P22726; FONG LG, 1990, J BIOL CHEM, V265, P11751; FOX PL, 1987, J BIOL CHEM, V262, P6046; GENG YJ, 1995, ARTERIOSCL THROM VAS, V15, P1995, DOI 10.1161/01.ATV.15.11.1995; GONG QQ, 1995, J BIOL CHEM, V270, P21672, DOI 10.1074/jbc.270.37.21672; GOSPODAROWICZ D, 1981, J CELL BIOL, V89, P568, DOI 10.1083/jcb.89.3.568; HABERLAND M, 1972, P NATL ACAD SCI USA, V70, P2313; HABERLAND ME, 1984, J BIOL CHEM, V259, P1305; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAHN AWA, 1991, BIOCHEM BIOPH RES CO, V178, P1465, DOI 10.1016/0006-291X(91)91058-K; HAJJAR D, 1994, ADV ENZYMOLOGY, P45; HAJJAR DP, 1992, FASEB J, V6, P2933, DOI 10.1096/fasebj.6.11.1644257; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HSU HY, 1994, J BIOL CHEM, V269, P9213; Huh HY, 1996, BLOOD, V87, P2020; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; KREUZER J, 1997, IN PRESS J LIPID RES; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KU G, 1992, J BIOL CHEM, V267, P14183; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; Li L, 1996, TOXICOL APPL PHARM, V139, P135, DOI 10.1006/taap.1996.0152; LI QQ, 1995, J BIOL CHEM, V270, P26216, DOI 10.1074/jbc.270.44.26216; LIU AC, 1994, J LIPID RES, V35, P2263; Lougheed M, 1996, J BIOL CHEM, V271, P11798, DOI 10.1074/jbc.271.20.11798; LUSIS AJ, 1993, BIOCHEM PHARMACOL, V46, P2119, DOI 10.1016/0006-2952(93)90599-R; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MOLDOVAN NI, 1994, CELL BIOL INT, V18, P985, DOI 10.1006/cbir.1994.1020; NATARAJAN V, 1995, J LIPID RES, V36, P2005; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; NICHOLSON AC, 1992, J BIOL CHEM, V267, P25982; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; OBRIEN ER, 1994, AM J PATHOL, V145, P883; PALKAMA T, 1991, IMMUNOLOGY, V74, P432; PALKAMA T, 1993, CLIN EXP IMMUNOL, V92, P353; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; PEARSON AM, 1993, J BIOL CHEM, V268, P3546; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; SCOTTBURDEN T, 1989, J BIOL CHEM, V264, P12582; SHACKELFORD RE, 1995, J BIOL CHEM, V270, P3475, DOI 10.1074/jbc.270.8.3475; STAFFORINI DM, 1994, J LIPID MEDIAT CELL, V10, P53; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	64	142	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					22975	22978		10.1074/jbc.272.37.22975	http://dx.doi.org/10.1074/jbc.272.37.22975			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287290	hybrid			2022-12-27	WOS:A1997XV74400001
J	Berhanu, P; Anderson, C; Hickman, M; Ciaraldi, TP				Berhanu, P; Anderson, C; Hickman, M; Ciaraldi, TP			Insulin signal transduction by a mutant human insulin receptor lacking the NPEY sequence - Evidence for an alternate mitogenic signalling pathway that is independent of Shc phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR-I; JUXTAMEMBRANE REGION; PHOSPHATIDYLINOSITOL 3-KINASE; NPXY MOTIF; CHO CELLS; DOMAIN; SUBSTRATE-1; ENDOCYTOSIS; PROTEINS	The cytoplasmic juxtamembrane domain of the human insulin receptor (hIR) contains a single copy of the tetrameric amino acid sequence Asn-Pro-Glu-Tyr (NPEY) (residues 969-972 in the exon 11-containing B-isoform), which exists in the context of NPXY, In this study, we examined the role of NPEY972 in mediating insulin signal transduction and cellular biological effects. Transfected Chinese hamster ovary cell lines expressing either the wild-type hIR-B isoform (hIR.WT) or a mutant receptor lacking the NPEY972 sequence (hIR Delta NPEY) and control Chinese hamster ovary Neo cells were used to comparatively analyze the following insulin effects: in vivo receptor tyrosine autophosphorylation and kinase activity, signal transduction to downstream signaling molecules, and stimulation of glycogen and DNA synthesis, The results showed that in comparison to hIR.WT, the hIR Delta NPEY mutant demonstrated the following: (a) normal insulin-mediated receptor tyrosine phosphorylation, but similar to 50% reduction in phosphorylation of p185-(insulin receptor substrate-1) and binding of the p85 subunit of phosphatidylinositol 3-kinase (PI 3-kinase), (b) an enhanced stimulation of PI 3-kinase enzymatic activity, (c) a complete inability to phosphorylate Shc, (d) minimal impairment of insulin sensitivity for glycogen synthesis, and (e) an augmented response to insulin-stimulated DNA synthesis via a high capacity, low sensitivity pathway. These results demonstrate the following: 1) the NPEY972 sequence is important but not absolutely essential for coupling of hIR kinase to insulin receptor substrate-1 and p85 or for mediating insulin's metabolic and mitogenic effects, 2) the NPEY972 sequence is necessary for She phosphorylation, and 3) the absence of Shc phosphorylation releases the constraints on maximal insulin-stimulated mitogenic response, thus indicating that alternate signaling pathway(s) exist for this insulin action, This alternate pathway appears to be associated with enhanced activation of PI 3-kinase and is of high capacity and low sensitivity.	UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92093	University of California System; University of California San Diego	Berhanu, P (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT MED,B151,4200 E 9TH AVE,DENVER,CO 80262, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032880] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32880] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; BERHANU P, 1994, MOL BIOL DIABETES, V2, P321; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CIARALDI TP, 1992, DIABETES, V41, P975, DOI 10.2337/diabetes.41.8.975; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KABURAGI Y, 1995, ENDOCRINOLOGY, V136, P3437, DOI 10.1210/en.136.8.3437; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; THIES RS, 1990, J BIOL CHEM, V265, P10132; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILDEN PA, 1995, J CELL PHYSIOL, V163, P9, DOI 10.1002/jcp.1041630103; WONG EHA, 1995, ENDOCRINOLOGY, V136, P1459, DOI 10.1210/en.136.4.1459; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	37	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22884	22890		10.1074/jbc.272.36.22884	http://dx.doi.org/10.1074/jbc.272.36.22884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278451	hybrid			2022-12-27	WOS:A1997XV49200072
J	Hoylaerts, MF; Manes, T; Millan, JL				Hoylaerts, MF; Manes, T; Millan, JL			Mammalian alkaline phosphatases are allosteric enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; UNCOMPETITIVE INHIBITION; CELLS; EXPRESSION; MECHANISM; SUBSTRATE; P-31; NMR	Mammalian alkaline phosphatases (APs) are zinc-containing metalloenzymes encoded by a multigene family and functional as dimeric molecules, Using human placental AP (FLAP) as a paradigm, we have investigated whether the monomers in a given FLAP dimer are subject to cooperativity during catalysis following an allosteric model or act via a half-of-sites model, in which at any time only one single monomer is operative. Wild type and mutant FLAP homodimers and heterodimers were produced by stably transfecting Chinese hamster ovary cells with mutagenized FLAP cDNAs followed by enzyme extraction, purification, and characterization [Gly(429)]PLAP manifested negative cooperativity when partially metalated as a consequence of the reduced affinity of the incompletely metalated AP monomers for the substrate, Upon full metalation with Zn2+, however the negative cooperativity disappeared, To distinguish between an allosteric and a half-of-sites model, a [Gly(429)]PLAP-[Ser(84)]PLAP heterodimer was produced by combining monomers displaying high and low sensitivity to the uncompetitive inhibitor L-Leu as well as a [Gly(429)]PLAP-[Ala(92)]PLAP heterodimer combining a catalytically active and inactive monomer, respectively. The L-Leu inhibition profile of the [Gly(429)]PLAP-[Ser(84)]PLAP heterodimer was intermediate to that for each homodimer as predicted by the allosteric model. Likewise, the [Gly(429)]PLAP-[Ala(92)]PLAP heterodimer was catalytically active, confirming that AP monomers act independently of each other, Although heterodimers are structurally asymmetrical, they migrate in starch gels with a smaller than expected weighted electrophoretic mobility, are more stable to heat denaturation than expected, and are more sensitive to L-Leu inhibition than predicted by a strict noncooperative model, We conclude that fully metalated mammalian APs: are noncooperative allosteric enzymes but that the stability and catalytic properties of each monomer are controlled by the conformation of the second AP subunit.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037; KATHOLIEKE UNIV LEUVEN,CTR MOL & VASC BIOL,B-3001 LOUVAIN,BELGIUM; UMEA UNIV,DEPT MED GENET,S-90185 UMEA,SWEDEN	Sanford Burnham Prebys Medical Discovery Institute; KU Leuven; Umea University			Millan, Jose Luis/B-6580-2008	Hoylaerts, Marc/0000-0002-6474-3933	NCI NIH HHS [CA42595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BLOCH W, 1974, J BIOL CHEM, V249, P1760; BOSSI M, 1993, J BIOL CHEM, V268, P25409; BYERS DA, 1972, EUR J BIOCHEM, V29, P197, DOI 10.1111/j.1432-1033.1972.tb01975.x; CHLEBOWSKI JF, 1976, J BIOL CHEM, V251, P1207; CIONI P, 1989, EUR J BIOCHEM, V185, P573, DOI 10.1111/j.1432-1033.1989.tb15152.x; COLEMAN JE, 1986, PROGR INORGANIC BIOC, V1, P77; COLEMAN JE, 1983, METAL IONS BIOL, V5, P153; GETTINS P, 1984, J BIOL CHEM, V259, P4991; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARRIS H, 1989, CLIN CHIM ACTA, V186, P133; HARRIS MI, 1968, J BIOL CHEM, V243, P5063; HENDRIX PG, 1990, CLIN CHEM, V36, P1793; HOYLAERTS MF, 1992, BIOCHEM J, V286, P23, DOI 10.1042/bj2860023; HOYLAERTS MF, 1992, CLIN CHEM, V38, P2493; HOYLAERTS MF, 1991, EUR J BIOCHEM, V202, P605, DOI 10.1111/j.1432-1033.1991.tb16414.x; HUMMER C, 1991, BIOCHEM J, V274, P91, DOI 10.1042/bj2740091; ITO F, 1984, J BIOL CHEM, V259, P2526; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; McComb Jr RB, 1979, ALKALINE PHOSPHATASE, DOI 10.1007/978-1-4613-2970-1_4; MEIGHEN E, 1975, BIOCHIM BIOPHYS ACTA, V412, P262, DOI 10.1016/0005-2795(75)90040-9; MILLAN JL, 1988, ANTICANCER RES, V8, P995; OLAFSDOTTIR S, 1989, J BIOL CHEM, V264, P4529; RAO NM, 1991, J BIOL CHEM, V266, P5018; Segel I.H., 1975, ENZYME KINETICS; SIMPSON RT, 1970, BIOCHEMISTRY-US, V9, P953, DOI 10.1021/bi00806a035; TOMIC M, 1990, NUCLEIC ACIDS RES, V18, P1656, DOI 10.1093/nar/18.6.1656; TSONIS PA, 1988, BIOCHEM J, V254, P623, DOI 10.1042/bj2540623; WATANABE S, 1989, J BIOL CHEM, V264, P12611; WATANABE T, 1991, J BIOL CHEM, V266, P21174; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	31	99	101	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22781	22787		10.1074/jbc.272.36.22781	http://dx.doi.org/10.1074/jbc.272.36.22781			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278439	hybrid			2022-12-27	WOS:A1997XV49200060
J	Mathupala, SP; Heese, C; Pedersen, PL				Mathupala, SP; Heese, C; Pedersen, PL			Glucose catabolism in cancer cells - The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BOUND HEXOKINASE; WILD-TYPE P53; DNA-BINDING; TRANSCRIPTIONAL ACTIVITY; GENE; SEQUENCES; PROTEINS; PHOSPHORYLATION; EXPRESSION; METABOLISM	The p53 tumor suppressor is found to be mutated and abundant in a wide variety of tumors. Within tumors showing rapid growth, the Type II isoform of hexokinase is also highly expressed to facilitate high rates of glucose catabolism, which in turn promote their rapid proliferation. We previously reported isolation of the proximal promoter of the Type II hexokinase gene from the highly glycolytic hepatoma AS-30D (Mathupala, S. P., Rempel, A., and Pedersen, P. L. (1995) J. Biol. Chem. 270, 16918-16925). Here, we show that a p53 protein, exhibiting two point mutations in its cDNA, is abundantly expressed in the AS-30D hepatoma. Co-expression studies showed that p53 overexpression significantly and reproducibly activated the Type II hexokinase promoter. Two functional p53 motifs were identified within this promoter by footprint and gel retardation analyses. Presence of functional p53 response elements on the Type II hexokinase promoter and the positive regulatory effect on the promoter by the mutant p53 indicates that in rapidly growing liver tumors, and perhaps in many other tumors as well, this highly abundant p53 protein plays a role in maintaining a high glycolytic rate. This is the first report of a possible link between less of cell cycle control in rapidly growing cancer cells and their high glycolytic phenotype.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University					NCI NIH HHS [CA 32742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARORA KK, 1988, J BIOL CHEM, V263, P17422; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; CHEN JY, 1993, ONCOGENE, V8, P2159; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DEVEREUX J, 1994, GCG ANAL SOFTWARE PA; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P264; FUNK WD, 1992, MOL CELL BIOL, V12, P2966; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HULLA JE, 1993, NUCLEIC ACIDS RES, V21, P713, DOI 10.1093/nar/21.3.713; KINGSTON RE, 1994, CURRENT PROTOCOLS MO; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; MUKHOPADHYAY T, 1995, SUPPRESSOR GENE; NAKASHIMA RA, 1984, CANCER RES, V44, P5702; NAKASHIMA RA, 1988, CANCER RES, V48, P913; PARK DJ, 1994, ONCOGENE, V9, P1899; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAULSKY G, 1991, CANCER RES, V51, P5232; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINSTEIN IB, 1975, CANCER RES, V35, P253; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555	34	186	195	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22776	22780		10.1074/jbc.272.36.22776	http://dx.doi.org/10.1074/jbc.272.36.22776			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278438	hybrid			2022-12-27	WOS:A1997XV49200059
J	Matsui, I; Svensson, B				Matsui, I; Svensson, B			Improved activity and modulated action pattern obtained by random mutagenesis at the fourth beta-alpha loop involved in substrate binding to the catalytic (beta/alpha)(8)-barrel domain of barley alpha-amylase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; TAKA-AMYLASE; AMYLASE/SUBTILISIN INHIBITOR; SACCHAROMYCES-CEREVISIAE; SUBSITE AFFINITIES; SECRETED PROTEINS; MASS-SPECTROMETRY; RATE PARAMETERS; CDNA CLONE; YEAST	The functionality of the sequence Arg(183)-Gly(184)-Tyr(185) of the substrate binding fourth beta-alpha loop in the (beta/alpha)(8)-barrel of barley alpha-amylase isozyme 1 (AMY1) was studied by random mutagenesis. A motif of polar Gly(184) hydrophobic residues was present in active mutants, selected by starch plate screening of yeast transformants. Gly(184) was important, probably due to the carbonyl group binding to Ca2+ and the spatial proximity of Phe(181). Mutation of both flanking residues as in Ser(183)-Gly(184)-Met(185) (SGM-) and TGL-AMY1 decreased the Ca2+ affinity. SGM-AMY1 has 2-fold increased activity for amylose but reduced activity on maltooligosaccharides, whereas KGY-AMY1 has up to 3-fold elevated activity toward the oligosaccharides. TGL-AMY1 has modest activity on all substrates. Shifted action pattern on maltooligosaccharides for NGY-, SGM-, and TGL-AMY1 support that Arg(183) in wild type is located at subsites +1 and +2, accommodating two sugar rings toward the reducing end from the site of cleavage. In the crystal structure of barley alpha-amylase 2 (AMY2), Lys(182) (equivalent to AMY1 Arg(183)) is hydrogen-bonded with sugar OH-3 in subsite +2. Higher K-i app for acarbose inhibition of KGY-AMY1 and parent AMY1 compared with the other mutants suggests favorable substrate interactions for Arg/Lys(183). KGY-AMY1 was not inhibited by the AMY2-specific proteinaceous barley alpha-amylase/subtilisin inhibitor, although Lys(182) Of AMY2 is salt-linked to the inhibitor.	CARLSBERG LAB, DEPT CHEM, DK-2500 COPENHAGEN, DENMARK					Svensson, Birte/0000-0002-2993-8196				ABE J, 1993, BIOCHEM J, V293, P151, DOI 10.1042/bj2930151; AJANDOUZ EH, 1992, BIOCHIM BIOPHYS ACTA, V1159, P193, DOI 10.1016/0167-4838(92)90025-9; ALLEN JD, 1976, BIOCHEM J, V159, P121, DOI 10.1042/bj1590121; ANDERSEN JS, 1994, BIOL MASS SPECTROM, V23, P547, DOI 10.1002/bms.1200230904; BAULCOMBE DC, 1987, MOL GEN GENET, V209, P33, DOI 10.1007/BF00329833; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERTOFT E, 1984, J I BREWING, V90, P298, DOI 10.1002/j.2050-0416.1984.tb04278.x; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BUSH DS, 1989, J BIOL CHEM, V264, P19392; FOX JD, 1991, ANAL BIOCHEM, V195, P93, DOI 10.1016/0003-2697(91)90300-I; GIBSON RM, 1986, CARLSBERG RES COMMUN, V51, P295, DOI 10.1007/BF02907163; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIROMI K, 1970, BIOCHEM BIOPH RES CO, V40, P1, DOI 10.1016/0006-291X(70)91037-5; HOLM L, 1990, PROTEIN ENG, V3, P181, DOI 10.1093/protein/3.3.181; HUANG N, 1992, GENE, V111, P223, DOI 10.1016/0378-1119(92)90690-Q; ISHIKAWA K, 1989, ARCH BIOCHEM BIOPHYS, V272, P356, DOI 10.1016/0003-9861(89)90229-4; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P6259, DOI 10.1021/bi00075a020; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V183, P286, DOI 10.1016/0006-291X(92)91641-3; IWASA S, 1974, J BIOCHEM-TOKYO, V75, P969, DOI 10.1093/oxfordjournals.jbchem.a130499; JANECEK S, 1994, FEBS LETT, V353, P119, DOI 10.1016/0014-5793(94)01019-6; JESPERSEN HM, 1991, BIOCHEM J, V280, P51, DOI 10.1042/bj2800051; JESPERSEN HM, 1993, J PROTEIN CHEM, V12, P791, DOI 10.1007/BF01024938; JONES RL, 1991, INT REV CYTOL, V126, P49; Juge N, 1996, PROTEIN EXPRES PURIF, V8, P204, DOI 10.1006/prep.1996.0093; JUGE N, 1995, FEBS LETT, V363, P299, DOI 10.1016/0014-5793(95)00291-G; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; KADZIOLA A, 1993, THESIS U COPENHAGEN; KOIZUKA N, 1990, PLANT PHYSIOL, V94, P1488, DOI 10.1104/pp.94.3.1488; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LACKS SA, 1982, CELL, V31, P327, DOI 10.1016/0092-8674(82)90126-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACGREGOR AW, 1986, CEREAL FOOD WORLD, V31, P688; MACGREGOR AW, 1978, CEREAL CHEM, V55, P754; MACGREGOR AW, 1992, CARBOHYD RES, V227, P301, DOI 10.1016/0008-6215(92)85080-J; MACHIUS M, 1995, J MOL BIOL, V246, P545, DOI 10.1006/jmbi.1994.0106; MATSUI I, 1992, FEBS LETT, V310, P216, DOI 10.1016/0014-5793(92)81335-J; MATSUI I, 1990, AGR BIOL CHEM TOKYO, V54, P2009, DOI 10.1080/00021369.1990.10870246; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MATSUI I, 1992, BIOCHEMISTRY-US, V31, P5232, DOI 10.1021/bi00137a019; MATSUI I, 1994, BIOCHEMISTRY-US, V33, P451, DOI 10.1021/bi00168a009; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MATSUURA Y, 1991, DENPUN KAGAKU, V38, P137; MCELROY D, 1995, BIO-TECHNOL, V13, P245, DOI 10.1038/nbt0395-245; MUNDY J, 1983, CARLSBERG RES COMMUN, V48, P81, DOI 10.1007/BF02906171; NAGASHIMA T, 1992, BIOSCI BIOTECH BIOCH, V56, P207, DOI 10.1271/bbb.56.207; QIAN MX, 1993, J MOL BIOL, V231, P785, DOI 10.1006/jmbi.1993.1326; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; RODENBURG KW, 1994, EUR J BIOCHEM, V221, P277, DOI 10.1111/j.1432-1033.1994.tb18739.x; ROGERS JC, 1983, J BIOL CHEM, V258, P8169; ROGERS JC, 1985, J BIOL CHEM, V260, P3731; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SOGAARD M, 1990, GENE, V94, P173, DOI 10.1016/0378-1119(90)90384-4; SOGAARD M, 1993, BIO-TECHNOL, V11, P1162, DOI 10.1038/nbt1093-1162; SOGAARD M, 1993, J BIOL CHEM, V268, P22480; SOGAARD M, 1991, P NATL ACAD SCI USA, V88, P8140, DOI 10.1073/pnas.88.18.8140; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; SVENSSON B, 1991, ACS SYM SER, V458, P28; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; SVENSSON B, 1991, DENPUN KAGAKU, V38, P125; TAKAHA T, 1993, J BIOL CHEM, V268, P1391; THOMA JA, 1970, BIOCHEMISTRY-US, V9, P1768, DOI 10.1021/bi00810a016; TRUSCHEIT E, 1981, REGULATORS INTESTINA, V2, P157; TSUKAMOTO A, 1988, BIOCHEM BIOPH RES CO, V151, P25, DOI 10.1016/0006-291X(88)90554-2; VALLEE F, 1994, J MOL BIOL, V236, P368, DOI 10.1006/jmbi.1994.1141; WESELAKE RJ, 1983, PLANT PHYSIOL, V72, P809, DOI 10.1104/pp.72.3.809; YAMANE K, 1992, BIOSCIENCE IND, V50, P13; YAMAUCHI D, 1994, PLANT CELL PHYSIOL, V35, P705, DOI 10.1093/oxfordjournals.pcp.a078647; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU JH, 1989, FEBS LETT, V255, P37, DOI 10.1016/0014-5793(89)81056-7	71	43	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22456	22463		10.1074/jbc.272.36.22456	http://dx.doi.org/10.1074/jbc.272.36.22456			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278396	hybrid			2022-12-27	WOS:A1997XV49200016
J	Nagaoka, I; TsutsumiIshii, Y; Yomogida, S; Yamashita, T				Nagaoka, I; TsutsumiIshii, Y; Yomogida, S; Yamashita, T			Isolation of cDNA encoding guinea pig neutrophil cationic antibacterial polypeptide of 11 kDa (CAP11) and evaluation of CAP11 mRNA expression during neutrophil maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING-PROTEIN; BONE-MARROW CELLS; MOLECULAR-CLONING; MESSENGER-RNA; CHEMICAL SYNTHESIS; PEPTIDE; SEQUENCE; LEUKOCYTES; GELATINASE; CYSTEINE	Neutrophils contain various antibacterial polypeptides and proteins in the granules that contribute to the killing of microorganisms. Recently, we have purified a cationic antibacterial polypeptide of 11 kDa (CAP11) from guinea pig neutrophil granules. CAP11 is a homodimer of G(1)LRKKFRKTRKRIQKLGRKIGKTGRKVWKAWREYGQIPYPCRI(48) joined with one disulfide bond. In this study, to understand the regulation of CAP11 expression, we isolated and analyzed cDNA encoding CAP11. Furthermore, we investigated the expression of CAP11 mRNA during neutrophil maturation and localization of CAP11 among neutrophil granule subsets. Sequence analysis of CAP11 cDNA isolated from guinea pig bone marrow cells using rapid amplification of cDNA ends technique indicated that CAP11 is synthesized as a precursor comprising 178 amino acid residues, which is composed of a signal peptide (N-terminal 29 residues), a propeptide (106 residues), and a C-terminal mature peptide (43 residues). Interestingly, the predicted CAP11 precursor displayed the characteristic features of cathelicidins, a novel protein family of antibacterial polypeptides with a conserved cathelin-like pro-region and a variable C-terminal antibacterial domain. Northern blot and Western blot analyses using neutrophils, macrophages, eosinophils, mononuclear cells, and bone marrow cells revealed that only neutrophils and bone marrow cells expressed CAP11 mRNA and contained CAP11, suggesting that expression of CAP11 is neutrophil lineage-specific. Furthermore, Northern blot analysis using bone marrow cells separated according to their maturation stages showed that CAP11 mRNA was predominantly expressed in the cells at later stages of neutrophil maturation. Consistent with this, in situ hybridization using CAP11-specific cRNA probe demonstrated that CAP11 mRNA was primarily expressed at metamyelocyte stage. In addition, extracellular release assay revealed that CAP11 was readily released from neutrophils accompanied with gelatinase by low concentrations of N-formyl-Met-Leu-Phe without release of specific and azurophil granule components, and CAP11 was found to be exclusively present in the fraction containing gelatinase granules, prepared by Percoll density gradient centrifugation. Together these observations indicate that CAP11 is a member of cathelicidin family and its mRNA is preferentially expressed at the later stage of neutrophil maturation (i.e. metamyelocyte stage). Furthermore, CAP11 may be stored in the granule subset, possibly the gelatinase granule.			Nagaoka, I (corresponding author), JUNTENDO UNIV, SCH MED, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN.							AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; BAINTON DF, 1992, INFLAMMATION BASIC P, P303; Borregaard N, 1996, Curr Opin Hematol, V3, P11; BORREGAARD N, 1995, BLOOD, V85, P812, DOI 10.1182/blood.V85.3.812.bloodjournal853812; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; DELSAL G, 1992, BIOCHEM BIOPH RES CO, V187, P467, DOI 10.1016/S0006-291X(05)81517-7; ELSBACH P, 1990, TRENDS BIOTECHNOL, V8, P26, DOI 10.1016/0167-7799(90)90127-J; Elsbach P, 1992, INFLAMMATION BASIC P, P603; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GALLIN JI, 1992, INFLAMMATION BASIC P, P859; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIRATA M, 1994, INFECT IMMUN, V62, P1421, DOI 10.1128/IAI.62.4.1421-1426.1994; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; JOHNSTON JJ, 1992, BLOOD, V79, P2998; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KJELDSEN L, 1994, BLOOD, V83, P1640, DOI 10.1182/blood.V83.6.1640.bloodjournal8361640; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P, P541; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LARRICK JW, 1991, BIOCHEM BIOPH RES CO, V179, P170, DOI 10.1016/0006-291X(91)91350-L; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; LEVY O, 1993, J BIOL CHEM, V268, P6058; NAGAOKA I, 1985, BIOCHIM BIOPHYS ACTA, V847, P67, DOI 10.1016/0167-4889(85)90154-5; NAGAOKA I, 1984, COMP BIOCHEM PHYS B, V79, P147, DOI 10.1016/0305-0491(84)90005-1; NAGAOKA I, 1991, FEBS LETT, V280, P287, DOI 10.1016/0014-5793(91)80314-S; NAGAOKA I, 1992, FEBS LETT, V302, P279, DOI 10.1016/0014-5793(92)80459-T; NAGAOKA I, 1994, FEBS LETT, V356, P33, DOI 10.1016/0014-5793(94)01229-6; OHWADA A, 1994, AM J RESP CELL MOL, V11, P214, DOI 10.1165/ajrcmb.11.2.8049082; PUNGERCAR J, 1993, FEBS LETT, V336, P284, DOI 10.1016/0014-5793(93)80821-B; RITONJA A, 1989, FEBS LETT, V255, P211, DOI 10.1016/0014-5793(89)81093-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCOCCHI M, 1994, FEBS LETT, V352, P197, DOI 10.1016/0014-5793(94)00954-6; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SRIKANTH S, 1994, J BIOL CHEM, V269, P32626; STORICI P, 1994, FEBS LETT, V337, P303, DOI 10.1016/0014-5793(94)80214-9; STORICI P, 1992, FEBS LETT, V314, P187, DOI 10.1016/0014-5793(92)80971-I; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1058, DOI 10.1006/bbrc.1993.2358; TOSSI A, 1994, FEBS LETT, V339, P108, DOI 10.1016/0014-5793(94)80395-1; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; Yomogida S, 1996, ARCH BIOCHEM BIOPHYS, V328, P219, DOI 10.1006/abbi.1996.0166; ZANETTI M, 1993, J BIOL CHEM, V268, P522; ZANETTI M, 1994, J BIOL CHEM, V269, P7855; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHAO CQ, 1994, FEBS LETT, V346, P285, DOI 10.1016/0014-5793(94)00493-5	52	51	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22742	22750		10.1074/jbc.272.36.22742	http://dx.doi.org/10.1074/jbc.272.36.22742			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278433	hybrid			2022-12-27	WOS:A1997XV49200054
J	Gu, J; Shumyatsky, G; Makan, N; Reddy, R				Gu, J; Shumyatsky, G; Makan, N; Reddy, R			Formation of 2',3'-cyclic phosphates at the 3' end of human U6 small nuclear RNA in vitro - Identification of 2',3'-cyclic phosphates at the 3' ends of human signal recognition particle and mitochondrial RNA processing RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III; MESSENGER-RNA; RIBOSE METHYLATION; SELF-CLEAVAGE; CELL EXTRACT; TRANSCRIPTION; SEQUENCES; ELEMENTS; EXCISION; GENES	Approximately 90% of human U6 small nuclear RNA (snRNA) contains uridine cyclic phosphate (U > p) at its 3'-end (Lund, E., and Dahlberg, J. E. (1992) Science 255, 327-330). We studied the formation of U > p at the 3' end of human U6 snRNA using an in vitro system where uridylic acid residues are added from UTP precursor and U > p is formed. Analysis of U6 snRNAs with varying number of uridylic acid residues showed that each of these species contains U > p where the phosphate originated from cx-phosphate of UTP precursor, The cyclic phosphate formation occurred on U6 snRNA in extracts where essential spliceosomal snRNAs were specifically degraded, thereby indicating that U > p formation is not coupled to pre-mRNA splicing, A subpopulation of human signal recognition particle and mitochondrial RNA processing RNAs isolated from HeLa cells also contained cyclic phosphates at their 3' ends. These data suggest that U > p in U6 snRNA is unlikely to be related to its participation in splicing of pre-mRNAs, It appears that cyclic phosphate is an intermediate product in the metabolism of these small RNAs.	BAYLOR COLL MED,DEPT PHARMACOL,HOUSTON,TX 77030	Baylor College of Medicine			Gu, Jian/Q-4780-2018	Gu, Jian/0000-0003-3499-0973	NIGMS NIH HHS [GM52901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052901] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; CLAYTON DA, 1994, P NATL ACAD SCI USA, V91, P4615, DOI 10.1073/pnas.91.11.4615; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; EDMONDS M, 1990, METHOD ENZYMOL, V181, P161; FILIPOWICZ W, 1990, METHOD ENZYMOL, V181, P499; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; Forne T, 1996, BIOCHIMIE, V78, P436, DOI 10.1016/0300-9084(96)84750-X; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HANNON GJ, 1989, MOL CELL BIOL, V9, P4422, DOI 10.1128/MCB.9.10.4422; HIRAI H, 1988, J BIOCHEM-TOKYO, V104, P991, DOI 10.1093/oxfordjournals.jbchem.a122597; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; REDDY R, 1981, J BIOL CHEM, V256, P8452; Reddy R., 1991, Progress in Molecular and Subcellular Biology, V12, P1; REDDY R, 1983, J BIOL CHEM, V258, P1383; REDDY R, 1987, J BIOL CHEM, V262, P75; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; SAKONJU S, 1980, CELL, V19, P13, DOI 10.1016/0092-8674(80)90384-0; SCHAUFELE F, 1986, NATURE, V323, P777, DOI 10.1038/323777a0; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHUMYATSKY GP, 1990, NUCLEIC ACIDS RES, V18, P6347, DOI 10.1093/nar/18.21.6347; Silberklang M, 1979, Methods Enzymol, V59, P58; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; TAZI J, 1993, MOL CELL BIOL, V13, P1641, DOI 10.1128/MCB.13.3.1641; Umen JG, 1995, RNA, V1, P869; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; Weber U, 1996, NUCLEIC ACIDS RES, V24, P2212, DOI 10.1093/nar/24.12.2212	41	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21989	21993		10.1074/jbc.272.35.21989	http://dx.doi.org/10.1074/jbc.272.35.21989			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268336	hybrid			2022-12-27	WOS:A1997XT85000048
J	Ismailov, II; KieberEmmons, T; Lin, CM; Berdiev, BK; Shlyonsky, VG; Patton, HK; Fuller, CM; Worrell, R; Zuckerman, JB; Sun, W; Eaton, DC; Benos, DJ; Kleyman, TR				Ismailov, II; KieberEmmons, T; Lin, CM; Berdiev, BK; Shlyonsky, VG; Patton, HK; Fuller, CM; Worrell, R; Zuckerman, JB; Sun, W; Eaton, DC; Benos, DJ; Kleyman, TR			Identification of an amiloride binding domain within the alpha-subunit of the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; DISTINCT EPITOPES; MEMBRANE TOPOLOGY; MOLECULAR-CLONING; ANTIBODIES; SELECTIVITY; PROTEINS; PORE	Limited information is available regarding domains within the epithelial Na+ channel (ENaC) which participate in amiloride binding, We previously utilized the anti-amiloride antibody (BA7.1) as a surrogate amiloride receptor to delineate amino acid residues that con??? tact amiloride, and identified a putative amiloride binding domain WYRFHY (residues 278-283) within the extracellular domain of alpha rENaC. Mutations were generated to examine the role of this sequence in amiloride binding, Functional analyses of wild type (wt) and mutant alpha rENaCs were performed by cRNA expression in Xenopus oocytes and by reconstitution into planar lipid bilayers, Wild type alpha rENaC was inhibited by amiloride with a K-i of 169 nM. Deletion of the entire WYRFHY tract (alpha rENaC Delta 278-283) resulted in a loss of sensitivity of the channel to submicromolar concentrations off amiloride (K-i = 26.5 mu M). Similar results were obtained when either alpha rENaC or alpha rENaC Delta 278-283 were co-expressed with wt beta- and alpha rENaC (K-i values of 155 nM and 22.8 mu m, respectively), Moreover, alpha rENaC H282D was insensitive to submicromolar concentrations of amiloride (K-i = 6.52 mu M), whereas alpha rENaC H282R was inhibited by amiloride with a K-i of 29 nM. These mutations do not alter ENaC Na+:K+ selectivity nor single-channel conductance,These data suggest that residues within the tract WYRFHY participate in amiloride binding, Our results, in conjunction with recent studies demonstrating that mutations within the membrane-spanning domains of alpha rENaC and mutations preceding the second membrane-spanning domains of alpha-, beta-, and gamma rENaC alters amiloride's K-i, suggest that selected regions of the extracellular loop of alpha rENaC may be in close proximity to residues within the channel pore.	VET ADM MED CTR, MED RES 151, PHILADELPHIA, PA 19104 USA; UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, BIRMINGHAM, AL 35294 USA; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, INST NEUROL SCI, PHILADELPHIA, PA 19104 USA; VET ADM MED CTR, PHILADELPHIA, PA 19104 USA; EMORY UNIV, DEPT PHYSIOL, ATLANTA, GA 30322 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); Emory University			Zuckerman, Jonathan/AAU-1857-2020; Fuller, Cathy/B-4046-2011	Shlyonsky, Vadim/0000-0003-2999-6553; Zuckerman, Jonathan/0000-0002-8190-9210; Eaton, Douglas/0000-0002-2686-6692	NIDDK NIH HHS [DK09215, DK51391, DK27206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051391, F32DK009215, R01DK051391] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1996, J AM SOC NEPHROL, V7, pA0137; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; BALABAN RS, 1979, J MEMBRANE BIOL, V49, P363, DOI 10.1007/BF01868992; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; Busch AE, 1996, PFLUG ARCH EUR J PHY, V432, P760, DOI 10.1007/s004240050196; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; Fuller CM, 1997, BIOPHYS J, V72, P1622, DOI 10.1016/S0006-3495(97)78808-8; FULLER CM, 1995, AM J PHYSIOL-CELL PH, V269, pC641, DOI 10.1152/ajpcell.1995.269.3.C641; GOTTLIEB GP, 1978, BIOPHYS J, V22, P125, DOI 10.1016/S0006-3495(78)85477-0; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; ISMAIIOV II, 1997, IN PRESS J PHYSL; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; KIEBEREMMONS T, 1995, KIDNEY INT, V48, P956, DOI 10.1038/ki.1995.377; KLEYMAN TR, 1986, AM J PHYSIOL, V250, pC165, DOI 10.1152/ajpcell.1986.250.1.C165; KLEYMAN TR, 1989, AM J PHYSIOL, V257, pC1135, DOI 10.1152/ajpcell.1989.257.6.C1135; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; KLEYMAN TR, 1991, AM J PHYSIOL, V260, pC271, DOI 10.1152/ajpcell.1991.260.2.C271; LI JHY, 1985, J MEMBRANE BIOL, V83, P45, DOI 10.1007/BF01868737; LI JHY, 1982, BASIC MECHANISMS ACT, P28; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LIN CM, 1994, J BIOL CHEM, V269, P2805; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; MYERS VB, 1972, BIOCHIM BIOPHYS ACTA, V274, P313, DOI 10.1016/0005-2736(72)90179-4; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; RENARD S, 1994, J BIOL CHEM, V269, P12981; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; VANDRIESSCHE W, 1983, PFLUG ARCH EUR J PHY, V398, P179, DOI 10.1007/BF00657149; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; WARNCKE J, 1985, J MEMBRANE BIOL, V86, P255, DOI 10.1007/BF01870605; YUN CHC, 1993, BIOCHEM BIOPH RES CO, V193, P532, DOI 10.1006/bbrc.1993.1656	43	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21075	21083		10.1074/jbc.272.34.21075	http://dx.doi.org/10.1074/jbc.272.34.21075			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261110	hybrid			2022-12-27	WOS:A1997XR78900020
J	Lundquist, AJ; Beger, RD; Bennett, SE; Bolton, PH; Mosbaugh, DW				Lundquist, AJ; Beger, RD; Bennett, SE; Bolton, PH; Mosbaugh, DW			Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein - Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BACILLUS-SUBTILIS; BACTERIOPHAGE-PBS2; REPAIR; EXPRESSION; SEQUENCE; CLONING; MIMICRY; GENE; UGI	Bacteriophage PBS2 uracil-DNA glycosylase inhibitor (Ugi) protein inactivates uracil-DNA glycosylase (Ung) by acting as a DNA mimic to bind Ung in an irreversible complex, Seven mutant Ugi proteins (E20I, E27A, E28L, E30L, E31L, D61G, and E78V) mere created to assess the role of various negatively charged residues in the binding mechanism, Each mutant Ugi protein was purified and characterized with respect to inhibitor activity and Ung binding properties relative to the wild type Ugi. Analysis of the Ugi protein solution structures by nuclear magnetic resonance indicated that the mutant Ugi proteins were folded into the same general conformation as wild type Ugi, All seven of the Ugi proteins were capable of forming a Ung Ugi complex but varied considerably in their individual ability to inhibit Ung activity, Like the wild type Ugi, five of the mutants formed an irreversible complex with Ung; however, the binding of Ugi E20I and E28L to Ung was shown to be reversible, The tertiary structure of [C-13,N-15]Ugi in complex with Ung was determined by solution state multi-dimensional nuclear magnetic resonance and compared with the unbound Ugi structure, Structural and functional analysis of these proteins have elucidated the two-step mechanism involved in Ung.Ugi association and irreversible complex formation.	WESLEYAN UNIV, DEPT CHEM, MIDDLETOWN, CT 06459 USA; OREGON STATE UNIV, ENVIRONM HLTH SCI CTR, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, DEPT AGR CHEM, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA	Wesleyan University; Oregon State University; Oregon State University; Oregon State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAN S, 1995, J BIOL CHEM, V270, P296, DOI 10.1074/jbc.270.1.296; BEGER RD, 1995, J BIOL CHEM, V270, P16840, DOI 10.1074/jbc.270.28.16840; BEGER RD, 1997, IN PRESS J BIOMOL NM; BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BENNETT SE, 1995, THESIS OREGON STATE; BRUNGER AT, 1993, SCIENCE, V261, P328, DOI 10.1126/science.8332897; Caradonna S, 1996, EXP CELL RES, V222, P345, DOI 10.1006/excr.1996.0044; CONE R, 1980, J BIOL CHEM, V255, P16354; DYSON HJ, 1994, 2 DIMENSIONAL NMR SP, P655; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; Hull W., 1994, 2 DIMENSIONAL NMR SP, P67; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; Kessler H., 1994, 2 DIMENSIONAL NMR SP, P619; KOLLMAN PA, 1990, ACCOUNTS CHEM RES, V23, P246, DOI 10.1021/ar00176a002; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMASTER DM, 1994, PROG NMR SPECTROSCOP, V26, P349; LONGLEY M J, 1989, Methods in Molecular and Cellular Biology, V1, P79; LONGLEY MJ, 1993, METHOD ENZYMOL, V218, P587; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; NIGLES M, 1988, FEBS LETT, V229, P317; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; PEAR LH, 1996, UDI PROTEIN DATA BAN, V1; PRICE AR, 1975, J BIOL CHEM, V250, P8804; REISNER AH, 1984, METHOD ENZYMOL, V104, P439; Sanderson RJ, 1996, J BIOL CHEM, V271, P29170, DOI 10.1074/jbc.271.46.29170; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SAVVA R, 1995, PROTEINS, V22, P287, DOI 10.1002/prot.340220310; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1991, GENE, V99, P31	41	21	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21408	21419		10.1074/jbc.272.34.21408	http://dx.doi.org/10.1074/jbc.272.34.21408			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261156	hybrid			2022-12-27	WOS:A1997XR78900066
J	Rohlff, C; Ahmad, S; Borellini, F; Lei, J; Glazer, RI				Rohlff, C; Ahmad, S; Borellini, F; Lei, J; Glazer, RI			Modulation of transcription factor Sp1 by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-60 LEUKEMIA-CELLS; MONOPHOSPHATE-RESPONSIVE SEQUENCE; CYCLIC-NUCLEOTIDE BINDING; RII-BETA-SUBUNIT; DNA-BINDING; NEGATIVE REGULATION; GENE-TRANSCRIPTION; SOMATOSTATIN GENE; RETROVIRAL VECTOR; PROMOTER REGION	Transcription factor Spl is a phosphoprotein whose level and DNA binding activity are markedly increased in doxorubicin-resistant HL-60 (HL-60/AR) leukemia cells, The trans-activating and DNA binding properties of Spl in HL-60/AR cells are stimulated by cAMP-dependent protein kinase (PKA) and PKA agonists and inhibited by PKA antagonists as well as by the PKA regulatory subunit, Reporter gene activity under the control of the Spl-dependent SV40 promoter is stimulated in insect cells transiently expressing Spl and PKA, and the DNA binding activity of recombinant Spl is activated by exogenous PKA in vitro, These results indicate that Spl is a cAMP-responsive transcription factor and that Spl-dependent genes may be modulated through a cAMP-dependent signaling pathway.	GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,LOMBARDI CANC CTR,WASHINGTON,DC 20007	Georgetown University; Georgetown University					NATIONAL CANCER INSTITUTE [P50CA058185, R55CA057244] Funding Source: NIH RePORTER; NCI NIH HHS [2P50-CA58185-04, R55CA57244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAKKE M, 1992, MOL ENDOCRINOL, V6, P1323, DOI 10.1210/me.6.8.1323; BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BHALLA K, 1985, CANCER RES, V45, P3657; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HABENER JF, 1990, EUR J BIOCHEM, V132, P297; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; He YF, 1996, BBA-GENE STRUCT EXPR, V1306, P179, DOI 10.1016/0167-4781(96)00005-X; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1990, J CELL BIOCHEM, V143, P118; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KERLAVAGE AR, 1982, J BIOL CHEM, V257, P1749; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LUND J, 1990, J BIOL CHEM, V265, P3304; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MCGEADY ML, 1990, J VIROL, V64, P3527, DOI 10.1128/JVI.64.7.3527-3531.1990; MERINO A, 1989, J BIOL CHEM, V264, P21266; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROHLFF C, 1993, MOL PHARMACOL, V43, P372; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; SMITHGALL TE, 1992, BIOCHEMISTRY-US, V31, P4828, DOI 10.1021/bi00135a013; SUMMERS MD, 1987, 1555 COLL STAT TEX A; TORTORA G, 1994, CELL GROWTH DIFFER, V5, P753; UEDA K, 1987, J BIOL CHEM, V262, P17432; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; ZHU QC, 1994, CANCER RES, V54, P4488	52	193	194	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21137	21141		10.1074/jbc.272.34.21137	http://dx.doi.org/10.1074/jbc.272.34.21137			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261118	hybrid			2022-12-27	WOS:A1997XR78900028
J	Tong, H; Hateboer, G; Perrakis, A; Bernards, R; Sixma, TK				Tong, H; Hateboer, G; Perrakis, A; Bernards, R; Sixma, TK			Crystal structure of murine/human Ubc9 provides insight into the variability of the ubiquitin-conjugating system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; SEQUENCE ALIGNMENT; YEAST UBC4; CDC34 UBC3; IN-VIVO; ENZYME; PROTEASOME; PROGRAM; PURIFICATION; REFINEMENT	Murine/human ubiquitin-conjugating enzyme Ubc9 is a functional homolog of Saccharomyces cerevisiae Ubc9 that is essential for the viability of yeast cells with a specific role in the G(2)-M transition of the cell cycle. The structure of recombinant mammalian Ubc9 has been determined from two crystal forms at 2.0 Angstrom resolution Like Arabidopsis thaliana Ubc1 and S. cerevisiae Ubc4, murine/human Ubc9 was crystallized as a monomer, suggesting that previously reported hetero-and homo-interactions among Ubcs may be relatively weak or indirect. Compared with the known crystal structures of Ubc1 and Ubc4, which regulate different cellular processes, Ubc9 has a 5-residue insertion that forms a very exposed tight beta-hairpin and a a-residue insertion that forms a bulge in a loop close to the active site, Mammalian Ubc9 also possesses a distinct electrostatic potential distribution that may provide possible clues to its remarkable ability to interact with other proteins. The a-residue insertion and other sequence and structural heterogeneity observed at the catalytic site suggest that different Ubcs may utilize catalytic mechanisms of varying efficiency and substrate specificity.	NETHERLANDS CANC INST,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			Perrakis, Anastassis/E-8704-2013	Perrakis, Anastassis/0000-0002-1151-6227; Bernards, Rene/0000-0001-8677-3423; Sixma, Titia K/0000-0001-6180-0632				ALKHODAIRY F, 1995, J CELL SCI, V108, P475; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3578; Betting J, 1996, J BIOL CHEM, V271, P25790, DOI 10.1074/jbc.271.42.25790; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; COOK WJ, 1992, J MOL BIOL, V223, P1183, DOI 10.1016/0022-2836(92)90270-T; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; *GEN COMP GROUP, 1991, GCG VERS 7; GIROD PA, 1993, PLANT J, V3, P545, DOI 10.1046/j.1365-313X.1993.03040545.x; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GWOZD CS, 1995, BIOCHEMISTRY-US, V34, P6296, DOI 10.1021/bi00019a006; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; HENDRICKSON W, 1995, METHOD ENZYMOL, V115, P252; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; Jiang WD, 1996, MOL GEN GENET, V251, P153; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PITLUK ZW, 1995, MOL CELL BIOL, V15, P1210; Rost B, 1996, METHOD ENZYMOL, V266, P525; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SULLIVAN ML, 1990, P NATL ACAD SCI USA, V86, P9861; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TONG H, 1994, J APPL CRYSTALLOGR, V27, P421, DOI 10.1107/S0021889893009926; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; Watanabe TK, 1996, CYTOGENET CELL GENET, V72, P86, DOI 10.1159/000134169; Wright DA, 1996, J BIOL CHEM, V271, P31037, DOI 10.1074/jbc.271.49.31037; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005; YUSHERMAN M, 1992, EMBO J, V11, P71	56	118	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21381	21387		10.1074/jbc.272.34.21381	http://dx.doi.org/10.1074/jbc.272.34.21381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261152	Green Published, hybrid			2022-12-27	WOS:A1997XR78900062
J	Akhlynina, TV; Jans, DA; Rosenkranz, AA; Statsyuk, NV; Balashova, IY; Toth, G; Pavo, I; Rubin, AB; Sobolev, AS				Akhlynina, TV; Jans, DA; Rosenkranz, AA; Statsyuk, NV; Balashova, IY; Toth, G; Pavo, I; Rubin, AB; Sobolev, AS			Nuclear targeting of chlorin e(6) enhances its photosensitizing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II SITE FLANKING; SV40 T-ANTIGEN; PHOTODYNAMIC THERAPY; PROTEIN-TRANSPORT; CARCINOMA-CELLS; PHOTOFRIN-II; INSULIN; PHOSPHORYLATION; LOCALIZATION; E6	Although photosensitizers, molecules that produce active oxygen species upon activation by visible light, are being extensively used in photodynamic therapy to treat cancer and other clinical conditions, problems include normal cell and tissue damage and associated side effects, which are attributable in part to the fact that cytotoxic effects are largely restricted to the plasma membrane, We have previously shown that the photosensitizer chlorin e(6) has significantly higher photosensitizing activity when present in conjugates containing specific ligands and thus able to be internalized by receptor-expressing cells. In this study we use insulin-containing conjugates to which variants of the simian virus SV40 large tumor antigen nuclear localization signal (NLS) were linked to target chlorin e(6) to the nucleus, a hypersensitive site for active oxygen species-induced damage. NLSs were either included as peptides crosslinked to the carrier bovine serum albumin or encoded within the sequence of a beta-galactosidase fusion protein carrier. The results for photosensitization demonstrate clearly for the first time that NLSs increase the photosensitizing activity of chlorin e(6), maximally reducing the EC50 by a factor of over 2000-fold. This has wide-reaching implications for achieving efficient cell type-specific photodynamic therapy.	MOSCOW MV LOMONOSOV STATE UNIV,FAC BIOL,DEPT BIOPHYS,MOSCOW 119899,RUSSIA; RUSSIAN INST AGR BIOTECHNOL,BIOPHYS LAB,MOSCOW 127550,RUSSIA; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOL BIOL,NUCL SIGNALING LAB,CANBERRA,ACT 2601,AUSTRALIA; UNIV SZEGED,INST MED CHEM,H-6720 SZEGED,HUNGARY	Lomonosov Moscow State University; All-Russia Research Institute of Agricultural Biotechnology; Australian National University; John Curtin School of Medical Research; Szeged University			Rosenkranz, Andrey A/J-3514-2015; Andrei, Rubin/U-6451-2019; Pavo, Imre/AAZ-6421-2021; Statsyuk, Natalia V./P-6383-2014; Sobolev, Alexander S./P-6302-2015	Rosenkranz, Andrey A/0000-0001-9941-6118; Pavo, Imre/0000-0002-2016-7049; Statsyuk, Natalia V./0000-0001-6159-148X; Sobolev, Alexander S./0000-0001-8315-7764				AKHLYNINA TV, 1995, CANCER RES, V55, P1014; AKHLYNINA TV, 1993, PHOTOCHEM PHOTOBIOL, V58, P45, DOI 10.1111/j.1751-1097.1993.tb04901.x; Alper T., 1979, CELLULAR RADIOBIOLOG; BACHOR R, 1991, P NATL ACAD SCI USA, V88, P1580, DOI 10.1073/pnas.88.4.1580; FINLAY GJ, 1984, ANAL BIOCHEM, V139, P272, DOI 10.1016/0003-2697(84)90002-2; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; LEVY JG, 1995, TRENDS BIOTECHNOL, V13, P14, DOI 10.1016/S0167-7799(00)88895-2; MANYAK MJ, 1988, J CLIN ONCOL, V6, P380, DOI 10.1200/JCO.1988.6.2.380; MONTIEL F, 1989, BIOCHEM J, V258, P147, DOI 10.1042/bj2580147; PATEL AK, 1987, BIOCHEM J, V248, P173, DOI 10.1042/bj2480173; POPOVIC EA, 1995, SEMIN SURG ONCOL, V11, P335, DOI 10.1002/ssu.2980110503; POZNANSKY MJ, 1984, SCIENCE, V223, P1304, DOI 10.1126/science.6367042; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBERTS WG, 1989, LASER SURG MED, V9, P102, DOI 10.1002/lsm.1900090204; ROBERTS WG, 1989, LASER SURG MED, V9, P90, DOI 10.1002/lsm.1900090203; SHECHTER Y, 1978, P NATL ACAD SCI USA, V75, P2135, DOI 10.1073/pnas.75.5.2135; SOBOLEV AS, 1992, BIOCHEM INT, V26, P445; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Tsukagoshi S, 1995, Gan To Kagaku Ryoho, V22, P1271; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; YANO T, 1995, RES COMMUN MOL PATH, V87, P367	26	112	126	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20328	20331		10.1074/jbc.272.33.20328	http://dx.doi.org/10.1074/jbc.272.33.20328			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252335	hybrid			2022-12-27	WOS:A1997XR22100005
J	Feil, R; Boyano, MD; Allen, ND; Kelsey, G				Feil, R; Boyano, MD; Allen, ND; Kelsey, G			Parental chromosome-specific chromatin conformation in the imprinted U2af1-rs1 gene in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLELE-SPECIFIC METHYLATION; DNASE-I SENSITIVITY; CPG BINDING-PROTEIN; DEVELOPMENTAL CONTROL; KINASE GENE; H19 GENE; TRANSCRIPTION; EXPRESSION; REPLICATION; SEQUENCE	The imprinted U2af1-rs1 gene on mouse chromosome 11 is expressed exclusively from the paternal allele. We found that U2af1-rs1 resides in a chromosomal domain that displays marked differences in chromatin conformation and DNA methylation between the parental chromosomes. Chromatin conformation was assayed in brain and liver, in fetuses, and in embryonic stem cells by sensitivity to nucleases in nuclei. In all these tissues, the unmethylated paternal chromosome is sensitive to DNase-I and MspI and has two DNase-I hypersensitive sites in the 5'-untranslated region. In brain and in differentiated stem cells, which display high levels of U2af1-rs1 expression, a paternal DNase-I hypersensitive site is also readily apparent in the promoter region. On the maternal chromosome, in contrast, the entire U2af1-rs1 gene and its promoter are highly resistant to DNase-I and MspI in all tissues analyzed and are fully methylated. No differential MNase sensitivity was detected in this imprinted domain. The parental chromosome-specific DNA methylation and chromatin conformation were also present in parthenogenetic and androgenetic cells and in tissues from animals maternally or paternally disomic for chromosome 11. This demonstrates that these parental chromosome-specific epigenotypes are independently established and maintained and provides no evidence for interallelic trans-sensing and counting mechanisms in U2af1-rs1.	UNIV BASQUE COUNTRY,DEPT CELL BIOL,LEIOA 48940,SPAIN	University of Basque Country	Feil, R (corresponding author), BABRAHAM INST,DEPT GENET & DEV,CAMBRIDGE CB2 4AT,ENGLAND.		allen, nick d/A-4336-2010; BOYANO LOPEZ, MARIA DOLORES/ABF-6668-2021; Boyano, Maria Dolores/D-9114-2012; Feil, Robert P/D-2087-2013	BOYANO LOPEZ, MARIA DOLORES/0000-0001-6051-1054; Feil, Robert P/0000-0002-5671-5860; Kelsey, Gavin/0000-0002-9762-5634; Allen, Nicholas/0000-0003-4009-186X				ALLEN ND, 1994, DEVELOPMENT, V120, P1473; ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BALL DJ, 1983, P NATL ACAD SCI USA, V80, P540; Bartolomei M.S., 1992, SEMIN DEV BIOL, V3, P107; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CAMPOY FJ, 1995, J BIOL CHEM, V270, P26473, DOI 10.1074/jbc.270.44.26473; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; FEIL R, 1995, DEV GENET, V17, P240, DOI 10.1002/dvg.1020170309; FEIL R, 1994, DEVELOPMENT, V120, P2933; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; HANSEN RS, 1988, MOL CELL BIOL, V8, P4692, DOI 10.1128/MCB.8.11.4692; HATADA I, 1995, NUCLEIC ACIDS RES, V23, P36, DOI 10.1093/nar/23.1.36; HATADA I, 1993, NUCLEIC ACIDS RES, V21, P5577, DOI 10.1093/nar/21.24.5577; HAYASHIZAKI Y, 1994, NAT GENET, V6, P33, DOI 10.1038/ng0194-33; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; IZUMIKAWA Y, 1991, HUM GENET, V87, P1, DOI 10.1007/BF01213082; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; John RM, 1996, CURR OPIN CELL BIOL, V8, P348, DOI 10.1016/S0955-0674(96)80008-1; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KOIDE T, 1994, GENOMICS, V24, P1, DOI 10.1006/geno.1994.1574; LASALLE JM, 1995, NAT GENET, V9, P386, DOI 10.1038/ng0495-386; LATHAM KE, 1995, DEV BIOL, V168, P670, DOI 10.1006/dbio.1995.1111; LATHAM KE, 1994, GENE DEV, V169, P670; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; MONK M, 1990, TRENDS GENET, V6, P110, DOI 10.1016/0168-9525(90)90124-O; Nabetani A, 1997, MOL CELL BIOL, V17, P789, DOI 10.1128/MCB.17.2.789; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; PERREAULT SD, 1992, MUTAT RES, V296, P43, DOI 10.1016/0165-1110(92)90031-4; REIK W, 1995, GENOMIC IMPRINTING C, P157; Sasaki H, 1995, DEVELOPMENT, V121, P4195; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SASAKI T, 1992, MOL CELL BIOL, V12, P3819, DOI 10.1128/MCB.12.9.3819; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; Shibata H, 1996, GENOMICS, V35, P248, DOI 10.1006/geno.1996.0348; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; SZABO P, 1994, DEVELOPMENT, V120, P1651; Szabo PE, 1996, EMBO J, V15, P6018, DOI 10.1002/j.1460-2075.1996.tb00990.x; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WEIH F, 1991, EMBO J, V10, P1559; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4	55	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20893	20900		10.1074/jbc.272.33.20893	http://dx.doi.org/10.1074/jbc.272.33.20893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252416	hybrid			2022-12-27	WOS:A1997XR22100086
J	Lechner, J; Welte, T; Tomasi, JK; Bruno, P; Cairns, C; Gustafsson, JA; Doppler, W				Lechner, J; Welte, T; Tomasi, JK; Bruno, P; Cairns, C; Gustafsson, JA; Doppler, W			Promoter-dependent synergy between glucocorticoid receptor and Stat5 in the activation of beta-casein gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; SITE-DIRECTED MUTAGENESIS; DNA-BINDING; NUCLEAR FACTOR; PROLACTIN REGULATION; RESPONSE ELEMENTS; REPORTER GENE; EXPRESSION; HORMONE; PROTEIN	Steroid hormone receptors and Stat factors comprise two distinct families of inducible transcription factors. Activation of a member of each family, namely the glucocorticoid receptor by glucocorticoids and Stat5 by prolactin, is required for the efficient induction of the expression of milk protein genes in the mammary epithelium. We have studied the mode of interaction between Stat5 and the glucocorticoid receptor in the activation of beta-casein gene transcription. The functional role of potential half-palindromic glucocorticoid receptor-binding sites mapped previously in the promoter region was investigated. beta-Casein gene promoter chloramphenicol acetyltransferase constructs containing mutations and deletions in these sites were tested for their responsiveness to the synergistic effect of prolactin and dexamethasone employing COS-7 cells or HC11 mammary epithelial cells. Synergism depended on promoter regions containing intact binding sites for the glucocorticoid receptor and Stat5. The carboxyl terminal transactivation domains of Stat5a and Stat5b were not required for this synergism. Our results suggest that in lactogenic hormone response elements glucocorticoid receptor molecules bound to nonclassical half-palindromic sites gain competence as transcriptional activators by the interaction with Stat5 molecules binding to vicinal sites.	UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA; HUDDINGE UNIV HOSP, KAROLINSKA INST, DEPT MED NUTR, NOVUM, S-14186 HUDDINGE, SWEDEN	University of Innsbruck; Karolinska Institutet				Lechner, Judith/0000-0002-2645-9421				BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BURDON TG, 1994, MOL ENDOCRINOL, V8, P1528, DOI 10.1210/me.8.11.1528; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CHAN GCK, 1991, J BIOL CHEM, V266, P22634; DAHLMAN K, 1989, J BIOL CHEM, V264, P804; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVINOY E, 1991, MOL CELL ENDOCRINOL, V81, P185, DOI 10.1016/0303-7207(91)90217-G; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOPPLER W, 1991, MOL ENDOCRINOL, V5, P1624, DOI 10.1210/mend-5-11-1624; DOPPLER W, 1994, REV PHYSIOL BIOCH P, V124, P93, DOI 10.1007/BFb0031032; DOPPLER W, 1990, MOL ENDOCRINOL, V4, P912, DOI 10.1210/mend-4-6-912; DOPPLER W, 1995, J BIOL CHEM, V270, P17962, DOI 10.1074/jbc.270.30.17962; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GOLDBERG Y, 1994, J BIOL CHEM, V269, P16566; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; LABAER J, 1994, J MOL BIOL, V239, P664, DOI 10.1006/jmbi.1994.1405; LI S, 1995, MOL CELL BIOL, V15, P2063; LI S, 1994, MOL ENDOCRINOL, V8, P1328, DOI 10.1210/me.8.10.1328; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PIERRE S, 1994, MOL ENDOCRINOL, V8, P1720, DOI 10.1210/me.8.12.1720; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Schumann RR, 1996, MOL CELL BIOL, V16, P3490; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SLATER EP, 1993, MOL ENDOCRINOL, V7, P907, DOI 10.1210/me.7.7.907; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WELTE T, 1993, J STEROID BIOCHEM, V47, P75, DOI 10.1016/0960-0760(93)90059-6; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YOSHIMURA M, 1990, P NATL ACAD SCI USA, V87, P3670, DOI 10.1073/pnas.87.10.3670	52	100	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20954	20960		10.1074/jbc.272.33.20954	http://dx.doi.org/10.1074/jbc.272.33.20954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252424	hybrid			2022-12-27	WOS:A1997XR22100094
J	Honing, S; Sosa, M; HilleRehfeld, A; vonFigura, K				Honing, S; Sosa, M; HilleRehfeld, A; vonFigura, K			The 46-kDa mannose 6-phosphate receptor contains multiple binding sites for clathrin adaptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; FACTOR-II RECEPTOR; CYTOPLASMIC DOMAIN; COATED VESICLES; INVITRO BINDING; COMPLEX AP-2; MEMBRANE; SIGNALS; PROTEINS; GOLGI	The two known mannose 6-phosphate receptors (MPR46 and MPR300) both mediate the transport of Man-6-P-containing lysosomal proteins to lysosomes. However, the MPRs cannot be detected in lysosomes, instead they recycle between the plasma membrane and endosomes and between endosomes and the trans-Golgi network. Both, endocytosis from the plasma membrane and budding of transport vesicles from the trans-Golgi network involves the interaction of the receptor with the clathrin-coated vesicles-associated protein complexes AP1 and AP2. We have analyzed this interaction between the Golgi-restricted AP1 complex and the plasma membrane-restricted AP2 complex with the MPR46 tail in vitro by using a biosensor. AP1 and AP2 both bind to and dissociate from the MPR46 tail with similar kinetics, Using synthetic peptides corresponding to different MPR receptor tail regions in inhibition and binding studies, a common high affinity binding site for AP1 and AP2 and two separate high affinity binding sites for AP1 and AP2, respectively, were identified.	UNIV GOTTINGEN,INST BIOCHEM 2,D-37073 GOTTINGEN,GERMANY	University of Gottingen								AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANTON PA, 1991, PEPTIDES, V12, P375, DOI 10.1016/0196-9781(91)90029-O; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHEN JH, 1997, J BIOL CHEM, V272, P7003; DENZER K, 1997, IN PRESS BIOCH J; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; HONING S, 1994, J CELL SCI, V107, P1185; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P22; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SMITH JS, 1991, ANAL BIOCHEM, V197, P247, DOI 10.1016/0003-2697(91)90384-6; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036	43	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19884	19890		10.1074/jbc.272.32.19884	http://dx.doi.org/10.1074/jbc.272.32.19884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242653	hybrid			2022-12-27	WOS:A1997XQ05900040
J	Mosser, G; Breyton, C; Olofsson, A; Popot, JL; Rigaud, JL				Mosser, G; Breyton, C; Olofsson, A; Popot, JL; Rigaud, JL			Projection map of cytochrome b(6)f complex at 8 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; CRYSTALS	The structure of the cytochrome b(6)f complex has been investigated by electron microscopy and image analysis of thin three-dimensional crystals. Electron micrographs of negatively stained specimens were recorded and showed optical diffraction peaks to 10 Angstrom resolution. A projection map was calculated at 8 Angstrom resolution and showed the presence of cytochrome b(6)f dimers. The extramembrane part of each monomer featured a C shape, with mean external diameter similar to of 53 Angstrom and an internal groove similar to 14 Angstrom long and similar to 9 Angstrom wide. Within each monomer, strong features were clearly resolved and tentatively attributed to some of the subunits of the cytochrome b(6)f complex, The data are consistent with the Rieske iron-sulfur protein lying close to the monomer-monomer interface and the heme-bearing domain of cytochrome f far from it.	CEA,LRC,F-75231 PARIS,FRANCE; CNRS UPR 9052,INST BIOL PHYS CHIM,F-75005 PARIS,FRANCE; UNIV PARIS 07,F-75005 PARIS,FRANCE	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Mosser, G (corresponding author), UMR CNR 168,SECT RECH,INST CURIE,11 RUE PIERRE & MARIE CURIE,F-75231 PARIS,FRANCE.		Mosser, Gervaise/M-4943-2018	Mosser, Gervaise/0000-0002-9812-5340				Akiba T, 1996, NAT STRUCT BIOL, V3, P553, DOI 10.1038/nsb0696-553; BOEKEMA EJ, 1994, J BIOENERG BIOMEMBR, V26, P17, DOI 10.1007/BF00763217; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BREYTON C, 1997, IN PRESS J BIOL CHEM, V272; CHAIN RK, 1991, PHOTOSYNTH RES, V28, P59, DOI 10.1007/BF00033715; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Finazzi G, 1997, BIOCHEMISTRY-US, V36, P2867, DOI 10.1021/bi962717y; HOVMOLLER S, 1981, FEBS LETT, V123, P118, DOI 10.1016/0014-5793(81)80033-6; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; KUHLBRANDT W, 1992, Q REV BIOPHYS, V25, P1; Link TA, 1996, BBA-BIOENERGETICS, V1275, P54, DOI 10.1016/0005-2728(96)00050-3; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; MORSCHEL E, 1983, J CELL BIOL, V97, P301, DOI 10.1083/jcb.97.2.301; MOSSER G, 1994, INT C EL MICR EL MIC, V3, P609; OLOFSSON A, 1994, J STRUCT BIOL, V113, P199, DOI 10.1006/jsbi.1994.1054; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; PIERRE Y, 1997, IN PRESS J BIOL CHEM, V272; POPOT JL, 1995, PHOTOSYNTHESIS LIGHT, V2, P507; Rigaud JL, 1997, J STRUCT BIOL, V118, P226, DOI 10.1006/jsbi.1997.3848; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; Vater J, 1996, BER BUNSEN PHYS CHEM, V100, P2107, DOI 10.1002/bbpc.19961001232; Young HS, 1997, BIOPHYS J, V72, P2545, DOI 10.1016/S0006-3495(97)78898-2	27	51	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20263	20268		10.1074/jbc.272.32.20263	http://dx.doi.org/10.1074/jbc.272.32.20263			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242706	hybrid			2022-12-27	WOS:A1997XQ05900093
J	Sakai, J; Nohturfft, A; Cheng, D; Ho, YK; Brown, MS; Goldstein, JL				Sakai, J; Nohturfft, A; Cheng, D; Ho, YK; Brown, MS; Goldstein, JL			Identification of complexes between the COOH-terminal domains of sterol regulatory element-binding proteins (SREBPs) and SREBP cleavage-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; COENZYME-A REDUCTASE; TRANSCRIPTION; RECEPTOR; CELLS; GENE; DEGRADATION; PROMOTER	SREBP cleavage-activating protein (SCAP) stimulates the proteolytic cleavage of membrane-bound SREBPs, thereby initiating the release of NH2-terminal fragments from cell membranes, The liberated fragments enter the nucleus and stimulate transcription of genes involved in synthesis and uptake of cholesterol and fatty acids, Sterols repress cleavage of SREBPs, apparently by interacting with the membrane attachment domain of SCAP, In the present studies we show that SCAP, like the SREBPs, is located in membranes of the endoplasmic reticulum and nuclear envelope, The COOH-terminal domain of SCAP, like that of the SREBPs, is located on the cytosolic face of the membranes. Co-immunoprecipitation experiments show that SCAP and SREBP-2 form a complex that can be precipitated with antibodies to either component, Complex formation occurs when cells express only the COOH-terminal domain of either SREBP-2 or SCAP, indicating that the complex forms between the two COOH-terminal domains, Truncation of SREBP-2 at its COOH terminus prevents the formation of complexes with SCAP and simultaneously reduces proteolytic cleavage. We conclude that proteolytic cleavage of SREBPs requires the formation of a complex with the COOH-terminal domain of SCAP and that SCAP is therefore a required element in the regulation of sterol and fatty acid metabolism in animal cells.			Sakai, J (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235, USA.			Nohturfft, Axel/0000-0001-9484-3209; Sakai, Juro/0000-0003-4043-1035	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HERZ J, 1990, J BIOL CHEM, V265, P21355; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LISCUM L, 1985, J BIOL CHEM, V260, P522; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Miserez AR, 1997, GENOMICS, V40, P31, DOI 10.1006/geno.1996.4525; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TOLLESHAUG H, 1982, CELL, V30, P715, DOI 10.1016/0092-8674(82)90276-8; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	31	194	201	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20213	20221		10.1074/jbc.272.32.20213	http://dx.doi.org/10.1074/jbc.272.32.20213			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242699	hybrid			2022-12-27	WOS:A1997XQ05900086
J	Mabuchi, K; Li, B; Ip, W; Tao, T				Mabuchi, K; Li, B; Ip, W; Tao, T			Association of calponin with desmin intermediate filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALPONIN; CHICKEN GIZZARD; THIN-FILAMENTS; ACTIN-BINDING; CALMODULIN; CELLS; ACTOMYOSIN; PROTEINS; MYOSIN	Our previous immunoelectron microscopy studies of chicken gizzard smooth muscle cells showed that in certain areas the distribution of anti-calponin exhibits a high degree of overlap with beta-actin, filamin, and in particular, desmin, suggesting that in situ a fraction of calponin may be associated with intermediate filaments of the cytoskeleton. In this work we further explore this idea by studying the interaction between calponin and desmin. We found that at physiological salt concentrations, calponin bound only weakly to synthetic desmin intermediate filaments. On the other hand, calponin bound strongly to nonfilamentous desmin tetramers and was incorporated into intermediate filaments when the two proteins were mixed in a buffer containing 6 M urea and dialyzed into a buffer containing 0.15 M NaCl. Anti-calponin was found to label a portion of intermediate filaments and dense bodies isolated from gizzard tissues. Our findings suggest that in chicken gizzard smooth muscle cells, calponin may be an integral component of desmin intermediate filaments in the vicinity of dense bodies. Since calponin is also known to bind actin, we hypothesize that one of the functions of calponin might be to bridge intermediate filaments with actin in dense bodies.	UNIV CINCINNATI,COLL MED,DEPT ANAT CELL BIOL & NEUROBIOL,CINCINNATI,OH 45267; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	University System of Ohio; University of Cincinnati; Harvard University; Harvard Medical School; Tufts University	Mabuchi, K (corresponding author), BOSTON BIOMED RES INST,MUSCLE RES GRP,BOSTON,MA 02114, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR41637] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; BAGBY RM, 1990, ULTRASTRUCTURE SMOOT, P23; GIMONA M, 1996, BIOCH SMOOTH MUSCLE, P91; GONG BJ, 1993, J BIOCHEM-TOKYO, V114, P453, DOI 10.1093/oxfordjournals.jbchem.a124197; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; LEHMAN W, 1989, BIOCHIM BIOPHYS ACTA, V996, P57, DOI 10.1016/0167-4838(89)90094-0; LI H, 1994, J CELL BIOL, V124, P287; MABUCHI H, 1996, J MUSCLE RES CELL M, V17, P243; MABUCHI K, 1990, J STRUCT BIOL, V103, P249, DOI 10.1016/1047-8477(90)90043-C; MABUCHI K, 1991, J STRUCT BIOL, V107, P22, DOI 10.1016/1047-8477(91)90027-T; NAKA M, 1990, BIOCHEM BIOPH RES CO, V171, P933, DOI 10.1016/0006-291X(90)90773-G; NORTH AJ, 1994, J CELL SCI, V107, P445; NORTH AJ, 1994, J CELL SCI, V107, P437; SMALL JV, 1995, BIOESSAYS, V17, P785, DOI 10.1002/bies.950170908; SMALL JV, 1992, EUR J BIOCHEM, V208, P559, DOI 10.1111/j.1432-1033.1992.tb17220.x; SOBIESZEK A, 1975, EUR J BIOCHEM, V55, P49, DOI 10.1111/j.1432-1033.1975.tb02137.x; STAFFORD WF, 1995, J BIOL CHEM, V270, P10576, DOI 10.1074/jbc.270.18.10576; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TSUKITA S, 1983, CELL TISSUE RES, V229, P233, DOI 10.1007/BF00214972; Wang PY, 1996, FEBS LETT, V392, P255, DOI 10.1016/0014-5793(96)00824-1; WILLS FL, 1993, BIOCHEMISTRY-US, V32, P2321, DOI 10.1021/bi00060a025; WINDER SJ, 1993, CELL SIGNAL, V5, P677, DOI 10.1016/0898-6568(93)90029-L; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WINDER SJ, 1993, BIOCHEMISTRY-US, V32, P13327, DOI 10.1021/bi00211a046	27	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22662	22666		10.1074/jbc.272.36.22662	http://dx.doi.org/10.1074/jbc.272.36.22662			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278424	hybrid			2022-12-27	WOS:A1997XV49200044
J	Orchansky, PL; Ayres, SD; Hilton, DJ; Schrader, JW				Orchansky, PL; Ayres, SD; Hilton, DJ; Schrader, JW			An interleukin (IL)-13 receptor lacking the cytoplasmic domain fails to transduce IL-13-induced signals and inhibits responses to IL-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CHAIN; ALPHA-CHAIN; STIMULATING FACTOR; T-CELLS; HEMATOPOIETIC-CELLS; KINASE ACTIVATION; BINDING SUBUNIT; JANUS KINASE; BETA-SUBUNIT; B-CELLS	Interleukin (IL)-13 is a pleiotropic immunoregulatory cytokine that shares many, although not all, of the biological activities of IL-4. The overlapping biological properties of IL-4 and IL-13 appear to be due to the existence of shared components of the receptors, and we and others showed that the IL-4 receptor-alpha is involved in signal transduction paths activated by both. We show here that expression of the IL-13 receptor-alpha in two factor-dependent cell lines, the premyeloid FD5 and the T lymphoid CT4.S, conferred the ability to grow continuously in response to IL-13; to respond to IL-13 with tyrosine phosphorylation of JAK1, Tyk2, IL-4R alpha, IRS-2, and STAT6; and to respond to IL-4 with tyrosine phosphorylation of Tyk2 in addition to those induced in parental cell lines. Expression of a truncated IL-13 receptor-alpha that lacked the cytoplasmic domain demonstrated that this domain was essential for IL-13-dependent growth and phosphorylation of the above substrates. Expression of this truncated IL-13 receptor also resulted in an inhibition of biochemical and biological responses to IL-4 that was exacerbated by the presence of IL-13. These dominant inhibitory effects indicate that the extracellular domain of the truncated IL-13 receptor competes with gamma c for complexes of IL-4 and the IL-4 receptor-alpha, or, when itself bound to IL-13, competes with IL-4 for the IL-4 receptor-alpha.	ROYAL MELBOURNE HOSP,COOPERAT RES CTR CELLULAR GROWTH FACTORS,MELBOURNE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Orchansky, PL (corresponding author), UNIV BRITISH COLUMBIA,BIOMED RES CTR,2222 HLTH SCI MALL,VANCOUVER,BC V6T 1Z3,CANADA.		Hilton, Douglas J/C-7250-2013	Hilton, Douglas J/0000-0002-7698-2392				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; deGroot RP, 1997, J BIOL CHEM, V272, P2319; FOLTZ IN, 1997, BLOOD, V272, P3296; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; Hilton CJ, 1995, GROWTH FACTORS, V12, P263, DOI 10.3109/08977199509028965; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HU LJ, 1989, J IMMUNOL, V142, P800; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Jiang N, 1996, J BIOL CHEM, V271, P16472, DOI 10.1074/jbc.271.28.16472; KAMMER, 1996, J BIOL CHEM, V271, P23634; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1995, J BIOL CHEM, V270, P19481, DOI 10.1074/jbc.270.33.19481; KUORO T, 1996, INT IMMUNOL, V8, P237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai SY, 1996, EMBO J, V15, P4506, DOI 10.1002/j.1460-2075.1996.tb00828.x; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MALEFYT RD, 1993, RES IMMUNOL, V144, P629, DOI 10.1016/S0923-2494(05)80016-1; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Murata T, 1996, J IMMUNOL, V156, P2972; MURATA T, 1996, J BIOL CHEM, V270, P30829; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; Nelson BH, 1996, MOL CELL BIOL, V16, P309; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; PalmerCrocker RL, 1996, J CLIN INVEST, V98, P604, DOI 10.1172/JCI118829; PERNIS A, 1995, P NATL ACAD SCI USA, V92, P7971, DOI 10.1073/pnas.92.17.7971; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAKAMAKI K, 1993, J BIOL CHEM, V268, P15833; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHRADER JW, 1986, P NATL ACAD SCI USA, V83, P2458, DOI 10.1073/pnas.83.8.2458; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; Welham MJ, 1997, J BIOL CHEM, V272, P1377, DOI 10.1074/jbc.272.2.1377; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	67	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22940	22947		10.1074/jbc.272.36.22940	http://dx.doi.org/10.1074/jbc.272.36.22940			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278458	hybrid			2022-12-27	WOS:A1997XV49200080
J	Sunahara, RK; Dessauer, CW; Whisnant, RE; Kleuss, C; Gilman, AG				Sunahara, RK; Dessauer, CW; Whisnant, RE; Kleuss, C; Gilman, AG			Interaction of G(s alpha) with the cytosolic domains of mammalian adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PURIFICATION; FORSKOLIN; FORM	Forskolin-and G(s alpha)-stimulated adenylyl cyclase activity is observed after mixture of two independently-synthesized similar to 25-kDa cytosolic fragments derived from mammalian adenylyl cyclases (native M-r similar to 120,000), The C-1a domain from type V adenylyl cyclase (VC1) and the C-2 domain from type II adenylyl cyclase (IIC2) can both be expressed in large quantities and purified to homogeneity, When mixed, their maximally stimulated specific activity, 150 mu mol/min/mg protein, substantially exceeds values observed previously with the intact enzyme, A soluble, high-affinity complex containing one molecule each of VC1, IIC2, and guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S)-G(s alpha) is responsible for the observed enzymatic activity and can be isolated, In addition, GTP gamma S-G(s alpha) interacts with homodimers of IIC2 to form a heterodimeric complex (one molecule each of G(s alpha) and IIC2) but not detectably with homodimers of VC1, Nevertheless, G(s alpha) can be cross-linked to VC1 in the activated heterotrimeric complex of VC1, IIC2, and G(s alpha), indicating its proximity to both components of the enzyme that are required for efficient catalysis, These results and those in the accompanying report (Dessauer, C. W., Scully, T. T., and Gilman, A. G. (1997) J. Biol. Chem. 272, 22272-22277) suggest that activators of adenylyl cyclase facilitate formation of a single, high-activity catalytic site at the interface between C-1 and C-2.			Sunahara, RK (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.		Sunahara, Roger/AAJ-8667-2020; Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497, GM16905] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; LEE E, 1994, METHOD ENZYMOL, V237, P146; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; POLLET RJ, 1985, METHOD ENZYMOL, V117, P3; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941	16	149	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22265	22271		10.1074/jbc.272.35.22265	http://dx.doi.org/10.1074/jbc.272.35.22265			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268375	hybrid			2022-12-27	WOS:A1997XT85000087
J	Witte, S; Krawinkel, U				Witte, S; Krawinkel, U			Specific interactions of the autoantigen L7 with multi-zinc finger protein ZNF7 and ribosomal protein S7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; CELL BIOLOGY; LOCALIZATION; SUBUNIT; SURFACE; IDENTIFICATION; AUTOANTIBODIES; EXPRESSION; ANTIBODIES; GENE	The eucaryotic protein L7, which associates with the large subunit of ribosomes, has been shown to be a major autoantigen in systemic autoimmune arthritis, The N terminus carries a sequence motif that is similar to the leucine zipper domain of eucaryotic transcription factors. This domain promotes the homodimerization of protein L7 through alpha helical coiled-coil formation and binds to distinct mRNAs, thereby inhibiting their cell-free translation, Using a yeast two-hybrid selection, we have identified from a Jurkat T lymphoma cDNA library ribosomal protein S7 and the multi-zinc finger protein ZNF7 as proteins that interact with protein L7, A fragment of L7 carrying the leucine zipper-like domain is fully sufficient to mediate these interactions, Their potential biological significance is indicated by low apparent dissociation constants of S7-L7 (15 x 10(-9) M) and, respectively, ZNF7-L7 (2 x 10(-9) M) complexes and co-immunoprecipitation of proteins S7, ZNF7, and L7 from a cell lysate with an anti-L7 antibody. We also show that ZNF7-like L7 and S7 can exist in a ribosome-bound form, This study provides further evidence suggesting that L7 is involved in translational regulation through interactions with components of the translational apparatus.			Witte, S (corresponding author), UNIV KONSTANZ, FAK BIOL, POSTFACH 5560, D-78434 CONSTANCE, GERMANY.							ANNILO T, 1995, GENE, V165, P297, DOI 10.1016/0378-1119(95)00576-R; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLEMIS EA, 1993, CURRENT PROTOCOLS MO, V3; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HADJIOLOV AA, 1985, CELL BIOL MONOGRAPH, V12; Harlow E., 1988, ANTIBODIES LAB MANUA; HEMMERICH P, 1993, NUCLEIC ACIDS RES, V21, P223, DOI 10.1093/nar/21.2.223; Hemmerich P, 1997, EUR J BIOCHEM, V245, P549, DOI 10.1111/j.1432-1033.1997.00549.x; KISILEVSKY R, 1987, BIOCHIM BIOPHYS ACTA, V910, P282, DOI 10.1016/0167-4781(87)90121-7; LANIA L, 1990, GENOMICS, V6, P333, DOI 10.1016/0888-7543(90)90574-E; LIN A, 1987, J BIOL CHEM, V262, P12665; LIN A, 1991, FEBS LETT, V287, P121, DOI 10.1016/0014-5793(91)80030-7; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; MARION MJ, 1987, BIOCHEM BIOPH RES CO, V149, P1077, DOI 10.1016/0006-291X(87)90518-3; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MUNDUS DA, 1993, MOL BIOL+, V27, P91; NEU E, 1995, CLIN EXP IMMUNOL, V100, P198; NEU E, 1997, IN PRESS ARTHRITIS R; Neumann F, 1997, EXP CELL RES, V230, P252, DOI 10.1006/excr.1996.3417; NEUMANN F, 1995, NUCLEIC ACIDS RES, V23, P195, DOI 10.1093/nar/23.2.195; NYGARD O, 1982, EMBO J, V1, P357, DOI 10.1002/j.1460-2075.1982.tb01174.x; STULTZ CM, 1993, PROTEIN SCI, V2, P305; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; TSURUGI K, 1976, J BIOL CHEM, V251, P7940; VONMIKECZ A, 1994, IMMUNOBIOLOGY, V192, P137, DOI 10.1016/S0171-2985(11)80413-4; VONMIKECZ AH, 1995, CLIN EXP IMMUNOL, V100, P205; Witte S, 1996, J BIOL CHEM, V271, P18171, DOI 10.1074/jbc.271.30.18171; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101	38	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22243	22247		10.1074/jbc.272.35.22243	http://dx.doi.org/10.1074/jbc.272.35.22243			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268371	hybrid			2022-12-27	WOS:A1997XT85000083
J	Grossmann, M; Wong, R; Szkudlinski, MW; Weintrauab, BD				Grossmann, M; Wong, R; Szkudlinski, MW; Weintrauab, BD			Human thyroid-stimulating hormone (hTSH) subunit gene fusion produces hTSH with increased stability and serum half-life and compensates for mutagenesis-induced defects in subunit association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; GLYCOPROTEIN HORMONES; ALPHA-SUBUNIT; BETA-SUBUNITS; METABOLIC-CLEARANCE; HUMAN THYROTROPIN; EXPRESSION; BIOACTIVITY; EVOLUTION; PITUITARY	The human thyroid-stimulating hormone (hTSH) subunits alpha and beta are transcribed from different genes and associate noncovalently to form the bioactive hTSH heterodimer, Dimerization is rate-limiting for hTSH secretion, and dissociation leads to hormone inactivation, Previous studies on human chorionic gonadotropin (hCG) and human follicle-stimulating hormone had shown that if was possible by subunit gene fusion to produce a bioactive, single chain hormone. However, neither the stability nor the clearance from the circulation of such fused glycoprotein hormones has been studied. We show here that genetic fusion of the hTSH alpha- and beta-subunits using the carboxyl-terminal peptide of the hCG beta-subunit as a linker created unimolecular hTSH whose receptor binding and bioactivity were comparable to native hTSH. Interestingly; the fused hTSH had higher thermostability and a longer plasma half-life than either native or dimeric hTSH containing the hCG beta-subunit-carboxyl-terminal peptide, suggesting that dimer dissociation may contribute to glycoprotein hormone inactivation in vivo. In addition, we show for the first time that synthesis of hTSH as a single polypeptide chain could overcome certain mutagenesis-induced defects in hTSH secretion, therefore enabling functional studies of such mutants, Thus, in addition to prolongation of plasma half-life, genetic fusion of hTSH subunits should be particularly relevant for the engineering of novel analogs where desirable features are offset by decreased dimer formation or stability, Such methods provide a general approach to expand the spectrum of novel recombinant glycoprotein hormones available for in vitro and in vivo study.	NHLBI,NIH,BETHESDA,MD 20892; UNIV MARYLAND,SCH MED,DEPT MED,MOL ENDOCRINOL LAB,BALTIMORE,MD 21201	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University System of Maryland; University of Maryland Baltimore	Grossmann, M (corresponding author), UNIV MARYLAND,CTR MED BIOTECHNOL,INST HUMAN VIROL,MOL ENDOCRINOL LAB,725 W LOMBARD ST N457,BALTIMORE,MD 21201, USA.							CAMPBELL KL, 1980, P NATL ACAD SCI-BIOL, V77, P4793, DOI 10.1073/pnas.77.8.4793; CONSTANT RB, 1986, ENDOCRINOLOGY, V119, P2720, DOI 10.1210/endo-119-6-2720; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; GROSSMANN M, 1995, J BIOL CHEM, V270, P29378, DOI 10.1074/jbc.270.49.29378; Grossmann M, 1996, MOL ENDOCRINOL, V10, P769, DOI 10.1210/me.10.6.769; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Grossmann M, 1997, ENDOCR REV, V18, P476, DOI 10.1210/er.18.4.476; GROSSMANN M, 1995, MOL ENDOCRINOL, V9, P948, DOI 10.1210/me.9.8.948; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IBANEZ CF, 1994, J NEUROBIOL, V25, P1349, DOI 10.1002/neu.480251104; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; JOSHI L, 1995, ENDOCRINOLOGY, V136, P3839, DOI 10.1210/en.136.9.3839; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; MAGNER JA, 1982, J BIOL CHEM, V257, P6709; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; Roth KE, 1996, BIOCHEMISTRY-US, V35, P7928, DOI 10.1021/bi952566j; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; SKUDLINSKI MW, 1996, NAT BIOTECHNOL, V14, P1257; Sugahara T, 1996, J BIOL CHEM, V271, P10445, DOI 10.1074/jbc.271.18.10445; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Szkudlinski MW, 1996, NAT BIOTECHNOL, V14, P1257, DOI 10.1038/nbt1096-1257; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; THOTAKURA NR, 1995, GLYCOBIOLOGY, V5, P3, DOI 10.1093/glycob/5.1.3; Tian Y, 1996, J BIOL CHEM, V271, P20250, DOI 10.1074/jbc.271.34.20250; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	32	41	44	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21312	21316		10.1074/jbc.272.34.21312	http://dx.doi.org/10.1074/jbc.272.34.21312			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261143	hybrid			2022-12-27	WOS:A1997XR78900053
J	Paschal, BM; Fritze, C; Guan, T; Gerace, L				Paschal, BM; Fritze, C; Guan, T; Gerace, L			High levels of the GTPase Ran/TC4 relieve the requirement for nuclear protein transport factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PORE COMPLEX; YEAST-CELLS; IMPORT; NUCLEOPORINS; IDENTIFICATION; DISSOCIATION; INHIBITION; INTERACTS; SUBSTRATE	The GTPase Ran/TC4 and the 14-kDa protein nuclear transport factor 2 (NTF2) are two of the cytosolic factors that mediate nuclear protein import in vertebrates. Previous biochemical studies have shown that NTF2 binds directly to the GDP-bound form of Ran/TC4 and to proteins of the nuclear pore complex that contain phenylalanine-glycine repeats, In the present study we have used molecular genetic approaches to study the Saccha romyces cerevisiae homologue of NTF2. The scNTF2 gene encodes a protein that is 44% identical to the human protein, We found that deletion of the scNTF2 gene is lethal and that repression of NTF2p expression by a regulatable promoter results in gross structural distortions of the nuclear envelope. In a screen for high copy number suppressors of a scNTF2 deletion, the only gene me isolated other than scNTF2 itself was GSP1, the S. cerevisiae homologue of Ran/TC4. Furthermore, me found that high levels of Ran/TC4 can relieve the requirement for NTF2 in a mammalian-permeabilized cell assay for nuclear protein import. These data suggest that certain of the nuclear protein import functions of NTF2 and Ran/TC4 are closely linked and that NTF2 may serve to modulate a transport step involving Ran/TC4.	SCRIPPS RES INST, DEPT CELL & MOL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NIGMS NIH HHS [GM41955] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041955] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BYERS B, 1991, METHOD ENZYMOL, V194, P602; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; KISER GL, 1995, YEAST, V11, P1311, DOI 10.1002/yea.320111312; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; Pante N, 1995, INT REV CYTOL, V162B, P225; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SIKORSKI RS, 1989, GENETICS, V122, P19; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	36	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21534	21539		10.1074/jbc.272.34.21534	http://dx.doi.org/10.1074/jbc.272.34.21534			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261173	hybrid			2022-12-27	WOS:A1997XR78900083
J	Xu, CF; Chambers, JA; Solomon, E				Xu, CF; Chambers, JA; Solomon, E			Complex regulation of the BRCA1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; BREAST; EXPRESSION; GROWTH; CELLS; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; MUTATIONS; TISSUES	We have analyzed the promoter region of the human BRCA1 gene in detail and demonstrate that the expression of the BRCA1 gene is under complex regulation. First, its transcription is under the control of two promoters generating two distinct transcripts alpha and beta, and second, promoter alpha is shared with the adjacent NBR2 gene and is bi-directional, Both promoter alpha and promoter beta are responsive: to estrogen stimulation. We also discerned that there are striking differences in both the genomic organization and immediate cis-control elements of the BRCA1 gene between humans and mice.			Xu, CF (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DIV MED & MOL GENET, 8TH FLOOR, GUYS TOWER, LONDON SE1 9RT, ENGLAND.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Xu, Chun-Fang/0000-0002-8747-0683				Ausubel FM, 1991, CURRENT PROTOCOLS MO; BOYD M, 1995, NATURE, V375, P541, DOI 10.1038/375541b0; Brown MA, 1996, ONCOGENE, V12, P2507; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; FREISS G, 1993, BREAST CANCER RES TR, V27, P57, DOI 10.1007/BF00683193; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GUDAS JM, 1995, CANCER RES, V55, P4561; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Spillman MA, 1996, ONCOGENE, V13, P1639; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Xu CF, 1996, SEMIN CANCER BIOL, V7, P33, DOI 10.1006/scbi.1996.0005; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259	28	125	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20994	20997		10.1074/jbc.272.34.20994	http://dx.doi.org/10.1074/jbc.272.34.20994			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261099	hybrid			2022-12-27	WOS:A1997XR78900009
J	Kumar, P; VanPatten, SM; Walsh, DA				Kumar, P; VanPatten, SM; Walsh, DA			Multiplicity of the beta form of the cAMP-dependent protein kinase inhibitor protein generated by post-translational modification and alternate translational initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; RAT TESTIS; INTRACELLULAR-LOCALIZATION; SKELETAL-MUSCLE; PHOSPHORYLATION; EXPRESSION; PEPTIDES; EXPORT; SIGNAL; YEAST	Two distinct species of the thermostable inhibitor of the cAMP-dependent protein kinase, PKI alpha and PKI beta, exist that are the products of separate genes. The PKI beta form, as first isolated from rat testis, is a 70-amino acid protein, but the genomic sequence suggested that an alternate form might exist, arising as a consequence of alternate translational initiation, This species, now termed PKI beta-78, has been synthesized by bacterial expression, demonstrated to be equipotent with PKI beta-70, and also now demonstrated to occur in vivo, By Western blot analyses, six additional species of PKI beta are also evident in tissues, Two of these represent the phospho forms of PKI beta-78 and PKI beta-70. The other four represent phospho and dephospho forms of two higher molecular mass PKI beta species, These latter forms are currently termed PKI beta-X and PKI beta-Y, awaiting the full elucidation of their molecular identity, In adult rat testis and cerebellum, PKI beta-70, PKI beta-X, and PKI beta-Y constitute 39, 23, and 32% and 15, 29, and 54% of the total tissue levels, respectively, In adult rat testis, 35-42% of each of these three species is present as a monophospho form, whereas no phosphorylation of them is evident in cerebellum, PKI beta-78 is present at much lower levels in both rat testis and cerebellum (similar to 6 and 2% of the total, respectively) and almost entirely as a monophospho species. PKI beta-78, like PKI beta-70, is a high affinity and specific inhibitor of the cAMP-dependent protein kinase. PKI beta-Y and PKI beta-X, in contrast, also significantly inhibit the cGMP-dependent protein kinase.	UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA	University of California System; University of California Davis								BEALE EG, 1977, J BIOL CHEM, V252, P6322; BEALE EG, 1977, ENDOCRINOLOGY, V101, P1621, DOI 10.1210/endo-101-5-1621; BEEBE SJ, 1992, J BIOL CHEM, V267, P25505; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; DEMAILLE JG, 1978, FEBS LETT, V86, P113, DOI 10.1016/0014-5793(78)80110-0; DUNCAN RJS, 1983, ANAL BIOCHEM, V132, P68, DOI 10.1016/0003-2697(83)90426-8; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1992, BIOCHEMISTRY-US, V31, P1728, DOI 10.1021/bi00121a021; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JINNO A, 1993, MOL CELL BIOL, V13, P4146, DOI 10.1128/MCB.13.7.4146; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MCPHERSON JM, 1979, BIOCHEMISTRY-US, V18, P4835, DOI 10.1021/bi00589a011; MITCHELL RD, 1995, BIOCHEMISTRY-US, V34, P528, DOI 10.1021/bi00002a018; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; PICKETTGIES CA, 1985, J BIOL CHEM, V260, P2046; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SLICE LW, 1989, J BIOL CHEM, V264, P20940; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; SOLDATI T, 1990, J BIOL CHEM, V265, P4498; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZMIGIELSKI A, 1977, J BIOL CHEM, V252, P3848; TASH JS, 1980, CELL, V21, P57, DOI 10.1016/0092-8674(80)90114-2; TASH JS, 1979, J BIOL CHEM, V254, P1241; VANPATTEN SM, 1987, J BIOL CHEM, V262, P3398; VanPatten SM, 1997, J BIOL CHEM, V272, P20021, DOI 10.1074/jbc.272.32.20021; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WESTON PD, 1980, BIOCHIM BIOPHYS ACTA, V612, P40, DOI 10.1016/0005-2744(80)90276-4; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, METHOD ENZYMOL, V99, P80; WHITEHOUSE S, 1980, ARCH BIOCHEM BIOPHYS, V203, P734, DOI 10.1016/0003-9861(80)90233-7	50	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20011	20020		10.1074/jbc.272.32.20011	http://dx.doi.org/10.1074/jbc.272.32.20011			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242671	hybrid			2022-12-27	WOS:A1997XQ05900058
J	Nadler, MJS; Chen, BB; Anderson, JS; Wortis, HH; Neel, BG				Nadler, MJS; Chen, BB; Anderson, JS; Wortis, HH; Neel, BG			Protein-tyrosine phosphatase SHP-1 is dispensable for Fc gamma RIIB-mediated inhibition of B cell antigen receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; MYC ONCOGENES; NEWBORN MICE; IMMUNOGLOBULIN; TRANSFORMATION; LYMPHOCYTES; RETROVIRUS; NEOPLASMS; SIGNAL; PTP1C	The inhibitory Fe receptor, Fc gamma RIIB, provides a signal that aborts B cell antigen receptor activation, blocking extracellular calcium influx. Because the protein-tyrosine phosphatase SHP-1 binds tyrosy1 phosphorylated Fc gamma RIIB and Fc gamma RIIB-mediated inhibition is defective in motheaten (me/me) mice, which do not express SHP-1, it was proposed that SHP-1 mediates Fc gamma RIIB signaling in B cells (D'Ambrosio, D., Hippen, K. L., Minskoff S. A., Mellman, I., Pani, G., Siminovitch, K. A., and Cambier, J. C. (1995) Science 268, 293-297). However, SHP-1 is dispensable for Fc gamma RIIB-mediated inhibition of Fc epsilon RI signaling in mast cells (One, M., Bolland, S., Tempst, P., and Ravetch, J. V. (1996) Nature 383, 263-266), prompting us to re-examine the role of SHP-1 in Fc gamma RIIB signaling in B cells. We generated immortalized sIgM+, Fc gamma RIIB+ cell lines from me/me mice and normal littermates. Co-Ligation of Fc gamma RIIB and the sIgM antigen receptor inhibits calcium influx in both cell lines. Inhibition is reversed by preincubation with anti-Fc gamma RIIB antibodies, indicating that it is mediated bg Fc gamma RIIB. The inositol 5' phosphatase SHIP is recruited to tyrosyl-phosphorylated Fc gamma RIIB in both cell Lines, Fc gamma RIIB-mediated CD19 dephosphorylation also occurs in the presence or the absence of SHP-1, Our results establish that SHP-1 is dispensable for Fc gamma RIIB-mediated inhibition of sIgM antigen receptor signaling.	TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111	Tufts University	Nadler, MJS (corresponding author), BETH ISRAEL DEACONESS MED CTR,DEPT MED,DIV HEMATOL ONCOL,CANC BIOL PROGRAM,BOSTON,MA 02215, USA.				NATIONAL CANCER INSTITUTE [R01CA066600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015803, R01AI015803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043773] Funding Source: NIH RePORTER; NCI NIH HHS [CA66600] Funding Source: Medline; NIAID NIH HHS [AI15803] Funding Source: Medline; NIAMS NIH HHS [AR43773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CHEN YW, 1992, INT IMMUNOL, V4, P1293, DOI 10.1093/intimm/4.11.1293; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; CYSTER JG, 1995, IMMUNITY, V2, P1; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DEARON M, 1995, J CLIN INVEST, V95, P577; DEARON M, 1995, IMMUNITY, V3, P635; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; Doody GM, 1996, CURR OPIN IMMUNOL, V8, P378, DOI 10.1016/S0952-7915(96)80128-2; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; TSUI FWL, 1994, IMMUNOL REV, V136, P185	26	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20038	20043		10.1074/jbc.272.32.20038	http://dx.doi.org/10.1074/jbc.272.32.20038			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242674	hybrid			2022-12-27	WOS:A1997XQ05900061
J	McKinsey, TA; Chu, ZL; Ballard, DW				McKinsey, TA; Chu, ZL; Ballard, DW			Phosphorylation of the PEST domain of I kappa B beta regulates the function of NF-kappa B/I kappa B beta complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1; C-FOS; EXPRESSION; ACTIVATION; PROTEINS; ENCODES; IDENTIFICATION; SUBUNIT; PRODUCT; CLONING	Activation of transcription factor NF-kappa B involves the signal-dependent degradation of basally phosphorylated inhibitors such as I kappa B alpha and I kappa B beta. The gene encoding I kappa B alpha is under NF-kappa B control, which provides a negative feedback loop to terminate the induced NF-kappa B response, However, recent studies have identified a hypophosphorylated pool of I kappa B beta that shields nuclear NF-kappa B from inhibition by newly synthesized I kappa B alpha. In the present work, we provide three lines of evidence indicating that this protection mechanism is regulated by the C-terminal PEST domain of I kappa B beta. First, disruption of two basal phosphoacceptors present in the I kappa B beta PEST domain (Ser-313 and Ser-315) yields a mutant that forms ternary complexes with NF-kappa B and its target DNA-binding site. Second, based on in vitro mixing experiments, these ternary complexes are resistant to the inhibitory action of I kappa B alpha. Third, mutants of I kappa B beta that are defective for phosphorylation at Ser-313 and Ser-315 fail to efficiently block NF-kappa B-directed transcription in vivo, whereas replacement of these two I kappa B beta residues with a phosphoserine mimetic generates a fully functional repressor, Taken together, our findings suggest that the functional fate of NF-kappa B when bound to I kappa B beta is critically dependent on the phosphorylation status of the I kappa B beta PEST domain.	VANDERBILT UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MICROBIOL & IMMUNOL, NASHVILLE, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033839] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI33839] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LINK E, 1992, J BIOL CHEM, V267, P239; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1	25	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22377	22380		10.1074/jbc.272.36.22377	http://dx.doi.org/10.1074/jbc.272.36.22377			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278383	hybrid			2022-12-27	WOS:A1997XV49200002
J	Nakagawa, N; Masui, R; Kato, R; Kuramitsu, S				Nakagawa, N; Masui, R; Kato, R; Kuramitsu, S			Domain structure of Thermus thermophilus UvrB protein - Similarity in domain structure to helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI UVRB; CRYSTAL-STRUCTURE; ATPASE ACTIVITY; RECA PROTEIN; PREINCISION COMPLEX; UVRABC ENDONUCLEASE; MICROCOCCUS-LUTEUS; EXCISION-REPAIR; DNA; GENE	UvrB protein plays an essential role in the prokaryotic excision repair system. UvrB protein shows cryptic ATPase activity, DNA binding, helicase-like activity, and incision activity by interacting with UvrA or UvrC proteins. To reveal the Structure-function relationship of this multifunctional protein, the domain structure of Thermus thermophilus UvrB protein (ttUvrB) was studied by limited proteolysis and denaturation experiments. Proteolytic profiles indicated that ttUvrB consists of four domains: the N domain (residues 2-105), M domain (106-455), C1 domain (456-590), and C2 domain (591-665). The properties of the proteolytic fragments indicated the involvement of the respective domains in the functions of the protein as follows: the N and C1 domains are necessary for ATPase activity, the C1 domain is indispensable for DNA binding, and the N and/or M domains are involved in UvrA binding. The structural stability of the C1 and C2 domains was higher than that of the N and M domains, which supports the proposed domain nature of ttUvrB. Based on these results and the crystal structure of PcrA helicase (Subramanya, H. S., Bird, L. E., Brannigan, J. A., and Wigley, D. B. (1996) Nature 384, 379-383), the domain organization of ttUvrB was proposed.	OSAKA UNIV, DEPT BIOL, GRAD SCH SCI, TOYONAKA, OSAKA 560, JAPAN	Osaka University				Kato, Ryuichi/0000-0003-2087-2896				ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BLACK CG, 1995, J BACTERIOL, V177, P1952, DOI 10.1128/jb.177.8.1952-1958.1995; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10903, DOI 10.1093/nar/16.22.10903; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FRIEDBERG EC, 1995, DNA REPAIR; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HSU DS, 1995, J BIOL CHEM, V270, P8319, DOI 10.1074/jbc.270.14.8319; KATO R, 1993, J BIOCHEM-TOKYO, V114, P926, DOI 10.1093/oxfordjournals.jbchem.a124278; Kato R, 1996, J BIOL CHEM, V271, P9612, DOI 10.1074/jbc.271.16.9612; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MATSUBARA H, 1966, ARCH BIOCHEM BIOPHYS, V115, P324, DOI 10.1016/0003-9861(66)90282-7; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; Ptitsyn Oleg B., 1992, P243; PUGH BF, 1988, J BIOL CHEM, V263, P76; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SHIOTA S, 1988, MOL GEN GENET, V213, P21, DOI 10.1007/BF00333393; SICARD N, 1992, J BACTERIOL, V174, P2412, DOI 10.1128/JB.174.7.2412-2415.1992; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Takamatsu S, 1996, NUCLEIC ACIDS RES, V24, P640, DOI 10.1093/nar/24.4.640; Yamamoto N, 1996, GENE, V171, P103, DOI 10.1016/0378-1119(96)00052-2; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	41	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22703	22713		10.1074/jbc.272.36.22703	http://dx.doi.org/10.1074/jbc.272.36.22703			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278428	hybrid			2022-12-27	WOS:A1997XV49200049
J	Booher, RN; Holman, PS; Fattaey, A				Booher, RN; Holman, PS; Fattaey, A			Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; DEPENDENT KINASES; FISSION YEAST; HELA-CELLS; G2 ARREST; ACTIVATION; P34CDC2; PROTEIN; WEE1; THREONINE-14	Activation of the Cdc2.cyclin B kinase is a pivotal step of mitotic initiation. This step is mediated principally by the dephosphorylation of residues threonine 14 (Thr(14)) and tyrosine 15 (Tyr(15)) on the Cdc2 catalytic subunit, In several organisms homologs of the Wee1 kinase have been shown to be the major activity responsible for phosphorylating the Tyr(15) inhibitory site, A membrane-bound kinase capable of phosphorylating residue Thr(14), the Myt1 kinase, has been identified in the frog Xenopus laevis and more recently in human. In this study, we have examined the substrate specificity and cell cycle regulation of the human Myt1 kinase, We find that human Myt1 phosphorylates and inactivates Cdc2-containing cyclin complexes but not complexes containing Cdk2 or Cdk4. Analysis of endogenous Myt1 demonstrates that it remains membrane-bound throughout the cell cycle, but its kinase activity decreased during M phase arrest, when Myt1 became hyperphosphorylated, Further, Cdc2.cyclin B1 was capable of phosphorylating Myt1 in vitro, but this phosphorylation did not affect Myt1 kinase activity, These findings suggest that human Myt1 is negatively regulated by an M phase-activated kinase and that Myt1 inhibits mitosis due to its specificity for Cdc2.cyclin complexes.			Booher, RN (corresponding author), ONYX PHARMACEUT, 3031 RES DR, RICHMOND, CA 94806 USA.							ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; CAMPBELL SD, 1995, MOL BIOL CELL, V6, P1333, DOI 10.1091/mbc.6.10.1333; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HONDA R, 1995, CHROMOSOME RES, V3, P300, DOI 10.1007/BF00713068; Iavarone A, 1997, NATURE, V387, P417; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LOCK RB, 1990, CANCER RES, V50, P3761; Matsuura I, 1996, J BIOL CHEM, V271, P5443, DOI 10.1074/jbc.271.10.5443; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	39	219	225	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22300	22306		10.1074/jbc.272.35.22300	http://dx.doi.org/10.1074/jbc.272.35.22300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268380	hybrid			2022-12-27	WOS:A1997XT85000092
J	Boronat, S; RichardFoy, H; Pina, B				Boronat, S; RichardFoy, H; Pina, B			Specific deactivation of the mouse mammary tumor virus long terminal repeat promoter upon continuous hormone treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; RECEPTOR MESSENGER-RNA; DOWN-REGULATION; CHROMATIN STRUCTURE; MMTV PROMOTER; IN-VIVO; GLUCOCORTICOID RESPONSIVENESS; POSITIONED NUCLEOSOMES; METALLOTHIONEIN-I; DNA	We have studied the transcriptional behavior of the mouse mammary tumor virus long repeat (MMTV-LTR) promoter during a prolonged exposure to glucocorticoids. When integrated into XC derived cells, MMTV-LTR expression reached its maximum during the first day of dexamethasone treatment, but longer exposure to the hormone resulted in the deactivation of the promoter. In contrast, glucocorticoid-responsive resident genes or MMTV-based transiently transfected plasmids maintained or even increased their mRNA levels during the same period of hormone treatment. An integrated chimeric construct containing the hormone-responsive elements from MMTV-LTR but in different sequence context became also deactivated after a prolonged hormone treatment but with a deactivation kinetics significantly slower than constructs containing the entire, chromatin-positioning MMTV-LTR sequence. The decrease on MMTV-LTR-driven transcription was concomitant with a parallel closure of the MMTV LTR chromatin and with a decrease in glucocorticoid receptor (GR) concentration in the cell. We concluded that the chromatin-organized MMTV-LTR promoter is particularly sensitive to any decrease on GR levels. We propose that chromatin structure may contribute decisively to the differential expression of MMTV-LTR by two mechanisms: limiting MMTV-LTR accessibility to activating transcription factors and accelerating its shutting down upon a decrease on GR levels.	CSIC,CID,DEPT MOL & CELLULAR BIOL,ES-08034 BARCELONA,SPAIN; CNRS,UPR 9006,LAB BIOL MOL EUCARYOTES,F-31062 TOULOUSE,FRANCE	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); Centre National de la Recherche Scientifique (CNRS)			Boronat, Susanna/H-5428-2015; Piña, Benjamin/A-1671-2011	Boronat, Susanna/0000-0003-1745-1556; Piña, Benjamin/0000-0001-9216-2768				ADOM J, 1991, J STEROID BIOCHEM, V40, P325, DOI 10.1016/0960-0760(91)90198-E; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; ARCHER TK, 1995, J STEROID BIOCHEM, V53, P421, DOI 10.1016/0960-0760(95)00088-H; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1753; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BEATO M, 1990, MOL ASPECTS CELLULAR, P287; BELLINGHAM DL, 1992, MOL ENDOCRINOL, V6, P2090, DOI 10.1210/me.6.12.2090; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHAVEZ S, 1995, MOL CELL BIOL, V15, P6987; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; KARIN M, 1984, CELL, V36, P371, DOI 10.1016/0092-8674(84)90230-7; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KIMURA G, 1972, VIROLOGY, V49, P394, DOI 10.1016/0042-6822(72)90492-8; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MAYO KE, 1981, J BIOL CHEM, V256, P2621; MCINTYRE WR, 1985, J BIOL CHEM, V260, P418; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OKRET S, 1986, P NATL ACAD SCI USA, V83, P5899, DOI 10.1073/pnas.83.16.5899; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PINA B, 1990, MOL CELL BIOL, V10, P625, DOI 10.1128/MCB.10.2.625; RICHARDFOY H, 1987, MOL ENDOCRINOL, V1, P659, DOI 10.1210/mend-1-9-659; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; SRINIVASAN AN, 1994, DNA CELL BIOL, V13, P651, DOI 10.1089/dna.1994.13.651; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	40	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21803	21810		10.1074/jbc.272.35.21803	http://dx.doi.org/10.1074/jbc.272.35.21803			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268310	hybrid			2022-12-27	WOS:A1997XT85000022
J	Namiki, M; Akiyama, S; Katagiri, T; Suzuki, A; Ueno, N; Yamaji, N; Rosen, V; Wozney, JM; Suda, T				Namiki, M; Akiyama, S; Katagiri, T; Suzuki, A; Ueno, N; Yamaji, N; Rosen, V; Wozney, JM; Suda, T			A kinase domain-truncated type I receptor blocks bone morphogenetic protein-2-induced signal transduction in C2C12 myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-SUPERFAMILY; GROWTH-FACTOR-BETA; DIFFERENTIATION PATHWAY; OSTEOGENIC PROTEIN-1; VENTRAL MESODERM; MOUSE; ACTIVATION; CLONING; MEMBER; IDENTIFICATION	Members of the transforming growth factor (TGF)-beta superfamily bind the transmembrane serine/threonine kinase complex consisting of type I and type II receptors. Their intracellular signals are propagated via respective type I receptors. Bone morphogenetic protein (BMP)-2, a member of the TGF-beta superfamily, induces ectopic bone formation when implanted into muscular tissues. Two type I receptors (BMPR-IA and BMPR-IB) have been identified for BMP-2. We have reported that BMP-2 inhibits the terminal differentiation of C2C12 myoblasts and converts their differentiation pathway into that of osteoblast lineage cells (Katagiri, T., Yamaguchi, A., Komaki, M., Abe, E., Takahashi, N., Ikeda, T., Rosen, V., Wozney, J. M., Fujisawa-Sehara, A. and Suda, T. (1994) J. Cell Biol. 127, 1755-1766). In the present study, we examined the involvement of functional BMP-2 type I receptors in signal transduction in C2C12 cells, which expressed mRNA for BMPR-IA, but not for BMPR-IB in Northern blotting. TGF-beta type I receptor (T beta R-I) mRNA was also expressed in C2C12 cells. Subclonal cell lines of C2C12 that stably expressed a kinase domain-truncated BMPR-IA (Delta BMPR-IA) differentiated into myosin heavy chain-expressing myotubes but not into alkaline phosphatase (ALP)-positive cells, even in the presence of BMP-2. In contrast, the differentiation of the Delta BMPR-IA-transfected C2C12 cells into myotubes was suppressed by TGF-beta 1, as in the parental C2C12 cells. BMP-2 did not efficiently suppress the mRNA expression of muscle-specific genes such as muscle creatine kinase, MyoD, and myogenin, nor did it induce the expression of ALP mRNA in the Delta BMPR-IA-transfected C2C12 cells. In contrast, TGF-beta 1 inhibited mRNA expression of the muscle-specific genes in those cells. When wild-type BMPR-IA was transiently transfected into the Delta BMPR-IA-transfected C2C12 cells, a number of ALP-positive cells appeared in the presence of BMP-2. Transfection of wild-type BMPR-IB or T beta R-I failed to increase the number of ALP-positive cells. These results suggest that the BMP-2-induced signals, which inhibit myogenic differentiation and induce osteoblast differentiation, are transduced via BMPR-IA in C2C12 myoblasts.	SHOWA UNIV,SCH DENT,DEPT BIOCHEM,SHINAGAWA KU,TOKYO 142,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN; YAMANOUCHI PHARMACEUT CO LTD,TOKYO 103,JAPAN; GENET INST INC,CAMBRIDGE,MA 02140	Showa University; Hokkaido University; Astellas Pharmaceuticals				Ueno, Naoto/0000-0002-8375-2317				AKIYAMA S, 1997, IN PRESS EXP CELL RE; Attisano L, 1996, MOL CELL BIOL, V16, P1066; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; FROLIK CA, 1984, J BIOL CHEM, V259, P995; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Komaki M, 1996, CELL TISSUE RES, V284, P9, DOI 10.1007/s004410050562; LIU F, 1995, MOL CELL BIOL, V15, P3479; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LUYTEN FP, 1989, J BIOL CHEM, V264, P13377; MAENO M, 1994, P NATL ACAD SCI USA, V91, P10260, DOI 10.1073/pnas.91.22.10260; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; RAFTERY LA, 1995, GENETICS, V139, P241; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SEKELSKY JJ, 1995, GENETICS, V139, P1347; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; SUZUKI A, 1994, BIOCHEM BIOPH RES CO, V198, P1063, DOI 10.1006/bbrc.1994.1151; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TERAO M, 1987, P NATL ACAD SCI USA, V84, P7051, DOI 10.1073/pnas.84.20.7051; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; YAMAJI N, 1994, BIOCHEM BIOPH RES CO, V205, P1944, DOI 10.1006/bbrc.1994.2898; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217	54	69	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22046	22052		10.1074/jbc.272.35.22046	http://dx.doi.org/10.1074/jbc.272.35.22046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268344	hybrid			2022-12-27	WOS:A1997XT85000056
J	Roman, RM; Wang, Y; Lidofsky, SD; Feranchak, AP; Lomri, N; Scharschmidt, BF; Fitz, JG				Roman, RM; Wang, Y; Lidofsky, SD; Feranchak, AP; Lomri, N; Scharschmidt, BF; Fitz, JG			Hepatocellular ATP-binding cassette protein expression enhances ATP release and autocrine regulation of cell volume	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MDR1 P-GLYCOPROTEIN; PERFUSED-RAT-LIVER; MULTIDRUG-RESISTANCE; DEPENDENT TRANSPORT; CHLORIDE CHANNELS; CYCLOSPORINE-A; HEPATOCYTES; INHIBITION; MECHANISM	In a model liver cell line, recovery from swelling is mediated by a sensitive autocrine pathway involving conductive release of ATP, P-2 receptor stimulation, and opening of membrane Cl- channels (Wang, Y,, Roman, R. M., Lidofsky, S. D., and Fitz, J. G. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 12020-12025), However, the mechanisms coupling changes in cell volume to ATP release are not known. Based on evidence that certain ATP binding cassette (ABC) proteins may function as ATP channels or channel regulators, we evaluated the potential role of ABC proteins by comparing ATP release and volume regulation in rat HTC and HTC-R hepatoma cells, the latter of which overexpress Mdr proteins, In both cell types, Cl- current activation (ICl-swell) and volume recovery following swelling were dependent on conductive ATP efflux, The rate of volume recovery was similar to 6-fold faster in HTC-R cells compared with HTC cells, This effect is likely due to enhanced ABC protein-dependent ATP release since (i) ICl-swell and cell volume recovery were eliminated by inhibition of P-glycoprotein transport (20 mu M verapamil and 15 mu M cyclosporin A); (ii) swelling-induced Cl- current density was similar in both cell types (approximately -50 pA/pF; not significant); and (iii) ATP conductance measured by whole-cell techniques was increased similar to 3-fold in HTC-R cells compared with HTC cells, Moreover, HTC R cells exhibited enhanced survival during hypotonic stress, By modulating ATP release, hepatic ABC proteins may play a key role in the cellular pathways coupling changes in cell volume to ion permeability and secretion.	UNIV CALIF SAN FRANCISCO, DEPT MED, DIV GASTROENTEROL, SAN FRANCISCO, CA 94143 USA; DUKE UNIV, MED CTR, DEPT MED, DIV GASTROENTEROL, DURHAM, NC 27710 USA	University of California System; University of California San Francisco; Duke University	Roman, RM (corresponding author), UNIV COLORADO, HLTH SCI CTR,DEPT MED,DIV GASTROENTEROL, CAMPUS BOX B-158,RM 6412, 4200 E 9TH AVE, DENVER, CO 80262 USA.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALHABORI M, 1994, INT J BIOCHEM, V26, P319, DOI 10.1016/0020-711X(94)90052-3; Bodily K, 1997, HEPATOLOGY, V25, P403; BOHME M, 1994, ADV ENZYME REGUL, V34, P371, DOI 10.1016/0065-2571(94)90023-X; Bosch I, 1996, AM J PHYSIOL-CELL PH, V271, pC1527, DOI 10.1152/ajpcell.1996.271.5.C1527; BROWN RS, 1995, P NATL ACAD SCI USA, V92, P5421, DOI 10.1073/pnas.92.12.5421; Carini R, 1996, HEPATOLOGY, V24, P446; CARINI R, 1995, BIOCHEM BIOPH RES CO, V206, P180, DOI 10.1006/bbrc.1995.1025; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; Chari RS, 1996, AM J PHYSIOL-GASTR L, V270, pG246; CORASANTI JG, 1990, AM J PHYSIOL, V258, pG290, DOI 10.1152/ajpgi.1990.258.2.G290; CROMER B, 1992, BIOCHEM PHARMACOL, V44, P1214; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GASBARRINI A, 1992, J BIOL CHEM, V267, P6654; GORES GJ, 1989, AM J PHYSIOL, V257, pC347, DOI 10.1152/ajpcell.1989.257.2.C347; GOSLAND M, 1993, CANCER RES, V53, P5382; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HAUSSINGER D, 1995, J HEPATOL, V22, P94, DOI 10.1016/0168-8278(95)80266-5; HAUSSINGER D, 1987, EUR J BIOCHEM, V167, P65; KADMON M, 1993, GASTROENTEROLOGY, V104, P1507, DOI 10.1016/0016-5085(93)90363-H; KEPPENS S, 1991, BRIT J PHARMACOL, V104, P301, DOI 10.1111/j.1476-5381.1991.tb12426.x; LEBOT MA, 1994, CANCER CHEMOTH PHARM, V35, P53, DOI 10.1007/BF00686284; Li CH, 1996, J BIOL CHEM, V271, P11623, DOI 10.1074/jbc.271.20.11623; Lomri N, 1996, SEMIN LIVER DIS, V16, P201, DOI 10.1055/s-2007-1007232; LUCKIE DB, 1994, AM J PHYSIOL, V267, pC650, DOI 10.1152/ajpcell.1994.267.2.C650; MULLER M, 1994, FEBS LETT, V343, P168, DOI 10.1016/0014-5793(94)80312-9; NUKINA S, 1994, AM J PHYSIOL, V266, pG99, DOI 10.1152/ajpgi.1994.266.1.G99; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; REISIN IL, 1994, J BIOL CHEM, V269, P20584; Ribeiro RCJ, 1996, J BIOL CHEM, V271, P17147, DOI 10.1074/jbc.271.29.17147; Roman RM, 1996, AM J PHYSIOL-GASTR L, V271, pG239, DOI 10.1152/ajpgi.1996.271.2.G239; Schlenker T, 1996, HEPATOLOGY, V24, P514; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SMELAND E, 1995, ANTICANCER RES, V15, P1221; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STAPF V, 1994, ANTICANCER RES, V14, P581; STRIGGOW F, 1993, FEBS LETT, V318, P341, DOI 10.1016/0014-5793(93)80542-3; TAKEGUCHI N, 1993, TRANSPLANTATION, V55, P646, DOI 10.1097/00007890-199303000-00033; Wang Y, 1996, J BIOL CHEM, V271, P18107, DOI 10.1074/jbc.271.30.18107; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; WATANABE T, 1992, J HEPATOL, V16, P77, DOI 10.1016/S0168-8278(05)80098-4	44	138	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21970	21976		10.1074/jbc.272.35.21970	http://dx.doi.org/10.1074/jbc.272.35.21970			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268333	hybrid			2022-12-27	WOS:A1997XT85000045
J	Yuan, YP; Dopheide, SM; Ivanidis, C; Salem, HH; Jackson, SP				Yuan, YP; Dopheide, SM; Ivanidis, C; Salem, HH; Jackson, SP			Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets - Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin alpha(IIb)beta(3)) in von Willebrand factor-induced signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; VONWILLEBRAND-FACTOR BINDING; HUMAN BLOOD-PLATELETS; MU-CALPAIN; CYTOPLASMIC DOMAIN; MEMBRANE SKELETON; CALCIUM INFLUX; CELL-ADHESION; ACTIVATION; AGGREGATION	The adhesion of platelets to sites of vascular injury is critically dependent on the binding of subendothelial bound von Willebrand factor (vWf) to the platelet surface glycoprotein complexes, GP Ib-V-IX and GP IIb-IIIa (integrin alpha(IIb)beta(3)). There is growing evidence that the binding of vWf to these receptors is not only essential for stable platelet adhesion but is also important for the transduction of activation signals required for changes in platelet morphology, granule secretion, and platelet aggregation. In this study we have investigated signaling events induced by vWf binding to GP Ib-V-IX in both spreading and aggregated platelets. The adhesion of platelets to vWf resulted in dramatic actin filament reorganization, as assessed by immunofluorescence with fluorescein isothiocyanate-conjugated phalloidin, and the cytoskeletal recruitment of various structural proteins (talin and integrin alpha(IIb)beta(3)) and signaling enzymes (pp60(c-src), focal adhesion kinase (FAK), phosphatidylinositol 3-kinase (PI 3-kinase), and protein-tyrosine phosphatase (PTP)-1B). Time course experiments in both spreading and aggregated platelets revealed that talin, FAK, and PTP-1B were proteolyzed after translocation to the cytoskeleton. The proteolysis of these proteins was dependent on the presence of extracellular calcium and was specifically inhibited by pretreating platelets with the membrane-permeable calpain inhibitors calpeptin, E64d, and MDL 28,170, but not with the membrane-impermeable inhibitors leupeptin, E64, and calpastatin. The cytoskeletal translocation of signaling enzymes in vWf-stimulated platelets was abolished by pretreating platelets with an anti-GP Ib-V-IX antibody but was unaffected by blocking ligand binding to integrin alpha(IIb)beta(3). In contrast, calpain activation in vWf-stimulated platelets required ligand binding to both GP Ib-V-IX and integrin alpha(IIb)beta(3). The activation of calpain in both spreading and aggregated platelets resulted in a substantial decrease in the level of tyrosine phosphorylation of multiple platelet proteins and was associated with a 50-80% reduction in the amount of cytoskeletal associated talin, integrin alpha(IIb)beta(3), PI 3-kinase, FAK, pp60(c-src), and PTP-1B. These studies suggest a potentially important role for calpain in regulating the formation and/or stability of cytoskeletal signaling complexes in vWf-stimulated platelets. Furthermore, they demonstrate distinct roles for GP Ib-V-IX and integrin alpha(IIb)beta(3) in vWf-induced signal transduction.	BOX HILL HOSP,DEPT MED,MONASH MED SCH,BOX HILL,VIC 3128,AUSTRALIA; BOX HILL HOSP,AUSTRALIAN CTR BLOOD DIS,BOX HILL,VIC 3128,AUSTRALIA; BOX HILL HOSP,DEPT PATHOL,BOX HILL,VIC 3128,AUSTRALIA	Box Hill Hospital; Monash University; Box Hill Hospital; Box Hill Hospital				Jackson, Shaun/0000-0002-4750-1991				ARIYOSHI H, 1995, ARTERIOSCL THROM VAS, V15, P511, DOI 10.1161/01.ATV.15.4.511; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BERTOLINO G, 1995, THROMB HAEMOSTASIS, V73, P689; CHOW TW, 1992, BLOOD, V80, P113; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DEMARCO L, 1985, J CLIN INVEST, V75, P198; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1995, THROMB HAEMOSTASIS, V72, P987; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; ODA A, 1993, J BIOL CHEM, V268, P12603; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; ROTH GJ, 1991, BLOOD, V77, P5; Ruggeri Z M, 1991, Prog Hemost Thromb, V10, P35; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SMITH CM, 1992, BLOOD, V80, P2774; SULTAN C, 1991, J BIOL CHEM, V266, P23554; TORTI M, 1994, P NATL ACAD SCI USA, V91, P4239, DOI 10.1073/pnas.91.10.4239; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WEISS HJ, 1973, J CLIN INVEST, V52, P2697, DOI 10.1172/JCI107464; WHITE GC, 1980, BIOCHIM BIOPHYS ACTA, V631, P130, DOI 10.1016/0304-4165(80)90061-6; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZHANG J, 1992, J BIOL CHEM, V267, P4686	49	92	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21847	21854		10.1074/jbc.272.35.21847	http://dx.doi.org/10.1074/jbc.272.35.21847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268316	hybrid			2022-12-27	WOS:A1997XT85000028
J	Zhou, X; Cahoon, M; Rosa, P; Hedstrom, L				Zhou, X; Cahoon, M; Rosa, P; Hedstrom, L			Expression, purification, and characterization of inosine 5'-monophosphate dehydrogenase from Borrelia burgdorferi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMP DEHYDROGENASE; MYCOPHENOLIC-ACID; SALMONELLA-TYPHIMURIUM; INHIBITION; VIRULENCE; MECHANISM; CELLS	Inosine 5'-monophosphate dehydrogenase (IMPDH) is the rate limiting enzyme in de novo guanine nucleotide biosynthesis, IMPDH converts IMP to xanthosine 5'-monophosphate with concomitant conversion of NAD(+) to NADH, All IMPDHs characterized to date contain a 130-residue ''subdomain'' that extends from an N-terminal loop of the alpha/beta barrel domain, The role of this subdomain is unknown, An IMPDH homolog has been cloned from Borrelia burgdorferi, the causative agent of Lyme disease (Margolis, N., Hogan, D., Tilly, K., and Rosa, P. A. (1994) J. Bacteriol. 176, 6427-6432), This homolog has replaced the subdomain with a 50-residue segment of unrelated sequence, We have expressed and characterized the B. burgdorferi IMPDH homolog, This protein has IMPDH activity, which unequivocally demonstrates that the subdomain is not required for catalytic activity, The monovalent cation and dinucleotide binding sites of B. burgdorferi IMPDH are significantly different from those of human IMPDH, Therefore, these sites are targets for the design of specific inhibitors for B. burgdorferi IMPDH. Such inhibitors might be new treatments for Lyme disease.	BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA; NIAID, MICROBIAL STRUCT & FUNCT LAB, ROCKY MT LABS, NIH, HAMILTON, MT 59840 USA	Brandeis University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ANDREWS SC, 1988, BIOCHEM J, V255, P35, DOI 10.1042/bj2550035; ATKINS CA, 1985, ARCH BIOCHEM BIOPHYS, V236, P807, DOI 10.1016/0003-9861(85)90687-3; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; CARR SF, 1993, J BIOL CHEM, V268, P27286; Farazi T, 1997, J BIOL CHEM, V272, P961, DOI 10.1074/jbc.272.2.961; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FLOREY HW, 1946, LANCET, V250, P46; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; GILBERT HJ, 1979, BIOCHEM J, V183, P481, DOI 10.1042/bj1830481; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HEYDE E, 1976, BIOCHIM BIOPHYS ACTA, V429, P635, DOI 10.1016/0005-2744(76)90313-2; HEYDE E, 1976, BIOCHIM BIOPHYS ACTA, V429, P645, DOI 10.1016/0005-2744(76)90314-4; HOLMES EW, 1974, BIOCHIM BIOPHYS ACTA, V364, P209, DOI 10.1016/0005-2744(74)90006-0; HUPE DJ, 1986, J BIOL CHEM, V261, P8363; KRISHNAIAH KV, 1975, ARCH BIOCHEM BIOPHYS, V170, P567, DOI 10.1016/0003-9861(75)90152-6; Link JO, 1996, J AM CHEM SOC, V118, P2091, DOI 10.1021/ja9534056; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; MARGOLIS N, 1994, J BACTERIOL, V176, P6427, DOI 10.1128/JB.176.21.6427-6432.1994; MARQUEZ VE, 1986, J MED CHEM, V29, P1726, DOI 10.1021/jm00159a027; MCFARLAND WC, 1987, MICROB PATHOGENESIS, V3, P129, DOI 10.1016/0882-4010(87)90071-4; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NIJKAMP HJJ, 1967, BIOCHIM BIOPHYS ACTA, V145, P31, DOI 10.1016/0005-2787(67)90651-X; Noriega FR, 1996, INFECT IMMUN, V64, P3055, DOI 10.1128/IAI.64.8.3055-3061.1996; ROBINS RK, 1982, NUCLEOS NUCLEOT, V1, P35, DOI 10.1080/07328318208079400; SAKAGUCHI K, 1975, CANCER RES, V35, P1643; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; SMITH RA, 1980, DEV ANTIVIRAL THERAP, P133; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; Wang W, 1996, BIOCHEMISTRY-US, V35, P95, DOI 10.1021/bi951499q; WANG W, 1997, IN PRESS BIOCHEMISTR; WEBER G, 1983, CANCER RES, V43, P3466; Wu John C., 1994, Perspectives in Drug Discovery and Design, V2, P185, DOI 10.1007/BF02171743; WU TW, 1973, CAN J BIOCHEM CELL B, V51, P1391, DOI 10.1139/o73-182; Xiang BS, 1996, J BIOL CHEM, V271, P1435, DOI 10.1074/jbc.271.3.1435; YAMADA Y, 1988, BIOCHEMISTRY-US, V27, P2193, DOI 10.1021/bi00406a057	36	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21977	21981		10.1074/jbc.272.35.21977	http://dx.doi.org/10.1074/jbc.272.35.21977			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268334	hybrid			2022-12-27	WOS:A1997XT85000046
J	Ambudkar, SV; Cardarelli, CO; Pashinsky, I; Stein, WD				Ambudkar, SV; Cardarelli, CO; Pashinsky, I; Stein, WD			Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT TUMOR-CELLS; EHRLICH ASCITES TUMOR; MULTIDRUG-RESISTANCE; WILD-TYPE; EXPRESSION; RECONSTITUTION; PURIFICATION; LEUKEMIA; CDNA	Considerable uncertainty surrounds the stoichiometry of coupling of ATP hydrolysis to drug pumping by P-glycoprotein, the multidrug transporter. To estimate relative turnovers far pumping of the drug vinblastine and ATP hydrolysis, we began by measuring the number of P-glycoprotein molecules an the surface of murine NIH3T3 cells expressing the human MDR1 gene, Fluorescence of cells treated with monoclonal antibody UIC2 was determined as a function of (i) amount of antibody at a fixed number of cells and (ii) increasing cell number at constant antibody, The two together gives 1.95 x 10(6) P-glycoprotein molecules/cell. Initial uptake rates of vinblastine +/- verapamil measure the ability of P-glycoprotein to extract vinblastine from the plasma membrane before it enters the cell, As a function of [vinblastine] at 37 degrees C, they give the maximum rats of this component of outward pumping as 2,1. x 10(6) molecules s(-1) cell(-1) or a turnover number of 1.1 s(-1), Initial rates of one-way efflux as a function of [vinblastine] at 25 degrees C +/- glucose give the maximum rate of this component of pumping as 0.59 x 10(6) molecules s(-1) cell(-1). The ratio of ATPase activity of P-glycoprotein at 31 and 25 degrees C is 4.6. Appropriating this ratio for pumping, maximum one-way efflux at 37 degrees C is 4.6 x 0.59 = 2.7 x 10(6) molecules s(-1) cell(-1), a turnover number of 1.4 s(-1), The vinblastine-stimulated ATPase activity of P-glycoprotein has a turnover number of 3.5 s(-1) at 37 degrees C, giving 2.8 molecules of AITP hydrolyzed for every vinblastine molecule transported in a particular direction, These calculations involve several approximations, but turnover numbers for pumping of vinblastine and for vinblastine-stimulated ATP hydrolysis are comparable, Thus, ATP hydrolysis is probably directly linked to drug transport by P-glycoprotein.	NCI,DIV BASIC SCI,MOL BIOL LAB,NIH,BETHESDA,MD 20892; HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT BIOCHEM,IL-91904 JERUSALEM,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hebrew University of Jerusalem	Ambudkar, SV (corresponding author), NCI,CELL BIOL LAB,NIH,BLDG 37,RM 1B-17,37 CONVENT DR,MSC 4255,BETHESDA,MD 20892, USA.		Ambudkar, Suresh V/L-1317-2016; Ambudkar, Suresh V/B-5964-2008					AMBUDKAR SV, 1995, J BIOENERG BIOMEMBR, V27, P23, DOI 10.1007/BF02110327; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMBUDKAR SV, 1997, IN PRESS METHODS ENZ; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; CARDARELLI CO, 1995, CANCER RES, V55, P1086; DECKER DA, 1995, ANN CLIN LAB SCI, V25, P52; Eytan GD, 1996, J BIOL CHEM, V271, P3172, DOI 10.1074/jbc.271.6.3172; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; Ghauharali RI, 1996, BBA-BIOMEMBRANES, V1278, P213, DOI 10.1016/0005-2736(95)00224-3; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; He Luowen, 1995, Chinese Medical Sciences Journal, V10, P12; Hollo Z, 1996, FEBS LETT, V383, P99, DOI 10.1016/0014-5793(96)00237-2; HOLMES JA, 1994, BRIT J CANCER, V69, P382, DOI 10.1038/bjc.1994.70; Lan LB, 1996, CANCER CHEMOTH PHARM, V38, P181, DOI 10.1007/s002800050468; MARIE JP, 1995, HEMATOL ONCOL CLIN N, V9, P239, DOI 10.1016/S0889-8588(18)30094-7; MECHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824, DOI 10.1073/pnas.89.13.5824; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; NIELSEN D, 1994, BIOCHEM PHARMACOL, V47, P2125, DOI 10.1016/0006-2952(94)90247-X; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RADERER M, 1993, CANCER, V72, P3553, DOI 10.1002/1097-0142(19931215)72:12<3553::AID-CNCR2820721203>3.0.CO;2-B; Ramachandra M, 1996, MOL BIOL CELL, V7, P1485, DOI 10.1091/mbc.7.10.1485; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; REDMOND SMS, 1991, CANCER RES, V51, P2092; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Schinkel A H, 1991, Semin Cancer Biol, V2, P213; SEHESTED M, 1989, VIRCHOWS ARCH B, V56, P327; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Stein W., 2012, TRANSPORT DIFFUSION; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; STEIN WD, 1994, MOL PHARMACOL, V45, P763; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008	35	167	173	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21160	21166		10.1074/jbc.272.34.21160	http://dx.doi.org/10.1074/jbc.272.34.21160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261121	hybrid			2022-12-27	WOS:A1997XR78900031
J	Lelianova, VG; Davletov, BA; Sterling, A; Rahman, MA; Grishin, EV; Totty, NF; Ushkaryov, YA				Lelianova, VG; Davletov, BA; Sterling, A; Rahman, MA; Grishin, EV; Totty, NF; Ushkaryov, YA			alpha-Latrotoxin receptor, latrophilin, is a novel member of the secretin family of G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDOW SPIDER VENOM; EXPRESSION CLONING; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; TRANSMITTER RELEASE; MEDIATED ACTIVATION; XENOPUS-OOCYTES; CALCIUM FLUXES; MESSENGER-RNA; HORMONE	alpha-Latrotoxin (LTX) stimulates massive exocytosis of synaptic vesicles and mag help to elucidate the mechanism of regulation of neurosecretion, We have recently isolated latrophilin, the synaptic Ca2+-independent LTX receptor. Now we demonstrate that latrophilin is a novel member of the secretin family of G protein-coupled receptors that are involved in secretion, Northern blot analysis shows that latrophilin message is present only in neuronal tissue, Upon expression in COS cells, the cloned protein is indistinguishable from brain latrophilin and binds LTX with high affinity, Latrophilin physically interacts with a G alpha(o) subunit of heterotrimeric G proteins, because the two proteins co-purify in a two-step affinity chromatography, interestingly, extracellular domain of latrophilin is homologous to olfactomedin, a soluble neuronal protein thought to participate in odorant binding, Our findings suggest that latrophilin may bind unidentified endogenous ligands and transduce signals into nerve terminals, thus implicating G proteins in the control of synaptic vesicle exocytosis.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; MM SHEMYAKIN INST BIOORGAN CHEM,MOSCOW 117871,RUSSIA	Imperial College London; Ludwig Institute for Cancer Research; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			Ushkaryov, Yuri/AAQ-2985-2020; Davletov, Bazbek/ABA-8569-2021	Ushkaryov, Yuri/0000-0002-5712-8297; Davletov, Bazbek/0000-0003-4658-3275	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; ARONIN N, 1992, J NEUROSCI, V12, P3435; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; DANIELSON PE, 1994, J NEUROSCI RES, V38, P468, DOI 10.1002/jnr.490380413; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; DERI Z, 1993, J NEUROCHEM, V61, P818, DOI 10.1111/j.1471-4159.1993.tb03592.x; FESCE LC, 1989, J GEN PHYSIOL, V88, P737; FILIPPOV AK, 1994, NEUROSCIENCE, V61, P179, DOI 10.1016/0306-4522(94)90070-1; FINKELSTEIN A, 1976, SCIENCE, V193, P1009, DOI 10.1126/science.948756; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; HAMANN J, 1995, J IMMUNOL, V155, P1942; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MARTY A, 1987, TRENDS NEUROSCI, V10, P373, DOI 10.1016/0166-2236(87)90074-9; MISLER S, 1979, P NATL ACAD SCI USA, V76, P991, DOI 10.1073/pnas.76.2.991; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; OZEKI Y, 1991, BIOCHEMISTRY-US, V30, P2391, DOI 10.1021/bi00223a014; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Poyer JF, 1996, J MEMBRANE BIOL, V153, P13; REAGAN JD, 1994, J BIOL CHEM, V269, P9; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; SCHEER H, 1984, J PHYSIOLOGY PARIS, V79, P216; SCHEER HW, 1990, CAN J PHYSIOL PHARM, V68, P1049, DOI 10.1139/y90-158; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; VICENTINI LM, 1984, BIOCHEM BIOPH RES CO, V121, P538, DOI 10.1016/0006-291X(84)90215-8; WANKE E, 1986, BIOCHEM BIOPH RES CO, V134, P320, DOI 10.1016/0006-291X(86)90565-6; YOKOE H, 1993, P NATL ACAD SCI USA, V90, P4655, DOI 10.1073/pnas.90.10.4655; ZELLES T, 1995, J NEUROSCI RES, V42, P242, DOI 10.1002/jnr.490420212	45	241	255	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21504	21508		10.1074/jbc.272.34.21504	http://dx.doi.org/10.1074/jbc.272.34.21504			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261169	hybrid			2022-12-27	WOS:A1997XR78900079
J	Iwaki, K; Ohashi, K; Ikeda, M; Tsujioka, K; Kajiya, F; Kurimoto, M				Iwaki, K; Ohashi, K; Ikeda, M; Tsujioka, K; Kajiya, F; Kurimoto, M			Decrease in the amount of focal adhesion kinase (p125(FAK)) in interleukin-1 beta-stimulated human umbilical vein endothelial cells by binding of human monocytic cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; TRANSENDOTHELIAL MIGRATION; EXTRACELLULAR-MATRIX; CROSS-TALK; PROTEIN; RECOGNITION; MOLECULE-1; PAXILLIN; ACTIVATION; EXPRESSION	Monocytes in the blood circulation migrate across endothelial cell monolayers lining the blood vessels and infiltrate into the underlying tissues in inflammation, However, little is known about the mechanisms by which leukocytes migrate across the endothelial barrier after binding and what molecules participate in the process, Addition of the human monocytic cell line THP-1 to interleukin-1 beta (IL-1 beta)-stimulated human umbilical vein endothelial cells (HUVEC) induced a decrease in the amount of focal adhesion kinase (p125(FAK)) protein, a tyrosine kinase localized at focal contacts and essential for cell attachment to the extracellular matrix, whereas little change was observed in the amount of other molecules associated with cell adhesion such as vascular cell adhesion molecule-1, alpha-catenin, and talin, A maximum decrease in the amount of p125(FAK) was observed 15-30 min after addition of THP-1 cells to HUVEC, after which the level of p125(FAK) gradually recovered, A reduction in the density of actin stress fibers in IL-1 beta-activated HUVEC was observed in parallel with the decrease in p125FAK. The p125(FAK) decrease was par tially inhibited by preventing THP-1 binding to HUVEC using a mixture of antibodies to adhesion molecules, We suggest that the decrease in p125(FAK) triggered by binding of monocytes in inflammation facilitates the transendothelial migration of the monocytes by altering the adhesiveness of endothelial cells to the extracellular matrix.	Kawasaki Med Sch, DEPT MED ENGN, KURASHIKI, OKAYAMA 70101, JAPAN; Kawasaki Med Sch, DEPT PHYSIOL, KURASHIKI, OKAYAMA 70101, JAPAN	Kawasaki Medical School; Kawasaki Medical School	Iwaki, K (corresponding author), HAYASHIBARA BIOCHEM LABS INC, FUJISAKI INST, 675-1 FUJISAKI, OKAYAMA 702, JAPAN.							BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NOBUHARA M, 1987, JPN J CANCER RES, V78, P193; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POBER JS, 1986, J IMMUNOL, V137, P1893; PRIETO J, 1994, CELL IMMUNOL, V156, P191, DOI 10.1006/cimm.1994.1164; RANKIN S, 1994, J BIOL CHEM, V269, P704; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275	33	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20665	20670		10.1074/jbc.272.33.20665	http://dx.doi.org/10.1074/jbc.272.33.20665			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252385	hybrid			2022-12-27	WOS:A1997XR22100055
J	Kummer, JL; Rao, PK; Heidenreich, KA				Kummer, JL; Rao, PK; Heidenreich, KA			Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PHEOCHROMOCYTOMA CELLS; INSULIN-RECEPTOR; PATHWAYS; STRESS	p38 is a member of the mitogen-activated protein (MAP) kinase superfamily activated by stress signals and implicated in cellular processes involving inflammation and apoptosis, Unlike the extracellular signal-regulated kinases (p42 and p44 MAP kinases), which are stimulated by insulin in many cell types, p38 activity is inhibited by insulin in postmitotic fetal neurons for which insulin is a potent survival factor (Heidenreich, K. A., and Kummer, J, L, (1996) J, Biol. Chem. 271, 9891-9894), These data suggested that insulin's effects on neuronal survival are mediated by inhibition of a p38-mediated apoptotic pathway, To better understand the relationship between p38 activity and cell survival, we induced apoptosis in two cell lines and examined the ability of insulin or a specific p38 inhibitor (a pyridinyl imidazole compound PD169316) to block p38 activity and cell death, In Rat-1 fibroblasts grown in the presence of serum, p38 activity was undetectable by immune complex assays, and the number of apoptotic cells was very low (< 0.5%), After the removal of serum for 16 h, p38 activity was markedly elevated, and apoptosis increased by 14-15-fold, Insulin (50 ng/ml) inhibited p38 activity by similar to 70% and blocked apoptosis by at least 80%, PD169316 also blocked p38 enzyme activity and apoptosis by approximately 80%, Similar results were obtained in differentiated PC12 cells that were deprived of nerve growth factor (NGF) for 16 h, In the presence of NGF, p38 activity and the number of apoptotic cells was very low (similar to 1.0%). After NGF withdrawal, p38 activity was selectively elevated and apoptosis increased to 15%, Both insulin and PD169316 markedly blocked the increase in p38 activity and apoptosis. The MAP kinase kinase inhibitor, PD98059, had no effect on apoptosis in Rat-1 fibroblasts and only partially blocked apoptosis in PC12 cells, PD98059 did not influence insulin's ability to block apoptosis, indicating that the extracellular signal-regulated kinase pathway does not mediate insulin's survival effects, These data further support the role of p38 in cellular apoptosis and support the hypothesis that insulin promotes cell survival, at least in part, by inhibiting the p38 pathway.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL C236,DENVER,CO 80262; DEPT VET AFFAIRS MED CTR,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; HEIDENREICH KA, 1988, J NEUROCHEM, V51, P878, DOI 10.1111/j.1471-4159.1988.tb01824.x; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zawada WM, 1996, EXP NEUROL, V140, P60, DOI 10.1006/exnr.1996.0115	29	436	442	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20490	20494		10.1074/jbc.272.33.20490	http://dx.doi.org/10.1074/jbc.272.33.20490			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252360	hybrid			2022-12-27	WOS:A1997XR22100030
J	Macfarlane, WM; Smith, SB; James, RFL; Clifton, AD; Doza, YN; Cohen, P; Docherty, K				Macfarlane, WM; Smith, SB; James, RFL; Clifton, AD; Doza, YN; Cohen, P; Docherty, K			The p38/reactivating kinase mitogen-activated protein kinase cascade mediates the activation of the transcription factor insulin upstream factor 1 and insulin gene transcription by high glucose in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC-REGULATION; HOMEODOMAIN PROTEIN; BINDING-PROTEINS; MAPKAP KINASE-2; ISLET ISOLATION; FACTOR-I; EXPRESSION; ENHANCER; PHOSPHORYLATION; INTERLEUKIN-1	Insulin upstream factor 1 (IUF1), a transcription factor present in pancreatic beta-cells, binds to the sequence C(C/T)TAATG present at several sites within the human insulin promoter, Here we isolated and sequenced cDNA encoding human IUF1 and exploited it to identify the signal transduction pathway by which glucose triggers its activation, In human islets, or in the mouse p-cell line MIN6, high glucose induced the binding of IUF1 to DNA, an effect mimicked by serine/threonine phosphatase inhibitors, indicating that DNA binding was induced by a phosphorylation mechanism, The glucose-stimulated binding of IUF1 to DNA and IUF1-dependent gene transcription were both prevented by SE 203580, a specific inhibitor of stress-activated protein kinase 2 (SAPK2, also termed p38 mitogen-activated protein kinase, reactivating kinase, CSBP, and Mxi2) but not by several other protein kinase inhibitors, Consistent with this finding, high glucose activated mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP kinase-a) (a downstream target of SAPK2) in MING cells, an effect that was also blocked by SE 203580, Cellular stresses that trigger the activation of SAPK2 and MAPKAP kinase-a (arsenite, heat shock) also stimulated IUF1 binding to DNA and IUF1 dependent gene transcription, and these effects were also prevented by SE 203580, IUF1 expressed in Escherichia coli was unable to bind to DNA, but binding was induced by incubation with MgATP, SAPK2, and a MING cell extract, which resulted in the conversion of IUF1 to a slower migrating form, SAPK2 could not be replaced by p42 MAP kinase, MAPKAP kinase-a, or MAPKAP kinase-3, The glucose-stimulated activation of IUF1 DNA binding and MAPKAP kinase-a (but not the arsenite-induced activation of these proteins) was prevented by wortmannin and LY 294002 at concentrations similar to those that inhibit phosphatidylinositide 3-kinase, Our results indicate that high glucose (a cellular stress) activates SAPK2 by a novel mechanism in which a wortmannin/LY 294002-sensitive component plays an essential role, SAPK2 then activates IUF1 indirectly by activating a novel IUF1-activating enzyme.	INST MED SCI,DEPT MOL & CELL BIOL,ABERDEEN AB25 2ZD,SCOTLAND; UNIV LEICESTER,DEPT SURG,LEICESTER ROYAL INFIRM,LEICESTER LE2 7LX,LEICS,ENGLAND; UNIV DUNDEE,DEPT BIOCHEM,INST MED SCI,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of Aberdeen; University of Leicester; University of Dundee				Docherty, Kevin/0000-0001-6765-2060	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOAM DSW, 1989, BIOCHEM J, V264, P233, DOI 10.1042/bj2640233; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK AR, 1993, FEBS LETT, V329, P139, DOI 10.1016/0014-5793(93)80210-L; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; COHEN P, 1997, IN PRESS TRENDS CELL; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DOCHERTY K, 1995, DIABETES CLIN SCI PR, P15; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LONDON NJM, 1994, CLIN TRANSPLANT, V8, P421; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Odagiri H, 1996, J BIOL CHEM, V271, P1909, DOI 10.1074/jbc.271.4.1909; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; READ ML, 1995, BIOCHEM J, V309, P231, DOI 10.1042/bj3090231; RICORDI C, 1989, DIABETES, V38, P140, DOI 10.2337/diab.38.1.S140; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STOKOE D, 1993, BIOCHEM J, V296, P842; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888	38	154	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20936	20944		10.1074/jbc.272.33.20936	http://dx.doi.org/10.1074/jbc.272.33.20936			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252422	hybrid			2022-12-27	WOS:A1997XR22100092
J	Lundgren, DW; Moore, RM; Collins, PL; Moore, JJ				Lundgren, DW; Moore, RM; Collins, PL; Moore, JJ			Hypotonic stress increases cyclooxygenase-2 expression and prostaglandin release from amnion-derived WISH cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAMMALIAN-CELLS; MEMBRANES; GENE	This report examines the effect of cell volume expansion on cyclooxygenase-a (COX-2) mRNA expression, COX-2 protein expression, and prostaglandin E-2 release from human amnion-derived WISH cells, Earle's balanced salts solution (EBSS) with limited NaCl concentration was utilized as the induction medium. COX-2 mRNA was elevated 6-fold in cells incubated for 1 h in hypotonic EBSS. COX-2 mRNA expression was not increased when raffinose or sucrose were used to reconstitute low NaCl, Actinomycin D blocked COX-2 mRNA increase by hypotonic stress, while cycloheximide enhanced COX-2 mRNA expression. COX-2 mRNA and protein concentrations increased as a function of decreasing media osmolarity and incubation time in hypotonic EBSS. Hypotonic EBSS induced a 3-fold increase in prostaglandin E-2 release, WISH cells transiently transfected with a luciferase expression vector driven by the human COX-2 promoter for the COX-2 gene show a 3-fold increase in luciferase activity when incubated in hypotonic EBSS. COX-2 mRNA levels in primary human amnion cells were also increased by hypotonic stress. This study suggests that amnion cell COX-2 gene expression is regulated by cell volume expansion and/or increased plasma membrane tension.	CASE WESTERN RESERVE UNIV,DEPT PEDIAT,LABOR RES FOCUS GRP,NEWBORN DIV,SCH MED,METROHLTH MED CTR,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT OBSTET & GYNECOL,LABOR RES FOCUS GRP,SCH MED,METROHLTH MED CTR,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,LABOR RES FOCUS GRP,SCH MED,METROHLTH MED CTR,CLEVELAND,OH 44109	Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System								AKAI Y, 1994, AM J PHYSIOL, V267, pC482, DOI 10.1152/ajpcell.1994.267.2.C482; ALGER LS, 1986, CLIN OBSTET GYNECOL, V29, P758, DOI 10.1097/00003081-198612000-00005; BENNETT PR, 1992, AM J OBSTET GYNECOL, V167, P212, DOI 10.1016/S0002-9378(11)91660-3; BERGER SL, 1987, GUIDE MOL CLONING TE, P49; CRAVEN PA, 1991, KIDNEY INT, V39, P591, DOI 10.1038/ki.1991.69; DANFORTH DN, 1958, AM J OBSTET GYNECOL, V75, P536, DOI 10.1016/0002-9378(58)90610-0; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; Fuentes A, 1996, PROSTAGLANDINS, V52, P261, DOI 10.1016/S0090-6980(96)00088-3; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARFIELD RE, 1994, CONTROL UTERINE CONT; Gibb W, 1996, J ENDOCRINOL, V150, P497, DOI 10.1677/joe.0.1500497; GOLDBERG VJ, 1975, PHYSIOL REV, V55, P325, DOI 10.1152/physrev.1975.55.3.325; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; KANAYAMA N, 1989, GYNECOL OBSTET INVES, V28, P123, DOI 10.1159/000293546; KITTRICH M, 1971, BIOL NEONATE, V18, P29; LUNDGREN DW, 1992, J BIOL CHEM, V267, P6841; MITCHELL MD, 1993, PLACENTA, V14, P615, DOI 10.1016/S0143-4004(05)80379-0; OKITA JR, 1983, IN VITRO CELL DEV B, V19, P117; OLSON DM, 1995, SEMIN PERINATOL, V19, P53; OTTO JC, 1993, J BIOL CHEM, V268, P18234; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Rosen K., 1990, FOCUS, V12, P23; SLATER DM, 1995, AM J OBSTET GYNECOL, V172, P77, DOI 10.1016/0002-9378(95)90087-X; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STRANGE K, 1994, CELLULAR MOL PHYSL C, P3; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; VanMeir CA, 1996, PLACENTA, V17, P291, DOI 10.1016/S0143-4004(96)90052-1; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Wu KK, 1996, J LAB CLIN MED, V128, P242, DOI 10.1016/S0022-2143(96)90023-2	33	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20118	20124		10.1074/jbc.272.32.20118	http://dx.doi.org/10.1074/jbc.272.32.20118			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242685	hybrid			2022-12-27	WOS:A1997XQ05900072
J	Schaner, P; Todd, RB; Seidah, NG; Nillni, EA				Schaner, P; Todd, RB; Seidah, NG; Nillni, EA			Processing of prothyrotropin-releasing hormone by the family of prohormone convertases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED SECRETORY PATHWAYS; PROPROTEIN CONVERTASES; RAT-BRAIN; FUNCTIONAL EXPRESSION; SUBSTRATE-SPECIFICITY; INSITU HYBRIDIZATION; ENDOPROTEASE FAMILY; MAMMALIAN-CELLS; TRH PROHORMONE; PRO-PROTEIN	The post-translational processing of prothyrotropin-releasing hormone (pro-TRH25-255) has been extensively studied in our laboratory, and the processing pathway to mature TRH has been elucidated. We have also demonstrated that recombinant PC1 and PC2 process partially purified pro-TRH to cryptic peptides in vitro and that pro-TRH and PC1 mRNAs are coexpressed in primary cultures of hypothalamic neurons. To further define the role of each convertase, and particularly PC1 and PC2, in pro-TRH processing, recombinant vaccinia viruses were used to coexpress the prohormone convertases PC1, PC2, PACE4, PC5-B, furin, or control dynorphin together with rat prepro-TRH in constitutively secreting LoVo cells or in the regulated endocrine GH4C1 cell line. Radioimmunoassays from LoVo-derived secreted products indicated that furin cleaves the precursor to generate both N- and C-terminal intermediates, PC1, PC2, and PACE4 only produced N-terminal intermediates, but less efficiently than furin, In GH4C1 cells, PC1, PC2, furin, PC5-B, and PACE4 produced both N-terminal and C-terminal forms, Significantly, TRH-Gly and TRH were mostly produced by PCI, PC2, and furin, Utilizing gel electrophoresis to further analyze the cleavage specificities of PC1 and PC2, we found that PC1 seems primarily responsible for cleavage to both intermediates and mature TRH, since it generated all products at significantly higher levels than PC2, The addition of 7B2 to the coinfection did not augment the ability of PC2 to cleave pro-TRH to either N- or C-terminal forms.	BROWN UNIV, DIV ENDOCRINOL, DEPT MED, RHODE ISL HOSP, SCH MED, PROVIDENCE, RI 02903 USA; CLIN RES INST MONTREAL, BIOCHEM NEUROENDOCRINOL LAB, MONTREAL, PQ H2W 1R7, CANADA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				ALARCON C, 1993, J BIOL CHEM, V268, P4276; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOWERS CY, 1971, BIOCHEM BIOPH RES CO, V45, P1033, DOI 10.1016/0006-291X(71)90441-4; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; BULANT M, 1990, ENDOCRINOLOGY, V127, P1978, DOI 10.1210/endo-127-4-1978; BULANT M, 1988, J BIOL CHEM, V263, P17189; COCKLE SM, 1990, FEBS LETT, V264, P253, DOI 10.1016/0014-5793(90)80261-G; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; Day R., 1993, HDB EXPT PHARM, P449, DOI [10.1007/978-3-642-77460-7_19, DOI 10.1007/978-3-642-77460-7_19]; DECROLY E, 1994, J BIOL CHEM, V269, P12240; delaCruz IP, 1996, J BIOL CHEM, V271, P22736, DOI 10.1074/jbc.271.37.22736; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; FRIEDMAN TC, 1995, ENDOCRINOLOGY, V136, P4462, DOI 10.1210/en.136.10.4462; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; HOFLEHNER J, 1995, FEBS LETT, V360, P294, DOI 10.1016/0014-5793(95)00127-U; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; HOOK VYH, 1984, P NATL ACAD SCI-BIOL, V81, P2776, DOI 10.1073/pnas.81.9.2776; JACKSON IMD, 1994, REGULATION THYROTROP, P179; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LECHAN RM, 1986, SCIENCE, V231, P159, DOI 10.1126/science.3079917; LECHAN RM, 1987, ENDOCRINOLOGY, V121, P1879, DOI 10.1210/endo-121-5-1879; Legradi G, 1996, BRAIN RES, V729, P10; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; Meerabux J, 1996, CANCER RES, V56, P448; METCALF G, 1974, NATURE, V252, P310, DOI 10.1038/252310a0; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; Nicholson WE, 1996, ENDOCRINOLOGY, V137, P2171, DOI 10.1210/en.137.5.2171; Nillni E. A., 1995, Molecular Biology of the Cell, V6, p331A; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1260, DOI 10.1210/en.132.3.1260; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; NILLNI EA, 1995, J NEUROCHEM, V65, P2462; Nillni EA, 1996, ENDOCRINOLOGY, V137, P5651, DOI 10.1210/en.137.12.5651; Pu LP, 1996, ENDOCRINOLOGY, V137, P1233, DOI 10.1210/en.137.4.1233; REDEI E, 1995, ENDOCRINOLOGY, V136, P3557, DOI 10.1210/en.136.8.3557; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; RITTENHOUSE PA, 1996, 10 INT C END JUN 12, P122; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUSSEL JP, 1991, NEUROENDOCRINOLOGY, V54, P559, DOI 10.1159/000125960; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCOTT AP, 1993, NATURE, V244, P64; SEGERSON TP, 1987, ENDOCRINOLOGY, V121, P98, DOI 10.1210/endo-121-1-98; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P175; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SEIDAH NG, 1995, INTRAMOLECULAR CHAPE, P181; SEVARINO KA, 1989, J BIOL CHEM, V264, P21529; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WILBER JF, 1968, P SOC EXP BIOL MED, V127, P488; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	72	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19958	19968		10.1074/jbc.272.32.19958	http://dx.doi.org/10.1074/jbc.272.32.19958			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242664	hybrid			2022-12-27	WOS:A1997XQ05900051
J	VanPatten, SM; Donaldson, LF; McGuinness, MP; Kumar, P; Alizadeh, A; Griswold, MD; Walsh, DA				VanPatten, SM; Donaldson, LF; McGuinness, MP; Kumar, P; Alizadeh, A; Griswold, MD; Walsh, DA			Specific testicular cellular localization and hormonal regulation of the PKI alpha and PKI beta isoforms of the inhibitor protein of the cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; MESSENGER-RNA; RAT TESTIS; CATALYTIC SUBUNIT; SERTOLI CELLS; ADENOSINE-MONOPHOSPHATE; MOLECULAR-CLONING; EPIDIDYMAL SPERM; GERM-CELLS; EXPRESSION	We have previously demonstrated that there exist two distinct genes for the thermostable inhibitor protein of the cAMP-dependent protein kinase, PKI alpha and PKI beta (Van Fatten, S. M., Howard, P., Walsh, D. A., and Maurer, R. A. (1992) Mel. Endocrinol, 6, 2114-2122), We have also shown that in the testis, at least eight forms of PKI beta exist, differing as a result of at least post-translational modification and alternate translational initiation (Kumar, P., Van Fatten, S. M., and Walsh, D. A. (1997) J. Biol. Chem. 272, 20011-20020), We now report that in the testis, there is a unique cellular distribution of protein kinase inhibitor forms, with PKI beta being essentially (if not exclusively) a germ cell protein and PKI alpha being expressed primarily in Sertoli cells, Furthermore, there is a progressive change in the forms of PKI beta that are present within germ cells with development that is initiated in testis tubules and continues as the germ cells migrate through the epididymis, These conclusions are derived from studies with isolated cell populations and with the at/at germ cell-deficient mouse line, by in situ hybridization, and by following the developmental expression of these proteins in both testis and epididymis, We have also shown that follicle-stimulating hormone (FSH) can increase the expression of both PKI alpha and PKI beta, The FSH-regulated expression of PKI alpha in the Sertoli cell likely occurs via the normal route of second messenger signal transduction. In contrast, the FSH-dependent PKI beta expression must arise by some form of Sertoli cell-germ cell intercommunication.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; WASHINGTON STATE UNIV,DEPT BIOPHYS & BIOCHEM,PULLMAN,WA 99164	University of California System; University of California Davis; Washington State University				Donaldson, Lucy/0000-0002-4242-5790				BEALE EG, 1977, J BIOL CHEM, V252, P6322; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BRANDT H, 1980, J BIOL CHEM, V255, P982; BROKAW CJ, 1987, J CELL BIOCHEM, V35, P175, DOI 10.1002/jcb.240350302; CHRISTENSEN AK, 1965, ENDOCRINOLOGY, V76, P646, DOI 10.1210/endo-76-4-646; De Kretser D. M., 1994, P1177; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DELMAS V, 1994, MOL CELL ENDOCRINOL, V100, P120; DONALDSON LF, 1992, MOL BRAIN RES, V16, P143, DOI 10.1016/0169-328X(92)90204-O; DORRINGTON JH, 1975, ENDOCRINOLOGY, V96, P879, DOI 10.1210/endo-96-4-879; FAKUNDING JL, 1977, ENDOCRINOLOGY, V101, P1358, DOI 10.1210/endo-101-5-1358; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GROOTEGOED JA, 1977, BIOCHEM J, V168, P23, DOI 10.1042/bj1680023; HANDEL MA, 1979, BIOL REPROD, V20, P1031, DOI 10.1095/biolreprod20.5.1031; HECKERT L, 1993, RECENT PROG HORM RES, V48, P61; HECKERT LL, 1991, MOL ENDOCRINOL, V5, P670, DOI 10.1210/mend-5-5-670; Hoskins D.D, 1990, CONTROLS SPERM MOTIL, P53; KARL AF, 1990, METHOD ENZYMOL, V190, P71; Kumar P, 1997, J BIOL CHEM, V272, P20011, DOI 10.1074/jbc.272.32.20011; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; LEE VWK, 1975, J REPROD FERTIL, V42, P121, DOI 10.1530/jrf.0.0420121; LONNERBERG P, 1992, BIOL REPROD, V46, P1057, DOI 10.1095/biolreprod46.6.1057; MEANS AR, 1976, BIOL REPROD, V14, P54, DOI 10.1095/biolreprod14.1.54; MEANS AR, 1974, J BIOL CHEM, V249, P1231; MOORE A, 1994, MOL REPROD DEV, V37, P181, DOI 10.1002/mrd.1080370209; NOLAND TD, 1987, BIOL REPROD, V37, P171, DOI 10.1095/biolreprod37.1.171; OYEN O, 1990, BIOL REPROD, V43, P46, DOI 10.1095/biolreprod43.1.46; OYEN O, 1987, BIOL REPROD, V37, P947, DOI 10.1095/biolreprod37.4.947; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; PARVINEN M, 1982, ENDOCRINOLOGY, V76, P646; PAUPARD MC, 1988, J CELL BIOCHEM, V37, P161, DOI 10.1002/jcb.240370204; PESCOVITZ OH, 1994, TRENDS ENDOCRIN MET, V5, P126, DOI 10.1016/1043-2760(94)90094-9; Russell L. D., 1993, SERTOLI CELL; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; STALLARD BJ, 1990, MOL ENDOCRINOL, V4, P393, DOI 10.1210/mend-4-3-393; Tash J.S., 1990, P229; TASH JS, 1982, BIOL REPROD, V26, P745, DOI 10.1095/biolreprod26.4.745; TASH JS, 1979, J BIOL CHEM, V254, P1241; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WEN W, 1994, J BIOL CHEM, V269, P32214	49	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20021	20029		10.1074/jbc.272.32.20021	http://dx.doi.org/10.1074/jbc.272.32.20021			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242672	hybrid			2022-12-27	WOS:A1997XQ05900059
J	Chen, CD; Doray, B; Kemper, B				Chen, CD; Doray, B; Kemper, B			Efficient assembly of functional cytochrome P450 2C2 requires a spacer sequence between the N-terminal signal anchor and catalytic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-COMPOSITION; PROLINE-RICH REGION; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; MEMBRANE; PROTEINS; IDENTIFICATION; GLYCOSYLATION; ORIENTATION; EXPRESSION	Cytochromes P450 (P450) are anchored to the endoplasmic reticulum membrane by an N-terminal transmembrane sequence with the catalytic domain facing the cytoplasmic side, Within the peptide sequence linking these two domains in P450 2C2 is a glycine-rich region from residues 22 to 28, To examine the role of this region, deletion and substitution mutations were constructed, and the activities and spectral properties were determined for the mutant proteins expressed in COS-1 cells, insect cells, and bacteria, Deletion of residues 22 to 28 or substitution of 7 valines for this region inactivated the proteins in COS-1 cells, and no P450 species was detected for these mutations in bacteria or insect cells, Substitution of the three glycine residues with alanine or proline or the entire sequence from 22 to 28 with 7 alanines did not reduce lauric acid hydroxylase activity of the proteins expressed in COS-1 cells, Reducing the number of alanines substituted to 4, 3, and 2 progressively decreased activity in COS-1 cells to undetectable levels when 2 alanines were substituted, The loss of activity in COS-1 cells correlated with decreased expression of hemoprotein with a reduced difference spectrum of 450 nm (P450 species) and a corresponding increase in the inactive P420 species in insect cells and bacteria, The activities expressed per nanomole of P450 in insect microsomes were similar for P450 2C2 and the alanine substitution mutants, including the mutant with 2 alanines which was inactive in COS-1 cells, The rates of conversion of P450 to P420 resulting from incubation at 48 degrees C in vitro were not changed sufficiently to explain the increase in expressed P420 observed for the mutants with 3 or 7 alanines substituted, These data are consistent with a role for the residue 22-28 region as a linker that facilitates the folding of P450; however, once the protein is properly folded into the functional P450 species, this region has little influence on the stability and activity of the enzyme.	UNIV ILLINOIS, COLL MED, DEPT MOL & INTEGRAT PHYSIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, COLL MED, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign				Doray, Balraj/0000-0003-3347-5013	NIGMS NIH HHS [GM35897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Chen CD, 1996, J BIOL CHEM, V271, P28607, DOI 10.1074/jbc.271.45.28607; CHOU KC, 1995, PROTEINS, V21, P319, DOI 10.1002/prot.340210406; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Deisenhofer, 1990, CURRENT TOPICS MEMBR, V36, P53; Dong MS, 1996, BIOCHEMISTRY-US, V35, P10031, DOI 10.1021/bi960873z; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; KING RD, 1990, J MOL BIOL, V216, P441, DOI 10.1016/S0022-2836(05)80333-X; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; LEVIN JM, 1988, BIOCHIM BIOPHYS ACTA, V955, P283, DOI 10.1016/0167-4838(88)90206-3; MAO BY, 1994, PROTEIN ENG, V7, P319, DOI 10.1093/protein/7.3.319; Martinis SA, 1996, BIOCHEMISTRY-US, V35, P14530, DOI 10.1021/bi961511u; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pernecky SJ, 1996, METHOD ENZYMOL, V272, P25, DOI 10.1016/S0076-6879(96)72005-0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARDSON TH, 1993, ARCH BIOCHEM BIOPHYS, V300, P510, DOI 10.1006/abbi.1993.1069; RICHARDSON TH, 1995, ARCH BIOCHEM BIOPHYS, V323, P87, DOI 10.1006/abbi.1995.0013; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; STRAUB P, 1993, J BIOL CHEM, V268, P21997; SZCZESNASKORUPA E, 1993, ARCH BIOCHEM BIOPHYS, V304, P170, DOI 10.1006/abbi.1993.1335; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; Von Wachenfeldt Claes, 1995, P183; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; YAMAZAKI S, 1993, J BIOCHEM-TOKYO, V114, P652, DOI 10.1093/oxfordjournals.jbchem.a124232; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	38	19	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22891	22897		10.1074/jbc.272.36.22891	http://dx.doi.org/10.1074/jbc.272.36.22891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278452	hybrid			2022-12-27	WOS:A1997XV49200073
J	Mertens, PR; Harendza, S; Pollock, AS; Lovett, DH				Mertens, PR; Harendza, S; Pollock, AS; Lovett, DH			Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; IV COLLAGENASE; MOLECULAR-CLONING; Y-BOX; ENHANCED EXPRESSION; PROMOTER; ELEMENT; GENES; SECRETE; ALPHA	Mesangial cell (MC) activation plays a pivotal role in the development of the end stage sclerotic lesion characteristic of most forms of chronic glomerular disease. We have previously demonstrated that RLC activation is directly linked to high level expression of the matrix metalloproteinase-2 (MMP-2) enzyme (Turck, J., Pollock, A. S., Lee, L., Marti, H.-P., and Lovett, D. H. (1996) J. Biol. Chem. 25, 15074-15083), the transcription of which is regulated in a tissue-specific fashion. Recent studies (Harendza, S., Pollock, A. Mertens, P. R., and Lovett, D. H. (1995) J. Biol. Chem. 270, 18786-18796) delineated a strong cis-acting enhancer element, designated MMP-2 RE1, within the 5'-flanking region of the rat MMP-2 gene. Gel shift, DNA footprint, and transcriptional analyses mapped the enhancer element to a unique 40-base pair (bp) sequence located at -1322 to -1282 bp relative to the translational start site. Bromodeoxyuridine-substituted UV cross-linking of the 40-bp enhancer element with MC nuclear extracts yielded a single protein of 52 kDa, while Southwestern blot analysis with MMP-2 RE1 demonstrated three hybridizing nuclear proteins of 52, 62, and 86 kDa size. Screening of a human MC cDNA expression library with MMP-2 RE1 exclusively yielded clones with the identical sequence of the transcription factor YB-1. Western blot and supershift gel analysis of MC nuclear extracts with an anti-YB-1 antibody confirmed the presence of YB-1 within the shifted complex. Examination of the MMP-2 RE1 sequence revealed an incomplete Y-box sequence (CTGCTGGGCAAG), which specifically interacted with recombinant YB-1 on DMS protection footprinting analysis. YB-1 protein preferentially bound the single-stranded components of the 40-bp MMP-2 RE1 and, with increasing concentrations, formed multimeric complexes. Co-transfection of YB-1 in MC increased the enhancer activity within the context of the native MMP-2 promoter, while transfection of non-MMP-2-synthesizing glomerular epithelial cells with YB-1 led to transcriptional suppression. This study indicates that YB-1 is a major, cell type-specific transactivator of MMP-2 transcription by glomerular mesangial cells.	UNIV CALIF SAN FRANCISCO,VET ADM MED CTR,DEPT MED 111J,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Mertens, Peter/AAI-7310-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031398, R01DK039776, R56DK039776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39776, DK 31398] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CAROME MA, 1994, J AM SOC NEPHROL, V5, P1391; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; COHEN I, 1991, NUCLEIC ACIDS RES, V19, P4753, DOI 10.1093/nar/19.17.4753; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; JOHNSON R, 1992, J AM SOC NEPHROL, V2, P1388; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LOVETT DH, 1992, AM J PATHOL, V141, P85; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; McMillan JI, 1996, J CLIN INVEST, V97, P1094, DOI 10.1172/JCI118502; Ohga T, 1996, CANCER RES, V56, P4224; OZER J, 1990, J BIOL CHEM, V265, P22143; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; REPONEN P, 1992, J BIOL CHEM, V267, P7856; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAKURA H, 1988, GENE, V73, P499; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SREENATH T, 1992, CANCER RES, V52, P4942; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YAN C, 1991, P NATL ACAD SCI USA, V88, P144, DOI 10.1073/pnas.88.1.144; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	37	135	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22905	22912		10.1074/jbc.272.36.22905	http://dx.doi.org/10.1074/jbc.272.36.22905			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278454	hybrid			2022-12-27	WOS:A1997XV49200075
J	Mihara, H; Kurihara, T; Yoshimura, T; Soda, K; Esaki, N				Mihara, H; Kurihara, T; Yoshimura, T; Soda, K; Esaki, N			Cysteine sulfinate desulfinase, a NIFS-like protein of Escherichia coli with selenocysteine lyase and cysteine desulfurase activities - Gene cloning, purification, and characterization of a novel pyridoxal enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROXY-ACID DEHYDRATASE; BETA-SUBSTITUTED ALANINES; ACTIVE-SITE PEPTIDE; FE-S CLUSTER; NUCLEOTIDE-SEQUENCE; NITROGEN-FIXATION; AZOTOBACTER-VINELANDII; AMINO-ACID; D-ISOMERS; IN-VITRO	Selenocysteine lyase (EC 4.4.1.16) exclusively decomposes selenocysteine to alanine and elemental selenium, whereas cysteine desulfurase (NIFS protein) of Azotobacter vinelandii acts indiscriminately on both cysteine and selenocysteine to produce elemental sulfur and selenium respectively, and alanine. These proteins exhibit some sequence homology, The Escherichia coli genome contains three genes with sequence homology to nifS. We have cloned the gene mapped at 63.4 min in the chromosome and have expressed, purified to homogeneity, and characterized the gene product, The enzyme comprises two identical subunits with 401 amino acid residues (M-r 43,238) and contains pyridoxal 5'-phosphate as a coenzyme. The enzyme catalyzes the removal of elemental sulfur and selenium atoms from L-cysteine, L-cystine, L-selenocysteine, and L-selenocystine to produce L-alanine, Because L-cysteine sulfinic acid was desulfinated to form L-alanine as the preferred substrate, we have named this new enzyme cysteine sulfinate desulfinase. Mutant enzymes having alanine substituted for each of the four cysteinyl residues (Cys-100, Cys-176, Cys-323, and Cys-358) were all active, Cys-358 corresponds to Cys-325 of A. vinelandii NIFS, which is conserved among all NIFS-like proteins and catalytically essential (Zheng, L., White, R. H., Cash, V. L., and Dean, D. R. (1994) Biochemistry 33, 4714-4720), is not required for cysteine sulfinate desulfinase. Thus, the enzyme is distinct from A. vinelandii NIFS in this respect.	KYOTO UNIV, INST CHEM RES, MICROBIAL BIOCHEM LAB, UJI, KYOTO 611, JAPAN; KANSAI UNIV, FAC ENGN, DEPT BIOTECHNOL, SUITA, OSAKA 564, JAPAN	Kyoto University; Kansai University			Mihara, Hisaaki/F-2172-2010	Mihara, Hisaaki/0000-0002-5153-4403				Aiba H, 1996, DNA Res, V3, P363, DOI 10.1093/dnares/3.6.363; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BADET B, 1984, BIOCHEMISTRY-US, V23, P5188, DOI 10.1021/bi00317a016; BEYNON J, 1987, J BACTERIOL, V169, P4024, DOI 10.1128/jb.169.9.4024-4029.1987; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BRAUNSTEIN AE, 1969, BIOCHIM BIOPHYS ACTA, V171, P366, DOI 10.1016/0005-2744(69)90173-9; CHOCAT P, 1983, J BACTERIOL, V156, P455, DOI 10.1128/JB.156.1.455-457.1983; CHOCAT P, 1985, J BACTERIOL, V163, P669, DOI 10.1128/JB.163.2.669-676.1985; ESAKI N, 1982, J BIOL CHEM, V257, P4386; ESAKI N, 1988, METALLOPROTEINS, P429; EVANS DJ, 1991, J BACTERIOL, V173, P5457, DOI 10.1128/jb.173.17.5457-5469.1991; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Flint DH, 1996, J BIOL CHEM, V271, P16068; Flint DH, 1996, J BIOL CHEM, V271, P16053, DOI 10.1074/jbc.271.27.16053; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P232, DOI 10.1073/pnas.91.1.232; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HEIDER J, 1993, ADV MICROB PHYSIOL, V35, P71, DOI 10.1016/S0065-2911(08)60097-1; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HOSOKAWA Y, 1990, BIOCHEM BIOPH RES CO, V168, P473, DOI 10.1016/0006-291X(90)92345-Z; JACKMAN DM, 1995, MICROBIOL-UK, V141, P2235, DOI 10.1099/13500872-141-9-2235; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KISHORE GM, 1984, J BIOL CHEM, V259, P669; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINWEBER FJ, 1987, METHOD ENZYMOL, V143, P15; LEONGMORGENTHALER P, 1994, BIOCHIMIE, V76, P45, DOI 10.1016/0300-9084(94)90061-2; LYONS EM, 1995, J BACTERIOL, V177, P1570, DOI 10.1128/jb.177.6.1570-1575.1995; MASEPOHL B, 1993, MOL GEN GENET, V238, P369, DOI 10.1007/BF00291996; MEHTA PK, 1993, EUR J BIOCHEM, V211, P373, DOI 10.1111/j.1432-1033.1993.tb19907.x; MEIJER WG, 1992, J BACTERIOL, V174, P3855, DOI 10.1128/jb.174.12.3855-3866.1992; MULLIGAN ME, 1989, J BIOL CHEM, V264, P19200; Neuhierl B, 1996, EUR J BIOCHEM, V239, P235, DOI 10.1111/j.1432-1033.1996.0235u.x; OBrien C, 1997, NATURE, V385, P472, DOI 10.1038/385472a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RECASENS M, 1980, BIOCHEMISTRY-US, V19, P4583, DOI 10.1021/bi00561a007; Reymond I, 1996, BBA-GENE STRUCT EXPR, V1307, P152, DOI 10.1016/0167-4781(96)00068-1; ROISE D, 1984, BIOCHEMISTRY-US, V23, P5195, DOI 10.1021/bi00317a017; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SINGH M, 1989, MOL GEN GENET, V219, P235, DOI 10.1007/BF00261182; SODA K, 1964, BIOCHEMISTRY-US, V3, P1450, DOI 10.1021/bi00898a010; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; TANAKA H, 1987, METHOD ENZYMOL, V143, P240; TATE SS, 1969, BIOCHEMISTRY-US, V8, P5016, DOI 10.1021/bi00840a051; THIEL T, 1995, P NATL ACAD SCI USA, V92, P9358, DOI 10.1073/pnas.92.20.9358; UENO H, 1982, BIOCHEMISTRY-US, V21, P4387, DOI 10.1021/bi00261a030; VERES Z, 1994, J BIOL CHEM, V269, P10597; WALSH CT, 1986, VITAMIN B6 PYRIDOXAL, P43; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAMOTO Y, 1977, DNA RES, V4, P91; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	61	142	150	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22417	22424		10.1074/jbc.272.36.22417	http://dx.doi.org/10.1074/jbc.272.36.22417			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278392	Green Submitted, hybrid			2022-12-27	WOS:A1997XV49200011
J	Hinnebusch, AG				Hinnebusch, AG			Translational regulation of yeast GCN4 - A window on factors that control initiator-tRNA binding to the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NUCLEOTIDE-EXCHANGE FACTOR; OPEN READING FRAMES; TRANSFER-RNA-SYNTHETASES; EIF-2-ALPHA KINASE GCN2; AMINO-ACID BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; MESSENGER-RNA; FACTOR-II; START-SITE				Hinnebusch, AG (corresponding author), NICHHD,LAB EUKARYOT GENE REGULAT,NIH,BETHESDA,MD 20892, USA.							ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P1920, DOI 10.1128/MCB.13.3.1920; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CASTILHOVALAVICIUS B, 1990, GENETICS, V124, P483; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CIGAN AM, 1993, P NATL ACAD SCI USA, V90, P5350, DOI 10.1073/pnas.90.11.5350; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P7920; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P461; DIALLINAS G, 1994, GENE, V143, P21, DOI 10.1016/0378-1119(94)90599-1; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DORRIS DR, 1995, EMBO J, V14, P2239, DOI 10.1002/j.1460-2075.1995.tb07218.x; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; GRANT CM, 1994, MOL CELL BIOL, V14, P2616, DOI 10.1128/MCB.14.4.2616; GRANT CM, 1994, MOL CELL BIOL, V14, P606, DOI 10.1128/MCB.14.1.606; GRANT CM, 1995, NUCLEIC ACIDS RES, V23, P3980, DOI 10.1093/nar/23.19.3980; HANNIG EM, 1990, GENETICS, V126, P549; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; HARASHIMA S, 1986, MOL CELL BIOL, V6, P3990, DOI 10.1128/MCB.6.11.3990; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HILL DE, 1988, NUCLEIC ACIDS RES, V16, P9253, DOI 10.1093/nar/16.19.9253; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; LANKER S, 1992, CELL, V70, P647, DOI 10.1016/0092-8674(92)90433-D; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MARTON MJ, 1997, IN PRESS MOL CELL BI; Merrick WC., 1996, TRANSLATION CONTROL, P31; MESSENGUY F, 1976, EUR J BIOCHEM, V67, P335, DOI 10.1111/j.1432-1033.1976.tb10696.x; MILLER PF, 1989, GENE DEV, V3, P1217, DOI 10.1101/gad.3.8.1217; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; MUELLER PP, 1988, MOL CELL BIOL, V8, P5439, DOI 10.1128/MCB.8.12.5439; MUELLER PP, 1987, P NATL ACAD SCI USA, V84, P2863, DOI 10.1073/pnas.84.9.2863; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MYERS PL, 1986, MOL CELL BIOL, V6, P3150, DOI 10.1128/MCB.6.9.3150; NARANDA T, 1994, J BIOL CHEM, V269, P32286; NIEDERBERGER P, 1986, CURR GENET, V10, P657, DOI 10.1007/BF00410913; PADDON CJ, 1989, GENETICS, V122, P543; PADDON CJ, 1989, GENETICS, V122, P551; PAVITT GD, 1996, MOL CELL BIOL, V17, P1298; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; Tavernarakis N, 1996, MOL GEN GENET, V251, P613, DOI 10.1007/BF02173652; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; TZAMARIAS D, 1988, EMBO J, V7, P3547, DOI 10.1002/j.1460-2075.1988.tb03231.x; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WEK SA, 1995, MOL CELL BIOL, V15, P4497; WILLIAMS NP, 1989, P NATL ACAD SCI USA, V86, P7515, DOI 10.1073/pnas.86.19.7515; WILLIAMS NP, 1988, MOL CELL BIOL, V8, P3827, DOI 10.1128/MCB.8.9.3827; WOLFNER M, 1975, J MOL BIOL, V96, P273, DOI 10.1016/0022-2836(75)90348-4; Yang WM, 1996, MOL CELL BIOL, V16, P6603; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	61	418	428	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21661	21664		10.1074/jbc.272.35.21661	http://dx.doi.org/10.1074/jbc.272.35.21661			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268289	hybrid			2022-12-27	WOS:A1997XT85000001
J	Pierre, Y; Breyton, C; Lemoine, Y; Robert, B; Vernotte, C; Popot, JL				Pierre, Y; Breyton, C; Lemoine, Y; Robert, B; Vernotte, C; Popot, JL			On the presence and role of a molecule of chlorophyll a in the cytochrome b(6)f complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTERS; ELECTRON-TRANSFER; CHLAMYDOMONAS-REINHARDTII; GLYCOGEN-PHOSPHORYLASE; BF COMPLEX; EVOLUTION; PROTEINS; POLYPEPTIDES; METABOLISM; SPECTRA	Highly purified preparations of cytochrome b(6)f complex from the unicellar freshwater alga Chlamydomonas reinhardtii contain about 1 molecule of chlorophyll a/cytochrome f. Several lines of evidence indicate that the chlorophyll is an authentic component of the complex rather than a contaminant. In particular, (i) the stoichiometry is constant; (ii) the chlorophyll is associated with the complex at a specific binding site, as evidenced by resonance Raman spectroscopy; (iii) it does not originate from free chlorophyll released from thylakoid membranes upon solubilization; and (iv) its rate of exchange with free, radioactive chlorophyll a is extremely slow (weeks). Some of the putative functional roles for a chlorophyll in the b(6)f complex are experimentally ruled out, and its possible evolutionary origin is briefly discussed.	INST BIOL PHYSICOCHIM, F-75005 PARIS, FRANCE; UNIV PARIS 07, CNRS UPR 9052, F-75005 PARIS, FRANCE; UNIV LILLE, F-75005 PARIS, FRANCE; ECOLE NORMALE SUPER, CNRS URA 1810, F-75005 PARIS, FRANCE; CTR ETUD SACLAY, CEA, CNRS URA 2096, F-91191 GIF SUR YVETTE, FRANCE; CNRS, UPR 9061, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; Universite de Lille; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Robert, Bruno/D-1264-2012	Robert, Bruno/0000-0001-5999-4538				AJLANI G, 1995, BBA-BIOENERGETICS, V1231, P189, DOI 10.1016/0005-2728(95)00086-X; ATTEIA A, 1992, J BIOL CHEM, V267, P226; Bald D., 1992, RES PHOTOSYNTHESIS, VI, P629; Barr R, 1971, METHOD ENZYMOL, V23, P372; BENNOUN P, 1995, P NATL ACAD SCI USA, V92, P10202, DOI 10.1073/pnas.92.22.10202; BLANKENSHIP RE, 1992, PHOTOSYNTH RES, V33, P91, DOI 10.1007/BF00039173; Breyton C, 1997, J BIOL CHEM, V272, P21892, DOI 10.1074/jbc.272.35.21892; BRITTON G, 1985, METHOD ENZYMOL, V111, P113, DOI 10.1016/S0076-6879(85)11007-4; CASTRESANA J, 1995, J MOL BIOL, V250, P202, DOI 10.1006/jmbi.1995.0371; CASTRESANA J, 1995, TRENDS BIOCHEM SCI, V20, P443, DOI 10.1016/S0968-0004(00)89098-2; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRAMER WA, 1994, CURR OPIN STRUC BIOL, V4, P536, DOI 10.1016/S0959-440X(94)90216-X; Dawson R.M.C., 1986, DATA BIOCH RES, V3rd, P232; EICHENBERGER W, 1962, HELV CHIM ACTA, V45, P974, DOI 10.1002/hlca.19620450325; FEILER U, 1994, J RAMAN SPECTROSC, V25, P365, DOI 10.1002/jrs.1250250513; FUJIWARA M, 1986, J PHYS CHEM-US, V90, P5646, DOI 10.1021/j100280a033; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Hauska G., 1996, OXYGENIC PHOTOSYNTHE, P377; HOLM L, 1995, EMBO J, V14, P1287, DOI 10.1002/j.1460-2075.1995.tb07114.x; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, EUR J BIOCHEM, V117, P591; Joliot A, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P615; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JOLIOT P, 1984, BIOCHIM BIOPHYS ACTA, V765, P210, DOI 10.1016/0005-2728(84)90015-X; Kaneko T, 1996, DNA Res, V3, P109; KOK B, 1956, BIOCHIM BIOPHYS ACTA, V22, P399, DOI 10.1016/0006-3002(56)90172-X; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; LUTZ M, 1988, BIOL APPLICATIONS RA, V3, P347; Lutz M., 1991, CHLOROPHYLLS, P855; MALKIN R, 1992, PHOTOSYNTH RES, V33, P121, DOI 10.1007/BF00039175; MARCUS RA, 1993, ANGEW CHEM INT EDIT, V32, P1111, DOI 10.1002/anie.199311113; MEYER TE, 1994, BIOSYSTEMS, V33, P167, DOI 10.1016/0303-2647(94)90002-7; NAVEKE A, 1997, IN PRESS J RAMAN SPE; NITSCHKE W, 1997, PHOTOSYNTHESIS COMPR; OLSON JM, 1987, ORIGINS LIFE EVOL B, V17, P419, DOI 10.1007/BF02386479; PALM D, 1990, BIOCHEMISTRY-US, V29, P1099, DOI 10.1021/bi00457a001; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; POPOT JL, 1995, PHOTOSYNTHESIS LIGHT, V2, P507; RICH PR, 1987, BIOCHIM BIOPHYS ACTA, V892, P138, DOI 10.1016/0005-2728(87)90256-8; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Watanabe T., 1991, CHLOROPHYLLS, P287; Woodbury NW, 1995, ANOXYGENIC PHOTOSYNT, P527, DOI [DOI 10.1007/0-306-47954-0_24, 10.1007/0-306-47954-0_24]	43	87	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21901	21908		10.1074/jbc.272.35.21901	http://dx.doi.org/10.1074/jbc.272.35.21901			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268323	hybrid			2022-12-27	WOS:A1997XT85000035
J	Schwemmle, M; De, B; Shi, LC; Banerjee, A; Lipkin, WI				Schwemmle, M; De, B; Shi, LC; Banerjee, A; Lipkin, WI			Borna disease virus P-protein is phosphorylated by protein kinase C epsilon and casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; STRAND RNA VIRUS; BLOOD MONONUCLEAR-CELLS; VIRAL PHOSPHOPROTEIN-P; TRANSCRIPTIONAL ACTIVITY; PSYCHIATRIC-PATIENTS; INFECTED-CELLS; RAT-BRAIN; EXPRESSION; BDV	Borna disease virus (BDV) is a newly classified nonsegmented negative-strand RNA virus (order of Mononegavirales) that persistently infects specific brain regions and circuits of warm-blooded animals to cause behavioral disturbances. Viruses within the order of Mononegavirales have phosphoproteins that typically serve as transcription factors and are modulated in functional activity through phosphorylation. To identify the kinases involved in BDV phosphoprotein (BDV-P) phosphorylation, in vitro phosphorylation as says were performed using recombinant phosphoprotein produced in Escherichia coli as substrate and cytoplasmic extracts from a rat glioma cell line (C6) or rat brain extracts as sources of kinase activity. These experiments revealed that BDV-P was phosphorylated predominantly by protein kinase C (PKC) and to a lesser extent by casein kinase II. Partial purification of the PKC from rat brain extract suggested that the BDV-P phosphorylating kinase is PKC epsilon. A role for PKC phosphorylation in vivo was confirmed by using the PKC-specific inhibitor GF109203X. Furthermore, peptide mapping studies indicated that BDV-P is phosphorylated at the same sites in vitro as it is in vivo. Mutational analysis identified Ser(26) and Ser(28) as sites for PKC phosphorylation and Ser(70) and Ser(86) as sites for casein kinase II phosphorylation. The anatomic distribution of PKC epsilon in the central nervous system may have implications for BDV neurotropism and pathogenesis.	UNIV CALIF IRVINE, DEPT NEUROL ANAT & NEUROBIOL & MICROBIOL & MOL GE, LAB NEUROVIROL, IRVINE, CA 92697 USA; CLEVELAND CLIN FDN, RES INST, DEPT MOL BIOL, CLEVELAND, OH 44195 USA	University of California System; University of California Irvine; Cleveland Clinic Foundation			Lipkin, W. Ian/ABE-6216-2020	Lipkin, W. Ian/0000-0002-8768-9386	NIAID NIH HHS [AI32027] Funding Source: Medline; NINDS NIH HHS [NS29425] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029425] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANERJEE AK, 1991, PHARMACOL THERAPEUT, V51, P47, DOI 10.1016/0163-7258(91)90041-J; BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; BARIK S, 1995, VIROLOGY, V213, P405, DOI 10.1006/viro.1995.0013; BODE L, 1995, NAT MED, V1, P232, DOI 10.1038/nm0395-232; Bode L, 1996, MOL PSYCHIATR, V1, P200; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRIESE T, 1994, P NATL ACAD SCI USA, V91, P4362, DOI 10.1073/pnas.91.10.4362; BRIESE T, 1992, P NATL ACAD SCI USA, V89, P11486, DOI 10.1073/pnas.89.23.11486; CARBONE KM, 1993, J VIROL, V67, P1453, DOI 10.1128/JVI.67.3.1453-1460.1993; CUBITT B, 1994, VIRUS RES, V34, P69, DOI 10.1016/0168-1702(94)90120-1; CUBITT B, 1994, J VIROL, V68, P1371, DOI 10.1128/JVI.68.3.1371-1381.1994; DAS T, 1995, J BIOL CHEM, V270, P24100, DOI 10.1074/jbc.270.41.24100; DAS T, 1995, VIROLOGY, V211, P218, DOI 10.1006/viro.1995.1394; DE BP, 1995, P NATL ACAD SCI USA, V92, P5204, DOI 10.1073/pnas.92.11.5204; DelaTorre JC, 1996, VIROLOGY, V223, P272, DOI 10.1006/viro.1996.0479; DELATORRE JC, 1994, J VIROL, V68, P7669, DOI 10.1128/JVI.68.12.7669-7675.1994; GAO Y, 1995, EMBO J, V14, P1240, DOI 10.1002/j.1460-2075.1995.tb07107.x; GOSZTONYI G, 1995, BORNA DIS, P39; IgataYi R, 1996, NAT MED, V2, P948, DOI 10.1038/nm0996-948b; KISHI M, 1995, FEBS LETT, V364, P293, DOI 10.1016/0014-5793(95)00406-Y; Kliche S, 1996, J VIROL, V70, P8133, DOI 10.1128/JVI.70.11.8133-8137.1996; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LUDWIG H, 1988, PROG MED VIROL, V35, P107; MAZUMDER B, 1994, VIROLOGY, V205, P104, DOI 10.1006/viro.1994.1624; MAZUMDER B, 1994, VIROLOGY, V205, P93, DOI 10.1006/viro.1994.1623; MEEK DW, 1992, BIOCHEM J, V287, P1; Nakaya T, 1996, FEBS LETT, V378, P145, DOI 10.1016/0014-5793(95)01439-X; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIAN CA, 1990, J NATL CANCER I, V82, P1734, DOI 10.1093/jnci/82.22.1734; RICHT JA, 1992, CLIN INFECT DIS, V14, P1240, DOI 10.1093/clinids/14.6.1240; SAITO N, 1993, BRAIN RES, V607, P241, DOI 10.1016/0006-8993(93)91512-Q; Sauder C, 1996, J VIROL, V70, P7713, DOI 10.1128/JVI.70.11.7713-7724.1996; SCHNEEMANN A, 1995, VIROLOGY, V210, P1, DOI 10.1006/viro.1995.1311; SCHNEIDER PA, 1994, J VIROL, V68, P5007, DOI 10.1128/JVI.68.8.5007-5012.1994; SCHWEMMLE M, 1995, VIROLOGY, V206, P545, DOI 10.1016/S0042-6822(95)80071-9; TAKACS AM, 1995, VIROLOGY, V208, P821, DOI 10.1006/viro.1995.1219; THIEDEMANN N, 1992, J GEN VIROL, V73, P1057, DOI 10.1099/0022-1317-73-5-1057; TOULLEC D, 1991, J BIOL CHEM, V266, P15771	39	52	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21818	21823		10.1074/jbc.272.35.21818	http://dx.doi.org/10.1074/jbc.272.35.21818			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268312	hybrid			2022-12-27	WOS:A1997XT85000024
J	Adhya, S; Ghosh, T; Das, A; Bera, SK; Mahapatra, S				Adhya, S; Ghosh, T; Das, A; Bera, SK; Mahapatra, S			Role of an RNA-binding protein in import of tRNA into Leishmania mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODED TRANSFER-RNAS; TRYPANOSOMA-BRUCEI; ORGANIZATION; TARENTOLAE; DONOVANI; INVIVO; YEAST; DNA	Nuclear-encoded cytoplasmic tRNAs are imported into the mitochondria of kinetoplastid protozoa by an unknown mechanism, In a Leishmania in organello system, ATP-dependent import of a cloned, unspliced tRNA(Tyr)(GUA) transcript was demonstrated by protection from ribonuclease, whereas import of a tRNA(Gln) (CUG) transcript was much less efficient, Specific binding of tRNA(Tyr) to two mitochondrial surface proteins of 15 and 22 kilodaltons was observed. Tubulin antisense-binding protein (TAB), the 15-kilodaton species, was purified to apparent homogeneity by RNA affinity chromatography. TAB forms stable complexes with the D stem-loop region of tRNA(Tyr). Immunocytochemical and cell fractionation experiments, combined with limited proteolysis, suggested the association of TAB with the outer mitochondrial membrane, Importantly, anti-TAB antibody specifically inhibited binding as well as import of tRNA(Tyr) and of a synthetic structural homolog, These results support the role of TAB as a membrane-bound receptor or carrier for RNA import into Leishmania mitochondria.			Adhya, S (corresponding author), INDIAN INST CHEM BIOL,GENET ENGN LAB,4 RAJA SC MULLICK RD,CALCUTTA 700032,W BENGAL,INDIA.							DAS S, 1990, J BIOSCIENCES, V15, P239, DOI 10.1007/BF02702665; GHOSH A, 1994, NUCLEIC ACIDS RES, V22, P1663, DOI 10.1093/nar/22.9.1663; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; HAYAISHI O, 1962, METHOD ENZYMOL, V5, P807, DOI 10.1016/S0076-6879(62)05316-1; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC SB, 1993, MOL BIOCHEM PARASIT, V60, P349, DOI 10.1016/0166-6851(93)90148-Q; Lima BD, 1996, RNA, V2, P429; LYE LF, 1993, MOL BIOCHEM PARASIT, V58, P233, DOI 10.1016/0166-6851(93)90045-Y; MAHAPATRA S, 1994, NUCLEIC ACIDS RES, V22, P3381, DOI 10.1093/nar/22.16.3381; Mahapatra S, 1996, J BIOL CHEM, V271, P20432, DOI 10.1074/jbc.271.34.20432; Maniatis T., 1982, MOL CLONING; MOTTRAM JC, 1991, J BIOL CHEM, V266, P18313; NAGLEY P, 1989, TRENDS GENET, V5, P67, DOI 10.1016/0168-9525(89)90028-0; Rusconi CP, 1996, EMBO J, V15, P3286, DOI 10.1002/j.1460-2075.1996.tb00693.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHNEIDER A, 1994, MOL CELL BIOL, V14, P2317, DOI 10.1128/MCB.14.4.2317; SHI XM, 1994, MOL BIOCHEM PARASIT, V65, P23, DOI 10.1016/0166-6851(94)90112-0; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SMALL I, 1992, EMBO J, V11, P1291, DOI 10.1002/j.1460-2075.1992.tb05172.x; TARASSOV I, 1995, EMBO J, V14, P3461, DOI 10.1002/j.1460-2075.1995.tb07352.x; TARASSOV I, 1995, J MOL BIOL, V245, P315, DOI 10.1006/jmbi.1994.0026; TARASSOV IA, 1992, NUCLEIC ACIDS RES, V20, P1277, DOI 10.1093/nar/20.6.1277	27	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21396	21402		10.1074/jbc.272.34.21396	http://dx.doi.org/10.1074/jbc.272.34.21396			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261154	hybrid			2022-12-27	WOS:A1997XR78900064
J	Butenas, S; vantVeer, C; Mann, KG				Butenas, S; vantVeer, C; Mann, KG			Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; HUMAN FACTOR-VIIA; FACTOR-XI ACTIVATION; BOVINE FACTOR-V; HUMAN FACTOR-IX; EXTRINSIC PATHWAY; FACTOR-XA; PLASMINOGEN-ACTIVATOR; HUMAN-PROTHROMBIN; THROMBIN	The initiation phase of enzyme generation in a reconstituted model of the tissue factor (TF) pathway to thrombin was evaluated, At 1.25 pM added TF, no thrombin generation was observed in the absence of factor V, The substitution of factor Va for factor V increased the rate of thrombin generation, Factor X activation during the initiation phase was not influenced by the absence of factor VIII or thrombin, leading to the conclusion that initially factor Xa is generated exclusively by the factor VIIa-TF complex, When thrombin was eliminated from the system, no contribution of the factor Ma-factor VIIIa complex to factor X activation was observed during the propagation phase, Similarly, factor V activation was also not observed in the absence of thrombin, indicating that thrombin is the only enzyme responsible for factor V and factor VIII activation, Only subnanomolar amounts of factor VII were activated when prothrombin activation was almost complete, In the absence of coagulation inhibitors, factor XI did not influence thrombin generation initiated by 1.25 pat factor VIIa-TF complex. The termination of factor XIa generation by added hirudin in the factor XI experiment indicates that factor XI activation occurs exclusively by thrombin.	UNIV VERMONT, DEPT BIOCHEM, BURLINGTON, VT 05405 USA	University of Vermont					NHLBI NIH HHS [HL46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASTRUP T, 1952, ARCH BIOCHEM BIOPHYS, V40, P346, DOI 10.1016/0003-9861(52)90121-5; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BARLOW GH, 1981, THROMB RES, V23, P541, DOI 10.1016/0049-3848(81)90177-8; BEGUIN S, 1989, THROMB HAEMOSTASIS, V61, P25; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BRUNNEE T, 1993, BLOOD, V81, P580; BUTENAS S, 1995, ANAL BIOCHEM, V225, P231, DOI 10.1006/abio.1995.1148; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; BUTENAS S, 1992, BIOCHEMISTRY-US, V31, P5399, DOI 10.1021/bi00138a023; Butenas S, 1996, BIOCHEMISTRY-US, V35, P1904, DOI 10.1021/bi951768c; BUTENAS S, 1994, BIOCHEMISTRY-US, V33, P3449, DOI 10.1021/bi00177a039; CHO K, 1984, BIOCHEMISTRY-US, V23, P644, DOI 10.1021/bi00299a009; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, BLOOD, V82, P813; GYZANDER E, 1984, THROMB RES, V35, P547, DOI 10.1016/0049-3848(84)90286-X; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HOFFMAN M, 1995, BLOOD, V86, P1794, DOI 10.1182/blood.V86.5.1794.bloodjournal8651794; JESTY J, 1979, J BIOL CHEM, V254, P2337; JONES KC, 1994, J BIOL CHEM, V269, P23367; KANE WH, 1981, J BIOL CHEM, V256, P1002; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KESSNER A, 1976, ARCH BIOCHEM BIOPHYS, V176, P411, DOI 10.1016/0003-9861(76)90183-1; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LE DT, 1992, J BIOL CHEM, V267, P15447; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MCRAE BJ, 1981, BIOCHEMISTRY-US, V20, P7196, DOI 10.1021/bi00528a022; NAITO K, 1991, J BIOL CHEM, V266, P7353; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PLOPLIS VA, 1987, J BIOL CHEM, V262, P9503; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; RADCLIFFE R, 1975, J BIOL CHEM, V250, P388; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; RAO LVM, 1988, BLOOD, V72, P396; RAO LVM, 1995, BLOOD, V85, P121, DOI 10.1182/blood.V85.1.121.bloodjournal851121; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; SCOTT CF, 1992, P NATL ACAD SCI USA, V89, P11189, DOI 10.1073/pnas.89.23.11189; SELIGSOHN U, 1978, BLOOD, V52, P978; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TANS G, 1991, J BIOL CHEM, V266, P21864; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vantVeer C, 1997, J BIOL CHEM, V272, P20721, DOI 10.1074/jbc.272.33.20721; vantVeer C, 1997, J BIOL CHEM, V272, P4367, DOI 10.1074/jbc.272.7.4367; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; VERHEIJEN JH, 1985, THROMB RES, V39, P281, DOI 10.1016/0049-3848(85)90223-3; VONDEMBORNE PAK, 1994, THROMB HAEMOSTASIS, V72, P397	55	111	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21527	21533		10.1074/jbc.272.34.21527	http://dx.doi.org/10.1074/jbc.272.34.21527			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261172	hybrid			2022-12-27	WOS:A1997XR78900082
J	Huang, HC; Goldberg, AL				Huang, HC; Goldberg, AL			Proteolytic activity of the ATP-dependent protease HslVU can be uncoupled from ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHAPERONE; LA; DEGRADATION; COMPONENT; BREAKDOWN; POTASSIUM; PEPTIDES; PROTEINS; BINDING	HslVU is a new Escherichia coli ATP-dependent protease composed of two multimeric complexes: the HslU ATPase and the HslV peptidases. Prior studies indicated that HslVU requires ATP hydrolysis for the cleavage of peptides and proteins. We show here that ATP concentrations that activate hydrolysis of benzyloxycarbonyl-Gly-Gly-Leu-7-amido-4-methylcoumarin are 50-100 fold lower than those necessary for degradation of proteins (e.g. casein). Also, the nonhydrolyzable analogs of ATP, 5'-adenylyl beta,gamma-imidodiphosphate (AMP-PNP) and adenosine 5'-(alpha,beta-methylene)triphosphate, can support peptide hydrolysis, but only after an initial time lag not seen with ATP. This delay decreased at higher temperatures and with higher HslU or HslV concentrations and was eliminated by preincubation of HslU and HslV together. Thus, ATP hydrolysis accelerates the association of HslU and HslV, which occurs slowly with the nonhydrolyzable analog. The addition of KCl stimulated 4-6-fold the peptidase activity with AMP-PNP present and eliminated the time lag, but KCl had no stimulatory effect with ATP. NH4+ and Cs+ had similar effects as K+, but Na+ and Li+ were ineffective. AMP-PNP by itself supported hydrolysis of casein and other polypeptides only 20% as well as ATP, but in the presence of K+, Cs+, or NH4+, AMP-PNP activated casein degradation even better than ATP, although it was not hydrolyzed. In addition, MgCl2, MnCl2, and CaCl2 allowed some peptidase and caseinase activity in the absence of any nucleotide. However, Mn2+ and Ca2+, unlike Mg2+, abolished ATP hydrolysis and prevented further activation by ATP or AMP-PNP. These findings indicate that ATP binding to a high affinity site triggers the formation of an active state capable of peptide cleavage, although ATP hydrolysis facilitates this process. Rapid degradation of proteins requires a distinct state of the enzyme, which is normally reached through ATP hydrolysis at low affinity sites. However, AMP-PNP binding together with K+ can induce a form of HslVU that degrades proteins without energy consumption.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051923, R01GM046147] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46147, GM51923] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; EDMUNDS T, 1986, J CELL BIOCHEM, V32, P187, DOI 10.1002/jcb.240320304; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Katayama T, 1996, BIOCHEM BIOPH RES CO, V229, P219, DOI 10.1006/bbrc.1996.1783; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MENON AS, 1987, J BIOL CHEM, V262, P14921; MENON AS, 1987, J BIOL CHEM, V262, P722; Missiakas D, 1996, EMBO J, V15, P6899, DOI 10.1002/j.1460-2075.1996.tb01082.x; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; RICE RH, 1971, J BIOL CHEM, V246, P831; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SEOL JH, 1997, IN PRESS EUR J BIOCH; Shin DH, 1996, FEBS LETT, V398, P151, DOI 10.1016/S0014-5793(96)01223-9; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WAXMAN L, 1985, J BIOL CHEM, V260, P2022; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOO KM, 1989, J BIOL CHEM, V264, P2088; Yoo SJ, 1996, J BIOL CHEM, V271, P14035, DOI 10.1074/jbc.271.24.14035	42	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21364	21372		10.1074/jbc.272.34.21364	http://dx.doi.org/10.1074/jbc.272.34.21364			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261150	hybrid			2022-12-27	WOS:A1997XR78900060
J	LeGouill, C; Parent, JL; RolaPleszczynski, M; Stankova, J				LeGouill, C; Parent, JL; RolaPleszczynski, M; Stankova, J			Structural and functional requirements for agonist-induced internalization of the human platelet-activating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ANGIOTENSIN-II RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; CYTOPLASMIC TAIL; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; MEDIATED ENDOCYTOSIS; MOLECULAR-CLONING	The receptor for platelet-activating factor (PAF) is a member of the G-protein-coupled receptor family. To study the structural elements and mechanisms involved in the internalization of human PAF receptor (hPAFR), we used the following mutants: a truncated mutant in the C-terminal tail of the receptor (Cys(317) --> Stop) and mutations in the (D/N)P(X)(2,3)Y motif (Asp(289) --> Asn,Ala and Tyr(293) --> Phe,Ala). Chinese hamster ovary cells expressing the Cys(317) --> Stop mutant exhibited a marked reduction in their capacity to internalize PAF, suggesting the existence of determinants important for endocytosis in the last 26 amino acids of the cytoplasmic tail. Substitution of Asp(289) to alanine abolished both internalization and G-protein coupling, whereas substitution of Tyr(293) to alanine abolished coupling but not internalization. Inhibition or activation of protein kinase C did not significantly affect the internalization process, Receptor sequestration and ligand uptake was, at least in part, blocked by concanavalin A and blockers of endocytosis mediated by clathrin-coated pits, Our data suggest that the internalization of a G-protein-coupled receptor and coupling to a G-protein can be two independent events. Moreover, the C terminus tail of hPAFR, but not the putative internalization motifs, may be involved in the internalization of hPAFR.	UNIV SHERBROOKE, FAC MED, DEPT PEDIAT, DIV IMMUNOL, SHERBROOKE, PQ J1H 5N4, CANADA	University of Sherbrooke								BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BECK KA, 1991, J BIOL CHEM, V266, P4442; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1987, PROSTAGLANDINS, V34, P143, DOI 10.1016/0090-6980(87)90190-0; CHASE PB, 1993, AM J RESP CELL MOL, V8, P240, DOI 10.1165/ajrcmb/8.3.240; CHEN CY, 1995, J BIOL CHEM, V270, P7825; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HARGRAVE PA, 1994, REGULATION CELLULAR, P25; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Hermans E, 1996, MOL PHARMACOL, V49, P365; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Koenig JA, 1997, BRIT J PHARMACOL, V120, P52, DOI 10.1038/sj.bjp.0700859; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAMEH J, 1992, J BIOL CHEM, V267, P13406; Laporte SA, 1996, MOL PHARMACOL, V49, P89; LIGGETT SB, 1994, REGULATION CELLULAR, P71; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; MORC O, 1994, J BIOL CHEM, V269, P6651; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; Muller S, 1997, FEBS LETT, V401, P25, DOI 10.1016/S0014-5793(96)01424-X; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NATHANSON NM, 1989, MUSCARINIC RECEPTORS, P419; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Parent JL, 1996, J BIOL CHEM, V271, P7949, DOI 10.1074/jbc.271.14.7949; Parent JL, 1996, BIOCHEM BIOPH RES CO, V219, P968, DOI 10.1006/bbrc.1996.0341; Parent JL, 1996, J BIOL CHEM, V271, P23298, DOI 10.1074/jbc.271.38.23298; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Petrou C, 1997, J BIOL CHEM, V272, P2326; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SLICE LW, 1994, J BIOL CHEM, V269, P21755; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; TAKANO T, 1994, J BIOL CHEM, V269, P22453; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANKOPPEN CJ, 1995, EUR J BIOCHEM, V234, P536; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; YAMADA M, 1993, J PHARMACOL EXP THER, V267, P128; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	63	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21289	21295		10.1074/jbc.272.34.21289	http://dx.doi.org/10.1074/jbc.272.34.21289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261140	hybrid			2022-12-27	WOS:A1997XR78900050
J	Lehmann, S; Harris, DA				Lehmann, S; Harris, DA			Blockade of glycosylation promotes acquisition of scrapie-like properties by the prion protein in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCOSYLATION; REPLICATION; SEPARATION; DISEASES; ACID; PRP	The conformational conversion of the prion protein, a sialoglycoprotein containing two N-linked oligosaccharide chains, from its normal form (PrPC) to a pathogenic form (PrPSc) is the central causative event in prion diseases, Although PrPSc can be generated in the absence of glycosylation, there is evidence that oligosaccharide chains may modulate the efficiency of the conversion process, and may also serve as molecular markers of diverse prion strains, In addition, mutational inactivation of one of the N-glycosylation sites has recently been associated with a familial spongiform encephalopathy, To investigate the role of N-glycans in determining the properties of PrP, we have expressed in transfected Chinese hamster ovary cells mouse PrP molecules in which N-glycosylation has been blocked either by treatment with the drug tunicamycin, or by substitution of alanine for threonine at one or both of the N-X-T consensus sites, We report that PrP molecules mutated at Thr(182) alone or at both Thr(182) and Thr(196) fail to reach the cell surface after synthesis, but that those mutated at Thr(196) or synthesized in the presence of tunicamycin can be detected on the plasma membrane, We also find that all three mutant PrPs, and to a limited extent wild-type PrP synthesized in the presence of inhibitor, acquire biochemical attributes reminiscent of PrPSc, We suggest that the PrP molecule has an intrinsic tendency to acquire some PrPSc-like properties, and that N-glycan chains protect against this change, However, pathogenic mutations, or presumably contact with exogenous prions, are necessary to fully convert the protein to a PrPSc state.	WASHINGTON UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Lehmann, Sylvain/P-1301-2017	Lehmann, Sylvain/0000-0001-6117-562X; Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035496] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35496] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORDIER C, 1981, J BIOL CHEM, V256, P1604; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8880; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Harris DA, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P631; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; Nitrini R., 1996, Neurobiology of Aging, V17, pS160, DOI 10.1016/S0197-4580(96)80645-2; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; PRUSINER SB, 1994, ANN NEUROL, V35, P385, DOI 10.1002/ana.410350404; Prusiner SB, 1996, VIROLOGY, P2901; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; ULRICH MJ, 1990, BLOOD, V75, P990; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	37	145	149	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21479	21487		10.1074/jbc.272.34.21479	http://dx.doi.org/10.1074/jbc.272.34.21479			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261166	hybrid			2022-12-27	WOS:A1997XR78900076
J	MontroseRafizadeh, C; Yang, H; Rodgers, BD; Beday, A; Pritchette, LA; Eng, J				MontroseRafizadeh, C; Yang, H; Rodgers, BD; Beday, A; Pritchette, LA; Eng, J			High potency antagonists of the pancreatic glucagon-like peptide-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG PANCREAS; FUNCTIONAL EXPRESSION; REPLACEMENT ANALOGS; DISPERSED ACINI; POLYPEPTIDE; EXENDIN-4; IDENTIFICATION; DEGRADATION; CLONING; BINDING	GLP-1-(7-36)-amide and exendin-4-(1-39) are glucagon-like peptide-1 (GLP-1) receptor agonists, whereas exendin-(9-39) is the only known antagonist, To analyze the transition from agonist to antagonist and to identify the amino acid residues involved in ligand activation of the GLP-1 receptor, we used exendin analogs with successive N-terminal truncations, Chinese hamster ovary cells stably transfected with the rat GLP-1 receptor were assayed for changes in intracellular cAMP caused by the test peptides in the absence or presence of half-maximal stimulatory doses of GLP-1. N-terminal truncation of a single amino acid reduced the agonist activity of the exendin peptide, whereas N-terminal truncation of 3-7 amino acids produced antagonists that were 4-10-fold more potent than exendin-(9-39), N-terminal truncation of GLP-1 by 2 amino acids resulted in weak agonist activity, but an 8-amino acid N-terminal truncation inactivated the peptide, Binding studies performed using I-125-labeled GLP-1 confirmed that all bioactive peptides specifically displaced tracer with high potency, In a set of exendin/GLP-1 chimeric peptides, substitution of GLP-1 sequences into exendin-(3-39) produced loss of antagonist activity with conversion to a weak agonist, The results show that receptor binding and activation occur in separate domains of exendin, but they are more closely coupled in GLP-1.	NIA,LAB CLIN PHYSIOL,NIH,BALTIMORE,MD 21224; VET ADM MED CTR,DEPT MED,BRONX,NY 10468; CUNY MT SINAI SCH MED,NEW YORK,NY 10029	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); US Department of Veterans Affairs; Veterans Health Administration (VHA); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Rodgers, Dan/AAA-5343-2020	Rodgers, Buel/0000-0003-0751-1105				ADELHORST K, 1994, J BIOL CHEM, V269, P6275; ANDREU D, 1987, EUR J BIOCHEM, V164, P585, DOI 10.1111/j.1432-1033.1987.tb11167.x; BROWN JC, 1981, PEPTIDES, V2, P241, DOI 10.1016/0196-9781(81)90038-3; DEACON CF, 1995, DIABETES, V44, P1126, DOI 10.2337/diabetes.44.9.1126; ENG J, 1992, J BIOL CHEM, V267, P7402; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GALLWITZ B, 1994, EUR J BIOCHEM, V225, P1151, DOI 10.1111/j.1432-1033.1994.1151b.x; Gallwitz B, 1996, REGUL PEPTIDES, V63, P17, DOI 10.1016/0167-0115(96)00019-5; Hjorth SA, 1996, ACTA PHYSIOL SCAND, V157, P343, DOI 10.1046/j.1365-201X.1996.37259000.x; HJORTH SA, 1994, J BIOL CHEM, V269, P30121; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; KNUDSEN LB, 1996, REGUL PEPTIDES, V64, P92; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; MONTROSERAFIZAD.C, 1996, REGUL PEPTIDES, V64, P131; NATHAN DM, 1992, DIABETES CARE, V15, P270, DOI 10.2337/diacare.15.2.270; RAUFMAN JP, 1992, J BIOL CHEM, V267, P21432; SIEGEL EG, 1992, EUR J CLIN INVEST, V22, P154, DOI 10.1111/j.1365-2362.1992.tb01820.x; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1994, J BIOL CHEM, V269, P12548; UNSON CG, 1993, ARCH BIOCHEM BIOPHYS, V300, P747, DOI 10.1006/abbi.1993.1103; UNSON CG, 1991, J BIOL CHEM, V266, P2763; UNSON CG, 1994, P NATL ACAD SCI USA, V91, P454, DOI 10.1073/pnas.91.2.454; UNSON CG, 1989, J BIOL CHEM, V264, P789; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; Widmann C, 1996, MOL ENDOCRINOL, V10, P62, DOI 10.1210/me.10.1.62	28	144	192	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21201	21206		10.1074/jbc.272.34.21201	http://dx.doi.org/10.1074/jbc.272.34.21201			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261127	hybrid			2022-12-27	WOS:A1997XR78900037
J	Zhu, YX; Sun, HB; Tsang, MLS; McMahel, J; Grigsby, S; Yin, TG; Yang, YC				Zhu, YX; Sun, HB; Tsang, MLS; McMahel, J; Grigsby, S; Yin, TG; Yang, YC			Critical cytoplasmic domains of human interleukin-9 receptor alpha chain in interleukin-9-mediated cell proliferation and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; IL-2 RECEPTOR; GAMMA-CHAIN; BETA-CHAIN; EXPRESSION CLONING; CYTOKINE RECEPTORS; THYMIC LYMPHOMAS; GROWTH-FACTOR; ACTIVATION; REGION	Interleukin-9 receptor (IL-9R) complex consists of a ligand specific au chain and IL-2R gamma chain, In this study, two regions in the cytoplasmic domain of human IL-9R alpha were found to be important for IL-9-mediated cell growth. A membrane-proximal region that contains the BOX1 consensus sequence is required for IL-9-induced cell proliferation and tyrosine phosphorylation of Janus kinases (JAKs), Deletion of this region or internal deletion of the BOX1 motif abrogated IL-9-induced cell proliferation and signal transduction. However, substitution of the Pro-X-Pro in the BOX1 motif with Ala-X-Ala failed to abolish IL-9-induced cell proliferation but decreased IL-g-mediated tyrosine phosphorylation of JAM kinases, insulin receptor substrate-2, and signal transducer and activator of transcription 3 (STAT3) and expression of c-myc and junB. Another important region is downstream of the BOX1 motif and contains a STAT3 binding motif YLPQ. Deletion of this region significantly impaired IL-9-induced cell growth, activation of JAK kinases, insulin receptor substrate-g, and STAT3 and expression of early response genes, A point mutation changing YLPQ into YLPA ,greatly reduced IL-9-induced activation of STAT3 and expression of c-myc but did not affect cell proliferation, These results suggest that cooperation or cross-talk of signaling molecules associated with different domains of IL-9R alpha other than STAT3 is essential for IL-9-mediated cell growth.	INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202; WALTHER CANC INST,INDIANAPOLIS,IN 46202; R&D SYST,MINNEAPOLIS,MN 55413	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050570] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK 50570] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; CHANG MS, 1994, BLOOD, V83, P3199; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER P, 1995, ONCOGENE, V10, P985; DASILVA L, 1994, J BIOL CHEM, V269, P18267; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; EEKLUND KK, 1993, J IMMUNOL, V151, P4266; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Higuchi M, 1996, EUR J IMMUNOL, V26, P1322, DOI 10.1002/eji.1830260622; HORIE M, 1993, J BIOL CHEM, V268, P968; HULTNER L, 1989, J IMMUNOL, V142, P3440; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IHLE JN, 1995, ADV IMMUNOL, V6, P1; KANG LY, 1995, J CELL PHYSIOL, V163, P623, DOI 10.1002/jcp.1041630324; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KIRKEN RA, 1995, CYTOKINE, V7, P689, DOI 10.1006/cyto.1995.0081; Kojima H, 1996, ONCOGENE, V12, P547; LUI J, 1992, CELL GROWTH DIFFER, V3, P307; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6943; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; WILLIAMS DE, 1990, BLOOD, V79, P906; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YANG L, 1995, BLOOD, V86, P2526, DOI 10.1182/blood.V86.7.2526.bloodjournal8672526; YANG YC, 1989, BLOOD, V74, P1880; YIN TG, 1995, BLOOD, V85, P3101, DOI 10.1182/blood.V85.11.3101.bloodjournal85113101; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; YIN TG, 1994, EXP HEMATOL, V22, P467	44	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21334	21340		10.1074/jbc.272.34.21334	http://dx.doi.org/10.1074/jbc.272.34.21334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261146	hybrid			2022-12-27	WOS:A1997XR78900056
J	ElHodiri, HM; Che, SL; NelmanGonzalez, M; Kuang, J; Etkin, LD				ElHodiri, HM; Che, SL; NelmanGonzalez, M; Kuang, J; Etkin, LD			Mitogen-activated protein kinase and cyclin B/Cdc2 phosphorylate Xenopus nuclear factor 7 (xnf7) in extracts from mature oocytes - Implications for regulation of xnf7 subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; MATURATION; ONCOGENE; PRODUCT; DOMAIN; LAEVIS; EGGS; MPF	Xenopus nuclear factor 7 (xnf7) is a maternally expressed putative transcription factor that exhibits phosphorylation-dependent changes in subcellular localization during early Xenopus development, Xnf7 is localized to the germinal vesicle (nucleus) of immature oocytes in a hypophosphorylated state, Xnf7 is phosphorylated during oocyte maturation and released to the cytoplasm, The protein is retained in the cytoplasm during early embryonic cleavage stages but returns to nuclei at the mid-blastula transition. Xnf7 is phosphorylated at two sites during oocyte maturation, designated P1, consisting of one threonine at position 103, and P2, consisting of three clustered threonines at positions 209, 212, and 218. Phosphorylation of both sites is important in regulating xnf7 localization, The P1 site can be phosphorylated by cyclin B/Cdc2 in vitro. , To further understand the mechanisms regulating subcellular localization of xnf7 during early development, kinases capable of catalyzing phosphorylation of the P2 site were purified from mature oocyte extracts. We found that mitogen-activated protein kinase phosphorylated Thr(212) and cyclin B/Cdc2 phosphorylated Thr (209) and Thr(212). NO other kinase in mature oocyte extracts phosphorylated the xnf7 P2 site to a significant extent. These results implicate mitogen-activated protein kinase and cyclin B/Cdca in regulating xnf7 localization during oocyte maturation, This also suggests that localization of xnf7 may be regulated by multiple kinase activation pathways.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CLIN INVEST,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DREYER C, 1983, CURRENT PROBLEMS GER, P322; Etkin L D, 1988, Dev Biol (N Y 1985), V5, P209; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; Hartley RS, 1996, DEV BIOL, V173, P408, DOI 10.1006/dbio.1996.0036; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Huang CYF, 1996, EMBO J, V15, P2169, DOI 10.1002/j.1460-2075.1996.tb00570.x; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; LI XX, 1994, EXP CELL RES, V213, P473, DOI 10.1006/excr.1994.1225; LI XX, 1994, J CELL BIOL, V124, P7, DOI 10.1083/jcb.124.1.7; LI XX, 1993, J CELL SCI, V105, P389; MILLER M, 1991, DEVELOPMENT, V113, P569; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; Shou WN, 1996, MOL CELL BIOL, V16, P990; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; WHITESIDE ST, 1993, J CELL SCI, V104, P949; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZAITSEVSKAYA T, 1992, CELL GROWTH DIFFER, V3, P773	32	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20463	20470		10.1074/jbc.272.33.20463	http://dx.doi.org/10.1074/jbc.272.33.20463			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252356	hybrid			2022-12-27	WOS:A1997XR22100026
J	Lange, S; Nussler, F; Kauschke, E; Lutsch, G; Cooper, EL; Herrmann, A				Lange, S; Nussler, F; Kauschke, E; Lutsch, G; Cooper, EL; Herrmann, A			Interaction of earthworm hemolysin with lipid membranes requires sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SEMLIKI-FOREST-VIRUS; PORE-FORMING DOMAIN; CELOMIC FLUID; LUMBRICUS-TERRESTRIS; EISENIA-FOETIDA; CATALYZED OXIDATION; COLICIN-A; CHOLESTEROL; TOXIN	Lytic activity in the coelomic fluid of earthworm (Eisenia fetida fetida) has been ascribed to eiseniapore, a hemolytic protein of 38 kDa. Since receptors for eiseniapore on target cell membranes are not known, we used lipid vesicles of various composition to determine whether specific lipids may serve as receptors, Lytic activity of eiseniapore was probed by the relief of fluorescence dequenching from the fluorophore 8-aminonaphthalene-1,3,6-trisulfonic acid originally incorporated into the vesicle lumen as a complex with p-xylene-bis-pyridinium bromide, Hemolysin binds to and disturbs the lipid bilayer only when distinct sphingolipids consisting of a hydrophilic head group as phosphorylcholine or galactosyl as well as the ceramide backbone, e,g. sphingomyelin, are present. Cholesterol enhances eiseniapore lytic activity toward sphingomyelin-containing vesicles probably due to interaction with sphingomyelin. Leakage of vesicles was most efficient when the lipid composition resembled that of the outer leaflet of human erythrocytes. Presumably, an oligomeric protein pore formed by six monomers is responsible for leakage of sphingomyelin-containing vesicles. The secondary structure of eiseniapore did not change upon binding to lipid membranes. The lytic activity of eiseniapore was completely abolished after its denaturation or after preincubation with polyclonal antibodies. Our results suggest that the presence of specific sphingolipids is sufficient to mediate lytic activity of eiseniapore, This action contributes to our understanding of earthworm immune responses.	HUMBOLDT UNIV BERLIN, MATH NAT WISSENSCH FAK 1, INST BIOL BIOPHYS, D-10115 BERLIN, GERMANY; MAX DELBRUCK CTR MOL MED, D-13122 BERLIN, GERMANY; UNIV GREIFSWALD, ZOOL INST & MUSEUM, D-17489 GREIFSWALD, GERMANY; UNIV CALIF LOS ANGELES, MED CTR, DEPT NEUROBIOL, LAB COMPARAT IMMUNOL, LOS ANGELES, CA 90095 USA	Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ernst Moritz Arndt Universitat Greifswald; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center								ALBRO PW, 1992, LIPIDS, V27, P136, DOI 10.1007/BF02535813; ANDRE FRANCIS, 1963, BULL BIOL FRANCE ET BELGIQUE, V97, P3; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BILEJ M, 1995, IMMUNOL LETT, V45, P123, DOI 10.1016/0165-2478(94)00248-P; Bouche M.B., 1972, LOMBRICIENS FRANCE E; CANICATTI C, 1987, DEV COMP IMMUNOL, V11, P29, DOI 10.1016/0145-305X(87)90005-X; CANICATTI C, 1990, EXPERIENTIA, V46, P239, DOI 10.1007/BF01951753; CHITWOOD DJ, 1995, LIPIDS, V30, P567, DOI 10.1007/BF02537032; COOPER EL, 1995, CELL IMMUNOL, V166, P113, DOI 10.1006/cimm.1995.0013; Cossarizza A, 1996, EXP CELL RES, V224, P174, DOI 10.1006/excr.1996.0125; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; EUE I, 1991, DEV COMP IMMUNOL S1, V15, P75; GRONBERG L, 1990, BIOCHEMISTRY-US, V29, P3173, DOI 10.1021/bi00465a003; HORI T, 1993, PROG LIPID RES, V32, P25, DOI 10.1016/0163-7827(93)90003-F; KANESHIRO ES, 1987, J LIPID RES, V28, P1241; KARNOVSKY ML, 1969, CHEM ZOOL, V4, P205; KAUSCHKE E, 1987, DEV COMP IMMUNOL, V11, P331, DOI 10.1016/0145-305X(87)90077-2; KAUSCHKE E, 1987, J COMP PHYSIOL B, V157, P77, DOI 10.1007/BF00702731; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LANGE S, 1995, 23 M FEBS BAS AUG 13, P285; Li J, 1996, J MOL BIOL, V257, P129, DOI 10.1006/jmbi.1996.0152; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACEK P, 1994, TOXICOLOGY, V87, P205, DOI 10.1016/0300-483X(94)90252-6; MALONEY MD, 1991, PARASITOL RES, V77, P294, DOI 10.1007/BF00930904; Marsh D, 1981, Mol Biol Biochem Biophys, V31, P51; MCLAUGHIN J, 1970, COMP BIOCH PHYSL B, V38, P147; MEINARDI E, 1995, BIOCHEM BIOPH RES CO, V216, P348, DOI 10.1006/bbrc.1995.2630; MOESBY L, 1995, BIOCHEMISTRY-US, V34, P10319, DOI 10.1021/bi00033a001; Mohrig W, 1996, COMP BIOCHEM PHYS A, V115, P19, DOI 10.1016/0300-9629(95)02100-0; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; NISHIMURA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P141, DOI 10.1016/0005-2760(91)90001-X; OKAMURA N, 1985, J NEUROCHEM, V45, P1875, DOI 10.1111/j.1471-4159.1985.tb10546.x; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PARRINELLO N, 1995, DEV COMP IMMUNOL, V19, P31, DOI 10.1016/0145-305X(94)00046-I; PODACK ER, 1982, J BIOL CHEM, V257, P5204; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; POMORSKI T, 1994, MOL MEMBR BIOL, V11, P39, DOI 10.3109/09687689409161028; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Quaglino D, 1996, EUR J CELL BIOL, V70, P278; Roch P, 1996, ITAL J ZOOL, V63, P311, DOI 10.1080/11250009609356151; ROCH P, 1991, DEV COMP IMMUNOL, V15, P27, DOI 10.1016/0145-305X(91)90044-Y; ROCH P, 1981, COMP BIOCHEM PHYS B, V69, P829, DOI 10.1016/0305-0491(81)90390-4; ROCH P, 1989, BIOCHIM BIOPHYS ACTA, V983, P193, DOI 10.1016/0005-2736(89)90233-2; SATOUCHI K, 1993, LIPIDS, V28, P837, DOI 10.1007/BF02536239; SCHREIER S, 1978, BIOCHIM BIOPHYS ACTA, V515, P395, DOI DOI 10.1016/0304-4157(78)90011-4; SCHWOCH G, 1973, MOL CELL BIOCHEM, V2, P197, DOI 10.1007/BF01795474; SIMA P, 1993, CRIT REV IMMUNOL, V13, P83; SLOTTE JP, 1993, BIOCHEMISTRY-US, V32, P7886, DOI 10.1021/bi00082a008; SLOTTE JP, 1992, BIOCHEMISTRY-US, V31, P5472, DOI 10.1021/bi00139a008; Smaby JM, 1996, BIOCHEMISTRY-US, V35, P5696, DOI 10.1021/bi953057k; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VANDERGOOT FG, 1994, NATO ASI SERIES 82, V2, P181; WOODLE MC, 1989, METHOD ENZYMOL, V171, P193; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	60	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20884	20892		10.1074/jbc.272.33.20884	http://dx.doi.org/10.1074/jbc.272.33.20884			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252415	hybrid			2022-12-27	WOS:A1997XR22100085
J	MartinezMoczygemba, M; Gutch, MJ; French, DL; Reich, NC				MartinezMoczygemba, M; Gutch, MJ; French, DL; Reich, NC			Distinct STAT structure promotes interaction of STAT2 with the p48 subunit of the interferon-alpha-stimulated transcription factor ISGF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTING COILED COILS; DNA-BINDING PROTEINS; SIGNAL-TRANSDUCTION; GENE FACTOR-3; ACTIVATION; DOMAINS; RNA; POLYPEPTIDE; PATHWAYS; RESIDUE	Cells express a variety of STAT (signal transducer and activator of transcription) transcription factors that are structurally homologous and yet function specifically in response to particular cytokines, The functions of the individual STATs are dependent on distinct protein-protein interactions. STAT1 and STATE are activated by tyrosine phosphorylation in response to type I interferons-alpha/beta (IFN-alpha/beta) and subsequently farm a multimeric transcription factor designated the IFN-alpha-stimulated gene factor 3 (ISGF3). ISGF3 is a unique STAT complex because it also contains a Iron-STAT molecule, p48, which is a critical DNA-binding component. We provide evidence that STATE specifically interacts with p48 in vivo before and after IFN-alpha stimulation, The specificity of ISGF3 formation is therefore a result of the distinct nature of the STATE molecule, Coimmunoprecipitation assays demonstrate p48 association with STAT2 but not STAT1. Hybrid STAT2.STAT1 molecules were used to identify a region of STATE which specifically associates with p48. The region of STATE interaction spans an amino-terminal region of two predicted coiled coils, The studies demonstrate the in vivo existence of a STAT2.p48 complex and a distinct STAT2.STAT1 complex after IFN-alpha stimulation. Data suggest that distinct bipartite complexes STAT2.p48 and STAT2.STAT1 translocate to the nucleus and associate on the DNA target site as ISGF3.	SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; MT SINAI SCH MED,DIV HEMATOL,NEW YORK,NY 10029	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [P01CA028146, R01CA050773] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA50773, P01CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; DALY C, 1995, J BIOL CHEM, V270, P23739, DOI 10.1074/jbc.270.40.23739; DALY C, 1994, TRENDS ENDOCRIN MET, V5, P159, DOI 10.1016/1043-2760(94)90013-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Demaeyer E., 1988, INTERFERONS OTHER RE; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; French D, 1987, Methods Enzymol, V151, P50, DOI 10.1016/S0076-6879(87)51008-4; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Galfre G, 1981, Methods Enzymol, V73, P3; GILMOUR KC, 1995, GENE EXPRESSION, V5, P1; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	35	99	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20070	20076		10.1074/jbc.272.32.20070	http://dx.doi.org/10.1074/jbc.272.32.20070			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242679	hybrid			2022-12-27	WOS:A1997XQ05900066
J	Morenweiser, R; Auerswald, EA; vandeLocht, A; Fritz, H; Sturzebecher, J; Stubbs, MT				Morenweiser, R; Auerswald, EA; vandeLocht, A; Fritz, H; Sturzebecher, J; Stubbs, MT			Structure-based design of a potent chimeric thrombin inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; HEPARIN COFACTOR-II; PRO-ARG CHLOROMETHYLKETONE; KAZAL-TYPE INHIBITOR; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; REACTIVE SITE; TRYPTASE INHIBITOR; TRYPSIN-INHIBITOR; HIRUDIN	Using the three-dimensional structures of thrombin and the leech-derived tryptase inhibitor (LDTI), which does not inhibit thrombin, we were able to construct three LDTI variants inhibiting thrombin, Trimming of the inhibitor reactive site loop to fit thrombin's narrow active site cleft resulted in inhibition constants (K-i) in the 10 nM concentration range; similar values were obtained by the addition of an acidic C-terminal peptide corresponding to hirudin's tail to LDTI. Combination of both modifications is additive, resulting in very strong inhibition of thrombin (K-i in the picomolar range), On the one hand, these results confirm the significance of the restricted active site cleft of thrombin in determining its high cleavage specificity; on the other, they demonstrate that sufficient binding energy at the fibrinogen recognition exosite can force thrombin to accept otherwise unfavorable residues in the active site cleft. The best inhibitor thus obtained is as effective as hirudin in plasma-based clotting assays.	UNIV MUNICH, KLINIKUM INNENSTADT, KLIN CHEM & KLIN BIOCHEM ABT, CHIRURG KLIN & POLIKLIN, D-80336 MUNICH, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; KLINIKUM UNIV JENA, ZENTRUM VASKULARE BIOL & MED, D-99089 ERFURT, GERMANY	University of Munich; Max Planck Society; Friedrich Schiller University of Jena				Stubbs, Milton/0000-0003-1278-9013				ASCENZI P, 1988, BIOCHIM BIOPHYS ACTA, V956, P156, DOI 10.1016/0167-4838(88)90262-2; AUERSWALD EA, 1994, BIOL CHEM H-S, V375, P695, DOI 10.1515/bchm3.1994.375.10.695; BAICI A, 1981, EUR J BIOCHEM, V119, P9, DOI 10.1111/j.1432-1033.1981.tb05570.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1992, PROTEIN SCI, V1, P426; CHEN XM, 1992, J BIOCHEM-TOKYO, V112, P45, DOI 10.1093/oxfordjournals.jbchem.a123863; DECRISTOFARO R, 1993, BIOCHEM J, V289, P475, DOI 10.1042/bj2890475; DIMAIO J, 1990, J BIOL CHEM, V265, P21698; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FINK E, 1986, BIOL CHEM H-S, V367, P1235, DOI 10.1515/bchm3.1986.367.2.1235; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; GUINTO ER, 1994, J BIOL CHEM, V269, P18395; JOHNSON DJD, 1994, THROMB HAEMOSTASIS, V71, P428; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; Matthews JH, 1996, BIOPHYS J, V71, P2830, DOI 10.1016/S0006-3495(96)79479-1; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MUHLHAHN P, 1994, FEBS LETT, V355, P290, DOI 10.1016/0014-5793(94)01225-3; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1986, NUCLEIC ACIDS RES, V14, P1073, DOI 10.1093/nar/14.2.1073; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SCHMITZ T, 1991, EUR J BIOCHEM, V195, P251, DOI 10.1111/j.1432-1033.1991.tb15701.x; SOMMERHOFF CP, 1994, BIOL CHEM H-S, V375, P685, DOI 10.1515/bchm3.1994.375.10.685; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; STEPHENS AW, 1987, J BIOL CHEM, V262, P1044; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Stubbs MT, 1997, J BIOL CHEM, V272, P19931, DOI 10.1074/jbc.272.32.19931; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; THEUNISSEN HJM, 1993, J BIOL CHEM, V268, P9035; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; vandeLocht A, 1996, EMBO J, V15, P6011, DOI 10.1002/j.1460-2075.1996.tb00989.x; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; WALSMANN P, 1981, PHARMAZIE, V36, P653	43	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19938	19942		10.1074/jbc.272.32.19938	http://dx.doi.org/10.1074/jbc.272.32.19938			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242661	hybrid			2022-12-27	WOS:A1997XQ05900048
J	Kojima, D; Terakita, A; Ishikawa, T; Tsukahara, Y; Maeda, A; Shichida, Y				Kojima, D; Terakita, A; Ishikawa, T; Tsukahara, Y; Maeda, A; Shichida, Y			Novel G(o)-mediated phototransduction cascade in scallop visual cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; BETA-GAMMA-SUBUNITS; INVERTEBRATE PHOTORECEPTORS; IMMUNOHISTOCHEMICAL LOCALIZATION; CYCLIC-GMP; CHANNELS; GENE; CONDUCTANCE; VERTEBRATE; MODULATION	Scallop retinas contain ciliary photoreceptor cells that respond to light by hyperpolarization like vertebrate rods and cones, but the response is generated by a different phototransduction cascade from those of rods and cones. To elucidate the cascade, we investigated a visual pigment and a G-protein functioning in the hyperpolarizing cell. Sequencing of cDNAs and in situ hybridization experiments showed that the hyperpolarizing cells express a novel subtype of visual pigment, which showed significant differences in amino acid sequence from other visual pigments. Cloning cDNA genes of G-protein and immunohistochemical analysis revealed the presence of an alpha subunit of a G(o) type G-protein, 83% identical in amino acid sequence to mammalian G(o(alpha)) in the nervous system, in the photoreceptive region of the cells. The results demonstrate that a novel, G(o)-mediated, phototransduction cascade is present in the hyperpolarizing cells. The phototransduction cascade in the scallop hyperpolarizing cell provides an alternative system to investigate G(o)-mediated transduction pathways in the nervous system. Molecular phylogenetic analysis strongly suggests that the G(o)-mediated phototransduction system emerged before the divergence of animals into vertebrate and invertebrate in the course of evolution.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN; INST PHYS & CHEM RES,RIKEN,PHOTODYNAM RES CTR,SENDAI,MIYAGI 980,JAPAN	Kyoto University; RIKEN			Kojima, Daisuke/G-4958-2014	Kojima, Daisuke/0000-0003-2658-780X; Terakita, Akihisa/0000-0002-8379-8913				ADACHI J, 1996, MOLPHY PROGRAM MOL P; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; FELSENSTEIN J, 1996, PHYLIP VERSION 3 572; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; Finn JT, 1997, NATURE, V385, P815, DOI 10.1038/385815a0; GOMEZ MD, 1995, NEURON, V15, P607, DOI 10.1016/0896-6273(95)90149-3; GOMEZ MD, 1994, J GEN PHYSIOL, V103, P939, DOI 10.1085/jgp.103.6.939; GORMAN ALF, 1969, SCIENCE, V165, P309, DOI 10.1126/science.165.3890.309; Hartline HK, 1938, J CELL COMPAR PHYSL, V11, P465, DOI 10.1002/jcp.1030110311; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Iwabe N, 1996, MOL BIOL EVOL, V13, P483, DOI 10.1093/oxfordjournals.molbev.a025609; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LEE YJ, 1994, NEURON, V13, P1143, DOI 10.1016/0896-6273(94)90052-3; MCREYNOLDS JS, 1970, J GEN PHYSIOL, V56, P376, DOI 10.1085/jgp.56.3.376; MCREYNOLDS JS, 1974, SCIENCE, V183, P658, DOI 10.1126/science.183.4125.658; SHEN DW, 1994, BIOCHEMISTRY-US, V33, P13117, DOI 10.1021/bi00248a022; SHIMATANI Y, 1995, J NEUROSCI, V15, P6489; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; Suzuki T, 1995, FEBS LETT, V377, P333, DOI 10.1016/0014-5793(95)01364-4; TERAKITA A, 1993, FEBS LETT, V330, P197, DOI 10.1016/0014-5793(93)80272-V; TERASHIMA T, 1987, BRAIN RES, V410, P97, DOI 10.1016/S0006-8993(87)80026-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4561, DOI 10.1073/pnas.83.12.4561; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; ZAMPONI GW, 1997, NATURE, V385, P422	28	111	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					22979	22982		10.1074/jbc.272.37.22979	http://dx.doi.org/10.1074/jbc.272.37.22979			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287291	hybrid			2022-12-27	WOS:A1997XV74400002
J	Yang, YK; Dickinson, C; HaskellLuevano, C; Gantz, I				Yang, YK; Dickinson, C; HaskellLuevano, C; Gantz, I			Molecular basis for the interaction of [Nle(4),D-Phe(7)]melanocyte stimulating hormone with the human melanocortin-1 receptor (melanocyte alpha-MSH receptor)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOTROPIN PEPTIDES; LIGAND-BINDING; IDENTIFICATION; RESIDUES; PROTEINS; POTENT; DESIGN; HMC1R; MODEL	The melanocortin-1 receptor (MC1R) is a seven-transmembrane (TM) G-protein-coupled receptor whose natural ligands are the melanocortin peptides, adrenocorticotropic hormone, and alpha-, beta-, gamma- melanocyte stimulating hormone (MSH). To test a previously constructed three-dimensional model of the molecular interaction between the long-acting, superpotent alpha-MSH analog [Nle(4),D-Phe(7)]MSH (NDP-MSH) and the human MC1R we examined the effects of site-directed receptor mutagenesis on the binding affinity and potency of NDP-MSH. In addition, we also examined the effects of these same mutations on the binding affinity and potency of the structurally related agonists alpha-MSH, gamma-MSH, and Ac-Nle(4)-cyclic-[Asp(5),His(6),D-Phe(7),Arg(8),Trp(9),Lys(10)]NH2 (MT-II). Mutagenesis of acidic receptor residues Glu(94) in TM2 and Asp(117) or Asp(121) in TM3 significantly altered the binding affinity and potency of all four agonists suggesting that these receptor residues are important to the ligand-receptor interactions of all. A disproportionate change in agonist potency versus affinity observed with simultaneous mutation of these acidic residues (mutant constructs D117A/D121A or E94A/D117A/D121A) or introduction of a single positive charge (mutant construct D121K) also implicates these residues in receptor activation. In addition, results from the individual mutation of aromatic receptor residues Phe(175), Phe(196), and Phe(357), and simultaneous mutation of multiple TM4, -5, and -6 tyrosine and phenylalanine residues suggests that aromatic-aromatic ligand-receptor interactions also participate in binding these melanocortins to the MC1R. These experiments appear to have identified some of the critical receptor residues involved in the ligand-receptor interactions between these melanocortins nad the hMC1R.	UNIV MICHIGAN, SCH MED, DEPT SURG, ANN ARBOR, MI 48109 USA; VET ADM MED CTR, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PEDIAT, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Ellenberg, Jan/I-4688-2014	Ellenberg, Jan/0000-0001-5909-701X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047398, F32DK009231] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK47398, NSRA DK09231] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALOBEIDI F, 1989, J MED CHEM, V32, P2555, DOI 10.1021/jm00132a010; ALOBEIDI F, 1989, J AM CHEM SOC, V111, P3413, DOI 10.1021/ja00191a044; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Chhajlani V, 1996, BIOCHEM BIOPH RES CO, V219, P521, DOI 10.1006/bbrc.1996.0266; CONE R, 1995, END SOC M WASH DC JU; DEWIED D, 1982, PHYSIOL REV, V62, P976, DOI 10.1152/physrev.1982.62.3.976; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; FRANDBERG PA, 1994, BIOCHEM BIOPH RES CO, V202, P1266, DOI 10.1006/bbrc.1994.2067; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Haskell-Luevano C, 1996, Drug Des Discov, V14, P197; HASKELLLUEVANO C, 1994, BIOCHEM BIOPH RES CO, V204, P1137, DOI 10.1006/bbrc.1994.2581; HaskellLuevano C, 1996, J MED CHEM, V39, P432, DOI 10.1021/jm950407s; Hruby V. J. W., 1984, PEPTIDE PROTEIN REV, V3, P1; HUANG RRC, 1995, BIOCHEMISTRY-US, V34, P10048, DOI 10.1021/bi00031a029; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; MOUNTJOY KG, 1994, MOL CELL ENDOCRINOL, V102, pR7, DOI 10.1016/0303-7207(94)90113-9; PRUSIS P, 1995, BIOCHEM BIOPH RES CO, V210, P205, DOI 10.1006/bbrc.1995.1647; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAWYER TK, 1993, ANN NY ACAD SCI, V680, P597, DOI 10.1111/j.1749-6632.1993.tb19749.x; SAWYER TK, 1980, P NATL ACAD SCI-BIOL, V77, P5754, DOI 10.1073/pnas.77.10.5754; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; STRADER CD, 1988, J BIOL CHEM, V263, P10267; TATRO JB, 1987, ENDOCRINOLOGY, V121, P1900, DOI 10.1210/endo-121-5-1900; TATRO JB, 1997, IN PRESS NEUROIMMUNO	26	136	139	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23000	23010		10.1074/jbc.272.37.23000	http://dx.doi.org/10.1074/jbc.272.37.23000			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287296	hybrid			2022-12-27	WOS:A1997XV74400007
J	Adeli, K; Macri, J; Mohammadi, A; Kito, M; Urade, R; Cavallo, D				Adeli, K; Macri, J; Mohammadi, A; Kito, M; Urade, R; Cavallo, D			Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ENDOPLASMIC-RETICULUM; G2 CELLS; HEP-G2 CELLS; RAT-LIVER; DEGRADATION; SECRETION; TRANSLOCATION; LIPOPROTEINS; MEMBRANE; GOLGI	Two ALLN (N-acetyl-leucyl-leucyl-norleucinal)-sensitive endoplasmic reticulum (ER)-localized proteases (ER-60 and ER-72) were recently purified from rat liver, We used an antibody to rat ER-60 to investigate the possible role of this protease in apolipoprotein B (apoB) degradation, First, immunoprecipitation and immunoblotting experiments with the anti-rat ER-60 antibody suggested that HepG2 cells contain a homologue of ER-60 with an approximate molecular mass of 58-60 kDa. The ER-60 homologue was mostly associated with the luminal contents of HepG2 microsomes, Evidence from co-immunoprecipitation and cross-linking experiments appear to suggest that the ER-60 homologue in HepG2 cells is associated with apoB intracellularly. A small pool of apoB was recovered when HepG2 lysates were subjected to immunoprecipitation with anti-rat ER-60 antibody followed by a second immunoprecipitation with anti-apoB antibody, Furthermore, cross-linking of permeabilized cells with dithiobis(succinimidylpropionate) further demonstrated association of apoB with the ER-60 homologue in HepG2 cells, Three polypeptides with molecular masses of 78, 66, and 50 kDa were consistently found to be associated with apoB as well as the 58-kDa ER-60 homologue, The 78-kDa protein associated with both apoB and ER-60 appeared to represent immunoglobulin heavy chain-binding protein (BiP) based on immunoprecipitation with a monoclonal antibody, Cross-linking and immunoblotting experiments suggested the association of the 78-kDa BiP with both the 58-kDa ER-60 homologue as well as the 550-kDa apoB. In summary, the data suggests that HepG2 cells contain a 58-kDa protein which is homologous to the rat liver ER-60 in size, antigenecity, and intracellular localization, The ER-60 homologue in HepG2 cells appears to be closely associated with apoB, as well as other proteins possibly representing ER chaperones such as BiP, We hypothesize that the ER-60 homologue may be involved in the degradation of apoB in the ER lumen of HepG2 cells.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University	Adeli, K (corresponding author), UNIV WINDSOR,DEPT CHEM & BIOCHEM,401 SUNSET AVE,WINDSOR,ON N9B 3P4,CANADA.			Adeli, Khosrow/0000-0002-5839-5709				ADELI K, 1994, J BIOL CHEM, V269, P9166; Adeli K, 1997, J BIOL CHEM, V272, P5031, DOI 10.1074/jbc.272.8.5031; ADELI K, 1990, FEBS LETT, V2, P345; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DU EZ, 1994, J BIOL CHEM, V269, P24169; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; HJELMELAND LM, 1980, P NATL ACAD SCI-BIOL, V77, P6368, DOI 10.1073/pnas.77.11.6368; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macri J, 1997, J BIOL CHEM, V272, P7328, DOI 10.1074/jbc.272.11.7328; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SALLACH SM, 1995, BBA-MOL CELL RES, V1265, P29, DOI 10.1016/0167-4889(95)00239-O; SATO R, 1990, J BIOL CHEM, V265, P11880; Sparks Janet D., 1993, Current Opinion in Lipidology, V4, P177, DOI 10.1097/00041433-199306000-00002; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; URADE R, 1993, J BIOL CHEM, V268, P22004; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	30	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22489	22494		10.1074/jbc.272.36.22489	http://dx.doi.org/10.1074/jbc.272.36.22489			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278400	hybrid			2022-12-27	WOS:A1997XV49200020
J	Brenner, B; Koppenhoefer, U; Weinstock, C; Linderkamp, O; Lang, F; Gulbins, E				Brenner, B; Koppenhoefer, U; Weinstock, C; Linderkamp, O; Lang, F; Gulbins, E			Fas- or ceramide-induced apoptosis is mediated by a rad-regulated activation of jun N-terminal kinase p38 kinases and GADD153	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CHOP; CELL-SURFACE ANTIGEN; ICE-LIKE PROTEASE; HUMAN T-CELLS; SIGNALING PATHWAY; ACIDIC SPHINGOMYELINASE; MAP KINASE; LYMPHOPROLIFERATIVE SYNDROME; RECEPTOR SUPERFAMILY; FAS/APO-1 CD95	In the present study, we show that Fas receptor ligation or cellular treatment with synthetic C-6-ceramide results in activation or phosphorylation, respectively, of the small G-protein Rac1, Jun N-terminal kinase (JNK)/ p38 kinases (p38-K), and the transcription factor GADD153. A signaling cascade from the Fas receptor via ceramide, Ras, Rad, and JNK/p38-K to GADD153 is demonstrated employing transfection of transdominant inhibitory N17Ras, N17Rac1, c-Jun, or treatment with a specific p38-K inhibitor. The critical function of this signaling cascade is indicated by prevention of Fas-or C-6-ceramide-induced apoptosis after inhibition of Ras,Rac1, or JNK/p38-K.	UNIV TUBINGEN,DEPT PHYSIOL,D-72076 TUBINGEN,GERMANY; UNIV HEIDELBERG,DEPT PEDIAT,INF 150,D-69120 HEIDELBERG,GERMANY; UNIV TUBINGEN,DEPT TRANSFUS MED,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen; Ruprecht Karls University Heidelberg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital			Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COLLINS M, 1995, AM J RESP CRIT CARE, V152, pS20, DOI 10.1164/ajrccm/152.4_Pt_2.S20; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLING GJ, 1994, PHILOS T ROY SOC B, V345, P257, DOI 10.1098/rstb.1994.0103; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 1996, J IMMUNOL, V157, P2844; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HANNUN YA, 1996, ASCIENCE, V274, P1855; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; LIU ZG, 1996, CELL, V87, P566; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LUCIANI MF, 1994, PHILOS T R SOC B, V345, P303, DOI 10.1098/rstb.1994.0110; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MERCEP M, 1989, J IMMUNOL, V142, P4058; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nunes JA, 1996, MOL IMMUNOL, V33, P63, DOI 10.1016/0161-5890(95)00121-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OEHM A, 1992, J BIOL CHEM, V267, P10709; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STEVENSON MA, 1994, CANCER RES, V54, P12; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	78	294	300	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22173	22181		10.1074/jbc.272.35.22173	http://dx.doi.org/10.1074/jbc.272.35.22173			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268362	hybrid			2022-12-27	WOS:A1997XT85000074
J	Cornet, F; Hallet, B; Sherratt, DJ				Cornet, F; Hallet, B; Sherratt, DJ			Xer recombination in Escherichia coli - Site-specific DNA topoisomerase activity of the XerC and XerD recombinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINUS REGION; FLP RECOMBINASE; INTEGRASE FAMILY; GENE-PRODUCT; IN-VITRO; CHROMOSOME; DIF; MECHANISM; CER; IDENTIFICATION	Xer site-specific recombination functions in maintaining circular replicons in the monomeric state in Escherichia coli. Two recombinases of the bacteriophage A integrase family, XerC and XerD, are required for recombination at the chromosomal site, dif, and at a range of plasmid-borne sites. Xer recombination core sites contain the 11-base pair binding sites for each recombinase separated by a 6 to 8-base pair central region. We report that both XerC and XerD act as site-specific type I topoisomerases by relaxing supercoiled plasmids containing a dif site. Relaxation by either XerC or XerD occurs in the absence of the partner recombinase and requires only a single recombination core site, XerC or XerD relaxation activities are completely inhibited by the addition of the partner recombinase, providing that the DNA recognition sequence for the inhibiting partner is present.	UNIV OXFORD,DEPT BIOCHEM,MICROBIOL UNIT,OXFORD OX1 3QU,ENGLAND	University of Oxford			Cornet, Francois/A-9201-2008	Cornet, Francois/0000-0001-8576-7451	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABREMSKI K, 1986, J BIOL CHEM, V261, P391; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; Arciszewska L, 1997, EMBO J, V16, P3731, DOI 10.1093/emboj/16.12.3731; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; Blakely G, 1996, GENE DEV, V10, P762, DOI 10.1101/gad.10.6.762; BLAKELY G, 1991, NEW BIOL, V3, P789; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; Blakely GW, 1997, J MOL BIOL, V265, P30, DOI 10.1006/jmbi.1996.0709; BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; CLERGET M, 1991, NEW BIOL, V3, P780; COLLOMS SD, 1990, J BACTERIOL, V172, P6973, DOI 10.1128/jb.172.12.6973-6980.1990; Colloms SD, 1996, EMBO J, V15, P1172, DOI 10.1002/j.1460-2075.1996.tb00456.x; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; EVANS BR, 1990, J BIOL CHEM, V265, P18504; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KUEMPEL PL, 1991, NEW BIOL, V3, P799; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LESLIE NR, 1995, EMBO J, V14, P1561, DOI 10.1002/j.1460-2075.1995.tb07142.x; LOVETT ST, 1991, J BACTERIOL, V173, P353, DOI 10.1128/jb.173.1.353-364.1991; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; NUNESDUBY, 1995, EMBO J, V13, P4421; PAN GH, 1992, J BIOL CHEM, V267, P12397; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; ROCCA J, 1995, TRENDS BIOCHEM SCI, V20, P156; Sambrook J., 2002, MOL CLONING LAB MANU; SHERRATT DJ, 1995, PHILOS T ROY SOC B, V347, P37, DOI 10.1098/rstb.1995.0006; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; SUMMERS DK, 1989, EMBO J, V8, P309, DOI 10.1002/j.1460-2075.1989.tb03378.x; TECKLENBURG M, 1995, P NATL ACAD SCI USA, V92, P1352, DOI 10.1073/pnas.92.5.1352; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	31	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21927	21931		10.1074/jbc.272.35.21927	http://dx.doi.org/10.1074/jbc.272.35.21927			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268326	hybrid			2022-12-27	WOS:A1997XT85000038
J	Holden, M; Mayhew, M; Bunk, D; Roitberg, A; Vilker, V				Holden, M; Mayhew, M; Bunk, D; Roitberg, A; Vilker, V			Probing the interactions of putidaredoxin with redox partners in camphor p450 5-monooxygenase by mutagenesis of surface residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; ELECTRON-TRANSFER; REDUCED PUTIDAREDOXIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; OXIDIZED PUTIDAREDOXIN; AFFECT BINDING; REDUCTASE; IDENTIFICATION; EXPRESSION	The role of surface amino acid residues in the interaction of putidaredoxin (Pdx) with its redox partners in the cytochrome P450(cam) (CYP101) system was investigated by site-directed mutagenesis. The mutated Pdx genes were expressed in Escherichia coli, and the proteins were purified and studied in vitro. Activity of the complete reconstituted P450(cam) system was measured, and kinetic parameters were determined, Partial assays were also conducted to determine the effect of the mutations on interactions with each redox partner. Some mutations altered interactions of Pdx with one redox partner but not the other, Other mutations affected interactions with both redox partners, suggesting some overlap in the binding sites on Pdx for putidaredoxin reductase and CYP101. Cysteine 73 of Pdx was identified as important in the interaction of Pdx with putidaredoxin reductase, whereas aspartate 38 serves a critical role in the subunit binding and electron transfer to CYP101.	NIST, CHEM SCI & TECHNOL LAB, DIV ANALYT CHEM, GAITHERSBURG, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA	Holden, M (corresponding author), NIST, CHEM SCI & TECHNOL LAB, DIV BIOTECHNOL, GAITHERSBURG, MD 20899 USA.		Roitberg, Adrian E/A-2378-2009					BECKERT V, 1994, J BIOL CHEM, V269, P2568; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; DAVIES MD, 1992, BIOCHEMISTRY-US, V31, P11383, DOI 10.1021/bi00161a016; DAVIES MD, 1990, J AM CHEM SOC, V112, P7396, DOI 10.1021/ja00176a050; GERBER NC, 1990, BIOCHEM BIOPH RES CO, V169, P1016, DOI 10.1016/0006-291X(90)91995-5; GEREN L, 1986, J BIOL CHEM, V261, P5491; Grayson DA, 1996, ARCH BIOCHEM BIOPHYS, V332, P239, DOI 10.1006/abbi.1996.0338; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; KOGA H, 1985, BIOCHEM BIOPH RES CO, V130, P412, DOI 10.1016/0006-291X(85)90432-2; KOGA H, 1989, J BIOCHEM-TOKYO, V106, P831, DOI 10.1093/oxfordjournals.jbchem.a122939; KOGA H, 1993, FEBS LETT, V331, P109, DOI 10.1016/0014-5793(93)80307-G; MOSELEY MA, 1991, ANAL CHEM, V63, P1467, DOI 10.1021/ac00014a023; Mueller Ernest J., 1995, P83; NAKAMURA K, 1994, BBA-PROTEIN STRUCT M, V1207, P40, DOI 10.1016/0167-4838(94)90049-3; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6433, DOI 10.1021/bi00187a007; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6424, DOI 10.1021/bi00187a006; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; ROOME PW, 1983, J BIOL CHEM, V258, P2593; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sibbesen O, 1996, J BIOL CHEM, V271, P22462, DOI 10.1074/jbc.271.37.22462; UNGER BP, 1986, J BIOL CHEM, V261, P1158; Unno M, 1996, J BIOL CHEM, V271, P17869, DOI 10.1074/jbc.271.30.17869; WADA A, 1992, J BIOL CHEM, V267, P22877; YE XM, 1992, BIOCHEMISTRY-US, V31, P1961, DOI 10.1021/bi00122a009	29	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21720	21725		10.1074/jbc.272.35.21720	http://dx.doi.org/10.1074/jbc.272.35.21720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268300	hybrid			2022-12-27	WOS:A1997XT85000012
J	Salet, C; Moreno, G; Ricchelli, F; Bernardi, P				Salet, C; Moreno, G; Ricchelli, F; Bernardi, P			Singlet oxygen produced by photodynamic action causes inactivation of the mitochondrial permeability transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; HEMATOPORPHYRIN DERIVATIVE PHOTOFRIN; CYCLOSPORINE-A; II PHOTOSENSITIZATION; MEMBRANE; INHIBITION; AGENTS; CA2+; TRANSLOCATOR; CYCLOPHILIN	We have studied the effects of singlet oxygen produced by photodynamic action on the cyclosporin A-sensitive permeability transition (PT) in isolated rat liver mitochondria. Mitochondria were incubated with 3 mu M hematoporphyrin and irradiated at 365 nm with a fluence rate of 25 watts/m(2). For short durations of irradiation (60 s) the adenine nucleotide translocase was inactivated, but mitochondria retained their ability to form a proton electrochemical gradient and accumulated Ca2+ and P-i at the same rate as non-irradiated controls, Strikingly, however, the oxidative effects of photodynamic action prevented opening of the PT pore which is normally induced by Ca2+ plus P-i or by treatment with diethyl pyrocarbonate (a histidine reagent) or diamide (a thiol oxidant), We show that the most likely targets for photodynamic action are critical histidines that undergo degradation. Irradiated, hematoporphyrin-loaded mitochondria treated with diethyl pyrocarbonate or diamide still undergo the PT when treated with phenylarsine oxide, which reacts with a critical dithiol involved in pore modulation (Petronilli, V,, Costantini, P,, Scorrano, L., Colonna, R,, Passamonti, S,, and Pernardi, P, (1994) J, Biol. Chem. 269, 16638-16642), These data suggest (i) that the dithiol cysteines are not oxidized by photodynamic action, but rather became inaccessible to oxidants; and (ii) that irradiation of hematoporphyrin-loaded mitochondria does not lead to pore denaturation, but rather to site-selective inactivation of discrete pore functional domains.	UNIV PADUA,CNR,CTR METALLOPROT,DIPARTIMENTO BIOL,I-35121 PADUA,ITALY; UNIV PADUA,CTR BIOMEMBRANE,DIPARTIMENTO SCI BIOMED SPERIMENTALI,I-35121 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Salet, C (corresponding author), MUSEUM NATL HIST NAT,LABS BIOPHYS & PHOTOBIOL,CNRS URA 481,INSERM,U201,43 RUE CUVIER,F-75231 PARIS 05,FRANCE.		Bernardi, Paolo/C-3656-2008	Bernardi, Paolo/0000-0001-9187-3736				ATLANTE A, 1989, J PHOTOCH PHOTOBIO B, V4, P35, DOI 10.1016/1011-1344(89)80100-9; ATLANTE A, 1990, J PHOTOCH PHOTOBIO B, V7, P21, DOI 10.1016/1011-1344(90)85140-R; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BRAGADIN M, 1980, BIOCHEMISTRY-US, V18, P5972; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; CHAPPEL GB, 1967, BIOCH MITOCHONDRIA, P75; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; DOUGHERTY TJ, 1993, PHOTOCHEM PHOTOBIOL, V58, P895, DOI 10.1111/j.1751-1097.1993.tb04990.x; HARIHARAN PV, 1980, INT J RADIAT BIOL, V37, P691, DOI 10.1080/713857576; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141, DOI 10.1152/ajpcell.1995.269.1.C141; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; PASSARELLA S, 1988, BIOCHEM BIOPH RES CO, V156, P978, DOI 10.1016/S0006-291X(88)80940-9; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; RICCHELLI F, 1993, PHOTOCHEM PHOTOBIOL, V58, P53, DOI 10.1111/j.1751-1097.1993.tb04903.x; RICCHELLI F, 1995, EUR J BIOCHEM, V233, P165, DOI 10.1111/j.1432-1033.1995.165_1.x; SALET C, 1990, J PHOTOCH PHOTOBIO B, V5, P133, DOI 10.1016/1011-1344(90)80002-F; Salet C, 1997, FREE RADICAL RES, V26, P201, DOI 10.3109/10715769709097800; SALET C, 1983, BIOCHEM BIOPH RES CO, V115, P76, DOI 10.1016/0006-291X(83)90970-1; SALET C, 1991, PHOTOCHEM PHOTOBIOL, V53, P391; SALET C, 1982, PHOTOCHEM PHOTOBIOL, V36, P291, DOI 10.1111/j.1751-1097.1982.tb04377.x; SALET C, 1981, INT J RADIAT BIOL, V399, P227; SANDBERG S, 1980, BIOCHIM BIOPHYS ACTA, V593, P187, DOI 10.1016/0005-2728(80)90056-0; STRAIGHT RC, 1985, SINGLET O2, V4, P92; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; TOMITA M, 1969, BIOCHEMISTRY-US, V8, P5149, DOI 10.1021/bi00840a069; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	35	77	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21938	21943		10.1074/jbc.272.35.21938	http://dx.doi.org/10.1074/jbc.272.35.21938			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268328	hybrid			2022-12-27	WOS:A1997XT85000040
J	Zhao, WN; McAlisterHenn, L				Zhao, WN; McAlisterHenn, L			Affinity purification and kinetic analysis of mutant forms of yeast NAD(+)-specific isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE; PHOSPHORYLATION; CLONING; BINDING; ENZYME; EXPRESSION; SEQUENCE; SUBUNITS	Polyhistidine tags were added to the carboxyl termini of the two homologous subunits of yeast NAD(+)-specific isocitrate dehydrogenase (IDH). The tag in either the IDH1 or IDH2 subunit permits one step affinity purification from yeast cellular extracts of catalytically active and allosterically responsive holoenzyme. This expression system was used to investigate subunit-specific contributions of residues with putative functions in adenine nucleotide binding, The primary effect of simultaneous replacement of the adjacent Asp-279 and Ile-280 residues in IDH1 with alanines is a dramatic loss of activation by AMP. In contrast, alanine replacement of the homologous Asp-286 and Ile-287 residues in IDH2 does not alter the allosteric response to AMP, but produces a 160-fold reduction in V-max due to a 70-fold increase in the S-0.5 value for NAD(+), These results suggest that the targeted aspartate/isoleucine residues may con tribute to regulator binding in IDH1 and to cofactor binding in IDHS, i.e. that these homologous residues are located in regions that have evolved for binding the adenine nucleotide components of different ligands, In other mutant enzymes, an alanine replacement of Asp 191 in IDH1 eliminates measurable catalytic activity, and a similar substitution of the homologous Asp-197 in IDH2 produces pleiotropic catalytic effects, A model is presented for the primary function of IDH2 in catalysis and of IDH1 in regulation, with crucial roles for these single aspartate residues in the communication and functional interdependence of the two subunits.	UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BARNES LD, 1972, BIOCHEMISTRY-US, V11, P4322, DOI 10.1021/bi00773a019; BOTSTEIN D, 1979, GENE, V9, P12; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHEN FR, 1963, BIOCHEMISTRY-US, V2, P1023, DOI 10.1021/bi00905a020; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DEAN AM, 1989, J BIOL CHEM, V264, P20482; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; HENGEN PN, 1995, TRENDS BIOCHEM SCI, V20, P285, DOI 10.1016/S0968-0004(00)89045-3; HUANG Y, 1986, J BIOL CHEM, V261, P14100; HUANG YC, 1989, J BIOL CHEM, V264, P12208; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; ILLINGWORTH JA, 1972, BIOCHEM J, V129, P1119, DOI 10.1042/bj1291119; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KUEHN GD, 1971, BIOCHEMISTRY-US, V10, P3945, DOI 10.1021/bi00797a023; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; NICHOLS BJ, 1993, BIOCHEM J, V295, P347, DOI 10.1042/bj2950347; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIKORSKI RS, 1989, GENETICS, V122, P19; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; Zhao WN, 1996, J BIOL CHEM, V271, P10347, DOI 10.1074/jbc.271.17.10347	32	33	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21811	21817		10.1074/jbc.272.35.21811	http://dx.doi.org/10.1074/jbc.272.35.21811			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268311	hybrid			2022-12-27	WOS:A1997XT85000023
J	Liden, J; Delaunay, F; Rafter, I; Gustafsson, JA; Okret, S				Liden, J; Delaunay, F; Rafter, I; Gustafsson, JA; Okret, S			A new function for the C-terminal zinc finger of the glucocorticoid receptor - Repression of RelA transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1; THYROID-HORMONE RECEPTORS; DNA-BINDING; TRANSCRIPTION FACTOR; MEDIATED REPRESSION; ESTROGEN-RECEPTOR; TRANS-ACTIVATION; RESPONSE ELEMENT; GENE-EXPRESSION	Glucocorticoids inhibit NF-kappa B signaling by interfering with the NF-kappa B transcription factor RelA, Previous studies have identified the DNA binding domain (DBD) in the glucocorticoid receptor (GR) as the major region responsible for this repressive activity, Using GR mutants with chimeric DBDs the repressive function was found to be located in the C-terminal zinc finger, As predicted from these results the mineralocorticoid receptor that contains a C-terminal zinc finger identical to that of the GR was also able to repress RelA-dependent transcription, Mutation of a conserved arginine or a lysine in the second zinc finger of the GR DBD (Arg-488 or Lys-490 in the rat GR) abolished the ability of GR to inhibit RelA activity, In contrast, C-terminal zinc finger GR mutants with mutations in the dimerization box or mutations necessary for full transcriptional GR activity were still able to repress RelA-dependent transcription. In addition, we found that the steroid analog ZK98299 known to induce GR transrepression of AP-1 had no inhibitory effect on RelA activity, In summary, these results demonstrate that the inhibition of NF-kappa B by glucocorticoids involves two critical amino acids in the C-terminal zinc finger of the GR. Furthermore, the results from the use of mineralocorticoid receptor and anti-glucocorticoids suggest that the mechanisms for GR-mediated repression of NF-kappa B and AP-1 are different.	HUDDINGE UNIV HOSP,KAROLINSKA INST,NOVUM F60,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet				Delaunay, Franck/0000-0003-4927-1701				Akerblom I.W., 1991, NUCLEAR HORMONE RECE, P175; ALI SA, 1995, BIOTECHNIQUES, V18, P746; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BEAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CARLSTEDTDUKE J, 1995, ENDOCRINOL METAB, P169; CATO ACB, 1992, J STEROID BIOCHEM, V43, P63, DOI 10.1016/0960-0760(92)90188-O; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DRCUIN J, 1993, EMBO J, V12, P145; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kleinert H, 1996, MOL PHARMACOL, V49, P15; LAUDET V, 1995, PROTEIN PROFILE, V2, P1173; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Ohtsuka T, 1996, J BIOL CHEM, V271, P1651, DOI 10.1074/jbc.271.3.1651; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZILLIACUS J, 1992, J BIOL CHEM, V267, P24941; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	52	133	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21467	21472		10.1074/jbc.272.34.21467	http://dx.doi.org/10.1074/jbc.272.34.21467			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261164	hybrid			2022-12-27	WOS:A1997XR78900074
J	Meng, JJ; Bornslaeger, EA; Green, KJ; Steinert, PM; Ip, W				Meng, JJ; Bornslaeger, EA; Green, KJ; Steinert, PM; Ip, W			Two-hybrid analysis reveals fundamental differences in direct interactions between desmoplakin and cell type-specific intermediate filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLOUS PEMPHIGOID ANTIGEN; PROTEIN-PROTEIN INTERACTIONS; DESMOSOMAL PLAQUE; SACCHAROMYCES-CEREVISIAE; CULTURED-CELLS; KERATIN; YEAST; TERMINUS; NETWORKS; PLECTIN	Desmosomes are cell junctions that act as sites of strong intercellular adhesion and also serve to anchor the intermediate filament (IF) cytoskeleton to the plasma membrane of a variety of cell types, Previous studies demonstrated that the COOH terminus of the desmosomal plaque protein, desmoplakin (DP), is required for the association of DP with IF networks in cultured cells and that this domain interacts directly with type II epidermal keratin polypeptides in vitro. However, these studies left open the question of how desmosomes might anchor other IF types known to associate with these junctions. In this report we used yeast two-hybrid and in vitro dot blot assays to further examine the requirements for direct interactions between desmoplakin and various IF types. Our results confirm the ability of the DP COOH terminus (DPCT) to interact with at least two regions of the head domain of the type II epidermal keratin K1 and also demonstrate that DPCT can interact with the type III IF family members, vimentin and desmin, as well as simple epithelial keratins. Unlike the situation for type II epidermal keratins, the interaction between DPCT and simple epithelial keratins appears to depend on heterodimerization of the type I and II keratin polypeptides, since both are required to detect an interaction. Furthermore, although the interaction between DPCT and K1 requires the keratin head domain, deletion of this domain from the simple epithelial keratins does not compromise interaction with DPCT. The interaction between DPCT and type III or simple epithelial keratins also appeared to be less robust than that between DPCT and K1, In the case of K8/K18, however, the interaction as assessed by yeast two-hybrid assays increased 9-fold when a serine located in a protein kinase A consensus phosphorylation site 23 residues from the end of DP was altered to a glycine. Taken together, these data indicate that DP interacts directly with different IF types in specific ways.	UNIV CINCINNATI, COLL MED, DEPT ANAT CELL BIOL & NEUROBIOL, CINCINNATI, OH 45267 USA; NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT DERMATOL, CHICAGO, IL 60611 USA; NIAMS, SKIN BIOL LAB, NIH, BETHESDA, MD 20892 USA	University System of Ohio; University of Cincinnati; Northwestern University; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)					NIAMS NIH HHS [R01 AR43380, R01 AR35973] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035973, R01AR043380] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; CANDI E, 1997, IN PRESS P NATL ACAD; Carpenter DA, 1996, J CELL SCI, V109, P2493; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; COLLINS JE, 1994, MOL BIOL DESMOSOMES; Cowin P, 1985, CELL CONTACT, P427; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fujiwara S, 1996, J INVEST DERMATOL, V106, P1125, DOI 10.1111/1523-1747.ep12340171; Gache Y, 1996, J CLIN INVEST, V97, P2289, DOI 10.1172/JCI118671; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; Green Kathleen J., 1994, P157; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; GREEN KJ, 1992, INT J BIOL MACROMOL, V14, P145, DOI 10.1016/S0141-8130(05)80004-2; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HATZFELD M, 1994, J CELL SCI, V107, P1959; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; JONES JCR, 1985, J CELL BIOL, V101, P506, DOI 10.1083/jcb.101.2.506; Jones JCR, 1991, CURR OPIN CELL BIOL, V3, P127, DOI 10.1016/0955-0674(91)90175-X; KAPPRELL HP, 1988, J CELL BIOL, V106, P1679, DOI 10.1083/jcb.106.5.1679; KARTASOVA T, 1993, J CELL BIOL, V120, P1251, DOI 10.1083/jcb.120.5.1251; KIMONIS V, 1994, J INVEST DERMATOL, V103, P764, DOI 10.1111/1523-1747.ep12412771; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1996, CURR TOP MEMBR, V43, P187; Leung CL, 1996, J BIOL CHEM, V271, P14041, DOI 10.1074/jbc.271.24.14041; McLean WHI, 1996, GENE DEV, V10, P1724, DOI 10.1101/gad.10.14.1724; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; Nikolic B, 1996, J CELL BIOL, V134, P1455, DOI 10.1083/jcb.134.6.1455; OKEEFE EJ, 1989, J BIOL CHEM, V264, P8310; Pin OY, 1996, J CELL BIOL, V135, P1027, DOI 10.1083/jcb.135.4.1027; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; SCHMIDT A, 1994, EUR J CELL BIOL, V65, P229; SCHWARZ MA, 1990, ANNU REV CELL BIOL, V6, P461, DOI 10.1146/annurev.cb.06.110190.002333; SIKORSKI RS, 1989, GENETICS, V122, P19; SKALLI O, 1994, J CELL BIOL, V125, P159, DOI 10.1083/jcb.125.1.159; Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; STAPPENBECK TS, 1994, J BIOL CHEM, V269, P29351; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; STEINBERG MS, 1987, CIBA F SYMP, V125, P3; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; TANAKA T, 1991, J BIOL CHEM, V266, P12555; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIRATA MLA, 1992, P NATL ACAD SCI USA, V89, P544, DOI 10.1073/pnas.89.2.544; WICHE G, 1991, J CELL BIOL, V114, P83, DOI 10.1083/jcb.114.1.83; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607; YE QA, 1995, EXP CELL RES, V219, P292, DOI 10.1006/excr.1995.1230; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	54	132	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21495	21503		10.1074/jbc.272.34.21495	http://dx.doi.org/10.1074/jbc.272.34.21495			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261168	hybrid			2022-12-27	WOS:A1997XR78900078
J	Meyer, T; Starr, DB; CarlstedtDuke, J				Meyer, T; Starr, DB; CarlstedtDuke, J			The rat glucocorticoid receptor mutant K461A differentiates between two different mechanisms of transrepression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; STEROID-HORMONE RECEPTORS; NF-KAPPA-B; RESPONSE ELEMENT; NEGATIVE REGULATION; GENE-EXPRESSION; TRANSCRIPTION FACTORS; OSTEOCALCIN GENE; GLA PROTEIN; REPRESSION	The glucocorticoid receptor (GR) can both activate and repress transcription of target genes by interaction with specific genomic response elements, glucocorticoid response elements (GREs). Activation of transcription is usually the result of the direct interaction between GR and the GRE, whereas GR-mediated transcription repression is either the result of the indirect action of GPE, mediated by a response element as a result of protein protein interaction or by an occlusion mechanism in which GR displaces a general or regulatory transcription factor, A specific mutation of rat GR, K461A, has previously been described to transform the indirect protein protein interaction-dependent transrepressive effect of GR into an activating function (Starr, D, B., Matsui, W,, Thomas, J. R,, and Yamamoto, K, R, (1996) Genes Dev. 10, 1271-1283), In HOS D4 and COS7 cells, this mutation was shown to transform the transrepressive effect of wild-type GR, acting on reporter constructs containing the composite GRE from the proliferin gene (plfG) or the negative tethering GRE from the collagenase A promoter (colA), into an activating function, In contrast, the K461A mutation had no effect on the transrepressive effect of GR on the human osteocalcin gene in which repression apparently occurs through the binding of GR to a negative GRE that overlaps the TATA box, The transrepressive function, typically 40% of the basal level in the absence of hormone, required only the isolated DNA-binding domain of wild type or mutant GR and was independent of the nature of transactivation domain, Thus, mutation of rat GR at position 461 differentiates between transrepressive functions of GR dependent oil GR DNA interaction (repression by occlusion) and GR protein interaction (active repression).	HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT MED NUTR,NOVUM,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT BIOSCI,NOVUM,S-14186 HUDDINGE,SWEDEN; UNIV CALIF SAN FRANCISCO,PIBS BIOCHEM & MOL BIOL PROGRAM,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PIBS BIOCHEM & MOL BIOL PROGRAM,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Karolinska Institutet; Karolinska Institutet; University of California System; University of California San Francisco; University of California System; University of California San Francisco								AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BIRNBERG NC, 1983, P NATL ACAD SCI-BIOL, V80, P6982, DOI 10.1073/pnas.80.22.6982; CAIRNS C, 1993, DNA CELL BIOL, V12, P695, DOI 10.1089/dna.1993.12.695; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HEINRICHS AAJ, 1993, BIOCHEMISTRY-US, V32, P11436, DOI 10.1021/bi00093a022; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARAGIANNI N, 1994, ONCOGENE, V9, P2327; KARIN M, 1993, EUR J CLIN PHARMACOL, V45, pS43; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEYER T, 1997, IN PRESS DNA CELL BI, V16; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Pei L, 1996, J BIOL CHEM, V271, P20879; RIEGEL AT, 1991, MOL ENDOCRINOL, V5, P1973, DOI 10.1210/mend-5-12-1973; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WEINER FR, 1987, J BIOL CHEM, V262, P6955	38	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21090	21095		10.1074/jbc.272.34.21090	http://dx.doi.org/10.1074/jbc.272.34.21090			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261112	hybrid			2022-12-27	WOS:A1997XR78900022
J	Smith, MD; Morris, PJ; Dawson, SJ; Schwartz, ML; Schlaepfer, WW; Latchman, DS				Smith, MD; Morris, PJ; Dawson, SJ; Schwartz, ML; Schlaepfer, WW; Latchman, DS			Coordinate induction of the three neurofilament genes by the Brn-3a transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU-DOMAIN PROTEIN; INTERMEDIATE FILAMENTS; ALPHA-INTERNEXIN; NEURONAL CELLS; REPORTER GENE; HEAVY GENE; IN-VITRO; FAMILY; EXPRESSION; ACID	The POU domain transcription factor Brn-3a is able to stimulate neurite outgrowth when overexpressed in the neuronal ND7 cell line, whereas the closely related Brn-3b factor does not have this effect. We show that Brn-3a overexpression also enhances the expression of the three neurofilament genes at both the mRNA and protein levels, whereas Brn-3b overexpression has no effect. In addition Brn-3a activates the three neurofilament gene promoters in co-transfection assays in both neuronal and non-neuronal cells. As observed for enhanced neurite outgrowth, the stimulation of neurofilament gene expression and activation of the neurofilament gene promoters is observed with the isolated POU domain of Brn-3a. A single amino acid change in the POU homeodomain of Bm-Ba to the equivalent amino acid in Brn-3b abolishes its ability to activate the neurofilament promoters, whereas the reciprocal change converts Brn-3b to an activator of these promoters.	UCL, SCH MED, DEPT MOL PATHOL, LONDON W1P 6DB, ENGLAND; UNIV PENN, SCH MED, DIV NEUROPATHOL, PHILADELPHIA, PA 19104 USA	University of London; University College London; UCL Medical School; University of Pennsylvania				Dawson, Sally/0000-0002-4421-2043				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BudhramMahadeo V, 1996, J BIOL CHEM, V271, P9108, DOI 10.1074/jbc.271.15.9108; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1991, J CELL SCI, P85; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Dawson SJ, 1996, J BIOL CHEM, V271, P11631, DOI 10.1074/jbc.271.20.11631; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FLIEGNER KH, 1990, EMBO J, V9, P749, DOI 10.1002/j.1460-2075.1990.tb08169.x; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; Liem RKH, 1990, CURR OPIN CELL BIOL, V2, P86, DOI 10.1016/S0955-0674(05)80036-5; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Liu YZ, 1996, J MOL NEUROSCI, V7, P77, DOI 10.1007/BF02736850; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; Marszalek JR, 1996, J CELL BIOL, V135, P711, DOI 10.1083/jcb.135.3.711; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Morris PJ, 1996, MOL BRAIN RES, V43, P279, DOI 10.1016/S0169-328X(96)00207-0; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; SAKAGUCHI T, 1993, NEUROSCI LETT, V153, P65, DOI 10.1016/0304-3940(93)90078-Y; SCHWARTZ ML, 1994, J BIOL CHEM, V269, P13444; SHNEIDMAN PS, 1992, MOL BRAIN RES, V13, P127, DOI 10.1016/0169-328X(92)90052-D; Smith MD, 1997, J BIOL CHEM, V272, P1382, DOI 10.1074/jbc.272.2.1382; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Xu ZS, 1996, J CELL BIOL, V133, P1061, DOI 10.1083/jcb.133.5.1061	52	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21325	21333		10.1074/jbc.272.34.21325	http://dx.doi.org/10.1074/jbc.272.34.21325			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261145	hybrid			2022-12-27	WOS:A1997XR78900055
J	Hu, JF; Vu, TH; Hoffman, AR				Hu, JF; Vu, TH; Hoffman, AR			Genomic deletion of an imprint maintenance element abolishes imprinting of both insulin-like growth factor II and H19	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR; MOUSE; GENE; METHYLATION; IGF2; EXPRESSION; ACTIVATION; RELAXATION; PROMOTERS; ALLELE	Insulin-like growth factor II (Igf2) is maternally imprinted in normal tissues with only the paternal copy of the gene being transcribed, whereas the contiguous gene H19 is paternally imprinted. Dysregulation of IGF2 imprinting is commonly observed in Wilns' tumor and other human tumors. Previous work comparing promoter-specific imprinting of human and mouse Igf2 suggested the presence of a cis element upstream of Igf2 that regulates or maintains the imprinting of three downstream promoters, To explore the molecular mechanism of maintenance of genomic imprinting, we targeted the region between insulin 2 and Igf2, where the cis imprint maintenance element (IME) resides in mouse fibroblasts, In those clones in which the targeting vector was randomly integrated into the genome, mouse Igf2 remained imprinted. However, when the targeted region containing the IME was deleted by homologous recombination, whether from the paternal or maternal allele, activation of the imprinted maternal allele of Igf2 was observed. In addition, there was a loss of H19 imprinting when the IME was deleted, The requirement of IME from both parental alleles for the maintenance of genomic imprinting thus suggests the importance of a spatial structure of DNA around Igf2 and H19, Modifications in the IME, like abnormal methylation in Wilms' tumors, may represent a novel mechanism for loss of genomic imprinting.	VET AFFAIRS PALO ALTO HLTH CARE SYST,GRECC,PALO ALTO,CA 94304; VET AFFAIRS PALO ALTO HLTH CARE SYST,MED SERV,PALO ALTO,CA 94304; STANFORD UNIV,DEPT MED,DIV ENDOCRINOL GERONTOL & METAB,PALO ALTO,CA 94304	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University			Hu, Jifan/Q-3003-2019	HU, Jifan/0000-0002-2174-0361	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036054] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36054] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANERJEE S, 1995, NAT GENET, V11, P237, DOI 10.1038/ng1195-237; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DELTOUR L, 1995, DEV BIOL, V168, P686, DOI 10.1006/dbio.1995.1114; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; FEIL R, 1994, DEVELOPMENT, V120, P2933; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; Hu JF, 1996, J BIOL CHEM, V271, P18253, DOI 10.1074/jbc.271.30.18253; KOU K, 1993, MOL ENDOCRINOL, V7, P291, DOI 10.1210/me.7.2.291; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LIU JQ, 1995, J CLIN ENDOCR METAB, V80, P492, DOI 10.1210/jc.80.2.492; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1994, DEVELOPMENT, V120, P361; Pfeifer K, 1996, P NATL ACAD SCI USA, V93, P13876, DOI 10.1073/pnas.93.24.13876; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SZABO P, 1994, DEVELOPMENT, V120, P1651; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; VILLAR AJ, 1995, DEV BIOL, V172, P264, DOI 10.1006/dbio.1995.0021; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; Vu TH, 1996, J BIOL CHEM, V271, P9014, DOI 10.1074/jbc.271.15.9014; WENTWORTH BM, 1986, J MOL EVOL, V23, P305, DOI 10.1007/BF02100639; Yballe CM, 1996, J CLIN ENDOCR METAB, V81, P1607, DOI 10.1210/jc.81.4.1607; ZHAN SL, 1995, J BIOL CHEM, V270, P27983; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	39	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20715	20720		10.1074/jbc.272.33.20715	http://dx.doi.org/10.1074/jbc.272.33.20715			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252392	hybrid			2022-12-27	WOS:A1997XR22100062
J	Newton, JP; Buckley, CD; Jones, EY; Simmons, DL				Newton, JP; Buckley, CD; Jones, EY; Simmons, DL			Residues on both faces of the first immunoglobulin fold contribute to hemophilic binding sites of PECAM-1/CD31	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; CARCINOEMBRYONIC ANTIGEN; MONOCLONAL-ANTIBODIES; CD31; CLONING; DOMAIN; SUPERFAMILY; RECOGNITION; LEUKOCYTES; LIGAND	CD31 (PECAM-1) is a member of the immunoglobulin superfamily whose extracellular domain is comprised of six immunoglobulin-like domains. It is widely expressed on endothelium, platelets, around 50% of lymphocytes, and cells of myeloid lineage. CD31 has been shown to be involved in interendothelial adhesion and leukocyte endothelial interactions, particularly during transmigration, CD31-mediated adhesion is complex, because CD31 is capable of mediating both hemophilic and multiple heterophilic adhesive interactions, Here we show that the NH2-terminal (membrane-distal) immunoglobulin domain of CD31 is necessary but not sufficient to support stable hemophilic adhesion, Key residues forming the binding site within this domain have been identified by analysis of 26 single point mutations, representing the most systematic analysis of a fully hemophilic interaction between immunoglobulin superfamily family members to date. This revealed five mutations that affect hemophilic binding, Uniquely, the residues involved are exposed on both faces of the immunoglobulin fold, leading us to propose a novel mechanism for CD31 hemophilic adhesion.	UNIV OXFORD, DEPT BIOCHEM, LAB MOL BIOPHYS, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, DEPT BIOCHEM, OXFORD CTR MOL SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP,CELL ADHES GRP,INST MOL MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND	University of Oxford; University of Oxford; Cancer Research UK; University of Oxford			Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BOSSY D, 1995, EUR J IMMUNOL, V25, P459, DOI 10.1002/eji.1830250223; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Buchstaller A, 1996, J CELL BIOL, V135, P1593, DOI 10.1083/jcb.135.6.1593; Buckley CD, 1996, J CELL SCI, V109, P437; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; FAWCETT J, 1995, J CELL BIOL, V128, P1229, DOI 10.1083/jcb.128.6.1229; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; GOLDBERGER A, 1994, J BIOL CHEM, V269, P17183; Hancock D C, 1992, Methods Mol Biol, V10, P23, DOI 10.1385/0-89603-204-3:23; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIAO F, 1995, J EXP MED, V182, P1337, DOI 10.1084/jem.182.5.1337; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Murohara T, 1996, J IMMUNOL, V156, P3550; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; Newham P, 1996, MOL MED TODAY, V2, P304, DOI 10.1016/1357-4310(96)10021-6; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OHTO H, 1985, BLOOD, V66, P873; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Prager E, 1996, J EXP MED, V184, P41, DOI 10.1084/jem.184.1.41; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1993, J BIOL CHEM, V268, P20630; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; Rival Y, 1996, J IMMUNOL, V157, P1233; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; Sun J, 1996, J BIOL CHEM, V271, P18561, DOI 10.1074/jbc.271.31.18561; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VANMOURIK JA, 1985, J BIOL CHEM, V260, P1300; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Wakelin MW, 1996, J EXP MED, V184, P229, DOI 10.1084/jem.184.1.229; WATT SM, 1994, BLOOD, V84, P200; YAN HC, 1995, J BIOL CHEM, V270, P23672, DOI 10.1074/jbc.270.40.23672; YAN HC, 1995, CELL ADHES COMMUN, V3, P45, DOI 10.3109/15419069509081277; ZEHNDER JL, 1995, BLOOD, V85, P1282, DOI 10.1182/blood.V85.5.1282.bloodjournal8551282; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	56	107	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20555	20563		10.1074/jbc.272.33.20555	http://dx.doi.org/10.1074/jbc.272.33.20555			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252369	hybrid, Green Published			2022-12-27	WOS:A1997XR22100039
J	Eberhardt, C; Gray, PW; Tjoelker, LW				Eberhardt, C; Gray, PW; Tjoelker, LW			Human lysophosphatidic acid acyltransferase - cDNA cloning, expression, and localization to chromosome 9q34.3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID; ESCHERICHIA-COLI; 1-ACYL-SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; MESANGIAL CELLS; PHOSPHOLIPASE-D; 2ND MESSENGER; RAT-BRAIN; IDENTIFICATION; FIBROBLASTS; PLATELETS	Lysophosphatidic acid (1-acyl-sn-glycero-3-phosphate (LPA)) is a phospholipid with diverse biological activities. The mediator serves as an intermediate in membrane phospholipid metabolism but is also produced in acute settings by activated platelets. LPA is converted to phosphatidic acid, itself a lipid mediator, by an LPA acyltransferase (LPAAT). A human expressed sequence tag was identified by homology with a coconut LPAAT and used to isolate a full-length human cDNA from a heart muscle library. The predicted amino acid sequence bears 33% identity with a Caenorhabditis elegans LPAAT homologue and 23-28% Identity with plant and prokaryotic LPAATs. Recombinant protein produced in COS 7 cells exhibited LPAAT activity with a preference for LPA as the acceptor phosphoglycerol and arachidonyl coenzyme A as the acyl donor. Northern blotting demonstrated that the mRNA is expressed in most human tissues including a panel of brain subregions; expression is highest in liver and pancreas and lowest in placenta. The human LPAAT gene is contained on six exons that map to chromosome 9, region q34.3.	ICOS CORP,BOTHELL,WA 98021	Icos Corporation								ABRAHAM E, 1995, J EXP MED, V181, P569, DOI 10.1084/jem.181.2.569; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BROWN AP, 1994, PLANT MOL BIOL, V26, P211, DOI 10.1007/BF00039533; BROWN AP, 1995, PLANT MOL BIOL, V29, P267, DOI 10.1007/BF00043651; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; BURSTEN SL, 1992, AM J PHYSIOL, V262, pC328, DOI 10.1152/ajpcell.1992.262.2.C328; BURSTEN SL, 1991, J BIOL CHEM, V266, P20732; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; HANKE C, 1995, EUR J BIOCHEM, V232, P806, DOI 10.1111/j.1432-1033.1995.tb20876.x; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1990, J BIOL CHEM, V265, P12232; Keller JN, 1996, J NEUROCHEM, V67, P2300; KESTER M, 1993, J CELL PHYSIOL, V156, P317, DOI 10.1002/jcp.1041560214; KNUTZON DS, 1995, PLANT PHYSIOL, V109, P999, DOI 10.1104/pp.109.3.999; LUTTINGER AL, 1991, NEW BIOL, V3, P687; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; RICE GC, 1994, P NATL ACAD SCI USA, V91, P3857, DOI 10.1073/pnas.91.9.3857; SOLING HD, 1989, J BIOL CHEM, V264, P10643; THOMPSON FJ, 1994, BIOCHEM J, V300, P457, DOI 10.1042/bj3000457; THOMSON FJ, 1995, BIOCHEM J, V306, P305, DOI 10.1042/bj3060305; TIGYI G, 1995, AM J PHYSIOL-HEART C, V268, pH2048, DOI 10.1152/ajpheart.1995.268.5.H2048; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; VANDERBEND RL, 1992, BIOCHIM BIOPHYS ACTA, V1125, P110, DOI 10.1016/0005-2760(92)90163-P; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; WATSON SP, 1985, BIOCHEM J, V232, P61, DOI 10.1042/bj2320061; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; XIE MS, 1994, ARCH BIOCHEM BIOPHYS, V312, P254, DOI 10.1006/abbi.1994.1307; XU Y, 1995, J CELL PHYSIOL, V163, P441, DOI 10.1002/jcp.1041630303; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0; ZHOU D, 1995, J BIOL CHEM, V270, P25549, DOI 10.1074/jbc.270.43.25549	44	108	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20299	20305		10.1074/jbc.272.32.20299	http://dx.doi.org/10.1074/jbc.272.32.20299			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242711	hybrid			2022-12-27	WOS:A1997XQ05900098
J	Hilchey, SP; Wu, L; Koudelka, GB				Hilchey, SP; Wu, L; Koudelka, GB			Recognition of nonconserved bases in the P22 operator by P22 repressor requires specific interactions between repressor and conserved bases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							434 REPRESSOR; CELL-DIVISION; NONCONTACTED BASES; ESCHERICHIA-COLI; DNA DODECAMER; ADENINE TRACT; AFFINITY; SEQUENCE; DOMAIN; COMPLEX	The ability of P22 repressor protein to distinguish between the six naturally occurring operator binding sites is critically important in determining whether the bacteriophage chooses to grow lytically or lysogenically. We have shown that changes in the highly conserved bases at P22 operator positions 3, 5, 6, and 7 prevent specific binding of P22 repressor, Moreover, studies of mutant proteins identified the three repressor amino acids that directly contact these conserved bases. The pattern of operator sequence conservation permits these direct amino acid-base pair interactions to occur in all except one of the 12 operator half-sites in the phage chromosome, Therefore, repressor differential affinity for these sites cannot be due to these highly conserved base pair-amino acid interactions, Our binding studies show that the nonconserved bases at positions 2 and 4 also play an important role in determining the relative affinity of the naturally occurring P22 operators for P22 repressor, Our data indicate that the direct contacts between the three solvent-exposed amino acids and the conserved bases in the binding site lock these amino acids in place, forming a scaffold allowing the rest of the amino acids side chains to form weaker interactions with the nonconserved bases in the binding site.	SUNY BUFFALO,DEPT SCI BIOL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042138, R29GM042138] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42138] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BEJAR S, 1985, MOL GEN GENET, V201, P146, DOI 10.1007/BF00425651; BEJAR S, 1988, MOL GEN GENET, V212, P11, DOI 10.1007/BF00322439; BEJAR S, 1986, NUCLEIC ACIDS RES, V14, P6821, DOI 10.1093/nar/14.17.6821; DALMAWEISZHAUSZ DD, 1991, NUCLEIC ACIDS RES, V19, P611, DOI 10.1093/nar/19.3.611; DEANDA J, 1983, J BIOL CHEM, V258, P536; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DIGABRIELE AD, 1993, J MOL BIOL, V231, P1024, DOI 10.1006/jmbi.1993.1349; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; Hilchey SP, 1997, J BIOL CHEM, V272, P1646, DOI 10.1074/jbc.272.3.1646; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LOMONOSSOFF GP, 1981, J MOL BIOL, V149, P745, DOI 10.1016/0022-2836(81)90356-9; Maniatis T., 1982, MOL CLONING; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; POTEETE AR, 1980, J MOL BIOL, V137, P81, DOI 10.1016/0022-2836(80)90158-8; POTEETE AR, 1982, J MOL BIOL, V157, P21, DOI 10.1016/0022-2836(82)90511-3; Ptashne M., 1986, A GENETIC SWITCH; SANGER F, 1973, P NATL ACAD SCI USA, V70, P1209, DOI 10.1073/pnas.70.4.1209; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SAUER RT, 1979, NATURE, V279, P396, DOI 10.1038/279396a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEVILLASIERRA P, 1994, J MOL BIOL, V235, P1003, DOI 10.1006/jmbi.1994.1053; TABOR S, 1990, CURRENT PROTCOLS MOL; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; WHARTON RP, 1985, CELL, V38, P361; WU L, 1993, J BIOL CHEM, V268, P18975; WU L, 1992, J BIOL CHEM, V267, P9134	32	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19898	19905		10.1074/jbc.272.32.19898	http://dx.doi.org/10.1074/jbc.272.32.19898			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242655	hybrid			2022-12-27	WOS:A1997XQ05900042
J	Saeki, K; Yuo, A; Kato, M; Miyazono, K; Yazaki, Y; Takaku, F				Saeki, K; Yuo, A; Kato, M; Miyazono, K; Yazaki, Y; Takaku, F			Cell density-dependent apoptosis in HL-60 cells, which is mediated by an unknown soluble factor, is inhibited by transforming growth factor beta 1 and overexpression of bcl-24	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; EPITHELIAL-CELLS; DEATH; FACTOR-BETA-1; PROLIFERATION; ACTIVATION; EXPRESSION; INDUCTION; RADIATION; RECEPTORS	We report a novel mode of apoptosis induction observed in human leukemic HL-60 cells, These cells spontaneously underwent apoptosis in the course of proliferation when the cell density became higher than 1 x 10(6)/ml, This occurred under ordinary in vitro culture conditions, with or without fetal calf serum, Even the low density cells were committed to undergo apoptosis if they were cultured under artificially concentrated conditions, Replacement of the culture supernatant of the low density cells by that of the high density ones resulted in apoptosis induction in the former cells. This apoptosis-inducing activity of the high density cell culture supernatant was completely eliminated by the action of trypsin but was fully restored following ultrafiltration by 3-kDa pore-sized membrane, A strong apoptosis-inducing activity was recovered from the culture supernatant of the high density HL-60 cells at a specific fraction in reverse-phase column chromatography, Neither an interleukin-beta converting enzyme inhibitor nor CPP-32 inhibitor blocked the induction of cell density-dependent apoptosis in HL-60 cells, although overexpression of Bcl-2 protein markedly attenuated the induction of this mode. Surprisingly, transforming growth factor-beta 1 and activin A did not induce but, rather, inhibited the induction of cell density-dependent apoptosis, These data suggest that HL-60 cells release an unknown low molecular weight peptide-containing factor in response to an increase in cell density to induce apoptosis in an autocrine manner and that the interleukin-beta converting enzyme-independent intracellular machinery for this mode of apoptosis is strongly affected by signaling events through the transforming growth factor-beta 1 receptor and by the action of Bcl-2 oncoprotein.	INT MED CTR JAPAN, RES INST, DEPT HEMATOL, SHINJUKU KU, TOKYO 162, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT BIOCHEM, TOKYO 170, JAPAN; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, TOKYO 113, JAPAN	National Center for Global Health & Medicine - Japan; Japanese Foundation for Cancer Research; University of Tokyo				Saeki, Kumiko/0000-0001-9161-139X				BIES J, 1995, CANCER RES, V55, P501; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GUNN A, 1983, IMMUNOLOGY, V50, P477; HARMON BV, 1990, INT J RADIAT BIOL, V58, P845, DOI 10.1080/09553009014552221; HAVRILESKY LJ, 1995, CANCER RES, V55, P944; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JURGENSMEIER JM, 1994, CANCER RES, V54, P393; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; LOTEM J, 1992, BLOOD, V80, P1750; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; NAGY L, 1995, MOL CELL BIOL, V15, P3540; OHYAMA H, 1985, RADIAT RES, V101, P123, DOI 10.2307/3576309; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; RIOPEL L, 1989, J CELL PHYSIOL, V140, P233, DOI 10.1002/jcp.1041400207; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SHIMIZU T, 1990, BIOCHEM BIOPH RES CO, V169, P1172, DOI 10.1016/0006-291X(90)92019-V; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SINKOVICS J G, 1991, International Reviews of Immunology, V7, P259, DOI 10.3109/08830189109114875; SPORN MB, 1990, HDB EXP PHARM, V95; TAEALE R, 1993, CANCER, V53, P3386; TERUI Y, 1995, J BIOCHEM-TOKYO, V117, P77, DOI 10.1093/oxfordjournals.jbchem.a124725; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YANAGIHARA K, 1992, CANCER RES, V52, P4042; ZHANG XH, 1995, J EXP MED, V182, P699, DOI 10.1084/jem.182.3.699	31	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20003	20010		10.1074/jbc.272.32.20003	http://dx.doi.org/10.1074/jbc.272.32.20003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242670	hybrid			2022-12-27	WOS:A1997XQ05900057
J	Elefteriou, F; Exposito, JY; Garrone, R; Lethias, C				Elefteriou, F; Exposito, JY; Garrone, R; Lethias, C			Characterization of the bovine tenascin-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; CLASS-III REGION; GENE; EXPRESSION; DOMAIN; FIBRONECTIN; FRAGMENTS; MOLECULE; COLLAGEN; SEQUENCE	The primary structure of flexilin, an extracellular matrix glycoprotein previously identified in bovine tissues (Lethias, e., Descollonges, Y., Boutillon, M.-M., and Garrone, R. (1996) Matrix: Biol. 15, 11-19) was determined by cDNA cloning. The deduced amino acid sequence (4135 residues) reveals that this protein is composed of a succession of peptide motifs characteristic of the tenascin family: an amino-terminal domain containing cysteine residues and heptads of hydrophobic amino acids, 18.5 epidermal growth factor-like repeats, 30 fibronectin type III-like (FNIII) domains, and a carboxyl-terminal fibrinogen-like motif. Sequence analysis indicated that this protein is the bovine orthologue of human tenascin-X. By rotary shadowing, bovine tenascin-X was identified as monomers with a flexible aspect, which are ended by a globule. More FNIII motifs were characterized in the bovine protein than in human tenascin-X The main difference between the human and bovine tenascin-X is found in the arrangement of the three classes of highly similar FNIII repeat types in the central region of tenascin-X. The bovine FNIII motif b10 exhibits an RGD putative cell attachment site. The functional role of this sequence is corroborated by cell adhesion on purified tenascin-X, which is inhibited by RGD peptides. Moreover, we demonstrate that this RGD site is conserved at the same location in the human molecule.	UNIV LYON 1,CNRS,UPR 412,IBCP,F-69367 LYON 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1			Elefteriou, Florent/P-2586-2017; Elefteriou, Florent/GMW-8429-2022	Elefteriou, Florent/0000-0002-2972-5633; Elefteriou, Florent/0000-0002-2972-5633; Exposito, Jean-Yves/0000-0002-4926-4942				BAUMGARTNER S, 1993, MECH DEVELOP, V40, P165, DOI 10.1016/0925-4773(93)90074-8; BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; BURCH GH, 1995, DEV DYNAM, V203, P491, DOI 10.1002/aja.1002030411; CHIQUET M, 1991, EUR J BIOCHEM, V199, P379, DOI 10.1111/j.1432-1033.1991.tb16134.x; CHIQUETEHRISMANN R, 1995, EXPERIENTIA, V51, P853, DOI 10.1007/BF01921736; CHIQUETEHRISMANN R, 1995, BIOESSAYS, V17, P873, DOI 10.1002/bies.950171009; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DARDEL F, 1988, COMPUT APPL BIOSCI, V4, P483; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; EXPOSITO JY, 1990, EUR J BIOCHEM, V190, P401, DOI 10.1111/j.1432-1033.1990.tb15589.x; GEFFROTIN C, 1995, EUR J BIOCHEM, V231, P83, DOI 10.1111/j.1432-1033.1995.0083f.x; GOODWIN AE, 1995, J IMMUNOL METHODS, V187, P213, DOI 10.1016/0022-1759(95)00187-6; Hagios C, 1996, J CELL BIOL, V134, P1499, DOI 10.1083/jcb.134.6.1499; HUMBERTDAVID N, 1993, EUR J BIOCHEM, V216, P255, DOI 10.1111/j.1432-1033.1993.tb18140.x; JOSHI P, 1993, J CELL SCI, V106, P389; Lethias C, 1996, MATRIX BIOL, V15, P11, DOI 10.1016/S0945-053X(96)90122-5; LETHIAS C, 1993, J INVEST DERMATOL, V101, P92, DOI 10.1111/1523-1747.ep12360433; MATSUDANAKAGAWA LM, 1991, PHILOS T R SOC LON B, V331, P323; MATSUMOTO K, 1992, IMMUNOGENETICS, V36, P400; MATSUMOTO K, 1994, J CELL BIOL, V125, P483, DOI 10.1083/jcb.125.2.483; MATSUMOTO K, 1992, GENOMICS, V12, P485, DOI 10.1016/0888-7543(92)90438-X; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; NIES DE, 1991, J BIOL CHEM, V266, P2818; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Sakai T, 1996, J CELL SCI, V109, P2069; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; Speek M, 1996, HUM MOL GENET, V5, P1749, DOI 10.1093/hmg/5.11.1749; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	35	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22866	22874		10.1074/jbc.272.36.22866	http://dx.doi.org/10.1074/jbc.272.36.22866			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278449	hybrid			2022-12-27	WOS:A1997XV49200070
J	Hauser, PJ; Agrawal, D; Chu, BK; Pledger, WJ				Hauser, PJ; Agrawal, D; Chu, BK; Pledger, WJ			p107 and p130 associated cyclin A has altered substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; CELL-CYCLE; GROWTH SUPPRESSION; TRANSCRIPTION FACTORS; FAMILY MEMBERS; CDK COMPLEXES; PROTEIN P107; E2F; INTERACTS; BINDING	We demonstrate that p107 and p130 immune complexes exhibit kinase activity. We have tested such immune complexes with four substrates commonly utilized to assay Cdk activity, including all three known members of the retinoblastoma family. Immunodepletion revealed this kinase activity could be abolished by removal of either cyclin A or Cdk2 but was unaffected by removal of Cdk4 or any D-type cyclin. The appearance of p101 associated activity followed the accumulation of p107 protein. In contrast, the kinase activity associated with p130 immune complexes became apparent after mid-G(1), coincident with p130 hyperphosphorylation. GST-Rb, GST-p107, and GST-p130 (where GST indicates glutathione S-transferase) were equally suitable substrates in p107 and p130 immune complex kinase assays, yielding activity equal to 25% of the cyclin A activity present. The p107 and p130 associated activity was unable to phosphorylate histone H1, suggesting the p107 and p130 associated cyclin A/Cdk2 may represent a distinct pool with a distinct substrate specificity. The p107 and p130 associated activity was released from the immune complexes upon incubation with ATP and Mg2+ and exhibited the same substrate preference observed with the untreated immune complex. Our data suggest that p107 and p130 recognize, or form by association, a distinct pool of cyclin A/Cdk2 that preferentially phosphorylates retinoblastoma family members.	UNIV S FLORIDA,COLL MED,H LEE MOFFITT CANC CTR,TAMPA,FL 33612; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37240; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOL BIOL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT MED MICROBIOL,TAMPA,FL 33612	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Vanderbilt University; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida					NATIONAL CANCER INSTITUTE [R01CA067360] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BEIJERSHERGEN R, 1994, EMBO J, V17, P4080; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DROZDOFF V, 1993, J CELL BIOL, V123, P909, DOI 10.1083/jcb.123.4.909; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Moberg K, 1996, MOL CELL BIOL, V16, P1436; NEVINS JR, 1992, SCIENCE, V258, P424; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XU HJ, 1994, P NATL ACAD SCI USA, V91, P9837, DOI 10.1073/pnas.91.21.9837; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22954	22959		10.1074/jbc.272.36.22954	http://dx.doi.org/10.1074/jbc.272.36.22954			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278460	hybrid			2022-12-27	WOS:A1997XV49200082
J	Kanemitsu, MY; Loo, LWM; Simon, S; Lau, AF; Eckhart, W				Kanemitsu, MY; Loo, LWM; Simon, S; Lau, AF; Eckhart, W			Tyrosine phosphorylation of connexin 43 by v-Src is mediated by SH2 and SH3 domain interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; GAP-JUNCTION PROTEIN; TEMPERATURE-SENSITIVE MUTANT; TO-CELL COMMUNICATION; FOCAL ADHESION KINASE; AMINO-TERMINAL DOMAIN; INTERCELLULAR COMMUNICATION; C-SRC; TRANSFORMED-CELLS; GENE-PRODUCT	Reduction of gap junctional communication in v-src transformed cells is accompanied by tyrosine phosphorylation of the gap junction protein, connexin 43 (Cx43). Cx43 is phosphorylated on tyrosine by v-Src. The Src homology 3 (SH3) and Src homology 2 (SH2) domains of v-Src mediate interactions with substrate proteins. SH3 domains interact with proline-rich peptide motifs. SH2 domains associate with short amino acid sequences containing phosphotyrosine. We present evidence that the SH3 and SH2 domains of v-Src bind to proline-rich motifs and a phosphorylated tyrosine residue in the C-terminal tail of Cx43. Cx43 bound to the SH3 domain of v-Src, but not c-Src, in vitro. Tyrosine-phosphorylated Cx43 bound to the SH2 domain of v-Src in vitro. v-Src coprecipitated with Cx43 from v-src-transformed Rat-1 fibroblasts. Mutations in the SH3 and SH2 domains of v-Src, and in the proline-rich region or tyrosine 265 of Cx43, reduced interactions between v-Src and Cx43 in vivo. Tyrosine phosphorylation of Cx43 was dependent on the association of v-Src and Cx43. These results provide further evidence for the direct involvement of v-Src in tyrosine phosphorylation of Cx43 and inhibition of gap junctional communication in v-src-transformed cells.	SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV HAWAII, CANC RES CTR HAWAII, HONOLULU, HI 96813 USA	Salk Institute; Cancer Research Center of Hawaii; University of Hawaii System					NCI NIH HHS [CA13884, CA09370, CA14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, T32CA009370, R37CA013884, R01CA013884] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; ATKINSON MM, 1988, AM J PHYSIOL, V255, pC674, DOI 10.1152/ajpcell.1988.255.5.C674; AZARNIA R, 1989, ONCOGENE, V4, P1161; AZARNIA R, 1987, MOL CELL BIOL, V7, P946, DOI 10.1128/MCB.7.2.946; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P213, DOI 10.1007/BF01871631; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; CROW DS, 1992, ONCOGENE, V7, P999; DEFEIJTER AW, 1990, MOL CARCINOGEN, V3, P54, DOI 10.1002/mc.2940030203; ELFOULY MH, 1989, MOL CARCINOGEN, V2, P131, DOI 10.1002/mc.2940020305; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GRAHAM FL, 1978, VIROLOGY, V86, P10, DOI 10.1016/0042-6822(78)90003-X; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KLAUNIG JE, 1990, LAB INVEST, V62, P135; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURATA WE, 1994, ONCOGENE, V9, P329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LEVINSON AD, 1980, J BIOL CHEM, V255, P1973; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS JT, 1984, CANCER CELLS ONCOGEN, P36; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Potts W M, 1988, Oncogene Res, V3, P343; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SAEZ JC, 1990, EUR J BIOCHEM, V192, P263, DOI 10.1111/j.1432-1033.1990.tb19223.x; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHAFFHAUSEN B, 1995, BBA-REV CANCER, V1242, P61, DOI 10.1016/0304-419X(95)00004-Y; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TRAUB O, 1987, EUR J CELL BIOL, V43, P48; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	100	160	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22824	22831		10.1074/jbc.272.36.22824	http://dx.doi.org/10.1074/jbc.272.36.22824			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278444	hybrid			2022-12-27	WOS:A1997XV49200065
J	Niswender, KD; Shiota, M; Postic, C; Cherrington, AD; Magnuson, MA				Niswender, KD; Shiota, M; Postic, C; Cherrington, AD; Magnuson, MA			Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE RESPONSE ELEMENT; DEPENDENT DIABETES-MELLITUS; ACID-SYNTHASE GENE; INSULIN-SECRETION; TRANSCRIPTIONAL CONTROL; REGULATORY PROTEIN; LIVER GLUCOKINASE; TRANSGENIC MICE; RAT HEPATOCYTES; EXPRESSION	The relationship between glucokinase (GK) gene copy number and glucose homeostasis was studied in transgenic mice with additional copies of the entire GK gene locus (Niswender, K. D., Postic, C., Jetton, T. L., Bennett, B. D., Piston, D. W., Efrat, S., and Magnuson, M. A. (1997) J. Biol. Chem. 272, 22564-22569). The plasma glucose concentration was reduced by 25 +/- 3% and 37 +/- 4% in mice with one or two extra copies of the gene locus, respectively. The basis for the hypoglycemic phenotype was determined using metabolic tracer techniques in chronically cannulated, conscious mice with one extra GK gene copy. Under basal conditions (6-h fasted) transgenic mice had a lower blood glucose concentration (-12 +/- 1%) and a slightly higher glucose turnover rate (+8 +/- 3%), resulting in a significantly higher glucose clearance rate (+21 +/- 2%). Plasma insulin levels were not different, suggesting that increased glucose clearance was due to augmented hepatic, not islet, GK gene expression. Under hyperglycemic clamp conditions the transgenic mice had glucose turnover and clearance rates similar to the controls, but showed a lower plasma insulin response (-48 +/- 5%). Net hepatic glycogen synthesis was markedly elevated (+360%), whereas skeletal muscle glycogen synthesis was decreased (-40%). These results indicate that increased GK gene dosage leads to increased hepatic glucose metabolism and, consequently, a lower plasma glucose concentration. Increased insulin secretion was not observed, even though the transgene is expressed in islets, because hypoglycemia causes a down-regulation in islet GK content (Niswender, K. D., Postic, C., Jetton, T. L., Bennett, B. D., Piston, D. W., Efrat, S., and Magnuson, M. A. (1997) J. Biol. Chem. 272, in press).	VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOL BIOPHYS, NASHVILLE, TN 37232 USA	Vanderbilt University			Postic, Catherine/P-2271-2017; Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021	Postic, Catherine/0000-0002-1875-6960; Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499	NIDDK NIH HHS [DK42612, DK43706, DK42502] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612, R01DK043706, R56DK043706] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; Bell GI, 1996, ANNU REV PHYSIOL, V58, P171, DOI 10.1146/annurev.physiol.58.1.171; CUIF MH, 1993, J BIOL CHEM, V268, P13769; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; FOUFELLE F, 1995, BIOCHEM J, V308, P521, DOI 10.1042/bj3080521; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; HERS HG, 1990, J INHERIT METAB DIS, V13, P395, DOI 10.1007/BF01799497; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LIANG Y, 1994, DIABETES, V43, P1138, DOI 10.2337/diabetes.43.9.1138; LIANG Y, 1990, J BIOL CHEM, V265, P16863; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEDOYA FJ, 1996, J BIOL CHEM, V261, P10760; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; Niswender KD, 1997, J BIOL CHEM, V272, P22564, DOI 10.1074/jbc.272.36.22564; NOLL F, 1984, METHOD ENZYMAT AN, V6, P582; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Pagliassotti M, 1994, ROLE LIVER MAINTAINI, P45; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; SCOTT D, 1997, DIABETES S1, V46, pA21; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SHIOTA M, 1984, BIOCHEM J, V222, P281, DOI 10.1042/bj2220281; STURIS J, 1994, DIABETES, V43, P718, DOI 10.2337/diabetes.43.5.718; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; Towle HC, 1996, BIOCHEM SOC T, V24, P364, DOI 10.1042/bst0240364; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VANSCHAFTINGEN E, 1992, ADV ENZYME REGUL, V32, P133; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; YIN L, 1992, DIABETES, V41, P792	49	124	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22570	22575		10.1074/jbc.272.36.22570	http://dx.doi.org/10.1074/jbc.272.36.22570			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278411	hybrid			2022-12-27	WOS:A1997XV49200031
J	Salceda, S; Caro, J				Salceda, S; Caro, J			Hypoxia-inducible factor 1 alpha (HIF-1 alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions - Its stabilization by hypoxia depends on redox-induced changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; TRANSCRIPTIONAL REGULATION; ENHANCER ELEMENT; EXPRESSION; PROTEOLYSIS; ACTIVATION; INHIBITORS; SEQUENCES; CELLS	The hypoxia-inducible factor 1 transcriptional activator complex (HIF-1) is involved in the activation of the erythropoietin and several other hypoxia-responsive genes, The HIF-1 complex is composed of two protein subunits: HIF-1 beta/ARNT (aryl hydrocarbon receptor nuclear translocator), which is constitutively expressed, and HIF-1 alpha, which is not present in normal cells but induced under hypoxic conditions. The HIF-1 alpha subunit is continuously synthesized and degraded under normoxic conditions, while it accumulates rapidly following exposure to low oxygen tensions. The involvement of the ubiquitin-proteasome system in the proteolytic destruction of HIF-1 in normoxia was studied by the use of specific inhibitors of the proteasome system. Lactacystin and MG-132 were found to protect the degradation of the HIF-1 complex in cells transferred from hypoxia to normoxia. The same inhibitors were able to induce HIF-1 complex formation when added to normoxic cells. Final confirmation of the involvement of the ubiquitin-proteasome system in the regulated degradation of HIF-1 alpha was obtained by the use of ts20TG(R) cells, which contain a temperature-sensitive mutant of E1, the ubiquitin-activating enzyme, Exposure of ts20 cells, under normoxic conditions, to the non-permissive temperature induced a rapid and progressive accumulation of HIF-1. The effect of proteasome inhibitors on the normoxic induction of HIF-1 binding activity was mimicked by the thiol reducing agent N-(2-mercaptopropionyl)glycine and by the oxygen radical scavenger 2-acetamidoacrylic acid. Furthermore, N-(2-mercaptopropionyl)-glycine induced gene expression as measured by the stimulation of a HIF-1-luciferase expression vector and by the induction of erythropoietin mRNA in normoxic Hep 3B cells. These last findings strongly suggest that the hypoxia induced changes in HIF-1 alpha stability and subsequent gene activation are mediated by redox-induced changes.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,CARDEZA FDN HEMATOL RES,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034642] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 F32 HL 09247] Funding Source: Medline; NIDDK NIH HHS [DK-34642] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK I, 1993, BLOOD, V82, P704; BECK I, 1991, J BIOL CHEM, V266, P15563; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dick LR, 1997, J BIOL CHEM, V272, P182; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HUNAG LE, 1996, J BIOL CHEM, V271, P32253; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Ratcliffe PJ, 1997, KIDNEY INT, V51, P514, DOI 10.1038/ki.1997.72; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Robertson NM, 1997, CANCER RES, V57, P43; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SIPE HJ, 1993, CHEM-BIOL INTERACT, V86, P93, DOI 10.1016/0009-2797(93)90114-E; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	30	1342	1383	6	76	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22642	22647		10.1074/jbc.272.36.22642	http://dx.doi.org/10.1074/jbc.272.36.22642			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278421	hybrid			2022-12-27	WOS:A1997XV49200041
J	Zimmermann, AG; Wright, KL; Ting, JPY; Mitchell, BS				Zimmermann, AG; Wright, KL; Ting, JPY; Mitchell, BS			Regulation of inosine-5'-monophosphate dehydrogenase type II gene expression in human T cells - Role for a novel 5' palindromic octamer sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE 5'-PHOSPHATE DEHYDROGENASE; HUMAN NORMAL LYMPHOCYTES; HUMAN IMP DEHYDROGENASE; LEUKEMIA-CELLS; MYCOPHENOLATE MOFETIL; INVIVO FOOTPRINT; UP-REGULATION; IN-VIVO; TRANSCRIPTION; PROMOTER	Expression of the gene encoding human inosine-5'-monophosphate dehydrogenase (IMPDH) type II, an enzyme catalyzing the rate-limiting step in the generation of guanine nucleotides, is increased more than 10-fold in activated peripheral blood T lymphocytes and is required for T cell activation, We have examined the 5'-regulatory sequences that are important for the transcriptional regulation of this gene in T cells, DNase I mapping of genomic DNA identified a hypersensitive element near the transcription initiation site, Fine mapping by in vivo footprinting demonstrated five transcription factor binding sites that are occupied in. both resting and activated peripheral blood T lymphocytes; these are tandem CRE motifs, a Sp1 site, an overlapping Egr-1/Sp1 site, and a novel palindromic octamer sequence (POS). The tandem CRE and POS sites are of major functional importance as judged by mutational and electrophoretic mobility shift analyses. These data provide evidence that expression of the human IMPDH type II gene is predominantly regulated by the nuclear factors ATF-2 and an as yet unidentified POS-binding protein. Additional major protein-DNA interactions do not occur within the promoter region after T lymphocyte activation, indicating a requirement for additional protein-protein interactions and/or post-translational modifications of pre-bound transcription factors to account for the observed increase in IMPDH type II gene expression.	UNIV N CAROLINA, SCH MED, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT INTERNAL MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Zimmermann, AG (corresponding author), UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, 1106 FLOB CB 7365, CHAPEL HILL, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA064192, R01CA034085] Funding Source: NIH RePORTER; NCI NIH HHS [CA64192, CA34085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRUNVAND MW, 1993, NUCLEIC ACIDS RES, V21, P4824, DOI 10.1093/nar/21.20.4824; CARR SF, 1993, J BIOL CHEM, V268, P27286; COLLART FR, 1992, CANCER RES, V52, P5826; COLLART FR, 1988, J BIOL CHEM, V263, P15769; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Danovitch G, 1996, TRANSPLANTATION, V61, P722; DAYTON JS, 1994, J IMMUNOL, V152, P984; DAYTON JS, 1992, MOL PHARMACOL, V41, P671; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAIRBANKS LD, 1995, J BIOL CHEM, V270, P29682; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GLESNE D, 1993, GENOMICS, V16, P274, DOI 10.1006/geno.1993.1177; GU JJ, 1994, GENOMICS, V24, P179, DOI 10.1006/geno.1994.1597; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; JONES DH, 1991, BIOTECHNIQUES, V10, P62; KIGUCHI K, 1990, EXP CELL RES, V187, P47, DOI 10.1016/0014-4827(90)90114-P; KIGUCHI K, 1990, CELL GROWTH DIFFER, V1, P259; KONNO Y, 1991, J BIOL CHEM, V266, P506; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; OLAH E, 1988, P NATL ACAD SCI USA, V85, P6533, DOI 10.1073/pnas.85.17.6533; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; SATAKE M, 1989, J VIROL, V63, P3669, DOI 10.1128/JVI.63.9.3669-3677.1989; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SOKOLOSKI JA, 1986, CANCER RES, V46, P2314; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; TIEDEMAN AA, 1991, GENE, V97, P289, DOI 10.1016/0378-1119(91)90065-J; TRICOT GJ, 1989, CANCER RES, V49, P3696; Tsai EY, 1996, MOL CELL BIOL, V16, P459; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; WEBER G, 1983, CANCER RES, V43, P3466; WEISS A, 1984, J IMMUNOL, V133, P123; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; ZIMMERMANN AG, 1995, J BIOL CHEM, V270, P6808, DOI 10.1074/jbc.270.12.6808	48	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22913	22923		10.1074/jbc.272.36.22913	http://dx.doi.org/10.1074/jbc.272.36.22913			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278455	hybrid			2022-12-27	WOS:A1997XV49200076
J	Adachi, S; Cross, AR; Babior, BM; Gottlieb, RA				Adachi, S; Cross, AR; Babior, BM; Gottlieb, RA			Bcl-2 and the outer mitochondrial membrane in the inactivation of cytochrome c during fas-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SUPEROXIDE-DISMUTASE; PROTEASE ACTIVATION; JURKAT CELLS; ACIDIFICATION; REQUIREMENT; EXTRACTS	Fas-driven apoptosis in Jurkat cells results in the inactivation of cytochrome c with cessation of oxygen consumption, Overexpression of Bcl-2 was found to protect against acidification and apoptosis mediated by Fas ligation in these cells. Bcl-2 is present in the outer mitochondrial membrane, but the molecular mechanism by which it protects cells is unknown. Because Bcl-2 projects into the mitochondrial intermembrane space and cytochrome c is located in the intermembrane space, we considered the possibility that Bcl-2 might protect cytochrome c from inactivation during Fas-mediated apoptosis. The present study shows that 1) in Jurkat cells, cytochrome c inactivation during Fas-driven apoptosis requires the permeabilization of the outer mitochondrial membrane; and 2) the post-mitochondrial fraction from CEM cells that overexpress Bcl-2 both prevents and reverses cytochrome c inactivation.	Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013501] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-01345] Funding Source: Medline; NIA NIH HHS [AG-13501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; HOBBS AJ, 1994, P NATL ACAD SCI USA, V91, P10992, DOI 10.1073/pnas.91.23.10992; HOLDEN MJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P396, DOI 10.1016/0005-2728(93)90126-Z; KIZAKI M, 1993, BLOOD, V82, P1142; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	21	162	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21878	21882		10.1074/jbc.272.35.21878	http://dx.doi.org/10.1074/jbc.272.35.21878			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268320	hybrid			2022-12-27	WOS:A1997XT85000032
J	Lee, CK; Bluyssen, HAR; Levy, DE				Lee, CK; Bluyssen, HAR; Levy, DE			Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GUANYLATE-BINDING PROTEIN; GAMMA-INTERFERON; TYROSINE-PHOSPHATASE; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; MESSENGER-RNA; ACTIVATION; GENE; STAT1	Daudi B lymphoblastoid cells are highly sensitive to the anti-growth and anti-viral effects of interferon (IFN). Unlike many cell lines, these cells show prolonged transcription of IFN-stimulated genes following treatment with IFN-alpha. This prolonged response correlated with the continued presence of the activated transcription factor, IFN-stimulated gene factor 3 (ISGF3). Pulse-chase labeling experiments indicated that the half life of the phosphorylation of signal transducers and activators of transcription (Stat)1 and Stat2 was short (<2 h) although the turnover of the proteins themselves was slow (>24 h), indicative of a constitutive phosphatase activity. The administration of protein-tyrosine kinase inhibitors at any time point during IFN stimulation led to rapid inhibition of the response, indicating that tyrosine kinase activity was continuously required. Catalytic activity of Jak1 and Tyk2 kinases remained elevated for prolonged periods following stimulation. Continuous presence of IFN-alpha was necessary for maintaining prolonged activation of ISGF3 and of Janus kinases, an activity that was blocked by antibodies to IFN-alpha or by cycloheximide. Conditioned medium of IFN-alpha-stimulated cells was capable of stimulating STAT activation in naive cells. Taken together, these results suggest that the response to IFN-alpha is controlled by the duration of stimulated Janus kinase activity over the background of constitutive dephosphorylation and that this response can be sustained by autocrine secretion of IFN-alpha.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			Levy, David/AAG-6202-2019; Lee, Chien-Kuo/AAZ-1039-2020; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; Lee, Chien-Kuo/0000-0001-8189-6045; Bluyssen, Hans/0000-0002-4568-6259	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DRON M, 1993, J INTERFERON RES, V13, P377, DOI 10.1089/jir.1993.13.377; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LAMB P, 1994, J INTERFERON RES, V14, P365, DOI 10.1089/jir.1994.14.365; LARNER AC, 1986, J BIOL CHEM, V261, P453; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TIWARI RK, 1987, EMBO J, V6, P3373, DOI 10.1002/j.1460-2075.1987.tb02659.x; TONKS NK, 1994, TRENDS BIOCHEM SCI, V19, P480; TOVEY MG, 1987, P NATL ACAD SCI USA, V84, P5038, DOI 10.1073/pnas.84.14.5038	32	77	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21872	21877		10.1074/jbc.272.35.21872	http://dx.doi.org/10.1074/jbc.272.35.21872			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268319	hybrid			2022-12-27	WOS:A1997XT85000031
J	Paris, S; BeraudDufour, S; Robineau, S; Bigay, J; Antonny, B; Chabre, M; Chardin, P				Paris, S; BeraudDufour, S; Robineau, S; Bigay, J; Antonny, B; Chabre, M; Chardin, P			Role of protein-phospholipid interactions in the activation of ARF1 by the guanine nucleotide exchange factor Arno	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; PLECKSTRIN-HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ESCHERICHIA-COLI; BINDING; MYRISTOYLATION; TRANSPORT; MEMBRANE; VESICLES; KINASE	Arno is a 47-kDa human protein recently identified as a guanine nucleotide exchange factor for ADP ribosylation factor 1 (ARF1) with a central Sec7 domain responsible for the exchange activity and a carboxyl-terminal pleckstrin homology (PH) domain (Chardin, P., Paris, S., Antonny, B., Robineau, S., Beraud-Dufour, S., Jackson, C. L., and Chabre, M. (1996) Nature 384, 481-484), Binding of the PH domain to phosphatidylinositol 4,5-bisphosphate (PIP2) greatly enhances Arno-mediated activation of myristoylated ARF1, We show here that in the absence of phospholipids, Arno promotes nucleotide exchange on [Delta 17]ARF1, a soluble mutant of ARF1 lacking the first 17 amino acids, This reaction is unaffected by PIP2, which suggests that the PIP2-PH domain interaction does not directly regulate the catalytic activity of Arno but rather serves to recruit Arno to membranes, Arno catalyzes the release of GDP more efficiently than that of GTP from [Delta 17]ARF1, and a stable complex between Arno Sec7 domain and nucleotide-free [Delta 17]ARF1 can be isolated, In contrast to [Delta 17]ARF1, full-length unmyristoylated ARF1 is not readily activated by Arno in solution, Its activation requires the presence of phospholipids and a reduction of ionic strength and Mg2+ concentration, PIP2 is strongly stimulatory, indicating that binding of Arno to phospholipids is involved, but in addition, electrostatic interactions between phospholipids and the amino-terminal portion of unmyristoylated ARF1(GDP) seem to be important. We conclude that efficient activation of full-length ARF1 by Arno requires a membrane surface and two distinct protein-phospholipid interactions: one between the PH domain of Arno and PIP2, add the other between amino-terminal cationic residues of ARF1 and anionic phospholipids. The latter interaction is normally induced by insertion of the amino-terminal myristate into the bilayer but can also be artificially facilitated by decreasing Mg2+ and salt concentrations.			Paris, S (corresponding author), CNRS, INST PHARMACOL MOL & CELLULAIRE, 660 ROUTE LUCIOLES, F-06560 VALBONNE, FRANCE.		Antonny, Bruno/ABH-7434-2020; BERAUD-DUFOUR, Sophie/M-4641-2016	Antonny, Bruno/0000-0002-9166-8668; Joelle, BIGAY/0000-0002-7487-3416; BERAUD-DUFOUR, Sophie/0000-0002-0062-6842				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frohman MA, 1996, CURR BIOL, V6, P945, DOI 10.1016/S0960-9822(02)00634-6; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Harter C, 1996, BBA-REV BIOMEMBRANES, V1286, P75, DOI 10.1016/0304-4157(96)00003-2; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; KAHN RA, 1992, J BIOL CHEM, V267, P13039; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	34	137	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22221	22226		10.1074/jbc.272.35.22221	http://dx.doi.org/10.1074/jbc.272.35.22221			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268368	hybrid			2022-12-27	WOS:A1997XT85000080
J	Vallet, VS; Henrion, AA; Bucchini, D; Casado, M; Raymondjean, M; Kahn, A; Vaulont, S				Vallet, VS; Henrion, AA; Bucchini, D; Casado, M; Raymondjean, M; Kahn, A; Vaulont, S			Glucose-dependent liver gene expression in upstream stimulatory factor 2 -/- mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE RESPONSE ELEMENT; TRANSCRIPTION FACTOR USF; PYRUVATE-KINASE; METABOLIC-REGULATION; TRANSGENIC MICE; RAT; PROMOTER; ORGANIZATION; SPECIFICITY; DEFINITION	Upstream stimulatory factors (USF) 1 and 2 belong to the Myc family of transcription factors characterized by a basic/helix loop helix/leucine zipper domain responsible for dimerization and DNA binding, These ubiquitous factors form homo- and heterodimers and recognize in vitro a CACGTG core sequence termed E box, Through binding to E boxes of target genes, USF factors have been demonstrated to activate gene transcription and to enhance expression of some genes in response to various stimuli. In particular, in the liver USF1 and USF2 have been shown to bind in vitro glucose/carbohydrate response elements of glycolytic and lipogenic genes and have been proposed, from ex vivo experiments, to be involved in their transcriptional activation by glucose, However, the direct involvement of these factors in gene expression and nutrient gene regulation in vivo has not yet been demonstrated, Therefore, to gain insight into the specific role of USF1 and USF2 in vivo, and in particular to determine whether the USF products are required for the response of genes to glucose, we have created, by homologous recombination, USF2 -/- mice, In this paper, we provide the first evidence that USF2 proteins are required in vivo for a normal transcriptional response of L-type pyruvate kinase and Spot 14 genes to glucose in the liver.	INSERM, INST COCHIN GENET MOL, U129, UNITE RECH PHYSIOL & PATHOL GENET & MOL, F-75014 PARIS, FRANCE; UNIV PARIS 05, INSERM, U257, LAB GENET CELLULAIRE & MOL, F-75014 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Casado, Marta/L-2078-2014; Vaulont, Sophie/O-6732-2017; Caude, Alexandra A Henrion/I-2778-2016	Casado, Marta/0000-0001-6457-4650; Caude, Alexandra A Henrion/0000-0002-8170-2260				Aperlo C, 1996, GENOMICS, V37, P337, DOI 10.1006/geno.1996.0568; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CUIF MH, 1993, J BIOL CHEM, V268, P13769; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Joyner AL, 1993, GENE TARGETING PRACT; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LIAW CW, 1984, J BIOL CHEM, V259, P7253; LIN Q, 1994, J BIOL CHEM, V269, P23894; LITTLEWOOD TD, 1995, PROTEIN PROFILE, V2, P621; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; MARIE J, 1976, BIOCHIM BIOPHYS ACTA, V438, P393, DOI 10.1016/0005-2744(76)90256-4; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCOTT RJ, 1983, DIFFERENTIATION, V25, P64; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405	30	90	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21944	21949		10.1074/jbc.272.35.21944	http://dx.doi.org/10.1074/jbc.272.35.21944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268329	hybrid			2022-12-27	WOS:A1997XT85000041
J	Oorni, K; Pentikainen, MO; Annila, A; Kovanen, PT				Oorni, K; Pentikainen, MO; Annila, A; Kovanen, PT			Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans - Dependence on oxidative modification of the lysine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B; PLASMA-LIPOPROTEINS; SCAVENGER RECEPTOR; ATHEROSCLEROTIC LESIONS; CHOLESTEROL DEPOSITION; LIPID-PEROXIDATION; MACROPHAGES; LDL; GLYCOSAMINOGLYCANS; DEGRADATION	Oxidation of low density lipoprotein (LDL) leads to its rapid uptake by macrophages in vitro, but no detailed studies have addressed the effect of oxidation on the binding of LDL to proteoglycans, We therefore treated LDL with various substances: copper sulfate, 2,2'-azo-bis(2-amidinopropane)hydrochloride (AAPH), soybean lipoxygenase, and mouse peritoneal macrophages, and determined the extent to which the oxidatively modified LDL bound to human aortic proteoglycans in an affinity column, Oxidation of LDL with copper, AAPH, or macrophages, all of which increased its electrophoretic mobility, was associated with reduced binding to proteoglycans, until strongly oxidized LDL was totally unable to bind to them, After treatment of LDL with soybean lipoxygenase, the change in electrophoretic mobility was small, and the amount of binding to proteoglycans was only slightly decreased, The increased electrophoretic mobility of oxidized LDL reflects modification of the lysine residues of apolipoprotein B-100 (apoB-100). To mimic the oxidative modification of lysines, we treated LDL with malondialdehyde, This treatment also totally prevented the binding of LDL to proteoglycans. in contrast, if the lysine residues of apoB-100 were methylated to shield them against oxidative modification, subsequent treatment of LDL with copper sulfate failed to reduce the degree of LDL binding to proteoglycans. Finally, the active lysine residues in the oxidized LDL particles, which are thought to be involved in this binding, were quantified with NMR spectroscopy, In oxidized LDL, the number of these residues was found to be decreased, The present results show that, after modification of the lysine residues of apoB-100 during oxidation, the binding of LDL to proteoglycans is decreased, and suggest that oxidation of LDL tends to lead to intracellular rather than extracellular accumulation of LDL during atherogenesis.	WIHURI RES INST, FIN-00140 HELSINKI, FINLAND; STATE TECH RES CTR FINLAND, FIN-02044 ESPOO, FINLAND	Wihuri Research Institute			Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250				AVIRAM M, 1988, J BIOL CHEM, V263, P16842; BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CAMEJO G, 1991, J LIPID RES, V32, P1983; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHANG GJ, 1994, ARTERIOSCLER THROMB, V14, P1808, DOI 10.1161/01.ATV.14.11.1808; ELSAADANI M, 1989, J LIPID RES, V30, P627; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FRANK JS, 1989, J LIPID RES, V30, P967; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HABERLAND ME, 1984, J BIOL CHEM, V259, P1305; HABERLAND ME, 1982, P NATL ACAD SCI-BIOL, V79, P1712, DOI 10.1073/pnas.79.6.1712; HABERLAND ME, 1992, MONOGR HUM GENET, V14, P35; HAVEL RJ, 1955, J CLIN INVEST, V77, P757; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Lougheed M, 1996, J BIOL CHEM, V271, P11798, DOI 10.1074/jbc.271.20.11798; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1991, J BIOL CHEM, V266, P2701; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; MACEK J, 1987, J CHROMATOGR-BIOMED, V414, P156, DOI 10.1016/0378-4347(87)80034-8; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; PAANANEN K, 1995, J BIOL CHEM, V270, P12257, DOI 10.1074/jbc.270.20.12257; PENTIKAINEN MO, 1995, ARTERIOSCL THROM VAS, V15, P740, DOI 10.1161/01.ATV.15.6.740; PIHA M, 1995, BIOCHEMISTRY-US, V34, P10120, DOI 10.1021/bi00032a004; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SPARROW CP, 1988, J LIPID RES, V29, P745; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG HF, 1993, J BIOL CHEM, V268, P5535	43	77	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21303	21311		10.1074/jbc.272.34.21303	http://dx.doi.org/10.1074/jbc.272.34.21303			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261142	hybrid			2022-12-27	WOS:A1997XR78900052
J	Blaikie, PA; Fournier, E; Dilworth, SM; Birnbaum, D; Borg, JP; Margolis, B				Blaikie, PA; Fournier, E; Dilworth, SM; Birnbaum, D; Borg, JP; Margolis, B			The role of the Shc phosphotyrosine interaction phosphotyrosine binding domain and tyrosine phosphorylation sites in polyoma middle T antigen-mediated cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; RETROVIRAL VECTORS; GENE-TRANSFER; EGF RECEPTOR; PROTEINS; KINASE; MOTIF; ASSOCIATION; ACTIVATION	The phosphotyrosine Interaction (PI)/phosphotyrosine binding (PTB) domain of She binds specific tyrosine-phosphorylated motifs found on activated growth factor receptors and proteins such as polyoma virus middle T antigen (MT), Phenylalanine 198 (Phe(198)) has been identified as a crucial residue involved in the interaction of the She PI/PTB with phosphopeptides. In MH3T3 cells expressing MT, p52 She carrying the F198V mutation is weakly phosphorylated and does not bind MT or Grb2. Overexpression of the PI/PTB domain alone as She amino acids 1-238 acted in a dominant interfering fashion blocking MT-induced transformation, However, expression of a slightly longer construct, She 1-260, which encompasses Tyr(239)/Tyr(240), a novel She tyrosine phosphorylation site, did not block transformation, This was found to be due to the ability of She 1-260 to become tyrosine-phosphorylated and bind Grb2. Furthermore, full-length She in which Tyr(239)/Tyr(240) had been mutated to phenylalanine did not become tyrosine-phosphorylated or bind Grb2 but did inhibit colony formation in soft agar, Conversely, p52 She carrying a mutation in the other tyrosine phosphorylation site, Tyr(317), became heavily tyrosine-phosphorylated, bound Grb2, and gave rise to colonies in soft agar.	UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED & BIOL CHEM, ANN ARBOR, MI 48109 USA; NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; ROYAL POSTGRAD MED SCH, DEPT METAB MED, LONDON W12 0NN, ENGLAND; INSERM, U1119, ONCOL MOL LAB, F-13009 MARSEILLE, FRANCE	University of Michigan System; University of Michigan; New York University; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm)	Blaikie, PA (corresponding author), UNIV MICHIGAN, MED CTR,SCH MED,HOWARD HUGHES MED INST, MSRBII RM 4570, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA.		Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382				ADAM MA, 1991, J VIROL, V65, P4985, DOI 10.1128/JVI.65.9.4985-4990.1991; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; COURTNEIDGE SA, 1986, CANCER SURV, V5, P173; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; GRIFFIN BE, 1983, ADV CANCER RES, V39, P183, DOI 10.1016/S0065-230X(08)61036-2; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; Ishihara H, 1997, J BIOL CHEM, V272, P9581; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	52	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20671	20677		10.1074/jbc.272.33.20671	http://dx.doi.org/10.1074/jbc.272.33.20671			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252386	hybrid			2022-12-27	WOS:A1997XR22100056
J	Jitrapakdee, S; Booker, GW; Cassady, AI; Wallace, JC				Jitrapakdee, S; Booker, GW; Cassady, AI; Wallace, JC			The rat pyruvate carboxylase gene structure - Alternate promoters generate multiple transcripts with the 5'-end heterogeneity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESPONSIVE ELEMENT; FACTOR-BINDING PROTEIN-1; ACETYL-COA CARBOXYLASE; AMINO-ACID-SEQUENCE; DOMAIN-STRUCTURE; BIOTIN ENZYMES; MESSENGER-RNAS; DNA-SEQUENCES; CDNA; IDENTIFICATION	Pyruvate carboxylase (EC 6.4.1.1) is a biotin-containing enzyme that plays an important role in gluconeogenesis and lipogenesis. Here we report the structural organization of the rat pyruvate carboxylase gene, which spans over 40 kilobases and is composed of 19 coding exons and 4 5'-untranslated region exons, From this data, it is clear that alternative splicing of the primary transcripts from two promoters is responsible for the occurrence of the multiple mRNA species previously reported (Jitrapakdee, S,, Walker, M. E., and Wallace, J. C. (1996) Biochem, Biophys. Res. Commun. 223, 695-700). The proximal promoter, which is active in gluconeogenic and lipogenic tissues, contains no TATA or CAAT boxes but includes a sequence that is typical of a housekeeping initiator protein 1 box while the distal promoter contains three CAAT boxes and multiple Spl binding sites. Several potential transcription factor binding sites are found in both promoters. A series of 5'-nested deletion constructs of both promoters were fused to a firefly luciferase reporter plasmid and transiently expressed in COS-l cells. The results show that the 153 and 187 base pairs, preceding the transcription start sites of the proximal and distal promoters, respectively, are required for basal transcription, Insulin selectively inhibits the expression of the proximal promoter-luciferase reporter gene by 50% but not the distal promoter in COS-1 cells, suggesting the presence of an insulin-responsive element in the proximal promoter. A half-maximal effect was found at similar to 1 nM insulin.	UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5005,AUSTRALIA; UNIV QUEENSLAND,CTR MOL & CELLULAR BIOL,BRISBANE,QLD 4072,AUSTRALIA	University of Adelaide; University of Queensland			, John/AAP-5150-2020; Cassady, Alan/AAY-2962-2021	Cassady, Alan/0000-0001-8585-5427				ATTWOOD PV, 1995, INT J BIOCHEM CELL B, V27, P231, DOI 10.1016/1357-2725(94)00087-R; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P5694; Barritt GJ, 1985, PYRUVATE CARBOXYLASE, P147; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREWSTER NK, 1994, ARCH BIOCHEM BIOPHYS, V284, P98; CHEN QK, 1995, COMPUT APPL BIOSCI, V11, P563; Dunn MF, 1996, J BACTERIOL, V178, P5960, DOI 10.1128/jb.178.20.5960-5970.1996; ElKhadirMounier C, 1996, BIOCHEM J, V314, P613; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FREYTAG SO, 1984, J BIOL CHEM, V259, P2831; *GEN COMP GROUP, 1995, PROGR MAN WISC PACK; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hsu MH, 1996, J BIOL CHEM, V271, P13584, DOI 10.1074/jbc.271.23.13584; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Jitrapakdee S, 1996, BIOCHEM J, V316, P631, DOI 10.1042/bj3160631; JITRAPAKDEE S, 1996, BIOCHEM BIOPH RES CO, V223, P965; LEHN DA, 1995, GENE, V165, P331, DOI 10.1016/0378-1119(95)00557-M; LI N, 1995, BIOCHEM BIOPH RES CO, V208, P756, DOI 10.1006/bbrc.1995.1402; LI SJ, 1992, J BIOL CHEM, V267, P855; LIM F, 1988, J BIOL CHEM, V263, P11493; LOPEZCASILLAS F, 1991, EUR J BIOCHEM, V201, P119, DOI 10.1111/j.1432-1033.1991.tb16264.x; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; MACKAY N, 1994, BIOCHEM BIOPH RES CO, V202, P1009, DOI 10.1006/bbrc.1994.2029; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; OBERMAYER M, 1976, TRENDS BIOCHEM SCI, V1, P169, DOI 10.1016/0968-0004(76)90198-5; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PHILLIPS M, 1986, J BIOL CHEM, V261, P821; POWELL DR, 1991, J BIOL CHEM, V266, P18868; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; ROCHELLE JM, 1992, GENOMICS, V14, P26, DOI 10.1016/S0888-7543(05)80278-2; Sambrook J., 2002, MOL CLONING LAB MANU; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SHIMURA Y, 1994, J BIOL CHEM, V269, P31908; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STUCKA R, 1991, MOL GEN GENET, V229, P307, DOI 10.1007/BF00272171; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; THORNTON CG, 1993, FEBS LETT, V330, P191, DOI 10.1016/0014-5793(93)80271-U; Tu ZJ, 1997, INSECT BIOCHEM MOLEC, V27, P133, DOI 10.1016/S0965-1748(96)00078-1; Val DL, 1995, BIOCHEM J, V312, P817, DOI 10.1042/bj3120817; WALKER ME, 1995, CYTOGENET CELL GENET, V69, P187, DOI 10.1159/000133958; Wallace J.C., 1985, P65; WALLACE JC, 1997, IN PRESS INT J BIOCH; WEINBERG MB, 1980, BIOCHEM J, V188, P601, DOI 10.1042/bj1880601; WEXLER ID, 1994, BBA-MOL BASIS DIS, V1227, P46, DOI 10.1016/0925-4439(94)90105-8; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P1766, DOI 10.1073/pnas.90.5.1766; ZHANG J, 1995, BIOCHEM J, V306, P205, DOI 10.1042/bj3060205	50	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20522	20530		10.1074/jbc.272.33.20522	http://dx.doi.org/10.1074/jbc.272.33.20522			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252365	hybrid			2022-12-27	WOS:A1997XR22100035
J	Stathakis, P; Fitzgerald, M; Matthias, LJ; Chesterman, CN; Hogg, PJ				Stathakis, P; Fitzgerald, M; Matthias, LJ; Chesterman, CN; Hogg, PJ			Generation of angiostatin by reduction and proteolysis of plasmin - Catalysis by a plasmin reductase secreted by cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; THIOREDOXIN; SURFACE; INHIBITION; RECEPTOR; MEMBRANE; GLUTATHIONE; BRIDGES; BIOLOGY; EXPORT	Extracellular manipulation of protein disulfide bonds has been implied in diverse biological processes, including penetration of viruses and endotoxin into cells and activation of certain cytokine receptors, We now demonstrate reduction of one or more disulfide bonds in the serine proteinase, plasmin, by a reductase secreted by Chinese hamster ovary or HT1080 cells, Reduction of plasmin disulfide bond(s) triggered proteolysis of the enzyme, generating fragments with the domain structure of the angiogenesis inhibitor, angiostatin. Two of the known reductases secreted by cultured cells are protein disulfide isomerase and thioredoxin, and incubation of plasmin with these purified reductases resulted in angiostatin fragments comparable with those generated from plasmin in cell culture. Thioredoxin-derived angiostatin inhibited proliferation of human dermal microvascular endothelial cells with half-maximal effect at approximately 0.2 mu g/ml, Angiostatin made by cells and by purified reductases contained free sulfhydryl group(s), and S-carbamidomethylation of these thiol group(s) ablated biological activity, Neither protein disulfide isomerase nor thioredoxin were the reductases used by cultured cells, because immunodepletion of conditioned medium of these proteins did not affect angiostatin generating activity, The plasmin reductase secreted by HT1080 cells required a small cofactor for activity, and physiologically relevant concentrations of reduced glutathione fulfilled this role, These results have consequences for plasmin activity and angiogenesis, particularly in the context of tumor growth and metastasis, Moreover, this is the first demonstration of extracellular reduction of a protein disulfide bond, which has general implications for cell biology.	UNIV NEW S WALES,SCH PATHOL,CTR THROMBOSIS & VASC RES,SYDNEY,NSW 2052,AUSTRALIA; UNIV NEW S WALES,PRINCE WALES HOSP,DEPT HAEMATOL,SYDNEY,NSW 2052,AUSTRALIA	University of New South Wales Sydney; University of New South Wales Sydney			Fitzgerald, Melinda/C-4235-2011	Fitzgerald, Melinda/0000-0002-4823-8179; Hogg, Philip/0000-0001-6486-2863				ABELL BA, 1993, J VIROL, V67, P5496, DOI 10.1128/JVI.67.9.5496-5501.1993; BANNAI S, 1979, J BIOL CHEM, V254, P3444; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CASTELLINO FJ, 1990, LIPOPROTEIN A, P87; DEAN MF, 1994, BIOCHEM J, V304, P861, DOI 10.1042/bj3040861; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gately S, 1996, CANCER RES, V56, P4887; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Hotchkiss KA, 1996, BIOCHEMISTRY-US, V35, P9761, DOI 10.1021/bi9603938; JACKSON CJ, 1990, J CELL SCI, V96, P257; KRONING H, 1994, SCAND J IMMUNOL, V39, P346, DOI 10.1111/j.1365-3083.1994.tb03384.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MARTIN H, 1991, BIOCHEM BIOPH RES CO, V175, P123, DOI 10.1016/S0006-291X(05)81209-4; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; RAO ASMK, 1993, P NATL ACAD SCI USA, V90, P2950, DOI 10.1073/pnas.90.7.2950; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; STACH RW, 1985, INT J NEUROSCI, V26, P87, DOI 10.3109/00207458508985608; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	33	138	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20641	20645		10.1074/jbc.272.33.20641	http://dx.doi.org/10.1074/jbc.272.33.20641			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252380	hybrid			2022-12-27	WOS:A1997XR22100050
J	Trost, JT; Chisholm, DA; Jordan, DB; Diner, BA				Trost, JT; Chisholm, DA; Jordan, DB; Diner, BA			The D1 C-terminal processing protease of photosystem II from Scenedesmus obliquus - Protein purification and gene characterization in wild type and processing mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST MEMBRANE POLYPEPTIDE; OXYGEN-EVOLVING COMPLEX; AMINO-ACID-RESIDUES; MANGANESE CLUSTER; PRECURSOR PROTEIN; OXIDIZING SIDE; BINDING; SPINACH; PHOTOACTIVATION; IDENTIFICATION	Polypeptide D1 of the photosystem II reaction center of oxygenic photosynthesis is expressed in precursor form (pre-D1), and it must be proteolytically processed at its C terminus to enable assembly of the manganese cluster responsible for photosynthetic water oxidation. A rapid and highly sensitive enzyme-linked immunosorbent assay-based microtiter plate method is described for assaying this D1 C-terminal processing protease. A protocol is described for the isolation and purification to homogeneity of the enzyme from the green alga, Scenedesmus obliquus. Amino acid sequence information on the purified protease was used to clone the corresponding gene, the translated sequence of which is presented. A comparison of the gene product with homologous proteases points to a region of conserved residues that likely corresponds to the active site of a new class of serine protease, The LF-1 mutant strain of Scenedesmus (isolated by Dr, Norman Bishop) is incapable of processing pre-D1. We show here that the C-terminal processing protease gene in this strain contains a single base deletion that causes a frame shift and a premature stop of translation within the likely active site of the enzyme. A suppressor strain, LF-1-RVT-1, which is photoautotrophic and capable of processing pre-D1 has a nearby single base insertion that restores the expression of active enzyme. These observations provide the first definitive proof that the enzyme isolated is responsible for in vivo proteolytic processing of pre-D1 and that no other protease can compensate for its loss.	DUPONT CO INC,DEPT CENT RES & DEV,EXPT STN,WILMINGTON,DE 19880; DUPONT CO INC,STINE HASKELL RES CTR,DEPT AGR PROD,NEWARK,DE 19714	DuPont; DuPont								ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; BEST S, 1994, TECHNIQUES PROTEIN C, V5, P565; BISHOP NI, 1983, OXYGEN EVOLVING SYST, P177; BISHOP NI, 1971, METHODS ENZYMOLOGY A, V23, P372; BOWYER JR, 1992, J BIOL CHEM, V267, P5424; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5839, DOI 10.1021/bi00017a016; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DINER BA, 1988, J BIOL CHEM, V263, P8972; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FUJITA S, 1995, PLANT CELL PHYSIOL, V36, P1169; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GREBANIER AE, 1978, J CELL BIOL, V78, P734, DOI 10.1083/jcb.78.3.734; HARA H, 1991, J BACTERIOL, V173, P4799, DOI 10.1128/jb.173.15.4799-4813.1991; Inagaki N, 1996, PLANT MOL BIOL, V30, P39, DOI 10.1007/BF00017801; INAGAKI N, 1990, CURRENT RES PHOTOSYN, V3, P763; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1992, J BIOL CHEM, V267, P17494; MARDER JB, 1984, J BIOL CHEM, V259, P3900; METZ J, 1980, BIOCHEM BIOPH RES CO, V94, P560, DOI 10.1016/0006-291X(80)91268-1; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; METZ JG, 1986, FEBS LETT, V205, P269, DOI 10.1016/0014-5793(86)80911-5; MINAMI E, 1985, PLANT CELL PHYSIOL, V26, P839; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; Oelmuller R, 1996, J BIOL CHEM, V271, P21848, DOI 10.1074/jbc.271.36.21848; REISFELD A, 1982, EUR J BIOCHEM, V124, P125, DOI 10.1111/j.1432-1033.1982.tb05914.x; SATOH K, 1993, PHOTOSYNTHETIC REACT, V1, P289; SAYRE RT, 1986, CELL, V47, P601, DOI 10.1016/0092-8674(86)90624-0; SCHRADER S, 1992, PLANT MOL BIOL, V19, P251, DOI 10.1007/BF00027346; Seibert M, 1993, PHOTOSYNTHETIC REACT, VI, P319, DOI DOI 10.1016/B978-0-12-208661-8.50016-4; SHACKLETON JB, 1991, J BIOL CHEM, V266, P12152; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; TAGUCHI F, 1993, FEBS LETT, V326, P227, DOI 10.1016/0014-5793(93)81796-3; TAKAHASHI M, 1988, FEBS LETT, V240, P6, DOI 10.1016/0014-5793(88)80330-2; Takahashi Y, 1996, PLANT CELL PHYSIOL, V37, P161, DOI 10.1093/oxfordjournals.pcp.a028927; TAKAHASHI Y, 1990, PLANT CELL PHYSIOL, V31, P273; TAYLOR MA, 1988, FEBS LETT, V237, P229, DOI 10.1016/0014-5793(88)80207-2; TAYLOR MA, 1988, FEBS LETT, V235, P109, DOI 10.1016/0014-5793(88)81243-2; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	43	48	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20348	20356		10.1074/jbc.272.33.20348	http://dx.doi.org/10.1074/jbc.272.33.20348			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252339	hybrid			2022-12-27	WOS:A1997XR22100009
J	Kuroki, R; Ito, Y; Kato, Y; Imoto, T				Kuroki, R; Ito, Y; Kato, Y; Imoto, T			A covalent enzyme-substrate adduct in a mutant hen egg white lysozyme (D52E)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 LYSOZYME; GOOSE LYSOZYME; MECHANISMS; MUTAGENESIS; DISTORTION; COMPLEXES; RESIDUES; MUTATION	A mutant hen egg white lysozyme, D52E, was designed to correspond to the structure of the mutant T4 lysozyme T26E (Kuroki, R., Weaver, L. H., and Matthews B. W. (1993) Science 262, 2030-2033) to investigate the role of the catalytic residue on the ct-side of the saccharide in these enzymes, The D52E mutant forms a covalent enzyme-substrate adduct, which was detected by electron ion spray mass spectrometry. X-ray crystallographic analysis showed that the covalent adduct was formed between Glu-52 and the C-1 carbon of the N-acetylglucosamine residue in subsite D of the saccharide binding site, It suggests that the catalytic mechanism of D52E mutant lysozyme proceeds through a covalent enzyme-substrate intermediate indicating a different catalytic mechanism from the wild type hen egg white lysozyme, It was confirmed that the substitution of Asp-52 with Glu is structurally and functionally equivalent to the substitution of Thr-26 with Glu in T4 lysozyme, Although the position of the catalytic residue on the beta-side of the saccharide is quite conserved among hen egg white lysozyme, goose egg white lysozyme, and T4 phage lysozyme, the adaptability of the side chain on the alpha-side of the saccharide is considered to be responsible for the functional variation in their glycosidase and transglycosidase activities.	KYUSHU UNIV, GRAD SCH PHARMACEUT SCI, FUKUOKA 81282, JAPAN	Kyushu University	Kuroki, R (corresponding author), KIRIN BREWERY CO LTD, CENT LABS KEY TECHNOL, KANAZAWA KU, 1-13-5 FUKUURA, YOKOHAMA, KANAGAWA 236, JAPAN.							ANAND NN, 1988, BIOCHEM BIOPH RES CO, V153, P862, DOI 10.1016/S0006-291X(88)81175-6; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; CHEETHAM JC, 1992, J MOL BIOL, V224, P613, DOI 10.1016/0022-2836(92)90548-X; DAHLQUIS.FW, 1969, BIOCHEMISTRY-US, V8, P694, DOI 10.1021/bi00830a035; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; GRUTTER MG, 1983, NATURE, V303, P828, DOI 10.1038/303828a0; HADFIELD AT, 1994, J MOL BIOL, V243, P856, DOI 10.1006/jmbi.1994.1688; HARDY LW, 1991, BIOCHEMISTRY-US, V30, P9457, DOI 10.1021/bi00103a010; Hashimoto Y, 1996, J BIOCHEM-TOKYO, V119, P145; Imoto T., 1972, ENZYMES, V7, P665; INOUE M, 1992, BIOCHEMISTRY-US, V31, P5545, DOI 10.1021/bi00139a017; JOHNSON LN, 1966, THESIS U LONDON; KUROKI R, 1995, NAT STRUCT BIOL, V2, P1007, DOI 10.1038/nsb1195-1007; KUROKI R, 1993, SCIENCE, V262, P2030, DOI 10.1126/science.8266098; KUROKI R, 1986, J BIOL CHEM, V261, P3571; LUMB KJ, 1992, FEBS LETT, V296, P153, DOI 10.1016/0014-5793(92)80368-Q; MAENAKA K, 1995, J MOL BIOL, V247, P281, DOI 10.1006/jmbi.1994.0139; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; Matsumura I, 1996, BIOCHEMISTRY-US, V35, P1881, DOI 10.1021/bi951671q; MATTHEWS BW, 1974, P NATL ACAD SCI USA, V71, P4178, DOI 10.1073/pnas.71.10.4178; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MURAKI M, 1991, BIOCHIM BIOPHYS ACTA, V1079, P229, DOI 10.1016/0167-4838(91)90130-R; PHILLIPS DC, 1966, SCI AM, V215, P78, DOI 10.1038/scientificamerican1166-78; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; Sinnott M. L., 1987, ENZYME MECHANISMS, P259; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; WEAVER LH, 1995, J MOL BIOL, V245, P54, DOI 10.1016/S0022-2836(95)80038-7; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; WILSON KP, 1992, J BIOL CHEM, V267, P10842	33	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19976	19981		10.1074/jbc.272.32.19976	http://dx.doi.org/10.1074/jbc.272.32.19976			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242666	hybrid			2022-12-27	WOS:A1997XQ05900053
J	Nair, P; Muthukkumar, S; Sells, SF; Han, SS; Sukhatme, VP; Rangnekar, VM				Nair, P; Muthukkumar, S; Sells, SF; Han, SS; Sukhatme, VP; Rangnekar, VM			Early growth response-1-dependent apoptosis is mediated by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; PROGRAMMED CELL-DEATH; TRANSCRIPTION FACTOR EGR-1; TUMOR GENE-PRODUCT; NGFI-A; INDUCE APOPTOSIS; BINDING-SITE; DNA-DAMAGE; EXPRESSION; PROTEIN	The early growth response-1 (EGR-1) protein is an anti-proliferative signal for certain tumor cells and is required for apoptosis induced by stimuli that elevate intracellular Ca2+. We present evidence that EGR-1 transactivates the promoter of the p53 gene and upregulates p53 RNA and protein levels. Inhibition of p53 function with dominant-negative p53 mutants abrogates EGR-1-dependent apoptosis. These findings establish a direct functional link between EGR-1 and the p53-mediated cell death pathway and suggest that mutant forms of p53 in tumor cells may provide resistance to the anti-proliferative effects of EGR-1.	UNIV KENTUCKY,DEPT SURG,DIV UROL,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,GRAD CTR TOXICOL,LEXINGTON,KY 40536; UNIV KENTUCKY,MARKEY CANC CTR,LEXINGTON,KY 40536; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; BETH ISRAEL DEACONESS MED CTR,DIV RENAL,BOSTON,MA 02215	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center			Sukhatme, Vikas/W-2776-2019	Han, Seong-Su/0000-0001-9824-6751	NATIONAL CANCER INSTITUTE [R29CA052837, R01CA060872] Funding Source: NIH RePORTER; NCI NIH HHS [CA60872, CA52837] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CONNOR J, 1988, PROSTATE, V13, P119, DOI 10.1002/pros.2990130204; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; FURUYA Y, 1994, CANCER RES, V54, P6167; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HEMEKING H, 1994, SCIENCE, V265, P2091; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANG RP, 1994, ONCOGENE, V9, P1367; HUANG RP, 1995, CANCER RES, V55, P5054; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIYASHITA T, 1995, CELL, V80, P293; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Preston GA, 1996, MOL CELL BIOL, V16, P211; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1995, MOL CELL BIOL, V15, P682; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SHRIVASTAVA S, 1990, NATURE, V348, P747; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHAN QM, 1994, ONCOGENE, V9, P3743	82	168	175	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20131	20138		10.1074/jbc.272.32.20131	http://dx.doi.org/10.1074/jbc.272.32.20131			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242687	hybrid			2022-12-27	WOS:A1997XQ05900074
J	Ray, P; Yang, LY; Zhang, DH; Ghosh, SK; Ray, A				Ray, P; Yang, LY; Zhang, DH; Ghosh, SK; Ray, A			Selective up-regulation of cytokine-induced RANTES gene expression in lung epithelial cells by overexpression of I kappa BR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; T-CELLS; SUBUNIT; FAMILY; CLONING; PROTEIN; P65; MIP-1-ALPHA; MIP-1-BETA; INHIBITION	We previously reported the cloning of a cDNA for I kappa BR (for I kappa B-related) from human lung alveolar epithelial cells, I kappa BR is related to the I kappa B proteins that function as regulators of the NF-kappa B family of transcription factors. Here, we investigated the consequence of I kappa BR overexpression on the expression of NF-kappa B-regulated chemokine genes in lung alveolar epithelial cells. Chemokines play an important role in many inflammatory diseases such as asthma and AIDS. Overexpression of I kappa BR in the lung cells resulted in a rapid 50-100-fold greater production of the RANTES (regulated upon activation, normal T expressed and presumably secreted) protein upon cytokine-induction compared with control cells, I kappa BR overexpression, however, did not enhance interleukin-8 or MIP-1 alpha gene expression, despite the fact that the expression of all three chemokine genes are regulated by NF-kappa B, The up-regulation of RANTES gene expression resulting from overexpression of I kappa BR correlated with increased amounts of a unique RANTES-kappa B binding activity and decreased binding of p50 homodimers, Previous studies have shown that p50 homodimers function as repressors of certain KB sites, Our studies suggest that I kappa BR can aid activation of select NF-kappa B-regulated genes by sequestering p50 homodimers.			Ray, P (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,PULM & CRIT CARE SECT,333 CEDAR ST,NEW HAVEN,CT 06520, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031137] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52014] Funding Source: Medline; NIAID NIH HHS [AI 31137] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; Berkman N, 1996, IMMUNOLOGY, V87, P599, DOI 10.1046/j.1365-2567.1996.477579.x; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KANG SM, 1992, SCIENCE, V256, P1451; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; KWON OJ, 1994, IMMUNOLOGY, V81, P389; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MATTOLI S, 1995, BIOCHEM BIOPH RES CO, V209, P316, DOI 10.1006/bbrc.1995.1505; NELSON PJ, 1993, J IMMUNOL, V151, P2601; Nelson PJ, 1996, J IMMUNOL, V157, P1139; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; RAY P, 1995, J BIOL CHEM, V270, P10680, DOI 10.1074/jbc.270.18.10680; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STELLATO C, 1995, J IMMUNOL, V155, P410; TAUB D, 1995, J IMMUNOL, V154, P2393; Teran LM, 1996, J IMMUNOL, V157, P1806; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANOTTEREN GM, 1995, J IMMUNOL, V154, P1900; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483; WIDMER U, 1993, J IMMUNOL, V150, P4996; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582	47	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20191	20197		10.1074/jbc.272.32.20191	http://dx.doi.org/10.1074/jbc.272.32.20191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242696	hybrid			2022-12-27	WOS:A1997XQ05900083
J	Jeyaseelan, R; Poizat, C; Baker, RK; Abdishoo, S; Isterabadi, LB; Lyons, GE; Kedes, L				Jeyaseelan, R; Poizat, C; Baker, RK; Abdishoo, S; Isterabadi, LB; Lyons, GE; Kedes, L			A novel cardiac-restricted target for doxorubicin - CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-BINDING; DEVELOPING HEART; MUSCLE; TRANSCRIPTION; PROTEIN; EMBRYOGENESIS; PROMOTER; NKX-2.5; FAMILY	Doxorubicin (Dox), a cardiotoxic antineoplastic drug, disrupts the cardiac-specific program of gene expression (Kurabayashi, M., Dutta, S., Jeyaseelan, R., and Kedes, L. (1995) Mel. Cell. Biol. 15, 6386-6397; Jeyaseelan, R., Poizat, C., Wu, H. Y., and Kedes, L. (1997) J. Biol. Chem. 272, 5828-5832). To determine whether this drug might interfere with the function of cardiac-specific regulatory pathways, we used a differential display strategy to clone from neonatal rat cardiomyocyte candidate mRNAs that were rapidly sensitive to Box. We report here the identification of a constitutively expressed, cardiac-restricted, nuclear protein whose mRNA level is exquisitely sensitive to Box Hence we have named this protein cardiac adriamycin-responsive protein (CARP). CARP mRNA is present at the earliest stages of cardiac morphogenesis. It was detected by in situ hybridization within the cardiogenic plate of 7.5-day post coitum (p.c.) embryos, and in 8.5-day p.c. embryos CARP transcripts are present in uniformly high levels in the myocardium. Throughout cardiac development, GARP expression is specific for the myocardium; endocardial cushions and valves exhibit only background levels of signal. Transcript levels persist but gradually decrease in neonatal, 2-week-old, and adult hearts. There were no stages when CARP mRNA could not be detected. The pattern and timing of CARP mRNA expression, including transient expression in the tongue at 14.5 days p.c., coincides with that of Nkx2.5/Csx (a putative homolog of tinman, the Drosophila melanogaster gene responsible for cardiac development). The cloned full-length 1749 nucleotide CARP cDNA encodes a 319-amino acid 40-kDa polypeptide containing five tandem ankyrin repeats. CARP appears to be the rat homolog of a previously reported human single-copy gene (C-193; Chu, W., Burns, D. K., Swerlick, R. A., and Presky, D. H. (1995) J. Biol. Chem. 270, 10236-10245), whose mRNA is inducible by cytokines only in human endothelial cells. CARP appears to function as a negative regulator of cardiac-specific gene expression. Over-expression of CARP in cardiomyocytes suppresses cardiac troponin C and atrial natriuretic factor transcription. Cotransfection experiments in HeLa cells indicate that CARP inhibits Nkx2.5 transactivation of atrial natriuretic factor promoter. When fused to a GAL4 DNA-binding domain, CARP has transcriptional inhibitory properties in noncardiac cells. CARP thus represents the first example of a cardiac-restricted transcriptional regulatory protein that is sensitive to Dox.	UNIV SO CALIF,SCH MED,INST GENET MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOL BIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033; UNIV WISCONSIN,SCH MED,DEPT ANAT,MADISON,WI 53706	University of Southern California; University of Southern California; University of Southern California; University of Wisconsin System; University of Wisconsin Madison								BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BODMER R, 1993, DEVELOPMENT, V118, P719; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTENSEN TH, 1993, MOL CELL BIOL, V13, P6752, DOI 10.1128/MCB.13.11.6752; CHU W, 1995, J BIOL CHEM, V270, P10236, DOI 10.1074/jbc.270.17.10236; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; Jeyaseelan R, 1997, J BIOL CHEM, V272, P5828, DOI 10.1074/jbc.272.9.5828; Kaufman M.H., 1992, ATLAS MOUSE DEV; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KURABAYASHI M, 1993, J BIOL CHEM, V268, P5524; KURABAYASHI M, 1994, J BIOL CHEM, V269, P6031; KURABAYASHI M, 1995, MOL CELL BIOL, V15, P6386; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LIANG P, 1992, CANCER RES, V52, P6966; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LYONS GE, 1994, TRENDS CARDIOVAS MED, V4, P70, DOI 10.1016/1050-1738(94)90012-4; Lyons GE, 1996, CURR OPIN GENET DEV, V6, P454, DOI 10.1016/S0959-437X(96)80067-0; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MANASEK FJ, 1986, HEART CARDIOVASCULAR, P965; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; RUGH R, 1990, MOUSE ITS REPRODUCTI; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Zou YM, 1997, DEVELOPMENT, V124, P793	39	165	173	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22800	22808		10.1074/jbc.272.36.22800	http://dx.doi.org/10.1074/jbc.272.36.22800			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278441	hybrid			2022-12-27	WOS:A1997XV49200062
J	Simpson, PB; Mehotra, S; Lange, GD; Russell, JT				Simpson, PB; Mehotra, S; Lange, GD; Russell, JT			High density distribution of endoplasmic reticulum proteins and mitochondria at specialized Ca2+ release sites in oligodendrocyte processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; CALCIUM WAVES; SARCOPLASMIC-RETICULUM; CELLS; RAT; CALRETICULIN; ASTROCYTES; STORES; LOCALIZATION; EXPRESSION	In oligodendrocyte processes, methacholine-evoked Ca2+ waves propagate via regions of specialized Ca2+ release kinetics (wave amplification sites) at which the amplitude and rate of rise of local Ca2+ signals are markedly higher than in surrounding areas (Simpson, P. B., and Russell, J. T. (1996) J. Biol. Chem. 271, 33493-33501). In the present study we have examined the effects of other phosphoinositide-coupled agonists on Ca2+ in these cells, and the structural specializations underlying regenerative wave amplification sites, Both bradykinin and norepinephrine evoke Ca2+ waves, which initiate at the same loci and propagate through the cell body and multiple processes via identical wave amplification sites, Antibodies against type 2 inositol 1,4,5-trisphosphate receptors (InsP(3)R2) and calreticulin identify expression of these proteins in oligodendrocyte membranes in Western blots, Immunocytochemistry followed by high resolution fluorescence microscopy revealed that both InsP(3)R2 and calreticulin are expressed in high intensity patches along processes. Cross-correlation analysis of the profiles of local Ca2+ release kinetics during a Ca2+ wave and immunofluorescence for these proteins along cellular processes showed that the domains of high endoplasmic reticulum protein expression correspond closely to wave amplification sites, Staining cells with the mitochondrial dye, MitoTracker(R), showed that mitochondria are only found in intimate association with these sites possessing high density endoplasmic reticulum proteins, and they remain in the same locations over relatively long periods of time. It appears, therefore, that multiple specializations are found at domains of elevated Ca2+ release in oligodendrocyte processes, including high levels of calreticulin, InsP(3)R2 Ca2+ release channels, and mitochondria.	NICHHD, LCMN, NIH, BETHESDA, MD 20892 USA; NINCDS, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Simpson, Peter/0000-0003-0364-2685				BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; Bootman MD, 1996, CURR BIOL, V6, P855, DOI 10.1016/S0960-9822(02)00609-7; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; COHEN RI, 1994, EUR J NEUROSCI, V6, P1213, DOI 10.1111/j.1460-9568.1994.tb00620.x; COHEN RI, 1993, NEUROREPORT, V4, P1115; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; Dent MAR, 1996, DEVELOPMENT, V122, P1029; ENYEDI P, 1993, CELL CALCIUM, V14, P485, DOI 10.1016/0143-4160(93)90007-S; FATATIS A, 1992, GLIA, V5, P95, DOI 10.1002/glia.440050203; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; JAFFE LF, 1993, CELL CALCIUM, V14, P736, DOI 10.1016/0143-4160(93)90099-R; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; KASTRITSIS CH, 1993, GLIA, V8, P106, DOI 10.1002/glia.440080206; LIU NG, 1994, J BIOL CHEM, V269, P28635; MARRIOTT DR, 1993, J NEUROCHEM, V61, P826, DOI 10.1111/j.1471-4159.1993.tb03593.x; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; NIXON GF, 1994, J MUSCLE RES CELL M, V15, P682, DOI 10.1007/BF00121075; NORI A, 1993, BIOCHEM J, V291, P199, DOI 10.1042/bj2910199; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; PRESS WH, 1989, NUMERICAL RECIPES PA, P120; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROTH BJ, 1995, CELL CALCIUM, V17, P53, DOI 10.1016/0143-4160(95)90102-7; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; SIMPSON PB, 1995, TRENDS NEUROSCI, V18, P299, DOI 10.1016/0166-2236(95)93919-O; SIMPSON PB, 1994, J NEUROCHEM, V63, P2369; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; TAKEI K, 1992, J NEUROSCI, V12, P489; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; YAGODIN S, 1995, MOL CELL BIOCHEM, V149, P137, DOI 10.1007/BF01076572; YAGODIN SV, 1994, J NEUROBIOL, V25, P265, DOI 10.1002/neu.480250307	40	146	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22654	22661		10.1074/jbc.272.36.22654	http://dx.doi.org/10.1074/jbc.272.36.22654			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278423	hybrid			2022-12-27	WOS:A1997XV49200043
J	Zanello, LP; Norman, AW				Zanello, LP; Norman, AW			Stimulation by 1 alpha,25(OH)(2)-vitamin D-3 of whole cell chloride currents in osteoblastic ROS 17/2.8 cells - A structure-function study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC BIOLOGICAL RESPONSES; D ENDOCRINE SYSTEM; PARATHYROID-HORMONE; CALCIUM-TRANSPORT; STEROID-HORMONE; RAT OSTEOBLASTS; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; OSTEOSARCOMA CELLS; NONGENOMIC ACTIONS; ROS-17/2.8 CELLS	1 alpha,25-Dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) can generate biological responses via genomic and nongenomic mechanisms, This article reports for the first time the effects of 1 alpha,25(OH)(2)D-3 and structurally related analogs on whole cell chloride currents in osteoblastic cells. 1 alpha,25(OH)(2)D-3 promoted the rapid enhancement of outwardly rectifying Cl- currents in 93% of the osteoblasts in a concentration-dependent manner, with a maximal increase of about 4-fold between 0.5 and 5 nM. This effect of 1 alpha,25(OH)(2)D-3 was blocked by 1 nM stereoisomer 1 beta,25(OH)(2)D-3. when added to the bath before 1 alpha,25(OH)(2)D-3. On the other hand, 1 nM of the 6-s-cis locked analog 1 alpha,25(OH)(2)-lumisterol(3) significantly increased by about 2.2-fold outward Cl- currents in the ROS 17/2.8 cells, whereas the increase promoted by same concentration of the 6-s-trans locked analog 1 alpha,25(OH)(2)-tachysterol (0.8-fold) was significantly lower, suggesting that the 6-s-cis locked or steroid-like form was preferred over the extended 6-s-trans conformer to promote these rapid effects of the hormone, We conclude that the agonist effects of 1 alpha,25(OH)(2)D-3 in osteoblasts at the cellular membrane level seem to be determined by some structural, features of the molecule which may be crucial for its interaction with a putative membrane receptor in the cell surface.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside					PHS HHS [OK-09012-033] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARAN DT, 1994, J CELL BIOCHEM, V56, P510, DOI 10.1002/jcb.240560411; BARAN DT, 1994, J CELL BIOCHEM, V56, P303, DOI 10.1002/jcb.240560305; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CHESNOYMARCHAIS D, 1994, J MEMBRANE BIOL, V140, P173; CHESNOYMARCHAIS D, 1988, J PHYSIOL-LONDON, V398, P291, DOI 10.1113/jphysiol.1988.sp017043; CHESNOYMARCHAIS D, 1993, BIOCHIM BIOPHYS ACTA, V1148, P239, DOI 10.1016/0005-2736(93)90135-M; CHESNOYMARCHAIS D, 1989, PFLUG ARCH EUR J PHY, V415, P104, DOI 10.1007/BF00373147; DAVIDSON RM, 1990, PFLUG ARCH EUR J PHY, V416, P646, DOI 10.1007/BF00370609; DEBOLAND AR, 1992, J CELL BIOCHEM, V49, P32, DOI 10.1002/jcb.240490107; DEBOLAND AR, 1990, ENDOCRINOLOGY, V127, P2475, DOI 10.1210/endo-127-5-2475; DIXON SJ, 1984, J MEMBRANE BIOL, V80, P49, DOI 10.1007/BF01868689; DUNCAN R, 1989, FEBS LETT, V251, P17, DOI 10.1016/0014-5793(89)81420-6; DUNCAN RL, 1992, FEBS LETT, V307, P219, DOI 10.1016/0014-5793(92)80771-8; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1876, DOI 10.1210/endo-129-4-1876; FERRIER J, 1986, J CELL PHYSIOL, V126, P237, DOI 10.1002/jcp.1041260212; FERRIER J, 1987, J CELL PHYSIOL, V130, P344, DOI 10.1002/jcp.1041300306; FRITSCH J, 1987, BONE MINER, V2, P463; GOSLING M, 1995, J PHYSIOL-LONDON, V485, P671, DOI 10.1113/jphysiol.1995.sp020761; Gosling M, 1996, J PHYSIOL-LONDON, V493, P613, DOI 10.1113/jphysiol.1996.sp021408; GUGGINO SE, 1989, P NATL ACAD SCI USA, V86, P2657; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANNAH SS, 1994, NUTR REV, V52, P376, DOI 10.1111/j.1753-4887.1994.tb01368.x; JOELS M, 1995, J NEUROSCI, V15, P4289; LOWE K E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P65; LOZA J, 1994, CALCIFIED TISSUE INT, V55, P128, DOI 10.1007/BF00297188; NEMERE I, 1984, ENDOCRINOLOGY, V115, P1476, DOI 10.1210/endo-115-4-1476; NEMERE I, 1994, J BIOL CHEM, V269, P23750; NEMERE I, 1987, J BONE MINER RES, V2, P99; NEMERE I, 1991, MOL CELL ENDOCRINOL, V80, pC165, DOI 10.1016/0303-7207(91)90132-C; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; NORMAN AW, 1992, BIOCHEM BIOPH RES CO, V189, P1450, DOI 10.1016/0006-291X(92)90237-F; NORMAN AW, 1997, IN PRESS MOL ENDOCRI; Takeuchi K, 1996, J BIOL CHEM, V271, P33335, DOI 10.1074/jbc.271.52.33335; TWYMAN RE, 1992, J PHYSIOL-LONDON, V456, P215, DOI 10.1113/jphysiol.1992.sp019334; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P4383; YPEY DL, 1988, J MEMBRANE BIOL, V101, P141, DOI 10.1007/BF01872829; YUKHIRO S, 1994, J BIOL CHEM, V269, P23889; Zanello LP, 1996, BIOCHEM BIOPH RES CO, V225, P551, DOI 10.1006/bbrc.1996.1210; ZHANG SJ, 1994, J NEUROENDOCRINOL, V6, P533, DOI 10.1111/j.1365-2826.1994.tb00616.x	42	91	92	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22617	22622		10.1074/jbc.272.36.22617	http://dx.doi.org/10.1074/jbc.272.36.22617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278418	hybrid			2022-12-27	WOS:A1997XV49200038
J	Defilippi, P; Venturino, M; Gulino, D; Duperray, A; Boquet, P; Fiorentini, C; Volpe, G; Palmieri, M; Silengo, L; Tarone, G				Defilippi, P; Venturino, M; Gulino, D; Duperray, A; Boquet, P; Fiorentini, C; Volpe, G; Palmieri, M; Silengo, L; Tarone, G			Dissection of pathways implicated in integrin-mediated actin cytoskeleton assembly - Involvement of protein kinase C, Rho GTPase, and tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION PATHWAYS; EXTRACELLULAR-MATRIX; STRESS FIBERS; FIBRONECTIN; ACTIVATION; PP125(FAK); PLATELETS; ALPHA(IIB)BETA(3)	A panel of antibodies to the alpha IIb beta 3 integrin was used to promote adhesion of Chinese hamster ovary cells transfected with the alpha IIb beta 3 fibrinogen receptor. While some alpha IIb beta 3 antibodies were not able to induce p125 focal adhesion kinase (p125FAK) tyrosine phosphorylation, all the antibodies equally support cell adhesion but not spreading and assembly of actin stress fibers, Absence of stress fibers was also obtained by plating on antibodies directed to the hamster beta 1 integrin. In contrast, cells plated on matrix proteins spread organizing actin stress fibers. Treatment with phorbol esters phorbol 12-myristate 13-acetate (PMA) induced cells to spread on antibodies-coated dishes but not to organize actin in stress fibers, The combination of PMA and cytotoxic necrotizing factor 1 (CNF1), a specific Rho activator, induced cell spreading and organization of stress fibers. PMA or the combination of PMA and CNF1 also increases tyrosine phosphorylation of p125FAK in response to antibodies that were otherwise unable to trigger this response, These data show that: 1) matrix proteins and antibodies differ in their ability to induce integrin-dependent actin cytoskeleton organization (while matrix induced stress fibers formation, antibodies did not); 2) p125FAK tyrosine phosphorylation is insufficient per se to trigger actin stress fibers formation since antibodies that activate p125FAK tyrosine phosphorylation did not lead to actin stress fibers assembly; and 3) the inability of anti-integrin antibodies to trigger stress fibers organization is overcome by concomitant activation of the protein kinase C (PKC) and Rho pathways; PKC activation leads to cell spreading and Rho activation is required to organize actin stress fibers.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO PSICOL,ROME,ITALY; INSERM,U217,HEMATOL LAB,GRENOBLE,FRANCE; FAC MED NICE,INSERM,U452,F-06034 NICE,FRANCE; IST SUPER SANITA,ULTRASTRUTTURE LAB,I-00161 ROME,ITALY	Sapienza University Rome; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Istituto Superiore di Sanita (ISS)	Defilippi, P (corresponding author), UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,VIA SANTENA 5 BIS,I-10126 TURIN,ITALY.		Duperray, Alain/E-8428-2012; Fiorentini, Carla/Q-2088-2015; FIORENTINI, CARLA/AAG-8005-2019; DEFILIPPI, Paola/L-2232-2014	Duperray, Alain/0000-0002-2719-252X; Fiorentini, Carla/0000-0003-1707-6282; FIORENTINI, CARLA/0000-0003-1707-6282; Defilippi, Paola/0000-0001-6427-4906; Tarone, Guido/0000-0003-4805-086X				ARCANGELI A, 1993, J CELL BIOL, V122, P1131, DOI 10.1083/jcb.122.5.1131; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; BROWN PJ, 1988, EXP CELL RES, V177, P376; BURRIDGE CA, 1997, ANN REV CELL DEV BIO, V12, P463; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DANIELS K, 1991, J CELL SCI, V100, P249; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1351, DOI 10.1083/jcb.113.6.1351; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; FIORENTINI C, 1997, IN PRESS J BIOL CHEM; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Flinn HM, 1996, J CELL SCI, V109, P1133; FRACHET P, 1992, BIOCHEMISTRY-US, V31, P2408, DOI 10.1021/bi00123a028; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GONZALEZRODRIGUEZ J, 1994, BIOCHEMISTRY-US, V33, P266, DOI 10.1021/bi00167a035; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GULINO D, 1990, J BIOL CHEM, V265, P9575; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HIRSCH E, 1994, DEV DYNAM, V201, P108, DOI 10.1002/aja.1002010203; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KELLER HU, 1994, J CELL PHYSIOL, V161, P526, DOI 10.1002/jcp.1041610316; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEONG L, 1995, J CELL SCI, V108, P3817; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NIIYA K, 1987, BLOOD, V70, P472; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OCONNOR TP, 1993, J CELL BIOL, V123, P1581; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; VUORI K, 1993, J BIOL CHEM, V268, P21459; WOODS A, 1992, J CELL SCI, V101, P277; [No title captured]	53	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21726	21734		10.1074/jbc.272.35.21726	http://dx.doi.org/10.1074/jbc.272.35.21726			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268301	hybrid			2022-12-27	WOS:A1997XT85000013
J	Haghighat, A; Sonenberg, N				Haghighat, A; Sonenberg, N			eIF4G dramatically enhances the binding of eIF4E to the mRNA 5'-cap structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION-FACTORS; PROTEIN-KINASE-C; MESSENGER-RNA; TRANSLATION INITIATION; FACTOR EIF-4E; 4E-BINDING PROTEINS; SECONDARY STRUCTURE; ESCHERICHIA-COLI; CROSS-LINKING; IN-VITRO	The cap structure, m(7)GpppN, is present at the 5'-end of all eukaryotic cellular (except organellar) mRNAs, Initiation of translation is mediated by the multisubunit initiation factor eIF4F, which binds the cap structure via its eIF4E subunit and facilitates the binding of mRNA to ribosomes, Here, we used recombinant proteins to reconstitute the cap recognition activity of eIF4F in vitro, We demonstrate that the interaction of eIF4E with the mRNA 5'-cap structure is dramatically enhanced by eIF4G, as determined by a UV-induced cross-linking assay, Furthermore, assembly of the eIF4F complex at the cap structure, as well as ATP hydrolysis, is shown to be a requisite for the cross-linking of another initiation factor, eIF4B, to the cap structure, In addition, the stimulatory effect of eIF4G on the cap recognition of eIF4E is inhibited by the translational repressor, 4E-BP1, These results suggest that eIF4E initially interacts with the mRNA cap structure as part of the eIF4F complex.	MCGILL UNIV,FAC MED,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University								BELSHAM G J, 1980, Biochemical Society Transactions, V8, P382; BU X, 1993, J BIOL CHEM, V268, P4975; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; EDERY I, 1983, J BIOL CHEM, V258, P1398; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; EDERY I, 1987, TRANSLATIONAL REGULA, P335; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; JOSHI B, 1994, J BIOL CHEM, V269, P2048; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LEE KAW, 1985, J VIROL, V54, P515, DOI 10.1128/JVI.54.2.515-524.1985; LEE KAW, 1982, P NATL ACAD SCI-BIOL, V79, P3447, DOI 10.1073/pnas.79.11.3447; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PELLETIER J, 1985, MOL CELL BIOL, V5, P3222, DOI 10.1128/MCB.5.11.3222; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; RAY BK, 1985, J BIOL CHEM, V260, P7651; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; SONENBERG N, 1981, NUCLEIC ACIDS RES, V9, P1643, DOI 10.1093/nar/9.7.1643; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Summers MD, 1987, MANUAL METHODS BACUL; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; UEDA H, 1991, J BIOCHEM-TOKYO, V109, P882, DOI 10.1093/oxfordjournals.jbchem.a123475; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831	38	197	211	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21677	21680		10.1074/jbc.272.35.21677	http://dx.doi.org/10.1074/jbc.272.35.21677			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268293	hybrid			2022-12-27	WOS:A1997XT85000005
J	Shilatifard, A; Haque, D; Conaway, RC; Conaway, JW				Shilatifard, A; Haque, D; Conaway, RC; Conaway, JW			Structure and function of RNA polymerase II elongation factor ELL - Identification of two overlapping ELL functional domains that govern its interaction with polymerase and the ternary elongation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-SIII; TUMOR-SUPPRESSOR PROTEIN; PROLINE-RICH PROTEIN; PREINITIATION COMPLEX; ACUTE LEUKEMIAS; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; ABORTIVE INITIATION; GENE-TRANSCRIPTION; MYELOID-LEUKEMIA	The human ELL gene on chromosome 19p13.1 undergoes frequent translocations with the trithorax-like MLL gene on chromosome 11q23 in acute myeloid leukemia, Recently, the human ELL gene was shown to encode an RNA polymerase II elongation factor that activates elongation by suppressing transient pausing by polymerase at many sites along the DNA. In this report, we identify and characterize two overlapping ELL functional domains that govern its interaction with RNA polymerase II and the ternary elongation complex. Our findings reveal that, in addition to its elongation activation domain, ELL contains a novel type of RNA polymerase II interaction domain that is capable of negatively regulating polymerase activity in promoter-specific transcription initiation in vitro. Notably, the MLL-ELL translocation results in deletion of a portion of this functional domain, and ELL mutants lacking sequences deleted by the translocation bind RNA polymerase II and are fully active in elongation, but fail to inhibit initiation. Taken together, these results raise the possibility that the MLL-ELL translocation could alter ELL-RNA polymerase II interactions that are not involved in regulation of elongation.	OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73190	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center				Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; ASO T, 1994, J BIOL CHEM, V269, P26575; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; IIDA S, 1993, ONCOGENE, V8, P3085; INOSTROZA JA, 1992, CELL, V70, P477; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KAUFMAN PD, 1991, P NATL ACAD SCI USA, V88, P2613, DOI 10.1073/pnas.88.7.2613; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee G, 1996, P NATL ACAD SCI USA, V93, P2570, DOI 10.1073/pnas.93.6.2570; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PETERSON MG, 1991, NATURE, V354, P369; POEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1994, TRANSCRIPTION MECHAN, P263; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAMBRIIJ H, 1989, MOL CLONING LAB MANU; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TAN SY, 1994, BIOTECHNIQUES, V16, P824; Thirman MJ, 1997, P NATL ACAD SCI USA, V94, P1408, DOI 10.1073/pnas.94.4.1408; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WU J, 1993, J VIROL, V67, P7547, DOI 10.1128/JVI.67.12.7547-7555.1993; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	59	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22355	22363		10.1074/jbc.272.35.22355	http://dx.doi.org/10.1074/jbc.272.35.22355			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268387	hybrid			2022-12-27	WOS:A1997XT85000099
J	Torpey, J; deMontellano, PRO				Torpey, J; deMontellano, PRO			Oxidation of alpha-meso-formylmesoheme by heme oxygenase - Electronic control of the reaction regiospecificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; REGIOISOMERS; MESSENGER; CLEAVAGE	The oxidation of heme to biliverdin Ma by heme oxygenase involves regiospecific alpha-meso hydroxylation followed by extrusion of the alpha-mese-carbon as CO, In an earlier study, enzymatic oxidation of the four meso-methylmesoheme isomers suggested that the reaction regiospecificity is sensitive to the electronic properties of the mesoe-methyl group (Torpey, J. W., and Ortiz de Montellano, P. R. (1996) J. Biol. Chem. 271, 26067-26073), although we could not exclude the possibility that the altered reaction regiochemistry was due to perturbation of the porphyrin structure by the meso substituent. To examine this possibility, we have synthesized the four meso-formylmesoporphyrin isomers and have examined their oxidation by heme oxygenase, The meso-formyl and meso methyl substituents differ in that the former is electron withdrawing and the latter is electron donating. In contrast to alpha-meso-methylmesoheme, which is exclusively oxidized at the methyl-substituted position, alpha-meso-formylmesoheme is exclusively oxidized at a non-formyl-substituted meso-carbon. The finding that the methyl and formyl groups channel the reaction regiospecificity in opposite directions establishes that the regiochemistry of the heme oxygenase reaction is primarily under electronic rather than steric control. It also confirms that the oxidation involves electrophilic addition of the oxygen to the porphyrin ring.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, R01DK030297] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01614] Funding Source: Medline; NIDDK NIH HHS [DK30297, 5 P30 DK26743] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONNETT R, 1973, J CHEM SOC PERK T 1, P881, DOI 10.1039/p19730000881; BROWN SB, 1981, NATURE, V289, P93, DOI 10.1038/289093a0; Hansch C., 1995, EXPLORING QSAR FUNDA, P1; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; LAGARIAS JC, 1982, BIOCHIM BIOPHYS ACTA, V717, P12, DOI 10.1016/0304-4165(82)90373-7; LIGHTNER DA, 1969, ARCH BIOCHEM BIOPHYS, V131, P566, DOI 10.1016/0003-9861(69)90431-7; Liu Y, 1997, J BIOL CHEM, V272, P6909, DOI 10.1074/jbc.272.11.6909; MAINES MD, 1992, HEME OXYGENASE CLIN, P203; MARKS GS, 1994, CELL MOL BIOL, V40, P863; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; SAITO S, 1982, P NATL ACAD SCI-BIOL, V79, P1393, DOI 10.1073/pnas.79.5.1393; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Torpey J, 1996, J BIOL CHEM, V271, P26067, DOI 10.1074/jbc.271.42.26067; TORPEY J, 1997, THESIS U CALIFORNIA; TORPEY JW, 1995, J ORG CHEM, V60, P2195, DOI 10.1021/jo00112a045; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1994, J BIOL CHEM, V269, P29553; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x	24	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22008	22014		10.1074/jbc.272.35.22008	http://dx.doi.org/10.1074/jbc.272.35.22008			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268339	hybrid			2022-12-27	WOS:A1997XT85000051
J	DeLuca, A; MacLachlan, TK; Bagella, L; Dean, C; Howard, CM; Claudio, PP; Baldi, A; Khalili, K; Giordano, A				DeLuca, A; MacLachlan, TK; Bagella, L; Dean, C; Howard, CM; Claudio, PP; Baldi, A; Khalili, K; Giordano, A			A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE FAMILY; CYCLIN-DEPENDENT KINASES; CELL-CYCLE; E2F FAMILY; PROTEIN; P107; MEMBER; EXPRESSION; CLONING; PRODUCT	The Cdk2 kinase has long been known to be involved in the progression of mammalian cells past the G(1) phase restriction point and through DNA replication in the cell cycle. The Rb family of proteins, consisting of pRb, p107, and pRb2/p130, has also been shown to monitor progression of G, phase, mostly through their interaction with E2F family members. p107 is able to inhibit Cdk2 kinase activity through this interaction via a p21-related domain present in the C terminus of the protein. We show here that pRb2/p130 also possesses this activity, but through a separate domain. Moreover, we correlate the increased expression of pRb2/p130 during various cellular processes with the decreased kinase activity of Cdk2. We hypothesize that pRb2/p130 may act not only to bind and modify E2F activity, but also to inhibit Cdk2 kinase activity in concert with p21 in a manner different from p107.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,SBARRO INST CANC RES & MOL MED,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOL MED,DEPT BIOCHEM & MOL BIOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University; Jefferson University			De Luca, Antonio/AAD-9562-2020; Claudio, Pier Paolo/AAW-7282-2021; Giordano, Antonio/F-1927-2010; Baldi, Alfonso/ABG-2397-2021	De Luca, Antonio/0000-0002-3905-6154; Claudio, Pier Paolo/0000-0001-7790-1622; Giordano, Antonio/0000-0002-5959-016X; Howard, Candace/0000-0001-6537-3551; Baldi, Alfonso/0000-0002-8693-3842; BAGELLA, Luigi/0000-0003-2815-037X	NCI NIH HHS [R01 CA60999-01A1] Funding Source: Medline; NINDS NIH HHS [P01 NS36466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BUCK V, 1995, ONCOGENE, V11, P31; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Claudio PP, 1996, CANCER RES, V56, P2003; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MAYOL X, 1993, ONCOGENE, V8, P2561; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; VANWIJNEN AJ, 1997, IN PRESS J CELL BIOC; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	21	76	78	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20971	20974		10.1074/jbc.272.34.20971	http://dx.doi.org/10.1074/jbc.272.34.20971			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261093	hybrid			2022-12-27	WOS:A1997XR78900003
J	Liu, JY; Rosen, BP				Liu, JY; Rosen, BP			Ligand interactions of the ArsC arsenate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SULFATE REDUCTION; HYDROGEN DONOR; GLUTAREDOXIN; GLUTATHIONE; THIOREDOXIN; PROTEIN; RESISTANCE; DISULFIDE; MUTANT	ArsC encoded by Escherichia coli plasmid R773 catalyzes the reduction of arsenate to arsenite, The enzymatic reaction requires reduced glutathione and glutaredoxin. In this study a direct association between ArsC and glutaredoxin was demonstrated. An arsC gene with six histidine codons added to the 5' end of the gene was constructed, and the resulting ArsC enyzme was shown to be functional. Interaction of the histidine-tagged ArsC and glutaredoxin was examined by Ni2+ affinity chromatography. The association required the presence of reduced glutathione and either the substrate arsenate or a competitive inhibitor, phosphate or sulfate. A free thiolate on glutathione was not required, A tryptophan residue was introduced into ArsC at the 11th position, immediately adjacent to tl-re active site Cys-la, Trp-ll fluorescence was quenched upon addition of arsenate, Addition of reduced glutathione after arsenate resulted in a rapid increase in fluorescence followed by a slower decay of the signal. These spectroscopic signals were specific for arsenate and reduced glutathione; neither competitive inhibitors nor non-thiol glutathione analogs produced this effect, Cys-12 thiolate was also required, Thus the intrinsic fluorescence of Trp-ll provides a useful probe to investigate the mechanism of this novel reductase.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM52216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken Alastair, 1996, P3, DOI 10.1007/978-1-60327-259-9_1; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7287; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1995, BIOCHEMISTRY-US, V34, P13572; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; Rosen BP, 1996, J BIOL INORG CHEM, V1, P273, DOI 10.1007/s007750050053; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; TURNER RJ, 1992, J BACTERIOL, V174, P3092, DOI 10.1128/JB.174.9.3092-3094.1992; WELLS WW, 1990, J BIOL CHEM, V265, P15361	21	39	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21084	21089		10.1074/jbc.272.34.21084	http://dx.doi.org/10.1074/jbc.272.34.21084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261111	hybrid			2022-12-27	WOS:A1997XR78900021
J	Benashski, SE; Harrison, A; PatelKing, RS; King, SM				Benashski, SE; Harrison, A; PatelKing, RS; King, SM			Dimerization of the highly conserved light chain shared by dynein and myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-ARM DYNEIN; PROTEIN SECONDARY STRUCTURE; CHLAMYDOMONAS FLAGELLA; INTERMEDIATE CHAIN; POLYPEPTIDE COMPOSITION; CIRCULAR-DICHROISM; TROUT SPERMATOZOA; PURIFICATION; SUBUNIT; BINDING	The M-r 8,000 light chain originally identified in Chlamydomonas flagellar dynein is also a component of both cytoplasmic dynein and myosin V, Furthermore, this small protein has been implicated as an inhibitor of neuronal nitric oxide synthase, suggesting that it may play multiple regulatory roles within the cell, Covalent cross-linking of both dynein and myosin V using 1,5-difluoro-2,4-dinitrobenzene revealed that this light chain exists as a dimer in situ, This observation was confirmed using two additional amine-selective crosslinking reagents (dimethyl pimelimidate and disuccinimidyl suberate). When expressed as a C-terminal fusion with maltose-binding protein, the presence of the light chain caused the recombinant molecule to dimerize. Analysis of fusions containing truncated light chains identified the predicted amphiphilic helix (residues 14-32) as sufficient to cause dimerization; cross-linking required a second helical segment (residues 33-46), Together the data presented suggest that two light chains interact to form a parallel dimeric structure, This arrangement has significant implications for the potential functions of this highly conserved molecule and suggests a mechanism by which it might dissociate nitric oxide synthase.	UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06032 USA	University of Connecticut					NIGMS NIH HHS [GM 51293] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051293] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckwith S. M., 1995, Molecular Biology of the Cell, V6, p5A; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P12; Dick T, 1996, MOL CELL BIOL, V16, P1966; Espindola F. S., 1996, Molecular Biology of the Cell, V7, p372A; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; GATTI JL, 1989, J BIOL CHEM, V264, P11450; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Holzbaur Erika L. F., 1994, V13, P251; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KING SM, 1995, METHOD CELL BIOL, V47, P9, DOI 10.1016/S0091-679X(08)60783-9; KING SM, 1986, METHOD ENZYMOL, V134, P291; KING SM, 1990, CELL MOTIL CYTOSKEL, V16, P266, DOI 10.1002/cm.970160406; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; KING SM, 1991, J BIOL CHEM, V266, P8401; KING SM, 1995, J CELL BIOL, V131, P399, DOI 10.1083/jcb.131.2.399; Luck D.J.L., 1989, CELL MOVEMENT, V1, P49; MITCHELL DR, 1986, CELL MOTIL CYTOSKEL, V6, P510, DOI 10.1002/cm.970060510; MITCHELL DR, 1991, J CELL BIOL, V113, P835, DOI 10.1083/jcb.113.4.835; MOSS AG, 1992, J CELL BIOL, V118, P1189, DOI 10.1083/jcb.118.5.1189; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; Phillis R, 1996, DEVELOPMENT, V122, P2955; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TANG WJY, 1982, J BIOL CHEM, V257, P508; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; Witman George B., 1994, V13, P229	32	115	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20929	20935		10.1074/jbc.272.33.20929	http://dx.doi.org/10.1074/jbc.272.33.20929			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252421	hybrid			2022-12-27	WOS:A1997XR22100091
J	Ishibashi, K; Kuwahara, M; Gu, Y; Kageyama, Y; Tohsaka, A; Suzuki, F; Marumo, F; Sasaki, S				Ishibashi, K; Kuwahara, M; Gu, Y; Kageyama, Y; Tohsaka, A; Suzuki, F; Marumo, F; Sasaki, S			Cloning and functional expression of a new water channel abundantly expressed in the testis permeable to water, glycerol, and urea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING DUCT; ESCHERICHIA-COLI; MOLECULAR-CLONING; FACILITATOR; SPERMATOZOA; AQUAPORIN; MEMBRANE; HOMOLOG; KINASE; CHIP28	A new member of the aquaporin (AQP) family has been identified from rat testis. This gene, referred as aquaporin 7 (AQP7), encodes a 269-amino acid protein that contained the conserved NPA motifs of MLP family proteins, AQP7 has the amino acid sequence homology with other aquaporins (similar to 30%), and it is highest with AQP3 (48%), suggesting that both AQP3 and AQP7 belong to a subfamily in the MIP family, Injection of AQP7-cRNA into Xenopus oocytes expressed a 26-kDa protein detected by immunoblotting, The expression of AQP7 in oocytes stimulated the osmotic water permeability by 10-fold which was not inhibited by 0.3 mm mercury chloride, The Arrhenius activation energy for the stimulated water permeability was low (2.1 kcal/mol), AQP7 also facilitated glycerol and urea transport by 5- and 9-fold, respectively. The activation energy for glycerol was also low (5.3 kcal/mol after the correction of the endogenous glycerol permeability of oocytes), Northern blot analysis revealed a 1.5-kilobase pair transcript expressed abundantly in testis. In situ hybridization of testis revealed the expression of AQP7 at late spermatids in seminiferous tubules. The immunohistochemistry of testis localized the AQP7 expression at late spermatids and at maturing sperms, AQP7 may play an important role in sperm function.	TOKYO MED & DENT UNIV,DEPT UROL,TOKYO 113,JAPAN; OUME GEN HOSP,RENAL UNIT,TOKYO 198,JAPAN; CHIBA UNIV,SCH MED,DEPT ANAT 2,CHIBA 260,JAPAN	Tokyo Medical & Dental University (TMDU); Chiba University	Ishibashi, K (corresponding author), TOKYO MED & DENT UNIV,DEPT INTERNAL MED 2,BUNKYO KU,1-5-45 YUSHIMA,TOKYO 113,JAPAN.							CALAMITA G, 1995, J BIOL CHEM, V270, P29063, DOI 10.1074/jbc.270.49.29063; CURRY MR, 1994, BIOL REPROD, V51, P1014, DOI 10.1095/biolreprod51.5.1014; DANIELS MJ, 1994, PLANT PHYSIOL, V106, P1325, DOI 10.1104/pp.106.4.1325; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Echevarria M, 1996, J BIOL CHEM, V271, P25079, DOI 10.1074/jbc.271.41.25079; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU C, 1995, BIOL REPROD, V52, P913, DOI 10.1095/biolreprod52.4.913; Ma TH, 1996, GENOMICS, V35, P543, DOI 10.1006/geno.1996.0396; MA TH, 1994, J BIOL CHEM, V269, P21845; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Shi LB, 1996, BIOCHEMISTRY-US, V35, P538, DOI 10.1021/bi9520038; STARGENT C, 1994, HUM MOL GENET, V3, P1317; VOEGELE RT, 1993, J BACTERIOL, V175, P1087, DOI 10.1128/JB.175.4.1087-1094.1993; WATSON PF, 1992, J ANDROL, V13, P131; WEISSENBORN DL, 1992, J BIOL CHEM, V267, P6122	19	317	335	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20782	20786		10.1074/jbc.272.33.20782	http://dx.doi.org/10.1074/jbc.272.33.20782			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252401	hybrid			2022-12-27	WOS:A1997XR22100071
J	Marcil, J; Harbour, D; Naccache, PH; Bourgoin, S				Marcil, J; Harbour, D; Naccache, PH; Bourgoin, S			Human phospholipase D1 can be tyrosine-phosphorylated in HL-60 granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; HUMAN NEUTROPHILS; ACTIVATION; CELLS; RHOA; DOWNSTREAM; FRACTIONS; MEMBRANE; ARF	The human phospholipase D1 (hPLD1) has recently been cloned, Although recent data have implicated PLD in receptor-stimulated secretion, the regulation of the activity of PLD enzymes remains to be clarified, Purified hPLD1 is activated by several cytosolic cofactors among which are protein kinase C alpha, ARF, and RhoA, In human granulocytes, a strong correlation between tyrosine phosphorylation of proteins and PLD activity has been established, In this study, the presence of hPLD1 in HL-60 granulocytes and its phosphorylation on tyrosine residues have been studied, We generated antipeptide antibodies (Abs) specific for hPLD1 but not PLD2 as shown by Western blotting (WE) of recombinant PLD1 and PLD2. These Abs identified the presence of hPLD1 in HL-60 cells with the bulk of it being detected in the membranes and only a minor fraction in the cytosol. The hPLD1 Abs detected a major band at 120 kDa (PLD1a) and a minor band at 115 kDa (PLD1b). The specificity of the Abs was confirmed using PLD antisera neutralized with the immunizing peptides, The two forms of hPLD1 were consistently detected by immunoprecipitation under nondenaturing and denaturing conditions following a WE analysis with hPLD1 Abs, Following exposure of HL-60 cells to peroxides of vanadate (V4+-OOH), an inhibitor of tyrosine phosphatases, hPLD1 was immuno-precipitated under nondenaturing conditions from HL-60 cell lysates and assayed for tyrosine phosphorylation by WB. hPLD1 comigrated with a 120-kDa tyrosine phosphorylated protein by gel electrophoresis, Other tyrosine-phosphorylated peptides of 160, 140, 135, 90, and 75-80 kDa were also detected in hPLD1 immune complexes, hPLD1 and the associated tyrosine-phosphorylated proteins were not immunoprecipitated by neutralized hPLD1 Abs, Using denaturing conditions, the PLD immunoprecipitates were sequentially immunoblotted with anti-PLD1 and anti-phosphotyrosine Abs. PLD1a and PLD1b were detected, and the major PLD1a protein was superimposable with a major tyrosine phosphorylated protein detected at 120 kDa, Conversely, PLD1a and PLD1b were recovered, at least in part, in the anti-phosphotyrosine immunoprecipitates. These results provide evidence that two PLD1 forms are expressed in human granulocytes. Furthermore, in response to stimulation by V4+-OOH, PLD1 was tyrosine-phosphorylated and associated with several, presently undefined, tyrosine-phosphorylated proteins.	CHUL,CTR RECH,CTR RECH RHUMATOL & IMMUNOL,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT MED,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT PHYSIOL,ST FOY,PQ G1V 4G2,CANADA	Laval University; Laval University; Laval University				Bourgoin, Sylvain/0000-0001-9779-0368				AlShami A, 1997, J IMMUNOL METHODS, V202, P183, DOI 10.1016/S0022-1759(97)00004-5; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Decker C, 1996, BIOCHEM J, V320, P885, DOI 10.1042/bj3200885; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GOMEZCAMBRONERO J, 1995, J INTERF CYTOK RES, V15, P877, DOI 10.1089/jir.1995.15.877; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OLSON SC, 1991, J BIOL CHEM, V266, P17236; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; Ribbes G, 1996, BIOCHEM BIOPH RES CO, V224, P206, DOI 10.1006/bbrc.1996.1008; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; Yoshimura S, 1996, BIOCHEM BIOPH RES CO, V225, P494, DOI 10.1006/bbrc.1996.1201	29	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20660	20664		10.1074/jbc.272.33.20660	http://dx.doi.org/10.1074/jbc.272.33.20660			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252384	hybrid			2022-12-27	WOS:A1997XR22100054
J	Hashim, MF; SchnetzBoutaud, N; Marnett, LJ				Hashim, MF; SchnetzBoutaud, N; Marnett, LJ			Replication of template-primers containing propanodeoxyguanosine by DNA polymerase beta - Induction of base pair substitution and frameshift mutations by template slippage and deoxynucleoside triphosphate stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM HISD3052; DUPLEX OLIGODEOXYNUCLEOTIDE; ESCHERICHIA-COLI; 2-BASE DELETION; IN-VITRO; HOT-SPOT; MUTAGENESIS; FIDELITY; ADDUCT; OPPOSITE	Propanodeoxyguanosine (PdG) is a model for several unstable exocyclic adducts formed by reaction of DNA with bifunctional carbonyl compounds generated by lipid peroxidation. The effect of PdG on DNA synthesis by human DNA polymerase beta was evaluated using template-primers containing PdG at defined sites, DNA synthesis was conducted in vitro and the products were analyzed by polyacrylamide gel electrophoresis and DNA sequencing, The extent of PdG bypass was low and the products comprised a mixture of base pair substitutions and deletions, Sequence analysis of all of the products indicated that the deoxynucleoside monophosphate incorporated ''opposite'' PdG was complementary to the base 5' to PdG in the template strand., These findings are very similar to recent results of Efrati et al., (Efrati, E., Tocco, G., Eritja, R., Wilson, S. H., and Goodman, M. F. (1997) J. Biol. Chem. 272, 2559-2569) obtained in DNA replication of template-primers containing abasic sites and suggest that PdG is a non-informational lesion when acted upon by polymerase (pol) beta, In addition to base pair substitutions and one- or two-base deletions, a four-base deletion was observed and the mechanism of its formation was probed by site-specific mutagenesis, The results indicated that this deletion occurred by one-base insertion followed by slippage to form a four-base loop followed by extension, All of the observations on pol beta replication of PdG-containing template-primers are consistent with a mechanism of lesion bypass that involves template slippage and dNTP stabilization followed by deoxynucleoside monophosphate incorporation and extension, This mechanism of PdG bypass is completely different than that previously determined for the Klenow fragment of DNA polymerase I and is consistent with recent structural models for DNA synthesis by pol beta.	VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,VANDERBILT CANC CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BURCHAM PC, 1994, J BIOL CHEM, V269, P28844; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; CHANG LMS, 1973, J BIOL CHEM, V248, P6983; CHARY P, 1995, NUCLEIC ACIDS RES, V23, P1398, DOI 10.1093/nar/23.8.1398; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Efrati E, 1997, J BIOL CHEM, V272, P2559; FEIG DI, 1994, J MOL BIOL, V235, P33, DOI 10.1016/S0022-2836(05)80009-9; Fink SP, 1996, CHEM RES TOXICOL, V9, P277, DOI 10.1021/tx950060w; FRIEDMANN T, 1978, NUCLEIC ACIDS RES, V5, P615, DOI 10.1093/nar/5.2.615; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Hashim MF, 1996, J BIOL CHEM, V271, P9160, DOI 10.1074/jbc.271.15.9160; Hoffmann JS, 1996, J BIOL CHEM, V271, P15386, DOI 10.1074/jbc.271.26.15831; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; JOHNSON KA, 1995, THESIS VANDERBILT U; KOUCHAKDJIAN M, 1990, BIOCHEMISTRY-US, V29, P4456, DOI 10.1021/bi00470a028; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; Levy DD, 1996, J MOL BIOL, V258, P251, DOI 10.1006/jmbi.1996.0247; LOECHLER EL, 1995, MOL CARCINOGEN, V13, P213, DOI 10.1002/mc.2940130404; MACCABEE M, 1994, J MOL BIOL, V236, P514, DOI 10.1006/jmbi.1994.1162; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; Marnett L J, 1994, IARC Sci Publ, P151; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER JH, 1983, ANNU REV GENET, V17, P215, DOI 10.1146/annurev.ge.17.120183.001243; MOE JG, 1994, CHEM RES TOXICOL, V7, P319, DOI 10.1021/tx00039a008; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PRASAD R, 1994, J BIOL CHEM, V269, P18096; RehaKrantz LJ, 1996, J BIOL CHEM, V271, P20088, DOI 10.1074/jbc.271.33.20088; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shibutani S, 1996, BIOCHEMISTRY-US, V35, P14992, DOI 10.1021/bi961446o; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; Singh J, 1996, J BIOL CHEM, V271, P28391, DOI 10.1074/jbc.271.45.28391; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Vogel EW, 1996, MUTAT RES-FUND MOL M, V353, P177, DOI 10.1016/0027-5107(96)00032-2; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEISENSEEL JP, 1995, BIOCHEMISTRY-US, V34, P50, DOI 10.1021/bi00001a007; Werz O, 1996, EUR J BIOCHEM, V242, P90, DOI 10.1111/j.1432-1033.1996.0090r.x	50	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20205	20212		10.1074/jbc.272.32.20205	http://dx.doi.org/10.1074/jbc.272.32.20205			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242698	hybrid			2022-12-27	WOS:A1997XQ05900085
J	Heise, T; Nath, A; Jungermann, K; Christ, B				Heise, T; Nath, A; Jungermann, K; Christ, B			Purification of a RNA-binding protein from rat liver - Identification as ferritin L chain and determination of the RNA/protein binding characteristics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PROSOME-LIKE PARTICLE; MESSENGER-RNA; GENE-TRANSCRIPTION; CYTOSOLIC PROTEIN; DEGRADATION; IRON; STABILIZATION; INSULIN; PHOSPHORYLATION	In cultured rat hepatocytes the degradation of phosphoenolpyruvate carboxykinase mRNA might be regulated by protein(s), which by binding to the mRNA alter its stability, The 3'-untranslated region of phosphoenolpyruvate carboxykinase mRNA as a potential target was used to select RNA-binding protein(s) from rat liver by the use of gel retardation assays, A cytosolic protein was isolated, which bound to the phosphoenolpyruvate carboxykinase mRNA 3'-untranslated region and other in vitro synthesized RNAs, The protein was purified to homogeneity; it had an apparent molecular mass of 400 kDa and consisted of identical subunits with an apparent size of 24.5 kDa, Sequence analysis of a tryptic peptide from the 24.5-kDa protein revealed its identity with rat ferritin light chain. Binding of ferritin to RNA was abolished after phosphorylation with cAMP-dependent protein kinase and was augmented after dephosphorylation with alkaline phosphatase. Weak binding was observed in extracts from okadaic acid-treated cultured hepatocytes compared with untreated cells, Preincubation of ferritin with an anti-phosphoserine or an anti-phosphothreonine antibody attenuated binding to RNA, while an anti-phosphotyrosine antibody generated a supershift indicating that phosphoserine and phosphothreonine but not phosphotyrosine residues were in close proximity to the RNA-binding region, Ferritin is the iron storage protein in the Liver, Binding of ferritin to RNA was diminished in the presence of increasing iron concentrations, whereas the iron chelator desferal was without effect, It is concluded that ferritin might function as RNA-binding protein and that it may have important functions in the general regulation of cellular RNA metabolism.	UNIV GOTTINGEN,INST BIOCHEM & MOL ZELLBIOL,D-37073 GOTTINGEN,GERMANY	University of Gottingen				Christ, Bruno/0000-0001-8213-9548				AKHAYAT O, 1987, EUR J BIOCHEM, V170, P23, DOI 10.1111/j.1432-1033.1987.tb13663.x; Alberts B., 1994, MOL BIOL CELL; ANDREONE TL, 1982, J BIOL CHEM, V257, P35; BEALE EG, 1985, J BIOL CHEM, V260, P748; BELASCO J, 1993, CONTROL MRNA STABILI; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BROWN BD, 1990, GENE DEV, V4, P1925, DOI 10.1101/gad.4.11.1925; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHRIST B, 1991, BIOCHEM BIOPH RES CO, V177, P1273, DOI 10.1016/0006-291X(91)90679-2; CHRIST B, 1993, EUR J BIOCHEM, V215, P541, DOI 10.1111/j.1432-1033.1993.tb18063.x; CHRIST B, 1994, HEPATOLOGY, V20, P1577, DOI 10.1002/hep.1840200629; CHRIST B, 1990, BIOL CHEM H-S, V371, P395, DOI 10.1515/bchm3.1990.371.1.395; COUX O, 1992, EUR J BIOCHEM, V207, P823, DOI 10.1111/j.1432-1033.1992.tb17113.x; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DEGRAAF J, 1990, EUR J BIOCHEM, V193, P737; DEHERDT E, 1979, EUR J BIOCHEM, V96, P423; DEHERDT E, 1981, BIOCHEM J, V194, P9, DOI 10.1042/bj1940009; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; HOD Y, 1988, J BIOL CHEM, V263, P7747; HUA JL, 1992, MOL ENDOCRINOL, V6, P1418, DOI 10.1210/me.6.9.1418; IHARA K, 1984, J BIOL CHEM, V259, P278; IWAI Y, 1991, J BIOL CHEM, V266, P17959; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MUNRO HN, 1978, PHYSIOL REV, V58, P317, DOI 10.1152/physrev.1978.58.2.317; NACHALIEL N, 1993, J BIOL CHEM, V268, P24203; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; ROHRER JS, 1987, J BIOL CHEM, V262, P13385; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; St. Johnston D., 1995, CELL, V81, P161, DOI DOI 10.1016/0092-8674(95)90324-0; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; VOORMA HO, 1994, MOL BIOL REP, V19, P139, DOI 10.1007/BF00986956; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857	42	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20222	20229		10.1074/jbc.272.32.20222	http://dx.doi.org/10.1074/jbc.272.32.20222			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242700	hybrid			2022-12-27	WOS:A1997XQ05900087
J	Obiri, NI; Murata, T; Debinski, W; Puri, RK				Obiri, NI; Murata, T; Debinski, W; Puri, RK			Modulation of interleukin (IL)-13 binding and signaling by the gamma(c) chain of the IL-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL CARCINOMA-CELLS; FUNCTIONAL COMPONENT; TRANSDUCTION; ACTIVATION; JAK1; SIMILARITIES	Interleukin (IL)-13 and IL-4 are cytokine products of T(H)2 cells which exert similar effects in a variety of cell types. We recently described IL-ISR expression on human renal cell and colon carcinoma cells and demonstrated that gamma(c) is not a component of IL-13R, or IL-4R systems in these cells, In lymphoid cells such as B cells and monocytes, which respond to IL-13, gamma(c) is a component of IL-4R but does not appear to be a component of IL-13R, Furthermore, while significant IL-13 binding is observed on carcinoma cells, IL-13 barely binds these lymphoid cells and the binding characteristics are different, To better understand the role of gamma(c) in IL-13 binding and signaling, we have transfected a renal cell carcinoma cell line with gamma(c) and examined IL-13 and IL-4 binding and signaling, IL-13 binding as well as IL-13 and IL-4 signaling through the JAK-STAT signaling pathway were severely inhibited, This inhibition was paralleled by a loss of expression of one of the IL-13R chains and intercellular cell adhesion molecule-1. Thus, although gamma(c) has been shown to enhance IL-4 binding and function in some cell types, its influence on IL-13R function in tumor cells appear to be largely negative.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT SURG,DIV NEUROSURG,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Obiri, NI (corresponding author), US FDA,LAB MOL TUMOR BIOL,DIV CELLULAR & GENE THERAPIES,CTR BIOL EVALUAT & RES,NIH,HFM-530,BETHESDA,MD 20892, USA.							Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Izuhara K, 1996, J BIOL CHEM, V271, P619, DOI 10.1074/jbc.271.2.619; Kammer W, 1996, J BIOL CHEM, V271, P23634, DOI 10.1074/jbc.271.39.23634; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; Lai SY, 1996, EMBO J, V15, P4506, DOI 10.1002/j.1460-2075.1996.tb00828.x; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murata T, 1997, CELL IMMUNOL, V175, P33, DOI 10.1006/cimm.1996.1051; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Murata T, 1996, J IMMUNOL, V156, P2972; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; OBIRI NI, 1995, INT J CANCER, V61, P635, DOI 10.1002/ijc.2910610509; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J IMMUNOL, V158, P756; Obiri NI, 1996, CLIN CANCER RES, V2, P1743; Puri RK, 1996, CELL IMMUNOL, V171, P80, DOI 10.1006/cimm.1996.0176; PURI RK, 1993, CANCER INVEST, V11, P473, DOI 10.3109/07357909309018879; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	33	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20251	20258		10.1074/jbc.272.32.20251	http://dx.doi.org/10.1074/jbc.272.32.20251			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242704	hybrid			2022-12-27	WOS:A1997XQ05900091
J	Kobayashi, C; Suga, Y; Yamamoto, K; Yomo, T; Ogasahara, K; Yutani, K; Urabe, I				Kobayashi, C; Suga, Y; Yamamoto, K; Yomo, T; Ogasahara, K; Yutani, K; Urabe, I			Thermal conversion from low- to high-activity forms of catalase I from Bacillus stearothermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PEROXIDASE; PURIFICATION; PROTEINS; TEMPERATURE; PRINCIPLES; KINETICS; SEQUENCE	Catalase I from Bacillus stearothermophilus has the interesting property of increasing its enzyme activity on heating. It was confirmed that after heating at 70 degrees C for 10 min or 65 degrees C for 20 min, almost all the enzyme molecules were converted irreversibly to the activated form. The increase in k(cat) from 1400 to 3930 s(-1) and the decrease in K-m for H2O2 from 4.4 to 2.7 mM by heat activation indicate changes in the kinetic property of the enzyme molecule. Therefore, it follows that catalase I has two active forms, a high-activity form and a low-activity form. The heat activation process followed the first-or der kinetics with an activation enthalpy (Delta H*) of 191 kJ/mol while the heat denaturation process had a Delta H* of 545 kJ/mol. The CD spectra of the two enzyme forms had small but marked differences. The conversion of the low-activity form to the high-activity form was an endothermic process with a T-m of 56 degrees C, which is much lower than that of the heat denaturation (T-m = 76 degrees C), and the enthalpy change for the transition was only 5% of that for the denaturation. It has to be noted that the high-activity form of the enzyme was converted back to a low-activity form through the process of denaturation, refolding, and reconstitution with heme. In addition, the newly obtained low-activity form was brought to a high-activity form by heating. These results suggest that the native state of catalase I has two active conformations that are roughly the same but not identical and are separated by a high energy barrier.	OSAKA UNIV, FAC ENGN, DEPT BIOTECHNOL, SUITA, OSAKA 565, JAPAN; NARA MED UNIV, DEPT CHEM, KASHIHARA, NARA 634, JAPAN; OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN	Osaka University; Nara Medical University; Osaka University								Aebi HE., 1973, METHODS ENZYMATIC AN, V3, P273; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; ANSARI A, 1985, P NATL ACAD SCI USA, V82, P5000, DOI 10.1073/pnas.82.15.5000; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BALDWIN MA, 1995, J BIOL CHEM, V270, P19197, DOI 10.1074/jbc.270.33.19197; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DILL KA, 1995, PROTEIN SCI, V4, P561; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0; FUHRHOP JH, 1975, PORPHYRINS METALLOPO, P803; Glasstone S., 1941, THEORY RATE PROCESSE, P10; HAN BD, 1990, J BACTERIOL, V172, P5089, DOI 10.1128/jb.172.9.5089-5096.1990; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HINDERBRANT AG, 1975, ARCH BIOCHEM BIOPHYS, V171, P385; KATAGIRI K, 1988, EUR J BIOCHEM, V176, P81, DOI 10.1111/j.1432-1033.1988.tb14253.x; KAWAMURA Y, 1982, J BIOCHEM-TOKYO, V92, P1227, DOI 10.1093/oxfordjournals.jbchem.a134040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESON DT, 1995, NAT STRUCT BIOL, V2, P848, DOI 10.1038/nsb1095-848; LIGHT WR, 1987, J BIOL CHEM, V262, P46; LOEWEN PC, 1990, MOL GEN GENET, V224, P147, DOI 10.1007/BF00259461; LOPRASERT S, 1990, APPL MICROBIOL BIOT, V32, P690, DOI 10.1007/BF00164741; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; SALI A, 1994, J MOL BIOL, V235, P1614, DOI 10.1006/jmbi.1994.1110; SAMEJIMA T, 1969, BIOCHIM BIOPHYS ACTA, V175, P24, DOI 10.1016/0005-2795(69)90141-X; Suga Y, 1996, J FERMENT BIOENG, V81, P259, DOI 10.1016/0922-338X(96)82218-5; TRAKULNALEAMSAI S, 1992, J FERMENT BIOENG, V74, P234, DOI 10.1016/0922-338X(92)90117-D; TRIGGSRAINE BL, 1987, GENE, V52, P121, DOI 10.1016/0378-1119(87)90038-2; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Woody RW, 1975, PROTEIN LIGAND INTER, P60	32	22	22	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23011	23016		10.1074/jbc.272.37.23011	http://dx.doi.org/10.1074/jbc.272.37.23011			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287297	hybrid			2022-12-27	WOS:A1997XV74400008
J	Nocentini, S; Coin, F; Saijo, M; Tanaka, K; Egly, JM				Nocentini, S; Coin, F; Saijo, M; Tanaka, K; Egly, JM			DNA damage recognition by XPA protein promotes efficient recruitment of transcription factor II H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; A XERODERMA-PIGMENTOSUM; RNA-POLYMERASE-II; COMPLEMENTING PROTEIN; CELL-EXTRACTS; ERCC1; GENE; REPLICATION; BTF2/TFIIH; TFIIH	The human basal transcription factor IIH (TFIIH) is an essential component of the nucleotide excision repair machinery. TFIIH is required for reaction steps concomitant with or prior to the formation of dual incisions in the damaged DNA strand. To understand the mechanism underlying the recruitment of TFIIH to DNA damage sites we have analyzed i) the direct affinity of TFIIH for damaged or undamaged DNA and ii) the interaction of TFIIH with XPA.DNA complexes, formed using unirradiated or UV-irradiated DNA. Filter binding assays showed that TFIIH has some affinity for the DNA, but in contrast to XPA, does not show any preference for UV-irradiated DNA. Pull-down experiments demonstrated that TFIIH binds to XPA DNA complexes in an UV damage-dependent manner by a direct protein-protein interaction with XPA. We propose that an enhancement of the affinity of XPA protein for TFIIH could arise from conformational changes of XPA when it binds to UV lesions on the DNA.	INST CURIE,LRC NO 1,CEA,SECT RECH,F-75248 PARIS 05,FRANCE; CU STRASBOURG,INST GENET & BIOL MOL CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; OSAKA UNIV,INST MOL & CELLULAR BIOL,DIV CELLULAR GENET,SUITA,OSAKA 565,JAPAN	CEA; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Osaka University	Nocentini, S (corresponding author), INST CURIE,CNRS,UMR 218,SECT RECH,26 RUE ULM,F-75248 PARIS 05,FRANCE.		Coin, Frédéric/F-5925-2013	Coin, Frédéric/0000-0002-5620-8519				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; CLEAVER JE, 1989, METABOLIC BASIS INHE, P2959; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; Kuraoka I, 1996, MUTAT RES-DNA REPAIR, V362, P87, DOI 10.1016/0921-8777(95)00038-0; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI L, 1995, MOL CELL BIOL, V15, P1993; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MA LB, 1994, MOL CELL BIOL, V14, P4126, DOI 10.1128/MCB.14.6.4126; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MIURA N, 1991, J BIOL CHEM, V266, P19786; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; NAGAI A, 1995, BIOCHEM BIOPH RES CO, V211, P960, DOI 10.1006/bbrc.1995.1905; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARKASH S, 1993, ANNU REV GENET, V27, P33; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; ROY R, 1994, J BIOL CHEM, V269, P9826; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SAIJO M, 1996, NUCLEIC ACIDS RES, V23, P4719; SATOKATA I, 1992, MUTAT RES, V273, P193, DOI 10.1016/0921-8777(92)90080-M; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; ZAVEL L, 1993, PROG NUCLEIC ACID RE, V44, P67	41	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					22991	22994		10.1074/jbc.272.37.22991	http://dx.doi.org/10.1074/jbc.272.37.22991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287294	hybrid			2022-12-27	WOS:A1997XV74400005
J	Haas, H; Angermayr, K; Zadra, I; Stoffler, G				Haas, H; Angermayr, K; Zadra, I; Stoffler, G			Overexpression of nreB, a new GATA factor-encoding gene of Penicillium chrysogenum, leads to repression of the nitrate assimilatory gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN REGULATORY PROTEIN; TRANSCRIPTION FACTOR GATA-1; PUTATIVE ZINC FINGER; DNA-BINDING DOMAIN; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; NEUROSPORA-CRASSA; CATABOLITE REPRESSION; METABOLITE REPRESSION; LEUCINE ZIPPER	To investigate the mechanism of nitrogen metabolite repression in the biotechnologically important fungus Penicillium chrysogenum a polymerase chain reaction approach was employed to identify transcription factors involved in this regulatory circuit, leading to the isolation of a new gene (nreB) encoding a 298 amino acid protein. Despite a low overall amino acid sequence identity of approximately 30%, it shares several features with Dal80p/Uga43p and Gzf3p/Nil2p, both repressors in nitrogen metabolism in Saccharomyces cerevisiae. All three proteins contain an N-terminal GATA-type zinc finger motif, displaying 86% amino acid sequence identity, and a putative leucine zipper motif in the C terminus. Northern blot analysis revealed the presence of two nreB transcripts, 1.8 and 1.5 kilobases in length, that differ in polyadenylation sites. The steady state level of both transcripts is subject to nitrogen metabolite repression. The putative DNA binding domain of NREB, expressed as a fusion protein in Escherichia coli, binds in vitro to GATA sites of its own 5'-upstream region as well as in the promoter of the nitrate assimilation gene cluster. Consistent with a role in the regulation of nitrogen metabolism, overexpression of nreB leads to repression of nitrate assimilatory genes. Hence, the simple view of nitrogen regulation by four GATA factors in yeast, but only one key regulator in filamentous ascomycetes seems no longer valid.			Haas, H (corresponding author), UNIV INNSBRUCK, SCH MED, DEPT MICROBIOL, FRITZ PREGL STR 3, A-6020 INNSBRUCK, AUSTRIA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Caddick Mark X., 1997, Genes and Function, V1, P37; CANTORAL JM, 1987, BIO-TECHNOL, V5, P494, DOI 10.1038/nbt0587-494; CHAE KS, 1995, MOL CELLS, V5, P146; Coffman JA, 1996, MOL CELL BIOL, V16, P847; Cooper TG, 1996, MYCOTA, V3, P139; COORNAERT D, 1992, CURR GENET, V21, P301, DOI 10.1007/BF00351687; CRAWFORD NM, 1993, ANNU REV GENET, V27, P115, DOI 10.1146/annurev.ge.27.120193.000555; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; FENG B, 1993, NUCLEIC ACIDS RES, V21, P3989, DOI 10.1093/nar/21.17.3989; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; Haas H, 1996, BBA-GENE STRUCT EXPR, V1309, P81, DOI 10.1016/S0167-4781(96)00150-9; HAAS H, 1993, GENE, V126, P237, DOI 10.1016/0378-1119(93)90372-A; Haas H, 1997, GENE, V184, P33, DOI 10.1016/S0378-1119(96)00570-7; HAAS H, 1995, CURR GENET, V27, P150, DOI 10.1007/BF00313429; HAAS H, 1995, CURR GENET, V28, P177, DOI 10.1007/BF00315785; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; KOLAR M, 1991, J BIOTECHNOL, V17, P67, DOI 10.1016/0168-1656(91)90027-S; KOLAR M, 1988, GENE, V62, P127, DOI 10.1016/0378-1119(88)90586-0; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LANGDON T, 1995, MOL MICROBIOL, V17, P877, DOI 10.1111/j.1365-2958.1995.mmi_17050877.x; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Martin J. F., 1986, REGULATION SECONDARY, P41; Marzluf GA, 1997, MICROBIOL MOL BIOL R, V61, P17, DOI 10.1128/.61.1.17-32.1997; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; PETERS DG, 1994, NUCLEIC ACIDS RES, V22, P5164, DOI 10.1093/nar/22.24.5164; Platt A, 1996, EMBO J, V15, P2791, DOI 10.1002/j.1460-2075.1996.tb00639.x; POLEY SD, 1996, FEBS LETT, V388, P200; RAI R, 1989, MOL CELL BIOL, V9, P602, DOI 10.1128/MCB.9.2.602; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; SoussiBoudekou S, 1997, MOL MICROBIOL, V23, P1157, DOI 10.1046/j.1365-2958.1997.3021665.x; STANBROUGH M, 1995, P NATL ACAD SCI USA, V92, P9450, DOI 10.1073/pnas.92.21.9450; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; VOISARD C, 1993, MOL CELL BIOL, V13, P7091, DOI 10.1128/MCB.13.11.7091; XIAO XD, 1995, BIOCHEMISTRY-US, V34, P8861, DOI 10.1021/bi00027a038; YANG HY, 1995, MOL CELL BIOL, V15, P1353; YELTON MM, 1984, P NATL ACAD SCI-BIOL, V81, P1470, DOI 10.1073/pnas.81.5.1470	49	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22576	22582		10.1074/jbc.272.36.22576	http://dx.doi.org/10.1074/jbc.272.36.22576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278412	hybrid			2022-12-27	WOS:A1997XV49200032
J	Krejci, E; Thomine, S; Boschetti, N; Legay, C; Sketelj, J; Massoulie, J				Krejci, E; Thomine, S; Boschetti, N; Legay, C; Sketelj, J; Massoulie, J			The mammalian gene of acetylcholinesterase-associated collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-FORMS; TAILED FORMS; CAUDATE-NUCLEUS; SUBUNIT; EXPRESSION; TORPEDO; CELLS; LOCALIZATION; DIAPHRAGM; COMPONENT	The collagen-tailed or asymmetric forms (A) represent a major component of acetylcholinesterase (AChE) in the neuromuscular junction of higher vertebrates. They are hetero-oligomeric molecules, in which tetramers of catalytic subunits of type T (AChE(T)) are attached to the subunits of a triple-stranded collagen ''tail.'' We report the cloning of at rat AChE-associated collagen subunit, Q. We show that collagen tails are encoded by a single gene, COLQ. The ColQ subunits form homotrimers and readily form collagen-tailed AChE, when coexpressed with rat AChE(T). We found that the same ColQ subunits are incorporated, in vivo, in asymmetric forms of both AChE and butyrylcholinesterase. A splice variant from the COLQ gene encodes a proline-rich AChE attachment domain without the collagen domain but does not represent the membrane anchor of the brain tetramer. The COLQ gene is expressed in cholinergic tissues, brain, muscle, and heart, and also in noncholinergic tissues such as lung and testis.	UNIV LJUBLJANA, SCH MED, INST PATHOPHYSIOL, LJUBLJANA 61105, SLOVENIA	University of Ljubljana	Krejci, E (corresponding author), ECOLE NORMALE SUPER, CNRS, URA 1857, NEUROBIOL CELLULAIRE & MOL LAB, 46 RUE ULM, F-75230 PARIS 05, FRANCE.			Thomine, Sebastien/0000-0003-0045-1701				ANGLISTER L, 1991, J CELL BIOL, V115, P755, DOI 10.1083/jcb.115.3.755; Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; BON S, 1978, EUR J BIOCHEM, V85, P1, DOI 10.1111/j.1432-1033.1978.tb12207.x; BRODBECK U, 1981, MEMBRANE PROTEINS LA, P85; CARTER JL, 1981, J NEUROCHEM, V36, P1018, DOI 10.1111/j.1471-4159.1981.tb01695.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUSSEN F, 1995, EUR J CELL BIOL, V67, P254; CRNEFINDERLE N, 1995, J NEUROSCI RES, V41, P745, DOI 10.1002/jnr.490410605; DEPREZ PN, 1995, J BIOL CHEM, V270, P11043, DOI 10.1074/jbc.270.19.11043; DUVAL N, 1992, EMBO J, V11, P3255, DOI 10.1002/j.1460-2075.1992.tb05403.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GENNARI K, 1987, J NEUROCHEM, V49, P12, DOI 10.1111/j.1471-4159.1987.tb03386.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; KRIEG PA, 1987, P NATL ACAD SCI USA, V84, P2331, DOI 10.1073/pnas.84.8.2331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SL, 1982, J BIOL CHEM, V257, P2292; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; LI Y, 1991, J BIOL CHEM, V266, P23083; LIAO J, 1993, J NEUROCHEM, V61, P1127, DOI 10.1111/j.1471-4159.1993.tb03629.x; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MASSOULIE J, 1991, CHOLINESTERASES, P285; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NYQUISTBATTIE C, 1987, J MOL CELL CARDIOL, V19, P935, DOI 10.1016/S0022-2828(87)80622-3; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; SOREQ H, 1982, P NATL ACAD SCI-BIOL, V79, P830, DOI 10.1073/pnas.79.3.830; TOUTANT JP, 1988, HDB EXP PHARM, V86, P225; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; VIGNY M, 1978, P NATL ACAD SCI USA, V75, P2588, DOI 10.1073/pnas.75.6.2588; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YOUNKIN SG, 1982, J BIOL CHEM, V257, P13630	37	140	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22840	22847		10.1074/jbc.272.36.22840	http://dx.doi.org/10.1074/jbc.272.36.22840			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278446	hybrid			2022-12-27	WOS:A1997XV49200067
J	Kume, K; Shimizu, T				Kume, K; Shimizu, T			Platelet-activating factor (PAF) induces growth stimulation, inhibition, and suppression of oncogenic transformation in NRK cells overexpressing the PAF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; PROTEIN-KINASE ACTIVATION; HIGH-AFFINITY RECEPTOR; HAMSTER OVARY CELLS; LYSOPHOSPHATIDIC ACID; FACTOR ACETYLHYDROLASE; SIGNAL TRANSDUCTION; FUNCTIONAL RECEPTOR; MOLECULAR-CLONING; RETINOIC ACID	Platelet-activating factor (PAF) is a phospholipid mediator with various physiological functions, including cellular growth and transformation. PAF exerts biological activities through G-protein-coupled receptors. In normal rat fibroblasts overexpressing a cloned PAF receptor, PAF induced immediate early oncogene expression and mitogenic responses, On the other hand, PAF strongly inhibited the epidermal growth factor-induced mitogenic growth response, growth acceleration, and anchorage-independent cell growth in a soft agar. Furthermore, PAF suppressed v-src-or v-ras-induced oncogenic morphological changes and anchorage-independent growth. Our observations suggest that PAF is a unique growth regulator with apparently diverse functions. Dual actions of PAF may relate to the point of action in the cell cycle; PAF stimulates the mitogenic response in G(0)-arrested cells in a pertussis toxin-sensitive manner, while it inhibits the G(1) to S transition through a pertussis toxin-resistant manner.			Kume, K (corresponding author), UNIV TOKYO,FAC MED,DEPT BIOCHEM & MOL BIOL,HONGO 7-3-1,TOKYO 113,JAPAN.			Kume, Kazuhiko/0000-0003-4232-1657				BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; BEHRENS TW, 1990, INT J IMMUNOPHARMACO, V12, P175, DOI 10.1016/0192-0561(90)90051-N; BENNETT SAL, 1993, CARCINOGENESIS, V14, P1289, DOI 10.1093/carcin/14.7.1289; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; CUSS FM, 1986, LANCET, V2, P189; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FILMUS J, 1994, ONCOGENE, V9, P3627; FUKAZAWA H, 1995, ANAL BIOCHEM, V228, P83, DOI 10.1006/abio.1995.1318; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1991, EUR J PHARMACOL, V196, P169, DOI 10.1016/0014-2999(91)90424-O; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; Ishii S, 1996, BIOCHEM J, V314, P671, DOI 10.1042/bj3140671; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KO TC, 1995, ONCOGENE, V10, P177; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KUME K, 1992, NEW BIOL, V4, P504; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LIU B, 1994, J BIOCHEM-TOKYO, V116, P882, DOI 10.1093/oxfordjournals.jbchem.a124611; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAGGI M, 1994, CANCER RES, V54, P4777; MASUDA A, 1992, NEW BIOL, V4, P489; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Mori M, 1996, J NEUROSCI, V16, P3590; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Mutoh H, 1996, P NATL ACAD SCI USA, V93, P774, DOI 10.1073/pnas.93.2.774; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1130, DOI 10.1006/bbrc.1994.2783; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; QIAN NX, 1994, J BIOL CHEM, V269, P17417; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHIMIZU T, 1992, BIOCHEM PHARMACOL, V44, P1001; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	53	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22898	22904		10.1074/jbc.272.36.22898	http://dx.doi.org/10.1074/jbc.272.36.22898			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278453	hybrid			2022-12-27	WOS:A1997XV49200074
J	Beaumelle, B; Taupiac, MP; Lord, JM; Roberts, LM				Beaumelle, B; Taupiac, MP; Lord, JM; Roberts, LM			Ricin A chain can transport unfolded dihydrofolate reductase into the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN; DIPHTHERIA-TOXIN; PSEUDOMONAS EXOTOXIN; PROTEIN; TRANSLOCATION; MEMBRANE; CYTOTOXICITY; BINDING; IMPORT; CELLS	Ricin is a heterodimeric protein toxin. The ricin A chain is able to cross the membrane of intracellular compartments to reach the cytosol where it catalytically inactivates protein synthesis. It is linked via a disulfide bond to the B chain, a galactose-specific lectin, which allows ricin binding at the cell surface and endocytosis, To examine the potential of ricin A to carry proteins into the cytosol and the requirement for unfolding of the passenger protein, we connected mouse dihydrofolate reductase (DHFR) to ricin A by gene fusion via a spacer peptide, DHFR-ricin A expressed in Escherichia coli displayed the biological activities of the parent proteins and associated quantitatively with ricin B to form DHFR-ricin, The resulting toxin was highly cytotoxic to cells (4-8-fold less than recombinant ricin), DHFR-ricin cytotoxicity was inhibited by methotrexate, a DHFR inhibitor stabilizing DHFR-ricin A in a folded conformation, The DHFR moiety of DHFR ricin bound to the plasma membrane. Although methotrexate prevented this binding, it did not significantly affect DHFR-ricin endocytosis, which proceeded via ricin B chain. Intoxication kinetics data and a cell-free translocation assay demonstrated that protection of cells from DHFR-ricin cytotoxicity resulted from a selective inhibition by methotrexate of DHFR-ricin A translocation. We conclude that ricin A is a potential carrier of proteins to the cytosol, provided that the passenger protein is able to unfold for transmembrane transport.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick	Beaumelle, B (corresponding author), UNIV MONTPELLIER 2,UMR 5539 CNRS,DEPT BIOL SANTE,CASE 107,F-34095 MONTPELLIER 05,FRANCE.			Beaumelle, Bruno/0000-0002-4912-9134				ARGENT RH, 1994, J BIOL CHEM, V269, P26705; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BEAUMELLE B, 1993, J BIOL CHEM, V268, P23661; BEAUMELLE BD, 1989, BIOCHEM J, V264, P137, DOI 10.1042/bj2640137; BRINKMANN U, 1992, P NATL ACAD SCI USA, V89, P3075, DOI 10.1073/pnas.89.7.3075; CHADDOCK JA, 1993, PROTEIN ENG, V6, P425, DOI 10.1093/protein/6.4.425; DONNELLY JJ, 1993, P NATL ACAD SCI USA, V90, P3530, DOI 10.1073/pnas.90.8.3530; EILERS M, 1986, NATURE, V322, P229; FALNES PO, 1994, J BIOL CHEM, V269, P8402; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GUERA A, 1993, PLANT MOL BIOL, V23, P309, DOI 10.1007/BF00029007; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; Klingenberg O, 1996, BIOCHEM J, V313, P647, DOI 10.1042/bj3130647; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OHARE M, 1990, FEBS LETT, V273, P200, DOI 10.1016/0014-5793(90)81084-2; OHARE M, 1987, FEBS LETT, V216, P73, DOI 10.1016/0014-5793(87)80759-7; Olsnes S., 1988, IMMUNOTOXINS, P39; Pastore E J, 1974, Methods Enzymol, V34, P281; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Robertus J, 1991, Semin Cell Biol, V2, P23; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1979, EXP CELL RES, V121, P15, DOI 10.1016/0014-4827(79)90439-7; SCHLENSTEDT G, 1994, FEBS LETT, V340, P139, DOI 10.1016/0014-5793(94)80189-4; SHACKELFORD DA, 1986, J BIOL CHEM, V261, P8334; SIMPSON JC, 1995, J BIOL CHEM, V270, P20078, DOI 10.1074/jbc.270.34.20078; STUBER D, 1984, EMBO J, V3, P3143; Walker D, 1996, J BIOL CHEM, V271, P4082; WIELDOCHA A, 1992, EMBO J, V11, P4835; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; YOULE RJ, 1982, J BIOL CHEM, V257, P1598	35	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22097	22102		10.1074/jbc.272.35.22097	http://dx.doi.org/10.1074/jbc.272.35.22097			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268352	Green Published, hybrid			2022-12-27	WOS:A1997XT85000064
J	Dong, BH; Silverman, RH				Dong, BH; Silverman, RH			A bipartite model of 2-5A-dependent RNase L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON ACTION; RIBONUCLEASE-L; CELLS; INFECTION; CLEAVAGE; 2-5A	The 2-5A-dependent RNase (RNase L) is a tightly regulated endoribonuclease of higher vertebrates that is catalytically active only after engaging unusual effector molecules consisting of the 2',5'-linked oligoadenylates, p(1-3)A(2'p5'A)(greater than or equal to 2) (2-5A), Progressive truncations from either terminus have provided insight into the structure, function, and regulation of RNase L, We determined that deletion of the N-terminal 335 amino acids of RNase L, about 45% of the enzyme, produced a constitutively active endoribonuclease, thus effectively eliminating the requirement for 2-5A. The truncated nuclease had 6-fold lower catalytic activity against an oligo(rU) substrate than wild type RNase L, However, the two enzymes showed identical RNA cleavage site preferences with an mRNA as substrate, The repressor function required only the last three of a series of nine ankyrin-like repeats present in the N-terminal part of RNase L, In contrast, the entire ankyrin repeat region was necessary and sufficient for 2-5A binding activity. Deletion of a 10-amino acid sequence near the C terminus of RNase L, between residues 710 and 720, eliminated both the catalytic and RNA substrate binding functions of the enzyme. The ability to bind native RNase L in response to 2-5A required amino acid sequences near both termini of the protein, A bipartite model for the structure of RNase L emerged in which the regulatory functions of the molecule are located in the N-terminal half, while the catalytic domain is present in the C-terminal half.	CLEVELAND CLIN FDN,DEPT CANC BIOL,LERNER RES INST,NN106,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NCI NIH HHS [CA 44059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORK P, 1993, FEBS LETT, V334, P149, DOI 10.1016/0014-5793(93)81701-Z; Carroll SS, 1996, J BIOL CHEM, V271, P4988; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; Cole JL, 1996, J BIOL CHEM, V271, P3979; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; DONG BH, 1994, J BIOL CHEM, V269, P14153; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; SILVERMAN RH, 1982, EUR J BIOCHEM, V124, P131, DOI 10.1111/j.1432-1033.1982.tb05915.x; SILVERMAN RH, 1997, RIBONUCLEASES STRUCT, P516; SOBOL RW, 1995, J BIOL CHEM, V270, P5963, DOI 10.1074/jbc.270.11.5963; WILLIAMS BRG, 1979, NATURE, V282, P582, DOI 10.1038/282582a0; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	20	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22236	22242		10.1074/jbc.272.35.22236	http://dx.doi.org/10.1074/jbc.272.35.22236			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268370	hybrid			2022-12-27	WOS:A1997XT85000082
J	Trzepacz, C; Lowy, AM; Kordich, JJ; Groden, J				Trzepacz, C; Lowy, AM; Kordich, JJ; Groden, J			Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34(cdc2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; BETA-CATENIN; COLORECTAL-CANCER; M-PHASE; PROTEIN; ASSOCIATION; IDENTIFICATION; CHROMOSOME-5Q21; MICROTUBULES; MUTATIONS	Mutations in the tumor suppressor gene APC invariably lead to the development of colorectal cancer, The vast majority of these mutations are nonsense or frame-shifts resulting in nonfunctional, truncated APC protein products, Eleven cyclin-dependent kinase (CDK) consensus phosphorylation sites have been identified in the frequently deleted carboxyl-terminal region of APC; loss of these phosphorylation sites by mutation could therefore compromise the ability of APC to inhibit cell growth. This report demonstrates that immunoprecipitates of full-length, but not truncated, APC protein include a mitosis-specific kinase activity in vivo, Biochemical and Western analysis of these immunoprecipitates confirms the presence of the CDK p34(cdc2). We also show that APC is a substrate for recombinant human p34(cdc2)-cyclin B1. Modification of APC by p34(cdc2) implicates phosphorylation as a mechanism for regulating APC function via a link to the cell cycle.	UNIV CINCINNATI, COLL MED, DEPT MOL GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT SURG, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati					NATIONAL CANCER INSTITUTE [R29CA063507, R01CA063507] Funding Source: NIH RePORTER; NCI NIH HHS [CA-63507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharjee RN, 1996, BIOCHEM BIOPH RES CO, V220, P192, DOI 10.1006/bbrc.1996.0379; BHATTACHARYA G, 1995, BIOCHEM BIOPH RES CO, V208, P103, DOI 10.1006/bbrc.1995.1311; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OOKATA K, 1993, J CELL SCI, V105, P873; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; TOMBES RM, 1991, CELL REGUL, V2, P861, DOI 10.1091/mbc.2.11.861; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x	24	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21681	21684		10.1074/jbc.272.35.21681	http://dx.doi.org/10.1074/jbc.272.35.21681			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268294	hybrid			2022-12-27	WOS:A1997XT85000006
J	Hung, IH; Suzuki, M; Yamaguchi, Y; Yuan, DS; Klausner, RD; Gitlin, JD				Hung, IH; Suzuki, M; Yamaguchi, Y; Yuan, DS; Klausner, RD; Gitlin, JD			Biochemical characterization of the Wilson disease protein and functional expression in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER TRANSPORTING ATPASE; P-TYPE ATPASES; MANNOSE 6-PHOSPHATE; IRON UPTAKE; GENE; CELLS; CERULOPLASMIN; ORGANIZATION; BIOGENESIS; MECHANISMS	Wilson disease is a disorder of copper metabolism characterized by hepatic cirrhosis and neuronal degeneration due to inherited mutations in a gene encoding a putative copper-transporting P-type ATPase. Polyclonal antisera generated against the amino terminus of the Wilson protein detected a specific 165-kDa protein in HepG2 and CaCo cell lysates, Further analysis revealed that this protein is synthesized as a single-chain polypeptide and localized to the trans-Golgi network under steady state conditions. An increase in the copper concentration resulted in the rapid movement of this protein to a cytoplasmic vesicular compartment. This copper-specific cellular redistribution of the Wilson protein is a reversible process that occurs independent of a new protein synthesis. Expression of the wild-type but not mutant Wilson protein in the ccc2 Delta strain of Saccharomyces cerevisiae restored copper incorporation into the multicopper oxidase Fet3p, providing direct evidence of copper transport by the Wilson protein. Taken together these data reveal a remarkable evolutionary conservation in the cellular mechanisms of copper metabolism and provide a unique model for the regulation of copper transport into the secretory pathway of eucaryotic cells.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K08HD058219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044464, R37DK044464] Funding Source: NIH RePORTER; NICHD NIH HHS [K08 HD058219] Funding Source: Medline; NIDDK NIH HHS [DK44464] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1995, METABOLIC BASIS INHE; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CUTHBERT JA, 1995, J INVEST MED, V43, P323; CZECH MP, 1995, ANN REV NUTR, V15, P44; Dierick HA, 1997, HUM MOL GENET, V6, P409, DOI 10.1093/hmg/6.3.409; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HUNG IH, 1997, OXFORD TXB CLIN HEPA; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; OWEN CA, 1973, AM J PHYSIOL, V224, P514; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1991, J BIOL CHEM, V266, P5128; Sherman F., 1978, METHODS YEAST GENETI; Siddique T, 1996, HUM MOL GENET, V5, P1465, DOI 10.1093/hmg/5.Supplement_1.1465; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	40	272	274	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21461	21466		10.1074/jbc.272.34.21461	http://dx.doi.org/10.1074/jbc.272.34.21461			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261163	hybrid			2022-12-27	WOS:A1997XR78900073
J	Murthy, KS; Makhlouf, GM				Murthy, KS; Makhlouf, GM			Differential coupling of muscarinic m(2) and m(3) receptors to adenylyl cyclases V/VI in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SIGNAL TRANSDUCTION PATHWAYS; INTESTINAL MUSCLE; LONGITUDINAL MUSCLE; GUINEA-PIG; RAT-BRAIN; CELLS; STIMULATION; CLONING; CALCIUM	Muscarinic m(2) and m(4) receptors couple preferentially to inhibition of adenylyl cyclase, whereas m(1), m(3), and m(5) receptors couple preferentially to activation of phospholipase C-beta and in some cells to stimulation of cAMP. Smooth muscle cells were shown to express adenylyl cyclases types V and/or VI. Acetylcholine (ACh) stimulated the binding of [S-35]GTP gamma S.G alpha complexes in smooth muscle membranes to G alpha(q/11) and G alpha(i3) antibody. Binding to G alpha(q/11) antibody was inhibited by the m(3) receptor antagonist, 4-DAMP, and binding to G alpha(i3) antibody was inhibited by the m(2) receptor antagonist, N,N'-bis[6[[(2-methoxyphenyl)methyl]amino]hexyl]-1,8-octanediamine tetrahydrochloride (methoctramine), The decrease in basal cAMP (35 +/- 5%) induced by ACh in dispersed muscle cells was accentuated by 4-DAMP or G(beta) antibody (55 +/- 8 to 63 +/- 6%). In contrast, methoctramine, pertussis toxin (PTx), or G alpha(i3) , antibody converted the decrease in cAMP to increase above basal level (+28 +/- 5 to +32 +/- 6%); the increase in cAMP was abolished by 4-DAMP or G(beta) antibody. In muscle cells where only m(3) receptors were preserved by selective receptor protection, ACh caused only an increase in cAMP that was abolished by 4-DAMP. Conversely, in muscle cells where only m(2) receptors were preserved, ACh caused an accentuated decrease in cAMP that was abolished by methoctramine or PTx, In conclusion, m(2) receptors in smooth muscle couple to inhibition of adenylyl cyclases V/VI via G alpha(i3), and m(3) receptors couple to activation of the enzymes via G beta gamma(q/11).	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYSIOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028300] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-28300] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARLOW RB, 1976, BRIT J PHARMACOL, V58, P613, DOI 10.1111/j.1476-5381.1976.tb08631.x; BAUMGOLD J, 1992, TRENDS PHARMACOL SCI, V13, P339, DOI 10.1016/0165-6147(92)90105-F; BAUMGOLD J, 1988, BIOCHEM BIOPH RES CO, V154, P1137, DOI 10.1016/0006-291X(88)90259-8; BITAR KN, 1986, J BIOL CHEM, V261, P6591; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CANDELL LM, 1990, MOL PHARMACOL, V38, P689; CAUFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOO LK, 1985, J PHARM PHARMACOL, V37, P656, DOI 10.1111/j.2042-7158.1985.tb05106.x; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; EGLEN RM, 1994, TRENDS PHARMACOL SCI, V15, P114, DOI 10.1016/0165-6147(94)90047-7; Ehlert FJ, 1997, MUSCARINIC RECEPTOR, P87; ESAUEDA EE, 1996, BIOCHEM PHARMACOL, V52, P643; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FELDER CC, 1989, J BIOL CHEM, V264, P20356; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GRIFFIN MT, 1992, J PHARMACOL EXP THER, V263, P221; HELLSTROM PM, 1994, J PHARMACOL EXP THER, V270, P236; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUEMMERLE JF, 1992, AM J PHYSIOL, V263, pG269, DOI 10.1152/ajpgi.1992.263.2.G269; KUEMMERLE JF, 1995, GASTROENTEROLOGY, V109, P1791, DOI 10.1016/0016-5085(95)90745-9; MICHEL AD, 1987, BRIT J PHARMACOL, V92, P755, DOI 10.1111/j.1476-5381.1987.tb11379.x; MORINI G, 1993, J PHARMACOL EXP THER, V264, P598; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; Murthy KS, 1996, MOL PHARMACOL, V50, P870; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; MURTHY KS, 1994, J BIOL CHEM, V269, P15977; Murthy KS, 1997, GASTROENTEROLOGY, V112, pA1175; MURTHY KS, 1996, GASTROENTEROLOGY, V110, pA1102; OKOMOTO T, 1992, FEBS LETT, V305, P125; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SUH BC, 1995, J NEUROCHEM, V64, P2500; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; WALL SJ, 1991, MOL PHARMACOL, V40, P783; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YU HJ, 1993, MOL PHARMACOL, V44, P689; ZHANG LB, 1991, MOL PHARMACOL, V40, P952	57	72	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21317	21324		10.1074/jbc.272.34.21317	http://dx.doi.org/10.1074/jbc.272.34.21317			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261144	hybrid			2022-12-27	WOS:A1997XR78900054
J	Pulli, T; Koivunen, E; Hyypia, T				Pulli, T; Koivunen, E; Hyypia, T			Cell-surface interactions of echovirus 22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; PHAGE-DISPLAY LIBRARIES; MOUTH-DISEASE VIRUS; AMINO-ACID SEQUENCE; COXSACKIEVIRUS A9; FACTOR CD55; VITRONECTIN RECEPTOR; PICORNAVIRUS GROUP; FILAMENTOUS PHAGE; INHIBIT BINDING	Echovirus 22 (EV22) is a picornavirus forming a distinct molecular cluster together with echovirus 23. EV22 has an Arg-Gly-Asp (RGD) peptide motif in its capsid protein VP1; similar motifs are known to mediate many cell-cell and microbe-host interactions, To identify pep tide sequences that specifically bind to EV22 and potentially play a role in receptor recognition, we have used here peptide libraries displayed in filamentous pha,be. We isolated an EV22-binding motif CLRSG(RIF)GC, The synthetic CLRSGRGC peptide was able to inhibit EV22 infection, The infection was also inhibited by an RGD-containing peptide representing the C terminus of the EV22 capsid protein VP1 and CWDDGWLC (an RGD-binding peptide; Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1995) J. Cell Biol. 130, 1189-1196). As the EV22-recognizing sequence LRSG is found in the integrin beta(1) chain and the entire LRSGRG hexapeptide occurs in the matrix metalloproteinase 9 (MMP-9), we carried out blocking experiments with anti-integrin and anti-MMP-9 antibodies. EV22 infection could be blocked in cell cultures with anti-alpha(v), -beta(1), and, to a lesser extent, with anti-MMP-9 antibodies. These results imply that EV22 recognizes preferentially alpha(v) beta(1)-integrin as a cellular receptor and MMP-9 may also play a role in the cell-surface interactions of the virus.	UNIV TURKU,MEDICITY RES LAB,FIN-20520 TURKU,FINLAND; UNIV HELSINKI,DIV BIOCHEM,FIN-00014 HELSINKI,FINLAND	University of Turku; University of Helsinki	Pulli, T (corresponding author), NATL PUBL HLTH INST,ENTEROVIRUS LAB,MANNERHEIMINTIE 166,FIN-00300 HELSINKI,FINLAND.			Koivunen, Erkki/0000-0002-6443-9595				ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BERGELSON JM, 1993, J VIROL, V67, P6847, DOI 10.1128/JVI.67.11.6847-6852.1993; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; BERINSTEIN A, 1995, J VIROL, V69, P2664, DOI 10.1128/JVI.69.4.2664-2666.1995; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; DEVERDUGO UR, 1995, J VIROL, V69, P6751, DOI 10.1128/JVI.69.11.6751-6757.1995; EHRNST A, 1993, SCAND J INFECT DIS, V25, P275, DOI 10.3109/00365549309008499; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; Germaschewski V, 1996, J VIROL METHODS, V58, P21, DOI 10.1016/0166-0934(95)01980-4; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Heiskanen T, 1997, J VIROL, V71, P3879, DOI 10.1128/JVI.71.5.3879-3885.1997; HONG SS, 1995, EMBO J, V14, P4714, DOI 10.1002/j.1460-2075.1995.tb00153.x; HUGHES PJ, 1995, J VIROL, V69, P8035, DOI 10.1128/JVI.69.12.8035-8040.1995; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYYPIA T, 1992, P NATL ACAD SCI USA, V89, P8847, DOI 10.1073/pnas.89.18.8847; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; MBIDA AD, 1992, RES VIROLOGY, V143, P397, DOI 10.1016/S0923-2516(06)80132-9; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; ROIVAINEN M, 1991, J VIROL, V65, P4735, DOI 10.1128/JVI.65.9.4735-4740.1991; ROIVAINEN M, 1994, VIROLOGY, V203, P357, DOI 10.1006/viro.1994.1494; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHAFREN DR, 1995, J VIROL, V69, P3873, DOI 10.1128/JVI.69.6.3873-3877.1995; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; STANWAY G, 1990, J GEN VIROL, V71, P2483, DOI 10.1099/0022-1317-71-11-2483; STANWAY G, 1994, J VIROL, V68, P8232, DOI 10.1128/JVI.68.12.8232-8238.1994; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; WARD T, 1994, EMBO J, V13, P5070, DOI 10.1002/j.1460-2075.1994.tb06836.x; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643	45	68	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21176	21180		10.1074/jbc.272.34.21176	http://dx.doi.org/10.1074/jbc.272.34.21176			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261123	hybrid			2022-12-27	WOS:A1997XR78900033
J	Sugasawa, T; MatsuzakiFujita, M; Guillaume, JL; Camoin, L; Morooka, S; Strosberg, AD				Sugasawa, T; MatsuzakiFujita, M; Guillaume, JL; Camoin, L; Morooka, S; Strosberg, AD			Characterization of a novel iodocyanopindolol and SM-11044 binding protein, which may mediate relaxation of depolarized rat colon tonus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATYPICAL BETA-ADRENOCEPTORS; POLYACRYLAMIDE-GEL ELECTROPHORESIS; HUMAN BETA-3-ADRENERGIC RECEPTOR; MOLECULAR CHARACTERIZATION; ALPHA-2B-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; CLONING; EXPRESSION; INHIBITION; SEPARATION	Studies under blockade of alpha-, beta 1-, and beta 2-adrenoreceptor tors revealed a good correlation between the responses of rat colon relaxation of depolarized tonus and of rat adipocyte lipolysis elicited by catecholamines or BRL-37344, a selective beta 3-adrenoreceptor agonist, suggesting beta 3-adrenoreceptor stimulation. In contrast, SM-11044, a nonselective beta-adrenoreceptor agonist, stimulated colon relaxation more efficiently than lipolysis; its effects were differently antagonized by cyanopindolol with pA(2) values of 8.31 in colon and of 7,32 in adipocytes, Binding studies in rat colon smooth muscle membranes using [I-125]iodocyanopindolol under blockade of adrenaline and serotonin receptors revealed the existence of a single class of sites (K-d = 11.0 nM, B-max = 716,7 fmol/mg protein). The specific binding was saturable and reversible and was displaced by SM-11044 but not by BRL-37344, isoproterenol, noradrenaline, adrenaline, serotonin, nor dopamine. This binding site was photoaffinity labeled using [I-125]iodocyanopindolol-diazirine. The labeling was prevented by SIM-11044 but not by BRL-37344, The amino-terminal amino acid sequences of the high performance liquid chromatography-purified peptides generated by enzymatic and chemical cleavages of the affinity labeled 34-kDa protein confirmed that the novel. iodocyanopindolol or SM-11044 binding protein of rat colon smooth muscle membranes is different from known adrenaline, serotonin, or dopamine receptors. Its functional role might include the relaxation of depolarized colon.	INST COCHIN GENET MOL,CNRS,UPR 0415,F-75014 PARIS,FRANCE; UNIV PARIS 07,F-75014 PARIS,FRANCE; SUMITOMO PHARMACEUT CO LTD,RES CTR,KAWASAKI KU,OSAKA 554,JAPAN	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite			Camoin, Luc/AAB-3856-2019	Camoin, Luc/0000-0002-1230-4787				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BENSAID M, 1993, FEBS LETT, V318, P223, DOI 10.1016/0014-5793(93)80516-W; BLUE DR, 1989, BRIT J PHARMACOL, V96, P246; BOND RA, 1988, BRIT J PHARMACOL, V95, P723, DOI 10.1111/j.1476-5381.1988.tb11698.x; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CROCI T, 1988, PHARMACOL RES, V20, P147, DOI 10.1016/S0031-6989(88)80007-9; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EK BA, 1986, GASTROENTEROLOGY, V90, P408, DOI 10.1016/0016-5085(86)90940-6; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; Fontana A, 1986, PRACTICAL PROTEIN CH, P67; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GUILLAUME JL, 1994, EUR J BIOCHEM, V224, P761, DOI 10.1111/j.1432-1033.1994.00761.x; HOYER D, 1994, PHARMACOL REV, V46, P157; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARD D, 1994, EUR J BIOCHEM, V220, P919, DOI 10.1111/j.1432-1033.1994.tb18695.x; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MANARA L, 1990, TRENDS PHARMACOL SCI, V11, P229, DOI 10.1016/0165-6147(90)90247-6; MCLAUGHLIN DP, 1990, BRIT J PHARMACOL, V101, P569, DOI 10.1111/j.1476-5381.1990.tb14122.x; MCLAUGHLIN DP, 1991, BRIT J PHARMACOL, V103, P1351, DOI 10.1111/j.1476-5381.1991.tb09792.x; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Strosberg AD, 1997, ANNU REV PHARMACOL, V37, P421, DOI 10.1146/annurev.pharmtox.37.1.421; SUGASAWA T, 1992, EUR J PHARMACOL, V216, P207; SUGASAWA T, 1992, AGENTS ACTIONS, V37, P233; SUGASAWA T, 1992, RECENT ADV CELLULAR, V3, P223; TATE KM, 1991, EUR J BIOCHEM, V196, P357, DOI 10.1111/j.1432-1033.1991.tb15824.x; VANDERVLIET A, 1990, J PHARMACOL EXP THER, V255, P218; WATSON S, 1996, RECEPTOR ION CHANNEL; WEINSHANK RL, 1990, MOL PHARMACOL, V38, P681; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	34	10	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21244	21252		10.1074/jbc.272.34.21244	http://dx.doi.org/10.1074/jbc.272.34.21244			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261134	hybrid			2022-12-27	WOS:A1997XR78900044
J	Arruda, LK; Vailes, LD; PlattsMills, TAE; Hayden, ML; Chapman, MD				Arruda, LK; Vailes, LD; PlattsMills, TAE; Hayden, ML; Chapman, MD			Induction of IgE antibody responses by glutathione S-transferase from the German cockroach (Blattella germanica)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOUSE-DUST MITE; MAJOR ALLERGEN; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; IMMUNOGLOBULIN-E; MUSCA-DOMESTICA; RISK-FACTORS; PURIFICATION; ASTHMA; EXPRESSION	We report that a major 23-kDa allergen from German cockroach (Blattella germanica) is a glutathione S-transferase (EC 2.5.1.18; GST). Natural B. germanica GST, purified from cockroach body extracts by glutathione affinity chromatography, and recombinant protein expressed in Escherichia coli using the pET21a vector, showed excellent IgE antibody binding activity. B. germanica GST caused positive immediate skin tests in cockroach-allergic patients using as little as 3 pg of recombinant protein. The NH2-terminal sequence of the natural protein and the deduced amino acid sequence from cDNA were identical except for one substitution (Phe(9) --> Cys). Assignment of this protein to the GST superfamily was based on binding to glutathione and sequence identity (42-51%) to the GST-S subfamily from insects, including Anopheles gambiae and Drosophila melanogaster. B. germanica GST contained 18 of the 26 invariable residues identified in mammalian GST by xray crystallography and exhibited enzymic activity against a GST substrate. Our results show that cockroach GST causes IgE antibody responses and is associated with asthma. The data strongly support the view that the immune response to GST plays an important role in allergic diseases.	UNIV VIRGINIA, HLTH SCI CTR, ASTHMA & ALLERG DIS CTR, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia			Arruda, L. Karla/D-5845-2013	Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632; Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI 34607, AI 32557] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032557, U19AI034607, U01AI034607] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; AURIAULT C, 1990, J CLIN MICROBIOL, V28, P1918, DOI 10.1128/JCM.28.9.1918-1924.1990; BEALL C, 1992, BIOCHEM GENET, V30, P515, DOI 10.1007/BF01037590; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BOARD P, 1994, BIOCHEM J, V299, P425, DOI 10.1042/bj2990425; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CAPRON M, 1994, SCIENCE, V264, P1876, DOI 10.1126/science.8009216; Chapman MD, 1997, INT ARCH ALLERGY IMM, V113, P102, DOI 10.1159/000237518; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1997, ALLERGY ALLERGIC DIS; CLARK AG, 1989, COMP BIOCHEM PHYS B, V92, P419, DOI 10.1016/0305-0491(89)90114-4; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; DUDLER T, 1995, J IMMUNOL, V155, P2605; FOURNIER D, 1992, J BIOL CHEM, V267, P1840; FRANCIOSA H, 1995, INSECT BIOCHEM MOLEC, V25, P311, DOI 10.1016/0965-1748(94)00053-K; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GULICK AM, 1992, J BIOL CHEM, V267, P18946; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYAOKA T, 1982, PESTIC BIOCHEM PHYS, V17, P113, DOI 10.1016/0048-3575(82)90015-3; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KHAN CMA, 1994, P NATL ACAD SCI USA, V91, P11261, DOI 10.1073/pnas.91.23.11261; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; ONEILL GM, 1994, BBA-GENE STRUCT EXPR, V1219, P521, DOI 10.1016/0167-4781(94)90080-9; OTTEA JA, 1984, PESTIC BIOCHEM PHYS, V22, P203, DOI 10.1016/0048-3575(84)90091-9; PENINGTON CJ, 1992, BIOCHEMISTRY-US, V31, P2912, DOI 10.1021/bi00126a010; PENROSE JF, 1995, AM J RESP CRIT CARE, V152, P283, DOI 10.1164/ajrccm.152.1.7599836; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER MJ, 1995, INSECT BIOCHEM MOLEC, V25, P455, DOI 10.1016/0965-1748(94)00083-B; STENERSEN J, 1987, COMP BIOCHEM PHYS C, V86, P73, DOI 10.1016/0742-8413(87)90147-2; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; SYVANEN M, 1994, MOL GEN GENET, V245, P25, DOI 10.1007/BF00279747; TANG AH, 1994, J BIOL CHEM, V269, P27876; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; WOOD E, 1986, COMP BIOCHEM PHYS B, V84, P607, DOI 10.1016/0305-0491(86)90130-6; Wu CH, 1996, J BIOL CHEM, V271, P17937, DOI 10.1074/jbc.271.30.17937; XU CB, 1993, J IMMUNOL, V150, P940	55	128	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20907	20912		10.1074/jbc.272.33.20907	http://dx.doi.org/10.1074/jbc.272.33.20907			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252418	hybrid			2022-12-27	WOS:A1997XR22100088
J	Gasparri, A; Sidoli, A; Sanchez, LP; Longhi, R; Siccardi, AG; Marchisio, PC; Corti, A				Gasparri, A; Sidoli, A; Sanchez, LP; Longhi, R; Siccardi, AG; Marchisio, PC; Corti, A			Chromogranin A fragments modulate cell adhesion - Identification and characterization of a pro-adhesive domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN-I; SOLID-PHASE SYNTHESIS; MESSENGER-RNA; MONOCLONAL-ANTIBODIES; CHROMAFFIN GRANULES; ENDOCRINE-CELLS; ADRENAL-MEDULLA; CLEAVAGE SITES; PEPTIDE; PANCREASTATIN	Although several functions have been suggested for chromogranin A, a glycoprotein secreted by many neuroendocrine cells, the physiological role of this protein and of its proteolytic fragments has not been established. We have found that mixtures of chromogranin A fragments can inhibit fibroblast adhesion. The anti-adhesive activity was converted into pro-adhesive activity by limited trypsin treatment. Pro-adhesive effects were observed also with recombinant N-terminal fragments corresponding to residues 1-78 and 1-115 and with a synthetic peptide encompassing the residues 7-57. These fragments induced adhesion and spreading of fibroblasts on plates coated with collagen I or IV, laminin, fetal calf serum (FCS) but not on bovine serum albumin. The long incubation time required for adhesion assays (4 h) and the FCS requirements for optimal adhesion suggest that the adhesive activity is likely indirect and requires other proteins present in the FCS or made by the cells. These findings suggest that chromogranin A and its fragments could play a role in the regulation of cell adhesion. Since chromogranin A is concentrated and stored within granules and rapidly released by neuroendocrine cells and neurons after an appropriate stimulus, this protein could be important for the local control of cell adhesion by stimulated cells.	SAN RAFFAELE SCI INST,DIBIT,DEPT BIOL & TECHNOL RES,I-20132 MILAN,ITALY; UNIV MILAN,DEPT BIOL & GENET MED SCI,I-20131 MILAN,ITALY; UNIV TURIN,SCH MED,DEPT BIOMED SCI & HUMAN ONCOL,I-10126 TURIN,ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; University of Turin			Corti, Angelo/F-7046-2012; Gasparri, Anna Maria/AAN-5071-2020	Corti, Angelo/0000-0002-0893-6191; Gasparri, Anna Maria/0000-0002-1757-8699; Subba, Rajkrishna/0000-0003-0051-0062				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; ADAMS LA, 1993, BRAIN RES, V602, P336, DOI 10.1016/0006-8993(93)90699-N; ANGELETTI RH, 1985, SCIENCE, V230, P89, DOI 10.1126/science.3898368; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BRANDT DW, 1994, P SOC EXP BIOL MED, V205, P316; CHEN M, 1992, J NEUROCHEM, V58, P1691, DOI 10.1111/j.1471-4159.1992.tb10042.x; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COHN DV, 1982, P NATL ACAD SCI-BIOL, V79, P6056, DOI 10.1073/pnas.79.19.6056; Corti A, 1996, EUR J BIOCHEM, V235, P275, DOI 10.1111/j.1432-1033.1996.00275.x; Corti A, 1996, BRIT J CANCER, V73, P924, DOI 10.1038/bjc.1996.183; DEFTOS LJ, 1990, BONE MINER, V9, P169, DOI 10.1016/0169-6009(90)90035-E; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; EHRHART M, 1988, J HISTOCHEM CYTOCHEM, V36, P467, DOI 10.1177/36.5.3282005; FERRER M, 1992, INT J PEPT PROT RES, V40, P194; GALINDO E, 1991, P NATL ACAD SCI USA, V88, P1426, DOI 10.1073/pnas.88.4.1426; GORR SU, 1988, BONE MINER, V4, P17; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; HUTTON JC, 1985, FEBS LETT, V188, P336, DOI 10.1016/0014-5793(85)80398-7; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; IGUCHI H, 1992, EUR J CANCER, V28A, P1458, DOI 10.1016/0959-8049(92)90543-B; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; LAZURE C, 1990, PEPTIDES, V11, P79, DOI 10.1016/0196-9781(90)90114-K; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MUNOZ DG, 1990, NEUROSCIENCE, V34, P533, DOI 10.1016/0306-4522(90)90162-W; OCONNOR DT, 1984, T ASSOC AM PHYSICIAN, V97, P242; PELAGI M, 1989, MOL CELL PROBE, V3, P87, DOI 10.1016/0890-8508(89)90039-X; QIAN J, 1988, J NEUROIMMUNOL, V17, P159, DOI 10.1016/0165-5728(88)90023-9; ROSA P, 1994, J ENDOCRINOL INVEST, V17, P207, DOI 10.1007/BF03347721; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SERCKHANSSEN G, 1984, J BIOL CHEM, V259, P1597; SIMON JP, 1989, BIOCHEM J, V262, P1; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STEINER HJ, 1990, J HISTOCHEM CYTOCHEM, V38, P845, DOI 10.1177/38.6.2139887; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; WOHLFARTER T, 1988, FEBS LETT, V231, P67, DOI 10.1016/0014-5793(88)80704-X; WU HJ, 1991, J BIOL CHEM, V266, P13130; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1990, J BIOL CHEM, V265, P14414	48	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20835	20843		10.1074/jbc.272.33.20835	http://dx.doi.org/10.1074/jbc.272.33.20835			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252409	hybrid			2022-12-27	WOS:A1997XR22100079
J	Li, YC; Zhang, WX; Mantell, LL; Kazzaz, JA; Fein, AM; Horowitz, S				Li, YC; Zhang, WX; Mantell, LL; Kazzaz, JA; Fein, AM; Horowitz, S			Nuclear factor-kappa B is activated by hyperoxia but does not protect from cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; PHOSPHORYLATION; KINASE; GENE; SPECIFICITY; ELEGANS	Oxidative insults that are lethal to epithelial cells kill either via apoptosis or necrosis. Nuclear factor-kappa B (NF-kappa B) is a redox-sensitive transcription factor that is activated by oxidative insult, and NF-kappa B activation can protect cells from apoptosis. To test if NF-kappa B can protect from necrotic cell death caused by high levels of molecular O-2 (hyperoxia), we exposed human alveolar epithelial (A549) cells to hyperoxia. NF-kappa B was shown to be activated and was translocated to the nucleus within minutes. Nuclear translocation persisted over the course of several days, and the levels of NF-kappa B protein and mRNA increased as well. In hyperoxia, NF-kappa B regulation was independent of mitogen-activated protein kinase (MAPK). In sharp contrast, there was neither nuclear translocation of NF-kappa B nor any increase in expression after exposure to H2O2 at a concentration where this oxidant induces both MAPK and widespread apoptosis. Despite the activation and increased expression of NF-kappa B in hyperoxia, this oxidant remained lethal to the cells. These observations confirm the notion that apoptosis occurs in the absence of NF-kappa B activation but indicate that protection from cell death by NF-kappa B is probably limited to apoptosis.	SUNY STONY BROOK,WINTHROP UNIV HOSP,CARDIOPULM RES INST,SCH MED,DEPT PEDIAT,MINEOLA,NY 11501; SUNY STONY BROOK,WINTHROP UNIV HOSP,DEPT PULM & CRIT CARE MED,MINEOLA,NY 11501	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital			weixian, zhang/H-4046-2013	weixian, zhang/0000-0002-0250-4013				ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; ANTWERP DJV, 1996, SCIENCE, V274, P787; Barinaga M, 1996, SCIENCE, V274, P724, DOI 10.1126/science.274.5288.724; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CAPPELLETTI G, 1994, CELL BIOL TOXICOL, V10, P255, DOI 10.1007/BF00756765; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; FORREST VJ, 1994, FREE RADICAL BIO MED, V16, P675, DOI 10.1016/0891-5849(94)90182-1; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MENON SD, 1993, J BIOL CHEM, V268, P26805; Morris A H, 1994, New Horiz, V2, P19; PAULSEN JE, 1995, GENETICS, V141, P1383; SANDSTROM PA, 1993, AIDS RES HUM RETROV, V9, P1107, DOI 10.1089/aid.1993.9.1107; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; STOGNER SW, 1992, ANN PHARMACOTHER, V26, P1554, DOI 10.1177/106002809202601214; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	28	93	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20646	20649		10.1074/jbc.272.33.20646	http://dx.doi.org/10.1074/jbc.272.33.20646			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252381	hybrid			2022-12-27	WOS:A1997XR22100051
J	Liu, YLE; Wang, MS; Greene, J; Su, J; Ullrich, S; Li, H; Sheng, SJ; Alexander, P; Sang, QXA; Shi, YE				Liu, YLE; Wang, MS; Greene, J; Su, J; Ullrich, S; Li, H; Sheng, SJ; Alexander, P; Sang, QXA; Shi, YE			Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASES; MATRIX METALLOPROTEINASES; METASTATIC ABILITY; MESSENGER-RNA; CHICK-EMBRYO; CELL-LINE; IN-VIVO; EXPRESSION; CANCER; INVASION	TIMP-4, a novel human tissue inhibitor of metalloproteinase, was identified and cloned (Greene, J., Wang, M., Raymond, L. A., Liu, Y. E., Rosen, C., and Shi, Y. E. (1996) J. Biol. Chem. 271, 30375-30380). In this report, the production and characterization of recombinant TIMP-4 (rTIMP4p) are described. rTIMP4p, expressed in baculovirus-infected insect cells, was purified to homogeneity by a combination of cation exchange, hydrophobic, and size-exclusion chromatographies. The purified protein migrated as a single 23-kDa band in SDS-polyacrylamide gel electrophoresis and in Western blot using a specific anti-TIMP-4 antibody. Inhibition of matrix metalloproteinase (MMP) activities by rTIMP4p was demonstrated in five MMPs. Enzymatic kinetic studies revealed IC50 values (concentration at 50% inhibition) of 19, 3, 45, 8, and 83 nM for MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9, respectively. Purified rTIMP4p demonstrated a strong inhibitory effect on the invasion of human breast cancer cells across reconstituted basement membranes. Thus, TIMP-4 is a new enzymatic inhibitor in MMP-mediated extracellular matrix degradation and may have therapeutic potential in treating cancer malignant progression.	LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,NEW HYDE PK,NY 11040; LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT PATHOL,NEW HYDE PK,NY 11040; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,INST MOL BIOPHYS,TALLAHASSEE,FL 32306; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC GENET,BOSTON,MA 02115; TRIPLE POINT BIOL,FOREST GROVE,OR 97116	Northwell Health; Yeshiva University; Northwell Health; Yeshiva University; GlaxoSmithKline; Human Genome Sciences Inc; State University System of Florida; Florida State University; State University System of Florida; Florida State University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA068064] Funding Source: NIH RePORTER; NCI NIH HHS [CA68064-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; BASSET P, 1994, CANCER-AM CANCER SOC, V74, P1045, DOI 10.1002/1097-0142(19940801)74:3+<1045::AID-CNCR2820741511>3.0.CO;2-7; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BOUJRAD N, 1995, SCIENCE, V268, P1609, DOI 10.1126/science.7777858; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; DECLERCK YA, 1992, CANCER RES, V52, P701; Denhardt D T, 1992, Matrix Suppl, V1, P281; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Fujimoto N, 1996, BIOCHEM J, V313, P827, DOI 10.1042/bj3130827; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Heppner KJ, 1996, AM J PATHOL, V149, P273; Imren S, 1996, CANCER RES, V56, P2891; JAY GD, 1990, ANAL BIOCHEM, V185, P324, DOI 10.1016/0003-2697(90)90302-P; JOHNSON MD, 1994, J CELL PHYSL, V160, P1984; KHOKHA R, 1992, CLIN EXP METASTAS, V10, P365, DOI 10.1007/BF00133464; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LENNARZ WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P149, DOI 10.1016/0304-4157(91)90022-O; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; Matsuzawa K, 1996, J NEUROPATH EXP NEUR, V55, P88, DOI 10.1097/00005072-199601000-00009; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; Nagase H, 1996, ADV EXP MED BIOL, V389, P23; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; OHBA Y, 1995, BBA-GEN SUBJECTS, V1245, P1, DOI 10.1016/0304-4165(95)00065-J; POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429; PYKE C, 1993, AM J PATHOL, V142, P359; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Sang QXA, 1996, J PROTEIN CHEM, V15, P243, DOI 10.1007/BF01887112; SHI YE, 1993, CANCER RES, V53, P1409; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; URIA JA, 1994, CANCER RES, V54, P2091; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; WICK M, 1994, J BIOL CHEM, V269, P18953; WILDE CG, 1994, DNA CELL BIOL, V13, P711, DOI 10.1089/dna.1994.13.711	49	105	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20479	20483		10.1074/jbc.272.33.20479	http://dx.doi.org/10.1074/jbc.272.33.20479			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252358	hybrid			2022-12-27	WOS:A1997XR22100028
J	Mann, KG; Hockin, MF; Bean, KJ; Kalafatis, M				Mann, KG; Hockin, MF; Bean, KJ; Kalafatis, M			Activated protein C cleavage of factor Va leads to dissociation of the A2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; PORCINE FACTOR-VIII; BOVINE FACTOR-V; PEPTIDE-BOND CLEAVAGES; FACTOR-XA; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; ANALYTICAL ULTRACENTRIFUGATION; SUBUNIT STRUCTURE; FACTOR VA(R506Q)	The products of cleavage of bovine factor Va by activated protein C (APC) in the presence and absence of phospholipid (25% phosphatidylserine, 75% phosphatidylcholine, PCPS) were evaluated using sedimentation velocity/equilibrium methods in the analytical ultracentrifuge and by immunoprecipitation using an antibody directed against the light chain of the factor Va molecule, The molecular weight and sedimentation coefficient of the associated heavy and light chains of factor Va, 173,000 (7.9 S) is reduced to 132,000 (7.1 S) by APC cleavage at Arg(505) and Arg(662), Complete cleavage of the factor Va heavy chain (with APC-PCPS) at Arg(505), Arg(662) and Arg(306) results in a drastic change in the molecular weight observed for the product, Two products are resolved with sedimentation coefficients of 3.3 and 6.3 S with estimated molecular weights of 48,000 and 114,000, respectively, Immunoprecipitation studies showed that the products of factor Va cleavage at Arg(505) and Arg(662) (A1A2(N).A2(C).LC) are mostly noncovalently associated and consequently immunoprecipitated with an antibody directed against the light chain of the factor Va molecule, In contrast, for factor Va cleaved at Arg(505), Arg(662), and Arg(306) the precipitated complex consisted of the Al domain (residues 1-306) and the light chain (residues 1537-2183) of factor Va (A1.LC). The fragments corresponding to residues 307-505 (A2(N)) and 506-662 (A2(C)) are found in the supernatant, The combined mass of these two products (48,000) is similar to the estimated mass of the 3.3 S fragment estimated from sedimentation velocity/equilibrium studies; while the combined mass of the 1-306 + 1537-2183 products corresponds to 114,000, the estimated mass of the 6.3 S fragment, These data lead to the conclusion that cleavages at Arg(306), Arg(505), and Arg(662) Of the factor Va molecule resulted in the dissociation of the entire A2 domain as two noncovalently associated fragments (A2(N).A2(C)). Enzyme kinetic and light scattering data suggest that the complete inactivation of the factor Va molecule involves not only cleavage at Arg(306) but also the dissociation of the A2 domain, These data also suggest that the complete APC inactivation of the factor Va molecule is analogous to the spontaneous inactivation of factor VIIIa, which occurs via the dissociation of the A2 domain.			Mann, KG (corresponding author), UNIV VERMONT,COLL MED,DEPT BIOCHEM,C401,GIVEN BLDG,BURLINGTON,VT 05405, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011293] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034575] Funding Source: NIH RePORTER; NCRR NIH HHS [RR11293] Funding Source: Medline; NHLBI NIH HHS [R37 HL34575] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FAY PJ, 1991, J BIOL CHEM, V266, P8957; GOLDBERG RJ, 1953, J PHYS CHEM-US, V57, P194, DOI 10.1021/j150503a014; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1993, METHOD ENZYMOL, P261; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1988, J BIOL CHEM, V263, P1037; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; XUE JC, 1993, BIOCHEMISTRY-US, V32, P5917, DOI 10.1021/bi00073a026; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	38	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20678	20683		10.1074/jbc.272.33.20678	http://dx.doi.org/10.1074/jbc.272.33.20678			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252387	hybrid			2022-12-27	WOS:A1997XR22100057
J	Sawada, Y; Suda, M; Yokoyama, H; Kanda, T; Sakamaki, T; Tanaka, S; Nagai, R; Abe, S; Takeuchi, T				Sawada, Y; Suda, M; Yokoyama, H; Kanda, T; Sakamaki, T; Tanaka, S; Nagai, R; Abe, S; Takeuchi, T			Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; CARDIAC GENE-EXPRESSION; PROTEIN-SYNTHESIS; ANGIOTENSIN-II; PROTEOLYTIC ACTIVATION; MECHANICAL-STRESS; ATRIAL MYOCYTES; FACTOR-BETA; RAT	When hypertrophic growth is induced in neonatal rat cardiocytes by stretching, the cardiocytes express high levels of brain-type natriuretic peptide (BNP) and the proprotein-processing enzyme furin. A BNP precursor, gamma BNP, possesses a furin-cleavable Arg-X-X-Arg motif, which is cleaved when gamma BNP is processed to form BNP-45, The Arg-X-X-Arg motif is found in many precursors of growth factors and growth-related proteins, To determine if furin converts gamma BNP to BNP-45 as well as other unidentified growth-promoting protein precursors to their active form that may induce hypertrophic growth in cardiocytes, we used two protease inhibitor systems, synthetic peptidyl chloromethyl ketones (CMK) (dec-Arg-Val-Lys-Arg-CMK and dec-Phe-Ala-Lys-Arg-CMK; where dec is decanoyl) and vaccinia vector-integrated native and variant alpha(1)-antitrypsins. The furin specific inhibitors, dec-Arg-Val-Lys-Arg-CMK and variant alpha(1)-antitrypsin with the inhibitory determinant Arg-X-X-Arg, suppressed the stretch-induced hypertrophic growth of cardiocytes as well as the processing of gamma BNP to BNP-45. The other serine protease inhibitors and variant alpha(1)-antitrypsin against elastase, or thrombin, however, neither suppressed the hypertrophic growth nor prevented the processing of gamma BNP to BNP-45. Thus, we suggest that furin catalyzes the conversion of gamma BNP to BNP-45 as well as growth-promoting proproteins to their active form, which might induce hypertrophic growth in cardiocytes.	GUNMA UNIV, INST MOL & CELLULAR REGULAT, DEPT MOL MED, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, INST MOL & CELLULAR REGULAT, DEPT CELL BIOL, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, DEPT INTERNAL MED 2, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, DEPT LAB MED, MAEBASHI, GUMMA 371, JAPAN; UNION CO, TAKASAKI, GUMMA 370, JAPAN	Gunma University; Gunma University; Gunma University; Gunma University								ABURAYA M, 1989, BIOCHEM BIOPH RES CO, V165, P880, DOI 10.1016/S0006-291X(89)80048-8; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BEAUBIEN G, 1995, CELL TISSUE RES, V279, P539; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLARK WA, 1981, J BIOL CHEM, V256, P4863; CLEUTJENS JPM, 1995, J MOL CELL CARDIOL, V27, P1281, DOI 10.1016/S0022-2828(05)82390-9; DEFTOS LJ, 1993, J CLIN INVEST, V92, P727, DOI 10.1172/JCI116643; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; ESPINER EA, 1994, J INTERN MED, V235, P527, DOI 10.1111/j.1365-2796.1994.tb01261.x; FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; HALBAN PA, 1994, BIOCHEM J, V299, P1; HAMA N, 1995, CIRCULATION, V92, P1558, DOI 10.1161/01.CIR.92.6.1558; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hruby D E, 1986, Methods Enzymol, V124, P295; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; Kayo T, 1996, J BIOL CHEM, V271, P10731, DOI 10.1074/jbc.271.18.10731; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; KOLLER KJ, 1992, CIRCULATION, V86, P1081, DOI 10.1161/01.CIR.86.4.1081; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LIU B, 1995, AM J PHYSIOL-ENDOC M, V268, pE832, DOI 10.1152/ajpendo.1995.268.5.E832; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Massfelder T, 1996, ENDOCRINOLOGY, V137, P3151, DOI 10.1210/en.137.8.3151; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MIZUNO K, 1987, BIOCHEM BIOPH RES CO, V144, P807, DOI 10.1016/S0006-291X(87)80036-0; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; MOSS B, 1986, FUNDAMENTAL VIROLOGY, P637; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; RICE AP, 1983, J VIROL, V47, P529, DOI 10.1128/JVI.47.3.529-539.1983; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SAITO Y, 1989, J CLIN INVEST, V83, P298, DOI 10.1172/JCI113872; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sawada Y, 1997, FEBS LETT, V400, P177, DOI 10.1016/S0014-5793(96)01385-3; Schluter KD, 1996, J BIOL CHEM, V271, P3074, DOI 10.1074/jbc.271.6.3074; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SEI CA, 1992, MOL ENDOCRINOL, V6, P309, DOI 10.1210/me.6.3.309; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; STEINHELPER ME, 1993, CIRC RES, V72, P984, DOI 10.1161/01.RES.72.5.984; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; STUDER R, 1994, J CLIN INVEST, V94, P301, DOI 10.1172/JCI117322; SUZUKI E, 1992, CIRC RES, V71, P1039, DOI 10.1161/01.RES.71.5.1039; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; URATA H, 1990, CIRC RES, V66, P883, DOI 10.1161/01.RES.66.4.883; URATA H, 1993, J CLIN INVEST, V91, P1269, DOI 10.1172/JCI116325; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; WATANABE M, 1995, J VIROL, V69, P3206, DOI 10.1128/JVI.69.5.3206-3210.1995; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANG ZH, 1993, CIRCULATION, V88, P832, DOI 10.1161/01.CIR.88.3.832	71	95	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20545	20554		10.1074/jbc.272.33.20545	http://dx.doi.org/10.1074/jbc.272.33.20545			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252368	hybrid			2022-12-27	WOS:A1997XR22100038
J	Vard, C; Guillot, D; Bargis, P; Lavergne, JP; Reboud, JP				Vard, C; Guillot, D; Bargis, P; Lavergne, JP; Reboud, JP			A specific role for the phosphorylation of mammalian acidic ribosomal protein P2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-II; DIMETHYLMALEIC ANHYDRIDE; PARTIAL RECONSTITUTION; PHOSPHOPROTEINS; SUBUNIT; P1	The acidic ribosomal proteins P1-P2 from rat liver were overproduced for the first time by expression of their cDNA in Escherichia coli, They were tested for their ability to reactivate inactive P1-P2-deficient core particles derived from 60 S ribosomal subunits treated with dimethylmaleic anhydride, in poly(U)-directed poly(Phe) synthesis, The recombinant P1-P2 were unable to reactivate these core particles although they could bind to them, When recombinant P1-P2 had been phosphorylated first with casein kinase II? they mere as efficient in the reactivation process as P1-P2 extracted with ethanol/KCl from the 60 S subunits, Reconstitution experiments were carried out using all possible combinations of the two recombinant proteins phosphorylated or not. Reactivation of the core particles required the presence of both P1 and P2 with the latter ill its phosphorylated form, These experiments reveal a distinct role for P1 and P2 in protein synthesis, Phosphorylated P2 produced a partial quenching of the intrinsic fluorescence of eukaryotic elongation factor 2, which was not observed with the unphosphorylated protein, This result demonstrates the existence of an interaction between phosphorylated P2 and eukaryotic elongation factor 2, P2 also quenched part of the intrinsic fluorescence of P1, due to the interaction between the two proteins.	CNRS, INST BIOL & CHIM PROTEINES, LAB BIOCHIM MED, F-69367 LYON 07, FRANCE	Centre National de la Recherche Scientifique (CNRS)								ABSI M, 1989, IMMUNOL LETT, V23, P35, DOI 10.1016/0165-2478(89)90152-1; Ballesta JPG, 1996, PROG NUCLEIC ACID RE, V55, P157, DOI 10.1016/S0079-6603(08)60193-2; CONQUET F, 1987, EUR J BIOCHEM, V163, P15, DOI 10.1111/j.1432-1033.1987.tb10730.x; ELKON K, 1986, P NATL ACAD SCI USA, V83, P7419, DOI 10.1073/pnas.83.19.7419; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HASLER P, 1991, J BIOL CHEM, V266, P13815; LAVERGNE JP, 1988, FEBS LETT, V236, P345, DOI 10.1016/0014-5793(88)80053-X; LAVERGNE JP, 1987, FEBS LETT, V216, P83, DOI 10.1016/0014-5793(87)80761-5; LILJAS A, 1991, INT REV CYTOL, V124, P103; MACCONNELL WP, 1982, J BIOL CHEM, V257, P5359; MARZOUKI A, 1989, FEBS LETT, V255, P72, DOI 10.1016/0014-5793(89)81063-4; REBOUD AM, 1980, J BIOL CHEM, V255, P6954; SANTOS C, 1994, J BIOL CHEM, V269, P15689; SONTAG B, 1993, BIOCHEMISTRY-US, V32, P1976, DOI 10.1021/bi00059a014; STRYCHARZ WA, 1978, J MOL BIOL, V126, P123, DOI 10.1016/0022-2836(78)90355-8; TSURUGI K, 1978, J BIOL CHEM, V253, P946; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; VIOQUE A, 1982, J BIOL CHEM, V257, P6477; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M	19	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20259	20262		10.1074/jbc.272.32.20259	http://dx.doi.org/10.1074/jbc.272.32.20259			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242705	hybrid			2022-12-27	WOS:A1997XQ05900092
J	Huang, DQ; Wilson, WA; Roach, PJ				Huang, DQ; Wilson, WA; Roach, PJ			Glucose-6-P control of glycogen synthase phosphorylation in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE TYPE-1; SACCHAROMYCES-CEREVISIAE; 2 FORMS; GENE; PHOSPHOFRUCTOKINASE; METABOLISM; SNF1; SYNTHETASE; DISRUPTION; EXISTENCE	The SNF1 gene encodes a protein kinase necessary for expression of glucose-repressible genes and for the synthesis of the storage polysaccharide glycogen, From a genetic screen, we have found that mutation of the PFK2 gene, which encodes the beta-subunit of 6-phosphofructo-1-kinase, restores glycogen accumulation in snf1 cells. Loss of PFK2 causes elevated levels of metabolites such as glucose-6-P, hyperaccumulation of glycogen, and activation of glycogen synthase, whereas glucose-6-P is reduced in snf1 cells, Other mutations that increase glucose-6-P, deletion of PFK1, which codes for the alpha-subunit of 6-phosphofructo-1-kinase, or of PGI1, the phosphoglucoisomerase gene, had similar effects on glycogen metabolism as did pfk2 mutants. We propose that elevated glucose-g-P mediates the effects of these mutations on glycogen storage. Glycogen synthase kinase activity was reduced in extracts from pfk2 cells but was restored to that of wild type if the extract was gel-filtered to remove small molecules, Also, added glucose-6-P inhibited the glycogen synthase kinase activity in extracts from wild-type cells, half-maximally at similar to 2 mM. We suggest that glucose-6-P controls glycogen synthase activity by two separate mechanisms. First, glucose-6-P is a direct activator of glycogen synthase, and second, it controls the phosphorylation state of glycogen synthase by inhibiting a glycogen synthase kinase.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis				Wilson, Wayne/0000-0003-2417-5756				BREITENBACHSCHMITT I, 1984, MOL GEN GENET, V195, P536, DOI 10.1007/BF00341459; CANNON JF, 1994, GENETICS, V136, P485; CARLSON M, 1981, GENETICS, V98, P25; CELENZA JL, 1984, MOL CELL BIOL, V4, P49, DOI 10.1128/MCB.4.1.49; CHESTER VE, 1967, NATURE, V214, P1237, DOI 10.1038/2141237a0; COROMINAS J, 1992, FEBS LETT, V310, P182, DOI 10.1016/0014-5793(92)81325-G; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P561, DOI 10.1111/j.1432-1033.1988.tb14135.x; FRANCOIS J, 1997, IN PRESS YEAST SUGAR; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; Guinovart JJ, 1997, BIOCHEM SOC T, V25, P157, DOI 10.1042/bst0250157; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HARDY TA, 1993, J BIOL CHEM, V268, P23799; HEINISCH J, 1989, GENE, V78, P309; HEINISCH J, 1986, MOL GEN GENET, V202, P75, DOI 10.1007/BF00330520; Huang DQ, 1996, MOL CELL BIOL, V16, P4357; Huang DQ, 1996, GENETICS, V143, P119; HUANG KP, 1974, J BIOL CHEM, V249, P3851; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG G, 1974, METHOD ENZYMAT AN, P1235; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; ROECH PJ, 1976, TRENDS BIOCHEM SCI, V1, P110; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHMANDENES LB, 1970, P NATL ACAD SCI USA, V66, P967, DOI 10.1073/pnas.66.3.967; SIKORSKI RS, 1989, GENETICS, V122, P19; Skurat Alexander V., 1996, P213; Stalmans W, 1997, BIOCHEM SOC T, V25, P19, DOI 10.1042/bst0250019; TARUI S, 1965, BIOCHEM BIOPH RES CO, V19, P517, DOI 10.1016/0006-291X(65)90156-7; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; Timblin BK, 1996, GENETICS, V143, P57; WILSON WA, 1995, THESIS U DUNDEE SCOT	37	35	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22495	22501		10.1074/jbc.272.36.22495	http://dx.doi.org/10.1074/jbc.272.36.22495			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278401	hybrid			2022-12-27	WOS:A1997XV49200021
J	Guzder, SN; Sung, P; Prakash, L; Prakash, S				Guzder, SN; Sung, P; Prakash, L; Prakash, S			Yeast Rad7-Rad16 complex, specific for the nucleotide excision repair of the nontranscribed DNA strand, is an ATP-dependent DNA damage sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIH; SACCHAROMYCES-CEREVISIAE; RECONSTITUTION; NUCLEASE; PROTEINS; SYSTEM; GENE	In eukaryotes, nucleotide excision repair of ultraviolet light-damaged DNA is a highly intricate process that requires a large number of evolutionarily conserved protein factors, Genetic studies in the yeast Saccharomyces cerevisiae have indicated a specific role of the RAD7 and RAD16 genes in the repair of transcriptionally inactive DNA. Here we show that the RAD7- and RAD16-encoded products exist as a complex of 1:1 stoichiometry, exhibiting an apparent dissociation constant (K-d) of <4 x 10(-10) M. The Rad7-Rad16 complex has been purified to near homogeneity in this study and is shown to bind, in an ATP-dependent manner and with high specificity, to DNA damaged by ultraviolet light, Importantly, inclusion of the Rad7-Rad16 complex in the in vitro nucleotide excision repair system that consists entirely of purified components results in a marked stimulation of damage specific incision. Thus, Rad7-Rad16 complex is the ATP-dependent DNA damage sensor that specifically functions with the ensemble of nucleotide excision repair factor (NEF) 1, NEF2, NEF3, and replication protein A in the repair of transcriptionally inactive DNA. We name this novel complex of Rad7 and Rad16 proteins NEF4.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL CANCER INSTITUTE [R37CA041261, R37CA035035, R01CA041261, R01CA035035] Funding Source: NIH RePORTER; NCI NIH HHS [CA41261, CA35035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MUELLER JP, 1995, NUCLEIC ACIDS RES, V23, P3457, DOI 10.1093/nar/23.17.3457; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635	15	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21665	21668		10.1074/jbc.272.35.21665	http://dx.doi.org/10.1074/jbc.272.35.21665			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268290	hybrid			2022-12-27	WOS:A1997XT85000002
J	Sherrington, PD; Scott, JL; Jin, BQ; Simmons, D; Dorahy, DJ; Lloyd, J; Brien, JH; Aebersold, RH; Adamson, J; Zuzel, M; Burns, GF				Sherrington, PD; Scott, JL; Jin, BQ; Simmons, D; Dorahy, DJ; Lloyd, J; Brien, JH; Aebersold, RH; Adamson, J; Zuzel, M; Burns, GF			TLiSA1 (PTA1) activation antigen implicated in T cell differentiation and platelet activation is a member of the immunoglobulin superfamily exhibiting distinctive regulation of expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE SURFACE PROTEIN; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; GENE; LYMPHOCYTES; SIGNAL; CLASSIFICATION; SPECIFICITY; INHIBITION; PREDICTION	T lineage-specific activation antigen 1 (TLiSA1) antigen was initially described as a T lineage-specific activation antigen involved in the differentiation of human cytotoxic T cells, Subsequently, the antigen was identified on platelets and was shown to be involved in platelet activation, hence it was renamed platelet and T cell antigen 1 (PTA1), although identity between the two antigens was not established, In the present study we have cloned the cDNA encoding TLiSA1 from Jurkat cells and show it to be a novel member of the immunoglobulin superfamily with the unusual structure of two V domains only, Identity between TLiSA1 and platelet PTA1 is established by immunological criteria, by internal peptide sequences obtained from the purified platelet glycoprotein and by sequencing the platelet transcript after reverse transcriptase-polymerase chain reaction, In Jurkat cells, TLiSA1/PTA1 mRNA and surface protein expression is greatly stimulated by treatment of the cells with phorbol ester, but the T cell proliferative signal of phorbol ester and ionophore combined greatly reduces or abrogates this response, and this suppressive effect of the ionophore is not reversed by incorporating FK506 to inhibit calcineurin. Together with the known signaling role of PTA1, these data substantiate the notion that this molecule is implicated in T cell differentiation, perhaps by engagement of an adhesive ligand.	UNIV NEWCASTLE, CANC RES UNIT, NEWCASTLE, NSW 2300, AUSTRALIA; UNIV OXFORD, INST MOL MED, OXFORD OX3 9DU, ENGLAND; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 1W5, CANADA	University of Newcastle; University of Oxford; University of British Columbia	Sherrington, PD (corresponding author), UNIV LIVERPOOL, DEPT HAEMATOL, DUNCAN BLDG, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AEBERSOLD RH, 1986, J BIOL CHEM, V261, P4229; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BARCLAY AN, 1993, LEUKOCYTE ANTIGEN FA, P38; Berke Gideon, 1993, P965; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BURNS GF, 1985, J EXP MED, V161, P1063, DOI 10.1084/jem.161.5.1063; CHEN LK, 1986, EUR J IMMUNOL, V16, P767, DOI 10.1002/eji.1830160709; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; EDISON AM, 1995, J BIOL CHEM, V270, P27112, DOI 10.1074/jbc.270.45.27112; *GEN CLMP GROUP, 1994, PROGR MAN WISC PACK; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JIN B, 1989, IMMUNOLOGY, V66, P570; LENS SMA, 1995, LEUCOCYTE TYPING 5, P357; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; MAKOVER D, 1991, ONCOGENE, V6, P455; Mazurov A V, 1992, Platelets, V3, P181, DOI 10.3109/09537109209013181; MESCHER MF, 1995, IMMUNOL REV, V146, P177, DOI 10.1111/j.1600-065X.1995.tb00689.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNGER WE, 1982, CANCER RES, V42, P5023; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAKAI K, 1996, PSORT PREDICTION PRO; NATHAN CF, 1979, J EXP MED, V149, P84, DOI 10.1084/jem.149.1.84; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RANGES GE, 1987, J EXP MED, V166, P991, DOI 10.1084/jem.166.4.991; RIVAS A, 1995, J IMMUNOL, V154, P4423; RUEGG CL, 1995, J IMMUNOL, V154, P4434; RYSAVY FR, 1992, COMPUT APPL BIOSCI, V8, P149; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SCOTT JL, 1994, J CELL BIOCHEM, V54, P135, DOI 10.1002/jcb.240540202; SCOTT JL, 1989, J BIOL CHEM, V264, P13475; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SIMMONS DL, 1992, J IMMUNOL, V148, P267; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG PL, 1992, J IMMUNOL, V148, P2600; Weiss Arthur, 1993, P467; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZUZEL M, 1991, BRIT J HAEMATOL, V79, P466, DOI 10.1111/j.1365-2141.1991.tb08057.x	48	37	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					21735	21744		10.1074/jbc.272.35.21735	http://dx.doi.org/10.1074/jbc.272.35.21735			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268302	hybrid			2022-12-27	WOS:A1997XT85000014
J	Clark, GJ; Drugan, JK; Rossmann, KL; Carpenter, JW; RogersGraham, K; Fu, H; Der, CJ; Campbell, SL				Clark, GJ; Drugan, JK; Rossmann, KL; Carpenter, JW; RogersGraham, K; Fu, H; Der, CJ; Campbell, SL			14-3-3 zeta negatively regulates Raf-1 activity by interactions with the Raf-1 cysteine-rich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DISTINCT BINDING DOMAINS; RAS TRANSFORMATION; 14-3-3-PROTEINS; PATHWAYS; CASCADE; CELLS; PHOSPHORYLATION; IDENTIFICATION; SUFFICIENT	Although Raf-l is a critical effector of nas signaling and transformation, the mechanism by which Ras promotes Raf-l activation is complex and remains pearly understood, We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-l activation, The Raf-CRD is located in the NH2-terminal negative regulatory domain of Raf-l and is highly homologous to cysteine-rich domains found in protein kinase C family members. Recent studies indicate that the structural integrity of the Raf-CRD is also critical for Raf-l interaction with 14-3-3 proteins. However, whether 14-3-3 proteins interact directly with the Raf-CRD and how this interaction may mediate Raf-1 function has not been determined. In the present study, we demonstrate that 14-3-3 zeta binds directly to the isolated Raf-CRD. Moreover, mutation of Raf-1 residues 143-145 impairs binding of 14-3-3, but not Ras, to the Raf-CRD. Introduction of mutations that impair 14-3-3 binding resulted in full-length Raf-1 mutants with enhanced transforming activity. Thus, 14-3-3 interaction with the Raf-CRD may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH, terminus of Raf-P to promote subsequent events necessary for full activation of Raf-1.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; EMORY UNIV, SCH MED, DEPT PHARMACOL, ATLANTA, GA 30322 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Emory University				Der, Channing/0000-0002-7751-2747; campbell, sharon/0000-0003-0311-409X	NCI NIH HHS [CA64569, CA70308, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064569, R01CA042978, R01CA070308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HURLEY JH, 1997, IN PRESS PROTEIN SCI; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MILLER AF, 1993, BIOCHEMISTRY-US, V32, P7367, DOI 10.1021/bi00080a006; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Rommel C, 1996, ONCOGENE, V12, P609; Sung YJ, 1996, J BIOL CHEM, V271, P30537, DOI 10.1074/jbc.271.48.30537; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	39	102	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20990	20993		10.1074/jbc.272.34.20990	http://dx.doi.org/10.1074/jbc.272.34.20990			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261098	hybrid			2022-12-27	WOS:A1997XR78900008
J	Ji, Y; Jian, B; Wang, N; Sun, Y; Moya, MDLL; Phillips, MC; Rothblat, GH; Swaney, JB; Tall, AR				Ji, Y; Jian, B; Wang, N; Sun, Y; Moya, MDLL; Phillips, MC; Rothblat, GH; Swaney, JB; Tall, AR			Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E; CELLS; HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; FIBROBLASTS; METABOLISM; PEPTIDES	Scavenger receptor BI (SR-EI) binds high density lipoproteins (HDL) with high affinity and mediates the selective uptake of HDL cholesteryl ester, We examined the potential role of SR-BI ill mediating cellular cholesterol efflux, In Chinese hamster ovary cells stably transfected with murine SR-BI, overexpression of SR-BI resulted in a 3-4-fold stimulation of initial cholesterol efflux rates. Efflux rates correlated with SB-BI expression in cells and HDL concentration in the medium. When incubated with synthetic cholesterol-free RDL, SR-BI-transfected cells showed similar to 3-fold increases in initial rates of efflux compared with control cells, indicating that SR-BI expression enhances net cholesterol efflux mediated by discoidal HDL. In six different cell types, including cultured macrophages, the rate of efflux of cholesterol mediated by RDL or serum was well correlated with cellular SR-BI expression level. In addition, in situ hybridization experiments revealed that SR-BI mRNA was expressed in the thickened intima of atheromatous aorta of apolipoprotein E knockout mice. Thus, SR-BI is an authentic HDL receptor mediating cellular cholesterol efflux, SR-BI may facilitate the initial steps of HDL-mediated cholesterol efflux in the arterial wall as well as later steps of reverse cholesterol transport involving uptake of HDL cholesterol in the liver.	COLUMBIA UNIV, DEPT MED, DIV MOL MED, NEW YORK, NY 10032 USA; ALLEGHENY UNIV HLTH SCI, MCP, HAHNEMANN SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19129 USA	Columbia University; Drexel University			Tall, Alan/AAT-8528-2021; Eckhardt, Erik/G-1567-2010	Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL22682, HL22633, HL54591] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL022682, P01HL054591, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DELALLERAMOYA M, 1994, ARTERIOSCLER THROMB, V14, P1056, DOI 10.1161/01.ATV.14.7.1056; EISENBERG S, 1984, J LIPID RES, V25, P1017; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1986, METHOD ENZYMOL, V128, P553; JONAS A, 1994, J LIPID RES, V35, P860; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MORTON RE, 1981, J BIOL CHEM, V256, P1992; Oram JF, 1996, J LIPID RES, V37, P2473; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rothblat G H, 1986, Methods Enzymol, V129, P628; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALL AR, 1996, ATHEROSCLEROSIS CORO, P105; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	32	619	646	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20982	20985		10.1074/jbc.272.34.20982	http://dx.doi.org/10.1074/jbc.272.34.20982			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261096	hybrid			2022-12-27	WOS:A1997XR78900006
J	Kok, JW; NikolovaKarakashian, M; Klappe, K; Alexander, C; Merrill, AH				Kok, JW; NikolovaKarakashian, M; Klappe, K; Alexander, C; Merrill, AH			Dihydroceramide biology - Structure-specific metabolism and intracellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-APPARATUS; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CULTURED FIBROBLASTS; RAT-LIVER; GLUCOSYLCERAMIDE SYNTHESIS; PHYSICAL-PROPERTIES; CYTOSOLIC SURFACE; FREE SPHINGOSINE; 2ND MESSENGER	This study utilized fluorescent analogs to characterize the intracellular transport and metabolism of dihydroceramide (DN-Cer), an intermediate in de novo sphingolipid biosynthesis, When 6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl) amino]hexanoyl-DH-Cer (C-6-NBD-DH-Cer) was incubated with HT29, NRK, BHK, or HL-60 cells, ii; mas efficiently converted to dihydrosphinogomyelin and dihydroglucosylceramide, and a number of other sphingolipids, with the nature of the products depending on the cell line, In addition, complex sphingolipids were formed that contained a desaturated (sphingosine) backbone, indicating that DH-Cer (and/or its metabolites) were substrates for the desaturase(s) that introduce the 4,5-trans double bond, Based on the kinetics and inhibitor studies, double bond addition did not appear to occur with the complex sphingolipids directly, but rather, during turnover and resynthesis. The conversion of C-6-NBD-DH-Cer to more complex sphingolipids was highly stereoselective for the natural D,erythro isomer of C-6-NBD-DH-Cer. Interestingly, the stereochemistry of the sphingoid base backbone also affected the localization of fluorescent sphingolipids: the D,erythro species appeared in the Golgi apparatus, whereas other stereo-isomers accumulated in the endoplasmic reticulum. In addition to C-6-NBD-Cer and C-6-NBD-DH-Cer, C-6-NBD-4-D-hydroxy-DH-Cer gave rise to formation of complex sphingolipids and localized at the Golgi, apparatus. These studies indicate that dihydroceramide is used as the initial backbone of complex (glyco)sphingolipids, perhaps to avoid build up of ceramide as an intermediate since this is such a potent bioactive compound, The stereoselectively in transport and metabolism suggests that trafficking of ceramide is protein-directed rather than simply a consequence of vesicular membrane flow.	EMORY UNIV, DEPT BIOCHEM, ATLANTA, GA 30322 USA	Emory University	Kok, JW (corresponding author), UNIV GRONINGEN, DEPT PHYSIOL CHEM, A DEUSINGLAAN 1, NL-9713 AV GRONINGEN, NETHERLANDS.			Merrill, Alfred/0000-0002-6673-968X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABIA T, 1993, INT J CANCER, V54, P839, DOI 10.1002/ijc.2910540519; BABIA T, 1994, EUR J CELL BIOL, V63, P172; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HOEKSTRA D, 1992, BIOCHIM BIOPHYS ACTA, V1113, P277, DOI 10.1016/0304-4157(92)90002-R; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; KOK JW, 1992, J CELL SCI, V103, P1139; KOK JW, 1995, BIOCHEM J, V309, P905, DOI 10.1042/bj3090905; KOK JW, 1993, FLUORESCENT LUMINESC, P100; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PUTZ U, 1995, EUR J CELL BIOL, V68, P113; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; TAN A, 1992, J CELL BIOL, V116, P1357, DOI 10.1083/jcb.116.6.1357; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623	32	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21128	21136		10.1074/jbc.272.34.21128	http://dx.doi.org/10.1074/jbc.272.34.21128			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261117	hybrid, Green Published			2022-12-27	WOS:A1997XR78900027
J	Kvaratskhelia, M; George, SJ; Thorneley, RNF				Kvaratskhelia, M; George, SJ; Thorneley, RNF			Salicylic acid is a reducing substrate and not an effective inhibitor of ascorbate peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; PLANT DEFENSE RESPONSES; HYDROGEN-PEROXIDE; 2,6-DICHLOROISONICOTINIC ACID; SPINACH-CHLOROPLASTS; MOLECULAR-PROPERTIES; 2 INDUCERS; SIGNAL; PURIFICATION; ARABIDOPSIS	This communication describes the interactions of salicylic acid (SA) with plant ascorbate peroxidase (APX). Contrary to a recent report (Durner, J., and Klessig, D. F. (1995) Proc. Natl. Acad. Sci, U. S, A. 92, 11312-11316) we show conclusively that ascorbate oxidation may APX is not inhibited by SA (10 mM), hut that SA is a slow reducing substrate of this enzyme, The suggestion that SA-dependent inhibition of ABX in planta may result in the elevation of H2O2 levels, which in turn acts as a second messenger in systemic acquired resistance signaling, is therefore not tenable. We conclude that APX remains a key antioxidant during systemic acquired resistance following pathogenic infection of plants, The transient products of SA oxidation by APX appear to be SA free radicals that undergo subsequent chemistry, APX-dependent oxidation of SA could he essential for diminishing the detrimental effects of this phenolic acid on plant cells.	JOHN INNES CTR PLANT SCI RES, NITROGEN FIXAT LAB, NORWICH NR4 7UH, NORFOLK, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center				George, Simon/0000-0002-4864-5479				ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; BALKE NE, 1987, ACS SYM SER, V330, P214; BI YM, 1995, PLANT J, V8, P235, DOI 10.1046/j.1365-313X.1995.08020235.x; Bunkelmann JR, 1996, PLANT PHYSIOL, V110, P589, DOI 10.1104/pp.110.2.589; CHEN GX, 1989, PLANT CELL PHYSIOL, V30, P987; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CONRATH U, 1995, P NATL ACAD SCI USA, V92, P7143, DOI 10.1073/pnas.92.16.7143; Dempsey D A, 1994, Trends Cell Biol, V4, P334, DOI 10.1016/0962-8924(94)90235-6; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DURNER J, 1995, P NATL ACAD SCI USA, V92, P11312, DOI 10.1073/pnas.92.24.11312; Durner J, 1996, J BIOL CHEM, V271, P28492, DOI 10.1074/jbc.271.45.28492; Einhellig F. A, 1986, SCI ALLELOPATHY, P317; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; GARA L, 1996, PLANT PEROXIDASES BI, P157; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; KLESSIG DF, 1994, PLANT MOL BIOL, V26, P1439, DOI 10.1007/BF00016484; Kvaratskhelia M, 1997, PLANT PHYSIOL, V114, P1237, DOI 10.1104/pp.114.4.1237; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MITTLER R, 1994, PLANT J, V5, P397, DOI 10.1111/j.1365-313X.1994.00397.x; MITTLER R, 1991, PLANT PHYSIOL, V97, P962, DOI 10.1104/pp.97.3.962; MIYAKE C, 1993, PLANT CELL PHYSIOL, V34, P881; NAKANO Y, 1981, PLANT CELL PHYSIOL, V22, P867; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NEUENSCHWANDER U, 1995, PLANT J, V8, P227, DOI 10.1046/j.1365-313X.1995.08020227.x; Ruffer M, 1995, FEBS LETT, V377, P175, DOI 10.1016/0014-5793(95)01334-2; SCHULZ M, 1993, PHYTOCHEMISTRY, V33, P291, DOI 10.1016/0031-9422(93)85505-L; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085	30	43	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20998	21001		10.1074/jbc.272.34.20998	http://dx.doi.org/10.1074/jbc.272.34.20998			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261100	hybrid			2022-12-27	WOS:A1997XR78900010
J	Mertz, P; Yu, L; Sikkink, R; Rusnak, F				Mertz, P; Yu, L; Sikkink, R; Rusnak, F			Kinetic and spectroscopic analyses of mutants of a conserved histidine in the metallophosphatases calcineurin and lambda protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURPLE ACID-PHOSPHATASE; CATALYTIC SUBUNIT; ACTIVE-SITE; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURES; CYCLOSPORINE-A; CALMODULIN; COMPLEX; PURIFICATION; SEQUENCE	Calcineurin belongs to a family of serine/threonine protein phosphatases that contain active site dinuclear metal cofactors. Bacteriophage lambda protein phosphatase is also considered to be a member of this family based on sequence comparisons (Lohse, D.L., Denu, J.M., and Dixon, J. E. (1995) Structure 3, 987-990). Using EPR spectroscopy, we demonstrate that lambda protein phosphatase accommodates a dinuclear metal center. Calcineurin and lambda protein phosphatase likewise contain a conserved histidine that is not a metal ligand but is within 5 Angstrom of either metal in calcineurin. in this study the conserved histidine in calcineurin was mutated to glutamine and the mutant protein analyzed by EPR spectroscopy and kinetic methods. Parallel studies with an analogous lambda protein phosphatase mutant were also carried out. Kinetic studies using paranitrophenyl phosphate as substrate showed a decrease in k(cat) of 460- and 590-fold far the calcineurin and lambda protein phosphatase mutants, respectively, compared with the wild type enzymes. With a phosphopeptide substrate, mutagenesis of the conserved histidine resulted in a decrease in k(cat) of 1,300-fold for calcineurin. With the analogous A protein phosphatase mutant, k(cat) decreased 530-fold compared with wild type lambda protein phosphatase using phenyl phosphate as a substrate, EPR studies of the iron-reconstituted enzymes indicated that. although both mutant enzymes can accommodate a dinuclear metal center, spectroscopic differences compared with wild type proteins suggest a perturbation of the ligand environment, possibly by disruption of a hydrogen bond between the histidine and a metal-coordinated solvent molecule.	MAYO CLIN & MAYO FDN, SECT HEMATOL RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOL BIOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic					NIGMS NIH HHS [GM46865] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046865] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARIK S, 1993, P NATL ACAD SCI USA, V90, P10633, DOI 10.1073/pnas.90.22.10633; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLERRANSOHOFF JE, 1992, J ORG CHEM, V57, P142, DOI 10.1021/jo00027a027; CHAN CP, 1986, J BIOL CHEM, V261, P9890; COHEN P, 1989, J BIOL CHEM, V264, P21435; DAY EP, 1988, J BIOL CHEM, V263, P15561; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HADDY A, 1994, BIOCHEM BIOPH RES CO, V200, P1221, DOI 10.1006/bbrc.1994.1581; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; Kennedy MT, 1996, J BIOL CHEM, V271, P26517, DOI 10.1074/jbc.271.43.26517; KIRBY AJ, 1965, J AM CHEM SOC, V87, P3209, DOI 10.1021/ja01092a036; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; KOONIN EV, 1994, PROTEIN SCI, V3, P356; KURTZ DM, 1990, CHEM REV, V90, P585, DOI 10.1021/cr00102a002; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOHSE DL, 1995, STRUCTURE, V3, P987, DOI 10.1016/S0969-2126(01)00234-9; MARTIN B, 1985, J BIOL CHEM, V260, P4932; MUELLER EG, 1993, J AM CHEM SOC, V115, P2974, DOI 10.1021/ja00060a055; PALLEN CJ, 1983, J BIOL CHEM, V258, P8550; Rusnak F, 1996, J BIOL INORG CHEM, V1, P388, DOI 10.1007/s007750050070; SAITOH Y, 1991, BIOMED RES-TOKYO, V12, P215, DOI 10.2220/biomedres.12.215; SCHRAY KJ, 1973, ENZYMES, P201; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; WOLFF DJ, 1985, J BIOL CHEM, V260, P4195; YU L, 1995, J AM CHEM SOC, V117, P10147, DOI 10.1021/ja00145a040; Zhang J, 1996, BIOCHEMISTRY-US, V35, P6276, DOI 10.1021/bi952954l; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	41	63	65	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21296	21302		10.1074/jbc.272.34.21296	http://dx.doi.org/10.1074/jbc.272.34.21296			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261141	hybrid			2022-12-27	WOS:A1997XR78900051
J	Turcatti, G; Zoffmann, S; Lowe, JA; Drozda, SE; Chassaing, G; Schwartz, TW; Chollet, A				Turcatti, G; Zoffmann, S; Lowe, JA; Drozda, SE; Chassaing, G; Schwartz, TW; Chollet, A			Characterization of non-peptide antagonist and peptide agonist binding sites of the NK1 receptor with fluorescent ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROKININ-1 RECEPTOR; SUBSTANCE-P ANTAGONIST; NONPEPTIDE ANTAGONIST; NK-1 RECEPTOR; DOMAINS; CELLS; DISCOVERY	Ligand recognition of the NK1 receptor (substance P receptor) by peptide agonist and non-peptide antagonist has been investigated and compared by the use of fluorescent ligands and spectrofluorometric methods, Analogues of substance P (SP) labeled with the environment-sensitive fluorescent group 5-dimethylaminonaphthalene-1 sulfonyl (dansyl) at either position 3, 8, or 11 or with fluorescein at the N-alpha position were synthesized and characterized. Peptides modified at the alpha-amino group or at positions 3 or 11 conserved a relatively good affinity for NK1 and agonistic properties, Modification at position 8 resulted in an 18,000-fold decrease in affinity, A fluorescent dansyl analogue of the non-peptide antagonist CP96,345 was prepared and characterized. The quantum yield of fluorescence for dansyl-CP96,345 was much higher than for any of the dansyl-labeled peptides indicating that the micro-environment of the binding site is more hydrophobic for the nonpeptide antagonist than for the peptide agonists, Comparison of collisional quenching of fluorescence by the water-soluble hydroxy-Tempo compound showed that dansyl-CP96,345 is buried and virtually inaccessible to aqueous quenchers, whereas dansyl-or fluoresceinyl-labeled peptides were exposed to the solvent, Anisotropy of all fluorescent ligands increased upon binding to NK1 indicating a restricted motional freedom, However, this increase in anisotropy was more pronounced for the dansyl attached to the non-peptide antagonist CP96,345 than for the fluorescent probes attached to different positions of SP, In conclusion, our data indicate that the environment surrounding non-peptide antagonist and peptide agonists are vastly different when bound to the NK1 receptor. These results support recent observations by mutagenesis and cross-linking work suggesting that peptide agonists have their major interaction points in the N-terminal extension and the loops forming the extracellular face of the NK1 receptor, Our data also suggest that neither the C terminus nor the N terminus of SP appears to penetrate deeply below the extracellular surface in the transmembrane domain of the receptor.	GLAXO WELLCOME,GENEVA BIOMED RES INST,CH-1228 GENEVA,SWITZERLAND; UNIV COPENHAGEN,INST MOL BIOL,DEPT PROT CHEM,DK-2100 COPENHAGEN,DENMARK; PFIZER INC,CENT RES,GROTON,CT 06340; UNIV PARIS 06,CNRS,URA 493,F-75252 PARIS,FRANCE	GlaxoSmithKline; University of Copenhagen; Pfizer; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite				Schwartz, Thue W./0000-0002-0261-6904				Alla SA, 1996, J BIOL CHEM, V271, P1748, DOI 10.1074/jbc.271.3.1748; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; BRADSHAW CG, 1994, J MED CHEM, V37, P1991, DOI 10.1021/jm00039a012; CHASSAING G, 1983, J ORG CHEM, V48, P1757, DOI 10.1021/jo00158a033; DEKROON AIPM, 1994, FEBS LETT, V342, P230, DOI 10.1016/0014-5793(94)80507-5; DESAI MC, 1992, J MED CHEM, V35, P4911, DOI 10.1021/jm00104a018; FAY SP, 1993, BIOCHEMISTRY-US, V32, P1627, DOI 10.1021/bi00057a029; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1993, NATURE, V362, P350; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; GETHER U, 1994, J BIOL CHEM, V269, P23959; Girault S, 1996, EUR J BIOCHEM, V240, P215, DOI 10.1111/j.1432-1033.1996.0215h.x; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; LAALI KK, 1993, J ORG CHEM, V58, P1385, DOI 10.1021/jo00058a018; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P111; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; LONDON E, 1986, ANAL BIOCHEM, V154, P57, DOI 10.1016/0003-2697(86)90495-1; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; LUNDSTROM K, 1994, EUR J BIOCHEM, V224, P917, DOI 10.1111/j.1432-1033.1994.00917.x; Macdonald D, 1996, MOL PHARMACOL, V49, P808; MAGGIO JE, 1994, TACHYKININ RECEPTORS, P1; MATKO J, 1992, BIOCHEMISTRY-US, V31, P703, DOI 10.1021/bi00118a010; MCLEAN S, 1991, SCIENCE, V251, P437, DOI 10.1126/science.1703324; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SCHWARTZ TW, 1995, CURR PHARM DESIGN, V1, P325; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; TOTA MR, 1995, J BIOL CHEM, V270, P26466, DOI 10.1074/jbc.270.44.26466; TOTA MR, 1994, BIOCHEMISTRY-US, V33, P13079, DOI 10.1021/bi00248a017; TOTA MR, 1990, J BIOL CHEM, V265, P16891; Turcatti G, 1996, J BIOL CHEM, V271, P19991, DOI 10.1074/jbc.271.33.19991; TURCATTI G, 1995, BIOCHEMISTRY-US, V34, P3972, DOI 10.1021/bi00012a015; TURCATTI G, 1993, J RECEPTOR RES, V13, P639, DOI 10.3109/10799899309073684; VALENZUELA CF, 1994, BIOCHEMISTRY-US, V33, P6586, DOI 10.1021/bi00187a028; WEAST RC, 1981, HDB CHEM PHYSICS, pF51; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	40	56	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21167	21175		10.1074/jbc.272.34.21167	http://dx.doi.org/10.1074/jbc.272.34.21167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261122	hybrid			2022-12-27	WOS:A1997XR78900032
J	Yu, M; Ives, D; Ramesha, CS				Yu, M; Ives, D; Ramesha, CS			Synthesis of prostaglandin E-2 ethanolamide from anandamide by cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CANNABINOID RECEPTOR; SYNTHASE-1; INHIBITION; ACID	Because of its structural similarity to polyunsaturated fatty acids, anandamide could serve as substrate for enzymes such as lipoxygenases and cyclooxygenases, which metabolize polyunsaturated fatty acids to potent bioactive metabolites. Here the ability of recombinant human cyclooxygenase-l (hCOX-1) and cyclooxygenase-2 (hCOX-2) to metabolize anandamide was studied. Baculovirus-expressed and -purified hCOX-2, but not hCOX-1, effectively oxygenated anandamide. Reverse phase high pressure liquid chromatography analysis of the products derived from 1-C-14-labeled anandamide showed that the products formed are similar to those formed with arachidonic acid as substrate. The major prostanoid product derived from anandamide was determined by mass spectrometry to be prostaglandin E-2 ethanolamide. Incubation of anandamide with lysates and the intact cell line expressing COX-2 but not that of COX-1 produced prostaglandin E-2 ethanolamide. These results demonstrate the existence of a COX-a-mediated pathway for anandamide metabolism, and the metabolites formed represent a novel class of prostaglandins.	ROCHE BIOSCI,DEPT BIOCHEM,INFLAMMATORY DIS UNIT,PALO ALTO,CA 94303	Roche Holding								BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BARNETTECURLEY D, 1995, P SOC EXP BIOL MED, V210, P64; Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; CRAWLEY JN, 1993, PHARMACOL BIOCHEM BE, V46, P967, DOI 10.1016/0091-3057(93)90230-Q; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAPSON AJ, 1995, BIOCHIM BIOPHYS ACTA, V1259, P173; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Kurumbail RG, 1997, NATURE, V385, P555, DOI 10.1038/385555b0; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; MEADE EA, 1993, J BIOL CHEM, V268, P6610; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAZ A, 1988, J BIOL CHEM, V263, P3022; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; SCHWARZ H, 1994, J NEUROIMMUNOL, V55, P107, DOI 10.1016/0165-5728(94)90152-X; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; Stefano GB, 1996, J BIOL CHEM, V271, P19238, DOI 10.1074/jbc.271.32.19238; UEDA N, 1995, ADV PROSTAG THROMB L, V23, P163; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823	23	327	345	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21181	21186		10.1074/jbc.272.34.21181	http://dx.doi.org/10.1074/jbc.272.34.21181			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261124	hybrid			2022-12-27	WOS:A1997XR78900034
J	Dickinson, CD; Ruf, W				Dickinson, CD; Ruf, W			Active site modification of factor VIIa affects interactions of the protease domain with tissue factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; BLOOD-COAGULATION; EXTRINSIC PATHWAY; FACTOR-X; BINDING; ACTIVATION; COFACTOR; AUTOACTIVATION; INITIATION	In the initiation of coagulation, tissue factor (TF) allosterically activates the serine protease factor VIIa (VIIa) through specific interactions with protease domain residues. These interactions, and consequently affinity for TF, may be influenced by conformational changes in the protease domain that result from zymogen-enzyme transition or occupancy of the active site by tight binding inhibitors, In functional competition and direct binding analysis, we determined affinities for zymogen and enzyme species of wild-type VII and of mutants at protease domain residues that contact TF. We demonstrate that TF binding is not influenced by zymogen activation, indicating that the protease domain of zymogen and enzyme dock similarly with TF, In contrast, active site occupancy enhanced the affinity for TF by predominantly decreasing the dissociation rate of the TF.VIIa complex. Of the three interface residues studied, only Met(306) played a major role in the inhibitor-induced increase in affinity. Met(306) is also important for transmitting the allosteric changes from TF to the active site, resulting in enhanced catalysis. This study thus provides evidence for a bidirectional conformational interdependence of the interface residue Met(306) and the active site of VIIa.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NHLBI NIH HHS [R01 HL-48752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; HIGASHI S, 1996, J BIOL CHEM, V271, P23569; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JESPERS LS, 1995, BIO-TECHNOL, V13, P378, DOI 10.1038/nbt0495-378; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; KUWADA M, 1981, ANAL BIOCHEM, V117, P259, DOI 10.1016/0003-2697(81)90720-X; MARTIN DMA, 1995, FASEB J, V9, P852, DOI 10.1096/fasebj.9.10.7615155; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; RUF W, 1995, BIOCHEMISTRY-US, V34, P6310, DOI 10.1021/bi00019a008; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605	27	75	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19875	19879		10.1074/jbc.272.32.19875	http://dx.doi.org/10.1074/jbc.272.32.19875			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242651	hybrid			2022-12-27	WOS:A1997XQ05900038
J	Chen, PQ; Mayne, M; Power, C; Nath, A				Chen, PQ; Mayne, M; Power, C; Nath, A			The Tat protein of HIV-1 induces tumor necrosis factor-alpha production - Implications for HIV-1-associated neurological diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMARY HUMAN ASTROCYTES; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; INCREASED EXPRESSION; GENE-EXPRESSION; CELL-ADHESION; BASIC DOMAIN; GLIAL-CELLS; TNF-ALPHA	Human immunodeficiency virus (HIV) infection may cause a dementing illness. HIV-mediated dementia is clinically and pathologically correlated with the infiltration of activated macrophages and elevated levels of tumor necrosis factor (TNF)-alpha, both of which occur in an environment of small numbers of infected cells. We examined the possibility that HIV protein Tat, which is released extracellularly from infected cells, may induce the production of TNF-alpha. Tat induced TNF-alpha mRNA and protein production dose-dependently, primarily in macrophages but also in astrocytic cells. The TNF-alpha induction was NF-kappa B-dependent and could be eliminated by inhibiting protein kinase A or protein tyrosine kinase activity. In addition, Tat-induced TNF-alpha release was also linked to phospholipase C activation. However, Tat effects were independent of protein kinase C. These observations suggest that Tat may provide an important link between HIV and macrophage/glial cell activation and suggest new therapeutic approaches for HIV dementia.	UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,DEPT MED,NEUROL SECT,WINNIPEG,MB R3E 0W3,CANADA	University of Manitoba; University of Manitoba			Power, Christopher/C-7181-2013	Power, Christopher/0000-0002-5131-9711				ALOISI F, 1992, J IMMUNOL, V149, P3379; Battey, 1986, BASIC METHODS MOL BI; Benveniste EN, 1995, FASEB J, V9, P1577, DOI 10.1096/fasebj.9.15.8529837; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; BRISCOE DM, 1992, J IMMUNOL, V149, P2954; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHENG J, 1997, IN PRESS NEUROSCI; Conant K, 1996, J VIROL, V70, P1384, DOI 10.1128/JVI.70.3.1384-1389.1996; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; FURER M, 1993, CELL ADHES COMMUN, V1, P223, DOI 10.3109/15419069309097256; GELBARD HA, 1993, DEV NEUROSCI-BASEL, V15, P417, DOI 10.1159/000111367; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GLASS JD, 1993, NEUROLOGY, V43, P2230, DOI 10.1212/WNL.43.11.2230; Han X, 1996, EUR J CLIN INVEST, V26, P286, DOI 10.1046/j.1365-2362.1996.116271.x; JOVELIN F, 1995, BIOTECHNIQUES, V19, P378; Lafortune L, 1996, J NEUROPATH EXP NEUR, V55, P515, DOI 10.1097/00005072-199605000-00003; LOCARDI C, 1990, J VIROL, V64, P5874, DOI 10.1128/JVI.64.12.5874-5882.1990; Ma MH, 1997, J VIROL, V71, P2495, DOI 10.1128/JVI.71.3.2495-2499.1997; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MATHEW TC, 1990, DEV BIOL, V141, P84, DOI 10.1016/0012-1606(90)90103-P; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; NATH A, 1989, ARCH VIROL, V107, P159, DOI 10.1007/BF01313888; New DR, 1997, J NEUROVIROL, V3, P168, DOI 10.3109/13550289709015806; NUOVO GJ, 1994, AM J PATHOL, V144, P659; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; Power C, 1995, CURR TOP MICROBIOL, V202, P89; RENIER G, 1994, J LIPID RES, V35, P1413; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SIPPY BD, 1995, J ACQ IMMUN DEF SYND, V10, P511; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; TARDIEU M, 1992, ANN NEUROL, V32, P11, DOI 10.1002/ana.410320104; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; VIKTOVIC L, 1994, HIV AIDS BRAIN, P203; VITKOVIC L, 1990, J NEUROIMMUNOL, V30, P153, DOI 10.1016/0165-5728(90)90099-9; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WILT SG, 1995, ANN NEUROL, V37, P381, DOI 10.1002/ana.410370315; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	44	190	197	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22385	22388		10.1074/jbc.272.36.22385	http://dx.doi.org/10.1074/jbc.272.36.22385			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278385	hybrid			2022-12-27	WOS:A1997XV49200004
J	Hammell, RL; HitchcockDeGregori, SE				Hammell, RL; HitchcockDeGregori, SE			The sequence of the alternatively spliced sixth exon of alpha-tropomyosin is critical for cooperative actin binding but not for interaction with troponin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE THIN FILAMENT; LABELED TROPOMYOSIN; FUNCTIONAL DOMAINS; CROSS-LINKING; F-ACTIN; FLUORESCENCE; FRAGMENTS; SURFACE; SITES; MUTAGENESIS	Tropomyosins, a family of highly conserved coiled-coil actin binding proteins, can differ as a consequence of alternative expression of several exons (Lees-Miller, J., and Helfman, D. (1991) BioEssays 13, 429-457). Exon 6, which encodes residues 189-213 in long, 284-residue tropomyosins, has two alternative forms, exon 6a or 6b, both highly conserved throughout evolution, In alpha-tropomyosin, exon 6a or 6b is not specific to any one of the nine isoforms, Exon 6b encodes part of a putative Ca2+-sensitive troponin binding site in striated muscle tropomyosins, suggesting that the exon 6-encoded region may be specialized for certain tropomyosin functions, A series of recombinant, unacetylated , tropomyosin exon 6 deletion and substitution mutants and chimeras was expressed in Escherichia coli to determine the requirements of exon 6 for tropomyosin function, Functional properties of the tropomyosins were defined by actin affinity measured by cosedimentation, troponin T affinity using a newly developed biosensor assay, and regulation of the actomyosin MgATPase. The region of tropomyosin encoded by exon 6 affects actin affinity but not thin filament assembly, troponin T binding, or regulation with troponin, The tropomyosins with exon 6a or 6b function normally whether a striated muscle exon 9a or smooth/non-muscle exon 9d is present, However, the effect of deleting 21 amino acids encoded by exon 6 or replacing it with a GCN4 leucine zipper sequence depends on the COOH-terminal sequence.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT CELL BIOL & NEUROSCI,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NHLBI NIH HHS [HL35726] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CARR HJ, 1988, J MUSCLE RES CELL M, V9, P384, DOI 10.1007/BF01774065; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; CHONG PCS, 1982, J BIOL CHEM, V257, P9152; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; GREENFIELD NJ, 1995, BIOCHEMISTRY-US, V34, P10797; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HAMMELL RL, 1993, MOL BIOL CELL, V4, pS259; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HitchcockDeGregori SE, 1996, J BIOL CHEM, V271, P3600; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P2573; HITCHCOCKDEGREGORI SE, 1988, ARCH BIOCHEM BIOPHYS, V264, P410, DOI 10.1016/0003-9861(88)90306-2; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; ISHII Y, 1991, J BIOL CHEM, V266, P6894; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; Jonsson U., 1992, ADV BIOSENSOR, P291; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMKIN M, 1983, BIOCHEMISTRY-US, V22, P3053, DOI 10.1021/bi00282a005; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; OBRIEN EJ, 1971, PHILOS T ROY SOC B, V261, P201, DOI 10.1098/rstb.1971.0051; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUCK P, 1996, TRENDS BIOCHEM SCI, V21, P458; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZCZESNA D, 1995, BIOCHEMISTRY-US, V34, P3614, DOI 10.1021/bi00011a016; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; UENO H, 1978, J BIOCHEM-TOKYO, V84, P1009, DOI 10.1093/oxfordjournals.jbchem.a132182; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; WATSON MH, 1990, J BIOL CHEM, V265, P18860; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; YANG YZ, 1979, J BIOL CHEM, V254, P7137; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	55	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22409	22416		10.1074/jbc.272.36.22409	http://dx.doi.org/10.1074/jbc.272.36.22409			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278391	hybrid			2022-12-27	WOS:A1997XV49200010
J	Itoh, T; Ikeda, T; Gomi, H; Nakao, S; Suzuki, T; Itohara, S				Itoh, T; Ikeda, T; Gomi, H; Nakao, S; Suzuki, T; Itohara, S			Unaltered secretion of beta-amyloid precursor protein in gelatinase a (matrix metalloproteinase 2)-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; NEXIN-II; CELLS; RAT; LOCALIZATION; SURFACE; DOMAIN; BRAIN; GENE	The beta-amyloid peptide, which forms extracellular cerebral deposits in Alzheimer's disease, is derived from a large membrane-spanning glycoprotein referred to as the beta-amyloid precursor protein (APP). The APP is normally cleaved within the beta-amyloid region by a putative proteinase (alpha-secretase) to generate large soluble amino-terminal derivatives of APP, and this event pre vents the beta-amyloid peptide formation. It has been suggested that the gelatinase A (matrix metalloproteinase 2, a 72-kDa type IV collagenase) may act either as alpha-secretase or as beta-secretase. Mice devoid of gelatinase A generated by gene targeting develop normally, except for a subtle delay in their growth, thus providing a useful system to examine the role of gelatinase A in the cleavage and secretion of APP in vivo. We show here that APP is cleaved within the beta-amyloid region and secreted into the extracellular milieu of brain and cultured fibroblasts without gelatinase A activity. The data suggest that gelatinase A does not play an essential role in the generation and release of soluble derivatives of APP at physiological conditions.	KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 60601,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	Kyoto University; University of Tokyo			Itohara, Shigeyoshi/I-8769-2012; Suzuki, Toshiharu/B-5342-2013	Itohara, Shigeyoshi/0000-0002-2410-9989; 				ARAKI W, 1994, NEUROSCI LETT, V167, P125, DOI 10.1016/0304-3940(94)91043-X; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HILBICH C, 1993, J BIOL CHEM, V268, P26571; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATO Y, 1992, J BIOL CHEM, V267, P11424; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; LePage RN, 1995, FEBS LETT, V377, P267, DOI 10.1016/0014-5793(95)01358-X; LOFFLER J, 1992, J NEUROCHEM, V59, P1316, DOI 10.1111/j.1471-4159.1992.tb08443.x; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MIYAZAKI K, 1994, NATURE, V368, P695, DOI 10.1038/368695b0; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; ROHER AE, 1994, BIOCHEM BIOPH RES CO, V205, P1757; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; VANNOSTRAND WE, 1989, NATURE, V341, P546; WALSH DM, 1994, NATURE, V367, P27, DOI 10.1038/367027a0; XIE B, 1994, J IMMUNOL, V152, P3637; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAMADA T, 1995, ACTA NEUROPATHOL, V89, P199	24	297	303	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22389	22392		10.1074/jbc.272.36.22389	http://dx.doi.org/10.1074/jbc.272.36.22389			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278386	hybrid			2022-12-27	WOS:A1997XV49200005
J	Nadal, F; LevyToledano, S; Grelac, F; Caen, JP; Rosa, JP; Bryckaert, M				Nadal, F; LevyToledano, S; Grelac, F; Caen, JP; Rosa, JP; Bryckaert, M			Negative regulation of mitogen-activated protein kinase activation by integrin alpha(IIb)beta(3) in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; MAP KINASE; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; PHORBOL ESTER; PHOSPHATASE; CELLS; THROMBASTHENIA; RECEPTORS	Activation of the mitogen-activated protein (MAP) kinase pathway in nucleated cells is dependent on both growth factor receptors and integrins engaged in cell adhesion, Human platelets are an interesting model for studying cell adhesion and the involvement of integrin engagement on extracellular signal-regulated kinase (ERK) activation, independently from the nuclear-DNA signal pathway, Maximal phosphorylation and activity of ERK2 occurred late during thrombin-induced platelet aggregation (90 s and later), an alpha(IIb)beta(3) integrin-dependent event, Surprisingly, alpha(IIb)beta(3) inhibition by the RGDS ligand peptide, or (Fab')(2) fragments of the AP-2 monoclonal antibody, resulted in a a-fold enhancement in ERK2 phosphorylation and activity. A similar 2-fold enhancement of ERK2 activation was observed in thrombasthenic platelets which are defective in alpha(IIb)beta(3) and do not aggregate, This suggests that ERK2 activation in thrombin-induced platelet aggregation is dependent on thrombin rather than on alpha(IIb)beta(3) and is down-regulated by alpha(IIb)beta(3) engaged in ligand (fibrinogen) binding and/or aggregation, Finally, in the absence of stirring which allows fibrinogen binding to alpha(IIb)beta(3) but prevents aggregation, ERK2 was again overactivated. This overactivation appears to be consecutive to inhibition of aggregation itself and to alpha(IIb)beta(3) ligand binding, We conclude that in platelets, alpha(IIb)beta(3) engaged in aggregation down-regulates thrombin-induced ERK2 activation, To our knowledge, this is the first report of a down-regulation of the MAP kinase pathway by integrin engagement.	HOP LARIBOISIERE,U348 INSERM,IFR CIRCULAT LARIBOISIERE,F-75475 PARIS 10,FRANCE; HOP LARIBOISIERE,IVS,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite			ROSA, JEAN-PHILIPPE/B-6245-2018	ROSA, JEAN-PHILIPPE/0000-0001-7342-0389; Bryckaert, Marijke/0000-0003-3398-0976				Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; ASHWORTH A, 1992, ONCOGENE, V7, P2555; Berrou E, 1996, BIOCHEM J, V316, P167, DOI 10.1042/bj3160167; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DJAFFAR I, 1993, HUM MOL GENET, V2, P2183, DOI 10.1093/hmg/2.12.2183; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENORMAND P, 1993, ADV SEC MESS PHOSPH, V28, P237; Li RY, 1997, THROMB HAEMOSTASIS, V77, P150; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PIDARD D, 1983, J BIOL CHEM, V258, P2582; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Toyoda H, 1996, THROMB HAEMOSTASIS, V76, P1053; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WHITE GC, 1995, THROMB HAEMOSTASIS, V73, P995; WILLIAMS MJ, 1995, SEMIN CELL BIOL, V6, P305, DOI 10.1006/scel.1995.0040; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	32	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22381	22384		10.1074/jbc.272.36.22381	http://dx.doi.org/10.1074/jbc.272.36.22381			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278384	hybrid			2022-12-27	WOS:A1997XV49200003
J	Rumbaugh, JA; Murante, RS; Shi, S; Bambara, RA				Rumbaugh, JA; Murante, RS; Shi, S; Bambara, RA			Creation and removal of embedded ribonucleotides in chromosomal DNA during mammalian Okazaki fragment processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-SPECIFIC ENDONUCLEASE; BLOOMS SYNDROME CELLS; CALF RTH-1 NUCLEASE; LIGASE-I; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; REPLICATION; REPAIR	Mammalian RNase HI has been shown to specifically cleave the initiator RNA of Okazaki fragments at the RNA-DNA junction, leaving a single ribonucleotide attached to the 5'-end of the downstream DNA segment, This monoribonucleotide can then be removed by the mammalian 5'- to 3'-exo-/endonuclease, a RAD2 homolog-1 (RTH-1) class nuclease, also known as flap endonuclease-l (FEN-1), Although FEN-1/RTH-1 nuclease often requires an upstream primer for efficient activity, the presence of an upstream primer is usually inhibitory or neutral for removal of this 5'-monoribonucleotide. Using model Okazaki fragment substrates, we found that DNA ligase I can seal a 5'-monoribonucleotide into DNA. When both ligase and FEN-1/RTH-1 were present simultaneously, some of the 5'-monoribonucleotides were ligated into DNA, while others were released, Thus, a 5'-monoribonucleotide, particularly one that is made resistant to FEN-1/RTH-1-directed cleavage by extension of an inhibitory upstream primer, can be ligated into the chromosome, despite the presence of FEN-1/RTH-1 nuclease, DNA ligase I was able to seal different monoribonucleotides into the DNA for all substrates tested, with an efficiency of 1-13% that of ligating DNA, These embedded monoribonucleotides can be removed by the combined action of RNase HI, cutting on the 5'-side, and FEN-1/RTR-1 nuclease, cleaving on the 3'-side. After FEN-1/RTH-1 action and extension by polymerization, DNA ligase I can join the entirely DNA strands to complete repair.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007356, R01GM024441] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM24441, T32GM07356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1977, BIOCHEMISTRY-US, V16, P4990, DOI 10.1021/bi00642a009; ARRAND JE, 1986, J BIOL CHEM, V261, P9079; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; CHAN JYH, 1988, J BIOL CHEM, V263, P18231; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; EDER PS, 1993, BIOCHIMIE, V75, P123, DOI 10.1016/0300-9084(93)90033-O; EDER PS, 1991, J BIOL CHEM, V266, P6472; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P668; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; HUSAIN I, 1995, J BIOL CHEM, V270, P9683, DOI 10.1074/jbc.270.16.9683; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JOHNSTON LH, 1978, NATURE, V274, P891, DOI 10.1038/274891a0; KAUFMANN G, 1977, J MOL BIOL, V116, P549, DOI 10.1016/0022-2836(77)90083-3; Komberg A., 1992, DNA REPLICATION, P307; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LASKO DD, 1990, MUTAT RES, V236, P277, DOI 10.1016/0921-8777(90)90011-S; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LI CJ, 1993, J CELL BIOCHEM, V53, P405, DOI 10.1002/jcb.240530418; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; LJUNGQUIST S, 1994, MUTAT RES, V314, P177, DOI 10.1016/0921-8777(94)90081-7; MALKAS LH, 1990, BIOCHEMISTRY-US, V29, P6362, DOI 10.1021/bi00479a004; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; NETHANEL T, 1992, J VIROL, V66, P6634, DOI 10.1128/JVI.66.11.6634-6640.1992; PETRINI JHJ, 1995, MOL CELL BIOL, V15, P4303; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; ROBERTS E, 1994, J BIOL CHEM, V269, P3789; Sambrook J., 2002, MOL CLONING LAB MANU; SODERHALL S, 1975, J BIOL CHEM, V250, P8438; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21726; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0; WILLIS AE, 1987, P NATL ACAD SCI USA, V84, P8016, DOI 10.1073/pnas.84.22.8016; YAMAMOTO KF, 1987, CELL TISSUE KINET, V20, P69	52	47	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22591	22599		10.1074/jbc.272.36.22591	http://dx.doi.org/10.1074/jbc.272.36.22591			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278414	hybrid			2022-12-27	WOS:A1997XV49200034
J	Smith, RA; Mosesson, MW; Rooney, MM; Lord, ST; Daniels, AU; Gartner, TK				Smith, RA; Mosesson, MW; Rooney, MM; Lord, ST; Daniels, AU; Gartner, TK			The role of putative fibrinogen A alpha-, B beta-, and gamma A-chain integrin binding sites in endothelial cell-mediated clot retraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIB; MONOCLONAL-ANTIBODY; RECOMBINANT FIBRINOGEN; ADHESION; AGGREGATION; CLEAVAGE; IIIA; FIBRONECTIN; TERMINUS; SEQUENCE	In this study, endothelial cell-mediated clot retraction was supported by fibrin generated from several purified fractions of plasma fibrinogen, purified proteolytic fragments of plasma fibrinogen, recombinant normal fibrinogen, and recombinant variant fibrinogen, These results were surprising because some of these fibrinogens lack domains that are known binding sites for the integrin receptors that support clot retraction. Specifically, fibrinogens lacking A alpha-chain RGD residues at 572-574 or lacking the gamma-chain residues AGDV 408-411 supported endothelial cell-mediated clot retraction as well as intact fibrinogen, Thus, clot retraction mediated by endothelial cells is not dependent on either of these sites, A variety of monoclonal antibodies against the integrin alpha(v) beta(3) partially inhibited the endothelial cell-mediated retraction of clots formed from plasma fibrinogen, As expected, an antibody to the platelet integrin alpha(IIb)beta(3) did not inhibit endothelial cell-mediated clot retraction. These results indicate that this retraction is mediated at least in part by alpha(v) beta(3). These results support the conclusion that (a) neither of the two fibrinogen cell binding sites described above is required to support clot retraction or that (b) either site alone or in conjunction with other fibrin(ogen) region(s) can support clot retraction, Thus, endothelial cell-mediated clot retraction appears to be dependent on fibrinogen cell binding sites other than those required to support adhesion of resting platelets to immobilized fibrinogen and platelet aggregation.	UNIV MEMPHIS,DEPT MICROBIOL & MOL CELL SCI,MEMPHIS,TN 38152; UNIV WISCONSIN,SCH MED,DEPT MED,SINAI SAMARITAN MED CTR,MILWAUKEE,WI 53233; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL & LAB MED,CHAPEL HILL,NC 27599	University of Memphis; University of Wisconsin System; University of Wisconsin Milwaukee; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Smith, RA (corresponding author), UNIV TENNESSEE,CAMPBELL CLIN,DEPT ORTHOPAED SURG,956 COURT AVE,ROOM A302,MEMPHIS,TN 38163, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL056369] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56369] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alemany M, 1996, BLOOD, V87, P592, DOI 10.1182/blood.V87.2.592.bloodjournal872592; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BUNCE LA, 1992, J CLIN INVEST, V89, P842, DOI 10.1172/JCI115663; CARR ME, 1995, THROMB HAEMOSTASIS, V73, P499; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DECLERCK R, 1975, BRIT J HAEMATOL, V29, P341; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FRANCIS CW, 1993, BLOOD CELLS, V19, P291; GARTNER TK, 1988, THROMB RES, V49, P43; GARTNER TK, 1993, THROMB RES, V71, P47; GARTNER TK, 1994, BLOOD COAGUL FIBRIN, V5, P747, DOI 10.1097/00001721-199410000-00011; HANTGAN RR, 1988, BIOCHIM BIOPHYS ACTA, V968, P36, DOI 10.1016/0167-4889(88)90041-9; HETTASCH JM, 1992, THROMB HAEMOSTASIS, V68, P701; Holmback K, 1996, EMBO J, V15, P5760, DOI 10.1002/j.1460-2075.1996.tb00962.x; KATAGIRI Y, 1995, J BIOL CHEM, V270, P1785, DOI 10.1074/jbc.270.4.1785; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOSESSON MW, 1974, J BIOL CHEM, V249, P4656; MOSESSON MW, 1966, BIOCHEMISTRY-US, V5, P2829, DOI 10.1021/bi00873a008; MOSESSON MW, 1963, J LAB CLIN MED, V62, P663; NEWMAN PJ, 1985, BLOOD, V65, P227; PANDY BV, 1991, BIOCHEMISTRY-US, V30, P162, DOI 10.1021/bi00215a024; PANDYA BV, 1984, BIOCHEMISTRY-US, V23, P460, DOI 10.1021/bi00298a010; PANDYA BV, 1985, J BIOL CHEM, V260, P2994; PONCZ M, 1987, J BIOL CHEM, V262, P8476; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAUBENFELD SM, 1995, THROMB HAEMOSTASIS, V74, P923; TUAN TL, 1989, J CELL PHYSIOL, V140, P577, DOI 10.1002/jcp.1041400324; Zaidi TN, 1996, BLOOD, V88, P2967, DOI 10.1182/blood.V88.8.2967.bloodjournal8882967	38	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22080	22085		10.1074/jbc.272.35.22080	http://dx.doi.org/10.1074/jbc.272.35.22080			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268349	Green Published, hybrid			2022-12-27	WOS:A1997XT85000061
J	Bhat, R; Bresnick, E				Bhat, R; Bresnick, E			Glycine N-methyltransferase is an example of functional diversity - Role as a polycyclic aromatic hydrocarbon-binding receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; NUCLEAR TRANSLOCATOR PROTEIN; RAT-LIVER CYTOSOL; AH-RECEPTOR; GENE-EXPRESSION; DNA METHYLATION; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; HYDROXYLASE; INDUCTION; DIOXIN	The cytochrome P-4501A1 (CYP1A1) gene is regulated by several trans-acting factors including the 4 S polycyclic aromatic hydrocarbon (PAH)-binding protein, which has recently been identified as glycine N-methyltransferase (GNMT) (Raha, A., Wagner, C.,;Macdonald, R. G,, and Bresnick, E, (1994) J, Biol, Chem. 269, 5750-5756), The role of GNMT as a 4 S PAH-binding protein in mediating the induction of cytochrome P-4501A1 has been investigated further, GNMT cDNA, which was cloned into a pMAMneo vector containing the Rous sarcoma virus promoter and the neomycin resistance gene, was stably transfected into D422 Chinese hamster ovary (CHO) cells. Several positive clones were selected by reverse transcription-polymerase chain reaction and assayed for the expression of recombinant protein, Western blot analysis indicated the expression of significant levels of the 4 S protein in the stably transfected CHO cells (CHO-GNMT). Cytosolic preparations from the CHO-GNMT showed high benzo[a]pyrene (E[a]P) binding but no 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) binding activity when compared with clones transfected with the pMAMneo vector alone (CHO-neo) or the parental CHO cells, Challanging the CHO-GNMT cells with 4 mu M B[a]P resulted in elevated levels of CYP1A1 mRNA, Equally effective in inducing CYP1A1 mRNA were benzo[e]pyrene and 3-methylcholanthrene. On the ether hand, TCDD did not induce CYP1A1 gene expression in these cells. B[a]P-treated CHO-GNMT, expressing the 4 S protein, also showed CYP1A1 protein by Western blotting and exhibited ethoxyresorufin-O-deethylase activity; neither the CHO-neo or parental CHO cells were positive for any of these measures, No Ah receptor message or protein was detectable in the parental CHO, CHO-neo, or CHO-GNMT cells, Furthermore, no XRE binding activity was observed in TCDD-treated cytosolic preparations or nuclear extracts from CHO-GNMT cells that were treated with TCDD, These studies unequivocally establish that GNMT is a PAH-binding protein that can mediate the induction of CYP1A1 by PAHs such as B[a]P through an Ah receptor independent pathway.	UNIV MASSACHUSETTS, MED CTR, DEPT MOL PHARMACOL & TOXICOL, RES OFF, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA 36105] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhat R, 1996, J BIOL CHEM, V271, P32551, DOI 10.1074/jbc.271.51.32551; BIGELOW SW, 1987, BIOCHEM J, V242, P375; BLUMENSTEIN J, 1960, BIOCHEM BIOPH RES CO, V3, P259, DOI 10.1016/0006-291X(60)90235-7; BRADLEY WEC, 1982, SOMAT CELL GENET, V8, P51, DOI 10.1007/BF01538650; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P3337, DOI 10.1016/0006-2952(85)90355-7; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; COLLINS S, 1984, MOL PHARMACOL, V26, P353; COOK RJ, 1981, ARCH BIOCHEM BIOPHYS, V208, P358, DOI 10.1016/0003-9861(81)90520-8; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fourney R.M., 1988, FOCUS, V10, P5; GIBBONS JA, 1992, CHEM-BIOL INTERACT, V83, P203, DOI 10.1016/0009-2797(92)90098-6; GIBBONS JA, 1990, TOXICOLOGIST, V10, P193; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUENTHNER TM, 1977, J BIOL CHEM, V252, P8981; HANKINSON O, 1991, METHOD ENZYMOL, V206, P381; HEINTZ NH, 1981, CANCER RES, V41, P1794; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOLDER GM, 1981, CANCER RES, V41, P4408; HOUSER WH, 1985, BIOCHEMISTRY-US, V24, P7839, DOI 10.1021/bi00347a050; HOUSER WH, 1987, ARCH BIOCHEM BIOPHYS, V259, P215, DOI 10.1016/0003-9861(87)90488-7; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KAMPS C, 1987, CANCER LETT, V34, P129, DOI 10.1016/0304-3835(87)90003-6; KERR SJ, 1972, J BIOL CHEM, V247, P4248; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MITCHELL AD, 1976, J NUTR, V106, P1702, DOI 10.1093/jn/106.12.1702; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEBERT DW, 1989, DNA-J MOLEC CELL BIO, V8, P1, DOI 10.1089/dna.1.1989.8.1; NEBERT DW, 1989, CRIT REV TOXICOL, V20, P153, DOI 10.3109/10408448909017908; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; OGAWA H, 1993, COMP BIOCHEM PHYS B, V106, P601, DOI 10.1016/0305-0491(93)90137-T; OGAWA H, 1982, J BIOL CHEM, V257, P3447; PISKORSKAPLISZCZYNSKA J, 1986, TOXICOL LETT, V34, P67, DOI 10.1016/0378-4274(86)90146-3; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; POLAND A, 1985, CLIN PHYSIOL BIOCH, V3, P147; PROBST MR, 1993, MOL PHARMACOL, V44, P511; RAHA A, 1994, J BIOL CHEM, V269, P5750; RAHA A, 1990, J TOXICOL ENV HEALTH, V29, P339, DOI 10.1080/15287399009531397; RAHA A, 1991, TOXICOLOGY, V66, P175, DOI 10.1016/0300-483X(91)90217-O; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RONAI Z, 1993, INT J BIOCHEM, V25, P1073, DOI 10.1016/0020-711X(93)90123-V; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SINCLAIR JF, 1992, CANCER RES, V52, P3615; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; TIERNEY B, 1980, ARCH BIOCHEM BIOPHYS, V200, P513, DOI 10.1016/0003-9861(80)90383-5; VADIMON L, 1982, P NATL ACAD SCI USA, V79, P1073; WHAL GM, 1981, TRANSFER IMMOBILIZAT; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; YEO EJ, 1994, P NATL ACAD SCI USA, V91, P210, DOI 10.1073/pnas.91.1.210; ZYTKOVICZ TH, 1982, CANCER RES, V42, P4387; [No title captured]	62	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21221	21226		10.1074/jbc.272.34.21221	http://dx.doi.org/10.1074/jbc.272.34.21221			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261130	hybrid			2022-12-27	WOS:A1997XR78900040
J	Ge, ZM; Chan, NWC; Palcic, MM; Taylor, DE				Ge, ZM; Chan, NWC; Palcic, MM; Taylor, DE			Cloning and heterologous expression of an alpha 1,3-fucosyltransferase gene from the gastric pathogen Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; HOMEODOMAIN-DNA COMPLEX; FUCOSYL-TRANSFERASE; MOLECULAR-CLONING; DETERMINES EXPRESSION; ULCER DISEASE; ELAM-1 LIGAND; PROTEINS; CARBOHYDRATE	Helicobacter pylori is an important human pathogen which causes both gastric and duodenal ulcers and is also associated with gastric cancer and lymphoma. This microorganism has been shown to express cell surface glycoconjugates including Lewis X (Le(x)) and Lewis Y. These bacterial oligosaccharides are structurally similar to tumor-associated carbohydrate antigens found in mammals, In this study, we report the cloning of a novel alpha 1,3-fucosyltransferase gene (HpfucT) involved in the biosynthesis of Le(x) within H. pylori. The deduced amino acid sequence of HpfucT consists of 478 residues with the calculated molecular mass of 56,194 daltons, which is approximately 100 amino acids longer than known mammalian alpha 1,3/1,4-fucosyltransferases. The similar to 52-kDa protein encoded by HpfucT was expressed in Escherichia coli CSRDE3 cells and gave rise to alpha 1,3-fucosyltransferase activity but neither alpha 1,4-fucosyltransferase nor alpha 1,2-fucosyltransferase activity as characterized by radiochemical assays and capillary zone electrophoresis, Truncation of the C-terminal 100 amino acids of HpFuc-T abolished the enzyme activity, An approximately 72-amino acid region of HpFuc-T exhibits significant sequence identity (40-45%) with the highly conserved C-terminal catalytic domain among known mammalian and chicken alpha 1,3-fucosyltransferases. These lines of evidence indicate that the HpFuc-T represents the bacterial alpha 1,3-fucosyltransferase. In addition, several structural features unique to HpFuc-T, including 10 direct repeats of seven amino acids and the lack of the transmembrane segment typical for known eukaryotic alpha 1,3-fucosyltransferases, were revealed, Notably, the repeat region contains a leucine zipper motif previously demonstrated to be responsible for dimerization of various basic region-leucine zipper proteins, suggesting that the HpFuc-T protein could form dimers.	UNIV ALBERTA, DEPT IMMUNOL & MED MICROBIOL, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT CHEM, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT SCI BIOL, EDMONTON, AB T6G 2H7, CANADA	University of Alberta; University of Alberta; University of Alberta								Appelmelk BJ, 1996, INFECT IMMUN, V64, P2031, DOI 10.1128/IAI.64.6.2031-2040.1996; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2489, DOI 10.1021/bi951852s; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2498, DOI 10.1021/bi951853k; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHAN NWC, 1995, GLYCOBIOLOGY, V5, P683, DOI 10.1093/glycob/5.7.683; FEIZI T, 1988, NATURE, V70, P1587; FORMAN D, 1993, LANCET, V341, P1359; Ge ZM, 1996, J BACTERIOL, V178, P6151, DOI 10.1128/jb.178.21.6151-6157.1996; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOKHALE UB, 1990, CAN J CHEM, V68, P1063, DOI 10.1139/v90-165; GRAHAM DY, 1991, J GASTROEN HEPATOL, V6, P105, DOI 10.1111/j.1440-1746.1991.tb01448.x; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; Hitoshi S, 1996, J BIOL CHEM, V271, P16975, DOI 10.1074/jbc.271.28.16975; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KELLY MM, 1995, DEV BRAIN RES, V85, P31, DOI 10.1016/0165-3806(94)00185-3; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lau PCK, 1997, P NATL ACAD SCI USA, V94, P1453, DOI 10.1073/pnas.94.4.1453; Lee A., 1988, Microbial Ecology in Health and Disease, V1, P1; Lee KP, 1996, J BIOL CHEM, V271, P32960, DOI 10.1074/jbc.271.51.32960; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LOUIE K, 1986, J BACTERIOL, V165, P805, DOI 10.1128/jb.165.3.805-812.1986; LOW JB, 1994, FRONTIERS MOL BIOL, P163; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MURAMATSU T, 1988, BIOCHIMIE, V70, P1587, DOI 10.1016/0300-9084(88)90294-5; Nakamura S, 1997, CANCER-AM CANCER SOC, V79, P3, DOI 10.1002/(SICI)1097-0142(19970101)79:1<3::AID-CNCR2>3.0.CO;2-P; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PAULSON S, 1996, J BIOL CHEM, V264, P17615; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RATHBONE BJ, 1986, GUT, V27, P642, DOI 10.1136/gut.27.6.642; RUBERTI I, 1991, EMBO J, V10, P1787, DOI 10.1002/j.1460-2075.1991.tb07703.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCHENA M, 1992, P NATL ACAD SCI USA, V89, P3894, DOI 10.1073/pnas.89.9.3894; SHERBURNE R, 1995, INFECT IMMUN, V63, P4564, DOI 10.1128/IAI.63.12.4564-4568.1995; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SODERMAN E, 1994, PLANT MOL BIOL, V26, P145, DOI 10.1007/BF00039527; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; WARREN JR, 1983, LANCET, V1, P1273; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	56	102	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21357	21363		10.1074/jbc.272.34.21357	http://dx.doi.org/10.1074/jbc.272.34.21357			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261149	hybrid			2022-12-27	WOS:A1997XR78900059
J	Wijkander, J; Holst, LS; Rahn, T; Resjo, S; Castan, I; Manganiello, V; Belfrage, P; Degerman, E				Wijkander, J; Holst, LS; Rahn, T; Resjo, S; Castan, I; Manganiello, V; Belfrage, P; Degerman, E			Regulation of protein kinase B in rat adipocytes by insulin, vanadate, and peroxovanadate - Membrane translocation in response to peroxovanadate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; GLUCOSE-TRANSPORT; SER/THR KINASE; AKT; HOMOLOGY; DOMAIN; PHOSPHORYLATION; ACTIVATION; 3-KINASE	Protein kinase B (PKB) (also referred to as RAC/Akt kinase) has been shown to be controlled by various growth factors, including insulin, using cell lines and transfected cells, However, information is so far scarce regarding its regulation in primary insulin-responsive cells, We have therefore used isolated rat adipocytes to examine the mechanisms, including membrane translocation, whereby insulin and the insulin-mimicking agents vanadate and peroxovanadate control PKB. Stimulation of adipocytes with insulin, vanadate, or peroxovanadate caused decreased PKB mobility on sodium dodecyl sulfate-polyacrylamide gels, indicative of increased phosphorylation, which correlated with an increase in kinase activity detected with the peptide KKRNRTLTK. This peptide was found to detect activated PKB selectively in crude cytosol and partially purified cytosol fractions from insulin-stimulated adipocytes. The decrease in electrophoretic mobility and activation of PKB induced by insulin was reversed both in vitro by treatment of the enzyme with alkaline phosphatase and in the intact adipocyte upon removal of insulin or addition of the phosphatidylinositol 3-kinase (PI I-kinase) inhibitor wortmannin. Significant translocation of PKB to membranes could not Its demonstrated after insulin stimulation, but peroxovanadate, which appeared to activate PI 3-kinase to a higher extent than insulin, induced substantial translocation, The translocation was prevented by wortmannin, suggesting that PI 3-kinase and/or the 3-phosphorylated phosphoinositides generated by PI 3-kinase are indeed involved in the membrane targeting of PKB.	NHLBI, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wijkander, J (corresponding author), LUND UNIV, DEPT CELL & MOL BIOL, SECT MOL SIGNALING, POB 94, S-22100 LUND, SWEDEN.			wijkander, jonny/0000-0002-2310-9039; Castan-Laurell, Isabelle/0000-0002-0488-9789				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHANG KJ, 1974, J BIOL CHEM, V249, P6854; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DEGERMAN E, 1994, BIOCHIM BIOPHYS ACTA, V1205, P1899; Degerman Eva, 1996, P197; DUNN B, 1992, CURRENT PROTOCOLS MO; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Matsuzaki H, 1996, FEBS LETT, V396, P305, DOI 10.1016/0014-5793(96)01120-9; MOSES AC, 1991, INSULIN LIKE GROWTH, P245; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; OKADA T, 1994, J BIOL CHEM, V269, P3568; RODBELL M, 1964, J BIOL CHEM, V239, P375; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHISHEVA A, 1992, BIOCHEMISTRY-US, V31, P8059, DOI 10.1021/bi00149a041; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001	40	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21520	21526		10.1074/jbc.272.34.21520	http://dx.doi.org/10.1074/jbc.272.34.21520			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261171	hybrid			2022-12-27	WOS:A1997XR78900081
J	Benoist, F; GrandPerret, T				Benoist, F; GrandPerret, T			Co-translational degradation of apolipoprotein B100 by the proteasome is prevented by microsomal triglyceride transfer protein - Synchronized translation studies on HepG2 cells treated with an inhibitor of microsomal triglyceride transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; B-CONTAINING LIPOPROTEINS; ENDOPLASMIC-RETICULUM; OLEIC-ACID; G2 CELLS; INTRACELLULAR DEGRADATION; DISULFIDE-ISOMERASE; MCA-RH7777 CELLS; LIPID-BINDING; MESSENGER-RNA	We studied the effect of inhibition of microsomal triglyceride transfer protein (MTP) on apolipoprotein (ape) B100 translation and secretion using HepG2 cells. The MTP-mediated lipid transfer activity was reduced using a specific MTP inhibitor, ApoB100 translation was synchronized by treatment with puromycin prior to L-[S-35]methionine pulse-chase labeling. During the first 4 min of chase, synthesis of apoB polypeptides the size of 100-200 kDa was insensitive to the inhibitor, suggesting that inhibition of MTP did not affect the initiation of apoB100 translation, After 15 min of chase, the 100-200-kDa species were chased into polypeptides larger than 320 kDa (i.e. apoB65 or 65% of full-length apoB100) in both control and inhibitor-treated cells, However, the amount of these polypeptides decreased (by 36% for apoB65-75, by 64% for apoB75-85, by 76% for apoB85-95, and by 77% for apoB100) upon MTP inhibition, No accumulation of smaller polypeptides was observed, but total immunoprecipitable apoB radioactivity was decreased suggesting that apoB could undergo cotranslational degradation when MTP activity was reduced. Inhibitors of the multicatalytic proteinase complex (proteasome) such as lactacystin or MG-115 could prevent apoB co-translational degradation, Nevertheless, MG-115 could not avoid the MTP inhibitor decreasing apoB100 secretion but rather induced the accumulation of secretion-incompetent apoB100 in the cell. These results indicate that MTP activity is required during the elongation of apoB100 polypeptides, particularly at the sequences downstream of carboxyl terminus of apoB65, Go-translational degradation might constitute a more general mechanism of early quality control for large or complex proteins.	CTR RECH,LAB GLAXO WELLCOME,F-91951 LES ULIS,FRANCE	GlaxoSmithKline								ADELI K, 1994, J BIOL CHEM, V269, P9166; ADELI K, 1995, CIRCULATION S1, V92, P228; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Benoist F, 1996, EUR J BIOCHEM, V240, P713, DOI 10.1111/j.1432-1033.1996.0713h.x; Benoist F, 1996, ARTERIOSCL THROM VAS, V16, P1229, DOI 10.1161/01.ATV.16.10.1229; BENOIST F, 1995, J LIPID RES, V36, P2243; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BROWN GD, 1983, J BIOL CHEM, V258, P4309; BYRNE CD, 1992, BIOCHEM J, V288, P101, DOI 10.1042/bj2880101; Cartwright IJ, 1996, BIOCHEM J, V314, P977, DOI 10.1042/bj3140977; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DU EZ, 1994, J BIOL CHEM, V269, P24169; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GIBBONS GF, 1992, BIOCHEM J, V287, P749, DOI 10.1042/bj2870749; GINSBERG HN, 1995, CIRCULATION S, V92, P228; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Haghpassand M, 1996, J LIPID RES, V37, P1468; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; JANERO DR, 1983, J BIOL CHEM, V258, P4496; KAPTEIN A, 1991, BIOCHEM J, V278, P557, DOI 10.1042/bj2780557; KAPTEIN A, 1994, ARTERIOSCLER THROMB, V14, P780, DOI 10.1161/01.ATV.14.5.780; KOBUTA S, 1984, BIOCHIM BIOPHYS ACTA, V802, P379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; SAKATA N, 1993, J BIOL CHEM, V268, P22967; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; Shelness GS, 1996, J LIPID RES, V37, P408; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWIFT LL, 1995, J LIPID RES, V36, P395; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WHITE AL, 1992, J BIOL CHEM, V267, P15657; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	73	131	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20435	20442		10.1074/jbc.272.33.20435	http://dx.doi.org/10.1074/jbc.272.33.20435			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252352	hybrid			2022-12-27	WOS:A1997XR22100022
J	Berge, A; Kihlberg, BM; Sjoholm, AG; Bjorck, L				Berge, A; Kihlberg, BM; Sjoholm, AG; Bjorck, L			Streptococcal protein H forms soluble complement-activating complexes with IgG, but inhibits complement activation by IgG-coated targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; GRAM-POSITIVE BACTERIA; SEPARATE BINDING-SITES; SURFACE-PROTEINS; IMMUNOGLOBULIN-G; C4B-BINDING PROTEIN; STAPHYLOCOCCUS-AUREUS; CHEMOTACTIC RESPONSE; ALBUMIN; PYOGENES	Protein H, a surface protein of Streptococcus pyogenes interacting with the constant Fc region of IgG, is known to be released from the streptococcal surface by a cysteine proteinase produced by the bacteria. Poststreptococcal glomerulonephritis and rheumatic fever are conditions in which immune complexes and autoimmune mechanisms have been suggested to play pathogenetic roles, The present study demonstrates that addition of protein H to human serum produces complement activation with dose-dependent cleavage of C3. The activation was IgG-dependent and the result of complexes formed between IgG and protein H. These complexes were size heterogeneous with molecular masses of 400 kDa to 1.4 MDa. Using complement-depleted serum reconstituted with complement proteins, the activation by protein H was found to be dependent of the classical, but independent of the alternative pathway of complement. In contrast to results of experiments based on soluble protein H IgG complexes, complement activation was inhibited by protein H when IgG was immobilized on a surface, The interaction between C1q and immunoglobulins represents the first step in the activation of the classical pathway, and protein H efficiently inhibited the binding of C1q to IgG immobilized on polyacrylamide beads, Protein H reduced C3 deposition on the IgG-coated beads and inhibited immune hemolysis of IgG-sensitized erythrocytes, Finally, significantly less C3 was deposited on the surface of protein II-expressing wild-type streptococci than on the surface of isogenic mutant bacteria devoid of protein H, The results demonstrate that protein H IgG complexes released from the streptococcal surface can produce complement breakdown at the sites of infection, whereas complement activation on bacterial surfaces is inhibited, This should have important implications for host-parasite relationships, In addition, soluble protein H IgG complexes might contribute to immunological complications of streptococcal infections.	LUND UNIV,DEPT MED MICROBIOL,S-22100 LUND,SWEDEN	Lund University	Berge, A (corresponding author), LUND UNIV,DEPT CELL & MOL BIOL,SECT MOL PATHOGENESIS,POB 94,S-22100 LUND,SWEDEN.							Akesson P, 1996, J BIOL CHEM, V271, P1081, DOI 10.1074/jbc.271.2.1081; AKESSON P, 1994, BIOCHEM J, V300, P877, DOI 10.1042/bj3000877; AKESSON P, 1990, MOL IMMUNOL, V6, P523; BARNUM SR, 1991, IMMUNOL RES, V10, P28, DOI 10.1007/BF02918165; BERGE A, 1993, J BIOL CHEM, V268, P25417; BERGE A, 1995, J BIOL CHEM, V270, P9862, DOI 10.1074/jbc.270.17.9862; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; BJORCK L, 1987, MOL IMMUNOL, V24, P1113, DOI 10.1016/0161-5890(87)90080-0; BJORCK L, 1984, J IMMUNOL, V133, P969; BUROVA LA, 1980, ACTA PATH MICRO IM B, V88, P199; CEDERVALL T, 1995, SCAND J IMMUNOL, V42, P433, DOI 10.1111/j.1365-3083.1995.tb03677.x; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBOGE H, 1989, GENE, V79, P325; DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583; DECHATEAU M, 1994, J BIOL CHEM, V269, P12147; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FORSGREN A, 1966, J IMMUNOL, V97, P822; FRANK MM, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P305; FREDLUND H, 1993, INT ARCH ALLERGY IMM, V100, P135, DOI 10.1159/000236400; FRICK IM, 1994, MOL MICROBIOL, V12, P143, DOI 10.1111/j.1365-2958.1994.tb01003.x; FRICK IM, 1992, P NATL ACAD SCI USA, V89, P8532, DOI 10.1073/pnas.89.18.8532; FRICK IM, 1995, EMBO J, V14, P1674, DOI 10.1002/j.1460-2075.1995.tb07156.x; GANROT PO, 1972, SCAND J CLIN LAB INV, V29, P39, DOI 10.3109/00365517209102749; GOMI H, 1990, J IMMUNOL, V144, P4046; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; INGANAS M, 1981, SCAND J IMMUNOL, V13, P343, DOI 10.1111/j.1365-3083.1981.tb00143.x; Johnsson E, 1996, J IMMUNOL, V157, P3021; JOINER KA, 1984, ANNU REV IMMUNOL, V2, P461, DOI 10.1146/annurev.immunol.2.1.461; KASTERN W, 1992, J BIOL CHEM, V267, P12820; Kihlberg BM, 1995, MICROB PATHOGENESIS, V19, P299, DOI 10.1016/S0882-4010(96)80003-9; Kihlberg BM, 1996, EUR J BIOCHEM, V240, P556, DOI 10.1111/j.1432-1033.1996.0556h.x; KRONVALL G, 1979, INFECT IMMUN, V25, P1; LINDAHL G, 1990, EPIDEMIOL INFECT, V105, P87, DOI 10.1017/S0950268800047683; MAGUIN E, 1992, J BACTERIOL, V174, P5633, DOI 10.1128/JB.174.17.5633-5638.1992; MARTIN DR, 1993, J INFECT DIS, V167, P1112, DOI 10.1093/infdis/167.5.1112; MICHAEL AF, 1966, J CLIN INVEST, V45, P237, DOI 10.1172/JCI105336; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PEREZCASAL J, 1993, MOL MICROBIOL, V8, P809, DOI 10.1111/j.1365-2958.1993.tb01628.x; RAEDER R, 1993, INFECT IMMUN, V61, P1378, DOI 10.1128/IAI.61.4.1378-1384.1993; RAPP HJ, 1970, MOL BASIS COMPLEMENT; REIS KJ, 1984, J IMMUNOL, V132, P3091; Sambrook J., 2002, MOL CLONING LAB MANU; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SJOHOLM AG, 1979, INT ARCH ALLER A IMM, V58, P274, DOI 10.1159/000232203; SJOHOLM AG, 1991, APMIS, V99, P1120; STONE GC, 1989, J IMMUNOL, V143, P565; TAO MH, 1993, J EXP MED, V178, P661, DOI 10.1084/jem.178.2.661; TENNER AJ, 1981, J IMMUNOL, V127, P648; THERN A, 1995, J IMMUNOL, V154, P375; TRUEDSSON L, 1983, J IMMUNOL METHODS, V63, P207, DOI 10.1016/0022-1759(83)90424-6; WEXLER DE, 1985, P NATL ACAD SCI USA, V82, P8144, DOI 10.1073/pnas.82.23.8144; WEXLER DE, 1983, INFECT IMMUN, V39, P239, DOI 10.1128/IAI.39.1.239-246.1983; ZABRISKIE JB, 1966, J EXP MED, V124, P661, DOI 10.1084/jem.124.4.661	58	82	83	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20774	20781		10.1074/jbc.272.33.20774	http://dx.doi.org/10.1074/jbc.272.33.20774			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252400	hybrid			2022-12-27	WOS:A1997XR22100070
J	Datta, R; Kojima, H; Yoshida, K; Kufe, D				Datta, R; Kojima, H; Yoshida, K; Kufe, D			Caspase-3-mediated cleavage of protein kinase C theta in induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNUCLEOSOMAL DNA FRAGMENTATION; POLY(ADP-RIBOSE) POLYMERASE; MOLECULAR-CLONING; SKELETAL-MUSCLE; LEUKEMIA-CELLS; FAMILY; INHIBITION; MEMBER; EXPRESSION; NPKC	Protein kinase C theta (PKC theta) is a member of the novel or nPKC family. A functional role for PKC theta is unknown. The present studies demonstrate that PKC theta is cleaved in the third variable region (V3) in apoptosis induced by diverse agents. PKC theta cleavage is blocked in cells that overexpress the anti-apoptotic Bcl-x(L) or the baculovirus p35 protein. PKC theta is cleaved by Caspase-3 and by apoptotic cell lysates at a DEVD354/K site. We also show that overexpression of the cleaved kinase-active PKC theta fragment, but not full-length PKC theta or a kinase-inactive fragment, results in induction of sub-G(1) phase DNA, nuclear fragmentation, and lethality. These findings indicate that proteolytic cleavage of PKC theta by Caspase-3 induces events characteristic of apoptosis.			Datta, R (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,44 BINNEY ST,BOSTON,MA 02115, USA.				NCI NIH HHS [CA66996, CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996, R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIER G, 1993, J BIOL CHEM, V268, P4997; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CASEIOLAROSEN L, 1996, J EXP MED, V183, P1957; CHANG JD, 1993, J BIOL CHEM, V268, P14208; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GUNJI H, 1991, CANCER RES, V51, P741; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Meller N, 1996, MOL CELL BIOL, V16, P5782; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3	29	262	267	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20317	20320		10.1074/jbc.272.33.20317	http://dx.doi.org/10.1074/jbc.272.33.20317			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252332	hybrid			2022-12-27	WOS:A1997XR22100002
J	Ke, SH; Coombs, GS; Tachias, K; Corey, DR; Madison, EL				Ke, SH; Coombs, GS; Tachias, K; Corey, DR; Madison, EL			Optimal subsite occupancy and design of a selective inhibitor of urokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SITE-SPECIFIC MUTAGENESIS; CRYSTAL-STRUCTURE; DIRECTED MUTAGENESIS; ALPHA-CHYMOTRYPSIN; SERINE PROTEINASES; TISSUE; TRYPSIN; IDENTIFICATION; FIBRINOLYSIS	Human urokinase type plasminogen activator (u-PA) is a member of the chymotrypsin family of serine proteases that can play important roles in both health and disease, We have used substrate phage display techniques to characterize the specificity of this enzyme in detail and to identify peptides that are cleaved 840-5300 times more efficiently by u-PA than peptides containing the physiological target sequence of the enzyme, In addition, unlike peptides containing the physiological target sequence, the peptide substrates selected in this study were cleaved as much as 120 times more efficiently by u-PA than by tissue type plasminogen activator (t-PA), an intimately related enzyme. Analysis of the selected peptide substrates strongly suggested that the primary sequence SGRSA, from position P3 to P2', represents optimal subsite occupancy for substrates of u-PA. Insights gained in these investigations were used to design a variant of plasminogen activator inhibitor type 1, the primary physiological inhibitor of both u-PA and t-PA, that inhibited u-PA approximately 70 times more rapidly than it inhibited t-PA. These observations provide a solid foundation for the design of highly selective, high affinity inhibitors of u-PA and, consequently, may facilitate the development of novel therapeutic agents to inhibit the initiation and/or progression of selected human tumors.	Scripps Res Inst, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	Scripps Research Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Coombs, Gary/0000-0002-0711-185X	NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline; NIGMS NIH HHS [T32GM08203] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL052475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DS, 1991, J BIOL CHEM, V266, P8476; ALPERT AJ, 1990, J CHROMATOGR, V499, P177, DOI 10.1016/S0021-9673(00)96972-3; BAGGIO R, 1996, BIOCHEMISTRY-US, V35, P3551; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BODE W, 1992, PROTEIN SCI, V1, P426; BRUNNER N, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P61; Carmeliet P, 1996, FIBRINOLYSIS, V10, P195, DOI 10.1016/S0268-9499(96)80017-8; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Castellino F. J, 1995, MOL BASIS THROMBOSIS, P495; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; COLLEN D, 1991, BLOOD, V78, P3114; Coombs GS, 1996, J BIOL CHEM, V271, P4461; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; DUFFY MJ, 1988, CANCER, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B; DUFFY MJ, 1993, FIBRINOLYSIS, V7, P295, DOI 10.1016/0268-9499(93)90144-K; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; HEARING VJ, 1988, CANCER RES, V48, P1270; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; JANICKE F, 1990, FIBRINOLYSIS, V4, P69, DOI 10.1016/0268-9499(90)90001-Z; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LOSKUTOFF DJ, 1993, J CLIN INVEST, V92, P2563, DOI 10.1172/JCI116866; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1993, METHOD ENZYMOL, V223, P249; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; Min HY, 1996, CANCER RES, V56, P2428; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; ROBERTS HR, 1995, MOL BASIS THROMBOSIS, P35; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Shapiro RL, 1996, CANCER RES, V56, P3597; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; Taylor J. R., 1982, INTRO ERROR ANAL STU; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; URANO T, 1988, BIOCHEM BIOPH RES CO, V150, P45, DOI 10.1016/0006-291X(88)90484-6; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	51	94	113	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20456	20462		10.1074/jbc.272.33.20456	http://dx.doi.org/10.1074/jbc.272.33.20456			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252355	hybrid			2022-12-27	WOS:A1997XR22100025
J	Lawrence, SD; Kindle, KL				Lawrence, SD; Kindle, KL			Alterations in the Chlamydomonas plastocyanin transit peptide have distinct effects on in vitro import and in vivo protein accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLASTIC PRECURSOR PROTEINS; THYLAKOID LUMEN PROTEINS; INTACT CHLOROPLASTS; SIGNAL PEPTIDE; SMALL SUBUNIT; ENVELOPE; MEMBRANE; BINDING; TRANSLOCATION; REINHARDTII	Nucleus-encoded chloroplast proteins that reside in the thylakoid lumen are synthesized as precursors with bipartite transit peptides that contain information for uptake and intra-chloroplast localization, We have begun to apply the superb molecular and genetic attributes of Chlamydomonas to study chloroplast protein import by creating a series of deletions in the transit peptide of plastocyanin and determining their effects on translocation into isolated Chlamydomonas chloroplasts, Most N-terminal mutations dramatically inhibited in vitro import, whereas replacement with a transit peptide from the gamma-subunit of chloroplast ATPase restored uptake. Thus, the N-terminal region has stroma-targeting function, Deletions within the C-terminal portion of the transit peptide resulted in the appearance of import intermediates, suggesting that this region is required for lumen translocation and processing, Thus, despite its short length and predicted structural differences, the Chlamydomonas plastocyanin transit peptide has functional domains similar to those of vascular plants, Similar mutations have been analyzed in vivo by transforming altered genes into a mutant defective at the plastocyanin locus (K. L. Kindle, manuscript in preparation), Most mutations affected in vitro import more severely than plastocyanin accumulation in vivo. One exception was a deletion that removed residues 2-8, which nearly eliminated in vivo accumulation but had a modest effect in vitro, We suggest that this mutant precursor may not compete successfully with other proteins for the translocation pathway in vivo. Apparently, in vivo and in vitro analyses reveal different aspects of chloroplast protein biogenesis.	CORNELL UNIV,PLANT SCI CTR,ITHACA,NY 14853	Cornell University				Lawrence, Susan/0000-0001-5825-2858				BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BAUERLE C, 1991, J BIOL CHEM, V266, P5884; BELKNAP WR, 1983, PLANT PHYSIOL, V72, P1130, DOI 10.1104/pp.72.4.1130; BOSCHETTI A, 1987, PROGR PHOTOSYNTHESIS, P585; Bruce B.D., 1994, PLANT MOL BIOL MANUA, VJ1, P1; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; Cline K., 1992, RES PHOTOSYNTHESIS, VIII, P149; CREIGHTON AM, 1993, PLANT MOL BIOL, V23, P1291, DOI 10.1007/BF00042363; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P167; DEBOER D, 1991, EMBO J, V10, P2765, DOI 10.1002/j.1460-2075.1991.tb07825.x; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GOLDSCHMIDTCLERMONT M, 1989, PLANT PHYSIOL, V89, P15, DOI 10.1104/pp.89.1.15; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; Halperin T, 1996, PLANT MOL BIOL, V30, P925, DOI 10.1007/BF00020804; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; Huber H, 1996, PLANT MOL BIOL, V31, P279, DOI 10.1007/BF00021790; HURT EC, 1986, EMBO J, V5, P1343, DOI 10.1002/j.1460-2075.1986.tb04365.x; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1996, J BIOL CHEM, V271, P31009, DOI 10.1074/jbc.271.49.31009; KUNTZ M, 1986, MOL GEN GENET, V205, P454, DOI 10.1007/BF00338082; LEE SY, 1990, BIOTECHNIQUES, V9, P676; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; Ma YK, 1996, J CELL BIOL, V134, P315, DOI 10.1083/jcb.134.2.315; MADUENO F, 1993, PLANT CELL, V5, P1865, DOI 10.1105/tpc.5.12.1865; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MISHKIND ML, 1985, J CELL BIOL, V100, P226, DOI 10.1083/jcb.100.1.226; OBLONG JE, 1992, J BIOL CHEM, V267, P14328; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; REED JE, 1990, EUR J BIOCHEM, V194, P35; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; Scott SV, 1996, J CELL BIOL, V132, P63, DOI 10.1083/jcb.132.1.63; SEEDORF M, 1995, FEBS LETT, V367, P19, DOI 10.1016/0014-5793(95)00529-I; SU QX, 1994, BIOCHEM J, V300, P787, DOI 10.1042/bj3000787; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5053, DOI 10.1021/bi00136a018; THEG SM, 1989, J BIOL CHEM, V264, P6730; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Waegemann K, 1996, J BIOL CHEM, V271, P6545, DOI 10.1074/jbc.271.11.6545; Walker D, 1996, J BIOL CHEM, V271, P4082; Wan JX, 1996, J BIOL CHEM, V271, P31227, DOI 10.1074/jbc.271.49.31227; WAN JX, 1995, J BIOL CHEM, V270, P16731, DOI 10.1074/jbc.270.28.16731; WASMANN CC, 1986, MOL GEN GENET, V205, P446, DOI 10.1007/BF00338081; YU LM, 1988, P NATL ACAD SCI USA, V85, P1369, DOI 10.1073/pnas.85.5.1369	60	14	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20357	20363		10.1074/jbc.272.33.20357	http://dx.doi.org/10.1074/jbc.272.33.20357			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252340	hybrid			2022-12-27	WOS:A1997XR22100010
J	Mastick, CC; Saltiel, AR				Mastick, CC; Saltiel, AR			Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; ACTIVATED PROTEIN-KINASE; GPI-ANCHORED PROTEINS; SIGNAL-TRANSDUCTION; TRANSFORMED-CELLS; RECEPTOR; TRANSPORT; COMPONENT; SEQUENCE; SEQUESTRATION	Previous work from this laboratory has shown that insulin stimulates the tyrosine phosphorylation of caveolin in 3T3-L1 adipocytes (Mastick, C. C., Brady, M. J., and Saltiel, A. R. (1995) J. Cell Biol. 129, 1523-1531). This phosphorylation is specific for insulin and involves the activation of a tyrosine kinase downstream of the insulin receptor, We report here that tyrosine phosphorylation of caveolin is detected only in fully differentiated adipocytes, not in fibroblasts (preadipocytes), despite the fact that both cell types express caveolin-1 and active insulin receptor, Caveolin copurifies with caveolin tyrosine kinase activity in both preadipocytes and adipocytes. Accumulating evidence indicates that this kinase is the Src family kinase Fyn. Fyn is expressed in the preadipocytes and the adipocytes and is colocalized with caveolin in low density Triton-insoluble complexes in both cell types, In adipocytes, overexpression of wild type Fyn leads to increased basal phosphorylation of caveolin and hyperphosphorylation of caveolin in response to insulin, In vitro kinase assays suggest that Fyn may be activated in response to insulin through the binding of a tyrosine-phosphorylated insulin receptor substrate protein. Previous work suggested that this protein may be c-Cbl (Ribon, V., and Saltiel, A. R. (1997) Biochem. J. 324, 839-846). In 3T3-L1 adipocytes, Cbl binds to Fyn in an insulin-dependent manner, and Cbl phosphorylation is adipocyte-specific. Here we show that phosphorylated Cbl is translocated into caveolin-enriched Triton-insoluble complexes after insulin stimulation, This may lead to the cell type-specific, com partmentalized activation of Fyn and the specific phosphorylation of proteins in the caveolae in response to insulin in adipocytes.			Mastick, CC (corresponding author), WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CELL BIOL,ANN ARBOR,MI 48105, USA.		Mastick, Cynthia/G-9841-2017; Saltiel, Alan/L-3632-2019	Mastick, Cynthia/0000-0003-4769-5412; Saltiel, Alan/0000-0002-9726-9828				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LIU XQ, 1993, ONCOGENE, V8, P1119; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; MASTICK CC, 1997, IN PRESS MOL CELL BI; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Pawson T, 1997, NATURE, V385, P582, DOI 10.1038/385582b0; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Shahripour A, 1996, BIOORG MED CHEM LETT, V6, P1209, DOI 10.1016/0960-894X(96)00208-9; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; TRAVIS J, 1993, SCIENCE, V262, P1208, DOI 10.1126/science.8235646; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	57	120	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20706	20714		10.1074/jbc.272.33.20706	http://dx.doi.org/10.1074/jbc.272.33.20706			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252391	hybrid			2022-12-27	WOS:A1997XR22100061
J	Minakami, R; Jinnai, N; Sugiyama, H				Minakami, R; Jinnai, N; Sugiyama, H			Phosphorylation and calmodulin binding of the metabotropic glutamate receptor subtype 5 (mGluR5) are antagonistic in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHARMACOLOGICAL CHARACTERIZATION; SPLICE VARIANTS; RAT-BRAIN; EXPRESSION; CELLS; CA2+-CALMODULIN; ACTIVATION; HYDROLYSIS; CLONING	Metabotropic glutamate receptors, which are members of a G protein-coupled receptor family, mediate the glutamate responses by coupling to the intracellular signal transduction pathway, We herein report that calmodulin (CaM) interacts with the metabotropic glutamate receptor subtype 5 (mGluR5) in a Ca2+-dependent manner in vitro, CaM is capable of binding on two distinct sites in the COOH-terminal intracellular region of the receptor with different affinities, The CaM binding domains are separated by an alternatively spliced exon cassette present in one of the splicing isoforms of mGluR5, By using fusion proteins and synthetic peptides we showed that protein kinase C phosphorylates both CaM binding regions, This phosphorylation is inhibited by the binding of CaM to the receptor, and conversely the binding is inhibited by the phosphorylation, These antagonisms of the CaM binding and phosphorylation thus suggest the possibility that they regulate the receptor responses in vivo.	KYUSHU UNIV,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 81281,JAPAN; KYUSHU UNIV,SCH HLTH SCI,HIGASHI KU,FUKUOKA 81282,JAPAN	Kyushu University; Kyushu University								ABE T, 1992, J BIOL CHEM, V267, P13361; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALALUF S, 1995, FEBS LETT, V367, P301, DOI 10.1016/0014-5793(95)00575-T; CANONICO PL, 1988, J NEUROCHEM, V51, P1049, DOI 10.1111/j.1471-4159.1988.tb03067.x; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P24911, DOI 10.1074/jbc.270.42.24911; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HERRERO I, 1994, EUR J NEUROSCI, V6, P115, DOI 10.1111/j.1460-9568.1994.tb00253.x; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOLY C, 1995, J NEUROSCI, V15, P3970; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MINAKAMI R, 1995, J NEUROCHEM, V65, P1536; MINAKAMI R, 1994, BIOCHEM BIOPH RES CO, V199, P1136, DOI 10.1006/bbrc.1994.1349; MINAKAMI R, 1993, BIOCHEM BIOPH RES CO, V194, P622, DOI 10.1006/bbrc.1993.1866; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAIMI Y, 1994, FEBS LETT, V350, P155, DOI 10.1016/0014-5793(94)00782-9; SAIMI Y, 1990, SCIENCE, V249, P1441, DOI 10.1126/science.2169650; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOEPP DD, 1988, BIOCHEM PHARMACOL, V37, P4299, DOI 10.1016/0006-2952(88)90610-7; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; THOMSEN C, 1993, BRAIN RES, V619, P22, DOI 10.1016/0006-8993(93)91592-G; VANELDIK LJ, 1984, BIOCHEM BIOPH RES CO, V124, P752, DOI 10.1016/0006-291X(84)91022-2; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501	35	121	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20291	20298		10.1074/jbc.272.32.20291	http://dx.doi.org/10.1074/jbc.272.32.20291			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242710	hybrid			2022-12-27	WOS:A1997XQ05900097
J	Roy, S; Lane, A; Yan, J; McPherson, R; Hancock, JF				Roy, S; Lane, A; Yan, J; McPherson, R; Hancock, JF			Activity of plasma membrane-recruited Raf-1 is regulated by Ras via the Raf zinc finger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE RAF; IN-VITRO; ACTIVATION; BINDING; PROTEIN; 14-3-3-PROTEINS; IDENTIFICATION; DOMAIN	Ras recruits Raf to the plasma membrane for activation by a combination of tyrosine phosphorylation and other as yet undefined mechanism(s), We show here that the Raf zinc finger is not required for plasma membrane recruitment of Raf by Ras but is essential for full activation of Raf at the plasma membrane, Membrane targeting cannot compensate for the absence of the zinc finger, One facet of the zinc finger activation defect is revealed using a constitutively activated Raf mutant, Targeting Raf Y340D,Y341D to the plasma membrane increments activity, but full activation requires coexpression with activated Ras. This sensitivity to regulation by Ras at the plasma membrane is abrogated by mutations in the Raf zinc finger but is unaffected by mutation of the minimal Ras binding domain. These data show for the first time that Ras has two separate roles in Raf activation: recruitment of Raf to the plasma membrane through an interaction with the minimal Ras binding domain and activation of membrane-localized Raf via a mechanism that requires the Raf zinc finger.	UNIV QUEENSLAND, SCH MED,DEPT PATHOL,QUEENSLAND CANC FUND, LAB EXPT ONCOL, BRISBANE, QLD 4006, AUSTRALIA	Cancer Council Queensland; University of Queensland			Yan, Jun/F-1224-2010	Yan, Jun/0000-0001-9617-0335; Hancock, John/0000-0003-0542-4710				BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	33	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20139	20145		10.1074/jbc.272.32.20139	http://dx.doi.org/10.1074/jbc.272.32.20139			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242688	hybrid			2022-12-27	WOS:A1997XQ05900075
J	Sato, K; Mori, H; Yoshida, M; Tagaya, M; Mizushima, S				Sato, K; Mori, H; Yoshida, M; Tagaya, M; Mizushima, S			In vitro analysis of the stop-transfer process during translocation across the cytoplasmic membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; PROTON MOTIVE FORCE; PROTEIN TRANSLOCATION; SECA-PROTEIN; PHENOTYPIC SELECTION; PLASMA-MEMBRANE; ATP; PHOSPHOLIPIDS; PREPROTEIN; GENE	In this study, using a derivative of proOmpA containing an artificial stop-transfer sequence (proOmpA2xH1), we analyzed the process of stop-transfer during translocation across the cytoplasmic membrane of Escherichia coli. ProOmpA2xH1 did not interfere with the transit of wild-type proOmpA. When proOmpA2xH1 was anchored in the membrane, membrane-inserted SecA was deinserted with the reversion of the inverted topology of SecG. Cross-linking experiments revealed that the anchored proOmpA2xH1 that does not interact with either SecY or SecA. These results, taken together, suggest that proOmpA2xH1 leaves the translocation pathway by means of a specific interaction between the stop-transfer sequence and the translocational channel.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, YOKOHAMA, KANAGAWA 226, JAPAN	Tokyo Institute of Technology	Sato, K (corresponding author), TOKYO UNIV PHARM & LIFE SCI, SCH LIFE SCI, 1432-1 HORINOUCHI, HACHIOJI, TOKYO 19203, JAPAN.							AKITA M, 1990, J BIOL CHEM, V265, P8164; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BYOCT CS, 1990, NATURE, V343, P669; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HELLER K, 1985, J BACTERIOL, V161, P896, DOI 10.1128/JB.161.3.896-903.1985; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KIM YJ, 1994, CELL, V78, P845; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1995, ADV CELL MOL BIOL M, V4, P61; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OLIVER DB, 1982, J BACTERIOL, V150, P686, DOI 10.1128/JB.150.2.686-691.1982; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; Sato K, 1997, J BIOL CHEM, V272, P5880, DOI 10.1074/jbc.272.9.5880; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; TOKUDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1415, DOI 10.1006/bbrc.1993.2201; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	36	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20082	20087		10.1074/jbc.272.32.20082	http://dx.doi.org/10.1074/jbc.272.32.20082			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242681	hybrid			2022-12-27	WOS:A1997XQ05900068
J	Nishikawa, T; Lee, ISM; Shiraishi, N; Ishikawa, T; Ohta, Y; Nishikimi, M				Nishikawa, T; Lee, ISM; Shiraishi, N; Ishikawa, T; Ohta, Y; Nishikimi, M			Identification of S100b protein as copper-binding protein and its suppression of copper-induced cell damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; METAL-IONS; DISEASE; ALBUMIN; CERULOPLASMIN; SEQUENCE; INJURY; FLUID; SERUM; ALPHA	We have isolated from bovine brain a protein with a high capacity to inhibit the copper ion-catalyzed oxidation of L-ascorbate and identified it as S100b protein, an EF-hand calcium-binding protein, by sequencing its proteolytic peptides. Copper binding studies showed that this protein has four copper binding sites per dimeric protein molecule with a dissociation constant of 0.46 mu M and that in the presence of L-ascorbate, copper ions bind to a total of six binding sites with a great increase in affinity. Furthermore, we examined whether S100b protein can prevent copper-induced cell damage. Bovine S100b protein was found to suppress dose-dependently the hemolysis of mouse erythrocytes induced by CuCl2. We transformed Escherichia coli cells with pGEX-5X-3 vector containing a cDNA for rat S100b protein, so that this protein could be expressed as a fusion protein with glutathione S-transferase. The transformed cells were demonstrated to be markedly resistant to a treatment with CuCl2 plus H2O2 as compared with the control cells expressing glutathione S-transferase alone. These results indicate that S100b protein does suppress oxidative cell damage by sequestering copper ions.	WAKAYAMA MED COLL,DEPT BIOCHEM,WAKAYAMA 640,JAPAN	Wakayama Medical University								BAUDIER J, 1986, J BIOL CHEM, V261, P8192; Buettner G R, 1986, Free Radic Res Commun, V1, P349, DOI 10.3109/10715768609051638; CAFFREY JM, 1990, BIOL TRACE ELEM RES, V25, P11, DOI 10.1007/BF02990259; CHEVION M, 1993, P NATL ACAD SCI USA, V90, P1102, DOI 10.1073/pnas.90.3.1102; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; EVANS PJ, 1984, FREE RADICAL RES COM, V7, P55; GUTTERIDGE JMC, 1986, BIOCHIM BIOPHYS ACTA, V869, P119, DOI 10.1016/0167-4838(86)90286-4; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; ISOBE T, 1977, BIOCHIM BIOPHYS ACTA, V494, P222, DOI 10.1016/0005-2795(77)90150-7; IYER KS, 1978, BIOCHEM J, V169, P61, DOI 10.1042/bj1690061; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KIMURA S, 1984, NEUROCHEM INT, V6, P513, DOI 10.1016/0197-0186(84)90123-2; KLINGMAN D, 1988, TIBS, V13, P437; KUWANO R, 1984, NUCLEIC ACIDS RES, V12, P7455, DOI 10.1093/nar/12.19.7455; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LVSTAD RA, 1984, INT J BIOCHEM, V16, P155; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; NISHIKIMI M, 1987, BIOCHEM INT, V14, P111; PALL HS, 1987, LANCET, V2, P238; SHAROYAN SG, 1977, BIOCHIM BIOPHYS ACTA, V493, P478, DOI 10.1016/0005-2795(77)90204-5; SIMPSON JA, 1990, FREE RADICAL RES COM, V10, P303, DOI 10.3109/10715769009149899; Yagi K, 1996, BIOCHEM BIOPH RES CO, V219, P486, DOI 10.1006/bbrc.1996.0260	24	76	78	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23037	23041		10.1074/jbc.272.37.23037	http://dx.doi.org/10.1074/jbc.272.37.23037			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287301	hybrid			2022-12-27	WOS:A1997XV74400012
J	Velasco, M; DiazGuerra, MJM; MartinSanz, P; Alvarez, A; Bosca, L				Velasco, M; DiazGuerra, MJM; MartinSanz, P; Alvarez, A; Bosca, L			Rapid up-regulation of I kappa B beta and abrogation of NF-kappa B activity in peritoneal macrophages stimulated with lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; DNA-BINDING; ACTIVATION; ALPHA; PHOSPHORYLATION; INDUCTION; DEGRADATION; EXPRESSION	Lipopolysaccharide (LPS) administration to mice elicited the activation of nuclear factor kappa B (NF-kappa B) in several tissues including liver and macrophages. Maximal activation was observed 1 h after treatment but declined at 3 and 6 h. The levels of I kappa B alpha and I kappa B beta were analyzed during this period in an attempt to correlate NF-kappa B activity with I kappa B resynthesis. Degradation of I kappa B alpha was very rapid and was followed by recovery 1 h after LPS administration. I kappa B beta degradation, which has been associated with persistent NF-kappa B activation, was complete at 1 h. However, a rapid recovery of I kappa B beta in these tissues was observed at 3 h in parallel with the abrogation of NF-kappa B activity. Immunolocalization of newly synthesized I kappa B beta by confocal microscopy revealed its preferential accumulation in the cytosol. Analysis of I kappa B beta by Western blot using high resolution polyacrylamide gel electrophoresis showed the presence of two bands in cytosolic extracts of LPS-treated macrophages at 3 h, but only one band with the same mobility as the control was detected at 6 h. Moreover, treatment of extracts of resynthesized I kappa B beta with alkaline phosphatase resulted in the accumulation of the protein of slightly higher electrophoretic mobility, indicating the prevalence of a rapid phosphorylation of the newly synthesized I kappa B beta. At the mRNA level, up-regulation of I kappa B beta was observed in macrophages stimulated for 1 h with LPS. When the effect of pro-inflammatory cytokines was investigated, tumor necrosis factor alpha, but not interleukin-1 or interferon-gamma, promoted an important degradation of I kappa B beta followed by an increase in the mRNA at 1 h. These results suggest the existence of LPS and tumor necrosis factor gamma-specific pathways involved in a rapid I kappa B beta degradation and resynthesis and might explain the transient period of activation of NF-kappa B in these tissues upon stimulation with these factors. This rapid control of NF-kappa B function may contribute to the attenuation of the inflammatory response of these cells.	UNIV COMPLUTENSE MADRID,FAC FARM,INST BIOQUIM,CSIC,E-28040 MADRID,SPAIN; UNIV COMPLUTENSE MADRID,FAC FARM,CTR CITOMETRIA FLUJO,E-28040 MADRID,SPAIN	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Complutense University of Madrid			Díaz-Guerra, María José M/M-2855-2014; Bosca, Lisardo/A-2059-2008; Martín-Sanz, Paloma/K-1303-2014; Alvarez-Barrientos, Alberto/L-9299-2014	Díaz-Guerra, María José M/0000-0003-3843-3912; Bosca, Lisardo/0000-0002-0253-5469; Alvarez-Barrientos, Alberto/0000-0003-4761-0212				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KOPP E, 1994, ADV IMMUNOL, V58, P1; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Ohtsuka T, 1996, J BIOL CHEM, V271, P1651, DOI 10.1074/jbc.271.3.1651; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Weil R, 1997, J BIOL CHEM, V272, P9942; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; XIE QW, 1994, J BIOL CHEM, V269, P4705	39	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23025	23030		10.1074/jbc.272.37.23025	http://dx.doi.org/10.1074/jbc.272.37.23025			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287299	hybrid			2022-12-27	WOS:A1997XV74400010
J	Besancon, M; Simon, A; Sachs, G; Shin, JM				Besancon, M; Simon, A; Sachs, G; Shin, JM			Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SECRETION; ALPHA-SUBUNIT; SARCOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGES; MEMBRANE TOPOLOGY; ATPASE; OMEPRAZOLE; NA+,K+-ATPASE; H+,K+-ATPASE; INHIBITION	The vesicular gastric H,K-ATPase catalyzes an electroneutral H for K exchange allowing acidification of the intravesicular space, There is a total of 28 cysteines present in the alpha subunit of the gastric H,K-ATPase, of which 10 are found in the predicted transmembrane segments and their connecting loop, and 9 are present in the beta subunit, of which 6 are disulfide-linked, To determine which of these was accessible to extracytoplasmic attack, the enzyme was inhibited by four different substituted 2-pyridylmethylsulfinyl benzimidazoles, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole (omeprazole), 2-[(4-trifluoroethoxy-3-methyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole (lansoprazole), 5-difluoromethoxy-2-[3,4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole (pantoprazole), and 2-[(4-(3-methoxypropoxy)-3-methyl)-2-pyridyl)methylsulfinyl]-1H-benzimidazole (rabeprazole), under acid transporting conditions, All of these compounds are weak bases that accumulate in the acidic space generated by the pump and undergo an acid catalyzed rearrangement to a cationic sulfenamide, which forms disulfides with accessible cysteines, The relative rates of acid activation of these compounds corresponded to the relative rates of inhibition of ATPase activity and acid transport, Fragmentation of the enzyme by trypsin followed by SDS-polyacrylamide gel electrophoresis showed that omeprazole bound covalently to one of the two cysteines in the domains containing the fifth and sixth transmembrane segments and their extracytoplasmic loop and to cysteine 892 in the loop between the seventh and eighth transmembrane segments, but inhibition correlated with the reaction with cysteines in the fifth and sixth domain, Lansoprazole bound to the cysteines in these two domains as well as to cysteine 321 toward the extracytoplasmic end of the third transmembrane segments, Pantoprazole bound only to either cysteine 813 or 822 in the fifth and sixth transmembrane region, The inhibition of Rabeprazole correlated also with its binding to this part of the protein, but this compound continued to bind after full inhibition, eventually binding also to cysteines 321 and 892. No binding was found to any of the cysteines in the seventh to tenth transmembrane segments, Thermolysin digestion of the isolated omeprazole-labeled fifth and sixth transmembrane pair showed that cysteine 813 was the site of labeling. It is concluded that binding of these sided reagents to cysteine 813 in the loop between transmembrane (TM)5 and TM6 is sufficient for inhibition of ATPase activity and acid transport by the gastric acid pump, Of the 10 cysteines present in the membrane and extracytoplasmic domain, only three are exposed sufficiently to allow reactivity with these cationic thiol reagents. The binding to cysteine 813 defines the location of the extracytoplasmic loop between TM5 and TM6 and places the carboxylic acids 820 and 824 conserved between the gastric H,K- and the Na,K-ATPases in TM6, consistent with their assumed role in cation binding.	VET ADM WADSWORTH HOSP CTR, LOS ANGELES, CA 90073 USA; UNIV CALIF LOS ANGELES, DEPT PHYSIOL & MED, LOS ANGELES, CA 90073 USA; BYK GULDEN LOMBERG GMBH, D-78467 CONSTANCE, GERMANY	University of California System; University of California Los Angeles; Altana					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R01DK017294, R01DK040615, R37DK017294] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40615, DK41301, DK17294] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BRANDSTROM A, 1989, ACTA CHEM SCAND, V43, P536, DOI 10.3891/acta.chem.scand.43-0536; ESMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1112, P215, DOI 10.1016/0005-2736(92)90394-2; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FRYKLUND J, 1988, BIOCHEM PHARMACOL, V37, P2543, DOI 10.1016/0006-2952(88)90244-4; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; JOHNSON CL, 1995, BIOCHEM J, V309, P187, DOI 10.1042/bj3090187; KAPLAN JH, 1991, SOC GEN PHY, V46, P117; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KEELING DJ, 1987, BIOCHEM PHARMACOL, V36, P339, DOI 10.1016/0006-2952(87)90291-7; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LINDBERG P, 1986, J MED CHEM, V29, P1327, DOI 10.1021/jm00158a001; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LORENTZON P, 1985, BIOCHIM BIOPHYS ACTA, V817, P25, DOI 10.1016/0005-2736(85)90064-1; LORENTZON P, 1987, BIOCHIM BIOPHYS ACTA, V897, P41, DOI 10.1016/0005-2736(87)90313-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSENKO S, 1997, J BIOL CHEM, V272, P5249; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; Mahanty SK, 1996, J BIOL CHEM, V271, P367, DOI 10.1074/jbc.271.1.367; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; Padmanabha K P, 1994, Symp Soc Exp Biol, V48, P33; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; RABON E, 1978, BIOCHEMISTRY-US, V17, P3345, DOI 10.1021/bi00609a027; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; RABON EC, 1990, J BIOL CHEM, V265, P19594; Rabon EC, 1996, J BIOL CHEM, V271, P32137, DOI 10.1074/jbc.271.50.32137; RABON EC, 1988, METHOD ENZYMOL, V157, P649; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; ROBINSON JD, 1974, FEBS LETT, V38, P325, DOI 10.1016/0014-5793(74)80083-9; SACHS G, 1977, REV PHYSIOL BIOCH P, V79, P133, DOI 10.1007/BFb0037090; SACHS G, 1995, ANNU REV PHARMACOL, V35, P277, DOI 10.1146/annurev.pa.35.040195.001425; Sachs G, 1993, ALIMENT PHARM THER S, V7, P4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONER W, 1971, ANGEW CHEM INT EDIT, V10, P882, DOI 10.1002/anie.197108821; SCOTT DR, 1993, BIOCHIM BIOPHYS ACTA, V1146, P73, DOI 10.1016/0005-2736(93)90340-6; SENNBILFINGER J, 1987, J ORG CHEM, V52, P4582, DOI 10.1021/jo00229a027; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; Singh P, 1991, Drug Des Deliv, V7, P131; SMITH DL, 1993, J BIOL CHEM, V268, P22469; Terauchi H, 1997, J MED CHEM, V40, P313, DOI 10.1021/jm9605593; VANDERHIJDEN HTWM, 1990, J MEMBRANE BIOL, V114, P245, DOI 10.1007/BF01869218; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	47	216	241	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22438	22446		10.1074/jbc.272.36.22438	http://dx.doi.org/10.1074/jbc.272.36.22438			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278394	hybrid			2022-12-27	WOS:A1997XV49200014
J	Chen, LH; Marechal, V; Moreau, J; Levine, AJ; Chen, JD				Chen, LH; Marechal, V; Moreau, J; Levine, AJ; Chen, JD			Proteolytic cleavage of the mdm2 oncoprotein during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE-LIKE PROTEASE; DEATH GENE CED-3; CELL-DEATH; TRANSCRIPTIONAL ACTIVATION; P53 PROTEIN; POLY(ADP-RIBOSE) POLYMERASE; P53-ASSOCIATED PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ICE/CED-3 PROTEASE	The mdm2 oncogene encodes a 90-kDa protein that can bind to the p53 tumor suppressor protein and negatively regulate its functions In transcription, cell cycle arrest, and apoptosis. The mdm2 gene is frequently amplified in human sarcomas, which may be responsible for the malignant transformations. We present evidence that the mdm2 oncoprotein is cleaved by an interleukin 1 beta-converting enzyme-like protease (caspase) during p53-mediated apoptosis. The protease that cleaves mdm2 has a specificity similar to that of CPP32 (caspase-3), and recombinant caspase-3 is able to cleave mdma in vitro. The protease cleavage site has been mapped to between residue 361 and 362 of human mdm2. The proteolytic cleavage removes the COOH-terminal RING finger domain of mdm2, resulting in the loss of RNA binding activity. The p53 binding and inhibition functions of mdm2 are not affected by the cleavage. The cleavage site sequence of mdm2 is evolutionarily conserved, suggesting that regulation by caspase cleavage during apoptosis is an important feature of mdm2.	LOUISIANA STATE UNIV,MED CTR,STANLEY S SCOTT CANC CTR,DEPT MICROBIOL IMMUNOL & PARASITOL,NEW ORLEANS,LA 70112; HOP ROTHSCHILD,MICROBIOL SERV,F-75571 PARIS,FRANCE; UNIV DENIS DIDEROT,INST JACQUES MONOD,EQUIPE EMBRYOL MOL,F-75251 PARIS,FRANCE; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Louisiana State University System; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Princeton University			marechal, vincent/P-7719-2017		NATIONAL CANCER INSTITUTE [R01CA072915] Funding Source: NIH RePORTER; NCI NIH HHS [CA72915-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARDONCARDO C, 1994, CANCER RES, V54, P794; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LENG P, 1995, ONCOGENE, V10, P1275; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LUNA RMD, 1995, NATURE, V378, P203; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	63	114	115	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22966	22973		10.1074/jbc.272.36.22966	http://dx.doi.org/10.1074/jbc.272.36.22966			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278461	hybrid			2022-12-27	WOS:A1997XV49200084
J	Skorey, K; Ly, HD; Kelly, J; Hammond, M; Ramachandran, C; Huang, Z; Gresser, MJ; Wang, QP				Skorey, K; Ly, HD; Kelly, J; Hammond, M; Ramachandran, C; Huang, Z; Gresser, MJ; Wang, QP			How does alendronate inhibit protein-tyrosine phosphatases?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CONTAINING PEPTIDES; FLUOROMETRIC ASSAY; HYDROGEN-PEROXIDE; REDOX REGULATION; BONE; OSTEOPOROSIS; CELLS; BISPHOSPHONATES; DITHIOTHREITOL	Alendronate (4-amino-1-hydroxybutylidene 1,l-bisphosphonate) is a drug used in the treatment of osteoporosis and other bone diseases. The inhibition of protein-tyrosine phosphatases (PTPs) by alendronate suggests that PTPs may be molecular targets, As a clear understanding of the inhibition mechanism is lacking, our aim was to analyze the mechanism to provide further insight into its therapeutic effect. We show here that the inhibition of PTPs by alendronate in the presence of calcium followed first-order kinetic behavior, and kinetic parameters for the process were determined, Evidence is presented that the inhibition by alendronate/calcium is active site-directed. However, this process was very sensitive to assay constituents such as EDTA and dithiothreitol, Furthermore, the inhibition of PTPs by alendronate/calcium was eliminated by the addition of catalase, These observations suggest that a combination of alendronate, metal ions, and hydrogen peroxide is responsible for the inhibition of PTPs, The individual effects of alendronate, calcium, or hydrogen peroxide on the inactivation of CD45 were determined. Electrospray ionization mass spectrometry demonstrated that the mass of PTP1B increased by 34 +/- 2 units after the enzyme was inactivated with alendronate/calcium, due to the oxidization of the catalytic cysteine to sulfinic acid (Cys-SO2H). The inhibited PTP1B could be partially reactivated by treatment with reducing agents such as hydroxylamine (NH2OH) and N,N'-dimethyl-N,N'-bis-(mercaptoacetyl)hydrazine, indicating the presence of other oxidized forms such as sulfenic acid (Cys-SOH). This further confirms that the inhibition is the result of oxidation of the catalytic cysteine, The relevance of this oxidative inhibition mechanism in a biological system is discussed.	MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOL BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA; MERCK FROSST CTR THERAPEUT RES,DEPT MED CHEM,POINTE CLAIRE,PQ H9R 4P8,CANADA	Merck & Company; Merck & Company								ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P596, DOI 10.1016/0006-291X(77)90221-2; DOWSON RMC, 1987, DATA BIOCH RES, P404; Endo N, 1996, J BONE MINER RES, V11, P535; GALLAGHER KE, 1993, BIOCHEM SOC T, V21, P98; GATTI D, 1994, J BONE MINER RES, V9, P1833; Gresser M. J., 1987, ADV PROTEIN PHOSPHAT, V4, P35; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAUGLAND RP, 1992, HDB FLUORESCENT PROB, P115; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; KANIS JA, 1995, OSTEOPOROSIS INT, V5, P1, DOI 10.1007/BF01623652; KITZ R, 1962, J BIOL CHEM, V237, P3245; KRIEGER NS, 1983, ENDOCRINOLOGY, V113, P324, DOI 10.1210/endo-113-1-324; LAMSON ML, 1984, INT J PHARM, V21, P143, DOI 10.1016/0378-5173(84)90089-9; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756-3282(96)00182-2; MEVKH AT, 1985, ANAL BIOCHEM, V150, P91, DOI 10.1016/0003-2697(85)90444-0; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NARDELLI M, 1983, INORG CHIM A-BIOINOR, V80, P259, DOI 10.1016/S0020-1693(00)91293-3; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OSTOVIC D, 1993, PHARMACEUT RES, V10, P470, DOI 10.1023/A:1018969112754; PERCIVAL MD, 1992, EUR J BIOCHEM, V210, P109, DOI 10.1111/j.1432-1033.1992.tb17397.x; Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722; RODAN GA, 1994, ANNU REP MED CHEM, V29, P275; SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539; Sawyer DT, 1996, ACCOUNTS CHEM RES, V29, P409, DOI 10.1021/ar950031c; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068; SHIBANUMA M, 1988, ONCOGENE, V3, P17; Siris E, 1996, J CLIN ENDOCR METAB, V81, P961, DOI 10.1210/jc.81.3.961; STANKIEWICZ PJ, 1987, BIOCHEMISTRY-US, V26, P1264, DOI 10.1021/bi00379a010; STONE RL, 1994, J BIOL CHEM, V269, P31323; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Taher MM, 1996, BIOCHEM MOL BIOL INT, V40, P159; TROTTA PP, 1974, J BIOL CHEM, V249, P1915; Vepa S, 1997, FREE RADICAL BIO MED, V22, P25, DOI 10.1016/S0891-5849(96)00241-9; WANG Q, 1997, IN PRESS BIOCH PHARM; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zhao F, 1996, PHARMACEUT RES, V13, P931, DOI 10.1023/A:1016021716274	41	63	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22472	22480		10.1074/jbc.272.36.22472	http://dx.doi.org/10.1074/jbc.272.36.22472			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9278398	hybrid			2022-12-27	WOS:A1997XV49200018
J	Atkin, AL; Schenkman, LR; Eastham, M; Dahlseid, JN; Lelivelt, MJ; Culbertson, MR				Atkin, AL; Schenkman, LR; Eastham, M; Dahlseid, JN; Lelivelt, MJ; Culbertson, MR			Relationship between yeast polyribosomes and Upf proteins required for nonsense mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TURNOVER; TRANSLATIONAL TERMINATION CODON; GENE; IDENTIFICATION; DEGRADATION; STABILITY; COMPONENT; PATHWAY; CELLS; DNA	In yeast, the accelerated rate of decay of nonsense mutant mRNAs, called nonsense-mediated mRNA decay, requires three proteins, Upf1p, Upf2p, and Upf3p. Single, double, and triple disruptions of the UPF genes had nearly identical effects on nonsense mRNA accumulation, suggesting that the encoded proteins function in a common pathway, We examined the distribution of epitope-tagged versions of Upf proteins by sucrose density gradient fractionation of soluble lysates and found that all three proteins co-distributed with 80 S ribosomal particles and polyribosomes. Treatment of lysates with RNase A caused a coincident collapse of polyribosomes and each Upf protein into fractions containing 80 S ribosomal particles, as expected for proteins that are associated with polyribosomes. Mutations in the cysteine-rich (zinc finger) and RNA helicase domains of Upf1p caused loss of function, but the mutant proteins remained polyribosome-associated. Density gradient profiles for Upf1p were unchanged in the absence of Upf3p, and although similar, were modestly shifted to fractions lighter than those containing polyribosomes in the absence of Upf2p. Upf2p shifted toward heavier polyribosome fractions in the absence of Upf1p and into fractions containing 80 S particles and lighter fractions in the absence of Upf3p, Our results suggest that the association of Upf2p with polyribosomes typically found in a wild-type strain depends on the presence and opposing effects of Upf1p and Upf3p.	UNIV WISCONSIN,LAB GENET & MOL BIOL,MADISON,WI 53706; UNIV NEBRASKA,SCH BIOL SCI,LINCOLN,NE 68588	University of Wisconsin System; University of Wisconsin Madison; University of Nebraska System; University of Nebraska Lincoln				Atkin, Audrey/0000-0001-5893-1068	NIGMS NIH HHS [GM26217] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026217] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKIN AL, 1995, MOL BIOL CELL, V6, P611; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; CUI Y, 1995, GENE DEV, V9, P423, DOI 10.1101/gad.9.4.423; CZAPLINSKI K, 1995, RNA, V1, P610; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN LL, 1988, J MOL BIOL, V200, P321, DOI 10.1016/0022-2836(88)90244-6; GREY M, 1992, CURR GENET, V22, P83, DOI 10.1007/BF00351746; He F, 1997, MOL CELL BIOL, V17, P1580, DOI 10.1128/MCB.17.3.1580; HE F, 1995, GENE DEV, V9, P437, DOI 10.1101/gad.9.4.437; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; KAUFER NF, 1983, NUCLEIC ACIDS RES, V11, P3123; KLESSIG DF, 1983, PLANT MOL BIOL REP, V1, P12; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; LEE BS, 1995, P NATL ACAD SCI USA, V92, P10354, DOI 10.1073/pnas.92.22.10354; LEE SY, 1990, BIOTECHNIQUES, V9, P676; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; Weng YM, 1996, MOL CELL BIOL, V16, P5491, DOI 10.1128/mcb.16.10.5491	27	92	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22163	22172		10.1074/jbc.272.35.22163	http://dx.doi.org/10.1074/jbc.272.35.22163			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268361	Green Published, hybrid			2022-12-27	WOS:A1997XT85000073
J	Hayflick, JS; Stine, J; Fox, R; Hoekstra, D; Gallatin, WM				Hayflick, JS; Stine, J; Fox, R; Hoekstra, D; Gallatin, WM			Functional mapping of the cytoplasmic region of intercellular adhesion molecule-3 reveals important roles for serine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESENTING B-CELLS; KINASE C-THETA; HELPER T-CELLS; TYROSINE PHOSPHORYLATION; AMINO-ACIDS; I-DOMAIN; PROTEIN; ANTIGEN; ICAM-3; EXPRESSION	Intercellular adhesion molecule-3 (ICAM-3), a ligand for beta(2) integrins, elicits a variety of activation responses in lymphocytes, We describe a functional mapping study that focuses on the 37-residue cytoplasmic region of ICAM-3. Carboxyl-terminal truncations delineated portions involved in T cell antigen receptor costimulation, homotypic aggregation, and cellular spreading, Truncation of the membrane distal 25 residues resulted in loss of T cell antigen receptor costimulation as determined by interleukin 2 secretion, Aggregation and cell spreading were sensitive to truncation of the membrane distal and proximal thirds of the cytoplasmic portion. Phosphoamino acid analysis revealed that ICAM-3 from activated cells contained phosphoserine and phosphopeptide mapping identified Ser(489) as a site of phosphorylation in vivo, Mutation of Ser(489) or Ser(515) to alanine blocked interleukin 2 secretion, aggregation and cell spreading, while mutation of other serine residues affected only a subset of functions, Ser(489) was a phosphorylation site in vitro for recombinant protein kinase C theta. Finally, treatment of Jurkat cells with chelerythrine chloride, a protein kinase C inhibitor, prevented ICAM-3-triggered spreading. This study delineates separable regions and amino acid residues within the cytoplasmic portion of ICAM-3 that are important for T cell function.			Hayflick, JS (corresponding author), ICOS CORP, 22021 20TH AVE SE, BOTHELL, WA 98021 USA.							ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BAIER G, 1993, J BIOL CHEM, V268, P4997; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Binnerts ME, 1996, J BIOL CHEM, V271, P9962, DOI 10.1074/jbc.271.17.9962; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMPANERO MR, 1994, J CELL BIOL, V127, P867, DOI 10.1083/jcb.127.3.867; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; CHANG JD, 1993, J BIOL CHEM, V268, P14208; CHIRATHAWORN C, 1995, J IMMUNOL, V155, P5479; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAHN WC, 1993, GENE, V127, P267, DOI 10.1016/0378-1119(93)90731-H; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JUAN M, 1994, J EXP MED, V179, P1747, DOI 10.1084/jem.179.6.1747; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; KUPFER A, 1987, J EXP MED, V165, P1565, DOI 10.1084/jem.165.6.1565; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LORENZ HM, 1993, CELL IMMUNOL, V147, P110, DOI 10.1006/cimm.1993.1052; LOZANO F, 1992, EUR J BIOCHEM, V203, P321, DOI 10.1111/j.1432-1033.1992.tb19862.x; MITCHISON A, 1995, IMMUNOLOGIST, V3, P259; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PHATAK PD, 1994, J CELL PHYSIOL, V159, P365, DOI 10.1002/jcp.1041590220; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SKUBITZ KM, 1995, J IMMUNOL, V154, P2888; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; vanKooyk Y, 1996, J EXP MED, V183, P1247, DOI 10.1084/jem.183.3.1247; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VILELLA R, 1990, TISSUE ANTIGENS, V36, P203, DOI 10.1111/j.1399-0039.1990.tb01830.x; YANG L, 1992, CURR OPIN IMMUNOL, V4, P265, DOI 10.1016/0952-7915(92)90075-P	38	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22207	22214		10.1074/jbc.272.35.22207	http://dx.doi.org/10.1074/jbc.272.35.22207			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268366	hybrid			2022-12-27	WOS:A1997XT85000078
J	Walsh, DM; Lomakin, A; Benedek, GB; Condron, MM; Teplow, DB				Walsh, DM; Lomakin, A; Benedek, GB; Condron, MM; Teplow, DB			Amyloid beta-protein fibrillogenesis - Detection of a protofibrillar intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL FRAGMENT; ALZHEIMERS-DISEASE; CEREBRAL-HEMORRHAGE; PEPTIDE; AGGREGATION; CONFORMATION; PRECURSOR; GROWTH; ZINC; PURIFICATION	Fibrillogenesis of the amyloid beta-protein (A beta) is a seminal pathogenetic event in Alzheimer's disease, Inhibiting fibrillogenesis is thus one approach toward disease therapy, Rational design of fibrillogenesis inhibitors requires elucidation of the stages and kinetics of A beta fibrillogenesis, We report results of studies designed to examine the initial stages of A beta oligomerization, Size exclusion chromatography, quasielastic light scattering spectroscopy, and electron microscopy were used to characterize fibrillogenesis intermediates, After dissolution in 0.1 M Tris-HCl, pH 7.4, and removal of preexistent seeds, A beta chromatographed almost exclusively as a single peak, The molecules composing the peak had average hydrodynamic radii of 1.8 +/- 0.2 nm, consistent with the predicted size of dimeric A beta. Over time, an additional peak, with a molecular weight >100,000, appeared, This peak contained predominantly curved fibrils, 6-8 nm in diameter and <200 nm in length, which we have termed ''protofibrils.'' The kinetics of protofibril formation and disappearance are consistent with protofibrils being intermediates in the evolution of amyloid fibers, Protofibrils appeared during the polymerization of A beta-(1-40), A beta-(1-42), and A beta-(1-40)-Gln(22), peptides associated with both sporadic and inherited forms of Alzheimer's disease, suggesting that protofibril formation may be a general phenomenon in A beta fibrillogenesis. If so, protofibrils could be attractive targets for fibrillogenesis inhibitors.	BRIGHAM & WOMENS HOSP, BIOPOLYMER LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROL NEUROSCI, BOSTON, MA 02115 USA; MIT, DEPT PHYS, CAMBRIDGE, MA 02139 USA; MIT, CTR MAT SCI & ENGN, CAMBRIDGE, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL EYE INSTITUTE [R37EY005127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014366] Funding Source: NIH RePORTER; NEI NIH HHS [5R37EY05127] Funding Source: Medline; NIA NIH HHS [1P01AG14366] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1994, J BIOL CHEM, V269, P12152; Chan W, 1996, BIOCHEMISTRY-US, V35, P7123, DOI 10.1021/bi952852v; Clements A, 1996, J NEUROCHEM, V66, P740; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; COHEN RJ, 1975, IMMUNOCHEMISTRY, V12, P349, DOI 10.1016/0019-2791(75)90188-3; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Esler WP, 1996, J NEUROCHEM, V66, P723; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1994, J BIOL CHEM, V269, P17741; Haass C, 1996, EUR ARCH PSY CLIN N, V246, P118, DOI 10.1007/BF02189111; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; IRVINE GB, 1997, IN PRESS ANAL CHEM A; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kametani F, 1995, BRAIN RES, V703, P237, DOI 10.1016/0006-8993(95)01195-1; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; Naslund J, 1996, J NEUROCHEM, V67, P294; Pecora R, 1985, BER BUNSEN PHYS CHEM, DOI DOI 10.1002/BBPC.19870910455; PEREZPAYA E, 1995, J BIOL CHEM, V270, P1048, DOI 10.1074/jbc.270.3.1048; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; SATO C, 1995, NEUROSCI LETT, V200, P105, DOI 10.1016/0304-3940(95)12089-M; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEN CL, 1993, BIOPHYS J, V65, P2383, DOI 10.1016/S0006-3495(93)81312-2; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Soto C, 1996, BIOCHEM J, V314, P701, DOI 10.1042/bj3140701; Teplow DB, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P311; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850	53	916	944	3	90	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	1997	272	35					22364	22372		10.1074/jbc.272.35.22364	http://dx.doi.org/10.1074/jbc.272.35.22364			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XT850	9268388	hybrid			2022-12-27	WOS:A1997XT85000100
J	Bito, A; Haider, M; Hadler, I; Breitenbach, M				Bito, A; Haider, M; Hadler, I; Breitenbach, M			Identification and phenotypic analysis of two glyoxalase II encoding genes from Saccharomyces cerevisiae, GLO2 and GLO4, and intracellular localization of the corresponding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; D-LACTATE; CLONING; YEAST; METHYLGLYOXAL; PURIFICATION; EXPRESSION; SEQUENCES; PATHWAY; CELLS	We have isolated and characterized two genes coding for the glyoxalase II enzyme from Saccharomyces cerevisiae, The coding region of the GLO2 gene corresponds to a protein with 274 amino acids and a molecular mass of 31,306 daltons, The open reading frame of the GLO4 gene could be translated into a protein with 285 amino acids and a molecular mass of 32,325 daltons, The amino acid sequences of the deduced proteins are 59.1% identical and show high similarities to the sequence of the human glyoxalase II, When grown on either glucose or glycerol as a carbon source, a glo2 glo4 double deletion strain contains no glyoxalase II activity at all and shows no obvious phenotype during vegetative growth, However, this strain showed a similar high sensitivity against exogenous methylglyoxal as compared with a glyoxalase I-deficient strain, Whereas the GLO2 gene is expressed on both glucose and glycerol, the GLO4 gene is only active on glycerol, The active Glo2p protein is localized in the cytoplasm and the active Glo4p in the mitochondrial matrix. Heterologous expression of the full-length GLO2 coding region in Escherichia coli resulted in an active protein, However, to get an active Glo4p protein in E. coli, the putative mitochondrial transit peptide at the N-terminal end had to be removed by shortening the 5' end of the GLO4 open reading frame.			Bito, A (corresponding author), SALZBURG UNIV, INST GENET & GEN BIOL, HELLBRUNNERSTR 34, A-5020 SALZBURG, AUSTRIA.							ALLEN RE, 1993, EUR J BIOCHEM, V213, P1261, DOI 10.1111/j.1432-1033.1993.tb17877.x; BALL JC, 1981, BIOCHEMISTRY-US, V20, P899, DOI 10.1021/bi00507a038; BERTHECORTI L, 1992, MUTAGENESIS, V7, P25, DOI 10.1093/mutage/7.1.25; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; COOPER RA, 1984, ANNU REV MICROBIOL, V38, P49, DOI 10.1146/annurev.mi.38.100184.000405; CREIGHTON DJ, 1988, BIOCHEMISTRY-US, V27, P7376, DOI 10.1021/bi00419a031; DARLING TN, 1988, MOL BIOCHEM PARASIT, V28, P121, DOI 10.1016/0166-6851(88)90059-X; DAUM G, 1982, J BIOL CHEM, V257, P13023; DESWAL R, 1993, BIOCHEM SOC T, V21, P527, DOI 10.1042/bst0210527; Espartero J, 1995, PLANT MOL BIOL, V29, P1223, DOI 10.1007/BF00020464; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; HAIDER M, 1994, MOL ANAL GENS GER 1; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOPKINS FG, 1945, BIOCHEM J, V39, P320, DOI 10.1042/bj0390320; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; JERZYKOWSKI T, 1978, INT J BIOCHEM, V9, P853, DOI 10.1016/0020-711X(78)90036-8; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KIM NS, 1993, J BIOL CHEM, V268, P11217; KOSUGI N, 1988, APPL MICROBIOL BIOT, V28, P263; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MISRA K, 1995, BIOCHEM J, V305, P999, DOI 10.1042/bj3050999; MURATA K, 1986, AGR BIOL CHEM TOKYO, V50, P2381, DOI 10.1080/00021369.1986.10867751; MURATA K, 1985, BIOCHEM BIOPH RES CO, V131, P190, DOI 10.1016/0006-291X(85)91788-7; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PRINCIPATO GB, 1987, BIOCHIM BIOPHYS ACTA, V911, P349, DOI 10.1016/0167-4838(87)90076-8; RANGANATHAN S, 1993, J BIOL CHEM, V268, P5661; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RHEE HI, 1988, AGR BIOL CHEM TOKYO, V52, P2243; RICHARD JP, 1993, BIOCHEM SOC T, V21, P549, DOI 10.1042/bst0210549; Ridderstrom M, 1997, BIOCHEM J, V322, P449, DOI 10.1042/bj3220449; Ridderstrom M, 1996, J BIOL CHEM, V271, P319, DOI 10.1074/jbc.271.1.319; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TALESA V, 1988, BIOCHIM BIOPHYS ACTA, V955, P103, DOI 10.1016/0167-4838(88)90183-5; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALLNER J, 1991, THESIS U VIENNA VIEN; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	46	64	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21509	21519		10.1074/jbc.272.34.21509	http://dx.doi.org/10.1074/jbc.272.34.21509			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261170	hybrid			2022-12-27	WOS:A1997XR78900080
J	Martin, SL; Edbrooke, MR; Hodgman, TC; vandenEijnden, DH; Bird, MI				Martin, SL; Edbrooke, MR; Hodgman, TC; vandenEijnden, DH; Bird, MI			Lewis X biosynthesis in Helicobacter pylori - Molecular cloning of an alpha(1,3)-fucosyltransferase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ALPHA-1-3 FUCOSYL-TRANSFERASE; CORE OLIGOSACCHARIDE REGIONS; UNIDENTIFIED CURVED BACILLI; E-SELECTIN LIGAND; GDP-FUCOSE; SCHISTOSOMA-MANSONI; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; DETERMINES EXPRESSION; MONOCLONAL-ANTIBODY	The lipopolysaccharide of certain strains of Helicobacter pylori was recently shown to contain the Lewis X (Le(x)) trisaccharide (Gal beta-1,4-(Fuc alpha(1,3))-GlcNAc). Le(x) is an oncofetal antigen which appears on human gastric epithelium, and its mimicry by carbohydrate structures on the surface of H. pylori may play an important part in the interaction of this pathogen with its host, Potential roles for bacterial Le(x) in mucosal adhesion, immune evasion, and autoantibody induction have been proposed (Moran, A, P., Prendergast, M. M., and Appelmelk, B. J. (1996) FEMS Immunol, Med, Microbiol, 16, 105-115). In mammals, the final step of Le(x) biosynthesis is the alpha(1,3)-fucosylation of GlcNAc in a terminal Gal beta(1-->4)-GlcNAc unit, and a corresponding GDP-fucose:N-acetylglucosaminyl alpha(1,3) fucosyltransferase (alpha(1,3)-Fuc-T) activity was recently discovered in H. pylori extracts, We used part of a human alpha(1,3)-Fuc-T amino acid sequence to search an H. pylori genomic data base for related sequences, Using a probe based upon weakly matching data base sequences, we retrieved clones from a plasmid library of H. pylori DNA, DNA sequence analysis of the library clones revealed a gene which we have named fucT, encoding a protein with localized homology to the human alpha(1,3)-Fuc-Ts. We have demonstrated that fucT encodes an active Fuc-T enzyme by expressing the gene in Escherichia coli, The recombinant enzyme shows a strong preference for type 2 (e.g. LacNAc) over type 1 (e.g. lacto-N-biose) accepters in vitro. Certain residues in a short segment of the H. pylori protein are completely conserved throughout the alpha(1,3)-Fuc-T family, defining an alpha(1,3)-Fuc-T motif which may be of use in identifying new fucosyltransferase genes.	GLAXO WELLCOME RES & DEV LTD, MED RES CTR, ADV TECHNOL & INFORMAT UNIT, STEVENAGE SG1 2NY, HERTS, ENGLAND; VRIJE UNIV AMSTERDAM, DEPT MED CHEM, AMSTERDAM, NETHERLANDS	GlaxoSmithKline; Vrije Universiteit Amsterdam	Martin, SL (corresponding author), GLAXO WELLCOME RES & DEV LTD, MED RES CTR, GLYCOBIOL UNIT, GUNNELS WOOD RD, STEVENAGE SG1 2NY, HERTS, ENGLAND.		Hodgman, Charlie/AAF-2405-2020	Hodgman, Charlie/0000-0001-5862-8296				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Appelmelk BJ, 1996, INFECT IMMUN, V64, P2031, DOI 10.1128/IAI.64.6.2031-2040.1996; ASPINALL GO, 1994, CARBOHYDR LETT, V0001; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2489, DOI 10.1021/bi951852s; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2498, DOI 10.1021/bi951853k; Britten CJ, 1997, BBA-GEN SUBJECTS, V1334, P57, DOI 10.1016/S0304-4165(96)00076-1; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CHAN NWC, 1995, GLYCOBIOLOGY, V5, P683, DOI 10.1093/glycob/5.7.683; DeBoseBoyd R, 1996, EXP PARASITOL, V82, P1, DOI 10.1006/expr.1996.0001; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DEVRIES T, 1997, IN PRESS GLYCOBIOLOG; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; HOLMES EH, 1992, ARCH BIOCHEM BIOPHYS, V296, P562, DOI 10.1016/0003-9861(92)90611-Y; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; *INT AG RES CANC, 1994, MONOGRAPH IARC, V61, P177; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KO AI, 1990, P NATL ACAD SCI USA, V87, P4159, DOI 10.1073/pnas.87.11.4159; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KOYABASHI K, 1993, AM J GASTROENTEROL, V88, P475; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; Labigne A, 1996, INFECT AGENT DIS, V5, P191; Lee KP, 1996, J BIOL CHEM, V271, P32960, DOI 10.1074/jbc.271.51.32960; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MARSHALL BJ, 1984, LANCET, V1, P1311; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Mulder H, 1996, GLYCOCONJUGATE J, V13, P107, DOI 10.1007/BF01049686; Nakamura S, 1997, CANCER-AM CANCER SOC, V79, P3, DOI 10.1002/(SICI)1097-0142(19970101)79:1<3::AID-CNCR2>3.0.CO;2-P; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NEGRINI R, 1991, GASTROENTEROLOGY, V101, P437, DOI 10.1016/0016-5085(91)90023-E; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; Ozawa M, 1996, J BIOCHEM-TOKYO, V119, P302; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; RATHBONE BJ, 1986, GUT, V27, P642, DOI 10.1136/gut.27.6.642; SajdelSulkowska EM, 1997, GLYCOCONJUGATE J, V14, P249, DOI 10.1023/A:1018550023637; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485; SHERBURNE R, 1995, INFECT IMMUN, V63, P4564, DOI 10.1128/IAI.63.12.4564-4568.1995; SimoonsSmit IM, 1996, J CLIN MICROBIOL, V34, P2196, DOI 10.1128/JCM.34.9.2196-2200.1996; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; WARREN JR, 1983, LANCET, V1, P1273; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WIRTH HP, 1996, INFECT IMMUN, V64, P4958; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	62	88	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21349	21356		10.1074/jbc.272.34.21349	http://dx.doi.org/10.1074/jbc.272.34.21349			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261148	hybrid			2022-12-27	WOS:A1997XR78900058
J	Persson, U; Souchelnytskyi, S; Franzen, P; Miyazono, K; tenDijke, P; Heldin, CH				Persson, U; Souchelnytskyi, S; Franzen, P; Miyazono, K; tenDijke, P; Heldin, CH			Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; EXPRESSION CLONING; GS DOMAIN; COMPLEX; BONE; TRANSDUCTION; TRANSPHOSPHORYLATION; PROTEINS; FORMS	Members of the transforming growth factor-beta (TGF-beta) superfamily signal via different heteromeric complexes of two sequentially acting serine/threonine kinase receptors, i,e, type I and type II receptors, We generated two different chimeric TGF-beta superfamily receptors, i.e. T beta R-I/BMPR-IB, containing the extracellular domain of TGF-beta type I receptor (TPR-I) and the intracellular domain of bone morphogenetic protein type IB receptor (BMPR-IB), and T beta R-II/ActR-IIB, containing the extracellular domain of TGF-beta type II receptor (TPR-II) and the intracellular domain of activin type IIB receptor (ActR-IIB), In the presence of TGF-beta 1, T beta R-I/BMPR-IB and T beta R-II/ActR-IIB formed heteromeric complexes with wild-type TPR-II and TPR-I, respectively, upon stable transfection in mink lung epithelial cell lines, We show that T beta R-II/ActR-IIB restored the responsiveness upon transfection in mutant cell lines lacking functional TPR II with respect to TGF-beta-mediated activation of a transcriptional signal, extracellular matrix formation, growth inhibition, and Smad phosphorylation. Moreover, T beta R-I/BMPR-IB and T beta R-II/ActR-IIB formed a functional complex in response to TGF-beta and induced phosphorylation of Smad1, However, complex formation is not enough for signal propagation, which is shown by the inability of T beta R-I/BMPR-IB to restore responsive ness to TGF-beta in cell lines deficient in functional TPR-I, The fact that the TGF-beta 1-induced complex between T beta R-II/ActR-IIB and TPR-I stimulated endogenous Smad2 phosphorylation, a TGF-beta-like response, is in agreement with the current model for receptor activation in which the type I receptor determines signal specificity.	JAPANESE FDN CANC RES,INST CANC,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research	Persson, U (corresponding author), LUDWIG INST CANC RES,BOX 595,S-75124 UPPSALA,SWEDEN.		Souchelnytskyi, Serhiy/J-9446-2014; Dijke, Peter ten/AAG-4660-2021; Souchelnytskyi, Serhiy/G-6491-2011	Dijke, Peter ten/0000-0002-7234-342X; Souchelnytskyi, Serhiy/0000-0001-8243-9276				Anders RA, 1996, J BIOL CHEM, V271, P21758, DOI 10.1074/jbc.271.36.21758; Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BASSING CH, 1994, J BIOL CHEM, V269, P14861; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1995, BIOCHEM BIOPH RES CO, V207, P682, DOI 10.1006/bbrc.1995.1241; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATTHEWS LS, 1993, J BIOL CHEM, V268, P19013; Muramatsu M, 1997, MOL BIOL CELL, V8, P469, DOI 10.1091/mbc.8.3.469; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; OKADOME T, 1994, J BIOL CHEM, V269, P30753; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; TSUCHIDA K, 1995, ENDOCRINOLOGY, V136, P5493, DOI 10.1210/en.136.12.5493; VERSCHUEREN K, 1995, MECH DEVELOP, V52, P109, DOI 10.1016/0925-4773(95)00395-H; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	49	28	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21187	21194		10.1074/jbc.272.34.21187	http://dx.doi.org/10.1074/jbc.272.34.21187			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261125	hybrid			2022-12-27	WOS:A1997XR78900035
J	Balsinde, J; Balboa, MA; Dennis, EA				Balsinde, J; Balboa, MA; Dennis, EA			Inflammatory activation of arachidonic acid signaling in murine P388D(1) macrophages via sphingomyelin synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; PHOSPHOLIPASE A(2); HUMAN-NEUTROPHILS; CELLS; DIACYLGLYCEROLS; INHIBITION; MOBILIZATION; STIMULATION; EXPRESSION	Ceramide has emerged as an important lipid messenger for many cellular processes triggered via surface receptors. In the present study, inflammatory activation of P388D(1) macrophages with bacterial lipopolysaccharide (LPS) and platelet-activating factor (PAF) stimulated a transient accumulation of ceramide. Moreover, cell-permeable ceramide mimicked LPS/PAF in triggering arachidonate mobilization in these cells. LPS/PAF-induced ceramide synthesis did not result from sphingomyelinase activation but from increased de novo synthesis. Participation of this pathway in arachidonate signaling was detected since fumonisin B-1, an inhibitor of de novo ceramide synthesis, was able to inhibit the LPS/PAF-induced response. These studies have uncovered a new role for sphingolipid metabolism in cellular signaling and constitute evidence that products of the sphingomyelin biosynthetic pathway may serve a specific role in signal transduction by influencing the activity of the novel Group V secretory phospholipase A(2).	UNIV CALIF SAN DIEGO, SCH MED, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, REVELLE COLL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Balboa, María A./V-9493-2018; Dennis, Edward A./M-5554-2019; Balsinde, Jesús/C-7833-2018	Balboa, María A./0000-0002-2130-5298; Dennis, Edward A./0000-0003-3738-3140; Balsinde, Jesús/0000-0002-4157-6714	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 20501] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASMIS R, 1994, BIOCHEM J, V298, P543, DOI 10.1042/bj2980543; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; Balsinde J, 1997, BIOCHEM J, V321, P805, DOI 10.1042/bj3210805; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chilton F, 1996, J CLIN INVEST, V97, P2161, DOI 10.1172/JCI118654; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; DAWSON RMC, 1984, BIOCHEM BIOPH RES CO, V125, P836, DOI 10.1016/0006-291X(84)90615-6; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; EMILSSON A, 1985, BIOCHIM BIOPHYS ACTA, V846, P265, DOI 10.1016/0167-4889(85)90074-6; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KRAMER RM, 1987, BIOCHEM J, V248, P779, DOI 10.1042/bj2480779; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Reyes JG, 1996, J BIOL CHEM, V271, P21375, DOI 10.1074/jbc.271.35.21375; ROLDAN ERS, 1994, BIOCHEM J, V297, P225, DOI 10.1042/bj2970225; ROSENTHAL MD, 1993, BIOCHIM BIOPHYS ACTA, V1177, P79, DOI 10.1016/0167-4889(93)90161-H; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	43	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20373	20377		10.1074/jbc.272.33.20373	http://dx.doi.org/10.1074/jbc.272.33.20373			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252342	Green Published, hybrid			2022-12-27	WOS:A1997XR22100012
J	Nguyen, L; HolgadoMadruga, M; Maroun, C; Fixman, ED; Kamikura, D; Fournier, T; Charest, A; Tremblay, ML; Wong, AJ; Park, M				Nguyen, L; HolgadoMadruga, M; Maroun, C; Fixman, ED; Kamikura, D; Fournier, T; Charest, A; Tremblay, ML; Wong, AJ; Park, M			Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MET RECEPTOR; SCATTER FACTOR; KINASE-ACTIVITY; CELL-DISSOCIATION; EPITHELIAL-CELLS; PROTOONCOGENE; MOTILITY; PHOSPHORYLATION; IDENTIFICATION; TRANSFORMATION	Hepatocyte growth factor/scatter factor is a multifunctional factor that induces mitogenesis, motility, invasion, and branching tubulogenesis of several epithelial and endothelial cell lines in culture, The receptor for hepatocyte growth factor has been identified as the Mettyrosine kinase, Upon stimulation with hepatocyte growth factor, the Met beta subunit becomes highly phosphorylated on tyrosine residues, one of which, tyrosine 1356 within the carboxyl terminus, is crucial for dissociation, motility, and branching tubule formation in Madin-Darby canine kidney epithelial cells, Tyrosine 1356 forms a multisubstrate binding site for the Grb2 and She adaptor proteins, the p85 subunit of phosphatidylinositol 3'-kinase, phospholipase C gamma, and a phosphatase, SHP2, To investigate additional signaling molecules that are activated by the Met receptor, we have identified hepatocyte growth factor-induced phosphoproteins in tubular epithelial cells, We have established that proteins of 100-130 kDa are highly phosphorylated following stimulation of epithelial cells and that one of these is the Grb2-associated binding protein Gab1, a possible insulin receptor substrate-1-like signal transducer, We show that Gab1 is the major substrate for the Met kinase in vitro and in vivo, Association of Gab1 with Met requires a functional Grb2 binding site involving tyrosine 1356 and to a lesser extent tyrosine 1349, Met receptor mutants that fail to induce branching tubulogenesis are impaired in their ability to interact with Gab1, suggesting that Gab1 may play a role in these processes.	MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT MED, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT ONCOL, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; KIMMEL CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA; KIMMEL CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Jefferson University; Jefferson University					NCI NIH HHS [CA69495] Funding Source: Medline; NINDS NIH HHS [NS34514] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034514] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HAUGUELDEMOUZON S, 1992, J CELL PHYSIOL, V150, P180, DOI 10.1002/jcp.1041500124; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; KOMADA M, 1993, ONCOGENE, V8, P2381; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MATSUMOTO K, 1993, HEPATOCYTE GROWTH FA, P226; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	47	152	164	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20811	20819		10.1074/jbc.272.33.20811	http://dx.doi.org/10.1074/jbc.272.33.20811			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252406	hybrid			2022-12-27	WOS:A1997XR22100076
J	Chen, HY; McCormick, DB				Chen, HY; McCormick, DB			Riboflavin 5'-hydroxymethyl oxidation - Molecular cloning, expression, and glycoprotein nature of the 5'-aldehyde-forming enzyme from Schizophyllum commune	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; AFFINITY-CHROMATOGRAPHY; PICHIA-PASTORIS; FAD SYNTHETASE; HUMAN-URINE; PURIFICATION; QUANTITATION; DEHYDROGENASE; FLAVOKINASE; CATABOLITES	Vitamin B-2-aldehyde-forming enzyme catalyzes oxidation of the 5'-hydroxymethyl of riboflavin to the formyl group. We have purified the enzyme from the culture media of Schizophyllum commune (ATCC 38719) by modifying the procedure of Tachibana and Oka (Tachibana, S., and Oka, M. (1981) J. Biol. Chem. 256, 6682-6685) for cell-free extract. By SDS-polyacrylamine gel electrophoresis, the enzyme appears to be 78 kDa, The enzyme has a blocked amino terminus, so fragments were obtained by cleaving the purified enzyme with lysyl endopeptidase. Selected peptides were sequenced from their amino termini, We have isolated a full-length cDNA clone using a DNA hybridization probe amplified by polymerase chain reaction with two degenerate oligonucleotide primers, the design of which was based on one of the partial amino acid sequences. From the cDNA clone, it is evident that the enzyme has a Ser/Thr-rich fragment near the COOH-terminal Asp, The enzyme was determined to be a glycoprotein; however, O-deglucosylation only slightly affects activity, Computer searches showed that the B-2-aldehyde-forming enzyme has little homology with other proteins, but domain motifs may reflect N-myristoylation of a dehydrogenase with a signature similar to 4Fe-4S ferredoxins. The enzyme cDNA was subcloned into a Pichia expression vector pPIC9K to produce a recombinant protein which exhibited B-2-aldehyde-forming enzyme activity.	EMORY UNIV,DEPT BIOCHEM,ROLLINS RES CTR,ATLANTA,GA 30322	Emory University					NIDDK NIH HHS [DK 38940] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038940] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attwood TK, 1997, NUCLEIC ACIDS RES, V25, P212, DOI 10.1093/nar/25.1.212; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKHOLZ RG, 1991, BIO-TECHNOL, V9, P1067, DOI 10.1038/nbt1191-1067; CHASTAIN JL, 1987, J NUTR, V117, P468, DOI 10.1093/jn/117.3.468; CHASTAIN JL, 1987, AM J CLIN NUTR, V46, P830, DOI 10.1093/ajcn/46.5.830; CHASTAIN JL, 1991, CHEM BIOCH FLAVINS, P195; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HARKNESS DR, 1964, ARCH BIOCHEM BIOPHYS, V108, P323, DOI 10.1016/0003-9861(64)90393-5; HORWITT MK, 1950, J NUTR, V41, P247, DOI 10.1093/jn/41.2.247; KASAI S, 1989, B CHEM SOC JPN, V62, P611, DOI 10.1246/bcsj.62.611; KEKELIDZE TN, 1994, ARCH BIOCHEM BIOPHYS, V315, P100, DOI 10.1006/abbi.1994.1476; MAVROTHALASSITIS G, 1988, P NATL ACAD SCI USA, V85, P3494, DOI 10.1073/pnas.85.10.3494; McCormick DB., 1994, MODERN NUTR HLTH DIS, P366; MERRILL AH, 1978, ANAL BIOCHEM, V89, P87, DOI 10.1016/0003-2697(78)90729-7; MERRILL AH, 1980, J BIOL CHEM, V255, P1335; MILES HT, 1959, J AM CHEM SOC, V81, P1946, DOI 10.1021/ja01517a042; MOYE WS, 1985, J BIOL CHEM, V260, P8502; OHKAWA H, 1983, J BIOL CHEM, V258, P5623; OKA M, 1987, J BIOL CHEM, V262, P7418; OKAZAKI N, 1988, GENE, V63, P337, DOI 10.1016/0378-1119(88)90537-9; PROKOP A, 1992, EXP MYCOL, V16, P197, DOI 10.1016/0147-5975(92)90028-P; ROMANOS MA, 1991, VACCINE, V9, P901, DOI 10.1016/0264-410X(91)90011-T; ROUGHEAD ZK, 1990, AM J CLIN NUTR, V52, P854, DOI 10.1093/ajcn/52.5.854; ROUGHEAD ZK, 1990, J NUTR, V120, P382, DOI 10.1093/jn/120.4.382; TACHIBANA S, 1982, J NUTR SCI VITAMINOL, V28, P335; TACHIBANA S, 1981, J BIOL CHEM, V256, P6682; Tachibana S, 1980, Methods Enzymol, V66, P333; TSAI L, 1963, BIOCHEM Z, V338, P561; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; YAMADA Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P125, DOI 10.1016/0003-9861(90)90240-Y; YANAGITA T, 1956, J BIOL CHEM, V221, P593; YANG CS, 1967, BIOCHIM BIOPHYS ACTA, V132, P511, DOI 10.1016/0005-2744(67)90171-4; Zempleni J, 1996, INT J VITAM NUTR RES, V66, P151	34	14	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20077	20081		10.1074/jbc.272.32.20077	http://dx.doi.org/10.1074/jbc.272.32.20077			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242680	hybrid			2022-12-27	WOS:A1997XQ05900067
J	Ijpenberg, A; Jeannin, E; Wahli, W; Desvergne, B				Ijpenberg, A; Jeannin, E; Wahli, W; Desvergne, B			Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR) retinoid X receptor heterodimer binding to DNA - A functional analysis of the malic enzyme gene PPAR response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; COA OXIDASE GENE; FATTY-ACIDS; DIRECT REPEATS; SIGNALING PATHWAYS; LIPID-METABOLISM; HIGH-AFFINITY; COUP-TF; EXPRESSION; RXR	The malic enzyme (ME) gene is a target for both thyroid hormone receptors and peroxisome proliferator-activated receptors (PPAR). Within the ME: promoter; two direct repeat (DR)-1-like elements, MEp and MEd, have cell identified as putative PPAR response elements (PPRE), We demonstrate that only MEp and not MEd is able to bind PPAR/retinoid X receptor (RXR) heterodimers and mediate peroxisome proliferator signaling. Taking advantage of the close sequence resemblance of MEp and MEd, we have identified crucial determinants of a PPRE, Using reciprocal mutation analyses of these two elements, we show the preference for adenine as the spacing nucleotide between the two half-sites of the PPRE and demonstrate the importance of the two first bases flanking the core DR1 in 5', This latter feature of the PPRE lead us to consider the polarity of the PPAR/RXR heterodimer bound to its cognate element, We demonstrate that, in contrast to the polarity of RXR/TR and RXR/RAR bound to DR4 and DR5 elements respectively, PPAR binds to the 5' extended half-site of the response element, while RXR occupies the 3' half-site, Consistent with this polarity is our finding that formation and binding of the PPAR/RXR. heterodimer requires an intact. hinge T region in RXR while its integrity is not required for binding of the RXR/TR heterodimer to a DR4.	UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND	University of Lausanne			Wahli, Walter/B-1398-2009; Wahli, Walter/I-3194-2019; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X				ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; BAES M, 1995, BIOCHEM BIOPH RES CO, V215, P338, DOI 10.1006/bbrc.1995.2471; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CASTELEIN H, 1993, FEBS LETT, V332, P24, DOI 10.1016/0014-5793(93)80474-9; Castelein H, 1996, MOL CELL ENDOCRINOL, V119, P11, DOI 10.1016/0303-7207(96)03794-X; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DESVERGNE B, 1994, MOL CELL ENDOCRINOL, V100, P125, DOI 10.1016/0303-7207(94)90291-7; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE, V1, P142; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; DIRENZO J, 1997, MOL CELL BIOL, V17, P13470; DOWHAN DH, 1994, ENDOCRINOLOGY, V135, P2595, DOI 10.1210/en.135.6.2595; DOZIN B, 1986, J BIOL CHEM, V261, P290; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GARCIAJIMENEZ C, 1993, ENDOCRINOLOGY, V132, P1537, DOI 10.1210/en.132.4.1537; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; Hertz R, 1996, BIOCHEM J, V319, P241, DOI 10.1042/bj3190241; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MORIOKA H, 1988, MOL CELL BIOL, V8, P3542, DOI 10.1128/MCB.8.8.3542; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REUE K, 1988, J BIOL CHEM, V263, P6857; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SCHWABE JWR, 1990, MOL ENDOCRINOL, V348, P428; Sears IB, 1996, MOL CELL BIOL, V16, P3410; TEBOUL M, 1992, ENDOCRINOLOGY, V130, P1475, DOI 10.1210/en.130.3.1475; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; WILLSON TM, 1997, IN PRESS CURR OPIN C; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Winrow Christopher J., 1994, Gene Expression, V4, P53; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	77	256	263	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20108	20117		10.1074/jbc.272.32.20108	http://dx.doi.org/10.1074/jbc.272.32.20108			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242684	hybrid			2022-12-27	WOS:A1997XQ05900071
J	Watanabe, G; Pena, P; Albanese, C; Wilsbacher, LD; Young, JB; Pestell, RG				Watanabe, G; Pena, P; Albanese, C; Wilsbacher, LD; Young, JB; Pestell, RG			Adrenocorticotropin induction of stress-activated protein kinase in the adrenal cortex in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; EPIDERMAL GROWTH-FACTOR; C-JUN; SIGNAL-TRANSDUCTION; HORMONAL-REGULATION; DEPENDENT ACTIVATION; ANGIOTENSIN-II; PHORBOL ESTER; GENE PROMOTER; TUMOR-CELLS	A broad array of stressors induce ACTH release from the anterior pituitary, with consequent stimulation of the adrenal cortex and release of glucocorticoids critical for survival of the animal, ACTH stimulates adrenocortical gene expression in vivo and inhibits adrenocortical cell proliferation, Binding of ACTH to its G-protein-coupled receptor stimulates the production of cAMP and activation of the protein kinase A pathway, The stress-activated protein kinases (SAPKs) (or c-Jun N-terminal kinases) and the extracellular signal-regulated kinases (ERKs) are members of the mitogen-activated protein kinase family of serine/threonine kinases, which have recently been implicated in G-protein-coupled receptor intracellular signaling, The SAPKs are preferentially induced by osmotic stress and UV light, whereas the ERKs are preferentially induced by growth factors and proliferative signals in cultured cells, In these studies, ACTH stimulated SAPK activity 3-4-fold both in the adrenal cortex in vivo and in the Y1 adrenocortical cell line, 12-O-Tetradecanoylphorbol-13-acetate but not cAMP induced SAPK activity in Y1 cells, The isoquinolinesulfonamide inhibitors H-8 and H-89 blocked ACTH induction of SAPK activity at protein kinase C inhibitory doses but not at protein kinase A inhibitory doses, The calcium chelating agent EGTA inhibited ACTH-induced SAPK activity and the calcium ionophore A23187 induced SAPK activity S-fold, In contrast with the induction of SAPK by ACTH, ERK activity was inhibited in the adrenal cortex in vivo and in Y1 adrenal cells, Together these findings suggest that ACTH induces SAPK activity through a PKC and Ca+2-dependent pathway. The induction of SAPK and inhibition of ERK by ACTH in vivo may preferentially regulate target genes involved in the adrenocortical stress responses in the whole animal.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,ALBERT EINSTEIN CANC CTR,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,ALBERT EINSTEIN CANC CTR,DEPT DEV & MOL BIOL,BRONX,NY 10461; NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Northwestern University					NATIONAL CANCER INSTITUTE [P30CA013330, R01CA070897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020378] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA13330-26, 1R29CA70897-01] Funding Source: Medline; NIDDK NIH HHS [DK 20378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROLA J, 1994, J ENDOCRINOL, V141, P285, DOI 10.1677/joe.0.1410285; BARBARA JG, 1995, J PHYSIOL-LONDON, V488, P609, DOI 10.1113/jphysiol.1995.sp020994; BIRD IM, 1990, J LIPID MEDIATOR, V2, P343; BIRD IM, 1990, J MOL ENDOCRINOL, V5, P191, DOI 10.1677/jme.0.0050191; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CACERES A, 1984, J NEUROSCI, V4, P394; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; ChristinMaitre S, 1996, J CLIN ENDOCR METAB, V81, P2080, DOI 10.1210/jc.81.6.2080; CLARKE BL, 1994, ENDOCRINOLOGY, V135, P1780, DOI 10.1210/en.135.5.1780; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; FARKASH Y, 1986, ENDOCRINOLOGY, V118, P1353, DOI 10.1210/endo-118-4-1353; Feuilloley M, 1996, ENDOCR REV, V17, P269, DOI 10.1210/er.17.3.269; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GAGLIARDINO JJ, 1995, ARCH PHYSIOL BIOCHEM, V103, P73, DOI 10.3109/13813459509007567; GOLDRING NB, 1987, ENDOCRINOLOGY, V120, P1942, DOI 10.1210/endo-120-5-1942; GOUELI BS, 1995, ANAL BIOCHEM, V225, P10, DOI 10.1006/abio.1995.1100; Halkerston I D, 1975, Adv Cyclic Nucleotide Res, V6, P99; Hall PF, 1995, J STEROID BIOCHEM, V55, P601, DOI 10.1016/0960-0760(95)00211-1; HEIKKILA P, 1995, J ENDOCRINOL, V145, P379, DOI 10.1677/joe.0.1450379; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IZAWA T, 1994, AM J PHYSIOL, V266, pE418, DOI 10.1152/ajpendo.1994.266.3.E418; KIMURA E, 1993, MOL ENDOCRINOL, V7, P1463, DOI 10.1210/me.7.11.1463; KIMURA E, 1990, J BIOL CHEM, V265, P3518; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LIN A, 1993, ADV SEC MESS PHOSPH, V28, P255; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATHIAS S, 1995, ENDOCR RES, V21, P121, DOI 10.3109/07435809509030428; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; PAPADOPOULOS V, 1990, MOL CELL ENDOCRINOL, V74, P109, DOI 10.1016/0303-7207(90)90113-M; Pestell RG, 1996, MOL ENDOCRINOL, V10, P1084, DOI 10.1210/me.10.9.1084; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PESTELL RG, 1993, J MOL ENDOCRINOL, V10, P297, DOI 10.1677/jme.0.0100297; PESTELL RG, 1995, J BIOL CHEM, V270, P18301, DOI 10.1074/jbc.270.31.18301; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; ROSSIER MF, 1993, ENDOCRINOLOGY, V132, P1035, DOI 10.1210/en.132.3.1035; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schimmer B P, 1980, Adv Cyclic Nucleotide Res, V13, P181; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUGIHARA H, 1985, CELL STRUCT FUNCT, V10, P295; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VIARD I, 1992, ENDOCRINOLOGY, V130, P1193, DOI 10.1210/en.130.3.1193; VILGRAIN I, 1984, J BIOL CHEM, V259, P3403; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WONG M, 1992, MOL ENDOCRINOL, V6, P1614, DOI 10.1210/me.6.10.1614; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WOODGETT JR, 1995, CLIN EXP PHARMACOL P, V22, P281, DOI 10.1111/j.1440-1681.1995.tb01995.x; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	69	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20063	20069		10.1074/jbc.272.32.20063	http://dx.doi.org/10.1074/jbc.272.32.20063			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242678	hybrid			2022-12-27	WOS:A1997XQ05900065
